

**METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS
OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE**

GOVERNMENT SUPPORT

[0001] This invention was made with government support under grant numbers U01AI142756, RM1HG009490, R01EB022376, and R35GM118062 awarded by the National Institutes of Health. The government has certain rights in the invention.

RELATED APPLICATIONS AND INCORPORATION BY REFERENCE

[0002] This application claims priority to U.S. Provisional Application No. 63/022,397, filed May 8, 2020, and U.S. Provisional Application No. 63/116,785, filed November 20, 2020, the entire contents each of which is incorporated herein by reference in their entireties.

[0003] This U.S. Provisional Application also refers to and incorporates by reference the following applications, namely, U.S. Provisional Application No. 62/820,813, filed March 19, 2019 (Attorney Docket No. B1195.70074US00), U.S. Provisional Application No. 62/858,958 (Attorney Docket No. B1195.70074US01), filed June 7, 2019, U.S. Provisional Application No. 62/889,996 (Attorney Docket No. B1195.70074US02), filed August 21, 2019, U.S. Provisional Application No. 62/922,654, filed August 21, 2019 (Attorney Docket No. B1195.70083US00), U.S. Provisional Application No. 62/913,553 (Attorney Docket No. B1195.70074US03), filed October 10, 2019, U.S. Provisional Application No. 62/973,558 (Attorney Docket No. B1195.70083US01), filed October 10, 2019, U.S. Provisional Application No. 62/931,195 (Attorney Docket No. B1195.70074US04), filed November 5, 2019, U.S. Provisional Application No. 62/944,231 (Attorney Docket No. B1195.70074US05), filed December 5, 2019, U.S. Provisional Application No. 62/974,537 (Attorney Docket No. B1195.70083US02), filed December 5, 2019, U.S. Provisional Application No. 62/991,069 (Attorney Docket No. B1195.70074US06), filed March 17, 2020, and U.S. Provisional Application No. (63/100,548) (Attorney Docket No. B1195.70083US03), filed March 17, 2020. In addition, this U.S. Provisional Application refers to and incorporates by reference International PCT Application Nos.: PCT/US20/23721; PCT/US20/23730; PCT/US20/23713; PCT/US20/23712; PCT/US20/23727; PCT/US20/23724; PCT/US20/23725; PCT/US20/23728; PCT/US20/23732; PCT/US20/23723; PCT/US20/23553; and PCT/US20/23583, each filed on March 19, 2020.

BACKGROUND OF THE INVENTION

[0004] Pathogenic single nucleotide mutations contribute to approximately 50% of human diseases for which there is a genetic component,⁷ according to some estimates. Unfortunately, treatment options for patients with these genetic disorders remain extremely limited, despite decades of gene therapy exploration⁸. Perhaps the most parsimonious solution to this therapeutic challenge is direct

correction of single nucleotide mutations in patient genomes, which would address the root cause of disease and would likely provide lasting benefit. Although such a strategy was previously unthinkable, recent improvements in genome editing capabilities brought about by the advent of the CRISPR/Cas system⁹ have now brought this therapeutic approach within reach. By straightforward design of a guide RNA (gRNA) sequence that contains ~20 nucleotides complementary to the target DNA sequence, nearly any conceivable genomic site can be specifically accessed by CRISPR associated (Cas) nucleases^{1,2}. To date, several monomeric bacterial Cas nuclease systems have been identified and adapted for genome editing applications¹⁰. This natural diversity of Cas nucleases, along with a growing collection of engineered variants¹¹⁻¹⁴, offers fertile ground for developing new genome editing technologies.

[0005] While gene disruption with CRISPR is now a mature technique, precision editing of single base pairs in the human genome remains a major challenge³. Homology directed repair (HDR) has long been used in human cells and other organisms to insert, correct, or exchange DNA sequences at sites of double strand breaks (DSBs) using donor DNA repair templates that encode the desired edits¹⁵. However, traditional HDR has very low efficiency in most human cell types, particularly in non-dividing cells, and competing non-homologous end joining (NHEJ) leads predominantly to insertion-deletion (indel) byproducts¹⁶. Other issues relate to the generation of DSBs, which can give rise to large chromosomal rearrangements and deletions at target loci¹⁷, or activate the p53 axis leading to growth arrest and apoptosis^{18,19}.

[0006] Several approaches have been explored to address these drawbacks of HDR. For example, repair of single-stranded DNA breaks (nicks) with oligonucleotide donors has been shown to reduce indel formation, but yields of desired repair products remain low²⁰. Other strategies attempt to bias repair toward HDR over NHEJ using small molecule and biologic reagents²¹⁻²³. However, the effectiveness of these methods is likely cell-type dependent, and perturbation of the normal cell state could lead to undesirable and unforeseeable effects.

[0007] Recently, the inventors, led by Prof. David Liu et al., developed base editing as a technology that edits target nucleotides without creating DSBs or relying on HDR^{4-6,24-27}. Direct modification of DNA bases by Cas-fused deaminase enzymes allows for C•G to T•A, or A•T to G•C, base pair conversions in a short target window (~5-7 bases) with very high efficiency. As a result, base editors have been rapidly adopted by the scientific community. However, the following factors limit their generality for precision genome editing: (1) “bystander editing” of non-target C or A bases within the target window are observed; (2) target nucleotide product mixtures are observed; (3) target bases must be located 15±2 nucleotides upstream of a PAM sequence; and (5) repair of small insertion and deletion mutations is not possible.

[0008] Therefore, the development of programmable editors that are flexibly capable of introducing any desired single nucleotide change and/or which could install base pair insertions or deletions (e.g.,

at least 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more base pair insertions or deletions) and/or which could alter or modify the nucleotide sequence at a target site with high specificity and efficiency would substantially expand the scope and therapeutic potential of genome editing technologies based on CRISPR.

SUMMARY OF THE INVENTION

[0009] The present invention describes a new platform for genome editing called “multi-flap prime editing” (including, for example, “dual-flap prime editing” and “quadruple-flap prime editing”) and represents an innovative advancement of “prime editing” or “classical prime editing,” as described by the present inventors in Anzalone, A. V. *et al.* Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature* **576**, 149–157 (2019), which is incorporated herein by reference. Whereas classical prime editing in various embodiments polymerizes at a nick site a single 3′ flap which becomes integrated into the target nucleic acid on the same strand, the presently described multi-flap prime editing systems involve distinct constructs, systems, and methodologies that, in various embodiments, generate pairs or multiple pairs of 3′ flaps on different strands, which form duplexes comprising desired edits and which become incorporated into target nucleic acid molecules, e.g., at specific loci or edit sites in a genome. In various aspects, the pairs or multiple pairs of 3′ flaps form duplexes because they comprise reverse complementary sequences which anneal to one another once generated by the prime editors described herein. The duplexes become incorporated into the target site by cell-driven mechanisms that naturally replace the endogenous duplex sequences located between adjacent nick sites. In certain embodiments, the new duplex sequences may be introduced at one or more locations (e.g., at adjacent genomic loci or on two different chromosomal locations), and may comprise one or more sequences of interest, e.g., protein-encoding sequence, peptide-encoding sequence, or RNA-encoding sequence. In one embodiment, the new duplex sequences installed by the multi-flap prime editing systems may comprise a recombinase site, e.g., a Bxb1 recombinase *attB* (38 bp) and/or *attP* (50 bp) site, or a recombinase site recognized by Hin recombinase, Gin recombinase, Tn3 recombinase, β -six recombinase, CinH recombinase, ParA recombinase, $\gamma\delta$ recombinase, ϕ C31 recombinase, TP901 recombinase, TG1 recombinase, ϕ BT1 recombinase, R4 recombinase, ϕ RV1 recombinase, ϕ FC1 recombinase, MR11 recombinase, A118 recombinase, U153 recombinase, and gp29 recombinase, Cre recombinase, FLP recombinase, R recombinase, Lambda recombinase, HK101 recombinase, HK022 recombinase, and pSAM2 recombinase.

[0010] The inventors recently developed prime editing which enables the insertion, deletion, or replacement of genomic DNA sequences without requiring error-prone double-strand DNA breaks. Prime editing uses an engineered Cas9 nickase–reverse transcriptase fusion protein (PE1 or PE2) paired with an engineered prime editing guide RNA (pegRNA) that both directs Cas9 to the target genomic site and encodes the information for installing the desired edit. Prime editing proceeds through a multi-step editing process: 1) the Cas9 domain binds and nicks the target genomic DNA

site, which is specified by the pegRNA's spacer sequence; 2) the reverse transcriptase domain uses the nicked genomic DNA as a primer to initiate the synthesis of an edited DNA strand using an engineered extension on the pegRNA as a template for reverse transcription—this generates a single-stranded 3' flap containing the edited DNA sequence; 3) cellular DNA repair resolves the 3' flap intermediate by the displacement of a 5' flap species that occurs via invasion by the edited 3' flap, excision of the 5' flap containing the original DNA sequence, and ligation of the new 3' flap to incorporate the edited DNA strand, forming a heteroduplex of one edited and one unedited strand; and 4) cellular DNA repair replaces the unedited strand within the heteroduplex using the edited strand as a template for repair, completing the editing process.

[0011] Efficient incorporation of the desired edit requires that the newly synthesized 3' flap contains a portion of sequence that is homologous to the genomic DNA site. This homology enables the edited 3' flap to compete with the endogenous DNA strand (the corresponding 5' flap) for incorporation into the DNA duplex. Because the edited 3' flap will contain less sequence homology than the endogenous 5' flap, the competition is expected to favor the 5' flap strand. Thus, a potential limiting factor in the efficiency of prime editing may be the efficiency of the invasion of the 3' flap of the endogenous DNA and the subsequent displacement and replacement of the 5' flap strand. Moreover, successful 3' flap invasion and removal of the 5' flap only incorporates the edit on one strand of the double-stranded DNA genome. Permanent installation of the edit requires cellular DNA repair to replace the unedited complementary DNA strand using the edited strand as a template. While the cell can be made to favor replacement of the unedited strand over the edited strand (step 4 above) by the introduction of a nick in the unedited strand adjacent to the edit using a secondary sgRNA (the PE3 system), this process still relies on a second stage of DNA repair. These DNA repair steps may be particularly inefficient for edits which require equilibration of long 5' and 3' flap intermediates or contain long non-homologous regions, such as long insertions or long deletions. Further developments in prime editing would advance the art.

[0012] In various aspects, this Specification describes a multi-flap prime editing system (including, for example, dual prime editing systems and quadruple prime editing systems) that addresses the challenges associated with flap equilibration and subsequent incorporation of the edit into the non-edited complementary genomic DNA strand by simultaneously editing both DNA strands. In the dual-flap prime editing system, for example, two pegRNAs are used to target opposite strands of a genomic site and direct the synthesis of two complementary 3' flaps containing edited DNA sequence (**FIG. 91**). Unlike classical prime editing, there is no requirement for the pair of edited DNA strands (3' flaps) to directly compete with 5' flaps in endogenous genomic DNA, as the complementary edited strand is available for hybridization instead. Since both strands of the duplex are synthesized as edited DNA, the dual-flap prime editing system obviates the need for the replacement of the non-edited complementary DNA strand required by classical prime editing. Instead, cellular DNA repair

machinery need only excise the paired 5' flaps (original genomic DNA) and ligate the paired 3' flaps (edited DNA) into the locus. Therefore, there is also no need to include sequences homologous to genomic DNA in the newly synthesized DNA strands, allowing selective hybridization of the new strands and facilitating edits that contain minimal genomic homology. Nuclease-active versions of prime editors that cut both strands of DNA could also be used to accelerate the removal of the original DNA sequence. The quadruple-flap prime editing system, using four pegRNAs, provides similar advantages.

[0013] Like classical prime editing, multi-flap prime editing is a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a nucleic acid programmable DNA binding protein ("napDNAbp") working in association with a polymerase (i.e., in the form of a fusion protein or otherwise provided *in trans* with the napDNAbp), wherein the prime editing system is programmed with a prime editing (PE) guide RNA ("PEgRNA") that both specifies the target site and templates the synthesis of the desired edit in the form of a replacement DNA strand by way of an extension (either DNA or RNA) engineered onto a guide RNA (e.g., at the 5' or 3' end, or at an internal portion of a guide RNA). The replacement strand containing the desired edit (e.g., a single nucleobase substitution) shares the same sequence as the endogenous strand of the target site to be edited (with the exception that it includes the desired edit). Through DNA repair and/or replication machinery, the endogenous strand of the target site is replaced by the newly synthesized replacement strand containing the desired edit. In some cases, prime editing may be thought of as a "search-and-replace" genome editing technology since the prime editors, as described herein, not only search and locate the desired target site to be edited, but at the same time, encode a replacement strand containing a desired edit, which is installed in place of the corresponding target site endogenous DNA strand.

[0014] The multi-flap prime editors of the present disclosure relate, in part, to the discovery that the mechanism of target-primed reverse transcription (TPRT) or "prime editing" can be leveraged or adapted for conducting precision CRISPR/Cas-based genome editing with high efficiency and genetic flexibility (e.g., as depicted in various embodiments of FIGs. 1A-1F). TPRT is naturally used by mobile DNA elements, such as mammalian non-LTR retrotransposons and bacterial Group II introns^{28,29}. The inventors have herein used Cas protein-reverse transcriptase fusions or related systems to target a specific DNA sequence with a guide RNA, generate a single strand nick at the target site, and use the nicked DNA as a primer for reverse transcription of an engineered reverse transcriptase template that is integrated with the guide RNA. However, while the concept begins with prime editors that use reverse transcriptases as the DNA polymerase component, the multi-flap prime editors described herein are not limited to reverse transcriptases but may include the use of virtually any DNA polymerase. Indeed, while the application throughout may refer to multi-flap prime editors with "reverse transcriptases," it is set forth here that reverse transcriptases are only one type of DNA

polymerase that may work with multi-flap prime editing. Thus, wherever the specification mentions “reverse transcriptases,” the person having ordinary skill in the art should appreciate that any suitable DNA polymerase may be used in place of the reverse transcriptase. Thus, in one aspect, the multi-flap prime editors may comprise Cas9 (or an equivalent napDNAbp) which is programmed to target a DNA sequence by associating it with a specialized guide RNA (i.e., PEgRNA) containing a spacer sequence that anneals to a complement of a protospacer sequence in the target DNA. The specialized guide RNA also contains new genetic information in the form of an extension that encodes a replacement strand of DNA containing a desired genetic alteration which is used to replace a corresponding endogenous DNA strand at the target site. To transfer information from the PEgRNA to the target DNA, the mechanism of multi-flap prime editing involves nicking the target site in one strand of the DNA to expose a 3'-hydroxyl group. The exposed 3'-hydroxyl group can then be used to prime the DNA polymerization of the edit-encoding extension on PEgRNA directly into the target site. In various embodiments, the extension—which provides the template for polymerization of the replacement strand containing the edit—can be formed from RNA or DNA. In the case of an RNA extension, the polymerase of the prime editor can be an RNA-dependent DNA polymerase (such as, a reverse transcriptase). In the case of a DNA extension, the polymerase of the prime editor may be a DNA-dependent DNA polymerase.

[0015] In classical prime editing, the newly synthesized strand (i.e., the replacement DNA strand containing the desired edit) that is formed by the herein disclosed prime editors would be homologous to the genomic target sequence (i.e., have the same sequence as) except for the inclusion of a desired nucleotide change (e.g., a single nucleotide change, a deletion, or an insertion, or a combination thereof). The newly synthesized (or replacement) strand of DNA may also be referred to as a single strand DNA flap, which would compete for hybridization with the complementary homologous endogenous DNA strand, thereby displacing the corresponding endogenous strand. In certain embodiments, the system can be combined with the use of an error-prone reverse transcriptase enzyme (e.g., provided as a fusion protein with the Cas9 domain, or provided *in trans* to the Cas9 domain). The error-prone reverse transcriptase enzyme can introduce alterations during synthesis of the single strand DNA flap. Thus, in certain embodiments, error-prone reverse transcriptase can be utilized to introduce nucleotide changes to the target DNA. Depending on the error-prone reverse transcriptase that is used with the system, the changes can be random or non-random.

[0016] In classical prime editing, resolution of the hybridized intermediate (comprising the single strand DNA flap synthesized by the reverse transcriptase hybridized to the endogenous DNA strand) can include removal of the resulting displaced flap of endogenous DNA (e.g., with a 5' end DNA flap endonuclease, FEN1), ligation of the synthesized single strand DNA flap to the target DNA, and assimilation of the desired nucleotide change as a result of cellular DNA repair and/or replication processes. Because templated DNA synthesis offers single nucleotide precision for the modification

of any nucleotide, including insertions and deletions, the scope of this approach is very broad and could foreseeably be used for myriad applications in basic science and therapeutics.

[0017] In some aspects, the specification provides a pair of prime editors, each comprising a nucleic acid programmable DNA binding protein (napDNAbp) and a DNA polymerase. In some embodiments, each prime editor is capable of carrying out genome editing by target-primed reverse transcription in the presence of an extended guide RNA.

[0018] In some aspects, the specification provides a pair of prime editors, each comprising a nucleic acid programmable DNA binding protein (napDNAbp) and a DNA polymerase, wherein the DNA polymerase is provided *in trans* with the napDNAbp. In various embodiments, each prime editor is capable of carrying out genome editing by target-primed reverse transcription in the presence of an extended guide RNA.

[0019] In some aspects, the specification provides a pair of prime editors, each comprising a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase. In various embodiments, each prime editor is capable of carrying out genome editing by target-primed reverse transcription in the presence of an extended guide RNA.

[0020] In some aspects, the specification provides a pair of prime editors, each comprising a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase, wherein the reverse transcriptase is provided *in trans* with the napDNAbp. In various embodiments, each prime editor is capable of carrying out genome editing by target-primed reverse transcription in the presence of an extended guide RNA.

[0021] In certain embodiments, the napDNAbp has a nickase activity. The napDNAbp may also be a Cas9 protein or functional equivalent thereof, such as a nuclease active Cas9, a nuclease inactive Cas9 (dCas9), or a Cas9 nickase (nCas9).

[0022] In certain embodiments, the napDNAbp is selected from the group consisting of: Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, and Argonaute and optionally has a nickase activity.

[0023] In other embodiments, each prime editor of the dual prime editors, when complexed with an extended guide RNA, is capable of binding to a target DNA sequence.

[0024] In still other embodiments, the target DNA sequence comprises a target strand and a complementary non-target strand.

[0025] In other embodiments, the binding of the prime editor complexed to the extended guide RNA forms an R-loop. The R-loop can comprise (i) an RNA-DNA hybrid comprising the extended guide RNA and the target strand, and (ii) the complementary non-target strand.

[0026] In still other embodiments, the complementary non-target strand is nicked to form a reverse transcriptase priming sequence having a free 3' end.

[0027] In various embodiments, the extended guide RNA comprises (a) a guide RNA and (b) an RNA extension at the 5' or the 3' end of the guide RNA, or at an intramolecular location in the guide RNA. The RNA extension can comprise (i) a reverse transcription template sequence comprising a desired nucleotide change, (ii) a reverse transcription primer binding site, and (iii) optionally, a linker sequence. In various embodiments, the reverse transcription template sequence may encode a single-strand DNA flap that is complementary to an endogenous DNA sequence adjacent to the nick site, wherein the single-strand DNA flap comprises the desired nucleotide change.

[0028] In various embodiments, the RNA extension is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, or at least 25 nucleotides in length.

[0029] In still other embodiments, the single-strand DNA flap may hybridize to the endogenous DNA sequence adjacent to the nick site, thereby installing the desired nucleotide change. In still other embodiments, the single-stranded DNA flap displaces the endogenous DNA sequence adjacent to the nick site and which has a free 5' end. In certain embodiments, the displaced endogenous DNA having the 5' end is excised by the cell.

[0030] In various embodiments, the cellular repair of the single-strand DNA flap results in installation of the desired nucleotide change, thereby forming a desired product.

[0031] In various other embodiments, the desired nucleotide change is installed in an editing window that is between about -4 to +10 of the PAM sequence.

[0032] In still other embodiments, the desired nucleotide change is installed in an editing window that is between about -5 to +5 of the nick site, or between about -10 to +10 of the nick site, or between about -20 to +20 of the nick site, or between about -30 to +30 of the nick site, or between about -40 to +40 of the nick site, or between about -50 to +50 of the nick site, or between about -60 to +60 of the nick site, or between about -70 to +70 of the nick site, or between about -80 to +80 of the nick site, or between about -90 to +90 of the nick site, or between about -100 to +100 of the nick site, or between about -200 to +200 of the nick site.

[0033] In various embodiments, the napDNAbp of the dual prime editors each comprise an amino acid sequence of SEQ ID NO: 18. In various other embodiments, the napDNAbp comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 26-39, 42-61, 75-76, 126, 130, 137, 141, 147, 153, 157, 445, 460, 467, and 482-487 (Cas9); SEQ ID NO: 77-86 (CP-Cas9); SEQ ID NO: 18-25 and 87-88 (SpCas9); and SEQ ID NOs: 62-72 (Cas12)

[0034] In other embodiments, the reverse transcriptase of the disclosed prime editors and/or compositions of the dual prime editors may comprise any one of the amino acid sequences of SEQ ID NOs: 89-100, 105-122, 128-129, 132, 139, 143, 149, 154, 159, 235, 454, 471, 516, 662, 700-716, 739-742, and 766. In still other embodiments, the reverse transcriptase may comprise an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 89-100, 105-122, 128-129, 132, 139, 143, 149, 154, 159, 235, 454, 471, 516, 662, 700-716, 739-742, and 766. These sequences may be naturally occurring reverse transcriptase sequences, e.g., from a retrovirus or a retrotransposon, of the sequences may be recombinant.

[0035] In various other embodiments, the prime editors of the dual prime editors herein disclosed may comprise various structural configurations. For example, in embodiments in which the prime editors are provided as a fusion protein, each of the dual prime editor fusion proteins may comprise the structure NH₂-[napDNAbp]-[reverse transcriptase]-COOH; or NH₂-[reverse transcriptase]-[napDNAbp]-COOH, wherein each instance of “[”-[]” indicates the presence of an optional linker sequence.

[0036] In various embodiments, the linker sequence comprises an amino acid sequence of SEQ ID NOs: 127, 165-176, 446, 453, and 767-769, or an amino acid sequence that is at least 80%, 85%, or 90%, or 95%, or 99% identical to any one of the linker amino acid sequence of SEQ ID NOs: 127, 165-176, 446, 453, and 767-769.

[0037] In various embodiments, the desired nucleotide change that is incorporated into the target DNA can be a single nucleotide change (e.g., a transition or transversion), an insertion of one or more nucleotides, or a deletion of one or more nucleotides.

[0038] In certain cases, the insertion is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, or at least 500 nucleotides in length.

[0039] In certain other cases, the deletion is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, or at least 500 nucleotides in length.

[0040] In another aspect, the present disclosure provides an extended guide RNA comprising a guide RNA and at least one RNA extension. The RNA extension can be positioned at the 3′ end of the guide RNA. In other embodiments, the RNA extension can be positioned at the 5′ of the guide RNA. In still other embodiments, the RNA extension can be positioned at an intramolecular position within

the guide RNA, however, preferable, the intramolecular positioning of the extended portion does not disrupt the functioning of the protospacer.

[0041] In various embodiments, the extended guide RNA is capable of binding to a napDNAbp and directing the napDNAbp to a target DNA sequence. The target DNA sequence can comprise a target strand and a complementary non-target strand, wherein the guide RNA hybridizes to the target strand to form an RNA-DNA hybrid and an R-loop.

[0042] In various embodiments of the extended guide RNA, the at least one RNA extension can comprise a reverse transcription template sequence. In various other embodiment, the RNA extension may further comprises a reverse transcription primer binding site. In still further embodiments, the RNA extension may comprise a linker or spacer sequence that joins the RNA extension to the guide RNA.

[0043] In various embodiments, the RNA extension can be at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides, at least 150 nucleotides, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, or at least 500 nucleotides in length.

[0044] In other embodiments, the reverse transcription template sequence is at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, or at least 500 nucleotides in length.

[0045] In still other embodiments, wherein the reverse transcription primer binding site sequence is at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90

nucleotides, at least 100 nucleotides, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, or at least 500 nucleotides in length.

[0046] In other embodiments, the optional linker or spacer sequence is at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, or at least 500 nucleotides in length.

[0047] In various embodiments of the extended guide RNAs, the reverse transcription template sequence may encode a single-strand DNA flap that is complementary to an endogenous DNA sequence adjacent to a nick site, wherein the single-strand DNA flap comprises a desired nucleotide change. The single-stranded DNA flap may displace an endogenous single-strand DNA at the nick site. The displaced endogenous single-strand DNA at the nick site can have a 5' end and form an endogenous flap, which can be excised by the cell. In various embodiments, excision of the 5' end endogenous flap can help drive product formation since removing the 5' end endogenous flap encourages hybridization of the single-strand 3' DNA flap to the corresponding complementary DNA strand, and the incorporation or assimilation of the desired nucleotide change carried by the single-strand 3' DNA flap into the target DNA.

[0048] In various embodiments of the extended guide RNAs, the cellular repair of the single-strand DNA flap results in installation of the desired nucleotide change, thereby forming a desired product.

[0049] [0043][0042] In certain embodiments, the PEgRNA comprises the nucleotide sequence of SEQ ID NOs: 101-104, 181-183, 223-234, 237-244, 277, 324-330, 332, 334, 336, 338, 340, 342, 344, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 394, 429-442, 499-505, 641-649, 678-692, 735-736, 757-761, 776-777, 2997-3103, 3113-3121, 3305-3455, 3479-3493, 3522-3540, 3549-3556, 3628-3698, 3755-3810, 3874, 3890-3901, 3905-3911, 3913-3929, and 3972-3989 or a nucleotide sequence having at least 85%, or at least 90%, or at least 95%, or at least 98%, or at least 99% sequence identity with any one of SEQ ID NOs: 101-104, 181-183, 223-234, 237-244, 277, 324-330, 332, 334, 336, 338, 340, 342, 344, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 394, 429-442, 499-505, 641-649, 678-692, 735-736, 757-761, 776-777, 2997-3103, 3113-3121, 3305-3455, 3479-3493, 3522-3540, 3549-3556, 3628-3698, 3755-3810, 3874, 3890-3901, 3905-3911, 3913-3929, and 3972-3989.

[0050] In yet another aspect of the invention, the specification provides for complexes comprising a prime editor described herein and any extended guide RNA described above.

[0051] In still other aspects of the invention, the specification provides a complex comprising a napDNAbp and an extended guide RNA. The napDNAbp can be a Cas9 nickase, or can be an amino acid sequence of SEQ ID NOs: 42-57 (Cas9 nickase) and 65 (AsCas12a nickase), or an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 42-57 (Cas9 nickase) and 65 (AsCas12a nickase).

[0052] In various embodiments involving a complex, the extended guide RNA is capable of directing the napDNAbp to a target DNA sequence. In various embodiments, a reverse transcriptase may be provided *in trans*, i.e., provided from a different source than the complex itself. For example, a reverse transcriptase could be provided to the same cell having the complex by introducing a separate vector separately encoding the reverse transcriptase.

[0053] In another aspect, the disclosure provides a system comprising a first and a second prime editor complex, each complex comprising a prime editor and a prime editing guide RNA (PEgRNA). In some embodiments, each prime editor comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a polypeptide having an RNA-dependent DNA polymerase activity, and each PEgRNA comprises a spacer sequence, a gRNA core, a DNA synthesis template, and a primer binding site. In certain embodiments, each DNA synthesis template encodes a single-stranded DNA sequence comprising an edited portion. Two single-stranded DNA sequences encoded may be complementary to one another and form a duplex that integrates into the target site to be edited. In some embodiments, the two single-stranded DNA sequences encoded may comprise a region of complementarity to one another. In certain embodiments, the two single-stranded DNA sequences encoded may comprise a region of complementarity to one another that is at least 2 bp, at least 3 bp, at least 4 bp, at least 5 bp, at least 10 bp, at least 20 bp, at least 30 bp, at least 40 bp, at least 50 bp, at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 600 bp, at least 700 bp, at least 800 bp, at least 900 bp, or at least 1000 bp long. In some embodiments, the prime editor is provided as a fusion protein. In certain embodiments, the components of the prime editor (*i.e.*, the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity) are provided *in trans*.

[0054] In another aspect, the disclosure provides a system comprising a first, a second, a third, and a fourth prime editor complex, each complex comprising a prime editor and a prime editing guide RNA (PEgRNA). In some embodiments, each prime editor comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a polypeptide having an RNA-dependent DNA polymerase activity, and each PEgRNA comprises a spacer sequence, a gRNA core, a DNA synthesis template, and a primer binding site. In certain embodiments, each DNA synthesis template encodes a single-stranded DNA sequence comprising an edited portion. Two single-stranded DNA sequences encoded may be complementary to one another and form a duplex that integrates into the target site to be edited. In some embodiments, the two single-stranded DNA sequences encoded may comprise a region of

complementarity to one another. In certain embodiments, the two single-stranded DNA sequences encoded may comprise a region of complementarity to one another that is at least 2 bp, at least 3 bp, at least 4 bp, at least 5 bp, at least 10 bp, at least 20 bp, at least 30 bp, at least 40 bp, at least 50 bp, at least 100 bp, at least 200 bp, at least 300 bp, at least 400 bp, at least 500 bp, at least 600 bp, at least 700 bp, at least 800 bp, at least 900 bp, or at least 1000 bp long. In some embodiments, the prime editor is provided as a fusion protein. In certain embodiments, the components of the prime editor (*i.e.*, the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity) are provided *in trans*.

[0055] In some embodiments, each napDNAbp is a Cas9 domain or variant thereof. In some embodiments, each napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, or a Cas9 nickase domain or a variant thereof. In certain embodiments, each napDNAbp is independently selected from the group consisting of: Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, and Argonaute and optionally has a nickase activity. In various embodiments, each napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 2-65, or an amino acid sequence at least 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 2-65.

[0056] In some embodiments, the polypeptide comprising an RNA-dependent DNA polymerase activity is a reverse transcriptase. In certain embodiments, the polypeptide comprising an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 37, 68-79, 82-98, 81, 98, and 110 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 37, 68-79, 82-98, 81, 98, and 110.

[0057] In some embodiments, each prime editor may comprise a linker that joins the napDNAbp and the reverse transcriptase. In certain embodiments, the linker comprises an amino acid sequence of any one of SEQ ID NOs: 119-128, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 119-128. Each linker may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.

[0058] In some embodiments, each PEgRNA may independently comprise a nucleotide sequence of any one of SEQ ID NOs: 192-203, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 192-203.

[0059] In various embodiments, each spacer sequence of each PEgRNA may bind to a specific binding site of the double-stranded DNA sequence adjacent the target site to be edited. In some embodiments, the binding of a spacer sequence of one prime editor complex to one strand of the double-stranded DNA sequence and the binding of a spacer sequence of another prime editor complex to the opposite strand of the double-stranded DNA sequence results in the nicking of both DNA strands at a nick site proximal to the PAM sequences on each strand.

[0060] In another aspect, the present disclosure provides polynucleotides. In some embodiments, the polynucleotides may encode any of the complexes described herein. In certain embodiments, the polynucleotides may encode any of the PEGRNAs described herein.

[0061] In yet another aspect, the specification provides polynucleotides. In certain embodiments, the polynucleotides may encode any of the prime editors disclosed herein. In certain other embodiments, the polynucleotides may encode any of the napDNABps disclosed herein. In still further embodiments, the polynucleotides may encode any of the reverse transcriptases disclosed herein. In yet other embodiments, the polynucleotides may encode any of the extended guide RNAs disclosed herein, any of the reverse transcription template sequences, or any of the reverse transcription primer sites, or any of the optional linker sequences.

[0062] In still other aspects, the specification provides vectors comprising the polynucleotides described herein. Thus, in certain embodiments, the vectors comprise polynucleotides for encoding the prime editors comprising a napDNABp and a reverse transcriptase (*i.e.*, as fusion protein, or expressed *in trans*). In certain embodiments, the vectors comprise polynucleotides for encoding any of the complexes described herein. In other embodiments, the vectors comprise polynucleotides that separately encode a napDNABp and reverse transcriptase. In still other embodiments, the vectors may comprise polynucleotides that encode the extended guide RNAs. In various embodiments, the vectors may comprise one or more polynucleotides that encode napDNABps, reverse transcriptase, and extended guide RNAs on the same or separate vectors. In some embodiments, the vectors comprise polynucleotides for encoding any of the pegRNAs described herein.

[0063] In still other aspects, the specification provides cells comprising a prime editor as described herein and an extended guide RNA. The cells may be transformed with the vectors comprising the prime editors, napDNABps, reverse transcriptase, and extended guide RNAs. These genetic elements may be comprised on the same vector or on different vectors. In some embodiments, the cells comprise any of the systems or complexes described herein. The cells may be transformed with polynucleotides encoding the any of the systems, complexes, and/or pegRNAs disclosed herein, or vectors comprising polynucleotides encoding the any of the systems, complexes, or pegRNAs disclosed herein.

[0064] In yet another aspect, the specification provides pharmaceutical compositions. In certain embodiments, the pharmaceutical compositions comprise one or more of a napDNABp, a prime editor, a reverse transcriptase, and an extended guide RNA. In certain embodiments, the pharmaceutical compositions comprise any of the systems and/or complexes described herein. In certain embodiments, the pharmaceutical compositions comprise any of the prime editors, systems, or complexes described herein and a pharmaceutically acceptable excipient. In other embodiments, the pharmaceutical compositions comprise any extend guide RNA described herein and a pharmaceutically acceptable excipient. In still other embodiments, the pharmaceutical compositions

comprise any extend guide RNA described herein in combination with any prime editor described herein and a pharmaceutically acceptable excipient. In yet other embodiments, the pharmaceutical compositions comprise any polynucleotide sequence encoding one or more of a napDNAbp, a prime editor, a reverse transcriptase, and an extended guide RNA, or any of the vectors disclosed herein. In still other embodiments, the various components disclosed herein may be separated into one or more pharmaceutical compositions. For example, a first pharmaceutical composition may comprise a prime editor or a napDNAbp, a second pharmaceutical compositions may comprise a reverse transcriptase, and a third pharmaceutical composition may comprise an extended guide RNA.

[0065] In still a further aspect, the present disclosure provides kits. In one embodiment, the kit comprises one or more polynucleotides encoding one or more components, including a prime editor, a napDNAbp, a reverse transcriptase, and an extended guide RNA. The kits may also comprise vectors, cells, and isolated preparations of polypeptides, including any prime editor, napDNAbp, or reverse transcriptase disclosed herein.

[0066] In yet another aspect, the present disclosure provides for methods of using the disclosed compositions of matter, including methods of using any of the systems described herein for simultaneously editing both complementary strands of a double-stranded DNA sequence at a target site. In some embodiments, the method comprises contacting the double-stranded DNA sequence with any of the system disclosed herein.

[0067] In one aspect, the disclosure provides methods comprising contacting a double-stranded DNA sequence at a target site with a first and a second prime editor complex, each complex comprising a prime editor and a prime editing guide RNA (PEgRNA). In some embodiments, each prime editor comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a polypeptide having an RNA-dependent DNA polymerase activity, and each PEgRNA comprises a spacer sequence, a gRNA core, a DNA synthesis template, and a primer binding site. In some embodiments, each prime editor is provided as a fusion protein. In some embodiments, the components of the prime editor are provided *in trans*. In certain embodiments, each DNA synthesis template encodes a single-stranded DNA sequence comprising an edited portion. Two single-stranded DNA sequences encoded may be complementary to one another and form a duplex that integrates into the target site to be edited. The various elements of the prime editor complexes may comprise any of the embodiments of the systems disclosed herein.

[0068] In another aspect, the disclosure provides methods comprising contacting a double-stranded DNA sequence at a target site with a first, a second, a third, and a fourth prime editor complex, each complex comprising a prime editor and a prime editing guide RNA (PEgRNA). In some embodiments, each prime editor comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a polypeptide having an RNA-dependent DNA polymerase activity, and each PEgRNA comprises a spacer sequence, a gRNA core, a DNA synthesis template, and a primer

binding site. In some embodiments, each prime editor is provided as a fusion protein. In some embodiments, the components of the prime editor are provided *in trans*. In certain embodiments, each DNA synthesis template encodes a single-stranded DNA sequence. Two single-stranded DNA sequences encoded may be complementary to one another and form a duplex that integrates into the target site to be edited. The various elements of the prime editor complexes may comprise any of the embodiments of the systems disclosed herein.

[0069] In some embodiments, the methods provided herein allow for inversion of a target DNA sequence. In some embodiments, the first single-stranded DNA sequence encoded by the first DNA synthesis template and the second single-stranded DNA sequence encoded by the second DNA synthesis template are on opposite ends of a target DNA sequence, and the third single-stranded DNA sequence encoded by the third DNA synthesis template and the fourth single-stranded DNA sequence encoded by the fourth DNA synthesis template are on opposite ends of the same target DNA sequence.

[0070] In some embodiments, the methods provided herein further comprise providing a circular DNA donor. In certain embodiments, the first single-stranded DNA sequence encoded by the first DNA synthesis template and the third single-stranded DNA sequence encoded by the third DNA synthesis template are on opposite ends of the target DNA sequence, and the second single-stranded DNA sequence encoded by the second DNA synthesis template and the fourth single-stranded DNA sequence encoded by the fourth DNA synthesis template are on the circular DNA donor. In some embodiments, the portion of the circular DNA donor between the second single-stranded DNA sequence and the fourth single-stranded DNA sequence replaces the target DNA sequence between the first single-stranded DNA sequence and the third single-stranded DNA sequence.

[0071] In some embodiments, the methods provided herein allow for translocation of a target DNA sequence from a first nucleic acid molecule (*e.g.*, a first chromosome) to a second nucleic acid molecule (*e.g.*, a second chromosome). In some embodiments, the first single-stranded DNA sequence encoded by the first DNA synthesis template and the third single-stranded DNA sequence encoded by the third single-stranded DNA synthesis template are on a first nucleic acid molecule, and the second single-stranded DNA sequence encoded by the second DNA synthesis template and the fourth single-stranded DNA sequence encoded by the fourth DNA synthesis template are on a second nucleic acid molecule. In certain embodiments, a portion of the first nucleic acid molecule between the first single-stranded DNA sequence and the third single-stranded DNA sequence is incorporated into the second nucleic acid molecule. In certain embodiments, a portion of the second nucleic acid molecule between the second single-stranded DNA sequence and the fourth single-stranded DNA sequence is incorporated into the first nucleic acid molecule.

[0072] In another aspect, the present disclosure provides a pair of PEGRNAs for use in multi-flap prime editing. In some embodiments, the pair comprises a first PEGRNA and a second PEGRNA, and

each PEGRNA independently comprises a spacer sequence, a gRNA core, a DNA synthesis template, and a primer binding site. In certain embodiments, each DNA synthesis template encodes a single-stranded DNA sequence. In various embodiments, the multi-flap prime editors are used in connection with a pair of PEGRNAs which target separate prime editors to either side of a target site, wherein the pair of PEGRNA each encode 3' nucleic acid flaps which comprise nucleic acid sequences which are reverse complements of each other. In various embodiments, the 3' flaps comprising the reverse complement sequences may anneal to one another to form a duplex comprising the desired edit or nucleic acid sequence encoding by the PEGRNAs. The duplex then becomes integrated into the target site by replacement of the corresponding endogenous duplex positioned between adjacent nick sites.

[0073] In another aspect, the present disclosure provides a plurality of PEGRNAs for use in multi-flap prime editing. In some embodiments, the plurality comprises a first, a second, a third, and a fourth PEGRNA. In some embodiments, each of the four PEGRNA independently comprises a spacer sequence, a gRNA core, a DNA synthesis template, and a primer binding site. In certain embodiments, each DNA synthesis template encodes a single-stranded DNA sequence. Two single-stranded DNA sequences encoded may be complementary to one another.

[0074] In various aspects, the present disclosure provides polynucleotides encoding any of the pairs or pluralities of PEGRNAs described herein. In certain aspects, the present disclosure provides vectors encoding a polynucleotide encoding any of the pairs or pluralities of PEGRNAs described herein. In yet another aspect, the present disclosure provides cells comprising a vector encoding a polynucleotide encoding any of the pairs or pluralities of PEGRNAs described herein. In other aspects, the disclosure provides pharmaceutical compositions comprising any of the pairs or pluralities of PEGRNAs described herein, a vector encoding any of the pairs or pluralities of PEGRNAs described herein, or a cell comprising a vector encoding any of the pairs or pluralities of PEGRNAs described herein. In certain embodiments, the pharmaceutical compositions comprise a pharmaceutical excipient.

[0075] In one embodiment, the methods relate to a method for installing a desired nucleotide change in a double-stranded DNA sequence. The method first comprises contacting the double-stranded DNA sequence with a complex comprising a prime editor and an extended guide RNA, wherein the prime editor comprises a napDNAbp and a reverse transcriptase and wherein the extended guide RNA comprises a reverse transcription template sequence comprising the desired nucleotide change. In some embodiments, each prime editor is provided as a fusion protein. In some embodiments, the components of the prime editor are provided *in trans*. Next, the method involves nicking the double-stranded DNA sequence on the non-target strand, thereby generating a free single-strand DNA having a 3' end. The method then involves hybridizing the 3' end of the free single-strand DNA to the reverse transcription template sequence, thereby priming the reverse transcriptase domain. The method then involves polymerizing a strand of DNA from the 3' end, thereby generating a single-

strand DNA flap comprising the desired nucleotide change. Then, the method involves replacing an endogenous DNA strand adjacent the cut site with the single-strand DNA flap, thereby installing the desired nucleotide change in the double-stranded DNA sequence.

[0076] In other embodiments, the disclosure provides for a method for introducing one or more changes in the nucleotide sequence of a DNA molecule at a target locus, comprising contacting the DNA molecule with a nucleic acid programmable DNA binding protein (napDNAbp) and a guide RNA which targets the napDNAbp to the target locus, wherein the guide RNA comprises a reverse transcriptase (RT) template sequence comprising at least one desired nucleotide change. Next, the method involves forming an exposed 3' end in a DNA strand at the target locus and then hybridizing the exposed 3' end to the RT template sequence to prime reverse transcription. Next, a single strand DNA flap comprising the at least one desired nucleotide change based on the RT template sequence is synthesized or polymerized by reverse transcriptase. Lastly, the at least one desired nucleotide change is incorporated into the corresponding endogenous DNA, thereby introducing one or more changes in the nucleotide sequence of the DNA molecule at the target locus.

[0077] In still other embodiments, the disclosure provides a method for introducing one or more changes in the nucleotide sequence of a DNA molecule at a target locus by target-primed reverse transcription, the method comprising: (a) contacting the DNA molecule at the target locus with a (i) prime editor comprising a nucleic acid programmable DNA binding protein (napDNAbp) and a reverse transcriptase and (ii) a guide RNA comprising an RT template comprising a desired nucleotide change; (b) conducting target-primed reverse transcription of the RT template to generate a single strand DNA comprising the desired nucleotide change; and (c) incorporating the desired nucleotide change into the DNA molecule at the target locus through a DNA repair and/or replication process.

[0078] In certain embodiments, the step of replacing the endogenous DNA strand comprises: (i) hybridizing the single-strand DNA flap to the endogenous DNA strand adjacent the cut site to create a sequence mismatch; (ii) excising the endogenous DNA strand; and (iii) repairing the mismatch to form the desired product comprising the desired nucleotide change in both strands of DNA.

[0079] In various embodiments, the desired nucleotide change can be a single nucleotide substitution (e.g., and transition or a transversion change), a deletion, or an insertion. For example, the desired nucleotide change can be (1) a G to T substitution, (2) a G to A substitution, (3) a G to C substitution, (4) a T to G substitution, (5) a T to A substitution, (6) a T to C substitution, (7) a C to G substitution, (8) a C to T substitution, (9) a C to A substitution, (10) an A to T substitution, (11) an A to G substitution, or (12) an A to C substitution.

[0080] In other embodiments, the desired nucleoid change can convert (1) a G:C basepair to a T:A basepair, (2) a G:C basepair to an A:T basepair, (3) a G:C basepair to C:G basepair, (4) a T:A basepair to a G:C basepair, (5) a T:A basepair to an A:T basepair, (6) a T:A basepair to a C:G

basepair, (7) a C:G basepair to a G:C basepair, (8) a C:G basepair to a T:A basepair, (9) a C:G basepair to an A:T basepair, (10) an A:T basepair to a T:A basepair, (11) an A:T basepair to a G:C basepair, or (12) an A:T basepair to a C:G basepair.

[0081] In still other embodiments, the method introduces a desired nucleotide change that is an insertion. In certain cases, the insertion is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, or at least 500 nucleotides in length.

[0082] In other embodiments, the method introduces a desired nucleotide change that is a deletion. In certain other cases, the deletion is at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, or at least 500 nucleotides in length.

[0083] In various embodiments, the desired nucleotide change corrects a disease-associated gene. The disease-associated gene can be associated with a monogenetic disorder selected from the group consisting of: Adenosine Deaminase (ADA) Deficiency; Alpha-1 Antitrypsin Deficiency; Cystic Fibrosis; Duchenne Muscular Dystrophy; Galactosemia; Hemochromatosis; Huntington's Disease; Maple Syrup Urine Disease; Marfan Syndrome; Neurofibromatosis Type 1; Pachyonychia Congenita; Phenylketonuria; Severe Combined Immunodeficiency; Sickle Cell Disease; Smith-Lemli-Opitz Syndrome; and Tay-Sachs Disease. In other embodiments, the disease-associated gene can be associated with a polygenic disorder selected from the group consisting of: heart disease; high blood pressure; Alzheimer's disease; arthritis; diabetes; cancer; and obesity.

[0084] The methods disclosed herein may involve fusion proteins having a napDNAbp that is a nuclease dead Cas9 (dCas9), a Cas9 nickase (nCas9), or a nuclease active Cas9. In other embodiments, a napDNAbp and reverse transcriptase are not encoded as a single fusion protein, but rather can be provided in separate constructs. Thus, in some embodiments, the reverse transcriptase can be provided *in trans* relative to the napDNAbp (rather than by way of a fusion protein).

[0085] In various embodiments involving methods, the napDNAbp may comprise an amino acid sequence of SEQ ID NOs: 26-61, 75-76, 126, 130, 137, 141, 147, 153, 157, 445, 460, 467, and 482-487 (Cas9); (SpCas9); SEQ ID NO: 77-86 (CP-Cas9); SEQ ID NO: 18-25 and 87-88 (SpCas9); and SEQ ID NOs: 62-72(Cas12). The napDNAbp may also comprise an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 26-61, 75-76, 126, 130, 137, 141, 147, 153, 157, 445, 460, 467, and 482-487 (Cas9); (SpCas9);

SEQ ID NO: 77-86 (CP-Cas9); SEQ ID NO: 18 -25 and 87-88 (SpCas9); and SEQ ID NOs: 62-72(Cas12).

[0086] In various embodiments involving methods, the reverse transcriptase may comprise any one of the amino acid sequences of SEQ ID NOs: 89-100, 105-122, 128-129, 132, 139, 143, 149, 154, 159, 235, 454, 471, 516, 662, 700-716, 739-742, and 766. The reverse transcriptase may also comprise an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 89-100, 105-122, 128-129, 132, 139, 143, 149, 154, 159, 235, 454, 471, 516, 662, 700-716, 739-742, and 766.

[0087] The methods may involve the use of a PEgRNA comprising a nucleotide sequence of SEQ ID NOs: 101-104, 181-183, 223-234, 237-244, 277, 324-330, 332, 334, 336, 338, 340, 342, 344, 346, 348, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 394, 429-442, 499-505, 641-649, 678-692, 735-736, 757-761, 776-777, 2997-3103, 3113-3121, 3305-3455, 3479-3493, 3522-3540, 3549-3556, 3628-3698, 3755-3810, 3874, 3890-3901, 3905-3911, 3913-3929, and 3972-3989, or a nucleotide sequence having at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99% sequence identity thereto. The methods may comprise the use of extended guide RNAs that comprise an RNA extension at the 3' end, wherein the RNA extension comprises the reverse transcription template sequence.

[0088] The methods may comprise the use of extended guide RNAs that comprise an RNA extension at the 5' end, wherein the RNA extension comprises the reverse transcription template sequence.

[0089] The methods may comprise the use of extended guide RNAs that comprise an RNA extension at an intramolecular location in the guide RNA, wherein the RNA extension comprises the reverse transcription template sequence.

[0090] The methods may comprise the use of extended guide RNAs having one or more RNA extensions that are at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 200, at least 300, at least 400, or at least 500 nucleotides in length.

[0091] It should be appreciated that the foregoing concepts, and additional concepts discussed below, may be arranged in any suitable combination, as the present disclosure is not limited in this respect. Further, other advantages and novel features of the present disclosure will become apparent from the following detailed description of various non-limiting embodiments when considered in conjunction with the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

[0092] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which can be better understood by reference to

one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0093] FIG. 1A provides a schematic of an exemplary process for introducing a single nucleotide change, and/or insertion, and/or deletion into a DNA molecule (e.g., a genome) using a fusion protein comprising a reverse transcriptase fused to a Cas9 protein in complex with an extended guide RNA molecule. In this embodiment, the guide RNA is extended at the 3' end to include a reverse transcriptase template sequence. The schematic shows how a reverse transcriptase (RT) fused to a Cas9 nickase, in a complex with a guide RNA (gRNA), binds the DNA target site and nicks the PAM-containing DNA strand adjacent to the target nucleotide. The RT enzyme uses the nicked DNA as a primer for DNA synthesis from the gRNA, which is used as a template for the synthesis of a new DNA strand that encodes the desired edit. The editing process shown may be referred to as target-primed reverse transcription editing (TRT editing) or equivalently, "prime editing."

[0094] FIG. 1B provides the same representation as in FIG. 1A, except that the prime editor complex is represented more generally as [napDNAbp]-[P]:PEgRNA or [P]-[napDNAbp]:PEgRNA, wherein "P" refers to any polymerase (e.g., a reverse transcriptase), "napDNAbp" refers to a nucleic acid programmable DNA binding protein (e.g., SpCas9), and "PEgRNA" refers to a prime editing guide RNA, and "[P]-" refers to an optional linker. As described elsewhere, e.g., FIGs. 3A-3G, the PEgRNA comprises an 5' extension arm comprising a primer binding site and a DNA synthesis template. Although not shown, it is contemplated that the extension arm of the PEgRNA (i.e., which comprises a primer binding site and a DNA synthesis template) can be DNA or RNA. The particular polymerase contemplated in this configuration will depend upon the nature of the DNA synthesis template. For instance, if the DNA synthesis template is RNA, then the polymerase can be an RNA-dependent DNA polymerase (e.g., reverse transcriptase). If the DNA synthesis template is DNA, then the polymerase can be a DNA-dependent DNA polymerase.

[0095] FIG. 1C provides a schematic of an exemplary process for introducing a single nucleotide change, and/or insertion, and/or deletion into a DNA molecule (e.g., a genome) using a fusion protein comprising a reverse transcriptase fused to a Cas9 protein in complex with an extended guide RNA molecule. In this embodiment, the guide RNA is extended at the 5' end to include a reverse transcriptase template sequence. The schematic shows how a reverse transcriptase (RT) fused to a Cas9 nickase, in a complex with a guide RNA (gRNA), binds the DNA target site and nicks the PAM-containing DNA strand adjacent to the target nucleotide. The RT enzyme uses the nicked DNA as a primer for DNA synthesis from the gRNA, which is used as a template for the synthesis of a new DNA strand that encodes the desired edit. The editing process shown may be referred to as target-primed reverse transcription editing (TRT editing) or equivalently, "prime editing."

[0096] FIG. 1D provides the same representation as in FIG. 1C, except that the prime editor complex is represented more generally as [napDNAbp]-[P]:PEgRNA or [P]-[napDNAbp]:PEgRNA, wherein

“P” refers to any polymerase (e.g., a reverse transcriptase), “napDNAbp” refers to a nucleic acid programmable DNA binding protein (e.g., SpCas9), and “PEgRNA” refers to a prime editing guide RNA, and “[” refers to an optional linker. As described elsewhere, e.g., FIGs. 3A-3G, the PEgRNA comprises an 3’ extension arm comprising a primer binding site and a DNA synthesis template. Although not shown, it is contemplated that the extension arm of the PEgRNA (i.e., which comprises a primer binding site and a DNA synthesis template) can be DNA or RNA. The particular polymerase contemplated in this configuration will depend upon the nature of the DNA synthesis template. For instance, if the DNA synthesis template is RNA, then the polymerase can be an RNA-dependent DNA polymerase (e.g., reverse transcriptase). If the DNA synthesis template is DNA, then the polymerase can be a DNA-dependent DNA polymerase. In various embodiments, the PEgRNA can be engineered or synthesized to incorporate a DNA-based DNA synthesis template.

[0097] FIG. 1E is a schematic depicting an exemplary process of how the synthesized single strand of DNA (which comprises the desired nucleotide change) becomes resolved such that the desired nucleotide change is incorporated into the DNA. As shown, following synthesis of the edited strand (or “mutagenic strand”), equilibration with the endogenous strand, flap cleavage of the endogenous strand, and ligation leads to incorporation of the DNA edit after resolution of the mismatched DNA duplex through the action of endogenous DNA repair and/or replication processes.

[0098] FIG. 1F is a schematic showing that “opposite strand nicking” can be incorporated into the resolution method of **FIG. 1E** to help drive the formation of the desired product versus the reversion product. In opposite strand nicking, a second Cas9/gRNA complex is used to introduce a second nick on the opposite strand from the initial nicked strand. This induces the endogenous cellular DNA repair and/or replication processes to preferentially replace the unedited strand (i.e., the strand containing the second nick site).

[0099] FIG. 1G provides another schematic of an exemplary process for introducing a single nucleotide change, and/or insertion, and/or deletion into a DNA molecule (e.g., a genome) of a target locus using a nucleic acid programmable DNA binding protein (napDNAbp) complexed with an extended guide RNA. This process may be referred to as an embodiment of prime editing. The extended guide RNA comprises an extension at the 3’ or 5’ end of the guide RNA, or at an intramolecular location in the guide RNA. In step (a), the napDNAbp/gRNA complex contacts the DNA molecule and the gRNA guides the napDNAbp to bind to the target locus. In step (b), a nick in one of the strands of DNA (the R-loop strand, or the PAM-containing strand, or the non-target DNA strand, or the protospacer strand) of the target locus is introduced (e.g., by a nuclease or chemical agent), thereby creating an available 3’ end in one of the strands of the target locus. In certain embodiments, the nick is created in the strand of DNA that corresponds to the R-loop strand, i.e., the strand that is not hybridized to the guide RNA sequence. In step (c), the 3’ end DNA strand interacts with the extended portion of the guide RNA in order to prime reverse transcription. In certain

embodiments, the 3' ended DNA strand hybridizes to a specific RT priming sequence on the extended portion of the guide RNA. In step (d), a reverse transcriptase is introduced which synthesizes a single strand of DNA from the 3' end of the primed site towards the 3' end of the guide RNA. This forms a single-strand DNA flap comprising the desired nucleotide change (e.g., the single base change, insertion, or deletion, or a combination thereof). In step (e), the napDNAbp and guide RNA are released. Steps (f) and (g) relate to the resolution of the single strand DNA flap such that the desired nucleotide change becomes incorporated into the target locus. This process can be driven towards the desired product formation by removing the corresponding 5' endogenous DNA flap that forms once the 3' single strand DNA flap invades and hybridizes to the complementary sequence on the other strand. The process can also be driven towards product formation with second strand nicking, as exemplified in **FIG. 1F**. This process may introduce at least one or more of the following genetic changes: transversions, transitions, deletions, and insertions.

[0100] FIG. 1H is a schematic depicting the types of genetic changes that are possible with the prime editing processes described herein. The types of nucleotide changes achievable by prime editing include deletions (including short and long deletions), single-nucleotide changes (including transitions and transversions), inversions, and insertions (including short and long deletions).

[0101] FIG. 1I is a schematic depicting temporal second strand nicking exemplified by PE3b (PE3b = PE2 prime editor fusion protein + PEgRNA + second strand nicking guide RNA). Temporal second strand nicking is a variant of second strand nicking in order to facilitate the formation of the desired edited product. The "temporal" term refers to the fact that the second-strand nick to the unedited strand occurs only after the desired edit is installed in the edited strand. This avoids concurrent nicks on both strands to lead to double-stranded DNA breaks.

[0102] FIGs. 1J-1K depict a variation of prime editing contemplated herein that replaces the napDNAbp (e.g., SpCas9 nickase) with any programmable nuclease domain, such as zinc finger nucleases (ZFN) or transcription activator-like effector nucleases (TALEN). As such, it is contemplated that suitable nucleases do not necessarily need to be "programmed" by a nucleic acid targeting molecule (such as a guide RNA), but rather, may be programmed by defining the specificity of a DNA-binding domain, such as and in particular, a nuclease. Just as in prime editing with napDNAbp moieties, it is preferable that such alternative programmable nucleases be modified such that only one strand of a target DNA is cut. In other words, the programmable nucleases should function as nickases, preferably. Once a programmable nuclease is selected (e.g., a ZFN or a TALEN), then additional functionalities may be engineered into the system to allow it to operate in accordance with a prime editing-like mechanism. For example, the programmable nucleases may be modified by coupling (e.g., via a chemical linker) an RNA or DNA extension arm thereto, wherein the extension arm comprises a primer binding site (PBS) and a DNA synthesis template. The programmable nuclease may also be coupled (e.g., via a chemical or amino acid linker) to a

polymerase, the nature of which will depend upon whether the extension arm is DNA or RNA. In the case of an RNA extension arm, the polymerase can be an RNA-dependent DNA polymerase (e.g., reverse transcriptase). In the case of a DNA extension arm, the polymerase can be a DNA-dependent DNA polymerase (e.g., a prokaryotic polymerase, including Pol I, Pol II, or Pol III, or a eukaryotic polymerase, including Pol α , Pol β , Pol γ , Pol δ , Pol ϵ , or Pol ζ). The system may also include other functionalities added as fusions to the programmable nucleases, or added *in trans* to facilitate the reaction as a whole (e.g., (a) a helicase to unwind the DNA at the cut site to make the cut strand with the 3' end available as a primer, (b) a flap endonuclease (e.g., FEN1) to help remove the endogenous strand on the cut strand to drive the reaction towards replacement of the endogenous strand with the synthesized strand, or (c) a nCas9:gRNA complex to create a second site nick on the opposite strand, which may help drive the integration of the synthesized repair through favored cellular repair of the non-edited strand). In an analogous manner to prime editing with a napeDNABp, such a complex with an otherwise programmable nuclease could be used to synthesize and then install a newly synthesized replacement strand of DNA carrying an edit of interest permanently into a target site of DNA.

[0103] FIG. 1L depicts, in one embodiment, the anatomical features of a target DNA that may be edited by prime editing. The target DNA comprises a “non-target strand” and a “target strand.” The target-strand is the strand that becomes annealed to the spacer of a PEgRNA of a prime editor complex that recognizes the PAM site (in this case, NGG, which is recognized by the canonical SpCas9-based prime editors). The target strand may also be referred to as the “non-PAM strand” or the “non-edit strand.” By contrast, the non-target strand (i.e., the strand containing the protospacer and the PAM sequence of NGG) may be referred to as the “PAM-strand” or the “edit strand.” In various embodiments, the nick site of the PE complex will be in the protospacer on the PAM-strand (e.g., with the SpCas9-based PE). The location of the nick will be characteristic of the particular Cas9 that forms the PE. For example, with an SpCas9-based PE, the nick site in the phosphodiester bond between bases three (“-3” position relative to the position 1 of the PAM sequence) and four (“-4” position relative to position 1 of the PAM sequence). The nick site in the protospacer forms a free 3' hydroxyl group, which as seen in the following figures, complexes with the primer binding site of the extension arm of the PEgRNA and provides the substrate to begin polymerization of a single strand of DNA code for by the DNA synthesis template of the extension arm of the PEgRNA. This polymerization reaction is catalyzed by the polymerase (e.g., reverse transcriptase) of the PE fusion protein in the 5' to 3' direction. Polymerization terminates before reaching the gRNA core (e.g., by inclusion of a polymerization termination signal, or secondary structure, which functions to terminate the polymerization activity of PE), producing a single strand DNA flap that is extended from the original 3' hydroxyl group of the nicked PAM strand. The DNA synthesis template codes for a single strand DNA that is homologous to the endogenous 5'-ended single strand of DNA that immediately follows the nick site on the PAM strand and incorporates the desired nucleotide change (e.g., single

base substitution, insertion, deletion, inversion). The position of the desired edit can be in any position following downstream of the nick site on the PAM strand, which can include position +1, +2, +3, +4 (the start of the PAM site), +5 (position 2 of the PAM site), +6 (position 3 of the PAM site), +7, +8, +9, +10, +11, +12, +13, +14, +15, +16, +17, +18, +19, +20, +21, +22, +23, +24, +25, +26, +27, +28, +29, +30, +31, +32, +33, +34, +35, +36, +37, +38, +39, +40, +41, +42, +43, +44, +45, +46, +47, +48, +49, +50, +51, +52, +53, +54, +55, +56, +57, +58, +59, +60, +61, +62, +63, +64, +65, +66, +67, +68, +69, +70, +71, +72, +73, +74, +75, +76, +77, +78, +79, +80, +81, +82, +83, +84, +85, +86, +87, +88, +89, +90, +91, +92, +93, +94, +95, +96, +97, +98, +99, +100, +101, +102, +103, +104, +105, +106, +107, +108, +109, +110, +111, +112, +113, +114, +115, +116, +117, +118, +119, +120, +121, +122, +123, +124, +125, +126, +127, +128, +129, +130, +131, +132, +133, +134, +135, +136, +137, +138, +139, +140, +141, +142, +143, +144, +145, +146, +147, +148, +149, or +150, or more (relative to the downstream position of the nick site). Once the 3' end single stranded DNA (containing the edit of interest) replaces the endogenous 5' end single stranded DNA, the DNA repair and replication processes will result in permanent installation of the edit site on the PAM strand, and then correction of the mismatch on the non-PAM strand that will exist at the edit site. In this way, the edit will extend to both strands of DNA on the target DNA site. It will be appreciated that reference to "edited strand" and "non-edited" strand only intends to delineate the strands of DNA involved in the PE mechanism. The "edited strand" is the strand that first becomes edited by replacement of the 5' ended single strand DNA immediately downstream of the nick site with the synthesized 3' ended single stranded DNA containing the desired edit. The "non-edited" strand is the strand pair with the edited strand, but which itself also becomes edited through repair and/or replication to be complementary to the edited strand, and in particular, the edit of interest.

[0104] FIG. 1M depicts the mechanism of prime editing showing the anatomical features of the target DNA, prime editor complex, and the interaction between the PEgRNA and the target DNA. First, a prime editor comprising a fusion protein having a polymerase (e.g., reverse transcriptase) and a napDNAbp (e.g., SpCas9 nickase, e.g., a SpCas9 having a deactivating mutation in an HNH nuclease domain (e.g., H840A) or a deactivating mutation in a RuvC nuclease domain (D10A)) is complexed with a PEgRNA and DNA having a target DNA to be edited. The PEgRNA comprises a spacer, gRNA core (aka gRNA scaffold or gRNA backbone) (which binds to the napDNAbp), and an extension arm. The extension arm can be at the 3' end, the 5' end, or somewhere within the PEgRNA molecule. As shown, the extension arm is at the 3' end of the PEgRNA. The extension arm comprises in the 3' to 5' direction a primer binding site and a DNA synthesis template (comprising both an edit of interest and regions of homology (i.e., homology arms) that are homologous with the 5' ended single stranded DNA immediately following the nick site on the PAM strand. As shown, once the nick is introduced thereby producing a free 3' hydroxyl group immediately upstream of the nick site, the region immediately upstream of the nick site on the PAM strand anneals to a

complementary sequence at the 3' end of the extension arm referred to as the "primer binding site," creating a short double-stranded region with an available 3' hydroxyl end, which forms a substrate for the polymerase of the prime editor complex. The polymerase (e.g., reverse transcriptase) then polymerase as strand of DNA from the 3' hydroxyl end to the end of the extension arm. The sequence of the single stranded DNA is coded for by the DNA synthesis template, which is the portion of the extension arm (i.e., excluding the primer binding site) that is "read" by the polymerase to synthesize new DNA. This polymerization effectively extends the sequence of the original 3' hydroxyl end of the initial nick site. The DNA synthesis template encodes a single strand of DNA that comprises not only the desired edit, but also regions that are homologous to the endogenous single strand of DNA immediately downstream of the nick site on the PAM strand. Next, the encoded 3' ended single strand of DNA (i.e., the 3' single strand DNA flap) displaces the corresponding homologous endogenous 5'-ended single strand of DNA immediately downstream of the nick site on the PAM strand, forming a DNA intermediate having a 5'-ended single strand DNA flap, which is removed by the cell (e.g., by a flap endonuclease). The 3'-ended single strand DNA flap, which anneals to the complement of the endogenous 5'-ended single strand DNA flap, is ligated to the endogenous strand after the 5' DNA flap is removed. The desired edit in the 3' ended single strand DNA flap, now annealed and ligate, forms a mismatch with the complement strand, which undergoes DNA repair and/or a round of replication, thereby permanently installing the desired edit on both strands.

[0105] FIG. 2 shows three Cas complexes (SpCas9, SaCas9, and LbCas12a) that can be used in the herein described prime editors and their PAM, gRNA, and DNA cleavage features. The figure shows designs for complexes involving SpCas9, SaCas9, and LbCas12a.

[0106] FIGs. 3A-3F show designs for engineered 5' prime editor gRNA (**FIG. 3A**), 3' prime editor gRNA (**FIG. 3B**), and an intramolecular extension (**FIG. 3C**). The extended guide RNA (or extended gRNA) may also be referred to herein as PEgRNA or "prime editing guide RNA." **FIG. 3D** and **FIG. 3E** provide additional embodiments of 3' and 5' prime editor gRNAs (PEgRNAs), respectively. **FIG. 3F** illustrates the interaction between a 3' end prime editor guide RNA with a target DNA sequence. The embodiments of **FIGs. 3A-3C** depict exemplary arrangements of the reverse transcription template sequence (i.e., or more broadly referred to as a DNA synthesis template, as indicated, since the RT is only one type of polymerase that may be used in the context of prime editors), the primer binding site, and an optional linker sequence in the extended portions of the 3', 5', and intramolecular versions, as well as the general arrangements of the spacer and core regions. The disclosed prime editing process is not limited to these configurations of extended guide RNAs. The embodiment of **FIG. 3D** provides the structure of an exemplary PEgRNA contemplated herein. The PEgRNA comprises three main component elements ordered in the 5' to 3' direction, namely: a spacer, a gRNA core, and an extension arm at the 3' end. The extension arm may further be divided into the following

structural elements in the 5' to 3' direction, namely: a primer binding site (A), an edit template (B), and a homology arm (C). In addition, the PEgRNA may comprise an optional 3' end modifier region (e1) and an optional 5' end modifier region (e2). Still further, the PEgRNA may comprise a transcriptional termination signal at the 3' end of the PEgRNA (not depicted). These structural elements are further defined herein. The depiction of the structure of the PEgRNA is not meant to be limiting and embraces variations in the arrangement of the elements. For example, the optional sequence modifiers (e1) and (e2) could be positioned within or between any of the other regions shown, and not limited to being located at the 3' and 5' ends. The PEgRNA could comprise, in certain embodiments, secondary RNA structure, such as, but not limited to, hairpins, stem/loops, toe loops, RNA-binding protein recruitment domains (e.g., the MS2 aptamer which recruits and binds to the MS2cp protein). For instance, such secondary structures could be positioned within the spacer, the gRNA core, or the extension arm, and in particular, within the e1 and/or e2 modifier regions. In addition to secondary RNA structures, the PEgRNAs could comprise (e.g., within the e1 and/or e2 modifier regions) a chemical linker or a poly(N) linker or tail, where "N" can be any nucleobase. In some embodiments (e.g., as shown in FIG. 72(c)), the chemical linker may function to prevent reverse transcription of the sgRNA scaffold or core. In addition, in certain embodiments (e.g., see FIG. 72(c)), the extension arm (3) could be comprised of RNA or DNA, and/or could include one or more nucleobase analogs (e.g., which might add functionality, such as temperature resilience). Still further, the orientation of the extension arm (3) can be in the natural 5'-to-3' direction, or synthesized in the opposite orientation in the 3'-to-5' direction (relative to the orientation of the PEgRNA molecule overall). It is also noted that one of ordinary skill in the art will be able to select an appropriate DNA polymerase, depending on the nature of the nucleic acid materials of the extension arm (i.e., DNA or RNA), for use in prime editing that may be implemented either as a fusion with the napDNAbp or as provided *in trans* as a separate moiety to synthesize the desired template-encoded 3' single-strand DNA flap that includes the desired edit. For example, if the extension arm is RNA, then the DNA polymerase could be a reverse transcriptase or any other suitable RNA-dependent DNA polymerase. However, if the extension arm is DNA, then the DNA polymerase could be a DNA-dependent DNA polymerase. In various embodiments, provision of the DNA polymerase could be *in trans*, e.g., through the use of an RNA-protein recruitment domain (e.g., an MS2 hairpin installed on the PEgRNA (e.g., in the e1 or e2 region, or elsewhere and an MS2cp protein fused to the DNA polymerase, thereby co-localizing the DNA polymerase to the PEgRNA). It is also noted that the primer binding site does not generally form a part of the template that is used by the DNA polymerase (e.g., reverse transcriptase) to encode the resulting 3' single-strand DNA flap that includes the desired edit. Thus, the designation of the "DNA synthesis template" refers to the region or portion of the extension arm (3) that is used as a template by the DNA polymerase to encode the desired 3' single-strand DNA flap containing the edit and regions of homology to the 5' endogenous single strand DNA

flap that is replaced by the 3' single strand DNA strand product of prime editing DNA synthesis. In some embodiments, the DNA synthesis template includes the "edit template" and the "homology arm", or one or more homology arms, e.g., before and after the edit template. The edit template can be as small as a single nucleotide substitution, or it may be an insertion, or an inversion of DNA. In addition, the edit template may also include a deletion, which can be engineered by encoding a homology arm that contains a desired deletion. In other embodiments, the DNA synthesis template may also include the e2 region or a portion thereof. For instance, if the e2 region comprises a secondary structure that causes termination of DNA polymerase activity, then it is possible that DNA polymerase function will be terminated before any portion of the e2 region is actually encoded into DNA. It is also possible that some or even all of the e2 region will be encoded into DNA. How much of e2 is actually used as a template will depend on its constitution and whether that constitution interrupts DNA polymerase function.

[0107] The embodiment of **FIG. 3E** provides the structure of another PEgRNA contemplated herein. The PEgRNA comprises three main component elements ordered in the 5' to 3' direction, namely: a spacer, a gRNA core, and an extension arm at the 3' end. The extension arm may further be divided into the following structural elements in the 5' to 3' direction, namely: a primer binding site (A), an edit template (B), and a homology arm (C). In addition, the PEgRNA may comprise an optional 3' end modifier region (e1) and an optional 5' end modifier region (e2). Still further, the PEgRNA may comprise a transcriptional termination signal on the 3' end of the PEgRNA (not depicted). These structural elements are further defined herein. The depiction of the structure of the PEgRNA is not meant to be limiting and embraces variations in the arrangement of the elements. For example, the optional sequence modifiers (e1) and (e2) could be positioned within or between any of the other regions shown, and not limited to being located at the 3' and 5' ends. The PEgRNA could comprise, in certain embodiments, secondary RNA structures, such as, but not limited to, hairpins, stem/loops, toe loops, RNA-binding protein recruitment domains (e.g., the MS2 aptamer which recruits and binds to the MS2cp protein). These secondary structures could be positioned anywhere in the PEgRNA molecule. For instance, such secondary structures could be positioned within the spacer, the gRNA core, or the extension arm, and in particular, within the e1 and/or e2 modifier regions. In addition to secondary RNA structures, the PEgRNAs could comprise (e.g., within the e1 and/or e2 modifier regions) a chemical linker or a poly(N) linker or tail, where "N" can be any nucleobase. In some embodiments (e.g., as shown in FIG. 72(c)), the chemical linker may function to prevent reverse transcription of the sgRNA scaffold or core. In addition, in certain embodiments (e.g., see FIG. 72(c)), the extension arm (3) could be comprised of RNA or DNA, and/or could include one or more nucleobase analogs (e.g., which might add functionality, such as temperature resilience). Still further, the orientation of the extension arm (3) can be in the natural 5'-to-3' direction, or synthesized in the opposite orientation in the 3'-to-5' direction (relative to the orientation of the PEgRNA molecule).

overall). It is also noted that one of ordinary skill in the art will be able to select an appropriate DNA polymerase, depending on the nature of the nucleic acid materials of the extension arm (i.e., DNA or RNA), for use in prime editing that may be implemented either as a fusion with the napDNAbp or as provided in trans as a separate moiety to synthesize the desired template-encoded 3' single-strand DNA flap that includes the desired edit. For example, if the extension arm is RNA, then the DNA polymerase could be a reverse transcriptase or any other suitable RNA-dependent DNA polymerase. However, if the extension arm is DNA, then the DNA polymerase could be a DNA-dependent DNA polymerase. In various embodiments, provision of the DNA polymerase could be in trans, e.g., through the use of an RNA-protein recruitment domain (e.g., an MS2 hairpin installed on the PEgRNA (e.g., in the e1 or e2 region, or elsewhere and an MS2cp protein fused to the DNA polymerase, thereby co-localizing the DNA polymerase to the PEgRNA). It is also noted that the primer binding site does not generally form a part of the template that is used by the DNA polymerase (e.g., reverse transcriptase) to encode the resulting 3' single-strand DNA flap that includes the desired edit. Thus, the designation of the "DNA synthesis template" refers to the region or portion of the extension arm (3) that is used as a template by the DNA polymerase to encode the desired 3' single-strand DNA flap containing the edit and regions of homology to the 5' endogenous single strand DNA flap that is replaced by the 3' single strand DNA strand product of prime editing DNA synthesis. In some embodiments, the DNA synthesis template includes the "edit template" and the "homology arm", or one or more homology arms, e.g., before and after the edit template. The edit template can be as small as a single nucleotide substitution, or it may be an insertion, or an inversion of DNA. In addition, the edit template may also include a deletion, which can be engineered by encoding homology arm that contains a desired deletion. In other embodiments, the DNA synthesis template may also include the e2 region or a portion thereof. For instance, if the e2 region comprises a secondary structure that causes termination of DNA polymerase activity, then it is possible that DNA polymerase function will be terminated before any portion of the e2 region is actual encoded into DNA. It is also possible that some or even all of the e2 region will be encoded into DNA. How much of e2 is actually used as a template will depend on its constitution and whether that constitution interrupts DNA polymerase function.

[0108] The schematic of **FIG. 3F** depicts the interaction of a typical PEgRNA with a target site of a double stranded DNA and the concomitant production of a 3' single stranded DNA flap containing the genetic change of interest. The double strand DNA is shown with the top strand (i.e., the target strand) in the 3' to 5' orientation and the lower strand (i.e., the PAM strand or non-target strand) in the 5' to 3' direction. The top strand comprises the complement of the "protospacer" and the complement of the PAM sequence and is referred to as the "target strand" because it is the strand that is target by and anneals to the spacer of the PEgRNA. The complementary lower strand is referred to as the "non-target strand" or the "PAM strand" or the "protospacer strand" since it contains the PAM sequence

(e.g., NGG) and the protospacer. Although not shown, the PEGRNA depicted would be complexed with a Cas9 or equivalent domain of a prime editor fusion protein. As shown in the schematic, the spacer of the PEGRNA anneals to the complementary region of the protospacer on the target strand. This interaction forms a DNA/RNA hybrid between the spacer RNA and the complement of the protospacer DNA, and induces the formation of an R loop in the protospacer. As taught elsewhere herein, the Cas9 protein (not shown) then induces a nick in the non-target strand, as shown. This then leads to the formation of the 3' ssDNA flap region immediately upstream of the nick site which, in accordance with *z*, interacts with the 3' end of the PEGRNA at the primer binding site. The 3' end of the ssDNA flap (i.e., the reverse transcriptase primer sequence) anneals to the primer binding site (A) on the PEGRNA, thereby priming reverse transcriptase. Next, reverse transcriptase (e.g., provided *in trans* or provided *cis* as a fusion protein, attached to the Cas9 construct) then polymerizes a single strand of DNA which is coded for by the DNA synthesis template (including the edit template (B) and homology arm (C)). The polymerization continues towards the 5' end of the extension arm. The polymerized strand of ssDNA forms a ssDNA 3' end flap which, as describe elsewhere (e.g., as shown in **FIG. 1G**), invades the endogenous DNA, displacing the corresponding endogenous strand (which is removed as a 5' ended DNA flap of endogenous DNA), and installing the desired nucleotide edit (single nucleotide base pair change, deletions, insertions (including whole genes) through naturally occurring DNA repair/replication rounds.

[0109] FIG. 3G depicts yet another embodiment of prime editing contemplated herein. In particular, the top schematic depicts one embodiment of a prime editor (PE), which comprises a fusion protein of a napDNAbp (e.g., SpCas9) and a polymerase (e.g., a reverse transcriptase), which are joined by a linker. The PE forms a complex with a PEGRNA by binding to the gRNA core of the PEGRNA. In the embodiment shown, the PEGRNA is equipped with a 3' extension arm that comprises, beginning at the 3' end, a primer binding site (PBS) followed by a DNA synthesis template. The bottom schematic depicts a variant of a prime editor, referred to as a “*trans* prime editor (tPE).” In this embodiment, the DNA synthesis template and PBS are decoupled from the PEGRNA and presented on a separate molecule, referred to as a *trans* prime editor RNA template (“tPERT”), which comprises an RNA-protein recruitment domain (e.g., a MS2 hairpin). The PE itself is further modified to comprise a fusion to a rPERT recruiting protein (“RP”), which is a protein which specifically recognizes and binds to the RNA-protein recruitment domain. In the example where the RNA-protein recruitment domain is an MS2 hairpin, the corresponding rPERT recruiting protein can be MS2cp of the MS2 tagging system. The MS2 tagging system is based on the natural interaction of the MS2 bacteriophage coat protein (“MCP” or “MS2cp”) with a stem-loop or hairpin structure present in the genome of the phage, i.e., the “MS2 hairpin” or “MS2 aptamer.” In the case of *trans* prime editing, the RP-PE:gRNA complex “recruits” a tPERT having the appropriate RNA-protein recruitment

domain to co-localize with the PE:gRNA complex, thereby providing the PBS and DNA synthesis template *in trans* for use in prime editing, as shown in the example depicted in FIG. 3H.

[0110] FIG. 3H depicts the process of *trans* prime editing. In this embodiment, the *trans* prime editor comprises a “PE2” prime editor (i.e., a fusion of a Cas9(H840A) and a variant MMLV RT) fused to an MS2cp protein (i.e., a type of recruiting protein that recognizes and binds to an MS2 aptamer) and which is complexed with an sgRNA (i.e., a standard guide RNA as opposed to a PEgRNA). The *trans* prime editor binds to the target DNA and nicks the nontarget strand. The MS2cp protein recruits a tPERT *in trans* through the specific interaction with the RNA-protein recruitment domain on the tPERT molecule. The tPERT becomes co-localized with the *trans* prime editor, thereby providing the PBS and DNA synthesis template functions *in trans* for use by the reverse transcriptase polymerase to synthesize a single strand DNA flap having a 3' end and containing the desired genetic information encoded by the DNA synthesis template.

[0111] FIGs. 4A-4E demonstrate *in vitro* TPRT assays (i.e., prime editing assays). **FIG. 4A** is a schematic of fluorescently labeled DNA substrates gRNA templated extension by an RT enzyme, PAGE. **FIG. 4B** shows TPRT (i.e., prime editing) with pre-nicked substrates, dCas9, and 5'-extended gRNAs of differing synthesis template length. **FIG. 4C** shows the RT reaction with pre-nicked DNA substrates in the absence of Cas9. **FIG. 4D** shows TPRT (i.e., prime editing) on full dsDNA substrates with Cas9(H840A) and 5'-extended gRNAs. **FIG. 4E** shows a 3'-extended gRNA template with pre-nicked and full dsDNA substrates. All reactions are with M-MLV RT.

[0112] FIG. 5 shows *in vitro* validations using 5'-extended gRNAs with varying length synthesis templates. Fluorescently labeled (Cy5) DNA targets were used as substrates, and were pre-nicked in this set of experiments. The Cas9 used in these experiments is catalytically dead Cas9 (dCas9), and the RT used is Superscript III, a commercial RT derived from the Moloney-Murine Leukemia Virus (M-MLV). dCas9:gRNA complexes were formed from purified components. Then, the fluorescently labeled DNA substrate was added along with dNTPs and the RT enzyme. After 1 hour of incubation at 37 °C, the reaction products were analyzed by denaturing urea-polyacrylamide gel electrophoresis (PAGE). The gel image shows extension of the original DNA strand to lengths that are consistent with the length of the reverse transcription template.

[0113] FIG. 6 shows *in vitro* validations using 5'-extended gRNAs with varying length synthesis templates, which closely parallels those shown in **FIG. 5**. However, the DNA substrates are not pre-nicked in this set of experiments. The Cas9 used in these experiments is a Cas9 nickase (SpyCas9 H840A mutant) and the RT used is Superscript III, a commercial RT derived from the Moloney-Murine Leukemia Virus (M-MLV). The reaction products were analyzed by denaturing urea-polyacrylamide gel electrophoresis (PAGE). As shown in the gel, the nickase efficiently cleaves the DNA strand when the standard gRNA is used (gRNA_0, lane 3).

[0114] **FIG. 7** demonstrates that 3' extensions support DNA synthesis and do not significantly effect Cas9 nickase activity. Pre-nicked substrates (black arrow) are near-quantitatively converted to RT products when either dCas9 or Cas9 nickase is used (lanes 4 and 5). Greater than 50% conversion to the RT product (red arrow) is observed with full substrates (lane 3). Cas9 nickase (SpyCas9 H840A mutant), catalytically dead Cas9 (dCas9) and Superscript III, a commercial RT derived from the Moloney-Murine Leukemia Virus (M-MLV) are used.

[0115] **FIG. 8** demonstrates dual color experiments that were used to determine if the RT reaction preferentially occurs with the gRNA in cis (bound in the same complex). Two separate experiments were conducted for 5'-extended and 3'-extended gRNAs. Products were analyzed by PAGE. Product ratio calculated as (Cy3cis/Cy3trans) / (Cy5trans/Cy5cis).

[0116] **FIGs. 9A-9D** demonstrates a flap model substrate. **FIG. 9A** shows a dual-FP reporter for flap-directed mutagenesis. **FIG. 9B** shows stop codon repair in HEK cells. **FIG. 9C** shows sequenced yeast clones after flap repair. **FIG. 9D** shows testing of different flap features in human cells.

[0117] **FIG. 10** demonstrates prime editing on plasmid substrates. A dual-fluorescent reporter plasmid was constructed for yeast (*S. cerevisiae*) expression. Expression of this construct in yeast produces only GFP. The *in vitro* prime editing reaction introduces a point mutation, and transforms the parent plasmid or an *in vitro* Cas9(H840A) nicked plasmid into yeast. The colonies are visualized by fluorescence imaging. Yeast dual-FP plasmid transformants are shown. Transforming the parent plasmid or an *in vitro* Cas9(H840A) nicked plasmid results in only green GFP expressing colonies. The prime editing reaction with 5'-extended or 3'-extended gRNAs produces a mix of green and yellow colonies. The latter express both GFP and mCherry. More yellow colonies are observed with the 3'-extended gRNA. A positive control that contains no stop codon is shown as well.

[0118] **FIG. 11** shows prime editing on plasmid substrates similar to the experiment in **FIG. 10**, but instead of installing a point mutation in the stop codon, prime editing installs a single nucleotide insertion (left) or deletion (right) that repairs a frameshift mutation and allows for synthesis of downstream mCherry. Both experiments used 3' extended gRNAs.

[0119] **FIG. 12** shows editing products of prime editing on plasmid substrates, characterized by Sanger sequencing. Individually colonies from the TRT transformations were selected and analyzed by Sanger sequencing. Precise edits were observed by sequencing select colonies. Green colonies contained plasmids with the original DNA sequence, while yellow colonies contained the precise mutation designed by the prime editing gRNA. No other point mutations or indels were observed.

[0120] **FIG. 13** shows the potential scope for the new prime editing technology is shown and compared to deaminase-mediated base editor technologies.

[0121] **FIG. 14** shows a schematic of editing in human cells.

[0122] **FIG. 15** demonstrates the extension of the primer binding site in gRNA.

[0123] **FIG. 16** shows truncated gRNAs for adjacent targeting.

[0124] FIGs. 17A-17C are graphs displaying the % T to A conversion at the target nucleotide after transfection of components in human embryonic kidney (HEK) cells. FIG. 17A shows data, which presents results using an N-terminal fusion of wild type MLV reverse transcriptase to Cas9(H840A) nickase (32-amino acid linker). FIG. 17B is similar to FIG. 17A, but for C-terminal fusion of the RT enzyme. FIG. 17C is similar to FIG. 17A but the linker between the MLV RT and Cas9 is 60 amino acids long instead of 32 amino acids.

[0125] FIG. 18 shows high purity T to A editing at HEK3 site by high-throughput amplicon sequencing. The output of sequencing analysis displays the most abundant genotypes of edited cells.

[0126] FIG. 19 shows editing efficiency at the target nucleotide (blue bars) alongside indel rates (orange bars). WT refers to the wild type MLV RT enzyme. The mutant enzymes (M1 through M4) contain the mutations listed to the right. Editing rates were quantified by high throughput sequencing of genomic DNA amplicons.

[0127] FIG. 20 shows editing efficiency of the target nucleotide when a single strand nick is introduced in the complementary DNA strand in proximity to the target nucleotide. Nicking at various distances from the target nucleotide was tested (triangles). Editing efficiency at the target base pair (blue bars) is shown alongside the indel formation rate (orange bars). The “none” example does not contain a complementary strand nicking guide RNA. Editing rates were quantified by high throughput sequencing of genomic DNA amplicons.

[0128] FIG. 21 demonstrates processed high throughput sequencing data showing the desired T to A transversion mutation and general absence of other major genome editing byproducts.

[0129] FIG. 22 provides a schematic of an exemplary process for conducting targeted mutagenesis with an error-prone reverse transcriptase on a target locus using a nucleic acid programmable DNA binding protein (napDNAbp) complexed with an extended guide RNA, i.e., prime editing with an error-prone RT. This process may be referred to as an embodiment of prime editing for targeted mutagenesis. The extended guide RNA comprises an extension at the 3' or 5' end of the guide RNA, or at an intramolecular location in the guide RNA. In step (a), the napDNAbp/gRNA complex contacts the DNA molecule and the gRNA guides the napDNAbp to bind to the target locus to be mutagenized. In step (b), a nick in one of the strands of DNA of the target locus is introduced (e.g., by a nuclease or chemical agent), thereby creating an available 3' end in one of the strands of the target locus. In certain embodiments, the nick is created in the strand of DNA that corresponds to the R-loop strand, i.e., the strand that is not hybridized to the guide RNA sequence. In step (c), the 3' end DNA strand interacts with the extended portion of the guide RNA in order to prime reverse transcription. In certain embodiments, the 3' ended DNA strand hybridizes to a specific RT priming sequence on the extended portion of the guide RNA. In step (d), an error-prone reverse transcriptase is introduced which synthesizes a mutagenized single strand of DNA from the 3' end of the primed site towards the 3' end of the guide RNA. Exemplary mutations are indicated with an asterisk “*”.

This forms a single-strand DNA flap comprising the desired mutagenized region. In step (e), the napDNAbp and guide RNA are released. Steps (f) and (g) relate to the resolution of the single strand DNA flap (comprising the mutagenized region) such that the desired mutagenized region becomes incorporated into the target locus. This process can be driven towards the desired product formation by removing the corresponding 5' endogenous DNA flap that forms once the 3' single strand DNA flap invades and hybridizes to the complementary sequence on the other strand. The process can also be driven towards product formation with second strand nicking, as exemplified in **FIG. 1F**. Following endogenous DNA repair and/or replication processes, the mutagenized region becomes incorporated into both strands of DNA of the DNA locus.

[0130] FIG. 23 is a schematic of gRNA design for contracting trinucleotide repeat sequences and trinucleotide repeat contraction with TPRT genome editing (i.e., prime editing). Trinucleotide repeat expansion is associated with a number of human diseases, including Huntington's disease, Fragile X syndrome, and Friedreich's ataxia. The most common trinucleotide repeat contains CAG triplets, though GAA triplets (Friedreich's ataxia) and CGG triplets (Fragile X syndrome) also occur. Inheriting a predisposition to expansion, or acquiring an already expanded parental allele, increases the likelihood of acquiring the disease. Pathogenic expansions of trinucleotide repeats could hypothetically be corrected using prime editing. A region upstream of the repeat region can be nicked by an RNA-guided nuclease, then used to prime synthesis of a new DNA strand that contains a healthy number of repeats (which depends on the particular gene and disease). After the repeat sequence, a short stretch of homology is added that matches the identity of the sequence adjacent to the other end of the repeat (red strand). Invasion of the newly synthesized strand, and subsequent replacement of the endogenous DNA with the newly synthesized flap, leads to a contracted repeat allele.

[0131] FIG. 24 is a schematic showing precise 10-nucleotide deletion with prime editing. A guide RNA targeting the HEK3 locus was designed with a reverse transcription template that encodes a 10-nucleotide deletion after the nick site. Editing efficiency in transfected HEK cells was assessed using amplicon sequencing.

[0132] FIG. 25 is a schematic showing gRNA design for peptide tagging genes at endogenous genomic loci and peptide tagging with TPRT genome editing (i.e., prime editing). The FIAsh and ReAsH tagging systems comprise two parts: (1) a fluorophore-biarsenical probe, and (2) a genetically encoded peptide containing a tetracysteine motif, exemplified by the sequence FLNCCPGCCMEP (SEQ ID NO: 1). When expressed within cells, proteins containing the tetracysteine motif can be fluorescently labeled with fluorophore-arsenic probes (see ref: J. Am. Chem. Soc., 2002, 124 (21), pp 6063–6076. DOI: 10.1021/ja017687n). The "sortagging" system employs bacterial sortase enzymes that covalently conjugate labeled peptide probes to proteins containing suitable peptide substrates (see ref: Nat. Chem. Biol. 2007 Nov;3(11):707-8. DOI: 10.1038/nchembio.2007.31). The FLAG-tag

(DYKDDDDK (SEQ ID NO: 2)), V5-tag (GKPIPNPLLGLDST (SEQ ID NO: 3)), GCN4-tag (EELLSKNYHLENEVARLKK (SEQ ID NO: 4)), HA-tag (YPYDVPDYA (SEQ ID NO: 5)), and Myc-tag (EQKLISEEDL (SEQ ID NO: 6)) are commonly employed as epitope tags for immunoassays. The pi-clamp encodes a peptide sequence (FCPF (SEQ ID NO: 622)) that can be labeled with a pentafluoro-aromatic substrates (ref: Nat. Chem. 2016 Feb;8(2):120-8. doi: 10.1038/nchem.2413).

[0133] FIG. 26A shows precise installation of a His₆-tag and a FLAG-tag into genomic DNA. A guide RNA targeting the HEK3 locus was designed with a reverse transcription template that encodes either an 18-nt His-tag insertion or a 24-nt FLAG-tag insertion. Editing efficiency in transfected HEK cells was assessed using amplicon sequencing. Note that the full 24-nt sequence of the FLAG-tag is outside of the viewing frame (sequencing confirmed full and precise insertion). **FIG. 26B** shows a schematic outlining various applications involving protein/peptide tagging, including (a) rendering proteins soluble or insoluble, (b) changing or tracking the cellular localization of a protein, (c) extending the half-life of a protein, (d) facilitating protein purification, and (e) facilitating the detection of proteins.

[0134] FIG. 27 shows an overview of prime editing by installing a protective mutation in *PRNP* that prevents or halts the progression of prion disease. The PEgRNA sequences correspond to residue numbers 1-20 of SEQ ID NO: 810 on the left (i.e., 5' of the sgRNA scaffold) and residue numbers 21-43 of SEQ ID NO: 810 on the right (i.e., 3' of the sgRNA scaffold).

[0135] FIG. 28A is a schematic of PE-based insertion of sequences encoding RNA motifs. **FIG. 28B** is a list (not exhaustive) of some example motifs that could potentially be inserted, and their functions.

[0136] FIG. 29A is a depiction of a prime editor. **FIG. 29B** shows possible modifications to genomic, plasmid, or viral DNA directed by a PE. **FIG. 29C** shows an example scheme for insertion of a library of peptide loops into a specified protein (in this case GFP) via a library of PEgRNAs. **FIG. 29D** shows an example of possible programmable deletions of codons or N-, or C-terminal truncations of a protein using different PEgRNAs. Deletions would be predicted to occur with minimal generation of frameshift mutations.

[0137] FIG. 30 shows a possible scheme for iterative insertion of codons in a continual evolution system, such as PACE.

[0138] FIG. 31 is an illustration of an engineered gRNA showing the gRNA core, ~20nt spacer matching the sequence of the targeted gene, the reverse transcription template with immunogenic epitope nucleotide sequence and the primer binding site matching the sequence of the targeted gene.

[0139] FIG. 32 is a schematic showing using prime editing as a means to insert known immunogenicity epitopes into endogenous or foreign genomic DNA, resulting in modification of the corresponding proteins.

[0140] FIG. 33 is a schematic showing PEGRNA design for primer binding sequence insertions and primer binding insertion into genomic DNA using prime editing for determining off-target editing. In this embodiment, prime editing is conducted inside a living cell, a tissue, or an animal model. As a first step, an appropriate PEGRNA is designed. The top schematic shows an exemplary PEGRNA that may be used in this aspect. The spacer in the PEGRNA (labeled “protospacer”) is complementary to one of the strands of the genomic target. The PE:PEGRNA complex (i.e., the PE complex) installs a single stranded 3' end flap at the nick site which contains the encoded primer binding sequence and the region of homology (coded by the homology arm of the PEGRNA) that is complementary to the region just downstream of the cut site (in red). Through flap invasion and DNA repair/replication processes, the synthesized strand becomes incorporated into the DNA, thereby installing the primer binding site. This process can occur at the desired genomic target, but also at other genomic sites that might interact with the PEGRNA in an off-target manner (i.e., the PEGRNA guides the PE complex to other off-target sites due to the complementarity of the spacer region to other genomic sites that are not the intended genomic site). Thus, the primer binding sequence may be installed not only at the desired genomic target, but at off-target genomic sites elsewhere in the genome. In order to detect the insertion of these primer binding sites at both the intended genomic target sites and the off-target genomic sites, the genomic DNA (post-PE) can be isolated, fragmented, and ligated to adapter nucleotides (shown in red). Next, PCR may be carried out with PCR oligonucleotides that anneal to the adapters and to the inserted primer binding sequence to amplify on-target and off-target genomic DNA regions into which the primer binding site was inserted by PE. High throughput sequencing then may be conducted and sequences aligned to identify the insertion points of PE-inserted primer binding sequences at either the on-target site or at off-target sites.

[0141] FIG. 34 is a schematic showing the precise insertion of a gene with PE.

[0142] FIG. 35A is a schematic showing the natural insulin signaling pathway. FIG. 35B is a schematic showing FKBP12-tagged insulin receptor activation controlled by FK1012.

[0143] FIG. 36 shows small-molecule monomers. References: bumped FK506 mimic (2)¹⁰⁷

[0144] FIGs. 37A-37B show small-molecule dimers. References: FK1012 4^{95,96}; FK1012 5¹⁰⁸; FK1012 6¹⁰⁷; AP1903 7¹⁰⁷; cyclosporin A dimer 8⁹⁸; FK506–cyclosporin A dimer (FkCsA) 9¹⁰⁰.

[0145] FIGs. 38A-38F provide an overview of prime editing and feasibility studies *in vitro* and in yeast cells. FIG. 38A shows the 75,122 known pathogenic human genetic variants in ClinVar (accessed July, 2019), classified by type. FIG. 38B shows that a prime editing complex consists of a prime editor (PE) protein containing an RNA-guided DNA-nicking domain, such as Cas9 nickase, fused to an engineered reverse transcriptase domain and complexed with a prime editing guide RNA (PEGRNA). The PE:PEGRNA complex binds the target DNA site and enables a large variety of precise DNA edits at a wide range of DNA positions before or after the target site's protospacer adjacent motif (PAM). FIG. 38C shows that upon DNA target binding, the PE:PEGRNA complex

nicks the PAM-containing DNA strand. The resulting free 3' end hybridizes to the primer-binding site of the PEGRNA. The reverse transcriptase domain catalyzes primer extension using the RT template of the PEGRNA, resulting in a newly synthesized DNA strand containing the desired edit (the 3' flap). Equilibration between the edited 3' flap and the unedited 5' flap containing the original DNA, followed by cellular 5' flap cleavage and ligation, and DNA repair or replication to resolve the heteroduplex DNA, results in stably edited DNA. **FIG. 38D** shows *in vitro* 5'-extended PEGRNA primer extension assays with pre-nicked dsDNA substrates containing 5'-Cy5 labeled PAM strands, dCas9, and a commercial M-MLV RT variant (RT, Superscript III). dCas9 was complexed with PEGRNAs containing RT template of varying lengths, then added to DNA substrates along with the indicated components. Reactions were incubated at 37 °C for 1 hour, then analyzed by denaturing urea PAGE and visualized for Cy5 fluorescence. **FIG. 38E** shows primer extension assays performed as in **FIG. 38D** using 3'-extended PEGRNAs pre-complexed with dCas9 or Cas9 H840A nickase, and pre-nicked or non-nicked 5'-Cy5- labeled dsDNA substrates. **FIG. 38F** shows yeast colonies transformed with GFP-mCherry fusion reporter plasmids edited *in vitro* with PEGRNAs, Cas9 nickase, and RT. Plasmids containing nonsense or frameshift mutations between GFP and mCherry were edited with 5'-extended or 3'- extended PEGRNAs that restore mCherry translation via transversion mutation, 1-bp insertion, or 1-bp deletion. GFP and mCherry double-positive cells (yellow) reflect successful editing.

[0146] **FIGs. 39A-39D** show prime editing of genomic DNA in human cells by PE1 and PE2. **FIG. 39A** shows PEGRNAs contain a spacer sequence, a sgRNA scaffold, and a 3' extension containing a primer-binding site (green) and a reverse transcription (RT) template (purple), which contains the edited base(s) (red). The primer-binding site hybridizes to the PAM-containing DNA strand immediately upstream of the site of nicking. The RT template is homologous to the DNA sequence downstream of the nick, with the exception of the encoded edit. **FIG. 39B** shows an installation of a T•A-to-A•T transversion edit at the HEK3 site in HEK293T cells using Cas9 H840A nickase fused to wild-type M-MLV reverse transcriptase (PE1) and PEGRNAs of varying primer-binding site lengths. **FIG. 39C** shows the use of an engineered pentamutant M-MLV reverse transcriptase (D200N, L603W, T306K, W313F, T330P) in PE2 substantially improves prime editing transversion efficiencies at five genomic sites in HEK293T cells, and small insertion and small deletion edits at HEK3. **FIG. 39D** is a comparison of PE2 editing efficiencies with varying RT template lengths at five genomic sites in HEK293T cells. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0147] **FIGs. 40A-40C** show PE3 and PE3b systems nick the non-edited strand to increase prime editing efficiency. **FIG. 40A** is an overview of the prime editing by PE3. After initial synthesis of the edited strand, DNA repair will remove either the newly synthesized strand containing the edit (3' flap excision) or the original genomic DNA strand (5' flap excision). 5' flap excision leaves behind a

DNA heteroduplex containing one edited strand and one non-edited strand. Mismatch repair machinery or DNA replication could resolve the heteroduplex to give either edited or non-edited products. Nicking the non-edited strand favors repair of that strand, resulting in preferential generation of stable duplex DNA containing the desired edit. **FIG. 40B** shows the effect of complementary strand nicking on PE3-mediated prime editing efficiency and indel formation. “None” refers to PE2 controls, which do not nick the complementary strand. **FIG. 40C** is a comparison of editing efficiencies with PE2 (no complementary strand nick), PE3 (general complementary strand nick), and PE3b (edit-specific complementary strand nick). All editing yields reflect the percentage of total sequencing reads that contain the intended edit and do not contain indels among all treated cells, with no sorting. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0148] FIGS. 41A-41K show targeted insertions, deletions, and all 12 types of point mutations with PE3 at seven endogenous human genomic loci in HEK293T cells. **FIG. 41A** is a graph showing all 12 types of single-nucleotide transition and transversion edits from position +1 to +8 (counting the location of the PEgRNA-induced nick as between position +1 and -1) of the HEK3 site using a 10-nt RT template. **FIG. 41B** is a graph showing long-range PE3 transversion edits at the HEK3 site using a 34-nt RT template. **FIGS. 41C-41H** are graphs showing all 12 types of transition and transversion edits at various positions in the prime editing window for (**FIG. 41C**) RNF2, (**FIG. 41D**) FANCF, (**FIG. 41E**) EMX1, (**FIG. 41F**) RUNX1, (**FIG. 41G**) VEGFA, and (**FIG. 41H**) DNMT1. **FIG. 41I** is a graph showing targeted 1- and 3-bp insertions, and 1- and 3-bp deletions with PE3 at seven endogenous genomic loci. **FIG. 41J** is a graph showing the targeted precise deletions of 5 to 80 bp at the HEK3 target site. **FIG. 41K** is a graph showing a combination edits of insertions and deletions, insertions and point mutations, deletions and point mutations, and double point mutations at three endogenous genomic loci. All editing yields reflect the percentage of total sequencing reads that contain the intended edit and do not contain indels among all treated cells, with no sorting. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0149] FIGS. 42A-42H show the comparison of prime editing and base editing, and off-target editing by Cas9 and PE3 at known Cas9 off-target sites. **FIG. 42A** shows total C•G-to-T•A editing efficiency at the same target nucleotides for PE2, PE3, BE2max, and BE4max at endogenous HEK3, FANCF, and EMX1 sites in HEK293T cells. **FIG. 42B** shows indel frequency from treatments in **FIG. 42A**. **FIG. 42C** shows the editing efficiency of precise C•G-to-T•A edits (without bystander edits or indels) for PE2, PE3, BE2max, and BE4max at HEK3, FANCF, and EMX1. For EMX1, precise PE combination edits of all possible combinations of C•G-to-T•A conversion at the three targeted nucleotides are also shown. **FIG. 42D** shows the total A•T-to-G•C editing efficiency for PE2, PE3, ABEdmax, and ABEmax at HEK3 and FANCF. **FIG. 42E** shows the precise A•T-to-G•C editing efficiency without bystander edits or indels for at HEK3 and FANCF. **FIG. 42F** shows indel

frequency from treatments in **FIG. 42D**. **FIG. 42G** shows the average triplicate editing efficiencies (percentage sequencing reads with indels) in HEK293T cells for Cas9 nuclease at four on-target and 16 known off-target sites. The 16 off-target sites examined were the top four previously reported off-target sites^{118,159} for each of the four on-target sites. For each on-target site, Cas9 was paired with a sgRNA or with each of four PEGRNAs that recognize the same protospacer. **FIG. 42H** shows the average triplicate on-target and off-target editing efficiencies and indel efficiencies (below in parentheses) in HEK293T cells for PE2 or PE3 paired with each PEGRNA in (**FIG. 42G**). On-target editing yields reflect the percentage of total sequencing reads that contain the intended edit and do not contain indels among all treated cells, with no sorting. Off-target editing yields reflect off-target locus modification consistent with prime editing. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0150] FIGs. 43A-43I show prime editing in various human cell lines and primary mouse cortical neurons, installation and correction of pathogenic transversion, insertion, or deletion mutations, and comparison of prime editing and HDR. **FIG. 43A** is a graph showing the installation (via T•A-to-A•T transversion) and correction (via A•T-to-T•A transversion) of the pathogenic E6V mutation in HBB in HEK293T cells. Correction either to wild-type HBB, or to HBB containing a silent mutation that disrupts the PEGRNA PAM, is shown. **FIG. 43B** is a graph showing the installation (via 4-bp insertion) and correction (via 4-bp deletion) of the pathogenic HEXA 1278+TATC allele in HEK293T cells. Correction either to wild-type HEXA, or to HEXA containing a silent mutation that disrupts the PEGRNA PAM, is shown. **FIG. 43C** is a graph showing the installation of the protective G127V variant in PRNP in HEK293T cells via G•C-to-T•A transversion. **FIG. 43D** is a graph showing prime editing in other human cell lines including K562 (leukemic bone marrow cells), U2OS (osteosarcoma cells), and HeLa (cervical cancer cells). **FIG. 43E** is a graph showing the installation of a G•C-to-T•A transversion mutation in DNMT1 of mouse primary cortical neurons using a dual split-intein PE3 lentivirus system, in which the N-terminal half is Cas9 (1-573) fused to N-intein and through a P2A self-cleaving peptide to GFP-KASH, and the C-terminal half is the C-intein fused to the remainder of PE2. PE2 halves are expressed from a human synapsin promoter that is highly specific for mature neurons. Sorted values reflect editing or indels from GFP-positive nuclei, while unsorted values are from all nuclei. **FIG. 43F** is a comparison of PE3 and Cas9-mediated HDR editing efficiencies at endogenous genomic loci in HEK293T cells. **FIG. 43G** is a comparison of PE3 and Cas9-mediated HDR editing efficiencies at endogenous genomic loci in K562, U2OS, and HeLa cells. **FIG. 43H** is a comparison of PE3 and Cas9-mediated HDR indel byproduct generation in HEK293T, K562, U2OS, and HeLa cells. **FIG. 43I** shows targeted insertion of a His6 tag (18 bp), FLAG epitope tag (24 bp), or extended LoxP site (44 bp) in HEK293T cells by PE3. All editing yields reflect the percentage of total sequencing reads that contain the intended edit and do not contain indels among all treated cells. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0151] FIGs. 44A-44G show *in vitro* prime editing validation studies with fluorescently labeled DNA substrates. **FIG. 44A** shows electrophoretic mobility shift assays with dCas9, 5'-extended PEgRNAs and 5'-Cy5-labeled DNA substrates. PEgRNAs 1 through 5 contain a 15-nt linker sequence (linker A for PEgRNA 1, linker B for PEgRNAs 2 through 5) between the spacer and the PBS, a 5-nt PBS sequence, and RT templates of 7 nt (PEgRNAs 1 and 2), 8 nt (PEgRNA 3), 15 nt (PEgRNA 4), and 22 nt (PEgRNA 5). PEgRNAs are those used in **FIG. 44E** and **44F**; full sequences are listed in Tables 2A-2C. **FIG. 44B** shows *in vitro* nicking assays of Cas9 H840A using 5'-extended and 3'-extended PEgRNAs. **FIG. 44C** shows Cas9-mediated indel formation in HEK293T cells at HEK3 using 5'-extended and 3'-extended PEgRNAs. **FIG. 44D** shows an overview of prime editing *in vitro* biochemical assays. 5'-Cy5-labeled pre-nicked and non-nicked dsDNA substrates were tested. sgRNAs, 5'-extended PEgRNAs, or 3'-extended PEgRNAs were pre-complexed with dCas9 or Cas9 H840A nickase, then combined with dsDNA substrate, M-MLV RT, and dNTPs. Reactions were allowed to proceed at 37 °C for 1 hour prior to separation by denaturing urea PAGE and visualization by Cy5 fluorescence. **FIG. 44E** shows primer extension reactions using 5'-extended PEgRNAs, pre-nicked DNA substrates, and dCas9 lead to significant conversion to RT products. **FIG. 44F** shows primer extension reactions using 5'-extended PEgRNAs as in **FIG. 44B**, with non-nicked DNA substrate and Cas9 H840A nickase. Product yields are greatly reduced by comparison to pre-nicked substrate. **FIG. 44G** shows an *in vitro* primer extension reaction using a 3'-PEgRNA generates a single apparent product by denaturing urea PAGE. The RT product band was excised, eluted from the gel, then subjected to homopolymer tailing with terminal transferase (TdT) using either dGTP or dATP. Tailed products were extended by poly-T or poly-C primers, and the resulting DNA was sequenced. Sanger traces indicate that three nucleotides derived from the gRNA scaffold were reverse transcribed (added as the final 3' nucleotides to the DNA product). Note that in mammalian cell prime editing experiments, PEgRNA scaffold insertion is much rarer than *in vitro* (**FIGs. 56A-56D**), potentially due to the inability of the tethered reverse transcriptase to access the Cas9-bound guide RNA scaffold, and/or cellular excision of mismatched 3' ends of 3' flaps containing PEgRNA scaffold sequences.

[0152] FIGs. 45A-45G show cellular repair in yeast of 3' DNA flaps from *in vitro* prime editing reactions. **FIG. 45A** shows that dual fluorescent protein reporter plasmids contain GFP and mCherry open reading frames separated by a target site encoding an in-frame stop codon, a +1 frameshift, or a -1 frameshift. Prime editing reactions were carried out *in vitro* with Cas9 H840A nickase, PEgRNA, dNTPs, and M-MLV reverse transcriptase, and then transformed into yeast. Colonies that contain unedited plasmids produce GFP but not mCherry. Yeast colonies containing edited plasmids produce both GFP and mCherry as a fusion protein. **FIG. 45B** shows an overlay of GFP and mCherry fluorescence for yeast colonies transformed with reporter plasmids containing a stop codon between GFP and mCherry (unedited negative control, top), or containing no stop codon or frameshift between

GFP and mCherry (pre-edited positive control, bottom). **FIGs. 45C-45F** show a visualization of mCherry and GFP fluorescence from yeast colonies transformed with *in vitro* prime editing reaction products. **FIG. 45C** shows a stop codon correction via T•A-to- A•T transversion using a 3'-extended PEgRNA, or a 5'-extended PEgRNA, as shown in **FIG. 45D**. **FIG. 45E** shows a +1 frameshift correction via a 1-bp deletion using a 3'-extended PEgRNA. **FIG. 45F** shows a -1 frameshift correction via a 1-bp insertion using a 3'-extended PEgRNA. **FIG. 45G** shows Sanger DNA sequencing traces from plasmids isolated from GFP-only colonies in **FIG. 45B** and GFP and mCherry double-positive colonies in **FIG. 45C**.

[0153] FIGs. 46A-46F show correct editing versus indel generation with PE1. **FIG. 46A** shows T•A-to-A•T transversion editing efficiency and indel generation by PE1 at the +1 position of HEK3 using PEgRNAs containing 10-nt RT templates and a PBS sequences ranging from 8-17 nt. **FIG. 46B** shows G•C-to-T•A transversion editing efficiency and indel generation by PE1 at the +5 position of EMX1 using PEgRNAs containing 13-nt RT templates and a PBS sequences ranging from 9- 17 nt. **FIG. 46C** shows G•C-to-T•A transversion editing efficiency and indel generation by PE1 at the +5 position of FANCF using PEgRNAs containing 17-nt RT templates and a PBS sequences ranging from 8-17 nt. **FIG. 46D** shows C•G-to-A•T transversion editing efficiency and indel generation by PE1 at the +1 position of RNF2 using PEgRNAs containing 11-nt RT templates and a PBS sequences ranging from 9-17 nt. **FIG. 46E** shows G•C-to-T•A transversion editing efficiency and indel generation by PE1 at the +2 position of HEK4 using PEgRNAs containing 13-nt RT templates and a PBS sequences ranging from 7-15 nt. **FIG. 46F** shows PE1-mediated +1 T deletion, +1 A insertion, and +1 CTT insertion at the HEK3 site using a 13-nt PBS and 10-nt RT template. Sequences of PEgRNAs are those used in **FIG. 39C** (see Tables 3A-3R). Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0154] FIGs. 47A-47S show the evaluation of M-MLV RT variants for prime editing. **FIG. 47A** shows the abbreviations for prime editor variants used in this figure. **FIG. 47B** shows targeted insertion and deletion edits with PE1 at the HEK3 locus. **FIGs. 47C-47H** show a comparison of 18 prime editor constructs containing M-MLV RT variants for their ability to install a +2 G•C-to-C•G transversion edit at HEK3 as shown in **FIG. 47C**, a 24-bp FLAG insertion at HEK3 as shown in **FIG. 47D**, a +1 C•G-to-A•T transversion edit at RNF2 as shown in **FIG. 47E**, a +1 G•C-to-C•G transversion edit at EMX1 as shown in **FIG. 47F**, a +2 T•A-to-A•T transversion edit at *HBB* as shown in **FIG. 47G**, and a +1 G•C-to-C•G transversion edit at FANCF as shown in **FIG. 47H**. **FIGs. 47I-47N** show a comparison of four prime editor constructs containing M-MLV variants for their ability to install the edits shown in **FIGs. 47C-47H** in a second round of independent experiments. **FIGs. 47O-47S** show PE2 editing efficiency at five genomic loci with varying PBS lengths. **FIG. 47O** shows a +1 T•A-to-A•T variation at HEK3. **FIG. 47P** shows a +5 G•C-to-T•A variation at EMX1. **FIG. 47Q** shows a +5 G•C-to-T•A variation at FANCF. **FIG. 47R** shows a +1 C•G-to-A•T variation

at RNF2. **FIG. 47S** shows a +2 G•C-to-T•A variation at HEK4. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0155] FIGs. 48A-48C show design features of PEgRNA PBS and RT template sequences. **FIG. 48A** shows PE2-mediated +5 G•C-to-T•A transversion editing efficiency (blue line) at VEGFA in HEK293T cells as a function of RT template length. Indels (gray line) are plotted for comparison. The sequence below the graph shows the last nucleotide templated for synthesis by the PEgRNA. G nucleotides (templated by a C in the PEgRNA) are highlighted; RT templates that end in C should be avoided during PEgRNA design to maximize prime editing efficiencies. **FIG. 48B** shows +5 G•C-to-T•A transversion editing and indels for DNMT1 as in **FIG. 48A**. **FIG. 48C** shows +5 G•C-to-T•A transversion editing and indels for RUNX1 as in **FIG. 48A**. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0156] FIGs. 49A-49B show the effects of PE2, PE2 R110S K103L, Cas9 H840A nickase, and dCas9 on cell viability. HEK293T cells were transfected with plasmids encoding PE2, PE2 R110S K103L, Cas9 H840A nickase, or dCas9, together with a HEK3-targeting PEgRNA plasmid. Cell viability was measured every 24 hours post-transfection for 3 days using the CellTiter-Glo 2.0 assay (Promega). **FIG. 49A** shows viability, as measured by luminescence, at 1, 2, or 3 days post-transfection. Values and error bars reflect the mean and s.e.m. of three independent biological replicates each performed in technical triplicate. **FIG. 49B** shows percent editing and indels for PE2, PE2 R110S K103L, Cas9 H840A nickase, or dCas9, together with a HEK3-targeting PEgRNA plasmid that encodes a +5 G to A edit. Editing efficiencies were measured on day 3 post-transfection from cells treated alongside of those used for assaying viability in **FIG. 49A**. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0157] FIGs. 50A-50B show PE3-mediated *HBB* E6V correction and *HEXA* 1278+TATC correction by various PEgRNAs. **FIG. 50A** shows a screen of 14 PEgRNAs for correction of the *HBB* E6V allele in HEK293T cells with PE3. All PEgRNAs evaluated convert the *HBB* E6V allele back to wild-type *HBB* without the introduction of any silent PAM mutation. **FIG. 50B** shows a screen of 41 PEgRNAs for correction of the *HEXA* 1278+TATC allele in HEK293T cells with PE3 or PE3b. Those PEgRNAs labeled *HEXAs* correct the pathogenic allele by a shifted 4-bp deletion that disrupts the PAM and leaves a silent mutation. Those PEgRNAs labeled *HEXA* correct the pathogenic allele back to wild-type. Entries ending in “b” use an edit-specific nicking sgRNA in combination with the PEgRNA (the PE3b system). Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0158] FIGs. 51A-51G show a PE3 activity in human cell lines and a comparison of PE3 and Cas9-initiated HDR. Efficiency of generating the correct edit (without indels) and indel frequency for PE3 and Cas9-initiated HDR in HEK293T cells as shown in **FIG. 51A**, K562 cells as shown in **FIG. 51B**, U2OS cells as shown in **FIG. 51C**, and HeLa cells as shown in **FIG. 51D**. Each bracketed editing

comparison installs identical edits with PE3 and Cas9-initiated HDR. Non-targeting controls are PE3 and a PEgRNA that targets a non-target locus. **FIG. 51E** shows control experiments with non-targeting PEgRNA+PE3, and with dCas9+sgRNA, compared with wild-type Cas9 HDR experiments confirming that ssDNA donor HDR template, a common contaminant that artificially elevates apparent HDR efficiencies, does not contribute to the HDR measurements in **FIGs. 51A-51D**. **FIGs. 51F-51G** show example HEK3 site allele tables from genomic DNA samples isolated from K562 cells after editing with PE3 or with Cas9-initiated HDR. Alleles were sequenced on an Illumina MiSeq and analyzed with CRISPResso2¹⁷⁸. The reference HEK3 sequence from this region is at the top. Allele tables are shown for a non-targeting PEgRNA negative control, a +1 CTT insertion at HEK3 using PE3, and a +1 CTT insertion at HEK3 using Cas9-initiated HDR. Allele frequencies and corresponding Illumina sequencing read counts are shown for each allele. All alleles observed with frequency $\geq 0.20\%$ are shown. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0159] FIGs. 52A-52D show distribution by length of pathogenic insertions, duplications, deletions, and indels in the ClinVar database. The ClinVar variant summary was downloaded from NCBI July 15, 2019. The lengths of reported insertions, deletions, and duplications were calculated using reference and alternate alleles, variant start and stop positions, or appropriate identifying information in the variant name. Variants that did not report any of the above information were excluded from the analysis. The lengths of reported indels (single variants that include both insertions and deletions relative to the reference genome) were calculated by determining the number of mismatches or gaps in the best pairwise alignment between the reference and alternate alleles.

[0160] FIGs. 53A-53E show FACS gating examples for GFP-positive cell sorting. Below are examples of original batch analysis files outlining the sorting strategy used for generating *HEXA* 1278+TATC and *HBB* E6V HEK293T cell lines. The image data was generated on a Sony LE-MA900 cytometer using Cell Sorter Software v. 3.0.5. Graphic 1 shows gating plots for cells that do not express GFP. Graphic 2 shows an example sort of P2A-GFP-expressing cells used for isolating the *HBB* E6V HEK293T cell lines. HEK293T cells were initially gated on population using FSC-A/BSC-A (Gate A), then sorted for singlets using FSC-A/FSC-H (Gate B). Live cells were sorted for by gating DAPI-negative cells (Gate C). Cells with GFP fluorescence levels that were above those of the negative-control cells were sorted for using EGFP as the fluorochrome (Gate D). **FIG. 53A** shows HEK293T cells (GFP-negative). **FIG. 53B** shows a representative plot of FACS gating for cells expressing PE2-P2A-GFP. **FIG. 53C** shows the genotypes for *HEXA* 1278+TATC homozygote HEK293T cells. **FIGs. 53D-53E** show allele tables for *HBB* E6V homozygote HEK293T cell lines.

[0161] FIG. 54 is a schematic which summarizes the PEgRNA cloning procedure.

[0162] FIGs. 55A-55G are schematics of PEgRNA designs. **FIG. 55A** shows a simple diagram of PEgRNA with domains labeled (left) and bound to nCas9 at a genomic site (right). **FIG. 55B** shows

various types of modifications to PEgRNA which are anticipated to increase activity. **FIG. 55C** shows modifications to PEgRNA to increase transcription of longer RNAs via promoter choice and 5', 3' processing and termination. **FIG. 55D** shows the lengthening of the P1 system, which is an example of a scaffold modification. **FIG. 55E** shows that the incorporation of synthetic modifications within the template region, or elsewhere within the PEgRNA, could increase activity. **FIG. 55F** shows that a designed incorporation of minimal secondary structure within the template could prevent formation of longer, more inhibitory, secondary structure. **FIG. 55G** shows a split PEgRNA with a second template sequence anchored by an RNA element at the 3' end of the PEgRNA (left). Incorporation of elements at the 5' or 3' ends of the PEgRNA could enhance RT binding.

[0163] FIGs. 56A-56D show the incorporation of PEgRNA scaffold sequence into target loci. HTS data were analyzed for PEgRNA scaffold sequence insertion as described in FIGs. 60A-60B. **FIG. 56A** shows an analysis for the EMX1 locus. Shown is the % of total sequencing reads containing one or more PEgRNA scaffold sequence nucleotides within an insertion adjacent to the RT template (left); the percentage of total sequencing reads containing a PEgRNA scaffold sequence insertion of the specified length (middle); and the cumulative total percentage of PEgRNA insertion up to and including the length specified on the X axis. **FIG. 56B** shows the same as **FIG. 56A**, but for FANCF. **FIG. 56C** shows the same as in **FIG. 56A** but for HEK3. **FIG. 56D** shows the same as **FIG. 56A** but for RNF2. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0164] FIGs. 57A-57I show the effects of PE2, PE2-dRT, and Cas9 H840A nickase on transcriptome-wide RNA abundance. Analysis of cellular RNA, depleted for ribosomal RNA, isolated from HEK293T cells expressing PE2, PE2-dRT, or Cas9 H840A nickase and a PRNP-targeting or HEXA-targeting PEgRNA. RNAs corresponding to 14,410 genes and 14,368 genes were detected in PRNP and HEXA samples, respectively. **FIGs. 57A-57F** show Volcano plot displaying the -log₁₀ FDR-adjusted p-value vs. log₂-fold change in transcript abundance for Aeach RNA, comparing (**FIG. 57A**) PE2 vs. PE2-dRT with PRNP-targeting PEgRNA, (**FIG. 57B**) PE2 vs. Cas9 H840A with PRNP-targeting PEgRNA, (**FIG. 57C**) PE2-dRT vs. Cas9 H840A with PRNP-targeting PEgRNA, (**FIG. 57D**) PE2 vs. PE2-dRT with HEXA-targeting PEgRNA, (**FIG. 57E**) PE2 vs. Cas9 H840A with HEXA-targeting PEgRNA, (**FIG. 57F**) PE2-dRT vs. Cas9 H840A with HEXA-targeting PEgRNA. Red dots indicate genes that show ≥ 2 -fold change in relative abundance that are statistically significant (FDR-adjusted $p < 0.05$). **FIGs. 57G-57I** are Venn diagrams of upregulated and downregulated transcripts (≥ 2 -fold change) comparing PRNP and HEXA samples for (**FIG. 57G**) PE2 vs PE2-dRT, (**FIG. 57H**) PE2 vs. Cas9 H840A, and (**FIG. 57I**) PE2-dRT vs. Cas9 H840A.

[0165] FIGs. 58A-58B show representative FACS gating for neuronal nuclei sorting. Nuclei were sequentially gated on the basis of DyeCycle Ruby signal, FSC/SSC ratio, SSC-Width/SSC-height ratio, and GFP/DyeCycle ratio.

[0166] **FIGs. 59A-59G** show the protocol for cloning 3'-extended PEgRNAs into mammalian U6 expression vectors by Golden Gate assembly. **FIG. 59A** shows the cloning overview. **FIG. 59B** shows 'Step 1: Digest pU6-PEgRNA-GG-Vector plasmid (component 1)'. **FIG. 59C** shows 'Steps 2 and 3: Order and anneal oligonucleotide parts (components 2, 3, and 4)'. **FIG. 59D** shows 'Step 2.b.ii.: sgRNA scaffold phosphorylation (unnecessary if oligonucleotides were purchased phosphorylated)'. **FIG. 59E** shows 'Step 4: PEgRNA assembly'. **FIG. 59F** shows 'Steps 5 and 6: Transformation of assembled plasmids'. **FIG. 59G** shows a diagram summarizing the PEgRNA cloning protocol.

[0167] **FIGs. 60A-60B** show the Python script for quantifying PEgRNA scaffold integration. A custom python script was generated to characterize and quantify PEgRNA insertions at target genomic loci. The script iteratively matches text strings of increasing length taken from a reference sequence (guide RNA scaffold sequence) to the sequencing reads within fastq files, and counts the number of sequencing reads that match the search query. Each successive text string corresponds to an additional nucleotide of the guide RNA scaffold sequence. Exact length integrations and cumulative integrations up to a specified length were calculated in this manner. At the start of the reference sequence, 5 to 6 bases of the 3' end of the new DNA strand synthesized by the reverse transcriptase are included to ensure alignment and accurate counting of short slices of the sgRNA.

[0168] **FIG. 61** is a graph showing the percent of total sequencing reads with the specified edit for SaCas9(N580A)-MMLV RT HEK3 +6 C>A. The values for the correct edits as well as indels are shown.

[0169] **FIGs. 62A-62B** show the importance of the protospacer for efficient installation of a desired edit at a precise location with prime editing. **FIG. 62A** is a graph showing the percent of total sequencing reads with target T•A base pairs converted to A•T for various HEK3 loci. **FIG. 62B** is a sequence analysis showing the same.

[0170] **FIG. 63** is a graph showing SpCas9 PAM variants in PAM editing (N=3). The percent of total sequencing reads with the targeted PAM edit is shown for SpCas9(H840A)-VRQR-MMLV RT, where NGA > NTA, and for SpCas9(H840A)-VRER-MMLV RT, where NGCG > NTCT. The PEgRNA primer binding site (PBS) length, RT template (RT) length, and PE system used are listed.

[0171] **FIGs. 64A-64F** depict a schematic showing the introduction of various site-specific recombinase (SSR) targets into the genome using PE. **FIG. 64A** provides a general schematic of the insertion of a recombinase target sequence by a prime editor. **FIG. 64B** shows how a single SSR target inserted by PE can be used as a site for genomic integration of a DNA donor template. **FIG. 64C** shows how a tandem insertion of SSR target sites can be used to delete a portion of the genome. **FIG. 64D** shows how a tandem insertion of SSR target sites can be used to invert a portion of the genome. **FIG. 64E** shows how the insertion of two SSR target sites at two distal chromosomal regions

can result in chromosomal translocation. **FIG. 64F** shows how the insertion of two different SSR target sites in the genome can be used to exchange a cassette from a DNA donor template.

[0172] FIG. 65 shows in 1) the PE-mediated synthesis of a SSR target site in a human cell genome and 2) the use of that SSR target site to integrate a DNA donor template comprising a GFP expression marker. Once successfully integrated, the GFP causes the cell to fluoresce.

[0173] FIG. 66 depicts one embodiment of a prime editor being provided as two PE half proteins which regenerate as whole prime editor through the self-splicing action of the split-intein halves located at the end or beginning of each of the prime editor half proteins.

[0174] FIGs. 67A-67B depict the mechanism of intein removal from a polypeptide sequence and the reformation of a peptide bond between the N-terminal and the C-terminal extein sequences. **FIG. 67A** depicts the general mechanism of two half proteins each containing half of an intein sequence, which when in contact within a cell result in a fully-functional intein which then undergoes self-splicing and excision. The process of excision results in the formation of a peptide bond between the N-terminal protein half (or the “N extein”) and the C-terminal protein half (or the “C extein”) to form a whole, single polypeptide comprising the N extein and the C extein portions. In various embodiments, the N extein may correspond to the N-terminal half of a split prime editor fusion protein and the C extein may correspond to the C-terminal half of a split prime editor. (b) shows a chemical mechanism of intein excision and the reformation of a peptide bond that joins the N extein half (the red-colored half) and the C extein half (the blue-colored half). Excision of the split inteins (i.e., the N intein and the C intein in the split intein configuration) may also be referred to as “trans splicing” as it involves the splicing action of two separate components provided *in trans*.

[0175] FIG. 68A demonstrates that delivery of both split intein halves of SpPE (SEQ ID NOs: 3875, 3876) at the linker maintains activity at three test loci when co-transfected into HEK293T cells.

[0176] FIG. 68B demonstrates that delivery of both split intein halves of SaPE2 (e.g., SEQ ID NO: 443 and SEQ ID NO: 450) recapitulate activity of full length SaPE2 (SEQ ID NO: 134) when co-transfected into HEK293T cells. Residues indicated in quotes are the sequence of amino acids 741-743 in SaCas9 (first residues of the C-terminal extein) which are important for the intein trans splicing reaction. ‘SMP’ are the native residues, which we also mutated to the ‘CFN’ consensus splicing sequence. The consensus sequence is shown to yield the highest reconstitution as measured by prime editing percentage.

[0177] FIG. 68C provides data showing that various disclosed PE ribonucleoprotein complexes (PE2 at high concentration, PE3 at high concentration and PE3 at low concentration) can be delivered in this manner.

[0178] FIG. 69 shows a bacteriophage plaque assay to determine PE effectiveness in PANCE. Plaques (dark circles) indicate phage able to successfully infect *E. coli*. Increasing concentration of L-

rhamnose results in increased expression of PE and an increase in plaque formation. Sequencing of plaques revealed the presence of the PE-installed genomic edit.

[0179] FIGs. 70A-70I provide an example of an edited target sequence as an illustration of a step-by-step instruction for designing PEgRNAs and nicking-sgRNAs for prime editing. **FIG. 70A: Step 1. Define the target sequence and the edit.** Retrieve the sequence of the target DNA region (~200bp) centered around the location of the desired edit (point mutation, insertion, deletion, or combination thereof). **FIG. 70B: Step 2. Locate target PAMs.** Identify PAMs in proximity to the edit location. Be sure to look for PAMs on both strands. While PAMs close to the edit position are preferred, it is possible to install edits using protospacers and PAMs that place the nick ≥ 30 nt from the edit position. **FIG. 70C: Step 3. Locate the nick sites.** For each PAM being considered, identify the corresponding nick site. For Sp Cas9 H840A nickase, cleavage occurs in the PAM-containing strand between the 3rd and 4th bases 5' to the NGG PAM. All edited nucleotides must exist 3' of the nick site, so appropriate PAMs must place the nick 5' to the target edit on the PAM-containing strand. In the example shown below, there are two possible PAMs. For simplicity, the remaining steps will demonstrate the design of a PEgRNA using PAM 1 only. **FIG. 70D: Step 4. Design the spacer sequence.** The protospacer of Sp Cas9 corresponds to the 20 nucleotides 5' to the NGG PAM on the PAM-containing strand. Efficient Pol III transcription initiation requires a G to be the first transcribed nucleotide. If the first nucleotide of the protospacer is a G, the spacer sequence for the PEgRNA is simply the protospacer sequence. If the first nucleotide of the protospacer is not a G, the spacer sequence of the PEgRNA is G followed by the protospacer sequence. **FIG. 70E: Step 5. Design a primer binding site (PBS).** Using the starting allele sequence, identify the DNA primer on the PAM-containing strand. The 3' end of the DNA primer is the nucleotide just upstream of the nick site (i.e. the 4th base 5' to the NGG PAM for Sp Cas9). As a general design principle for use with PE2 and PE3, a PEgRNA primer binding site (PBS) containing 12 to 13 nucleotides of complementarity to the DNA primer can be used for sequences that contain ~40-60% GC content. For sequences with low GC content, longer (14- to 15-nt) PBSs should be tested. For sequences with higher GC content, shorter (8- to 11-nt) PBSs should be tested. Optimal PBS sequences should be determined empirically, regardless of GC content. To design a length- p PBS sequence, take the reverse complement of the first p nucleotides 5' of the nick site in the PAM-containing strand using the starting allele sequence. **FIG. 70F: Step 6. Design an RT template.** The RT template encodes the designed edit and homology to the sequence adjacent to the edit. Optimal RT template lengths vary based on the target site. For short-range edits (positions +1 to +6), it is recommended to test a short (9 to 12 nt), a medium (13 to 16 nt), and a long (17 to 20 nt) RT template. For long-range edits (positions +7 and beyond), it is recommended to use RT templates that extend at least 5 nt (preferably 10 or more nt) past the position of the edit to allow for sufficient 3' DNA flap homology. For long-range edits, several RT templates should be screened to identify functional designs. For larger insertions and

deletions (≥ 5 nt), incorporation of greater 3' homology (~ 20 nt or more) into the RT template is recommended. Editing efficiency is typically impaired when the RT template encodes the synthesis of a G as the last nucleotide in the reverse transcribed DNA product (corresponding to a C in the RT template of the PEgRNA). As many RT templates support efficient prime editing, avoidance of G as the final synthesized nucleotide is recommended when designing RT templates. To design a length- r RT template sequence, use the *desired* allele sequence and take the reverse complement of the first r nucleotides 3' of the nick site in the strand that originally contained the PAM. Note that compared to SNP edits, insertion or deletion edits using RT templates of the same length will not contain identical homology. **FIG. 70G: Step 7. Assemble the full PEgRNA sequence.** Concatenate the PEgRNA components in the following order (5' to 3'): spacer, scaffold, RT template and PBS. **FIG. 70H: Step 8. Designing nicking-sgRNAs for PE3.** Identify PAMs on the non-edited strand upstream and downstream of the edit. Optimal nicking positions are highly locus-dependent and should be determined empirically. In general, nicks placed 40 to 90 nucleotides 5' to the position across from the PEgRNA-induced nick lead to higher editing yields and fewer indels. A nicking sgRNA has a spacer sequence that matches the 20-nt protospacer in the *starting* allele, with the addition of a 5'-G if the protospacer does not begin with a G. **FIG. 70I: Step 9. Designing PE3b nicking-sgRNAs.** If a PAM exists in the complementary strand and its corresponding protospacer overlaps with the sequence targeted for editing, this edit could be a candidate for the PE3b system. In the PE3b system, the spacer sequence of the nicking-sgRNA matches the sequence of the desired edited allele, but not the starting allele. The PE3b system operates efficiently when the edited nucleotide(s) falls within the seed region (~ 10 nt adjacent to the PAM) of the nicking-sgRNA protospacer. This prevents nicking of the complementary strand until after installation of the edited strand, preventing competition between the PEgRNA and the sgRNA for binding the target DNA. PE3b also avoids the generation of simultaneous nicks on both strands, thus reducing indel formation significantly while maintaining high editing efficiency. PE3b sgRNAs should have a spacer sequence that matches the 20-nt protospacer in the *desired* allele, with the addition of a 5' G if needed.

[0180] FIG. 71A shows the nucleotide sequence of a SpCas9 PEgRNA molecule (top) which terminates at the 3' end in a "UUU" and does not contain a toeloop element. The lower portion of the figure depicts the same SpCas9 PEgRNA molecule but is further modified to contain a toeloop element having the sequence 5'-"GAAANNNN"-3' inserted immediately before the "UUU" 3' end. The "N" can be any nucleobase.

[0181] FIG. 71B demonstrates that the efficiency of prime editing in HEK cells or EMX cells is increased using PEgRNA containing toeloop elements, whereas the percent of indel formation is largely unchanged.

[0182] FIGs. 72A-72C depict alternative PEgRNA configurations that can be used in prime editing. **FIG. 72A** depicts the PE2:PEgRNA embodiment of prime editing. This embodiment involves a PE2

(a fusion protein comprising a Cas9 and a reverse transcriptase) complexed with a PEgRNA (as also described in FIGs. 1A-II and/or FIGs. 3A-3E). In this embodiment, the template for reverse transcription is incorporated into a 3' extension arm on the sgRNA to make the PEgRNA, and the DNA polymerase enzyme is a reverse transcriptase (RT) fused directly to Cas9. **FIG. 72B** depict the MS2cp-PE2:sgRNA + tPERT embodiment. This embodiment comprises a PE2 fusion (Cas9 + a reverse transcriptase) that is further fused to the MS2 bacteriophage coat protein (MS2cp) to form the MS2cp-PE2 fusion protein. To achieve prime editing, the MS2cp-PE2 fusion protein is complexed with an sgRNA that targets the complex to a specific target site in the DNA. The embodiment then involves the introduction of a *trans* prime editing RNA template ("tPERT"), which operates in place of a PEgRNA by providing a primer binding site (PBS) and an DNA synthesis template on separate molecule, i.e., the tPERT, which is also equipped with a MS2 aptamer (stem loop). The MS2cp protein recruits the tPERT by binding to the MS2 aptamer of the molecule. **FIG. 72C** depict alternative designs for PEgRNAs that can be achieved through known methods for chemical synthesis of nucleic acid molecules. For example, chemical synthesis can be used to synthesize a hybrid RNA/DNA PEgRNA molecule for use in prime editing, wherein the extension arm of the hybrid PEgRNA is DNA instead of RNA. In such an embodiment, a DNA-dependent DNA polymerase can be used in place of a reverse transcriptase to synthesize the 3' DNA flap comprising the desired genetic change that is formed by prime editing. In another embodiment, the extension arm can be synthesized to include a chemical linker that prevents the DNA polymerase (e.g., a reverse transcriptase) from using the sgRNA scaffold or backbone as a template. In still another embodiment, the extension arm may comprise a DNA synthesis template that has the reverse orientation relative to the overall orientation of the PEgRNA molecule. For example, and as shown for a PEgRNA in the 5'-to-3' orientation and with an extension attached to the 3' end of the sgRNA scaffold, the DNA synthesis template is orientated in the opposite direction, i.e., the 3'-to-5' direction. This embodiment may be advantageous for PEgRNA embodiments with extension arms positioned at the 3' end of a gRNA. By reverse the orientation of the extension arm, the DNA synthesis by the polymerase (e.g., reverse transcriptase) will terminate once it reaches the newly orientated 5' of the extension arm and will thus, not risk using the gRNA core as a template.

[0183] FIG. 73 demonstrates prime editing with tPERTs and the MS2 recruitment system (aka MS2 tagging technique). An sgRNA targeting the prime editor protein (PE2) to the target locus is expressed in combination with a tPERT containing a primer binding site (a13-nt or 17-nt PBS), an RT template encoding a His6 tag insertion and a homology arm, and an MS2 aptamer (located at the 5' or 3' end of the tPERT molecule). Either prime editor protein (PE2) or a fusion of the MS2cp to the N-terminus of PE2 was used. Editing was carried out with or without a complementary-strand nicking sgRNA, as in the previously developed PE3 system (designated in the x-axis as labels "PE2+nick" or "PE2", respectively). This is also referred to and defined herein as "second-strand nicking."

[0184] FIG. 74 demonstrates that the MS2 aptamer expression of the reverse transcriptase *in trans* and its recruitment with the MS2 aptamer system. The PEgRNAPEgRNA contains the MS2 RNA aptamer inserted into either one of two sgRNA scaffold hairpins. The wild-type M-MLV reverse transcriptase is expressed as an N-terminal or C-terminal fusion to the MS2 coat protein (MCP). Editing is at the HEK3 site in HEK293T cells.

[0185] FIG. 75 provides a bar graph comparing the efficiency (i.e., “% of total sequencing reads with the specified edit or indels”) of PE2, PE2-trunc, PE3, and PE3-trunc over different target sites in various cell lines. The data shows that the prime editors comprising the truncated RT variants were about as efficient as the prime editors comprising the non-truncated RT proteins.

[0186] FIG. 76 demonstrates the editing efficiency of intein-split prime editors. HEK293T cells were transfected with plasmids encoding full-length PE2 or intein-split PE2, PEgRNA and nicking guide RNA. Consensus sequence (most amino-terminal residues of C terminal extein) are indicated. Percent editing at two sites is shown: HEK3 +1 CTT insertion and PRNP +6 G to T. Replicate n=3 independent transfections.

[0187] FIG. 77 demonstrates the editing efficiency of intein-split prime editors. Editing assessed by targeted deep sequencing in bulk cortex and GFP+ subpopulation upon delivery of 5E10vg per SpPE3 half and a small amount 1E10 of nuclear-localized GFP:KASH to P0 mice by ICV injection. Editors and GFP were packaged in AAV9 with EFS promoter. Mice were harvested three weeks post injection and GFP+ nuclei were isolated by flow cytometry. Individual data points are shown, with 1-2 mice per condition analyzed.

[0188] FIG. 78 demonstrates the editing efficiency of intein-split prime editors. Specifically, the figure depicts AAV split-SpPE3 constructs. Co-transduction by AAV particles separately expressing SpPE3-N and SpPE3-C recapitulates PE3 activity. Note N-terminal genome contains a U6-sgRNA cassette expressing the nicking sgRNA, and the C-terminal genome contains a U6-PEgRNA cassette expressing the PEgRNA.

[0189] FIG. 79 shows the editing efficiency of certain optimized linkers. In particular, the data shows the editing efficiency of the PE2 construct with the current linker (noted as PE2 – white box) compared to various versions with the linker replaced with a sequence as indicated at the HEK3, EMX1, FANCF, RNF2 loci for representative PEgRNAs for transition, transversion, insertion, and deletion edits. The replacement linkers are referred to as “1x SGGs”(SEQ ID NO: 174), “2x SGGs”(SEQ ID NO: 446), “3x SGGs” (SEQ ID NO: 3889), “1x XTEN” (SEQ ID NO: 171), “no linker”, “1x Gly”, “1x Pro”, “1x EAAAK”(SEQ ID NO: 3968), “2x EAAAK” (SEQ ID NO: 3969), and “3x EAAAK ” (SEQ ID NO: 3970).. The editing efficiency is measured in bar graph format relative to the “control” editing efficiency of PE2. The linker of PE2 is SGGSSGGSSGSETPGTSESATPESSGGSSGGSS (SEQ ID NO: 127). All editing was done in the

context of the PE3 system, i.e., which refers the PE2 editing construct plus the addition of the optimal secondary sgRNA nicking guide.

[0190] FIG. 80. Taking the average fold efficacy relative to PE2 yields the graph shown, indicating that use of a 1x XTEN (SEQ ID NO: 171) linker sequence improves editing efficiency by 1.14 fold on average (n=15).

[0191] FIG. 81 depicts the transcription level of PEgRNAs from different promoters.

[0192] FIG. 82 Depicts the impact of different types of modifications on PEgRNA structure on editing efficiency relative to unmodified PEgRNA.

[0193] FIG. 83 Depicts a PE experiment that targeted editing of the HEK3 gene, specifically targeting the insertion of a 10 nt insertion at position +1 relative to the nick site and using PE3.

[0194] FIG. 84A depicts an exemplary PEgRNA having a spacer, gRNA core, and an extension arm (RT template + primer binding site), which is modified at the 3' end of the PEgRNA with a tRNA molecule, coupled through a UCU linker. The tRNA includes various post-transcriptional modifications. Said modification are not required, however.

[0195] FIG. 84B depicts structure of tRNA that can be used to modify PEgRNA structures. The P1 can be variable in length. The P1 can be extended to help prevent RNaseP processing of the PEgRNA-tRNA fusion.

[0196] FIG. 85 depicts a PE experiment that targeted editing of the FANCF gene, specifically targeting a G-to-T conversion at position +5 relative to the nick site and using PE3 construct.

[0197] FIG. 86 depicts a PE experiment that targeted editing of the HEK3 gene, specifically targeting the insertion of a 71 nt FLAG tag insertion at position +1 relative to the nick site and using PE3 construct.

[0198] FIG. 87 results from a screen in N2A cells where the pegRNA installs 1412Adel, with details about the primer binding site (PBS) length and reverse transcriptase (RT) template length. (Shown with and without indels).

[0199] FIG. 88 results from a screen in N2A cells where the pegRNA installs 1412Adel, with details about the primer binding site (PBS) length and reverse transcriptase (RT) template length. (Shown with and without indels).

[0200] FIG. 89 depicts results of editing at a proxy locus in the β -globin gene and at HEK3 in healthy HSCs, varying the concentration of editor to pegRNA and nicking gRNA.

[0201] FIG. 90 provides a schematic of an embodiment of dual-flap prime editing. A DNA target sequence is acted upon by two prime editing complexes (guided by pegRNA-A and pegRNA-B). The two pegRNAs target opposite strands of the double helix. Each prime editor (PE2•pegRNA) nicks a single DNA strand, then synthesizes a 3' DNA flap using the pegRNA as a template. The action of the two prime editor complexes results in the production of an intermediate containing two 3' flaps on opposite strands of the DNA. The two 3' flaps are complementarity to one another at their 3' ends.

Annealing of the 3' ends of the 3' flaps results in the formation of a double-duplex structure, with one duplex made of paired 3' flaps containing the new DNA sequence (red), and the other duplex made of paired 5' flaps containing the original DNA sequence (black). Excision of the intervening original DNA duplex (black paired 5' flaps) yields a double-nicked DNA species containing the desired new DNA sequence (red) having replaced the original DNA sequence. Ligation of both nicks completes the editing process.

[0202] FIGs. 91A-91B provide results from Example 7. **FIG. 91A** shows Crispresso2 output allele table (aligned for desired product) for the replacement of a 90-bp sequence with a new 22-bp sequence at the HEK3 site in HEK293T cells using dual prime editors. The desired product accounts for over 80% of the sequencing reads. The reference starting allele is shown above the sequenced alleles, for comparison. **FIG. 91B** shows Sequences of pegRNAs used to achieve the sequence replacement shown in FIG. 91A. pegRNA1 and pegRNA 2 target different strands of the DNA double helix, and generate 5' displaced nicks as drawn in FIG. 90.

[0203] FIG. 92 shows design embodiments of pegRNA designs for dual-flap prime editing. Two pegRNAs are used for dual-flap prime editing, shown in the drawing as pegRNA A and pegRNA B. Each pegRNA contains a spacer sequence (dark blue) that guides the prime editing complex to the target DNA site. The two pegRNAs target opposite strands of the DNA double helix. Like other pegRNAs, dual-flap prime editing pegRNAs contain a 3' extension with a primer binding sequence (PBS, green) that anneals to the nicked genomic DNA strand to initiate reverse transcription, and a reverse transcription template (RT template, light blue) that templates the synthesis of new DNA by the reverse transcriptase enzyme. Unlike pegRNAs used for classic prime editing, which require the newly synthesized edited 3' flap to compete with the endogenous 5' flap, there is no need to encode homology to the target site within the RT template. Instead, the 3' ends of the two synthesized 3' flaps need only contain complementarity to each other (i.e. the 3' ends of the 3' flaps are the reverse complement sequences of one another). This complementarity allows the two 3' flaps to anneal and promote the formation of the desired edited DNA sequence.

[0204] FIGs. 93A-93B show the results of Example 7 of using dual prime editing to install Bxb1 attB and attP sites with dual-flap prime editing. **FIG. 93A** shows the installation of a 38-bp Bxb1 attB site at HEK3. Six pegRNAs were constructed, three targeting the (+) strand (A1, A2 and A3) and three targeting the (-) strand (B1, B2 and B3). These differ in the amounts of attB sequence encoded in the RT template, leading to a different number of complementary nucleotides between the two flaps. The 3x3 matrix of pegRNAs was evaluated for installation of the attB sequence at the target genomic location in HEK293T cells. **FIG. 93A** and **FIG. 93B** show the installation of a 50-bp Bxb1 attP site at HEK3. Six pegRNAs were constructed, three targeting the (+) strand (A1, A2 and A3) and three targeting the (-) strand (B1, B2 and B3). These differ in the amounts of attP sequence encoded in the RT template, leading to a different number of complementary nucleotides between the two flaps.

The 3x3 matrix of pegRNAs was evaluated for installation of the attP sequence at the target genomic location in HEK293T cells. For both edits in FIG. 93A and FIG. 93B, the installation of the attB or attP site occurs with concomitant deletion of the 90-bp of genomic DNA sequence located between the two nick sites.

[0205] FIG. 94 shows the results of installation of Bxb1 attB and attP sites at human safe-harbor loci with dual-flap prime editing. Installation of Bxb1 attP sites at the AAVS1 locus (left) or Bxb1 attB sites at the CCR5 locus (right) in HEK293T cells. Correct edits are shown in blue (AAVS1) and red (CCR5), while indel byproducts are shown in gray.

[0206] FIG. 95 provides a schematic of genomic sequence inversion with quadruple-flap prime editing. A region of genomic DNA is targeted for inversion (green and orange segment). Four pegRNAs are delivered to cells with the PE2 prime editor. One pair of pegRNAs targets a single genomic DNA strand and templates the synthesis of two complementary DNA flaps (A and A', blue), while the second pair targets the other genomic DNA strand and templates the synthesis of two complementary DNA flaps with an orthogonal DNA sequence (B and B', pink). The complementary flaps anneal to form 3' overhang duplexes. The 5' overhang duplexes are excised by endogenous cellular repair enzymes. Nicks are ligated to produce the product allele containing an inverted DNA sequence (green and orange segments) and the pegRNA-templated sequences at the inversion junctions (blue and pink segments).

[0207] FIG. 96 shows the results of amplicon sequencing of AAVS1 inversion junctions. CRISPResso2 analysis output of a 2.7-kb inversion at the AAVS1 locus in HEK293T cells using the quadruple-flap primed editing strategy. PCR amplification and sequencing of the expected inversion junctions showed the desired products with Bxb1 attP or attB sequences inserted at the junctions of the inversion.

[0208] FIGs. 97A-97B show the results of targeted integration of a circular DNA plasmid into the genome using quadruple-flap prime editing. (FIG. 97A) A region of genomic DNA and a region of plasmid DNA are targeted for quadruple flap prime editing integration. Four pegRNAs are delivered to cells with the PE2 prime editor. Two pegRNAs template complementary sequences, one targeting a single genomic DNA strand, and the other targeting a single plasmid DNA strand (generating blue flaps). The other two pegRNAs target opposite genomic DNA and plasmid DNA strands from those of the first two pegRNAs, and they template the synthesis of two complementary DNA flaps (pink) that are orthogonal to the first pair. The complementary flaps anneal to form 3' overhang duplexes. The 5' overhang duplexes are excised by endogenous cellular repair enzymes. Nicks are ligated to produce the product allele containing an integrated plasmid DNA sequence (green and orange segments) and the pegRNA-templated sequences at the integration junctions (blue and pink segments). (FIG. 97B) CRISPResso2 analysis of amplicon sequencing of anticipated junction,

showing plasmid backbone and genomic DNA sequence bridged by the pegRNA-templated attP sequence.

[0209] FIGs. 98A-98B show the results of targeted chromosomal translocation with quadruple-flap prime editing. (FIG. 98A) pegRNAs target two regions on different chromosomes. Complementary 3' DNA flaps bridge the two chromosome sequences and direct the orientation of the translocation. (FIG. 98B) Targeted translocation between MYC and TIMM44 loci in HEK293T cells. CRISPResso2 analysis output from amplicon sequencing of the expected junctions from translocation between the MYC locus on chromosome 8 and the TIMM44 locus on chromosome 19. The majority of sequencing reads correspond to the desired allele sequence.

[0210] FIG. 99 shows installation of Bxb1 attB and attP sites with dual-flap prime editing at IDS locus. HEK293T cells were transfected with PE2 and different pairs of pegRNAs (e.g. in the first column pegRNA A1_a and pegRNA B2_a with templates for installing attP site in the forward direction). The efficiency was measured by HTS. This data shows that dual-flap editing can successfully insert the sequence of interest to the IDS locus with an efficiency up to ~80%.

[0211] FIGs. 100A-100B describe dual-flap-mediated duplication. FIG. 100A is a schematic showing dual-flap-mediated duplication at AAVS1 locus in 293T cells. FIG. 100B shows results of using dual-flap pegRNA with PE2 for inducing duplication of genetic sequences at AAVS1.

[0212] FIG. 101 shows multi-flap induced new translocation MYC-CCR5. MYC-CCR5 translocation was induced by quad-flap pegRNAs and PE2. MYC-CCR5 translocation events were induced by quadruple-pegRNAs. Four different sets of pegRNAs were tested in HEK293T cells. The translocation junction products between derived chr8 and chr3 were amplified by junction primers. The % of reads aligned to the expected junction alleles are shown in the graph. The result shows that quadruple-flap can mediate translocation of MYC and CCR5 gene with product purity near 100% at junction 1 and ~50% at junction 2. A representative allele plot shows the sequences aligned to the expected allele sequences at junction 1.

[0213] FIGs. 102A-102B show dual-flap and multi-flap editing in other human cell lines. FIG. 102A shows dual-flap editing in four different human cell lines. HEK293T and HeLa cells were transfected with dual pegRNAs and PE2 for editing three different genomic loci (IDS, MYC, and TIMM44). U2OS and K562 cells were nucleofected with the same components. Dual-flap has shown robust editing across all four human cells at the targeted loci, particularly at HEK293T and K562 cells. The cellular mechanism for enabling dual-flap editing are conserved across many human cell types. FIG. 102B shows multi-flap (quadruple-pegRNA) directed 2.7 kb inversion at the AAVS1 in HeLa cells.

[0214] FIG. 103A-103B shows results of inversion efficiency measurement by HTS at CCR5 locus. Percentage of the expected inversion edit allele was measured by HTS. Four quad-pegRNA sets PE2 were transfected in HEK293T cells, respectively. FIG. 103A shows dual-flap mediated sequence duplication (~100nt) at CCR5 locus in HEK293T cells. The editing efficiency achieves ~1.5% via

HTS 300-cycle pair-end sequencing analysis. FIG. 103B shows quadruple-flap-mediated sequence inversion (~95-117nt) at CCR5 locus in HeLa cells. The editing efficiency achieves ~1.2% via HTS 300-cycle pair-end sequencing analysis. This result shows that multi-flap can successfully mediate duplication and inversion at CCR5 locus precisely. The editing specificity is high when the targeted sequence is duplicated (percentage of indels < 2%).

[0215] FIGs. 104A-104E show targeted cellular repair pathway for dual-flap editing. In FIGs. 104A-104D, HEK293T cells were transfected with the plasmids that express Exo1, Fen1, Red Fluorescence Protein (control), DNA2, Mlh1 neg, and P53 inhibitor with pegRNA and PE2. The editing efficiency was measured by HTS. The editing efficiency was compared between the candidate and the RFP control. In FIG. 104E, HEK293T cells were transfected with the siRNA plasmids and pegRNA and PE2 for each target locus. Non-targeting siRNA (siNT) was used as the control. The editing efficiency was measured by HTS. The editing efficiency was compared between each siRNA knockdown and the siNT ctrl at each target locus. HEK293T cells were transfected with dual-pegRNAs, PE2, and the plasmids that express Exo1, Fen1, Red Fluorescence Protein (ctrl), DNA2, Mlh1 neg, and P53 inhibitor respectively. The editing efficiency was measured by HTS. The editing efficiency was compared between the candidate and the RFP ctrl. Two-tailed, paired Student t-test was used to measure statistical difference between each treatment and RFP control ($P < 0.05$, *; $P < 0.01$, **; $P < 0.001$, ***). Overexpression of FEN1 improves dual flap editing efficiency in all four targeted loci (MYC, TIMM44, IDS, CCR5).

[0216] FIGs. 105A-105B show dual-flap-mediated sequence duplication at AAVS1 locus. FIG. 105A shows a schematic diagram of dual-flap-mediated sequence duplication at AAVS1 locus. FIG. 105B shows that by using dual pegRNAs that generate two unique 3' flap structures, a ~300bp sequence duplication was induced at AAVS1 locus in 293T cells. Expected alleles are amplified with specific primers and are subjected for HTS. ~94% reads are aligned to the expected alleles with duplication. Duplication products are not observed in the untreated samples.

[0217] FIG. 106 shows targeted IDS genomic sequence inversion with quadruple-flap prime editing. ~13% of Hunter syndrome patients have been shown to have an inversion of the IDS gene sequences (Bondeson et al., Human Molecular Genetics, 1995). Quadruple-flap prime editing was applied to induce this pathogenic inversion of the ~40kb IDS genomic sequence in the HEK293T cells. Six sets of quadruple pegRNAs were tested by transfecting HEK293T cells with the pegRNAs and PE2. Primers were used to specifically amplify the inverted sequences at junction "ab" and junction "cd". ~95% of the expected inverted allele sequences were observed at both junctions with IDS_QF1. Other sets of pegRNAs also yield high percentage of the expected allele sequences at both junctions. Inverted junction products are not observed in the untreated samples.

[0218] FIG. 107 shows that PegRNA 3' motif modification improves dual-flap editing efficiency at IDS locus. To further improve the dual flap editing efficiency, a pseudoknot evoPreQ1 motif was

introduced to protect the pegRNA 3' end. By comparing the editing efficiency generated by the unmodified and evoPreQ1-modified dual pegRNAs, there is an overall increase of the editing efficiency with modified pegRNAs at the targeted IDS locus. The improvement of dual-flap editing efficiency can reach up to 5.3-fold.

[0219] FIGs. 108A-108C show an overview of twinPE and twinPE-mediated sequence replacement. FIG. 108A shows that twinPE systems target genomic DNA sequences that contain two protospacer sequences on opposite strands of DNA. PE2•pegRNA complexes target each protospacer, generate a single-stranded nick, and reverse transcribe the pegRNA-encoded template containing the desired insertion sequence. After synthesis and release of the 3' DNA flaps, a hypothetical intermediate exists possessing annealed 3' flaps containing the edited DNA sequence and annealed 5' flaps containing the original DNA sequence. Excision of the original DNA sequence contained in the 5' flap, followed by ligation of the 3' flaps to the corresponding excision site, generates the desired edited product. FIG. 108B shows an example of twinPE-mediated replacement of a 90-bp sequence in *HEK site 3* with a 38-bp Bxb1 *attB* sequence. FIG. 108C shows an evaluation of twinPE in HEK293T cells for the installation of the 38-bp Bxb1 *attB* site as shown in FIG. 108B or the 50-bp Bxb1 *attP* site at *HEK site 3* using pegRNAs that template varying lengths of the insertion sequence. Values and error bars reflect the mean and s.d. of three independent biological replicates.

[0220] FIGs. 109A-109E show targeted sequence insertion, deletion, and recoding with twinPE in human cells. FIG. 109A shows insertion of FKBP coding sequence fragments with PE3 (12 bp, 36 bp, 108 bp, or 321 bp) or twinPE (108 bp) at *HEK site 3* in HEK293T cells. FIG. 109B shows recoding of sequence within exons 4 and 7 in *PAH* in HEK293T cells using twinPE. A 64-bp target sequence in exon 4 was edited using 24, 36, or 59 bp of overlapping flaps, a 46-bp target sequence in exon 7 was edited using 22 or 42 bp of overlapping flaps, or a 64-bp sequence in exon 7 was edited using 24 or 47 bp of overlapping flaps. Editing activity was compared using standard pegRNAs or epegRNAs containing 3' evoPreQ1 motifs. FIG. 109C is a schematic diagram of three distinct dual-flap deletion strategies that were investigated for carrying out targeted deletions. The "Basic-Anchor (BA)" twinPE strategy allows for flexible deletion starting at an arbitrary position 3' of one nick site and ending at the other nick site. The "Hybrid-Anchor (HA)" twinPE strategy allows for flexible deletion of sequence at arbitrarily chosen positions between the two nick sites. The "PrimeDel (PD)" strategy tested here allows for deletion of the sequence starting at one nick site and ending at another nick site. FIG. 109D shows deletion of sequences at *HEK site 3* in HEK293T cells using the BA-twinPE, HA-twinPE, or PD strategies targeting the same protospacer pair. Editing activity was compared using standard pegRNAs or epegRNAs containing 3' evoPreQ1 motifs. FIG. 109E shows deletion of exon 51 sequence at the *DMD* locus in HEK293T cells using BA-twinPE, PD, paired Cas9 nuclease, or twinPE-mediated *attB* sequence replacement. Values and error bars reflect the mean and s.d. of three

independent biological replicates. In the DMD exon 51 skipping experiment, at least two independent biological replicates were performed.

[0221] FIGs. 110A-110E show site-specific genomic integration of DNA cargo with twinPE and Bxb1 recombinase in human cells. FIG. 110A shows screening of twinPE pegRNA pairs for installation of the Bxb1 *attP* sequence at the *AAVS1* locus in HEK293T cells. FIG. 110B shows screening of twinPE pegRNA pairs for installation of the Bxb1 *attB* sequence at the *CCR5* locus in HEK293T cells. FIG. 110C shows single transfection knock-in of 5.6-kb DNA donors using twinPE pegRNA pairs targeting *CCR5* (four left-most bars) or *AAVS1* (three right-most bars). The twinPE pegRNAs install *attB* at *CCR5* or *attP* at *AAVS1*. Bxb1 then integrates a donor bearing the corresponding attachment site into the genomic attachment site. FIG. 110D shows optimization of single transfection knock-in at *CCR5* using the 531/584 twinPE pegRNA pair. Identity of the templated edit (*attB* vs. *attP*), identity of the central dinucleotide (wild-type GT vs. orthogonal mutant GA), and length of the overlap between flaps were varied to identify the combination that supported the highest knock-in efficiency. FIG. 110E shows insertion of the Bxb1 *attB* sequence within intron 1 of *ALB* in HEK293T and Huh7 cells lines. FIG. 110F shows a comparison of single transfection knock-in efficiencies at *CCR5* and *ALB* in HEK293T and Huh7 cell lines.

[0222] FIGs. 111A-111E show site-specific genomic sequence inversion with twinPE and Bxb1 recombinase in human cells. FIG. 111A is a schematic diagram of recombination hot spots in *IDS* and *IDS2* that lead to pathogenic 39-kb inversions, and the combined twinPE-Bxb1 strategy for installing or correcting the *IDS* inversion mutation. FIG. 111B shows a screen of pegRNA pairs at *IDS* and *IDS2* for installation of *attP* or *attB* recombination site insertion at *IDS* and *IDS2* loci with specific DNA targets. FIG. 111C shows a DNA sequencing analysis of the *attP* or *attB* insertion with sequential DNA transfection. FIG. 111D shows inversion product purity at the inverted junction 1 and junction 2 (sequential transfection), indicating the successful inversion at the two junctions. FIG. 111E shows the quantification of inversion efficiency at the junctions (sequential transfection and “one-pot” RNA nucleofection).

[0223] FIG. 112 shows the recoding of sequences within exon 10, 11, and 12 in *PAH* in HEK293T cells via twinPE. A 64-bp target sequence in exon 10 was edited using 28 bp of overlapping flaps, a 61-bp and 55-bp target sequence in exon 11 was edited using 25 bp of overlapping flaps, or a 68-bp and 58-bp sequence in exon 12 was edited using 27 and 24 bp of overlapping flaps, respectively. Values and error bars reflect the mean and s.d. of three independent biological replicates

[0224] FIG. 113 shows transfection of HEK293T clonal cell line containing homozygous *attB* site insertion with BxBI plasmids and *attP*-containing donor DNA plasmids. The knock-in efficiency is between 12-17% at the target site as measured by ddPCR.

[0225] FIG. 114 shows HTS measurement of expected junction sequences containing *attL* and *attR* recombination products after twinPE and BxBI-mediated one-pot knock-in. The product purities

range from 71-95%. Values and error bars reflect the mean and s.d. of three independent biological replicates

[0226] FIG. 115A shows twinPE mediated *attB* insertion efficiency with reduced flap overlap length in the dual pegRNAs.

[0227] FIG. 115B shows PCR products amplified by specific primer for capturing the recombination between donor DNA and pegRNA plasmids shown on the agarose gel. Recombination between donor DNA and pegRNA plasmid was reduced with smaller flap overlap.

[0228] FIG. 116 is a schematic diagram of the developed PCR strategies for quantifying *IDS* inversion efficiency.

DEFINITIONS

[0229] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

Antisense strand

[0230] In genetics, the “antisense” strand of a segment within double-stranded DNA is the template strand, and which is considered to run in the 3' to 5' orientation. By contrast, the “sense” strand is the segment within double-stranded DNA that runs from 5' to 3', and which is complementary to the antisense strand of DNA, or template strand, which runs from 3' to 5'. In the case of a DNA segment that encodes a protein, the sense strand is the strand of DNA that has the same sequence as the mRNA, which takes the antisense strand as its template during transcription, and eventually undergoes (typically, not always) translation into a protein. The antisense strand is thus responsible for the RNA that is later translated to protein, while the sense strand possesses a nearly identical makeup to that of the mRNA. Note that for each segment of dsDNA, there will possibly be two sets of sense and antisense, depending on which direction one reads (since sense and antisense is relative to perspective). It is ultimately the gene product, or mRNA, that dictates which strand of one segment of dsDNA is referred to as sense or antisense.

Bi-specific ligand

[0231] The term “bi-specific ligand” or “bi-specific moiety,” as used herein, refers to a ligand that binds to two different ligand-binding domains. In certain embodiments, the ligand is a small molecule compound, or a peptide, or a polypeptide. In other embodiments, ligand-binding domain is a

“dimerization domain,” which can be install as a peptide tag onto a protein. In various embodiments, two proteins each comprising the same or different dimerization domains can be induced to dimerize through the binding of each dimerization domain to the bi-specific ligand. As used herein, “bi-specific ligands” may be equivalently refer to “chemical inducers of dimerization” or “CIDs”.

Cas9

[0232] The term “Cas9” or “Cas9 nuclease” refers to an RNA-guided nuclease comprising a Cas9 domain, or a fragment thereof (*e.g.*, a protein comprising an active or inactive DNA cleavage domain of Cas9, and/or the gRNA binding domain of Cas9). A “Cas9 domain” as used herein, is a protein fragment comprising an active or inactive cleavage domain of Cas9 and/or the gRNA binding domain of Cas9. A “Cas9 protein” is a full length Cas9 protein. A Cas9 nuclease is also referred to sometimes as a *casn1* nuclease or a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat)-associated nuclease. CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements, and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (*rnc*) and a Cas9 domain. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, Cas9/crRNA/tracrRNA endonucleolytically cleaves a linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3'-5' exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNAs. However, single guide RNAs (“sgRNA”, or simply “gRNA”) can be engineered to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, *e.g.*, Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. *Science* 337:816-821(2012), the entire contents of which are hereby incorporated by reference. Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self. Cas9 nuclease sequences and structures are well known to those of skill in the art (see, *e.g.*, “Complete genome sequence of an M1 strain of *Streptococcus pyogenes*.” Ferretti *et al.*, J.J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P., Qian Y., Jia H.G., Najar F.Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S.W., Roe B.A., McLaughlin R.E., *Proc. Natl. Acad. Sci. U.S.A.* 98:4658-4663(2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E., Chylinski K., Sharma C.M., Gonzales K., Chao Y., Pirzada Z.A., Eckert M.R., Vogel J., Charpentier E., *Nature* 471:602-607(2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. *Science* 337:816-821(2012), the entire contents of each of which are incorporated herein by reference). Cas9 orthologs have been

described in various species, including, but not limited to, *S. pyogenes* and *S. thermophilus*.

Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) *RNA Biology* 10:5, 726-737; the entire contents of which are incorporated herein by reference. In some embodiments, a Cas9 nuclease comprises one or more mutations that partially impair or inactivate the DNA cleavage domain.

[0233] A nuclease-inactivated Cas9 domain may interchangeably be referred to as a "dCas9" protein (for nuclease-"dead" Cas9). Methods for generating a Cas9 domain (or a fragment thereof) having an inactive DNA cleavage domain are known (see, e.g., Jinek *et al.*, *Science*. 337:816-821(2012); Qi *et al.*, "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression" (2013) *Cell*. 28;152(5):1173-83, the entire contents of each of which are incorporated herein by reference). For example, the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain. The HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations D10A and H840A completely inactivate the nuclease activity of *S. pyogenes* Cas9 (Jinek *et al.*, *Science*. 337:816-821(2012); Qi *et al.*, *Cell*. 28;152(5):1173-83 (2013)). In some embodiments, proteins comprising fragments of Cas9 are provided. For example, in some embodiments, a protein comprises one of two Cas9 domains: (1) the gRNA binding domain of Cas9; or (2) the DNA cleavage domain of Cas9. In some embodiments, proteins comprising Cas9 or fragments thereof are referred to as "Cas9 variants." A Cas9 variant shares homology to Cas9, or a fragment thereof. For example, a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, at least about 99.8% identical, or at least about 99.9% identical to wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 18). In some embodiments, the Cas9 variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more amino acid changes compared to wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 18). In some embodiments, the Cas9 variant comprises a fragment of SEQ ID NO: 18 Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 18). In some embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least

50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild type Cas9 (e.g., SpCas9 of SEQ ID NO: 18).

cDNA

[0234] The term "cDNA" refers to a strand of DNA copied from an RNA template. cDNA is complementary to the RNA template.

Circular permutant

[0235] As used herein, the term "circular permutant" refers to a protein or polypeptide (e.g., a Cas9) comprising a circular permutation, which is a change in the protein's structural configuration involving a change in the order of amino acids appearing in the protein's amino acid sequence. In other words, circular permutants are proteins that have altered N- and C-termini as compared to a wild-type counterpart, e.g., the wild-type C-terminal half of a protein becomes the new N-terminal half. Circular permutation (or CP) is essentially the topological rearrangement of a protein's primary sequence, connecting its N- and C-terminus, often with a peptide linker, while concurrently splitting its sequence at a different position to create new, adjacent N- and C-termini. The result is a protein structure with different connectivity, but which often can have the same overall similar three-dimensional (3D) shape, and possibly include improved or altered characteristics, including, reduced proteolytic susceptibility, improved catalytic activity, altered substrate or ligand binding, and/or improved thermostability. Circular permutant proteins can occur in nature (e.g., concanavalin A and lectin). In addition, circular permutation can occur as a result of posttranslational modifications or may be engineered using recombinant techniques.

Circularly permuted Cas9

[0236] The term "circularly permuted Cas9" refers to any Cas9 protein, or variant thereof, that has been occurs as a circular permutant, whereby its N- and C-termini have been topically rearranged. Such circularly permuted Cas9 proteins ("CP-Cas9"), or variants thereof, retain the ability to bind DNA when complexed with a guide RNA (gRNA). See, Oakes et al., "Protein Engineering of Cas9 for enhanced function," *Methods Enzymol*, 2014, 546: 491–511 and Oakes et al., "CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification," *Cell*, January 10, 2019, 176: 254-267, each of which are incorporated herein by reference. The instant disclosure contemplates any previously known CP-Cas9 or use of a new CP-Cas9 so long as the resulting circularly permuted protein retains the ability to bind DNA when complexed with a guide RNA (gRNA). Exemplary CP-Cas9 proteins are SEQ ID NOs: 77-86.

CRISPR

[0237] CRISPR is a family of DNA sequences (i.e., CRISPR clusters) in bacteria and archaea that represent snippets of prior infections by a virus that have invaded the prokaryote. The snippets of DNA are used by the prokaryotic cell to detect and destroy DNA from subsequent attacks by similar

viruses and effectively compose, along with an array of CRISPR-associated proteins (including Cas9 and homologs thereof) and CRISPR-associated RNA, a prokaryotic immune defense system. In nature, CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In certain types of CRISPR systems (e.g., type II CRISPR systems), correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc) and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, Cas9/crRNA/tracrRNA endonucleolytically cleaves a linear or circular dsDNA target complementary to the RNA. Specifically, the target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3'-5' exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNAs. However, single guide RNAs ("sgRNA", or simply "gRNA") can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species – the guide RNA. See, e.g., Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. *Science* 337:816-821(2012), the entire contents of which is hereby incorporated by reference. Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish self versus non-self. CRISPR biology, as well as Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g., "Complete genome sequence of an M1 strain of *Streptococcus pyogenes*." Ferretti *et al.*, J.J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P., Qian Y., Jia H.G., Najjar F.Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S.W., Roe B.A., McLaughlin R.E., *Proc. Natl. Acad. Sci. U.S.A.* 98:4658-4663(2001); "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III." Deltcheva E., Chylinski K., Sharma C.M., Gonzales K., Chao Y., Pirzada Z.A., Eckert M.R., Vogel J., Charpentier E., *Nature* 471:602-607(2011); and "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. *Science* 337:816-821(2012), the entire contents of each of which are incorporated herein by reference). Cas9 orthologs have been described in various species, including, but not limited to, *S. pyogenes* and *S. thermophilus*. Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems" (2013) *RNA Biology* 10:5, 726-737; the entire contents of which are incorporated herein by reference.

[0238] In certain types of CRISPR systems (e.g., type II CRISPR systems), correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc), and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, Cas9/crRNA/tracrRNA endonucleolytically cleaves a linear or circular nucleic acid target complementary to the RNA. Specifically, the target strand not complementary to crRNA is first

cut endonucleolytically, then trimmed 3'-5' exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNAs. However, single guide RNAs ("sgRNA", or simply "gRNA") can be engineered to incorporate embodiments of both the crRNA and tracrRNA into a single RNA species—the guide RNA.

[0239] In general, a "CRISPR system" refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans-activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), or other sequences and transcripts from a CRISPR locus. The tracrRNA of the system is complementary (fully or partially) to the tracr mate sequence present on the guide RNA.

DNA synthesis template

[0240] As used herein, the term "DNA synthesis template" refers to the region or portion of the extension arm of a PEgRNA that is utilized as a template strand by a polymerase of a prime editor to encode a 3' single-strand DNA flap that contains the desired edit and which then, through the mechanism of prime editing, replaces the corresponding endogenous strand of DNA at the target site. In various embodiments, the DNA synthesis template is shown in FIG. 3A (in the context of a PEgRNA comprising a 5' extension arm), FIG. 3B (in the context of a PEgRNA comprising a 3' extension arm), FIG. 3C (in the context of an internal extension arm), FIG. 3D (in the context of a 3' extension arm), and FIG. 3E (in the context of a 5' extension arm). The extension arm, including the DNA synthesis template, may be comprised of DNA or RNA. In the case of RNA, the polymerase of the prime editor can be an RNA-dependent DNA polymerase (e.g., a reverse transcriptase). In the case of DNA, the polymerase of the prime editor can be a DNA-dependent DNA polymerase. In various embodiments (e.g., as depicted in FIGs. 3D-3E), the DNA synthesis template (4) may comprise the "edit template" and the "homology arm", and all or a portion of the optional 5' end modifier region, e2. That is, depending on the nature of the e2 region (e.g., whether it includes a hairpin, toeloop, or stem/loop secondary structure), the polymerase may encode none, some, or all of the e2 region, as well. Said another way, in the case of a 3' extension arm, the DNA synthesis template (3) can include the portion of the extension arm (3) that spans from the 5' end of the primer binding site (PBS) to 3' end of the gRNA core that may operate as a template for the synthesis of a single-strand of DNA by a polymerase (e.g., a reverse transcriptase). In the case of a 5' extension arm, the DNA synthesis template (3) can include the portion of the extension arm (3) that spans from the 5' end of the PEgRNA molecule to the 3' end of the edit template. Preferably, the DNA synthesis template excludes the primer binding site (PBS) of PEgRNAs either having a 3' extension arm or a 5' extension arm. Certain embodiments described here (e.g, FIG. 71A) refer to an "an RT template,"

which is inclusive of the edit template and the homology arm, i.e., the sequence of the PEGRNA extension arm which is actually used as a template during DNA synthesis. The term “RT template” is equivalent to the term “DNA synthesis template.”

[0241] In the case of *trans* prime editing (e.g., FIG. 3G and FIG. 3H), the primer binding site (PBS) and the DNA synthesis template can be engineered into a separate molecule referred to as a *trans* prime editor RNA template (tPERT).

Dimerization domain

[0242] The term “dimerization domain” refers to a ligand-binding domain that binds to a binding moiety of a bi-specific ligand. A “first” dimerization domain binds to a first binding moiety of a bi-specific ligand and a “second” dimerization domain binds to a second binding moiety of the same bi-specific ligand. When the first dimerization domain is fused to a first protein (e.g., via PE, as discussed herein) and the second dimerization domain (e.g., via PE, as discussed herein) is fused to a second protein, the first and second protein dimerize in the presence of a bi-specific ligand, wherein the bi-specific ligand has at least one moiety that binds to the first dimerization domain and at least another moiety that binds to the second dimerization domain.

Downstream

[0243] As used herein, the terms “upstream” and “downstream” are terms of relativity that define the linear position of at least two elements located in a nucleic acid molecule (whether single or double-stranded) that is orientated in a 5′-to-3′ direction. In particular, a first element is upstream of a second element in a nucleic acid molecule where the first element is positioned somewhere that is 5′ to the second element. For example, a SNP is upstream of a Cas9-induced nick site if the SNP is on the 5′ side of the nick site. Conversely, a first element is downstream of a second element in a nucleic acid molecule where the first element is positioned somewhere that is 3′ to the second element. For example, a SNP is downstream of a Cas9-induced nick site if the SNP is on the 3′ side of the nick site. The nucleic acid molecule can be a DNA (double or single stranded), RNA (double or single stranded), or a hybrid of DNA and RNA. The analysis is the same for single strand nucleic acid molecule and a double strand molecule since the terms upstream and downstream are in reference to only a single strand of a nucleic acid molecule, except that one needs to select which strand of the double stranded molecule is being considered. Often, the strand of a double stranded DNA which can be used to determine the positional relativity of at least two elements is the “sense” or “coding” strand. In genetics, a “sense” strand is the segment within double-stranded DNA that runs from 5′ to 3′, and which is complementary to the antisense strand of DNA, or template strand, which runs from 3′ to 5′. Thus, as an example, a SNP nucleobase is “downstream” of a promoter sequence in a genomic DNA (which is double-stranded) if the SNP nucleobase is on the 3′ side of the promoter on the sense or coding strand.

Edit template

[0244] The term “edit template” refers to a portion of the extension arm that encodes the desired edit in the single strand 3' DNA flap that is synthesized by the polymerase, e.g., a DNA-dependent DNA polymerase, RNA-dependent DNA polymerase (e.g., a reverse transcriptase). Certain embodiments described here (e.g., FIG. 71A) refer to “an RT template,” which refers to both the edit template and the homology arm together, i.e., the sequence of the PEGRNA extension arm which is actually used as a template during DNA synthesis. The term “RT edit template” is also equivalent to the term “DNA synthesis template,” but wherein the RT edit template reflects the use of a prime editor having a polymerase that is a reverse transcriptase, and wherein the DNA synthesis template reflects more broadly the use of a prime editor having any polymerase.

Effective amount

[0245] The term “effective amount,” as used herein, refers to an amount of a biologically active agent that is sufficient to elicit a desired biological response. For example, in some embodiments, an effective amount of a prime editor (PE) may refer to the amount of the editor that is sufficient to edit a target site nucleotide sequence, e.g., a genome. In some embodiments, an effective amount of a prime editor (PE) provided herein, e.g., of a fusion protein comprising a nickase Cas9 domain and a reverse transcriptase may refer to the amount of the fusion protein that is sufficient to induce editing of a target site specifically bound and edited by the fusion protein. As will be appreciated by the skilled artisan, the effective amount of an agent, e.g., a fusion protein, a nuclease, a hybrid protein, a protein dimer, a complex of a protein (or protein dimer) and a polynucleotide, or a polynucleotide, may vary depending on various factors as, for example, on the desired biological response, e.g., on the specific allele, genome, or target site to be edited, on the cell or tissue being targeted, and on the agent being used.

Error-prone reverse transcriptase

[0246] As used herein, the term “error-prone” reverse transcriptase (or more broadly, any polymerase) refers to a reverse transcriptase (or more broadly, any polymerase) that occurs naturally or which has been derived from another reverse transcriptase (e.g., a wild type M-MLV reverse transcriptase) which has an error rate that is less than the error rate of wild type M-MLV reverse transcriptase. The error rate of wild type M-MLV reverse transcriptase is reported to be in the range of one error in 15,000 (higher) to 27,000 (lower). An error rate of 1 in 15,000 corresponds with an error rate of 6.7×10^{-5} . An error rate of 1 in 27,000 corresponds with an error rate of 3.7×10^{-5} . See Boutabout et al. (2001) “DNA synthesis fidelity by the reverse transcriptase of the yeast retrotransposon Ty1,” *Nucleic Acids Res* 29(11):2217–2222, which is incorporated herein by reference. Thus, for purposes of this application, the term “error prone” refers to those RT that have an error rate that is greater than one error in 15,000 nucleobase incorporation (6.7×10^{-5} or higher), e.g., 1 error in 14,000 nucleobases (7.14×10^{-5} or higher), 1 error in 13,000 nucleobases or fewer (7.7×10^{-5} or higher), 1 error in 12,000 nucleobases or fewer (7.7×10^{-5} or higher), 1 error in 11,000

nucleobases or fewer (9.1×10^{-5} or higher), 1 error in 10,000 nucleobases or fewer (1×10^{-4} or 0.0001 or higher), 1 error in 9,000 nucleobases or fewer (0.00011 or higher), 1 error in 8,000 nucleobases or fewer (0.00013 or higher), 1 error in 7,000 nucleobases or fewer (0.00014 or higher), 1 error in 6,000 nucleobases or fewer (0.00016 or higher), 1 error in 5,000 nucleobases or fewer (0.0002 or higher), 1 error in 4,000 nucleobases or fewer (0.00025 or higher), 1 error in 3,000 nucleobases or fewer (0.00033 or higher), 1 error in 2,000 nucleobase or fewer (0.00050 or higher), or 1 error in 1,000 nucleobases or fewer (0.001 or higher), or 1 error in 500 nucleobases or fewer (0.002 or higher), or 1 error in 250 nucleobases or fewer (0.004 or higher).

Extein

[0247] The term “extein,” as used herein, refers to an polypeptide sequence that is flanked by an intein and is ligated to another extein during the process of protein splicing to form a mature, spliced protein. Typically, an intein is flanked by two extein sequences that are ligated together when the intein catalyzes its own excision. Exteins, accordingly, are the protein analog to exons found in mRNA. For example, a polypeptide comprising an intein may be of the structure extein(N) – intein – extein(C). After excision of the intein and splicing of the two exteins, the resulting structures are extein(N) – extein(C) and a free intein. In various configurations, the exteins may be separate proteins (e.g., half of a Cas9 or PE fusion protein), each fused to a split-intein, wherein the excision of the split inteins causes the splicing together of the extein sequences.

Extension arm

[0248] The term “extension arm” refers to a nucleotide sequence component of a PEgRNA which provides several functions, including a primer binding site and an edit template for reverse transcriptase. In some embodiments, e.g., FIG. 3D, the extension arm is located at the 3' end of the guide RNA. In other embodiments, e.g., FIG. 3E, the extension arm is located at the 5' end of the guide RNA. In some embodiments, the extension arm also includes a homology arm. In various embodiments, the extension arm comprises the following components in a 5' to 3' direction: the homology arm, the edit template, and the primer binding site. Since polymerization activity of the reverse transcriptase is in the 5' to 3' direction, the preferred arrangement of the homology arm, edit template, and primer binding site is in the 5' to 3' direction such that the reverse transcriptase, once primed by an annealed primer sequence, polymerizes a single strand of DNA using the edit template as a complementary template strand. Further details, such as the length of the extension arm, are described elsewhere herein.

[0249] The extension arm may also be described as comprising generally two regions: a primer binding site (PBS) and a DNA synthesis template, as shown in FIG. 3G (top), for instance. The primer binding site binds to the primer sequence that is formed from the endogenous DNA strand of the target site when it becomes nicked by the prime editor complex, thereby exposing a 3' end on the endogenous nicked strand. As explained herein, the binding of the primer sequence to the primer

binding site on the extension arm of the PEgRNA creates a duplex region with an exposed 3' end (i.e., the 3' of the primer sequence), which then provides a substrate for a polymerase to begin polymerizing a single strand of DNA from the exposed 3' end along the length of the DNA synthesis template. The sequence of the single strand DNA product is the complement of the DNA synthesis template. Polymerization continues towards the 5' of the DNA synthesis template (or extension arm) until polymerization terminates. Thus, the DNA synthesis template represents the portion of the extension arm that is encoded into a single strand DNA product (i.e., the 3' single strand DNA flap containing the desired genetic edit information) by the polymerase of the prime editor complex and which ultimately replaces the corresponding endogenous DNA strand of the target site that sits immediately downstream of the PE-induced nick site. Without being bound by theory, polymerization of the DNA synthesis template continues towards the 5' end of the extension arm until a termination event. Polymerization may terminate in a variety of ways, including, but not limited to (a) reaching a 5' terminus of the PEgRNA (e.g., in the case of the 5' extension arm wherein the DNA polymerase simply runs out of template), (b) reaching an impassable RNA secondary structure (e.g., hairpin or stem/loop), or (c) reaching a replication termination signal, e.g., a specific nucleotide sequence that blocks or inhibits the polymerase, or a nucleic acid topological signal, such as, supercoiled DNA or RNA.

Flap endonuclease (e.g., FEN1)

[0250] As used herein, the term “flap endonuclease” refers to an enzyme that catalyzes the removal of 5' single strand DNA flaps. These are naturally occurring enzymes that process the removal of 5' flaps formed during cellular processes, including DNA replication. The prime editing methods herein described may utilize endogenously supplied flap endonucleases or those provided *in trans* to remove the 5' flap of endogenous DNA formed at the target site during prime editing. Flap endonucleases are known in the art and can be found described in Patel et al., “Flap endonucleases pass 5'-flaps through a flexible arch using a disorder-thread-order mechanism to confer specificity for free 5'-ends,”

Nucleic Acids Research, 2012, 40(10): 4507-4519, Tsutakawa et al., “Human flap endonuclease structures, DNA double-base flipping, and a unified understanding of the FEN1 superfamily,” *Cell*, 2011, 145(2): 198-211, and Balakrishnan et al., “Flap Endonuclease 1,” *Annu Rev Biochem*, 2013, Vol 82: 119-138 (each of which are incorporated herein by reference). An exemplary flap endonuclease is FEN1, which can be represented by the following amino acid sequence:

DESCRIPTI ON	SEQUENCE	SEQ ID NO:
FEN1 WILD TYPE	MGIQGLAKLIADVAPSAIRENDIKSYFGRKVAIDASMSIYQFL IAVRQGGDVLQNEEGETTSHLMGMFYRTIRMMENGIKPVY VFDGKPPQLKSGELAKRSERRAEAEKQLQQAQAAGAEQEV EKFTKRLVKVTKQHNDECKHLLSLMGIPYLDAPSEAEASCA ALVKAGKVYAAATEDMDCLTFGSPVLMRHLTASEAKKLP EFHLSRILQELGLNQEQFVLDLCILLGSDYCESIRGIGPKRAVD LIQKHKSIEEIVRRDPNKYPVPENWLHKEAHQLFLEPEVLD	SEQ ID NO: 7

	PESVELKWSEPNEEELIKFMCGEKQFSEERIRSGVKRLSKSR QGSTQGRLLDDFFKVTGSLSSAKRKEPEPKGSTKKKAKTGAA GKFKRGK	
--	---	--

Functional equivalent

[0251] The term “functional equivalent” refers to a second biomolecule that is equivalent in function, but not necessarily equivalent in structure to a first biomolecule. For example, a “Cas9 equivalent” refers to a protein that has the same or substantially the same functions as Cas9, but not necessarily the same amino acid sequence. In the context of the disclosure, the specification refers throughout to “a protein X, or a functional equivalent thereof.” In this context, a “functional equivalent” of protein X embraces any homolog, paralog, fragment, naturally occurring, engineered, mutated, or synthetic version of protein X which bears an equivalent function.

Fusion protein

[0252] The term “fusion protein” as used herein refers to a hybrid polypeptide which comprises protein domains from at least two different proteins. One protein may be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy-terminal (C-terminal) protein thus forming an “amino-terminal fusion protein” or a “carboxy-terminal fusion protein,” respectively. A protein may comprise different domains, for example, a nucleic acid binding domain (*e.g.*, the gRNA binding domain of Cas9 that directs the binding of the protein to a target site) and a nucleic acid cleavage domain or a catalytic domain of a nucleic-acid editing protein. Another example includes a Cas9 or equivalent thereof to a reverse transcriptase. Any of the proteins provided herein may be produced by any method known in the art. For example, the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker. Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, *Molecular Cloning: A Laboratory Manual* (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)), the entire contents of which are incorporated herein by reference.

Gene of interest (GOI)

[0253] The term “gene of interest” or “GOI” refers to a gene that encodes a biomolecule of interest (*e.g.*, a protein or an RNA molecule). A protein of interest can include any intracellular protein, membrane protein, or extracellular protein, *e.g.*, a nuclear protein, transcription factor, nuclear membrane transporter, intracellular organelle associated protein, a membrane receptor, a catalytic protein, and enzyme, a therapeutic protein, a membrane protein, a membrane transport protein, a signal transduction protein, or an immunological protein (*e.g.*, an IgG or other antibody protein), etc. The gene of interest may also encode an RNA molecule, including, but not limited to, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), antisense RNA, guide RNA, microRNA (miRNA), small interfering RNA (siRNA), and cell-free RNA (cfRNA).

Guide RNA (“gRNA”)

[0254] As used herein, the term “guide RNA” is a particular type of guide nucleic acid which is mostly commonly associated with a Cas protein of a CRISPR-Cas9 and which associates with Cas9, directing the Cas9 protein to a specific sequence in a DNA molecule that includes complementarity to the protospacer sequence of the guide RNA. However, this term also embraces the equivalent guide nucleic acid molecules that associate with Cas9 equivalents, homologs, orthologs, or paralogs, whether naturally occurring or non-naturally occurring (e.g., engineered or recombinant), and which otherwise program the Cas9 equivalent to localize to a specific target nucleotide sequence. The Cas9 equivalents may include other Cas proteins from any type of CRISPR system (e.g., type II, V, VI), including Cpf1 (a type-V CRISPR-Cas systems), C2c1 (a type V CRISPR-Cas system), C2c2 (a type VI CRISPR-Cas system) and C2c3 (a type V CRISPR-Cas system). Further Cas-equivalents are described in Makarova et al., “C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector,” *Science* 2016; 353(6299), the contents of which are incorporated herein by reference. Exemplary sequences and structures of guide RNAs are provided herein. In addition, methods for designing appropriate guide RNA sequences are provided herein. As used herein, the “guide RNA” may also be referred to as a “traditional guide RNA” to contrast it with the modified forms of guide RNA termed “prime editing guide RNAs” (or “PEgRNAs”) which have been invented for the prime editing methods and composition disclosed herein.

[0255] Guide RNAs or PEgRNAs may comprise various structural elements that include, but are not limited to:

[0256] Spacer sequence – the sequence in the guide RNA or PEgRNA (having about 20 nts in length) which binds to the protospacer in the target DNA.

[0257] gRNA core (or gRNA scaffold or backbone sequence) - refers to the sequence within the gRNA that is responsible for Cas9 binding, it does not include the 20 bp spacer/targeting sequence that is used to guide Cas9 to target DNA.

[0258] Extension arm – a single strand extension at the 3' end or the 5' end of the PEgRNA which comprises a primer binding site and a DNA synthesis template sequence that encodes via a polymerase (e.g., a reverse transcriptase) a single stranded DNA flap containing the genetic change of interest, which then integrates into the endogenous DNA by replacing the corresponding endogenous strand, thereby installing the desired genetic change.

[0259] Transcription terminator – the guide RNA or PEgRNA may comprise a transcriptional termination sequence at the 3' of the molecule.

Homology arm

[0260] The term “homology arm” refers to a portion of the extension arm that encodes a portion of the resulting reverse transcriptase-encoded single strand DNA flap that is to be integrated into the target DNA site by replacing the endogenous strand. The portion of the single strand DNA flap

encoded by the homology arm is complementary to the non-edited strand of the target DNA sequence, which facilitates the displacement of the endogenous strand and annealing of the single strand DNA flap in its place, thereby installing the edit. This component is further defined elsewhere. The homology arm is part of the DNA synthesis template since it is by definition encoded by the polymerase of the prime editors described herein.

Host cell

[0261] The term “host cell,” as used herein, refers to a cell that can host, replicate, and express a vector described herein, e.g., a vector comprising a nucleic acid molecule encoding a fusion protein comprising a Cas9 or Cas9 equivalent and a reverse transcriptase.

Inteins

[0262] As used herein, the term “intein” refers to auto-processing polypeptide domains found in organisms from all domains of life. An intein (*intervening protein*) carries out a unique auto-processing event known as protein splicing in which it excises itself out from a larger precursor polypeptide through the cleavage of two peptide bonds and, in the process, ligates the flanking extein (external protein) sequences through the formation of a new peptide bond. This rearrangement occurs post-translationally (or possibly co-translationally), as intein genes are found embedded in frame within other protein-coding genes. Furthermore, intein-mediated protein splicing is spontaneous; it requires no external factor or energy source, only the folding of the intein domain. This process is also known as *cis*-protein splicing, as opposed to the natural process of *trans*-protein splicing with “split inteins.” Inteins are the protein equivalent of the self-splicing RNA introns (see Perler et al., *Nucleic Acids Res.* 22:1125-1127 (1994)), which catalyze their own excision from a precursor protein with the concomitant fusion of the flanking protein sequences, known as exteins (reviewed in Perler et al., *Curr. Opin. Chem. Biol.* 1:292-299 (1997); Perler, F. B. *Cell* 92(1):1-4 (1998); Xu et al., *EMBO J.* 15(19):5146-5153 (1996)).

[0263] As used herein, the term “protein splicing” refers to a process in which an interior region of a precursor protein (an intein) is excised and the flanking regions of the protein (exteins) are ligated to form the mature protein. This natural process has been observed in numerous proteins from both prokaryotes and eukaryotes (Perler, F. B., Xu, M. Q., Paulus, H. *Current Opinion in Chemical Biology* 1997, 1, 292-299; Perler, F. B. *Nucleic Acids Research* 1999, 27, 346-347). The intein unit contains the necessary components needed to catalyze protein splicing and often contains an endonuclease domain that participates in intein mobility (Perler, F. B., Davis, E. O., Dean, G. E., Gimble, F. S., Jack, W. E., Neff, N., Noren, C. J., Thomer, J., Belfort, M. *Nucleic Acids Research* 1994, 22, 1127-1127). The resulting proteins are linked, however, not expressed as separate proteins. Protein splicing may also be conducted in *trans* with split inteins expressed on separate polypeptides spontaneously combine to form a single intein which then undergoes the protein splicing process to join to separate proteins.

[0264] The elucidation of the mechanism of protein splicing has led to a number of intein-based applications (Comb, et al., U.S. Pat. No. 5,496,714; Comb, et al., U.S. Pat. No. 5,834,247; Camarero and Muir, J. Amer. Chem. Soc., 121:5597-5598 (1999); Chong, et al., Gene, 192:271-281 (1997), Chong, et al., Nucleic Acids Res., 26:5109-5115 (1998); Chong, et al., J. Biol. Chem., 273:10567-10577 (1998); Cotton, et al. J. Am. Chem. Soc., 121:1100-1101 (1999); Evans, et al., J. Biol. Chem., 274:18359-18363 (1999); Evans, et al., J. Biol. Chem., 274:3923-3926 (1999); Evans, et al., Protein Sci., 7:2256-2264 (1998); Evans, et al., J. Biol. Chem., 275:9091-9094 (2000); Iwai and Pluckthun, FEBS Lett. 459:166-172 (1999); Mathys, et al., Gene, 231:1-13 (1999); Mills, et al., Proc. Natl. Acad. Sci. USA 95:3543-3548 (1998); Muir, et al., Proc. Natl. Acad. Sci. USA 95:6705-6710 (1998); Otomo, et al., Biochemistry 38:16040-16044 (1999); Otomo, et al., J. Biolmol. NMR 14:105-114 (1999); Scott, et al., Proc. Natl. Acad. Sci. USA 96:13638-13643 (1999); Severinov and Muir, J. Biol. Chem., 273:16205-16209 (1998); Shingledecker, et al., Gene, 207:187-195 (1998); Southworth, et al., EMBO J. 17:918-926 (1998); Southworth, et al., Biotechniques, 27:110-120 (1999); Wood, et al., Nat. Biotechnol., 17:889-892 (1999); Wu, et al., Proc. Natl. Acad. Sci. USA 95:9226-9231 (1998a); Wu, et al., Biochim Biophys Acta 1387:422-432 (1998b); Xu, et al., Proc. Natl. Acad. Sci. USA 96:388-393 (1999); Yamazaki, et al., J. Am. Chem. Soc., 120:5591-5592 (1998)). Each reference is incorporated herein by reference.

Ligand-dependent intein

[0265] The term “ligand-dependent intein,” as used herein refers to an intein that comprises a ligand-binding domain. Typically, the ligand-binding domain is inserted into the amino acid sequence of the intein, resulting in a structure intein (N) – ligand-binding domain – intein (C). Typically, ligand-dependent inteins exhibit no or only minimal protein splicing activity in the absence of an appropriate ligand, and a marked increase of protein splicing activity in the presence of the ligand. In some embodiments, the ligand-dependent intein does not exhibit observable splicing activity in the absence of ligand but does exhibit splicing activity in the presence of the ligand. In some embodiments, the ligand-dependent intein exhibits an observable protein splicing activity in the absence of the ligand, and a protein splicing activity in the presence of an appropriate ligand that is at least 5 times, at least 10 times, at least 50 times, at least 100 times, at least 150 times, at least 200 times, at least 250 times, at least 500 times, at least 1000 times, at least 1500 times, at least 2000 times, at least 2500 times, at least 5000 times, at least 10000 times, at least 20000 times, at least 25000 times, at least 50000 times, at least 100000 times, at least 500000 times, or at least 1000000 times greater than the activity observed in the absence of the ligand. In some embodiments, the increase in activity is dose dependent over at least 1 order of magnitude, at least 2 orders of magnitude, at least 3 orders of magnitude, at least 4 orders of magnitude, or at least 5 orders of magnitude, allowing for fine-tuning of intein activity by adjusting the concentration of the ligand. Suitable ligand-dependent inteins are known in the art, and include those provided below and those described in published U.S. Patent

Application U.S. 2014/0065711 A1; Mootz *et al.*, “Protein splicing triggered by a small molecule.” *J. Am. Chem. Soc.* 2002; **124**, 9044–9045; Mootz *et al.*, “Conditional protein splicing: a new tool to control protein structure and function *in vitro* and *in vivo*.” *J. Am. Chem. Soc.* 2003; **125**, 10561–10569; Buskirk *et al.*, *Proc. Natl. Acad. Sci. USA*. 2004; **101**, 10505–10510; Skretas & Wood, “Regulation of protein activity with small-molecule-controlled inteins.” *Protein Sci.* 2005; **14**, 523–532; Schwartz, *et al.*, “Post-translational enzyme activation in an animal via optimized conditional protein splicing.” *Nat. Chem. Biol.* 2007; **3**, 50–54; Peck *et al.*, *Chem. Biol.* 2011; **18** (5), 619–630; the entire contents of each are hereby incorporated by reference. Exemplary sequences are as follows:

NAME	SEQUENCE OF LIGAND-DEPENDENT INTEIN
2-4 INTEIN:	CLAEGTRIFDPVTGTTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGAIVWATPDHKVLTEYGWRAAGELRK GDRVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCV EGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDM LAEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 8)
3-2 INTEIN	CLAEGTRIFDPVTGTTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGAIVWATPDHKVLTEYGWRAAGELRK GDRVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCV EGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYTNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDM LAEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 9)
30R3-1 INTEIN	CLAEGTRIFDPVTGTTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRK GDRVAGPGGS GNSLALSLTADQMVSALLDAEPPIPYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCV EGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDM LAEGLRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 10)
30R3-2 INTEIN	CLAEGTRIFDPVTGTTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRK GDRVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCV EGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDM LAEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 11)
30R3-3 INTEIN	CLAEGTRIFDPVTGTTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRK GDRVAGPGGS GNSLALSLTADQMVSALLDAEPPIPYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCV EGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII

	LLNSGVYTFLLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLAEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 12)
37R3-1 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAADKDGTLARPVVSWFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRKGDVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYNPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLEAWLEILMIGLVWRSMHPGKL LFAPNLLLDNRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEFVCLKSII LLNSGVYTFLLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLAEGLRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC ((SEQ ID NO: 13)
37R3-2 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAADKDGTLARPVVSWFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRKGDVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLEAWLEILMIGLVWRSMHPGKL LFAPNLLLDNRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEFVCLKSII LLNSGVYTFLLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLAEGLRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 14)
37R3-3 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAADKDGTLARPVVSWFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRKGDVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLEAWLEILMIGLVWRSMHPGKL LFAPNLLLDNRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEFVCLKSII LLNSGVYTFLLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLAEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 15)

Linker

[0266] The term “linker,” as used herein, refers to a molecule linking two other molecules or moieties. The linker can be an amino acid sequence in the case of a linker joining two fusion proteins. For example, a Cas9 can be fused to a reverse transcriptase by an amino acid linker sequence. The linker can also be a nucleotide sequence in the case of joining two nucleotide sequences together. For example, in the instant case, the traditional guide RNA is linked via a spacer or linker nucleotide sequence to the RNA extension of a prime editing guide RNA which may comprise a RT template sequence and an RT primer binding site. In other embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker is 5-100 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. Longer or shorter linkers are also contemplated.

Isolated

[0267] “Isolated” means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not “isolated,” but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is “isolated.” An

isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.

[0268] In some embodiments, a gene of interest is encoded by an isolated nucleic acid. As used herein, the term “isolated,” refers to the characteristic of a material as provided herein being removed from its original or native environment (e.g., the natural environment if it is naturally occurring). Therefore, a naturally-occurring polynucleotide or protein or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated by human intervention from some or all of the coexisting materials in the natural system, is isolated. An artificial or engineered material, for example, a non-naturally occurring nucleic acid construct, such as the expression constructs and vectors described herein, are, accordingly, also referred to as isolated. A material does not have to be purified in order to be isolated. Accordingly, a material may be part of a vector and/or part of a composition, and still be isolated in that such vector or composition is not part of the environment in which the material is found in nature.

MS2 tagging technique

[0269] In various embodiments (e.g., as depicted in the embodiments of FIGs. 72-73 and in Example 19), the term “MS2 tagging technique” refers to the combination of an “RNA-protein interaction domain” (aka “RNA-protein recruitment domain or protein”) paired up with an RNA-binding protein that specifically recognizes and binds to the RNA-protein interaction domain, e.g., a specific hairpin structure. These types of systems can be leveraged to recruit a variety of functionalities to a prime editor complex that is bound to a target site. The MS2 tagging technique is based on the natural interaction of the MS2 bacteriophage coat protein (“MCP” or “MS2cp”) with a stem-loop or hairpin structure present in the genome of the phage, i.e., the “MS2 hairpin.” In the case of prime editing, the MS2 tagging technique comprises introducing the MS2 hairpin into a desired RNA molecule involved in prime editing (e.g., a PEgRNA or a tPERT), which then constitutes a specific interactable binding target for an RNA-binding protein that recognizes and binds to that structure. In the case of the MS2 hairpin, it is recognized and bound by the MS2 bacteriophage coat protein (MCP). And, if MCP is fused to another protein (e.g., a reverse transcriptase or other DNA polymerase), then the MS2 hairpin may be used to “recruit” that other protein *in trans* to the target site occupied by the prime editing complex.

[0270] The prime editors described herein may incorporate as an aspect any known RNA-protein interaction domain to recruit or “co-localize” specific functions of interest to a prime editor complex. A review of other modular RNA-protein interaction domains are described in the art, for example, in Johansson et al., “RNA recognition by the MS2 phage coat protein,” *Sem Virol.*, 1997, Vol. 8(3): 176-185; Delebecque et al., “Organization of intracellular reactions with rationally designed RNA assemblies,” *Science*, 2011, Vol. 333: 470-474; Mali et al., “Cas9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering,” *Nat. Biotechnol.*,

2013, Vol.31: 833-838; and Zalatan et al., “Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds,” *Cell*, 2015, Vol.160: 339-350, each of which are incorporated herein by reference in their entirety. Other systems include the PP7 hairpin, which specifically recruits the PCP protein, and the “com” hairpin, which specifically recruits the Com protein. See Zalatan et al.

[0271] The nucleotide sequence of the MS2 hairpin (or equivalently referred to as the “MS2 aptamer”) is: GCCAACATGAGGATCACCCATGTCTGCAGGGCC (SEQ ID NO: 763).

[0272] The amino acid sequence of the MCP or MS2cp is:

GSASNFTQFVLVDNGGTGDVTVAPSNFANGVAEWISSNSRSQAYKVTCSVRQSSAQNRKYTI
KVEVPKVATQTVGGEELPVAGWRSYLNMEITIPFATNSDCELVKAMQGLLKDGNIPIPSAIA
ANSIGY (SEQ ID NO: 764).

[0273] The MS2 hairpin (or “MS2 aptamer”) may also be referred to as a type of “RNA effector recruitment domain”(or equivalently as “RNA-binding protein recruitment domain” or simply as “recruitment domain”) since it is a physical structure (e.g., a hairpin) that is installed into a PEgRNA or tPERT that effectively recruits other effector functions (e.g., RNA-binding proteins having various functions, such as DNA polymerases or other DNA-modifying enzymes) to the PEgRNA or rPERT that is so modified, and thus, co-localizing effector functions *in trans* to the prime editing machinery. This application is not intended to be limited in any way to any particular RNA effector recruitment domains and may include any available such domain, including the MS2 hairpin. Example 19 and FIG. 72(b) depicts the use of the MS2 aptamer joined to a DNA synthesis domain (i.e., the tPERT molecule) and a prime editor that comprises an MS2cp protein fused to a PE2 to cause the co-localization of the prime editor complex (MS2cp-PE2:sgRNA complex) bound to the target DNA site and the DNA synthesis domain of the tPERT molecule to effectuate the

napDNAbp

[0274] As used herein, the term “nucleic acid programmable DNA binding protein” or “napDNAbp,” of which Cas9 is an example, refer to proteins that use RNA:DNA hybridization to target and bind to specific sequences in a DNA molecule. Each napDNAbp is associated with at least one guide nucleic acid (e.g., guide RNA), which localizes the napDNAbp to a DNA sequence that comprises a DNA strand (i.e., a target strand) that is complementary to the guide nucleic acid, or a portion thereof (e.g., the protospacer of a guide RNA). In other words, the guide nucleic-acid “programs” the napDNAbp (e.g., Cas9 or equivalent) to localize and bind to a complementary sequence.

[0275] Without being bound by theory, the binding mechanism of a napDNAbp – guide RNA complex, in general, includes the step of forming an R-loop whereby the napDNAbp induces the unwinding of a double-strand DNA target, thereby separating the strands in the region bound by the napDNAbp. The guide RNA protospacer then hybridizes to the “target strand.” This displaces a “non-target strand” that is complementary to the target strand, which forms the single strand region of the R-loop. In some embodiments, the napDNAbp includes one or more nuclease activities, which

then cut the DNA, leaving various types of lesions. For example, the napDNAbp may comprise a nuclease activity that cuts the non-target strand at a first location, and/or cuts the target strand at a second location. Depending on the nuclease activity, the target DNA can be cut to form a “double-stranded break” whereby both strands are cut. In other embodiments, the target DNA can be cut at only a single site, i.e., the DNA is “nicked” on one strand. Exemplary napDNAbp with different nuclease activities include “Cas9 nickase” (“nCas9”) and a deactivated Cas9 having no nuclease activities (“dead Cas9” or “dCas9”). Exemplary sequences for these and other napDNAbp are provided herein.

Nickase

[0276] The term “nickase” refers to a Cas9 with one of the two nuclease domains inactivated. This enzyme is capable of cleaving only one strand of a target DNA.

Nuclear localization sequence (NLS)

[0277] The term “nuclear localization sequence” or “NLS” refers to an amino acid sequence that promotes import of a protein into the cell nucleus, for example, by nuclear transport. Nuclear localization sequences are known in the art and would be apparent to the skilled artisan. For example, NLS sequences are described in Plank *et al.*, international PCT application, PCT/EP2000/011690, filed November 23, 2000, published as WO/2001/038547 on May 31, 2001, the contents of which are incorporated herein by reference for its disclosure of exemplary nuclear localization sequences. In some embodiments, a NLS comprises the amino acid sequence PKKKRKV (SEQ ID NO: 16) or MDSLLMNRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 17).

Nucleic acid molecule

[0278] The term “nucleic acid,” as used herein, refers to a polymer of nucleotides. The polymer may include natural nucleosides (i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, C5 bromouridine, C5 fluorouridine, C5 iodouridine, C5 propynyl uridine, C5 propynyl cytidine, C5 methylcytidine, 7 deazaadenosine, 7 deazaguanosine, 8 oxoadenosine, 8 oxoguanosine, O(6) methylguanine, 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, dihydrouridine, methylpseudouridine, 1-methyl adenosine, 1-methyl guanosine, N6-methyl adenosine, and 2-thiocytidine), chemically modified bases, biologically modified bases (e.g., methylated bases), intercalated bases, modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, 2'-O-methylcytidine, arabinose, and hexose), or modified phosphate groups (e.g., phosphorothioates and 5' N phosphoramidite linkages).

PEgRNA

[0279] As used herein, the terms “prime editing guide RNA” or “PEgRNA” or “extended guide RNA” refer to a specialized form of a guide RNA that has been modified to include one or more additional sequences for implementing the prime editing methods and compositions described herein.

As described herein, the prime editing guide RNA comprise one or more “extended regions” of nucleic acid sequence. The extended regions may comprise, but are not limited to, single-stranded RNA or DNA. Further, the extended regions may occur at the 3′ end of a traditional guide RNA. In other arrangements, the extended regions may occur at the 5′ end of a traditional guide RNA. In still other arrangements, the extended region may occur at an intramolecular region of the traditional guide RNA, for example, in the gRNA core region which associates and/or binds to the napDNAbp. The extended region comprises a “DNA synthesis template” which encodes (by the polymerase of the prime editor) a single-stranded DNA which, in turn, has been designed to be (a) homologous with the endogenous target DNA to be edited, and (b) which comprises at least one desired nucleotide change (e.g., a transition, a transversion, a deletion, or an insertion) to be introduced or integrated into the endogenous target DNA. The extended region may also comprise other functional sequence elements, such as, but not limited to, a “primer binding site” and a “spacer or linker” sequence, or other structural elements, such as, but not limited to aptamers, stem loops, hairpins, toe loops (e.g., a 3′ toeloop), or an RNA-protein recruitment domain (e.g., MS2 hairpin). As used herein the “primer binding site” comprises a sequence that hybridizes to a single-strand DNA sequence having a 3′ end generated from the nicked DNA of the R-loop.

[0280] In certain embodiments, the PEgRNAs are represented by FIG. 3A, which shows a PEgRNA having a 5′ extension arm, a spacer, and a gRNA core. The 5′ extension further comprises in the 5′ to 3′ direction a reverse transcriptase template, a primer binding site, and a linker. As shown, the reverse transcriptase template may also be referred to more broadly as the “DNA synthesis template” where the polymerase of a prime editor described herein is not an RT, but another type of polymerase.

[0281] In certain other embodiments, the PEgRNAs are represented by FIG. 3B, which shows a PEgRNA having a 5′ extension arm, a spacer, and a gRNA core. The 5′ extension further comprises in the 5′ to 3′ direction a reverse transcriptase template, a primer binding site, and a linker. As shown, the reverse transcriptase template may also be referred to more broadly as the “DNA synthesis template” where the polymerase of a prime editor described herein is not an RT, but another type of polymerase.

[0282] In still other embodiments, the PEgRNAs are represented by FIG. 3D, which shows a PEgRNA having in the 5′ to 3′ direction a spacer (1), a gRNA core (2), and an extension arm (3). The extension arm (3) is at the 3′ end of the PEgRNA. The extension arm (3) further comprises in the 5′ to 3′ direction a “primer binding site” (A), an “edit template” (B), and a “homology arm” (C). The extension arm (3) may also comprise an optional modifier region at the 3′ and 5′ ends, which may be the same sequences or different sequences. In addition, the 3′ end of the PEgRNA may comprise a transcriptional terminator sequence. These sequence elements of the PEgRNAs are further described and defined herein.

[0283] In still other embodiments, the PEgRNAs are represented by FIG. 3E, which shows a PEgRNA having in the 5' to 3' direction an extension arm (3), a spacer (1), and a gRNA core (2). The extension arm (3) is at the 5' end of the PEgRNA. The extension arm (3) further comprises in the 3' to 5' direction a "primer binding site" (A), an "edit template" (B), and a "homology arm" (C). The extension arm (3) may also comprise an optional modifier region at the 3' and 5' ends, which may be the same sequences or different sequences. The PEgRNAs may also comprise a transcriptional terminator sequence at the 3' end. These sequence elements of the PEgRNAs are further described and defined herein.

PE1

[0284] As used herein, "PE1" refers to a PE complex comprising a fusion protein comprising Cas9(H840A) and a wild type MMLV RT having the following structure: [NLS]-[Cas9(H840A)]-[linker]-[MMLV_RT(wt)] + a desired PEgRNA, wherein the PE fusion has the amino acid sequence of SEQ ID NO: 123, which is shown as follows;

MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHS
IKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRL
ESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLYDSTDKADLRLIYLALAHMI
KFRGHFLIEGDLNPDNSDVKLFIQLVQTYNQLFEEPNINASGVDAKAILSARLSKSRRL
NLIAQLPGEKKNGLFGNLIASLGLTPNFKSDFDLAEDAKLQLSKDYYDDDLNLLAQIG
DQYADFLAAKNLSDAILSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL
PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKNLREDLLRKQ
RTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNREKIEKILTFRIPYYVGPLARGNSRFA
WMTRKSEETITPWNFEEVVDKGASQSFIERMTNFDKNLPNEKVLPHSLLYEYFTVYN
ELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEIS
GVEDRFNASLGTYHDLKKIKDKDFLDNEENEDILEDIVLTTLTFEDREMIEERLKYAHL
FDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFQMQLHDD
SLTFKEDIQKAQVSGQGDLSHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENI
VIEMARENQTTQKGQKNSRERMKRIEIGIKELGSQILKEHPVENTQLQNEKLYLYLQ
NGRDMYVDQELDINRLSDYDVAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEVV
KMKMYWRQLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQI
LDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKREINNYHHAHDAYLNAV
GTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLA
NGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNVKKEVQTTGGFSKESILPK
RNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVAKVEKGKSKKLKSVKELLGITIMERS
SFEKNPIDFLEAKGYKEVKKDLIHLKPKYSLFELENGRKRMLASAGELQKGNELALPSK
YVNFYLYASHYEKLKGSPEQNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVL
SAYNKHDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSI
TGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSSSTLNIEDEYRLHETS
KEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLKATSTPVSQKQYPMSQEARLGKPHIQL
LDQGILVPCQSPWNTPLLPVKPGTNDYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYT
VLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSTPLFDEALHRDLADFRI
QHPDLILLQYVDDLLAATSELDCCQGTALLQTLGNLGYRASAKKAQICQKQVKYLYGILLKEGQR
WLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLTKGTFLNFWGPDQQA
YQEIQALLTAPALGPLDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPC
LRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLDTRVQFGP
VVALNPATLLPLPEEGLQHNCILDILAEAHGTRPDLDQPLPDADHTWYTDGSSLLQEGQRKAGAAV
TTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLVYTDSTRYAFATAHIHGEIYRRRGLTSEG
KEIKNKDEILALLKALFLPKRLSIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENS
PSGGSKRTADGSEFEPKKRKV (SEQ ID NO: 123)

KEY:

NUCLEAR LOCALIZATION SEQUENCE (NLS) TOP:(SEQ ID NO: 124), BOTTOM: (SEQ ID NO: 133)

CAS9(H840A) (SEQ ID NO: 126)

33-AMINO ACID LINKER (SEQ ID NO: 127)

M-MLV reverse transcriptase (SEQ ID NO: 128).

PE2

[0285] As used herein, “PE2” refers to a PE complex comprising a fusion protein comprising Cas9(H840A) and a variant MMLV RT having the following structure: [NLS]-[Cas9(H840A)]-[linker]-[MMLV_RT(D200N)(T330P)(L603W)(T306K)(W313F)] + a desired PEgRNA, wherein the PE fusion has the amino acid sequence of SEQ ID NO: 134, which is shown as follows:

MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHS
 IKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRL
 ESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLLIYLALAHMI
 KFRGFHFLIEGDLNPDNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRL
 NLIAQLPGEKKNGFLGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLNLLAQIG
 DQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQL
 PEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELVLKLNREDLLRKQ
 RTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNREKIEKILTFRIPYYVGPLARGNSRFA
 WMTRKSEETITPWNFEEVVDKGASQSFIERMTNFDKNLPNEKVLPHKSLLYEYFTVYN
 ELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEIS
 GVEDRFNASLGTYHDLKHKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKYAHL
 FDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMLIHDD
 SLTFKEDIQKAQVSGQGDLSHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENI
 VIEMARENQTTQKGQKNSRERMKRIEKGELGSQILKEHPVENTQLQNEKLYLYYLQ
 NGRDMYVDQELDINRLSDYDVAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVV
 KKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQI
 LDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVINNYHHAHDAYLNAV
 GTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLA
 NGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNIKKTEVQTGGFSKESILPK
 RNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVAKVEKGKSKKLKSVKELLGITIMERS
 SFEKNPIDFLEAKGYKEVKKDLIHLKPKYSLFELENGRKRMLASAGELQKGNELALPSK
 YVNFLYLASHYEKLKGSPEDEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL
 SAYNKHDKPIREQAENIIHLFTLNLGAPAAFKYFDTTIDRKRYTSTKEVLDTLIHQSI
 TGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSSESATPESSGGSSGGSSTLNIEDEYRLHETS
 KEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLKATSTPVSQYPMSEARLGKPHIQRL
 LDQGILVPCQSPWNTPLLVPKKPGTNDYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYT
 VLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSTPLFNEALHRDLADFRIQ
 HPDLILLQYVDDLLAATSELDCCQGTALLQTLGNLGYRASAKKAQICQKQVKYLYLLKEGQRW
 LTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDPQKAY
 QEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAAGWPPCL
 RMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPV
 VALNPATLLPLPEEGLQHNCILDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVT
 TETEVIAKALPAGTSAQRAELIALTQALKMAEGKKLVYTDSTRYAFATAHIHGEIYRRRGWLTSEGK
 EIKNKDEILALLKALFLPKRLSIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP
 SGGSKRTADGSEFEPKKKKRKV (SEQ ID NO: 134)

KEY:

NUCLEAR LOCALIZATION SEQUENCE (NLS) TOP:(SEQ ID NO: 124), BOTTOM: (SEQ ID NO: 133)

CAS9(H840A) (SEQ ID NO: 137)

33-AMINO ACID LINKER (SEQ ID NO: 127)

M-MLV reverse transcriptase (SEQ ID NO: 139).

PE3

[0286] As used herein, “PE3” refers to PE2 plus a second-strand nicking guide RNA that complexes with the PE2 and introduces a nick in the non-edited DNA strand in order to induce preferential replacement of the edited strand.

PE3b

[0287] As used herein, “PE3b” refers to PE3 but wherein the second-strand nicking guide RNA is designed for temporal control such that the second strand nick is not introduced until after the installation of the desired edit. This is achieved by designing a gRNA with a spacer sequence that matches only the edited strand, but not the original allele. Using this strategy, referred to hereafter as PE3b, mismatches between the protospacer and the unedited allele should disfavor nicking by the sgRNA until after the editing event on the PAM strand takes place.

PE-short

[0288] As used herein, “PE-short” refers to a PE construct that is fused to a C-terminally truncated reverse transcriptase, and has the following amino acid sequence:

**MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRH
SIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRL
EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLV DSTDKADLRLIYLALAH
MIKFRGHFLIEGDLNPDNSDVKLFQILVQTYNQLFEENPINASGVDAKAILSARLSKSR
RLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFLAEDAKLQLSKD TYDDDLNLL
AQIGDQYADLFLAAKNLSAAILSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALV
RQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDL
LRKQFTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNREKIEKILTFRIPYYVGPLARG
NSRFQAWMTRKSEETITPWNFEVVDKGASQSFIERMTNFDKNLPNEKVLPHSLLEYE
FTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECF
DSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERL
KTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDFANRNF
MQLIHDDSLTFKEDIQKAQVSGQGDLSHEHIANLAGSPAIKKGILQTVKVVDELVKVMG
RHKPENIVIAMARENQTTQKGQKNSRERMKRIE EGKELGSQILKEHPVENTQLQNEKL
YLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNV
PSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRLVETRQIT
KHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVINNYHHAHDA
YLNNAVGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFF
KTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVL SMPQVNIVKKTEVQTGGF
SKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKELL
GITIMERSSEFKNPIDFLEAKGYKEVKKDLI KLPKYSLFELENGRKRMLASAGELQKGN
ELALPSKYVNFLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLAD
ANLDKVL SAYNKH RDKPIREQAENIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLD
ATLIHQ SITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGGSS TLNIED
EYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLKATSTPVS IKQYPMSQEARLG
IKPHIQRLLDQ GILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREV NKRVEDIHPTVPNPYNLLSGL
PPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALH
RDLADFRIQHPDLILLQYVDDLLAATSELD CQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLG**

*YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFN
WGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD
PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLL
DTRVQFGPVVALNPATLLPLPEEGLQHNCLDNSRLINSGGSKRTADGSEFEPKKKRKV* (SEQ
ID NO: 765)

KEY:

NUCLEAR LOCALIZATION SEQUENCE (NLS) TOP:(SEQ ID NO: 124), BOTTOM: (SEQ ID
NO: 133)

CAS9(H840A) (SEQ ID NO: 157)

33-AMINO ACID LINKER 1 (SEQ ID NO: 127)

M-MLV TRUNCATED REVERSE TRANSCRIPTASE

(SEQ ID NO: 766)

Peptide tag

[0289] The term “peptide tag” refers to a peptide amino acid sequence that is genetically fused to a protein sequence to impart one or more functions onto the proteins that facilitate the manipulation of the protein for various purposes, such as, visualization, purification, solubilization, and separation, etc. Peptide tags can include various types of tags categorized by purpose or function, which may include “affinity tags” (to facilitate protein purification), “solubilization tags” (to assist in proper folding of proteins), “chromatography tags” (to alter chromatographic properties of proteins), “epitope tags” (to bind to high affinity antibodies), “fluorescence tags” (to facilitate visualization of proteins in a cell or in vitro).

Polymerase

[0290] As used herein, the term “polymerase” refers to an enzyme that synthesizes a nucleotide strand and that may be used in connection with the prime editor systems described herein. The polymerase can be a “template-dependent” polymerase (i.e., a polymerase that synthesizes a nucleotide strand based on the order of nucleotide bases of a template strand). The polymerase can also be a “template-independent” polymerase (i.e., a polymerase that synthesizes a nucleotide strand without the requirement of a template strand). A polymerase may also be further categorized as a “DNA polymerase” or an “RNA polymerase.” In various embodiments, the prime editor system comprises a DNA polymerase. In various embodiments, the DNA polymerase can be a “DNA-dependent DNA polymerase” (i.e., whereby the template molecule is a strand of DNA). In such cases, the DNA template molecule can be a PEgRNA, wherein the extension arm comprises a strand of DNA. In such cases, the PEgRNA may be referred to as a chimeric or hybrid PEgRNA which comprises an RNA portion (i.e., the guide RNA components, including the spacer and the gRNA core) and a DNA portion (i.e., the extension arm). In various other embodiments, the DNA polymerase can be an “RNA-dependent DNA polymerase” (i.e., whereby the template molecule is a strand of RNA). In such cases, the PEgRNA is RNA, i.e., including an RNA extension. The term “polymerase” may also refer to an enzyme that catalyzes the polymerization of nucleotide (i.e., the polymerase activity). Generally, the enzyme will initiate synthesis at the 3'-end of a primer annealed to a polynucleotide template sequence (e.g., such as a primer sequence annealed to the primer binding

site of a PEgRNA) and will proceed toward the 5' end of the template strand. A "DNA polymerase" catalyzes the polymerization of deoxynucleotides. As used herein in reference to a DNA polymerase, the term DNA polymerase includes a "functional fragment thereof". A "functional fragment thereof" refers to any portion of a wild-type or mutant DNA polymerase that encompasses less than the entire amino acid sequence of the polymerase and which retains the ability, under at least one set of conditions, to catalyze the polymerization of a polynucleotide. Such a functional fragment may exist as a separate entity, or it may be a constituent of a larger polypeptide, such as a fusion protein.

Prime editing and multi-flap prime editing

[0291] As used herein, the term "prime editing" or "classical prime editing" refers to an approach for gene editing using napDNABps, a polymerase (e.g., a reverse transcriptase), and specialized guide RNAs that include a DNA synthesis template for encoding desired new genetic information (or deleting genetic information) that is then incorporated into a target DNA sequence. Certain embodiments of prime editing are described in the embodiments of FIGs. 1A-1H and FIG. 72(a)-72(c), among other figures. Classical prime editing is described in the inventors publication of Anzalone, A. V. *et al.* Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature* **576**, 149–157 (2019), which is incorporated herein by reference in its entirety.

[0292] Prime editing represents a platform for genome editing that is a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a nucleic acid programmable DNA binding protein ("napDNABp") working in association with a polymerase (i.e., in the form of a fusion protein or otherwise provided *in trans* with the napDNABp), wherein the prime editing system is programmed with a prime editing (PE) guide RNA ("PEgRNA") that both specifies the target site and templates the synthesis of the desired edit in the form of a replacement DNA strand by way of an extension (either DNA or RNA) engineered onto a guide RNA (e.g., at the 5' or 3' end, or at an internal portion of a guide RNA). The replacement strand containing the desired edit (e.g., a single nucleobase substitution) shares the same (or is homologous to) sequence as the endogenous strand (immediately downstream of the nick site) of the target site to be edited (with the exception that it includes the desired edit). Through DNA repair and/or replication machinery, the endogenous strand downstream of the nick site is replaced by the newly synthesized replacement strand containing the desired edit. In some cases, prime editing may be thought of as a "search-and-replace" genome editing technology since the prime editors, as described herein, not only search and locate the desired target site to be edited, but at the same time, encode a replacement strand containing a desired edit which is installed in place of the corresponding target site endogenous DNA strand. The prime editors of the present disclosure relate, in part, to the discovery that the mechanism of target-primed reverse transcription (TPRT) or "prime editing" can be leveraged or adapted for conducting precision CRISPR/Cas-based genome editing with high efficiency and genetic flexibility (e.g., as depicted in various embodiments of FIGs. 1A-1F). TPRT is naturally used by mobile DNA

elements, such as mammalian non-LTR retrotransposons and bacterial Group II introns^{28,29}. The inventors have herein used Cas protein-reverse transcriptase fusions or related systems to target a specific DNA sequence with a guide RNA, generate a single strand nick at the target site, and use the nicked DNA as a primer for reverse transcription of an engineered reverse transcriptase template that is integrated with the guide RNA. However, while the concept begins with prime editors that use reverse transcriptase as the DNA polymerase component, the prime editors described herein are not limited to reverse transcriptases but may include the use of virtually any DNA polymerase. Indeed, while the application throughout may refer to prime editors with “reverse transcriptases,” it is set forth here that reverse transcriptases are only one type of DNA polymerase that may work with prime editing. Thus, wherever the specification mentions a “reverse transcriptase,” the person having ordinary skill in the art should appreciate that any suitable DNA polymerase may be used in place of the reverse transcriptase. Thus, in one aspect, the prime editors may comprise Cas9 (or an equivalent napDNAbp) which is programmed to target a DNA sequence by associating it with a specialized guide RNA (i.e., PEGRNA) containing a spacer sequence that anneals to a complement of a protospacer in the target DNA. The specialized guide RNA also contains new genetic information in the form of an extension that encodes a replacement strand of DNA containing a desired genetic alteration which is used to replace a corresponding endogenous DNA strand at the target site. To transfer information from the PEGRNA to the target DNA, the mechanism of prime editing involves nicking the target site in one strand of the DNA to expose a 3'-hydroxyl group. The exposed 3'-hydroxyl group can then be used to prime the DNA polymerization of the edit-encoding extension on PEGRNA directly into the target site. In various embodiments, the extension—which provides the template for polymerization of the replacement strand containing the edit—can be formed from RNA or DNA. In the case of an RNA extension, the polymerase of the prime editor can be an RNA-dependent DNA polymerase (such as, a reverse transcriptase). In the case of a DNA extension, the polymerase of the prime editor may be a DNA-dependent DNA polymerase. The newly synthesized strand (i.e., the replacement DNA strand containing the desired edit) that is formed by the herein disclosed prime editors would be homologous to the genomic target sequence (i.e., have the same sequence as) except for the inclusion of a desired nucleotide change (e.g., a single nucleotide change, a deletion, or an insertion, or a combination thereof). The newly synthesized (or replacement) strand of DNA may also be referred to as a single strand DNA flap, which would compete for hybridization with the complementary homologous endogenous DNA strand, thereby displacing the corresponding endogenous strand. In certain embodiments, the system can be combined with the use of an error-prone reverse transcriptase enzyme (e.g., provided as a fusion protein with the Cas9 domain, or provided *in trans* to the Cas9 domain). The error-prone reverse transcriptase enzyme can introduce alterations during synthesis of the single strand DNA flap. Thus, in certain embodiments, error-prone reverse transcriptase can be utilized to introduce nucleotide changes to the target DNA. Depending

on the error-prone reverse transcriptase that is used with the system, the changes can be random or non-random. Resolution of the hybridized intermediate (comprising the single strand DNA flap synthesized by the reverse transcriptase hybridized to the endogenous DNA strand) can include removal of the resulting displaced flap of endogenous DNA (e.g., with a 5' end DNA flap endonuclease, FEN1), ligation of the synthesized single strand DNA flap to the target DNA, and assimilation of the desired nucleotide change as a result of cellular DNA repair and/or replication processes. Because templated DNA synthesis offers single nucleotide precision for the modification of any nucleotide, including insertions and deletions, the scope of this approach is very broad and could foreseeably be used for myriad applications in basic science and therapeutics.

[0293] In various embodiments, prime editing operates by contacting a target DNA molecule (for which a change in the nucleotide sequence is desired to be introduced) with a nucleic acid programmable DNA binding protein (napDNAbp) complexed with a prime editing guide RNA (PEgRNA). In reference to FIG. 1G, the prime editing guide RNA (PEgRNA) comprises an extension at the 3' or 5' end of the guide RNA, or at an intramolecular location in the guide RNA and encodes the desired nucleotide change (e.g., single nucleotide change, insertion, or deletion). In step (a), the napDNAbp/extended gRNA complex contacts the DNA molecule and the extended gRNA guides the napDNAbp to bind to a target locus. In step (b), a nick in one of the strands of DNA of the target locus is introduced (e.g., by a nuclease or chemical agent), thereby creating an available 3' end in one of the strands of the target locus. In certain embodiments, the nick is created in the strand of DNA that corresponds to the R-loop strand, i.e., the strand that is not hybridized to the guide RNA sequence, i.e., the "non-target strand." The nick, however, could be introduced in either of the strands. That is, the nick could be introduced into the R-loop "target strand" (i.e., the strand hybridized to the protospacer of the extended gRNA) or the "non-target strand" (i.e., the strand forming the single-stranded portion of the R-loop and which is complementary to the target strand). In step (c), the 3' end of the DNA strand (formed by the nick) interacts with the extended portion of the guide RNA in order to prime reverse transcription (i.e., "target-primed RT"). In certain embodiments, the 3' end DNA strand hybridizes to a specific RT priming sequence on the extended portion of the guide RNA, i.e., the "reverse transcriptase priming sequence" or "primer binding site" on the PEgRNA. In step (d), a reverse transcriptase (or other suitable DNA polymerase) is introduced which synthesizes a single strand of DNA from the 3' end of the primed site towards the 5' end of the prime editing guide RNA. The DNA polymerase (e.g., reverse transcriptase) can be fused to the napDNAbp or alternatively can be provided *in trans* to the napDNAbp. This forms a single-strand DNA flap comprising the desired nucleotide change (e.g., the single base change, insertion, or deletion, or a combination thereof) and which is otherwise homologous to the endogenous DNA at or adjacent to the nick site. In step (e), the napDNAbp and guide RNA are released. Steps (f) and (g) relate to the resolution of the single strand DNA flap such that the desired nucleotide change becomes

incorporated into the target locus. This process can be driven towards the desired product formation by removing the corresponding 5' endogenous DNA flap that forms once the 3' single strand DNA flap invades and hybridizes to the endogenous DNA sequence. Without being bound by theory, the cells endogenous DNA repair and replication processes resolves the mismatched DNA to incorporate the nucleotide change(s) to form the desired altered product. The process can also be driven towards product formation with "second strand nicking," as exemplified in FIG. 1F. This process may introduce at least one or more of the following genetic changes: transversions, transitions, deletions, and insertions.

[0294] The term "prime editor (PE) system" or "prime editor (PE)" or "PE system" or "PE editing system" refers the compositions involved in the method of genome editing using target-primed reverse transcription (TPRT) describe herein, including, but not limited to the napDNAbps, reverse transcriptases, fusion proteins (e.g., comprising napDNAbps and reverse transcriptases), prime editing guide RNAs, and complexes comprising fusion proteins and prime editing guide RNAs, as well as accessory elements, such as second strand nicking components (e.g., second strand sgRNAs) and 5' endogenous DNA flap removal endonucleases (e.g., FEN1) for helping to drive the prime editing process towards the edited product formation.

[0295] Although in the embodiments described thus far the PEgRNA constitutes a single molecule comprising a guide RNA (which itself comprises a spacer sequence and a gRNA core or scaffold) and a 5' or 3' extension arm comprising the primer binding site and a DNA synthesis template (e.g., see FIG. 3D, the PEgRNA may also take the form of two individual molecules comprised of a guide RNA and a *trans* prime editor RNA template (tPERT), which essentially houses the extension arm (including, in particular, the primer binding site and the DNA synthesis domain) and an RNA-protein recruitment domain (e.g., MS2 aptamer or hairpin) in the same molecule which becomes co-localized or recruited to a modified prime editor complex that comprises a tPERT recruiting protein (e.g., MS2cp protein, which binds to the MS2 aptamer). See FIG. 3G and FIG. 3H as an example of a tPERT that may be used with prime editing.

[0296] In the "dual-flap prime editing system", two pegRNAs are used to target opposite strands of a genomic site and direct the synthesis of two complementary 3' flaps containing edited DNA sequence (**FIG. 91**). Unlike classical prime editing, there is no requirement for the pair of edited DNA strands (3' flaps) to directly compete with 5' flaps in endogenous genomic DNA, as the complementary edited strand is available for hybridization instead. Since both strands of the duplex are synthesized as edited DNA, the dual-flap prime editing system obviates the need for the replacement of the non-edited complementary DNA strand required by classical prime editing. Instead, cellular DNA repair machinery need only excise the paired 5' flaps (original genomic DNA) and ligate the paired 3' flaps (edited DNA) into the locus. Therefore, there is also no need to include sequences homologous to genomic DNA in the newly synthesized DNA strands, allowing selective hybridization of the new

strands and facilitating edits that contain minimal genomic homology. Nuclease-active versions of prime editors that cut both strands of DNA could also be used to accelerate the removal of the original DNA sequence.

[0297] Like classical prime editing, multi-flap prime editing (including dual-flap and quadruple-flap prime editing) is a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a nucleic acid programmable DNA binding protein (“napDNAbp”) working in association with a polymerase (i.e., in the form of a fusion protein or otherwise provided *in trans* with the napDNAbp), wherein the prime editing system is programmed with a prime editing (PE) guide RNA (“PEgRNA”) that both specifies the target site and templates the synthesis of the desired edit in the form of a replacement DNA strand by way of an extension (either DNA or RNA) engineered onto a guide RNA (e.g., at the 5′ or 3′ end, or at an internal portion of a guide RNA). The replacement strand containing the desired edit (e.g., a single nucleobase substitution) shares the same sequence as the endogenous strand of the target site to be edited (with the exception that it includes the desired edit). Through DNA repair and/or replication machinery, the endogenous strand of the target site is replaced by the newly synthesized replacement strand containing the desired edit. In some cases, prime editing may be thought of as a “search-and-replace” genome editing technology since the prime editors, as described herein, not only search and locate the desired target site to be edited, but at the same time, encode a replacement strand containing a desired edit which is installed in place of the corresponding target site endogenous DNA strand.

Prime editor

[0298] The dual prime editing system described herein comprises a pair of prime editors. The term “prime editor” refers to the herein described fusion constructs comprising a napDNAbp (e.g., Cas9 nickase) and a reverse transcriptase and is capable of carrying out prime editing on a target nucleotide sequence in the presence of a PEgRNA (or “extended guide RNA”). The term “prime editor” may refer to the fusion protein or to the fusion protein complexed with a PEgRNA, and/or further complexed with a second-strand nicking sgRNA. In some embodiments, the prime editor may also refer to the complex comprising a fusion protein (reverse transcriptase fused to a napDNAbp), a PEgRNA, and a regular guide RNA capable of directing the second-site nicking step of the non-edited strand as described herein. In other embodiments, the reverse transcriptase component of the “primer editor” may be provided *in trans*.

[0299] The dual-flap prime editing system described herein comprises a pair of prime editors. The quadruple-flap prime editing system described herein comprises four prime editors.

Primer binding site

[0300] The term “primer binding site” or “the PBS” refers to the nucleotide sequence located on a PEgRNA as a component of the extension arm (typically at the 3′ end of the extension arm) and serves to bind to the primer sequence that is formed after Cas9 nicking of the target sequence by the

prime editor. As detailed elsewhere, when the Cas9 nickase component of a prime editor nicks one strand of the target DNA sequence, a 3'-ended ssDNA flap is formed, which serves a primer sequence that anneals to the primer binding site on the PEGRNA to prime reverse transcription.

Promoter

[0301] The term “promoter” is art-recognized and refers to a nucleic acid molecule with a sequence recognized by the cellular transcription machinery and able to initiate transcription of a downstream gene. A promoter can be constitutively active, meaning that the promoter is always active in a given cellular context, or conditionally active, meaning that the promoter is only active in the presence of a specific condition. For example, a conditional promoter may only be active in the presence of a specific protein that connects a protein associated with a regulatory element in the promoter to the basic transcriptional machinery, or only in the absence of an inhibitory molecule. A subclass of conditionally active promoters are inducible promoters that require the presence of a small molecule “inducer” for activity. Examples of inducible promoters include, but are not limited to, arabinose-inducible promoters, Tet-on promoters, and tamoxifen-inducible promoters. A variety of constitutive, conditional, and inducible promoters are well known to the skilled artisan, and the skilled artisan will be able to ascertain a variety of such promoters useful in carrying out the instant invention, which is not limited in this respect.

Protospacer

[0302] As used herein, the term “protospacer” refers to the sequence (~20 bp) in DNA adjacent to the PAM (protospacer adjacent motif) sequence. The protospacer shares the same sequence as the spacer sequence of the guide RNA. The guide RNA anneals to the complement of the protospacer sequence on the target DNA (specifically, one strand thereof, i.e., the “target strand” versus the “non-target strand” of the target DNA sequence). In order for Cas9 to function it also requires a specific protospacer adjacent motif (PAM) that varies depending on the bacterial species of the Cas9 gene. The most commonly used Cas9 nuclease, derived from *S. pyogenes*, recognizes a PAM sequence of NGG that is found directly downstream of the target sequence in the genomic DNA, on the non-target strand. The skilled person will appreciate that the literature in the state of the art sometimes refers to the “protospacer” as the ~20-nt target-specific guide sequence on the guide RNA itself, rather than referring to it as a “spacer.” Thus, in some cases, the term “protospacer” as used herein may be used interchangeably with the term “spacer.” The context of the description surrounding the appearance of either “protospacer” or “spacer” will help inform the reader as to whether the term is in reference to the gRNA or the DNA target.

Protospacer adjacent motif (PAM)

[0303] As used herein, the term “protospacer adjacent sequence” or “PAM” refers to an approximately 2-6 base pair DNA sequence that is an important targeting component of a Cas9 nuclease. Typically, the PAM sequence is on either strand, and is downstream in the 5' to 3' direction

of the Cas9 cut site. The canonical PAM sequence (i.e., the PAM sequence that is associated with the Cas9 nuclease of *Streptococcus pyogenes* or SpCas9) is 5'-NGG-3' wherein "N" is any nucleobase followed by two guanine ("G") nucleobases. Different PAM sequences can be associated with different Cas9 nucleases or equivalent proteins from different organisms. In addition, any given Cas9 nuclease, e.g., SpCas9, may be modified to alter the PAM specificity of the nuclease such that the nuclease recognizes alternative PAM sequence.

[0304] For example, with reference to the canonical SpCas9 amino acid sequence is SEQ ID NO: 18, the PAM sequence can be modified by introducing one or more mutations, including (a) D1135V, R1335Q, and T1337R "the VQR variant", which alters the PAM specificity to NGAN or NGNG, (b) D1135E, R1335Q, and T1337R "the EQR variant", which alters the PAM specificity to NGAG, and (c) D1135V, G1218R, R1335E, and T1337R "the VRER variant", which alters the PAM specificity to NGCG. In addition, the D1135E variant of canonical SpCas9 still recognizes NGG, but it is more selective compared to the wild type SpCas9 protein.

[0305] It will also be appreciated that Cas9 enzymes from different bacterial species (i.e., Cas9 orthologs) can have varying PAM specificities. For example, Cas9 from *Staphylococcus aureus* (SaCas9) recognizes NGRRT or NGRRN. In addition, Cas9 from *Neisseria meningitis* (NmCas9) recognizes NNNNGATT. In another example, Cas9 from *Streptococcus thermophilis* (StCas9) recognizes NNAGAAW. In still another example, Cas9 from *Treponema denticola* (TdCas9) recognizes NAAAAC. These are examples and are not meant to be limiting. It will be further appreciated that non-SpCas9s bind a variety of PAM sequences, which makes them useful when no suitable SpCas9 PAM sequence is present at the desired target cut site. Furthermore, non-SpCas9s may have other characteristics that make them more useful than SpCas9. For example, Cas9 from *Staphylococcus aureus* (SaCas9) is about 1 kilobase smaller than SpCas9, so it can be packaged into adeno-associated virus (AAV). Further reference may be made to Shah et al., "Protospacer recognition motifs: mixed identities and functional diversity," *RNA Biology*, 10(5): 891-899 (which is incorporated herein by reference).

Recombinase

[0306] The term "recombinase," as used herein, refers to a site-specific enzyme that mediates the recombination of DNA between recombinase recognition sequences, which results in the excision, integration, inversion, or exchange (e.g., translocation) of DNA fragments between the recombinase recognition sequences. Recombinases can be classified into two distinct families: serine recombinases (e.g., resolvases and invertases) and tyrosine recombinases (e.g., integrases). Examples of serine recombinases include, without limitation, Hin, Gin, Tn3, β -six, CinH, ParA, $\gamma\delta$, Bxb1, ϕ C31, TP901, TG1, ϕ BT1, R4, ϕ RV1, ϕ FC1, MR11, A118, U153, and gp29. Examples of tyrosine recombinases include, without limitation, Cre, FLP, R, Lambda, HK101, HK022, and pSAM2. The serine and tyrosine recombinase names stem from the conserved nucleophilic amino acid residue that

the recombinase uses to attack the DNA and which becomes covalently linked to the DNA during strand exchange. Recombinases have numerous applications, including the creation of gene knockouts/knock-ins and gene therapy applications. See, *e.g.*, Brown *et al.*, “Serine recombinases as tools for genome engineering.” *Methods*. 2011;53(4):372-9; Hirano *et al.*, “Site-specific recombinases as tools for heterologous gene integration.” *Appl. Microbiol. Biotechnol.* 2011; 92(2):227-39; Chavez and Calos, “Therapeutic applications of the Φ C31 integrase system.” *Curr. Gene Ther.* 2011;11(5):375-81; Turan and Bode, “Site-specific recombinases: from tag-and-target- to tag-and-exchange-based genomic modifications.” *FASEB J.* 2011; 25(12):4088-107; Venken and Bellen, “Genome-wide manipulations of *Drosophila melanogaster* with transposons, Flp recombinase, and Φ C31 integrase.” *Methods Mol. Biol.* 2012; 859:203-28; Murphy, “Phage recombinases and their applications.” *Adv. Virus Res.* 2012; 83:367-414; Zhang *et al.*, “Conditional gene manipulation: Creating a new biological era.” *J. Zhejiang Univ. Sci. B.* 2012; 13(7):511-24; Karpenshif and Bernstein, “From yeast to mammals: recent advances in genetic control of homologous recombination.” *DNA Repair (Amst)*. 2012; 1;11(10):781-8; the entire contents of each are hereby incorporated by reference in their entirety. The recombinases provided herein are not meant to be exclusive examples of recombinases that can be used in embodiments of the invention. The methods and compositions of the invention can be expanded by mining databases for new orthogonal recombinases or designing synthetic recombinases with defined DNA specificities (See, *e.g.*, Groth *et al.*, “Phage integrases: biology and applications.” *J. Mol. Biol.* 2004; 335, 667-678; Gordley *et al.*, “Synthesis of programmable integrases.” *Proc. Natl. Acad. Sci. U S A.* 2009; 106, 5053-5058; the entire contents of each are hereby incorporated by reference in their entirety). Other examples of recombinases that are useful in the methods and compositions described herein are known to those of skill in the art, and any new recombinase that is discovered or generated is expected to be able to be used in the different embodiments of the invention. In some embodiments, the catalytic domains of a recombinase are fused to a nuclease-inactivated RNA-programmable nuclease (*e.g.*, dCas9, or a fragment thereof), such that the recombinase domain does not comprise a nucleic acid binding domain or is unable to bind to a target nucleic acid (*e.g.*, the recombinase domain is engineered such that it does not have specific DNA binding activity). Recombinases lacking DNA binding activity and methods for engineering such are known, and include those described by Klippel *et al.*, “Isolation and characterisation of unusual gin mutants.” *EMBO J.* 1988; 7: 3983–3989; Burke *et al.*, “Activating mutations of Tn3 resolvase marking interfaces important in recombination catalysis and its regulation.” *Mol Microbiol.* 2004; 51: 937–948; Olorunniji *et al.*, “Synapsis and catalysis by activated Tn3 resolvase mutants.” *Nucleic Acids Res.* 2008; 36: 7181–7191; Rowland *et al.*, “Regulatory mutations in Sin recombinase support a structure-based model of the synaptosome.” *Mol Microbiol.* 2009; 74: 282–298; Akopian *et al.*, “Chimeric recombinases with designed DNA sequence recognition.” *Proc Natl Acad Sci USA.* 2003;100: 8688–8691; Gordley *et al.*, “Evolution of programmable zinc finger-

recombinases with activity in human cells. *J Mol Biol.* 2007; 367: 802–813; Gordley *et al.*, “Synthesis of programmable integrases.” *Proc Natl Acad Sci USA.* 2009;106: 5053–5058; Arnold *et al.*, “Mutants of Tn3 resolvase which do not require accessory binding sites for recombination activity.” *EMBO J.* 1999;18: 1407–1414; Gaj *et al.*, “Structure-guided reprogramming of serine recombinase DNA sequence specificity.” *Proc Natl Acad Sci USA.* 2011;108(2):498-503; and Proudfoot *et al.*, “Zinc finger recombinases with adaptable DNA sequence specificity.” *PLoS One.* 2011;6(4):e19537; the entire contents of each are hereby incorporated by reference. For example, serine recombinases of the resolvase-invertase group, *e.g.*, Tn3 and $\gamma\delta$ resolvases and the Hin and Gin invertases, have modular structures with autonomous catalytic and DNA-binding domains (See, *e.g.*, Grindley *et al.*, “Mechanism of site-specific recombination.” *Ann Rev Biochem.* 2006; 75: 567–605, the entire contents of which are incorporated by reference). The catalytic domains of these recombinases are thus amenable to being recombined with nuclease-inactivated RNA-programmable nucleases (*e.g.*, dCas9, or a fragment thereof) as described herein, *e.g.*, following the isolation of ‘activated’ recombinase mutants which do not require any accessory factors (*e.g.*, DNA binding activities) (See, *e.g.*, Klippel *et al.*, “Isolation and characterisation of unusual gin mutants.” *EMBO J.* 1988; 7: 3983–3989; Burke *et al.*, “Activating mutations of Tn3 resolvase marking interfaces important in recombination catalysis and its regulation. *Mol Microbiol.* 2004; 51: 937–948; Olorunniji *et al.*, “Synapsis and catalysis by activated Tn3 resolvase mutants.” *Nucleic Acids Res.* 2008; 36: 7181–7191; Rowland *et al.*, “Regulatory mutations in Sin recombinase support a structure-based model of the synaptosome.” *Mol Microbiol.* 2009; 74: 282–298; Akopian *et al.*, “Chimeric recombinases with designed DNA sequence recognition.” *Proc Natl Acad Sci USA.* 2003;100: 8688–8691). Additionally, many other natural serine recombinases having an N-terminal catalytic domain and a C-terminal DNA binding domain are known (*e.g.*, phiC31 integrase, TnpX transposase, IS607 transposase), and their catalytic domains can be co-opted to engineer programmable site-specific recombinases as described herein (See, *e.g.*, Smith *et al.*, “Diversity in the serine recombinases.” *Mol Microbiol.* 2002;44: 299–307, the entire contents of which are incorporated by reference). Similarly, the core catalytic domains of tyrosine recombinases (*e.g.*, Cre, λ integrase) are known, and can be similarly co-opted to engineer programmable site-specific recombinases as described herein (See, *e.g.*, Guo *et al.*, “Structure of Cre recombinase complexed with DNA in a site-specific recombination synapse.” *Nature.* 1997; 389:40–46; Hartung *et al.*, “Cre mutants with altered DNA binding properties.” *J Biol Chem* 1998; 273:22884–22891; Shaikh *et al.*, “Chimeras of the Flp and Cre recombinases: Tests of the mode of cleavage by Flp and Cre. *J Mol Biol.* 2000; 302:27–48; Rongrong *et al.*, “Effect of deletion mutation on the recombination activity of Cre recombinase.” *Acta Biochim Pol.* 2005; 52:541–544; Kilbride *et al.*, “Determinants of product topology in a hybrid Cre-Tn3 resolvase site-specific recombination system.” *J Mol Biol.* 2006; 355:185–195; Warren *et al.*, “A chimeric cre recombinase with regulated directionality.” *Proc Natl Acad Sci USA.* 2008 105:18278–

18283; Van Duyne, "Teaching Cre to follow directions." *Proc Natl Acad Sci USA*. 2009 Jan 6;106(1):4-5; Numrych *et al.*, "A comparison of the effects of single-base and triple-base changes in the integrase arm-type binding sites on the site-specific recombination of bacteriophage λ ." *Nucleic Acids Res.* 1990; 18:3953–3959; Tirumalai *et al.*, "The recognition of core-type DNA sites by λ integrase." *J Mol Biol.* 1998; 279:513–527; Aihara *et al.*, "A conformational switch controls the DNA cleavage activity of λ integrase." *Mol Cell.* 2003; 12:187–198; Biswas *et al.*, "A structural basis for allosteric control of DNA recombination by λ integrase." *Nature*. 2005; 435:1059–1066; and Warren *et al.*, "Mutations in the amino-terminal domain of λ -integrase have differential effects on integrative and excisive recombination." *Mol Microbiol.* 2005; 55:1104–1112; the entire contents of each are incorporated by reference).

Recombinase recognition sequence

[0307] The term "recombinase recognition sequence", or equivalently as "RRS" or "recombinase target sequence" or "recombinase site," as used herein, refers to a nucleotide sequence target recognized by a recombinase and which undergoes strand exchange with another DNA molecule having a the RRS that results in excision, integration, inversion, or exchange of DNA fragments between the recombinase recognition sequences. In various embodiments, the multi-strand prime editors may install one or more recombinase sites in a target sequence, or in more than one target sequence. When more than one recombinase site is installed by a multi-strand prime editor, the recombinase sites can be installed at adjacent target sites or non-adjacent target sites (*e.g.*, separate chromosomes). In various embodiments, single installed recombinase sites can be used as "landing sites" for a recombinase-mediated reaction between the genomic recombinase site and a second recombinase site within an exogenously supplied nucleic acid molecule, *e.g.*, a plasmid. This enables the targeted integration of a desired nucleic acid molecule. In other embodiments, where two recombinase sites are inserted in adjacent regions of DNA (*e.g.*, separated by 25-50 bp, 50-100 bp, 100-200 bp, 200-300 bp, 300-400 bp, 400-500 bp, 500-600 bp, 600-700 bp, 700-800 bp, 800-900 bp, 900-1000 bp, 1000-2000 bp, 2000-3000 bp, 3000-4000 bp, 4000-5000 bp, or more), the recombinase sites can be used for recombinase-mediated excision or inversion of the intervening sequence, or for recombinase-mediated cassette exchange with exogenous DNA having the same recombinase sites. When the two or more recombinase sites are installed by multi-flap prime editors on two different chromosomes, translocation of the intervening sequence can occur from a first chromosomal location to the second.

Recombine or recombination

[0308] The term "recombine," or "recombination," in the context of a nucleic acid modification (*e.g.*, a genomic modification), is used to refer to the process by which two or more nucleic acid molecules, or two or more regions of a single nucleic acid molecule, are modified by the action of a recombinase protein (*e.g.*, an inventive recombinase fusion protein provided herein). Recombination

can result in, *inter alia*, the insertion, inversion, excision, or translocation of nucleic acids, *e.g.*, in or between one or more nucleic acid molecules.

Reverse transcriptase

[0309] The term "reverse transcriptase" describes a class of polymerases characterized as RNA-dependent DNA polymerases. All known reverse transcriptases require a primer to synthesize a DNA transcript from an RNA template. Historically, reverse transcriptase has been used primarily to transcribe mRNA into cDNA which can then be cloned into a vector for further manipulation. Avian myoblastosis virus (AMV) reverse transcriptase was the first widely used RNA-dependent DNA polymerase (Verma, *Biochim. Biophys. Acta* 473:1 (1977)). The enzyme has 5'-3' RNA-directed DNA polymerase activity, 5'-3' DNA-directed DNA polymerase activity, and RNase H activity. RNase H is a processive 5' and 3' ribonuclease specific for the RNA strand for RNA-DNA hybrids (Perbal, *A Practical Guide to Molecular Cloning*, New York: Wiley & Sons (1984)). Errors in transcription cannot be corrected by reverse transcriptase because known viral reverse transcriptases lack the 3'-5' exonuclease activity necessary for proofreading (Saunders and Saunders, *Microbial Genetics Applied to Biotechnology*, London: Croom Helm (1987)). A detailed study of the activity of AMV reverse transcriptase and its associated RNase H activity has been presented by Berger et al., *Biochemistry* 22:2365-2372 (1983). Another reverse transcriptase which is used extensively in molecular biology is reverse transcriptase originating from Moloney murine leukemia virus (M-MLV). See, *e.g.*, Gerard, G. R., *DNA* 5:271-279 (1986) and Kotewicz, M. L., et al., *Gene* 35:249-258 (1985). M-MLV reverse transcriptase substantially lacking in RNase H activity has also been described. See, *e.g.*, U.S. Pat. No. 5,244,797. The invention contemplates the use of any such reverse transcriptases, or variants or mutants thereof.

[0310] In addition, the invention contemplates the use of reverse transcriptases that are error-prone, *i.e.*, that may be referred to as error-prone reverse transcriptases or reverse transcriptases that do not support high fidelity incorporation of nucleotides during polymerization. During synthesis of the single-strand DNA flap based on the RT template integrated with the guide RNA, the error-prone reverse transcriptase can introduce one or more nucleotides which are mismatched with the RT template sequence, thereby introducing changes to the nucleotide sequence through erroneous polymerization of the single-strand DNA flap. These errors introduced during synthesis of the single strand DNA flap then become integrated into the double strand molecule through hybridization to the corresponding endogenous target strand, removal of the endogenous displaced strand, ligation, and then through one more round of endogenous DNA repair and/or sequencing processes.

Reverse transcription

[0311] As used herein, the term "reverse transcription" indicates the capability of an enzyme to synthesize a DNA strand (that is, complementary DNA or cDNA) using RNA as a template. In some embodiments, the reverse transcription can be "error-prone reverse transcription," which refers to the

properties of certain reverse transcriptase enzymes which are error-prone in their DNA polymerization activity.

PACE

[0312] The term “phage-assisted continuous evolution (PACE),” as used herein, refers to continuous evolution that employs phage as viral vectors. The general concept of PACE technology has been described, for example, in International PCT Application, PCT/US2009/056194, filed September 8, 2009, published as WO 2010/028347 on March 11, 2010; International PCT Application, PCT/US2011/066747, filed December 22, 2011, published as WO 2012/088381 on June 28, 2012; U.S. Application, U.S. Patent No. 9,023,594, issued May 5, 2015, International PCT Application, PCT/US2015/012022, filed January 20, 2015, published as WO 2015/134121 on September 11, 2015, and International PCT Application, PCT/US2016/027795, filed April 15, 2016, published as WO 2016/168631 on October 20, 2016, the entire contents of each of which are incorporated herein by reference.

Phage

[0313] The term “phage,” as used herein interchangeably with the term “bacteriophage,” refers to a virus that infects bacterial cells. Typically, phages consist of an outer protein capsid enclosing genetic material. The genetic material can be ssRNA, dsRNA, ssDNA, or dsDNA, in either linear or circular form. Phages and phage vectors are well known to those of skill in the art and non-limiting examples of phages that are useful for carrying out the PACE methods provided herein are λ (Lysogen), T2, T4, T7, T12, R17, M13, MS2, G4, P1, P2, P4, Phi X174, N4, Φ 6, and Φ 29. In certain embodiments, the phage utilized in the present invention is M13. Additional suitable phages and host cells will be apparent to those of skill in the art and the invention is not limited in this aspect. For an exemplary description of additional suitable phages and host cells, see Elizabeth Kutter and Alexander Sulakvelidze: Bacteriophages: Biology and Applications. CRC Press; 1st edition (December 2004), ISBN: 0849313368; Martha R. J. Clokie and Andrew M. Kropinski: Bacteriophages: Methods and Protocols, Volume 1: Isolation, Characterization, and Interactions (Methods in Molecular Biology) Humana Press; 1st edition (December, 2008), ISBN: 1588296822; Martha R. J. Clokie and Andrew M. Kropinski: Bacteriophages: Methods and Protocols, Volume 2: Molecular and Applied Aspects (Methods in Molecular Biology) Humana Press; 1st edition (December 2008), ISBN: 1603275649; all of which are incorporated herein in their entirety by reference for disclosure of suitable phages and host cells as well as methods and protocols for isolation, culture, and manipulation of such phages).

Protein, peptide, and polypeptide

[0314] The terms “protein,” “peptide,” and “polypeptide” are used interchangeably herein, and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long. A protein, peptide, or polypeptide may refer to an

individual protein or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. A protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex. A protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination thereof. Any of the proteins provided herein may be produced by any method known in the art. For example, the proteins provided herein may be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker. Methods for recombinant protein expression and purification are well known, and include those described by Green and Sambrook, *Molecular Cloning: A Laboratory Manual* (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)), the entire contents of which are incorporated herein by reference.

Protein splicing

[0315] The term “protein splicing,” as used herein, refers to a process in which a sequence, an intein (or split inteins, as the case may be), is excised from within an amino acid sequence, and the remaining fragments of the amino acid sequence, the exteins, are ligated via an amide bond to form a continuous amino acid sequence. The term “trans” protein splicing refers to the specific case where the inteins are split inteins and they are located on different proteins.

Second-strand nicking

[0316] The resolution of heteroduplex DNA (i.e., containing one edited and one non-edited strand) formed as a result of prime editing determines long-term editing outcomes. In words, a goal of prime editing is to resolve the heteroduplex DNA (the edited strand paired with the endogenous non-edited strand) formed as an intermediate of PE by permanently integrating the edited strand into the complement, endogenous strand. The approach of “second-strand nicking” can be used herein to help drive the resolution of heteroduplex DNA in favor of permanent integration of the edited strand into the DNA molecule. As used herein, the concept of “second-strand nicking” refers to the introduction of a second nick at a location downstream of the first nick (i.e., the initial nick site that provides the free 3' end for use in priming of the reverse transcriptase on the extended portion of the guide RNA), preferably on the unedited strand. In certain embodiments, the first nick and the second nick are on opposite strands. In other embodiments, the first nick and the second nick are on opposite strands. In yet another embodiment, the first nick is on the non-target strand (i.e., the strand that forms the single strand portion of the R-loop), and the second nick is on the target strand. In still other embodiments, the first nick is on the edited strand, and the second nick is on the unedited strand. The second nick can be positioned at least 5 nucleotides downstream of the first nick, or at least 6, 7, 8, 9, 10, 11, 12,

13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 or more nucleotides downstream of the first nick. The second nick, in certain embodiments, can be introduced between about 5-150 nucleotides on the unedited strand away from the site of the PEGRNA-induced nick, or between about 5-140, or between about 5-130, or between about 5-120, or between about 5-110, or between about 5-100, or between about 5-90, or between about 5-80, or between about 5-70, or between about 5-60, or between about 5-50, or between about 5-40, or between about 5-30, or between about 5-20, or between about 5-10. In one embodiment, the second nick is introduced between 14-116 nucleotides away from the PEGRNA-induced nick.

Without being bound by theory, the second nick induces the cell's endogenous DNA repair and replication processes towards replacement or editing of the unedited strand, thereby permanently installing the edited sequence on both strands and resolving the heteroduplex that is formed as a result of PE. In some embodiments, the edited strand is the non-target strand and the unedited strand is the target strand. In other embodiments, the edited strand is the target strand, and the unedited strand is the non-target strand.

Sense strand

[0317] In genetics, a “sense” strand is the segment within double-stranded DNA that runs from 5' to 3', and which is complementary to the antisense strand of DNA, or template strand, which runs from 3' to 5'. In the case of a DNA segment that encodes a protein, the sense strand is the strand of DNA that has the same sequence as the mRNA, which takes the antisense strand as its template during transcription, and eventually undergoes (typically, not always) translation into a protein. The antisense strand is thus responsible for the RNA that is later translated to protein, while the sense strand possesses a nearly identical makeup to that of the mRNA. Note that for each segment of dsDNA, there will possibly be two sets of sense and antisense, depending on which direction one reads (since sense and antisense is relative to perspective). It is ultimately the gene product, or mRNA, that dictates which strand of one segment of dsDNA is referred to as sense or antisense.

[0318] In the context of a PEGRNA, the first step is the synthesis of a single-strand complementary DNA (i.e., the 3' ssDNA flap, which becomes incorporated) oriented in the 5' to 3' direction which is templated off of the PEGRNA extension arm. Whether the 3' ssDNA flap should be regarded as a sense or antisense strand depends on the direction of transcription since it well accepted that both strands of DNA may serve as a template for transcription (but not at the same time). Thus, in some embodiments, the 3' ssDNA flap (which overall runs in the 5' to 3' direction) will serve as the sense strand because it is the coding strand. In other embodiments, the 3' ssDNA flap (which overall runs in the 5' to 3' direction) will serve as the antisense strand and thus, the template for transcription.

Sequence Homology

[0319] A “homologous sequence” or a sequence exhibiting “homology” to another sequence means a sequence of a nucleic acid molecule exhibiting at least about 65%, 70%, 75%, 80%, 85%, or 90%

sequence identity to another nucleic acid molecule. In other embodiments, a “homologous sequence” of nucleic acids may exhibit 93%, 95% or 98% sequence identity to the reference nucleic acid.

[0320] When a percentage of sequence homology or identity is specified, in the context of two nucleic acid sequences or two polypeptide sequences, the percentage of homology or identity generally refers to the alignment of two or more sequences across a portion of their length when, compared and aligned for maximum correspondence. Unless stated otherwise, sequence homology or identity is assessed over the specified length of the nucleic acid, polypeptide, or portion thereof. In some embodiments, the homology or identity is assessed over a functional portion or specified portion of the length.

[0321] Alignment of sequences for assessment of sequence homology can be conducted by algorithms known in the art, such as the Basic Local Alignment Search Tool (BLAST) algorithm, which is described in Altschul et al, J. Mol. Biol. 215:403- 410, 1990. A publicly available internet interface for performing BLAST analyses is accessible through the National Center for Biotechnology Information. Additional known algorithms include those published in: Smith & Waterman, “Comparison of Biosequences”, Adv. Appl. Math. 2:482, 1981; Needleman & Wunsch, “A general method applicable to the search for similarities in the amino acid sequence of two proteins” J. Mol. Biol. 48:443, 1970; Pearson & Lipman “Improved tools for biological sequence comparison”, Proc. Natl. Acad. Sci. USA 85:2444, 1988; or by automated implementation of these or similar algorithms. Global alignment programs may also be used to align similar sequences of roughly equal size. Examples of global alignment programs include NEEDLE (available at www.ebi.ac.uk/Tools/psa/emboss_needle/) which is part of the EMBOSS package (Rice P et al., Trends Genet., 2000; 16: 276-277), and the GGSEARCH program [fasta.bioch. Virginia.edu/fasta_www2/fasta_www.cgi?rm=compare&pgm=gnw](http://fasta.bioch.virginia.edu/fasta_www2/fasta_www.cgi?rm=compare&pgm=gnw)), which is part of the FASTA package (Pearson W and Lipman D, 1988, Proc. Natl. Acad. Sci. USA, 85: 2444-2448). Both of these programs are based on the Needleman-Wunsch algorithm which is used to find the optimum alignment (including gaps) of two sequences along their entire length. A detailed discussion of sequence analysis can also be found in Unit 19.3 of Ausubel et al (“Current Protocols in Molecular Biology” John Wiley & Sons Inc, 1994-1998, Chapter 15, 1998).

Spacer sequence

[0322] As used herein, the term “spacer sequence” in connection with a guide RNA or a PEgRNA refers to the portion of the guide RNA or PEgRNA of about 20 nucleotides which contains a nucleotide sequence that shares the same sequence as the protospacer sequence in the target DNA sequence. The spacer sequence anneals to the complement of the protospacer sequence to form a ssRNA/ssDNA hybrid structure at the target site and a corresponding R loop ssDNA structure of the endogenous DNA strand.

Subject

[0323] The term “subject,” as used herein, refers to an individual organism, for example, an individual mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal. In some embodiments, the subject is a non-human primate. In some embodiments, the subject is a rodent. In some embodiments, the subject is a sheep, a goat, a cattle, a cat, or a dog. In some embodiments, the subject is a vertebrate, an amphibian, a reptile, a fish, an insect, a fly, or a nematode. In some embodiments, the subject is a research animal. In some embodiments, the subject is genetically engineered, e.g., a genetically engineered non-human subject. The subject may be of either sex and at any stage of development.

Split intein

[0324] Although inteins are most frequently found as a contiguous domain, some exist in a naturally split form. In this case, the two fragments are expressed as separate polypeptides and must associate before splicing takes place, so-called protein trans-splicing.

[0325] An exemplary split intein is the *Ssp* DnaE intein, which comprises two subunits, namely, DnaE-N and DnaE-C. The two different subunits are encoded by separate genes, namely *dnaE-n* and *dnaE-c*, which encode the DnaE-N and DnaE-C subunits, respectively. DnaE is a naturally occurring split intein in *Synechocystis sp.* PCC6803 and is capable of directing trans-splicing of two separate proteins, each comprising a fusion with either DnaE-N or DnaE-C.

[0326] Additional naturally occurring or engineered split-intein sequences are known in the art or can be made from whole-intein sequences described herein or those available in the art. Examples of split-intein sequences can be found in Stevens et al., “A promiscuous split intein with expanded protein engineering applications,” PNAS, 2017, Vol.114: 8538-8543; Iwai et al., “Highly efficient protein trans-splicing by a naturally split DnaE intein from *Nostoc punctiforme*,” FEBS Lett, 580: 1853-1858, each of which are incorporated herein by reference. Additional split intein sequences can be found, for example, in WO 2013/045632, WO 2014/055782, WO 2016/069774, and EP2877490, the contents each of which are incorporated herein by reference.

[0327] In addition, protein splicing in trans has been described *in vivo* and *in vitro* (Shingledecker, et al., *Gene* 207:187 (1998), Southworth, et al., *EMBO J.* 17:918 (1998); Mills, et al., *Proc. Natl. Acad. Sci. USA*, 95:3543-3548 (1998); Lew, et al., *J. Biol. Chem.*, 273:15887-15890 (1998); Wu, et al., *Biochim. Biophys. Acta* 35732:1 (1998b), Yamazaki, et al., *J. Am. Chem. Soc.* 120:5591 (1998), Evans, et al., *J. Biol. Chem.* 275:9091 (2000); Otomo, et al., *Biochemistry* 38:16040-16044 (1999); Otomo, et al., *J. Biomol. NMR* 14:105-114 (1999); Scott, et al., *Proc. Natl. Acad. Sci. USA* 96:13638-13643 (1999)) and provides the opportunity to express a protein as to two inactive fragments that subsequently undergo ligation to form a functional product, e.g., as shown in FIGs. 66 and 67 with regard to the formation of a complete PE fusion protein from two separately-expressed halves.

Target site

[0328] The term “target site” refers to a sequence within a nucleic acid molecule that is edited by a prime editor (PE) disclosed herein. The target site further refers to the sequence within a nucleic acid molecule to which a complex of the prime editor (PE) and gRNA binds.

tPERT

[0329] See definition for “*trans* prime editor RNA template (tPERT).”

Temporal second-strand nicking

[0330] As used herein, the term “temporal second-strand nicking” refers to a variant of second strand nicking whereby the installation of the second nick in the unedited strand occurs only after the desired edit is installed in the edited strand. This avoids concurrent nicks on both strands that could lead to double-stranded DNA breaks. The second-strand nicking guide RNA is designed for temporal control such that the second strand nick is not introduced until after the installation of the desired edit. This is achieved by designing a gRNA with a spacer sequence that matches only the edited strand, but not the original allele. Using this strategy, mismatches between the protospacer and the unedited allele should disfavor nicking by the sgRNA until after the editing event on the PAM strand takes place.

Trans prime editing

[0331] As used herein, the term “*trans* prime editing” or similarly, “trans dual prime editing,” refers to a modified form of prime editing or dual prime editing that utilizes a split PEgRNA, i.e., wherein the PEgRNA is separated into two separate molecules: an sgRNA and a *trans* prime editing RNA template (tPERT). The sgRNA serves to target the prime editor (or more generally, to target the napDNAbp component of the prime editor) to the desired genomic target site, while the tPERT is used by the polymerase (e.g., a reverse transcriptase) to write new DNA sequence into the target locus once the tPERT is recruited *in trans* to the prime editor by the interaction of binding domains located on the prime editor and on the tPERT. In one embodiment, the binding domains can include RNA-protein recruitment moieties, such as a MS2 aptamer located on the tPERT and an MS2cp protein fused to the prime editor. An advantage of *trans* prime editing is that by separating the DNA synthesis template from the guide RNA, one can potentially use longer length templates.

[0332] An embodiment of *trans* prime editing is shown in FIGs. 3G and 3H. FIG. 3G shows the composition of the *trans* prime editor complex on the left (“RP-PE:gRNA complex”), which comprises an napDNAbp fused to each of a polymerase (e.g., a reverse transcriptase) and a rPERT recruiting protein (e.g., MS2sc), and which is complexed with a guide RNA. FIG. 3G further shows a separate tPERT molecule, which comprises the extension arm features of a PEgRNA, including the DNA synthesis template and the primer binding sequence. The tPERT molecule also includes an RNA-protein recruitment domain (which, in this case, is a stem loop structure and can be, for example, MS2 aptamer). As depicted in the process described in FIG. 3H, the RP-PE:gRNA complex binds to and nicks the target DNA sequence. Then, the recruiting protein (RP) recruits a tPERT to co-localize to the prime editor complex bound to the DNA target site, thereby allowing the primer binding site to

bind to the primer sequence on the nicked strand, and subsequently, allowing the polymerase (e.g., RT) to synthesize a single strand of DNA against the DNA synthesis template up through the 5' of the tPERT.

[0333] While the tPERT is shown in FIG. 3G and FIG. 3H as comprising the PBS and DNA synthesis template on the 5' end of the RNA-protein recruitment domain, the tPERT in other configurations may be designed with the PBS and DNA synthesis template located on the 3' end of the RNA-protein recruitment domain. However, the tPERT with the 5' extension has the advantage that synthesis of the single strand of DNA will naturally terminate at the 5' end of the tPERT and thus, does not risk using any portion of the RNA-protein recruitment domain as a template during the DNA synthesis stage of prime editing.

Trans prime editor RNA template (tPERT)

[0334] As used herein, a “trans prime editor RNA template (tPERT)” refers to a component used in trans prime editing or trans dual prime editing, a modified version of prime editing which operates by separating the PEGRNA into two distinct molecules: a guide RNA and a tPERT molecule. The tPERT molecule is programmed to co-localize with the prime editor complex at a target DNA site, bringing the primer binding site and the DNA synthesis template to the prime editor in trans. For example, see FIG. 3G for an embodiment of a trans prime editor (tPE) which shows a two-component system comprising (1) an RP-PE:gRNA complex and (2) a tPERT that includes the primer binding site and the DNA synthesis template joined to an RNA-protein recruitment domain, wherein the RP (recruiting protein) component of the RP-PE:gRNA complex recruits the tPERT to a target site to be edited, thereby associating the PBS and DNA synthesis template with the prime editor in trans. Said another way, the tPERT is engineered to contain (all or part of) the extension arm of a PEGRNA, which includes the primer binding site and the DNA synthesis template.

Transitions

[0335] As used herein, “transitions” refer to the interchange of purine nucleobases ($A \leftrightarrow G$) or the interchange of pyrimidine nucleobases ($C \leftrightarrow T$). This class of interchanges involves nucleobases of similar shape. The compositions and methods disclosed herein are capable of inducing one or more transitions in a target DNA molecule. The compositions and methods disclosed herein are also capable of inducing both transitions and transversion in the same target DNA molecule. These changes involve $A \leftrightarrow G$, $G \leftrightarrow A$, $C \leftrightarrow T$, or $T \leftrightarrow C$. In the context of a double-strand DNA with Watson-Crick paired nucleobases, transversions refer to the following base pair exchanges: $A:T \leftrightarrow G:C$, $G:C \leftrightarrow A:T$, $C:G \leftrightarrow T:A$, or $T:A \leftrightarrow C:G$. The compositions and methods disclosed herein are capable of inducing one or more transitions in a target DNA molecule. The compositions and methods disclosed herein are also capable of inducing both transitions and transversion in the same target DNA molecule, as well as other nucleotide changes, including deletions and insertions.

Transversions

[0336] As used herein, “transversions” refer to the interchange of purine nucleobases for pyrimidine nucleobases, or in the reverse and thus, involve the interchange of nucleobases with dissimilar shape. These changes involve $T \leftrightarrow A$, $T \leftrightarrow G$, $C \leftrightarrow G$, $C \leftrightarrow A$, $A \leftrightarrow T$, $A \leftrightarrow C$, $G \leftrightarrow C$, and $G \leftrightarrow T$. In the context of a double-strand DNA with Watson-Crick paired nucleobases, transversions refer to the following base pair exchanges: $T:A \leftrightarrow A:T$, $T:A \leftrightarrow G:C$, $C:G \leftrightarrow G:C$, $C:G \leftrightarrow A:T$, $A:T \leftrightarrow T:A$, $A:T \leftrightarrow C:G$, $G:C \leftrightarrow C:G$, and $G:C \leftrightarrow T:A$. The compositions and methods disclosed herein are capable of inducing one or more transversions in a target DNA molecule. The compositions and methods disclosed herein are also capable of inducing both transitions and transversion in the same target DNA molecule, as well as other nucleotide changes, including deletions and insertions.

Treatment

[0337] The terms “treatment,” “treat,” and “treating,” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. As used herein, the terms “treatment,” “treat,” and “treating” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed and/or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, *e.g.*, to prevent or delay onset of a symptom or inhibit onset or progression of a disease. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (*e.g.*, in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to prevent or delay their recurrence.

Trinucleotide repeat disorder

[0338] As used herein, a “trinucleotide repeat disorder” (or alternatively, “expansion repeat disorder” or “repeat expansion disorder”) refers to a set of genetic disorders which are caused by “trinucleotide repeat expansion,” which is a kind of mutation where a certain trinucleotide repeats in certain genes or introns. Trinucleotide repeats were once thought to be commonplace iterations in the genome, but the 1990s clarified these disorders. These apparently ‘benign’ stretches of DNA can sometimes expand and cause disease. Several defining features are shared amongst disorders caused by trinucleotide repeat expansions. First, the mutant repeats show both somatic and germline instability and, more frequently, they expand rather than contract in successive transmissions. Secondly, an earlier age of onset and increasing severity of phenotype in subsequent generations (anticipation) generally are correlated with larger repeat length. Finally, the parental origin of the disease allele can often influence anticipation, with paternal transmissions carrying a greater risk of expansion for many of these disorders.

[0339] Triplet expansion is thought to be caused by slippage during DNA replication. Due to the repetitive nature of the DNA sequence in these regions 'loop out' structures may form during DNA

replication while maintaining complementary base pairing between the parent strand and daughter strand being synthesized. If the loop out structure is formed from sequence on the daughter strand this will result in an increase in the number of repeats. However, if the loop out structure is formed on the parent strand a decrease in the number of repeats occurs. It appears that expansion of these repeats is more common than reduction. Generally the larger the expansion the more likely they are to cause disease or increase the severity of disease. This property results in the characteristic of anticipation seen in trinucleotide repeat disorders. Anticipation describes the tendency of age of onset to decrease and severity of symptoms to increase through successive generations of an affected family due to the expansion of these repeats.

[0340] Nucleotide repeat disorders may include those in which the triplet repeat occurs in a non-coding region (i.e., a non-coding trinucleotide repeat disorder) or in a coding region

[0341] The prime editor (PE) system described herein may use to treat nucleotide repeat disorders, which may include fragile X syndrome (FRAXA), fragile XE MR (FRAXE), Friedreich ataxia (FRDA), myotonic dystrophy (DM), spinocerebellar ataxia type 8 (SCA8), and spinocerebellar ataxia type 12 (SCA12), among others.

Upstream

[0342] As used herein, the terms “upstream” and “downstream” are terms of relativity that define the linear position of at least two elements located in a nucleic acid molecule (whether single or double-stranded) that is orientated in a 5'-to-3' direction. In particular, a first element is upstream of a second element in a nucleic acid molecule where the first element is positioned somewhere that is 5' to the second element. For example, a SNP is upstream of a Cas9-induced nick site if the SNP is on the 5' side of the nick site. Conversely, a first element is downstream of a second element in a nucleic acid molecule where the first element is positioned somewhere that is 3' to the second element. For example, a SNP is downstream of a Cas9-induced nick site if the SNP is on the 3' side of the nick site. The nucleic acid molecule can be a DNA (double or single stranded), RNA (double or single stranded), or a hybrid of DNA and RNA. The analysis is the same for single strand nucleic acid molecule and a double strand molecule since the terms upstream and downstream are in reference to only a single strand of a nucleic acid molecule, except that one needs to select which strand of the double stranded molecule is being considered. Often, the strand of a double stranded DNA which can be used to determine the positional relativity of at least two elements is the “sense” or “coding” strand. In genetics, a “sense” strand is the segment within double-stranded DNA that runs from 5' to 3', and which is complementary to the antisense strand of DNA, or template strand, which runs from 3' to 5'. Thus, as an example, a SNP nucleobase is “downstream” of a promoter sequence in a genomic DNA (which is double-stranded) if the SNP nucleobase is on the 3' side of the promoter on the sense or coding strand.

Variant

[0343] As used herein the term “variant” should be taken to mean the exhibition of qualities that have a pattern that deviates from what occurs in nature, e.g., a variant Cas9 is a Cas9 comprising one or more changes in amino acid residues as compared to a wild type Cas9 amino acid sequence. The term “variant” encompasses homologous proteins having at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99% percent identity with a reference sequence and having the same or substantially the same functional activity or activities as the reference sequence. The term also encompasses mutants, truncations, or domains of a reference sequence, and which display the same or substantially the same functional activity or activities as the reference sequence.

Vector

[0344] The term “vector,” as used herein, refers to a nucleic acid that can be modified to encode a gene of interest and that is able to enter into a host cell, mutate and replicate within the host cell, and then transfer a replicated form of the vector into another host cell. Exemplary suitable vectors include viral vectors, such as retroviral vectors or bacteriophages and filamentous phage, and conjugative plasmids. Additional suitable vectors will be apparent to those of skill in the art based on the instant disclosure.

Wild type

[0345] As used herein the term “wild type” is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.

5′ endogenous DNA flap

[0346] As used herein, the term “5′ endogenous DNA flap” refers to the strand of DNA situated immediately downstream of the PE-induced nick site in the target DNA. The nicking of the target DNA strand by PE exposes a 3′ hydroxyl group on the upstream side of the nick site and a 5′ hydroxyl group on the downstream side of the nick site. The endogenous strand ending in the 3′ hydroxyl group is used to prime the DNA polymerase of the prime editor (e.g., wherein the DNA polymerase is a reverse transcriptase). The endogenous strand on the downstream side of the nick site and which begins with the exposed 5′ hydroxyl group is referred to as the “5′ endogenous DNA flap” and is ultimately removed and replaced by the newly synthesized replacement strand (i.e., “3′ replacement DNA flap”) the encoded by the extension of the PEGRNA.

5′ endogenous DNA flap removal

[0347] As used herein, the term “5′ endogenous DNA flap removal” or “5′ flap removal” refers to the removal of the 5′ endogenous DNA flap that forms when the RT-synthesized single-strand DNA flap competitively invades and hybridizes to the endogenous DNA, displacing the endogenous strand in the process. Removing this endogenous displaced strand can drive the reaction towards the formation of the desired product comprising the desired nucleotide change. The cell’s own DNA repair enzymes may catalyze the removal or excision of the 5′ endogenous flap (e.g., a flap

endonuclease, such as EXO1 or FEN1). Also, host cells may be transformed to express one or more enzymes that catalyze the removal of said 5' endogenous flaps, thereby driving the process toward product formation (e.g., a flap endonuclease). Flap endonucleases are known in the art and can be found described in Patel et al., "Flap endonucleases pass 5'-flaps through a flexible arch using a disorder-thread-order mechanism to confer specificity for free 5'-ends," *Nucleic Acids Research*, 2012, 40(10): 4507-4519 and Tsutakawa et al., "Human flap endonuclease structures, DNA double-base flipping, and a unified understanding of the FEN1 superfamily," *Cell*, 2011, 145(2): 198-211 (each of which are incorporated herein by reference).

3' replacement DNA flap

[0348] As used herein, the term "3' replacement DNA flap" or simply, "replacement DNA flap," refers to the strand of DNA that is synthesized by the prime editor and which is encoded by the extension arm of the prime editor PEgRNA. More in particular, the 3' replacement DNA flap is encoded by the polymerase template of the PEgRNA. The 3' replacement DNA flap comprises the same sequence as the 5' endogenous DNA flap except that it also contains the edited sequence (e.g., single nucleotide change). The 3' replacement DNA flap anneals to the target DNA, displacing or replacing the 5' endogenous DNA flap (which can be excised, for example, by a 5' flap endonuclease, such as FEN1 or EXO1) and then is ligated to join the 3' end of the 3' replacement DNA flap to the exposed 5' hydroxyl end of endogenous DNA (exposed after excision of the 5' endogenous DNA flap, thereby reforming a phosphodiester bond and installing the 3' replacement DNA flap to form a heteroduplex DNA containing one edited strand and one unedited strand. DNA repair processes resolve the heteroduplex by copying the information in the edited strand to the complementary strand permanently installs the edit in to the DNA. This resolution process can be driven further to completion by nicking the unedited strand, i.e., by way of "second-strand nicking," as described herein.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

[0349] Adoption of the clustered regularly interspaced short palindromic repeat (CRISPR) system for genome editing has revolutionized the life sciences¹⁻³. Although gene disruption using CRISPR is now routine, the precise installation of single nucleotide edits remains a major challenge, despite being necessary for studying or correcting a large number of disease-causative mutations. Homology directed repair (HDR) is capable of achieving such edits, but suffers from low efficiency (often <5%), a requirement for donor DNA repair templates, and deleterious effects of double-stranded DNA break (DSB) formation. Recently, Prof. David Liu *et al.*'s laboratory developed base editing, which achieves efficient single nucleotide editing without DSBs. Base editors (BEs) combine the CRISPR system with base-modifying deaminase enzymes to convert target C•G or A•T base pairs to A•T or G•C, respectively⁴⁻⁶. Although already widely used by researchers worldwide, current BEs enable only four of the twelve possible base pair conversions and are unable to correct small insertions or

deletions. Moreover, the targeting scope of base editing is limited by the editing of non-target C or A bases adjacent to the target base (“bystander editing”) and by the requirement that a PAM sequence exist 15±2 bp from the target base. Overcoming these limitations would therefore greatly broaden the basic research and therapeutic applications of genome editing.

[0350] New precision editing approaches (*e.g.*, classical prime editing) have been developed that offer many of the benefits of base editing—namely, avoidance of double strand breaks and donor DNA repair templates—while overcoming its major limitations. The proposed approach described herein achieves the direct installation of edited DNA strands at target genomic sites using target-primed reverse transcription (TPRT). In the design discussed herein, CRISPR guide RNA (gRNA) will be engineered to carry a reverse transcriptase (RT) template sequence encoding a single-stranded DNA comprising a desired nucleotide change. The CRISPR nuclease (Cas9)-nicked target site DNA will serve as the primer for reverse transcription of the template sequence on the modified gRNA, allowing for direct incorporation of any desired nucleotide edit.

[0351] The mechanism of target-primed reverse transcription (TPRT) can be leveraged or adapted for conducting precision CRISPR/Cas-based genome editing with high efficiency and genetic flexibility (*e.g.*, as depicted in various embodiments of FIGs. 1A-1F). Cas protein-reverse transcriptase fusions are used to target a specific DNA sequence with a modified guide RNA (“an extended guide RNA”), generate a single strand nick at the target site, and use the nicked DNA as a primer for reverse transcription of an engineered reverse transcriptase template that is integrated into the extended guide RNA. The newly synthesized strand would be homologous to the genomic target sequence except for the inclusion of a desired nucleotide change (*e.g.*, a single nucleotide change, a deletion, or an insertion, or a combination thereof). The newly synthesized strand of DNA may be referred to as a single strand DNA flap, which would compete for hybridization with the complementary homologous endogenous DNA strand, thereby displacing the corresponding endogenous strand. Resolution of this hybridized intermediate can include removal of the resulting displaced flap of endogenous DNA (*e.g.*, with a 5′ end DNA flap endonuclease, FEN1), ligation of the synthesized single strand DNA flap to the target DNA, and assimilation of the desired nucleotide change as a result of cellular DNA repair and/or replication processes. Because templated DNA synthesis offers single nucleotide precision, the scope of this approach is very broad and could foreseeably be used for myriad applications in basic science and therapeutics.

[0352] The present invention describes a new platform for genome editing called “multi-flap prime editing” (including, for example, “dual-flap prime editing” and “quadruple-flap prime editing”) and represents an innovative advancement of “prime editing” or “classical prime editing,” as described by the present inventors in Anzalone, A. V. *et al.* Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature* **576**, 149–157 (2019), which is incorporated herein by reference. Whereas classical prime editing in various embodiments polymerizes at a nick site a single 3′ flap

which becomes integrated into the target nucleic acid on the same strand, the presently described multi-flap prime editing systems involve distinct constructs, systems, and methodologies that, in various embodiments, generate pairs or multiple pairs of 3' flaps on different strands, which form duplexes comprising desired edits and which become incorporated into target nucleic acid molecules, e.g., at specific loci or edit sites in a genome. In various aspects, the pairs or multiple pairs of 3' flaps form duplexes because they comprise reverse complementary sequences which anneal to one another once generated by the prime editors described herein. The duplexes become incorporated into the target site by cell-driven mechanisms that naturally replace the endogenous duplex sequences located between adjacent nick sites. In certain embodiments, the new duplex sequences may be introduced at one or more locations (e.g., at adjacent genomic loci or on two different chromosomal locations), and may comprise one or more sequences of interest, e.g., protein-encoding sequence, peptide-encoding sequence, or RNA-encoding sequence. In one embodiment, the new duplex sequences installed by the multi-flap prime editing systems may comprise a recombinase site, e.g., a Bxb1 recombinase *attB* (38 bp) and/or *attP* (50 bp) site, or a recombinase site recognized by Hin recombinase, Gin recombinase, Tn3 recombinase, β -six recombinase, CinH recombinase, ParA recombinase, $\gamma\delta$ recombinase, ϕ C31 recombinase, TP901 recombinase, TG1 recombinase, ϕ BT1 recombinase, R4 recombinase, ϕ RV1 recombinase, ϕ FC1 recombinase, MR11 recombinase, A118 recombinase, U153 recombinase, and gp29 recombinase, Cre recombinase, FLP recombinase, R recombinase, Lambda recombinase, HK101 recombinase, HK022 recombinase, and pSAM2 recombinase.

[0353] In various aspects, this Specification describes a multi-flap prime editing system (including, for example, dual prime editing systems and quadruple prime editing systems) that addresses the challenges associated with flap equilibration and subsequent incorporation of the edit into the non-edited complementary genomic DNA strand by simultaneously editing both DNA strands. In the dual-flap prime editing system, for example, two PEgRNAs are used to target opposite strands of a genomic site and direct the synthesis of two complementary 3' flaps containing edited DNA sequence (**FIG. 90**). Unlike classical prime editing, there is no requirement for the pair of edited DNA strands (3' flaps) to directly compete with 5' flaps in endogenous genomic DNA, as the complementary edited strand is available for hybridization instead. Since both strands of the duplex are synthesized as edited DNA, the dual-flap prime editing system obviates the need for the replacement of the non-edited complementary DNA strand required by classical prime editing. Instead, cellular DNA repair machinery need only excise the paired 5' flaps (original genomic DNA) and ligate the paired 3' flaps (edited DNA) into the locus. Therefore, there is also no need to include sequences homologous to genomic DNA in the newly synthesized DNA strands, allowing selective hybridization of the new strands and facilitating edits that contain minimal genomic homology. Nuclease-active versions of prime editors that cut both strands of DNA could also be used to accelerate the removal of the original

DNA sequence. The quadruple-flap prime editing system, using four PEGRNAs, provides similar advantages.

[1] napDNAbp

[0354] The multi-flap prime editors described herein may comprise a nucleic acid programmable DNA binding protein (napDNAbp).

[0355] In one aspect, a napDNAbp can be associated with or complexed with at least one guide nucleic acid (e.g., guide RNA or a PEGRNA), which localizes the napDNAbp to a DNA sequence that comprises a DNA strand (i.e., a target strand) that is complementary to the guide nucleic acid, or a portion thereof (e.g., the spacer of a guide RNA which anneals to the protospacer of the DNA target). In other words, the guide nucleic-acid “programs” the napDNAbp (e.g., Cas9 or equivalent) to localize and bind to complementary sequence of the protospacer in the DNA.

[0356] Any suitable napDNAbp may be used in the multi-flap prime editors described herein. In various embodiments, the napDNAbp may be any Class 2 CRISPR-Cas system, including any type II, type V, or type VI CRISPR-Cas enzyme. Given the rapid development of CRISPR-Cas as a tool for genome editing, there have been constant developments in the nomenclature used to describe and/or identify CRISPR-Cas enzymes, such as Cas9 and Cas9 orthologs. This application references CRISPR-Cas enzymes with nomenclature that may be old and/or new. The skilled person will be able to identify the specific CRISPR-Cas enzyme being referenced in this Application based on the nomenclature that is used, whether it is old (i.e., “legacy”) or new nomenclature. CRISPR-Cas nomenclature is extensively discussed in Makarova et al., “Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?,” *The CRISPR Journal*, Vol. 1. No. 5, 2018, the entire contents of which are incorporated herein by reference. The particular CRISPR-Cas nomenclature used in any given instance in this Application is not limiting in any way and the skilled person will be able to identify which CRISPR-Cas enzyme is being referenced.

[0357] For example, the following type II, type V, and type VI Class 2 CRISPR-Cas enzymes have the following art-recognized old (i.e., legacy) and new names. Each of these enzymes, and/or variants thereof, may be used with the multi-flap prime editors described herein:

Legacy nomenclature	Current nomenclature*
<i>type II CRISPR-Cas enzymes</i>	
Cas9	same
<i>type V CRISPR-Cas enzymes</i>	
Cpf1	Cas12a
CasX	Cas12e
C2c1	Cas12b1
Cas12b2	same
C2c3	Cas12c
CasY	Cas12d
C2c4	same
C2c8	same
C2c5	same

C2c10	same
C2c9	same
<i>type VI CRISPR-Cas enzymes</i>	
C2c2	Cas13a
Cas13d	same
C2c7	Cas13c
C2c6	Cas13b

* See Makarova et al., *The CRISPR Journal*, Vol. 1, No. 5, 2018

[0358] Without being bound by theory, the mechanism of action of certain napDNAbp contemplated herein includes the step of forming an R-loop whereby the napDNAbp induces the unwinding of a double-strand DNA target, thereby separating the strands in the region bound by the napDNAbp. The guide RNA spacer then hybridizes to the “target strand” at the protospacer sequence. This displaces a “non-target strand” that is complementary to the target strand, which forms the single strand region of the R-loop. In some embodiments, the napDNAbp includes one or more nuclease activities, which then cut the DNA leaving various types of lesions. For example, the napDNAbp may comprise a nuclease activity that cuts the non-target strand at a first location, and/or cuts the target strand at a second location. Depending on the nuclease activity, the target DNA can be cut to form a “double-stranded break” whereby both strands are cut. In other embodiments, the target DNA can be cut at only a single site, i.e., the DNA is “nicked” on one strand. Exemplary napDNAbp with different nuclease activities include “Cas9 nickase” (“nCas9”) and a deactivated Cas9 having no nuclease activities (“dead Cas9” or “dCas9”).

[0359] The below description of various napDNAbps which can be used in connection with the presently disclosed multi-flap prime editors is not meant to be limiting in any way. The multi-flap prime editors may comprise the canonical SpCas9, or any ortholog Cas9 protein, or any variant Cas9 protein—including any naturally occurring variant, mutant, or otherwise engineered version of Cas9—that is known or that can be made or evolved through a directed evolutionary or otherwise mutagenic process. In various embodiments, the Cas9 or Cas9 variants have a nickase activity, i.e., only cleave one strand of the target DNA sequence. In other embodiments, the Cas9 or Cas9 variants have inactive nucleases, i.e., are “dead” Cas9 proteins. Other variant Cas9 proteins that may be used are those having a smaller molecular weight than the canonical SpCas9 (e.g., for easier delivery) or having modified or rearranged primary amino acid structure (e.g., the circular permutant formats).

[0360] The multi-flap prime editors described herein may also comprise Cas9 equivalents, including Cas12a (Cpf1) and Cas12b1 proteins which are the result of convergent evolution. The napDNAbps used herein (e.g., SpCas9, Cas9 variant, or Cas9 equivalents) may also contain various modifications that alter/enhance their PAM specificities. Lastly, the application contemplates any Cas9, Cas9 variant, or Cas9 equivalent which has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least

98%, at least 99%, or at least 99.9% sequence identity to a reference Cas9 sequence, such as a reference SpCas9 canonical sequence or a reference Cas9 equivalent (e.g., Cas12a (Cpf1)).

[0361] The napDNAbp can be a CRISPR (clustered regularly interspaced short palindromic repeat)-associated nuclease. As outlined above, CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids). CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids. CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA). In type II CRISPR systems, correct processing of pre-crRNA requires a trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (rnc), and a Cas9 protein. The tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA. Subsequently, Cas9/crRNA/tracrRNA endonucleolytically cleaves a linear or circular dsDNA target complementary to the spacer. The target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3'-5' exonucleolytically. In nature, DNA-binding and cleavage typically requires protein and both RNAs. However, single guide RNAs ("sgRNA", or simply "gRNA") can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M. et al., *Science* 337:816-821(2012), the entire contents of which is hereby incorporated by reference.

[0362] In some embodiments, the napDNAbp directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the napDNAbp directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. In some embodiments, a vector encodes a napDNAbp that is mutated to with respect to a corresponding wild-type enzyme such that the mutated napDNAbp lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. For example, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from *S. pyogenes* converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A in reference to the canonical SpCas9 sequence, or to equivalent amino acid positions in other Cas9 variants or Cas9 equivalents.

[0363] As used herein, the term "Cas protein" refers to a full-length Cas protein obtained from nature, a recombinant Cas protein having a sequence that differs from a naturally occurring Cas protein, or any fragment of a Cas protein that nevertheless retains all or a significant amount of the requisite basic functions needed for the disclosed methods, i.e., (i) possession of nucleic-acid programmable binding of the Cas protein to a target DNA, and (ii) ability to nick the target DNA sequence on one strand. The Cas proteins contemplated herein embrace CRISPR Cas 9 proteins, as well as Cas9 equivalents, variants (e.g., Cas9 nickase (nCas9) or nuclease inactive Cas9 (dCas9)) homologs, orthologs, or paralogs, whether naturally occurring or non-naturally occurring (e.g.,

engineered or recombinant), and may include a Cas9 equivalent from any Class 2 CRISPR system (e.g., type II, V, VI), including Cas12a (Cpf1), Cas12e (CasX), Cas12b1 (C2c1), Cas12b2, Cas12c (C2c3), C2c4, C2c8, C2c5, C2c10, C2c9 Cas13a (C2c2), Cas13d, Cas13c (C2c7), Cas13b (C2c6), and Cas13b. Further Cas-equivalents are described in Makarova et al., “C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector,” *Science* 2016; 353(6299) and Makarova et al., “Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?,” *The CRISPR Journal*, Vol. 1. No. 5, 2018, the contents of which are incorporated herein by reference.

[0364] The terms “Cas9” or “Cas9 nuclease” or “Cas9 moiety” or “Cas9 domain” embrace any naturally occurring Cas9 from any organism, any naturally-occurring Cas9 equivalent or functional fragment thereof, any Cas9 homolog, ortholog, or paralog from any organism, and any mutant or variant of a Cas9, naturally-occurring or engineered. The term Cas9 is not meant to be particularly limiting and may be referred to as a “Cas9 or equivalent.” Exemplary Cas9 proteins are further described herein and/or are described in the art and are incorporated herein by reference. The present disclosure is unlimited with regard to the particular Cas9 that is employed in the multi-flap prime editors described herein.

[0365] As noted herein, Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g., “Complete genome sequence of an M1 strain of *Streptococcus pyogenes*.” Ferretti et al., J.J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K., Primeaux C., Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P., Qian Y., Jia H.G., Najar F.Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S.W., Roe B.A., McLaughlin R.E., *Proc. Natl. Acad. Sci. U.S.A.* 98:4658-4663(2001); “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E., Chylinski K., Sharma C.M., Gonzales K., Chao Y., Pirzada Z.A., Eckert M.R., Vogel J., Charpentier E., *Nature* 471:602-607(2011); and “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. *Science* 337:816-821(2012), the entire contents of each of which are incorporated herein by reference).

[0366] Examples of Cas9 and Cas9 equivalents are provided as follows; however, these specific examples are not meant to be limiting. The multi-flap prime editors of the present disclosure may use any suitable napDNAbp, including any suitable Cas9 or Cas9 equivalent.

A. Wild type canonical SpCas9

[0367] In one embodiment, the multi-flap prime editor constructs described herein may comprise the “canonical SpCas9” nuclease from *S. pyogenes*, which has been widely used as a tool for genome engineering and is categorized as the type II subgroup of enzymes of the Class 2 CRISPR-Cas systems. This Cas9 protein is a large, multi-domain protein containing two distinct nuclease domains. Point mutations can be introduced into Cas9 to abolish one or both nuclease activities, resulting in a nickase Cas9 (nCas9) or dead Cas9 (dCas9), respectively, that still retains its ability to bind DNA in a

sgRNA-programmed manner. In principle, when fused to another protein or domain, Cas9, or a variant thereof (e.g., nCas9) can target that protein to virtually any DNA sequence simply by co-expression with an appropriate sgRNA. As used herein, the canonical SpCas9 protein refers to the wild type protein from *Streptococcus pyogenes* having the following amino acid sequence:

Description	Sequence	SEQ ID NO:
SpCas9 <i>Streptococcus pyogenes</i> M1 SwissProt Accession No. Q99ZW2 Wild type	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDR HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYL QEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVD EVAYHEKYPTIYHLRKKLVDSDDKADLRILIYALAHMIKFR GHFLIEGDLNPDNSDVKLFIQLVQTYNQLFEENPINASGVD AKAILSARLSKSRRLLENLIAQLPGEKKNGLFGNLIALSLGLTP NFKSNFDLAEDAKLQLSKDITYDDDLNLLAQIGDQYADLF LAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDL TLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFY KFIKPILEKMDGTEELLVKNLREDLLRKQRTFDNGSIPHQIHL GELHAILRRQEDFYPLKDNREKIEKILTFRIPIYVGPLARGN SRFAWMTRKSEETITPWNFEEVVDKGASQSFIERMTNFDK NLPNEKVLPHKSLLEYFTVYNELTKVKYVTEGMRKPAFLS GEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGV EDRFNASLGTYHDLLKIKDKDFLDNEENEDILEDIVLTLTLF EDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRLSRKL INGIRDKQSGKTILDFLKSDFANRNFQMQLIHDDSLTFKEDIQ KAQVSGQGDSLHEHIANLAGSPAIIKKGILQTVKVVDELVKV MGRHKPENIVIAMARENQTTQKGQKNSRERMKRIIEGKEL GSQILKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDIN RLSDYDVHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVP EEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREV KVITLKSCLVSDFRKDFQFYKVINNYHHAHDAYLNAV GTALIKKYPKLESEFVYGDYKVDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG RDFATVRKVLSPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLLK SVKELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHY EKLKGSPEDEQKQLFVEQHKHYLDEIIEQISEFSKRVLADA NLDKVL SAYNKHDKPIREQAENIIHLFTLTNLGAPAAFKYF DTTIDRKRYTSTKEVLDTLIHQSIITGLYETRIDLSQLGGD	SEQ ID NO: 18
SpCas9 Reverse translation of SwissProt Accession No. Q99ZW2 <i>Streptococcus pyogenes</i>	ATGGATAAAAAATATAGCATTGGCCTGGATATTGGCACC AACAGCGTGGGCTGGGCGGTGATTACCGATGAATATAAA GTGCCGAGCAAAAAATTTAAAGTGCTGGGCAACACCGAT CGCCATAGCATTAAAAAAACCTGATTGGCGCGCTGCTG TTTGATAGCGGCGAAACCGCGGAAGCGACCCGCTGAAA CGCACCGCGCGCCGCGCTATACCCGCGCAAAAACCGC ATTTGCTATCTGCAGGAAATTTTATGCAACGAAATGGCGA AAGTGGATGATAGCTTTTTTCATCGCCTGGAAGAAAGCTT TCTGGTGGAAGAAGATAAAAAACATGAACGCCATCCGAT TTTTGGCAACATTGTGGATGAAGTGGCGTATCATGAAAA ATATCCGACCATTTATCATCTGCGCAAAAACTGGTGGAT AGCACCGATAAAGCGGATCTGCGCCTGATTTATCTGGCG CTGGCGCATATGATTAAATTTTCGCGGCCATTTTCTGATTG AAGGCGATCTGAACCCGATAACAGCGATGTGGATAAAC	SEQ ID NO: 19

<p> TGTTTATTCAGCTGGTGCAGACCTATAACCAGCTGTTTGA AGAAAACCCGATTAACGCGAGCGCGTGGATGCGAAAGC GATTCTGAGCGCGCGCCTGAGCAAAAGCCGCCGCTGGA AAACCTGATTGCGCAGCTGCCGGGCGAAAAAAAACGG CCTGTTTGGCAACCTGATTGCGCTGAGCCTGGGCCTGACC CCGAACCTTTAAAAGCAACTTTGATCTGGCGGAAGATGCG AACTGCAGCTGAGCAAAGATACCTATGATGATGATCTG GATAACCTGCTGGCGCAGATTGGCGATCAGTATGCGGAT CTGTTTCTGGCGGCGAAAAACCTGAGCGATGCGATTCTGC TGAGCGATATTCTGCGCGTGAACACCGAAATTACCAAAG CGCCGCTGAGCGCGAGCATGATTAACGCTATGATGAAC ATCATCAGGATCTGACCCTGCTGAAAGCGCTGGTGCGCC AGCAGCTGCCGGAATAATAAAGAAATTTTTTTTGTATC AGACAAAAACGGCTATGCGGGCTATATTGATGGCGGCG CGAGCCAGGAAGAATTTTATAAATTTATTAACCGATTCT GGAAAAATGGATGGCACCGAAGAACTGCTGGTGAAACT GAACCGCGAAGATCTGCTGCGCAAACAGCGCACCTTTGA TAACGGCAGCATTCCGCATCAGATTCATCTGGGCGAACT GCATGCGATTCTGCGCCGCCAGGAAGATTTTTATCCGTTT CTGAAAGATAACCGCGAAAAAATTGAAAAAATCTGACC TTTCGATTCCGTATTATGTGGGCCCCGTGGCGCGCGGCA ACAGCCGCTTTGCGTGGATGACCCGCAAAAGCGAAGAAA CCATTACCCCGTGGAACCTTTGAAGAAGTGGTGGATAAAG GCGCGAGCGCGCAGAGCTTTATTGAACGCATGACCAACT TTGATAAAAACCTGCCGAACGAAAAAGTGCTGCCGAAAC ATAGCCTGCTGTATGAATATTTTACCGTGTATAACGAAC GACCAAAGTGAAATATGTGACCGAAGGCATGCGCAAACC GGCGTTTCTGAGCGGCGAACAGAAAAAAGCGATTGTGGA TCTGCTGTTTAAAACCAACCGCAAAGTGACCGTGAAACA GCTGAAAGAAGATTATTTTAAAAAAATTGAATGCTTTGAT AGCGTGGAAATTAGCGGCGTGGAAGATCGCTTTAACGCG AGCCTGGGCACCTATCATGATCTGCTGAAAAATTATTAAG ATAAAGATTTTCTGGATAACGAAGAAAACGAAGATATTC TGGAAGATATTGTGCTGACCCTGACCCTGTTTGAAGATCG CGAAATGATTGAAGAACGCCTGAAAACCTATGCGCATCT GTTTGATGATAAAGTGATGAAACAGCTGAAACGCCGCCG CTATACCGGCTGGGGCCGCTGAGCCGCAAACTGATTAA CGGCATTTCGCGATAAACAGAGCGGCAAAACCATCTGGA TTTTCTGAAAAGCGATGGCTTTGCGAACCAGCAACTTTATG CAGCTGATTCATGATGATAGCCTGACCTTTAAAGAAGAT ATTCAGAAAAGCGCAGGTGAGCGGCCAGGGCGATAGCCTG CATGAACATATTGCGAACCTGGCGGGCAGCCCGGCGATT AAAAAAGGCATTCTGCAGACCGTGAAAGTGGTGGATGAA CTGGTGAAAGTGATGGGCCGCCATAAACCGGAAAAACATT GTGATTGAAATGGCGCGCGAAAACAGACCACCCAGAAA GGCCAGAAAAACAGCCGCGAACGCATGAAACGCATTGA AGAAGGCATTAAAGAACTGGGCAGCCAGATTCTGAAAGA ACATCCGGTGGAACACCCAGCTGCAGAACGAAAAACT GTATCTGTATTATCTGCAGAACGGCCGCGATATGTATGTG GATCAGGAACTGGATATTAACCGCCTGAGCGATTATGAT GTGGATCATATTGTGCCGCGAGCCTTTCTGAAAGATGATA GCATTGATAACAAAGTGCTGACCCGCGAGCGATAAAAACC GCGGCAAAAGCGATAACGTGCCGAGCGAAGAAGTGGTG AAAAAATGAAAACTATTGGCGCCAGCTGCTGAACGCG </p>	
---	--

AAACTGATTACCCAGCGCAAATTTGATAACCTGACCAA GCGGAACGCGGCGGCTGAGCGAACTGGATAAAGCGGG CTTTATTAAACGCCAGCTGGTGAAACCCGCCAGATTACC AAACATGTGGCGCAGATTCTGGATAGCCGCATGAACACC AAATATGATGAAAACGATAAACTGATTCGCGAAGTGAAA GTGATTACCCTGAAAAGCAAACCTGGTGAGCGATTTTCGC AAAGATTTTCAGTTTATAAAAGTGCGCGAAATTAACAAC ATCATCATGCGCATGATGCGTATCTGAACGCGGTGGTGG GCACCGCGCTGATTAAAAAATATCCGAACTGGAAAAGCG AATTTGTGTATGGCGATTATAAAGTGTATGATGTGCGCAA AATGATTGCGAAAAGCGAACAGGAAATTGGCAAAGCGA CCGCGAAATATTTTTTTATAGCAACATTATGAACTTTTTT AAAACCGAAATTACCCTGGCGAACGGCGAAATTCGCAAA CGCCCGCTGATTGAAACCAACGGCGAAACCGGCGAAATT GTGTGGGATAAAGGCCGCGATTTTGCACCGTGCGCAAA GTGCTGAGCATGCCGCAGGTGAACATTGTGAAAAAAACC GAAGTGCAGACCGGCGGCTTTAGCAAAGAAAGCATTCTG CCGAAACGCAACAGCGATAAACTGATTGCGCGCAAAAAA GATTGGGATCCGAAAAAATATGGCGGCTTTGATAGCCCG ACCGTGGCGTATAGCGTGCTGGTGGTGGCGAAAGTGGA AAAGGCAAAAGCAAAAAAAGTGAAGCGTGAAAGAACT GCTGGGCATTACCATTATGGAACGCAGCAGCTTTGAAAA AAACCCGATTGATTTTCTGGAAGCGAAAGGCTATAAAGA AGTGAAAAAAGATCTGATTATTAAGTCCGAAATATAG CCTGTTTGAAGTGAAGAACGGCCGCAACGCATGCTGGC GAGCGCGGCGGCAACTGCAGAAAGGCAACGAACTGGCGC TGCCGAGCAAATATGTGAACTTTCTGTATCTGGCGAGCCA TTATGAAAAAAGTGAAGGCAGCCCGGAAGATAACGAACA GAAACAGCTGTTTGTGGAACAGCATAAACATTATCTGGA TGAAATTATTGAACAGATTAGCGAATTTAGCAAACGCGT GATTCTGGCGGATGCGAACCTGGATAAAGTGCTGAGCGC GTATAACAAACATCGCGATAAACCGATTTCGCGAACAGGC GGAAAACATTATTCATCTGTTTACCCTGACCAACCTGGGC GCGCCGGCGGCGTTTAAATATTTGATACCACCATTGATC GCAAACGCTATAACCAGCACCAAAGAGTGCTGGATGCGA CCCTGATTTCATCAGAGCATTACCGGCCTGTATGAAACCCG CATTGATCTGAGCCAGCTGGGCGGCGAT	
---	--

[0368] The multi-flap prime editors described herein may include canonical SpCas9, or any variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity with a wild type Cas9 sequence provided above. These variants may include SpCas9 variants containing one or more mutations, including any known mutation reported with the SwissProt Accession No. Q99ZW2 (SEQ ID NO: 18) entry, which include:

SpCas9 mutation (relative to the amino acid sequence of the canonical SpCas9 sequence, SEQ ID NO: 18)	Function/Characteristic (as reported) (see UniProtKB – Q99ZW2 (CAS9_STRPT1) entry – incorporated herein by reference)
D10A	Nickase mutant which cleaves the protospacer strand (but no cleavage of non-protospacer strand)
S15A	Decreased DNA cleavage activity
R66A	Decreased DNA cleavage activity
R70A	No DNA cleavage
R74A	Decreased DNA cleavage

R78A	Decreased DNA cleavage
97-150 deletion	No nuclease activity
R165A	Decreased DNA cleavage
175-307 deletion	About 50% decreased DNA cleavage
312-409 deletion	No nuclease activity
E762A	Nickase
H840A	Nickase mutant which cleaves the non-protospacer strand but does not cleave the protospacer strand
N854A	Nickase
N863A	Nickase
H982A	Decreased DNA cleavage
D986A	Nickase
1099-1368 deletion	No nuclease activity
R1333A	Reduced DNA binding

[0369] Other wild type SpCas9 sequences that may be used in the present disclosure, include:

Description	Sequence	SEQ ID NO:
SpCas9 <i>Streptococcus pyogenes</i> MGAS1882 wild type NC_017053.1	ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAA TAGCGTCGGATGGGCGGTGATCACTGATGATTATAAGGTTTC CGTCTAAAAAGTTCAAGGTTCTGGGAAATACAGACCGCCAC AGTATCAAAAAAATCTTATAGGGGCTCTTTTATTGGCAG TGGAGAGACAGCGGAAGCGACTCGTCTCAAACGGACAGCT CGTAGAAGGTATACACGTCGGAAGAATCGTATTTGTTATCT ACAGGAGATTTTTCAAATGAGATGGCGAAAGTAGATGATA GTTTCTTTCATCGACTTGAAGAGTCTTTTTTGGTGGAAGAAG ACAAGAAGCATGAACGTCATCCTATTTTTGGAAATATAGTA GATGAAGTTGCTTATCATGAGAAATATCCAATATCTATCA TCTGCGAAAAAATTGGCAGATTCTACTGATAAAGCGGATT TGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTC GTGGTCATTTTTTGATTGAGGGAGATTAAATCCTGATAATA GTGATGTGGACAACTATTTATCCAGTTGGTACAAATCTAC AATCAATTATTTGAAGAAAACCTATTAACGCAAGTAGAGT AGATGCTAAAGCGATTCTTTCTGCACGATTGAGTAAATCAA GACGATTAGAAAATCTCATTGCTCAGCTCCCCGGTGAGAAG AGAAATGGCTTGTTTGGGAATCTCATTGCTTTGTCATTGGGA TTGACCCCTAATTTTAAATCAAATTTTGATTGGCAGAAGAT GCTAAATTACAGCTTTCAAAGATACTTACGATGATGATTT AGATAATTTATTGGCGCAAATTGGAGATCAATATGCTGATT TGTTTTTGGCAGCTAAGAATTTATCAGATGCTATTTTACTTT CAGATATCCTAAGAGTAAATAGTGAAATAACTAAGGCTCCC CTATCAGCTTCAATGATTAAGCGCTACGATGAACATCATCA AGACTTGACTCTTTTAAAAGCTTTAGTTTCGACAACAACCTCC AGAAAAGTATAAAGAAATCTTTTTTGATCAATCAAAAAACG GATATGCAGGTTATATTGATGGGGGAGCTAGCCAAGAAGA ATTTTATAAATTTATCAAACCAATTTAGAAAAAATGGATG GTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTG CTGCGCAAGCAACGGACCTTTGACAACGGCTCTATTCCCCA TCAAATTCACCTGGGTGAGCTGCATGCTATTTTGAGAAGAC AAGAAGACTTTTATCCATTTTTTAAAAGACAATCGTGAGAAG ATTGAAAAAATCTTGACTTTTCGAATTCCTTATTATGTTGGT CCATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCG GAAGTCTGAAGAAACAATTACCCCATGGAATTTTGAAGAAG TTGTCGATAAAGGTGCTTCAGCTCAATCATTTATTGAACGC ATGACAACTTTGATAAAAAATCTTCCAAATGAAAAAGTACT	SEQ ID NO: 20

<p> ACCAAAACATAGTTTGCTTTATGAGTATTTTACGGTTTATAA CGAATTGACAAAGGTCAAATATGTTACTGAGGGAATGCGA AAACCAGCATTTCTTTCAGGTGAACAGAAGAAAGCCATTGT TGATTTACTCTTCAAAACAAATCGAAAAGTAACCGTTAAGC AATTAAGAAGATTATTTCAAAAAAATAGAATGTTTTGAT AGTGTGAAATTTGAGGAGTTGAAGATAGATTAAATGCTTC ATTAGGCGCCTACCATGATTTGCTAAAAATTATTAAAGATA AAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTAGAG GATATTGTTTTAACATTGACCTTATTTGAAGATAGGGGGAT GATTGAGGAAAGACTTAAACATATGCTCACCTCTTTGATG ATAAGGTGATGAAACAGCTTAAACGTCGCCGTTATACTGGT TGGGGACGTTTGTCTCGAAAATTGATTAATGGTATTAGGGA TAAGCAATCTGGCAAAACAATATTAGATTTTTTGAAATCAG ATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATG ATAGTTTGACATTTAAAGAAGATATTCAAAAAGCACAGGTG TCTGGACAAGGCCATAGTTTACATGAACAGATTGCTAACTT AGCTGGCAGTCTGCTATTAAGGATTTTACAGACTG TAAAAATTGTTGATGAACTGGTCAAAGTAATGGGGCATAAG CCAGAAAATATCGTTATTGAAATGGCACGTGAAAATCAGAC AACTCAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAAA CGAATCGAAGAAGGTATCAAAGAATTAGGAAGTCAGATTC TTAAAGAGCATCCTGTTGAAAATACTCAATTGCAAAATGAA AAGCTCTATCTATTATCTACAAAATGGAAGAGACATGTA TGTGGACCAAGAATTAGATATTAATCGTTTAAAGTGATTATG ATGTCGATCACATTGTTCCACAAAGTTTCATTAAAGACGAT TCAATAGACAATAAGGTACTAACGCGTTCTGATAAAAAATCG TGTTAAATCGGATAACGTTCCAAGTGAAGAAGTAGTCAAA AAGATGAAAAACTATTGGAGACAACCTCTAAACGCCAAGTT AATCACTCAACGTAAGTTTGATAATTTAACGAAAGCTGAAC GTGGAGGTTTGAGTGAACCTTGATAAAGCTGGTTTTATCAA CGCCAATTGGTTGAACTCGCCAAATCACTAAGCATGTGGC ACAAATTTGGATAGTCGCATGAATACTAAATACGATGAAA ATGATAAACTTATTCGAGAGGTTAAAGTGATTACCTTAAAA TCTAAATTAGTTTCTGACTTCCGAAAAGATTTCCAATTCTAT AAAGTACGTGAGATTAACAATTACCATCATGCCCATGATGC GTATCTAAATGCCGTCGTTGGAACCTGCTTTGATTAAGAAAT ATCCAAAACCTGAATCGGAGTTTGTCTATGGTGATTATAAA GTTTATGATGTTTCGTAATGATTGCTAAGTCTGAGCAAGA AATAGGCAAAGCAACCGCAAATATTTCTTTTACTCTAATA TCATGAACTTCTTCAAAACAGAAATTACACTTGCAAATGGA GAGATTCGCAAACGCCCTCTAATCGAACTAATGGGGAAA CTGGAGAAATTGTCTGGGATAAAGGGCGAGATTTTGCCACA GTGCGCAAAGTATTGTCCATGCCCCAAGTCAATATTGTCAA GAAAACAGAAGTACAGACAGGCGGATTCTCCAAGGAGTCA ATTTTACCAAAAAGAAATTCGGACAAGCTTATTGCTCGTAA AAAAGACTGGGATCCAAAAAATATGGTGGTTTTGATAGTC CAACGGTAGCTTATTCAGTCCTAGTGGTTGCTAAGGTGGAA AAAGGGAAATCGAAGAAGTTAAATCCGTTAAAGAGTTAC TAGGGATCACAATTATGGAAAAGTTTCTTTGAAAAAAT CCGATTGACTTTTTAGAAAGCTAAAGGATATAAGGAAGTTAA AAAAGACTTAATCATTAACTACCTAAATATAGTCTTTTTG AGTTAGAAAACGGTCGTAAACGGATGCTGGCTAGTGCCGG AGAATTACAAAAAGGAAATGAGCTGGCTCTGCCAAGCAAA TATGTGAATTTTTATATTTAGCTAGTCATTATGAAAAGTTG </p>	
---	--

	AAGGGTAGTCCAGAAGATAACGAACAAAAACAATTGTTTG TGGAGCAGCATAAGCATTATTTAGATGAGATTATTGAGCAA ATCAGTGAATTTTCTAAGCGTGTTATTTTAGCAGATGCCAAT TTAGATAAAGTTCTTAGTGCATATAACAAACATAGAGACAA ACCAATACGTGAACAAGCAGAAAAATATTATTCATTTATTTA CGTTGACGAATCTTGGAGCTCCCGCTGCTTTTAAATATTTTG ATACAACAATTGATCGTAAACGATATACGTCTACAAAAGAA GTTTTAGATGCCACTCTTATCCATCAATCCATCACTGGTCTT TATGAAACACGCATTGATTTGAGTCAGCTAGGAGGTGACTG A	
SpCas9 <i>Streptococcus</i> <i>pyogenes</i> MGAS1882 wild type NC_017053.1	MDKKYSIGLDIGTNSVGWAVITDDYKVPSKKFKVLGNTDRHS IKKNLIGALLFGSGETAETRLKRTARRRYTRRKNRICYLQEIF SNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYH EKYPTIYHLRKKLADSTDKADLRILIYLAHMIKFRGHFLIEG DLNPDNSDVKLFIQLVQIYNQLFEENPINASRVDAKAILSARL SKSRRLLENLIAQLPGEKRNGLFGNLIALSLGLTPNFKSNFDLAE DAKLQLSKDTYDDDLNLLAQIGDQYADLFLAAKNLSDAILL SDILRVNSEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE KYKEIFFDQSKNGYAGYIDGGASQEIFYKFIKPILEKMDGTEEL LVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPL KDNREKIEKILTFRIPIYVGPLARGNSRFAWMTRKSEETITPW NFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSHLLYEYFT VYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTV KQLKEDYFKKIECFDSVEISGVEDRFNASLGAYHDLLKIKDKD FLDNEENEDILEDIVLTLTFEDRGMIEERLKYAHLFDDKVM KQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANR NFMQLIHDDSLTFKEDIQKAQVSGQGHSLEHIANLAGSPAIF KGILQTVKIVDELVKVMGHKPNENIVEMARENQTTQKGQKNS RERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGR DMYVDQELDINRLSDYDVDHIVPQSFIKDDSIDNKVLTRSDKN RGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAE RGGELSELDKAGFIKRLVETRQITKHVAQILDSRMNTKYDEND KLIREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLN AVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKA TAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDK GRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKL IARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSV KELLGITIMERSSEFKNPIDFLEAKGYKEVKKDLIILPKYSLFE LENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKG SPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL SAYNKHDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKR YTSTKEVLDTLIHQSIITGLYETRIDLSQLGGD	SEQ ID NO: 21
SpCas9 <i>Streptococcus</i> <i>pyogenes</i> wild type SWBC2D7W0 14	ATGGATAAAAAGTATTCTATTGGTTTAGACATCGGCACTAA TTCCGTTGGATGGGCTGTCATAACCGATGAATACAAAGTAC CTTCAAAGAAATTTAAGGTGTTGGGGAACACAGACCGTCAT TCGATTAAAAAGAATCTTATCGGTGCCCTCCTATTTCGATAGT GGCGAAACGGCAGAGGCGACTCGCCTGAAACGAACCGCTC GGAGAAGGTATACACGTCGCAAGAACCGAATATGTACTTA CAAGAAATTTTTAGCAATGAGATGGCCAAAGTTGACGATTC TTTCTTTACCGTTTGAAGAGTCCTTCCTTGTCGAAGAGGA CAAGAAACATGAACGGCACCCCATCTTTGGAAACATAGTA GATGAGGTGGCATATCATGAAAAGTACCCAACGATTTATCA CCTCAGAAAAAAGCTAGTTGACTCAACTGATAAAGCGGAC CTGAGGTAAATCTACTTGGCTCTTGCCCATATGATAAAGTTC	SEQ ID NO: 22

<p> CGTGGGCACTTTCTCATTGAGGGTGATCTAAATCCGGACAA CTCGGATGTCGACAAACTGTTTCATCCAGTTAGTACAAACCT ATAATCAGTTGTTTGAAGAGAACCCTATAAATGCAAGTGGC GTGGATGCGAAGGCTATTCTTAGCGCCCGCCTCTCTAAATC CCGACGGCTAGAAAACCTGATCGCACAAATTACCCGGAGAG AAGAAAAATGGGTTGTTTCGGTAACCTTATAGCGCTCTCACT AGGCCTGACACCAAATTTTAAGTCGAACCTTCGACTTAGCTG AAGATGCCAAATTGCAGCTTAGTAAGGACACGTACGATGAC GATCTCGACAATCTACTGGCACAAATTGGAGATCAGTATGC GGACTTATTTTTGGCTGCCAAAACCTTAGCGATGCAATCC TCCTATCTGACATACTGAGAGTTAATACTGAGATTACCAAG GCGCCGTTATCCGCTTCAATGATCAAAAGGTACGATGAACA TCACCAAGACTTGACACTTCTCAAGGCCCTAGTCCGTCAGC AACTGCCTGAGAAATATAAGGAAATATTCTTTGATCAGTCG AAAAACGGGTACGCAGGTTATATTGACGGCGGAGCGAGTC AAGAGGAATTCTACAAGTTTATCAAACCCATATTAGAGAAG ATGGATGGGACGGAAGAGTTGCTTGTAAACTCAATCGCGA AGATCTACTGCGAAAGCAGCGGACTTTTCGACAACGGTAGC ATTCCACATCAAATCCACTTAGGCGAATTGCATGCTATACTT AGAAGGCAGGAGGATTTTTATCCGTTCTCAAAGACAATCG TGAAAAGATTGAGAAAATCCTAACCTTTTCGCATACCTTACT ATGTGGGACCCCTGGCCCGAGGGAACCTCTCGGTTTCGCATGG ATGACAAGAAAGTCCGAAGAAACGATTACTCCATGGAATTT TGAGGAAGTTGTCGATAAAGGTGCGTCAGCTCAATCGTTCA TCGAGAGGATGACCAACTTTGACAAGAATTTACCGAACGAA AAAGTATTGCCTAAGCACAGTTTACTTTACGAGTATTTCAC AGTGTACAATGAACTCACGAAAGTTAAGTATGTCAGTGAAG GCATGCGTAAACCCGCCTTTCTAAGCGGAGAACAGAAGAA AGCAATAGTAGATCTGTTATTCAAGACCAACCGCAAAGTGA CAGTTAAGCAATTGAAAGAGGACTACTTTAAGAAAATTGAA TGCTTCGATTCTGTGCGAGATCTCCGGGGTAGAAGATCGATT TAATGCGTCACTTGGTACGTATCATGACCTCCTAAAGATAA TTAAGATAAGGACTTCCTGGATAACGAAGAGAATGAAGA TATCTTAGAAGATATAGTGTGACTCTTACCCTCTTTGAAGA TCGGGAAATGATTGAGGAAAGACTAAAAACATACGCTCAC CTGTTTCGACGATAAGGTTATGAAACAGTTAAAGAGGCGTCG CTATACGGGCTGGGGACGATTGTGTCGGGAACTTATCAACG GGATAAGAGACAAGCAAAGTGGTAAACTATTCTCGATTTT CTAAGAGCGACGGCTTCGCCAATAGGAACCTTATGCAGCT GATCCATGATGACTCTTTAACCTTCAAAGAGGATATACAAA AGGCACAGGTTTCCGGACAAGGGGACTCATTGCACGAACA TATTGCGAATCTTGCTGGTTCGCCAGCCATCAAAAAGGGCA TACTCCAGACAGTCAAAGTAGTGGATGAGCTAGTTAAGGTC ATGGGACGTCACAAACCGGAAAACATTGTAATCGAGATGG CACGCGAAAATCAAACGACTCAGAAGGGGCAAAAAACAG TCGAGAGCGGATGAAGAGAATAGAAGAGGGTATTAAAGAA CTGGGCAGCCAGATCTTAAAGGAGCATCCTGTGGAAAATAC CCAATTGCAGAACGAGAACTTTACCTCTATTACCTACAAA ATGGAAGGGACATGTATGTTGATCAGGAACCTGGACATAAA CCGTTTATCTGATTACGACGTCGATCACATTGTACCCCAATC CTTTTTGAAGGACGATTCAATCGACAATAAAGTGCTTACAC GCTCGGATAAGAACCGAGGGGAAAAGTGACAATGTTCCAAG CGAGGAAGTCGTAAAGAAAATGAAGAATATTGGCGGCAG CTCTAAATGCGAACTGATAACGCAAAGAAAGTTTCGATAA </p>	
--	--

	CTTAACATAAAGCTGAGAGGGGTGGCTTGTCTGAACTTGACA AGGCCGGATTTATTAACGTCAGCTCGTGGAACCCGCCAA ATCACAAAGCATGTTGCACAGATACTAGATTCCCGAATGAA TACGAAATACGACGAGAACGATAAGCTGATTCTGGGAAGTC AAAGTAATCACTTTAAAGTCAAAATTGGTGTCTGGACTTCAG AAAGGATTTTCAATTCTATAAAGTTAGGGAGATAAATAACT ACCACCATGCGCACGACGCTTATCTTAATGCCGTCGTAGGG ACCGCACTCATTAAAGAAATACCCGAAGCTAGAAAGTGAGTT TGTGTATGGTGATTACAAAGTTTATGACGTCCGTAAGATGA TCGCGAAAAGCGAACAGGAGATAGGCAAGGCTACAGCCAA ATACTTCTTTTATTCTAACATTATGAATTTCTTTAAGACGGA AATCACTCTGGCAAACGGAGAGATACGCAAACGACCTTTA ATTGAAACCAATGGGGAGACAGGTGAAATCGTATGGGATA AGGGCCGGGACTTCGCGACGGTGAGAAAAGTTTTGTCCATG CCCCAAGTCAACATAGTAAAGAAAAGTGGGTGCAGACCG GAGGGTTTTCAAAGGAATCGATTCTTCCAAAAAGGAATAGT GATAAGCTCATCGCTCGTAAAAAGGACTGGGACCCGAAAA AGTACGGTGGCTTCGATAGCCCTACAGTTGCCTATTCTGTCC TAGTAGTGGCAAAAAGTTGAGAAGGGAAAAATCCAAGAACT GAAGTCAGTCAAAGAATTATTGGGGATAACGATTATGGAGC GCTCGTCTTTTGAAAAGAACCCCATCGACTTCCTTGAGGCG AAAGGTTACAAGGAAGTAAAAAAGGATCTCATAATTAAC TACCAAAGTATAGTCTGTTTGAGTTAGAAAATGGCCGAAAA CGGATGTTGGCTAGCGCCGGAGAGCTTCAAAGGGGAACG AACTCGCACTACCGTCTAAATACGTGAATTTCTGTATTAG CGTCCCATTACGAGAAGTTGAAAGGTTACCTGAAGATAAC GAACAGAAGCAACTTTTTGTTGAGCAGCACAAACATTATCT CGACGAAATCATAGAGCAAATTTGGAATTCAGTAAGAGA GTCATCCTAGCTGATGCCAATCTGGACAAAGTATTAAGCGC ATACAACAAGCACAGGGATAAACCCATACGTGAGCAGGCG GAAAATATTATCCATTTGTTTACTCTTACCAACCTCGGCGCT CCAGCCGCATTCAAGTATTTTGACACAACGATAGATCGCAA ACGATACACTTCTACCAAGGAGGTGCTAGACGCGACACTGA TTCACCAATCCATCACGGGATTATATGAACTCGGATAGAT TTGTACAGCTTGGGGGTGACGGATCCCCCAAGAAGAAGA GGAAAGTCTCGAGCGACTACAAAGACCATGACGGTGATTAT AAAGATCATGACATCGATTACAAGGATGACGATGACAAGG CTGCAGGA	
SpCas9 <i>Streptococcus</i> <i>pyogenes</i> wild type Encoded product of SWBC2D7W0 14	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGD LNPDNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAED AKLQLSKDITYDDDLNLLAQIGDQYADLFLAAKNLSAAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPLK DNREKIEKILTFRIPYVVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLEYEFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF	SEQ ID NO: 23

	<p> MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKGI LQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRG KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETROITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSPQVNVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKE LLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLEFE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLSDKVLSA YNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDATLIHQSIITGLYETRIDLSQLGGDGSPKKRKVSSDY KDHDGDYKDHDIDYKDDDDKAAG </p>	
<p> SpCas9 <i>Streptococcus</i> <i>pyogenes</i> M1GAS wild type NC_002737.2 </p>	<p> ATGGATAAGAAATACTCAATAGGCTTAGATATCGGCACAAA TAGCGTCGGATGGGCGGTGATCACTGATGAATATAAGGTTC CGTCTAAAAAGTTCAAGGTTCTGGGAAATACAGACCGCCAC AGTATCAAAAAAATCTTATAGGGGCTCTTTTATTGACAG TGGAGAGACAGCGGAAGCGACTCGTCTCAAACGGACAGCT CGTAGAAGGTATACACGTCGGAAGAATCGTATTTGTTATCT ACAGGAGATTTTTTCAAATGAGATGGCGAAAGTAGATGATA GTTTCTTTCATCGACTTGAAGAGTCTTTTTTGGTGGAAGAAG ACAAGAAGCATGAACGTCATCCTATTTTTGGAAATATAGTA GATGAAGTTGCTTATCATGAGAAATATCCAATCTATCTATCA TCTGCGAAAAAATTTGGTAGATTCTACTGATAAAGCGGATT TGCGCTTAATCTATTTGGCCTTAGCGCATATGATTAAGTTTC GTGGTCATTTTTTGATTGAGGGAGATTAAATCCTGATAATA GTGATGTGGACAACTATTTATCCAGTTGGTACAAACCTAC AATCAATTATTTGAAGAAAACCCTATTAACGCAAGTGGAGT AGATGCTAAAGCGATTCTTTCTGCACGATTGAGTAAATCAA GACGATTAGAAAATCTCATTGCTCAGCTCCCCGGTGAGAAG AAAAATGGCTTATTTGGGAATCTCATTGCTTTGTCATTGGGT TTGACCCCTAATTTTAAATCAAATTTTGATTGGCAGAAGAT GCTAAATTACAGCTTTCAAAGATACTTACGATGATGATTT AGATAATTTATTGGCGCAAATTGGAGATCAATATGCTGATT TGTTTTTGGCAGCTAAGAATTTATCAGATGCTATTTTACTTT CAGATATCCTAAGAGTAAATACTGAAATAACTAAGGCTCCC CTATCAGCTTCAATGATTAAACGCTACGATGAACATCATCA AGACTTGACTCTTTTAAAAGCTTTAGTTGACAAACAACTTCC AGAAAAGTATAAAGAAATCTTTTTTGATCAATCAAAAAACG GATATGCAGGTTATATTGATGGGGGAGCTAGCCAAGAAGA ATTTTATAAATTTATCAAACCAATTTTAGAAAAAATGGATG GTACTGAGGAATTATTGGTGAAACTAAATCGTGAAGATTTG CTGCGCAAGCAACGGACCTTTGACAACGGCTCTATTCCCA TCAAATTCATTGGGTGAGCTGCATGCTATTTTGAGAAGAC AAGAAGACTTTTATCCATTTTAAAAGACAATCGTGAGAAG ATTGAAAAATCTTGACTTTTCGAATTCCTTATTATGTTGGT CCATTGGCGCGTGGCAATAGTCGTTTTGCATGGATGACTCG GAAGTCTGAAGAAACAATTACCCCATGGAATTTGAAGAAG TTGTGATAAAGGTGCTTCAGCTCAATCATTTATTGAACGC ATGACAACTTTGATAAAAAATCTTCAAATGAAAAAGTACT </p>	SEQ ID NO: 24

<p> ACCAAAACATAGTTTGCTTTATGAGTATTTTACGGTTTATAA CGAATTGACAAAGGTCAAATATGTTACTGAAGGAATGCGA AAACCAGCATTTCTTTTCAGGTGAACAGAAGAAAGCCATTGT TGATTTACTCTTCAAAACAAATCGAAAAGTAACCGTTAAGC AATTAAAAGAAGATTATTTCAAAAAAATAGAATGTTTTGAT AGTGTGAAATTTTCAGGAGTTGAAGATAGATTTAATGCTTC ATTAGGTACCTACCATGATTTGCTAAAAATTATTAAAGATA AAGATTTTTTGGATAATGAAGAAAATGAAGATATCTTAGAG GATATTGTTTTAACATTGACCTTATTTGAAGATAGGGAGAT GATTGAGGAAAGACTTAAACATATGCTCACCTCTTTGATG ATAAGGTGATGAAACAGCTTAAACGTCGCCGTTATACTGGT TGGGGACGTTTGTCTCGAAAATTGATTAATGGTATTAGGGA TAAGCAATCTGGCAAAACAATATTAGATTTTTTGAAATCAG ATGGTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATG ATAGTTTGACATTTAAAGAAGACATTCAAAAAGCACAAGTG TCTGGACAAGGCGATAGTTTACATGAACATATTGCAAATTT AGCTGGTAGCCCTGCTATTAAAAAAGGTATTTTACAGACTG TAAAAGTTGTTGATGAATTGGTCAAAGTAATGGGGCGGCAT AAGCCAGAAAATATCGTTATTGAAATGGCACGTGAAAATCA GACAACTCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATG AAACGAATCGAAGAAGGTATCAAAGAATTAGGAAGTCAGA TTCTTAAAGAGCATCCTGTTGAAAAATACTCAATTGCAAAAT GAAAAGCTCTATCTCTATTATCTCCAAAATGGAAGAGACAT GTATGTGGACCAAGAATTAGATATTAATCGTTTAAGTGATT ATGATGTCGATCACATTGTTCCACAAAGTTTCTTAAAGAC GATTCAATAGACAATAAGGTCTTAACGCGTTCTGATAAAAA TCGTGGTAAATCGGATAACGTTCCAAGTGAAGAAGTAGTCA AAAAGATGAAAACTATTGGAGACAACTTCTAAACGCCAA GTTAATCACTCAACGTAAGTTTGATAATTTAACGAAAGCTG AACGTGGAGGTTTGAGTGAACCTTGATAAAGCTGGTTTTATC AAACGCCAATTGGTTGAACTCGCCAAATCACTAAGCATGT GGCACAAATTTTGATAGTCGCATGAATACTAAATACGATG AAAATGATAAACTTATTCGAGAGGTTAAAGTGATTACCTTA AAATCTAAATTAGTTTCTGACTTCCGAAAAGATTTCCAATTC TATAAAGTACGTGAGATTAACAATTACCATCATGCCCATGA TGCGTATCTAAATGCCGTCGTTGGAACCTGCTTTGATTAAGA AATATCCAAAACCTGAATCGGAGTTTGTCTATGGTGATTAT AAAGTTTATGATGTTTCGTAAAATGATTGCTAAGTCTGAGCA AGAAATAGGCAAAGCAACCGCAAAATATTTCTTTTACTCTA ATATCATGAACCTTCTTCAAAACAGAAATTACACTTGCAAAT GGAGAGATTTCGCAAACGCCCTCTAATCGAAACTAATGGGG AAACCTGGAGAAATTGTCTGGGATAAAGGGCGAGATTTTGCC ACAGTGCGCAAAGTATTGTCCATGCCCAAGTCAATATTGT CAAGAAAACAGAAGTACAGACAGGCGGATTCTCCAAGGAG TCAATTTTACCAAAAAGAAATTCGGACAAGCTTATTGCTCG TAAAAAAGACTGGGATCCAAAAAATATGGTGGTTTTGATA GTCCAACGGTAGCTTATTCAAGTCCTAGTGGTTGCTAAGGTG GAAAAAGGGAAATCGAAGAAGTTAAATCCGTTAAAGAGT TACTAGGGATCACAATTATGGAAAGAAGTTCCTTTGAAAAA AATCCGATTGACTTTTTAGAAAGCTAAAGGATATAAGGAAGT TAAAAAAGACTTAATCATTAACTACCTAAATATAGTCTTT TTGAGTTAGAAAACGGTCGTAAACGGATGCTGGCTAGTGCC GGAGAATTACAAAAAGGAAATGAGCTGGCTCTGCCAAGCA AATATGTGAATTTTTTATATTTAGCTAGTCATTATGAAAAGT </p>	
--	--

	TGAAGGGTAGTCCAGAAGATAACGAACAAAAACAATTGTT TGTGGAGCAGCATAAGCATTATTTAGATGAGATTATTGAGC AAATCAGTGAATTTTCTAAGCGTGTTATTTTAGCAGATGCC AATTTAGATAAAGTTCTTAGTGCATATAACAAACATAGAGA CAAACCAATACGTGAACAAGCAGAAAAATATTATTCATTTAT TTACGTTGACGAATCTTGGAGCTCCCGCTGCTTTTAAATATT TTGATACAACAATTGATCGTAAACGATATACGTCTACAAAA GAAGTTTTAGATGCCACTCTTATCCATCAATCCATCACTGGT CTTTATGAAACACGCATTGATTTGAGTCAGCTAGGAGGTGA CTGA	
SpCas9 <i>Streptococcus</i> <i>pyogenes</i> M1GAS wild type Encoded product of NC_002737.2 (100% identical to the canonical Q99ZW2 wild type)	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADLRILIYLAHMIKFRGHFLIEGD LNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAED AKLQLSKDITYDDDLNLLAQIGDQYADFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTFRIPYYVGPLARGNSRFWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSHLLYEYFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLKIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDFANRNF MLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAICKGI LQTVKVVDELVKVMGRHKPENIVIEARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDHDHIVPQSFLKDDSIDNKVLTRSDKNRG KSDNVPSEEVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSPQVNIVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVAKVEKGKSKKLKSVKE LLGITIMERSSEFKNPIDFLEAKGYKEVKDLIIKLPKYSLFELE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVLSA YNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDATLIHQSIITGLYETRIDLSQLGGD	SEQ ID NO: 25

[0370] The multi-flap prime editors described herein may include any of the above SpCas9 sequences, or any variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity thereto.

B. Wild type Cas9 orthologs

[0371] In other embodiments, the Cas9 protein can be a wild type Cas9 ortholog from another bacterial species different from the canonical Cas9 from *S. pyogenes*. For example, the following Cas9 orthologs can be used in connection with the multi-flap prime editor constructs described in this specification. In addition, any variant Cas9 orthologs having at least 80%, at least 85%, at least 90%,

at least 95%, or at least 99% sequence identity to any of the below orthologs may also be used with the multi-flap present prime editors.

Description	Sequence
LfCas9 <i>Lactobacillus fermentum</i> wild type GenBank: SNX31424.1 1	MKEYHIGLDIGTSSIGWAVTDSQFKLMRIKGKTAIGVRLFEEGKTA AERTFRTRRRRLKRRKWRLHYLDEIFAPHLQEVDENFLRRLKQSNHPEDPTKNQAFIGKLLFPDLLKKNERGYPTLIKMRDELPVEQRAHYPVMNIYKLREAMINEDRQFDLREVYLA VHHIVKYRGHFLNNASVDKFKVGRIDFDKSFNVLEAYEELQNGEGSFTI EPSKVEKIGQLLLDTKMRKLD RQKAVAKLLEV K VADKEETKR NKQIATAMSK LVLGYKADFATVAMANGNEWKIDLSSETSEDEIEK FREELSDAQNDILTEITSLF SQIMLNEIVPNGMSISESMMDRYW THERQLAEVKEYLATQPASARKEFDQVYN KYIGQAPKERGF DLEKGLKKILSKKENWKEIDELLKAGDFLPKQRTSANGVIPH QMHQQELDR IIEKQAKYYPWLATENPATGERDRHQAKYELDQLVSFRIPYYVG PLVTPVQKATSGAKFAWAKRKEDGEITPWNLWDKIDRAESA EAFIKRMTV KD TYLLNEDVLPANSLLYQKYNVLNELLNNVRVNGRRLSVG I QD IY TELFKKKKT VKASDVASLVMAKTRGVNKP SVEGLSDPKKFNSNLATYLDLKSIVGDKVDDN RYQTDLEN IIEWRSVFEDGEIFADKLTEVEWL TDEQRSALVKKRYKGWGRLSK KLLTGIVDENGQRIIDLMWNTDQNFKEIVDQPVFKEQIDQLNQKAITNDGMTLR ERVESVLDDAYTSPQNKKAIWQVVRVVEDIVKAVGNAPKSI SIEFARNEGKGE ITRSRRTQLQKLFEDQAHEL VKDTSLTEELEKAPDLSDRYYFYFTQGGKDMYT GDPINFDEISTKYDIDHILPQS FVKDNSLDNRVLTSRKENNKSDQVPAKLYAA KMKPYNQLLKQGLITQRKFENLT KDVDQNIKYRSLGFVQRQLVETRQVIKLT ANILGSMYQEAGTEI IETRAGLTKQLREEFDLPKVREVN DYHHA VDAYLTTFAG QYLNRRYPKLR SFFVYGEYMKFKHGS DLKLRNFNFH ELMEGDKS QGKVVDQ QTGELITTRDEVA KSFDRLLNMKYMLVSKEVHDRSDQLYGATIVTAKESGKLT SPIEIKKNRLVDLYGAYTNGTS AFMTIHKFTGNKPKYKVIGIPTTSAASLKRAGKP GSESYNQELHRIKSNPKVKKGFEIVVPHVSYGQLIVDGDCKFTLASPTVQHPAT QLVLSKKSLETISSGYKILKDKPAIANERLIRVFDEVVGQMNR YFTIFDQRSNRQ KVADARDKFLSLPTESKYEGAKKVQVGKTEVITNLLMGLHANATQGD LKVLG LATFGFFQSTTGLSLSEDTMIVYQSPTGLFERRICLKDI (SEQ ID NO: 26)
SaCas9 <i>Staphylococcus aureus</i> wild type GenBank: AYD60528.1	MDKKYSIGLDIGTNSVGWAVITDEYKVP SKKFKVLGNTDRHSIKKNLIGALLFD SGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDD SFFHRLEESFLVEE DKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTD KADLR LIYLA LAHMIK FRGHFLIEGDLNPDNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSK SRRLLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKD TYD DDLDNLLAQIGDQYADLF LA AKNLSDAILLSDILRVNTEITKAPLSASMIKRYDE HHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEK MDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY PFLKDN REKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFE EVVDKGASAQSF IERMTNFDKNLPNEKVL PKHSLLYEYFTVYNELTKVKYVTEGM RKP AFLSGEQ KKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGT YHDLL KIKDKDFLDNEENEDILEDIVLTLTLFEDREMIERLKTYAHLFDDKVMKQLKR RRYTGWGRLSRKLINGIRDKQSGKTILD FLKSDGFANRNF MQLIHDDSLTFKEDI QKAQVSGQGDSLHEHIANLAGSPA I KKGILQTVKVVD ELVKVMGRHKPENIVIE MARENQTTQKGQKNSRERMKRIE EG I KELGSQILKEHPVENTQLQNEKLYLYY LQNGRDMYVDQELDINRLSDYD VDHIVPQSFLKDDSIDNKVLTRSDKNRGKSD NVPSEEVVKMKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIK RQL VETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKV REINNYHHAHDAYLNAVVG TALIKKYPKLESEFVYGDYKVYDVRKMI AKSEQ EIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFAT VRKVL SMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFD SPTVAYSVLVAKVEKGKSKKLKSVKELLGITIMERS SFEKNPIDFLEAKGYKE VKKDLI IKLPKYSLFEL ENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYE KLKGS PEDNEQKQLFVEQH KH YLDEIIEQISEFSKR VILADANLDKVL SAYNKH

Description	Sequence
	RDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSI GLYETRIDLSQLGGD (SEQ ID NO: 27)
SaCas9 <i>Staphylococcus aureus</i>	MGKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHSELGINPYEARVKGLSQLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSYVKEAKQLLKVKQAYHQLDQSFIDTYIDLLETRRTYYEGPGEPSFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYEYKFQIENVFQKQKKPTLKQIAKEILVNEEDIKGYRVSTGKPEFTNLKVYHDIKDITARKEIENAEELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVKPKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNQRTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNPPFNIEVDHIIPRSVSFDNSFNKVLVKQEENSKKGNRTPFQYLSSSSDSKSYETFKKHILNLAGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLRSYFRVNNLDVVKVSINGGFTSFLRRKWKFKKERNKGYKHHAAEDALIIANA DFIFKEWKLDKAKKVMENQMFEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKPNRKLINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLLKLINKSPEKLLMYHHPQTYQKLKLIMEQYGDENPLYKYEETGNLYTKYSKKDNGPVIKKIKYYGNKLNALHDITDDYPNSRNKVVKLSLKPYPFVDVLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKISNQAEIFASYKNDLIKINGELYRIVGVNNDLLNRIEVNMDITYREYLENMNDKRPPIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKK (SEQ ID NO: 28)
StCas9 <i>Streptococcus thermophilus</i> UniProtKB/Swiss-Prot: G3ECR1.2 Wild type	MLFNKCIISINLDFSNEKECMTKPYSIGLDIGTNSVGWAVITDNYKVPSKKMKV LGNTSKKYIKKNLLGVLLFDSGITAEGRRLKRTARRRYTRRRNRILYLQEIFSTEMATLDDAFFQRLDDSFVLPDDKRDSKYPIFGNLVEEKVYHDEFPTIYHLRKYLA DSTKKADRLVYLALAHMIKYRGHFLIEGEFNSKNNDIQKNFQDFLDYNAIFE SDLSENSKQLEEVKDKISKLEKKDRILKLPGEKNSGIFSEFLKLIVGNQADFR KCFNLDEKASLHFSKESYDEDLETLLGYIGDDYSDVFLKAKKLYDAILLSGFLT VTDNETEAPLSSAMIKRYNEHKEDLALLKEYIRNLSLKTYNVFKDDTKNGYAG YIDGKTNQEDFYVYLKNLLAEFEGADYFLEKIDREDFLRKQRTFDNGSIPYQIHL QEMRAILDKQAKFYFPLAKNKERIEKILTFRIPIYVGPLARGNSDFAWSIRKRNE KITPWNFEDVIDKESSAEAFINRMTSFDLYLPEEKVLPKHSLLYETFNVYNELTK VRFIAESMRDYQFLDSKQKDIVRLYFKDKRKVTDKDIEYLHAIYGYDGIELK GIEKQFNSSLSTYHDLNINDKEFLDDSSNEAIIIEIHTLTIFEDREMIKQRLSKF ENIFDKSVLKKLSRRHYTGWGKLSAKLINGIRDEKSGNTILDYLDIDGINSRNF QLIHDDALSFKKKIQKAQIIGDEDKGNIKEVVKSLPGSPAIAKKGILQSIKIVDEL KVMGGRKPESIVVEMARENQYTNQGKSNSQQLKRLEKSLKELGSKILKENIPA KLSKIDNNALQNDRLYLYLQNGKDMYTGDDLDIDRLSNYDIDHIIPQAFKDN SIDNKVLVSSASNRGKSDDFPSLEVVKRKTFWYQLLKSCLISQRKFDNLTAE RGGLLPEDKAGFIQRQLVETRQITKHVARLLDEKFNNKKDENNRAVRTVKIITL KSTLVSQFRKDFELYKVREINDFHHAHDAYLNAVIAASALLKKYPKLEPEFVYGD YPKYNFRERKSATEKVYFYSNIMNIFKKSISLADGRVIERPLIEVNEETGESVW NKESDLATVRRVLSYPQVNVVKKVEEQNHGLDRGPKGLFNANLSSKPKPNSN ENLVGAKEYLDPKKYGGYAGISNSFAVLVKGITIEGAKKKITNVLEFQGISILD RINYRKDKLNFLEKGYKDIELIIELPKYSLFELSDGSRMLASILSTNNKRGEIH KGNQIFLSQKFVKLLYHAKRISNTINENHRKYVENHKKFEELFYIILEFNENYV GAKKNGKLLNSAFQSWQNHSIDELCSSFIGPTGSEKGLFELTSRGSAADEFELG VKIPRYRDYTPSSLLKDATLIHQSVTGLYETRIDLAKLGEG (SEQ ID NO: 29)
LcCas9 <i>Lactobacillus crispatus</i>	MKIKNYNLALTPTSAGVHVEVDDDLNILEPVHHQKAIGVAKFGEGETAEARR LARSARRTTKRRANRINHYFNEIMKPEIDKVDPLMFDRKQAGLSPLDERKEFRT VIFDRPNIASYYHNQFPTIWHLQKYLMITDEKADIRLIYWALHSLLKHRGHFFNT TPMSQFKPGKLNLDKDDMLALDDYNDLEGLSFAVANSPEIEKVIKDRSMHKKKEK

Description	Sequence
NCBI Reference Sequence: WP_1334780 44.1 Wild type	IAELKKLIVNDVDPKDLAKRNNKIITQIVNAIMGNSFHLNFIFDMDLDKLTSKA WSFKLDDPELDTKFDASGSM TDNQIGIFETLQKIYSAISLLDILNGSSNVVDAKN ALYDKHKRDLNLYFKFLNTLPDEIAKTLKAGYTLYIGNRKKDLAARKLLKVN VAKNFSQDDFYKLINKELKSIDKQGLQTRFSEKVGELVAQNNFLPVQRSSDNV IPYQLNAITFNKILENQGKYDFLVKPNPAKKDRKNAPYELSQLMQFTIPYVVG PLVTPPEQVKSIGPKTSRFAWMVRKDNGAITPWNFYDKVDIEATADKFIKRSIA KDSYLLSELVLPKHSLLYEKEYEVFNELSNVSLDGGKLSGGVKQILFNEVFKKTN KVNTSRILKALAKHNIPGSKITGLSNPEEFTSSLQTYNAWKKYFPNQIDNFAYQQ DLEKMIEWSTVFEDHKILAKKLDEIEWLDDDDQKKFVANTRLRGWGRLSKRLLT GLKDNYGKSIMQRLETTKANFQQIVYKPEFREIDKISQAAAKNQSLDILANS YTSPSNRKAIRKTMSVVDEYIKLNHGKEPKIFLMFQRSEQEKGGKQTEARSKQL NRILSQLKADKSANKLFSKQLADEFSNAIKKSKYKLNDKQYFYFQQLGRDALT GEVIDYDELYKYTVLHIIIPRSKLTDDSQNNKVLTKYKIVDGSVALFGNSYSDA LGMPIKAFWTELNRKLIPKGLLNLTDFSTLNKYQRDGYIARQLVETQQIVK LLATIMQSRFKHTKIIIVRNSQVANIRYQFDYFRIKNLNEYRGFDAYLAAVVG TYLYKVYPKARRLFVYGQYLKPKKTNQENQDMHLDSEKKSQGFNFWNLLYG KQDQIFVNGTDVIAFNRKDLITKMTVYNYKSQKISLAIDYHNGAMFKATLFP NDRDTAKTRKLIPKKDYDTDIYGGYTSNVDGYMLLAEIIRKRDGNKQYGFYGV PSRLVSELDTLKKTRYTEYEEKLKEIHKPELGVDLKKIKKIKILKNKVPFNQVIID KGSKFITSTSYRWNYRQLLSAESQQTLMDLVVDPDFSNHKARKDARKNADE RLIKVYEEILYQVKNYMPMFVELHRCYEKLVD AQKTFKSLKISDKAMVLNQILI LLHSNATSPVLEKLGYHTRFTLGKKHNLISENAVLVTQSITGLKENHVSQKML (SEQ ID NO: 30)
PdCas9 <i>Pedicoccus damnosus</i> NCBI Reference Sequence: WP_0629132 73.1 Wild type	MTNEKYSIGLDIGTSSIGFAVVNDNNRVIRVKGKNAIGVRLFDEGKAAADRRSF RTTRRSFRTTRRRLSRRRWRLKLLREIFDAYITPVDEAFFIRLKESNLSPKDSKKQ YSGDILFNDRSDKDFYEKYPTIYHLRNALMTEHRKFDVREIYLAIIHIMKFRGH FLNATPANNFKVGRLNLEEKFEELNDIYQRFVFPDESIEFRDNLLEQIEVLNDNK RSRADRQRTLVSIDIYQSSDKDIEKRNKAVATEILKASLGNKAKLNVITNVEVD KEAAKEWSITFDSESIDDLAKIEGQMTDDGHEIIEVLRSLYSGITLSAIVPENHT LSQSMVAKYDLHKDHLKLFKKLINGMTDTKKAKNLRAAYDGYIDGVKGKVLV QEDFYKQVQVNLDDSAEANEIQTIDQDIFMPKQRTKANGSIPHQLQQQELDQI IENQKAYYPWLAELNPNPDKKRQQLAKYKLDELVTFRVPYVVGPMITAKDQK NQSGAEFAWMIRKEPGNITPWNFDQKVDRMATANQFIKRMTTTDTYLLGEDV LPAQSLLYQKFEVLNENKIRIDHKPISIEQKQIFNDLQKQFKNVTIKHLQDYL V SQGQYSKRPLIEGLADEKRFNSSLSTYSIDLGGIFGAKLVEENDRQEDLEKII EWS TIFEDKKIYRAKLNLDLWLTDDQKEKLATKRYQGWGRLSRKLVLGLKNSEHR NIMDILWITNENFMQIQAEPDFAKLVDANKGMLEKTDSDQDVINDLYTSPQNK KAIRQILLVVDIQNAMHGQAPAKIHVEFARGEERNPRRSVQRQRQVEAAEYK VSNELVSAKVRQEFKEAINNKRD FKDRLFLYFMQGGIDIYTGKQLNIDQLSSYQI DHILPQAFVKDDSLTNRVLTNENQVKADSVPIDIFGKKMLS VWGRMKDQGLIS KGKYRNLTMPENISAHTENGFINRQLVETRQVIKLVNLADEYGDSTQIISVK ADLSHQMREDFELLKNRDVNDYHHAFDAYLAAFIGNYLLKRYPKLESYFVYG DFKKFTQKETKMRRFNFIYDLKHCDQVVKETGEILWTKDEDIKYIRHLFAYK KILVSHEVREKRGALYNQTIYKAKDDKGSQESKKLIRIKDDKETKIYGGYSGK SLAYMTIVQITKKNKVS YRVIGIPTLALARLNKLENDSTENNGELYKIIKPQFTH YKVDKKNGEIETDDFKIVVSKVRFQQLIDDAGQFFMLASDTYKNNAAQQLVIS NNALKAINNTNITDCPRDDLRLDLNRLDSAFDEIVKKMDKYFSAYDANNFRE KIRNSNLIFYQLPVEDQWENNKITELGKRTVLTRILQGLHANATTTDMSIFIKIT PFGQLRQRSGISLSENAQLIYQSPTGLFERRVQLNKK (SEQ ID NO: 31)
FnCas9 <i>Fusobacteriu m nucleatum</i>	MKKQKFSDY YLGF DIGTNSVGWCVTDL DYNVLRFNKKDMWGSRLFEEAKTA AERRVQRNSRRRLKRRKWRLNLEEIFSNEILKIDSNFFRRLKESSLWLEDKSSK EKFTLFNDNDYKDYDFYKQYPTIFHLRNELIKNPEKKDIRLVYLAHSIFKSRGH FLFEGQNLKEIKNFETLYNNLIAFLLEDNGINKIIDKNNEIEKLEKIVCDSSKGLKDK

Description	Sequence
NCBI Reference Sequence: WP_0607989 84.1	EKEFKEIFNSDKQLVAIFKLSVGSSVSLNDLFDTDDEYKKGEVEKEKISFREQIYED DKPIYYISILGEKIELLDIAKTFYDFMVLNNILADSQYISEAKVKLYEEHKKDLKN LKYIIRKYNKGNYDKLFKDKNENNYSA YIGLNKEKSKKEVIEKSRLKIDDLIKNI KGYLPKVEEIEEKDKAIFNKILNKIELKTILPKQRISDNGTLPYQIHEAELEKILEN QSKYYDFLNYEENGITKDKLLMTFKFRIPYYVGPLNSYHKDKGGNSWIVRKEE GKILPWNFEQKVDIEKSAEEFIKRTMNKCTYLNGEDVIPKDTFLYSEYVILNELN KVQVNDEFLNEENKRKIIDELFKENKKVSEKKFKEYLLVKQIVDGTIELKGVKD SFNSNYISYIRFKDIFGEKLNLDIYKEISEKSILWKCLYGGDDKKIFEKKIKNEYGDI LTKDEIKKINTFKFNNWGRLEKLLTGIEFINLETGECYSSVMDALRRTNYNLM ELLSSKFTLQESINNENKEMNEASYRDLIEESYVSPSLKRAIFQTLKIYEEIRKITG RVPKKVFIEMARGGDESMKNKKIPARQEQLKKLYDSCGNDIANFSIDIKEMKNS LISYDNNSLRQKKLYLYLQFGKCMYTGREIDLDRLLQNNNDTYDIDHIYPRSKV IKDDSFNLLVLKNENAEKSNEYVPVKKIEQEKMSFWRFLKEKNFISDEKIKYR LTGKDDFELRGFMARQLVNVVRQTTEKVGKILQQIEPEIKIVSKAEIASSFREMF DFIKVRELNDTHHAKDAYLNIVAGNVYNTKFTEKPYRYLQEIKENYDVKKIYN YDIKNAWDKENSLEIVKKNMEKNTVNITRIFKEKKGQLFDLNPICKGETSNEIISI KPKVYNGKDDKLEKYGYKSLNPAYFLYVEHKEKNKRIKSFERNLVDVNN IKDEKSLVKYLIENKKLVEPRVIKKVYKRQVILINDYPYSIVTLDNSKLMDFENL KPLFLENKYEKILKNVIFLEDNQGKSEENYKFIYLLKKDRYEKNETLESVKDR YNLEFNEMYDKFLEKLDISKDYKNYMNNKKYQELLDVKEKFIKLNLFDKAFTL KSFLDLFNRKTMADFSKVGLTKYLKGKIQKISSNVLSKNELYLLEESVTGLFVKKI KL (SEQ ID NO: 32)
EcCas9 <i>Enterococcus cecorum</i> NCBI Reference Sequence: WP_0473385 01.1 Wild type	RRKQRIQILQELLGEEVLKTDPGFFHRMKESRYVVEDKRTLDGKQVELPYALFV DKDYTDKEYYKQFPTINHLIVYLMTTSDTPDIRLVYLALHYMKNRGNFLHSG DINNVDINDILEQLDNVLETFLDGWNLKLSYVEDIKNIYNRDLGRGERKKAF VNTLGAKTKAEKAFCSLISGGSTNLAELFDDSSLKEIETPKIEFASSLEDKIDGIQ EALEDRFAVIEAAKRLYDWKTLTDILGDSSSLAEARVNSYQMHHEQLLELKSL VKEYLDRKVFQEVFVSLNVANNYPAYIGHTKINGKKKELEVKRTKRNDFYSYV KKQVIEPIKKKVSDAVALTKLSEIESLIEVDKYLPLQVNSDNGVIPYQVKLNELT RIFDNLNRIPLVRENDRDKIITFKFRIPYYVGSNGVVKNGKCTNWMVRKEEG KIYPWNFEDKVDLEASAEQFIRMTNKCTYLVNEDVLPKYSLLYSKYLVLSLN NLRIDGRPLDVKIKQDIYENVFKNRKVTLLKKIKYLLKEGIITDDDELSGLADD VKSSLTAYRDFKEKLGHLDLSEAQMENIILNITLFGDDKLLKKRLAALYPFIDD KSLNRIATLNYRDWGRLSERFLSGITSVDQETGELRTIIQCMYETQANLMQLLA EPYHFVEAIEKENPKVDLESISYRIVNDLYVSPAVKRQIWQTLLVIKDIKQVMKH DPERIFIEMAREKQESKTKSRKQVLSEVYKKAKEYEHLFEKLSLTEEQLRSK KIYLYFTQLGKCMYSGEPIDFENLVSANSYDIDHIYPQSKTIDDSFNIVLVKK SLNAYKSNHYPIDKNIRDNEKVKTLWNTLVSKGLITKEKYERLIRSTPFSDEELA GFIARQLVETRQSTKAVAEILSNWFPSEIVYSKAKNVSNFRQDFEILKVRELND CHHAHDAYLNIVVGNAHYHTKFTNSPYRFIKNKANQEYNLRKLLQKVNKIESNG VVAWVGQSENNPGTIATVKKVIRRNNTVLISRMVKEVDGQLFDLTLMKKGKGQ VPIKSSDERLTDISKYGGYNKATGAYFTFVKSCKRGKVRSFEYVPLHLSKQFE NNNELLKEYIEKDRGLTDVEILIPKVLINSLFRYNGSLVRITGRGDTRLLLVEHQ LYVSNSFVQQLKSVSSYKLKSENDNAKLTATATEKLSNIDELYDGLLRKLDLP IYSYWFSSIKEYLVESRTKYIKLSIEEKALVIFEILHLFQSDAQVPLNKILGLSTKP SRIRIQKNLKD TDKMSIIHQSPSGIFEHEIELTSL (SEQ ID NO: 33)
AhCas9 <i>Anaerostipes hadrus</i> NCBI Reference Sequence:	MQNGFLGITVSSEQVGWAVTNPKYELERASRKDLWGVRLFDKAETAEDRRMF RTNRRNLNQRKKNRHYLRDIFHEEVNQKDPNFFQQLDESNFCEDDRTVEFNFD NLYKNQFPTVYHLRKYLMETKDKPDRLVYLAFSKFMKNRGHFLYKGNLGEV MDFENSMKGFCESLEKFNIDFPTLSDEQVKEVRDILCDHAKIAKTVKKKNITITK VKSHTAKAWIGLFCGCSVPVKVLFQDIDEEIVTDPEKISFEDASYDDYIANIEKG VGIIYEAIVSAKMLFDWSILNEILGDHQLLSDAMIAEYNKHHDDLKRLQKIIKG TGSRELYQDIFINDVSGNYVCYVGHAKTMSSADQKQFYTFLLKNRLKNVNGISSE

Description	Sequence
WP_0449242 78.1 Wild type	DAEWIDTEIKNGTLLPKQTKRDNSVIPHQQLREFELILDNMQEMYPFLENRE KLLKIFNFVIPYYVGPLKGVVRKGESTNWMVPKKGDIHPWNFDEMVDKEAS AECFISMTGNCSYLFNEKVLPKNSLLYETFEVLNELNPLKINGEPISVELKQRIY EQLFLTGKKVTKKSLTKYLIKNGYDKDIELSGIDNEFHNSLKSHIDFEDYDNLSD EEVEQIILRITVFEDKQLLDYLNREFVKLSEDERKQICSLSYKGGWNLSEMLLN GITVTDNSNGVEVSVMMDMLWNTNLNLMQILSKKYGYKAEIEHYNKEHEKTIYNR EDLMDYLNIPPAQRRKVNQLITIVKSLKKTGYGVPNKIFFKISREHQDDPKRTSSR KEQLKYLYKSLKSEDEKHLMKELDELNDHELSDNDKVLYFLQKGRCIYSGKKL NLSRLRKSNIYQNDIDYIPLSAVNDRSMNNKVLGTGIENRADKYTYFPVDSEIQ KKMKGFWMELVLQGFMTKEKYFRLSRENDFSKSELVSFIEREISDNQQSGRMIA SVLQYYFPESKIVFVKEKLISFKRDFHLISSYGHNLQAADAYITIVVGNVYH TKFTMDPAIYFKNHKKRKYDLNRLFLENISRDGQIAWESGPYGSIQTVRKEYAQ NHIAVTKRVVEVKGGLFKQMPKKGHGEYPLKTNDRPRFGNIAQYGGYTNVTG SYFVLVESMEKGKKRISLEYVPVYLHERLEDDPGHKLLKEYLVDHRKLNHPKIL LAKVRKNSLLKIDGFYRLNGRSGNALILTNAVELIMDDWQTKTANKISGYMK RRAIDKKARVYQNEFHIQELEQLYDFYLDKLKNGVYKNRKNNAELIHNEKEQ FMELKTEDQCVLLTEIKLKFVCSMPQADLTIGGSKHTGMIAMSSNVTKADFA VIAEDPLGLRNKVIYSHKGEK (SEQ ID NO: 34)
KvCas9 <i>Kandleria vitulina</i> NCBI Reference Sequence: WP_0315899 69.1 Wild type	MSQNNNKIYNIGLDIGDASVGWAVVDEHYNLLKRHGKHMWGSRLFTQANTA VERRSSSRSTRRRYNKRREIRILLREIMEDMVLVDVPTFFIRLANVSFLDQEDKK DYLKENYHSNYNLFIDKDFNDKTYDYKYPTIYHLRKKHLCESKEKEDPRLIYLA HHIVKYRGNFLYEGQKFSMDVSNIEDKMIDVLRQFNEINLFEYVEDRKKIDEVL NVLKEPLSKKHKAFAFALFDTTKDNKAAYKELCAALAGNKFNVTKMLKEAE LHDEDEKDISFKFSDATFDDAFVEKQPLLGDCEVIDLLHDIYSWVELQNILGSA HTSEPSISAAMIQRYEDHKNDLKLKDVIRKYLPKKYFEVFRDEKSKNNYCN INHPSKTPVDEFYKYIKKLIKIDDPDVKTILNKIELESFMLKQNSRTNGAVPYQ MQLDELNKILENQSYYSDLKDNEDKIRSILTFRIPYYFGLNITKDRQFDWIKK EGKENERILPWNANEIVDVKTADEFIKRMRNFCTYFPDEPVMANKSLTVSKY EVLNEINKLRINDHLIKRDMKDKMLHTLFMDHKSISANAMKKWLKQYFSN TDDIKIEGFQKENACSTSLTPWIDFTKIFGKINESNYDFIEKIIYDVTVFEDKKILR RRLKKEYDLDEEKIKKILKLKYSWWSRLSKLLSGIKTKYKDSTRTPETVLEVM ERTNMNLMQVINDEKLGFKKTIDDANSTSVSGKFSYAEVQELAGSPAIRGIWQ ALLIVDEIKKIMKHEPAHVYIEFARNEDEKERKDSFVNQMLKLYKDYDFELETE KEANKHLKGEDAKSKIRSERLKLYYTQMGKCMYTGKSLDIDRLDTYQVDHIVP QSLKDDSIDNKVLVLSSSENQRKLLDLVIPSSIRNKMFGWEKLFNNKIISPKKF YSLIKTEFNEKDQERFINRQIVETRQITKHVAQIIDNHYENTKVVTVRADLSHQF RERYHIYKNRDINDFHHAHDAYIATILGTIYIGHRFESLDAKYIYGEYKRIFRNQK NKGKEMKKNNNDGFILNSMRNIYADKDTGEIVWDPNYIDRIKKCFYKDCFVTK KLEENNGTFFNVTVLNPDNTNSDKDNTLATVPVNKYRSNVNKGFGSGVNSFIV AIKGGKKKGKKVIEVNKLGIPLMYKNADEEIKINYLKQAEDELEVQIGKEILK NQLIEKDGLYYIVAPTEIINAKQLILNESQTKLVCEIYKAMKYKNYDNLNLDSEKI IDLYRLLINKMELYYPEYRKQLVKKFEDRYEQLKVISIEEKCNIQILATLHCNS SIGKIMYSDFKISTTIGRLNGRTISLDDISFIAESPTGMYSKKYKL (SEQ ID NO: 35)
EfCas9 <i>Enterococcus faecalis</i> NCBI Reference Sequence: WP_0166310 44.1	MRLFEEGHTAEDRRLKRTARRRISRRRNRLRYLQAFEEAMTDLDENFFARLQE SFLVPEDKKWHRHPIFAKLEDEVAYHETYPTIYHLRKKLADSSEQADRLRIYLA LAHIVKYRGHFLIEGKLSTENTS VKDQFQQFMVIYNQTFVNGESRLVSAPLPESV LIEEELTEKASRTKKSEKVLQFPQEKANGLFGQFLKLMVGNAKDFKVFGL EEAKITYASESYEEDLEGILAKVGDEYSVFLAAKNVYDAVELSTILADSDKKS HAKLSSSMIVRFTEHQEDLKKFKRFIRENCPEYDNLFKNEQKDGAGYIAHAG KVSQKLFYQYVKKIQQDIAGAEYFLEKIAQENFLRKQRTFDNGVIPHQIHLAELQ AIIHRQAAYYPFLKENQEKEQLVTFRIPYYVGPLSKGDASTFAWLKRQSEPIRP

Description	Sequence
Wild type	WNLQETVDLDQSATAFIERMTNFDTYLPSEKVLPHSLLYEKFMVFNELTKISY TDDRGIKANFSGKEKEKIFDYLFKTRRKVKKKDIIQFYRNEYNTEIVTLSGLEED QFNASFSTYQDLLKCGLTRAELDHPDNAEKLEDIIKILTIFEDRQRIRTLSTFKG QFSAEVLKKLERKHHTGWGRLSKKLINGIYDKESGKTILDYLVKDDGVSKHYN RNFMLINDSQLSFKNAIQKAQSSEHEETLSETVNELAGSPAIIKGIYQSLKIVD ELVAIMGYAPKRIVVEMARENQTTSTGKRRSIQRLKIVEKAMAEIGSNLLKEQP TTNEQLRDTRLFLYYMQNGKDMYTGDELSLHRLSHYDIDHIIPQSFMKDDSLD NLVLVGSTENRGKSDDVPSKEVVKDMKAYWEKLYAAGLISQRKFQRLTKGEQ GGTLLEDKAHFIRQLVETRQITKNVAGILDQRYNAKSKEKKVQIITLKASLTSQ FRSIFGLYKRVENDYHHGQDAYLNCVVATTLLKVYPNLAPEFVYGEYPKFQT FKENKATAKAIYTNLLRFFTEDEPRFTKDGEILWSNSYLTIKKELNYHQMNV KKVEVQKGGFSKESIKPKGPSNKLIPVKNGLDPQKYGGFDSPPVAYTVLFTHEK GKKPLIKQEILGITIMEKTRFEQNPILFLEEKGFLRPRVLMKLPKYTLTYEFPEGRR RLLASAKEAQKGNQMVLPHELLTLLYHAKQCLLPNQSESLAYVEQHQPFEQEI LERVVDFAEVHTLAKSKVQIVKLFEANQTADVKEIAASFIQLMQFNAMGAPS TFKFFQKDIERARYTSIKEIFDATIYQSPTGLYETRRKVVD (SEQ ID NO: 36)
<i>Staphylococcus aureus</i> Cas9	KRNYILGLDIGITSVGYGIIYETRDVIDAGVRLFKEANVENNEGRRSKRGARRL KRRRRHRIQVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALL HLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGE VRGSINRFKTSYVKEAKQLLKVKQAYHQLDQSFIDTYIDLLETTRTYEYGPGE GSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITR DENEKLEYEYKFQIENVFQKQKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFT NLKVYHDIKDITARKEIENAEELLDQIAKILTIYQSSEDIQEELTNLNSLTQEEIE QISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDSLQKKEI PTTLVDDFILSPVVKRSFIQSIKVINAIKKYGLPNDIIIELAREKNSKDAQKMINE MQKRNQRTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLN NPFNYEVDHIIPRSVSFDNSFNKVLVKQEENSKKGNRTPFQYLSDDSKISYETF KKHILNLAGKGRISKTKKEYLLEERDINRFSVQKDFINRLVDTRYATRGLMN LLRSYFRVNNLDVVKVSINGGFTSFLRRKWKFKKERNKGYKHHAAEDALIIANA DFIFKEWKLDKAKKVMENQMFEKQAESMPEIETEYQYKEIFITPHQIKHIKDF KDYKYSHRVDKKNRELINDTLSTRKDDKGNTLIVNNLNGLYDKDNDKLLK LINKSPEKLLMYHHPQTYQKLKLIMEQYGDENPLYKYEETGNLYTKYSKK DNGPVIKKIKYYGNKLNHLDTDDYPNSRNKVVKLSLKPYPYRFDVYLDNGVYK FVTVKNLDVIKKENYYEVNSKCYEEAKLKKISNQAEIFASFYNNDLIKINGEL YRVIGVNNDLLNRIEVENMIDITYREYLENMNDKRPPIIKTIASKTQSIKKYSTDI LGNLYEVKSKKHPQIIKKG (SEQ ID NO: 37)
<i>Geobacillus thermodenitri- ficans</i> Cas9	MKYKIGLDIGITSIGWAVINLDIPRIEDLGVRIFDRAENPKTGESLALPRRLARSA RRRLRRRKHRLERIRRLFVREGILTKEELNKLFEKKHEIDVWQLRVEALDRKLN NDELARILLHLAKRRGFRRSNRKSERTNKENSTMLKHIEENQSILSSYRTVAEMV VKDPKFSLHKRNKEDNYTNTVARDDLEREIKLIFAKQREYGNIVCTEAFEHEYIS IWASQRPFASKDDIEKKVGCTFEPKEKRAPKATYTFQSFTVWEHINKLRLVSP GGIRALTDDERRLIYQAFHKNKITFHDVRLTLLNLPDDTRFKGLLYDRNTTLKE NEKVRFLELGAYHKIRKAIDSVYKGGAAKSFRPIDFDTFGYALTMFKDDTDIRS YLRNEYEQNGKRMEANLADKVYDEELIEELLNLSFSKFGHLSLKALRNILPYMEQ GEVYSTACERAGYTFTGPKKKQKTVLLPNIPPIANPVVMRALTQARKVVAIIK KYGSPVSIHIELARELSQSFDERRKMQKEQEGNRKKNETAIRQLVEYGLTLNPT GLDIVKFKLWSEQNGKCAYSLQPIEIERLLEPGYTEVDHVIPYSRLDDSYTNKV LVLTKENREKGNRTPAEYLGGLSERWQQFETFVLTKQFSKKKRDRLRLHYD ENEENEFKNRNLNDTRYISRFLANFIREHLKFADSDDKQKVYTVNGRITAHLSR RWNFNKNREESNLHHAVIDAAIVACTTPSDIARVTAIFYQRREQNKELSKTDPQ FPQPWPHFADELQARLSKNPKESIKALNLGNYDNEKLESLLQPVFVSRMPKRSIT GAAHQETLRRYIGIDERSGKIQTVVKKKLSEIQLDKTGHFPMYKGESDPRTYEA

Description	Sequence
	RQRLLEHNNDPKKAFQEPLYKPKKNGELGPIIRTIKIIDTTNQVIPLNDGKTVAY NSNIVRVDFEKGDKYYCVPYITIDMMKGILPNKAIEPNKPYSEWKEMTEDYTF RFSLYPNDLIRIEFPREKTIKTA VGEEIKIKDLFAYYQTIDSSNGGLSLVSHDNNS LRSIGSRTLKRFEKYQVDVLGNIYKVRGEKRVGVASSSHSKAGETIRPL (SEQ ID NO: 38)
ScCas9 <i>S. canis</i> 1375 AA 159.2 kDa	MEKKYSIGLDIGTNSVGWAVITDDYKVPSSKKFKVLGNTNRKSIKKNLMGALLF DSGETAEATRLKRTARRRYTRRKNRIRYLQEIFANEMAKLDDSFQRLEESFLV EEDKKNERHPIFGNLADEVAYHRNYPTIYHLRKKLADSPEKADRLIYLALAHII KFRGHFLIEGKLN AENS DVAKLFYQLIQTYNQLFEESPLDEIEVDAKGILSARLS KSKRLEKLI A VFPNEKKNGLFGNIIALALGLTPNFKSNFDLTEDAKLQLSKDITYD DDLDELLGQIGDQYADLFSAAKNLSAAILSDILRSNSEVTKAPLSASMVKRYD EHHQDLALLKTLVRQQFPEKYAEIFKDDTKNGYAGYVGIGIKHRKRTTKLATQ EEFYKFIKPILEKMDGAEELLAKLNRRDDLRLKQRTFDNGSIPHQIHLKELHAILR RQEEFYFPLKENREKIEKILTFRIPYYVGPLARGNSRFAWLTRKSEEAITPWNFEE VVDKGASAQSFIERMTNFDLQPNKKVLPKHSLLYEYFTVYNELTKVKYVTER MRKPEFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEIIGVEDRFN ASLGTYHDLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFD DKVMKQLKRRHYTGWGRLSRKMINGIRDKQSGKTILDFLKSDFSNRNFQMQLI HDDSLTFKEEIEKAQVSGQGDSLHEQIADLAGSPAIIKKGILQTVKIVDELVKVM GHKPNIVIAMARENQTTTKGLQQSRERKKRIEEGIKELESQILKENPVENTQLQ NEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFIKDDSIDNKVLTRSV ENRGKSDNPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGGLSEADK AGFIKRQLVETRQITKHVARILDSRMNTKRDKNDKPIREVKVITLKSCLVSDFRK DFQLYKVRDINNYHHAHDAYLNAVVG TALIKKYPKLESEFVYGDYKVYDVRK MIAKSEQEIGKATAKRFFYSNIMNFFKTEVKLANGEIRKRPLIETNGETGEVW NKEKDFATVRKVLAMPQVNIVKKTEVQTGGFSKESILSKRESAKLIPRKKGWD TRKYGGFGSPTVAYSILVVAKEKGAKKLKSVKVLVGITIMEKGSYEKDPGF LEAKGYKDIKKELIFKLPKYSLEFENGRRRMLASATELQKANELVLPQHLVRL LYYTQNISATTGSNNLGYIEQHREEFKEIFEKIIDFSEKYILKNKVNSNLKSSFDE QFAVSDSILLSNSFVSLKYTSFGASGGFTFLDLVDVKQGRRLRYQTVTEVLDTLI YQSITGLYETRTDLSQLGGD (SEQ ID NO: 39)

[0372] The multi-flap prime editors described herein may include any of the above Cas9 ortholog sequences, or any variants thereof having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity thereto.

[0373] The napDNAbp may include any suitable homologs and/or orthologs or naturally occurring enzymes, such as, Cas9. Cas9 homologs and/or orthologs have been described in various species, including, but not limited to, *S. pyogenes* and *S. thermophilus*. Preferably, the Cas moiety is configured (e.g., mutagenized, recombinantly engineered, or otherwise obtained from nature) as a nickase, i.e., capable of cleaving only a single strand of the target double-stranded DNA. Additional suitable Cas9 nucleases and sequences will be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference. In some embodiments, a Cas9 nuclease has an inactive (e.g., an inactivated) DNA cleavage domain; that is, the Cas9 is a nickase. In some embodiments, the Cas9 protein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of

a Cas9 protein as provided by any one of the variants of Table 3. In some embodiments, the Cas9 protein comprises an amino acid sequence that is at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a Cas9 protein as provided by any one of the Cas9 orthologs in the above tables.

C. Dead Cas9 variant

[0374] In certain embodiments, the multi-flap prime editors described herein may include a dead Cas9, e.g., dead SpCas9, which has no nuclease activity due to one or more mutations that inactivate both nuclease domains of Cas9, namely the RuvC domain (which cleaves the non-protospacer DNA strand) and HNH domain (which cleaves the protospacer DNA strand). The nuclease inactivation may be due to one or more mutations that result in one or more substitutions and/or deletions in the amino acid sequence of the encoded protein, or any variants thereof having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity thereto.

[0375] As used herein, the term “dCas9” refers to a nuclease-inactive Cas9 or nuclease-dead Cas9, or a functional fragment thereof, and embraces any naturally occurring dCas9 from any organism, any naturally-occurring dCas9 equivalent or functional fragment thereof, any dCas9 homolog, ortholog, or paralog from any organism, and any mutant or variant of a dCas9, naturally-occurring or engineered. The term dCas9 is not meant to be particularly limiting and may be referred to as a “dCas9 or equivalent.” Exemplary dCas9 proteins and method for making dCas9 proteins are further described herein and/or are described in the art and are incorporated herein by reference.

[0376] In other embodiments, dCas9 corresponds to, or comprises in part or in whole, a Cas9 amino acid sequence having one or more mutations that inactivate the Cas9 nuclease activity. In other embodiments, Cas9 variants having mutations other than D10A and H840A are provided which may result in the full or partial inactivation of the endogenous Cas9 nuclease activity (e.g., nCas9 or dCas9, respectively). Such mutations, by way of example, include other amino acid substitutions at D10 and H840, or other substitutions within the nuclease domains of Cas9 (e.g., substitutions in the HNH nuclease subdomain and/or the RuvC1 subdomain) with reference to a wild type sequence such as Cas9 from *Streptococcus pyogenes* (NCBI Reference Sequence: NC_017053.1). In some embodiments, variants or homologues of Cas9 (e.g., variants of Cas9 from *Streptococcus pyogenes* (NCBI Reference Sequence: NC_017053.1 (SEQ ID NO: 20))) are provided which are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to NCBI Reference Sequence: NC_017053.1. In some embodiments, variants of dCas9 (e.g., variants of NCBI Reference Sequence: NC_017053.1 (SEQ ID NO: 20)) are provided having amino acid sequences which are shorter, or longer than NC_017053.1 (SEQ ID NO: 20) by about 5 amino acids, by about 10 amino acids, by about 15 amino acids, by about 20 amino acids, by

about 25 amino acids, by about 30 amino acids, by about 40 amino acids, by about 50 amino acids, by about 75 amino acids, by about 100 amino acids or more.

[0377] In one embodiment, the dead Cas9 may be based on the canonical SpCas9 sequence of Q99ZW2 and may have the following sequence, which comprises a D10X and an H810X, wherein X may be any amino acid, substitutions (underlined and bolded), or a variant be variant of SEQ ID NO: 40 having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity thereto.

[0378] In one embodiment, the dead Cas9 may be based on the canonical SpCas9 sequence of Q99ZW2 and may have the following sequence, which comprises a D10A and an H810A substitutions (underlined and bolded), or be a variant of SEQ ID NO: 41 having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity thereto.

Description	Sequence	SEQ ID NO:
dead Cas9 or dCas9 <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with D10 <u>X</u> and H810 <u>X</u> Where “X” is any amino acid	MDKKYISGL <u>X</u> IGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLLESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLV DSTDKADLRILIY LALAHMIKFRGHFLIEGD LNPDSNDVDKLFQILVQTYNQLFEENPINASGVDAKAILSARLS KSRRLLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAED AKLQLSKD TYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLYEYFTVY NELTKVKYVTEGMRKPAFLSGEQKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIKDKDFL DNEENEDILEDIVLTTLTFEDREMIEERLKYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAICKGI LQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVD <u>X</u> IVPQSFLKDDSIDNKVLTRSDKNRG KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVL SMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPK KYGGFDSPTVAYSVLVAKVEKGKSKKLKSVKE LLGITIMERSSEFKNPIDFLEAKGYKEVKKDLIIKLPKYSLEFE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL SA YNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDATLIHQ SITGLYETRIDLSQLGGD	SEQ ID NO: 40
dead Cas9 or dCas9	MDKKYISGL <u>A</u> IGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLLESFLVEEDKKHERHPIFGNIVDEVAYHE	SEQ ID NO: 41

Description	Sequence	SEQ ID NO:
<i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with D10A and H810A	KYPTIYHLRKKLV DSTDKADLR LIYLALAHMIKFRGHFLIEGD LNPDNSDV DKLFIQLVQTYNQ LFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFDLAED AKLQLSKD TYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTFRIPYYVGPLARGNSRF AWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNF DNLPNEKVLPKHSLLYEYFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDL LKIIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFL KSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGD SLHEHIANLAGSPAICKGI LQTVKVVDELVKVMGRHKPENIV IEMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRG KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYG DYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVL SMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKE LLGITIMERSSEFEKNPIDFLEAKGYKEVKKDLIIKL PKYSLFELE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL SA YNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDATLIHQ SITGLYETRIDLSQLGGD	

D. Cas9 nickase variant

[0379] In one embodiment, the multi-flap prime editors described herein comprise a Cas9 nickase. The term “Cas9 nickase” or “nCas9” refers to a variant of Cas9 which is capable of introducing a single-strand break in a double strand DNA molecule target. In some embodiments, the Cas9 nickase comprises only a single functioning nuclease domain. The wild type Cas9 (e.g., the canonical SpCas9) comprises two separate nuclease domains, namely, the RuvC domain (which cleaves the non-protospacer DNA strand) and HNH domain (which cleaves the protospacer DNA strand). In one embodiment, the Cas9 nickase comprises a mutation in the RuvC domain which inactivates the RuvC nuclease activity. For example, mutations in aspartate (D) 10, histidine (H) 983, aspartate (D) 986, or glutamate (E) 762, have been reported as loss-of-function mutations of the RuvC nuclease domain and the creation of a functional Cas9 nickase (e.g., Nishimasu et al., “Crystal structure of Cas9 in complex with guide RNA and target DNA,” *Cell* 156(5), 935–949, which is incorporated herein by reference). Thus, nickase mutations in the RuvC domain could include D10X, H983X, D986X, or E762X, wherein X is any amino acid other than the wild type amino acid. In certain embodiments, the nickase could be D10A, H983A, D986A, or E762A, or a combination thereof.

[0380] In various embodiments, the Cas9 nickase can have a mutation in the RuvC nuclease domain and have one of the following amino acid sequences, or a variant thereof having an amino acid sequence that has at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity thereto.

Description	Sequence	SEQ ID NO:
Cas9 nickase	MDKKYSIGLXIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI	SEQ ID NO: 42
<i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with D10X, wherein X is any alternate amino acid	KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGD LNPNDSDVDKLFQILVQTYNQLFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFDLAED AKLQLSKDXYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLEYEFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAICKGI LQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRE RMKRIIEGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVHDHVPQSFLKDDSIDNKVLTRSDKNRG KSDNPSEEVVKMKKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSPQVNVKKTETVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVAKVEKGKSKKLKSVKE LLGITIMERSSEKPNIDFLEAKGYKEVKKDLIILPKYSLFELE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLKVLSA YNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKR YSTKEVLDATLIHQSIITGLYETRIDLSQLGGD	
Cas9 nickase	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI	SEQ ID NO: 43
<i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with E762X, wherein X is any alternate amino acid	KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGD LNPNDSDVDKLFQILVQTYNQLFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFDLAED AKLQLSKDXYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLEYEFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQ	

Description	Sequence	SEQ ID NO:
	LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKGI LQTVKVVDELVKVMGRHKPENIVIXMARENQTTQKGQKNSR ERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRD MYVDQELDINRLSDYDVHIVPQSFLKDDSIDNKVLTRSDKNR GKSDNPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDK LIREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNA VVG TALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKAT AKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG RDFATVRKVL SMPQVNIVKKTEVQTGGFSKESILPKRNSDKLI ARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVK ELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLFEL ENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL AYNKHARDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRY TSTKEVL DATLIHQ SITGLYETRIDLSQLGGD	
Cas9 nickase <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with H983X, wherein X is any alternate amino acid	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADRLIYLALAHMIKFRGHFLIEGD LNPDNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNLIASLGLTPNFKNFDLAED AKLQLSKDTYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPLK DNREKIEKILTRIPYVVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLYEYFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKGI LQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRE RMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVHIVPQSFLKDDSIDNKVLTRSDKNRG KSDNPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVREINNYHXAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVL SMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKE LLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLFEL NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL AYNKHARDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVL DATLIHQ SITGLYETRIDLSQLGGD	SEQ ID NO: 44
Cas9 nickase <i>Streptococcus pyogenes</i>	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADRLIYLALAHMIKFRGHFLIEGD	SEQ ID NO: 45

Description	Sequence	SEQ ID NO:
Q99ZW2 Cas9 with D986X, wherein X is any alternate amino acid	LNPDSNDVDKLFQILVQTYNQLFEEENPINASGVDAKAILSARLS KSRRLLENLIAQLPGEKKNGLFGNLIASLGLTPNFKNFDLAED AKLQLSKDQYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLEYEFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKGI LQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRE RMKRIEIEGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRG KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTAKERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVRINNYHHAHAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSPQVNIKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKE LLGITIMERSSEFKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL SAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDATLIHQSIITGLYETRIDLSQLGGD	
Cas9 nickase <i>Streptococcus</i> <i>pyogenes</i> Q99ZW2 Cas9 with D10A	MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHREESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVSDTDKADRLRIYLALAHMIKFRGHFLIEGD LNPDSNDVDKLFQILVQTYNQLFEEENPINASGVDAKAILSARLS KSRRLLENLIAQLPGEKKNGLFGNLIASLGLTPNFKNFDLAED AKLQLSKDQYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLEYEFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKGI LQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRE RMKRIEIEGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRG KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTAKERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVRINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR	SEQ ID NO: 46

Description	Sequence	SEQ ID NO:
	DFATVRKVLSPQVNIIVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPPKKYGGFDSPTVAYSVLVVAKEKGKSKKLKSVKE LLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLNDKVL SAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRY STKEVLDATLIHQSIITGLYETRIDLSQLGGD	
Cas9 nickase <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with E762A	MDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSSTDKADLRLIYLALAHMIKFRGHFLIEGD LNPDNSDVKLFQILVQTYNQLFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNIALSLGLTPNFKSNFDLAED AKLQLSKDTYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTFRIPYVVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLYEYFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDLSHEHIANLAGSPAIIKKGI LQTVKVVDELVKVMGRHKPENIVIAAMARENQTTQKGQKNSR ERMKRIEEGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRD MYVDQELDINRLSDYDVHIVPQSFLKDDSIDNKVLTRSDKNR GKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAER GGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDK LIREVKVITLKSCLVSDFRKDFQFYKVRINNYYHHAHDAYLNA VVGTAIIKKYPKLESEFVYGDYKVYDVVRKMIKSEQEIGKAT AKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG RDFATVRKVLSPQVNIIVKKTEVQTGGFSKESILPKRNSDKLI ARKKDWDPPKKYGGFDSPTVAYSVLVVAKEKGKSKKLKSVK ELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFE ENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLNDKVL SAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRY TSTKEVLDATLIHQSIITGLYETRIDLSQLGGD	SEQ ID NO: 47
Cas9 nickase <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with H983A	MDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSSTDKADLRLIYLALAHMIKFRGHFLIEGD LNPDNSDVKLFQILVQTYNQLFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNIALSLGLTPNFKSNFDLAED AKLQLSKDTYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTFRIPYVVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLYEYFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFL	SEQ ID NO: 48

Description	Sequence	SEQ ID NO:
	DNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGI LQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRE RMKRIEEGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRG KSDNPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTAKERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVREINNYHA ^A AHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSPQVNVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVAKVEKGSKKLSVKE LLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVL YKHKRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDTLIHQSIITGLYETRIDLSQLGGD	
Cas9 nickase <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with D986A	MDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVSDTDKADLRILIYLAHAMIKFRGHFLIEGD LNPDSNDVDKLFQILVQTYNQLFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNLIASLSGLTPNFKSNFDLAED AKLQLSKDTYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTRIPYYVGPLARGNSRFAMWTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHSLLYEYFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLKIIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGI LQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRE RMKRIEEGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRG KSDNPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTAKERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAH ^A AYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSPQVNVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVAKVEKGSKKLSVKE LLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLGSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVL YKHKRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDTLIHQSIITGLYETRIDLSQLGGD	SEQ ID NO: 49

[0381] In another embodiment, the Cas9 nickase comprises a mutation in the HNH domain which inactivates the HNH nuclease activity. For example, mutations in histidine (H) 840 or asparagine (R)

863 have been reported as loss-of-function mutations of the HNH nuclease domain and the creation of a functional Cas9 nickase (e.g., Nishimasu et al., “Crystal structure of Cas9 in complex with guide RNA and target DNA,” *Cell* 156(5), 935–949, which is incorporated herein by reference). Thus, nickase mutations in the HNH domain could include H840X and R863X, wherein X is any amino acid other than the wild type amino acid. In certain embodiments, the nickase could be H840A or R863A or a combination thereof.

[0382] In various embodiments, the Cas9 nickase can have a mutation in the HNH nuclease domain and have one of the following amino acid sequences, or a variant thereof having an amino acid sequence that has at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity thereto.

Description	Sequence	SEQ ID NO:
Cas9 nickase <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with H840X, wherein X is any alternate amino acid	MDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGD LNPDSNDVDKLFQILVQTYNQLFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFDLAED AKLQLSKDITYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPFLK DNREKIEKILTFRIPYYVGPLARGNSRFAMWTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLEYFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIKDKDFL DNEENEDILEDIVLTLTLFEDREMIERLKYAHLFDDKVMKQ LKRRRYTGWRSLSRKLINGIRDQKSGKTILDFLKSDGFANRF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGI LQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRE RMKRIEEGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVDXIVPQSFLKDDSIDNKVLTRSDKNRG KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSPQVNIVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVAKVEKGKSKKLKSVKE LLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLKVLSA YNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDTLIHQSIITGLYETRIDLSQLGGD	SEQ ID NO: 50
Cas9 nickase <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with H840A	MDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGD LNPDSNDVDKLFQILVQTYNQLFEENPINASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFDLAED	SEQ ID NO: 51

Description	Sequence	SEQ ID NO:
	AKLQLSKDITYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPFLK DNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNF DNLPNEKVLPHKSLLYEYFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIAKKGI LQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRE RMKRIEEGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVAIVPQSFLKDDSIDNKVLTRSDKNRG KSDNVPSEEVVKMKKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVL SMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKE LLGITIMERSSEFKNPIDFLEAKGYKEVKKDLIIKLPKYSLEFE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL SAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDTLIHQITGLYETRIDLSQLGGD	
Cas9 nickase <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with R863X, wherein X is any alternate amino acid	MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLV DSTDKADLRLLIYLAHMIKFRGHFLIEGD LNPDNSDVKLFQILVQTYNQLFEEPNIPASGVDAKAILSARLS KSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAED AKLQLSKDITYDDDLNLLAQIGDQYADLFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPFLK DNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNF EEVVDKGASAQSFIERMTNF DNLPNEKVLPHKSLLYEYFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFL DNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIAKKGI LQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRE RMKRIEEGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVHIVPQSFLKDDSIDNKVLTRSDKNXG KSDNVPSEEVVKMKKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVL SMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKE	SEQ ID NO: 52

Description	Sequence	SEQ ID NO:
	LLGITIMERSSEFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLGKSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL YKHKRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDATLIHQSIITGLYETRIDLSQLGGD	
Cas9 nickase <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with R863A	MDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSI KKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHE KYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGD LNPDSNDVDKLFQILVQTYNQLFEENPINASGVDAKAILSARLS KSRRLLENLIAQLPGEKKNGLFGNLIALLSLGLTPNFKSNFDLAED AKLQLSKDYYDDDLNLLAQIGDQYADFLAAKNLSDAILLS DILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEK YKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLK DNREKIEKILTFRIPYYVGPLARGNSRFAMWTRKSEETITPWNF EEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLYEYFTVY NELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQ LKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLKIKDKDFL DNEENEDILEDIVLTTLTFEDREMIEERLKYAHLFDDKVMKQ LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGI LQTVKVVDELVKVMGRHKPENIVIEAMARENQTTQKGQKNSRE RMKRIIEGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVHIVPQSFLKDDSIDNKVLTRSDKNAAG KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRLVETRQITKHVAQILDSRMNTKYDENDKL IREVKVITLKSCLVSDFRKDFQFYKVRINNYHHAHDAYLNAV VGTALIKKYPKLESEFVYGDYKVDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGR DFATVRKVLSPQVNVKKTETVQTGGFSKESILPKRNSDKLIA RKKDWDPKKYGGFDSPTVAYSVLVAKVEKGKSKKLKSVKE LLGITIMERSSEFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLGKSP EDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL YKHKRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYT STKEVLDATLIHQSIITGLYETRIDLSQLGGD	SEQ ID NO: 53

[0383] In some embodiments, the N-terminal methionine is removed from a Cas9 nickase, or from any Cas9 variant, ortholog, or equivalent disclosed or contemplated herein. For example, methionine-minus Cas9 nickases include the following sequences, or a variant thereof having an amino acid sequence that has at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity thereto.

Description	Sequence
Cas9 nickase (Met minus) <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with H840X	DKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSIKKNLIGALLFD SGETAETRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLV EEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH MIKFRGHFLIEGDLNPDSNDVDKLFQILVQTYNQLFEENPINASGVDAKAILSARLS KSRRLLENLIAQLPGEKKNGLFGNLIALLSLGLTPNFKSNFDLAEDAKLQLS KDYDDDLNLLAQIGDQYADFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEF

wherein X is any alternate amino acid	YKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQ EDFYFPLKDNREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPHKSHLLYEYFTVYNELTKVKYVTE GMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTY AHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANR NFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKKGILQTVKVV DELVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEEGKELGSQIL KEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDXIVPQSFL KDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD NLTKAERGGSELDAKAFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSCLVSDFRKDFQFYKVRINNYHHAHDAYLNAVVGTAIIKKYPK LESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE IRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNVKKTEVQTGGFSKES ILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSV KELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFENGRKRML ASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHY LDEIIEQISEFSKRVLADANLDKVL SAYNKHDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKRYTSTKEVL DATLIHQ SITGLYETRIDLSQLGGD (SEQ ID NO: 54)
Cas9 nickase (Met minus) <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with H840A	DKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFD SGETAETRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLV EEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADRLIYLALAH MIKFRGHFLIEGDLNPDNSDVKLFQILVQTYNQLFEENPINASGVDAKAILS RLSKSRRLLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFDLAEDAKLQLS KDYTDDDLNDLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEF YKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQ EDFYFPLKDNREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPHKSHLLYEYFTVYNELTKVKYVTE GMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTY AHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANR NFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKKGILQTVKVV DELVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEEGKELGSQIL KEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDXIVPQSFL KDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFD NLTKAERGGSELDAKAFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSCLVSDFRKDFQFYKVRINNYHHAHDAYLNAVVGTAIIKKYPK LESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE IRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNVKKTEVQTGGFSKES ILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSV KELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFENGRKRML ASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHY LDEIIEQISEFSKRVLADANLDKVL SAYNKHDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKRYTSTKEVL DATLIHQ SITGLYETRIDLSQLGGD (SEQ ID NO: 55)
Cas9 nickase (Met minus) <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with R863X,	DKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFD SGETAETRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLV EEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADRLIYLALAH MIKFRGHFLIEGDLNPDNSDVKLFQILVQTYNQLFEENPINASGVDAKAILS RLSKSRRLLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFDLAEDAKLQLS KDYTDDDLNDLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEF

wherein X is any alternate amino acid	YKFIKPILEKMDGTEELLVKLNRDILLRKQRTFDNGSIPHQIHLGELHAILRRQ EDFYFPLKDNREKIEKILTFRIPIYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLEYEFTVYNELTKVKYVTE GMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTY AHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANR NFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKKGILQTVKVV DELVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRIIEGKELGSQIL KEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFL KDDSIDNKVLTRSDKNXGKSDNPSEEVVKKMKNYWRQLLNAKLITQRKFD NLTKAERGGSELDAKAGFIKRLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSCLVSDFRKDFQFYKVRINNYHHAHDAYLNAVVGTAIIKKYPK LESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE IRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNVKKTEVQTGGFSKES ILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSV KELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFENGRKRML ASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHY LDEIIEQISEFSKRVLADANLDKVL SAYNKHDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKRYTSTKEVL DATLIHQ SITGLYETRIDLSQLGGD (SEQ ID NO: 56)
Cas9 nickase (Met minus) <i>Streptococcus pyogenes</i> Q99ZW2 Cas9 with R863A	DKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFD SGETAETRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLV EEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADRLIYLALAH MIKFRGHFLIEGDLNPDNSDVKLFQILVQTYNQLFEENPINASGVDAKAILS RLSKSRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLS KDTYDDDLNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEF YKFIKPILEKMDGTEELLVKLNRDILLRKQRTFDNGSIPHQIHLGELHAILRRQ EDFYFPLKDNREKIEKILTFRIPIYYVGPLARGNSRFAWMTRKSEETITPWNFEE VVDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLEYEFTVYNELTKVKYVTE GMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVED RFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTY AHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANR NFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKKGILQTVKVV DELVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRIIEGKELGSQIL KEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFL KDDSIDNKVLTRSDKNAGKSDNPSEEVVKKMKNYWRQLLNAKLITQRKFD NLTKAERGGSELDAKAGFIKRLVETRQITKHVAQILDSRMNTKYDENDKLIR EVKVITLKSCLVSDFRKDFQFYKVRINNYHHAHDAYLNAVVGTAIIKKYPK LESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLANGE IRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNVKKTEVQTGGFSKES ILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSV KELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFENGRKRML ASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHY LDEIIEQISEFSKRVLADANLDKVL SAYNKHDKPIREQAENIIHLFTLTNLGA PAAFKYFDTTIDRKRYTSTKEVL DATLIHQ SITGLYETRIDLSQLGGD (SEQ ID NO: 57)

E. Other Cas9 variants

[0384] Besides dead Cas9 and Cas9 nickase variants, the Cas9 proteins used herein may also include other “Cas9 variants” having at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least

about 99.9% identical to any reference Cas9 protein, including any wild type Cas9, or mutant Cas9 (e.g., a dead Cas9 or Cas9 nickase), or fragment Cas9, or circular permutant Cas9, or other variant of Cas9 disclosed herein or known in the art. In some embodiments, a Cas9 variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acid changes compared to a reference Cas9. In some embodiments, the Cas9 variant comprises a fragment of a reference Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild type Cas9. In some embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild type Cas9 (e.g., SEQ ID NO: 18).

[0385] In some embodiments, the disclosure also may utilize Cas9 fragments that retain their functionality and that are fragments of any herein disclosed Cas9 protein. In some embodiments, the Cas9 fragment is at least 100 amino acids in length. In some embodiments, the fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, or at least 1300 amino acids in length.

[0386] In various embodiments, the multi-flap prime editors disclosed herein may comprise one of the Cas9 variants described as follows, or a Cas9 variant thereof having at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to any reference Cas9 variants.

F. Small-sized Cas9 variants

[0387] In some embodiments, the multi-flap prime editors contemplated herein can include a Cas9 protein that is of smaller molecular weight than the canonical SpCas9 sequence. In some embodiments, the smaller-sized Cas9 variants may facilitate delivery to cells, e.g., by an expression vector, nanoparticle, or other means of delivery. In certain embodiments, the smaller-sized Cas9 variants can include enzymes categorized as type II enzymes of the Class 2 CRISPR-Cas systems. In some embodiments, the smaller-sized Cas9 variants can include enzymes categorized as type V enzymes of the Class 2 CRISPR-Cas systems. In other embodiments, the smaller-sized Cas9 variants can include enzymes categorized as type VI enzymes of the Class 2 CRISPR-Cas systems.

[0388] The canonical SpCas9 protein is 1368 amino acids in length and has a predicted molecular weight of 158 kilodaltons. The term “small-sized Cas9 variant”, as used herein, refers to any Cas9

variant—naturally occurring, engineered, or otherwise—that is less than at least 1300 amino acids, or at least less than 1290 amino acids, or than less than 1280 amino acids, or less than 1270 amino acid, or less than 1260 amino acid, or less than 1250 amino acids, or less than 1240 amino acids, or less than 1230 amino acids, or less than 1220 amino acids, or less than 1210 amino acids, or less than 1200 amino acids, or less than 1190 amino acids, or less than 1180 amino acids, or less than 1170 amino acids, or less than 1160 amino acids, or less than 1150 amino acids, or less than 1140 amino acids, or less than 1130 amino acids, or less than 1120 amino acids, or less than 1110 amino acids, or less than 1100 amino acids, or less than 1050 amino acids, or less than 1000 amino acids, or less than 950 amino acids, or less than 900 amino acids, or less than 850 amino acids, or less than 800 amino acids, or less than 750 amino acids, or less than 700 amino acids, or less than 650 amino acids, or less than 600 amino acids, or less than 550 amino acids, or less than 500 amino acids, but at least larger than about 400 amino acids and retaining the required functions of the Cas9 protein. The Cas9 variants can include those categorized as type II, type V, or type VI enzymes of the Class 2 CRISPR-Cas system.

[0389] In various embodiments, the multi-flap prime editors disclosed herein may comprise one of the small-sized Cas9 variants described as follows, or a Cas9 variant thereof having at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to any reference small-sized Cas9 protein.

Description	Sequence	SEQ ID NO:
SaCas9	MGKRNYYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVEN	SEQ ID NO: 58
<i>Staphylococcus aureus</i>	NEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSTG	
1053 AA	NPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDT	
123 kDa	GNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRF	
	KTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYE	
	GPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNAD	
	LYNALNDLNNLVITRDENEKLEYEKFQIENVFKQKKKPTLK	
	QIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEII	
	ENAELLDQIAKILTIYQSSEDIQEELTNLNSLTQEEIEQISNLKG	
	YTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDLS	
	QQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIKKYGLPNDIIEL	
	AREKNSKDAQKMINEMQKRNRTNERIEEIIIRTTGKENAKYLI	
	EKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSF	
	DNSFNKVLVKQEENSKKGNRTPFQYLSSSDSKISYETFKKHIL	
	NLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYA	
	TRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKER	
	NKGYKHHAEDALIANADFIFKEWKKLDKAKKVMENQMFEE	
	KQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKP	
	NRKLINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLIN	
	KSPEKLLMYHHPQTYQKLKLIMEQYGDEKNPLYKYEEETGN	
	YLTKYSKKDNBPVIKKIKYYGNKLNALDITDDYPNSRNKVV	
	KLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCY	
	EEAKKLKISNQAEFISFYKNDLIKINGELYRVIGVNNDLLNR	

Description	Sequence	SEQ ID NO:
	IEVNMIDITYREYLENMNDKRPPHIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKK	
NmeCas9 <i>N. meningitidis</i> 1083 AA 124.5 kDa	MAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRFERAEVPKTGDSLAMARRLARSVRRLTRRRRAHRLRLTRRLLKREGVLQAANFDENGLIKSLPNTPWQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVAGNAHALQTGDFRTPAELALNKFEEKESGHIRNQRSYSHTFSRKDLQAEILLFEKQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKNTYTAERFIWLTCLNNLRILEQGSERPLTDTERRATLMDEPYRKSKLTYAQAARKLLGLEDTAFFKGLRYGKDNAAEASTLMEMKAYHAISRALEKEGLKDKKSPLNLSPELQDEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKDFVQISLKALRRIVPLMEQGKRYDEACAEIYGDHYGKKNTTEEKIYLPPIPADEIRNPVVLRLALSQARKVINGVRRYGGSPARIHIETAREVGKSFKDRKEIEKRQEENRDKREKAAAKFREYFPNFVGEPKSKDILKLRLYEQHGKCLYSKEINLGRLEKGYVEIDAALPFSRTWDDSFNNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRILLQKFDEDDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNLLRGFWGLRKVRAENDRHALLDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTIDKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLAEKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSARKLDEGVSVLRVPLTQLKLKDLKEMVNREREPKLYEALKARLEAHKDDPAKAFAPFYKYDKAGNRTQQVKAVRVEQVQKTGVWVRNHNIGIADNATMVRVDVFEKGDKYLVPIYSWQVAKGILPDRAVVQKGDEEDWQLIDDSFNFKFSLHPNDLVEVITTKARMFGYFASCHRGFTGNINIRIHDLDHKIGKNGILEGIGVKTALSFKQYQIDELGKEIRPCRLKKRPPVR	SEQ ID NO: 59
CjCas9 <i>C. jejuni</i> 984 AA 114.9 kDa	MARILAFDIGISSIGWAFSENDELKDCGVRIFTKVENPKTGESLALPRRLARSARKRLARRKARLNHLKHLIANEFKLNIEDYQSFDESLAKAYKGLISPYELRFRALNELLKQDFARVILHIAKRRGYDDIKNSDDKEKGAILKAIKQNEEKLANYQSVGEYLYKEYFQKFKENSKEFTNVRNKKESYERCIASFLKDELKLIFKKQREFGFSFSKKFEEVLSVAFYKRALKDFSHLVGNCSSFTDEKRAPKNSPLAFMFVALTRIINLLNNLKNTEGILYTKDDLNALLNEVLKNGTLTYKQTKLLGLSDDYEFKGEKGTIFYIEFKKYKEFIKALGEHNLSQDDLNEIAKDITLIKDEIKLKKALAKYDLNQNQIDSLSKLEFKDHLNISFKALKLVTPLMLEGKKYDEACNELNLKVAINEDKDKDFLPAFNETYYKDEVTPNPVVLRAIKEYRKVLNALLKKYGVHKINIELAREVGKNHSQRAKIEKEQNENYKAKKDAELECEKGLKINSKNILKLRLFKEQKEFCAYSGEKIKISDLQDEKMLEIDHIYPYSRSFDDSYMKNVLVFTKQNKQEKLNQTPFEAFGNDSAKWQKIEVLAKNLPKTKQKRILDKNYKDKEQKNFKDRNLNDTRYIARLVNLNYTKDYLDLPLSDDENTKLNDTQKGSKVHVEAKSGMLTSALRHTWGFSAKDRNNHLHHAIDAVIIAYANNSIVKAFSDFKKEQESNSAELYAKKISELDYKNKRKFFEPFSGFRQKVLDKIDEIFVSKPERKKPSGALHEETFRKEEFYQSYGGKEGVLKALELGKIRKVNKIVKNGDMFRVDIFKHKKTNKFYAVPIYTMDFALLKVLPNKAVARSKKGEIKDWILMDENYFCFSLYKDSLILIQTKDMQEPEFVYNAFTSSTVSLIVSKHDNKFETLSKNQKILFKNANEKEVIAKSIGIQNLKVFEKYIVSALGEVTKAEFRQREDFKK	SEQ ID NO: 60
GeoCas9	MRYKIGLDIGITSVGWAVMNLDPRIEDLGVRIFDRAENPQTGESLALPRRLARSARRRLRRRKHRLERIRRLVIREGILTKEELDKL	SEQ ID NO: 61

Description	Sequence	SEQ ID NO:
<p><i>G. stearothermophilus</i></p> <p>1087 AA 127 kDa</p>	<p>FEEKHEIDVWQLRVEALDRKLNDELARVLLHLAKRRGFKSN RKSESRNKENSTMLKHIEENRAILSSYRTVGEMIVKDPKFALH KRNGENYNTIARDDLEREIRLIFSKQREFGNMSCTEEFENEY ITIWASQRPVASKDDIEKKVGFCTFEPKEKRAPKATYTFQSFIA WEHINKLRLISPSGARGLTDEERRLLYEQAFQKNKITYHDIRTL LHLPDDTYFKGIVYDRGESRKQENIRFLELDAYHQIRKAVDK VYGKGKSSSFLPIDFDTFGYALTFLKDDADIHSYLRNEYEQNG KRMPNLANKVVDNELIEELLNLSFTKFGHLSLKALRSILPYME QGEVYSSACERAGYTFTGPKKKQKTMLLPNIPPIANPVVMRAL TQARKVVNAIIKKYGSPVSIHIELARDLSQTFDERRKTKKEQDE NRKKNETAIRQLMEYGLTLNPTGHDIVKFKLWSEQNGRCAYS LQPIEIERLLEPGYVEVDHVIPYSRSLDDSYTNKVLVLTRENRE KGNRIPEYLGVGTERWQQFETFVLTKNQFSKKRDRLLRLH YDENEETEFKNRNLNDTRYISRFFANFIREHLKFAESDDKQKV YTVNGRVT AHLRSRWEFNKNREESDLHHA VDAVIVACTTPSD IAKVTAFYQRREQNKELAKKTEPHFPQPWPHFADELARLSK HPKESIKALNLGNYDDQKLESLOPVFVSRMPKRSVTGAAHQE TLRRYVGIDERSGKIQT VVKTKLSEIKLDASGHFPMYGKESDP RTYEAIRQRLLEHNNDPKKAFQEPLYKPKKNGEPGPVIRTVKII DTKNQVIPLNDGKTVA YNSNIVRVDVFEKDGKYYCVPVYTM DIMKGILPNKAIEPNKPYSEWKEMTEDYTFRFSLYPNDLIRIEL PREKTVKTAAGEEINVKDVVYKYKTIDSANGGLELISHDHRFS LRGVGSRTLKRFEKYQVDVLGNIYKVRGEKRVGLASSAHSKP GKTIRPLQSTRD</p>	
<p>LbaCas12a</p> <p><i>L. bacterium</i></p> <p>1228 AA 143.9 kDa</p>	<p>MSKLEKFTNCYSLSKTLRFKAIPVGKTQENIDNKRLLEVEDEKR AEDYKGVKKLLDRYYLSFINDVLHSIKLKNLNNYISLFRKKTR TEKENKELENLEINLRKEIAKAFKGNEGYKSLFKKDIIETILPEF LDDKDEIALVNSFNGFTTAFTGFFDNRENMFSEEAKSTSIAFRC INENLTRYISNMDIFEKVDAIFDKHEVQEIKEKILNSDYDVEDFF EGEFFNFVLTQEGIDVYNAIIGGFVTESGEIKIKGLNEYINLYNQ KTKQKLPKFKPLYKQVLS DRESLSFYGEGYTSDEEVLEVFRNT LNKNSEIFSSIKKLEKLFKNFDEYSSAGIFVKNGPAISTISKDIFG EWNVIRDKWNAEYDDIHLKKKAVVTEKYEDDRRKSFKKIGSF SLEQLQEYADADLSVVEKLKEIIIQKVDEIYKVYGSSEKLFADAD FVLEKSLKKNDAVVAIMKDLLDSVKS FENYIKAFFGEGKETNR DESFGDFVLAYDILLKVDHIYDAIRNYVTQKPYSKDKFKLYF QNPQFMGGWDKDKETDYRATILRYGSKYYLAIMDKKYAKCL QKIDKDDVNGNYEKINYKLLPGPNKMLPKVFFSKKWMAYYN PSEDIQKIYKNGTFKKGDMFNLNDCHKLIDFFKDSISRYPKWS NAYDFNFSETEKYKDIAGFYREVVEEQGYKVSFESASKKEVDK LVEEGKLYMFQIYNKDFSDKSHGTPNLHTMYFKLLFDENNHG QIRLSGGAELFMRRASLKKEELV VHPANSPIANKNPDNP KKT TLSYDVYKDKRFSEDQYELHIPIAINKCPKNIFKINTEVRVLLK HDDNPYVIGIDRGERNLLYIVVVDGKGNIVEQYSLNEIINNFG IRIKTDYHSLDDKKEKERFEARQNWTSIENIKELKAGYISQVVH KICELVEKYDAVIALEDLNSGFKNSRVKVEKQVYQKFEKMLID KLNYMVDKKS NPCATGGALKGYQITNKFESFKSMSTQNGFIF YIPAWLTSKIDPSTGFVNLLKTKYTSIADSKKFISFDRIMYVPE EDLFEFALDYKNFSRTDADYIKKWKLYSYGNRIRIFRNPKKNN VFDWEEVCLTSAYKELFNKYGINYQQGDIRALLCEQSDKAFY SSFMALMSLMLQMRNSITGRTDVDFLISPVKNSDGIFYDSRNY EAQENAILPKNADANGAYNIARKVLWAIGQFKKAEDEKLDKV KIAISNKEWLEYAQTSVKH</p>	SEQ ID NO: 62

Description	Sequence	SEQ ID NO:
BhCas12b	MATRSFILKIEPNEEVKKGLWKTHEVLNHGIAYYMNLKLIRQ	SEQ ID NO: 63
<i>B. hisashii</i>	EAIYEHHEQDPKNPKKVSKEIQAEWDFVLKMQKNSFTHE	
1108 AA	VDKDEVFNILRELYEELVPSSVEKKGEANQLSNKFLYPLVDPN	
130.4 kDa	SQSGKGTASSGRKPRWYNLKIAGDPSWEEKKKWEEDKKKD	
	PLAKILGKLAEYGLIPLFIPYTDSEPIVKEIKWMEKSRNQSVR	
	RLDKDMFIQALERFLSWESWNLKVKEEYKVEKEYKTLEERI	
	KEDIQALKALEQYKERQEQLLRDTLNTNEYRLSKRGLRGWR	
	EIIQKWLKMDENEPSEKYLEVFKDYQRKHPREAGDYSVYEFL	
	SKKENHFIWRNHPEYPYLYATFCEIDKKKKDAKQATFTLAD	
	PINHPLWVRFEERSGSNLNKYRILTEQLHTEKLKKKLTQVLD	
	LIYPTESGGWEEKGKVDIVLLPSRQFYNQIFLDIEEKGKHAFTY	
	KDESIKFPLKGTGGARVQFDRDHLRRYPHKVESGNVGRIFYN	
	MTVNIEPTESPVSKSLKIHRDDFPKVVNFKPKELTEWIKDSKG	
	KKLKSGIESLEIGLRVMSIDLQGRQAAAASIFEVVDQKPDIEGK	
	LFFPIKGTLEYAVHRASFNIKLPGETLVKSREVLKAREDNKL	
	MNQKLNFLRNVLHFQQFEDITEREKRVTKWISRQENSVDPLV	
	YQDELIQIRELMYKPYKDWVAFKQLHKLRLVEIGKEVKHWR	
	KSLSDGRKGLYGISLKNIDEIDRTRKFLLRWSLRPTEPGEVRL	
	EPGQRFAIDQLNHLNALKEDRLKKMANTHMHALGYCYDVRK	
	KKWQAKNPACQILFEDLSNYPYEERSRFENSKLMKWSRREI	
	PRQVALQGEIYGLQVGEVGAQFSSRFHAKTGSPGIRCSVVTKE	
	KLQDNRRFFKNLQREGRLTLDKIAVLKEGDLYPDKGGEKFISLS	
	KDRKCVTTHADINAAQNLQKRFWTRTHGFYKVYCKAYQVDG	
	QTVYIPESKDQKQKIIIEFGEYFILKDGVEYEWVNAGKLKIKK	
	GSSKQSSSELVDSILKDSFDLASELKGEKLMLYRDPSGNVFP	
	DKWMAAGVFFGKLERILISKLTNQYSISTIEDDSSKQSM	

G. Cas9 equivalents

[0390] In some embodiments, the multi-flap prime editors described herein can include any Cas9 equivalent. As used herein, the term “Cas9 equivalent” is a broad term that encompasses any napDNAAbp protein that serves the same function as Cas9 in the present multi-flap prime editors despite that its amino acid primary sequence and/or its three-dimensional structure may be different and/or unrelated from an evolutionary standpoint. Thus, while Cas9 equivalents include any Cas9 ortholog, homolog, mutant, or variant described or embraced herein that are evolutionarily related, the Cas9 equivalents also embrace proteins that may have evolved through convergent evolution processes to have the same or similar function as Cas9, but that do not necessarily have any similarity with regard to amino acid sequence and/or three-dimensional structure. The multi-flapprime editors described here embrace any Cas9 equivalent that would provide the same or similar function as Cas9 despite that the Cas9 equivalent may be based on a protein that arose through convergent evolution. For instance, if Cas9 refers to a type II enzyme of the CRISPR-Cas system, a Cas9 equivalent can refer to a type V or type VI enzyme of the CRISPR-Cas system.

[0391] For example, Cas12e (CasX) is a Cas9 equivalent that reportedly has the same function as Cas9 but which evolved through convergent evolution. Thus, the Cas12e (CasX) protein described in Liu et al., “CasX enzymes comprises a distinct family of RNA-guided genome editors,” *Nature*, 2019,

Vol.566: 218-223, is contemplated to be used with the multi-flap prime editors described herein. In addition, any variant or modification of Cas12e (CasX) is conceivable and within the scope of the present disclosure.

[0392] Cas9 is a bacterial enzyme that evolved in a wide variety of species. However, the Cas9 equivalents contemplated herein may also be obtained from archaea, which constitute a domain and kingdom of single-celled prokaryotic microbes different from bacteria.

[0393] In some embodiments, Cas9 equivalents may refer to Cas12e (CasX) or Cas12d (CasY), which have been described in, for example, Burstein et al., “New CRISPR–Cas systems from uncultivated microbes.” *Cell Res.* 2017 Feb 21. doi: 10.1038/cr.2017.21, the entire contents of which is hereby incorporated by reference. Using genome-resolved metagenomics, a number of CRISPR–Cas systems were identified, including the first reported Cas9 in the archaeal domain of life. This divergent Cas9 protein was found in little-studied nanoarchaea as part of an active CRISPR–Cas system. In bacteria, two previously unknown systems were discovered, CRISPR–Cas12e and CRISPR–Cas12d, which are among the most compact systems yet discovered. In some embodiments, Cas9 refers to Cas12e, or a variant of Cas12e. In some embodiments, Cas9 refers to a Cas12d, or a variant of Cas12d. It should be appreciated that other RNA-guided DNA binding proteins may be used as a nucleic acid programmable DNA binding protein (napDNAbp) and are within the scope of this disclosure. Also see Liu et al., “CasX enzymes comprises a distinct family of RNA-guided genome editors,” *Nature*, 2019, Vol.566: 218-223. Any of these Cas9 equivalents are contemplated.

[0394] In some embodiments, the Cas9 equivalent comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a naturally-occurring Cas12e (CasX) or Cas12d (CasY) protein. In some embodiments, the napDNAbp is a naturally-occurring Cas12e (CasX) or Cas12d (CasY) protein. In some embodiments, the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a wild-type Cas moiety or any Cas moiety provided herein.

[0395] In various embodiments, the nucleic acid programmable DNA binding proteins include, without limitation, Cas9 (*e.g.*, dCas9 and nCas9), Cas12e (CasX), Cas12d (CasY), Cas12a (Cpf1), Cas12b1 (C2c1), Cas13a (C2c2), Cas12c (C2c3), Argonaute, and Cas12b1. One example of a nucleic acid programmable DNA-binding protein that has different PAM specificity than Cas9 is Clustered Regularly Interspaced Short Palindromic Repeats from *Prevotella* and *Francisella* 1 (*i.e.*, Cas12a (Cpf1)). Similar to Cas9, Cas12a (Cpf1) is also a Class 2 CRISPR effector, but it is a member of type V subgroup of enzymes, rather than the type II subgroup. It has been shown that Cas12a (Cpf1) mediates robust DNA interference with features distinct from Cas9. Cas12a (Cpf1) is a single RNA-

guided endonuclease lacking tracrRNA, and it utilizes a T-rich protospacer-adjacent motif (TTN, TTTN, or YTN). Moreover, Cpf1 cleaves DNA via a staggered DNA double-stranded break. Out of 16 Cpf1-family proteins, two enzymes from *Acidaminococcus* and *Lachnospiraceae* are shown to have efficient genome-editing activity in human cells. Cpf1 proteins are known in the art and have been described previously, for example Yamano *et al.*, “Crystal structure of Cpf1 in complex with guide RNA and target DNA.” *Cell* (165) 2016, p. 949-962; the entire contents of which is hereby incorporated by reference.

[0396] In still other embodiments, the Cas protein may include any CRISPR associated protein, including but not limited to, Cas12a, Cas12b1, Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof, and preferably comprising a nickase mutation (e.g., a mutation corresponding to the D10A mutation of the wild type Cas9 polypeptide of SEQ ID NO: 18).

[0397] In various other embodiments, the napDNAbp can be any of the following proteins: a Cas9, a Cas12a (Cpf1), a Cas12e (CasX), a Cas12d (CasY), a Cas12b1 (C2c1), a Cas13a (C2c2), a Cas12c (C2c3), a GeoCas9, a CjCas9, a Cas12g, a Cas12h, a Cas12i, a Cas13b, a Cas13c, a Cas13d, a Cas14, a Csn2, an xCas9, an SpCas9-NG, a circularly permuted Cas9, or an Argonaute (Ago) domain, or a variant thereof.

[0398] Exemplary Cas9 equivalent protein sequences can include the following:

Description	Sequence
AsCas12a (previously known as Cpf1)	MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYKELKPIID RIYKTYADQCLQLVQLDWENLSAIDSYRKEKTEETRNALIEEQATYRNAIHD YFIGRTDNLTDANKRHAIEIYKGLFKAELFNGKVLKQLGTVTTTEHENALLRSF DKFTTYFSGFYENRKNVFSADISTAIPHRIVQDNFPKFKENCHIFTRLITAVPSL REHFENVKKAIGIFVSTSIIEVFSPFYNNQLLTQTQIDLYNQLLGGISREAGTEKI KGLNEVLNLAIQKNDETAHIIASLPHRFIPLFKQILSDRNTLSFILEEFKSDEEVIQ SFCKYKTLLRNENVLETAELFNELNSIDLTHIFISHKKLETISSALCDHWDTLR NALYERRISELTGKITSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQKTSEI LSHAHAALDQPLPTTLKKQEEKEILKSQDLSLLGLYHLLDWFAVDESNEVDPEF SARLTGIKLEMEPSLSFYNNKARNYATKKPYSVEKFKLNFQMPTLASGWDVNKE KNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTSEKTFSEGFDKMYDYFPDAA KMIPKCSTQLKAVTAHFQTHHTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTA YAKKTGDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQYKDLGEYY AELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYW TGLFSPENLAKTSIKLNGQAEFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPI PDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEIHKDRRFTSDKFFFHV PITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQR SLNTIQQFDYQKKLDNREKERVAAQAWSVVGTIKDLKQGYLSQVIHEIVDLM IHQAVVVLENLNFQKSKRTGIAEKAVYQQFEKMLIDKLNCLVLKDYPAEKV GGVLNPPYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKIDPLTGFDVDFVWKTIKN HESRKHFLGFDLHYDVKTGDFILHFKMNRNLSFQRLPGFMPAWDIVFEKN ETQFDAKGTPIAGKRIVPVNIENHRFTGRYRDLYPANELIALLEEKGIVFRDGSNI LPKLLNDDSHAIDTMVALIRSVLQMRNSNAATGEDYINSPVRDLNGVCFDSRF
Acidaminoco ccus sp. (strain BV3L6)	
UniProtKB U2UMQ6	

	QNPEWPMADANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRN (SEQ ID NO: 64)
AsCas12a nickase (e.g., R1226A)	MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNNDHYKELKPIID RIYKTYADQCLQLVQLDWENLSAIDSYRKEKTEETRNALIEEQATYRNAIHD YFIGRTDNLTDANKRHAIEYKGLFKAELFNGKVLKQLGTVTTEHENALLRSF DKFTTYFSGFYENRKNVFSADISTAIPHRIVQDNFPPKFKENCHIFTRLITAVPSL REHFENVKKAIGIFVSTSIIEVFSFPFYNNQLLTQTQIDLYNQLLGGISREAGTEKI KGLNEVLNLAIQKNDETAHIIASLPHRFIPLFKQILSDRNTLSFILEEFKSDEEVIQ SFCKYKTLRNENVLETAELFNLNSIDLTHIFISHKKLETISSALCDHWDTLR NALYERRISELTGKITSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQKTSEI LSHAHAALDQPLPTTLKKQEEKEILKSQDLSLLGLYHLLDWFAVDESNEVDPEF SARLTGIKLEMEPSLSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDVNKE KNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTTEKTEGFDKMYDYDFPDAA KMPKCSQTLKAVTAHFQTHTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTA YAKKTGDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQYKDLGEYY AELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYW TGLFSPENLAKTSIKLNGQAEFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPI PDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEIHKDRRFTSDKFFFHV PITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQR SLNTIQQFDYQKKLDNREKERVAAARQAWSVVGTIKDLKQGYLSQVIHEIVDLM IHQAVVVLENLNFQFKSKRTGIAEKAVYQQFEKMLIDKLNCLVLKDYPAEKV GGVLNPNYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKN HESRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKN ETQFDAKGTPIAGKRIVPVIEHRFTGRYRDLYPANELIALLEEKGIVFRDGSNI LPKLLNDDSHADTMVALIRSVLQMANSNAATGEDYINSPVRDLNGVCFDSRF QNPEWPMADANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRN (SEQ ID NO: 65)
LbCas12a (previously known as Cpf1) <i>Lachnospira ceae bacterium GAM79</i>	MNYKTGLEDFIGKESLSKTLRNALIPTESTKIHMEEMGVIRDDELRAEKQQELK EIMDDYYRTFIEEKLQIQIQWNSLFQKMEETMEDISVRKDLDKIQNEKRKEI CCYFTSDKRFKDLFNAKLITDILPNFIKDNKEYTEEEKAEKEQTRVLFQRFATAF TNYFNQRRNNSFEDNISTAISFRIVNENSEIHLQNMRAFQRIEQQYPEEVCGMEE EYKDMQLQEWQMKHIYSVDYDRELTPQGIYYNGICGKINEHNMNQFCQKNRIN KNDFRMKKLHKQILCKKSSYYEIPFRFESDQEVYDALNEFIKTMKKKEIIRRCV HLGQECDDYDLGKIYISSNKYEQISNALYGSWDTIRKCIKEEYMDALPGKGEKK EEKAEAAAKKEEYRSIADIDKIISLYGSEMDRTISAKKCITEICDMAGQISIDPLV CNSDIKLLQNKEKTTEIKTILDSFLHVVYQWGQTFIVSDIIEKDSYFYSELEDVLED FEGITTLYNHVRSYVTQKPYSTVKFKLHFGSPTLANGWSQSKEYDNNAILLMR DQKFYLGFNVNRNPKDKQIIKGHEKEEKGDYKKMIYNLLPGPSKMLPKVFITSR SGQETYKPSKHILDGYNEKRHIKSSPKFDLGYCWDLIDYYKECIHKHPDWKNY DFHFSDTKDYEDISGFYREVEMQGYQIKWYISADEIQKLDEKGQIFLFIYQNK DFSVDSTGKDNLHTMYLKNLFSEENLKDVLKLNGEAELFFRKASIKTPIVHKK GSVLVNRSYTQTVGNKEIRVSIPEEYYTEIYNYLNNHIGKGLSSEAQRYLDEGKI KSFTATKDIVKNRYCCDHYFLHLPITINFKAKSDVAVNERTLAYIAKKEDIHII GIDRGERNLLYISVVDVHGNIREQRSFNIVNGYDYQQKLKDREKSRDAARKNW EEIEKIKELKEGYLSMVIHYIAQLVVKYNAVVMEDLNYGFKTGRFKVERQVY QKFETMLIEKLHLYLDFKREVCEEGLRGYQLTYIPESLKKVKGKQCGFIFYVP AGYTSKIDPTTGfVNLFSFKNLNRESRQDFVGKFDEIRYDRDKKMFESFDYN NYIKKGITLASTKWKVYTNTRLKRIVVNGKYTSQSMEVELTDAMEKMLQRA GIEYHDGKDLKGQIVEKGIEAEIIFRLTVQMRNSRSESEDREYDRLISPVNDK GEFFDTATADKTLQDADANGAYCIALKGLYEYVQIKENWKENEQFPRNKL VDNKTWFDQMFKKRYL (SEQ ID NO: 66)
Ref Seq. WP_119623 382.1	
PcCas12a – previously	MAKNFEDFKRLYSLSKTLRFEAKPIGATLDNIVKSGLLDEDEHRAASYVKVKK LIDEYHKVFIDRVLDDGCLPLENKGNNNSLAEEYYSVSRAQDEDAKKKFKFI QQNLSVIAKKLTEDKAYANLFGNKLIESYKDKEDKKKIIDSLLIQFINTAESTQ

known at Cpf1 <i>Prevotella copri</i> Ref Seq. WP_119227 726.1	LDSMSQDEAKELVKEFWGFVTYFYGFFDNRKNMYTAEKSTGIA YRLVNENL PKFIDNIEAFNRAITRPEIQENMGVLYSDFSEYLNVESIQEMFQLDYNNMLLTQK QIDVYNAIIGGKTDDEHDVKIKGINEYINLYNQHKDDKLPKLKALFKQILSDR NAISWLPEEFNSDQEV LNAIKDCYERLAENVLGDKVLKSLGSLADYSLDGIFIR NDLQLTDISQKMFNGWGV IQNAIMQNIKR VAPARKHKESEEDYEKRIAGIFKK ADSFSISYINDCLNEADPNNA YFVENYFATFGAVNTPTMQRENLFALVQNA YT EVAALLHSDYPTVKHLA QDKANVSKIKALLDAIKSLQH FVKPLLKGKDESDDK ERFYGELASLWAE LDTVTPLYNMIRNYMTRKPY SQKKIKLNFENPQLLGGWD ANKEKDYATIILRRNGLYYLAIMDKDSRKL LGKAMP SDGECYEKMVYKFFKD VTTMIPKCSTQLKDVQAYFKVNTDDYVLNSKAFNKPLTITKEVFDLNNVLYGK YKKFQKGYLTATGDNVGYTHAVNVWIKFCMDFLNSYDSTCIYDFSSLKPESYL SLDAFYQDANLLLYKLSFARASVSYINQLVEEGKMYLFQIYNKDFSEYSKGT MHTLYWKALFDERNLADV VYKLNQAEMFYRKKSIENTHPTHPANHPILNKN KDNKKKESLFDYDLIKDRRYTVDKFMFHPITMNFKSVGSENNINQDVKAYLRH ADDMHIIGIDRGERHLLYLVIDLQGNIKEQYSLNEIVNEYNGNTYHTNYHDL DVREEERL KARQSWQT IENIKELKEGYLSQVIHKITQLMVRYHAIVVLEDLSKG FMRSRQKVEKQVYQKFEKMLIDKLNLYVDKKT DVSTPGGLLNAYQLTCKSDS SQKL GKQSGFLFYIPAWNTSKIDPVTG FVNLLDTHSLNSKEKIKAFFSKFDAIRY NKDKKWFENLDYDKFGKKAEDTRTKWTLCTRGMRIDTFRNKEKNSQWDNQ EVDLTTEMKSLLEHY YIDIHGNLKD AISAQTDKAFFTGLLHILKLTLMRNSITG TETDYL VSPVADENGIFYDSRSCGNQLPENADANGAYNIARKGLMLIEQIKNAE DLNNVKFDISNKAWLNFAQQKPYKNG (SEQ ID NO: 67)
ErCas12a – previously known at Cpf1 <i>Eubacterium rectale</i> Ref Seq. WP_119223 642.1	MFSAKLISDILPEFVIHNNNYSASEKEEKTQVIKLSRFATSFKDYFKNRANCFS ANDISSSSCHRIVNDNAEIFFSNALVYRRIVKNLSNDDINKISGDMKDSLKEMSL EEIYSYEKYGEFITQEGISFYNDICGKVNLFMNL YCQKNKENKNLYKLRKLHKQ ILCIADTSYEVYPYKFESDEEVYQSVNGFLDNISSKHIVERLRKIGENYNGYNLDK IYIVSKFYESVSQKTYRDWETINTALEIHYNNILPGNGKSKADKVKKAVKNDLQ KSITEINELVSNYKLCPPDDNIKAET YIHEISHILNNFEAQELKYNPEIHLVESELKA SELKNVLDVIMNAFWCSVFMTEELVDKDN NFYAELEEIYDEIYPVISLYNLVR NYVTQKPYSTKKIKLNF GIPTLADGWSKSKEYSNNAILMRDNL YLGFNAKN KPDKKIIEGNTSENKGDYK KMIYNLLPGPNKMIPKVFLSSTGTGVETYKPSAYILE GYKQNKHLKSSKDFDITFCHDLIDYFKNCIAIHP EWKNFGDFSDTSTYEDISGF YREVELQGYKIDWTYISEKDIDLLQEK GQLYLFQIYNKDFSKSSGNDNLHTM YLKNLFSEENLKDIVLKLNGEAEIFFRKSSIKNPIIHKKSILVNRTYEAEEKDQF GNIQIVRKTI PENIYQELYKYFNDKSDKELSDEAAKLKNVVGHH EAATNIVKDY RYTYDKYFLHMPITINFKANKTSFINDRILQYIAKEKDLHVIGIDRGERNLIYVSV IDTCGNIVEQKSFNIVNGYDYQIKLKQ QEGARQIARKEWKEIGKIKEIKEGYLSL VIHEISKMVIKYNAIAMEDLSYGFKKGRFKVERQVYQKFETMLINKLNLYL VFK DISITENGGLLKGYQLTYIPDKLKNVGHQCGCIFYPAA YTSKIDPTTGFVNIFK FKDLTVDAKREFIKKFDSIRYDSDKNLFCFTFDYNNFITQNTVM SKSSWSVYTY GVRIKRRFVNGRFSNESDITIDTKMEKTLEMTDINWRDGHDLRQDIIDYEVQ HIFEIFKLTVQMRNSLSELED RDYDRLISPVLNENNIFYDSAKAGDALPKDADA NGAYCIALKGLYEIKQITENWKEDGKFSRDKLKISNKDWDFIQNKRYL (SEQ ID NO: 68)
CsCas12a – previously known at Cpf1 <i>Clostridium sp. AF34- 10BH</i>	MNYKTGLEDFIGKESL SKTLRNALIPTESTKIHMEEMGVIRDELRAEQQELK EIMDDYYRAFIEEKL GQIQGIQWNSLFQKMEETMEDISVRKDLDKIQNEKRKEI CCYFTSDKRFKDLFNAKLITDILPNFIKDNKEYTEEEKAEKEQTRVLFQRFATAF TNYFNQRRNNFSEDNISTAISFRIVNENSEIHLQNMRAFQRIEQQYPEEVCGMEE EYKDMLQEWQMKHIYLVDFYDRVLTQPGIEY YNGICGKINEHMNQFCQKNRI NKNDFRMKKLHKQILCKKSSYYEIPRFESDQEVYDALNEFIKTMKEKEIICRCV HLGQKCDDYDLGKIYISSNKYEQISNALYGSWD TIRKCIKEEYMDALPGKGEK KEEKAEAAAKKEEYRSIADIDKIISLYGSEMDRTISAKKCITEICDMAGQISTDPL VCNSDIKLLQNKEKTTEIKTILDSFLHVYQWGQTFIVSDIIEKDSYFYSELEDVLE DFEGITTLYNHVRSYVTQKPYSTVKFKLHFGSPTLANGWSQSKEYDNNAILLM

Ref Seq. WP_118538 418.1	RDQKFYLGIFNVRNKPDKQIIKGHEKEEKGDYKKMIYNLLPGPSKMLPKVFTTS RSGQETYKPSKHILDGYNEKRHIKSSPKFDLGYCWDLDYKECIHKHPDWKN YDFHFSDTKDYEDISGFYREVEMQGYQIKWTYISADEIQKLDEKGQIFLFIYN KDFSVDHSTGKDNLHTMYLKNLFSEENLKDIVLKLNGEAEFFRKASIKTPVVHK KGSVLVNRSTQTVGDKEIRVSIPEEYYTEIYNLHNHIGRGKLSTEAQRYLEER KIKSFTATKDIVKNYRYCCDHYFLHLPITINFKAKS DIAVNERTLAYIAKKEDIHI IGIDRGERNLLYISVVDVHGNIREQRSFNIVNGYDYQQKLKDREKSRDAARKN WEEIEKIKELKEGYLSMVIHYIAQLVVKYNVAVVAMEDLNYGFKTGRFKVERQV YQKFETMLIEKLHYLVFKDREVCEEGLRGYQLTYIPESLKKVVGKQCGFIFYV PAGYTSKIDPTTGFVNLFSEKLTNRRESRQDFVGKFEIRYDRDKKMFESFDY NNYIKKGTMLASTKWVYTNGTRLKRIVVNGKYTSQSMEVELTDAMEKMLQ RAGIEYHDGKDLKGQIVEKGIEAEIIDIFRLTVQMRNSRSESEDREYDRLISPVLN DKGEFFDTATADKTLPODADANGAYCIALKGLYEVKQIKENWKENEQFPRNK LVQDNKTFWDFMQKKRYL (SEQ ID NO: 69)
BhCas12b <i>Bacillus hisashii</i> Ref Seq. WP_095142 515.1	MATRSFILKIEPNEEVKKGLWKTHEVLNHGIAYYMNILKLIRQEAIYEHHEQDP KNPKKVSKAEIQAELWDFVLKMQKCNSTHEVDKDEVFNILRELYEELVPSV EKKGEANQLSNKFLYPLVDPNSQSGKGTASSGRKPRWYNLKIAGDPSWEEKK KWEEDKKKDPLAKILGKLAEYGLIPLFIPYTDSEPIVKEIKWMEKSRNQSVRR LDKDMFIQALERFLSWESWNLKVKEEYKVEKEYKTLEERIKEDIQALKALEQ YEKERQEQLLRDTLNTNEYRLSKRGLRGWREIIQKWLKMDENEPSEKYLEVFK DYQRKHPREAGDYSVYEFSLKKENHFIWRNHPEYPYLYATFCEIDKKKKDAKQ QATFTLADPINHPLWVRFEERSGSLNKNYRILTEQLHTEKLKKKLTVQLDRLIY PTESGGWEEKGKVDIVLLPSRQFYNQIFLDIEEKKGKHAFTYKDESIKFLKGTLG GARVQFDRDHLRRYPHKVESGNVGRIFYNMTVNIEPTESPVSKSLKIHRDDFPK VVNFKPKELTEWIKDSKGKKLKSIGESLEIGLRVMSIDLQGRQAAAASIFEVVD QKPDIEGKLFPIKGTLEYAVHRASFNIKLPGETLVKSREVLKAKAREDNLKL MN QKLNFLRNVLHFQQFEDITEREKRVTKWISRQENS DVPLVYQDELIQIRELMYK PYKDWVAFLLKQLHKKRLEVEIGKEVKHWRKSLSDGRKGLYGISLKNIDEIDRTR KFLLRWSLRPTEPGEVRRLEPGQRFAIDQLNHLNALKEDRLKKMANTIIMHAL GYCYDVRKKKWQAKNPACQIILFEDLSNYPYEEERSRFENSKLMKWSRREIPR QVALQGEIYGLQVGEVGAQFSSRFHAKTGSPGIRCSVVTKEKLQDNRRFFKNLQ REGRLTLDKIAVLKEGDLYPDKGGEKFISLSKDRKCVTTHADINAAQNLQKRF WTRTHGFYKVYCKAYQVDGQTVYIPESKDQKQKIIIEFGEGYFILKDGVEYEWV NAGKLKIKKGSSKQSSSELVDSIDLKDSFDLASELKGEKLMLYRDPSPGNVFPSPD KWMAAGVFFGKLERILISKLNTNQYSISTIEDDSSKQSM (SEQ ID NO: 70)
ThCas12b <i>Thermomona s hydrotherma lis</i> Ref Seq. WP_072754 838	MSEKTTQRAYTLRLNRASGECAVCQNNSCDCWHDALWATHKAVNRGAKAFG DWLLTLRGGLCHTLVEMEVPAKGNPPQRPTDQERRDRRVLLALSWLSVEDE HGAPKEFIVATGRDSADDRACKVEEKLREILEKRDQFEHEIDAWLQDCGPSLK AHIREDAVWVNRRALFDAVERIKTLTWEEAWDFLEPFFGTQYFAGIGDGKDK DDAEGPARQGEKAKDLVQKAGQWLSARFGIGTGADFMMSMAEAYEKIAK WAS QAQNGDNGKATIEKLACALRPSEPPTLDTVLKCSGPGHKSATREYLKTLDDKKS TVTQEDLNQLRKLADEDARNCRKKVGKKGKKPWADEVLDKDVENSELTLYLQ DNSPARHREFSVMLDHAARRVSMASWIKKAEQRRRQFESDAQKLKNLQERA PSAVEWLDRFCESRSMTTGANTGSGYRIRKRAIEGWSYVQAWAEASCDTED KRIAAARKVQADPEIEKFGDIQLFEALAADAICVWRDQEGTQNP SILIDYVTG KTAEHNQKRFKVPAYRHPDEL RHPVFCDFGNSRWSIQFAIHKEIRD RDKGAKQ DTRQLQNRHGLKMRLWNGRSMTDVNLHWSSKRLTADLALDQNP NPNPTEVT RADRLGRAASSAFDHVKIKNVFNEKEWNGRLQAPRAELDRIAKLEE QGKTEQA EKLRKRLRWYVSFSPCLSPSGPFIVYAGQHNIQPKRSQYAPHAQANKGRARL AQLILSRPLDLRILSVDLGHRFAAACAVWETLSSDAFRREIQGLNVL AGGSGEG DLFLHVEMTGDDGKRRTTVYRRIGPDQLLDNTPHPAPWARLDRQFLIKLQGED EGVREASNEELWTVHKLEVEVGRTVPLIDRMVRSFGKTEKQKERLKKLRELG WISAMPNEPSAETDEKEGEIRSISRVSDEL MSSALGTLRLALKRHGNRARI AFA MTADYKPMPPGGQKYFHEAKEASKNDDETKRRDNQIEFLQDALSLWHDLFSS

	PDWEDNEAKKLWQNHIAITLPNYQTPEEISAELKRVERNNKKRKENRDKLRTAA KALAENDQLRQHLHDTWKERWESDDQQWKERLRLSLKDWIFPRGKAEDNPSIR HVGGLSITRINTISGLYQILKAFKMRPEPDDLRLKNIPQKGDDELENFNRRLLER DRLREQRVKQLASRIIEAALGVGRIKIPKNGKLPKRPRTTVDTTPCHAVVIESLKT YRPDDLRLTRRENRLMQWSSAKVRKYLKEGCELYGLHFLEVPANYTSRQCSR TGLPGIRCDDVPTGDFLKAPWWRRRAINTAREKNGGDAKDRFLVDLYDHLNNL QSKGEALPATVRVPRQGGNLFIAQAQLDDTNKERRAIQADLNAAANIGLRALL DPDWRGRWWYVPCKDGTSEPALDRIEGSTAFNDVRSPLPTGDNSSRRAPREIEN LWRDPSPGSDLESGETWSPTRAYWDTVQSRVIELLRHAGLPTS (SEQ ID NO: 71)
LsCas12b <i>Laceyella sacchari</i> WP_132221 894.1	MSIRSFKLKLTSGVNAEQLRRGLWRTHQLINDGIAYYMNWLVLRRQEDLFI RNKETNEIEKRSKEEIQAVLLERVHKQQQRNQWSGEVDEQTLQALRQLYEEI VPSVIGKSGNASLKAFFLGPLVDPNNKTTKDVSKSGPTPKWKKMKDAGDPN WVQEYKEYMAERQTLVRLEEMGLIPLFPMYTDEVGDIHWLPQASGYTRTWDR DMFQQAIERLLSWESWNRRVRERRAQFEKKTTHDFASRFESDVQWMNKLREY EAQDEKSLEENAFAPNEPYALTKKALRGWERVYHSWMRLDSAASEEAYWQE VATCQTAMRGEFGDPAIYQFLAQKENHDIWRGYPERVIDFAELNHLQRELRA KEDATFTLPDSVDHPLWVRYEAPGGTNIHGVDLVQDTKRNLTLILDKFILPDEN GSWHEVKKVPFSLAKSKQFHRQVWLQEEQKQKKREVVFYDYSTNPLHLGTLA GAKLQWDRNFLNKRQQQIEETGEIGKVFVNISVDVRPAVEVKNRGLQNGLGK ALTVLTHPDGKIVTGWKAQLEKWWGESGRVSSLGLDSLSEGLRVMSIDLGG RTSATVSVFEITKEAPDNPYKFFYQLEGTEMFAVHQRSFLLALPGENPPQKIKQ MREIRWKERNRIKQVQDQLSAILRLHKKVNEDERIQAIKLLQKVASWQLNEEI ATAWNQALSQLYSKAKENDLQWNQAIKNAHHQLEPVVGKQISLWRKDLSTG RQGIAGLSLWSIEELEATKKLLTRWSKRSREPGVVKRIERFETFAKIQIHHINQV KENRLKQLANLIVMTALGYKYDQEQKKWIEVYPACQVVLFFENLRSYRFSFERS RRENKKLMEWSHRISPKLVQMKGELFGLQVADVYAAYSRYHGRTGAPGIRC HALTEADLRNETNIIHELIEAGFIKEEHRPYLQQGDLVPWSGGELFATLQKPYD NPRILTLHADINAAQNIQKRFWHPSMWFRVNCESVMEGEIVTYVPKNKTVHKK QGKTRFRVKVEGSDVYEWAKWSKNRNKNTFSSITERKPPSSMILFRDPSGTFFK EQEWVEQKTFWGVQSMIQAAYMKKTIVQRMEE (SEQ ID NO: 72)
DtCas12b <i>Dsulfonatron um thiodismutan s</i> WP_031386 437	MVLGRKDDTAELRRALWTTHEHVNLAFAEVERVLLRCRGRSYWTLDRRGDP VHVPESQVAEDALAMAREAQRNRNGWPVVGEDDEILLALRYLYEQIVPSCLLDD LGKPLKGDAQKIGTNYAGPLFSDTCRRDEGKDVACCGPFHEVAGKYLALPE WATPISKQEFDGKDASHLRFKATGGDDAFFRVSIEKANAWYEDPANQDALKN KAYNKDDWKKEKDKGISSWAVKYIQKQLQLGQDPRTEVRRKLWLELGLLPLF IPVFDKTMVGNLWNLAVRLALAHLLSWESWNHRAVQDQALAKRDELAA LFLGMEDGFAGLREYELRRNESIKQHAPEPVDPRPYVVSGRALRSWTRVREEWL RHGDTQESRKNICNRLQDRLRGKFGDPDVFHWAEDGQEALWKERDCVTSFS LLNDADGLLEKRKGYALMTFADARLHPRWAMYEAAGGSNLRTYQIRKTENGL WADVLLSPRNESAAVEEKTFFNRLAPSGQLSNVSFDQIQKGSKMVGRCRYQS ANQQFEGLLGGAELFDRKRIANEQHGATDLASKPGHVWFKLTLDRPQAPQG WLDGKGRPALPPEAKHFKTALSNSKSFADQVRPGLRVLSVDLGVRSFAACSVF ELVRGGPDQGTYPFAADGRTVDDPEKLWAKHERSFKITLPGENPSRKEEARRA AMEELRSLNGDIRRLKAILRLSVLQEDDPRTEHLRLFMEDIAVDDPAKSALNAEL FKGFGDDRFRSTPDLWKQHCHFFHDKAEKVVAERFSRWRTEPRKSSSWQDW RERRGYAGGKSYWAVTYLEAVRGLILRWNMGRRTYGEVNRQDKKQFGTVAS ALLHHINQLKEDRIKTGADMIIQAARGFVPRKNGAGWVQVHEPCRLILFEDLAR YRFRTRSRRENSRLMRWSHREIVNEVGMQGEYGLHVDTEAGFSSRYLASS GAPGVRCRHLVEEDFHDGLPGMHLVGELDWLLPKDKDRTANEARLLGGMV RPGMLVPWDGGELFATLNAASQLHVIHADINAAQNLQRRFWGRCGEAIRVCN QLSVDGSTRYEMAKAPKARLLGALQQLKNGDAPFHLTSIPNSQKPENSYVMTP TNAGKKYRAGPGEKSSGEEDELALDIVEQAEELAQGRKTFRRDPSGVFFAPDR WLPSEIYWSRIRRIWQVTLERNSSGRQERAEMDEMPY (SEQ ID NO: 73)

[0399] The multi-flap prime editors described herein may also comprise Cas12a (Cpf1) (dCpf1) variants that may be used as a guide nucleotide sequence-programmable DNA-binding protein domain. The Cas12a (Cpf1) protein has a RuvC-like endonuclease domain that is similar to the RuvC domain of Cas9 but does not have a HNH endonuclease domain, and the N-terminal of Cas12a (Cpf1) does not have the alpha-helical recognition lobe of Cas9. It was shown in Zetsche *et al.*, *Cell*, 163, 759–771, 2015 (which is incorporated herein by reference) that, the RuvC-like domain of Cas12a (Cpf1) is responsible for cleaving both DNA strands and inactivation of the RuvC-like domain inactivates Cas12a (Cpf1) nuclease activity.

[0400] In some embodiments, the napDNAbp is a single effector of a microbial CRISPR-Cas system. Single effectors of microbial CRISPR-Cas systems include, without limitation, Cas9, Cas12a (Cpf1), Cas12b1 (C2c1), Cas13a (C2c2), and Cas12c (C2c3). Typically, microbial CRISPR-Cas systems are divided into Class 1 and Class 2 systems. Class 1 systems have multi-subunit effector complexes, while Class 2 systems have a single protein effector. For example, Cas9 and Cas12a (Cpf1) are Class 2 effectors. In addition to Cas9 and Cas12a (Cpf1), three distinct Class 2 CRISPR-Cas systems (Cas12b1, Cas13a, and Cas12c) have been described by Shmakov *et al.*, “Discovery and Functional Characterization of Diverse Class 2 CRISPR Cas Systems”, *Mol. Cell*, 2015 Nov 5; 60(3): 385–397, the entire contents of which are hereby incorporated by reference.

[0401] Effectors of two of the systems, Cas12b1 and Cas12c, contain RuvC-like endonuclease domains related to Cas12a. A third system, Cas13a contains an effector with two predicted HEPN RNase domains. Production of mature CRISPR RNA is tracrRNA-independent, unlike production of CRISPR RNA by Cas12b1. Cas12b1 depends on both CRISPR RNA and tracrRNA for DNA cleavage. Bacterial Cas13a has been shown to possess a unique RNase activity for CRISPR RNA maturation distinct from its RNA-activated single-stranded RNA degradation activity. These RNase functions are different from each other and from the CRISPR RNA-processing behavior of Cas12a. See, e.g., East-Seletsky, *et al.*, “Two distinct RNase activities of CRISPR-Cas13a enable guide-RNA processing and RNA detection”, *Nature*, 2016 Oct 13;538(7624):270-273, the entire contents of which are hereby incorporated by reference. *In vitro* biochemical analysis of Cas13a in *Leptotrichia shahii* has shown that Cas13a is guided by a single CRISPR RNA and can be programmed to cleave ssRNA targets carrying complementary protospacers. Catalytic residues in the two conserved HEPN domains mediate cleavage. Mutations in the catalytic residues generate catalytically inactive RNA-binding proteins. See e.g., Abudayyeh *et al.*, “C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector”, *Science*, 2016 Aug 5; 353(6299), the entire contents of which are hereby incorporated by reference.

[0402] The crystal structure of *Alicyclobaccillus acidoterrastris* Cas12b1 (AacC2c1) has been reported in complex with a chimeric single-molecule guide RNA (sgRNA). See e.g., Liu *et al.*, “C2c1-sgRNA Complex Structure Reveals RNA-Guided DNA Cleavage Mechanism”, *Mol. Cell*,

2017 Jan 19;65(2):310-322, the entire contents of which are hereby incorporated by reference. The crystal structure has also been reported in *Alicyclobacillus acidoterrestris* C2c1 bound to target DNAs as ternary complexes. See e.g., Yang et al., “PAM-dependent Target DNA Recognition and Cleavage by C2C1 CRISPR-Cas endonuclease”, *Cell*, 2016 Dec 15;167(7):1814-1828, the entire contents of which are hereby incorporated by reference. Catalytically competent conformations of AacC2c1, both with target and non-target DNA strands, have been captured independently positioned within a single RuvC catalytic pocket, with C2c1-mediated cleavage resulting in a staggered seven-nucleotide break of target DNA. Structural comparisons between C2c1 ternary complexes and previously identified Cas9 and Cpf1 counterparts demonstrate the diversity of mechanisms used by CRISPR-Cas9 systems.

[0403] In some embodiments, the napDNAbp may be a C2c1, a C2c2, or a C2c3 protein. In some embodiments, the napDNAbp is a C2c1 protein. In some embodiments, the napDNAbp is a Cas13a protein. In some embodiments, the napDNAbp is a Cas12c protein. In some embodiments, the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a naturally-occurring Cas12b1 (C2c1), Cas13a (C2c2), or Cas12c (C2c3) protein. In some embodiments, the napDNAbp is a naturally-occurring Cas12b1 (C2c1), Cas13a (C2c2), or Cas12c (C2c3) protein.

H. Cas9 circular permutants

[0404] In various embodiments, the multi-flap prime editors disclosed herein may comprise a circular permutant of Cas9.

[0405] The term “circularly permuted Cas9” or “circular permutant” of Cas9 or “CP-Cas9”) refers to any Cas9 protein, or variant thereof, that occurs or has been modified to be engineered as a circular permutant variant, which means the N-terminus and the C-terminus of a Cas9 protein (e.g., a wild type Cas9 protein) have been topically rearranged. Such circularly permuted Cas9 proteins, or variants thereof, retain the ability to bind DNA when complexed with a guide RNA (gRNA). See, Oakes et al., “Protein Engineering of Cas9 for enhanced function,” *Methods Enzymol*, 2014, 546: 491–511 and Oakes et al., “CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification,” *Cell*, January 10, 2019, 176: 254-267, each of which are incorporated herein by reference. The instant disclosure contemplates any previously known CP-Cas9 or use a new CP-Cas9 so long as the resulting circularly permuted protein retains the ability to bind DNA when complexed with a guide RNA (gRNA).

[0406] Any of the Cas9 proteins described herein, including any variant, ortholog, or naturally occurring Cas9 or equivalent thereof, may be reconfigured as a circular permutant variant.

[0407] In various embodiments, the circular permutants of Cas9 may have the following structure: N-terminus-[original C-terminus] – [optional linker] – [original N-terminus]-C-terminus.

[0408] As an example, the present disclosure contemplates the following circular permutants of canonical *S. pyogenes* Cas9 (1368 amino acids of UniProtKB - Q99ZW2 (CAS9_STRP1) (numbering is based on the amino acid position in SEQ ID NO: 18)):

N-terminus-[1268-1368]-[optional linker]-[1-1267]-C-terminus;
 N-terminus-[1168-1368]-[optional linker]-[1-1167]-C-terminus;
 N-terminus-[1068-1368]-[optional linker]-[1-1067]-C-terminus;
 N-terminus-[968-1368]-[optional linker]-[1-967]-C-terminus;
 N-terminus-[868-1368]-[optional linker]-[1-867]-C-terminus;
 N-terminus-[768-1368]-[optional linker]-[1-767]-C-terminus;
 N-terminus-[668-1368]-[optional linker]-[1-667]-C-terminus;
 N-terminus-[568-1368]-[optional linker]-[1-567]-C-terminus;
 N-terminus-[468-1368]-[optional linker]-[1-467]-C-terminus;
 N-terminus-[368-1368]-[optional linker]-[1-367]-C-terminus;
 N-terminus-[268-1368]-[optional linker]-[1-267]-C-terminus;
 N-terminus-[168-1368]-[optional linker]-[1-167]-C-terminus;
 N-terminus-[68-1368]-[optional linker]-[1-67]-C-terminus; or
 N-terminus-[10-1368]-[optional linker]-[1-9]-C-terminus, or the corresponding circular permutants of other Cas9 proteins (including other Cas9 orthologs, variants, etc).

[0409] In particular embodiments, the circular permuant Cas9 has the following structure (based on *S. pyogenes* Cas9 (1368 amino acids of UniProtKB - Q99ZW2 (CAS9_STRP1) (numbering is based on the amino acid position in SEQ ID NO: 18)):

N-terminus-[102-1368]-[optional linker]-[1-101]-C-terminus;
 N-terminus-[1028-1368]-[optional linker]-[1-1027]-C-terminus;
 N-terminus-[1041-1368]-[optional linker]-[1-1043]-C-terminus;
 N-terminus-[1249-1368]-[optional linker]-[1-1248]-C-terminus; or
 N-terminus-[1300-1368]-[optional linker]-[1-1299]-C-terminus, or the corresponding circular permutants of other Cas9 proteins (including other Cas9 orthologs, variants, etc).

[0410] In still other embodiments, the circular permuant Cas9 has the following structure (based on *S. pyogenes* Cas9 (1368 amino acids of UniProtKB - Q99ZW2 (CAS9_STRP1) (numbering is based on the amino acid position in SEQ ID NO: 18)):

N-terminus-[103-1368]-[optional linker]-[1-102]-C-terminus;
 N-terminus-[1029-1368]-[optional linker]-[1-1028]-C-terminus;
 N-terminus-[1042-1368]-[optional linker]-[1-1041]-C-terminus;
 N-terminus-[1250-1368]-[optional linker]-[1-1249]-C-terminus; or
 N-terminus-[1301-1368]-[optional linker]-[1-1300]-C-terminus, or the corresponding circular permutants of other Cas9 proteins (including other Cas9 orthologs, variants, etc).

[0411] In some embodiments, the circular permutant can be formed by linking a C-terminal fragment of a Cas9 to an N-terminal fragment of a Cas9, either directly or by using a linker, such as an amino acid linker. In some embodiments, The C-terminal fragment may correspond to the C-terminal 95% or more of the amino acids of a Cas9 (e.g., amino acids about 1300-1368), or the C-terminal 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5% or more of a Cas9 (e.g., any one of SEQ ID NOs: 77-86). The N-terminal portion may correspond to the N-terminal 95% or more of the amino acids of a Cas9 (e.g., amino acids about 1-1300), or the N-terminal 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5% or more of a Cas9 (e.g., of SEQ ID NO: 18).

[0412] In some embodiments, the circular permutant can be formed by linking a C-terminal fragment of a Cas9 to an N-terminal fragment of a Cas9, either directly or by using a linker, such as an amino acid linker. In some embodiments, the C-terminal fragment that is rearranged to the N-terminus includes or corresponds to the C-terminal 30% or less of the amino acids of a Cas9 (e.g., amino acids 1012-1368 of SEQ ID NO: 18). In some embodiments, the C-terminal fragment that is rearranged to the N-terminus, includes or corresponds to the C-terminal 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the amino acids of a Cas9 (e.g., the Cas9 of SEQ ID NO: 18). In some embodiments, the C-terminal fragment that is rearranged to the N-terminus, includes or corresponds to the C-terminal 410 residues or less of a Cas9 (e.g., the Cas9 of SEQ ID NO: 18). In some embodiments, the C-terminal portion that is rearranged to the N-terminus, includes or corresponds to the C-terminal 410, 400, 390, 380, 370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, or 10 residues of a Cas9 (e.g., the Cas9 of SEQ ID NO: 18). In some embodiments, the C-terminal portion that is rearranged to the N-terminus includes or corresponds to the C-terminal 357, 341, 328, 120, or 69 residues of a Cas9 (e.g., the Cas9 of SEQ ID NO: 18).

[0413] In other embodiments, circular permutant Cas9 variants may be defined as a topological rearrangement of a Cas9 primary structure based on the following method, which is based on *S. pyogenes* Cas9 of SEQ ID NO: 18: (a) selecting a circular permutant (CP) site corresponding to an internal amino acid residue of the Cas9 primary structure, which dissects the original protein into two halves: an N-terminal region and a C-terminal region; (b) modifying the Cas9 protein sequence (e.g., by genetic engineering techniques) by moving the original C-terminal region (comprising the CP site amino acid) to precede the original N-terminal region, thereby forming a new N-terminus of the Cas9 protein that now begins with the CP site amino acid residue. The CP site can be located in any domain of the Cas9 protein, including, for example, the helical-II domain, the RuvCIII domain, or the CTD domain. For example, the CP site may be located (relative the *S. pyogenes* Cas9 of SEQ ID NO: 18) at original amino acid residue 181, 199, 230, 270, 310, 1010, 1016, 1023, 1029, 1041, 1247, 1249,

or 1282. Thus, once relocated to the N-terminus, original amino acid 181, 199, 230, 270, 310, 1010, 1016, 1023, 1029, 1041, 1247, 1249, or 1282 would become the new N-terminal amino acid.

Nomenclature of these CP-Cas9 proteins may be referred to as Cas9-CP¹⁸¹, Cas9-CP¹⁹⁹, Cas9-CP²³⁰, Cas9-CP²⁷⁰, Cas9-CP³¹⁰, Cas9-CP¹⁰¹⁰, Cas9-CP¹⁰¹⁶, Cas9-CP¹⁰²³, Cas9-CP¹⁰²⁹, Cas9-CP¹⁰⁴¹, Cas9-CP¹²⁴⁷, Cas9-CP¹²⁴⁹, and Cas9-CP¹²⁸², respectively. This description is not meant to be limited to making CP variants from SEQ ID NO: 18, but may be implemented to make CP variants in any Cas9 sequence, either at CP sites that correspond to these positions, or at other CP sites entirely. This description is not meant to limit the specific CP sites in any way. Virtually any CP site may be used to form a CP-Cas9 variant.

[0414] Exemplary CP-Cas9 amino acid sequences, based on the Cas9 of SEQ ID NO: 18, are provided below in which linker sequences are indicated by underlining and optional methionine (M) residues are indicated in bold. It should be appreciated that the disclosure provides CP-Cas9 sequences that do not include a linker sequence or that include different linker sequences. It should be appreciated that CP-Cas9 sequences may be based on Cas9 sequences other than that of SEQ ID NO: 18 and any examples provided herein are not meant to be limiting. Exemplary CP-Cas9 sequences are as follows:

CP name	Sequence	SEQ ID NO:
CP1012	DYKVDYDVRKMIKSEGEIGKATAKYFFYSNIMNFFKTEITLA NGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNI KKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDS PTVAYSVLVVAKEKGKSKKLKSVKELLGITIMERSSEKNI DFLEAKGYKEVKKDLIKLPKYSLEFENGRKRMLASAGEL QKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQ HKHYLDEIIEQISEFSKRVILADANLDKVL SAYNKHDKPIRE QAENIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVL DATL IHQSITGLYETRIDLSQLGGDGGSGGSGGSGGSGGSGGSGG KKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK KNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSFHRL EESFLVEEDKKHERHPIFGNIVDEVAYH EKYPTIYHLRKKLV DSTDKADLRILIY LALAHMIKFRGHFLIE GDLNPDNSDVKLFQVLVQTYNQLFEENPINASGVDAKAILS ARLSKSRRL ENLIAQLPGEKKNGLFGNLI ALSGLTPNFKSNF DLAEDAKLQLSKD TYDDDLNLLAQIGDQYADLFLAAKNL SDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALV RQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEK MDGTEELLV KLNREDLLRKQRTFDNGSIPHQIHLGELHAILR RQEDFY PFLKDNREKIEKILTFRIPIYVVGPLARGNSRFAWMT RKSEETITPWNFEVVDK GASAQSFIERMTNFDKNLPNEKV LPKHSLLEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAI VDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNAS LGTYHDLLKIIKDKDFLDNEENEDILEDIVLTTLTFEDREMIE ERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDK QSGKTILDFLKSDFANRNFMLIHDDSLTFKEDIQKAQVSG QGDSLHEHIANLAGSPA IKKGI LQTVKVVDELVKVMGRHKP ENIVIMARENQTTQKGQKNSRERMKRIE EGIKELGSQILKE HPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDV	SEQ ID NO: 77

CP name	Sequence	SEQ ID NO:
	DHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKMK KNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQ LVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS VSDFRKDFQFYKVREINNYHHAHDAYLNAVVG TALIKKYPK LESEFVYG	
CP1028	EIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETG EIVWDKGRDFATVRKVL SMPQVNIVKKTEVQTGGFSKESIL PKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEK GKSKKLKSVKELLGITIMERSSEFEKNPIDFLEAKGYKEVKKD LIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNF LYLASHYEKLKGSPEDEQKQLFVEQHKHYLDEIIEQISEFS KRVILADANLDKVL SAYNKH RDKPIREQAENIIHLFTLTNLG APAAFKYFDTTIDRKRYTSTKEVLDATLIHQ SITGLYETRIDL SQLGGDGGSGGSGGSGGSGGMDKKYSIGLAIGTNSVGWAVITDEYKV PSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTAR RRYTRRKNRICYLQEIFS NEMAKVDDSF FHRLEESFLVEEDK KHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLR LIYLALAHMIKFRGHFLIEGDLNPDNSD VDKLFIQLVQTYNQ LFEENPINASGVDAKAILSARLSKSRRL ENLIAQLPGEKKNG LFGNLIASLGLTPNFKS NFDLAEDAKL QLSKDTYDDDLNLLAQIGDQYADFLAAKNLSDAILLSDI LRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLP EYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEE LLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY PFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETI TPWNFEVVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLL YEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKT NRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHD LLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKY AHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTIL DFLKSDGFANRNFMLIHDDSLTFKEDIQKAQVSGQGDSLH EHIANLAGSPAIIKKGILQTVKVDELVKVMGRHKPENIVIE MARENQTTQKGQKNSRERMKRIEIGIKELGSQILKEHPVEN TQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVDHIVP QSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKMKKNYWR QLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVET RQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS VSDFRKDFQFYKVREINNYHHAHDAYLNAVVG TALIKKYPKLES EFVYGDYKVYDVRKMIKSEQ	SEQ ID NO: 78
CP1041	NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFAT VRKVL SMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKK DWDPKKYGGFDSPTVAYSVLVVAKEK GKSKKLKSVKELL GITIMERSSEFEKNPIDFLEAKGYKEVKKD LIIKLPKYSLFELE NGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDK VL SAYNKH RDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTI DRKRYTSTKEVLDATLIHQ SITGLYETRIDLSQLGGDGGSGG SGGSGGSGGSGGSGGDKKYSIGLAIGTNSVGWAVITDEYKV PSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTAR RRYTRRKNRICYLQEIFS NEMAKVDDSF FHRLEESFLVEEDK KHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLR LIYLALAHMIKFRGHFLIEGDLNPDNSD VDKLFIQLVQTYNQ LFEENPINASGVDAKAILSARLSKSRRL ENLIAQLPGEKKNG	SEQ ID NO: 79

CP name	Sequence	SEQ ID NO:
	LFGNLIASLGLTPNFKSNFDLAEDAKLQLSKD TYDDDLN LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAG YIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQR TFDNGSIPHQIHLGELHAILRRQEDFY PFLKDNREKIEKILTR IPYYVGPLARGNSRFAWMTRKSEETITPWNFEVVVDKGASA QSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYF KKIECFDSVEISGVEDRFNASLGTYHDLKIIKDKDFLDNEE NEDILEDIVLTTLTFEDREMIEERLKTYAHLFDDKVMKQLKR RRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF QLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAICKG ILQTVKVVDDELVKVMGRHKPENIVIAMARENQTTQKGQKN SRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQN GRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTR SDKNRGKSDNVPSEEVVKMKKNYWRQLLNAKLITQRKFDN LTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMN TKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVREINNY HHAHDAYLNAVVG TALIKKYPKLESEFVYGDYKVYDVRK MIAKSEQEIGKATAKYFFYS	
CP1249	PEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKV LSAYNKHDKPIREQAENIHLFTLNLGAPAAFKYFDTTIDR KRYTSTKEVL DATLIHQSI TGLYETRIDLSQLGGDGGSGSG <u>GSGSGSGSGSGGMDKKYSIGLAIGTNSVGWAVITDEYKV</u> PSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTAR RRYTRRKNRICYLQEIFSNEMAKVDDSFHRLEESFLVEEDK KHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVSTDKADLR LIYLALAHMIKFRGHFLIEGDLNPDNSDVKLFIQLVQTYNQ LFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNG LFGNLIASLGLTPNFKSNFDLAEDAKLQLSKD TYDDDLN LLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAG YIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQR TFDNGSIPHQIHLGELHAILRRQEDFY PFLKDNREKIEKILTR IPYYVGPLARGNSRFAWMTRKSEETITPWNFEVVVDKGASA QSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYF KKIECFDSVEISGVEDRFNASLGTYHDLKIIKDKDFLDNEE NEDILEDIVLTTLTFEDREMIEERLKTYAHLFDDKVMKQLKR RRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNF QLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAICKG ILQTVKVVDDELVKVMGRHKPENIVIAMARENQTTQKGQKN SRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQN GRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTR SDKNRGKSDNVPSEEVVKMKKNYWRQLLNAKLITQRKFDN LTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMN TKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVREINNY HHAHDAYLNAVVG TALIKKYPKLESEFVYGDYKVYDVRK MIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLI ETNGETGEIVWDKGRDFATVRKVL SMPQVNIVKKTEVQTG GFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVL VVAKEVGKSKKLKSVKELLGITIMERSSEKPNIDFLEAKG	SEQ ID NO: 80

CP name	Sequence	SEQ ID NO:
	YKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGS	
CPI300	KPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSTGLYETRIDLSQLGGDGGSGGSGGSGGSGGSGGSGGDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRLENLIAQLPGEKKNGLFGNLIASLG LTPNFKSNFDLAEDAKLQLSKDYYDDDLNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEFYKFIKPILEKMDGTEELLVVLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPLKDNREKIEKILTFRIPIYVGPLARGNSRFAWMTRKSEETITPWNFEVVDKGASASQSFIERMTNFDKNLPNEKVLPHKSLLEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKHKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGLSELDKAGFIKRLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDEQKQLFVEQHKHYLDEIIIEQISEFSKRVLADANLDKVL SAYNKH RD	SEQ ID NO: 81

[0415] The Cas9 circular permutants may be useful in the multi-flap prime editing constructs described herein. Exemplary C-terminal fragments of Cas9, based on the Cas9 of SEQ ID NO: 18, which may be rearranged to an N-terminus of Cas9, are provided below. It should be appreciated that such C-terminal fragments of Cas9 are exemplary and are not meant to be limiting. These exemplary CP-Cas9 fragments have the following sequences:

CP name	Sequence	SEQ ID NO:
CP1012 C-terminal fragment	DYKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDEQKQLFVEQHKHYLDEIIIEQISEFSKRVLADANLDKVL SAYNKH RDKP IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSTGLYETRIDLSQLGGD	SEQ ID NO: 82

CP name	Sequence	SEQ ID NO:
CP1028 C-terminal fragment	EIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFLENGRKRMLASAGELQKGNELALPSKYVNFLLYLASHYEKLKGPEDNEQKQLFVEQHKHYLDEIIQISEFSKRVILADANLDKVL SAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSI TGLYETRIDLSQLGGD	SEQ ID NO: 83
CP1041 C-terminal fragment	NIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLEFLENGRKRMLASAGELQKGNELALPSKYVNFLLYLASHYEKLKGPEDNEQKQLFVEQHKHYLDEIIQISEFSKRVILADANLDKVL SAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSI TGLYETRIDLSQLGGD	SEQ ID NO: 84
CP1249 C-terminal fragment	PEDNEQKQLFVEQHKHYLDEIIQISEFSKRVILADANLDKVL SAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSI TGLYETRIDLSQLGGD	SEQ ID NO: 85
CP1300 C-terminal fragment	KPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSI TGLYETRIDLSQLGGD	SEQ ID NO: 86

I. Cas9 variants with modified PAM specificities

[0416] The multi-flap prime editors of the present disclosure may also comprise Cas9 variants with modified PAM specificities. Some aspects of this disclosure provide Cas9 proteins that exhibit activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3', where N is A, C, G, or T) at its 3'-end. In some embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NGG-3' PAM sequence at its 3'-end. In some embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NNG-3' PAM sequence at its 3'-end. In some embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NNA-3' PAM sequence at its 3'-end. In some embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NNC-3' PAM sequence at its 3'-end. In some embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NNT-3' PAM sequence at its 3'-end. In some embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NGT-3' PAM sequence at its 3'-end. In some embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NGA-3' PAM sequence at its 3'-end. In some embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NGC-3' PAM sequence at its 3'-end. In some embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NAA-3' PAM sequence at its 3'-end. In some embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NAC-3' PAM sequence at its 3'-end. In some embodiments, the Cas9 protein exhibits

activity on a target sequence comprising a 5'-NAT-3' PAM sequence at its 3'-end. In still other embodiments, the Cas9 protein exhibits activity on a target sequence comprising a 5'-NAG-3' PAM sequence at its 3'-end.

[0417] It should be appreciated that any of the amino acid mutations described herein, (e.g., A262T) from a first amino acid residue (e.g., A) to a second amino acid residue (e.g., T) may also include mutations from the first amino acid residue to an amino acid residue that is similar to (e.g., conserved) the second amino acid residue. For example, mutation of an amino acid with a hydrophobic side chain (e.g., alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, or tryptophan) may be a mutation to a second amino acid with a different hydrophobic side chain (e.g., alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, or tryptophan). For example, a mutation of an alanine to a threonine (e.g., a A262T mutation) may also be a mutation from an alanine to an amino acid that is similar in size and chemical properties to a threonine, for example, serine. As another example, mutation of an amino acid with a positively charged side chain (e.g., arginine, histidine, or lysine) may be a mutation to a second amino acid with a different positively charged side chain (e.g., arginine, histidine, or lysine). As another example, mutation of an amino acid with a polar side chain (e.g., serine, threonine, asparagine, or glutamine) may be a mutation to a second amino acid with a different polar side chain (e.g., serine, threonine, asparagine, or glutamine). Additional similar amino acid pairs include, but are not limited to, the following: phenylalanine and tyrosine; asparagine and glutamine; methionine and cysteine; aspartic acid and glutamic acid; and arginine and lysine. The skilled artisan would recognize that such conservative amino acid substitutions will likely have minor effects on protein structure and are likely to be well tolerated without compromising function. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to a threonine may be an amino acid mutation to a serine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to an arginine may be an amino acid mutation to a lysine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to an isoleucine, may be an amino acid mutation to an alanine, valine, methionine, or leucine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to a lysine may be an amino acid mutation to an arginine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to an aspartic acid may be an amino acid mutation to a glutamic acid or asparagine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to a valine may be an amino acid mutation to an alanine, isoleucine, methionine, or leucine. In some embodiments, any amino of the amino acid mutations provided herein from one amino acid to a glycine may be an amino acid mutation to an alanine. It should be appreciated, however, that additional conserved amino acid residues would be recognized by the skilled artisan and any of the amino acid mutations to other conserved amino acid residues are also within the scope of this disclosure.

[0418] In some embodiments, the Cas9 protein comprises a combination of mutations that exhibit activity on a target sequence comprising a 5'-NAA-3' PAM sequence at its 3'-end. In some embodiments, the combination of mutations are present in any one of the clones listed in Table 1. In some embodiments, the combination of mutations are conservative mutations of the clones listed in Table 1. In some embodiments, the Cas9 protein comprises the combination of mutations of any one of the Cas9 clones listed in Table 1.

[0419] Table 1: NAA PAM Clones

Mutations from wild-type SpCas9 (e.g., SEQ ID NO: 18)
D177N, K218R, D614N, D1135N, P1137S, E1219V, A1320V, A1323D, R1333K
D177N, K218R, D614N, D1135N, E1219V, Q1221H, H1264Y, A1320V, R1333K
A10T, I322V, S409I, E427G, G715C, D1135N, E1219V, Q1221H, H1264Y, A1320V, R1333K
A367T, K710E, R1114G, D1135N, P1137S, E1219V, Q1221H, H1264Y, A1320V, R1333K
A10T, I322V, S409I, E427G, R753G, D861N, D1135N, K1188R, E1219V, Q1221H, H1264H, A1320V, R1333K
A10T, I322V, S409I, E427G, R654L, V743I, R753G, M1021T, D1135N, D1180G, K1211R, E1219V, Q1221H, H1264Y, A1320V, R1333K
A10T, I322V, S409I, E427G, V743I, R753G, E762G, D1135N, D1180G, K1211R, E1219V, Q1221H, H1264Y, A1320V, R1333K
A10T, I322V, S409I, E427G, R753G, D1135N, D1180G, K1211R, E1219V, Q1221H, H1264Y, S1274R, A1320V, R1333K
A10T, I322V, S409I, E427G, A589S, R753G, D1135N, E1219V, Q1221H, H1264H, A1320V, R1333K
A10T, I322V, S409I, E427G, R753G, E757K, G865G, D1135N, E1219V, Q1221H, H1264Y, A1320V, R1333K
A10T, I322V, S409I, E427G, R654L, R753G, E757K, D1135N, E1219V, Q1221H, H1264Y, A1320V, R1333K
A10T, I322V, S409I, E427G, K599R, M631A, R654L, K673E, V743I, R753G, N758H, E762G, D1135N, D1180G, E1219V, Q1221H, Q1256R, H1264Y, A1320V, A1323D, R1333K
A10T, I322V, S409I, E427G, R654L, K673E, V743I, R753G, E762G, N869S, N1054D, R1114G, D1135N, D1180G, E1219V, Q1221H, H1264Y, A1320V, A1323D, R1333K
A10T, I322V, S409I, E427G, R654L, L727I, V743I, R753G, E762G, R859S, N946D, F1134L, D1135N, D1180G, E1219V, Q1221H, H1264Y, N1317T, A1320V, A1323D, R1333K
A10T, I322V, S409I, E427G, R654L, K673E, V743I, R753G, E762G, N803S, N869S, Y1016D, G1077D, R1114G, F1134L, D1135N, D1180G, E1219V, Q1221H, H1264Y, V1290G, L1318S, A1320V, A1323D, R1333K
A10T, I322V, S409I, E427G, R654L, K673E, V743I, R753G, E762G, N803S, N869S, Y1016D, G1077D, R1114G, F1134L, D1135N, K1151E, D1180G, E1219V, Q1221H, H1264Y, V1290G, L1318S, A1320V, R1333K
A10T, I322V, S409I, E427G, R654L, K673E, V743I, R753G, E762G, N803S, N869S, Y1016D, G1077D, R1114G, F1134L, D1135N, D1180G, E1219V, Q1221H, H1264Y, V1290G, L1318S, A1320V, A1323D, R1333K
A10T, I322V, S409I, E427G, R654L, K673E, F693L, V743I, R753G, E762G, N803S, N869S, L921P, Y1016D, G1077D, F1080S, R1114G, D1135N, D1180G, E1219V, Q1221H, H1264Y, L1318S, A1320V, A1323D, R1333K
A10T, I322V, S409I, E427G, E630K, R654L, K673E, V743I, R753G, E762G, Q768H, N803S, N869S, Y1016D, G1077D, R1114G, F1134L, D1135N, D1180G, E1219V, Q1221H, H1264Y, L1318S, A1320V, R1333K
A10T, I322V, S409I, E427G, R654L, K673E, F693L, V743I, R753G, E762G, Q768H, N803S, N869S, Y1016D, G1077D, R1114G, F1134L, D1135N, D1180G, E1219V, Q1221H, G1223S, H1264Y, L1318S, A1320V, R1333K

A10T, I322V, S409I, E427G, R654L, K673E, F693L, V743I, R753G, E762G, N803S, N869S, L921P, Y1016D, G1077D, F1801S, R1114G, D1135N, D1180G, E1219V, Q1221H, H1264Y, L1318S, A1320V, A1323D, R1333K
A10T, I322V, S409I, E427G, R654L, V743I, R753G, M1021T, D1135N, D1180G, K1211R, E1219V, Q1221H, H1264Y, A1320V, R1333K
A10T, I322V, S409I, E427G, R654L, K673E, V743I, R753G, E762G, M673I, N803S, N869S, G1077D, R1114G, D1135N, V1139A, D1180G, E1219V, Q1221H, A1320V, R1333K
A10T, I322V, S409I, E427G, R654L, K673E, V743I, R753G, E762G, N803S, N869S, R1114G, D1135N, E1219V, Q1221H, A1320V, R1333K

[0420] In some embodiments, the Cas9 protein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of a Cas9 protein as provided by any one of the variants of Table 1. In some embodiments, the Cas9 protein comprises an amino acid sequence that is at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a Cas9 protein as provided by any one of the variants of Table 1.

[0421] In some embodiments, the Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3') at its 3' end as compared to *Streptococcus pyogenes* Cas9 as provided by SEQ ID NO: 18. In some embodiments, the Cas9 protein exhibits an activity on a target sequence having a 3' end that is not directly adjacent to the canonical PAM sequence (5'-NGG-3') that is at least 5-fold increased as compared to the activity of *Streptococcus pyogenes* Cas9 as provided by SEQ ID NO: 18 on the same target sequence. In some embodiments, the Cas9 protein exhibits an activity on a target sequence that is not directly adjacent to the canonical PAM sequence (5'-NGG-3') that is at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of *Streptococcus pyogenes* as provided by SEQ ID NO: 18 on the same target sequence. In some embodiments, the 3' end of the target sequence is directly adjacent to an AAA, GAA, CAA, or TAA sequence. In some embodiments, the Cas9 protein comprises a combination of mutations that exhibit activity on a target sequence comprising a 5'-NAC-3' PAM sequence at its 3'-end. In some embodiments, the combination of mutations are present in any one of the clones listed in Table 2. In some embodiments, the combination of mutations are conservative mutations of the clones listed in Table 2. In some embodiments, the Cas9 protein comprises the combination of mutations of any one of the Cas9 clones listed in Table 2.

[0422] Table 2: NAC PAM Clones

MUTATIONS FROM WILD-TYPE SPCAS9 (E.G., SEQ ID NO: 18)
T472I, R753G, K890E, D1332N, R1335Q, T1337N
I1057S, D1135N, P1301S, R1335Q, T1337N
T472I, R753G, D1332N, R1335Q, T1337N
D1135N, E1219V, D1332N, R1335Q, T1337N
T472I, R753G, K890E, D1332N, R1335Q, T1337N
I1057S, D1135N, P1301S, R1335Q, T1337N

T472I, R753G, D1332N, R1335Q, T1337N
T472I, R753G, Q771H, D1332N, R1335Q, T1337N
E627K, T638P, K652T, R753G, N803S, K959N, R1114G, D1135N, E1219V, D1332N, R1335Q, T1337N
E627K, T638P, K652T, R753G, N803S, K959N, R1114G, D1135N, K1156E, E1219V, D1332N, R1335Q, T1337N
E627K, T638P, V647I, R753G, N803S, K959N, G1030R, I1055E, R1114G, D1135N, E1219V, D1332N, R1335Q, T1337N
E627K, E630G, T638P, V647A, G687R, N767D, N803S, K959N, R1114G, D1135N, E1219V, D1332G, R1335Q, T1337N
E627K, T638P, R753G, N803S, K959N, R1114G, D1135N, E1219V, N1266H, D1332N, R1335Q, T1337N
E627K, T638P, R753G, N803S, K959N, I1057T, R1114G, D1135N, E1219V, D1332N, R1335Q, T1337N
E627K, T638P, R753G, N803S, K959N, R1114G, D1135N, E1219V, D1332N, R1335Q, T1337N
E627K, M631I, T638P, R753G, N803S, K959N, Y1036H, R1114G, D1135N, E1219V, D1251G, D1332G, R1335Q, T1337N
E627K, T638P, R753G, N803S, V875I, K959N, Y1016C, R1114G, D1135N, E1219V, D1251G, D1332G, R1335Q, T1337N, I1348V
K608R, E627K, T638P, V647I, R654L, R753G, N803S, T804A, K848N, V922A, K959N, R1114G, D1135N, E1219V, D1332N, R1335Q, T1337N
K608R, E627K, T638P, V647I, R753G, N803S, V922A, K959N, K1014N, V1015A, R1114G, D1135N, K1156N, E1219V, N1252D, D1332N, R1335Q, T1337N
K608R, E627K, R629G, T638P, V647I, A711T, R753G, K775R, K789E, N803S, K959N, V1015A, Y1036H, R1114G, D1135N, E1219V, N1286H, D1332N, R1335Q, T1337N
K608R, E627K, T638P, V647I, T740A, R753G, N803S, K948E, K959N, Y1016S, R1114G, D1135N, E1219V, N1286H, D1332N, R1335Q, T1337N
K608R, E627K, T638P, V647I, T740A, N803S, K948E, K959N, Y1016S, R1114G, D1135N, E1219V, N1286H, D1332N, R1335Q, T1337N
I670S, K608R, E627K, E630G, T638P, V647I, R653K, R753G, I795L, K797N, N803S, K866R, K890N, K959N, Y1016C, R1114G, D1135N, E1219V, D1332N, R1335Q, T1337N
K608R, E627K, T638P, V647I, T740A, G752R, R753G, K797N, N803S, K948E, K959N, V1015A, Y1016S, R1114G, D1135N, E1219V, N1266H, D1332N, R1335Q, T1337N
I570T, A589V, K608R, E627K, T638P, V647I, R654L, Q716R, R753G, N803S, K948E, K959N, Y1016S, R1114G, D1135N, E1207G, E1219V, N1234D, D1332N, R1335Q, T1337N
K608R, E627K, R629G, T638P, V647I, R654L, Q740R, R753G, N803S, K959N, N990S, T995S, V1015A, Y1036D, R1114G, D1135N, E1207G, E1219V, N1234D, N1266H, D1332N, R1335Q, T1337N
I562F, V565D, I570T, K608R, L625S, E627K, T638P, V647I, R654I, G752R, R753G, N803S, N808D, K959N, M1021L, R1114G, D1135N, N1177S, N1234D, D1332N, R1335Q, T1337N
I562F, I570T, K608R, E627K, T638P, V647I, R753G, E790A, N803S, K959N, V1015A, Y1036H, R1114G, D1135N, D1180E, A1184T, E1219V, D1332N, R1335Q, T1337N
I570T, K608R, E627K, T638P, V647I, R654H, R753G, E790A, N803S, K959N, V1015A, R1114G, D1127A, D1135N, E1219V, D1332N, R1335Q, T1337N
I570T, K608R, L625S, E627K, T638P, V647I, R654I, T703P, R753G, N803S, N808D, K959N, M1021L, R1114G, D1135N, E1219V, D1332N, R1335Q, T1337N
I570S, K608R, E627K, E630G, T638P, V647I, R653K, R753G, I795L, N803S, K866R, K890N, K959N, Y1016C, R1114G, D1135N, E1219V, D1332N, R1335Q, T1337N
I570T, K608R, E627K, T638P, V647I, R654H, R753G, E790A, N803S, K959N, V1016A, R1114G, D1135N, E1219V, K1246E, D1332N, R1335Q, T1337N
K608R, E627K, T638P, V647I, R654L, K673E, R753G, E790A, N803S, K948E, K959N, R1114G, D1127G, D1135N, D1180E, E1219V, N1286H, D1332N, R1335Q, T1337N

K608R, L625S, E627K, T638P, V647I, R654I, I670T, R753G, N803S, N808D, K959N, M1021L, R1114G, D1135N, E1219V, N1286H, D1332N, R1335Q, T1337N
E627K, M631V, T638P, V647I, K710E, R753G, N803S, N808D, K948E, M1021L, R1114G, D1135N, E1219V, D1332N, R1335Q, T1337N, S1338T, H1349R

[0423] In some embodiments, the Cas9 protein comprises an amino acid sequence that is at least 80% identical to the amino acid sequence of a Cas9 protein as provided by any one of the variants of Table 2. In some embodiments, the Cas9 protein comprises an amino acid sequence that is at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of a Cas9 protein as provided by any one of the variants of Table 2.

[0424] In some embodiments, the Cas9 protein exhibits an increased activity on a target sequence that does not comprise the canonical PAM (5'-NGG-3') at its 3' end as compared to *Streptococcus pyogenes* Cas9 as provided by SEQ ID NO: 18. In some embodiments, the Cas9 protein exhibits an activity on a target sequence having a 3' end that is not directly adjacent to the canonical PAM sequence (5'-NGG-3') that is at least 5-fold increased as compared to the activity of *Streptococcus pyogenes* Cas9 as provided by SEQ ID NO: 18 on the same target sequence. In some embodiments, the Cas9 protein exhibits an activity on a target sequence that is not directly adjacent to the canonical PAM sequence (5'-NGG-3') that is at least 10-fold, at least 50-fold, at least 100-fold, at least 500-fold, at least 1,000-fold, at least 5,000-fold, at least 10,000-fold, at least 50,000-fold, at least 100,000-fold, at least 500,000-fold, or at least 1,000,000-fold increased as compared to the activity of *Streptococcus pyogenes* as provided by SEQ ID NO: 18 on the same target sequence. In some embodiments, the 3' end of the target sequence is directly adjacent to an AAC, GAC, CAC, or TAC sequence.

[0425] In some embodiments, the Cas9 protein comprises a combination of mutations that exhibit activity on a target sequence comprising a 5'-NAT-3' PAM sequence at its 3'-end. In some embodiments, the combination of mutations are present in any one of the clones listed in Table 3. In some embodiments, the combination of mutations are conservative mutations of the clones listed in Table 3. In some embodiments, the Cas9 protein comprises the combination of mutations of any one of the Cas9 clones listed in Table 3.

[0426] Table 3: NAT PAM Clones

MUTATIONS FROM WILD-TYPE SPCAS9 (E.G., SEQ ID NO: 18)
K961E, H985Y, D1135N, K1191N, E1219V, Q1221H, A1320A, P1321S, R1335L
D1135N, G1218S, E1219V, Q1221H, P1249S, P1321S, D1322G, R1335L
V743I, R753G, E790A, D1135N, G1218S, E1219V, Q1221H, A1227V, P1249S, N1286K, A1293T, P1321S, D1322G, R1335L, T1339I
F575S, M631L, R654L, V748I, V743I, R753G, D853E, V922A, R1114G D1135N, G1218S, E1219V, Q1221H, A1227V, P1249S, N1286K, A1293T, P1321S, D1322G, R1335L, T1339I
F575S, M631L, R654L, R664K, R753G, D853E, V922A, R1114G D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, N1286K, P1321S, D1322G, R1335L
M631L, R654L, R753G, K797E, D853E, V922A, D1012A, R1114G D1135N, G1218S, E1219V, Q1221H, P1249S, N1317K, P1321S, D1322G, R1335L

F575S, M631L, R654L, R664K, R753G, D853E, V922A, R1114G, Y1131C, D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, P1321S, D1322G, R1335L
F575S, M631L, R654L, R664K, R753G, D853E, V922A, R1114G, Y1131C, D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, P1321S, D1322G, R1335L
F575S, D596Y, M631L, R654L, R664K, R753G, D853E, V922A, R1114G, Y1131C, D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, Q1256R, P1321S, D1322G, R1335L
F575S, M631L, R654L, R664K, K710E, V750A, R753G, D853E, V922A, R1114G, Y1131C, D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, P1321S, D1322G, R1335L
F575S, M631L, K649R, R654L, R664K, R753G, D853E, V922A, R1114G, Y1131C, D1135N, K1156E, D1180G, G1218S, E1219V, Q1221H, P1249S, P1321S, D1322G, R1335L
F575S, M631L, R654L, R664K, R753G, D853E, V922A, R1114G, Y1131C, D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, P1321S, D1322G, R1335L
F575S, M631L, R654L, R664K, R753G, D853E, V922A, I1057G, R1114G, Y1131C, D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, N1308D, P1321S, D1322G, R1335L
M631L, R654L, R753G, D853E, V922A, R1114G, Y1131C, D1135N, E1150V, D1180G, G1218S, E1219V, Q1221H, P1249S, P1321S, D1332G, R1335L
M631L, R654L, R664K, R753G, D853E, I1057V, Y1131C, D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, P1321S, D1332G, R1335L
M631L, R654L, R664K, R753G, I1057V, R1114G, Y1131C, D1135N, D1180G, G1218S, E1219V, Q1221H, P1249S, P1321S, D1332G, R1335L

[0427] The above description of various napDNAbps which can be used in connection with the presently disclosed multi-flap prime editors is not meant to be limiting in any way. The multi-flap prime editors may comprise the canonical SpCas9, or any ortholog Cas9 protein, or any variant Cas9 protein—including any naturally occurring variant, mutant, or otherwise engineered version of Cas9—that is known or which can be made or evolved through a directed evolutionary or otherwise mutagenic process. In various embodiments, the Cas9 or Cas9 variants have a nickase activity, i.e., only cleave one strand of the target DNA sequence. In other embodiments, the Cas9 or Cas9 variants have inactive nucleases, i.e., are “dead” Cas9 proteins. Other variant Cas9 proteins that may be used are those having a smaller molecular weight than the canonical SpCas9 (e.g., for easier delivery) or having modified or rearranged primary amino acid structure (e.g., the circular permutant formats). The multi-flap prime editors described herein may also comprise Cas9 equivalents, including Cas12a/Cpf1 and Cas12b proteins which are the result of convergent evolution. The napDNAbps used herein (e.g., SpCas9, Cas9 variant, or Cas9 equivalents) may also contain various modifications that alter/enhance their PAM specificities. Lastly, the application contemplates any Cas9, Cas9 variant, or Cas9 equivalent which has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.9% sequence identity to a reference Cas9 sequence, such as a reference SpCas9 canonical sequences or a reference Cas9 equivalent (e.g., Cas12a/Cpf1).

[0428] In a particular embodiment, the Cas9 variant having expanded PAM capabilities is SpCas9 (H840A) VRQR (SEQ ID NO: 87), which has the following amino acid sequence (with the V, R, Q, R substitutions relative to the SpCas9 (H840A) of SEQ ID NO: 51 being shown in bold underline. In addition, the methionine residue in SpCas9 (H840) was removed for SpCas9 (H840A) VRQR):

DKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATR
 LKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDE
 VAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVKLFIQ
 LVQTYNQLFEENPINASGVDAKAILSARLSKSRLENLIAQLPGEKKNGLFGNLIALSLGLTP
 NFKSNFDLAEDAQLQLSKDQYDDDLNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTE
 ITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFY
 KFIKPILEKMDGTEELLVKNLREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDN
 REKIEKILTRIPYVVGPLARGNSRFAWMTRKSEETITPWNFEVVVDKGASQSFIERMTNF
 DKNLPNEKVLPHKSLLEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRK
 VTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKHKDKDFLDNEENEDILEDIVL
 TLTLFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDF
 LKSDGFANRNFQMQLIHDDSLTFKEDIQKAQVSGQDLSLHEHIANLAGSPAICKGILQTVKV
 VDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEKGKELGSQILKEHPVENT
 QLQNEKLYLYLQNGRDMYVDQELDNRLSDYDVAIVPQSFLKDDSIDNKVLTRSDKNR
 GKSDNVPSEEVVKMKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRLVET
 RQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKREINNYHHAH
 DAYLNAVVGTAIIKKYPKLESEFVYGDYKVDVRKMIKSEGEIGKATAKYFFYSNIMNFF
 KTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNIKKTEVQTGGFSKE
 SILPKRNSDKLIARKKDWDPKKYGGFVSPTVAYSVLVVAKEGKSKKLKSVKELLGITIM
 ERSSFEKNPIDFLEAKGYKEVKKDLIKLPKYSLEFENGRKRMLASARELQKGNELALPSK
 YVNFLYLASHYEKLKGPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSA
 YNKHARDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKQYRSTKEVLDTLIHQSTIGLY
 ETRIDLSQLGGD (SEQ ID NO: 87)

[0429] In another particular embodiment, the Cas9 variant having expanded PAM capabilities is

SpCas9 (H840A) VRER, which has the following amino acid sequence (with the V, R, E, R substitutions relative to the SpCas9 (H840A) of SEQ ID NO: 51 being shown in bold underline . In addition, the methionine residue in SpCas9 (H840) was removed for SpCas9 (H840A) VRER):

DKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATR
 LKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDE
 VAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVKLFIQ
 LVQTYNQLFEENPINASGVDAKAILSARLSKSRLENLIAQLPGEKKNGLFGNLIALSLGLTP
 NFKSNFDLAEDAQLQLSKDQYDDDLNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTE
 ITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFY
 KFIKPILEKMDGTEELLVKNLREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDN
 REKIEKILTRIPYVVGPLARGNSRFAWMTRKSEETITPWNFEVVVDKGASQSFIERMTNF
 DKNLPNEKVLPHKSLLEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRK
 VTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKHKDKDFLDNEENEDILEDIVL
 TLTLFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDF
 LKSDGFANRNFQMQLIHDDSLTFKEDIQKAQVSGQDLSLHEHIANLAGSPAICKGILQTVKV
 VDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEKGKELGSQILKEHPVENT
 QLQNEKLYLYLQNGRDMYVDQELDNRLSDYDVAIVPQSFLKDDSIDNKVLTRSDKNR
 GKSDNVPSEEVVKMKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRLVET
 RQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKREINNYHHAH
 DAYLNAVVGTAIIKKYPKLESEFVYGDYKVDVRKMIKSEGEIGKATAKYFFYSNIMNFF
 KTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNIKKTEVQTGGFSKE
 SILPKRNSDKLIARKKDWDPKKYGGFVSPTVAYSVLVVAKEGKSKKLKSVKELLGITIM
 ERSSFEKNPIDFLEAKGYKEVKKDLIKLPKYSLEFENGRKRMLASARELQKGNELALPSK
 YVNFLYLASHYEKLKGPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSA
 YNKHARDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKERYRSTKEVLDTLIHQSTIGLY
 ETRIDLSQLGGD (SEQ ID NO: 88)

[0430] In some embodiments, the napDNAbp that functions with a non-canonical PAM sequence is an Argonaute protein. One example of such a nucleic acid programmable DNA binding protein is an

Argonaute protein from *Natronobacterium gregoryi* (NgAgo). NgAgo is a ssDNA-guided endonuclease. NgAgo binds 5' phosphorylated ssDNA of ~24 nucleotides (gDNA) to guide it to its target site and will make DNA double-strand breaks at the gDNA site. In contrast to Cas9, the NgAgo-gDNA system does not require a protospacer-adjacent motif (PAM). Using a nuclease inactive NgAgo (dNgAgo) can greatly expand the bases that may be targeted. The characterization and use of NgAgo have been described in Gao *et al.*, *Nat Biotechnol.*, 2016 Jul;34(7):768-73. PubMed PMID: 27136078; Swarts *et al.*, *Nature*. 507(7491) (2014):258-61; and Swarts *et al.*, *Nucleic Acids Res.* 43(10) (2015):5120-9, each of which is incorporated herein by reference.

[0431] In some embodiments, the napDNAbp is a prokaryotic homolog of an Argonaute protein. Prokaryotic homologs of Argonaute proteins are known and have been described, for example, in Makarova K., et al., "Prokaryotic homologs of Argonaute proteins are predicted to function as key components of a novel system of defense against mobile genetic elements", *Biol Direct*. 2009 Aug 25;4:29. doi: 10.1186/1745-6150-4-29, the entire contents of which is hereby incorporated by reference. In some embodiments, the napDNAbp is a *Marinitoga piezophila* Argonaute (MpAgo) protein. The CRISPR-associated *Marinitoga piezophila* Argonaute (MpAgo) protein cleaves single-stranded target sequences using 5'-phosphorylated guides. The 5' guides are used by all known Argonautes. The crystal structure of an MpAgo-RNA complex shows a guide strand binding site comprising residues that block 5' phosphate interactions. This data suggests the evolution of an Argonaute subclass with noncanonical specificity for a 5'-hydroxylated guide. See, e.g., Kaya et al., "A bacterial Argonaute with noncanonical guide RNA specificity", *Proc Natl Acad Sci U S A*. 2016 Apr 12;113(15):4057-62, the entire contents of which are hereby incorporated by reference). It should be appreciated that other argonaute proteins may be used, and are within the scope of this disclosure.

[0432] Some aspects of the disclosure provide Cas9 domains that have different PAM specificities. Typically, Cas9 proteins, such as Cas9 from *S. pyogenes* (spCas9), require a canonical NGG PAM sequence to bind a particular nucleic acid region. This may limit the ability to edit desired bases within a genome. In some embodiments, the base editing fusion proteins provided herein may need to be placed at a precise location, for example where a target base is placed within a 4 base region (e.g., a "editing window"), which is approximately 15 bases upstream of the PAM. See Komor, A.C., *et al.*, "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage" *Nature* 533, 420-424 (2016), the entire contents of which are hereby incorporated by reference. Accordingly, in some embodiments, any of the fusion proteins provided herein may contain a Cas9 domain that is capable of binding a nucleotide sequence that does not contain a canonical (e.g., NGG) PAM sequence. Cas9 domains that bind to non-canonical PAM sequences have been described in the art and would be apparent to the skilled artisan. For example, Cas9 domains that bind non-canonical PAM sequences have been described in Kleinstiver, B. P., *et al.*, "Engineered CRISPR-Cas9

nucleases with altered PAM specificities” *Nature* 523, 481-485 (2015); and Kleinstiver, B. P., *et al.*, “Broadening the targeting range of *Staphylococcus aureus* CRISPR-Cas9 by modifying PAM recognition” *Nature Biotechnology* 33, 1293-1298 (2015); the entire contents of each are hereby incorporated by reference.

[0433] For example, a napDNAbp domain with altered PAM specificity, such as a domain with at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity with wild type *Francisella novicida* Cpf1 (D917, E1006, and D1255) (SEQ ID NO: 74), which has the following amino acid sequence:

```
MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKAKQIIDKYHQFFIE
EILSSVCISEDLLQNYSDVYFKLKKSDDDNLQKDFKSAKDTIKKQISEYIKDSEKFNLFNQ
NLIDAKKGQESDLILWLKQSKDNGIELFKANS DITDIDEALEIISFKGWTTYFKGFHENRK
NVYSSNDIPTSIHYRIVDDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKT
SEVNQRVFSLDEVFEIANFNYYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINLYSQQIND
KTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTMQSFYEQIAAFKTVEEKSIKETLS
LLFDDLKAQKLDLSKIYFKNDKSLDLSQQVFDDYSVIGTAVLEYITQQIAPKNLDNPSKKE
QELIAKTEKAKYLSLETIKLALAEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNL
QISIKYQNQGGKDLLQASAEDDVKAIKDLLDQTNLLHKLKIFHISQSEDKANILDKDEHF
YLVFEECYFELANIVPLYNKIRNYITQKPYSEKFKLNFENSTLANGWDKNKEPDNTAILFI
KDDKYYLGVMMNKKNNKIFDDKAIKENKGEGYKKIVYKLLPGANKMLPKVFFSAKSIKFI
NPSEDILRIRNHSTHTKNGSPQKGYEKFENIEDCRKFIDFYKQSISKHPEWKDFGFRFSDTQ
RYNSIDEFYREVENQGYKLTFFENISESYIDSVVNQGLYLFQIYNKDFSAYS SKGRPNLHTLY
WKALFDERNLQDVVYKLNGEAELFYRKQSIKPKITHPAKEAIANKNDNPKKESVFEYDLI
KDKRFTEDKFFFHCPIITNFKSSGANKFNDEINLLLKEKANDVHILSIDRGERHLAYYTLVD
GKGNIIKQDFTFNIIGNDRMKTNYHDKLAAIEKDRDSARKDWKKNNIKEMKEGYLSQVH
EIAKLVEIYNAIVVFEDLNFQFKRGRFKVEKQVYQKLEKMLIEKLNLYLVFKDNEFDKTGGV
LRAYQLTAPFETFKKMGKQTGIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFSKFD
KICYNLDKGYFEFSFDYKNFGDKAAKGKWTIASFGSRLINFRNSDKNHNWDTREVPYPTKE
LEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTILQMRNSKTGTEDLYLISPVAD
VNGNFFDSRQAPKNMPQDADANGAYHIGLGLMLLGRKNNQEGKKLNLVIKNEEYFEFV
QNRNN (SEQ ID NO: 74)
```

[0434] An additional napDNAbp domain with altered PAM specificity, such as a domain having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity with wild type *Geobacillus thermodenitrificans* Cas9 (SEQ ID NO: 75), which has the following amino acid sequence:

```
MKYKIGLDIGITSIGWAVINLDIPRIEDLGVRIFDRAENPKTGESLALPRRLARSARRRLRRR
KHLERIRRLFVREGILTKEELNKLFEKKHEIDVWQLRVEALDRKLNNDELARILLHLAKR
RGFRSNRKSERTNKENSTMLKHIEENQSILSSYRTVAEMVVKDPKFSHLKRNKEDNYTNTV
ARDDLEREIKLIFAKQREYGNIVCTEAFEHEYISIWASQRPFASKDDIEKKVGFCTFEPKEKR
APKATYTFQSFTVWEHINKLRLVSPGGIRALTDDERRLIYKQAFHKNKITFHDVRTLLNLPD
DTRFKGLLYDRNTTLKENEKVRFLELGAYHKIRKAIDSVYGKGAASFRPIDFDTFGYALT
MFKDDTDIRSILRNEYEQNGKR MENLADKVYDEELIEELLNLSFSKFGHLSLKALRNILPY
MEQGEVYSTACERAGYTFTGPKKKQKTVLLPNIPPIANPVVMRALTQARKVVNAIIKKYGS
PVSIIHELARELSQSFDERRKMQKEQEGNRKKNETAIRQLVEYGLTLNPTGLDIVKFKLWSE
QNGKCAYSLQPIEIERLLEPGYTEVDHVIPYSRSLDDSYTNKVLVLTENREKGNRTPAEYL
GLGSERWQQFETFVLTNKQFSKKRDRLLRLHYDENEENEKFNRLNDTRYISRFLANFIR
EHLKFADSDDKQKVYTVNGRITAHLSRWNFNKNREESNLHHAVDAAIVACTTPSDIARVT
AFYQRREQNKELSKKTDPPQFPQWPHFADELQARLSKNPKESIKALNLGNYDNEKLESLQP
VFSRMPKRSITGAHQETLRRYIGIDERSGKIQTVVKKKLSEIQLDKTGHFPMYKGESDPR
```

TYEAIQRLLLEHNNDPKKAFQEPLYKPKKNGELGPIIRTIKIIDTTNQVIPLNDGKTVAYNSNI
VRVDVFEKDGKYYCVPIYTIDMMKGILPNKAIEPNKPYSEWKEMTEDYTFRFSLYPNDLIRI
EFPREKTIKTAVGEEIKIKDLFAYYQTIDSSNGGLSLVSHDNNFSLRSIGSRTLKRFEKYQVDV
LGNIYKVRGEKRVGVASSSHSKAGETIRPL (SEQ ID NO: 75)

[0435] In some embodiments, the nucleic acid programmable DNA binding protein (napDNAbp) is a nucleic acid programmable DNA binding protein that does not require a canonical (NGG) PAM sequence. In some embodiments, the napDNAbp is an argonaute protein. One example of such a nucleic acid programmable DNA binding protein is an Argonaute protein from *Natronobacterium gregoryi* (NgAgo). NgAgo is a ssDNA-guided endonuclease. NgAgo binds 5' phosphorylated ssDNA of ~24 nucleotides (gDNA) to guide it to its target site and will make DNA double-strand breaks at the gDNA site. In contrast to Cas9, the NgAgo–gDNA system does not require a protospacer-adjacent motif (PAM). Using a nuclease inactive NgAgo (dNgAgo) can greatly expand the bases that may be targeted. The characterization and use of NgAgo have been described in Gao *et al.*, *Nat Biotechnol.*, 34(7): 768-73 (2016), PubMed PMID: 27136078; Swarts *et al.*, *Nature*, 507(7491): 258-61 (2014); and Swarts *et al.*, *Nucleic Acids Res.* 43(10) (2015): 5120-9, each of which is incorporated herein by reference. The sequence of *Natronobacterium gregoryi* Argonaute is provided in SEQ ID NO: 76.

[0436] The disclosed fusion proteins may comprise a napDNAbp domain having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity with wild type *Natronobacterium gregoryi* Argonaute (SEQ ID NO: 76), which has the following amino acid sequence:

MTVIDLDSTTTADELTSGHTYDISVTLTGVDNTDEQHPRMSLAFEQDNGERRYITLWKNT
TPKDVFTYDYATGSTYIFTNIDYEVKDGYNLTATYQTTVENATAQEVGTTDEDETFAAGGEP
LDHHLDDALNETPDDAETESDSGHVMTSFASRDQLPEWTLHTYTLTATDGAKTDEYARR
TLAYTVRQELYTDHDAAPVATDGLMLLTPEPLGETPLDLDCGVRVEADETRTLDTYTTAKDR
LLARELVEEGLKRSLWDDYLVRGIDEVLSKEPVLTCDLHERYDLSVEVGHSGRAYLHI
NFRHRFVPKLTLADIDDDNIYPGLRVKTTYRPRRGHIVWGLRDECATDSLNTLGNQSVVAY
HRNNQTPINTDLLDAIEAADRRVVETRRQGHGDDAVSFPQELLAVEPNTHQIKQFASDGFH
QQARSKTRLSASRCSEKAQAFARLDPVRLNGSTVEFSSEFFTGNNEQQLRLLYENGESVLT
FRDGARGAHPDETFSKGIVNPPESFEVAVVLPEQQADTCKAQWDTMADLLNQAGAPPTRS
ETVQYDAFSSPESISLNVAGAI DPSEVDAAFVVLPPDQEGFADLASPTETYDELKKALANM
GIYSQMAYFDRFRDAKIFYTRNVALGLLAAAGGVAFTTEHAMPGDADMFIGIDVSRYPED
GASGQINIAATATAVYKDGITLGHSSSTRPQLGEKLQSTDVRDIMKNAILGYQQVTGESPTHI
VIHRDGMNEDLDPATEFLNEQGVEYDIVEIRKQPQTRLLAVSDVQYDTPVKSI AAINQNEP
RATVATFGAPEYLATR DGGGLPRPIQIERVAGETDIETLTRQVYLLSQSHIQVHNSTARLPITT
AYADQASTHATKGYLVQTGAFESNVGFL (SEQ ID NO: 76)

[0437] In addition, any available methods may be utilized to obtain or construct a variant or mutant Cas9 protein. The term “mutation,” as used herein, refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or a deletion or insertion of one or more residues within a sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook,

Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)). Mutations can include a variety of categories, such as single base polymorphisms, microduplication regions, indel, and inversions, and is not meant to be limiting in any way. Mutations can include “loss-of-function” mutations which is the normal result of a mutation that reduces or abolishes a protein activity. Most loss-of-function mutations are recessive, because in a heterozygote the second chromosome copy carries an unmutated version of the gene coding for a fully functional protein whose presence compensates for the effect of the mutation. Mutations also embrace “gain-of-function” mutations, which is one which confers an abnormal activity on a protein or cell that is otherwise not present in a normal condition. Many gain-of-function mutations are in regulatory sequences rather than in coding regions, and can therefore have a number of consequences. For example, a mutation might lead to one or more genes being expressed in the wrong tissues, these tissues gaining functions that they normally lack. Because of their nature, gain-of-function mutations are usually dominant.

[0438] Mutations can be introduced into a reference Cas9 protein using site-directed mutagenesis. Older methods of site-directed mutagenesis known in the art rely on sub-cloning of the sequence to be mutated into a vector, such as an M13 bacteriophage vector, that allows the isolation of single-stranded DNA template. In these methods, one anneals a mutagenic primer (i.e., a primer capable of annealing to the site to be mutated but bearing one or more mismatched nucleotides at the site to be mutated) to the single-stranded template and then polymerizes the complement of the template starting from the 3' end of the mutagenic primer. The resulting duplexes are then transformed into host bacteria and plaques are screened for the desired mutation. More recently, site-directed mutagenesis has employed PCR methodologies, which have the advantage of not requiring a single-stranded template. In addition, methods have been developed that do not require sub-cloning. Several issues must be considered when PCR-based site-directed mutagenesis is performed. First, in these methods it is desirable to reduce the number of PCR cycles to prevent expansion of undesired mutations introduced by the polymerase. Second, a selection must be employed in order to reduce the number of non-mutated parental molecules persisting in the reaction. Third, an extended-length PCR method is preferred in order to allow the use of a single PCR primer set. And fourth, because of the non-template-dependent terminal extension activity of some thermostable polymerases it is often necessary to incorporate an end-polishing step into the procedure prior to blunt-end ligation of the PCR-generated mutant product.

[0439] Mutations may also be introduced by directed evolution processes, such as phage-assisted continuous evolution (PACE) or phage-assisted noncontinuous evolution (PANCE). The term “phage-assisted continuous evolution (PACE),” as used herein, refers to continuous evolution that employs phage as viral vectors. The general concept of PACE technology has been described, for example, in International PCT Application, PCT/US2009/056194, filed September 8, 2009, published

as WO 2010/028347 on March 11, 2010; International PCT Application, PCT/US2011/066747, filed December 22, 2011, published as WO 2012/088381 on June 28, 2012; U.S. Application, U.S. Patent No. 9,023,594, issued May 5, 2015, International PCT Application, PCT/US2015/012022, filed January 20, 2015, published as WO 2015/134121 on September 11, 2015, and International PCT Application, PCT/US2016/027795, filed April 15, 2016, published as WO 2016/168631 on October 20, 2016, the entire contents of each of which are incorporated herein by reference. Variant Cas9s may also be obtain by phage-assisted non-continuous evolution (PANCE),” which as used herein, refers to non-continuous evolution that employs phage as viral vectors. PANCE is a simplified technique for rapid in vivo directed evolution using serial flask transfers of evolving ‘selection phage’ (SP), which contain a gene of interest to be evolved, across fresh *E. coli* host cells, thereby allowing genes inside the host *E. coli* to be held constant while genes contained in the SP continuously evolve. Serial flask transfers have long served as a widely-accessible approach for laboratory evolution of microbes, and, more recently, analogous approaches have been developed for bacteriophage evolution. The PANCE system features lower stringency than the PACE system.

[0440] Any of the references noted above which relate to Cas9 or Cas9 equivalents are hereby incorporated by reference in their entireties, if not already stated so.

J. Divided napDNAbp domains for split PE delivery

[0441] In various embodiments, the prime editors described herein may be delivered to cells as two or more fragments which become assembled inside the cell (either by passive assembly, or by active assembly, such as using split intein sequences) into a reconstituted prime editor. In some cases, the self assembly may be passive whereby the two or more prime editor fragments associate inside the cell covalently or non-covalently to reconstitute the prime editor. In other cases, the self-assembly may be catalyzed by dimerization domains installed on each of the fragments. Examples of dimerization domains are described herein. In still other cases, the self-assembly may be catalyzed by split intein sequences installed on each of the prime editor fragments.

[0442] Split PE delivery may be advantageous to address various size constraints of different delivery approaches. For example, delivery approaches may include virus-based delivery methods, messenger RNA-based delivery methods, or RNP-based delivery (ribonucleoprotein-based delivery). And, each of these methods of delivery may be more efficient and/or effective by dividing up the prime editor into smaller pieces. Once inside the cell, the smaller pieces can assemble into a functional prime editor. Depending on the means of splitting, the divided prime editor fragments can be reassembled in a non-covalent manner or a covalent manner to reform the prime editor. In one embodiment, the prime editor can be split at one or more split sites into two or more fragments. The fragments can be unmodified (other than being split). Once the fragments are delivered to the cell (e.g., by direct delivery of a ribonucleoprotein complex or by nucleic delivery – e.g., mRNA delivery or virus vector based delivery), the fragments can reassociate covalently or non-covalently to

reconstitute the prime editor. In another embodiment, the prime editor can be split at one or more split sites into two or more fragments. Each of the fragments can be modified to comprise a dimerization domain, whereby each fragment that is formed is coupled to a dimerization domain. Once delivered or expressed within a cell, the dimerization domains of the different fragments associate and bind to one another, bringing the different prime editor fragments together to reform a functional prime editor. In yet another embodiment, the prime editor fragment may be modified to comprise a split intein. Once delivered or expressed within a cell, the split intein domains of the different fragments associate and bind to one another, and then undergo trans-splicing, which results in the excision of the split-intein domains from each of the fragments, and a concomitant formation of a peptide bond between the fragments, thereby restoring the prime editor.

[0443] In one embodiment, the prime editor can be delivered using a split-intein approach.

[0444] The location of the split site can be positioned between any one or more pair of residues in the prime editor and in any domains therein, including within the napDNABp domain, the polymerase domain (e.g., RT domain), linker domain that joins the napDNABp domain and the polymerase domain.

[0445] In one embodiment, depicted in FIG. 66, the prime editor (PE) is divided at a split site within the napDNABp.

[0446] In certain embodiments, the napDNABp is a canonical SpCas9 polypeptide of SEQ ID NO: 18, as follows:

SpCas9 <i>Streptococcus pyogenes</i> M1 SwissProt Accession No. Q99ZW2 Wild type 1368 AA	MDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDR HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYL QEIFSNEMAKVDDSFHRLSESLVEEDKKHERHPIFGNIVD EVAYHEKYPTIYHLRKKLV DSTDKADRLIYLALAHMIKFR GHFLIEGDLNPDNSDVKLFQILVQTYNQLFEENPINASGVD AKAILSARLSKSRRLLENLIAQLPGEKKNGLFGNLIALSLGLTP NFKSNFDLAEDAKLQLSKD TYDDDLNLLAQIGDQYADLF LAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDL TLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFY KFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHL GELHAILRRQEDFYFPLKDNREKIEKILTFRIPYYVGPLARGN SRFAWMTRKSEETITPWNFEEVVDKGASQSFIERMTNFDK NLPNEKVLPHKSLLEYFTVYNELTKVKYVTEGMRKPAFLS GEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGV EDRFNASLGT YHDLLKHKDKDFLDNEENEDILEDIVLTLTLF EDREMIEERLKT YAHLFDDKVMKQLKRRRYTGWGRLSRKL INGIRDKQSGKTILDFLKSDGFANRNF MQLIHDDSLTFKEDIQ KAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKV MGRHKPENIVIE MARENQTTQKGQKNSRERMKRIE EGIKEL GSQILKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDIN RLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPS EEVVKMKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELD KAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREV KVITLKSCLVSDFRKDFQFYKVINNYHHAHDAYLNAV GTALIKKYPKLESEFVYGDYKVDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRLIETNGETGEIVWDKG	SEQ ID NO: 18
---	--	---------------

	RDFATVRKVLSPQVNIKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFDSPTVAYSVLVAKVEKGKSKKLK SVKELLGITIMERSSFENPIDFLEAKGYKEVKKDLIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHY EKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADA NLDKVL SAYNKH RD KPIREQAENIIHLFTLTNLGAPAAFKYF DTTIDRKRYTSTKEVL DATLIHQ SITGLYETRIDLSQLGGD	
--	--	--

[0447] In certain embodiments, the SpCas9 is split into two fragments at a split site located between residues 1 and 2, or 2 and 3, or 3 and 4, or 4 and 5, or 5 and 6, or 6 and 7, or 7 and 8, or 8 and 9, or 9 and 10, or between any two pair of residues located anywhere between residues 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 1000-1100, 1100-1200, 1200-1300, or 1300-1368 of canonical SpCas9 of SEQ ID NO: 18.

[0448] In certain embodiments, a napDNAbp is split into two fragments at a split site that is located at a pair of residue that corresponds to any two pair of residues located anywhere between positions 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 1000-1100, 1100-1200, 1200-1300, or 1300-1368 of canonical SpCas9 of SEQ ID NO: 18.

[0449] In certain embodiments, the SpCas9 is split into two fragments at a split site located between residues 1 and 2, or 2 and 3, or 3 and 4, or 4 and 5, or 5 and 6, or 6 and 7, or 7 and 8, or 8 and 9, or 9 and 10, or between any two pair of residues located anywhere between residues 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 1000-1100, 1100-1200, 1200-1300, or 1300-1368 of canonical SpCas9 of SEQ ID NO: 18. In certain embodiments, the split site is located one or more polypeptide bond sites (i.e., a “split site or split-intein split site”), fused to a split intein, and then delivered to cells as separately-encoded fusion proteins. Once the split-intein fusion proteins (i.e., protein halves) are expressed within a cell, the proteins undergo trans-splicing to form a complete or whole PE with the concomitant removal of the joined split-intein sequences.

[0450] For example, as shown in FIG. 66, the N-terminal extein can be fused to a first split-intein (e.g., N intein) and the C-terminal extein can be fused to a second split-intein (e.g., C intein). The N-terminal extein becomes fused to the C-terminal extein to reform a whole prime editor fusion protein comprising an napDNAbp domain and a polymerase domain (e.g., RT domain) upon the self-association of the N intein and the C intein inside the cell, followed by their self-excision, and the concomitant formation of a peptide bond between the N-terminal extein and C-terminal extein portions of a whole prime editor (PE).

[0451] To take advantage of a split-PE delivery strategy using split-inteins, the prime editor needs to be divided at one or more split sites to create at least two separate halves of a prime editor, each of which may be rejoined inside a cell if each half is fused to a split-intein sequence.

[0452] In certain embodiments, the prime editor is split at a single split site. In certain other embodiments, the prime editor is split at two split sites, or three split sites, or four split sites, or more.

[0453] In a preferred embodiment, the prime editor is split at a single split site to create two separate halves of a prime editor, each of which can be fused to a split intein sequence

[0454] An exemplary split intein is the *Ssp* DnaE intein, which comprises two subunits, namely, DnaE-N and DnaE-C. The two different subunits are encoded by separate genes, namely *dnaE-n* and *dnaE-c*, which encode the DnaE-N and DnaE-C subunits, respectively. DnaE is a naturally occurring split intein in *Synechocytis sp.* PCC6803 and is capable of directing trans-splicing of two separate proteins, each comprising a fusion with either DnaE-N or DnaE-C.

[0455] Additional naturally occurring or engineered split-intein sequences are known in the art or can be made from whole-intein sequences described herein or those available in the art. Examples of split-intein sequences can be found in Stevens et al., “A promiscuous split intein with expanded protein engineering applications,” PNAS, 2017, Vol.114: 8538-8543; Iwai et al., “Highly efficient protein trans-splicing by a naturally split DnaE intein from *Nostoc punctiforme*,” FEBS Lett, 580: 1853-1858, each of which are incorporated herein by reference. Additional split intein sequences can be found, for example, in WO 2013/045632, WO 2014/055782, WO 2016/069774, and EP2877490, the contents each of which are incorporated herein by reference.

[0456] In addition, protein splicing in trans has been described *in vivo* and *in vitro* (Shingledecker, et al., *Gene* 207:187 (1998), Southworth, et al., *EMBO J.* 17:918 (1998); Mills, et al., *Proc. Natl. Acad. Sci. USA*, 95:3543-3548 (1998); Lew, et al., *J. Biol. Chem.*, 273:15887-15890 (1998); Wu, et al., *Biochim. Biophys. Acta* 35732:1 (1998b), Yamazaki, et al., *J. Am. Chem. Soc.* 120:5591 (1998), Evans, et al., *J. Biol. Chem.* 275:9091 (2000); Otomo, et al., *Biochemistry* 38:16040-16044 (1999); Otomo, et al., *J. Biolmol. NMR* 14:105-114 (1999); Scott, et al., *Proc. Natl. Acad. Sci. USA* 96:13638-13643 (1999)) and provides the opportunity to express a protein as two inactive fragments that subsequently undergo ligation to form a functional product, e.g., as shown in FIGs. 66 and 67 with regard to the formation of a complete PE fusion protein from two separately-expressed halves.

[0457] In various embodiments described herein, the continuous evolution methods (e.g., PACE) may be used to evolve a first portion of a base editor. A first portion could include a single component or domain, e.g., a Cas9 domain, a deaminase domain, or a UGI domain. The separately evolved component or domain can be then fused to the remaining portions of the base editor within a cell by separately expressing both the evolved portion and the remaining non-evolved portions with split-intein polypeptide domains. The first portion could more broadly include any first amino acid portion of a base editor that is desired to be evolved using a continuous evolution method described herein. The second portion would in this embodiment refer to the remaining amino acid portion of the base editor that is not evolved using the herein methods. The evolved first portion and the second portion of the base editor could each be expressed with split-intein polypeptide domains in a cell. The natural

protein splicing mechanisms of the cell would reassemble the evolved first portion and the non-evolved second portion to form a single fusion protein evolved base editor. The evolved first portion may comprise either the N- or C-terminal part of the single fusion protein. In an analogous manner, use of a second orthogonal trans-splicing intein pair could allow the evolved first portion to comprise an internal part of the single fusion protein.

[0458] Thus, any of the evolved and non-evolved components of the base editors herein described may be expressed with split-intein tags in order to facilitate the formation of a complete base editor comprising the evolved and non-evolved component within a cell.

[0459] The mechanism of the protein splicing process has been studied in great detail (Chong, et al., J. Biol. Chem. 1996, 271, 22159-22168; Xu, M-Q & Perler, F. B. EMBO Journal, 1996, 15, 5146-5153) and conserved amino acids have been found at the intein and extein splicing points (Xu, et al., EMBO Journal, 1994, 13 5517-522). The constructs described herein contain an intein sequence fused to the 5'-terminus of the first gene (e.g., the evolved portion of the base editor). Suitable intein sequences can be selected from any of the proteins known to contain protein splicing elements. A database containing all known inteins can be found on the World Wide Web (Perler, F. B. Nucleic Acids Research, 1999, 27, 346-347). The intein sequence is fused at the 3' end to the 5' end of a second gene. For targeting of this gene to a certain organelle, a peptide signal can be fused to the coding sequence of the gene. After the second gene, the intein-gene sequence can be repeated as often as desired for expression of multiple proteins in the same cell. For multi-intein containing constructs, it may be useful to use intein elements from different sources. After the sequence of the last gene to be expressed, a transcription termination sequence must be inserted. In one embodiment, a modified intein splicing unit is designed so that it can both catalyze excision of the exteins from the inteins as well as prevent ligation of the exteins. Mutagenesis of the C-terminal extein junction in the *Pyrococcus* species GB-D DNA polymerase was found to produce an altered splicing element that induces cleavage of exteins and inteins but prevents subsequent ligation of the exteins (Xu, M-Q & Perler, F. B. EMBO Journal, 1996, 15, 5146-5153). Mutation of serine 538 to either an alanine or glycine induced cleavage but prevented ligation. Mutation of equivalent residues in other intein splicing units should also prevent extein ligation due to the conservation of amino acids at the C-terminal extein junction to the intein. A preferred intein not containing an endonuclease domain is the *Mycobacterium xenopi* GyrA protein (Telenti, et al. J. Bacteriol. 1997, 179, 6378-6382). Others have been found in nature or have been created artificially by removing the endonuclease domains from endonuclease containing inteins (Chong, et al. J. Biol. Chem. 1997, 272, 15587-15590). In a preferred embodiment, the intein is selected so that it consists of the minimal number of amino acids needed to perform the splicing function, such as the intein from the *Mycobacterium xenopi* GyrA protein (Telenti, A., et al., J. Bacteriol. 1997, 179, 6378-6382). In an alternative embodiment, an intein without endonuclease activity is selected, such as the intein from the *Mycobacterium xenopi* GyrA

protein or the *Saccharomyces cerevisiae* VMA intein that has been modified to remove endonuclease domains (Chong, 1997). Further modification of the intein splicing unit may allow the reaction rate of the cleavage reaction to be altered allowing protein dosage to be controlled by simply modifying the gene sequence of the splicing unit.

[0460] Inteins can also exist as two fragments encoded by two separately transcribed and translated genes. These so-called split inteins self-associate and catalyze protein-splicing activity in trans. Split inteins have been identified in diverse cyanobacteria and archaea (Caspi et al, *Mol Microbiol.* 50: 1569-1577 (2003); Choi J. et al, *J Mol Biol.* 556: 1093-1106 (2006.); Dassa B. et al, *Biochemistry.* 46:322-330 (2007.); Liu X. and Yang J., *J Biol Chem.* 275:26315-26318 (2003); Wu H. et al.

[0461] *Proc Natl Acad Sci USA.* 95:9226-9231 (1998.); and Zettler J. et al, *FEBS Letters.* 553:909-914 (2009)), but have not been found in eukaryotes thus far. Recently, a bioinformatic analysis of environmental metagenomic data revealed 26 different loci with a novel genomic arrangement. At each locus, a conserved enzyme coding region is interrupted by a split intein, with a freestanding endonuclease gene inserted between the sections coding for intein subdomains. Among them, five loci were completely assembled: DNA helicases (gp41-I, gp41-8); Inosine-5'-monophosphate dehydrogenase (IMPDH-1); and Ribonucleotide reductase catalytic subunits (NrdA-2 and NrdJ-1). This fractured gene organization appears to be present mainly in phages (Dassa et al, *Nucleic Acids Research.* 57:2560-2573 (2009)).

[0462] The split intein Npu DnaE was characterized as having the highest rate reported for the protein trans-splicing reaction. In addition, the Npu DnaE protein splicing reaction is considered robust and high-yielding with respect to different extein sequences, temperatures from 6 to 37°C, and the presence of up to 6M Urea (Zettler J. et al, *FEBS Letters.* 553:909-914 (2009); Iwai I. et al, *FEBS Letters* 550: 1853-1858 (2006)). As expected, when the Cys1 Ala mutation at the N-domain of these inteins was introduced, the initial N to S-acyl shift and therefore protein splicing was blocked. Unfortunately, the C-terminal cleavage reaction was also almost completely inhibited. The dependence of the asparagine cyclization at the C-terminal splice junction on the acyl shift at the N-terminal scissile peptide bond seems to be a unique property common to the naturally split DnaE intein alleles (Zettler J. et al. *FEBS Letters.* 555:909-914 (2009)).

[0463] The mechanism of protein splicing typically has four steps [29-30]: 1) an N-S or N-O acyl shift at the intein N-terminus, which breaks the upstream peptide bond and forms an ester bond between the N-extein and the side chain of the intein's first amino acid (Cys or Ser); 2) a transesterification relocating the N-extein to the intein C-terminus, forming a new ester bond linking the N-extein to the side chain of the C-extein's first amino acid (Cys, Ser, or Thr); 3) Asn cyclization breaking the peptide bond between the intein and the C-extein; and 4) a S-N or O-N acyl shift that replaces the ester bond with a peptide bond between the N-extein and C-extein.

[0464] Protein trans-splicing, catalyzed by split inteins, provides an entirely enzymatic method for protein ligation [31]. A split-intein is essentially a contiguous intein (e.g. a mini-intein) split into two pieces named N-intein and C-intein, respectively. The N-intein and C-intein of a split intein can associate non-covalently to form an active intein and catalyze the splicing reaction essentially in same way as a contiguous intein does. Split inteins have been found in nature and also engineered in laboratories [31-35]. As used herein, the term "split intein" refers to any intein in which one or more peptide bond breaks exists between the N-terminal and C-terminal amino acid sequences such that the N-terminal and C-terminal sequences become separate molecules that can non-covalently reassociate, or reconstitute, into an intein that is functional for trans-splicing reactions. Any catalytically active intein, or fragment thereof, may be used to derive a split intein for use in the methods of the invention. For example, in one aspect the split intein may be derived from a eukaryotic intein. In another aspect, the split intein may be derived from a bacterial intein. In another aspect, the split intein may be derived from an archaeal intein. Preferably, the split intein so-derived will possess only the amino acid sequences essential for catalyzing trans-splicing reactions.

[0465] As used herein, the "N-terminal split intein (In)" refers to any intein sequence that comprises an N- terminal amino acid sequence that is functional for trans-splicing reactions. An In thus also comprises a sequence that is spliced out when trans-splicing occurs. An In can comprise a sequence that is a modification of the N-terminal portion of a naturally occurring intein sequence. For example, an In can comprise additional amino acid residues and/or mutated residues so long as the inclusion of such additional and/or mutated residues does not render the In non-functional in trans-splicing. Preferably, the inclusion of the additional and/or mutated residues improves or enhances the trans-splicing activity of the In.

[0466] As used herein, the "C-terminal split intein (Ic)" refers to any intein sequence that comprises a C- terminal amino acid sequence that is functional for trans-splicing reactions. In one aspect, the Ic comprises 4 to 7 contiguous amino acid residues, at least 4 amino acids of which are from the last β -strand of the intein from which it was derived. An Ic thus also comprises a sequence that is spliced out when trans-splicing occurs. An Ic can comprise a sequence that is a modification of the C-terminal portion of a naturally occurring intein sequence. For example, an Ic can comprise additional amino acid residues and/or mutated residues so long as the inclusion of such additional and/or mutated residues does not render the In non-functional in trans-splicing. Preferably, the inclusion of the additional and/or mutated residues improves or enhances the trans-splicing activity of the Ic.

[0467] In some embodiments of the invention, a peptide linked to an Ic or an In can comprise an additional chemical moiety including, among others, fluorescence groups, biotin, polyethylene glycol (PEG), amino acid analogs, unnatural amino acids, phosphate groups, glycosyl groups, radioisotope labels, and pharmaceutical molecules. In other embodiments, a peptide linked to an Ic can comprise one or more chemically reactive groups including, among others, ketone, aldehyde, Cys residues and

Lys residues. The N-intein and C-intein of a split intein can associate non-covalently to form an active intein and catalyze the splicing reaction when an "intein-splicing polypeptide (ISP)" is present. As used herein, "intein-splicing polypeptide (ISP)" refers to the portion of the amino acid sequence of a split intein that remains when the Ic, In, or both, are removed from the split intein. In certain embodiments, the In comprises the ISP. In another embodiment, the Ic comprises the ISP. In yet another embodiment, the ISP is a separate peptide that is not covalently linked to In nor to Ic.

[0468] Split inteins may be created from contiguous inteins by engineering one or more split sites in the unstructured loop or intervening amino acid sequence between the -12 conserved beta-strands found in the structure of mini-inteins [25-28]. Some flexibility in the position of the split site within regions between the beta-strands may exist, provided that creation of the split will not disrupt the structure of the intein, the structured beta-strands in particular, to a sufficient degree that protein splicing activity is lost.

[0469] In protein trans-splicing, one precursor protein consists of an N-extein part followed by the N-intein, another precursor protein consists of the C-intein followed by a C-extein part, and a trans-splicing reaction (catalyzed by the N- and C-inteins together) excises the two intein sequences and links the two extein sequences with a peptide bond. Protein trans-splicing, being an enzymatic reaction, can work with very low (e.g. micromolar) concentrations of proteins and can be carried out under physiological conditions.

[2] Other programmable nucleases

[0470] In various embodiments described herein, the multi-flap prime editors comprise a napDNAbp, such as a Cas9 protein. These proteins are "programmable" by way of their becoming complexed with a guide RNA (or a PEgRNA, as the case may be), which guides the Cas9 protein to a target site on the DNA which possess a sequence that is complementary to the spacer portion of the gRNA (or PEgRNA) and also which possesses the required PAM sequence. However, in certain embodiment envisioned here, the napDNAbp may be substituted with a different type of programmable protein, such as a zinc finger nuclease or a transcription activator-like effector nuclease (TALEN).

[0471] FIG. 1J depicts such a variation of prime editing contemplated herein that replaces the napDNAbp (e.g., SpCas9 nickase) with any programmable nuclease domain, such as zinc finger nucleases (ZFN) or transcription activator-like effector nucleases (TALEN). As such, it is contemplated that suitable nucleases do not necessarily need to be "programmed" by a nucleic acid targeting molecule (such as a guide RNA), but rather, may be programmed by defining the specificity of a DNA-binding domain, such as and in particular, a nuclease. Just as in prime editing with napDNAbp moieties, it is preferable that such alternative programmable nucleases be modified such that only one strand of a target DNA is cut. In other words, the programmable nucleases should function as nickases, preferably. Once a programmable nuclease is selected (e.g., a ZFN or a TALEN), then additional functionalities may be engineered into the system to allow it to operate in

accordance with a prime editing-like mechanism. For example, the programmable nucleases may be modified by coupling (e.g., via a chemical linker) an RNA or DNA extension arm thereto, wherein the extension arm comprises a primer binding site (PBS) and a DNA synthesis template. The programmable nuclease may also be coupled (e.g., via a chemical or amino acid linker) to a polymerase, the nature of which will depend upon whether the extension arm is DNA or RNA. In the case of an RNA extension arm, the polymerase can be an RNA-dependent DNA polymerase (e.g., reverse transcriptase). In the case of a DNA extension arm, the polymerase can be a DNA-dependent DNA polymerase (e.g., a prokaryotic polymerase, including Pol I, Pol II, or Pol III, or a eukaryotic polymerase, including Pol α , Pol β , Pol γ , Pol δ , Pol ϵ , or Pol ζ). The system may also include other functionalities added as fusions to the programmable nucleases, or added *in trans* to facilitate the reaction as a whole (e.g., (a) a helicase to unwind the DNA at the cut site to make the cut strand with the 3' end available as a primer, (b) a FEN1 to help remove the endogenous strand on the cut strand to drive the reaction towards replacement of the endogenous strand with the synthesized strand, or (c) a nCas9:gRNA complex to create a second site nick on the opposite strand, which may help drive the integration of the synthesized repair through favored cellular repair of the non-edited strand). In an analogous manner to prime editing with a napDNAbp, such a complex with an otherwise programmable nuclease could be used to synthesize and then install a newly synthesized replacement strand of DNA carrying an edit of interest permanently into a target site of DNA.

[0472] Suitable alternative programmable nucleases are well known in the art which may be used in place of a napDNAbp:gRNA complex to construct an alternative prime editor system that can be programmed to selectively bind a target site of DNA, and which can be further modified in the manner described above to co-localize a polymerase and an RNA or DNA extension arm comprising a primer binding site and a DNA synthesis template to specific nick site. For example, and as represented in FIG. 1J, Transcription Activator-Like Effector Nucleases (TALENs) may be used as the programmable nuclease in the multi-flap prime editing methods and compositions of matter described herein. TALENs are artificial restriction enzymes generated by fusing the TAL effector DNA binding domain to a DNA cleavage domain. These reagents enable efficient, programmable, and specific DNA cleavage and represent powerful tools for genome editing *in situ*. Transcription activator-like effectors (TALEs) can be quickly engineered to bind practically any DNA sequence. The term TALEN, as used herein, is broad and includes a monomeric TALEN that can cleave double stranded DNA without assistance from another TALEN. The term TALEN is also used to refer to one or both members of a pair of TALENs that are engineered to work together to cleave DNA at the same site. TALENs that work together may be referred to as a left-TALEN and a right-TALEN, which references the handedness of DNA. See U.S. Ser. No. 12/965,590; U.S. Ser. No. 13/426,991 (U.S. Pat. No. 8,450,471); U.S. Ser. No. 13/427,040 (U.S. Pat. No. 8,440,431); U.S. Ser. No. 13/427,137 (U.S. Pat. No. 8,440,432); and U.S. Ser. No. 13/738,381, all of which are incorporated by

reference herein in their entirety. In addition, TALENs are described in WO 2015/027134, US 9,181,535, Boch et al., "Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors", *Science*, vol. 326, pp. 1509-1512 (2009), Bogdanove et al., TAL Effectors: Customizable Proteins for DNA Targeting, *Science*, vol. 333, pp. 1843-1846 (2011), Cade et al., "Highly efficient generation of heritable zebrafish gene mutations using homo- and heterodimeric TALENs", *Nucleic Acids Research*, vol. 40, pp. 8001-8010 (2012), and Cermak et al., "Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting", *Nucleic Acids Research*, vol. 39, No. 17, e82 (2011), each of which are incorporated herein by reference.

[0473] As represented in FIG. 1J, zinc finger nucleases may also be used as alternative programmable nucleases for use in multi-flap prime editing in place of napDNAbps, such as Cas9 nickases. Like with TALENs, the ZFN proteins may be modified such that they function as nickases, i.e., engineering the ZFN such that it cleaves only one strand of the target DNA in a manner similar to the napDNAbp used with the multi-flap prime editors described herein. ZFN proteins have been extensively described in the art, for example, in Carroll et al., "Genome Engineering with Zinc-Finger Nucleases," *Genetics*, Aug 2011, Vol. 188: 773-782; Durai et al., "Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells," *Nucleic Acids Res*, 2005, Vol. 33: 5978-90; and Gaj et al., "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering," *Trends Biotechnol.* 2013, Vol.31: 397-405, each of which are incorporated herein by reference in their entirety.

[3] Polymerases (e.g., reverse transcriptases)

[0474] In various embodiments, the multi-flap prime editor system disclosed herein includes a polymerase (e.g., DNA-dependent DNA polymerase or RNA-dependent DNA polymerase, such as, reverse transcriptase), or a variant thereof, which can be provided as a fusion protein with a napDNAbp or other programmable nuclease, or provide *in trans*.

[0475] Any polymerase may be used in the multi-flap prime editors disclosed herein. The polymerases may be wild type polymerases, functional fragments, mutants, variants, or truncated variants, and the like. The polymerases may include wild type polymerases from eukaryotic, prokaryotic, archaeal, or viral organisms, and/or the polymerases may be modified by genetic engineering, mutagenesis, directed evolution-based processes. The polymerases may include T7 DNA polymerase, T5 DNA polymerase, T4 DNA polymerase, Klenow fragment DNA polymerase, DNA polymerase III and the like. The polymerases may also be thermostable, and may include Taq, Tne, Tma, Pfu, Tfl, Tth, Stoffel fragment, VENT® and DEEPVENT® DNA polymerases, KOD, Tgo, JDF3, and mutants, variants and derivatives thereof (see U.S. Pat. No. 5,436,149; U.S. Pat. No. 4,889,818; U.S. Pat. No. 4,965,185; U.S. Pat. No. 5,079,352; U.S. Pat. No. 5,614,365; U.S. Pat. No. 5,374,553; U.S. Pat. No. 5,270,179; U.S. Pat. No. 5,047,342; U.S. Pat. No. 5,512,462; WO 92/06188; WO 92/06200; WO 96/10640; Barnes, W. M., *Gene* 112:29-35 (1992); Lawyer, F. C., et al., PCR

Meth. Appl. 2:275-287 (1993); Flaman, J.-M, et al., Nuc. Acids Res. 22(15):3259-3260 (1994), each of which are incorporated by reference). For synthesis of longer nucleic acid molecules (e.g, nucleic acid molecules longer than about 3-5 Kb in length), at least two DNA polymerases can be employed. In certain embodiments, one of the polymerases can be substantially lacking a 3' exonuclease activity and the other may have a 3' exonuclease activity. Such pairings may include polymerases that are the same or different. Examples of DNA polymerases substantially lacking in 3' exonuclease activity include, but are not limited to, Taq, Tne(exo-), Tma(exo-), Pfu(exo-), Pwo(exo-), exo-KOD and Tth DNA polymerases, and mutants, variants and derivatives thereof.

[0476] Preferably, the polymerase usable in the multi-flap prime editors disclosed herein are “template-dependent” polymerase (since the polymerases are intended to rely on the DNA synthesis template to specify the sequence of the DNA strand under synthesis during prime editing. As used herein, the term “template DNA molecule” refers to that strand of a nucleic acid from which a complementary nucleic acid strand is synthesized by a DNA polymerase, for example, in a primer extension reaction of the DNA synthesis template of a PEGRNA.

[0477] As used herein, the term “template dependent manner” is intended to refer to a process that involves the template dependent extension of a primer molecule (e.g., DNA synthesis by DNA polymerase). The term “template dependent manner” refers to polynucleotide synthesis of RNA or DNA wherein the sequence of the newly synthesized strand of polynucleotide is dictated by the well-known rules of complementary base pairing (see, for example, Watson, J. D. et al., In: Molecular Biology of the Gene, 4th Ed., W. A. Benjamin, Inc., Menlo Park, Calif. (1987)). The term “complementary” refers to the broad concept of sequence complementarity between regions of two polynucleotide strands or between two nucleotides through base-pairing. It is known that an adenine nucleotide is capable of forming specific hydrogen bonds (“base pairing”) with a nucleotide which is thymine or uracil. Similarly, it is known that a cytosine nucleotide is capable of base pairing with a guanine nucleotide. As such, in the case of prime editing, it can be said that the single strand of DNA synthesized by the polymerase of the prime editor against the DNA synthesis template is said to be “complementary” to the sequence of the DNA synthesis template.

A. Exemplary polymerases

[0478] In various embodiments, the multi-flap prime editors described herein comprise a polymerase. The disclosure contemplates any wild type polymerase obtained from any naturally-occurring organism or virus, or obtained from a commercial or non-commercial source. In addition, the polymerases usable in the multi-flap prime editors of the disclosure can include any naturally-occurring mutant polymerase, engineered mutant polymerase, or other variant polymerase, including truncated variants that retain function. The polymerases usable herein may also be engineered to contain specific amino acid substitutions, such as those specifically disclosed herein. In certain preferred embodiments, the polymerases usable in the multi-flap prime editors of the disclosure are

template-based polymerases, i.e., they synthesize nucleotide sequences in a template-dependent manner.

[0479] A polymerase is an enzyme that synthesizes a nucleotide strand and which may be used in connection with the multi-flap prime editor systems described herein. The polymerases are preferably “template-dependent” polymerases (i.e., a polymerase which synthesizes a nucleotide strand based on the order of nucleotide bases of a template strand). In certain configurations, the polymerases can also be a “template-independent” (i.e., a polymerase which synthesizes a nucleotide strand without the requirement of a template strand). A polymerase may also be further categorized as a “DNA polymerase” or an “RNA polymerase.” In various embodiments, the multi-flap prime editor systems comprise a DNA polymerase. In various embodiments, the DNA polymerase can be a “DNA-dependent DNA polymerase” (i.e., whereby the template molecule is a strand of DNA). In such cases, the DNA template molecule can be a PEGRNA, wherein the extension arm comprises a strand of DNA. In such cases, the PEGRNA may be referred to as a chimeric or hybrid PEGRNA which comprises an RNA portion (i.e., the guide RNA components, including the spacer and the gRNA core) and a DNA portion (i.e., the extension arm). In various other embodiments, the DNA polymerase can be an “RNA-dependent DNA polymerase” (i.e., whereby the template molecule is a strand of RNA). In such cases, the PEGRNA is RNA, i.e., including an RNA extension. The term “polymerase” may also refer to an enzyme that catalyzes the polymerization of nucleotide (i.e., the polymerase activity). Generally, the enzyme will initiate synthesis at the 3'-end of a primer annealed to a polynucleotide template sequence (e.g., such as a primer sequence annealed to the primer binding site of a PEGRNA), and will proceed toward the 5' end of the template strand. A “DNA polymerase” catalyzes the polymerization of deoxynucleotides. As used herein in reference to a DNA polymerase, the term DNA polymerase includes a “functional fragment thereof”. A “functional fragment thereof” refers to any portion of a wild-type or mutant DNA polymerase that encompasses less than the entire amino acid sequence of the polymerase and which retains the ability, under at least one set of conditions, to catalyze the polymerization of a polynucleotide. Such a functional fragment may exist as a separate entity, or it may be a constituent of a larger polypeptide, such as a fusion protein.

[0480] In some embodiments, the polymerases can be from bacteriophage. Bacteriophage DNA polymerases are generally devoid of 5' to 3' exonuclease activity, as this activity is encoded by a separate polypeptide. Examples of suitable DNA polymerases are T4, T7, and phi29 DNA polymerase. The enzymes available commercially are: T4 (available from many sources e.g., Epicentre) and T7 (available from many sources, e.g. Epicentre for unmodified and USB for 3' to 5' exo T7 “Sequenase” DNA polymerase).

[0481] The other embodiments, the polymerases are archaeal polymerases. There are 2 different classes of DNA polymerases which have been identified in archaea: 1. Family B/pol I type (homologs of Pfu from *Pyrococcus furiosus*) and 2. pol II type (homologs of *P. furiosus* DP1/DP2 2-subunit

polymerase). DNA polymerases from both classes have been shown to naturally lack an associated 5' to 3' exonuclease activity and to possess 3' to 5' exonuclease (proofreading) activity. Suitable DNA polymerases (pol I or pol II) can be derived from archaea with optimal growth temperatures that are similar to the desired assay temperatures.

[0482] Thermostable archaeal DNA polymerases are isolated from *Pyrococcus* species (*furiosus*, species GB-D, *woesii*, *abyssi*, *horikoshii*), *Thermococcus* species (*kodakaraensis* KOD1, *litoralis*, species 9 degrees North-7, species JDF-3, *gorgonarius*), *Pyrodictium occultum*, and *Archaeoglobus fulgidus*.

[0483] Polymerases may also be from eubacterial species. There are 3 classes of eubacterial DNA polymerases, pol I, II, and III. Enzymes in the Pol I DNA polymerase family possess 5' to 3' exonuclease activity, and certain members also exhibit 3' to 5' exonuclease activity. Pol II DNA polymerases naturally lack 5' to 3' exonuclease activity, but do exhibit 3' to 5' exonuclease activity. Pol III DNA polymerases represent the major replicative DNA polymerase of the cell and are composed of multiple subunits. The pol III catalytic subunit lacks 5' to 3' exonuclease activity, but in some cases 3' to 5' exonuclease activity is located in the same polypeptide.

[0484] There are a variety of commercially available Pol I DNA polymerases, some of which have been modified to reduce or abolish 5' to 3' exonuclease activity.

[0485] Suitable thermostable pol I DNA polymerases can be isolated from a variety of thermophilic eubacteria, including *Thermus* species and *Thermotoga maritima* such as *Thermus aquaticus* (Taq), *Thermus thermophilus* (Tth) and *Thermotoga maritima* (Tma UITma).

[0486] Additional eubacteria related to those listed above are described in Thermophilic Bacteria (Kristjansson, J. K., ed.) CRC Press, Inc., Boca Raton, Fla., 1992.

[0487] The invention further provides for chimeric or non-chimeric DNA polymerases that are chemically modified according to methods disclosed in U.S. Pat. Nos. 5,677,152, 6,479,264 and 6,183,998, the contents of which are hereby incorporated by reference in their entirety.

[0488] Additional archaea DNA polymerases related to those listed above are described in the following references: Archaea: A Laboratory Manual (Robb, F. T. and Place, A. R., eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1995 and Thermophilic Bacteria (Kristjansson, J. K., ed.) CRC Press, Inc., Boca Raton, Fla., 1992.

B. Exemplary reverse transcriptases

[0489] In various embodiments, the multi-flap prime editors described herein comprise a reverse transcriptase as the polymerase. The disclosure contemplates any wild type reverse transcriptase obtained from any naturally-occurring organism or virus, or obtained from a commercial or non-commercial source. In addition, the reverse transcriptases usable in the multi-flap prime editors of the disclosure can include any naturally-occurring mutant RT, engineered mutant RT, or other variant RT,

including truncated variants that retain function. The RTs may also be engineered to contain specific amino acid substitutions, such as those specifically disclosed herein.

[0490] Reverse transcriptases are multi-functional enzymes typically with three enzymatic activities including RNA- and DNA-dependent DNA polymerization activity, and an RNaseH activity that catalyzes the cleavage of RNA in RNA-DNA hybrids. Some mutants of reverse transcriptases have disabled the RNaseH moiety to prevent unintended damage to the mRNA. These enzymes that synthesize complementary DNA (cDNA) using mRNA as a template were first identified in RNA viruses. Subsequently, reverse transcriptases were isolated and purified directly from virus particles, cells or tissues. (e.g., see Kacian et al., 1971, Biochim. Biophys. Acta 46: 365-83; Yang et al., 1972, Biochem. Biophys. Res. Comm. 47: 505-11; Gerard et al., 1975, J. Virol. 15: 785-97; Liu et al., 1977, Arch. Virol. 55 187-200; Kato et al., 1984, J. Virol. Methods 9: 325-39; Luke et al., 1990, Biochem. 29: 1764-69 and Le Grice et al., 1991, J. Virol. 65: 7004-07, each of which are incorporated by reference). More recently, mutants and fusion proteins have been created in the quest for improved properties such as thermostability, fidelity and activity. Any of the wild type, variant, and/or mutant forms of reverse transcriptase which are known in the art or which can be made using methods known in the art are contemplated herein.

[0491] The reverse transcriptase (RT) gene (or the genetic information contained therein) can be obtained from a number of different sources. For instance, the gene may be obtained from eukaryotic cells which are infected with retrovirus, or from a number of plasmids which contain either a portion of or the entire retrovirus genome. In addition, messenger RNA-like RNA which contains the RT gene can be obtained from retroviruses. Examples of sources for RT include, but are not limited to, Moloney murine leukemia virus (M-MLV or MLVRT); human T-cell leukemia virus type 1 (HTLV-1); bovine leukemia virus (BLV); Rous Sarcoma Virus (RSV); human immunodeficiency virus (HIV); yeast, including *Saccharomyces*, *Neurospora*, *Drosophila*; primates; and rodents. See, for example, Weiss, et al., U.S. Pat. No. 4,663,290 (1987); Gerard, G. R., DNA:271-79 (1986); Kotewicz, M. L., et al., Gene 35:249-58 (1985); Tanese, N., et al., Proc. Natl. Acad. Sci. (USA):4944-48 (1985); Roth, M. J., et al., J. Biol. Chem. 260:9326-35 (1985); Michel, F., et al., Nature 316:641-43 (1985); Akins, R. A., et al., Cell 47:505-16 (1986), EMBO J. 4:1267-75 (1985); and Fawcett, D. F., Cell 47:1007-15 (1986) (each of which are incorporated herein by reference in their entireties).

Wild type RTs

[0492] Exemplary enzymes for use with the herein disclosed multi-flap prime editors can include, but are not limited to, M-MLV reverse transcriptase and RSV reverse transcriptase. Enzymes having reverse transcriptase activity are commercially available. In certain embodiments, the reverse transcriptase provided *in trans* to the other components of the multi-flap prime editor (PE) system. That is, the reverse transcriptase is expressed or otherwise provided as an individual component, i.e., not as a fusion protein with a napDNAbp.

[0493] A person of ordinary skill in the art will recognize that wild type reverse transcriptases, including but not limited to, Moloney Murine Leukemia Virus (M-MLV); Human Immunodeficiency Virus (HIV) reverse transcriptase and avian Sarcoma-Leukosis Virus (ASLV) reverse transcriptase, which includes but is not limited to Rous Sarcoma Virus (RSV) reverse transcriptase, Avian Myeloblastosis Virus (AMV) reverse transcriptase, Avian Erythroblastosis Virus (AEV) Helper Virus MCAV reverse transcriptase, Avian Myelocytomatosis Virus MC29 Helper Virus MCAV reverse transcriptase, Avian Reticuloendotheliosis Virus (REV-T) Helper Virus REV-A reverse transcriptase, Avian Sarcoma Virus UR2 Helper Virus UR2AV reverse transcriptase, Avian Sarcoma Virus Y73 Helper Virus YAV reverse transcriptase, Rous Associated Virus (RAV) reverse transcriptase, and Myeloblastosis Associated Virus (MAV) reverse transcriptase may be suitably used in the subject methods and composition described herein.

[0494] Exemplary wild type RT enzymes are as follows:

DESCRIPTION	SEQUENCE
REVERSE TRANSCRIPTASE (M- MLV RT) WILD TYPE MOLONEY MURINE LEUKEMIA VIRUS USED IN PE1 (PRIME EDITOR 1 FUSION PROTEIN DISCLOSED HEREIN)	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQA PLIIPKATSTPVSQKQYPMSQEARLGKPHIQRLDQGILVPCQSPWN TPLL PVKKPGTNDYRPVQDLREV NKRVEDIHPTVPNPYNLLSGLPPS HQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRL PQGFKN SPTLFDEALHRDLADFR IQHPDLILLQYVDDLLLAATSELD CQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLYLLKEGQRW LTEARKETVMGQPTPKTPRQLREFLG TAGFCRLWIPGFAEMAAPLYP LTKTGTLFNWGPDQKAYQEIQALLTAPALGLPDLTKPFELFVDEK QGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAIAV LTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALL LDTDRVQFGPVVALNPATLLPLPEEGLQHNCILDILAEAHGTRPDLTD QPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETETEVIAKALPAGTS AQRAELIALTQALKMAEGKKNVYTD SRYAFATAHIHGEIYRRRGLL TSEGKEIKNKDEILALLKALFLPKRLSIHCPGHQKGHSAEARGNRM ADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 700)
REVERSE TRANSCRIPTASE MOLONEY MURINE LEUKEMIA VIRUS REF SEQ. AAA66622.1	AFPLERPDWDYTTQAGRNHLVHYRQLLLAGLQNAGRSPTNLAKVK GITQGPNESPSAFLERLKEAYRRYTPYDPEDPGQETNVSMFSIWQSA PDIGRKLGRLEDLKS KTLGDLVREAEKIFNKRETPEREERIRRETEE KEERRRTVDEQKEKERDRRRHREMSKLLATVVIGQEQRQEGGERK RPQLDKDQCAYCKEKGHWAKDCPKKPRGPRGPQTSLTLGDGXG GQGQDPPPEPRITLKVGGQPVTFVLVD TGAQHSVLTQNPGLSDKSA WVQGATGGKRYRWTTDRKVHLATGKVTHSFLHVPDCPYPLGRDL LTKLKAQIHFEFGSAQVVGPMGQPLQVLTNIEDEYRLHETSKEPDV SLGFTWLSDFPQAWAESGGMGLAVRQA PLIIPKATSTPVSQKQYPM SQEARLGKPHIQRLDQGILVPCQSPWNTPLL PVKKPGTNDYRPVQ DLREV NKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRL PQGFKN SPTLFDEALHRD LADFR (SEQ ID NO: 90)
REVERSE TRANSCRIPTASE FELINE LEUKEMIA VIRUS REF SEQ. NP955579.1	TLQLEEEYRLFEPSTQKQEMDIWLKNFPQAWAETGGMGTAHCQA PVLIQLKATATPISIRQYMPHEAYQGKPHIRRM LDQGILKPCQSPW NTPLL PVKKPGTNDYRPVQDLREV NKRVEDIHPTVPNPYNLLSTLPP SHPWYTVLDLKD AFFCLR LHSESQLLFAFEWRDPEIGLSGQLTWTRL PQGFKN SPTLFDEALHSDLADFRVRYPALVLLQYVDDLLLAATRTE CLEGTKALLET LGNKG YRASAKKAQICLQEVTYLGYSLKDGQRWL TKARKEAILSIPVKN SRQVREFLG TAGYCRLWIPGFAELAAPLYPLT

DESCRIPTION	SEQUENCE
	RPGTLFQWGTEQQALAFEDIKKALLSSPALGLPDITKPFELFIDENSGF AKGVLVQKLGPWKRPVAYLSKKLDTVASGWPPCLRMVAAIAILVKD AGKLTGQPLTILTSHPVEALVRQPPNKWLSNARMTHYQAMLLDAE RVHFGPTVSLNPATLLPLPSGGNHHDCLOLAETHGTRPDLTQPLPD ADLTWYTDGSSFIRNGEREAGAAVTTESEVIWAAPLPPGTSAQRAEL IALTQALKMAEGKKLTVYTDSRYAFATTHVHGEIYRRRGLLTSEGKE IKNKNEILALLEALFLPKRLSIHCPGHQKGDSPQAKGNRLADDTAK KAATETHSSSLTVL SEQ ID NO: 91)
REVERSE TRANSCRIPTASE HIV-1 RT, CHAIN A REF SEQ. ITL3-A	PISPIETVPVKLPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKIS KIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIP HPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIR YQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLIV GSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELH PDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGKIVRQLXK LLRGTKALTEVIPLTEEALELAENREILKEPVHGVYDPSKDLIAEI QKQGGQWQTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQ KITTESIVIWGKTPKFKLPIKETWETWWTEYWQATWIPEWEFVNT PPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNRGRQ KVVTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGHIQAQPD QSESELVNQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAIRK V(SEQ ID NO: 92) SEE MARTINELLI ET AL., VIROLOGY, 1990, 174(1): 135-144, WHICH IS INCORPORATED BY REFERENCE
REVERSE TRANSCRIPTASE HIV-1 RT, CHAIN B REF SEQ. ITL3-B	PISPIETVPVKLPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKIS KIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIP HPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAFTIPSINNETPGIR YQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLIV GSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELH PDKWTVQPIVLPEKDSWTVNDIQKLVGKLNWASQIYPGKIVRQLCK LLRGTKALTEVIPLTEEALELAENREILKEPVHGVYDPSKDLIAEI QKQGGQWQTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQ KITTESIVIWGKTPKFKLPIKETWETWWTEYWQATWIPEWEFVNT PPLVKLWYQLEKEPIVGAETF(SEQ ID NO: 93) SEE STAMMERS ET AL., J. MOL. BIOL., 1994, 242(4): 586-588, WHICH IS INCORPORATED BY REFERENCE
REVERSE TRANSCRIPTASE ROUS SARCOMA VIRUS RT REF SEQ. ACL14945	TVALHLAIPLKWKPNHTPVWIDQWPLPEGKLVALTQLVEKELQLGHI EPSLSCWNTVPFVIRKASGSYRLLHDLRAVNAKLVPFGAVQQGAPV LSALPRGWPLMVLDLKDCFFSIPLAEQDREAFATLPSVNNQAPARR FQWKVLPQGMTCSPICQLIVGQILEPLRLKHPSLRMLHYMDDLIL AASSHDGLEAAGEEVISTLERAGFTISPDKVQKEPGVQYLGYKLGST YAAPVGLVAEPRIATLWDVQKLVGSLQWLRPALGIPRLRGPFEYQL RGSDPNEAREWNLDKMAWREIVQLSTTAALERWDPALPLEGAVA RCEQGAIGVLGQGLSTHPRPCLWLFSTQPTKAFTAWLEVLTLLITKL RASAVRTFGKEVDILLPACFRDELPLPEGILLALRGFAGKIRSSDTPS IFDIARPLHVS LKVRVTDHPVPGPTVFTDASSSTHKGVVVWREGPR WEIKEIADLGASVQQLERAVAMALLWPTTPTNVVTDSAFVAKML LKMGEQGV PSTAAAFILEDALSQRSAMAAVLHVRSHSEVPFFTEG NDVADSQATFQAYPLREAKDLHTALHIGPRALSKACNISMQQAREV VQTCPHCNSAPALEAGVNPRGLGPLQIWQTDFTLEPRMAPRSWLAV TVDTASSAIVVTQHGRVTSVAAQHHWATVIAVLGRPKAIKTDNGSCF TSKSTREWLARWGIAHTTGIPGNSQGGQAMVERANRLKDKIRVLAE

DESCRIPTION	SEQUENCE
	<p>GDGFMKRIPTSKQGELLAKAMYALNHFERGENTKTPIQKHWRPTVL TEGPPVKIRIETGEWEKGWNVLVWGRGYAAVKNRDTDKVIWVPSR KVKPDIAQKDEVTKKDEASPLFA(SEQ ID NO: 94)</p> <p>SEE YASUKAWA ET AL., J. BIOCHEM. 2009, 145(3): 315-324, WHICH IS INCORPORATED BY REFERENCE</p>
<p>REVERSE TRANSCRIPTASE</p> <p>CAULIFLOWER MOSAIC VIRUS RT</p> <p>REF SEQ. AGT42196</p>	<p>MMDHLLQKTQIQNQTEQVMNITNPNSIYIKGRLYFKGYKKIELHCF VDTGASLCIASKFVPIEEHWINAERPIMVKIADGSSITINKVCRDIDLII AGEIFHIPTVYQQESGIDFIIIGNNFCQLYEPFIQFTDRVIFTKDRTPVH IAKLTRAVRVGTEGFLESMKKRSKTQQPEPVNISTNKIAILSEGRRLS EEKLFITQQRMQKIEELLEKVCSENPLDPNKTQQWMKASIKLSDPSK AIKVKPMKYSPMDREEFDKQIKELLDLKVIPSXSPHMAPAFVNNNE AEKRRGKKRMVVNYKAMNKATVGDAYNLPNKDELTLIRGKKIFS SFDCKSGFWQVLLDQDSRPLTAFTCPQGHYEWNVVPFGLKQAPSIF QRHMDEAFRVFRKFCVYVDDILVFSNNEEDHLLHVAMILQKCNQH GIILSKKKAQLFKKKINFLGLEIDEGTHKPQGHILEHINKFPDTLEDK KQLQRFLGILTYASDYIPKLAQIRKPLQAKLKENVPWKWTKEDTLY MQKVKKNLQGFPLHPLPEEKLIETDASDDYWGGMKAIKINEG TNTLICRYASGSFKAEEKNYHSNDKETLAVINTIKKFSIYLTVPVHFLI RTDNTHFKSFVNLNYKGDSKLGRNIRWQAWLSHYSDVEHIKGTD NHFADFLSREFNRVNS(SEQ ID NO: 95)</p> <p>SEE FARZADFAR ET AL., VIRUS GENES, 2013, 47(2): 347-356, WHICH IS INCORPORATED BY REFERENCE</p>
<p>REVERSE TRANSCRIPTASE</p> <p>KLEBSIELLA PNEUMONIA</p> <p>REF SEQ. RFF81513.1</p>	<p>MKEKISKIDKNFYTDIFIKTSFQNEFEAGGVIPPIAKNQVSTISNKNKT FYSLAHSSPHYSIQTRIEKFLLKNIPLSASSFAFRKERSYLHYLEPHTQ NVKYCHLDIVSFFHSIDVNIVRDTFSVYFSDEFLVKEKQSLDADFMA SVTLTAELDGVKETFIPMGFKSSPSISNIIFRKIDILIQKFCDKNKITYT RYADDLLFSTKKENNILSSTFFINEISSILSINKFKLNKSKYLYKEGTIS LGGYVIENILKDNSSGNIRLSSSKLNPLYKALYEIKKGSSSKHICIKVF NLKLKRFIYKKNKEKFEAKFYSSQLKNKLLGYRSYLLSFVIFHKKYK CINPIFLEKCVFLISEIESIMNRKF(SEQ ID NO: 96)</p>
<p>REVERSE TRANSCRIPTASE</p> <p>ESCHERICHIA COLI RT</p> <p>REF SEQ. TGH57013</p>	<p>MKITSNNVTAVINGKGWHSINWKKCHQHVKTIQTRIAKAACNQQW RTVGRLQRLVRSFSARALAVKRV TENS GRKTPGVDGQIWSTPESK WEAIFKLRRKGKPLPLKRVFIPKSNGKKRPLGIPVMLDRAMQALH LLGLEPVSETNADHNSYGFRPARCTADAIQQVCNMYSSRNASKWVL EGDIKGCFEHISHEWLLNIPMDKQILRNWLKAGIIEKSIFSCTLSTGTP QGGIISPVLANMALDGLERLLQNRFRGRNRLI(SEQ ID NO: 97)</p>
<p>REVERSE TRANSCRIPTASE</p> <p>BACILLUS SUBTILIS RT</p> <p>REF SEQ. QBJ66766</p>	<p>MSKIKINYEKYHIKPFPHFDQRIKVNKKVKENLQNPFIYIAAHSFYFPI HYKKISYKFKNGLTSSPKERDIFYSGHMDGYIYKHYGEILNHNKYN TCIGKGIDHVS LAYRNKMGKSNIHFAAEVINFISEQQAFIFVSDFS SYFDSL DHAILKEKLIEVLEEQDKLSKDWWNVFKHITRYNWVEKEE VISDLECTKEKIARDKKSRRERYTPEAFREFRKRNVNIKSNDTGVGIPQ GTAISAVLANVY AIDLQKLNQYALKYGGIYRRYSDDIIMVLPMTSD GQDPSNDHVSFIKSVVKNKVTMGDSKTSVLYYANNNIYEDYQRK RESKMDYLGFSFDGMTVKIREKSLFKYYHRTYKINSINWASVKKE KKVGRKKLYLLYSHLGRNYKGHG NFISYCKKAHAVFEGNKKIESLI NQQIKRHWKKIQKRLVDV(SEQ ID NO: 98)</p>
<p>EUBACTERIUM RECTALE GROUP II INTRON RT</p>	<p>DTSNLMEQLSSDNLNRAYLQVVRNKGAEVGDGMKYTELKEHLAK NGETIKGQLRTRKYKQPARRVEIPKPDGGVRNLGVPTVTDRFIQQA IAQVLTPIYEEQFHDHSYGFRPNRCAQQAILTALNIMNDGNDWIVDI DLEKFFDTVNHDKLMTLIGRTIKDGDVISIVRKYLVSIGIMIDDEYEDS</p>

DESCRIPTION	SEQUENCE
	IVGTPQGGNLSPLLANIMLNELDKEMEKRGLENFVRYADDCIIMVGSE MSANRVMRNISRFIEEKLGLKVNMTKSKVDRPSGLKYLGFYFDP RAHQFKAKPHAKSVAKFKKRMKELTCRSWGVSNYSYKVEKLNQLIR GWINYFKIGSMKTLCKELDSRIRYRLRMCIWKQWKTQPNQEKNLV KLGIDRNTARRVAYTGKRIAYVCNKGAVNVAISNKRLASFGLISMLD YYIEKCVTC(SEQ ID NO: 99)
GEOBACILLUS STEAROTHERMOPHIL US GROUP II INTRON RT	ALLERILARDNLITALKRVEANQGAPGIDGVSTDQLRDYIRAHWSTI HAQLLAGTYRPAPVRRVEIPKPGGGTRQLGIPTVVDRLIQQAILQELT PIFDPDFSSSSFGFRPGRNAHDAVRQAQGYIQEGYRYVVDMDLEKFF DRVNHDILMSRVARKVKDKRVLKLIRAYLQAGVMIEGVKVQTEEGT PQGGPLSPLLANILLDDLDKELEKRGKLCRYADDCNIYVKSRLAGQ RVKQSIQRFLKTLKLKVNEEKSAVDRPWKRAFLGFSFTPERKARIR LAPRSIQRLKQIRQLTNPNWSISMPERIHRVNQYVMGWIGYFRLVE TPSVLQTIEGWIRRLRLCQWLQWKRVRTRIRELRLALGLKETAVMEI ANTRKGAWRTTKTPQLHQALGKTYWTAQGLKSLTQR(SEQ ID NO: 100)

Variant and error-prone RTs

[0495] Reverse transcriptases are essential for synthesizing complementary DNA (cDNA) strands from RNA templates. Reverse transcriptases are enzymes composed of distinct domains that exhibit different biochemical activities. The enzymes catalyze the synthesis of DNA from an RNA template, as follows: In the presence of an annealed primer, reverse transcriptase binds to an RNA template and initiates the polymerization reaction. RNA-dependent DNA polymerase activity synthesizes the complementary DNA (cDNA) strand, incorporating dNTPs. RNase H activity degrades the RNA template of the DNA:RNA complex. Thus, reverse transcriptases comprise (a) a binding activity that recognizes and binds to a RNA/DNA hybrid, (b) an RNA-dependent DNA polymerase activity, and (c) an RNase H activity. In addition, reverse transcriptases generally are regarded as having various attributes, including their thermostability, processivity (rate of dNTP incorporation), and fidelity (or error-rate). The reverse transcriptase variants contemplated herein may include any mutations to reverse transcriptase that impacts or changes any one or more of these enzymatic activities (e.g., RNA-dependent DNA polymerase activity, RNase H activity, or DNA/RNA hybrid-binding activity) or enzyme properties (e.g., thermostability, processivity, or fidelity). Such variants may be available in the art in the public domain, available commercially, or may be made using known methods of mutagenesis, including directed evolutionary processes (e.g., PACE or PANCE).

[0496] In various embodiments, the reverse transcriptase may be a variant reverse transcriptase. As used herein, a “variant reverse transcriptase” includes any naturally occurring or genetically engineered variant comprising one or more mutations (including singular mutations, inversions, deletions, insertions, and rearrangements) relative to a reference sequences (e.g., a reference wild type sequence). RT naturally have several activities, including an RNA-dependent DNA polymerase activity, ribonuclease H activity, and DNA-dependent DNA polymerase activity. Collectively, these activities enable the enzyme to convert single-stranded RNA into double-stranded cDNA. In retroviruses and retrotransposons, this cDNA can then integrate into the host genome, from which

new RNA copies can be made via host-cell transcription. Variant RT's may comprise a mutation which impacts one or more of these activities (either which reduces or increases these activities, or which eliminates these activities all together). In addition, variant RTs may comprise one or more mutations which render the RT more or less stable, less prone to aggregation, and facilitates purification and/or detection, and/or other the modification of properties or characteristics.

[0497] A person of ordinary skill in the art will recognize that variant reverse transcriptases derived from other reverse transcriptases, including but not limited to Moloney Murine Leukemia Virus (M-MLV); Human Immunodeficiency Virus (HIV) reverse transcriptase and avian Sarcoma-Leukosis Virus (ASLV) reverse transcriptase, which includes but is not limited to Rous Sarcoma Virus (RSV) reverse transcriptase, Avian Myeloblastosis Virus (AMV) reverse transcriptase, Avian Erythroblastosis Virus (AEV) Helper Virus MCAV reverse transcriptase, Avian Myelocytomatosis Virus MC29 Helper Virus MCAV reverse transcriptase, Avian Reticuloendotheliosis Virus (REV-T) Helper Virus REV-A reverse transcriptase, Avian Sarcoma Virus UR2 Helper Virus UR2AV reverse transcriptase, Avian Sarcoma Virus Y73 Helper Virus YAV reverse transcriptase, Rous Associated Virus (RAV) reverse transcriptase, and Myeloblastosis Associated Virus (MAV) reverse transcriptase may be suitably used in the subject methods and composition described herein.

[0498] One method of preparing variant RTs is by genetic modification (e.g., by modifying the DNA sequence of a wild-type reverse transcriptase). A number of methods are known in the art that permit the random as well as targeted mutation of DNA sequences (see for example, Ausubel et. al. *Short Protocols in Molecular Biology* (1995) 3.sup.rd Ed. John Wiley & Sons, Inc.). In addition, there are a number of commercially available kits for site-directed mutagenesis, including both conventional and PCR-based methods. Examples include the QuikChange Site-Directed Mutagenesis Kits (AGILENT®), the Q5® Site-Directed Mutagenesis Kit (NEW ENGLAND BIOLABS®), and GeneArt™ Site-Directed Mutagenesis System (THERMOFISHER SCIENTIFIC®).

[0499] In addition, mutant reverse transcriptases may be generated by insertional mutation or truncation (N-terminal, internal, or C-terminal insertions or truncations) according to methodologies known to one skilled in the art. The term "mutation," as used herein, refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or a deletion or insertion of one or more residues within a sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook, *Molecular Cloning: A Laboratory Manual* (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)). Mutations can include a variety of categories, such as single base polymorphisms, microduplication regions, indel, and inversions, and is not meant to be limiting in any way. Mutations can include "loss-of-function" mutations which is the normal

result of a mutation that reduces or abolishes a protein activity. Most loss-of-function mutations are recessive, because in a heterozygote the second chromosome copy carries an unmutated version of the gene coding for a fully functional protein whose presence compensates for the effect of the mutation. Mutations also embrace “gain-of-function” mutations, which is one which confers an abnormal activity on a protein or cell that is otherwise not present in a normal condition. Many gain-of-function mutations are in regulatory sequences rather than in coding regions, and can therefore have a number of consequences. For example, a mutation might lead to one or more genes being expressed in the wrong tissues, these tissues gaining functions that they normally lack. Because of their nature, gain-of-function mutations are usually dominant.

[0500] Older methods of site-directed mutagenesis known in the art rely on sub-cloning of the sequence to be mutated into a vector, such as an M13 bacteriophage vector, that allows the isolation of single-stranded DNA template. In these methods, one anneals a mutagenic primer (i.e., a primer capable of annealing to the site to be mutated but bearing one or more mismatched nucleotides at the site to be mutated) to the single-stranded template and then polymerizes the complement of the template starting from the 3' end of the mutagenic primer. The resulting duplexes are then transformed into host bacteria and plaques are screened for the desired mutation.

[0501] More recently, site-directed mutagenesis has employed PCR methodologies, which have the advantage of not requiring a single-stranded template. In addition, methods have been developed that do not require sub-cloning. Several issues must be considered when PCR-based site-directed mutagenesis is performed. First, in these methods it is desirable to reduce the number of PCR cycles to prevent expansion of undesired mutations introduced by the polymerase. Second, a selection must be employed in order to reduce the number of non-mutated parental molecules persisting in the reaction. Third, an extended-length PCR method is preferred in order to allow the use of a single PCR primer set. And fourth, because of the non-template-dependent terminal extension activity of some thermostable polymerases it is often necessary to incorporate an end-polishing step into the procedure prior to blunt-end ligation of the PCR-generated mutant product.

[0502] Methods of random mutagenesis, which will result in a panel of mutants bearing one or more randomly situated mutations, exist in the art. Such a panel of mutants may then be screened for those exhibiting the desired properties, for example, increased stability, relative to a wild-type reverse transcriptase.

[0503] An example of a method for random mutagenesis is the so-called “error-prone PCR method.” As the name implies, the method amplifies a given sequence under conditions in which the DNA polymerase does not support high fidelity incorporation. Although the conditions encouraging error-prone incorporation for different DNA polymerases vary, one skilled in the art may determine such conditions for a given enzyme. A key variable for many DNA polymerases in the fidelity of amplification is, for example, the type and concentration of divalent metal ion in the buffer. The use

of manganese ion and/or variation of the magnesium or manganese ion concentration may therefore be applied to influence the error rate of the polymerase.

[0504] In various aspects, the RT of the multi-flap prime editors may be an “error-prone” reverse transcriptase variant. Error-prone reverse transcriptases that are known and/or available in the art may be used. It will be appreciated that reverse transcriptases naturally do not have any proofreading function; thus the error rate of reverse transcriptase is generally higher than DNA polymerases comprising a proofreading activity. The error-rate of any particular reverse transcriptase is a property of the enzyme’s “fidelity,” which represents the accuracy of template-directed polymerization of DNA against its RNA template. An RT with high fidelity has a low-error rate. Conversely, an RT with low fidelity has a high-error rate. The fidelity of M-MLV-based reverse transcriptases are reported to have an error rate in the range of one error in 15,000 to 27,000 nucleotides synthesized. See Boutabout et al., “DNA synthesis fidelity by the reverse transcriptase of the yeast retrotransposon Ty1,” *Nucleic Acids Res*, 2001, 29: 2217-2222, which is incorporated by reference. Thus, for purposes of this application, those reverse transcriptases considered to be “error-prone” or which are considered to have an “error-prone fidelity” are those having an error rate that is less than one error in 15,000 nucleotides synthesized.

[0505] Error-prone reverse transcriptase also may be created through mutagenesis of a starting RT enzyme (e.g., a wild type M-MLV RT). The method of mutagenesis is not limited and may include directed evolution processes, such as phage-assisted continuous evolution (PACE) or phage-assisted noncontinuous evolution (PANCE). The term “phage-assisted continuous evolution (PACE),” as used herein, refers to continuous evolution that employs phage as viral vectors. The general concept of PACE technology has been described, for example, in International PCT Application, PCT/US2009/056194, filed September 8, 2009, published as WO 2010/028347 on March 11, 2010; International PCT Application, PCT/US2011/066747, filed December 22, 2011, published as WO 2012/088381 on June 28, 2012; U.S. Application, U.S. Patent No. 9,023,594, issued May 5, 2015, International PCT Application, PCT/US2015/012022, filed January 20, 2015, published as WO 2015/134121 on September 11, 2015, and International PCT Application, PCT/US2016/027795, filed April 15, 2016, published as WO 2016/168631 on October 20, 2016, the entire contents of each of which are incorporated herein by reference.

[0506] Error-prone reverse transcriptases may also be obtain by phage-assisted non-continuous evolution (PANCE),” which as used herein, refers to non-continuous evolution that employs phage as viral vectors. PANCE is a simplified technique for rapid in vivo directed evolution using serial flask transfers of evolving ‘selection phage’ (SP), which contain a gene of interest to be evolved, across fresh *E. coli* host cells, thereby allowing genes inside the host *E. coli* to be held constant while genes contained in the SP continuously evolve. Serial flask transfers have long served as a widely-accessible approach for laboratory evolution of microbes, and, more recently, analogous approaches

have been developed for bacteriophage evolution. The PANCE system features lower stringency than the PACE system.

[0507] Other error-prone reverse transcriptases have been described in the literature, each of which are contemplated for use in the herein methods and compositions. For example, error-prone reverse transcriptases have been described in Bebenek et al., “Error-prone Polymerization by HIV-1 Reverse Transcriptase,” *J Biol Chem*, 1993, Vol. 268: 10324-10334 and Sebastian-Martin et al., “Transcriptional inaccuracy threshold attenuates differences in RNA-dependent DNA synthesis fidelity between retroviral reverse transcriptases,” *Scientific Reports*, 2018, Vol. 8: 627, each of which are incorporated by reference. Still further, reverse transcriptases, including error-prone reverse transcriptases can be obtained from a commercial supplier, including ProtoScript® (II) Reverse Transcriptase, AMV Reverse Transcriptase, WarmStart® Reverse Transcriptase, and M-MuLV Reverse Transcriptase, all from NEW ENGLAND BIOLABS®, or AMV Reverse Transcriptase XL, SMARTScribe Reverse Transcriptase, GPR ultra-pure MMLV Reverse Transcriptase, all from TAKARA BIO USA, INC. (formerly CLONTECH).

[0508] The herein disclosure also contemplates reverse transcriptases having mutations in RNaseH domain. As mentioned above, one of the intrinsic properties of reverse transcriptases is the RNase H activity, which cleaves the RNA template of the RNA:cDNA hybrid concurrently with polymerization. The RNase H activity can be undesirable for synthesis of long cDNAs because the RNA template may be degraded before completion of full-length reverse transcription. The RNase H activity may also lower reverse transcription efficiency, presumably due to its competition with the polymerase activity of the enzyme. Thus, the present disclosure contemplates any reverse transcriptase variants that comprise a modified RNaseH activity.

[0509] The herein disclosure also contemplates reverse transcriptases having mutations in the RNA-dependent DNA polymerase domain. As mentioned above, one of the intrinsic properties of reverse transcriptases is the RNA-dependent DNA polymerase activity, which incorporates the nucleobases into the nascent cDNA strand as coded by the template RNA strand of the RNA:cDNA hybrid. The RNA-dependent DNA polymerase activity can be increased or decreased (i.e., in terms of its rate of incorporation) to either increase or decrease the processivity of the enzyme. Thus, the present disclosure contemplates any reverse transcriptase variants that comprise a modified RNA-dependent DNA polymerase activity such that the processivity of the enzyme of either increased or decreased relative to an unmodified version.

[0510] Also contemplated herein are reverse transcriptase variants that have altered thermostability characteristics. The ability of a reverse transcriptase to withstand high temperatures is an important aspect of cDNA synthesis. Elevated reaction temperatures help denature RNA with strong secondary structures and/or high GC content, allowing reverse transcriptases to read through the sequence. As a result, reverse transcription at higher temperatures enables full-length cDNA synthesis and higher

yields, which can lead to an improved generation of the 3' flap ssDNA as a result of the multi-flap prime editing process. Wild type M-MLV reverse transcriptase typically has an optimal temperature in the range of 37-48°C; however, mutations may be introduced that allow for the reverse transcription activity at higher temperatures of over 48°C, including 49°C, 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, and higher.

[0511] The variant reverse transcriptases contemplated herein, including error-prone RTs, thermostable RTs, increase-processivity RTs, can be engineered by various routine strategies, including mutagenesis or evolutionary processes. In some cases, the variants can be produced by introducing a single mutation. In other cases, the variants may require more than one mutation. For those mutants comprising more than one mutation, the effect of a given mutation may be evaluated by introduction of the identified mutation to the wild-type gene by site-directed mutagenesis in isolation from the other mutations borne by the particular mutant. Screening assays of the single mutant thus produced will then allow the determination of the effect of that mutation alone.

[0512] Variant RT enzymes used herein may also include other "RT variants" having at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to any reference RT protein, including any wild type RT, or mutant RT, or fragment RT, or other variant of RT disclosed or contemplated herein or known in the art.

[0513] In some embodiments, an RT variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or up to 100, or up to 200, or up to 300, or up to 400, or up to 500 or more amino acid changes compared to a reference RT. In some embodiments, the RT variant comprises a fragment of a reference RT, such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of the reference RT. In some embodiments, the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild type RT (M-MLV reverse transcriptase) (*e.g.*, SEQ ID NO: 89) or to any of the reverse transcriptases of SEQ ID NOs: 90-100.

[0514] In some embodiments, the disclosure also may utilize RT fragments which retain their functionality and which are fragments of any herein disclosed RT proteins. In some embodiments, the

RT fragment is at least 100 amino acids in length. In some embodiments, the fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, or up to 600 or more amino acids in length.

[0515] In still other embodiments, the disclosure also may utilize RT variants which are truncated at the N-terminus or the C-terminus, or both, by a certain number of amino acids which results in a truncated variant which still retains sufficient polymerase function. In some embodiments, the RT truncated variant has a truncation of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 amino acids at the N-terminal end of the protein. In other embodiments, the RT truncated variant has a truncation of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 amino acids at the C-terminal end of the protein. In still other embodiments, the RT truncated variant has a truncation at the N-terminal and the C-terminal end which are the same or different lengths.

[0516] For example, the multi-flap prime editors disclosed herein may include a truncated version of M-MLV reverse transcriptase. In this embodiment, the reverse transcriptase contains 4 mutations (D200N, T306K, W313F, T330P; noting that the L603W mutation present in PE2 is no longer present due to the truncation). The DNA sequence encoding this truncated editor is 522 bp smaller than PE2, and therefore makes its potentially useful for applications where delivery of the DNA sequence is challenging due to its size (i.e., adeno-associated virus and lentivirus delivery). This embodiment is referred to as MMLV-RT(trunc) and has the following amino acid sequence:

MMLV-RT(TRUNC)	<i>TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIP LKATSTPVSIKQYPMSQEARLGKPHIQRLDQGILVPCQSPWNTPLLPVK KPGTNDYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLK DAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSTPLFNEA LHRDLADFRIQHPDLILLQYVDDLLAATSELDCCQGTRALLQTLGNLGY RASAKKAQICQKQVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLR EFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQA LLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLD PVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPD RWLSNARMTHYQALLDTRVQFGPVVALNPATLLPLPEEGLQHNCLDN SRLIN (SEQ ID NO: 766)</i>
----------------	---

[0517] In various embodiments, the multi-flap prime editors disclosed herein may comprise one of the RT variants described herein, or a RT variant thereof having at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to any reference Cas9 variants.

[0518] In still other embodiments, the present methods and compositions may utilize a DNA polymerase that has been evolved into a reverse transcriptase, as described in Effefson et al., “Synthetic evolutionary origin of a proofreading reverse transcriptase,” *Science*, June 24, 2016, Vol. 352: 1590-1593, the contents of which are incorporated herein by reference.

[0519] In certain other embodiments, the reverse transcriptase is provided as a component of a fusion protein also comprising a napDNAbp. In other words, in some embodiments, the reverse transcriptase is fused to a napDNAbp as a fusion protein.

[0520] In various embodiments, variant reverse transcriptases can be engineered from wild type M-MLV reverse transcriptase as represented by SEQ ID NO: 89.

[0521] In various embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising one or more of the following mutations: P51L, S67K, E69K, L139P, T197A, D200N, H204R, F209N, E302K, E302R, T306K, F309N, W313F, T330P, L345G, L435G, N454K, D524G, E562Q, D583N, H594Q, L603W, E607K, or D653N in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence.

[0522] Some exemplary reverse transcriptases that can be fused to napDNAbp proteins or provided as individual proteins according to various embodiments of this disclosure are provided below.

Exemplary reverse transcriptases include variants with at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to the following wild-type enzymes or partial enzymes:

Description	Sequence (variant substitutions relative to wild type)
Reverse transcriptase (M-MLV RT) wild type moloney murine leukemia virus Used in PE1 (prime editor 1 fusion protein disclosed herein)	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSTPLFDEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLG TAGFCRLWIP GFAEMAAPLYPLTKGT LFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVA AIA VLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTD RVQFGPVVALNPATLLPLPEEGLQHNC LDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALK MAEGKKLNVYTDSRYAFATAHIIHGEIYRRRGLLTSEGKEIKNKDEILALLKAL FLPKRLSIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 89)
M-MLV RT D200N	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR

Description	Sequence (variant substitutions relative to wild type)
	LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFLNEALHRDLADFR QHDPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTKTGTFLFNWGPDDQKAYQEIKQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLG PWRRPVAYLSKKLDPVAAGWPPCLRMVAAIA VLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLD TD RVQFGPVVALNPATLLPLPEEGLQHNC LDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALK MAEGKKLVYTD SRYAFATAHIIHGEIYRRRGLLTSEGKEIKNKDEILALLKAL FLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 701)
M-MLV RT D200N T330P	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLG I KPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFLNEALHRDLADFR QHDPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTKPGTFLFNWGPDDQKAYQEIKQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLG PWRRPVAYLSKKLDPVAAGWPPCLRMVAAIA VLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLD TD RVQFGPVVALNPATLLPLPEEGLQHNC LDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALK MAEGKKLVYTD SRYAFATAHIIHGEIYRRRGLLTSEGKEIKNKDEILALLKAL FLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 702)
M-MLV RT D200N T330P L603W	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLG I KPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFLNEALHRDLADFR QHDPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTKPGTFLFNWGPDDQKAYQEIKQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLG PWRRPVAYLSKKLDPVAAGWPPCLRMVAAIA VLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLD TD RVQFGPVVALNPATLLPLPEEGLQHNC LDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALK MAEGKKLVYTD SRYAFATAHIIHGEIYRRRGWLTSEGKEIKNKDEILALLKA LFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 740)
M-MLV RT D200N T330P L603W E69K	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQKARLG I KPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFLNEALHRDLADFR QHDPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTKPGTFLFNWGPDDQKAYQEIKQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLG PWRRPVAYLSKKLDPVAAGWPPCLRMVAAIA VLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLD TD RVQFGPVVALNPATLLPLPEEGLQHNC LDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALK MAEGKKLVYTD SRYAFATAHIIHGEIYRRRGWLTSEGKEIKNKDEILALLKA LFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 703)

Description	Sequence (variant substitutions relative to wild type)
M-MLV RT D200N T330P L603W E302R	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLVPKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSTLFLNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGYYLLKEGQRWLTEARKETVMGQPTPKTPRQLRREFLGTAGFCRLWIP GFAEMAAPLYPLTKPGTFLNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLGWRRPVAYLSKKLDPVAAGWPPCLRMVAIA VLTGDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLDLD RVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALK MAEGKKLVYTDSTRYAFATAHIIHGEIYRRRGWLTSEGKEIKNKDEILALLKA LFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 704)
M-MLV RT D200N T330P L603W E607K	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLVPKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSTLFLNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGYYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTKPGTFLNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLGWRRPVAYLSKKLDPVAAGWPPCLRMVAIA VLTGDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLDLD RVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALK MAEGKKLVYTDSTRYAFATAHIIHGEIYRRRGWLTSGKEIKNKDEILALLKA LFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 705)
M-MLV RT D200N T330P L603W L139P	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLVPKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSTLFLNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGYYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTKPGTFLNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLGWRRPVAYLSKKLDPVAAGWPPCLRMVAIA VLTGDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLDLD RVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALK MAEGKKLVYTDSTRYAFATAHIIHGEIYRRRGWLTSEGKEIKNKDEILALLKA LFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 706)
M-MLV RT D200N T330P L603W L435G	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLVPKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSTLFLNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGYYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTKPGTFLNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLGWRRPVAYLSKKLDPVAAGWPPCLRMVAIA VLTGDAGKLTMGQPLVIGAPHAVEALVKQPPDRWLSNARMTHYQALLDLD DRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALK

Description	Sequence (variant substitutions relative to wild type)
	MAEGKKLVNYTDSRYAFATAHGHGEIYRRRG <u>W</u> LTSEGKEIKNKDEILALLKA LFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 707)
M-MLV RT D200N T330P L603W N454K	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLCLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLF <u>N</u> EALHRDLADFRI QHPDLILLQYVDDLALLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTK <u>P</u> GTFLNWGPDQQKAYQEIQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLGWRRPVAYLSKKLDPVAAGWPPCLRMVAIA VLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLS <u>K</u> ARMTHYQALLLDTD RVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIAKALPAGTSAQRAELIALTQALK MAEGKKLVNYTDSRYAFATAHGHGEIYRRRG <u>W</u> LTSEGKEIKNKDEILALLKA LFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 708)
M-MLV RT D200N T330P L603W T306K	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLCLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLF <u>N</u> EALHRDLADFRI QHPDLILLQYVDDLALLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTK <u>P</u> GTFLNWGPDQQKAYQEIQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLGWRRPVAYLSKKLDPVAAGWPPCLRMVAIA VLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTD RVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETEVIAKALPAGTSAQRAELIALTQALK MAEGKKLVNYTDSRYAFATAHGHGEIYRRRG <u>W</u> LTSEGKEIKNKDEILALLKA LFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 709)
M-MLV RT D200N T330P L603W W313F	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLCLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLF <u>N</u> EALHRDLADFRI QHPDLILLQYVDDLALLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRL <u>F</u> IPG FAEMAAPLYPLTK <u>P</u> GTFLNWGPDQQKAYQEIQALLTAPALGLPDLTKPFEL FVDEKQGYAKGVLTQKLGWRRPVAYLSKKLDPVAAGWPPCLRMVAIAV LTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTD RVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTW YTDGSSLLQEGQRKAGAAVTTETEVIAKALPAGTSAQRAELIALTQALKMA EGKKLVNYTDSRYAFATAHGHGEIYRRRG <u>W</u> LTSEGKEIKNKDEILALLKALFL PKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 710)
M-MLV RT D200N T330P L603W D524G E562Q D583N	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLCLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLF <u>N</u> EALHRDLADFRI QHPDLILLQYVDDLALLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTK <u>P</u> GTFLNWGPDQQKAYQEIQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLGWRRPVAYLSKKLDPVAAGWPPCLRMVAIA

Description	Sequence (variant substitutions relative to wild type)
	VLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTD RVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHT WYT <u>G</u> GSSLLQEGQRKAGAAVTTETETEWAKALPAGTSAQRAQALIALTQALK MAEGKKLNVT <u>N</u> SRYAFATAHIGHEIYRRRG <u>W</u> LTSSEGKEIKNKDEILALLKA LFLPKRLSIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 711)
M-MLV RT D200N T330P L603W E302R W313F	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSQIKQYPMSEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDFAFFCLR LHPTSQPLFAFEWRDPENGISGQLTWTRLPQGFKNSTPLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLR <u>R</u> FLGTAGFCRL <u>F</u> IPG FAEMAAPLYPLTK <u>P</u> GTLFNWGPDDQKAYQEIKQALLTAPALGLPDLTKPFEL FVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAIAV LTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTD RVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTW YTDGSSLLQEGQRKAGAAVTTETETEWAKALPAGTSAQRAELIALTQALKMA EGKKLNVTDSRYAFATAHIGHEIYRRRG <u>W</u> LTSSEGKEIKNKDEILALLKALFL PKRLSIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 712)
M-MLV RT D200N T330P L603W E607K L139P	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSQIKQYPMSEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGPPPSHQWYTVLDLKDFAFFCLR LHPTSQPLFAFEWRDPENGISGQLTWTRLPQGFKNSTPLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIP GFAEMAAPLYPLTK <u>P</u> GTLFNWGPDDQKAYQEIKQALLTAPALGLPDLTKPFE LFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAIA VLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTD RVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHT WYTDGSSLLQEGQRKAGAAVTTETETEWAKALPAGTSAQRAELIALTQALK MAEGKKLNVTDSRYAFATAHIGHEIYRRRG <u>W</u> LTSK <u>G</u> KEIKNKDEILALLKA LFLPKRLSIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 713)
M-MLV RT P51L S67K T197A H204R E302K F309N W313F T330P L435G N454K D524G D583N H594Q D653N	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLI <u>L</u> LK ATSTPVSQIKQYPM <u>K</u> QEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGT NDYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDFAFFCL RLHPTSQPLFAFEWRDPENGISGQLTWTRLPQGFKNSTPLFDEAL <u>R</u> RDLADFR IQHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQ KQVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLR <u>K</u> FLGTAG <u>N</u> CRLE <u>F</u> PGFAEMAAPLYPLTK <u>P</u> GTLFNWGPDDQKAYQEIKQALLTAPALGLPDLTKPF ELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAIA AVLTKDAGKLTMGQPLVIGAPHAVEALVKQPPDRWLS <u>K</u> ARMTHYQALLLD TDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADH TWYT <u>G</u> GSSLLQEGQRKAGAAVTTETETEWAKALPAGTSAQRAELIALTQALK MAEGKKLNVT <u>N</u> SRYAFATAHIGHEIYRRRGLLTSEGKEIKNKDEILALLKAL FLPKRLSIHCPGHQKGHSAEARGNRMAN <u>N</u> QAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 714)
M-MLV RT D200N P51L S67K T197A H204R E302K	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLI <u>L</u> LK ATSTPVSQIKQYPM <u>K</u> QEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGT NDYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDFAFFCL RLHPTSQPLFAFEWRDPENGISGQLTWTRLPQGFKNSTPLFNEAL <u>R</u> RDLADFR IQHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQ

Description	Sequence (variant substitutions relative to wild type)
F309N W313F T330P L345G N454K D524G D583N H594Q D653N	KQVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLR K FLGTAG N CRL F PGFAEMAAPLYPLTK P GTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPF ELFVDEKQGYAKGVLTKQLGPWRRPVAYLSKKLDPVAAGWPPCLRMVA AVLTKDAGKLTMGQPLV G APHAVEALVKQPPDRWLS K ARMTHYQALLD TDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADH TWYT G GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALK MAEGKKLVY T NSRYAFATAH I QGEIYRRRGLLTSEGKEIKNKDEILALLKAL FLPKRLSIHCPGHQKGHSAEARGNRMAN N QAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 715)
M-MLV RT D200N T330P L603W T306K W313F in PE2	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSQYPMSEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSTL F NEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLG K AGFCRL F IPG FAEMAAPLYPLTK P GTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFEL FVDEKQGYAKGVLTKQLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAIAV LTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLD T DR VQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTW YTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMA EGKKLVY T DSRYAFATAH I HGEIYRRRG W LTSEGKEIKNKDEILALLKALFL PKRLSIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 716)

[0523] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising one or more of the following mutations: P51X, S67X, E69X, L139X, T197X, D200X, H204X, F209X, E302X, T306X, F309X, W313X, T330X, L345X, L435X, N454X, D524X, E562X, D583X, H594X, L603X, E607X, or D653X in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid.

[0524] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a P51X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is L.

[0525] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a S67X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is K.

[0526] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a E69X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another

wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is K.

[0527] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a L139X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is P.

[0528] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a T197X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is A.

[0529] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a D200X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is N.

[0530] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a H204X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is R.

[0531] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a F209X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is N.

[0532] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a E302X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is K.

[0533] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a E302X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another

wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is R.

[0534] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a T306X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is K.

[0535] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a F309X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is N.

[0536] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a W313X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is F.

[0537] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a T330X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is P.

[0538] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a L345X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is G.

[0539] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a L435X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is G.

[0540] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a N454X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another

wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is K.

[0541] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a D524X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is G.

[0542] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a E562X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is Q.

[0543] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a D583X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is N.

[0544] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a H594X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is Q.

[0545] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a L603X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is W.

[0546] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a E607X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is K.

[0547] In various other embodiments, the multi-flap prime editors described herein (with RT provided as either a fusion partner or *in trans*) can include a variant RT comprising a D653X mutation in the wild type M-MLV RT of SEQ ID NO: 89 or at a corresponding amino acid position in another

wild type RT polypeptide sequence, wherein “X” can be any amino acid. In certain embodiments, X is N.

[0548] Some exemplary reverse transcriptases that can be fused to napDNAbp proteins or provided as individual proteins according to various embodiments of this disclosure are provided below.

Exemplary reverse transcriptases include variants with at least 80%, at least 85%, at least 90%, at least 95% or at least 99% sequence identity to the following wild-type enzymes or partial enzymes:

DESCRIPTION	SEQUENCE (VARIANT SUBSTITUTIONS RELATIVE TO WILD TYPE)
REVERSE TRANSCRIPTASE (M-MLV RT) WILD TYPE MOLONEY MURINE LEUKEMIA VIRUS USED IN PE1 (PRIME EDITOR 1 FUSION PROTEIN DISCLOSED HEREIN)	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPPEMGISGQLTWTRLPQGFKNSPTLFDEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPG FAEMAAPLYPLTKTGTLFNWGPDPQKAYQEIQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLVNYTDSRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLS IIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 89)
M-MLV RT D200N	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPG FAEMAAPLYPLTKTGTLFNWGPDPQKAYQEIQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLVNYTDSRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLS IIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 106)
M-MLV RT D200N T330P	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPG FAEMAAPLYPLTKPGTLFNWGPDPQKAYQEIQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK

DESCRIPTION	SEQUENCE (VARIANT SUBSTITUTIONS RELATIVE TO WILD TYPE)
	KLNVTDSRYAFATAHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLS IIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 107)
M-MLV RT D200N T330P L603W	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPGMSGQLTWTRLPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAFCRLWIPG FAEMAAPLYPLTKPGTLFNWGPDDQKAYQEIQAALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLDLDTRVQ FGPVVALNPATLLPLPEEGLQHNCDDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRL SIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 108)
M-MLV RT E69K D200N T330P L603W	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIIKQYPMSQKARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPGMSGQLTWTRLPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAFCRLWIPG FAEMAAPLYPLTKPGTLFNWGPDDQKAYQEIQAALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLDLDTRVQ FGPVVALNPATLLPLPEEGLQHNCDDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRL SIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 109)
M-MLV RT D200N T330P L603W E302R	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPGMSGQLTWTRLPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAFCRLWIPG FAEMAAPLYPLTKPGTLFNWGPDDQKAYQEIQAALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLDLDTRVQ FGPVVALNPATLLPLPEEGLQHNCDDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRL SIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 110)
M-MLV RT D200N T330P L603W E607K	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPGMSGQLTWTRLPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAFCRLWIPG FAEMAAPLYPLTKPGTLFNWGPDDQKAYQEIQAALLTAPALGLPDLTKPFELF

DESCRIPTION	SEQUENCE (VARIANT SUBSTITUTIONS RELATIVE TO WILD TYPE)
	VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETETEWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHIGEIYRRRG <u>W</u> LTS <u>K</u> GKEIKNKDEILALLKALFLPKRL SIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 111)
M-MLV RT D200N T330P L603W L139P	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGPPPSHQWYTVLDLKDFAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGYYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAAGFCRLWIPG FAEMAAPLYPLTKPGTLFNWGPDQOKAYQEIKQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETETEWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHIGEIYRRRG <u>W</u> LTS <u>K</u> GKEIKNKDEILALLKALFLPKRL SIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 112)
M-MLV RT D200N T330P L603W L435G	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDFAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGYYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAAGFCRLWIPG FAEMAAPLYPLTKPGTLFNWGPDQOKAYQEIKQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVIGAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETETEWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHIGEIYRRRG <u>W</u> LTS <u>K</u> GKEIKNKDEILALLKALFLPKRL SIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 113)
M-MLV RT D200N T330P L603W N454K	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDFAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLGYYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAAGFCRLWIPG FAEMAAPLYPLTKPGTLFNWGPDQOKAYQEIKQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSKARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETETEWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHIGEIYRRRG <u>W</u> LTS <u>K</u> GKEIKNKDEILALLKALFLPKRL SIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 114)
M-MLV RT D200N T330P	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDFAFFCLR

DESCRIPTION	SEQUENCE (VARIANT SUBSTITUTIONS RELATIVE TO WILD TYPE)
L603W T306K	LHPTSQPLFAFEWRDPEMGISGQLTWTRLPPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLWIPG FAEMAAPLYPLTKPGTLFNWGPDQKQAYQEIKQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDTRVQ FGPVVALNPATLLPLPEEGLQHNCILDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRL SIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 115)
M-MLV RT D200N T330P L603W W313F	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLG TAGFCRLFIPG FAEMAAPLYPLTKPGTLFNWGPDQKQAYQEIKQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDTRVQ FGPVVALNPATLLPLPEEGLQHNCILDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRL SIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 116)
M-MLV RT D200N T330P L603W D524G E562Q D583N	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLG TAGFCRLWIPG FAEMAAPLYPLTKPGTLFNWGPDQKQAYQEIKQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDTRVQ FGPVVALNPATLLPLPEEGLQHNCILDILAEAHGTRPDLTDQPLPDADHTWYTG GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAQLIALTQALKMAEGK KLNVTNSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRL SIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 117)
M-MLV RT D200N T330P L603W E302R W313F	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLRFLGTAGFCRLFIPG FAEMAAPLYPLTKPGTLFNWGPDQKQAYQEIKQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDTRVQ FGPVVALNPATLLPLPEEGLQHNCILDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRL

DESCRIPTION	SEQUENCE (VARIANT SUBSTITUTIONS RELATIVE TO WILD TYPE)
	SIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 118)
M-MLV RT D200N T330P L603W E607K L139P	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLL PVKKPGTN DYRPVQDLREV NKRVEDIHPTVPNPYNLLSGPPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDP EMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFR I QHPDLILLQYVDDL LLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLG TAGFCRLWIPG FAEMAAPLYPLTKPGTLFNWGP DQKAYQEIQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLG PWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNC LDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTYDSRYAFATAHIHGEIYRRRGWLTSGKEIKNKDEILALLKALFLPKRL SIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 119)
M-MLV RT P51L S67K T197A H204R E302K F309N W313F T330P L435G N454K D524G D583N H594Q D653N	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIILLLK ATSTPVSIKQYPMKQEARLGKPHIQRLLDQGILVPCQSPWNTPLL PVKKPGTN DYRPVQDLREV NKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDP EMGISGQLTWTRLPQGFKNSPALFDEALRRDLADFR I QHPDLILLQYVDDL LLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLRKFLGTAGNCR LFIPG FAEMAAPLYPLTKPGTLFNWGP DQKAYQEIQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLG PWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVIGAPHAVEALVKQPPDRWLSKARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNC LDILAEAHGTRPDLTDQPLPDADHTWYTG GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTYNSRYAFATAHIQGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLS IIHCPGHQKGHSAEARGNRMANQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 120)
M-MLV RT P51L S67K T197A D200N H204R E302K F309N W313F T330P L345G N454K D524G D583N H594Q D653N	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIILLLK ATSTPVSIKQYPMKQEARLGKPHIQRLLDQGILVPCQSPWNTPLL PVKKPGTN DYRPVQDLREV NKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDP EMGISGQLTWTRLPQGFKNSPALFNEALRRDLADFR I QHPDLILLQYVDDL LLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLRKFLGTAGNCR LFIPG FAEMAAPLYPLTKPGTLFNWGP DQKAYQEIQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLG PWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVIGAPHAVEALVKQPPDRWLSKARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNC LDILAEAHGTRPDLTDQPLPDADHTWYTG GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTYNSRYAFATAHIQGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLS IIHCPGHQKGHSAEARGNRMANQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 121)
M-MLV RT D200N T330P L603W T306K W313F IN PE2	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLL PVKKPGTN DYRPVQDLREV NKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDP EMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFR I QHPDLILLQYVDDL LLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRL FIPG FAEMAAPLYPLTKPGTLFNWGP DQKAYQEIQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLG PWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT

DESCRIPTION	SEQUENCE (VARIANT SUBSTITUTIONS RELATIVE TO WILD TYPE)
	KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETETEVIAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRL SIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 122)

[0549] The multi-flap prime editor system described here contemplates any publicly-available reverse transcriptase described or disclosed in any of the following U.S. patents (each of which are incorporated by reference in their entireties): U.S. Patent Nos: 10,202,658; 10,189,831; 10,150,955; 9,932,567; 9,783,791; 9,580,698; 9,534,201; and 9,458,484, and any variant thereof that can be made using known methods for installing mutations, or known methods for evolving proteins. The following references describe reverse transcriptases in art. Each of their disclosures are incorporated herein by reference in their entireties.

[0550] Herzog, E., Voronin, N., Kucherenko, N. & Hizi, A. A Novel Leu92 Mutant of HIV-1 Reverse Transcriptase with a Selective Deficiency in Strand Transfer Causes a Loss of Viral Replication. *J. Virol.* **89**, 8119–8129 (2015).

[0551] Mohr, G. *et al.* A Reverse Transcriptase-Cas1 Fusion Protein Contains a Cas6 Domain Required for Both CRISPR RNA Biogenesis and RNA Spacer Acquisition. *Mol. Cell* **72**, 700-714.e8 (2018).

[0552] Zhao, C., Liu, F. & Pyle, A. M. An ultraprocessive, accurate reverse transcriptase encoded by a metazoan group II intron. *RNA* **24**, 183–195 (2018).

[0553] Zimmerly, S. & Wu, L. An Unexplored Diversity of Reverse Transcriptases in Bacteria. *Microbiol Spectr* **3**, MDNA3-0058–2014 (2015).

[0554] Ostertag, E. M. & Kazazian Jr, H. H. Biology of Mammalian L1 Retrotransposons. *Annual Review of Genetics* **35**, 501–538 (2001).

[0555] Perach, M. & Hizi, A. Catalytic Features of the Recombinant Reverse Transcriptase of Bovine Leukemia Virus Expressed in Bacteria. *Virology* **259**, 176–189 (1999).

[0556] Lim, D. *et al.* Crystal structure of the moloney murine leukemia virus RNase H domain. *J. Virol.* **80**, 8379–8389 (2006).

[0557] Zhao, C. & Pyle, A. M. Crystal structures of a group II intron maturase reveal a missing link in spliceosome evolution. *Nature Structural & Molecular Biology* **23**, 558–565 (2016).

[0558] Griffiths, D. J. Endogenous retroviruses in the human genome sequence. *Genome Biol.* **2**, REVIEWS1017 (2001).

[0559] Baranauskas, A. *et al.* Generation and characterization of new highly thermostable and processive M-MuLV reverse transcriptase variants. *Protein Eng Des Sel* **25**, 657–668 (2012).

- [0560] Zimmerly, S., Guo, H., Perlman, P. S. & Lambowitz, A. M. Group II intron mobility occurs by target DNA-primed reverse transcription. *Cell* **82**, 545–554 (1995).
- [0561] Feng, Q., Moran, J. V., Kazazian, H. H. & Boeke, J. D. Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. *Cell* **87**, 905–916 (1996).
- [0562] Berkhout, B., Jebbink, M. & Zsíros, J. Identification of an Active Reverse Transcriptase Enzyme Encoded by a Human Endogenous HERV-K Retrovirus. *Journal of Virology* **73**, 2365–2375 (1999).
- [0563] Kotewicz, M. L., Sampson, C. M., D'Alessio, J. M. & Gerard, G. F. Isolation of cloned Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity. *Nucleic Acids Res* **16**, 265–277 (1988).
- [0564] Arezi, B. & Hogrefe, H. Novel mutations in Moloney Murine Leukemia Virus reverse transcriptase increase thermostability through tighter binding to template-primer. *Nucleic Acids Res* **37**, 473–481 (2009).
- [0565] Blain, S. W. & Goff, S. P. Nuclease activities of Moloney murine leukemia virus reverse transcriptase. Mutants with altered substrate specificities. *J. Biol. Chem.* **268**, 23585–23592 (1993).
- [0566] Xiong, Y. & Eickbush, T. H. Origin and evolution of retroelements based upon their reverse transcriptase sequences. *EMBO J* **9**, 3353–3362 (1990).
- [0567] Herschhorn, A. & Hizi, A. Retroviral reverse transcriptases. *Cell. Mol. Life Sci.* **67**, 2717–2747 (2010).
- [0568] Taube, R., Loya, S., Avidan, O., Perach, M. & Hizi, A. Reverse transcriptase of mouse mammary tumour virus: expression in bacteria, purification and biochemical characterization. *Biochem. J.* **329** (Pt 3), 579–587 (1998).
- [0569] Liu, M. *et al.* Reverse Transcriptase-Mediated Tropism Switching in Bordetella Bacteriophage. *Science* **295**, 2091–2094 (2002).
- [0570] Luan, D. D., Korman, M. H., Jakubczak, J. L. & Eickbush, T. H. Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non-LTR retrotransposition. *Cell* **72**, 595–605 (1993).
- [0571] Nottingham, R. M. *et al.* RNA-seq of human reference RNA samples using a thermostable group II intron reverse transcriptase. *RNA* **22**, 597–613 (2016).
- [0572] Telesnitsky, A. & Goff, S. P. RNase H domain mutations affect the interaction between Moloney murine leukemia virus reverse transcriptase and its primer-template. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 1276–1280 (1993).
- [0573] Halvas, E. K., Svarovskaia, E. S. & Pathak, V. K. Role of Murine Leukemia Virus Reverse Transcriptase Deoxyribonucleoside Triphosphate-Binding Site in Retroviral Replication and In Vivo Fidelity. *Journal of Virology* **74**, 10349–10358 (2000).

- [0574] Nowak, E. *et al.* Structural analysis of monomeric retroviral reverse transcriptase in complex with an RNA/DNA hybrid. *Nucleic Acids Res* **41**, 3874–3887 (2013).
- [0575] Stamos, J. L., Lentzsch, A. M. & Lambowitz, A. M. Structure of a Thermostable Group II Intron Reverse Transcriptase with Template-Primer and Its Functional and Evolutionary Implications. *Molecular Cell* **68**, 926-939.e4 (2017).
- [0576] Das, D. & Georgiadis, M. M. The Crystal Structure of the Monomeric Reverse Transcriptase from Moloney Murine Leukemia Virus. *Structure* **12**, 819–829 (2004).
- [0577] Avidan, O., Meer, M. E., Oz, I. & Hizi, A. The processivity and fidelity of DNA synthesis exhibited by the reverse transcriptase of bovine leukemia virus. *European Journal of Biochemistry* **269**, 859–867 (2002).
- [0578] Gerard, G. F. *et al.* The role of template-primer in protection of reverse transcriptase from thermal inactivation. *Nucleic Acids Res* **30**, 3118–3129 (2002).
- [0579] Monot, C. *et al.* The Specificity and Flexibility of L1 Reverse Transcription Priming at Imperfect T-Tracts. *PLOS Genetics* **9**, e1003499 (2013).
- [0580] Mohr, S. *et al.* Thermostable group II intron reverse transcriptase fusion proteins and their use in cDNA synthesis and next-generation RNA sequencing. *RNA* **19**, 958–970 (2013).
- [0581] Any of the references noted above which relate to reverse transcriptases are hereby incorporated by reference in their entireties, if not already stated so.

[4] Prime Editors

[0582] The disclosure provides systems comprising prime editors. In one aspect, this disclosure provides systems for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited comprising a first prime editor complex and a second prime editor complex, wherein each of the first and second prime editor complexes comprises (1) a prime editor comprising (i) a nucleic acid programmable DNA binding protein (napDNAbp), and (ii) a polypeptide having an RNA-dependent DNA polymerase activity; and (2) a pegRNA comprising a spacer sequence, gRNA core, a DNA synthesis template, and a primer binding site, wherein the DNA synthesis template of the pegRNA of the first prime editor complex encodes a first single-stranded DNA sequence and the DNA synthesis template of the pegRNA of the second prime editor complex encodes a second single-stranded DNA sequence, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence each comprises a region of complementarity to the other, and wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence form a duplex comprising an edited portion as compared to the DNA sequence at the target site to be edited, which integrates into the target site to be edited.

[0583] In another aspect, the present disclosure provides systems for editing one or more double-stranded DNA sequences, the system comprising:

- a) a first prime editor complex comprising:

- i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (first napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEGRNA) that binds to a first binding site on a first strand of a first double-stranded DNA sequence at a first target site to be edited;
- b) a second prime editor complex comprising:
- i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a second prime editing guide RNA (second PEGRNA) that binds to a second binding site on a second strand of the first double-stranded DNA sequence at the first target site to be edited;
- c) a third prime editor complex comprising:
- i. a third prime editor comprising a third nucleic acid programmable DNA binding protein (third napDNAbp) and a third polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a third prime editing guide RNA (third PEGRNA) that binds to a first binding site on a first strand of a second double-stranded DNA sequence at a second target site to be edited;
- d) a fourth prime editor complex comprising:
- i. a fourth prime editor comprising a fourth nucleic acid programmable DNA binding protein (fourth napDNAbp) and a fourth polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a fourth prime editing guide RNA (fourth PEGRNA) that binds to a second binding site on a second strand of the second double-stranded DNA sequence at the second target site to be edited;

wherein the first PEGRNA comprises a first DNA synthesis template encoding a first single-stranded DNA sequence, the second PEGRNA comprises a second DNA synthesis template encoding a second single-stranded DNA sequence, the third PEGRNA comprises a third DNA synthesis template encoding a third single-stranded DNA sequence, and the fourth PEGRNA comprises a fourth DNA synthesis template encoding a fourth single-stranded DNA sequence;

wherein the first and the third single-stranded DNA sequence each comprise a region of complementarity to the other; and wherein, wherein the second and the fourth single-stranded DNA sequence each comprise a region of complementarity to the other.

[0584] In some embodiments, the prime editors used in the systems described herein (*e.g.*, the first prime editor, second prime editor, third prime editor, and/or fourth prime editor in the systems described above) are provided as fusion proteins. In some embodiments, the prime editor fusion proteins comprise a napDNAbp and a polymerase (*e.g.*, DNA-dependent DNA polymerase or RNA-dependent DNA polymerase, such as, reverse transcriptase). In some embodiments, the napDNAbp and the polymerase are optionally joined by linker to form the fusion protein. Various configurations of the prime editor fusion proteins and additional domains of the fusion proteins are described further herein. In various embodiments, the systems and methods provided by the present disclosure contemplate the use of any of the prime editor fusion proteins described herein.

[0585] In some embodiments, the prime editor complexes used in the systems described herein comprise a prime editor (*e.g.*, the first prime editor, second prime editor, third prime editor, and/or fourth prime editor in the systems described above) where the components of one or more of the prime editors are provided *in trans*, as is described in additional detail throughout the present specification. In some embodiments, the prime editor comprises a napDNAbp and a polymerase expressed *in trans*. In some embodiments, the napDNAbp and the polymerase are expressed from one or more vectors (*e.g.*, both components are expressed from the same vector, or each component is expressed from a different vector). In certain embodiments, the prime editors comprise additional components as described herein expressed *in trans*. In some embodiments, the prime editors used in the systems described herein may comprise both one or more prime editors provided as fusion proteins and one or more prime editors whose components are provided *in trans*.

[0586] In some embodiments, the multi-flap prime editor systems described herein contemplate fusion proteins comprising a napDNAbp and a polymerase (*e.g.*, DNA-dependent DNA polymerase or RNA-dependent DNA polymerase, such as, reverse transcriptase), and optionally joined by a linker. The application contemplates any suitable napDNAbp and polymerase (*e.g.*, DNA-dependent DNA polymerase or RNA-dependent DNA polymerase, such as, reverse transcriptase) to be combined in a single fusion protein. Examples of napDNAbps and polymerases (*e.g.*, DNA-dependent DNA polymerase or RNA-dependent DNA polymerase, such as, reverse transcriptase) are each defined herein. Since polymerases are well-known in the art, and the amino acid sequences are readily available, this disclosure is not meant in any way to be limited to those specific polymerases identified herein.

[0587] In various embodiments, the fusion proteins may comprise any suitable structural configuration. For example, the fusion protein may comprise from the N-terminus to the C-terminus direction, a napDNAbp fused to a polymerase (*e.g.*, DNA-dependent DNA polymerase or RNA-dependent DNA polymerase, such as, reverse transcriptase). In other embodiments, the fusion protein may comprise from the N-terminus to the C-terminus direction, a polymerase (*e.g.*, a reverse transcriptase) fused to a napDNAbp. The fused domain may optionally be joined by a linker, *e.g.*, an

amino acid sequence. In other embodiments, the fusion proteins may comprise the structure NH₂-[napDNABp]-[polymerase]-COOH; or NH₂-[polymerase]-[napDNABp]-COOH, wherein each instance of “]-[“ indicates the presence of an optional linker sequence. In embodiments wherein the polymerase is a reverse transcriptase, the fusion proteins may comprise the structure NH₂-[napDNABp]-[RT]-COOH; or NH₂-[RT]-[napDNABp]-COOH, wherein each instance of “]-[“ indicates the presence of an optional linker sequence.

[0588] An exemplary fusion protein is depicted in FIG. 14, which shows a fusion protein comprising an MLV reverse transcriptase (“MLV-RT”) fused to a nickase Cas9 (“Cas9(H840A)”) via a linker sequence. This example is not intended to limit scope of fusion proteins that may be utilized for the prime editor (PE) system described herein.

[0589] In various embodiments, the multi-flap prime editor fusion protein may have the following amino acid sequence (referred to herein as “PE1”), which includes a Cas9 variant comprising an H840A mutation (i.e., a Cas9 nickase) and an M-MLV RT wild type, as well as an N-terminal NLS sequence (19 amino acids) and an amino acid linker (32 amino acids) that joins the C-terminus of the Cas9 nickase domain to the N-terminus of the RT domain. The PE1 fusion protein has the following structure: [NLS]-[Cas9(H840A)]-[linker]-[MMLV_RT(wt)]. The amino acid sequence of PE1 and its individual components are as follows:

DESCRIPTION	SEQUENCE
PE1 FUSION PROTEIN	<p> MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFK VLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQ EIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT IYHLRKKLVDDSTDKADRLRIYLALAHMIKFRGHFLIEGDLNPDNSDVKL FIQLVQTYNQLFEEENPINASGVDAKAILSARLSKSRLENLIAQLPGEKKN GLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDQYDDDLNLLAQIGDQ YADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGT EELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPLKDN REKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEVVDKGA AQSFIERMTNFDKNLPNEKVLPHKSLLEYFTVYNELTKVKYVTEGMRK PAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVDR FNASLGTYHDLLKHKDKDFLDNEENEDILEDIVLTTLTFEDREMIEERLKT YAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDG FANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGIL QTVKVVDLVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEE GIKELGSQILKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDINRLSDY DVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRLVETRQITKHVAQIL DSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAH DAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIKSEGEIGKATAK YFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKV LSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPPKKYGGFD SPTVAYSVLVAKVEKGSKKLKSVKELLGITIMERSSEFKNPIDFLEAKG YKEVKKDLIIKLPKYSLEFLENGRKRMLASAGELQKGNELALPSKYVNFL YLASHYEKLGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANL DKVLSAYNKHDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTS </p>

DESCRIPTION	SEQUENCE
	<p><u>TKEVLDATLIHQSIITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATP</u> <u>ESSGGSSGGSS</u><u>TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVR</u> <u>QAPLIPLKATSTPVSIKQYPMSQEARLGKPHIQRLDQGILVPCQSPWNTPLLPVK</u> <u>KPGTNDYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFC</u> <u>LRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFDEALHRDLADFRI</u> <u>QHPDLILLQYVDDLAAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKY</u> <u>LGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAFCRLWIPGFAEMAAP</u> <u>LYPLTKTGTLFNWGPDQQKAYQEIQALLTAPALGLPDLTKPFELFVDEKQGYAK</u> <u>GVLTQKLGWRRPVAYLSKKLDPVAAGWPPCLRMVAIAVLTKDAGKLTMGQPLV</u> <u>ILAPHAVEALVKQPPDRWLSNARMTHYQALLDTRVQFGPVVALNPATLLPLPEE</u> <u>GLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTET</u> <u>EVIWAKALPAGTSAQRAELIALTQALKMAEGKKLVYTDSTRYAFATAHIGEIVRRRG</u> <u>LLTSEGKEIKNKDEILALLKALFLPKRLSIHCPGHQKGHSAEARGNRMADQAARK</u> <u>AAITETPDTSTLLIENSSPSGGSKRTADGSEFEPKKKRKV</u> (SEQ ID NO: 123)</p> <p>KEY: <u>NUCLEAR LOCALIZATION SEQUENCE (NLS)</u> TOP:(SEQ ID NO: 124), BOTTOM: (SEQ ID NO: 133) CAS9(H840A) (SEQ ID NO: 126) 33-AMINO ACID LINKER (SEQ ID NO: 127) <i>M-MLV REVERSE TRANSCRIPTASE</i> (SEQ ID NO: 128)</p>
PE1 – N-TERMINAL NLS	MKRTADGSEFESPKKKRKV (SEQ ID NO: 124)
PE1 – CAS9 (H840A) (MET MINUS)	<p>DKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSIKKNLIGALLFDS GETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLVEE DKKHERHPFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRILIYLAHMI KFRGHFLIEGDLNPDNSDVKLFQILVQTYNQLFEENPINASGVDAKAILSARL SKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDAEDAKLQLSKDT YDDDLNLLAQIGDQYADLFLAAKNLSDAILSDILRVNTEITKAPLSASMIKR YDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIK PILEKMDGTEELLVKNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYP FLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEVVVDKG ASAQSFIERMTNFDKNLPNEKVLPHKSLLYEYFTVYNELTKVKYVTEGMRKP AFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNAS LGTYHDLKIIKDKDFLDNEENEDILEDIVLTTLTFEDREMIEERLKYAHLFDD KVMKQLKRRRYTGWGRSLRKLINGIRDKQSGKTILDFLKSDGFANRNFQMQLI HDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKV MGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEEGKELGSQILKEHPVEN TQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVAJVPQSFLKDDSIDNK VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVRINNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYGD YKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETN GETGEIVWDKGRDFATVRKVLSPQVNVKKTETVQTGGFSKESILPKRNSDKL IARKKDWDPKKYGGFDSPTVAYSVLVAKVEKGKSKKLKSVKELLGITIMERS SFEKNPIDFLEAKGYKEVKKDLIKLPKYSLENGRKRMLASAGELQKGNE LALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKR VILADANLDKVL SAYNKHARDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDR KRYTSTKEVLDATLIHQSIITGLYETRIDLSQLGGD (SEQ ID NO: 130)</p>
PE1 – LINKER BETWEEN	SGGSSGGSSGSETPGTSESATPSSGGSSGGSS (SEQ ID NO: 127)

DESCRIPTION	SEQUENCE
CAS9 DOMAIN AND RT DOMAIN (33 AMINO ACIDS)	
PE1 – M-MLV RT	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSIIKQYPMSQEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTN DYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFDEALHRDLADFRI QHPDLILLQYVDDLLLAATSELDCCQGGTRALLQTLGNLGYRASAKKAQICQK QVKYLGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAFCRLWIPG FAEMAAPLYPLTKTGTLFNWGPDDQKAYQEIQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHIGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLS IIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 132)
PE1 – C- TERMINAL NLS	SGGSKRTADGSEFEPKKKRV (SEQ ID NO: 133)

[0590] In another embodiment, the multi-flap prime editor fusion protein may have the following amino acid sequence (referred to herein as “PE2”), which includes a Cas9 variant comprising an H840A mutation (i.e., a Cas9 nickase) and an M-MLV RT comprising mutations D200N, T330P, L603W, T306K, and W313F, as well as an N-terminal NLS sequence (19 amino acids) and an amino acid linker (33 amino acids) that joins the C-terminus of the Cas9 nickase domain to the N-terminus of the RT domain. The PE2 fusion protein has the following structure: [NLS]-[Cas9(H840A)]-[linker]-[MMLV_RT(D200N)(T330P)(L603W)(T306K)(W313F)]. The amino acid sequence of PE2 is as follows:

PE2 FUSION PROTEIN	MKRTADGSEFESPKKKRKYV DKKYSIGLDIGTNSVGWAVITDEYKVPSKKFK VLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQ EIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT IYHLRKKLVDS TDKADLRILIYALAHMIKFRGHFLIEGDLNPDNSDVKL FIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKN GLFGNLIASLGLTPNFKSNFDLAEDAKLQLSKDITYDDDLNLLAQIGDQ YADFLAAKNLSDAILSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGT EELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDN REKIEKILTRIPYVVGPLARGNSRFWMTRKSEETITPWNFEFVVDKGAS AQSFIERMTNFDKNLPNEKVLPHKSLLEYFTVYNELTKVKYVTEGMRK PAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDR FNASLGTYHDLKIKDKDFLDNEENEDILEDIVLTTLTFEDREMIEERLKT YAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDG FANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGIL QTVKVVDELVKVMGRHKKPENIVIAMARENQTTQKGQKNSRERMKRIIE GIKELGSQILKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDINRLSDY
-----------------------	---

	<p>DVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRLVETRQITKHVAQIL DSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAH DAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATAK YFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKV LSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFD SPTVAYSVLVVAKEGKSKKLKSVKELLGITIMERSSSFENPIDFLEAKG YKEVKKDLIIKLPKYSLEFENGRKRMLASAGELQKGNELALPSKYVNFL YLASHYEKLGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANL DKVLSAYNKHDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTS TKEVLDATLIHQSTGLYETRIDLSQLGGDSSGSSGSSGSETPGTSESATP <u>ESSGSSGSSGSS</u>TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVR QAPLIIPKATSTPVSIKQYPMSQEARLGIKPHIQRLDQGLVPCQSPWNTPLLPVK KPGTNDYRPVQDLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFC LRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRI QHPDLILLQYVDDLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKY LGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAP LYPLTKPGTLFNWGPDDQKAYQEIQALLTAPALGLPDLTKPFELFVDEKQGYAK GVLTKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLV ILAPHAVEALVKQPPDRWLSNARMTHYQALLDTRVQFGPVVALNPATLLPLPEE GLQHNCILDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTET EVIWAKALPAGTSAQRAELIALTQALKMAEGKKLVYTDSDRYAFATAHIHGEIYRRRG WLTSEGKEIKNKDEILALLKALFLPKRLSIHCPGHQKGHSAEARGNRMADQAARK AAITETPDTSTLLIENSSPSGSSKRTADGSEFEPKKRKV (SEQ ID NO: 134)</p> <p>KEY: NUCLEAR LOCALIZATION SEQUENCE (NLS) TOP:(SEQ ID NO: 124), BOTTOM: (SEQ ID NO: 133) CAS9(H840A) (SEQ ID NO: 137) 33-AMINO ACID LINKER (SEQ ID NO: 127) M-MLV REVERSE TRANSCRIPTASE (SEQ ID NO: 139)</p>
PE2 – N- TERMINAL NLS	MKRTADGSEFESPKKKRKV (SEQ ID NO: 124)
PE2 – CAS9 (H840A) (MET MINUS)	<p>DKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDS GETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSSFFHRLEESFLVEE DKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRILIYALAHMI KFRGHFLIEGDLNPDNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARL SKSRRLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFDLAEDAKLQLSKDT YDDDLNLLAQIGDQYADLFLAAKNLSDAILSDILRVNTEITKAPLSASMIKR YDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIK PILEKMDGTEELLVKNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYF FLKDNREKIEKILTFRIPIYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKG ASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKP AFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNAS LGTYHDLLKIKDKDFLDNEENEDILEDIVLTTLTFEDREMIEERLKYAHLFDD KVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDFANRNFQMQLI HDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIIKGILQTVKVVDLVKV MGRHKPENIVIAMARENQTTQKGQKNSRERMKRIIEGKELGSQILKEHPVEN TQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNK VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERG GLSELDKAGFIKRLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKS KLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYGD YKVYDVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETN</p>

	GETGEIVWDKGRDFATVRKVLSPQVNVKKTEVQTGGFSKESILPKRNSDKL IARKKDWDPKKYGGFDSPTVAYSVLVAKVEKGKSKKLKSVKELLGITIMERS SFEKNPIDFLEAKGYKEVKKDLIKLPKYSLFELNGRKRMLASAGELQKGNE LALPSKYVNFLYLASHYEKLKGSPEDEQKQLFVEQHKHYLDEIEQISEFSKR VILADANLDKVL SAYNKH RD KPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDR KRYTSTKEVL DATLIHQ SITGLYETRIDLSQLGGD (SEQ ID NO: 141)
PE2 – LINKER BETWEEN CAS9 DOMAIN AND RT DOMAIN (33 AMINO ACIDS)	SGGSSGGSSGSETPGTSESATPESSGGSSGGSS (SEQ ID NO: 127)
PE2 – MMLV_RT D200N T330P L603W T306K W313F	TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLK ATSTPVSISKQYPMSEARLGKPHIQRLLDQGILVPCQSPWNTPLLPVKPGTN DYRPVQDLREV NKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKD AFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFD EALHRDLADFR I QHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQK QVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGKAGFCRL FIPG FAEMAAPLYPLTKPGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELF VDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQ FGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTD GSSLLQEGQRKAGAAVTTEVIWAKALPAGTSAQRAELIALTQALKMAEGK KLNVTDSRYAFATAHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRL SIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSP (SEQ ID NO: 143)
PE2 – C- TERMINAL NLS	SGGSKRTADGSEFEPKKKRV (SEQ ID NO: 133)

[0591] In still other embodiments, the prime editor fusion protein may have the following amino acid sequences:

PE FUSION PROTEIN MMLV_RT(W T)-32AA- CAS9(H840A)	<u>MKRTADGSEFESPKKKRKVTLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAET</u> <u>GGMGLAVRQAPLIPLKATSTPVSISKQYPMSEARLGKPHIQRLLDQGILVPCQSP</u> <u>WNTPLLPVKPGTNDYRPVQDLREV NKRVEDIHPTVPNPYNLLSGLPPSHQWYTV</u> <u>LDLKD AFFCLR LHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFD EAL</u> <u>HRDLADFR IQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKA</u> <u>QICQKQVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLG TAGFCRLWI</u> <u>PGFAEMAAPLYPLTKGTFLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFV</u> <u>DEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLT KDAGK</u> <u>LTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNP</u> <u>ATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRK</u> <u>AGAAVTTEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVTDSRYAFATAHI</u> <u>HGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR</u> <u>MADQAARKAAITETPDTSTLLIENSSP</u> <u>SGGSSGGSSGSETPGTSESATPESSGGS</u> <u>SGGSSDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNL</u> <u>IGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSF</u> <u>HRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKA</u> <u>DLRLIYLALAHMIKFRGHFLIEGDLNPDNSDV DKLFIQLVQTYNQLFEENP</u> <u>INASGVDAKAILSARLSKSRRLLENLIAQLPGEKKNGLFGNLIALSLGLTPN</u> <u>FKSNFDLAEDAKLQLSKDTYDDDLNLLAQIGDQYADLFLAAKNLSDAIL</u> <u>LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFF</u>
--	---

	<p>DQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQ RTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNREKIEKILTRIPYYVGP LARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLP NEKVLPHKSHLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLF KTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKHKD KDFLDNEENEDILEDIVLTTLTFEDREMIEERLKTYAHLFDDKVMKQLKR RRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMLIHDDSLT FKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGR HKPENIVIAMARENQTTQKGQKNSRERMKRIEEGKELGSQILKEHPVEN TQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSID NKVLTRSDKNRGKSDNPSEEVVKMKMKNYWRQLLNAKLITQRKFDNLT KAERGGLSELDKAGFIKQQLVETRQITKHVAQILDSRMNTKYDENDALKIR EVKVITLKSCLVSDFRKDFQFYKVVREINNYHHAHDAYLNAVVGDTALIKKY PKLESEFVYGDKVYDVVRKMIKSEQEIGKATAKYFFYSNIMNFFKTEITL ANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNVIVKKTEVQT GGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVAKVEKG KSKKLKSVKELLGITIMERSSEKKNPIDFLEAKGYKEVKKDLIKLPKYSL FELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDN EQKQLFVEQHKHYLDEHIEQISEFSKRVILADANLDKVL SAYNKHRRDKPIR EQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSGITGL YETRIDLSQLGGDSSGGSKRTADGSEFEPKKRKRV (SEQ ID NO: 145)</p> <p>KEY: <u>NUCLEAR LOCALIZATION SEQUENCE (NLS)</u> TOP:(SEQ ID NO: 124), BOTTOM: (SEQ ID NO: 133) CAS9(H840A) (SEQ ID NO: 147) <u>33-AMINO ACID LINKER</u> (SEQ ID NO: 127) M-MLV REVERSE TRANSCRIPTASE (SEQ ID NO: 149)</p>
PE FUSION PROTEIN MMLV_RT(W T)-60AA- CAS9(H840A)	<p>MKRTADGSEFESPKKKRKVTLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAET GGMGLAVRQAPLIPLKATSTPVSQKQYPMSEARLGKPHIQRLLDQGILVPCQSP WNTPLLVPKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTV LDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFDAL HRDLADFRIQHPDLILLQYVDDLLAATSELDCQQGTRALLQTLGNLGYRASAKKA QICQKQVKYLYGILLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGAGFCRLWI PGFAEMAAPLYPLTKGTGFNWDGPDQQKAYQEIQALLTAPALGLPDLTKPFELFV DEKQGYAKGVLTQKLGWRRPVAYLSKKLDPVAAGWPPCLRMVAIAVLTKDAGK LTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLDTRVQFGPVVALNP ATLLPLPEEGLQHNCDLAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRK AGAAVTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLVNVTDSRYAFATAHI HGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNR MADQAARKAAITETPDTSTLLIENSSPSGGSSGGSSGSETPGTSESATPESAGSY PYDVDPDYAGSAAPAAKKKKLDGSGSGSSGSSGSDKKYSIGLDIGTNSVGWA VITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARR RYTRRKNRICYLQEIFSNEMAKVDDSFHRLVESFLVEEDKKHERHPIFG NIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIE GDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLL ENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYD DDLNDLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIK RYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFY KFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILR RQEDFYFPLKDNREKIEKILTRIPYYVGP LARGNSRFAWMTRKSEETITP WNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPHKSHLLYEYFTVYNELT KVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIEC FDSVEISGVEDRFNASLGTYHDLLKHKDKDFLDNEENEDILEDIVLTTLTF</p>

	<p>EDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQS GKTILDFLKSDGFANRNFMLIHDDSLTFKEDIQKAQVSGQGDSLHEHIA NLAGSPAIAKKGILQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQ KNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMY VDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEE VVKMKKNYWRQLLNAKLITQRKFDNLTAKAERGGLSELKAGFIKRQLV ETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQF YKVINNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMI IAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIV WDKGRDFATVRKVLSPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARK KDWDPKKYGGFDSPTVAYSVLVVAKEVGKSKKLKSVKELLGITIMERS FEKNPIDFLEAKGYKEVKKDLIHKLPKYSLEFENGRKRMLASAGELQKG NELALPSKYVNFLYLASHYEKLKGSPEDEQKQLFVEQHKHYLDEIIEQIS EFSKRVLADANLDKVL SAYNKHDKPIREQAENIHLFTLTNLGAPAAFK YFDTTIDRKRYTSTKEVLDTLHQSIITGLYETRIDLSQLGGDSSGSKRTAD <u>GSEFEPKKRKV</u> (SEQ ID NO: 150)</p> <p>KEY: <u>NUCLEAR LOCALIZATION SEQUENCE (NLS)</u> TOP:(SEQ ID NO: 124), BOTTOM: (SEQ ID NO: 133) <u>CAS9(H840A)</u>(SEQ ID NO: 153) <u>AMINO ACID LINKER</u> (SEQ ID NO: 175) <u>M-MLV REVERSE TRANSCRIPTASE</u> (SEQ ID NO: 149)</p>
PE FUSION PROTEIN CAS9(H840A) -FEN1- MMLV_RT D200N T330P L603W T306K W313F	<p>MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFK VLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQ EIFSNEMAKVDDSSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT IYHLRKKLVSDTKADLRILIYALAHMIKFRGHFLIEGDLNPDNSDVDKL FIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLLENLIAQLPGEKKN GLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDITYDDDLNLLAQIGDQ YADFLAAKNLSDAILSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLK ALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGT EELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDN REKIEKILTRIPYVGPLARGNSRFWMTRKSEETITPWNFEVVDKGAS AQSFIERMTNFDKNLPNEKVLPHKSLLEYFTVYNELTKVKYVTEGMRK PAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDR FNASLGTYHDLLKIKDKDFLDNEENEDILEDIVLTTLTFEDREMIEERLKT YAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDG FANRNFMLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIAKKGIL QTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEE GIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDY DVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKMKKNYWRQ LLNAKLITQRKFDNLTAKAERGGLSELKAGFIKRQLVETRQITKHVAQIL DSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVINNYHHAH DAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATAK YFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKV LSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFD SPTVAYSVLVVAKEVGKSKKLKSVKELLGITIMERSSEFEKNPIDFLEAKG YKEVKKDLIHKLPKYSLEFENGRKRMLASAGELQKGNELALPSKYVNFL YLASHYEKLKGSPEDEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANL DKVLSAYNKHDKPIREQAENIHLFTLTNLGAPAAFKYFDTTIDRKRYTS TKEVLDTLHQSIITGLYETRIDLSQLGGDSSGSSGSSGSETPGTSESATP <u>ESSGSSGSSG</u>GIQGLAKLIADVAPSAIRENDIKSYFGRKVAIDASMSIYQFLIA VRQGGDVLQNEGETTSHLMGMFYRTIRMMENGIKPVYVFDGKPPQLKSGE LAKRSERRAEAEKQLQQAQAAGAEQEVEKFTKRLVKVTKQHNDCKHLLSL</p>

	<p>MGIPYLDAPSEAEASCAALVKAGKVYAAATEDMDCLTFGSPVLMRHLTASEA KKLP IQEFHLSRILQELGLNQE QFVDLCILLGSDYCESIRGIGPKRAVDLIQKHK SIEEIVRRLDPNKYPVPENWLHKEAHQLFLEPEVLDPESELKWSPEPNEEELIK FMCGEKQFSEERIRSGVKRLSKSRQGSTQGRLLDDFFKVTGSLSSAKRKEPEPK GSTKKKAKTGAAGKFKRGKSGSSSGSSGSETPGTSESATPESSGGSSGGSS TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLKATST PVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQ DLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDFAFFCLRLHPTSQPLFA FEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIOHPDLILLQYVD DLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRW LTEARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGTLFN WGPDOQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPPWR PVAYLSKKLDPVAAGWPPCLRMVAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQ PPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEA HGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTEVEIWAKALPAGTS AQRAELIALTQALKMAEGKKLVYTDSTRYAFATAHIHGEIYRRRGWLTSEGKEIKNK DEILALLKALFLPKRLSIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLL IENSSPSGGSKRTADGSEFEPKKRKV (SEQ ID NO: 154)</p> <p>KEY: <u>NUCLEAR LOCALIZATION SEQUENCE (NLS)</u> TOP:(SEQ ID NO: 124), BOTTOM: (SEQ ID NO: 133) CAS9(H840A) (SEQ ID NO: 157) 33-AMINO ACID LINKER 1 (SEQ ID NO: 127) <i>M-MLV REVERSE TRANSCRIPTASE</i> (SEQ ID NO: 159) 33-AMINO ACID LINKER 2 (SEQ ID NO: 127) FEN1 (SEQ ID NO: 161)</p>
--	--

[0592] In other embodiments, the multi-flap prime editor fusion proteins can be based on SaCas9 or on SpCas9 nickases with altered PAM specificities, such as the following exemplary sequences:

SACAS9-M-MLV RT PRIME EDITOR	<p>MKRTADGSEFESPKKKRKVGKRN YILGLDIGITSVGYGIIDYETRDVID AGVRLFKEANVENNEGRRSKRGARRLKR RRRRHRIQRVKKLLFDYNLL TDHSELSGINPYEARVKGLSQKLSEEFSAALLHLAKRRGVHNVNEVE EDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKT SDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTY YEGPGE GSPF GWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVI TRDENEKLEYEYKFQIENVFQK KKKPTLKQIAKEILVNEEDIKGYRVT STGKPEFTNLKVYHDIKDITARKEIIEAELLDQIAKILTIYQSSEDIQEE LTNLNSEL TQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAI FNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIKKY GLPNDIIELAREKNSKDAQKMINEMQKRN RQTNERIEEII RTTGKENA KYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNPNFNYEVDHIIPRSVSFD NSFNKVLVKQEEASKKGNRTPFQYLSSSDSKISYETFKKHILNLAKG KGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNL LRS YFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHH AEDALIIA NADFIFKEWKKLDKAKKVMENQMFE EKQAESMPEIETE QEYKEIFITP HQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNL NGLYDKDNDKLKLINKSPEKLLMYH HDPQTYQKLKLIMEQY GDEK NPLYKYEEETGNYLTKYSKKN DNGPVIKKIKYYGNKLNAHL DITDDYP NSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENY YEVNS KCYEEAKKKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIE VNMIDITYREYLENMNDKRPPRIKTIASKTQSIKKYSTDILGNLYEVK SKKHPQIIKKGSGSGSGSGSGSETPGTSESATPESSGGSSGSSSTLNIED EYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLKA</p>
------------------------------	---

	<p>TSTPVS IKQYPMSQE AR LGIKPHIQRL LDQ GILVPCQSPWNTPLLPVKK PGTNDYRPVQDLREV NKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLD LKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTL FDEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQT LGNLGYRASAKKAQICQKQVKYLG YLLKEGQRWLTEARKETVMGQP TPKTTPRQLREFLG TAGFCRLWIPGFAEMAAPLYPLTKGT LFNWGPDQ QKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPW RRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVIL APHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPAT LLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPADHTWYTDGSSLLQ EGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKK LNVYTDSRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLP KRLSIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLLIENS SPSGGSKRTADGSEFEPK KKRKV (SEQ ID NO: 162)</p>
<p>SPCAS9(H840A)- VRQR-MALONEY MURINE LEUKEMIA VIRUS REVERSE TRANSCRIPTASE PRIME EDITOR</p>	<p>MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGVAVITDEYKVP SK KFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNR ICYLQEIFS NEMAKVDDSFHRLEESFLVEEDKKHERHPFGNIVDEVA YHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLN PDNSDV DKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRL NLIAQLPG EKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTY DDDLNLLAQIGDQYADLF LAAKNLSDAILLSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGA SQEEFYKFIKPILEKMDGTEELLV KLNREDLLRKQRTFDNGSIPHQIHL GELHAILRRQEDFY PFLKDNREKIEKILTFRIPIYVGPLARGNSRFAWM TRKSEETITPWNFE EVVDKGASAQSFIERMTNFDKNLPNEKVLPKHS LYEYFTVYNELTKVKYVTEGMRKPAFLS GEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLKKIHKDKDFLD NEENEDILEDIVLT LTLFEDREMIEERLKYAHLFDDKVMKQLKRRRY TGWGRLSRKLINGIRDKQSGKTILDFL KSDGFANRNFQMQLIHDDSLTF KEDIQKAQVSGQGDSLHEHIANLAGSPA IKGILQTVKVVDELVKVM GRHKPENIVIE MARENQTTQKGQKNSRERMKRIE EGIKELGSQILKEH PVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSF LKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLI TQRKFDNLTKAERGGLSEL DKA GFIKRQLVETRQITKHVAQILDSRMN TKYDENDKLIREVKVITL KSKLVSDFRKDFQFYK VREINNYHHAHDA YLN AVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATV RKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKK YGGFVSPTVAYSVLVAKVEKGKSKKLKSVKELLGITIMERSSSF EKNPI DFLEAKGYKEVKKDLI KLPKYSLFELENGKRMLASARELQKGNEL ALPSKYVNFLYLASHYEKLKGS PEDNEQKQLFVEQHKHYLDEIIEQIS EFSKRVLADANLDKVL SAYNKH RDKPIREQAENIIHLFTLTNLGAPAA FKYFDTTIDRKQYRSTKEVLDATLIHQ SITGLYETRIDLSQLGGDSGGS SGGSSGSETPGTSESATP ESSGGSSGGSSTLNIEDEYRLHETSKEPDVSL GSTWLSDFPQAWAETGGMGLAVRQAPLIPLKATSTPVS IKQYPMSQE AR LGIKPHIQRL LDQ GILVPCQSPWNTPLLPVKKPGTNDYRPVQDLRE VNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQ PLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQ HPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQ ICQKQVKYLG YLLKEGQRWLTEARKETVMGQP TPKTTPRQLREFLGKA GFCRLFIPGFAEMAAPLYPLTKPGT LFNWGPDQQKAYQEIKQALLTAP ALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPV AAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPD RWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCL</p>

	DILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTE TEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLVYTDSTRYAFAT AHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIHCPGHQ KGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSPSGGSKRTADG SEFEPKKKRKV (SEQ ID NO: 163)
SPCAS9(H840A)- VRER-MALONEY MURINE LEUKEMIA VIRUS REVERSE TRANSCRIPTASE PRIME EDITOR	MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGVAVITDEYKVP SKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNR ICYLQEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVDEVA YHEKYPTIYHLRKKLVSTDKADRLIYLALAHMIKFRGHFLIEGDLN PDNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRL NLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTY DDDLNLLAQIGDQYADFLAAKNLSDAILSDILRVNTEITKAPLSAS MIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGA SQEEFYKFIKPILEKMDGTEELLVKNLREDLLRKQRTFDNGSIPHQIHL GELHAILRRQEDFYPLKDNREKIEKILTFRIPYVVGPLARGNSRFAWM TRKSEETITPWNFEVVDKGASASQSFIERMTNFDKNLPNEKVLPKHSL LYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVT VKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIKDKDFLD NEENEDILEDIVLTTLTFEDREMIEERLKYAHLFDDKVMKQLKRRRY TGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFQMQLIHDDSLTF KEDIQKAQVSGQGSLSHEHIANLAGSPAICKGILQTVKVVDELVKVM GRHKPENIVIMARENQTTQKGQKNSRERMKRIEIGIKELGSQILKEH PVENTQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVAIVPQSF LKDDSIDNKVLRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNKLI TQRKFDNLTKAERGGLSELDKAGFIKRLVETRQITKHVAQILDSRMN TKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVINNYHHAHDA YLNNAVGTALIKKYPKLESEFVYGDYKVDVRKMIKSEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATV RKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKK YGGFVSPTVAYSVLVAKVEKGSKKLKSVKELLGITIMERSSEFKNPI DFLEAKGYKEVKKDLIKLPKYSLSFELENGRKRMLASARELQKGNEL ALPSKYVNFLYLASHYEKLKGSPEDEQKQLFVEQHKHYLDEIIEQIS EFSKRVILADANLDKVL SAYNKHDKPIREQAENIIHLFTLTNLGAPAA FKYFDTTIDRKEYRSTKEVLDTLHQSITGLYETRIDLSQLGGDSGGSS GGSSGSETPGTSESATPESSGGSSGSSSTLNIEDEYRLHETSKEPDVSLG STWLSDFPQAWAETGGMGLAVRQAPLIPLKATSTPVSIKQYPMQSQA RLGIKPHIQRLLDQGLVPCQSPWNTPLLPVKKPGTNDYRPVQDLREV NKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQP LFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFNEALHRDLADFRIQH PDLILLQYVDDLLAATSELDCQQGTALLQTLGNLGYRASAKKAI CQKQVKYLYGILLKEGQRLTEARKETVMGQPTPKTPRQLREFLGKA GFCRLFIPGFAEMAAPLYPLTKPGTLFNWGPQQKAYQEIQALLTAP ALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPV AAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPD RWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNC L DILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTE TEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLVYTDSTRYAFAT AHIHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIHCPGHQ KGHSAEARGNRMADQAARKAAITETPDTSTLLIENSSPSGGSKRTADG SEFEPKKKRKV (SEQ ID NO: 164)

[0593] In yet other embodiments, the multi-flap prime editor fusion proteins contemplated herein may include a Cas9 nickase (e.g., Cas9 (H840A)) fused to a truncated version of M-MLV reverse transcriptase. In this embodiment, the reverse transcriptase also contains 4 mutations (D200N,

T306K, W313F, T330P; noting that the L603W mutation present in PE2 is no longer present due to the truncation). The DNA sequence encoding this truncated editor is 522 bp smaller than PE2, and therefore makes its potentially useful for applications where delivery of the DNA sequence is challenging due to its size (i.e. adeno-associated virus and lentivirus delivery). This embodiment is referred to as Cas9(H840A)-MMLV-RT(trunc) or “PE2-short” or “PE2-trunc” and has the following amino acid sequence:

CAS9(H840A)- MMLV-RT(TRUNC) OR PE2-SHORT	<p>MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVP SKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYT RRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIF GNIVDEVAYHEKYPTIYHLRKKLV DSTDKADRLIYLALAHMIKIF RGHFLIEGDLNPDNSDVKLFQILVQTYNQLFEEPNINASGVDAK AILSARLSKSRLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSN FDLAEDAKLQLSKD TYDDLDNLLAQIGDQYADFLAAKNLSDAI LLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQPE KYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELL VKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKD NREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEFV VDKGASAQSFIERMTNFDKNLPNEKVLPHKSLLEYFTVYNELTK VKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFK KIECFDSVEISGVEDRFNASLGTYHDLLKHKDKDFLDNEENEDILE DIVLTLTLFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWR LSRKLINGIRDKQSGKTILDFLKSDGFANRNFMLIHDDSLTFKED IQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMG RHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSIK EHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVAI VPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH VAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKV REINNYHHAHDAYLNAVVG TALIKKYPKLESEFVYGDYKVYDVR KMAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIET NGETGEIVWDKGRDFATVRKVL SMPQVNIVKKTEVQTGGFSKES ILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVAKVEKGK SKKLKSVKELLGITIMERSSEFEKNPIDFLEAKGYKEVKKDLIHKLP KYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYE KLKGSPEDEQKQLFVEQHKHYLDEHIEQISEFSKRVLADANLDK VLSAYNKHHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKR YTSTKEVL DATLIHQ SITGLYETRIDLSQLGGDSGGSSGGSSGSETP GTSESATPESGGSSGGSS<u>TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQ AWAETGGMGLAVRQAPLIPLKATSTPVS IKQYPMSEARLG IKPHIQRL DQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVNP YNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQ LTWTRL PQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLAATSE LDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLG YLLKEGQRWLTE ARKETVMGQPTPKTPRQLREFLGKAGFCRLFIPGFAEMAAPLYPLTKPGT LFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVL TQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQ PLVILAPHAVEALVKQPPDRWLSNARMTHYQALLDTRVQFGPVVALNP ATLLPLPEEGLQHNCLDNSRLINS</u><u>GGGSKRTADGSEFEPKKRKV</u> (SEQ ID NO: 765)</p> <p>KEY:</p>
--	--

	<p>NUCLEAR LOCALIZATION SEQUENCE (NLS) TOP:(SEQ ID NO: 124), BOTTOM: (SEQ ID NO: 133) CAS9(H840A) (SEQ ID NO: 157) 33-AMINO ACID LINKER 1 (SEQ ID NO: 127) <i>M-MLV TRUNCATED REVERSE TRANSCRIPTASE</i> (SEQ ID NO: 766)</p>
--	--

[0594] See FIG. 75, which provides a bar graph comparing the efficiency (i.e., “% of total sequencing reads with the specified edit or indels”) of PE2, PE2-trunc, PE3, and PE3-trunc over different target sites in various cell lines. The data shows that the prime editors comprising the truncated RT variants were about as efficient as the prime editors comprising the non-truncated RT proteins.

[0595] In various embodiments, the multi-flap prime editor fusion proteins contemplated herein may also include any variants of the above-disclosed sequences having an amino acid sequence that is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to PE1, PE2, or any of the above indicated prime editor fusion sequences.

[0596] In certain embodiments, linkers may be used to link any of the peptides or peptide domains or moieties of the invention (e.g., a napDNAbp linked or fused to a reverse transcriptase).

[5] Linkers and other domains

[0597] The PE fusion proteins may comprise various other domains besides the napDNAbp (e.g., Cas9 domain) and the polymerase domain (e.g., RT domain). For example, in the case where the napDNAbp is a Cas9 and the polymerase is a RT, the PE fusion proteins may comprise one or more linkers that join the Cas9 domain with the RT domain. The linkers may also join other functional domains, such as nuclear localization sequences (NLS) or a FEN1 (or other flap endonuclease) to the PE fusion proteins or a domain thereof.

[0598] In addition, in embodiments involving *trans* prime editing, linkers may be used to link tPERT recruitment protein to a prime editor, e.g., between the tPERT recruitment protein and the napDNAbp. See e.g., FIG. 3G for an exemplary schematic of a *trans* prime editor (tPE) that includes linkers to separately fuse a polymerase domain and a recruiting protein domain to a napDNAbp.

A. Linkers

[0599] As defined above, the term “linker,” as used herein, refers to a chemical group or a molecule linking two molecules or moieties, e.g., a binding domain and a cleavage domain of a nuclease. In some embodiments, a linker joins a gRNA binding domain of an RNA-programmable nuclease and the catalytic domain of a polymerase (e.g., a reverse transcriptase). In some embodiments, a linker joins a dCas9 and reverse transcriptase. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two. In some embodiments, the linker is an amino acid or a plurality of amino acids

(e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker is 5-100 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length.

Longer or shorter linkers are also contemplated.

[0600] The linker may be as simple as a covalent bond, or it may be a polymeric linker many atoms in length. In certain embodiments, the linker is a polypeptide or based on amino acids. In other embodiments, the linker is not peptide-like. In certain embodiments, the linker is a covalent bond (e.g., a carbon-carbon bond, disulfide bond, carbon-heteroatom bond, etc.). In certain embodiments, the linker is a carbon-nitrogen bond of an amide linkage. In certain embodiments, the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker. In certain embodiments, the linker is polymeric (e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoalkanoic acid. In certain embodiments, the linker comprises an aminoalkanoic acid (e.g., glycine, ethanoic acid, alanine, beta-alanine, 3-aminopropanoic acid, 4-aminobutanoic acid, 5-pentanoic acid, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminohexanoic acid (Ahx). In certain embodiments, the linker is based on a carbocyclic moiety (e.g., cyclopentane, cyclohexane). In other embodiments, the linker comprises a polyethylene glycol moiety (PEG). In other embodiments, the linker comprises amino acids. In certain embodiments, the linker comprises a peptide. In certain embodiments, the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a phenyl ring. The linker may included functionalized moieties to facilitate attachment of a nucleophile (e.g., thiol, amino) from the peptide to the linker. Any electrophile may be used as part of the linker. Exemplary electrophiles include, but are not limited to, activated esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and isothiocyanates.

[0601] In some other embodiments, the linker comprises the amino acid sequence (GGGGS)_n (SEQ ID NO: 165), (G)_n (SEQ ID NO: 166), (EAAAK)_n (SEQ ID NO: 167), (GGS)_n (SEQ ID NO: 168), (SGGS)_n (SEQ ID NO: 169), (XP)_n (SEQ ID NO: 170), or any combination thereof, wherein n is independently an integer between 1 and 30, and wherein X is any amino acid. In some embodiments, the linker comprises the amino acid sequence (GGS)_n (SEQ ID NO: 176), wherein n is 1, 3, or 7. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 171). In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPESSGGSSGGS (SEQ ID NO: 172). In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGGS (SEQ ID NO: 173). In some embodiments, the linker comprises the amino acid sequence SGGGS (SEQ ID NO: 174). In other embodiments, the linker comprises the amino acid sequence

SGGSSGGSSGSETPGTSESATPESAGSYPDVPDYAGSAAPAAKKKKLDGSGSGGSSGGS
(SEQ ID NO: 175, 60AA).

[0602] In certain embodiments, linkers may be used to link any of the peptides or peptide domains or moieties of the invention (e.g., a napDNAbp linked or fused to a reverse transcriptase).

[0603] As defined above, the term “linker,” as used herein, refers to a chemical group or a molecule linking two molecules or moieties, e.g., a binding domain and a cleavage domain of a nuclease. In some embodiments, a linker joins a gRNA binding domain of an RNA-programmable nuclease and the catalytic domain of a recombinase. In some embodiments, a linker joins a dCas9 and reverse transcriptase. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two. In some embodiments, the linker is an amino acid or a plurality of amino acids (e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker is 5-100 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length. Longer or shorter linkers are also contemplated.

[0604] The linker may be as simple as a covalent bond, or it may be a polymeric linker many atoms in length. In certain embodiments, the linker is a polypeptide or based on amino acids. In other embodiments, the linker is not peptide-like. In certain embodiments, the linker is a covalent bond (e.g., a carbon-carbon bond, disulfide bond, carbon-heteroatom bond, etc.). In certain embodiments, the linker is a carbon-nitrogen bond of an amide linkage. In certain embodiments, the linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker. In certain embodiments, the linker is polymeric (e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoalkanoic acid. In certain embodiments, the linker comprises an aminoalkanoic acid (e.g., glycine, ethanoic acid, alanine, beta-alanine, 3-aminopropanoic acid, 4-aminobutanoic acid, 5-pentanoic acid, etc.). In certain embodiments, the linker comprises a monomer, dimer, or polymer of aminoHEXAnoic acid (Ahx). In certain embodiments, the linker is based on a carbocyclic moiety (e.g., cyclopentane, cycloHEXAno). In other embodiments, the linker comprises a polyethylene glycol moiety (PEG). In other embodiments, the linker comprises amino acids. In certain embodiments, the linker comprises a peptide. In certain embodiments, the linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a phenyl ring. The linker may include functionalized moieties to facilitate attachment of a nucleophile (e.g., thiol, amino) from the peptide to the linker. Any electrophile may be used as part of the linker. Exemplary electrophiles include, but are not limited to, activated esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and isothiocyanates.

[0605] In some other embodiments, the linker comprises the amino acid sequence (GGGGS)_n (SEQ ID NO: 165), (G)_n (SEQ ID NO: 166), (EAAAK)_n (SEQ ID NO: 167), (GGS)_n (SEQ ID NO: 168), (SGGS)_n (SEQ ID NO: 169), (XP)_n (SEQ ID NO: 170), or any combination thereof, wherein n is independently an integer between 1 and 30, and wherein X is any amino acid. In some embodiments, the linker comprises the amino acid sequence (GGS)_N (SEQ ID NO: 176), wherein n is 1, 3, or 7. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 171). In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPESGGSSGGSS (SEQ ID NO: 172). In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGGSS (SEQ ID NO: 173). In some embodiments, the linker comprises the amino acid sequence SGGSS (SEQ ID NO: 174).

[0606] In particular, the following linkers can be used in various embodiments to join prime editor domains with one another:

GGSS (SEQ ID NO: 767);

GGSSGGSS (SEQ ID NO: 768);

GGSSGGSSGGSS (SEQ ID NO: 769);

SGGSSGGSSGSETPGTSESATPESGGSSGGSS (SEQ ID NO: 127);

SGSETPGTSESATPES (SEQ ID NO: 171);

SGGSSGGSSGSETPGTSESATPESAGSYYPYDVPDYAGSAAPAAKKKKLDGSGSGGSSGGSS (SEQ ID NO: 175).

B. Nuclear localization sequence (NLS)

[0607] In various embodiments, the PE fusion proteins may comprise one or more nuclear localization sequences (NLS), which help promote translocation of a protein into the cell nucleus.

Such sequences are well-known in the art and can include the following examples:

DESCRIPTION	SEQUENCE	SEQ ID NO:
NLS OF SV40 LARGE T-AG	PKKKRKV	SEQ ID NO: 16
NLS	MKRTADGSEFESPKKKRKV	SEQ ID NO: 124
NLS	MDSLLMNRRKFLYQFKNVRWAKGRRETYLC	SEQ ID NO: 17
NLS OF NUCLEOPLASMIN	AVKRPAATKKAGQAKKKKLD	SEQ ID NO: 190
NLS OF EGL-13	MSRRRKANPTKLSNAKKLAKEVEN	SEQ ID NO: 191
NLS OF C-MYC	PAAKRVKLD	SEQ ID NO: 192
NLS OF TUS-PROTEIN	KLKIKRPVK	SEQ ID NO: 193

NLS OF POLYOMA LARGE T- AG	VSRKRPRP	SEQ ID NO: 194
NLS OF HEPATITIS D VIRUS ANTIGEN	EGAPPAKRAR	SEQ ID NO: 195
NLS OF MURINE P53	PPQPKKKPLDGE	SEQ ID NO: 196
NLS OF PE1 AND PE2	SGGSKRTADGSEFEPKKKRKV	SEQ ID NO: 133

[0608] The NLS examples above are non-limiting. The PE fusion proteins may comprise any known NLS sequence, including any of those described in Cokol et al., “Finding nuclear localization signals,” *EMBO Rep.*, 2000, 1(5): 411-415 and Freitas et al., “Mechanisms and Signals for the Nuclear Import of Proteins,” *Current Genomics*, 2009, 10(8): 550-7, each of which are incorporated herein by reference.

[0609] In various embodiments, the multi-flap prime editors and constructs encoding the prime editors disclosed herein further comprise one or more, preferably, at least two nuclear localization signals. In certain embodiments, the multi-flap prime editors comprise at least two NLSs. In embodiments with at least two NLSs, the NLSs can be the same NLSs or they can be different NLSs. In addition, the NLSs may be expressed as part of a fusion protein with the remaining portions of the multi-flap prime editors. In some embodiments, one or more of the NLSs are bipartite NLSs (“bpNLS”). In certain embodiments, the disclosed fusion proteins comprise two bipartite NLSs. In some embodiments, the disclosed fusion proteins comprise more than two bipartite NLSs.

[0610] The location of the NLS fusion can be at the N-terminus, the C-terminus, or within a sequence of a prime editor (e.g., inserted between the encoded napDNAbp component (e.g., Cas9) and a polymerase domain (e.g., a reverse transcriptase domain).

[0611] The NLSs may be any known NLS sequence in the art. The NLSs may also be any future-discovered NLSs for nuclear localization. The NLSs also may be any naturally-occurring NLS, or any non-naturally occurring NLS (e.g., an NLS with one or more desired mutations).

[0612] The term “nuclear localization sequence” or “NLS” refers to an amino acid sequence that promotes import of a protein into the cell nucleus, for example, by nuclear transport. Nuclear localization sequences are known in the art and would be apparent to the skilled artisan. For example, NLS sequences are described in Plank et al., International PCT application PCT/EP2000/011690, filed November 23, 2000, published as WO/2001/038547 on May 31, 2001, the contents of which are incorporated herein by reference. In some embodiments, an NLS comprises the amino acid sequence PKKKRKV (SEQ ID NO: 16), MDSLLMNRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 17), KRTADGSEFEPKKKRKV (SEQ ID NO: 3864), or KRTADGSEFEPKKKRKV (SEQ ID NO:

125). In other embodiments, NLS comprises the amino acid sequences NLSKRPAAIKKAGQAKKKK (SEQ ID NO: 136), PAAKRVKLD (SEQ ID NO: 192), RQRRNELKRSF (SEQ ID NO: 3934), NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO: 3935).

[0613] In one aspect of the disclosure, a multi-flap prime editor may be modified with one or more nuclear localization signals (NLS), preferably at least two NLSs. In certain embodiments, the multi-flap prime editors are modified with two or more NLSs. The disclosure contemplates the use of any nuclear localization signal known in the art at the time of the disclosure, or any nuclear localization signal that is identified or otherwise made available in the state of the art after the time of the instant filing. A representative nuclear localization signal is a peptide sequence that directs the protein to the nucleus of the cell in which the sequence is expressed. A nuclear localization signal is predominantly basic, can be positioned almost anywhere in a protein's amino acid sequence, generally comprises a short sequence of four amino acids (Autieri & Agrawal, (1998) *J. Biol. Chem.* 273: 14731-37, incorporated herein by reference) to eight amino acids, and is typically rich in lysine and arginine residues (Magin *et al.*, (2000) *Virology* 274: 11-16, incorporated herein by reference). Nuclear localization signals often comprise proline residues. A variety of nuclear localization signals have been identified and have been used to effect transport of biological molecules from the cytoplasm to the nucleus of a cell. See, e.g., Tinland *et al.*, (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89:7442-46; Moede *et al.*, (1999) *FEBS Lett.* 461:229-34, which is incorporated by reference. Translocation is currently thought to involve nuclear pore proteins.

[0614] Most NLSs can be classified in three general groups: (i) a monopartite NLS exemplified by the SV40 large T antigen NLS (PKKKRKV (SEQ ID NO: 16)); (ii) a bipartite motif consisting of two basic domains separated by a variable number of spacer amino acids and exemplified by the *Xenopus nucleoplasmin* NLS (KRXXXXXXXXXXKKKL (SEQ ID NO: 3936)); and (iii) noncanonical sequences such as M9 of the hnRNP A1 protein, the influenza virus nucleoprotein NLS, and the yeast Gal4 protein NLS (Dingwall and Laskey 1991).

[0615] Nuclear localization signals appear at various points in the amino acid sequences of proteins. NLS's have been identified at the N-terminus, the C-terminus, and in the central region of proteins. Thus, the disclosure provides multi-flap prime editors that may be modified with one or more NLSs at the C-terminus, the N-terminus, as well as at an internal region of the multi-flap prime editor. The residues of a longer sequence that do not function as component NLS residues should be selected so as not to interfere, for example tonically or sterically, with the nuclear localization signal itself. Therefore, although there are no strict limits on the composition of an NLS-comprising sequence, in practice, such a sequence can be functionally limited in length and composition.

[0616] The present disclosure contemplates any suitable means by which to modify a multi-flap prime editor to include one or more NLSs. In one aspect, the multi-flap prime editors may be

engineered to express a prime editor protein that is translationally fused at its N-terminus or its C-terminus (or both) to one or more NLSs, i.e., to form a prime editor-NLS fusion construct. In other embodiments, the prime editor-encoding nucleotide sequence may be genetically modified to incorporate a reading frame that encodes one or more NLSs in an internal region of the encoded prime editor. In addition, the NLSs may include various amino acid linkers or spacer regions encoded between the prime editor and the N-terminally, C-terminally, or internally-attached NLS amino acid sequence, e.g., and in the central region of proteins. Thus, the present disclosure also provides for nucleotide constructs, vectors, and host cells for expressing fusion proteins that comprise a prime editor and one or more NLSs.

[0617] The multi-flap prime editors described herein may also comprise nuclear localization signals which are linked to a prime editor through one or more linkers, e.g., and polymeric, amino acid, nucleic acid, polysaccharide, chemical, or nucleic acid linker element. The linkers within the contemplated scope of the disclosure are not intended to have any limitations and can be any suitable type of molecule (e.g., polymer, amino acid, polysaccharide, nucleic acid, lipid, or any synthetic chemical linker domain) and be joined to the prime editor by any suitable strategy that effectuates forming a bond (e.g., covalent linkage, hydrogen bonding) between the prime editor and the one or more NLSs.

C. Flap endonucleases (e.g., FEN1)

[0618] In various embodiments, the PE fusion proteins may comprise one or more flap endonucleases (e.g., FEN1), which refers to an enzyme that catalyzes the removal of 5' single strand DNA flaps. These are naturally occurring enzymes that process the removal of 5' flaps formed during cellular processes, including DNA replication. The multi-flap prime editing methods herein described may utilize endogenously supplied flap endonucleases or those provided *in trans* to remove the 5' flap of endogenous DNA formed at the target site during multi-flap prime editing. Flap endonucleases are known in the art and can be found described in Patel et al., "Flap endonucleases pass 5'-flaps through a flexible arch using a disorder-thread-order mechanism to confer specificity for free 5'-ends," *Nucleic Acids Research*, 2012, 40(10): 4507-4519 and Tsutakawa et al., "Human flap endonuclease structures, DNA double-base flipping, and a unified understanding of the FEN1 superfamily," *Cell*, 2011, 145(2): 198-211 (each of which are incorporated herein by reference). An exemplary flap endonuclease is FEN1, which can be represented by the following amino acid sequence:

Description	Sequence	SEQ ID NO:
FEN1 Wild type (wt)	MGIQGLAKLIADVAPSAIRENDIKSYFGRKVAIDASMSIYQF LIAVRQGGDVLQNEEGETTSHLMGMFYRTIRMMENGIKPV YVFDGKPPQLKSGELAKRSERRAEAEKQLQQAQAAGAEQE VEKFTKRLVKVTKQHNDCKHLLSLMGIPYLDAPSEAEASC AALVKAGKVYAAATEDMDCLTFGSPVLMRHLTASEAKKLP IQEFHLSRILQELGLNQEQFVDLCILLGSDYCESIRGIGPKRA VDLIQKHKSIEEIVRRLLDPNKYPVPENWLHKEAHQLFLEPEV	SEQ ID NO: 198

	LDPESELKWSSEPNEEELIKFMCGEKQFSEERIRSGVKRLSK SRQGSTQGRLLDDFFKVTGSLSSAKRKEPEPKGSTKKKAKTG AAGKFKRGK	
--	---	--

[0619] The flap endonucleases may also include any FEN1 variant, mutant, or other flap

endonuclease ortholog, homolog, or variant. Non-limiting FEN1 variant examples are as follows:

Description	Sequence	SEQ ID NO:
FEN1 K168R (relative to FEN1 wt)	MGIQGLAKLIADVAPSAIRENDIKSYFGRKVAIDASMSIYQF LIAVRQGGDVLQNEEGETTSHLMGMFYRTIRMMENGIKPV YVFDGKPPQLKSGELAKRSERRAEAEKQLQQAQAAGAEQE VEKFTKRLVKVTKQHNDCKHLLSLMGIPYLDAPSEAEASC AALV R AGKVYAAATEDMDCLTFGSPVLMRHLTASEAKKLP IQEFHLSRILQELGLNQEQQFVLDLCILLGSDYCESIRGIGPKRA VDLIQKHKSIEEIVRRLLDPNKYPVPENWLHKEAHQLFLEPEV LDPESELKWSSEPNEEELIKFMCGEKQFSEERIRSGVKRLSK SRQGSTQGRLLDDFFKVTGSLSSAKRKEPEPKGSTKKKAKTG AAGKFKRGK	SEQ ID NO: 199
FEN1 S187A (relative to FEN1 wt)	MGIQGLAKLIADVAPSAIRENDIKSYFGRKVAIDASMSIYQF LIAVRQGGDVLQNEEGETTSHLMGMFYRTIRMMENGIKPV YVFDGKPPQLKSGELAKRSERRAEAEKQLQQAQAAGAEQE VEKFTKRLVKVTKQHNDCKHLLSLMGIPYLDAPSEAEASC AALVKAGKVYAAATEDMDCLTFG A PVLMRHLTASEAKKL PIQEFHLSRILQELGLNQEQQFVLDLCILLGSDYCESIRGIGPKRA VDLIQKHKSIEEIVRRLLDPNKYPVPENWLHKEAHQLFLEPEV LDPESELKWSSEPNEEELIKFMCGEKQFSEERIRSGVKRLSK SRQGSTQGRLLDDFFKVTGSLSSAKRKEPEPKGSTKKKAKTG AAGKFKRGK	SEQ ID NO: 200
FEN1 K354R (relative to FEN1 wt)	MGIQGLAKLIADVAPSAIRENDIKSYFGRKVAIDASMSIYQF LIAVRQGGDVLQNEEGETTSHLMGMFYRTIRMMENGIKPV YVFDGKPPQLKSGELAKRSERRAEAEKQLQQAQAAGAEQE VEKFTKRLVKVTKQHNDCKHLLSLMGIPYLDAPSEAEASC AALVKAGKVYAAATEDMDCLTFGSPVLMRHLTASEAKKLP IQEFHLSRILQELGLNQEQQFVLDLCILLGSDYCESIRGIGPKRA VDLIQKHKSIEEIVRRLLDPNKYPVPENWLHKEAHQLFLEPEV LDPESELKWSSEPNEEELIKFMCGEKQFSEERIRSGVKRLSK SRQGSTQGRLLDDFFKVTGSLSSA R RKEPEPKGSTKKKAKTG AAGKFKRGK	SEQ ID NO: 201
GEN1	MGVNDLWQILEPVKQHIPLRNLGGKTIAVDLSLWVCEAQT VKMMGSMVMKPHLRNLFFRISYLTQMDVKLVFVMEGEPPK LKADVISKRNSRYGSSGKSWSQKTGRSHFKSVLRECLHML ECLGIPWVQAAGEAEAMCAYLNAGGHVDGCLTNDGDTFL YGAQTVYRNFTMNTKDPHVDCYTMSISKSLGLDRDALVG LAILLGCDYLPKGVPGVGKEQALKLIQILKGQSLQRFNRW NETSCNPPQLLVTKLAHCSVCSHPGSPKDHENGCRLCK SDKYCEPHDYEYCCPCEWHRTEHDRQLSEVENNIKKKACC CEGFPFHEVIQEFLNNDKLKLVIRYQRPDLLLLFQFRTLEKM EWPNNHYACEKLLVLLTHYDMIERKLGSRSNQLQPIRIVKT RIRNGVHCFEIEWEKPEHYAMEDKQHGEFALLTIEEESLFEA AYPEIVAVYQKQKLEIKGKKQKRIKPKENNLPEPDEVMSFQ SHMTLKPTCEIFHKQNSKLNSGISPDPTLPQESISASLNSLLP KNTPCLNAQEQQMSSLRPLAIQKIKAVSKSLISESSQPNTSSH NISVIADLHLSTIDWEGTSFSNSPAIQRNTFSHDLKSEVESELS AIPDGFENIPEQLSCESERYTANIKKVLDESDGISPEEHLLS GITDLCLQDLPLKERIFTKLSYPQDNLQPDVNLKTLISLSVKE	SEQ ID NO: 202

	SCIANSQSDCTSHLSKDLPGIPLQNESRDSKILKGDQLLQEDY KVNTSVPYSVSNTVVKTCNVRPPNTALDHSRKVDMQTTRKI LMKKSVCCLDRHSSDEQSAPVFGKAKYTTQRMKHSSQKHNS SHFKESGHNLSSPKIHIKETEQCVRSYETAENEESCFFDSTK SSLSSLQCHKKENNSGTCLDSPLPLRQRLKLRQST	
ERCC5	MGVQGLWKLLECSGRQVSPEALEGKILAVDISIWLNQALKG VRDRHGNSIENPHLLTLFHRCLKLLFFRIRPIFVFDGDAPLLK KQTLVKRRQRKDLASSDSRKTTEKLLKTFLKRQAIKTAFRS KRDEALPSLTQVRRENDLYVLPPLQEEKHSSSEEEDEKEWQ ERMNQKQALQEEFFHNPQAIDIESEDFSSLPPEVKHEILTDM KEFTKRRRTLFEAMPEESDDFSQYQLKGLLKKNYLNQHIEH VQKEMNQHSGHIRRQYEDEGGFLKEVESRRVVSSEDTSYI LIKGIQAKTVAEVDSESLPSSSKMHGMSFDVKSSPCEKLTKE KEPDATPPSPRTLLAMQAALLGSSSEEELESENRRQARGRN APAAVDEGSISPRTL SAIKRALDDDEDVKVCAGDDVQTGGP GAEEMRINSSTENSDEGLKVRDGKGIPFTATLASSSVNSAEE HVA STNEG REPTDSVPKEQMSLVHVGTEAFPISDESMIKDR KDRLPLESAVVRHSDAPGLPNGRELTPASPTCTNSVSKNETH AEVLEQQNELCPYESKFDSSLLSSDDETKCKPNSASEVIGPV SLQETSSIVSVPSEAVDNVENVVSFNAKEHENFLETIQEQQT TESAGQDLISIPKAVEPMEIDSESESDGSFIEVQSVISDEELQ AEFPETSKPPSEQGEEELVGTREGEAPAESSELLRDNSERDD VDGEPQEA EKDAEDSLHEWQDINLEELETLESNLLAQQNSL KAQKQQQERIAATVTGQMFLSQELLRLFGIPYIQAPMEAE AQCAILDLDQTS GTITDDSDIWLFGARHVYRNFFNKNKFV EYYQYVDFHNQLGLDRNKLINLAYLLGSDYTEGIPTVGCVT AMEILNEFPGHGLEPLLKFSEWWHEAQKNPKIRPNPHDTKV KKKLRTLQLTPGFNPNAVAEAYLKPVVDDSKGSFLWGKPD LDKIREFCQRYFGWNRKTDES LFPVLKQLDAQQTQLRISF FRLAQKEKEDAKRIKSQRLNRAVTCMLRKEKEAAASEIEAV SVAMEKEFELLDKAKRKTQKRGITNTLEESSSLKRKRLSDS KRKNTCGGFLGETCLSESSDGSSSEDAESSSLMNVQRRTA KEPKTSASDSQNSVKEAPVKNGGATTSSSSSDSDDDGGKEK MVLVTARSVFGKKRRKLRRARGRKRKT	SEQ ID NO: 203

[0620] In various embodiments, the multi-flap prime editor fusion proteins contemplated herein may include any flap endonuclease variant of the above-disclosed sequences having an amino acid sequence that is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to any of the above sequences.

[0621] Other endonucleases that may be utilized by the instant methods to facilitate removal of the 5' end single strand DNA flap include, but are not limited to (1) trex 2, (2) exo1 endonuclease (e.g., Keijzers et al., *Biosci Rep.* 2015, 35(3): e00206)

Trex 2

[0622] 3' three prime repair exonuclease 2 (TREX2) - human

[0623] Accession No. NM_080701

MSEAPRAETFVFLDLEATGLPSVEPEIAELSLFAVHRSSLENPEHDESGALVLPRLVDKLTLC
MCPERPFTAKASEITGLSSEGLARCRKAGFDGAVVRTLQAFLSRQAGPICLVAHNGFDYDFPL
LCAELRRLGARLPRDTVCLDTLPALRGLDRAHSHGTRARGRQGYSLGSLFHRYFRAEPSAAH
SAEGDVHTLLLIFLHRAAELLAWADEQARGWAHIEPMYLPDDPSLEA (SEQ ID NO: 3865).

[0624] 3' three prime repair exonuclease 2 (TREX2) - mouse

[0625] Accession No. NM_011907

[0626] MSEPPRAETFVFLDLEATGLPNMDPEIAEISLFAVHRSSLENPERDDSGSLVLPRLVDK
LTLCMCPERPFTAKASEITGLSSESLMHCCKAGFNGAVVRTLQGFLSRQEGPICLVAHNGFDY
DFPLLCTELQRLGAHL PQDTVCLDTLPALRGLDRAHSHGTRAQGRKSYSLASLFHRYFQAEP
SAAHSAEGDVHTLLLIFLHRAPELLAWADEQARSWAHIEPMYVPPDGPSLEA (SEQ ID NO:
3866).

[0627] 3' three prime repair exonuclease 2 (TREX2) - rat

[0628] Accession No. NM_001107580

[0629] MSEPLRAETFVFLDLEATGLPNMDPEIAEISLFAVHRSSLENPERDDSGSLVLPRLVDK
LTLCMCPERPFTAKASEITGLSSEGLMNCRKAAFNDAVVRTLQGFLSRQEGPICLVAHNGFD
YDFPLLCTELQRLGAHLPRDTVCLDTLPALRGLDRVHSHGTRAQGRKSYSLASLFHRYFQAE
PSAAHSAEGDVNTLLLIFLHRAPELLAWADEQARSWAHIEPMYVPPDGPSLEA (SEQ ID NO:
3867).

ExoI

[0630] Human exonuclease 1 (EXO1) has been implicated in many different DNA metabolic processes, including DNA mismatch repair (MMR), micro-mediated end-joining, homologous recombination (HR), and replication. Human EXO1 belongs to a family of eukaryotic nucleases, Rad2/XPG, which also include FEN1 and GEN1. The Rad2/XPG family is conserved in the nuclease domain through species from phage to human. The EXO1 gene product exhibits both 5' exonuclease and 5' flap activity. Additionally, EXO1 contains an intrinsic 5' RNase H activity. Human EXO1 has a high affinity for processing double stranded DNA (dsDNA), nicks, gaps, pseudo Y structures and can resolve Holliday junctions using its inherit flap activity. Human EXO1 is implicated in MMR and contain conserved binding domains interacting directly with MLH1 and MSH2. EXO1 nucleolytic activity is positively stimulated by PCNA, MutS α (MSH2/MSH6 complex), 14-3-3, MRN and 9-1-1 complex.

[0631] exonuclease 1 (EXO1) Accession No. NM_003686 (Homo sapiens exonuclease 1 (EXO1), transcript variant 3) – isoform A

MGIQGLLQFIKEASEPIHVRKYKGQVVAVDTYCWLHKGAIAEKLAKGEPTDRYVGFCEMK
FVNMLLSHGKIPILVFDGCTLPKKEVERSRERRRQANLLKGKQLLREGKVSEARECFTRSINI
THAMAHKVIKAARSQGVDCLVAPYEADAQLAYLNKAGIVQAIITEDSDLLAFGCKKVILKM
DQFGNGLEIDQARLGMCRLGDVFTEEFKFRYMCILSGCDYLSSLRGIGLAKACKVLRANNP
DIVKVIKKIGHYLMKNITVPEDYINGFIRANNFTLYQLVFDPIKRKLIPLNAYEDDVDPETLSY
AGQYVDDSIALLQIALGNKDINTFEQIDDYNDPTAMPASRSWSWDDKTCQKSANVSSIWHRN
YSPRPESGTVSDAPQLKENPSTVGVERVISTKGLNLPRKSSIVKRPRSAELSEDDLLSQYSLSFT
KKTKKNSSEGKSLSFSEVFVFDLVNGPTNKKSVSTPPRTRNKFATFLQRKNEESGAVVVP

TRSRFFCSDSTDCVSNKVSQPLDETA VTDKENNLHESEYGDQEGKRLVDTDVARNSSDDIP
 NNHDPGDHDPKATVFTDEESYSFESSKFTRTISPPTLGLRSCFSWSGGLGDFSRTPSPSTAL
 QQFRRKSDSPTSLPENNMDSVSQLKSEESSDDESHPLREEACSSQSQESGEFSLQSSNASKLSQ
 CSSKSDSDSEESDCNIKLLDSQSDQTSKLRLSHFSKKDTPLRNKVPGLYKSSSADSLSTTKIKPL
 GPARASGLSKKPASIQRKHHNAENKPGLQIKLNELWKNFGFKKF (SEQ ID NO: 3868).

[0632] exonuclease 1 (EXO1) Accession No. NM_006027 (Homo sapiens exonuclease 1 (EXO1),
 transcript variant 3) – isoform B

[0633] MGIQGLLQFIKEASEPIHVRKYKGQVVAVD TYCWLHKGAIAECAEKLAKGEPTDRYV
 GFCMKFVNMLLSHGKIPILVFDGCTLPSKKEVERSRERRRQANLLKGKQLLREGKVSEAREC
 FTRSINITHAMAHKVIKAARSQGVDCLVAPYEADAQLAYLNKAGIVQAIITEDSDLLAFGCKK
 VILKMDQFGNGLEIDQARLGMCRLQGDVFTEEFKFRYMCILSGCDYLSLRGIGLAKACKVLR
 LANNPDIVKVIKKIGHYLMNITVPEDYINGFIRANNTFLYQLVFDPIKRKLIPLNAYEDDVP
 ETLSYAGQYVDDSIQIALGNKDINTFEQIDDYNPDTAMPAHSRSHSWDDKTCQKSANVSSI
 WHRNYSPRPESGTVSDAPQLKENPSTVGVERVISTKGLNLPRKSSIVKRPRSAELSEDDLLSQ
 YLSFTKKTCKNSSEGNKSLSFSEVFVPDLVNGPTNKKSVSTPPRTRNKFATFLQRKNEESGA
 VVVPGTRSRFFCSDSTDCVSNKVSQPLDETA VTDKENNLHESEYGDQEGKRLVDTDVARN
 SSDDIPNNHDPGDHDPKATVFTDEESYSFESSKFTRTISPPTLGLRSCFSWSGGLGDFSRTPSP
 SPSTALQQFRRKSDSPTSLPENNMDSVSQLKSEESSDDESHPLREEACSSQSQESGEFSLQSSN
 ASKLSQCSSKSDSDSEESDCNIKLLDSQSDQTSKLRLSHFSKKDTPLRNKVPGLYKSSSADSLST
 TKIKPLGPARASGLSKKPASIQRKHHNAENKPGLQIKLNELWKNFGFKKDSEKLPPCKKPLS
 PVRDNIQLTPEAEEDIFNKPECGRVQRAIFQ (SEQ ID NO: 3869).

[0634] exonuclease 1 (EXO1) Accession No. NM_001319224 (Homo sapiens exonuclease 1
 (EXO1), transcript variant 4) – isoform C

[0635] MGIQGLLQFIKEASEPIHVRKYKGQVVAVD TYCWLHKGAIAECAEKLAKGEPTDRYV
 GFCMKFVNMLLSHGKIPILVFDGCTLPSKKEVERSRERRRQANLLKGKQLLREGKVSEAREC
 FTRSINITHAMAHKVIKAARSQGVDCLVAPYEADAQLAYLNKAGIVQAIITEDSDLLAFGCKK
 VILKMDQFGNGLEIDQARLGMCRLQGDVFTEEFKFRYMCILSGCDYLSLRGIGLAKACKVLR
 LANNPDIVKVIKKIGHYLMNITVPEDYINGFIRANNTFLYQLVFDPIKRKLIPLNAYEDDVP
 ETLSYAGQYVDDSIQIALGNKDINTFEQIDDYNPDTAMPAHSRSHSWDDKTCQKSANVSSI
 WHRNYSPRPESGTVSDAPQLKENPSTVGVERVISTKGLNLPRKSSIVKRPRSELEDDLLSQYS
 LSFTKKTCKNSSEGNKSLSFSEVFVPDLVNGPTNKKSVSTPPRTRNKFATFLQRKNEESGAVV
 VPGTRSRFFCSDSTDCVSNKVSQPLDETA VTDKENNLHESEYGDQEGKRLVDTDVARNSS
 DDIPNNHDPGDHDPKATVFTDEESYSFESSKFTRTISPPTLGLRSCFSWSGGLGDFSRTPSPSP
 STALQQFRRKSDSPTSLPENNMDSVSQLKSEESSDDESHPLREEACSSQSQESGEFSLQSSNAS
 KLSQCSSKSDSDSEESDCNIKLLDSQSDQTSKLRLSHFSKKDTPLRNKVPGLYKSSSADSLSTTK
 IKPLGPARASGLSKKPASIQRKHHNAENKPGLQIKLNELWKNFGFKKDSEKLPPCKKPLSPV
 RDNIQLTPEAEEDIFNKPECGRVQRAIFQ (SEQ ID NO: 3870).

D. Inteins and split-inteins

[0636] It will be understood that in some embodiments (e.g., delivery of a multi-flap prime editor *in vivo* using AAV particles), it may be advantageous to split a polypeptide (e.g., a deaminase or a napDNAbp) or a fusion protein (e.g., a multi-flap prime editor) into an N-terminal half and a C-terminal half, delivery them separately, and then allow their colocalization to reform the complete protein (or fusion protein as the case may be) within the cell. Separate halves of a protein or a fusion protein may each comprise a split-intein tag to facilitate the reformation of the complete protein or fusion protein by the mechanism of protein trans splicing.

[0637] Protein trans-splicing, catalyzed by split inteins, provides an entirely enzymatic method for protein ligation. A split-intein is essentially a contiguous intein (e.g. a mini-intein) split into two pieces named N-intein and C-intein, respectively. The N-intein and C-intein of a split intein can associate non-covalently to form an active intein and catalyze the splicing reaction essentially in same way as a contiguous intein does. Split inteins have been found in nature and also engineered in laboratories. As used herein, the term "split intein" refers to any intein in which one or more peptide bond breaks exists between the N-terminal and C-terminal amino acid sequences such that the N-terminal and C-terminal sequences become separate molecules that can non-covalently reassociate, or reconstitute, into an intein that is functional for trans-splicing reactions. Any catalytically active intein, or fragment thereof, may be used to derive a split intein for use in the methods of the invention. For example, in one aspect the split intein may be derived from a eukaryotic intein. In another aspect, the split intein may be derived from a bacterial intein. In another aspect, the split intein may be derived from an archaeal intein. Preferably, the split intein so-derived will possess only the amino acid sequences essential for catalyzing trans-splicing reactions.

[0638] As used herein, the "N-terminal split intein (In)" refers to any intein sequence that comprises an N- terminal amino acid sequence that is functional for trans-splicing reactions. An In thus also comprises a sequence that is spliced out when trans-splicing occurs. An In can comprise a sequence that is a modification of the N-terminal portion of a naturally occurring intein sequence. For example, an In can comprise additional amino acid residues and/or mutated residues so long as the inclusion of such additional and/or mutated residues does not render the In non-functional in trans-splicing. Preferably, the inclusion of the additional and/or mutated residues improves or enhances the trans-splicing activity of the In.

[0639] As used herein, the "C-terminal split intein (Ic)" refers to any intein sequence that comprises a C- terminal amino acid sequence that is functional for trans-splicing reactions. In one aspect, the Ic comprises 4 to 7 contiguous amino acid residues, at least 4 amino acids of which are from the last β -strand of the intein from which it was derived. An Ic thus also comprises a sequence that is spliced out when trans-splicing occurs. An Ic can comprise a sequence that is a modification of the C-terminal portion of a naturally occurring intein sequence. For example, an Ic can comprise additional amino acid residues and/or mutated residues so long as the inclusion of such additional and/or mutated

residues does not render the In non-functional in trans-splicing. Preferably, the inclusion of the additional and/or mutated residues improves or enhances the trans-splicing activity of the Ic.

[0640] In some embodiments of the invention, a peptide linked to an Ic or an In can comprise an additional chemical moiety including, among others, fluorescence groups, biotin, polyethylene glycol (PEG), amino acid analogs, unnatural amino acids, phosphate groups, glycosyl groups, radioisotope labels, and pharmaceutical molecules. In other embodiments, a peptide linked to an Ic can comprise one or more chemically reactive groups including, among others, ketone, aldehyde, Cys residues and Lys residues. The N-intein and C-intein of a split intein can associate non-covalently to form an active intein and catalyze the splicing reaction when an "intein-splicing polypeptide (ISP)" is present. As used herein, "intein-splicing polypeptide (ISP)" refers to the portion of the amino acid sequence of a split intein that remains when the Ic, In, or both, are removed from the split intein. In certain embodiments, the In comprises the ISP. In another embodiment, the Ic comprises the ISP. In yet another embodiment, the ISP is a separate peptide that is not covalently linked to In nor to Ic.

[0641] Split inteins may be created from contiguous inteins by engineering one or more split sites in the unstructured loop or intervening amino acid sequence between the -12 conserved beta-strands found in the structure of mini-inteins. Some flexibility in the position of the split site within regions between the beta-strands may exist, provided that creation of the split will not disrupt the structure of the intein, the structured beta-strands in particular, to a sufficient degree that protein splicing activity is lost.

[0642] In protein trans-splicing, one precursor protein consists of an N-extein part followed by the N-intein, another precursor protein consists of the C-intein followed by a C-extein part, and a trans-splicing reaction (catalyzed by the N- and C-inteins together) excises the two intein sequences and links the two extein sequences with a peptide bond. Protein trans-splicing, being an enzymatic reaction, can work with very low (e.g. micromolar) concentrations of proteins and can be carried out under physiological conditions.

[0643] Exemplary sequences are as follows:

NAME	SEQUENCE OF LIGAND-DEPENDENT INTEIN
2-4 INTEIN:	CLAEGRIFDPVTGTTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGAIVWATPDHKVLTEYGWRAAGELRKGDRVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQHQQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPYDLLLLMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLAEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 8)
3-2 INTEIN	CLAEGRIFDPVTGTTTHRIEDVVDGRKPIHVVA VAKDGTLLARPVVS WFD QGTRDVIGLRIAGGAIVWATPDHKVLTEYGWRAAGELRKGDRVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII

	LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYTNVVPYDLLLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 9)
30R3-1 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAADKDGTLARPVVSWFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRKGDVAGPGGS GNSLALSLTADQMVSALLDAEPPIPYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCVGEMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPYDLLLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 10)
30R3-2 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAADKDGTLARPVVSWFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRKGDVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCVGEMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPYDLLLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 11)
30R3-3 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAADKDGTLARPVVSWFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRKGDVAGPGGS GNSLALSLTADQMVSALLDAEPPIPYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCVGEMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPYDLLLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 12)
37R3-1 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAADKDGTLARPVVSWFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRKGDVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYNPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLERAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCVGEMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPYDLLLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC ((SEQ ID NO: 13)
37R3-2 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAADKDGTLARPVVSWFD QGTRDVIGLRIAGGAIVWATPDHKVLTEYGWRAAGELRKGDVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLERAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCVGEMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPYDLLLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 14)
37R3-3 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAADKDGTLARPVVSWFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRKGDVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLERAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCVGEMVEIFDMLLATSSRFRMMNLQGEEFVCLKSII

	LLNSGVYTFSLSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLAEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 15)
--	--

[0644] Although inteins are most frequently found as a contiguous domain, some exist in a naturally split form. In this case, the two fragments are expressed as separate polypeptides and must associate before splicing takes place, so-called protein trans-splicing.

[0645] An exemplary split intein is the *Ssp* DnaE intein, which comprises two subunits, namely, DnaE-N and DnaE-C. The two different subunits are encoded by separate genes, namely *dnaE-n* and *dnaE-c*, which encode the DnaE-N and DnaE-C subunits, respectively. DnaE is a naturally occurring split intein in *Synechocystis sp.* PCC6803 and is capable of directing trans-splicing of two separate proteins, each comprising a fusion with either DnaE-N or DnaE-C.

[0646] Additional naturally occurring or engineered split-intein sequences are known in the art or can be made from whole-intein sequences described herein or those available in the art. Examples of split-intein sequences can be found in Stevens et al., “A promiscuous split intein with expanded protein engineering applications,” PNAS, 2017, Vol.114: 8538-8543; Iwai et al., “Highly efficient protein trans-splicing by a naturally split DnaE intein from *Nostoc punctiforme*, FEBS Lett, 580: 1853-1858, each of which are incorporated herein by reference. Additional split intein sequences can be found, for example, in WO 2013/045632, WO 2014/055782, WO 2016/069774, and EP2877490, the contents each of which are incorporated herein by reference.

[0647] In addition, protein splicing in trans has been described *in vivo* and *in vitro* (Shingledecker, et al., *Gene* 207:187 (1998), Southworth, et al., *EMBO J.* 17:918 (1998); Mills, et al., *Proc. Natl. Acad. Sci. USA*, 95:3543-3548 (1998); Lew, et al., *J. Biol. Chem.*, 273:15887-15890 (1998); Wu, et al., *Biochim. Biophys. Acta* 35732:1 (1998b), Yamazaki, et al., *J. Am. Chem. Soc.* 120:5591 (1998), Evans, et al., *J. Biol. Chem.* 275:9091 (2000); Otomo, et al., *Biochemistry* 38:16040-16044 (1999); Otomo, et al., *J. Biolmol. NMR* 14:105-114 (1999); Scott, et al., *Proc. Natl. Acad. Sci. USA* 96:13638-13643 (1999)) and provides the opportunity to express a protein as to two inactive fragments that subsequently undergo ligation to form a functional product, e.g., as shown in FIGs. 66 and 67 with regard to the formation of a complete PE fusion protein from two separately-expressed halves.

E. RNA-protein interaction domain

[0648] In various embodiments, two separate protein domains (e.g., a Cas9 domain and a polymerase domain) may be colocalized to one another to form a functional complex (akin to the function of a fusion protein comprising the two separate protein domains) by using an “RNA-protein recruitment system,” such as the “MS2 tagging technique.” Such systems generally tag one protein domain with an “RNA-protein interaction domain” (aka “RNA-protein recruitment domain”) and the other with an “RNA-binding protein” that specifically recognizes and binds to the RNA-protein interaction domain, e.g., a specific hairpin structure. These types of systems can be leveraged to colocalize the domains

of a multi-flap prime editor, as well as to recruitment additional functionalities to a multi-flap prime editor, such as a UGI domain. In one example, the MS2 tagging technique is based on the natural interaction of the MS2 bacteriophage coat protein (“MCP” or “MS2cp”) with a stem-loop or hairpin structure present in the genome of the phage, i.e., the “MS2 hairpin.” In the case of the MS2 hairpin, it is recognized and bound by the MS2 bacteriophage coat protein (MCP). Thus, in one exemplary scenario a deaminase-MS2 fusion can recruit a Cas9-MCP fusion.

[0649] A review of other modular RNA-protein interaction domains are described in the art, for example, in Johansson et al., “RNA recognition by the MS2 phage coat protein,” *Sem Virol.*, 1997, Vol. 8(3): 176-185; Delebecque et al., “Organization of intracellular reactions with rationally designed RNA assemblies,” *Science*, 2011, Vol. 333: 470-474; Mali et al., “Cas9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering,” *Nat. Biotechnol.*, 2013, Vol.31: 833-838; and Zalatan et al., “Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds,” *Cell*, 2015, Vol.160: 339-350, each of which are incorporated herein by reference in their entireties. Other systems include the PP7 hairpin, which specifically recruits the PCP protein, and the “com” hairpin, which specifically recruits the Com protein. See Zalatan et al.

[0650] The nucleotide sequence of the MS2 hairpin (or equivalently referred to as the “MS2 aptamer”) is: GCCAACATGAGGATCACCCATGTCTGCAGGGCC (SEQ ID NO: 763).

[0651] The amino acid sequence of the MCP or MS2cp is:

GSASNFTQFVLVDNGGTGDVTVAPSNFANGVAEWISSNSRSQAYKVTCSVRQSSAQNRKYTI
KVEVPKVATQTVGGEELPVAGWRSYLNMEITIPFATNSDCELVKAMQGLLKDGNPIPSAIA
ANSGLY (SEQ ID NO: 764).

F. UGI domain

[0652] In other embodiments, the multi-flap prime editors described herein may comprise one or more uracil glycosylase inhibitor domains. The term “uracil glycosylase inhibitor (UGI)” or “UGI domain,” as used herein, refers to a protein that is capable of inhibiting a uracil-DNA glycosylase base-excision repair enzyme. In some embodiments, a UGI domain comprises a wild-type UGI or a UGI as set forth in SEQ ID NO: 3873. In some embodiments, the UGI proteins provided herein include fragments of UGI and proteins homologous to a UGI or a UGI fragment. For example, in some embodiments, a UGI domain comprises a fragment of the amino acid sequence set forth in SEQ ID NO: 3873. In some embodiments, a UGI fragment comprises an amino acid sequence that comprises at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid sequence as set forth in SEQ ID NO: 3873. In some embodiments, a UGI comprises an amino acid sequence homologous to the amino acid sequence set forth in SEQ ID NO: 3873, or an amino acid sequence homologous to a fragment of the amino acid sequence set forth in SEQ ID NO:

3873. In some embodiments, proteins comprising UGI or fragments of UGI or homologs of UGI or UGI fragments are referred to as “UGI variants.” A UGI variant shares homology to UGI, or a fragment thereof. For example a UGI variant is at least 70% identical, at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, at least 99.5% identical, or at least 99.9% identical to a wild type UGI or a UGI as set forth in SEQ ID NO: 3873. In some embodiments, the UGI variant comprises a fragment of UGI, such that the fragment is at least 70% identical, at least 80% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, at least 99% identical, at least 99.5% identical, or at least 99.9% to the corresponding fragment of wild-type UGI or a UGI as set forth in SEQ ID NO: 3873. In some embodiments, the UGI comprises the following amino acid sequence:

[0653] Uracil-DNA glycosylase inhibitor:

[0654] >sp|P14739|UNGL_BPPB2

MTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPE
YKPWALVIQDSNGENKIKML (SEQ ID NO: 3873).

[0655] The multi-flap prime editors described herein may comprise more than one UGI domain, which may be separated by one or more linkers as described herein.

G. Additional PE elements

[0656] In certain embodiments, the multi-flap prime editors described herein may comprise an inhibitor of base repair. The term “inhibitor of base repair” or “IBR” refers to a protein that is capable in inhibiting the activity of a nucleic acid repair enzyme, for example a base excision repair enzyme. In some embodiments, the IBR is an inhibitor of OGG base excision repair. In some embodiments, the IBR is an inhibitor of base excision repair (“iBER”). Exemplary inhibitors of base excision repair include inhibitors of APE1, Endo III, Endo IV, Endo V, Endo VIII, Fpg, hOGG1, hNEIL1, T7 EndoI, T4PDG, UDG, hSMUG1, and hAAG. In some embodiments, the IBR is an inhibitor of Endo V or hAAG. In some embodiments, the IBR is an iBER that may be a catalytically inactive glycosylase or catalytically inactive dioxygenase or a small molecule or peptide inhibitor of an oxidase, or variants thereof. In some embodiments, the IBR is an iBER that may be a TDG inhibitor, MBD4 inhibitor or an inhibitor of an AlkBH enzyme. In some embodiments, the IBR is an iBER that comprises a catalytically inactive TDG or catalytically inactive MBD4. An exemplary catalytically inactive TDG is an N140A mutant of SEQ ID NO: 3872 (human TDG).

[0657] Some exemplary glycosylases are provided below. The catalytically inactivated variants of any of these glycosylase domains are iBERs that may be fused to the napDNAbp or polymerase domain of the multi-flap prime editors provided in this disclosure.

[0658] OGG (human)

[0659] MPARALLPRRMGHRRLASTPALWASIPCPRSELRLDLVLP SGQSFRWREQSPAHSWG
VLADQVWTLTQTEEQ LHCTVYRGDKSQASRPTDELEAVRKYFQLDVT LAQLYHHWGSVD
SHFQEVAQKFQGVRLLRQDPIECLFSFICSSNNNIARITGMVERLCQAFGPRLIQLDDVTYHGF
PSLQALAGPEVEAHLRKLGLGYRARYVVSASARAILEEQGGLAWLQQ LRESSYEEAHKALCIL
PGVGTKVADICLMALDKPQAVPVDVHMWHIAQRDYSWHPTTSQAKGPSPQTNKELGNFF
RSLWGPYAGWAQAVLFSADLRQSRHAQEPPAKRRKGSKGPEG (SEQ ID NO: 3937)

[0660] MPG (human)

[0661] MVTPALQMKKPKQFCRRMGQKKQRPARAGQPHSSSDAAQAPAEQPHSSSDAAQAP
CPRERCLGPPTTPGPYRSIYFSSPKGHLTRLGLEFFDQPAVPLARAFLGQVLVRRLPNGTEL RG
RIVETEAYLGPEDAAHSRGGRTPRNRGMFMKPGTLYVYIYGYFCMNISSQGDGACVLL
RALEPLEGLETMRQLRSTLRKGTASRVLKDRELCSGPSKLCQALAINKSFDQRDLAQDEAVW
LERGPLEPSEPAVVAAARVGVGHAGEWARKPLRFYVRGSPWVSVVDRVAEQDTQA (SEQ
ID NO: 3938)

[0662] MBD4 (human)

[0663] MGTGLESLSLGD RGAAPTVTSSERLVPDPPNDRKEDVAMELERVGEDEEQMMIK
RSSECNPLLQEPIASAQFGATAGTECRKSVPCGWERVVKQRLFGKTAGRFDVYFISPQGLKFR
SKSSLANYLHKNGETSLKPEDFDFTVLSKRGIKSRYKDCSMAALTSHLQNQSNNSNWNLRTR
SKCKKDVFMPPSSSELQESRGLSNFTSTHLLLKEDEGVDDVNFRKVRKPKGKVITLKGPIK
KTKKGCRCSCSGFVQSDSKRESVCNKADA ESEPVAQKSQLDRTVCISDAGACGETLSVTSEE
NSLVKKKERSLSSGSNFCSEQKTSGIINKFCSAKDSEHNEKYEDTFLESEEIGTKVEVVERKEH
LHTDILKRGSEMDNNCSPTRKDFTGEKIFQEDTIPRTQIERRKTSLYFSSKYNKEALSPRRKA
FKKWTPPRSPFNLVQETLFHDPWKLLIATIFLNRTSGKMAIPVLWKFLEKYP SAEVARTADW
RDVSELLKPLGLYDLRAKTIVKFSDEYLTQWKYPIELHGIGKYGNDSYRIFCVNEWKQVHP
EDHKL NKYHDWLWENHEKLSLS (SEQ ID NO: 3871)

[0664] TDG (human)

[0665] MEAENAGSYSLQQAQAFYTFPFQQLMAEAPNMAVVNEQQMP EEPAPAPAEQEPVQ
EAPKGRKRKPRTEPKQPV EPKPVESKSGKS AKSKEKQEKITDTFKV KRKVDRFNGVSEA
ELLTKTLPDILTFNLDIV IGINPGLMAAYKGHHYPGPGNHFWKCLFMSGLSEVQLNHMDDH
TLPGKYGIGFTNMVERTTPGSKDLSSKEFREGGRILVQKLQKYQPRIAVFNGKCIYEIFSKEVF
GVVKVKNLEFGLQPHKIPDTETLCYVMPSSSARCAQFPRAQDKVHYYIKLKD LRDQLKGIERN
MDVQEVQYTFDLQLAQEDAKKMAVKEEKYDPGYEAA YGGAYGENPCSSEPCGFSSNGLIES
VELRGESAFSGIPNGQWMTQSFTDQIPSF SNHCGTQE QEEESHA (SEQ ID NO: 3872)

[0666] In some embodiments, the fusion proteins described herein may comprise one or more heterologous protein domains (e.g., about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the prime editor components). A fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains. Other exemplary

features that may be present are localization sequences, such as cytoplasmic localization sequences, export sequences, such as nuclear export sequences, or other localization sequences, as well as sequence tags that are useful for solubilization, purification, or detection of the fusion proteins.

[0667] Examples of protein domains that may be fused to a multi-flap prime editor or component thereof (e.g., the napDNAbp domain, the polymerase domain, or the NLS domain) include, without limitation, epitope tags, and reporter gene sequences. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP). A multi-flap prime editor may be fused to a gene sequence encoding a protein or a fragment of a protein that bind DNA molecules or bind other cellular molecules, including, but not limited to, maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. Additional domains that may form part of a prime editor are described in US Patent Publication No. 2011/0059502, published March 10, 2011 and incorporated herein by reference in its entirety.

[0668] In an aspect of the disclosure, a reporter gene which includes, but is not limited to, glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofluorescent proteins including blue fluorescent protein (BFP), may be introduced into a cell to encode a gene product which serves as a marker by which to measure the alteration or modification of expression of the gene product. In certain embodiments of the disclosure the gene product is luciferase. In a further embodiment of the disclosure the expression of the gene product is decreased.

[0669] Suitable protein tags provided herein include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc-tags, calmodulin-tags, FLAG-tags, hemagglutinin (HA)-tags, polyhistidine tags, also referred to as histidine tags or His-tags, maltose binding protein (MBP)-tags, nus-tags, glutathione-S-transferase (GST)-tags, green fluorescent protein (GFP)-tags, thioredoxin-tags, S-tags, Softags (e.g., Softag 1, Softag 3), strep-tags, biotin ligase tags, FAsH tags, V5 tags, and SBP-tags. Additional suitable sequences will be apparent to those of skill in the art. In some embodiments, the fusion protein comprises one or more His tags.

[0670] In some embodiments of the present disclosure, the activity of the multi-flap prime editing system may be temporally regulated by adjusting the residence time, the amount, and/or the activity of the expressed components of the PE system. For example, as described herein, the PE may be fused

with a protein domain that is capable of modifying the intracellular half-life of the PE. In certain embodiments involving two or more vectors (e.g., a vector system in which the components described herein are encoded on two or more separate vectors), the activity of the PE system may be temporally regulated by controlling the timing in which the vectors are delivered. For example, in some embodiments a vector encoding the nuclease system may deliver the PE prior to the vector encoding the template. In other embodiments, the vector encoding the PEgRNA may deliver the guide prior to the vector encoding the PE system. In some embodiments, the vectors encoding the PE system and PEgRNA are delivered simultaneously. In certain embodiments, the simultaneously delivered vectors temporally deliver, e.g., the PE, PEgRNA, and/or second strand guide RNA components. In further embodiments, the RNA (such as, e.g., the nuclease transcript) transcribed from the coding sequence on the vectors may further comprise at least one element that is capable of modifying the intracellular half-life of the RNA and/or modulating translational control. In some embodiments, the half-life of the RNA may be increased. In some embodiments, the half-life of the RNA may be decreased. In some embodiments, the element may be capable of increasing the stability of the RNA. In some embodiments, the element may be capable of decreasing the stability of the RNA. In some embodiments, the element may be within the 3' UTR of the RNA. In some embodiments, the element may include a polyadenylation signal (PA). In some embodiments, the element may include a cap, e.g., an upstream mRNA or PEgRNA end. In some embodiments, the RNA may comprise no PA such that it is subject to quicker degradation in the cell after transcription. In some embodiments, the element may include at least one AU-rich element (ARE). The AREs may be bound by ARE binding proteins (ARE-BPs) in a manner that is dependent upon tissue type, cell type, timing, cellular localization, and environment. In some embodiments the destabilizing element may promote RNA decay, affect RNA stability, or activate translation. In some embodiments, the ARE may comprise 50 to 150 nucleotides in length. In some embodiments, the ARE may comprise at least one copy of the sequence AUUUA. In some embodiments, at least one ARE may be added to the 3' UTR of the RNA. In some embodiments, the element may be a Woodchuck Hepatitis Virus (WHP).

[0671] Posttranscriptional Regulatory Element (WPRE), which creates a tertiary structure to enhance expression from the transcript. In further embodiments, the element is a modified and/or truncated WPRE sequence that is capable of enhancing expression from the transcript, as described, for example in Zufferey et al., *J Virol*, 73(4): 2886-92 (1999) and Flajolet et al., *J Virol*, 72(7): 6175-80 (1998). In some embodiments, the WPRE or equivalent may be added to the 3' UTR of the RNA. In some embodiments, the element may be selected from other RNA sequence motifs that are enriched in either fast- or slow-decaying transcripts.

[0672] In some embodiments, the vector encoding the PE or the PEgRNA may be self-destroyed via cleavage of a target sequence present on the vector by the PE system. The cleavage may prevent continued transcription of a PE or a PEgRNA from the vector. Although transcription may occur on

the linearized vector for some amount of time, the expressed transcripts or proteins subject to intracellular degradation will have less time to produce off-target effects without continued supply from expression of the encoding vectors.

[6] PEgRNAs

[0673] The multi-flap prime editing system described herein contemplates the use of any suitable PEgRNAs. The mechanism of target-primed reverse transcription (TPRT) can be leveraged or adapted for conducting precision and versatile CRISPR/Cas-based genome editing through the use of a specially configured guide RNA comprising a reverse transcription (RT) template sequence that codes for the desired nucleotide change. The application refers to this specially configured guide RNA as an “extended guide RNA” or a “PEgRNA” since the RT template sequence can be provided as an extension of a standard or traditional guide RNA molecule. The application contemplates any suitable configuration or arrangement for the extended guide RNAs for use in dual-flap and quadruple-flap prime editing.

[0674] The general designs of pegRNAs used for dual-flap and multi-flap prime editing are shown in **FIG. 92**. pegRNAs used for dual-flap and multi-flap prime editing have a similar design to those used for classic prime editing, however it is not necessary for the RT template region to encode any homology to the target locus. Instead, the two pegRNAs can in various embodiments contain RT templates that encode the synthesis of 3′ flaps whose 3′ ends are reverse complement sequences of one another. This complementarity between the 3′ flaps promotes their annealing and replacement of the endogenous DNA sequence with the intended new DNA sequence. This necessitates that the 5′ regions of the RT templates in the two pegRNAs are reverse complement sequences to one another, and this amount of complementarity can vary (**FIG. 92**).

PEgRNA architecture

[0675] FIG. 3A shows one embodiment of an extended guide RNA usable in the multi-flap prime editing system disclosed herein whereby a traditional guide RNA (the green portion) includes a ~20 nt protospacer sequence and a gRNA core region, which binds with the napDNABp. In this embodiment, the guide RNA includes an extended RNA segment at the 5′ end, i.e., a 5′ extension. In this embodiment, the 5′ extension includes a reverse transcription template sequence, a reverse transcription primer binding site, and an optional 5-20 nucleotide linker sequence. As shown in FIGs. 1A-1B, the RT primer binding site hybridizes to the free 3′ end that is formed after a nick is formed in the non-target strand of the R-loop, thereby priming reverse transcriptase for DNA polymerization in the 5′-3′ direction.

[0676] FIG. 3B shows another embodiment of an extended guide RNA usable in the prime editing system disclosed herein whereby a traditional guide RNA (the green portion) includes a ~20 nt protospacer sequence and a gRNA core, which binds with the napDNABp. In this embodiment, the guide RNA includes an extended RNA segment at the 3′ end, i.e., a 3′ extension. In this embodiment,

the 3' extension includes a reverse transcription template sequence, and a reverse transcription primer binding site. As shown in FIGs. 1C-1D, the RT primer binding site hybridizes to the free 3' end that is formed after a nick is formed in the non-target strand of the R-loop, thereby priming reverse transcriptase for DNA polymerization in the 5'-3' direction.

[0677] FIG. 3C shows another embodiment of an extend guide RNA usable in the prime editing system disclosed herein whereby a traditional guide RNA (the green portion) includes a ~20 nt protospacer sequence and a gRNA core, which binds with the napDNAp. In this embodiment, the guide RNA includes an extended RNA segment at an intermolecular position within the gRNA core, i.e., an intramolecular extension. In this embodiment, the intramolecular extension includes a reverse transcription template sequence, and a reverse transcription primer binding site. The RT primer binding site hybridizes to the free 3' end that is formed after a nick is formed in the non-target strand of the R-loop, thereby priming reverse transcriptase for DNA polymerization in the 5'-3' direction.

[0678] In one embodiment, the position of the intermolecular RNA extension is not in the protospacer sequence of the guide RNA. In another embodiment, the position of the intermolecular RNA extension is in the gRNA core. In still another embodiment, the position of the intermolecular RNA extension is any with the guide RNA molecule except within the protospacer sequence, or at a position which disrupts the protospacer sequence.

[0679] In one embodiment, the intermolecular RNA extension is inserted downstream from the 3' end of the protospacer sequence. In another embodiment, the intermolecular RNA extension is inserted at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides downstream of the 3' end of the protospacer sequence.

[0680] In other embodiments, the intermolecular RNA extension is inserted into the gRNA, which refers to the portion of the guide RNA corresponding or comprising the tracrRNA, which binds and/or interacts with the Cas9 protein or equivalent thereof (i.e., a different napDNAp). Preferably the insertion of the intermolecular RNA extension does not disrupt or minimally disrupts the interaction between the tracrRNA portion and the napDNAp.

[0681] The length of the RNA extension (which includes at least the RT template and primer binding site, e.g., see FIG. 92) can be any useful length. In various embodiments, the RNA extension is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17

nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, or at least 500 nucleotides in length.

[0682] The RT template sequence can also be any suitable length. For example, the RT template sequence can be at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, or at least 500 nucleotides in length.

[0683] In still other embodiments, wherein the reverse transcription primer binding site sequence is at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, or at least 500 nucleotides in length.

[0684] In other embodiments, the optional linker or spacer sequence is at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 30 nucleotides, at least 40 nucleotides, at least 50 nucleotides, at least 60 nucleotides, at least 70 nucleotides, at least 80 nucleotides, at least 90 nucleotides, at least 100 nucleotides, at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, or at least 500 nucleotides in length.

[0685] The RT template sequence, in certain embodiments, encodes a single-stranded DNA molecule which is homologous to the non-target strand (and thus, complementary to the corresponding site of the target strand) but includes one or more nucleotide changes. The least one nucleotide change may

include one or more single-base nucleotide changes, one or more deletions, and one or more insertions.

[0686] As depicted in FIG. 1G, the synthesized single-stranded DNA product of the RT template sequence is homologous to the non-target strand and contains one or more nucleotide changes. The single-stranded DNA product of the RT template sequence hybridizes in equilibrium with the complementary target strand sequence, thereby displacing the homologous endogenous target strand sequence. The displaced endogenous strand may be referred to in some embodiments as a 5' endogenous DNA flap species (e.g., see FIG. 1E). This 5' endogenous DNA flap species can be removed by a 5' flap endonuclease (e.g., FEN1) and the single-stranded DNA product, now hybridized to the endogenous target strand, may be ligated, thereby creating a mismatch between the endogenous sequence and the newly synthesized strand. The mismatch may be resolved by the cell's innate DNA repair and/or replication processes.

[0687] In various embodiments, the nucleotide sequence of the RT template sequence corresponds to the nucleotide sequence of the non-target strand which becomes displaced as the 5' flap species and which overlaps with the site to be edited.

[0688] In various embodiments of the extended guide RNAs, the reverse transcription template sequence may encode a single-strand DNA flap that is complementary to an endogenous DNA sequence adjacent to a nick site, wherein the single-strand DNA flap comprises a desired nucleotide change. The single-stranded DNA flap may displace an endogenous single-strand DNA at the nick site. The displaced endogenous single-strand DNA at the nick site can have a 5' end and form an endogenous flap, which can be excised by the cell. In various embodiments, excision of the 5' end endogenous flap can help drive product formation since removing the 5' end endogenous flap encourages hybridization of the single-strand 3' DNA flap to the corresponding complementary DNA strand, and the incorporation or assimilation of the desired nucleotide change carried by the single-strand 3' DNA flap into the target DNA.

[0689] In various embodiments of the extended guide RNAs, the cellular repair of the single-strand DNA flap results in installation of the desired nucleotide change, thereby forming a desired product.

[0690] In still other embodiments, the desired nucleotide change is installed in an editing window that is between about -5 to +5 of the nick site, or between about -10 to +10 of the nick site, or between about -20 to +20 of the nick site, or between about -30 to +30 of the nick site, or between about -40 to +40 of the nick site, or between about -50 to +50 of the nick site, or between about -60 to +60 of the nick site, or between about -70 to +70 of the nick site, or between about -80 to +80 of the nick site, or between about -90 to +90 of the nick site, or between about -100 to +100 of the nick site, or between about -200 to +200 of the nick site. In other embodiments, the desired nucleotide change is installed in an editing window that is between about +1 to +2 from the nick site, or about +1 to +3, +1 to +4, +1 to +5, +1 to +6, +1 to +7, +1 to +8, +1 to +9, +1 to +10, +1 to +11, +1 to +12, +1 to +13, +1 to +14,

+1 to +15, +1 to +16, +1 to +17, +1 to +18, +1 to +19, +1 to +20, +1 to +21, +1 to +22, +1 to +23, +1 to +24, +1 to +25, +1 to +26, +1 to +27, +1 to +28, +1 to +29, +1 to +30, +1 to +31, +1 to +32, +1 to +33, +1 to +34, +1 to +35, +1 to +36, +1 to +37, +1 to +38, +1 to +39, +1 to +40, +1 to +41, +1 to +42, +1 to +43, +1 to +44, +1 to +45, +1 to +46, +1 to +47, +1 to +48, +1 to +49, +1 to +50, +1 to +51, +1 to +52, +1 to +53, +1 to +54, +1 to +55, +1 to +56, +1 to +57, +1 to +58, +1 to +59, +1 to +60, +1 to +61, +1 to +62, +1 to +63, +1 to +64, +1 to +65, +1 to +66, +1 to +67, +1 to +68, +1 to +69, +1 to +70, +1 to +71, +1 to +72, +1 to +73, +1 to +74, +1 to +75, +1 to +76, +1 to +77, +1 to +78, +1 to +79, +1 to +80, +1 to +81, +1 to +82, +1 to +83, +1 to +84, +1 to +85, +1 to +86, +1 to +87, +1 to +88, +1 to +89, +1 to +90, +1 to +90, +1 to +91, +1 to +92, +1 to +93, +1 to +94, +1 to +95, +1 to +96, +1 to +97, +1 to +98, +1 to +99, +1 to +100, +1 to +101, +1 to +102, +1 to +103, +1 to +104, +1 to +105, +1 to +106, +1 to +107, +1 to +108, +1 to +109, +1 to +110, +1 to +111, +1 to +112, +1 to +113, +1 to +114, +1 to +115, +1 to +116, +1 to +117, +1 to +118, +1 to +119, +1 to +120, +1 to +121, +1 to +122, +1 to +123, +1 to +124, or +1 to +125 from the nick site.

[0691] In still other embodiments, the desired nucleotide change is installed in an editing window that is between about +1 to +2 from the nick site, or about +1 to +5, +1 to +10, +1 to +15, +1 to +20, +1 to +25, +1 to +30, +1 to +35, +1 to +40, +1 to +45, +1 to +50, +1 to +55, +1 to +100, +1 to +105, +1 to +110, +1 to +115, +1 to +120, +1 to +125, +1 to +130, +1 to +135, +1 to +140, +1 to +145, +1 to +150, +1 to +155, +1 to +160, +1 to +165, +1 to +170, +1 to +175, +1 to +180, +1 to +185, +1 to +190, +1 to +195, or +1 to +200, from the nick site.

[0692] In various aspects, the extended guide RNAs are modified versions of a guide RNA. Guide RNAs maybe naturally occurring, expressed from an encoding nucleic acid, or synthesized chemically. Methods are well known in the art for obtaining or otherwise synthesizing guide RNAs and for determining the appropriate sequence of the guide RNA, including the protospacer sequence which interacts and hybridizes with the target strand of a genomic target site of interest.

[0693] In various embodiments, the particular design aspects of a guide RNA sequence will depend upon the nucleotide sequence of a genomic target site of interest (i.e., the desired site to be edited) and the type of napDNAbp (e.g., Cas9 protein) present in the multi-flap prime editing systems described herein, among other factors, such as PAM sequence locations, percent G/C content in the target sequence, the degree of microhomology regions, secondary structures, etc.

[0694] In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a napDNAbp (e.g., a Cas9, Cas9 homolog, or Cas9 variant) to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-

limiting example of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). In some embodiments, a guide sequence is about or more than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length.

[0695] In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a multi-flap prime editor to a target sequence may be assessed by any suitable assay. For example, the components of a multi-flap prime editor, including the guide sequence to be tested, may be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of a multi-flap prime editor disclosed herein, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay as described herein. Similarly, cleavage of a target polynucleotide sequence may be evaluated in a test tube by providing the target sequence, components of a multi-flap prime editor, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions. Other assays are possible, and will occur to those skilled in the art.

[0696] A guide sequence may be selected to target any target sequence. In some embodiments, the target sequence is a sequence within a genome of a cell. Exemplary target sequences include those that are unique in the target genome. For example, for the *S. pyogenes* Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMNNNNNNNNNNXGG (SEQ ID NO: 204) where NNNNNNNNNNNXGG (SEQ ID NO: 205) (N is A, G, T, or C; and X can be anything). A unique target sequence in a genome may include an *S. pyogenes* Cas9 target site of the form MMMMMMMNNNNNNNNNNXGG (SEQ ID NO: 206) where NNNNNNNNNNNXGG (SEQ ID NO: 207) (N is A, G, T, or C; and X can be anything). For the *S. thermophilus* CRISPR1Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMNNNNNNNNNNXXAGAAW (SEQ ID NO: 208) where NNNNNNNNNNNXXAGAAW (SEQ ID NO: 209) (N is A, G, T, or C; X can be anything; and W is A or T). A unique target sequence in a genome may include an *S. thermophilus* CRISPR 1 Cas9 target site of the form MMMMMMMNNNNNNNNNNXXAGAAW (SEQ ID NO: 210) where NNNNNNNNNNNXXAGAAW (SEQ ID NO: 211) (N is A, G, T, or C; X can be anything; and W is A or T). For the *S. pyogenes* Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMNNNNNNNNNNXGGXG (SEQ ID NO: 212) where NNNNNNNNNNNXGGXG (SEQ ID NO: 213) (N is A, G, T, or C; and X can be anything). A unique target sequence in a genome may include an *S. pyogenes* Cas9 target site of the form

MMMMMMMMMNNNNNNNNNNXGGXG (SEQ ID NO: 214) where NNNNNNNNNNNXGGXG (SEQ ID NO: 215) (N is A, G, T, or C; and X can be anything). In each of these sequences “M” may be A, G, T, or C, and need not be considered in identifying a sequence as unique.

[0697] As used herein in a PEgRNA or guide RNA sequence, unless indicated otherwise, it should be appreciated that the letter “T” or “thymine” indicates a nucleobase in a DNA sequence that encodes the PEgRNA or guide RNA sequence, and is intended to refer to a uracil (U) nucleobase of the PEgRNA or guide RNA or any chemically modified uracil nucleobase known in the art, such as 5-methoxyuracil.

[0698] In some embodiments, a guide sequence is selected to reduce the degree of secondary structure within the guide sequence. Secondary structure may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another example folding algorithm is the online webserver RNAfold, developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g. A. R. Gruber et al., 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62). Further algorithms may be found in U.S. application Ser. No. 61/836,080; Broad Reference BI-2013/004A); incorporated herein by reference.

[0699] In general, a tracr mate sequence includes any sequence that has sufficient complementarity with a tracr sequence to promote one or more of: (1) excision of a guide sequence flanked by tracr mate sequences in a cell containing the corresponding tracr sequence; and (2) formation of a complex at a target sequence, wherein the complex comprises the tracr mate sequence hybridized to the tracr sequence. In general, degree of complementarity is with reference to the optimal alignment of the tracr mate sequence and tracr sequence, along the length of the shorter of the two sequences. Optimal alignment may be determined by any suitable alignment algorithm, and may further account for secondary structures, such as self-complementarity within either the tracr sequence or tracr mate sequence. In some embodiments, the degree of complementarity between the tracr sequence and tracr mate sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher. In some embodiments, the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length. In some embodiments, the tracr sequence and tracr mate sequence are contained within a single transcript, such that hybridization between the two produces a transcript having a secondary structure, such as a hairpin. Preferred loop forming sequences for use in hairpin structures are four nucleotides in length, and most preferably have the sequence GAAA. However, longer or shorter loop sequences may be used, as may alternative sequences. The sequences preferably include a nucleotide triplet (for example, AAA), and an

additional nucleotide (for example C or G). Examples of loop forming sequences include CAAA and AAAG. In an embodiment of the invention, the transcript or transcribed polynucleotide sequence has at least two or more hairpins. In preferred embodiments, the transcript has two, three, four or five hairpins. In a further embodiment of the invention, the transcript has at most five hairpins. In some embodiments, the single transcript further includes a transcription termination sequence; preferably this is a polyT sequence, for example six T nucleotides. Further non-limiting examples of single polynucleotides comprising a guide sequence, a tracr mate sequence, and a tracr sequence are as follows (listed 5' to 3'), where "N" represents a base of a guide sequence, the first block of lower case letters represent the tracr mate sequence, and the second block of lower case letters represent the tracr sequence, and the final poly-T sequence represents the transcription terminator:

(1)NNNNNNNGTTTTGTACTCTCAAGATTTAGAAATAAATCTTGCAGAAGCTACAAAGAT
AAGGCTTCATGCCGAAATCAACACCCTGTCATTTTATGGCAGGGTGTTTTCGTTATTTAATT
TTTT (SEQ ID NO: 216);

[0700] (2)NNNNNNNNNNNNNNNNNNNGTTTTGTACTCTCAGAAATGCAGAAGCTACAAAG
ATAAGGCTTCATGCCGAAATCAACACCCTGTCATTTTATGGCAGGGTGTTTTCGTTATTTAA
TTTTTT (SEQ ID NO: 217);

[0701] (3)NNNNNNNNNNNNNNNNNNNGTTTTGTACTCTCAGAAATGCAGAAGCTACAA
AGATAAGGCTTCATGCCGAAATCAACACCCTGTCATTTTATGGCAGGGTGTTTTTT (SEQ ID
NO: 218);

[0702] (4)NNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG
GCTAGTCCGTTATCAACTTGAAAAAGTGCCACCGAGTCGGTGCTTTTTTT (SEQ ID NO: 219);

[0703] (5)NNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG
GCTAGTCCGTTATCAACTTGAAAAAGTGTTTTTTT (SEQ ID NO: 220); AND

[0704] (6)
NNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGT
CCGTTATCATTTTTTTT (SEQ ID NO: 221).

[0705] In some embodiments, sequences (1) to (3) are used in combination with Cas9 from *S. thermophilus* CRISPR1. In some embodiments, sequences (4) to (6) are used in combination with Cas9 from *S. pyogenes*. In some embodiments, the tracr sequence is a separate transcript from a transcript comprising the tracr mate sequence.

[0706] It will be apparent to those of skill in the art that in order to target any of the fusion proteins comprising a Cas9 domain and a single-stranded DNA binding protein, as disclosed herein, to a target site, e.g., a site comprising a point mutation to be edited, it is typically necessary to co-express the fusion protein together with a guide RNA, e.g., an sgRNA. As explained in more detail elsewhere herein, a guide RNA typically comprises a tracrRNA framework allowing for Cas9 binding, and a

guide sequence, which confers sequence specificity to the Cas9:nucleic acid editing enzyme/domain fusion protein.

[0707] In some embodiments, the guide RNA comprises a structure 5'-[guide sequence]-GUUUUAGAGCUAGAAAUAGCAAGUAAAAUAAAGGCUAGUCCGUUAUCAACUUGAAA AAGUGGCACCGAGUCGGUGCUUUUU-3' (SEQ ID NO: 222), wherein the guide sequence comprises a sequence that is complementary to the target sequence. The guide sequence is typically 20 nucleotides long. The sequences of suitable guide RNAs for targeting Cas9:nucleic acid editing enzyme/domain fusion proteins to specific genomic target sites will be apparent to those of skill in the art based on the instant disclosure. Such suitable guide RNA sequences typically comprise guide sequences that are complementary to a nucleic sequence within 50 nucleotides upstream or downstream of the target nucleotide to be edited. Some exemplary guide RNA sequences suitable for targeting any of the provided fusion proteins to specific target sequences are provided herein. Additional guide sequences are well known in the art and can be used with the multi-flap prime editor described herein.

[0708] In other embodiments, the PEgRNAs include those depicted in FIG. 3D.

[0709] In still other embodiments, the PEgRNAs may include those depicted in FIG. 3E.

[0710] FIG. 3D provides the structure of an embodiment of a PEgRNA contemplated herein and which may be designed in accordance with the methodology defined in Example 2. The PEgRNA comprises three main component elements ordered in the 5' to 3' direction, namely: a spacer, a gRNA core, and an extension arm at the 3' end. The extension arm may further be divided into the following structural elements in the 5' to 3' direction, namely: a primer binding site (A), an edit template (B), and a homology arm (C). In addition, the PEgRNA may comprise an optional 3' end modifier region (e1) and an optional 5' end modifier region (e2). Still further, the PEgRNA may comprise a transcriptional termination signal at the 3' end of the PEgRNA (not depicted). These structural elements are further defined herein. The depiction of the structure of the PEgRNA is not meant to be limiting and embraces variations in the arrangement of the elements. For example, the optional sequence modifiers (e1) and (e2) could be positioned within or between any of the other regions shown, and not limited to being located at the 3' and 5' ends.

[0711] FIG. 3E provides the structure of another embodiment of a PEgRNA contemplated herein may be designed in accordance with the methodology defined in Example 2. The PEgRNA comprises three main component elements ordered in the 5' to 3' direction, namely: a spacer, a gRNA core, and an extension arm at the 3' end. The extension arm may further be divided into the following structural elements in the 5' to 3' direction, namely: a primer binding site (A), an edit template (B), and a homology arm (C). In addition, the PEgRNA may comprise an optional 3' end modifier region (e1) and an optional 5' end modifier region (e2). Still further, the PEgRNA may comprise a transcriptional termination signal on the 3' end of the PEgRNA (not depicted). These structural elements are further

defined herein. The depiction of the structure of the PEgRNA is not meant to be limiting and embraces variations in the arrangement of the elements. For example, the optional sequence modifiers (e1) and (e2) could be positioned within or between any of the other regions shown, and not limited to being located at the 3' and 5' ends.

PEgRNA improvements

[0712] The PEgRNAs may also include additional design improvements that may modify the properties and/or characteristics of PEgRNAs thereby improving the efficacy of multi-flap prime editing. In various embodiments, these improvements may belong to one or more of a number of different categories, including but not limited to: (1) designs to enable efficient expression of functional PEgRNAs from non-polymerase III (pol III) promoters, which would enable the expression of longer PEgRNAs without burdensome sequence requirements; (2) improvements to the core, Cas9-binding PEgRNA scaffold, which could improve efficacy; (3) modifications to the PEgRNA to improve RT processivity, enabling the insertion of longer sequences at targeted genomic loci; and (4) addition of RNA motifs to the 5' or 3' termini of the PEgRNA that improve PEgRNA stability, enhance RT processivity, prevent misfolding of the PEgRNA, or recruit additional factors important for genome editing.

[0713] In one embodiment, PEgRNA could be designed with polIII promoters to improve the expression of longer-length PEgRNA with larger extension arms. sgRNAs are typically expressed from the U6 snRNA promoter. This promoter recruits pol III to express the associated RNA and is useful for expression of short RNAs that are retained within the nucleus. However, pol III is not highly processive and is unable to express RNAs longer than a few hundred nucleotides in length at the levels required for efficient genome editing. Additionally, pol III can stall or terminate at stretches of U's, potentially limiting the sequence diversity that could be inserted using a PEgRNA. Other promoters that recruit polymerase II (such as pCMV) or polymerase I (such as the U1 snRNA promoter) have been examined for their ability to express longer sgRNAs. However, these promoters are typically partially transcribed, which would result in extra sequence 5' of the spacer in the expressed PEgRNA, which has been shown to result in markedly reduced Cas9:sgRNA activity in a site-dependent manner. Additionally, while pol III-transcribed PEgRNAs can simply terminate in a run of 6-7 U's, PEgRNAs transcribed from pol II or pol I would require a different termination signal. Often such signals also result in polyadenylation, which would result in undesired transport of the PEgRNA from the nucleus. Similarly, RNAs expressed from pol II promoters such as pCMV are typically 5'-capped, also resulting in their nuclear export.

[0714] Previously, Rinn and coworkers screened a variety of expression platforms for the production of long-noncoding RNA- (lncRNA) tagged sgRNAs¹⁸³. These platforms include RNAs expressed from pCMV and that terminate in the ENE element from the MALAT1 ncRNA from humans¹⁸⁴, the PAN ENE element from KSHV¹⁸⁵, or the 3' box from U1 snRNA¹⁸⁶. Notably, the MALAT1 ncRNA

and PAN ENes form triple helices protecting the polyA-tail^{184, 187}. These constructs could also enhance RNA stability. It is contemplated that these expression systems will also enable the expression of longer PEgRNAs.

[0715] In addition, a series of methods have been designed for the cleavage of the portion of the pol II promoter that would be transcribed as part of the PEgRNA, adding either a self-cleaving ribozyme such as the hammerhead¹⁸⁸, pistol¹⁸⁹, hatchet¹⁸⁹, hairpin¹⁹⁰, VS¹⁹¹, twister¹⁹², or twister sister¹⁹² ribozymes, or other self-cleaving elements to process the transcribed guide, or a hairpin that is recognized by Csy4¹⁹³ and also leads to processing of the guide. Also, it is hypothesized that incorporation of multiple ENE motifs could lead to improved PEgRNA expression and stability, as previously demonstrated for the KSHV PAN RNA and element¹⁸⁵. It is also anticipated that circularizing the PEgRNA in the form of a circular intronic RNA (ciRNA) could also lead to enhanced RNA expression and stability, as well as nuclear localization¹⁹⁴.

[0716] In various embodiments, the PEgRNA may include various above elements, as exemplified by the following sequence.

[0717] Non-limiting example 1 - PEgRNA expression platform consisting of pCMV, Csy4 hairpin, the PEgRNA, and MALAT1 ENE

```
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGT
TACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATGACG
TCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT
GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACG
CCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCAGTACATGACCTT
ATGGGACTTTCCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGC
GGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCTCAAGTCT
CCACCCCATGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAA
ATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGT
CTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCGTTCACTGCCGTATAGGCAGGGCC
CAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAATAAGGCTAGTCCGTT
ATCAACTTGAAAAAGTGGGACCGAGTCGGTCTCTGCCATCAAAGCGTGCTCAGTCTGTT
TTAGGGTCATGAAGTTTTTCTTTTCTTGAGAAAAACAACACGTATTGTTTTCTCAGGTTTTG
CTTTTTGGCCTTTTTCTAGCTTAAAAAAGCAAAAGATGCTGGTGGTTGGCACT
CCTGGTTTCCAGGACGGGGTTCAAATCCCTGCGGCGTCTTTGCTTTGACT (SEQ ID NO:
223)
```

[0718] Non-limiting example 2 - PEgRNA expression platform consisting of pCMV, Csy4 hairpin, the PEgRNA, and PAN ENE

```
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGT
TACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATGACG
TCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT
GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACG
CCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCAGTACATGACCTT
ATGGGACTTTCCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGC
GGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCTCAAGTCT
CCACCCCATGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAA
ATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGT
CTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCGTTCACTGCCGTATAGGCAGGGCC
CAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAATAAGGCTAGTCCGTT
```

ATCAACTTGAAAAAGTGGGACCGAGTCGGTCCTCTGCCATCAAAGCGTGCTCAGTCTGTT
 TTGTTTTGGCTGGGTTTTTCCTTGTTTCGACCCGGACACCTCCAGTGACCAGACGGCAAGG
 TTTTATCCCAGTGTATATTGGAAAAACATGTTATACTTTTGACAATTTAACGTGCCTAGAG
 CTCAAATTAATAATACCATAACGTAATGCAACTTACAACATAAATAAAGGTCAATGTTTA
 ATCCATAAAAAAAAAAAAAAAAAAAAAA (SEQ ID NO: 224)

[0719] Non-limiting example 3 - PEgRNA expression platform consisting of pCMV, Csy4 hairing, the PEgRNA, and 3xPAN ENE

TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGT
 TACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATGACG
 TCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT
 GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACG
 CCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCAGTACATGACCTT
 ATGGGACTTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGC
 GGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCGAAGTCT
 CCACCCCATGACGTCAATGGGAGTTTGTGTTTTGGCACCAAAATCAACGGGACTTTCCAAA
 ATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGGTGACGGTGGGAGGT
 CTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCGTTCCTGCGGTATAGGCAGGGCC
 CAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAATAAGGCTAGTCCGTT
 ATCAACTTGAAAAAGTGGGACCGAGTCGGTCCTCTGCCATCAAAGCGTGCTCAGTCTGTT
 TTGTTTTGGCTGGGTTTTTCCTTGTTTCGACCCGGACACCTCCAGTGACCAGACGGCAAGG
 TTTTATCCCAGTGTATATTGGAAAAACATGTTATACTTTTGACAATTTAACGTGCCTAGAG
 CTCAAATTAATAATACCATAACGTAATGCAACTTACAACATAAATAAAGGTCAATGTTTA
 ATCCATAAAAAAAAAAAAAAAAAAAAAACACACTGTTTTGGCTGGGTTTTTCCTTGTTTCGCA
 CCGGACACCTCCAGTGACCAGACGGCAAGGTTTTATCCCAGTGTATATTGGAAAAACATG
 TTATACTTTTGACAATTTAACGTGCCTAGAGCTCAAATTAATAATAATACCATAACGTAATGC
 AACTTACAACATAAATAAAGGTCAATGTTTAAATCCATAAAAAAAAAAAAAAAAAAAATCTCT
 CTGTTTTGGCTGGGTTTTTCCTTGTTTCGACCCGGACACCTCCAGTGACCAGACGGCAAGG
 TTTTATCCCAGTGTATATTGGAAAAACATGTTATACTTTTGACAATTTAACGTGCCTAGAG
 CTCAAATTAATAATACCATAACGTAATGCAACTTACAACATAAATAAAGGTCAATGTTTA
 ATCCATAAAAAAAAAAAAAAAAAAAAAA (SEQ ID NO: 225)

[0720] Non-limiting example 4 - PEgRNA expression platform consisting of pCMV, Csy4 hairing, the PEgRNA, and 3' box

TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGT
 TACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATGACG
 TCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGT
 GGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACG
 CCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCAGTACATGACCTT
 ATGGGACTTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGC
 GGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCGAAGTCT
 CCACCCCATGACGTCAATGGGAGTTTGTGTTTTGGCACCAAAATCAACGGGACTTTCCAAA
 ATGTCGTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGGTGACGGTGGGAGGT
 CTATATAAGCAGAGCTGGTTTAGTGAACCGTCAGATCGTTCCTGCGGTATAGGCAGGGCC
 CAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAATAAGGCTAGTCCGTT
 ATCAACTTGAAAAAGTGGGACCGAGTCGGTCCTCTGCCATCAAAGCGTGCTCAGTCTGTT
 TGTTTCAAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTGGTTTGTGTCTTGGT
 TGGCGTCTTAAA (SEQ ID NO: 226)

[0721] Non-limiting example 5 - PEgRNA expression platform consisting of pU1, Csy4 hairing, the PEgRNA, and 3' box

CTAAGGACCAGCTTCTTTGGGAGAGAACAGACGCAGGGGCGGGAGGGAAAAAGGGAGA
 GGCAGACGTCACTTCCCCCTGGCGGCTCTGGCAGCAGATTGGTTCGGTTGAGTGGCAGAAA
 GGCAGACGGGGACTGGGCAAGGCACTGTCCGTGACATCACGGACAGGGCGACTTCTATG

TAGATGAGGCAGCGCAGAGGCTGCTGCTTCGCCACTTGCTGCTTCACCACGAAGGAGTTCCCGTGCCCTGGGAGCGGGTTTCAGGACCGCTGATCGGAAGTGAGAATCCCAGCTGTGTGTCAGGGCTGGAAGGGCTCGGGAGTGCGCGGGGCAAGTGACCGTGTGTGTAAAGAGTGAGGCGTATGAGGCTGTGTGCGGGCAGAGGCCCAAGATCTCAGTTCACTGCCGTATAGGCAGGGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCCTCTGCCATCAAAGCGTGCTCAGTCTGTTTCAGCAAGTTCAGAGAAATCTGAACCTTGCTGGATTTTGGAGCAGGGAGATGGAATAGGAGCTTGCTCCGTCCACTCCACGCATCGACCTGGTATTGCAGTACCTCCAGGAACGGTGACCCACTTTCTGGAGTTTCAAAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTTGTTTGTGTCTTGTTGGCGTCTTAAA (SEQ ID NO: 227).

[0722] In various other embodiments, the PEgRNA may be improved by introducing improvements to the scaffold or core sequences. This can be done by introducing known

[0723] The core, Cas9-binding PEgRNA scaffold can likely be improved to enhance PE activity. Several such approaches have already been demonstrated. For instance, the first pairing element of the scaffold (P1) contains a GTTTT-AAAAC (SEQ ID NO: 3939) pairing element. Such runs of Ts have been shown to result in pol III pausing and premature termination of the RNA transcript. Rational mutation of one of the T-A pairs to a G-C pair in this portion of P1 has been shown to enhance sgRNA activity, suggesting this approach would also be feasible for PEgRNAs¹⁹⁵. Additionally, increasing the length of P1 has also been shown to enhance sgRNA folding and lead to improved activity¹⁹⁵, suggesting it as another avenue for the improvement of PEgRNA activity. Example improvements to the core can include:

[0724] PEgRNA containing a 6 nt extension to P1

GGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGCTCATGAAAATGAGCTAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCCTCTGCCATCAAA GCGTGCTCAGTCTGTTTTTTT (SEQ ID NO: 228)

[0725] PEgRNA containing a T-A to G-C mutation within P1

GGCCCAGACTGAGCACGTGAGTTTGAGAGCTAGAAATAGCAAGTTTAAATAAGGCTAGTCGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCCTCTGCCATCAAAGCGTGCTCAGTCTGTTTTTTT (SEQ ID NO: 229)

[0726] In various other embodiments, the PEgRNA may be improved by introducing modifications to the edit template region. As the size of the insertion templated by the PEgRNA increases, it is more likely to be degraded by endonucleases, undergo spontaneous hydrolysis, or fold into secondary structures unable to be reverse-transcribed by the RT or that disrupt folding of the PEgRNA scaffold and subsequent Cas9-RT binding. Accordingly, it is likely that modification to the template of the PEgRNA might be necessary to affect large insertions, such as the insertion of whole genes. Some strategies to do so include the incorporation of modified nucleotides within a synthetic or semi-synthetic PEgRNA that render the RNA more resistant to degradation or hydrolysis or less likely to adopt inhibitory secondary structures¹⁹⁶. Such modifications could include 8-aza-7-deazaguanosine, which would reduce RNA secondary structure in G-rich sequences; locked-nucleic acids (LNA) that reduce degradation and enhance certain kinds of RNA secondary structure; 2'-O-methyl, 2'-fluoro, or

2'-O-methoxyethoxy modifications that enhance RNA stability. Such modifications could also be included elsewhere in the PEgRNA to enhance stability and activity. Alternatively or additionally, the template of the PEgRNA could be designed such that it both encodes for a desired protein product and is also more likely to adopt simple secondary structures that are able to be unfolded by the RT. Such simple structures would act as a thermodynamic sink, making it less likely that more complicated structures that would prevent reverse transcription would occur. Finally, one could also split the template into two, separate PEgRNAs. In such a design, a PE would be used to initiate transcription and also recruit a separate template RNA to the targeted site via an RNA-binding protein fused to Cas9 or an RNA recognition element on the PEgRNA itself such as the MS2 aptamer. The RT could either directly bind to this separate template RNA, or initiate reverse transcription on the original PEgRNA before swapping to the second template. Such an approach could enable long insertions by both preventing misfolding of the PEgRNA upon addition of the long template and also by not requiring dissociation of Cas9 from the genome for long insertions to occur, which could possibly be inhibiting PE-based long insertions.

[0727] In still other embodiments, the PEgRNA may be improved by introducing additional RNA motifs at the 5' and 3' termini of the PEgRNAs, or even at positions therein between (e.g., in the gRNA core region, or the the spacer). Several such motifs - such as the PAN ENE from KSHV and the ENE from MALAT1 were discussed above as possible means to terminate expression of longer PEgRNAs from non-pol III promoters. These elements form RNA triple helices that engulf the polyA tail, resulting in their being retained within the nucleus^{184, 187}. However, by forming complex structures at the 3' terminus of the PEgRNA that occlude the terminal nucleotide, these structures would also likely help prevent exonuclease-mediated degradation of PEgRNAs.

[0728] Other structural elements inserted at the 3' terminus could also enhance RNA stability, albeit without enabling termination from non-pol III promoters. Such motifs could include hairpins or RNA quadruplexes that would occlude the 3' terminus¹⁹⁷, or self-cleaving ribozymes such as HDV that would result in the formation of a 2'-3'-cyclic phosphate at the 3' terminus and also potentially render the PEgRNA less likely to be degraded by exonucleases¹⁹⁸. Inducing the PEgRNA to cyclize via incomplete splicing - to form a ciRNA - could also increase PEgRNA stability and result in the PEgRNA being retained within the nucleus¹⁹⁴.

[0729] Additional RNA motifs could also improve RT processivity or enhance PEgRNA activity by enhancing RT binding to the DNA-RNA duplex. Addition of the native sequence bound by the RT in its cognate retroviral genome could enhance RT activity¹⁹⁹. This could include the native primer binding site (PBS), polypurine tract (PPT), or kissing loops involved in retroviral genome dimerization and initiation of transcription¹⁹⁹.

[0730] Addition of dimerization motifs - such as kissing loops or a GNRA tetraloop/tetraloop receptor pair²⁰⁰ - at the 5' and 3' termini of the PEgRNA could also result in effective circularization

of the PEgRNA, improving stability. Additionally, it is envisioned that addition of these motifs could enable the physical separation of the PEgRNA spacer and primer, prevention occlusion of the spacer which would hinder PE activity. Short 5' extensions or 3' extensions to the PEgRNA that form a small toehold hairpin in the spacer region or along the primer binding site could also compete favorably against the annealing of intracomplementary regions along the length of the PEgRNA, e.g., the interaction between the spacer and the primer binding site that can occur. Finally, kissing loops could also be used to recruit other template RNAs to the genomic site and enable swapping of RT activity from one RNA to the other. As exemplary embodiments of various secondary structures, the PEgRNA depicted in FIG. 3D and FIG. 3E list a number secondary RNA structures that may be engineered into any region of the PEgRNA, including in the terminal portions of the extension arm (i.e., e1 and e2), as shown.

[0731] Example improvements include, but are not limited to:

[0732] PEgRNA-HDV fusion

GGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTC
CGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCTCTGCCATCAAAGCGTGCTCAGTC
TGGGCCGGCATGGTCCAGCCTCCTCGCTGGCGCCGGCTGGGCAACATGCTTCGGCATGG
CGAATGGGACTTTTTTTT (SEQ ID NO: 230)

[0733] PEgRNA-MMLV kissing loop

GGTGGGAGACGTCCACCGGCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCA
AGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCTCTGC
CATCAAAGCTTCGACCGTGCTCAGTCTGGTGGGAGACGTCCACCTTTTTTTT (SEQ ID NO:
231)

[0734] PEgRNA-VS ribozyme kissing loop

GAGCAGCATGGCGTCGCTGCTCACGGCCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAA
TAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCC
TCTGCCATCAAAGCTTCGACCGTGCTCAGTCTCCATCAGTTGACACCCTGAGGTTTTTTT
(SEQ ID NO: 232)

[0735] PEgRNA-GNRA tetraloop/tetraloop receptor

GCAGACCTAAGTGGUGACATATGGTCTGGGCCCAGACTGAGCACGTGAGTTTTAGAGCTA
UACGTAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTUACGAAGTGGGACCGAGTCG
GTCTCTGCCATCAAAGCTTCGACCGTGCTCAGTCTGCATGCGATTAGAAATAATCGCATG
TTTTTTT (SEQ ID NO: 233)

[0736] PEgRNA template switching secondary RNA-HDV fusion

TCTGCCATCAAAGCTGCGACCGTGCTCAGTCTGGTGGGAGACGTCCACCGGCCGGCATG
GTCCCAGCCTCCTCGCTGGCGCCGGCTGGGCAACATGCTTCGGCATGGCGAATGGGACTT
TTTTT (SEQ ID NO: 234)

[0737] PEgRNA scaffolds could be further improved via directed evolution, in an analogous fashion to how SpCas9 and prime editors (PE) have been improved. Directed evolution could enhance PEgRNA recognition by Cas9 or evolved Cas9 variants. Additionally, it is likely that different PEgRNA scaffold sequences would be optimal at different genomic loci, either enhancing PE activity at the site in question, reducing off-target activities, or both. Finally, evolution of PEgRNA scaffolds to which other RNA motifs have been added would almost certainly improve the activity of the fused

PEgRNA relative to the unevolved, fusion RNA. For instance, evolution of allosteric ribozymes composed of c-di-GMP-I aptamers and hammerhead ribozymes led to dramatically improved activity²⁰², suggesting that evolution would improve the activity of hammerhead-PEgRNA fusions as well. In addition, while Cas9 currently does not generally tolerate 5' extension of the sgRNA, directed evolution will likely generate enabling mutations that mitigate this intolerance, allowing additional RNA motifs to be utilized.

[0738] The present disclosure contemplates any such ways to further improve the efficacy of the multi-flap prime editing systems disclosed here.

[0739] In various embodiments, it may be advantageous to limit the appearance of consecutive sequence of Ts from the extension arm as consecutive series of T's may limit the capacity of the PEgRNA to be transcribed. For example, strings of at least consecutive three T's, at least consecutive four T's, at least consecutive five T's, at least consecutive six T's, at least consecutive seven T's, at least consecutive eight T's, at least consecutive nine T's, at least consecutive ten T's, at least consecutive eleven T's, at least consecutive twelve T's, at least consecutive thirteen T's, at least consecutive fourteen T's, or at least consecutive fifteen T's should be avoided when designing the PEgRNA, or should be at least removed from the final designed sequence. In one embodiment, one can avoid the includes of unwanted strings of consecutive T's in PEgRNA extension arms but avoiding target sites that are rich in consecutive A:T nucleobase pairs.

Split PEgRNA designs for *trans* prime editing

[0740] The instant disclosure also contemplates *trans* prime editing, which refers to a modified version of prime editing which operates by separating the PEgRNA into two distinct molecules: a guide RNA and a tPERT molecule. The tPERT molecule is programmed to co-localize with the prime editor complex at a target DNA site, bringing the primer binding site and the DNA synthesis template to the prime editor *in trans*. For example, see FIG. 3G for an embodiment of a *trans* prime editor (tPE) which shows a two-component system comprising (1) an recruiting protein (RP)-PE:gRNA complex and (2) a tPERT that includes a primer binding site and a DNA synthesis template joined to an RNA-protein recruitment domain (e.g., stem loop or hairpin), wherein the recruiting protein component of the RP-PE:gRNA complex recruits the tPERT to a target site to be edited, thereby associating the PBS and DNA synthesis template with the prime editor *in trans*. Said another way, the tPERT is engineered to contain (all or part of) the extension arm of a PEgRNA, which includes the primer binding site and the DNA synthesis template. One advantage of this approach is to separate the extension arm of a PEgRNA from the guide RNA, thereby minimizing annealing interactions that tend to occur between the PBS of the extension arm and the spacer sequence of the guide RNA.

[0741] A key feature of *trans* prime editing is the ability of the *trans* prime editor to recruit the tPERT to the site of DNA editing, thereby effectively co-localizing all of the functions of a PEgRNA

at the site of prime editing. Recruitment can be achieved by installing an RNA-protein recruitment domain, such as a MS2 aptamer, into the tPERT and fusing a corresponding recruiting protein to the prime editor (e.g., via a linker to the napDNAbp or via a linker to the polymerase) that is capable of specifically binding to the RNA-protein recruitment domain, thereby recruiting the tPERT molecule to the prime editor complex. As depicted in the process described in FIG. 3H, the RP-PE:gRNA complex binds to and nicks the target DNA sequence. Then, the recruiting protein (RP) recruits a tPERT to co-localize to the prime editor complex bound to the DNA target site, thereby allowing the primer binding site, located on the tPERT, to bind to the primer sequence on the nicked strand, and subsequently, allowing the polymerase (e.g., RT) to synthesize a single strand of DNA against the DNA synthesis template, located on the tPERT, up through the 5' end of the tPERT.

[0742] While the tPERT is shown in FIG. 3G and FIG. 3H as comprising the PBS and DNA synthesis template on the 5' end of the RNA-protein recruitment domain, the tPERT in other configurations may be designed with the PBS and DNA synthesis template located on the 3' end of the RNA-protein recruitment domain. However, the tPERT with the 5' extension has the advantage that synthesis of the single strand of DNA will naturally terminate at the 5' end of the tPERT and thus, does not risk using any portion of the RNA-protein recruitment domain as a template during the DNA synthesis stage of prime editing.

PEgRNA design method

[0743] The present disclosure also relates to methods for designing PEgRNAs.

[0744] In one aspect of design, the design approach can take into account the particular application for which prime editing is being used. For instance, and as exemplified and discussed herein, prime editing can be used, without limitation, to (a) install mutation-correcting changes to a nucleotide sequence, (b) install protein and RNA tags, (c) install immunopeptides on proteins of interest, (d) install inducible dimerization domains in proteins, (e) install or remove sequences to alter that activity of a biomolecule, (f) install recombinase target sites to direct specific genetic changes, and (g) mutagenesis of a target sequence by using an error-prone RT. In addition to these methods which, in general, insert, change, or delete nucleotide sequences at target sites of interest, prime editors can also be used to construct highly programmable libraries, as well as to conduct cell data recording and lineage tracing studies. In these various uses, there may be as described herein particular design aspects pertaining to the preparation of a PEgRNA that is particularly useful for any given of these applications.

[0745] When designing a PEgRNA for any particular application or use of prime editing, a number of considerations may be taken into account, which include, but are not limited to:

(a) the target sequence, i.e., the nucleotide sequence in which one or more nucleobase modifications are desired to be installed by the prime editor;

- (b) the location of the cut site within the target sequence, i.e., the specific nucleobase position at which the prime editor will induce a single-stand nick to create a 3' end RT primer sequence on one side of the nick and the 5' end endogenous flap on the other side of the nick (which ultimately is removed by FEN1 or equivalent thereto and replaced by the 3' ssDNA flap. The cut site is analogous to the "edit location" since this what creates the 3' end RT primer sequence which becomes extended by the RT during RNA-depending DNA polymerization to create the 3' ssDNA flap containing the desired edit, which then replaces the 5' endogenous DNA flap in the target sequence.
- (c) the available PAM sequences (including the canonical SpCas9 PAM sites, as well as non-canonical PAM sites recognized by Cas9 variants and equivalents with expanded or differing PAM specificities);
- (d) the spacing between the available PAM sequences and the location of the cut site in the target sequence;
- (e) the particular Cas9, Cas9 variant, or Cas9 equivalent of the prime editor being used;
- (f) the sequence and length of the primer binding site;
- (g) the sequence and length of the edit template;
- (h) the sequence and length of the homology arm;
- (i) the spacer sequence and length; and
- (j) the core sequence.

[0746] The instant disclosure discusses these aspects above.

[0747] In one embodiment, an approach to designing a suitable PEGRNA, and optionally a nicking-sgRNA design guide for second-site nicking, is hereby provided. This embodiment provides a step-by-step set of instructions for designing PEGRNAs and nicking-sgRNAs for prime editing which takes into account one or more of the above considerations. The steps reference the examples shown in FIGs. 70A-70I.

1. **Define the target sequence and the edit.** Retrieve the sequence of the target DNA region (~200bp) centered around the location of the desired edit (point mutation, insertion, deletion, or combination thereof). See FIG. 70A.
2. **Locate target PAMs.** Identify PAMs in the proximity to the desired edit location. PAMs can be identified on either strand of DNA proximal to the desired edit location. While PAMs close to the edit position are preferred (i.e., wherein the nick site is less than 30 nt from the edit position, or less than 29 nt, 28 nt, 27 nt, 26 nt, 25 nt, 24 nt, 23 nt, 22 nt, 21 nt, 20 nt, 19 nt, 18 nt, 17 nt, 16 nt, 15 nt, 14 nt, 13 nt, 12 nt, 11 nt, 10 nt, 9 nt, 8 nt, 7 nt, 6 nt, 5 nt, 4 nt, 3 nt, or 2 nt from the edit position to the nick site), it is possible to install edits using protospacers and PAMs that place the nick $\geq$ 30 nt from the edit position. See FIG. 70B.
3. **Locate the nick sites.** For each PAM being considered, identify the corresponding nick site and on which strand. For Sp Cas9 H840A nickase, cleavage occurs in the PAM-containing

strand between the 3rd and 4th bases 5' to the NGG PAM. All edited nucleotides must exist 3' of the nick site, so appropriate PAMs must place the nick 5' to the target edit on the PAM-containing strand. In the example shown below, there are two possible PAMs. For simplicity, the remaining steps will demonstrate the design of a PEgRNA using PAM 1 only. See FIG. 70C.

4. **Design the spacer sequence.** The protospacer of Sp Cas9 corresponds to the 20 nucleotides 5' to the NGG PAM on the PAM-containing strand. Efficient Pol III transcription initiation requires a G to be the first transcribed nucleotide. If the first nucleotide of the protospacer is a G, the spacer sequence for the PEgRNA is simply the protospacer sequence. If the first nucleotide of the protospacer is not a G, the spacer sequence of the PEgRNA is G followed by the protospacer sequence. See FIG. 70D.
5. **Design a primer binding site (PBS).** Using the starting allele sequence, identify the DNA primer on the PAM-containing strand. The 3' end of the DNA primer is the nucleotide just upstream of the nick site (i.e. the 4th base 5' to the NGG PAM for Sp Cas9). As a general design principle for use with PE2 and PE3, a PEgRNA primer binding site (PBS) containing 12 to 13 nucleotides of complementarity to the DNA primer can be used for sequences that contain ~40-60% GC content. For sequences with low GC content, longer (14- to 15-nt) PBSs should be tested. For sequences with higher GC content, shorter (8- to 11-nt) PBSs should be tested. Optimal PBS sequences should be determined empirically, regardless of GC content. To design a length-*p* PBS sequence, take the reverse complement of the first *p* nucleotides 5' of the nick site in the PAM-containing strand using the starting allele sequence. See FIG. 70E.
6. **Design an RT template (or DNA synthesis template).** The RT template (or DNA synthesis template where the polymerase is not reverse transcriptase) encodes the designed edit and homology to the sequence adjacent to the edit. In one embodiment, these regions correspond to the DNA synthesis template of FIG. 3D and FIG. 3E, wherein the DNA synthesis template comprises the "edit template" and the "homology arm." Optimal RT template lengths vary based on the target site. For short-range edits (positions +1 to +6), it is recommended to test a short (9 to 12 nt), a medium (13 to 16 nt), and a long (17 to 20 nt) RT template. For long-range edits (positions +7 and beyond), it is recommended to use RT templates that extend at least 5 nt (preferably 10 or more nt) past the position of the edit to allow for sufficient 3' DNA flap homology. For long-range edits, several RT templates should be screened to identify functional designs. For larger insertions and deletions (≥ 5 nt), incorporation of greater 3' homology (~20 nt or more) into the RT template is recommended. Editing efficiency is typically impaired when the RT template encodes the synthesis of a G as the last nucleotide in the reverse transcribed DNA product (corresponding to a C in the RT template of the

PEgRNA). As many RT templates support efficient prime editing, avoidance of G as the final synthesized nucleotide is recommended when designing RT templates. To design a length-*r* RT template sequence, use the *desired* allele sequence and take the reverse complement of the first *r* nucleotides 3' of the nick site in the strand that originally contained the PAM. Note that compared to SNP edits, insertion or deletion edits using RT templates of the same length will not contain identical homology. See FIG. 70F.

7. **Assemble the full PEGRNA sequence.** Concatenate the PEGRNA components in the following order (5' to 3'): spacer, scaffold, RT template and PBS. See FIG. 70G.
8. **Designing nicking-sgRNAs for PE3.** Identify PAMs on the non-edited strand upstream and downstream of the edit. Optimal nicking positions are highly locus-dependent and should be determined empirically. In general, nicks placed 40 to 90 nucleotides 5' to the position across from the PEGRNA-induced nick lead to higher editing yields and fewer indels. A nicking sgRNA has a spacer sequence that matches the 20-nt protospacer in the *starting* allele, with the addition of a 5'-G if the protospacer does not begin with a G. See FIG. 70H.
9. **Designing PE3b nicking-sgRNAs.** If a PAM exists in the complementary strand and its corresponding protospacer overlaps with the sequence targeted for editing, this edit could be a candidate for the PE3b system. In the PE3b system, the spacer sequence of the nicking-sgRNA matches the sequence of the desired edited allele, but not the starting allele. The PE3b system operates efficiently when the edited nucleotide(s) falls within the seed region (~10 nt adjacent to the PAM) of the nicking-sgRNA protospacer. This prevents nicking of the complementary strand until after installation of the edited strand, preventing competition between the PEGRNA and the sgRNA for binding the target DNA. PE3b also avoids the generation of simultaneous nicks on both strands, thus reducing indel formation significantly while maintaining high editing efficiency. PE3b sgRNAs should have a spacer sequence that matches the 20-nt protospacer in the *desired* allele, with the addition of a 5' G if needed. See FIG. 70I.

[0748] The above step-by-step process for designing a suitable PEGRNA and a second-site nicking sgRNA is not meant to be limiting in any way. The disclosure contemplates variations of the above-described step-by-step process which would be derivable therefrom by a person of ordinary skill in the art.

[7] Applications utilizing multi-flap prime editing

[0749] Dual-flap and quadruple-flap prime editing (*i.e.*, multi-flap prime editing) have many potential applications, such as installing peptide tags, RNA tags, immunopeptides, dimerization domains, and recombinase target sites. One such application of dual-flap prime editing is the installation of recombinase or integrase sequences at user-specified locations in the genome. **FIG. 93** illustrates the installation of Bxb1 recombinase *attB* (38 bp) and *attP* (50 bp) sites into a targeted

region of the human genome (*HEK293T site 3*, or *HEK3*) with simultaneous deletion of 90 bp of intervening sequence between the two nick sites. Various degrees of complementarity between 3' flaps allow for successful editing, though longer sequences of complementarity produce more favorable ratios of desired edits to indels. Other dual-flap prime editing applications include endogenous tagging of genes with peptide or protein sequences, or the replacement of exons with new DNA sequences that have the potential to substitute for multiple variants for which the mutation falls within the exon sequence.

[0750] Dual-flap prime editing can be used to introduce one or two recombinase sites at targeted positions in the human genome. If single recombinase sites are inserted, these can be used as landing sites for a recombinase-mediated reaction between the genomic recombinase site and a second recombinase site within an exogenously supplied DNA, such as a plasmid. This enables the targeted integration of DNA cargo. If two recombinase sites are inserted in adjacent regions of DNA, depending on the orientation of the recombinase sites, these can be used for recombinase-mediated excision or inversion of the intervening sequence, or for recombinase-mediated cassette exchange with exogenous DNA for cargo integration. Integration of compatible recombinase sites on different chromosomes enables targeted and directional chromosomal translocation. Dual-flap prime editing can be used to efficiently introduce recombinase sites at a number of loci in the human genome (**FIG. 94**). Thus, the pairing of recombinase site integration by dual-flap prime editing with DNA recombinase enzymes represents a powerful approach for achieving many types of SV edits and target integration of DNA cargo.

[0751] The multi-flap prime editors (e.g., the embodiment depicted in FIG. 90) described herein may be used for the precise insertion of new DNA sequence, the precise deletion of endogenous genomic DNA sequence, or the replacement of an endogenous genomic DNA sequence with a new DNA sequence.

[0752] For example, and as exemplified and discussed herein, dual prime editing can be used to (a) install mutation-correcting changes to a nucleotide sequence, (b) install protein and RNA tags, (c) installation of immunoepitopes on proteins of interest, (d) install inducible dimerization domains in proteins, (e) install recombinase target sites to direct specific genetic changes. In addition to these methods which, in general, insert, change, or delete nucleotide sequences at target sites of interest, dual prime editors can also be used to construct highly programmable libraries, as well as to conduct cell data recording and lineage tracing studies.

[0753] These specific exemplary uses of dual prime editing are in no way intended to be limiting. The present Application contemplates any use for dual prime editing which involves, in general, some form of the installation, deletion, and/or replacement of one or more nucleobases at a target site in a nucleotide sequence, e.g., a genomic DNA.

[0754] For any of the exemplified uses for dual prime editing, one may use any prime editor disclosed herein, including PE1, PE2, PE3, and PE3b, or PE-short.

A. Prime editing versus multi-flap prime editing

Classical prime editing

[0755] In various embodiments, prime editing (or “prime editing”) operates by contacting a target DNA molecule (for which a change in the nucleotide sequence is desired to be introduced) with a nucleic acid programmable DNA binding protein (napDNAbp) complexed with an extended guide RNA. In reference to FIG. 1G, the extended guide RNA comprises an extension at the 3′ or 5′ end of the guide RNA, or at an intramolecular location in the guide RNA and encodes the desired nucleotide change (e.g., single nucleotide change, insertion, or deletion). In step (a), the napDNAbp/extended gRNA complex contacts the DNA molecule and the extended gRNA guides the napDNAbp to bind to a target locus. In step (b), a nick in one of the strands of DNA of the target locus is introduced (e.g., by a nuclease or chemical agent), thereby creating an available 3′ end in one of the strands of the target locus. In certain embodiments, the nick is created in the strand of DNA that corresponds to the R-loop strand, i.e., the strand that is not hybridized to the guide RNA sequence, i.e., the “non-target strand.” The nick, however, could be introduced in either of the strands. That is, the nick could be introduced into the R-loop “target strand” (i.e., the strand hybridized to the protospacer sequence of the extended gRNA) or the “non-target strand” (i.e., the strand forming the single-stranded portion of the R-loop and which is complementary to the target strand). In step (c), the 3′ end of the DNA strand (formed by the nick) interacts with the extended portion of the guide RNA in order to prime reverse transcription (i.e., “target-primed RT”). In certain embodiments, the 3′ end DNA strand hybridizes to a specific RT priming sequence on the extended portion of the guide RNA, i.e., the “reverse transcriptase priming sequence.” In step (d), a reverse transcriptase is introduced (as a fusion protein with the napDNAbp or *in trans*) which synthesizes a single strand of DNA from the 3′ end of the primed site towards the 5′ end of the extended guide RNA. This forms a single-strand DNA flap comprising the desired nucleotide change (e.g., the single base change, insertion, or deletion, or a combination thereof) and which is otherwise homologous to the endogenous DNA at or adjacent to the nick site. In step (e), the napDNAbp and guide RNA are released. Steps (f) and (g) relate to the resolution of the single strand DNA flap such that the desired nucleotide change becomes incorporated into the target locus. This process can be driven towards the desired product formation by removing the corresponding 5′ endogenous DNA flap (e.g., by FEN1 or similar enzyme that is provide *in trans*, as a fusion with the prime editor, or endogenously provided) that forms once the 3′ single strand DNA flap invades and hybridizes to the endogenous DNA sequence. Without being bound by theory, the cells endogenous DNA repair and replication processes resolves the mismatched DNA to incorporate the nucleotide change(s) to form the desired altered product. The process can

also be driven towards product formation with “second strand nicking,” as exemplified in FIG. 1G, or “temporal second strand nicking,” as exemplified in FIG. 1I and discussed herein.

[0756] The process of prime editing may introduce at least one or more of the following genetic changes: transversions, transitions, deletions, and insertions. In addition, prime editing may be implemented for specific applications. For example, and as exemplified and discussed herein, prime editing can be used to (a) install mutation-correcting changes to a nucleotide sequence, (b) install protein and RNA tags, (c) installation of immunopeptides on proteins of interest, (d) install inducible dimerization domains in proteins, (e) install or remove sequences to alter that activity of a biomolecule, (f) install recombinase target sites to direct specific genetic changes, and (g) mutagenesis of a target sequence by using an error-prone RT. In addition to these methods which, in general, insert, change, or delete nucleotide sequences at target sites of interest, prime editors can also be used to construct highly programmable libraries, as well as to conduct cell data recording and lineage tracing studies. The inventors have also contemplated additional design features of PEGRNAs that are aimed to improve the efficacy of prime editing. Still further, the inventors have conceived of methods for successfully delivering prime editors using vector delivery systems and which involve splitting the napDNABp using intein domains.

[0757] The term “prime editing system” or “prime editor (PE)” refers the compositions involved in the method of genome editing using target-primed reverse transcription (TPRT) describe herein, including, but not limited to the napDNABps, reverse transcriptases, fusion proteins (e.g., comprising napDNABps and reverse transcriptases), extended guide RNAs, and complexes comprising fusion proteins and extended guide RNAs, as well as accessory elements, such as second strand nicking components and 5′ endogenous DNA flap removal endonucleases (e.g., FEN1) for helping to drive the prime editing process towards the edited product formation.

[0758] In another embodiment, the schematic of FIG. 3F depicts the interaction of a typical PEGRNA with a target site of a double stranded DNA and the concomitant production of a 3′ single stranded DNA flap containing the genetic change of interest. The double strand DNA is shown with the top strand in the 3′ to 5′ orientation and the lower strand in the 5′ to 3′ direction. The top strand comprises the “protospacer” and the PAM sequence and is referred to as the “target strand.” The complementary lower strand is referred to as the “non-target strand.” Although not shown, the PEGRNA depicted would be complexed with a Cas9 or equivalent. As shown in the schematic, the spacer of the PEGRNA anneals to a complementary region on the target strand, which is referred to as the protospacer, which is located just downstream of the PAM sequence is approximately 20 nucleotides in length. This interaction forms a DNA/RNA hybrid between the spacer RNA and the protospacer DNA, and induces the formation of an R loop in the region opposite the protospacer. As taught elsewhere herein, the Cas9 protein (not shown) then induces a nick in the non-target strand, as shown. This then leads to the formation of the 3′ ssDNA flap region which, in accordance with *Z*, interacts

with the 3' end of the PEGRNA at the primer binding site. The 3' end of the ssDNA flap (i.e., the reverse transcriptase primer sequence) anneals to the primer binding site (A) on the PEGRNA, thereby priming reverse transcriptase. Next, reverse transcriptase (e.g., provided *in trans* or provided *cis* as a fusion protein, attached to the Cas9 construct) then polymerizes a single strand of DNA which is coded for by the edit template (B) and homology arm (C). The polymerization continues towards the 5' end of the extension arm. The polymerized strand of ssDNA forms a ssDNA 3' end flap which, as describe elsewhere (e.g., as shown in FIG. 1G), invades the endogenous DNA, displacing the corresponding endogenous strand (which is removed as a 5' DNA flap of endogenous DNA), and installing the desired nucleotide edit (single nucleotide base pair change, deletions, insertions (including whole genes) through naturally occurring DNA repair/replication rounds.

[0759] This application of prime editing can be further described in Example 1.

Dual prime editing

[0760] This Specification describes a dual prime editing system (or a dual-flap prime editing system) that addresses the challenges associated with flap equilibration and subsequent incorporation of the edit into the non-edited complementary genomic DNA strand by simultaneously editing both DNA strands. In the dual-flap prime editing system, two pegRNAs are used to target opposite strands of a genomic site and direct the synthesis of two complementary 3' flaps containing edited DNA sequence (**FIG. 91**). Unlike classical prime editing, there is no requirement for the pair of edited DNA strands (3' flaps) to directly compete with 5' flaps in endogenous genomic DNA, as the complementary edited strand is available for hybridization instead. Since both strands of the duplex are synthesized as edited DNA, the dual-flap prime editing system obviates the need for the replacement of the non-edited complementary DNA strand required by classical prime editing. Instead, cellular DNA repair machinery need only excise the paired 5' flaps (original genomic DNA) and ligate the paired 3' flaps (edited DNA) into the locus. Therefore, there is also no need to include sequences homologous to genomic DNA in the newly synthesized DNA strands, allowing selective hybridization of the new strands and facilitating edits that contain minimal genomic homology. Nuclease-active versions of prime editors that cut both strands of DNA could also be used to accelerate the removal of the original DNA sequence. Accordingly, in certain embodiments, a dual flap prime editing system involves a pair of newly synthesized DNA strands (e.g. 3' flaps) that share homology with the endogeneous DNA sequence at a target site to be edited. In some embodiments, a dual flap prime editing system involves a pair of newly synthesized DNA strands, where at least one of the newly synthesized DNA strands does not share homology with the endogeneous DNA sequence at the target site to be edited. In some embodiments, one of the newly synthesized DNA strands comprises homology with the endogenous DNA sequence at the target site and not with the other newly synthesized DNA strand. In some embodiments, each of the the newly synthesized DNA strands comprises homology with the endogenous DNA sequence at the target site and not with the other newly synthesized DNA strand.

For example, a newly synthesized 3' flap encoded by one of the dual-flap pegRNAs may comprise a region of complementarity to a protospacer sequence of the other dual-flap pegRNA. Accordingly, in some embodiments, a pair of dual-flap pegRNAs each having complementarity to a spacer sequence of the other pegRNA may result in deletion of the endogenous DNA sequence positioned between protospacer sequences of the pair of dual-flap pegRNAs. In some embodiments, a dual flap prime editing system involves a pair of newly synthesized DNA strands, where neither of the newly synthesized DNA strands share homology with the endogenous DNA sequence at the target site to be edited. Rather, the two newly synthesized DNA strands (e.g. 3' flaps) each comprises a region of complementarity to each other and may form a duplex by the complementarity. A desired edited portion as compared to the endogenous DNA sequence target site to be edited in the duplex may then be incorporated at the target site. Like classical prime editing, dual prime editing is a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a nucleic acid programmable DNA binding protein ("napDNAbp") working in association with a polymerase (i.e., in the form of a fusion protein or otherwise provided *in trans* with the napDNAbp), wherein the prime editing system is programmed with a prime editing (PE) guide RNA ("PEgRNA") that both specifies the target site and templates the synthesis of the desired edit in the form of a replacement DNA strand by way of an extension (either DNA or RNA) engineered onto a guide RNA (e.g., at the 5' or 3' end, or at an internal portion of a guide RNA). The replacement strand containing the desired edit (e.g., a single nucleobase substitution) shares the same sequence as the endogenous strand of the target site to be edited (with the exception that it includes the desired edit). Through DNA repair and/or replication machinery, the endogenous strand of the target site is replaced by the newly synthesized replacement strand containing the desired edit. In some cases, prime editing may be thought of as a "search-and-replace" genome editing technology since the prime editors, as described herein, not only search and locate the desired target site to be edited, but at the same time, encode a replacement strand containing a desired edit which is installed in place of the corresponding target site endogenous DNA strand.

B. Use of dual prime editing for peptide tagging

[0761] In another aspect, the disclosure provides a method of using the herein described dual prime editors for genetically grafting one or more peptide tags onto a protein using prime editing (such as the embodiment shown in FIG. 90). More in particular, the disclosure provides a method for genetically installing one or more peptide tags onto a protein comprising: contacting a target nucleotide sequence encoding the protein with a prime editor configured to insert therein a second nucleotide sequence encoding the one or more peptide tags to result in a recombinant nucleotide sequence that encodes a fusion protein comprising the protein fused to the protein tag.

[0762] In other embodiments, the disclosure provides a method for making a fusion protein comprising a peptide of interest and one or more peptide tags, the method comprising: contacting a

target nucleotide sequence encoding the protein with a prime editor configured to insert therein a second nucleotide sequence encoding the one or more peptide tags to result in a recombinant nucleotide sequence that encodes the fusion protein comprising the protein fused to the protein tag.

[0763] In various embodiments, the target nucleotide sequence is a specific gene of interest in a genomic DNA. The gene of interest may encode a protein of interest (e.g., a receptor, an enzyme, a therapeutic protein, a membrane protein, a transport protein, a signal transduction protein, or an immunological protein, etc.). The gene of interest may also encode an RNA molecule, including, but not limited to, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), antisense RNA, guide RNA, microRNA (miRNA), small interfering RNA (siRNA), and cell-free RNA (cfRNA).

[0764] The peptide tag may be any peptide tag or variant thereof which imparts one or more functions onto a protein for purposes such as separation, purification, visualization, solubilization, or detection. The peptides tags can include “affinity tags” (to facilitate protein purification), “solubilization tags” (to assist in proper folding of proteins), “chromatography tags” (to alter chromatographic properties of proteins), “epitope tags” (to bind to high affinity antibodies), and “fluorescence tags” (to facilitate visualization of proteins in a cell or in vitro). Examples of peptide tags include, but are not limited to the following tags:

NAME	AMINO ACID SEQUENCE	SEQ ID NO:
AVITAG™	GLNDIFEAQKIEWHE	SEQ ID NO: 245
C-TAG	EPEA	SEQ ID NO: 246
CALMODULIN-TAG	KRRWKKNFIAVSAANRFKKISSSGAL	SEQ ID NO: 247
POLYGLUTAMATE TAG	EEEEEE	SEQ ID NO: 248
E-TAG	GAPVPYPDPLEPR	SEQ ID NO: 249
FLAG-TAG	DYKDDDDK	SEQ ID NO: 250
HA-TAG	YPYDVPDYA	SEQ ID NO: 251
HIS-TAG	H (HIS ₁) HH (HIS ₂) HHH (HIS ₃) HHHH (HIS ₄) HHHHH (HIS ₅) HHHHHH (HIS ₆) HHHHHHH (HIS ₇) HHHHHHHH (HIS ₈) HHHHHHHHH (HIS ₉) HHHHHHHHHH (HIS ₁₀) HHHHHHHHHH...H...(HIS _N , WHEREIN N = 1-25)	SEQ ID NO: 252 SEQ ID NO: 253 SEQ ID NO: 254 SEQ ID NO: 255 SEQ ID NO: 256 SEQ ID NO: 257 SEQ ID NO: 258 SEQ ID NO: 259 SEQ ID NO: 260 SEQ ID NO: 261 SEQ ID NO: 262
MYC-TAG	EQKLISEEDL	SEQ ID NO: 263
NE-TAG	TKENPRSNQEESYDDNES	SEQ ID NO: 264
RHO1D4-TAG	TETSQVAPA	SEQ ID NO: 265
S-TAG	KETAAAKFERQHMDS	SEQ ID NO: 266
SBP-TAG	MDEKTTGWRGGHVVEGLAGELEQLR ARLEHHPQGQREP	SEQ ID NO: 267
SOFTAG-1	SLAELLNAGLGGS	SEQ ID NO: 268
SOFTAG-2	TQDPSRVG	SEQ ID NO: 269

SPOT-TAG	PDRVRAVSHWSS	SEQ ID NO: 270
STREP-TAG	WSHPQFEK	SEQ ID NO: 271
TC TAG	CCPGCC	SEQ ID NO: 272
TY TAG	EVHTNQDPLD	SEQ ID NO: 273
V5 TAG	GKPIPNPLLGLDST	SEQ ID NO: 274
VSV-TAG	YTDIEMNRLGK	SEQ ID NO: 275
XPRESS TAG	DLYDDDDK	SEQ ID NO: 276

[0765] Peptide tags may also be the following affinity tags (for separation and/or purification of proteins) (as described in Table 9.9.1 of Kimple et al., “Overview of Affinity Tags for Protein Purification,” *Curr Protoc Protein Sci*, 2013, 73:Unit-9.9, which is incorporated herein by reference).

NAME	AMINO ACID SEQUENCE	
AU1 EPI TOPE	DTYRYI	SEQ ID NO: 278
AU5 EPI TOPE	TDFYLYK	SEQ ID NO: 279
BACTERIOPHAGE T7 EPI TOPE (T7-TAG)	MASMTGGGQMG	SEQ ID NO: 280
BLUETONGUE VIRUS TAG (B-TAG)	QYPALT	SEQ ID NO: 281
E2 EPI TOPE	SSTSSDFRDR	SEQ ID NO: 282
HISTIDINE AFFINITY TAG (HAT)	KDHLIHNVHKEFHAAHANK	SEQ ID NO: 283
HSV EPI TOPE	QPELAPED	SEQ ID NO: 284
POLYARGININE (ARG-TAG)	RRRRR	SEQ ID NO: 285
POLYASPARTATE (ASP-TAG)	CCCC	SEQ ID NO: 286
POLYPHENYLALANINE (PHE-TAG)	FFFFFFFFF	SEQ ID NO: 287
S1-TAG	NANPDWDF	SEQ ID NO: 288
S-TAG	KETAAAKFERQHMS	SEQ ID NO: 289
VSV-G	YTDIEMNRLGK	SEQ ID NO: 290

[0766] In particular embodiments, the peptide tags may include a His⁶ tag, FLAG-tag, V5-tag, GCN4-tag, HA-tag, Myc-Tag, FIAsH/ReAsH-tag, Sortase substrate, pi-clamp.

[0767] In various embodiments, the peptide tags may be used for applications that include protein fluorescent labeling, immunoprecipitation, immunoblotting, immunohistochemistry, protein recruitment, inducible protein degrons, and genome-wide screening.

[0768] In various other embodiments, the peptide tag may include an intein sequence to install protein self-splicing function. As used herein, the term “intein” refers to auto-processing polypeptide domains found in organisms from all domains of life. An intein (*intervening protein*) carries out a unique auto-processing event known as protein splicing in which it excises itself out from a larger precursor polypeptide through the cleavage of two peptide bonds and, in the process, ligates the flanking extein (external protein) sequences through the formation of a new peptide bond. This rearrangement occurs post-translationally (or possibly co-translationally), as intein genes are found embedded in frame within other protein-coding genes. Furthermore, intein-mediated protein splicing is spontaneous; it requires no external factor or energy source, only the folding of the intein domain. This process is also known as *cis*-protein splicing, as opposed to the natural process of *trans*-protein splicing with “split inteins.” Inteins are the protein equivalent of the self-splicing RNA introns (see

Perler et al., *Nucleic Acids Res.* 22:1125-1127 (1994)), which catalyze their own excision from a precursor protein with the concomitant fusion of the flanking protein sequences, known as exteins (reviewed in Perler et al., *Curr. Opin. Chem. Biol.* 1:292-299 (1997); Perler, F. B. *Cell* 92(1):1-4 (1998); Xu et al., *EMBO J.* 15(19):5146-5153 (1996)).

[0769] The mechanism of the protein splicing process has been studied in great detail (Chong, et al., *J. Biol. Chem.* 1996, 271, 22159-22168; Xu, M-Q & Perler, F. B. *EMBO Journal*, 1996, 15, 5146-5153) and conserved amino acids have been found at the intein and extein splicing points (Xu, et al., *EMBO Journal*, 1994, 13 5517-5522).

[0770] Inteins can also exist as two fragments encoded by two separately transcribed and translated genes. These so-called split inteins self-associate and catalyze protein-splicing activity in trans. Split inteins have been identified in diverse cyanobacteria and archaea (Caspi et al, *Mol Microbiol.* 50: 1569-1577 (2003); Choi J. et al, *J Mol Biol.* 556: 1093-1106 (2006.); Dassa B. et al, *Biochemistry.* 46:322-330 (2007.); Liu X. and Yang J., *J Biol Chem.* 275:26315-26318 (2003); Wu H. et al. *Proc Natl Acad Sci USA.* 95:9226-9231 (1998.); and Zettler J. et al, *FEBS Letters.* 553:909-914 (2009)), but have not been found in eukaryotes thus far. Recently, a bioinformatic analysis of environmental metagenomic data revealed 26 different loci with a novel genomic arrangement. At each locus, a conserved enzyme coding region is interrupted by a split intein, with a freestanding endonuclease gene inserted between the sections coding for intein subdomains. Among them, five loci were completely assembled: DNA helicases (gp41-l, gp41-8); Inosine-5'-monophosphate dehydrogenase (IMPDH-1); and Ribonucleotide reductase catalytic subunits (NrdA-2 and NrdJ-1). This fractured gene organization appears to be present mainly in phages (Dassa et al, *Nucleic Acids Research.* 57:2560-2573 (2009)).

[0771] In certain embodiments, the prime editors described herein can be used to insert split-intein tags in two different proteins, causing their intracellular ligation when co-expressed to form a fusion protein. In protein trans-splicing, one precursor protein consists of an N-extein part followed by the N-intein, another precursor protein consists of the C-intein followed by a C-extein part, and a trans-splicing reaction (catalyzed by the N- and C-inteins together) excises the two intein sequences and links the two extein sequences with a peptide bond. Protein trans-splicing, being an enzymatic reaction, can work with very low (e.g., micromolar) concentrations of proteins and can be carried out under physiological conditions.

[0772] The split intein Npu DnaE was characterized as having the highest rate reported for the protein trans-splicing reaction. In addition, the Npu DnaE protein splicing reaction is considered robust and high-yielding with respect to different extein sequences, temperatures from 6 to 37°C, and the presence of up to 6M Urea (Zettler J. et al, *FEBS Letters.* 553:909-914 (2009); Iwai I. et al, *FEBS Letters* 550: 1853-1858 (2006)). As expected, when the Cysl Ala mutation at the N-domain of these inteins was introduced, the initial N to S- acyl shift and therefore protein splicing was blocked.

Unfortunately, the C- terminal cleavage reaction was also almost completely inhibited. The dependence of the asparagine cyclization at the C-terminal splice junction on the acyl shift at the N-terminal scissile peptide bond seems to be a unique property common to the naturally split DnaE intein alleles (Zettler J. et al. FEBS Letters. 555:909-914 (2009)).

[0773] Protein trans-splicing, catalyzed by split inteins, provides an entirely enzymatic method for protein ligation. A split-intein is essentially a contiguous intein (e.g. a mini-intein) split into two pieces named N-intein and C-intein, respectively. The N-intein and C-intein of a split intein can associate non-covalently to form an active intein and catalyze the splicing reaction essentially in same way as a contiguous intein does. Split inteins have been found in nature and also engineered in laboratories. As used herein, the term "split intein" refers to any intein in which one or more peptide bond breaks exists between the N-terminal and C-terminal amino acid sequences such that the N-terminal and C-terminal sequences become separate molecules that can non-covalently reassociate, or reconstitute, into an intein that is functional for trans-splicing reactions. Any catalytically active intein, or fragment thereof, may be used to derive a split intein for use in the methods of the invention. For example, in one aspect the split intein may be derived from a eukaryotic intein. In another aspect, the split intein may be derived from a bacterial intein. In another aspect, the split intein may be derived from an archaeal intein. Preferably, the split intein so-derived will possess only the amino acid sequences essential for catalyzing trans-splicing reactions.

[0774] Split inteins may be created from contiguous inteins by engineering one or more split sites in the unstructured loop or intervening amino acid sequence between the -12 conserved beta-strands found in the structure of mini-inteins. Some flexibility in the position of the split site within regions between the beta-strands may exist, provided that creation of the split will not disrupt the structure of the intein, the structured beta-strands in particular, to a sufficient degree that protein splicing activity is lost.

[0775] The prime editors described herein may incorporate peptide tags (including inteins) into the C-terminal end of a protein of interest. In other embodiments, the peptide tags (including inteins) may be incorporated into the N-terminal end of a protein of interest. The peptide tags may also be incorporated into the interior of a protein of interest. The resulting fusion proteins created by the herein described prime editors may have the following structures:

[0776] [protein of interest] – [peptide tag];

[0777] [peptide tag] – [protein of interest]; or

[0778] [protein of interest – N-terminal region] – [peptide tag] – [protein of interest – C-terminal region].

[0779] The principles of guide RNA design for use in peptide tagging throughout may be applied to peptide tagging. For example, in one embodiment, the PEgRNA structure for peptide tagging may have the following structure: 5'-[spacer sequence]-[gRNA core or scaffold]-[extension arm]-3',

wherein the extension arm comprises in the 5' to 3' direction, a homology arm, edit template (comprising the sequence that encodes the peptide tag), and a primer binding site. This configuration is depicted in FIG. 3D and in FIG. 24.

[0780] In another embodiment, the PEGRNA structure for peptide tagging may have the following structure: 5'-[extension arm]-[spacer sequence]-[gRNA core or scaffold]-3', wherein the extension arm comprises in the 5' to 3' direction, a homology arm, edit template (comprising the sequence that encodes the peptide tag), and a primer binding site. This configuration is depicted in FIG. 3E.

[0781] Embodiments of peptide tagging using prime editing is depicted in FIGs. 25 and 26 and described in Example 4.

C. Use of dual prime editing for RNA tagging

[0782] Dual prime editing may also be used to manipulate, alter, and otherwise modify the sequences of DNA encoding RNA functions through RNA tagging, and in this way provides a means to indirectly modify the structure and function of RNA. For example, dual PE can be used to insert motifs that are functional at the RNA level (hereafter RNA motifs) to tag or otherwise manipulate non-coding RNAs or mRNAs. These motifs could serve to increase gene expression, decrease gene expression, alter splicing, change post-transcriptional modification, affect the sub-cellular location of the RNA, enable isolation or determination of the intra- or extra-cellular location of the RNA (using, for instance, fluorescent RNA aptamers such as Spinach, Spinach2, Baby Spinach, or Broccoli), recruit endogenous or exogenous protein or RNA binders, introduce sgRNAs, or induce processing of the RNA, by either self-cleavage or RNases (see FIG. 28B and Example 6 for further details).

[0783] The following RNA tags or motifs may be inserted into a gene of interest using dual prime editing (e.g., with the dual PE methodology of FIG. 90) with an appropriate PEGRNA (designed using the guidance provided herein) to affect various properties of RNA, including RNA transport, expression level, splicing, and detection.

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
POLYOMAVIRUS SIMIAN VIRUS 40 (SV40) TYPE1	AACTTGTTTATTGCAGCTTAT AATGGTTACAAATAAAGCAA TAGCATCACAAATTCACAA ATAAAGCATTTTTTTCAGTGC ATTCTAGTTGTGGTTTGTCCA AACTCATCAATGTATCTTA (SEQ ID NO: 331)	TERMINATION OF TRANSCRIPTION OF THE TAGGED GENE; TRANSPORT OF MRNA INTO CYTOSOL; INCREASED RNA STABILITY	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC TAGAAATAGCAAGTT TAAATAAGGCTAGTC CGTTATCAACTTGAA AAAGTGGGACCGAG TCGGTCCACCTGAACC GTATATCTAAGATACA TTGATGAGTTTGGA CAAACCACAACTAG AATGCAGTGAAAAA AATGCTTTATTTGTG

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
		AND EXPRESSION OF ENCODED PROTEIN	AAATTTGTGATGCTA TTGCTTTATTTGTAA CCATTATAAGCTGCA ATAAACAAAGTTCTAT GGCCCTGACTGGAA (SEQ ID NO: 332)
POLYOMAVIRUS SIMIAN VIRUS 40 (SV40) TYPE2	CCATGGCCCAACTTGTATT GCAGCTTATAATGGTTACAA ATAAAGCAATAGCATCACAA ATTTCACAAATAAAGCATTTT TTTCACTGCATTCTAGTTGTG GTTTGTCCAACTCATCAAT GTATCTTATCATGTCTGGATC TC (SEQ ID NO: 333)	TERMINATION OF TRANSCRIPTION OF THE TAGGED GENE; TRANSPORT OF MRNA INTO CYTOSOL; INCREASED RNA STABILITY AND EXPRESSION OF ENCODED PROTEIN	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC TAGAAATAGCAAGTT TAAATAAGGCTAGTC CGTTATCAACTTGAA AAAGTGGGACCGAG TCGGTCCACCTGAACC GTATATCGAGATCCA GACATGATAAGATAC ATTGATGAGTTTGG ACAAACCACAATA GAATGCAGTGAAAA AAATGCTTTATTTGT GAAATTTGTGATGC TATTGCTTTATTTGT AACCATTATAAGCTG CAATAAACAAAGTTG GGCCATGGCTATGGC CCTGACTGGAA (SEQ ID NO: 334)
POLYOMAVIRUS SIMIAN VIRUS 40 (SV40) TYPE3	TGATCATAATCAAGCCATATC ACATCTGTAGAGGTTTACTT GCTTTAAAAACCTCCACAC CTCCCCCTGAACCTGAAACA TAAATGAATGCAATTGTTG TTGTTAACTTGTATTGTCAG CTTATAATGGTTACAAATAAA GCAATAGCATCACAAATTC ACAAATAAAGCATTTTTTC ACTGCATTCTAGTTGTGGTTT GTCCAACTCATCAATGTAT CTTATCATGTCTGGATCTGC (SEQ ID NO: 335)	TERMINATION OF TRANSCRIPTION OF THE TAGGED GENE; TRANSPORT OF MRNA INTO CYTOSOL; INCREASED RNA STABILITY AND EXPRESSION OF ENCODED PROTEIN	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC TAGAAATAGCAAGTT TAAATAAGGCTAGTC CGTTATCAACTTGAA AAAGTGGGACCGAG TCGGTCCACCTGAACC GTATATCGCAGATCC AGACATGATAAGATA CATTGATGAGTTTG GACAAACCACAATA AGAATGCAGTGAAA AAAATGCTTTATTTG TGAAATTTGTGATG CTATTGCTTTATTTG TAACCATTATAAGCT GCAATAAACAAAGTT AACAAACAATTG CATTCATTTTATGTT TCAGGTTGAGGGG AGGTGTGGAGGTTT TTAAAGCAAGTAA

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
			ACCTCTACAGATGT GATATGGCTTGATTA TGATCACTATGGCCC TGACTGGAA (SEQ ID NO: 336)
HUMAN GROWTH HORMONE (HGH)	ACGGGTGGCATCCCTGTGAC CCCTCCCCAGTGCCTCTCCT GGCCCTGGAAGTTGCCACTC CAGTGCCCAACCAGCCTTGTC CTAATAAAATTAAGTTGCATC ATTTTGTCTGACTAGGTGTC CTTCTATAATATTATGGGGTG GAGGGGGGTGGTATGGAGC AAGGGGCAAGTTGGGAAGA CAACCTGTAGGGCCTGCGGG GTCTATTGGGAACCAAGCTG GAGTGCAGTGGCACAATCTT GGCTCACTGCAATCTCCGCC TCCTGGGTTCAAGCGATTCT CCTGCCTCAGCCTCCCGAGT TGTTGGGATTCCAGGCATGC ATGACCAGGCTCAGCTAATT TTTGTTTTTTTGGTAGAGAC GGGGTTTCACCATATTGGCC AGGCTGGTCTCCAACCTCCTA ATCTCAGGTGATCTACCCAC CTTGGCCTCCCAAATTGCTG GGATTACAGGCGTGAACCAC TGCTCCCTTCCCTGTCCTT (SEQ ID NO: 337)	TRANSPORT OF RNA INTO CYTOPLASM; ENHANCED RNA STABILITY AND EXPRESSION OF ENCODED PROTEIN	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCCGTCCACCTGAACC</u> <u>GTATATCAAGGACAG</u> <u>GGAAGGGAGCAGT</u> <u>GGTTCACGCCTGTA</u> <u>ATCCCAGCAATTTG</u> <u>GGAGGCCAAGGTG</u> <u>GGTAGATCACCTGA</u> <u>GATTAGGAGTTGGA</u> <u>GACCAGCCTGGCCA</u> <u>ATATGGTGAAACCC</u> <u>CGTCTCTACCAAAA</u> <u>AAACAAAAATTAGC</u> <u>TGAGCCTGGTCATG</u> <u>CATGCCTGGAATCC</u> <u>CAACAACTCGGGAG</u> <u>GCTGAGGCAGGAGA</u> <u>ATCGCTTGAACCCA</u> <u>GGAGGCGGAGATTG</u> <u>CAGTGAGCCAAGAT</u> <u>TGTGCCACTGCACT</u> <u>CCAGCTTGTTCCC</u> <u>AATAGACCCCGCAG</u> <u>GCCCTACAGGTTGT</u> <u>CTTCCCAACTTGCC</u> <u>CCTTGCTCCATACC</u> <u>ACCCCCCTCCACCC</u> <u>CATAATATTATAGAA</u> <u>GGACACCTAGTCAG</u> <u>ACAAAATGATGCAA</u> <u>CTTAATTTTATTAGG</u> <u>ACAAGGCTGGTGGG</u> <u>CACTGGAGTGGCAA</u> <u>CTTCCAGGGCCAGG</u> <u>AGAGGCACTGGGGA</u> <u>GGGGTCACAGGGAT</u> <u>GCCACCCGTCTATGG</u> <u>CCCTGACTGGAA</u>

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
			(SEQ ID NO: 338)
BOVINE GROWTH HORMONE (BGH)	CGACTGTGCCTTCTAGTTGC CAGCCATCTGTTGTTTGCCC CTCCCCGTGCCTTCCTTGA CCCTGGAAGGTGCCACTCCC ACTGTCCTTTCCTAATAAAAT GAGGAAATTGCATCGCATTG TCTGAGTAGGTGTCATTCTAT TCTGGGGGGTGGGGTGGGG CAGGACAGCAAGGGGGAGG ATTGGGAAGACAATAGCAGG CATGCTGGGGATGCGGTGGG CTCTATGG (SEQ ID NO: 339)	TRANSPORT OF RNA INTO CYTOPLASM; ENHANCED RNA STABILITY AND EXPRESSION OF ENCODED PROTEIN	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCCGTCCACCTGAACC</u> <u>GTATATCCCATAGAGC</u> <u>CCACCGCATCCCCA</u> <u>GCATGCCTGCTATT</u> <u>GTCTTCCCAATCCT</u> <u>CCCCCTTGCTGTCC</u> <u>TGCCCCACCCACC</u> <u>CCCCAGAATAGAAT</u> <u>GACACCTACTCAGA</u> <u>CAATGCGATGCAAT</u> <u>TTCCTCATTTTATTA</u> <u>GGAAAGGACAGTGG</u> <u>GAGTGGCACCTTCC</u> <u>AGGGTCAAGGAAGG</u> <u>CACGGGGGAGAGG</u> <u>CAAACAACAGATGG</u> <u>CTGGCAACTAGAAG</u> <u>GCACAGTCGCTATG</u> <u>GCCCTGACTGGAA</u> (SEQ ID NO: 340)
RABBIT BETA- GLOBIN (RBGLOB)	TTCACTCCTCAGGTGCAGGC TGCCTATCAGAAGGTGGTGG CTGGTGTGGCCAATGCCCTG GCTCACAATACCACTGAGA TCTTTTTCCCTCTGCCAAA ATTATGGGGACATCATGAAG CCCCTTGAGCATCTGACTTC TGGCTAATAAAGGAAATTTA TTTTTCATTGCAATAGTGTGT GGAATTTTTTGTGTCTCTCAC TCGGAAGGACATATGGGAGG GCAATCATTTAAAACATCA GAATGAGTATTTGGTTTAGA GTTTGGCAACATATGCCATA TGCTGGCTGCCATGAACAAA GGTTGGCTATAAAGAGGTCA TCAGTATATGAAACAGCCCC CTGCTGTCCATTCCCTTATCC ATAGAAAAGCCTTGACTTGA GGTTAGATTTTTTTTATATTTT GTTTTGTGTATTTTTTTCTT	TRANSPORT OF RNA INTO CYTOPLASM; ENHANCED RNA STABILITY AND EXPRESSION OF ENCODED PROTEIN	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCCGTCCACCTGAACC</u> <u>GTATATCGATCTCCAT</u> <u>AAGAGAAGAGGGAC</u> <u>AGCTATGACTGGGA</u> <u>GTAGTCAGGAGAGG</u> <u>AGGAAAAATCTGGC</u> <u>TAGTAAAACATGTAA</u> <u>GGAAAATTTTAGGG</u> <u>ATGTTAAAGAAAAA</u> <u>AATAACACAAAACA</u> <u>AAATATAAAAAAAT</u> <u>CTAACCTCAAGTCA</u> <u>AGGCTTTTCTATGG</u> <u>AATAAGGAATGGAC</u> <u>AGCAGGGGGCTGTT</u>

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
	TAACATCCCTAAAATTTTCCT TACATGTTTTACTAGCCAGAT TTTTCTCCTCTCCTGACTAC TCCCAGTCATAGCTGTCCCT CTTCTCTTATGGAGATC (SEQ ID NO: 341)		TCATATACTGATGAC CTCTTTATAGCCAAC CTTTGTTCATGGCA GCCAGCATATGGGC ATATGTTGCCAACT CTAAACCAAATACTC ATTCTGATGTTTTAA ATGATTTGCCCTCC CATATGTCCTTCCGA GTGAGAGACACAAA AAATTCCAACACAC TATTGCAATGAAAAT AAATTTCTTTATTA GCCAGAAGTCAGAT GCTCAAGGGGCTTC ATGATGTCCCCATAA TTTTTGGCAGAGGG AAAAAGATCTCAGT GGTATTTGTGAGCC AGGGCATTGGCCAC ACCAGCCACCCT TCTGATAGGCAGCC TGCACCTGAGGAGT GAACTATGGCCCTGA CTGGAA (SEQ ID NO: 342)
THYMIDINE KINASE (TK)	GGGGGAGGCTAACTGAAAC ACGGAAGGAGACAATACCG GAAGGAACCCGCGCTATGAC GGCAATAAAAAGACAGAATA AAACGCACGGGTGTTGGGT CGTTTGTTTCATAAACGCGGG GTTTCGGTCCCAGGGCTGGCA CTCTGTGATACCCACCGA GACCCCATTTGGGGCCAATAC GCCCCGTTTTCTTCCTTTTCC CCACCCACCCCCCAAGTTC GGGTGAAGGCCAGGGCTC GCAGCCAACGTCGGGGCGG CAGGCCCTGCCATAG (SEQ ID NO: 343)	TRANSPORT OF RNA INTO CYTOPLASM; ENHANCED RNA STABILITY AND EXPRESSION OF ENCODED PROTEIN	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC TAGAAATAGCAAGTT TAAATAAGGCTAGTC CGTTATCAACTTGAA AAAGTGGGACCGAG TCGGTCCACCTGAACC GTATATCCTATGGCAG GGCCTGCCGCCCGG ACGTTGGCTGCGAG CCCTGGGCCTTCAC CCGAACCTTGGGGGG TGGGGTGGGGAAAA GGAAGAAACGCGG GCGTATTGGCCCCA ATGGGGTCTCGGTG GGGTATCGACAGAG TGCCAGCCCTGGGA CCGAACCCCGCGTT TATGAACAAACGAC CCAACACCCGTGCG TTTATTCTGTCTTT

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
			TTATTGCCGTCATAG CGCGGGTTCCTTCC GGTATTGTCTCCTTC CGTGTTTCAGTTAG CCTCCCCCTATGGC CCTGACTGGAA (SEQ ID NO: 344)
MALAT1 ENE- MASC RNA	TAGGGTCATGAAGGTTTTTC TTTTCTGAGAAAACAACAC GTATTGTTTTCTCAGGTTTTG CTTTTGGCCTTTTTCTAGCT TAAAAAAAAAAAAAGCAAA AGATGCTGGTGGTTGGCACT CCTGGTTTCCAGGACGGGGT TCAAATCCCTGCGGCGTCTT TGCTTTGACT (SEQ ID NO: 345)	RESULTS IN RETENTION OF RNA IN NUCLEUS, TRANSCRIPT TERMINATION AND STABILIZATIO N	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <u>GTATATCAGTCAAAG</u> <u>CAAAGACGCCGCAG</u> <u>GGATTTGAACCCCG</u> <u>TCCTGGAAACCAGG</u> <u>AGTGCCAACCACCA</u> <u>GCATCTTTTGCTTTT</u> <u>TTTTTTTTTAAGCTA</u> <u>GAAAAAGGCCAAAA</u> <u>AGCAAAACCTGAGA</u> <u>AAACAATACGTGTT</u> <u>GTTTTCTCAGGAAA</u> <u>AGAAAAACCTTCAT</u> <u>GACCCTACTATGGCC</u> <u>CTGACTGGAA</u> (SEQ ID NO: 346)
KSHV PAN ENE	TGTTTTGGCTGGGTTTTTCCT TGTTTCGACCGGACACCTCC AGTGACCAGACGGCAAGGT TTTTATCCCAGTGTATATTGG AAAAACATGTTATACTTTTG ACAATTTAACGTGCCTAGAG CTCAAATTAACTAATACCAT AACGTAATGCAACTTACAAC ATAAATAAAGGTCAATGTTT AATCCATAAAAAAAAAAAAA AAAAAAA (SEQ ID NO: 347)	RESULTS IN RETENTION OF RNA IN NUCLEUS, TRANSCRIPT TERMINATION AND STABILIZATIO N	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <u>GTATATCTTTTTTTTT</u> <u>TTTTTTTTTTTATGGA</u> <u>TAAACATTGACCTT</u> <u>TATTTATGTTGTAAG</u> <u>TTGCATTACGTTATG</u> <u>GTATTAGTTTAATTT</u> <u>GAGCTCTAGGCACG</u> <u>TTAAATTGTCAAAA</u> <u>GTATAACATGTTTTT</u> <u>CCAATATACACTGG</u> <u>GATAAAAACCTTGC</u> <u>CGTCTGGTCACTGG</u>

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
			AGGTGTCCGGTGCG AACAAGGAAAAACC CAGCCAAAACACTAT GGCCCTGACTGGAA (SEQ ID NO: 348)
THREE, SEQUENTIAL KSHV PAN ENES WITH SHORT, UNCONSERVE D RNA LINKERS	TGTTTTGGCTGGGTTTTTCCT TGTTTCGCACCGGACACCTCC AGTGACCAGACGGCAAGGT TTTTATCCCAGTGTATATTGG AAAAACATGTTATACTTTTG ACAATTTAACGTGCCTAGAG CTCAAATTAACATAATACCAT AACGTAATGCAACTTACAAC ATAAATAAAGGTCAATGTTT AATCCATAAAAAAAAAAAAA AAAAAAAAACACACTGTTTTG GCTGGGTTTTTCCTTGTTTCG CACCGGACACCTCCAGTGAC CAGACGGCAAGGTTTTTATC CCAGTGTATATTGGAAAAAC ATGTTATACTTTTGACAATTT AACGTGCCTAGAGCTCAAAT TAAACTAATACCATAACGTA ATGCAACTTACAACATAAAT AAAGGTCAATGTTTAATCCA TAAAAAAAAAAAAAAAAAAAA ATCTCTCTGTTTTGGCTGGGT TTTTTCCTTGTTTCGCACCGGA CACCTCCAGTGACCAGACG GCAAGGTTTTTATCCCAGTG TATATTGGAAAAACATGTTAT ACTTTTGACAATTTAACGTG CCTAGAGCTCAAATTAACCT AATACCATAACGTAATGCAA CTTACAACATAAATAAAGGT CAATGTTTAATCCATAAAAA AAAAAAAAAAAAAAAAAAAA (SEQ ID NO: 349)	RESULTS IN RETENTION OF RNA IN NUCLEUS, TRANSCRIPT TERMINATION AND STABILIZATIO N, PREDICTED TO BE GREATER THAN A SINGLE PAN ENE	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCCGTCCACCTGAACC</u> <u>GTATATCTTTTTTTTT</u> <u>TTTTTTTTTTTATGGA</u> <u>TTAAACATTGACCTT</u> <u>TATTTATGTTGTAAG</u> <u>TTGCATTACGTTATG</u> <u>GTATTAGTTTAATTT</u> <u>GAGCTCTAGGCACG</u> <u>TTAAATTGTCAAAA</u> <u>GTATAACATGTTTTT</u> <u>CCAATATACACTGG</u> <u>GATAAAAACCTTGC</u> <u>CGTCTGGTCACTGG</u> <u>AGGTGTCCGGTGCG</u> <u>AACAAGGAAAAACC</u> <u>CAGCCAAAACAGAG</u> <u>AGATTTTTTTTTTTTT</u> <u>TTTTTTTATGGATTA</u> <u>AACATTGACCTTTAT</u> <u>TTATGTTGTAAGTTG</u> <u>CATTACGTTATGGTA</u> <u>TTAGTTTAATTTGAG</u> <u>CTCTAGGCACGTTA</u> <u>AATTGTCAAAAGTAT</u> <u>AACATGTTTTTTCCA</u> <u>ATATACACTGGGATA</u> <u>AAAACCTTGCCGTC</u> <u>TGGTCACTGGAGGT</u> <u>GTCCGGTGCGAACA</u> <u>AGGAAAAACCCAGC</u> <u>CAAAACAGTGTGTT</u> <u>TTTTTTTTTTTTTTTT</u> <u>TTTATGGATTAAACA</u> <u>TTGACCTTTATTTAT</u> <u>GTTGTAAGTTGCAT</u> <u>TACGTTATGGTATTA</u> <u>GTTTAATTTGAGCTC</u>

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
			TAGGCACGTTAAAT TGTCAAAAGTATAA CATGTTTTTCCAATA TACACTGGGATAAA AACCTTGCCGTCTG GTCACTGGAGGTGT CCGGTGC GAACAAG GAAAAACCCAGCCA AAACACTATGGCCCT GACTGGAA (SEQ ID NO: 350)
SMBOX/U1 SNRNA BOX	CAGCAAGTTCAGAGAAATCT GAACTTGCTGGATTTTTGGA GCAGGGAGATGGAATAGGA GCTTGCTCCGTCCACTCCAC GCATCGACCTGGTATTGCAG TACCTCCAGGAACGGTGCAC CCACTTTCTGGAGTTTCAAA AGTAGACTGTACGCTAAGGG TCATATCTTTTTTTGTTTGGT TTGTGTCTTGGTTGGCGTCT TAAA (SEQ ID NO: 351)	RESULTS IN RETENTION OF RNA IN NUCLEUS AND TRANSCRIPT TERMINATION	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <u>GTATATCTTTAAGACG</u> CCAACCAAGACACA AACCAAAACAAAAA AGATATGACCCTTA GCGTACAGTCTACT TTTGAAACTCCAGA AAGTGGGTGCACCG TTCCTGGAGGTACT GCAATACCAGGTCTG ATGCGTGGAGTGGA CGGAGCAAGCTCCT ATTCCATCTCCCTGC TCCAAAAATCCAGC AAGTTCAGATTTCT CTGAACTTGCTGCT ATGGCCCTGACTGGAA (SEQ ID NO: 352)
U1 SNRNA 3' BOX	GTTTCAAAAGTAGACTGTAC GCTAAGGGTCATATCTTTTTT TGTTTGTTTGTGTCTTGGTT GGCGTCTTAAA (SEQ ID NO: 353)	RESULTS IN RETENTION OF RNA IN NUCLEUS AND TRANSCRIPT TERMINATION	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <u>GTATATCTTTAAGACG</u> CCAACCAAGACACA AACCAAAACAAAAA AGATATGACCCTTA GCGTACAGTCTACT

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
			TTTGAAACCTATGGC CCTGACTGGAA (SEQ ID NO: 354)
TRNA-LYSINE	GCCCGGCTAGCTCAGTCGGT AGAGCATGAGACTCTTAATC TCAGGGTCGTGGGTTTCGAGC CCCACGTTGGGCG (SEQ ID NO: 355)	REPORTED TO ENABLE TRANSPORT OF RNA TO MITOCHONDRI A	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <u>GTATATC</u> CGCCCAACGTGGGG CTCGAACCACGAC CCTGAGATTAAGAG TCTCATGCTCTACC GACTGAGCTAGCCG GGCCTATGGCCCTGA CTGGAA (SEQ ID NO: 356)
BROCCOLI APTAMER	GAGACGGTCGGGTCCAGATA TTCGTATCTGTGAGTAGAG TGTGGGCTC (SEQ ID NO: 357)	VISUALIZATIO N (FLUORESCEN CE)	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <u>GTATATCGAGCCCAC</u> ACTCTACTCGACAG ATACGAATATCTGGA CCCGACCGTCTCCT ATGGCCCTGACTGGAA (SEQ ID NO: 358)
SPINACH APTAMER	GACGCAACTGAATGAAATGG TGAAGGACGGGTCCAGGTG TGGCTGCTTCGGCAGTGCAG CTTGTTGAGTAGAGTGTGAG CTCCGTAAGTAGTCGCGTC (SEQ ID NO: 359)	VISUALIZATIO N (FLUORESCEN CE)	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <u>GTATATCGACGCGAC</u> TAGTTACGGAGCTC ACACTCTACTCAAC AAGCTGCACTGCCG AAGCAGCCACACCT GGACCCGTCCTTCA CCATTTCAATTCAGTT GCGTCCTATGGCCCT GACTGGAA

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
			(SEQ ID NO: 360)
SPINACH2 APTAMER	GATGTAAGTGAATGAAATGG TGAAGGACGGGTCCAGTAG GCTGCTTCGGCAGCCTACTT GTTGAGTAGAGTGTGAGCTC CGTAACTAGTTACATC (SEQ ID NO: 361)	VISUALIZATIO N (FLUORESCEN CE)	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <u>GTATATCGATGTAAC</u> <u>AGTTACGGAGCTCA</u> <u>CACTCTACTCAACA</u> <u>AGTAGGCTGCCGAA</u> <u>GCAGCCTACTGGAC</u> <u>CCGTCCTTCACCAT</u> <u>TTCATTCAGTTACAT</u> <u>CCTATGGCCCTGACTG</u> <u>GAA</u> (SEQ ID NO: 362)
MANGO APTAMER	GGCACGTACGAAGGGACGG TGCGGAGAGGAGAGTACGT GC (SEQ ID NO: 363)	VISUALIZATIO N (FLUORESCEN CE)	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <u>GTATATCGCACGTAC</u> <u>TCTCCTCTCCGCAC</u> <u>CGTCCCTTCGTACG</u> <u>TGCCCTATGGCCCTG</u> <u>ACTGGAA</u> (SEQ ID NO: 364)
HDV RIBOZYME	GGCCGGCATGGTCCCAGCCT CCTCGCTGGCGCCGGCTGGG CAACATGCTTCGGCATGGCG AATGGGAC (SEQ ID NO: 365)	3' END RNA PROCESSING	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC <u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <u>GTATATCGTCCCATTC</u> <u>GCCATGCCGAAGCA</u> <u>TGTTGCCCAGCCGG</u> <u>CGCCAGCGAGGAG</u> <u>GCTGGGACCATGCC</u> <u>GGCCCTATGGCCCTG</u> <u>ACTGGAA</u> (SEQ ID NO: 366)
N ⁶ - METHYLADEN	GG <u>ACT</u> CTAGG <u>ACT</u> GG <u>ACT</u> TTT GG <u>ACT</u> (SEQ ID NO: 367)	TARGET FOR METHYLATION	ATCCTTCCAGTCAGG GCCATGTTTGAGAGC

RNA MOTIF	SEQUENCE OF RNA MOTIF	FUNCTION/ EFFECT	EXEMPLARY PEGRNA FOR PRIME EDITING INSERTION OF RNA MOTIF INTO THE EXEMPLARY HEXA GENE*
OSINE MARKER (M ⁶ A)		(UNDERLINED A'S ARE METHYLATED) . M6A METHYLATION CAN RESULT IN ENHANCED RNA STABILITY AND EXPRESSION, BUT IS NOT YET FULLY UNDERSTOOD	<u>TAGAAATAGCAAGTT</u> <u>TAAATAAGGCTAGTC</u> <u>CGTTATCAACTTGAA</u> <u>AAAGTGGGACCGAG</u> <u>TCGGTCCACCTGAACC</u> <i>GTATATCAGTCCAAA</i> GTCCAGTCCTAGAG TCCCTATGGCCCTGA <i>CTGGAA</i> (SEQ ID NO: 368)

* each PEGRNA is shown in the 5' to 3' direction and has the following structural elements of FIG. 3F as designated by font type, as follows: 5' – spacer sequence (normal font) – gRNA core (underlined sequence) – homology arm (italicized) – RT template (bolded font) – primer binding site (italicized) – 3'.

[0784] The PEGRNAs of the above table are designed to site-specifically insert examples of the above motifs into the *HEXA* gene (defective in Tay-Sachs disease) (e.g., GenBank No. KR710351.1 (SEQ ID NO: 369), however, this is only for purposes of illustration. The use of prime editing in RNA tagging is not limited to the *HEXA* gene and indeed may be any any. The *HEXA* mRNA has the following nucleotide sequence:

GTTCGTTGCAACAAATTGATGAGCAATGCTTTTTTATAATGCCAACTTTGTACAAAAAAGT
TGGCATGACAAGTTCCAGGCTTTGGTTTTCGCTGCTGCTGGCGGCAGCGTTCGCAGGACG
GGCGACGGCCCTCTGGCCCTGGCCTCAGAACTTCCAAACCTCCGACCAGCGCTACGTCCT
TTACCCGAACAACCTTTCAATTCCAGTACGATGTCAGCTCGGCCGCGCAGCCCGGCTGCTCA
GTCCTCGACGAGGCCTTCCAGCGCTATCGTGACCTGCTTTTCGGTTCCGGGTCTTGCCCC
GTCCTTACCTCACAGGGAAACGGCATACTGGAGAAGAATGTGTTGGTTGTCTCTGTAG
TCACACCTGGATGTAACCAGCTTCCTACTTTGGAGTCAGTGGAGAATTATACCCTGACCAT
AAATGATGACCAGTGTTTACTCCTCTCTGAGACTGTCTGGGGAGCTCTCCGAGGTCTGGA
GACTTTTAGCCAGCTTGTTTGAAATCTGCTGAGGGCACATTCTTTATCAACAAGACTGAG
ATTGAGGACTTTCCCCGCTTTCCTACCGGGGCTTGCTGTTGGATACATCTCGCCATTACCT
GCCACTCTCTAGCATCCTGGACACTCTGGATGTCATGGCGTACAATAAATTGAACGTGTTC
CACTGGCATCTGGTAGATGATCCTTCCTTCCCATATGAGAGCTTCACTTTTCCAGAGCTCAT
GAGAAAGGGGTCCTACAACCCTGTACCCACATCTACACAGCACAGGATGTGAAGGAGG
TCATTGAATACGCACGGCTCCGGGGTATCCGTGTGCTTGACAGAGTTTGACACTCCTGGCCA
CACTTTGTCTGTTGGGACCAGGTATCCCTGGATTACTGACTCCTTGCTACCCTGGGTCTGAG

CCCTCTGGCACCTTTGGACCAGTGAATCCCAGTCTCAATAATACCTATGAGTTCATGAGCA
 CATTCTTCTTAGAAGTCAGCTCTGTCTTCCCAGATTTTTATCTTCATCTTGGAGGAGATGAG
 GTTGATTTACCTGCTGGAAGTCCAACCCAGAGATCCAGGACTTTATGAGGAAGAAAGGC
 TTCGGTGAGGACTTCAAGCAGCTGGAGTCCTTCTACATCCAGACGCTGCTGGACATCGTCT
 CTTCTTATGGCAAGGGCTATGTGGTGTGGCAGGAGGTGTTTGATAATAAAGTAAAGATTCA
 GCCAGACACAATCATAAGGTGTGGCGAGAGGATATTCCAGTGAACCTATATGAAGGAGCT
 GGAAGTGGTCACCAAGGCCGGCTTCCGGGCCCTTCTCTCTGCCCCCTGGTACCTGAACCG
 TATATCCTATGGCCCTGACTGGAAGGATTTCTACGTAGTGGAACCCCTGGCATTGAAGGTA
 CCCCTGAGCAGAAGGCTCTGGTGATTGGTGGAGAGGCTTGTATGTGGGGAGAATATGTGG
 ACAACACAAACCTGGTCCCCAGGCTCTGGCCCAGAGCAGGGGCTGTTGCCGAAAGGCTG
 TGGAGCAACAAGTTGACATCTGACCTGACATTTGCCTATGAACGTTTGTACACTTCCGCT
 GTGAGTTGCTGAGGCGAGGTGTCCAGGCCCAACCCCTCAATGTAGGCTTCTGTGAGCAGG
 AG
 TTTGAACAGACCTGCCCAACTTTCTTGTACAAAGTTGGCATTATAAGAAAGCATTGCTTAT
 CAATTTGTTGCAACGAAC (SEQ ID NO: 369).

[0785] The corresponding HEXA protein has the following amino acid sequence:

MTSSRLWFSLLLAFAFRATALWPWPQNFQTSQRYVLYPNNFQFYDVSSAAQPGCSVL
 DEAFQRYRDLLFGSGSWPRPYLTGKRHTLEKNVLVSVVTPGCNQLPTLESVENYTLTINDD
 QCLLLSETVWGALRGLETFSQLVWKSAGTFFINKTEIEDFPRFPHRGLLLDTSRHYLPSSIL
 DTLDMAYNKLNVFHWHLVDDPSFPYESFTPELMRKGSYNPVTHIYTAQDVKEVIEYARLR
 GIRVLAEFDTPGHTLSWGPPIGLLTPCYPGSEPSGTFGPVNPSLNNTYEFMSTFFLEVSSVFPD
 FYLHLGGDEVDFTCWKSNIQDFMRKKGFGEDEFKQLESFYIQTLLDIVSSYGKGYVWQEV
 FDNKVKIQPDTHIQVWREDIPVNYMKELELVTKAGFRALLSAPWYLNRIYGPDWKDFYVVE
 PLAFEGTPEQKALVIGGEACMWGEYVDNTNLVPRLWPRAGAVAERLWSNKLTSDLTFAYERL
 SHFRCELLRRGVQAQPLNVGFCEQEFEQT (SEQ ID NO: 370).

[0786] Notably, the resulting RNA motifs would be included within the translated region of the *HEXA* gene, disrupting the function of the protein coding gene. Inserted polyadenylation motifs would result in premature transcript termination. This site is merely illustrative of the potential PEgRNAs that could result in insertion of the listed RNA motifs of the above table within a genomic site that is transcribed and thus which would produce an RNA product.

[0787] PEgRNAs for use with PE for RNA tagging could be expressed from a U6 promoter (in which case a single guanosine would be added to the 5' end of the PEgRNA for guides that include protospacers that do not begin with a G and 6-7 thymine would be added to the 3' end) or a pol II promoter such as pCMV (in which case it might be necessary to remove the intrinsically transcribed sequence of this promoter from the 5' end of the RNA via a self-cleaving element or Csy4 motif, and a termination motif would need to be added to the 3' end of the RNA that does not result in export of

the RNA from the nucleus, such as the 3' box motif listed above. Note that this motif would *not* be inserted into the genome as a result of PE, as it would be 3' of the annealing region). The core PEgRNA scaffold is underlined, the homology and annealing regions are italicized, and the inserted sequence is bolded. Note that the sequence inserted is the reverse complement of the above examples – as described below and therefore these PEgRNAs would need to be targeted to the coding strand.

[0788] Also, note that self-cleaving ribozymes other than HDV need in some embodiments to be tailored to the given target site; that is, while HDV cleaves the encoded transcript immediately 5' to itself, the cut sites for all other self-cleaving ribozymes are within the ribozyme itself. Therefore, the first and last roughly 5-10 nucleotides (and in some instances potentially more than 10) would actually be a part of the encoded sequence. As an example, to cleave the sequence 5'NNNNNTCATCCTGATAAACTGCAAA3' (SEQ ID NO: 371) after the 5 Ns, where N is any nucleotide, using a hammerhead self-cleaving ribozyme, the following sequence would be inserted, where the underlined sequences form an imperfect RNA pairing element.

[0789] 5'NNNNNCAGTTTGTACGGATGACTGATGAGTCCCAAATAGGACGAAACGCGCTTC GGTGCGTCTCATCCTGATAAACTGCAAA-3' (SEQ ID NO: 372).

[0790] There is significant flexibility in terms of the length and nature of this pairing element, and this would be true for any of the non-HDV self-cleaving ribozymes listed in the original submission. To install a hammerhead ribozyme to cleave the hexA mRNA using a PEgRNA with the same protospacer as the above listed constructs, the following PEgRNA sequence could be used (labels same as above):

[0791] 5'ACCTGAACCGTATATCGACGCACCGAAGCGCGTTTCGTCCTATTTGGGACTCATC AGGATATACGGTTCAGGTGATATACGGTTCAGGTGACGCACCGAAGCGCGTTTCGTCCTAT TTGGGACTCATCAGACCTGAACCGTATATCATCCTTCCAGTCAGGGCCATGTTTGAGAGCT AGAAATAGCAAGTTTAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGGACCGAGTC GGTCCACCTGAACCGTATATCGACGCACCGAAGCGCGTTTCGTCCTATTTGGGACTCA **TCAGGATATACGGTTCAGGTCTATGGCCCTGACTGGAA-3'** (wherein the core PEgRNA scaffold is underlined, the homology and annealing regions are italicized, and the inserted sequence is bolded) (SEQ ID NO: 373).

[0792] Designing other PEgRNA for insertion of RNA motifs may follow the general principle described herein. However, it is noted that many of RNA motifs are potentially highly structured, which could make it difficult for them to be reverse-transcribed and inserted into the genome. Although for some RNA sequences, such as simple hairpins, both the RNA sequence itself and its complement are structured. However, that is unlikely to be true for the sequences noted above. Therefore, when inserting these motifs, it would most likely be best for the PEgRNA to encode the reverse complement of these sequences, resulting in the insertion of the DNA sequence actually encoding the motif into the genome. Similarly, inclusion of a self-cleaving ribozyme in the PEgRNA

template region would result in processing and inefficient activity, while inclusion of its reverse complement would not. Thus, these PEGRNAs will likely have to target the coding strand, whereas PEGRNAs encoding other types of insertions (such as therapeutic correction) would be able to theoretically target either strand.

[0793] Also, note that for many of the inserted motifs, the resulting PEGRNA might not be able to be transcribed from the U6 promoter, necessitating use of other promoters, such as pCMV. Similarly, longer PEGRNAs could also be less stable. Shorter motifs, such as m⁶A markers, would not have this challenge.

D. Use of dual prime editing for insertion of immunopeptides

[0794] Dual prime editing (e.g., such as the embodiment shown in FIG. 90) may also be used as a means to insert known immunogenicity epitopes into endogenous or foreign genomic DNA, resulting in modification of the corresponding proteins for therapeutic or biotechnological applications (see FIGs. 31 and 32). Prior to the invention of classical prime editing or dual prime editing, such insertions could be achieved only inefficiently and with high rates of indel formation from DSBs. prime editing solves the problem of high indel formation from insertion edits while generally offering higher efficiency than HDR. This lower rate of indel formation presents a major advantage of prime editing over HDR as a method for targeted DNA insertions, especially in the described application of inserting immunogenicity epitopes. The length of epitopes is in a range from few bases to hundreds of bases. Prime editor is an efficient approach to achieve such targeted insertions in mammalian cells.

[0795] The key concept of the invention is the use of dual prime editors to insert a nucleotide sequence containing previously described immunogenicity epitopes into endogenous or foreign genomic DNA for the downregulation and/or destruction of their protein products and/or expressing cell types. Nucleotide sequences for immunogenic epitope insertion would be targeted to genes in a manner to produce fusion proteins of the targeted gene's coded protein and the inserted immunogenic epitope's corresponding protein translation. Patient's immune systems will have been previously trained to recognize these epitopes as a result of standard prior immunization from routine vaccination against, for example, tetanus or diphtheria or measles. As a result of the immunogenic nature of the fused epitopes, patient's immune systems would be expected to recognize and disable the prime edited protein (not just the inserted epitope) and potentially the cells from which it was expressed.

[0796] Precise genome targeting technologies using the CRISPR/Cas system have recently been explored in a wide range of applications, including the insertion of engineered DNA sequences into targeted genomic loci. Previously, homology-directed repair (HDR) has been used for this application, requiring an ssDNA donor template and repair initiation by means of a double-stranded DNA break (DSB). This strategy offers the broadest range of possible changes to be made in cells and is the only method available to insert large DNA sequences into mammalian cells. However, HDR is hampered by undesired cellular side effects stemming from its initiating DSB, such as high levels of indel

formation, DNA translocations, large deletions, and P53 activation. In addition to these drawbacks, HDR is limited by low efficiency in many cell types (T cells are a notable exception to this observation). Recent efforts to overcome these drawbacks include fusing human Rad51 mutants to a Cas9 D10A nickase (RDN), resulting in a DSB-free HDR system that features improved HDR product:indel ratios and lower off target editing, but is still hampered by cell-type dependencies and only modest HDR editing efficiency.

[0797] Recently developed fusions of Cas9 to reverse transcriptases (“Prime editors”) coupled with PEGRNAs represent a novel genome editing technology that offers a number of advantages over existing genome editing methods, including the ability to install any single nucleotide substitution, and to insert or delete any short stretch of nucleotides (up to at least several dozen bases) in a site-specific manner. Notably, PE edits are achieved with generally low rates of unintended indels. As such, PE enables targeted insertion-based editing applications that have been previously impossible or impractical.

[0798] This particular aspect describes a method for using prime editing as a means to insert known immunogenicity epitopes into endogenous or foreign genomic DNA, resulting in modification of the corresponding proteins for therapeutic or biotechnological applications (see FIGs. 31 and 32). Prior to the invention of prime editing, such insertions could be achieved only inefficiently and with high rates of indel formation from DSBs. prime editing solves the problem of high indel formation from insertion edits while generally offering higher efficiency than HDR. This lower rate of indel formation presents a major advantage of prime editing over HDR as a method for targeted DNA insertions, especially in the described application of inserting immunogenicity epitopes. The length of epitopes is in a range from few bases to hundreds of bases. Prime editor is the most efficient and cleanest technology to achieve such targeted insertions in mammalian cells.

[0799] The key concept of this aspect is the use of prime editors to insert a nucleotide sequence containing previously described immunogenicity epitopes into endogenous or foreign genomic DNA for the downregulation and/or destruction of their protein products and/or expressing cell types. Nucleotide sequences for immunogenic epitope insertion would be targeted to genes in a manner to produce fusion proteins of the targeted gene’s coded protein and the inserted immunogenic epitope’s corresponding protein translation. Patient’s immune systems will have been previously trained to recognize these epitopes as a result of standard prior immunization from routine vaccination against, for example, tetanus or diphtheria or measles. As a result of the immunogenic nature of the fused epitopes, patient’s immune systems would be expected to recognize and disable the prime edited protein (not just the inserted epitope) and potentially the cells from which it was expressed.

[0800] Fusions to targeted genes would be engineered as needed to ensure the inserted epitope protein translation is exposed for immune system recognition. This could include targeted nucleotide insertions resulting in protein translations yielding C-terminal fusions of immunogenicity epitopes to

targeted genes, N-terminal fusions of immunogenicity epitopes to targeted genes, or the insertion of nucleotides into genes so that immunogenicity epitopes are coded within surfaced-exposed regions of protein structure.

[0801] Protein linkers encoded as nucleotides inserted between the target gene sequence and the inserted immunogenicity epitope nucleotide sequence may need to be engineered as part of this invention to facilitate immune system recognition, cellular trafficking, protein function, or protein folding of the targeted gene. These inserted nucleotide-encoded protein linkers may include (but are not limited to) variable lengths and sequences of the XTEN linker or variable lengths and sequences of Glycine-Serine linkers. These engineered linkers have been previously used to successfully facilitate protein fusions. Exemplary linkers may include any of those described herein, including the amino acid sequence (GGGGS)_n (SEQ ID NO: 165), (G)_n (SEQ ID NO: 166), (EAAAK)_n (SEQ ID NO: 167), (GGG)_n (SEQ ID NO: 168), (SGGS)_n (SEQ ID NO: 169), (XP)_n (SEQ ID NO: 170), or any combination thereof, wherein n is independently an integer between 1 and 30, and wherein X is any amino acid. In some embodiments, the linker comprises the amino acid sequence (GGG)_n (SEQ ID NO: 176), wherein n is 1, 3, or 7. In some embodiments, the linker comprises the amino acid sequence SGSETPGTSESATPES (SEQ ID NO: 171). In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPESGGSSGGGS (SEQ ID NO: 172). In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGGGS (SEQ ID NO: 173). In some embodiments, the linker comprises the amino acid sequence SGGGS (SEQ ID NO: 174).

[0802] Distinguishing features of this aspect include the ability to use previously acquired immune responses to specific amino acid sequences as a means to induce an immune response against otherwise non-immunogenic proteins. Another distinguishing feature is the ability to insert the nucleotide sequences of these immunogenic epitopes in a targeted manner that does not induce high levels of unwanted indels as a by-product of editing and is efficient in its insertion. This specific application of PE has the ability to combine cell type-specific delivery methods (such as AAV serotypes) to insert epitopes in cell types that are of interest to trigger an immune response to.

[0803] Prime editing as a means of inserting immunogenic epitopes into pathogenic genes could be used to program the patient's immune system to fight a wide variety of diseases (not limited to cancer as with immuno-oncology strategies). An immediately relevant use of this technology would be as a cancer therapeutic as it could undermine a tumor's immune escape mechanism by causing an immune response to a relevant oncogene like HER2 or growth factors like EGFR. Such an approach could seem similar to T-cell engineering, but one novel advance of this approach is that it can be utilized in many cell types and for diseases beyond cancer, without needing to generate and introduce engineered T-cells into patients.

[0804] Using PE to insert an immunogenicity epitope which most people are already vaccinated against (tetanus, pertussis, diphtheria, measles, mumps, rubella, etc.) into a foreign or endogenous gene that drives a disease, so the patient's immune system learns to disable that protein.

[0805] Diseases that stand to have a potential therapeutic benefit from the aforementioned strategy include those caused by aggregation of toxic proteins, such as in fatal familial insomnia. Other diseases that could benefit include those caused by pathogenic overexpression of an otherwise nontoxic endogenous protein, and those caused by foreign pathogens.

[0806] Primary therapeutic indications include those mentioned above such as therapeutics for cancer, prion and other neurodegenerative diseases, infectious diseases, and preventative medicine. Secondary therapeutic indications may include preventative care for patients with late-onset genetic diseases. It is expected that current standard of care medicines may be used in conjunction with prime editing for some diseases, like particularly aggressive cancers, or in cases where medications help alleviate disease symptoms until the disease completely cured. Below are examples of immunoepitopes that may be inserted into genes by the herein disclosed prime editors:

VACCIN E	DISEASE	EPITOPE AMINO ACID SEQUENCE	EXAMPLE NUCLEIC ACID SEQUENCE (8)
1	TETANUS TOXOID	QYIKANSKFIGITEL (SEQ ID NO: 396)	CATGATATAAAAGCAAATTCTAAATTTATA GGTATAACTGAACTA (SEQ ID NO: 397)
2	DIPHTE RIN A TOXIN MUTANT CRM197	GADDVVDSSKSFV MENFSSYHGTPKPG YVDSIQKGIQPKPS GTQGNYYDDDWKEF YSTDNKYDAAGYS VDNENPLSGKAGG VVKVTYPGLTKVL ALKVDNAETIKKEL GLSLTEPLMEQVGT EEFIKRFGDGASRV VLSLPFAEGSSSVEY INNWEQAKALSVE LEINFETRGRKRGQD AMYEYMAQACAG NRVRRSVGSSLSCI NLDWDVIRDKTKT KIESLKEHGPIKNK MSESPNKTVSEEKA KQYLEEFHQTALEH PELSELKTVTGTNP VFAGANYAAWAVN VAQVIDSETADNLE KTTAALSILPGIGSV MGIADGAVHHNTE EIVAQSIALSSLMVA QAIPLVGELVDIGFA	GGCGCCGACGACGTGGTGGACAGCAGCA AGAGCTTCGTGATGGAGAACTTCAGCAGC TACCACGGCACCAAGCCCGGTACGTGGA CAGCATCCAGAAGGGCATCCAGAAGCCCA AGAGCGGCACCCAGGGCAACTACGACGA CGACTGGAAGGAGTTCTACAGCACCGAC AACAAGTACGACGCCGCGGTACAGCGT GGACAACGAGAACCCCTGAGCGGCAAG GCCGGCGGCGTGGTGAAGGTGACCTACCC CGGCCTGACCAAGGTGCTGGCCCTGAAG GTGGACAACGCCGAGACCATCAAGAAGG AGCTGGGCCTGAGCCTGACCGAGCCCCTG ATGGAGCAGGTGGGCACCGAGGAGTTCAT CAAGAGGTTCCGGCAGCGGCCAGCAGG GTGGTGTGAGCCTGCCCTTCGCCGAGGG CAGCAGCAGCGTGGAGTACATCAACAAC GGGAGCAGGCCAAGGCCCTGAGCGTGA GCTGGAGATCAACTTCGAGACCAGGGGC AAGAGGGGCCAGGACGCCATGTACGAGT ACATGGCCCAGGCCTGCGCCGGCAACAG GGTGAGGAGGAGCGTGGGCAGCAGCCTG AGCTGCATCAACCTGGACTGGGACGTGAT CAGGGACAAGACCAAGACCAAGATCGAG AGCCTGAAGGAGCAGGCCCCATCAAGA ACAAGATGAGCGAGAGCCCCAACAAGAC CGTGAGCGAGGAGAAGGCCAAGCAGTAC

VACCINE	DISEASE	EPITOPE AMINO ACID SEQUENCE	EXAMPLE NUCLEIC ACID SEQUENCE (8)
		AYNFVESIINLFQVV HNSYNRPAYSPGHK TQPFLHDGYAVSW NTVEDSIIRTGFQGE SGHDIKITAENTPLP IAGVLLPTIPGKLDV NKSSTHISVNGRKI RMRCRAIDGDVTF CRPKSPVYVGNV HANLHVAFHRSSSE KIHSNEISSDSIGVL GYQKTV DHTKVNS KLSLFFEIKS (SEQ ID NO: 398)	CTGGAGGAGTTCCACCAGACCGCCCTGGA GCACCCCGAGCTGAGCGAGCTGAAGACC GTGACCGGCACCAACCCCGTGTTCGCCGG CGCCAACTACGCCGCTGGGCCGTGAACG TGGCCCAGGTGATCGACAGCGAGACCGCC GACAACCTGGAGAAGACCACCGCCGCC TGAGCATCCTGCCCGGCATCGGCAGCGTG ATGGGCATCGCCGACGGCGCCGTGCACCA CAACACCGAGGAGATCGTGGCCCAGAGC ATCGCCCTGAGCAGCCTGATGGTGGCCCA GGCCATCCCCCTGGTGGGCGAGCTGGTGG ACATCGGCTTCGCCGCCTACAACCTTCGTG GAGAGCATCATCAACCTGTTCCAGGTGGT GCAACAACAGCTACAACAGGCCCGCCTACA GCCCGGCCACAAGACCCAGCCCTTCCTG CACGACGGCTACGCCGTGAGCTGGAACA CCGTGGAGGACAGCATCATCAGGACCGGC TTCCAGGGCGAGAGCGGCCACGACATCA AGATCACCGCCGAGAACACCCCTGCCC ATCGCCGGCGTGCTGCTGCCACCATCCC CGGCAAGCTGGACGTGAACAAGAGCAAG ACCCACATCAGCGTGAACGGCAGGAAGAT CAGGATGAGGTGCAGGGCCATCGACGGC GACGTGACCTTCTGCAGGCCCAAGAGCCC CGTGTACGTGGGCAACGGCGTGACGCCA ACCTGCACGTGGCCTTCCACAGGAGCAGC AGCGAGAAGATCCACAGCAACGAGATCA GCAGCGACAGCATCGGCGTGCTGGGCTAC CAGAAGACCGTGGACCACACCAAGGTGA ACAGCAAGCTGAGCCTGTTCTTCGAGATC AAGAGC (SEQ ID NO: 399)
3	MUMPS IMMUNOEP ITOPE 1	GTYRLIPNARANLT A (SEQ ID NO: 400)	GGCACCTACAGGCTGATCCCCAACGCCAG GGCCAACCTGACCGCC (SEQ ID NO: 401)
4	MUMPS IMMUNOEP ITOPE 2 MUMPS IMMUNOEP ITOPE 1	PSKFFTISDSATFAP GPVSNA (SEQ ID NO: 402) PSKLFIMLDNATFAP GPVVNA (SEQ ID NO: 404)	CCGAGCAAATTTTTTACCATTAGCGATAGC GCGACCTTTGCGCCGGGCCCGGTGAGCAA CGCG (SEQ ID NO: 403) CCGAGCAAACCTGTTTATTATGCTGGATAAC GCGACCTTTGCGCCGGGCCCGGTGGTGAA CGCG (SEQ ID NO: 405) SELECTED EXAMPLES FROM HEMAGGLUTININ-NEURAMINIDASE (HN) DIVERSITY AMONG OUTBREAK STRAINS (TABLE1) DIVERGENCE BETWEEN VACCINE STRAIN JL5 AND OUTBREAK STRAINS (TABLE2)

VACCIN E	DISEASE	EPITOPE AMINO ACID SEQUENCE	EXAMPLE NUCLEIC ACID SEQUENCE (8)
5	RUBELLA VIRUS (RV)	TPPPYQVSCGGESD RASARVIDPAAQS (SEQ ID NO: 406)	ACCCCCCCCCCTACCAGGTGAGCTGCGG CGGCGAGAGCGACAGGGCCAGCGCCAGG GTGATCGACCCCGCCGCCAGAGC (SEQ ID NO: 407)
6	HEMAGGL UTININ	PEYAYKIVKNKKME DGFLQGMVDGWY GHHSNEQGSGLME NERTLDKANPNND LCSWSDHEASSNNT NQEDLLQRESRRK KRIGTSTLNQRGNC NTKCQTTEEARLKRE EVSLVKSDQCSNGS LQCRANNSTEQVD (SEQ ID NO: 408)	CCCGAGTACGCCTACAAGATCGTGAAGAA CAAGAAGATGGAGGACGGCTTCCTGCAG GGCATGGTGGACGGCTGGTACGGCCACCA CAGCAACGAGCAGGGCAGCGGCCTGATG GAGAACGAGAGGACCCTGGACAAGGCCA ACCCCAACAACGACCTGTGCAGCTGGAG CGACCACGAGGCCAGCAGCAACAACACC AACCAGGAGGACCTGCTGCAGAGGGAGA GCAGGAGGAAGAAGAGGATCGGCACCAG CACCTGAACCAGAGGGGGCAACTGCAAC ACCAAGTGCCAGACCGAGGAGGCCAGGC TGAAGAGGGAGGAGGTGAGCCTGGTGAA GAGCGACCAAGTGCAGCAACGGCAGCCTG CAGTGCAGGGCCAACAACAGCACCGAGC AGGTGGAC (SEQ ID NO: 409)
7	NEURAMIN IDASE	TKSTNSRSGGISGP DNEAPVGEAPSPYG DNPRPNDGNNIRIG SKGYNGIITDTIEES CSCYPDAKVVKSV ELDSTIWTSGSPN QKIITIGWDPNGWT GTPMSPNGAYGTD GPSNGQANQHQAE SISAGNSSLCPIRDN WHGSNRSWSWPD GAE (SEQ ID NO: 410)	ACCAAGAGCACCAACAGCAGGAGCGGCG GCATCAGCGGCCCCGACAACGAGGCCCCC GTGGGCGAGGCCCCCAGCCCTACGGCG ACAACCCAGGCCCAACGACGGCAACAA CATCAGGATCGGCAGCAAGGGCTACAACG GCATCATCACCGACACCATCGAGGAGAGC TGCAGCTGCTACCCCGACGCCAAGGTGGT GAAGAGCGTGGAGCTGGACAGCACCATC TGGACCAGCGGCAGCAGCCCCAACCAGA AGATCATCACCATCGGCTGGGACCCCAAC GGCTGGACCGGCACCCCATGAGCCCCAA CGGCGCTACGGCACCGACGGCCCCAGC AACGGCCAGGCCAACCAGCACCAGGCCG AGAGCATCAGCGCCGGCAACAGCAGCCT GTGCCCCATCAGGGACAACCTGGCACGGCA GCAACAGGAGCTGGAGCTGGCCCCGACGG CGCCGAG (SEQ ID NO: 411)
8	TAP1 (TRANSPOR T ANTIGEN PRESENTAT ION) ON H5N1 VIRUS HEMAGGL UTININ	EKIVLLLAMMEKIV LLLAKCQTPMGAIK AVDGVNKNCPYLG SPSF (SEQ ID NO: 412)	GAGAAGATCGTGCTGCTGCTGGCCATGAT GGAGAAGATCGTGCTGCTGCTGGCCAAGT GCCAGACCCCATGGGCGCCATCAAGGCC GTGGACGGCGTGACCAACAAGTGCCCCTA CCTGGGCAGCCCCAGCTTC (SEQ ID NO: 413)
9	TAP2	IRPCFWVELNPNQK IITIRPCFWVELICYP	ATCAGGCCCTGCTTCTGGGTGGAGCTGAA CCCCAACCAGAAGATCATCACCATCAGGC

VACCINE	DISEASE	EPITOPE AMINO ACID SEQUENCE	EXAMPLE NUCLEIC ACID SEQUENCE (8)
	(TRANSPORT ANTIGEN PRESENTATION) ON H5N1 VIRUS NEURAMINIDASE	DAGEIT (SEQ ID NO: 414)	CCTGCTTCTGGGTGGAGCTGATCTGCTAC CCCGACGCCGGCGAGATCACC (SEQ ID NO: 415)
10	HEMAGGLUTININ EPITOPES TOWARD CLASS I HLA	MEKIVLLLAEKIVLLAMCPYLGSPSPFKCQTPMGAIAVDGVTNK (SEQ ID NO: 416)	ATGGAGAAGATCGTGCTGCTGCTGGCCGA GAAGATCGTGCTGCTGCTGGCCATGTGCC CCTACCTGGGCAGCCCCAGCTTCAAGTGC CAGACCCCATGGGCGCCATCAAGGCCGT GGACGGCGTGACCAACAAG (SEQ ID NO: 417)
11	NEURAMINIDASE EPITOPES TOWARD CLASS I HLA	NPNQKIITICYPDAGEITIRPCFWVELRPCFWVELI (SEQ ID NO: 418)	AACCCCAACCAGAAGATCATCACCATCTGC TACCCCGACGCCGGCGAGATCACCATCAGG CCCTGCTTCTGGGTGGAGCTGAGGCCCTGC TTCTGGGTGGAGCTGATC (SEQ ID NO: 419)
12	HEMAGGLUTININ EPITOPES TOWARD CLASS II HLA	MVSLVKSDQIGTSTLNQR (SEQ ID NO: 420)	ATGGTGAGCCTGGTGAAGAGCGACCAGATC GGCACCAGCACCCTGAACCAGAGG (SEQ ID NO: 421)
13	NEURAMINIDASE EPITOPES TOWARD CLASS II HLA	YNGIITDTI (SEQ ID NO: 422)	TACAACGGCATCATCACCGACACCATC (SEQ ID NO: 423)
14	HEMAGGLUTININ EPITOPE H5N1-BOUND CLASS I AND CLASS II HLA	MEKIVLLLAEKIVLLLAMMVSLVKSDQCPYLGSPSFIGTSTLNQRKCQTPMGAIAVDGVTNK (SEQ ID NO: 424)	ATGGAGAAGATCGTGCTGCTGCTGGCCGAG AAGATCGTGCTGCTGCTGGCCATGATGGTG AGCCTGGTGAAGAGCGACCAGTGCCCTAC CTGGGCAGCCCCAGCTTCATCGGCACCAGC ACCCTGAACCAGAGG (SEQ ID NO: 425)
15	NEURAMINIDASE EPITOPE H5N1-BOUND	NPNQKIITIYNGIITDTICYPDAGEITIRPCFWVELRPCFWVELI (SEQ ID NO: 426)	AACCCCAACCAGAAGATCATCACCATCTAC AACGGCATCATCACCGACACCATCTGCTAC CCCGACGCCGGCGAGATCACCATCAGGCC TGCTTCTGGGTGGAGCTGAGGCCCTGCTTC TGGGTGGAGCTGATC (SEQ ID NO: 427)

VACCIN E	DISEASE	EPITOPE AMINO ACID SEQUENCE	EXAMPLE NUCLEIC ACID SEQUENCE (8)
	CLASS I AND CLASS II HLA		

[0807] Additional immunopeptides may also be installed which are known in the art. Any of the immunopeptides available from the Immune Epitope Database and Analysis Resource (iedb.org/epitopedetails_v3.php) (the contents of which are incorporated herein by reference) may be installed by the prime editors disclosed herein.

[0808] In some embodiments, the immunopeptides which may be installed by the prime editors disclosed herein may include any of the following epitopes:

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1	TETANUS TOXOID	QYIKANSKFIGITEL	396	NA
2	DIPHTHERIA TOXIN MUTANT CRM197	GADDVVDSSKSFVMENFSSYHGTPGY VDSIQKGIQPKSGTQGNYYYYWKEFYS TDNKYDAAGYSVDNENPLSGKAGGVV KVTPGLTKVLALKVDNAETIKKELGLS LTEPLMEQVGTEEFIKRFGDGASRVVLSL PFAEGSSSVEYINNWEQAKALSVELEINF ETRGKRGQDAMYEYMAQACAGNRVRR SVGSSLSCINLDWDVIRDKTKTKIESLKE HGPIKNKMSESPNKTVSEKAKQYLEEF HQTALHPSELKKTGTNPVFAGANY AAWAVNVAQVIDSETADNLEKTTAALSIL PGIGSVMGIADGAVHHNTEEIVAQSIALS SLMVAQAIPLVGELVDIGFAAYNFVESIIN LFQVVHNSYNRPAYSPGHKTQPFLHDGY AVSWNTVEDSIIRTFQGESGHDIKITAE NTPLPIAGVLLPTIPGKLDVNKSKTHISV NGRKIRMRCRAIDGDTFCRPKSPVYVG NGVHANLHVAFHRSSSEKHSNEISSDSIG VLGYQKTVTDHTKVNKSLSLFFEIKS	428	NA
3	MUMPS	GTYRLIPNARANLTA	400	NA
4	MUMPS	PSKFFTISDSATFAPGPVSNA; PSKLFIMLDNATFAPGPVVNA	402; 404	NA
5	RUBELLA VIRUS (RV)	TPPPYQVSCGESDRASARVIDPAAQS	406	NA
6	HEMAGGLUTININ	PEYAYKIVKNKKMEDGFLQGMVDGWY GHHSNEQGSGLMENERTLDKANPNNDL CSWSDHEASSNNTNQEDLLQRESRRKK RIGTSTLNQRGNCNTKCQTTEARLKREE VSLVKSDQCSNGSLQCRANNSTEQVD	408	NA
7	NEURAMINIDASE	TKSTNSRSGGISGPDNEAPVGEAPSPYGD NPRPNDGNNIRIGSKGYNGIITDIEESCS CYPDAKVVKSVELDSTIWTSGSSPNQKII TIGWDPNGWTGTMPSPNGAYGTDGPSN	410	NA

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
		GQANQHQAESISAGNSSLCPIRDNWHGS NRSWSWPDGAE		
8	TAP (TRANSPORT ANTIGEN PRESENTATION) ON H5N1 VIRUS HEMAGGLUTININ	EKIVLLLAMMEKIVLLLAKCQTPMGAIK AVDGVTNKCPYLGSPSF	412	NA
9	TAP (TRANSPORT ANTIGEN PRESENTATION) ON H5N1 VIRUS NEURAMINIDASE	IRPCFWVELNPNQKIITIRPCFWVELICYP DAGEIT	414	NA
10	HEMAGGLUTININ EPITOPES TOWARD CLASS I HLA	MEKIVLLLAEKIVLLLAMCPYLGSPSFKC QTPMGAIKAVDGVTNK	416	NA
11	NEURAMINIDASE EPITOPES TOWARD CLASS I HLA	NPNQKIITICYPDAGEITIRPCFWVELRPC FWVELI	418	NA
12	HEMAGGLUTININ EPITOPES TOWARD CLASS II HLA	MVSLVKSDQIGTSTLNQR	420	NA
13	NEURAMINIDASE EPITOPES TOWARD CLASS II HLA	YNGIITDTI	422	NA
14	HEMAGGLUTININ EPITOPE H5N1-BOUND CLASS I AND CLASS II HLA	MEKIVLLLAEKIVLLLAMMVSLVKSDQC PYLGSPSFIGTSTLNQRKCQTPMGAIKAV DGVTNK	424	NA
15	NEURAMINIDASE EPITOPE H5N1-BOUND CLASS I AND CLASS II HLA	NPNQKIITIYNGIITDTICYPDAGEITIRPCF WVELRPCFWVELI	426	NA
16	CORYNEBACTERIUM DIPHTHERIAE	AACAGNRVRRSVGSSLKC	899	SRC28029 2
17	MEASLES VIRUS STRAIN EDMONSTON	AADHCPVVEVNGVTI	900	P69353.1
18	MEASLES VIRUS STRAIN EDMONSTON	AAHLPTGTPLDID	901	P04851.1
19	BORDETELLA PERTUSSIS	AALAVWAGLAVQ	902	Q00879.1
20	MEASLES VIRUS STRAIN EDMONSTON	AALGVATAAQITAGI	903	P69353.1
21	RUBELLA VIRUS STRAIN THERIEN	AALLNTPPPYQVSCGGESDRATAR	904	P07566.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
22	RUBELLA VIRUS	AAQSFTGVVYGTHTT	905	BAA28178.1
23	RUBELLA VIRUS	ACEVEPAFGHSDAAC	906	BAA28178.1
24	RUBELLA VIRUS	ACTFWAVNAYSSGGY	907	BAA28178.1
25	RUBELLA VIRUS	ADDPLLR	908	BAA19893.1
26	RUBELLA VIRUS	ADDPLLRT	909	CAJ88851.1
27	MEASLES VIRUS STRAIN EDMONSTON	AEMICDIDTYIVEAG	910	P04851.1
28	MEASLES VIRUS STRAIN EDMONSTON	AEMICDIDTYIVEAGLASFI	911	P04851.1
29	MEASLES VIRUS STRAIN EDMONSTON	AEPLLSC	912	P04851.1
30	BORDETELLA PERTUSSIS	AFVSTSSRRYTEVY	913	CAD44970.1
31	BORDETELLA PERTUSSIS	AGFIYRETFCTITTYKTGQPAADHYYSKVTA	914	P04979.1
32	RUBELLA VIRUS	AGLLACCAKCLYYLR	915	BAA28178.1
33	RUBELLA VIRUS	AHTTSDPWHPG	916	BAA19893.1
34	MEASLES VIRUS STRAIN EDMONSTON	AIAKLEDAKELLESS	917	P69353.1
35	MEASLES VIRUS STRAIN EDMONSTON	AIDNLRASLETTNQA	918	P69353.1
36	BORDETELLA PERTUSSIS	AKGVEFR	919	ACI16088.1
37	MEASLES VIRUS STRAIN EDMONSTON	AKWAVPTTRTDDKLR	920	P08362.1
38	MEASLES VIRUS STRAIN EDMONSTON	ALAEVLKKPV	921	ABO69699.1
39	MEASLES VIRUS STRAIN EDMONSTON	ALGVINTLEWIPRFK	922	P08362.1
40	MEASLES VIRUS STRAIN EDMONSTON	ALHQSMLENSQAIDNL	923	P69353.1
41	MEASLES VIRUS STRAIN EDMONSTON	ALIGILSLFV	924	ABI54110.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
42	RUBELLA VIRUS	ALLNTPPPYQVSCGGESDRA	925	CAJ88851.1
43	RUBELLA VIRUS STRAIN M33	ALLNTPPPYQVSCGGESDRASARV	926	CAJ88851.1
44	RUBELLA VIRUS	ALVEGLAPGGGNCHL	927	BAA28178.1
45	BORDETELLA PERTUSSIS	AMAAWSERAGEA	928	P04977.1
46	MEASLES VIRUS STRAIN EDMONSTON	ANCASILCKCYTTGT	929	P69353.1
47	BORDETELLA PERTUSSIS	ANPNPYTSRRSV	930	P04977.1
48	RUBELLA VIRUS	APGPGEVW	931	CAJ88851.1
49	RUBELLA VIRUS	APLPHTTERIETRSARHPWRIR	932	ABD64214.1
50	RUBELLA VIRUS VACCINE STRAIN RA27/3	APPMPPQPPRAHGQHYGHHHHQLPFLG	933	CAA33016.1
51	RUBELLA VIRUS STRAIN THERIEN	APPTLPQPPCAHGQHYGHHHHQLPFLG	934	P07566.1
52	RUBELLA VIRUS	APPTLPQPPRAHGQHYGHHHHQLPFLG	935	ABD64214.1
53	BORDETELLA PERTUSSIS	APQPGPQPPQPPQPEAPAPQ	936	P14283.3
54	RUBELLA VIRUS	AQLASYFNPGGSYK	937	BAA28178.1
55	MEASLES VIRUS STRAIN EDMONSTON	ARAAHLPTGTPLD	938	P04851.1
56	MEASLES VIRUS STRAIN EDMONSTON	ARLVSEIAMHTTEDK	939	P04851.1
57	MEASLES VIRUS STRAIN EDMONSTON	ARLVSEIAMHTTEDKISRAV	940	P04851.1
58	MEASLES VIRUS STRAIN EDMONSTON-B	ASDVETAEGGEIHELLR	941	P03422.1
59	MEASLES MORBILLIVIRUS	ASDVETAEGGEIHELLRLQ	942	ABO69699.1
60	MEASLES VIRUS STRAIN EDMONSTON-B	ASDVETAEGGEIHELLRLQSR	943	P03422.1
61	MEASLES MORBILLIVIRUS	ASDVETAEGGEIHKLLRLQ	944	AAA63285.1
62	RUBELLA VIRUS STRAIN M33	ASDVLPQHWLQG	945	NP_740663.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
63	MEASLES VIRUS STRAIN EDMONSTON	ASELGITAEDARLVS	946	P04851.1
64	MEASLES VIRUS STRAIN EDMONSTON	ASELGITAEDARLVSEIAMH	947	P04851.1
65	MEASLES VIRUS STRAIN EDMONSTON	ASESSQDPQDSRR	948	P04851.1
66	MEASLES VIRUS STRAIN EDMONSTON	ASILCKCYTTGTIIN	949	P69353.1
67	RUBELLA VIRUS	ASPVCQRHSPDCSRL	950	BAA28178.1
68	BORDETELLA PERTUSSIS	ASQARWTGATRA	951	BAF35031.1
69	RUBELLA VIRUS STRAIN THERIEN	ASYFNPGGSYKQYHPTACEVEPAFGHS	952	P07566.1
70	MEASLES VIRUS STRAIN EDMONSTON	ASYKVMTRSSHQSLV	953	P69353.1
71	BORDETELLA PERTUSSIS	ASYVKKPKEDVD	954	ACI16088.1
72	MEASLES VIRUS STRAIN EDMONSTON	ATAAQITAGIALHQS	955	P69353.1
73	RUBELLA VIRUS	ATPERPRL	956	CAJ88851.1
74	MEASLES VIRUS STRAIN EDMONSTON	AVCLGGLIGIPALIC	957	P69353.1
75	MEASLES VIRUS STRAIN EDMONSTON	AVGPRQAQVSF	958	P04851.1
76	RUBELLA VIRUS	AVNAYSSGGYAQLAS	959	BAA28178.1
77	RUBELLA VIRUS	AVSETRQTWAEWAAA	960	BAA28178.1
78	MEASLES VIRUS STRAIN EDMONSTON	AVTAPDTAADSELRR	961	P04851.1
79	MEASLES VIRUS STRAIN EDMONSTON	AVTAPDTAADSELRRWIKYT	962	P04851.1
80	BORDETELLA PERTUSSIS	AYGGIIKDAPPGAGFIYRETFC	963	P04979.1
81	RUBELLA VIRUS	CALPLAGLLACCAKC	964	BAA28178.1
82	RUBELLA VIRUS	CARIWNGTQRACTFW	965	BAA28178.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
83	MEASLES VIRUS STRAIN EDMONSTON	CARTLVSGSFGNRFI	966	P69353.1
84	BORDETELLA PERTUSSIS	CASPYEGRYRDMYDALRBRLLY	967	SRC280066
85	BORDETELLA PERTUSSIS	CAVFRSGQPVIGA	968	AAA83981.1
86	RUBELLA VIRUS	CCAKCLYYLRGAIAPR	969	BAA28178.1
87	MEASLES VIRUS STRAIN EDMONSTON	CCRGRCNKKGEQVGM	970	P69353.1
88	RUBELLA VIRUS	CEIPTDVSCEGLGAW	971	BAA28178.1
89	BORDETELLA PERTUSSIS	CFGKDLKRPSSPMEV	972	P0A3R5.1
90	MEASLES MORBILLIVIRUS	CFQQACKGKIQUALCE	973	P06830.1
91	MEASLES MORBILLIVIRUS	CFQQACKGKIQUALCENPEWAPLKDNRIPS	974	AAR89413.1
92	RUBELLA VIRUS	CGGESDRASARVIDP	975	BAA28178.1
93	BORDETELLA PERTUSSIS	CITTIYKTGQPAADHYYSKVTA	976	P04979.1
94	MEASLES MORBILLIVIRUS	CKGKIQUALCENPEWA	977	AAR89413.1
95	MEASLES VIRUS STRAIN EDMONSTON	CKPWQESRKNKAQ	978	P04851.1
96	MEASLES VIRUS STRAIN EDMONSTON	CNKKGEQVGMSRPGL	979	P69353.1
97	RUBELLA VIRUS	CNVTTEHPFCNTPHG	980	BAA28178.1
98	BORDETELLA PERTUSSIS	CQVGSSNSAF	981	P04977.1
99	MEASLES MORBILLIVIRUS	CSGPTTIRGQFS	982	P08362.1
100	BORDETELLA PERTUSSIS	CTSPYDGKYWSMYSRL	983	AAA83981.1
101	MEASLES VIRUS STRAIN EDMONSTON	CVLADSESGGHITHS	984	P08362.1
102	MEASLES MORBILLIVIRUS	CYTTGTIINQDPDKILTYIAADHC	985	AAF02706.1
103	RUBELLA VIRUS	DADDPLLR	986	CAJ88851.1
104	MEASLES VIRUS STRAIN EDMONSTON	DARAAHLPTGTPLDI	987	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
105	MEASLES VIRUS STRAIN EDMONSTON	DARAAHLPTGTPLDIDTASE	988	P04851.1
106	MEASLES VIRUS STRAIN EDMONSTON	DCHAPTYLPAEVDGD	989	P08362.1
107	RUBELLA VIRUS	DCSRLVGATPERPRL	990	BAA28178.1
108	MEASLES VIRUS STRAIN EDMONSTON	DDKLRMETCFQQACK	991	P08362.1
109	RUBELLA VIRUS	DDPLLRTA	992	CAJ88851.1
110	RUBELLA VIRUS	DDPLLRTAPGPGEVW	993	BAA28178.1
111	BORDETELLA PERTUSSIS	DDPPATVYRYD	994	P04977.1
112	BORDETELLA PERTUSSIS	DDPPATVYRYDSRPPED	995	CAD44970.1
113	BORDETELLA PERTUSSIS	DDPPATVYRYDSRPPEDV	996	ACI04548.1
114	MEASLES MORBILLIVIRUS	DEVGLRTPQRFTDLV	997	P06830.1
115	MEASLES VIRUS STRAIN EDMONSTON	DHCPVVEVNGVTIQV	998	P69353.1
116	MEASLES VIRUS STRAIN EDMONSTON	DIDTASESSQDPQ	999	P04851.1
117	MEASLES VIRUS STRAIN EDMONSTON	DINKVLEKLGYSGGD	1000	P69353.1
118	BORDETELLA PERTUSSIS	DLIAYKQ	1001	ACI16088.1
119	MEASLES VIRUS STRAIN EDMONSTON	DLIGQKLGLKLLRY	1002	P69353.1
120	RUBELLA VIRUS	DLQKALEAQSRAELAA	1003	P07566.1
121	MEASLES MORBILLIVIRUS	DLQYVLATYDTSRVE	1004	P06830.1
122	MEASLES VIRUS STRAIN EDMONSTON	DLSLRRFMV	1005	P04851.1
123	MEASLES VIRUS STRAIN EDMONSTON	DLSNCMVALGELKLA	1006	P08362.1
124	RUBELLA VIRUS	DLVEYIMNYTGNQQRWGLGSPNC	1007	CAJ88851.1
125	MEASLES MORBILLIVIRUS	DLVKFISDKIKFLNP	1008	AAR89413.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
126	MEASLES MORBILLIVIRUS	DLVKFISTKIKFLNP	1009	SRC28011.7
127	MEASLES VIRUS STRAIN EDMONSTON	DLYKSNHNNV	1010	P08362.1
128	BORDETELLA PERTUSSIS	DNVLDHLTGR	1011	ACI04548.1
129	BORDETELLA PERTUSSIS	DNVLDHLTGRSC	1012	P04977.1
130	BORDETELLA PERTUSSIS	DNVLDHLTGRSCQ	1013	P04977.1
131	MEASLES MORBILLIVIRUS	DPDKILTYIAA	1014	AAF02706.1
132	RUBELLA VIRUS STRAIN THERIEN	DPGDLVEYIMNYTGNQQSR	1015	P07566.1
133	RUBELLA VIRUS	DPLLRTAP	1016	CAJ88851.1
134	RUBELLA VIRUS	DPLLRTAPGPGEVWVTPVIGSQ	1017	CAJ88851.1
135	MEASLES VIRUS STRAIN EDMONSTON	DPQDSRRSAEPLL	1018	P04851.1
136	MEASLES VIRUS STRAIN EDMONSTON	DPVIDRLYLSSHGRV	1019	P08362.1
137	MEASLES VIRUS STRAIN EDMONSTON	DQILRSMKGLSSTSI	1020	P69353.1
138	MEASLES MORBILLIVIRUS	DQYCADVAAEELMNA	1021	P06830.1
139	MEASLES VIRUS STRAIN EDMONSTON	DSESGGHITH	1022	P08362.1
140	MEASLES VIRUS STRAIN EDMONSTON	DTASESSQDPQDS	1023	P04851.1
141	RUBELLA VIRUS	DTVMSVFALASYVQH	1024	BAA28178.1
142	BORDETELLA PERTUSSIS	DVFQNGFTAWGNND	1025	P04977.1
143	RUBELLA VIRUS	DVGAVPPGKFVTAAL	1026	BAA28178.1
144	CORYNEBACTERIUM DIPHTHERIAE	DVNKSKTHISVNGRKI	1027	CAE11230.1
145	RUBELLA VIRUS	DVSCEGLGAWVPAAP	1028	BAA28178.1
146	RUBELLA VIRUS STRAIN THERIEN	DWASPVCQRHSPDCSRLVGATPERPRL	1029	P07566.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
147	MEASLES VIRUS STRAIN EDMONSTON	EARESYRETGPSR	1030	P04851.1
148	BORDETELLA PERTUSSIS	EAVEAERAGRGTG	1031	ACI04548.1
149	MEASLES VIRUS STRAIN EDMONSTON	EDAKELLESSDQILR	1032	P69353.1
150	MEASLES VIRUS STRAIN EDMONSTON	EDRRVKQSRGEAR	1033	P04851.1
151	MEASLES VIRUS STRAIN EDMONSTON	EDSITIPYQSGKGV	1034	P08362.1
152	RUBELLA VIRUS	EEAFTYLCTAPGCAT	1035	BAA28178.1
153	MEASLES VIRUS STRAIN EDMONSTON	EGFNMILGTILAQIW	1036	P04851.1
154	MEASLES VIRUS STRAIN EDMONSTON	EGFNMILGTILAQIWVLLAK	1037	P04851.1
155	RUBELLA VIRUS	EHPFCNTPHGQLEVQ	1038	BAA28178.1
156	MEASLES VIRUS STRAIN EDMONSTON	EISDIEVQDPEGFNM	1039	P04851.1
157	MEASLES VIRUS STRAIN EDMONSTON	EISDIEVQDPEGFNMILGTI	1040	P04851.1
158	MEASLES VIRUS STRAIN EDMONSTON	EKPNLSSKRSE	1041	P08362.1
159	MEASLES VIRUS STRAIN EDMONSTON	ELKLAALCHGEDSIT	1042	P08362.1
160	MEASLES MORBILLIVIRUS	ELMNALVNSTLLETR	1043	P06830.1
161	MEASLES VIRUS STRAIN EDMONSTON	ELPRL	1044	P04851.1
162	MEASLES MORBILLIVIRUS	ENPEWAPLKDNRIPSYGVLSVDL	1045	AAR89413.1
163	MEASLES VIRUS STRAIN EDMONSTON	EPIRDALNAMTQNIR	1046	P69353.1
164	MEASLES VIRUS STRAIN EDMONSTON	EQVGMSRPLKPDLT	1047	P69353.1
165	RUBELLA VIRUS	ERPRLRLV	1048	CAJ88851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
166	RUBELLA VIRUS	ERPRLRLVDADDPLL	1049	BAA28178.1
167	MEASLES VIRUS CAM/RB	ESPGQLIQRITDDPDVS	1050	P04851.1
168	MEASLES VIRUS STRAIN EDMONSTON	ESRGIKARITHVDTE	1051	P69353.1
169	MEASLES VIRUS STRAIN EDMONSTON	ESSCTFMPEGTVCSQ	1052	P69353.1
170	MEASLES VIRUS STRAIN EDMONSTON	ESSQDPQDSRRSA	1053	P04851.1
171	MEASLES VIRUS STRAIN EDMONSTON	ETRTTNQFLAVSKGN	1054	P08362.1
172	MEASLES VIRUS STRAIN EDMONSTON	EVDGDVKLSSNLVIL	1055	P08362.1
173	MEASLES VIRUS STRAIN EDMONSTON-B	EVNGVTIQV	1056	P26031.1
174	RUBELLA VIRUS	EVWVTPVI	1057	CAJ88851.1
175	RUBELLA VIRUS	EVWVTPVIGSQA	1058	BAA19893.1
176	RUBELLA VIRUS	EWAAAHWWQLTLGAT	1059	BAA28178.1
177	MEASLES MORBILLIVIRUS	EWIPRFKVSPYLFTV	1060	P06830.1
178	BORDETELLA PERTUSSIS	FEYVDTYGDNAG	1061	P04977.1
179	MEASLES MORBILLIVIRUS	FGPLITHGSGMDLYK	1062	P06830.1
180	MEASLES VIRUS STRAIN EDMONSTON	FIFDALAEV	1063	ABK40531.1
181	MEASLES VIRUS STRAIN EDMONSTON	FISDKIKFL	1064	P08362.1
182	MEASLES VIRUS STRAIN EDMONSTON	FKRNKDKPPITSGSG	1065	P04851.1
183	MEASLES VIRUS STRAIN EDMONSTON	FKRNKDKPPITSGSGGAIRG	1066	P04851.1
184	RUBELLA VIRUS	FKTVRPVALPRTLAP	1067	BAA28178.1
185	MEASLES VIRUS STRAIN EDMONSTON	FLMDRHIIV	1068	ABK40531.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
186	MEASLES VIRUS STRAIN EDMONSTON	FMAVLLTLQTPTGQI	1069	P69353.1
187	MEASLES VIRUS STRAIN EDMONSTON	FMPEGTVCSQNALYP	1070	P69353.1
188	MEASLES MORBILLIVIRUS	FMYMSLLGV	1071	AAN09804.1
189	MEASLES VIRUS STRAIN EDMONSTON	FNVPIKEAGEDCHAP	1072	P08362.1
190	MEASLES MORBILLIVIRUS	FRDLTWCINPPERIK	1073	AAC35876.2
191	MEASLES VIRUS STRAIN EDMONSTON	FSHDDPISSDQSRFG	1074	P04851.1
192	MEASLES VIRUS STRAIN EDMONSTON	FSHDDPISSDQSRFGWFENK	1075	P04851.1
193	MEASLES MORBILLIVIRUS	FTDLVKFISDKIKFL	1076	P06830.1
194	MEASLES MORBILLIVIRUS	FTWDQKLWCRHFCVL	1077	P06830.1
195	BORDETELLA PERTUSSIS	FVRDGQSVIGACASPYEGRYRDLYDALRRLLY	1078	SRC28006.6
196	BORDETELLA PERTUSSIS	FVRSGQPVIGACTSPYDGKYWSILYSRLRKMLY	1079	SRC28006.6
197	MEASLES MORBILLIVIRUS	FYKDNPHPKGSRIVI	1080	P06830.1
198	BORDETELLA PERTUSSIS	GAASSYFEYVDTYG	1081	ACI04548.1
199	BORDETELLA PERTUSSIS	GAFDLKTTFCIMTTRNTGQPA	1082	AAA83981.1
200	MEASLES VIRUS STRAIN EDMONSTON	GALIGILSLFVESPG	1083	P04851.1
201	MEASLES VIRUS STRAIN EDMONSTON	GALIGILSLFVESPGQLIQR	1084	P04851.1
202	RUBELLA VIRUS	GATPERPR	1085	CAJ88851.1
203	BORDETELLA PERTUSSIS	GAYGRCPNGTRALTVAELRGNAEL	1086	P04979.1
204	RUBELLA VIRUS	GCFAPWDLEATGACI	1087	BAA28178.1
205	MEASLES MORBILLIVIRUS	GDINKVLEKLGYS	1088	BAB60865.1
206	MEASLES MORBILLIVIRUS	GDINKVLEKLGYSGGDLLG	1089	AAL29688.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
207	RUBELLA VIRUS	GDLRAVHHRPVPA	1090	CAA28880.1
208	RUBELLA VIRUS	GDLVEYIMNYTGNQQ	1091	BAA28178.1
209	MEASLES VIRUS STRAIN EDMONSTON	GDSSITTRSRLDLRL	1092	P04851.1
210	MEASLES VIRUS STRAIN EDMONSTON	GDSSITTRSRLDLRLVRLIG	1093	P04851.1
211	MEASLES MORBILLIVIRUS	GEDCHAPTYLPAEVD	1094	P06830.1
212	MEASLES VIRUS STRAIN EDMONSTON	GELSTLESLMNLYQQ	1095	P04851.1
213	MEASLES VIRUS STRAIN EDMONSTON	GELSTLESLMNLYQQMGKPA	1096	P04851.1
214	MUMPS RUBULAVIRUS	GEQARYLALLEA	1097	P21186.1
215	RUBELLA VIRUS	GEVWVT	1098	BAA19893.1
216	RUBELLA VIRUS	GEVWVTPV	1099	CAJ88851.1
217	RUBELLA VIRUS	GEVWVTPVIGSQAR	1100	BAA19893.1
218	BORDETELLA PERTUSSIS	GEYGGVIKDGTPGGA	1101	AAA83981.1
219	RUBELLA VIRUS	GFLSGVGPMRLRHGADT	1102	SRC265968
220	MEASLES VIRUS STRAIN EDMONSTON-B	GFRASDVETAEGGEIHELLRLQ	1103	P03422.1
221	BORDETELLA PERTUSSIS	GGAVPGGAVPGGAVPGGFPGGFGP	1104	P14283.3
222	BORDETELLA PERTUSSIS	GGAVPGGAVPGGFPGGFGP	1105	CAA09475.1
223	BORDETELLA PERTUSSIS	GGAVPGGAVPGGFPGGFGP	1106	CAA09474.1
224	MEASLES MORBILLIVIRUS	GGHITHSGMVGMGVS	1107	P06830.1
225	MEASLES MORBILLIVIRUS	GILES RGIKARITHVDTESY	1108	P26032.1
226	BORDETELLA PERTUSSIS	GITGETTTTEYSNARYV	1109	CAD44970.1
227	MEASLES VIRUS STRAIN EDMONSTON	GKEDRRVKQSRGE	1110	P04851.1
228	BORDETELLA PERTUSSIS	GKVTNGS	1111	ACI16088.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
229	RUBELLA VIRUS	GLGAWVPAAPCARIW	1112	BAA28178.1
230	MEASLES VIRUS STRAIN EDMONSTON	GLIGIPALICCCRGR	1113	P69353.1
231	RUBELLA VIRUS STRAIN THERIEN	GLLACCAKCLYYLRGAIAPR	1114	P07566.1
232	MEASLES MORBILLIVIRUS	GLLAIAGIRLHRAAI	1115	P06830.1
233	RUBELLA VIRUS	GLQPRADMAAPPTLPQ	1116	NP_740663.1
234	MEASLES MORBILLIVIRUS	GMGVSCTVTREDGTNRR	1117	AAR89413.1
235	MEASLES MORBILLIVIRUS	GMYGTTYLVEKP	1118	AAR89413.1
236	BORDETELLA PERTUSSIS	GNAELQTYLRQITPGWSIYGLYDGYLG	1119	P04979.1
237	RUBELLA VIRUS	GNCHLTVNGEDVGAV	1120	BAA28178.1
238	BORDETELLA PERTUSSIS	GNNDNVLDHLTGR	1121	P04977.1
239	BORDETELLA PERTUSSIS	GNNDNVLDHLTGRSC	1122	P04977.1
240	MEASLES VIRUS STRAIN EDMONSTON	GNERFILSQGNLIANC	1123	P69353.1
241	RUBELLA VIRUS	GNRGRGQRRDWSRAPPPPEERQETRSQT PAPKPS	1124	P07566.1
242	RUBELLA VIRUS	GPGEVWVT	1125	CAJ88851.1
243	RUBELLA VIRUS STRAIN THERIEN	GPMRLRHGADTRCGRLI	1126	P07566.1
244	BORDETELLA PERTUSSIS	GNHHTKV	1127	ACI16083.1
245	MEASLES VIRUS STRAIN HALLE	GPRQAQVSF	1128	P10050.1
246	MEASLES VIRUS STRAIN EDMONSTON	GPRQAQVSFLQGDQS	1129	P04851.1
247	MEASLES VIRUS STRAIN EDMONSTON	GPRQAQVSFLQGDQSENELP	1130	P04851.1
248	MEASLES MORBILLIVIRUS	GRGYNVSSIVTMTSQ	1131	P06830.1
249	BORDETELLA PERTUSSIS	GRTPFII	1132	ACI16083.1
250	RUBELLA VIRUS	GSPNCHGPDWASPVC	1133	BAA28178.1
251	RUBELLA VIRUS	GSQARKCGLHIRAGP	1134	BAA28178.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
252	BORDETELLA PERTUSSIS	GSSNSAFVSTSSRR	1135	P04977.1
253	MEASLES VIRUS STRAIN EDMONSTON	GSTKSCARTLVSGSF	1136	P69353.1
254	RUBELLA VIRUS	GSYYKQYHPTACEVE	1137	BAA28178.1
255	RUBELLA VIRUS	GTHTTAVSETRQTTA	1138	BAA28178.1
256	MEASLES VIRUS STRAIN EDMONSTON	GTIINQDPDKILTYI	1139	P69353.1
257	BORDETELLA PERTUSSIS	GTLVRMAPVIG	1140	ADA85124.1
258	MEASLES VIRUS STRAIN EDMONSTON	GTPLDIDTASESS	1141	P04851.1
259	BORDETELLA PERTUSSIS	GTYLQGAYGGIHKDAPPGAGFIYRETF	1142	P04979.1
260	BORDETELLA PERTUSSIS	GVATKGLGVHAKSSDWG	1143	P15318.2
261	CORYNEBACTERIUM DIPHTHERIAE	GVLLPTIPGKLDVNKSKTHI	1144	AAV70486.1
262	MEASLES MORBILLIVIRUS	GVLSVDLSLTVELKI	1145	P06830.1
263	MEASLES MORBILLIVIRUS	GVPIELQVECFTWDQ	1146	P06830.1
264	MEASLES VIRUS STRAIN EDMONSTON	GVSCVTVTREDGTNRR	1147	P08362.1
265	MEASLES VIRUS STRAIN EDMONSTON	GVSYNIGSQEWYTTV	1148	P69353.1
266	MEASLES VIRUS STRAIN EDMONSTON	GYNVSSIIVTMTSQGM	1149	P08362.1
267	MEASLES MORBILLIVIRUS	HFCVLADSESGGHIT	1150	P06830.1
268	MEASLES MORBILLIVIRUS	HGEDSITIPYQGSGK	1151	P06830.1
269	RUBELLA VIRUS	HGPDWASP	1152	BAA19893.1
270	RUBELLA VIRUS	HGPDWASPVCRHSP	1153	BAA28178.1
271	RUBELLA VIRUS	HGPDWASPVCRHSPDCSRLVG	1154	CAJ88851.1
272	RUBELLA VIRUS STRAIN M33	HGPDWASPVCRHSPDCSRLVGATPERPRLRLV	1155	CAJ88851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
273	MEASLES VIRUS STRAIN EDMONSTON	HITHSGMEGMGVST	1156	P08362.1
274	MEASLES MORBILLIVIRUS	HKSLSTNLDVTSIE	1157	P06830.1
275	MEASLES VIRUS STRAIN EDMONSTON	HLMIDRPYV	1158	P08362.1
276	MEASLES VIRUS STRAIN EDMONSTON	HLPTGTPLDIDTA	1159	P04851.1
277	MEASLES VIRUS STRAIN EDMONSTON-B	HLPTGTPLDIDTATESSQDPQDSR	1160	Q77M43.1
278	MEASLES MORBILLIVIRUS	HMTNYLEQPVSNDLS	1161	P06830.1
279	MEASLES VIRUS STRAIN EDMONSTON	HQSLVIKLPNITLL	1162	P69353.1
280	MEASLES MORBILLIVIRUS	HRAAIYTAEIHKSL	1163	P06830.1
281	BORDETELLA PERTUSSIS	HRMQEAVEAERAGRGTGH	1164	P04977.1
282	MEASLES VIRUS STRAIN EDMONSTON	HVDTESYFIVLSIAY	1165	P69353.1
283	MEASLES VIRUS STRAIN EDMONSTON	HWGNLSKIGVVGIGS	1166	P69353.1
284	RUBELLA VIRUS	HWWQLTLGATCALPL	1167	BAA28178.1
285	RUBELLA VIRUS	HYRNASDVLPGHWLQGGWGCYNL	1168	NP_740663.1
286	MEASLES VIRUS STRAIN EDMONSTON	IDLGPPISLERLDVG	1169	P69353.1
287	MEASLES VIRUS STRAIN EDMONSTON	IEAIRQAGQEMILAV	1170	P69353.1
288	RUBELLA VIRUS STRAIN M33	IETRSARHP	1171	CAA28880.1
289	MEASLES VIRUS STRAIN EDMONSTON	IGSQEWYTTVPKYVA	1172	P69353.1
290	MEASLES VIRUS STRAIN EDMONSTON	IKGVIVHRLEGVSYN	1173	P69353.1
291	MEASLES VIRUS STRAIN EDMONSTON	IKHIIIIVIPGDSSI	1174	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
292	MEASLES VIRUS STRAIN EDMONSTON	IKHHIVPIPGDSSITTRSR	1175	P04851.1
293	BORDETELLA PERTUSSIS	IKLKDCP	1176	ACI16083.1
294	MEASLES VIRUS STRAIN EDMONSTON	IKLMPNITLLNNCTR	1177	P69353.1
295	MEASLES MORBILLIVIRUS	ILLERLDVGT	1178	AAF85664.1
296	MEASLES MORBILLIVIRUS	ILPGQDLQYV	1179	P08362.1
297	MEASLES VIRUS STRAIN EDMONSTON	ILTYIAADHCPVVEV	1180	P69353.1
298	MEASLES MORBILLIVIRUS	INQDPDKILTY	1181	AAL29688.1
299	MEASLES VIRUS STRAIN EDMONSTON	IPRFKVSPYLFNVPI	1182	P08362.1
300	MEASLES VIRUS STRAIN EDMONSTON	IQALSYALGGDINKV	1183	P69353.1
301	RUBELLA VIRUS	IRAGPYGHATVEMPE	1184	BAA28178.1
302	BORDETELLA PERTUSSIS	IRMGTDK	1185	ACI16088.1
303	MEASLES VIRUS STRAIN EDMONSTON	ISNFDESSCTFMPEG	1186	P69353.1
304	MEASLES VIRUS STRAIN EDMONSTON	ITAGIALHQSMNSQ	1187	P69353.1
305	MEASLES VIRUS STRAIN EDMONSTON	ITDDPDVSIRLLEV	1188	P04851.1
306	MEASLES VIRUS STRAIN EDMONSTON	ITDDPDVSIRLLEVQSDQS	1189	P04851.1
307	BORDETELLA PERTUSSIS	ITTYV	1190	ACI16083.1
308	MEASLES VIRUS STRAIN EDMONSTON	IVEAGLASFILTIKF	1191	P04851.1
309	MEASLES VIRUS STRAIN EDMONSTON	IVEAGLASFILTIKFGIETM	1192	P04851.1
310	MEASLES VIRUS STRAIN EDMONSTON	IVEAGLASFILTIKFGIETMYPALG	1193	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
311	RUBELLA VIRUS	KALEAQSRLRAELAA	1194	P07566.1
312	MEASLES VIRUS STRAIN EDMONSTON	KARITHVDTESYFIV	1195	P69353.1
313	RUBELLA VIRUS	KCGLHIRAGPYGHAT	1196	BAA28178.1
314	MEASLES VIRUS STRAIN EDMONSTON	KCYTTGTIINQDPDK	1197	P69353.1
315	MEASLES VIRUS STRAIN EDMONSTON	KDNPHPKGSR	1198	P08362.1
316	MEASLES VIRUS STRAIN EDMONSTON	KDNRIPSYGVLSVDL	1199	P08362.1
317	MEASLES MORBILLIVIRUS	KFLNPDREYDFRDLT	1200	AAC35876.2
318	RUBELLA VIRUS	KFVTAALLN	1201	BAA28178.1
319	MEASLES VIRUS STRAIN EDMONSTON	KGNCSGPTTIR	1202	P08362.1
320	MEASLES MORBILLIVIRUS	KIKFLNPDREYDFRD	1203	P06830.1
321	RUBELLA VIRUS	KIVDGGCFAPWDLEA	1204	BAA28178.1
322	MEASLES VIRUS STRAIN EDMONSTON	KLGLKLLRYYTEILS	1205	P69353.1
323	MEASLES VIRUS STRAIN EDMONSTON	KLGVWKSPTDMQSWV	1206	P08362.1
324	BORDETELLA PERTUSSIS	KLKECPQ	1207	ACI16088.1
325	MEASLES MORBILLIVIRUS	KLLRYYTEI	1208	P26031.1
326	MEASLES VIRUS STRAIN EDMONSTON	KLMPFSGDFV	1209	ABK40531.1
327	MEASLES MORBILLIVIRUS	KLMPNITLL	1210	P26031.1
328	MEASLES MORBILLIVIRUS	KLRMETCFQQACKGKIQALCENPEWA	1211	AAR89413.1
329	MEASLES MORBILLIVIRUS	KLWCRHFCV	1212	P08362.1
330	MEASLES VIRUS STRAIN EDMONSTON	KLWCRHFCVL	1213	P08362.1
331	MEASLES MORBILLIVIRUS	KLWESPQEI	1214	BAB60863.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
332	MEASLES VIRUS STRAIN EDMONSTON	KMSSAVGFV	1215	ABO69699.1
333	MEASLES VIRUS STRAIN EDMONSTON-B	KMSSAVGFVPDTGPASR	1216	P03422.1
334	BORDETELLA PERTUSSIS	KMVYATN	1217	ACI16083.1
335	MEASLES VIRUS STRAIN EDMONSTON	KPDLTGTSKSYVRSL	1218	P69353.1
336	MEASLES MORBILLIVIRUS	KPNLSSKRSELSQLS	1219	P08362.1
337	MEASLES VIRUS STRAIN EDMONSTON	KPNLSSKRSELSQLSMYRVF	1220	P08362.1
338	MEASLES VIRUS STRAIN EDMONSTON	KQSRGEARESYRETG	1221	P04851.1
339	MEASLES VIRUS STRAIN EDMONSTON	KQSRGEARESYRETGPSRAS	1222	P04851.1
340	MEASLES VIRUS STRAIN EDMONSTON	KRFAGVVLAGAALGV	1223	P69353.1
341	MEASLES VIRUS STRAIN EDMONSTON	KRTPGNKPRIAEMIC	1224	P04851.1
342	MEASLES VIRUS STRAIN EDMONSTON	KRTPGNKPRIAEMICDIDTY	1225	P04851.1
343	MEASLES MORBILLIVIRUS	KSNHNNVYWLTIIPPMKNLALGVINTL	1226	AAR89413.1
344	MEASLES MORBILLIVIRUS	KVSPYLFNV	1227	P08362.1
345	BORDETELLA PERTUSSIS	KVVQLPKISKNALKANG	1228	ACI16083.1
346	BORDETELLA PERTUSSIS	KVVQLPKISKNALRNDG	1229	ACI16087.1
347	BORDETELLA PERTUSSIS	LAHRRIPPENIR	1230	P04977.1
348	BORDETELLA PERTUSSIS	LALALWAGFALS	1231	P11092.1
349	RUBELLA VIRUS	LAPGGGNCHLTVNGE	1232	BAA28178.1
350	MEASLES VIRUS STRAIN EDMONSTON	LAQIWVLLAKAVTAP	1233	P04851.1
351	MEASLES VIRUS STRAIN EDMONSTON	LAQIWVLLAKAVTAPDTAAD	1234	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
352	RUBELLA VIRUS	LASYFNPGGSYYKQYHPTACEVEPAFGHS	1235	BAA19893.1
353	MEASLES MORBILLIVIRUS	LAVSKGNCSGPTTIR	1236	P06830.1
354	MEASLES VIRUS STRAIN EDMONSTON	LCENPEWAPLKDNRI	1237	P08362.1
355	MEASLES MORBILLIVIRUS	LDRLVRLIG	1238	ABI54110.1
356	CORYNEBACTERIUM DIPHTHERIAE	LEEEGVTP	1239	P33120.2
357	BORDETELLA PERTUSSIS	LEHRMQEAVEAERAGRGTGHFI	1240	CAD44970.1
358	MEASLES VIRUS STRAIN EDMONSTON	LEKLGYSGGDLLGIL	1241	P69353.1
359	MEASLES VIRUS STRAIN EDMONSTON	LEQPVSNDLS	1242	P08362.1
360	MEASLES VIRUS STRAIN EDMONSTON	LERKWLDVVRNIIAE	1243	P04851.1
361	MEASLES VIRUS STRAIN EDMONSTON	LERKWLDVVRNIIAEDLSLR	1244	P04851.1
362	MEASLES VIRUS STRAIN EDMONSTON	LFGPSLRDPISAEIS	1245	P69353.1
363	MEASLES MORBILLIVIRUS	LGELKLAALCHGEDS	1246	P06830.1
364	MEASLES VIRUS STRAIN EDMONSTON	LGGKEDRRVKQSR	1247	P04851.1
365	RUBELLA VIRUS	LGHDGHHGGTLRVGQHHRNASDVL	1248	ABD64214.1
366	RUBELLA VIRUS STRAIN THERIEN	LGSPNCHGPDWASPVCQRHS	1249	P07566.1
367	RUBELLA VIRUS STRAIN THERIEN	LGSPNCHGPDWASPVCQRHSPDCSRLV	1250	P07566.1
368	RUBELLA VIRUS	LHDPDTEAPTEACVTSWL	1251	ABD64214.1
369	MEASLES VIRUS STRAIN EDMONSTON	LIANCASILCKCYTT	1252	P69353.1
370	MEASLES MORBILLIVIRUS	LIGLLAIAGIRLHRAAIYTAEIHK	1253	AAR89413.1
371	MEASLES VIRUS STRAIN EDMONSTON	LIPSMNQLSCDLIGQ	1254	P69353.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
372	MEASLES VIRUS STRAIN EDMONSTON	LKIKIASGFGPLITH	1255	P08362.1
373	MEASLES MORBILLIVIRUS	LKIKIASGFGPLITHGSGMDLYK	1256	AAR89413.1
374	BORDETELLA PERTUSSIS	LKLYFEP	1257	ACI16088.1
375	MEASLES VIRUS STRAIN EDMONSTON	LLAVLFVMFL	1258	P08362.1
376	MEASLES VIRUS STRAIN EDMONSTON	LLDRLVRLIGNPDVS	1259	P04851.1
377	MEASLES VIRUS STRAIN EDMONSTON	LLDRLVRLIGNPDVSGPKLT	1260	P04851.1
378	MEASLES VIRUS STRAIN EDMONSTON	LLESSDQILRSMKGL	1261	P69353.1
379	MEASLES MORBILLIVIRUS	LLETRTTNQFLAVSK	1262	P06830.1
380	MEASLES VIRUS STRAIN EDMONSTON	LLEVVSQDQSQSGLT	1263	P04851.1
381	MEASLES VIRUS STRAIN EDMONSTON	LLEVVSQDQSQSGLTFASR	1264	P04851.1
382	MEASLES VIRUS STRAIN EDMONSTON	LLEVVSQDQSQSGLTFASRG	1265	P04851.1
383	MEASLES MORBILLIVIRUS	LLGILESIRGIKARIT	1266	AAL29688.1
384	RUBELLA VIRUS	LLRTAPGP	1267	CAJ88851.1
385	MEASLES VIRUS STRAIN EDMONSTON	LLRYYTEILSLFGPS	1268	P69353.1
386	RUBELLA VIRUS STRAIN THERIEN	LLVPWVLIFMVCRRACRRRG	1269	P07566.1
387	MEASLES VIRUS STRAIN EDMONSTON	LLWRSRCKIV	1270	ABK40528.1
388	MEASLES MORBILLIVIRUS	LLWSYAMGV	1271	P04851.1
389	MEASLES VIRUS STRAIN EDMONSTON	LLWSYAMGVGVLEEN	1272	P04851.1
390	MEASLES VIRUS STRAIN EDMONSTON	LLWSYAMGVGVLEENSMGGL	1273	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
391	MEASLES MORBILLIVIRUS	LMIDRPYVL	1274	P08362.1
392	MEASLES VIRUS STRAIN EDMONSTON	LNAMTQNIRPVQSV	1275	P69353.1
393	RUBELLA VIRUS	LNTPPPYQVSCGGES	1276	BAA28178.1
394	MEASLES VIRUS STRAIN EDMONSTON	LRDPISAEISIQALS	1277	P69353.1
395	BORDETELLA PERTUSSIS	LRGSGDLQEYLRHVTR	1278	AAA83981.1
396	RUBELLA VIRUS	LRLVDADD	1279	CAJ88851.1
397	RUBELLA VIRUS	LRLVDADDPLLR	1280	BAA19893.1
398	RUBELLA VIRUS	LRLVDADDPLLRTPAPGPGEVWVTPVIGS QAR	1281	BAA19893.1
399	BORDETELLA PERTUSSIS	LRRLLYMIYMSGLAVRVHVSKEEQYYD Y	1282	P04979.1
400	RUBELLA VIRUS	LRTAPGPG	1283	CAJ88851.1
401	RUBELLA VIRUS	LRVGQHYRNASDVLPQHWLQ	1284	NP_740663.1
402	BORDETELLA PERTUSSIS	LRYLA	1285	ACI16088.1
403	MEASLES VIRUS STRAIN EDMONSTON	LSCKPWQESRKNK	1286	P04851.1
404	MEASLES MORBILLIVIRUS	LSEIKGVIVHRLEGV	1287	AAL29688.1
405	MEASLES VIRUS STRAIN EDMONSTON	LSIAYPTLSEIKGVI	1288	P69353.1
406	MEASLES VIRUS STRAIN EDMONSTON	LSLLDLYLGRGYNVS	1289	P08362.1
407	MEASLES VIRUS STRAIN EDMONSTON	LSQGNLIANCASILC	1290	P69353.1
408	MEASLES MORBILLIVIRUS	LSSHRGVIADNQAKW	1291	P06830.1
409	MEASLES VIRUS STRAIN EDMONSTON	LSVDLSLTVELKIKI	1292	P08362.1
410	BORDETELLA PERTUSSIS	LTGISICNPGSSLC	1293	AAA83981.1
411	MEASLES VIRUS STRAIN EDMONSTON	LTIKFGIETMYPALG	1294	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
412	MEASLES VIRUS STRAIN EDMONSTON	LTIKFGIETMYPALGLHEFA	1295	P04851.1
413	MEASLES VIRUS STRAIN EDMONSTON	LTQTPTGQIHWGNL	1296	P69353.1
414	RUBELLA VIRUS	LVDADDPL	1297	CAJ88851.1
415	RUBELLA VIRUS	LVDADDPLLR	1298	BAA19893.1
416	MEASLES VIRUS STRAIN EDMONSTON	LVEKPNLSSKRSELS	1299	P08362.1
417	RUBELLA VIRUS	LVGATPE	1300	BAA19893.1
418	RUBELLA VIRUS	LVGATPER	1301	CAJ88851.1
419	MEASLES MORBILLIVIRUS	LVKLG VWKSPTGMQS	1302	P06830.1
420	MEASLES VIRUS STRAIN EDMONSTON-B	LVSGSFGNRFILSQGNLI	1303	P26031.1
421	MEASLES VIRUS STRAIN EDMONSTON	LYKSNHNNVYWLTP	1304	P08362.1
422	MEASLES VIRUS STRAIN EDMONSTON	LYPMSPLLQECLRGSTKSCARTLVS	1305	P69353.1
423	RUBELLA VIRUS	MASTTPITMEDLQKALEA	1306	P07566.1
424	RUBELLA VIRUS	MASTTPITMEDLQKALEAQSR	1307	ABD64200.1
425	RUBELLA VIRUS STRAIN THERIEN	MASTTPITMEDLQKALEAQSRALRAELA A	1308	P07566.1
426	RUBELLA VIRUS	MASTTPITMEDLQKALEAQSRALRAGLA A	1309	ABD64200.1
427	RUBELLA VIRUS VACCINE STRAIN RA27/3	MASTTPITMEDLQKALETQSRVLRAGLT A	1310	CAA33016.1
428	MEASLES VIRUS STRAIN EDMONSTON	MATLLRSLALFKRNK	1311	P04851.1
429	MEASLES VIRUS STRAIN EDMONSTON	MATLLRSLALFKRNKDKPPI	1312	P04851.1
430	MEASLES MORBILLIVIRUS	MDLYKSNHNNVYWLT	1313	P06830.1
431	RUBELLA VIRUS	MEDLQKALEAQSRA	1314	P07566.1
432	RUBELLA VIRUS	MEDLQKALEAQSRALRAELAA	1315	P07566.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
433	MEASLES VIRUS STRAIN EDMONSTON	MGLKVNVS AIFMAVL	1316	P69353.1
434	MEASLES MORBILLIVIRUS	MIDRPYVLLAVLFVM	1317	P06830.1
435	MEASLES VIRUS STRAIN EDMONSTON	MILAVQGVQDYINNE	1318	P69353.1
436	MEASLES VIRUS STRAIN EDMONSTON	MLNSQAIDNLRASLE	1319	P69353.1
437	MEASLES VIRUS STRAIN EDMONSTON	MNALVNSTLLETTRT	1320	P08362.1
438	RUBELLA VIRUS	MNYTGNQQRWGLGSPNCHGPDWASPV CQRHS	1321	BAA19893.1
439	MEASLES VIRUS STRAIN EDMONSTON	MQSWVPLSTDDPVID	1322	P08362.1
440	MEASLES MORBILLIVIRUS	MSLSLLDLYLGRGYN	1323	P06830.1
441	MEASLES VIRUS STRAIN EDMONSTON	MSPLLQECLRGSTKS	1324	P69353.1
442	MEASLES MORBILLIVIRUS	MSPQRDRINAFYKDN	1325	P06830.1
443	MEASLES MORBILLIVIRUS	MYRVFEVSVIRNPGL	1326	P06830.1
444	MEASLES VIRUS STRAIN EDMONSTON	NALYPMSPLLQECLR	1327	P69353.1
445	RUBELLA VIRUS STRAIN THERIEN	NCHGPDWASPV CQRHSPDCSRLVGAT	1328	P07566.1
446	MEASLES VIRUS STRAIN EDMONSTON	NFGRSYFDPAYFRLG	1329	P04851.1
447	MEASLES VIRUS STRAIN EDMONSTON	NFGRSYFDPAYFRLGQEMVR	1330	P04851.1
448	RUBELLA VIRUS	NGTQRACTFWAVNAY	1331	BAA28178.1
449	MEASLES VIRUS STRAIN EDMONSTON	NGVTIQVGSRRYPDA	1332	P69353.1
450	MEASLES VIRUS STRAIN EDMONSTON	NIIAEDLSLRRFMVA	1333	P04851.1
451	MEASLES VIRUS STRAIN EDMONSTON	NIIAEDLSLRRFMVALIDI	1334	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
452	MEASLES VIRUS STRAIN EDMONSTON	NITLLNNCTRVEIAE	1335	P69353.1
453	MEASLES MORBILLIVIRUS	NLALGVINTLEWIPR	1336	P06830.1
454	CORYNEBACTERIUM DIPHTHERIAE	NLFQVVHWSYNRPAYSPG	1337	SRC280292
455	MEASLES VIRUS STRAIN EDMONSTON	NLVILPGQDLQYVLA	1338	P08362.1
456	MEASLES VIRUS STRAIN EDMONSTON	NLYQQMGKPAPYMVN	1339	P04851.1
457	MEASLES VIRUS STRAIN EDMONSTON	NLYQQMGKPAPYMVNLENSI	1340	P04851.1
458	MEASLES VIRUS STRAIN EDMONSTON	NNCTRVEIAEYRRL	1341	P69353.1
459	MEASLES VIRUS STRAIN EDMONSTON	NPDREYDFRD	1342	P08362.1
460	MEASLES VIRUS STRAIN HALLE	NPDVSGPKL	1343	P10050.1
461	MEASLES VIRUS STRAIN EDMONSTON	NPDVSGPKLTGALIG	1344	P04851.1
462	MEASLES VIRUS STRAIN EDMONSTON	NPDVSGPKLTGALIGILSLF	1345	P04851.1
463	MEASLES MORBILLIVIRUS	NPPERIKLDYDQYCA	1346	P06830.1
464	MEASLES MORBILLIVIRUS	NQAKWAVPTTRTDDK	1347	P06830.1
465	MEASLES MORBILLIVIRUS	NQDPDKILTYIAADH	1348	AAF02706.1
466	MEASLES VIRUS STRAIN EDMONSTON	NQLSCDLIGQKLGLK	1349	P69353.1
467	RUBELLA VIRUS	NQQRWGLGSPNCHGPDWASPVCQRHS	1350	ABD64214.1
468	MUMPS RUBULAVIRUS	NSTLGVKSAREF	1351	ABP48111.1
469	RUBELLA VIRUS	NTPHGQLEVQVPPDP	1352	BAA28178.1
470	MEASLES VIRUS STRAIN EDMONSTON	NVSAIFMAVLLTLQT	1353	P69353.1
471	MEASLES MORBILLIVIRUS	PAEVDGDVKLSSNLV	1354	P06830.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
472	RUBELLA VIRUS	PAFGHSDAACWGFPT	1355	BAA28178.1
473	MEASLES VIRUS STRAIN EDMONSTON	PALICCCRGRGNKKG	1356	P69353.1
474	MEASLES MORBILLIVIRUS	PDKILTYIAADHC	1357	AAF02706.1
475	MEASLES VIRUS STRAIN EDMONSTON	PERIKLDYDQYCADV	1358	P08362.1
476	RUBELLA VIRUS	PERPRLRL	1359	CAJ88851.1
477	RUBELLA VIRUS	PGCATQAPVPVRLAG	1360	BAA28178.1
478	RUBELLA VIRUS VACCINE STRAIN RA27/3	PGCATQAPVPVRLAGVRFESKIVDGGCF A	1361	CAJ88851.1
479	RUBELLA VIRUS	PGEVWVTP	1362	CAJ88851.1
480	RUBELLA VIRUS	PGEVWVTPVIGSQAR	1363	BAA28178.1
481	CORYNEBACTERIUM DIPHTHERIAE	PGKLDVNKSKTHISVN	1364	CAE11230.1
482	MEASLES VIRUS STRAIN EDMONSTON	PGLGAPVFHMTNYLE	1365	P08362.1
483	RUBELLA VIRUS	PGPGEVWV	1366	CAJ88851.1
484	RUBELLA VIRUS	PHKTVRVKFHTETRT	1367	BAA28178.1
485	MEASLES MORBILLIVIRUS	PIELQVECFTWDQKL	1368	AAR89413.1
486	MEASLES VIRUS STRAIN EDMONSTON-B	PISLERLDVG	1369	P26031.1
487	MEASLES VIRUS STRAIN EDMONSTON	PISLERLDVGTNLGN	1370	P69353.1
488	BORDETELLA PERTUSSIS	PKALFTQQGGAYGRC	1371	P04979.1
489	MEASLES VIRUS STRAIN EDMONSTON	PKYVATQGYLISNFD	1372	P69353.1
490	MEASLES VIRUS STRAIN EDMONSTON	PLDIDTASESSQD	1373	P04851.1
491	RUBELLA VIRUS	PLGLKFKTVRPVALP	1374	BAA28178.1
492	MEASLES VIRUS STRAIN EDMONSTON	PLITHGSGMDLYKSN	1375	P08362.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
493	MEASLES MORBILLIVIRUS	PLKDNRIPSYGVLSV	1376	P06830.1
494	RUBELLA VIRUS	PLLRTAPG	1377	CAJ88851.1
495	MEASLES VIRUS STRAIN EDMONSTON	PLLSCKPWQESRK	1378	P04851.1
496	BORDETELLA PERTUSSIS	PPATVYRYDSRPPE	1379	P04977.1
497	MEASLES MORBILLIVIRUS	PPISLERLDVGT	1380	AAL29688.1
498	RUBELLA VIRUS	PPPPEERQETRSQTPAPKPS	1381	P07566.1
499	BORDETELLA PERTUSSIS	PQEITQHGSPYGRG	1382	AAA83981.1
500	BORDETELLA PERTUSSIS	PQEITQHGSPYGRGANK	1383	AAA83981.1
501	BORDETELLA PERTUSSIS	PQPGPQPPQPPQPEAPAPQPPAG	1384	P14283.3
502	MEASLES VIRUS STRAIN EDMONSTON	PRLGGKEDRRVKQ	1385	P04851.1
503	RUBELLA VIRUS	PRLRLVDA	1386	CAJ88851.1
504	RUBELLA VIRUS	PRNVRVTGCYQCGTP	1387	BAA28178.1
505	MEASLES VIRUS STRAIN EDMONSTON	PSRASDARAAHLP	1388	P04851.1
506	MEASLES VIRUS STRAIN EDMONSTON	PTGQIHWGNLSKIGV	1389	P69353.1
507	MEASLES VIRUS STRAIN EDMONSTON	PTGTPLDIDTASE	1390	P04851.1
508	MEASLES VIRUS STRAIN EDMONSTON	PTLSEIKGVIVHRLE	1391	P69353.1
509	MEASLES MORBILLIVIRUS	PTTIRGQFSNMSLSL	1392	P06830.1
510	MEASLES MORBILLIVIRUS	PTTRTDDKLR	1393	AAR89413.1
511	MEASLES MORBILLIVIRUS	PTTRTDDKLRMETCFQQACKG	1394	AAR89413.1
512	RUBELLA VIRUS	PVALPRTLAPPRNVR	1395	BAA28178.1
513	CORYNEBACTERIUM DIPHTHERIAE	PVFAGANYAAWAVNVAQVI	1396	AAV70486.1
514	RUBELLA VIRUS	PVIGSQAR	1397	CAJ88851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
515	MEASLES MORBILLIVIRUS	PVVEVNGVTIQVGSR	1398	AAL29688.1
516	RUBELLA VIRUS STRAIN THERIEN	PWELVVLTARPEDGWTCRGV	1399	P07566.1
517	MEASLES VIRUS STRAIN EDMONSTON	PWQESRKNKAQTR	1400	P04851.1
518	MEASLES VIRUS STRAIN EDMONSTON	PYMVNLENSIQNKFS	1401	P04851.1
519	MEASLES VIRUS STRAIN EDMONSTON	PYMVNLENSIQNKFSAGSYP	1402	P04851.1
520	MEASLES VIRUS STRAIN EDMONSTON	PYQGSKGKVS	1403	P08362.1
521	RUBELLA VIRUS	PYQVSCGGESDRASA	1404	BAA28178.1
522	MEASLES MORBILLIVIRUS	QACKGKIQALCEN	1405	P08362.1
523	MEASLES VIRUS STRAIN EDMONSTON	QAGQEMILAVQGVQD	1406	P69353.1
524	MEASLES MORBILLIVIRUS	QALCENPECVPLKDN	1407	P06830.1
525	BORDETELLA PERTUSSIS	QALGALK	1408	ACI16088.1
526	RUBELLA VIRUS	QAPVPVRLAGVRFES	1409	BAA28178.1
527	RUBELLA VIRUS	QCGTPALVEGLAPGG	1410	BAA28178.1
528	MEASLES VIRUS STRAIN EDMONSTON	QDPDKILTYIAADHC	1411	P69353.1
529	MEASLES VIRUS STRAIN EDMONSTON	QECLRGSTKSCARTL	1412	P69353.1
530	BORDETELLA PERTUSSIS	QEQITQHGSPLYGRC	1413	AAA83981.1
531	MEASLES VIRUS STRAIN EDMONSTON	QESRKNKAQTRTP	1414	P04851.1
532	MEASLES VIRUS STRAIN EDMONSTON	QGDQSENELPRLGGK	1415	P04851.1
533	MEASLES VIRUS STRAIN EDMONSTON	QGDQSENELPRLGGKEDRRV	1416	P04851.1
534	CORYNEBACTERIUM DIPHTHERIAE	QGESGHDIKITAENTPLPIA	1417	AAV70486.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
535	MEASLES MORBILLIVIRUS	QGSGKGVSFQLVKLG	1418	P06830.1
536	MEASLES VIRUS STRAIN EDMONSTON	QGVQDYINNELIPSM	1419	P69353.1
537	RUBELLA VIRUS	QLEVQVPPDPGDLVE	1420	BAA28178.1
538	MEASLES MORBILLIVIRUS	QLPEATFMV	1421	ABK40528.1
539	RUBELLA VIRUS	QLPFLGHDGHHGGTLRVGQHYNAS	1422	NP_740663.1
540	MEASLES VIRUS STRAIN EDMONSTON	QLSMYRVFEV	1423	P08362.1
541	BORDETELLA PERTUSSIS	QLSNIT	1424	ACI16083.1
542	MEASLES VIRUS STRAIN EDMONSTON	QNIRPVQSVASSRRH	1425	P69353.1
543	MEASLES VIRUS STRAIN EDMONSTON	QNKFSAGSYPLLWSY	1426	P04851.1
544	MEASLES VIRUS STRAIN EDMONSTON	QNKFSAGSYPLLWSYAMGVG	1427	P04851.1
545	MEASLES VIRUS STRAIN EDMONSTON	QNKFSAGSYPLLWSYAMGVGVELEN	1428	P04851.1
546	MEASLES VIRUS STRAIN EDMONSTON	QQACKGKIQALCENP	1429	P08362.1
547	MEASLES VIRUS STRAIN EDMONSTON	QQRRVVGEFRLERKW	1430	P04851.1
548	MEASLES VIRUS STRAIN EDMONSTON	QQRRVVGEFRLERKWLDVVR	1431	P04851.1
549	BORDETELLA PERTUSSIS	QQTRANPNPYTSRRSVAS	1432	P04977.1
550	RUBELLA VIRUS	QRHSPDCSRLVGATP	1433	BAA28178.1
551	MEASLES VIRUS STRAIN EDMONSTON	QSGLTFASRGTNMED	1434	P04851.1
552	MEASLES VIRUS STRAIN EDMONSTON	QSGLTFASRGTNMEDEADQY	1435	P04851.1
553	CORYNEBACTERIUM DIPHTHERIAE	QSIALSSLMVAQAIPLVGEL	1436	AAV70486.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
554	MEASLES VIRUS STRAIN EDMONSTON	QSRFGWFENKEISDI	1437	P04851.1
555	MEASLES VIRUS STRAIN EDMONSTON	QSRFGWFENKEISDIEVQDP	1438	P04851.1
556	MEASLES VIRUS STRAIN EDMONSTON	QSRGEAR	1439	P04851.1
557	MEASLES VIRUS STRAIN EDMONSTON	QSRGEARESYRETGPSRA	1440	P04851.1
558	RUBELLA VIRUS STRAIN THERIEN	QTGRGGSAPRPELGPPTN	1441	P07566.1
559	RUBELLA VIRUS STRAIN THERIEN	QTPAPKPSRAPPQQPQPPRMQTGRG	1442	P07566.1
560	MEASLES VIRUS STRAIN EDMONSTON	QVGSRRYPDAVYLHR	1443	P69353.1
561	MEASLES VIRUS STRAIN EDMONSTON	QVSFLQGDQSENE	1444	P04851.1
562	RUBELLA VIRUS	QYHPTACEVEPAFGH	1445	BAA28178.1
563	MEASLES VIRUS STRAIN EDMONSTON	QYVLATYDTSRVEHA	1446	P08362.1
564	BORDETELLA PERTUSSIS	RANPNPYTSRRSV	1447	ACI04548.1
565	MEASLES VIRUS STRAIN EDMONSTON	RASDARAAHLPTG	1448	P04851.1
566	MEASLES VIRUS STRAIN EDMONSTON	RASLETTNQAIEAIR	1449	P69353.1
567	RUBELLA VIRUS STRAIN THERIEN	RCGRLICGLSTTAQYPTRF	1450	P07566.1
568	BORDETELLA PERTUSSIS	RDGQSVIGACASPYEGRYR	1451	P04979.1
569	MEASLES VIRUS STRAIN EDMONSTON	RESYRETGPSRAS	1452	P04851.1
570	MEASLES VIRUS STRAIN EDMONSTON	RETGPSRASDARA	1453	P04851.1
571	MUMPS RUBULAVIRUS	RFAKYQQQGRLEAR	1454	P21186.1
572	RUBELLA VIRUS STRAIN THERIEN	RFGAPQAFLAGLLLATVAVGTARA	1455	P07566.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
573	MEASLES VIRUS STRAIN EDMONSTON	RFMVALILDIKRTPG	1456	P04851.1
574	MEASLES VIRUS STRAIN EDMONSTON	RFMVALILDIKRTPGNKPRI	1457	P04851.1
575	MEASLES VIRUS STRAIN EDMONSTON	RGEARESYRETGP	1458	P04851.1
576	RUBELLA VIRUS	RGTTTPPAYG	1459	CAA28880.1
577	RUBELLA VIRUS STRAIN M33	RIETRSARH	1460	ABD64214.1
578	BORDETELLA PERTUSSIS	RILAGALATYQ	1461	P04977.1
579	BORDETELLA PERTUSSIS	RIPPENIRRV	1462	ACI04548.1
580	BORDETELLA PERTUSSIS	RISNLND	1463	ACI16083.1
581	BORDETELLA PERTUSSIS	RLANLNG	1464	ACI16088.1
582	MEASLES VIRUS STRAIN EDMONSTON	RLDVGTNLGNIAKL	1465	P69353.1
583	MEASLES VIRUS STRAIN EDMONSTON	RLERKWLDV	1466	P04851.1
584	MEASLES VIRUS STRAIN EDMONSTON	RLGGKEDRRVKQSRG	1467	P04851.1
585	MEASLES VIRUS STRAIN EDMONSTON	RLGGKEDRRVKQSRGEARES	1468	P04851.1
586	MEASLES VIRUS STRAIN EDMONSTON	RLDRLVRL	1469	ABI54110.1
587	RUBELLA VIRUS	RLRLVDAD	1470	CAJ88851.1
588	RUBELLA VIRUS	RLRLVDADDPLL	1471	BAA19893.1
589	RUBELLA VIRUS	RLRLVDADDPLLRTAPGPGEVWVTPVIGSQA	1472	BAA19893.1
590	RUBELLA VIRUS	RLRLVQDADDPLLRIAPGPGEVWVTPVIGSQA	1473	SRC26596.8
591	MEASLES VIRUS STRAIN EDMONSTON	RLSDNGYYTV	1474	ABK40528.1
592	RUBELLA VIRUS	RLVDADDP	1475	CAJ88851.1
593	RUBELLA VIRUS	RLVDADDPLLRTAPG	1476	BAA28178.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
594	RUBELLA VIRUS	RLVGATPE	1477	CAJ88851.1
595	RUBELLA VIRUS	RMQTGRGGSAPRPELGPPTNPFQAAVA	1478	ABD64216.1
596	MEASLES MORBILLIVIRUS	RMSKGVFKV	1479	ABY21184.1
597	MEASLES MORBILLIVIRUS	RNPGLGAPVFHMTNY	1480	P06830.1
598	RUBELLA VIRUS	RPRLRLVD	1481	CAJ88851.1
599	BORDETELLA PERTUSSIS	RQAESSEAMAAWSERAGEA	1482	P04977.1
600	RUBELLA VIRUS	RQTWAEWAAAHWWQL	1483	BAA28178.1
601	MEASLES VIRUS STRAIN EDMONSTON	RRVKQSRGEARES	1484	P04851.1
602	MEASLES MORBILLIVIRUS	RRYPDAVYL	1485	ACA09725.1
603	MEASLES VIRUS STRAIN EDMONSTON	RRYPDAVYLHRIDLG	1486	P69353.1
604	MEASLES VIRUS STRAIN EDMONSTON	RSAGKVSSTLASELG	1487	P04851.1
605	MEASLES VIRUS STRAIN EDMONSTON	RSAGKVSSTLASELGITAED	1488	P04851.1
606	MEASLES VIRUS STRAIN EDMONSTON	RSELSQLS	1489	P08362.1
607	MEASLES VIRUS STRAIN EDMONSTON	RSELSQLSMYRVFEV	1490	P08362.1
608	RUBELLA VIRUS	RSQTPAPKPSRAPPQQPQPPRMQT	1491	ABD64214.1
609	RUBELLA VIRUS	RTAPGPGE	1492	CAJ88851.1
610	RUBELLA VIRUS	RTAPGPGEVWVTPVI	1493	BAA28178.1
611	MEASLES MORBILLIVIRUS	RTDDKLRMETCFQQA	1494	P06830.1
612	RUBELLA VIRUS	RTLAPPRNVRVTGCV	1495	BAA28178.1
613	MEASLES VIRUS STRAIN EDMONSTON	RTVLEPIRDALNAMT	1496	P69353.1
614	MEASLES VIRUS STRAIN EDMONSTON	RVEHAVVYYVYSPSR	1497	P08362.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
615	MEASLES VIRUS STRAIN EDMONSTON	RVFEVGVIRNPGLGA	1498	P08362.1
616	BORDETELLA PERTUSSIS	RVHVSKEEQYYDYEDATFE	1499	P04978.2
617	RUBELLA VIRUS	RVIDPAAQ	1500	BAA28178.1
618	RUBELLA VIRUS	RVKFHTETRTVWQLS	1501	BAA28178.1
619	BORDETELLA PERTUSSIS	RVYHNGITGET	1502	ACI04548.1
620	BORDETELLA PERTUSSIS	RYDSRPPEDVF	1503	ACI04548.1
621	MEASLES VIRUS STRAIN EDMONSTON	RYPDAVYLHRIDLGP	1504	P69353.1
622	MEASLES VIRUS STRAIN EDMONSTON	SAEISIQALSALGG	1505	P69353.1
623	MEASLES VIRUS STRAIN EDMONSTON	SAEPLLSCKPWQESR	1506	P04851.1
624	MEASLES VIRUS STRAIN EDMONSTON	SAEPLLSCKPWQESRKNAQ	1507	P04851.1
625	MEASLES MORBILLIVIRUS	SAGKVSSTLASELG	1508	P04851.1
626	MEASLES VIRUS STRAIN EDMONSTON	SAGKVSSTLASELGITAEDARLVS	1509	P04851.1
627	MEASLES VIRUS STRAIN EDMONSTON	SCTVTREDGT	1510	P08362.1
628	RUBELLA VIRUS	SDAACWGFPTDTVMS	1511	BAA28178.1
629	MEASLES VIRUS STRAIN EDMONSTON	SDARAAHLPTGTP	1512	P04851.1
630	RUBELLA VIRUS STRAIN THERIEN	SDWHQGTHVCHTKHMDFWCVEHD	1513	P07566.1
631	MEASLES VIRUS STRAIN EDMONSTON	SELRRWIKYTQRRV	1514	P04851.1
632	MEASLES VIRUS STRAIN EDMONSTON	SELRRWIKYTQRRVVGEFR	1515	P04851.1
633	MEASLES VIRUS STRAIN EDMONSTON	SELSQL	1516	P08362.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
634	MEASLES VIRUS STRAIN EDMONSTON	SELSQLS	1517	P08362.1
635	BORDETELLA PERTUSSIS	SEYLAHRRIPPENIRRVTRV	1518	CAD44970.1
636	MEASLES VIRUS STRAIN EDMONSTON	SFLQGDQSENELP	1519	P04851.1
637	MEASLES VIRUS STRAIN EDMONSTON	SGKGVSFQLVKLGWV	1520	P08362.1
638	MEASLES VIRUS STRAIN EDMONSTON	SHRGVIADNQAKWAV	1521	P08362.1
639	MEASLES VIRUS STRAIN EDMONSTON	SIEHQVKDVLTPFK	1522	P08362.1
640	MEASLES VIRUS STRAIN EDMONSTON	SKIGVVGIGSASYKV	1523	P69353.1
641	MEASLES MORBILLIVIRUS	SKRSELSQLSMYRVF	1524	P06830.1
642	MEASLES MORBILLIVIRUS	SLFVESPGQLIQRITDDPDVS	1525	ABI54110.1
643	MEASLES VIRUS STRAIN EDMONSTON	SLSTNLDVTNSIEHQ	1526	P08362.1
644	MEASLES VIRUS STRAIN EDMONSTON	SLSTNLDVTNSIEHQVKDVLTPFK	1527	P08362.1
645	MEASLES VIRUS STRAIN EDMONSTON	SLWGSGLML	1528	BAE98296.1
646	MEASLES VIRUS STRAIN EDMONSTON	SMKGLSSTSIVYILI	1529	P69353.1
647	MEASLES MORBILLIVIRUS	SMYRVFEVGV	1530	P08362.1
648	MEASLES MORBILLIVIRUS	SNDLSNCMVALGELK	1531	P06830.1
649	MEASLES VIRUS STRAIN HALLE	SPGQLIQR	1532	P10050.1
650	MEASLES VIRUS STRAIN EDMONSTON	SQDPQDSRRSAEP	1533	P04851.1
651	MEASLES MORBILLIVIRUS	SRIVINREHLMIDRP	1534	P06830.1
652	MEASLES VIRUS STRAIN EDMONSTON	SRKNKAQTRTPLQ	1535	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
653	RUBELLA VIRUS	SRLVGATP	1536	CAJ88851.1
654	RUBELLA VIRUS	SRLVGATPERPRLRLVDADDPLLR	1537	CAJ88851.1
655	MEASLES VIRUS STRAIN EDMONSTON	SRPGLKPDLTGTSKS	1538	P69353.1
656	BORDETELLA PERTUSSIS	SRRSVASIVGTLVRM	1539	CAD44970.1
657	RUBELLA VIRUS	SRWGLGSPNCHGPDW	1540	BAA28178.1
658	BORDETELLA PERTUSSIS	SSATK	1541	ACI16088.1
659	RUBELLA VIRUS	SSGGYAQLASYFNPG	1542	BAA28178.1
660	BORDETELLA PERTUSSIS	SSLGNGV	1543	ACI16083.1
661	MEASLES MORBILLIVIRUS	SSNLVILPGQDLQYV	1544	P06830.1
662	MEASLES VIRUS STRAIN EDMONSTON	SSQDPQDSRRSAEPL	1545	P04851.1
663	MEASLES VIRUS STRAIN EDMONSTON	SSQDPQDSRRSAEPLLCKP	1546	P04851.1
664	MEASLES VIRUS STRAIN EDMONSTON	SSRRHKRFAGVVLAG	1547	P69353.1
665	MEASLES VIRUS STRAIN EDMONSTON	SSTSIVYILIAVCLG	1548	P69353.1
666	BORDETELLA PERTUSSIS	STPGIVI	1549	AAA83981.1
667	BORDETELLA PERTUSSIS	STPGIVIPPQEITQHGSPYGRC	1550	AAA83981.1
668	BORDETELLA PERTUSSIS	STSSRRRYTEVY	1551	P04977.1
669	MEASLES VIRUS STRAIN EDMONSTON	SYFIVLSIAYPTLSE	1552	P69353.1
670	MEASLES VIRUS STRAIN EDMONSTON	SYRETGPSRASDA	1553	P04851.1
671	BORDETELLA PERTUSSIS	SYVK	1554	ACI16083.1
672	RUBELLA VIRUS	SYVQHPHKTVRVKFH	1555	BAA28178.1
673	RUBELLA VIRUS	TAPGPGEV	1556	CAJ88851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
674	BORDETELLA PERTUSSIS	TATRLLSSTNSRLC	1557	AAA83981.1
675	MEASLES MORBILLIVIRUS	TDDPVIDRLYLSSHR	1558	P06830.1
676	MEASLES VIRUS STRAIN EDMONSTON	TEILSLFGPSLRDPI	1559	P69353.1
677	RUBELLA VIRUS	TETRTVWQLSVAGVS	1560	BAA28178.1
678	BORDETELLA PERTUSSIS	TEVYLEHRMQEAVE	1561	P04977.1
679	MEASLES VIRUS STRAIN EDMONSTON	TFMPEGTVCSQNALY	1562	P69353.1
680	RUBELLA VIRUS	TGACICEIPTDVSCE	1563	BAA28178.1
681	BORDETELLA PERTUSSIS	TGDLRAY	1564	ACI16083.1
682	MEASLES MORBILLIVIRUS	TGMQSWVPLSTDDPV	1565	P06830.1
683	RUBELLA VIRUS	TGNQQSRWGLGSPNC	1566	BAA28178.1
684	MEASLES VIRUS STRAIN EDMONSTON	TGPSRASDARAAH	1567	P04851.1
685	MEASLES MORBILLIVIRUS	TGTIINQDPDKILTY	1568	AAF02706.1
686	RUBELLA VIRUS	TGVVYGTHTTAVSET	1569	BAA28178.1
687	MEASLES VIRUS STRAIN EDMONSTON	TIRGQFSNMSLSLLD	1570	P08362.1
688	RUBELLA VIRUS	TLGATCALPLAGLLA	1571	BAA28178.1
689	MEASLES MORBILLIVIRUS	TLLNNCTRV	1572	P26031.1
690	MEASLES VIRUS STRAIN EDMONSTON-B	TLNVPPPPDPGR	1573	P03422.1
691	MEASLES VIRUS STRAIN EDMONSTON-B	TLNVPPPPDPGRASTSGTPIKK	1574	P03422.1
692	MEASLES MORBILLIVIRUS	TMTSQGMYGGTYPVE	1575	P06830.1
693	MEASLES VIRUS STRAIN EDMONSTON	TNLGNAIAKLEDAKE	1576	P69353.1
694	MEASLES VIRUS STRAIN EDMONSTON	TNMEDEADQYFSHDD	1577	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
695	MEASLES VIRUS STRAIN EDMONSTON	TNMEDEADQYFSHDDPISSD	1578	P04851.1
696	RUBELLA VIRUS STRAIN M33	TNPFQAAVARGLRPP	1579	CAA28880.1
697	MEASLES MORBILLIVIRUS	TNSIEHQVKDVLTP	1580	P06830.1
698	MEASLES VIRUS STRAIN EDMONSTON	TNYLEQPVSNDSLNC	1581	P08362.1
699	MEASLES MORBILLIVIRUS	TNYLEQPVSNDSLNCMVALGELKLAAL	1582	AAR89413.1
700	RUBELLA VIRUS	TPERPRLR	1583	CAJ88851.1
701	RUBELLA VIRUS STRAIN THERIEN	TPERPRLRLVDADDPLLRTA	1584	P07566.1
702	MEASLES VIRUS STRAIN HALLE	TPGNKPRIA	1585	P10050.1
703	MEASLES VIRUS STRAIN EDMONSTON	TPLDIDTASESSQDP	1586	P04851.1
704	MEASLES VIRUS STRAIN EDMONSTON	TPLDIDTASESSQDPQDSRR	1587	P04851.1
705	MEASLES VIRUS STRAIN EDMONSTON	TPLFKIIGDEVGLRT	1588	P08362.1
706	MEASLES VIRUS STRAIN EDMONSTON	TPLQCTM	1589	P04851.1
707	RUBELLA VIRUS	TPVIGSQA	1590	CAJ88851.1
708	RUBELLA VIRUS	TPVIGSQARK	1591	BAA19893.1
709	MEASLES VIRUS STRAIN EDMONSTON	TQGYLISNFDESSCT	1592	P69353.1
710	BORDETELLA PERTUSSIS	TRANPNPYTSRRSVASIVGTLVRM	1593	P04977.1
711	RUBELLA VIRUS	TRFGCAMRWGLPP	1594	NP_740663.1
712	BORDETELLA PERTUSSIS	TRNTGQPATDHYYSNV	1595	AAA83981.1
713	MEASLES VIRUS STRAIN EDMONSTON	TRTPLQCTMTEIF	1596	P04851.1
714	RUBELLA VIRUS	TRWHRLLRMPVR	1597	ABD64216.1
715	MEASLES VIRUS STRAIN EDMONSTON	TSGSGGAIRGIKHII	1598	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
716	MEASLES VIRUS STRAIN EDMONSTON	TSGSGGAIRGIKHIIIVPIP	1599	P04851.1
717	MEASLES VIRUS STRAIN EDMONSTON	TSQGMYG GTYLVEKP	1600	P08362.1
718	MEASLES MORBILLIVIRUS	TSRVEHAVVYVYSP	1601	P06830.1
719	BORDETELLA PERTUSSIS	TSSRRYTEVYL	1602	ACI04548.1
720	BORDETELLA PERTUSSIS	TSYVG	1603	ACI16088.1
721	MEASLES VIRUS STRAIN EDMONSTON	TTEDKISRAGPRQA	1604	P04851.1
722	MEASLES VIRUS STRAIN EDMONSTON	TTEDKISRAGPRQAQVSFL	1605	P04851.1
723	RUBELLA VIRUS STRAIN M33	TTERIETRSARHP	1606	ABD64214.1
724	MEASLES VIRUS STRAIN EDMONSTON	TTNQAIEAIRQAGQE	1607	P69353.1
725	RUBELLA VIRUS	TTSDPWHPGPGGLK	1608	BAA28178.1
726	MEASLES VIRUS STRAIN EDMONSTON	TVCSQNALYPMSPLL	1609	P69353.1
727	RUBELLA VIRUS	TVNGEDVGAVPPGKF	1610	BAA28178.1
728	MEASLES MORBILLIVIRUS	TYPVEKPNLSSKRSE	1611	P06830.1
729	RUBELLA VIRUS	VAGVSCNVTTEHPFC	1612	BAA28178.1
730	BORDETELLA PERTUSSIS	VAPGIVPPKALFTQQGGAYGRC	1613	P04979.1
731	RUBELLA VIRUS	VCHTKHMDFWCVEHDRPPPATPTPL	1614	NP_740663.1
732	RUBELLA VIRUS	VCQRHSPDCSRLVGATPER	1615	BAA19893.1
733	RUBELLA VIRUS	VDADDPLL	1616	CAJ88851.1
734	RUBELLA VIRUS	VDADDPLLRTAPGPGEVWVT	1617	BAA19893.1
735	CORYNEBACTERIUM DIPHTHERIAE	VDIGFAAYNFVESIINLFQV	1618	AAV70486.1
736	MEASLES VIRUS STRAIN EDMONSTON	VEIAEYRRLRLTVLE	1619	P69353.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
737	MEASLES VIRUS STRAIN EDMONSTON	VELENSMGGLNFGRS	1620	P04851.1
738	MEASLES VIRUS STRAIN EDMONSTON	VELENSMGGLNFGRSYFDPA	1621	P04851.1
739	MEASLES MORBILLIVIRUS	VELKIKIASGFGPLI	1622	P06830.1
740	RUBELLA VIRUS	VEMDEWIHAHTTSD	1623	SRC265968
741	RUBELLA VIRUS	VEMPEWIHAHTTSDP	1624	BAA28178.1
742	CORYNEBACTERIUM DIPHTHERIAE	VERRLVKVL	1625	P33120.2
743	MEASLES MORBILLIVIRUS	VESPGQLI	1626	ABI54110.1
744	MEASLES VIRUS STRAIN EDMONSTON	VESPGQLIQRITDDP	1627	P04851.1
745	MEASLES VIRUS STRAIN EDMONSTON	VESPGQLIQRITDDPDVSIR	1628	P04851.1
746	RUBELLA VIRUS	VFALASYVQHPKTV	1629	BAA28178.1
747	RUBELLA VIRUS	VGATPERP	1630	CAJ88851.1
748	RUBELLA VIRUS	VGATPERPRL	1631	BAA19893.1
749	RUBELLA VIRUS	VGATPERPRLRLVDA	1632	BAA28178.1
750	MEASLES VIRUS STRAIN EDMONSTON	VGIGSASYKVMTRSS	1633	P69353.1
751	MEASLES VIRUS STRAIN EDMONSTON	VGLRTPQRFTDLVKF	1634	P08362.1
752	CORYNEBACTERIUM DIPHTHERIAE	VHHNTEEIVAQSIALSSLMV	1635	AAV70486.1
753	MEASLES VIRUS STRAIN EDMONSTON	VHRLEGVSYNIGSQE	1636	P69353.1
754	RUBELLA VIRUS	VIGSQARK	1637	CAJ88851.1
755	BORDETELLA PERTUSSIS	VITGSI	1638	ACI16088.1
756	BORDETELLA PERTUSSIS	VITGTI	1639	ACI16083.1
757	MEASLES VIRUS STRAIN EDMONSTON	VKQSRGEA	1640	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
758	MEASLES VIRUS STRAIN EDMONSTON	VL FVMFLSLI	1641	P08362.1
759	MEASLES MORBILLIVIRUS	VL FVMFLSLIGLLAI	1642	P06830.1
760	MEASLES MORBILLIVIRUS	VL TPLFKIIGDEVGL	1643	P06830.1
761	MEASLES VIRUS STRAIN EDMONSTON	VM TRSSHQSLVIKLM	1644	P69353.1
762	RUBELLA VIRUS	VPAAPCARIWNGTQR	1645	BAA28178.1
763	RUBELLA VIRUS	VPPDPGDLVEYIMNY	1646	BAA28178.1
764	MEASLES VIRUS STRAIN EDMONSTON	VQSVASSRRHKRFAG	1647	P69353.1
765	BORDETELLA PERTUSSIS	VQTGGTSRTVTMRYLAS	1648	ACI16083.1
766	BORDETELLA PERTUSSIS	VQVRI	1649	ACI16083.1
767	RUBELLA VIRUS	VRAYNQPADGV	1650	NP_740662.1
768	RUBELLA VIRUS	VRFESKIVDGGCFAP	1651	BAA28178.1
769	RUBELLA VIRUS	VRLAGVRFESKIVDG	1652	BAA28178.1
770	MEASLES VIRUS STRAIN EDMONSTON	VSGSFGNRFILSQGN	1653	P69353.1
771	BORDETELLA PERTUSSIS	VSKEEQYYDYEDAT	1654	AAA83981.1
772	MEASLES VIRUS STRAIN EDMONSTON	VSKGNCSGPTTIRGQ	1655	P08362.1
773	RUBELLA VIRUS	VT AALLNTPPPYQVS	1656	BAA28178.1
774	RUBELLA VIRUS	VTGCRYQCGTPALVEG	1657	BAA28178.1
775	RUBELLA VIRUS	VTPVIGSQ	1658	CAJ88851.1
776	RUBELLA VIRUS STRAIN THERIEN	VTTEHPFCNTPHGQLEVQVPPD	1659	P07566.1
777	MEASLES VIRUS STRAIN EDMONSTON	VVLAGAALGVATAAQ	1660	P69353.1
778	RUBELLA VIRUS	VWQLSVAGVSCNVT	1661	BAA28178.1
779	RUBELLA VIRUS	VWVTPVIG	1662	CAJ88851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
780	RUBELLA VIRUS	VWVTPVIGSQAR	1663	BAA19893.1
781	MEASLES VIRUS STRAIN EDMONSTON	VYILIAVCLGGLIGI	1664	P69353.1
782	MEASLES VIRUS STRAIN EDMONSTON	VYLHRIDLGPPISLE	1665	P69353.1
783	BORDETELLA PERTUSSIS	VYRYDSRP	1666	P04977.1
784	BORDETELLA PERTUSSIS	VYRYDSRPPEDV	1667	P04977.1
785	MEASLES MORBILLIVIRUS	VYWLTIIPPMKNLALG	1668	P06830.1
786	RUBELLA VIRUS	WDLEATGACICEIPT	1669	BAA28178.1
787	MEASLES MORBILLIVIRUS	WDQKLWCRHFCVLAD	1670	AAR89413.1
788	RUBELLA VIRUS	WGFPDVTVMVSFALA	1671	BAA28178.1
789	RUBELLA VIRUS	WHPPGPLGLKFKTVR	1672	BAA28178.1
790	RUBELLA VIRUS	WIHAHTTSDPWHPG	1673	BAA28178.1
791	MEASLES VIRUS STRAIN EDMONSTON	WLTIPPMKNLALGVI	1674	P08362.1
792	MEASLES VIRUS STRAIN EDMONSTON	WQESRKNKAQTRTPLQCTMT	1675	P04851.1
793	RUBELLA VIRUS	WVCIFMVCRRACR	1676	SRC265968
794	RUBELLA VIRUS	WVTPVIGS	1677	CAJ88851.1
795	MEASLES VIRUS STRAIN EDMONSTON	WYTTVPKYVATQGYL	1678	P69353.1
796	MEASLES VIRUS STRAIN EDMONSTON	YALGGDINKVLEKLG	1679	P69353.1
797	MEASLES VIRUS STRAIN EDMONSTON	YAMGVGVELE	1680	P04851.1
798	MEASLES MORBILLIVIRUS	YAMGVGVELEN	1681	ABI54110.1
799	MEASLES MORBILLIVIRUS	YCADVAAEELMNALV	1682	AAR89413.1
800	MEASLES MORBILLIVIRUS	YDFRDLTWCINPPER	1683	P06830.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
801	BORDETELLA PERTUSSIS	YFEPGPT	1684	ACI16083.1
802	RUBELLA VIRUS	YFNPGGSYKQYHPT	1685	BAA28178.1
803	MEASLES VIRUS STRAIN EDMONSTON	YFRLGQEMVRRSAGK	1686	P04851.1
804	MEASLES VIRUS STRAIN EDMONSTON	YFRLGQEMVRRSAGKVSSTL	1687	P04851.1
805	MEASLES MORBILLIVIRUS	YFYFRLPIKGVPIE	1688	P06830.1
806	BORDETELLA PERTUSSIS	YGDNAGRILAGALAT	1689	P04977.1
807	RUBELLA VIRUS	YGHATVEMPEWIAH	1690	BAA28178.1
808	RUBELLA VIRUS	YIMNYTGNQQRWGL	1691	BAA28178.1
809	MEASLES VIRUS STRAIN EDMONSTON	YINNELIPSMNQLSC	1692	P69353.1
810	RUBELLA VIRUS	YLCTAPGCATQAPVP	1693	BAA28178.1
811	MEASLES MORBILLIVIRUS	YLFTVPIKEAGEDCH	1694	P06830.1
812	MEASLES VIRUS STRAIN EDMONSTON	YLHDPEFNL	1695	ABK40531.1
813	MEASLES VIRUS STRAIN EDMONSTON	YLNMSRLFV	1696	ABK40531.1
814	MEASLES VIRUS STRAIN HALLE	YPALGLHEF	1697	P10050.1
815	MEASLES MORBILLIVIRUS	YPALGLHEFA	1698	ABI54110.1
816	MEASLES VIRUS STRAIN EDMONSTON	YPALGLHEFAGELST	1699	P04851.1
817	MEASLES VIRUS STRAIN EDMONSTON	YPALGLHEFAGELSTLESML	1700	P04851.1
818	MEASLES VIRUS STRAIN EDMONSTON	YPFRLPIKGVPIELQ	1701	P08362.1
819	MEASLES VIRUS STRAIN HALLE	YPLLWSYAM	1702	P10050.1
820	MUMPS RUBULAVIRUS	YQQQGRL	1703	P21186.1
821	BORDETELLA PERTUSSIS	YQSEYLAHRR	1704	P04977.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
822	MEASLES VIRUS STRAIN EDMONSTON	YRETGPSRASDARAA	1705	P04851.1
823	MEASLES VIRUS STRAIN EDMONSTON	YRETGPSRASDARAAHLPTG	1706	P04851.1
824	RUBELLA VIRUS	YRNASDVLPQHWLQGGWGCYNLSDW	1707	NP_740663.1
825	MEASLES VIRUS STRAIN EDMONSTON	YRRLRLRTVLEPIRDA	1708	P69353.1
826	BORDETELLA PERTUSSIS	YRYDSRPP	1709	P04977.1
827	MEASLES VIRUS STRAIN EDMONSTON	YSGGDLGILESIRGI	1710	P69353.1
828	BORDETELLA PERTUSSIS	YSKVTATBLLASTNSRLCAVFVRDG	1711	SRC280066
829	MEASLES VIRUS STRAIN EDMONSTON	YSPSRFSFYFYPFRL	1712	P08362.1
830	RUBELLA VIRUS STRAIN THERIEN	YTGNQQSRWGLGSPNCHGPDWASPV	1713	P07566.1
831	MEASLES MORBILLIVIRUS	YVLLAVLFV	1714	P08362.1
832	MEASLES MORBILLIVIRUS	YVYSPGRSFSFYFYPF	1715	P06830.1
833	BORDETELLA PERTUSSIS	YYDYEDATFQTYALTGISLCNPAASIC	1716	P04979.1
834	MEASLES MORBILLIVIRUS	GDLLGILESIRGIKAR	1717	AAF02706.1
835	MEASLES MORBILLIVIRUS	TVPKYVATQGYLISN	1718	AAL29688.1
836	MEASLES MORBILLIVIRUS	KPWDSPQEI	1719	P26035.1
837	MEASLES MORBILLIVIRUS	KPWESPQEI	1720	CAA34579.1
838	BORDETELLA PERTUSSIS	ATYQSEYLAHRRIPP	1721	ACI04548.1
839	BORDETELLA PERTUSSIS	CMARQAESSEAMAAWSERAGEAMVLVYYESIAYSF	1722	ACI04548.1
840	BORDETELLA PERTUSSIS	CQVGSSNSAFVSTSSRRYTEVYL	1723	ACI04548.1
841	BORDETELLA PERTUSSIS	DDPPATVYRYDSRPP	1724	ACI04548.1
842	BORDETELLA PERTUSSIS	GALATYQSEYLAHRRIPP	1725	ACI04548.1
843	BORDETELLA PERTUSSIS	MAAWSERAGEAMVLVYYESIAYSF	1726	ACI04548.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
844	BORDETELLA PERTUSSIS	MVLVYYESIAYSF	1727	ACI04548.1
845	BORDETELLA PERTUSSIS	PATVYRYDSRPPEDV	1728	ACI04548.1
846	BORDETELLA PERTUSSIS	YDSRPPEDV	1729	ACI04548.1
847	BORDETELLA PERTUSSIS	EPGITTNYDT	1730	ACI16087.1
848	BORDETELLA PERTUSSIS	GDLRAYKMOVYATNPQTQLSN	1731	ACI16083.1
849	BORDETELLA PERTUSSIS	KNGDVEASAITTYVGFSVVYP	1732	ACI16083.1
850	BORDETELLA PERTUSSIS	KVTNGSKSYTLRYLASVVK	1733	ACI16088.1
851	BORDETELLA PERTUSSIS	QALGALKLYFEPGITTNYDTGDLIAYKQTYNASGN	1734	ACI16088.1
852	BORDETELLA PERTUSSIS	YATNPQTQLS	1735	ACI16083.1
853	CORYNEBACTERIUM DIPHTHERIAE	DNENPLSGKAGGVVKVTYPGLTKV	1736	AAV70486.1
854	CORYNEBACTERIUM DIPHTHERIAE	ENFSSYHGKTPGYVDSI	1737	AAV70486.1
855	CORYNEBACTERIUM DIPHTHERIAE	KVDNAETIKKELGLSLTEP	1738	AAV70486.1
856	RUBELLA VIRUS STRAIN M33	MEDLQKALEAQSRALRAGLAA	1739	CAA28880.1
857	CORYNEBACTERIUM DIPHTHERIAE	QKGIQKPKSGTQGNYYDDWKGFY	1740	AAV70486.1
858	RUBELLA VIRUS STRAIN M33	RTGAWQRKDWSRAPPPEERQESRSQTPAPKPSR	1741	CAA28880.1
859	RUBELLA VIRUS	AAGASQSRPRPPRHARAQHLPEMTPAVT	1742	SRC26596.8
860	RUBELLA VIRUS	CVTSWLWSEGEAVFYRVDLHFINLGTP	1743	CAA28880.1
861	RUBELLA VIRUS	FRVGGTRWHRLLRMPVRGLDGDTPALP	1744	CAA28880.1
862	CORYNEBACTERIUM DIPHTHERIAE	GRKIRMRCRAIDGDVTFCRPKSPVYVGN	1745	1007216A
863	RUBELLA VIRUS	GTPPLDEDGRWDPALMYNPCGPEPPAHV	1746	CAA28880.1
864	CORYNEBACTERIUM DIPHTHERIAE	GVHANLHVAFHRSSEKIHSNEISSDSIGV LGYQKTVDHTKVNSKLSLFFEIKS	1747	AAV70486.1
865	RUBELLA VIRUS	MASTTPITMEDLQKALEAQSRALRAGLAG	1748	ABD64200.1
866	RUBELLA VIRUS	PELGPPTNPQAAVARGLRPPLHDPDTEAPTEAC	1749	CAA28880.1
867	RUBELLA VIRUS	PLPPHTTERIETRSARHPWRIRFGAP	1750	CAA28880.1
868	RUBELLA VIRUS	SRAPPPEERQESRSQTPAPKPSRAPP	1751	CAA28880.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
869	RUBELLA VIRUS	SRAPPQQPQPPRMQTGRGGSAPRPELGP	1752	CAA28880.1
870	RUBELLA VIRUS	TPAVTPEGPAPPRTGAWQRKDWSRAPP	1753	CAA28880.1
871	RUBELLA VIRUS	VRAYNQPAGDVRGVWGKGERTYAEQDFRV	1754	CAA28880.1
872	RUBELLA VIRUS	AFGHSDAACWGFPTDTVMSV	1755	CAA28880.1
873	RUBELLA VIRUS	CARIWNGTQRACTFWAVNAYS	1756	CAA28880.1
874	RUBELLA VIRUS	EEAFTYLCTAPGCATQTPVPVR	1757	CAA28880.1
875	RUBELLA VIRUS	FAPWDLEATGACICEIPTDV	1758	CAA28880.1
876	RUBELLA VIRUS	GEDVGAFPPGKFVTAAL	1759	CAA28880.1
877	RUBELLA VIRUS	GEVWVTPVIGSQARKCGLHI	1760	CAA28880.1
878	RUBELLA VIRUS	GQLEVQVPPDPGDLVEYIMN	1761	CAA28880.1
879	RUBELLA VIRUS	GSYYKQYHPTACEVEPAFGH	1762	CAA28880.1
880	RUBELLA VIRUS	IHAHTTSDPWHPPGPLGLKF	1763	CAA28880.1
881	RUBELLA VIRUS	IMNYTGNQQSRWGLGSPNCH	1764	CAA28880.1
882	RUBELLA VIRUS	LHIRAGPYGHATVEMPEWIH	1765	CAA28880.1
883	RUBELLA VIRUS	LKFKTVRPVALPRALAPPRN	1766	CAA28880.1
884	RUBELLA VIRUS	LNTPPPYQVSCGGESDRASAGH	1767	CAA28880.1
885	RUBELLA VIRUS	NCHGPDWASPVCQRHSPDCS	1768	CAA28880.1
886	RUBELLA VIRUS	PDCSRLVGATPERPRLRLVD	1769	CAA28880.1
887	RUBELLA VIRUS	PRNVRVTGCYQCCTPALVEG	1770	CAA28880.1
888	RUBELLA VIRUS	PTDVSCEGLGAWVPTAPCARI	1771	CAA28880.1
889	RUBELLA VIRUS	RLVDADDPLLRTAPGPGEVW	1772	CAA28880.1
890	RUBELLA VIRUS	SVFALASYVQHHPKTVRVKF	1773	CAA28880.1
891	RUBELLA VIRUS	VEGLAPGGGNCHLTVNGEDV	1774	CAA28880.1
892	RUBELLA VIRUS	VKFHTETRTVWQLSVAGVSC	1775	CAA28880.1
893	RUBELLA VIRUS	VPVRLAGVGFESKIVDGGCF	1776	CAA28880.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
894	RUBELLA VIRUS	VSCNVTTEHPFCNTPHGQLE	1777	CAA28880.1
895	BORDETELLA PERTUSSIS	AAASSPDAHVPF	1778	AAA22983.1
896	BORDETELLA PERTUSSIS	AASSPDA	1779	AAA22983.1
897	BORDETELLA PERTUSSIS	AKLGAAASSPDA	1780	AAA22983.1
898	BORDETELLA PERTUSSIS	AMKPYEVTPTRM	1781	AAA22983.1
899	BORDETELLA PERTUSSIS	AMTHLSPALADVPLYVLVKTNMVVT	1782	AAA22983.1
900	BORDETELLA PERTUSSIS	ASSPDAHVPFCF	1783	AAA22983.1
901	BORDETELLA PERTUSSIS	ASSPDAHVPFCFGKDLKRPSSPME	1784	AAA22983.1
902	BORDETELLA PERTUSSIS	CFGKDLKRPSS	1785	AAA22983.1
903	BORDETELLA PERTUSSIS	CFGKDLKRPSSPMEVMLRAVFMQQ	1786	AAA22983.1
904	BORDETELLA PERTUSSIS	CGIAAKLGAAAS	1787	AAA22983.1
905	BORDETELLA PERTUSSIS	CGIAAKLGAAASSPDAHVPFCFGKD	1788	AAA22983.1
906	BORDETELLA PERTUSSIS	DAHVPFCFGKDL	1789	AAA22983.1
907	BORDETELLA PERTUSSIS	DLKRPSSPMEV	1790	AAA22983.1
908	BORDETELLA PERTUSSIS	DVPYVLVKTNMV	1791	AAA22983.1
909	BORDETELLA PERTUSSIS	DVPYVLVKTNMVVTSVAMKPYEVTPT	1792	AAA22983.1
910	BORDETELLA PERTUSSIS	EVMLRAVFMQQR	1793	AAA22983.1
911	BORDETELLA PERTUSSIS	FEGKPALELIRM	1794	AAA22983.1
912	BORDETELLA PERTUSSIS	FLGPKQLTFEGK	1795	AAA22983.1
913	BORDETELLA PERTUSSIS	FLGPKQLTFEGKPALELIRMVECSG	1796	AAA22983.1
914	BORDETELLA PERTUSSIS	FMQQRPLRMFLGPKQLT	1797	AAA22983.1
915	BORDETELLA PERTUSSIS	GKDLKRPSSPM	1798	AAA22983.1
916	BORDETELLA PERTUSSIS	GKDLKRPSSPME	1799	AAA22983.1
917	BORDETELLA PERTUSSIS	GKPALELIRMVE	1800	AAA22983.1
918	BORDETELLA PERTUSSIS	GPKQLTFEGKPA	1801	AAA22983.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
919	BORDETELLA PERTUSSIS	HVPFCFGKDLKR	1802	AAA22983.1
920	BORDETELLA PERTUSSIS	IAAKLGAAASSP	1803	AAA22983.1
921	BORDETELLA PERTUSSIS	KPYEVTPTTMLV	1804	AAA22983.1
922	BORDETELLA PERTUSSIS	KQLTFEGKPALE	1805	AAA22983.1
923	BORDETELLA PERTUSSIS	KRPGSSPMEVML	1806	AAA22983.1
924	BORDETELLA PERTUSSIS	LELIRMVECSGK	1807	AAA22983.1
925	BORDETELLA PERTUSSIS	LGAAASSPDAHV	1808	AAA22983.1
926	BORDETELLA PERTUSSIS	LIRMVECSGKQD	1809	AAA22983.1
927	BORDETELLA PERTUSSIS	LVCGIAAKLGAA	1810	AAA22983.1
928	BORDETELLA PERTUSSIS	MKPYEVTPTMR	1811	AAA22983.1
929	BORDETELLA PERTUSSIS	MLRAVFMQQRPL	1812	AAA22983.1
930	BORDETELLA PERTUSSIS	MQQRPLRM	1813	AAA22983.1
931	BORDETELLA PERTUSSIS	MQQRPLRMFLGP	1814	AAA22983.1
932	BORDETELLA PERTUSSIS	MVVTSVAMKPYE	1815	AAA22983.1
933	BORDETELLA PERTUSSIS	MVVTSVAMKPYEVTPTTMLVCGIAA	1816	AAA22983.1
934	BORDETELLA PERTUSSIS	PALELIRMVECS	1817	AAA22983.1
935	BORDETELLA PERTUSSIS	PALELIRMVECSGK	1818	AAA22983.1
936	BORDETELLA PERTUSSIS	PFCFGKDLKRP	1819	AAA22983.1
937	BORDETELLA PERTUSSIS	PGSSPMEVMLRA	1820	AAA22983.1
938	BORDETELLA PERTUSSIS	PGSSPMEVMLRAVF	1821	AAA22983.1
939	BORDETELLA PERTUSSIS	PKQLTFEGK	1822	AAA22983.1
940	BORDETELLA PERTUSSIS	PLRMFLGPKQLT	1823	AAA22983.1
941	BORDETELLA PERTUSSIS	PTTMLVCGIAAK	1824	AAA22983.1
942	BORDETELLA PERTUSSIS	PYVLVKTNMVVT	1825	AAA22983.1
943	BORDETELLA PERTUSSIS	QLTFEGKPALELIRMVECSGKQDCP	1826	AAA22983.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
944	BORDETELLA PERTUSSIS	QRPLRMFLGPKQ	1827	AAA22983.1
945	BORDETELLA PERTUSSIS	RAVFMQQRPLRM	1828	AAA22983.1
946	BORDETELLA PERTUSSIS	RMFLGPKQLTFE	1829	AAA22983.1
947	BORDETELLA PERTUSSIS	RMLVCGIAAKLG	1830	AAA22983.1
948	BORDETELLA PERTUSSIS	RMVECSGKQDCP	1831	AAA22983.1
949	BORDETELLA PERTUSSIS	SPDAHVPFCFGK	1832	AAA22983.1
950	BORDETELLA PERTUSSIS	SSPMEVMLRAVF	1833	AAA22983.1
951	BORDETELLA PERTUSSIS	SSPMEVMLRAVFMQQRPLRMFLGPK	1834	AAA22983.1
952	BORDETELLA PERTUSSIS	SVAMKPYEVTPT	1835	AAA22983.1
953	BORDETELLA PERTUSSIS	VECSGKQDCP	1836	AAA22983.1
954	BORDETELLA PERTUSSIS	VFMQQRPLRMFL	1837	AAA22983.1
955	BORDETELLA PERTUSSIS	VFMQQRPLRMFLGPKQLTFEGKPAL	1838	AAA22983.1
956	BORDETELLA PERTUSSIS	VKTNMNVTSVAM	1839	AAA22983.1
957	BORDETELLA PERTUSSIS	VLVKTNMNVTSV	1840	AAA22983.1
958	BORDETELLA PERTUSSIS	VTPTMLVCGIA	1841	AAA22983.1
959	BORDETELLA PERTUSSIS	VTSVAMKPYEVT	1842	AAA22983.1
960	BORDETELLA PERTUSSIS	YEVTPTRMLVCG	1843	AAA22983.1
961	BORDETELLA PERTUSSIS	YEVTPTRMLVCGIAAKLGAAASSPD	1844	AAA22983.1
962	BORDETELLA PERTUSSIS	CASPYEGRYRDMYDALR	1845	P04979.1
963	BORDETELLA PERTUSSIS	CAVFVRDQSV	1846	P04979.1
964	BORDETELLA PERTUSSIS	CITTIYKTG	1847	P04979.1
965	BORDETELLA PERTUSSIS	CPNGTRALTV	1848	P04979.1
966	BORDETELLA PERTUSSIS	DALRRLLYMIYMSG	1849	P04979.1
967	RUBELLA VIRUS STRAIN THERIEN	GNRGRGQRRDWSRAPPPEERQETRS	1850	P07566.1
968	BORDETELLA PERTUSSIS	GQPAADHYYSKVT	1851	P04979.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
969	RUBELLA VIRUS	GSPNCHGPDWASPVCQRHS	1852	ABD64214.1
970	MEASLES VIRUS STRAIN EDMONSTON	HKSLSTNLDVTNSIEHQ	1853	P08362.1
971	BORDETELLA PERTUSSIS	LFTQQGGAYGRC	1854	P04979.1
972	MEASLES VIRUS STRAIN EDMONSTON	LIGLLAIAGIRLHRAAIYTAEI	1855	P08362.1
973	MEASLES MORBILLIVIRUS	PDTAADSELRRWIKY	1856	ABI54110.1
974	RUBELLA VIRUS STRAIN THERIEN	PNCHGPDWASPVCQRHS	1857	P07566.1
975	RUBELLA VIRUS	QTPAPKPSRAPPQQPQPPRMQTGR	1858	ABD64216.1
976	RUBELLA VIRUS VACCINE STRAIN RA27/3	RAGLTAGASQSRRPRPPR	1859	CAA33016.1
977	RUBELLA VIRUS VACCINE STRAIN RA27/3	RFGAPQAFLAGLLLAHAVGTARA	1860	ABD64214.1
978	BORDETELLA PERTUSSIS	RGNAELQTYLRQITPG	1861	P04979.1
979	BORDETELLA PERTUSSIS	RVHVSKEEQYYDYED	1862	P04979.1
980	BORDETELLA PERTUSSIS	SIYGLYDGTYL	1863	P04979.1
981	BORDETELLA PERTUSSIS	SKVTATRLLASTNS	1864	P04979.1
982	BORDETELLA PERTUSSIS	TQQGGAYGRCPNGTRA	1865	P04979.1
983	BORDETELLA PERTUSSIS	VAPGIVIPPKAL	1866	P04979.1
984	BORDETELLA PERTUSSIS	DSRPPEDVFQNGFTAWG	1867	ACI04548.1
985	BORDETELLA PERTUSSIS	EHRMQEAVEAERAGR	1868	ACI04548.1
986	MEASLES VIRUS STRAIN EDMONSTON	ETCFQQACKGKIQALCENPEWA	1869	P08362.1
987	BORDETELLA PERTUSSIS	EYVDTYGDNAGRILAGALATYQ	1870	ACI04548.1
988	BORDETELLA PERTUSSIS	HRRIPPENIRRVTR	1871	ACI04548.1
989	BORDETELLA PERTUSSIS	MARQAESSE	1872	ACI04548.1
990	BORDETELLA PERTUSSIS	MQEAVEAERAGR	1873	ACI04548.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
991	BORDETELLA PERTUSSIS	SQQTRANPNPYTSRR	1874	ACI04548.1
992	BORDETELLA PERTUSSIS	TRANPNPYTSRRSVASIVGTLVHG	1875	SRC280066
993	BORDETELLA PERTUSSIS	TVYRYDSRPPED	1876	ACI04548.1
994	MEASLES MORBILLIVIRUS	NDRNLLD	1877	P10050.1
995	MEASLES MORBILLIVIRUS	NMEDEADQYFSHDDPISSDQSRFGWFENK	1878	P04851.1
996	MEASLES MORBILLIVIRUS	SRASDARAAHLPTGTPLDID	1879	P04851.1
997	BORDETELLA PERTUSSIS	EDVFQNGFTAW	1880	ACI04548.1
998	CORYNEBACTERIUM DIPHtheriae	AEGSSSVEYINNWEQAK	1881	AAV70486.1
999	CORYNEBACTERIUM DIPHtheriae	GPIKNKMSSEPNKT	1882	AAV70486.1
1000	MEASLES VIRUS STRAIN HALLE	GPKLTGALIGILSLFVESPGQLIQRITDDPDV	1883	P10050.1
1001	CORYNEBACTERIUM DIPHtheriae	GYQKTVDHTKVNK	1884	AAV70486.1
1002	CORYNEBACTERIUM DIPHtheriae	KTVDH	1885	AAV70486.1
1003	CORYNEBACTERIUM DIPHtheriae	SESPNK	1886	AAV70486.1
1004	CORYNEBACTERIUM DIPHtheriae	AEGSSSVEYINNWEQAKALS	1887	AAV70486.1
1005	CORYNEBACTERIUM DIPHtheriae	AQAIPLVGELVDIGFAAYNF	1888	AAV70486.1
1006	CORYNEBACTERIUM DIPHtheriae	ASRVVLSLPFAEGSSSVEYI	1889	AAV70486.1
1007	CORYNEBACTERIUM DIPHtheriae	CINLDWDVIRDKTKTKIESL	1890	AAV70486.1
1008	CORYNEBACTERIUM DIPHtheriae	CRAIDGDVTFCRPKSPVYVG	1891	AAV70486.1
1009	CORYNEBACTERIUM DIPHtheriae	CRPKSPVYVGNVHANLHVA	1892	AAV70486.1
1010	CORYNEBACTERIUM DIPHtheriae	DAAGYSVDNENPLSGKAGGV	1893	AAV70486.1
1011	CORYNEBACTERIUM DIPHtheriae	DKTKTKIESLKEHGPIKNKM	1894	AAV70486.1
1012	CORYNEBACTERIUM DIPHtheriae	EEFIKRFGDGASRVVLSLPF	1895	AAV70486.1
1013	CORYNEBACTERIUM DIPHtheriae	EKAKQYLEEFHQTALEHPEL	1896	AAV70486.1
1014	CORYNEBACTERIUM DIPHtheriae	FHRSSSEKIHSNEISSDSIG	1897	AAV70486.1
1015	CORYNEBACTERIUM DIPHtheriae	GADDVVDSSKSFVMENFSSY	1898	CAE11230.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1016	CORYNEBACTERIU M DIPHTHERIAE	GKRGQDAMYEYMAQACAGNR	1899	AAV70486 .1
1017	CORYNEBACTERIU M DIPHTHERIAE	GSVMGIADGAVHHNTEEIVA	1900	AAV70486 .1
1018	CORYNEBACTERIU M DIPHTHERIAE	GTQGNYYDDWKGIFYSTDNKY	1901	AAV70486 .1
1019	CORYNEBACTERIU M DIPHTHERIAE	HDGYAVSWNTVEDSIIRTGF	1902	AAV70486 .1
1020	CORYNEBACTERIU M DIPHTHERIAE	HGTPKPGYVDSIQKGIQPKPS	1903	AAV70486 .1
1021	CORYNEBACTERIU M DIPHTHERIAE	HQTALEHPELSELKTVTGTN	1904	AAV70486 .1
1022	CORYNEBACTERIU M DIPHTHERIAE	IQKGIQPKPSGTQGNYYDDW	1905	AAV70486 .1
1023	CORYNEBACTERIU M DIPHTHERIAE	KEHGPIKNKMSSEPNKTVSE	1906	AAV70486 .1
1024	CORYNEBACTERIU M DIPHTHERIAE	KGFYSTDNKYDAAGYSVDNE	1907	AAV70486 .1
1025	CORYNEBACTERIU M DIPHTHERIAE	LDVNKSKTHISVNGRKIRM	1908	AAV70486 .1
1026	RUBELLA VIRUS	MASTIPITMEDLQKALEA	1909	SRC26596 8
1027	CORYNEBACTERIU M DIPHTHERIAE	NGVHANLHVAFHRSSSEKIH	1910	AAV70486 .1
1028	CORYNEBACTERIU M DIPHTHERIAE	NNWEQAKALSVELEINFETR	1911	AAV70486 .1
1029	CORYNEBACTERIU M DIPHTHERIAE	NPLSGKAGGVVKVTYPGLTK	1912	AAV70486 .1
1030	CORYNEBACTERIU M DIPHTHERIAE	PVFAGANYAAWAVNVAQVID	1913	AAV70486 .1
1031	CORYNEBACTERIU M DIPHTHERIAE	SELKTVTGTNPVFAGANYAA	1914	AAV70486 .1
1032	CORYNEBACTERIU M DIPHTHERIAE	SESPNKTVSEEKAKQYLEEF	1915	AAV70486 .1
1033	CORYNEBACTERIU M DIPHTHERIAE	SETADNLEKTTAALSILPGI	1916	AAV70486 .1
1034	CORYNEBACTERIU M DIPHTHERIAE	SFVMENFSSYHGTPKGYVDS	1917	AAV70486 .1
1035	CORYNEBACTERIU M DIPHTHERIAE	SNEISSDSIGVLGYQKTVDH	1918	AAV70486 .1
1036	CORYNEBACTERIU M DIPHTHERIAE	SPGHKTQPFLHDGYAVSWNT	1919	AAV70486 .1
1037	CORYNEBACTERIU M DIPHTHERIAE	SVNGRKIRMRCRAIDGDVTF	1920	AAV70486 .1
1038	CORYNEBACTERIU M DIPHTHERIAE	TAALSILPGIGSVMGIADGA	1921	AAV70486 .1
1039	CORYNEBACTERIU M DIPHTHERIAE	TAENTPLPIAGVLLPTIPGK	1922	AAV70486 .1
1040	CORYNEBACTERIU M DIPHTHERIAE	TEPLMEQVGTEEFIKRFGDG	1923	AAV70486 .1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
104 1	CORYNEBACTERIU M DIPHTHERIAE	TIKKELGLSLTEPLMEQVGT	1924	AAV70486 .1
104 2	CORYNEBACTERIU M DIPHTHERIAE	TKVNSKLSLFFEIKS	1925	AAV70486 .1
104 3	CORYNEBACTERIU M DIPHTHERIAE	VEDSIIRTGFQGESGHDIKI	1926	AAV70486 .1
104 4	CORYNEBACTERIU M DIPHTHERIAE	VELEINFETRGRKRGQDAMYE	1927	AAV70486 .1
104 5	CORYNEBACTERIU M DIPHTHERIAE	VESIINLFQVVHNSYNRPAY	1928	AAV70486 .1
104 6	CORYNEBACTERIU M DIPHTHERIAE	VHNSYNRPAYSPGHKTQPFL	1929	AAV70486 .1
104 7	CORYNEBACTERIU M DIPHTHERIAE	VKVTPGLTKVLALKVDNAE	1930	AAV70486 .1
104 8	CORYNEBACTERIU M DIPHTHERIAE	VLALKVDNAETIKKELGLSL	1931	AAV70486 .1
104 9	CORYNEBACTERIU M DIPHTHERIAE	VLGYQKTVTDHTKVNKLSLF	1932	AAV70486 .1
105 0	CORYNEBACTERIU M DIPHTHERIAE	VRRSVGSSLSCINLDWDVIR	1933	AAV70486 .1
105 1	CORYNEBACTERIU M DIPHTHERIAE	WAVNVAQVIDSETADNLEKT	1934	AAV70486 .1
105 2	CORYNEBACTERIU M DIPHTHERIAE	YMAQACAGNRVRRSVGSSLS	1935	AAV70486 .1
105 3	BORDETELLA PERTUSSIS	AKAPPAPKPAPQPGP	1936	ABO77783 .1
105 4	BORDETELLA PERTUSSIS	APKPAPQPGP	1937	ABO77783 .1
105 5	BORDETELLA PERTUSSIS	APKPAPQPGPQPPQP	1938	ABO77783 .1
105 6	MEASLES VIRUS STRAIN EDMONSTON	AQTRTPLQCTMTEIF	1939	P04851.1
105 7	MEASLES VIRUS STRAIN EDMONSTON	ASRGTNMEDEADQYFSHDD	1940	P04851.1
105 8	BORDETELLA PERTUSSIS	ATIRR	1941	ABO77783 .1
105 9	BORDETELLA PERTUSSIS	DNRAG	1942	ABO77783 .1
106 0	BORDETELLA PERTUSSIS	EAPAPQPPAGRELSA	1943	ABO77783 .1
106 1	MEASLES VIRUS STRAIN EDMONSTON	EMVRRSAGKVSSTLASELGI	1944	P04851.1
106 2	BORDETELLA PERTUSSIS	GASEL	1945	ABO77783 .1
106 3	BORDETELLA PERTUSSIS	GDALAGGAVP	1946	AAA22980 .1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1064	BORDETELLA PERTUSSIS	GDAPAGGAVP	1947	ABO77783.1
1065	BORDETELLA PERTUSSIS	GDTWDDD	1948	ABO77783.1
1066	BORDETELLA PERTUSSIS	GERQH	1949	ABO77783.1
1067	BORDETELLA PERTUSSIS	GGAVP	1950	ABO77783.1
1068	BORDETELLA PERTUSSIS	GGFGP	1951	P14283.3
1069	BORDETELLA PERTUSSIS	GGFGPGGFGP	1952	BAF35031.1
1070	BORDETELLA PERTUSSIS	GGFGPVLDGW	1953	ABO77783.1
1071	MEASLES VIRUS STRAIN EDMONSTON	GGKEDRRVKQSRGEARESYR	1954	P04851.1
1072	BORDETELLA PERTUSSIS	GILLEN	1955	ABO77783.1
1073	BORDETELLA PERTUSSIS	GIRRF	1956	ABO77783.1
1074	MEASLES VIRUS STRAIN EDMONSTON	HDDPISSDQSRFGWFENKEI	1957	P04851.1
1075	MEASLES VIRUS STRAIN EDMONSTON	HEFAGELSTLESLMNL	1958	P04851.1
1076	BORDETELLA PERTUSSIS	HLGGLAGY	1959	ABO77783.1
1077	MEASLES VIRUS STRAIN EDMONSTON	HTTEDKISRAGVPRQAQVSFL	1960	P04851.1
1078	MEASLES VIRUS STRAIN EDMONSTON	ICDIDTYIVEAGLASFILTI	1961	P04851.1
1079	MEASLES VIRUS STRAIN EDMONSTON	IIIVPIPGDSSITTRSRLD	1962	P04851.1
1080	MEASLES VIRUS STRAIN EDMONSTON	ILDIKRTPGNKPRIAEMICD	1963	P04851.1
1081	BORDETELLA PERTUSSIS	KALLYR	1964	ABO77783.1
1082	MEASLES VIRUS STRAIN EDMONSTON	KPPITSGSGGAIRGIKHIII	1965	P04851.1
1083	BORDETELLA PERTUSSIS	LAGSGL	1966	ABO77783.1
1084	MEASLES VIRUS STRAIN EDMONSTON	LGITAEDARLVSEIAMHTTE	1967	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1085	MEASLES VIRUS STRAIN EDMONSTON	LGTLAQIWVLLAKAVTA	1968	P04851.1
1086	MEASLES VIRUS STRAIN EDMONSTON	LPTGTPLDIDTASESSQD	1969	P04851.1
1087	MEASLES VIRUS STRAIN EDMONSTON	MATLLRSLALFKRNKDK	1970	P04851.1
1088	BORDETELLA PERTUSSIS	PAPQP	1971	ABO77783.1
1089	MEASLES VIRUS STRAIN EDMONSTON	PDTAADSELRRWIKYTQRR	1972	P04851.1
1090	MEASLES VIRUS STRAIN EDMONSTON	PKLTGALIGILSLFVESPGQ	1973	P04851.1
1091	BORDETELLA PERTUSSIS	PQP	1974	ABO77783.1
1092	BORDETELLA PERTUSSIS	PQPGP	1975	ABO77783.1
1093	BORDETELLA PERTUSSIS	PQPGPQPQPQPQP	1976	ABO77783.1
1094	MEASLES VIRUS STRAIN EDMONSTON	QDPQDSRRSAEPLLSCKPWQ	1977	P04851.1
1095	MEASLES VIRUS STRAIN EDMONSTON	QRRVVGEFRLEKWLVDVVR	1978	P04851.1
1096	BORDETELLA PERTUSSIS	RELSA	1979	ABO77783.1
1097	BORDETELLA PERTUSSIS	RFAPQ	1980	ABO77783.1
1098	MEASLES VIRUS STRAIN EDMONSTON	SIQNKFSAGSYPLLWSYAMG	1981	P04851.1
1099	BORDETELLA PERTUSSIS	SITLQAGAH	1982	ABO77783.1
1100	BORDETELLA PERTUSSIS	SLQPED	1983	ABO77783.1
1101	BORDETELLA PERTUSSIS	SNALSKRL	1984	ABO77783.1
1102	MEASLES VIRUS STRAIN EDMONSTON	SPGQLIQRITDDPDVSIRLL	1985	P04851.1
1103	BORDETELLA PERTUSSIS	TELPSIPG	1986	ABO77783.1
1104	BORDETELLA PERTUSSIS	TFTLANK	1987	ABO77783.1
1105	BORDETELLA PERTUSSIS	TWDDD	1988	ABO77783.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1106	MEASLES VIRUS STRAIN EDMONSTON	VSFLQGDQSENELPRLGGKE	1989	P04851.1
1107	MEASLES VIRUS STRAIN EDMONSTON	WQESRKNKAQTRTPLQC	1990	P04851.1
1108	MEASLES VIRUS STRAIN EDMONSTON	YAMGVGVELENSMGGLNFGR	1991	P04851.1
1109	MEASLES VIRUS STRAIN EDMONSTON	YQQMGKPAPYMVNLENSI	1992	P04851.1
1110	MEASLES VIRUS STRAIN HALLE	MTRSSHQSLVIKLMF	1993	P69355.1
1111	MEASLES VIRUS STRAIN HALLE	PIRDALNAMTQNIRP	1994	P69355.1
1112	RUBELLA VIRUS STRAIN M33	ALLNTPPPYQVSCGGESDRASAGH	1995	CAA28880.1
1113	RUBELLA VIRUS STRAIN THERIEN	GLGSPNCHGPDWASPVCQRHS	1996	P07566.1
1114	RUBELLA VIRUS STRAIN THERIEN	GLGSPNCHGPDWASPVCQRHSPDCSRLV	1997	P07566.1
1115	RUBELLA VIRUS STRAIN THERIEN	NYTGNQQSRWGLGSPNCHGPDWASPV	1998	P07566.1
1116	RUBELLA VIRUS STRAIN THERIEN	TLPQPPCAHGQHYGHHHHQL	1999	P07566.1
1117	RUBELLA VIRUS STRAIN THERIEN	TVRVKFHTETRTVWQLSVAGVSCNVT	2000	P07566.1
1118	RUBELLA VIRUS	ASYFNPGGSYKQYH	2001	BAA28178.1
1119	RUBELLA VIRUS	FALASYVQHPKTVR	2002	BAA28178.1
1120	RUBELLA VIRUS	GGESDRASARVIDPAAQSFTG	2003	BAA28178.1
1121	RUBELLA VIRUS	GPGEVWVTPVIGSQARKC	2004	BAA28178.1
1122	RUBELLA VIRUS	GSQARKCGLHIRAG	2005	BAA28178.1
1123	RUBELLA VIRUS	LVGATPERPRLRLVDADDPLLRTAP	2006	BAA28178.1
1124	RUBELLA VIRUS	TAPGPGEVWVTPVI	2007	BAA28178.1
1125	MEASLES MORBILLIVIRUS	FIVLSIAYPTLSEIK	2008	AAL29688.1
1126	MEASLES VIRUS STRAIN EDMONSTON-ZAGREB	ETCFQQACKGKIQALCENPEWAPLKDNR IPSY	2009	P08362.1
1127	MEASLES MORBILLIVIRUS	LPRLGGKEDR	2010	P04851.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1128	MEASLES MORBILLIVIRUS	MSKTEWNASQ	2011	SRC280080
1129	MEASLES MORBILLIVIRUS	SRFGWFENKE	2012	P04851.1
1130	RUBELLA VIRUS	EACVTSWLWSEGEAVFYRVDLHFINLGT	2013	CAA28880.1
1131	RUBELLA VIRUS	MDFWCVEHDRPPATPTSLTT	2014	CAA33016.1
1132	RUBELLA VIRUS	PFLGHDGHHGGTLRVGQHHRNASDV	2015	CAA33016.1
1133	RUBELLA VIRUS	RVKFHTETRTVWQLSVAGVSC	2016	BAA19893.1
1134	MEASLES MORBILLIVIRUS	AEEQARHVKNLE	2017	ABO69699.1
1135	MEASLES MORBILLIVIRUS	ESPQEISKHQALG	2018	SRC280080
1136	MEASLES MORBILLIVIRUS	GVGVELENSMGGNLF	2019	ABI54110.1
1137	MEASLES MORBILLIVIRUS	IKGANDLAKFHQMLMKIIMK	2020	ABO69699.1
1138	MEASLES MORBILLIVIRUS	MSKTLHAQLGFKKT	2021	ABK40528.1
1139	MEASLES MORBILLIVIRUS	NASGLSRPSPSAH	2022	BAE98296.1
1140	MEASLES MORBILLIVIRUS	VRVIDPSLGDRKDE	2023	SRC280148
1141	BORDETELLA PERTUSSIS	DLSDGDLLV	2024	AAC31207.1
1142	BORDETELLA PERTUSSIS	EAERAGRGTG	2025	ACI04548.1
1143	BORDETELLA PERTUSSIS	YRYDSRPPEDV	2026	ACI04548.1
1144	BORDETELLA PERTUSSIS	YVDTYGDNAG	2027	ACI04548.1
1145	MEASLES MORBILLIVIRUS	SFSYFYPPFR	2028	CAB43772.1
1146	MUMPS RUBULAVIRUS	DIFIVSPR	2029	ADF49557.1
1147	MEASLES MORBILLIVIRUS	QDSRRSADALLRLQAMAGISEEQGSDTDTPIVYNDRN	2030	CAA59302.1
1148	MEASLES MORBILLIVIRUS	SAEALLRLQA	2031	BAH22350.1
1149	MEASLES MORBILLIVIRUS	RIVINREHL	2032	BAB39835.1
1150	MEASLES VIRUS GENOTYPE A	IPRFK	2033	BAB39848.1
1151	BORDETELLA PERTUSSIS	AAALSPMEI	2034	P15318.2
1152	BORDETELLA PERTUSSIS	AAASVVGAPV	2035	P15318.2

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1153	BORDETELLA PERTUSSIS	AALGRQDSI	2036	P15318.2
1154	BORDETELLA PERTUSSIS	AAQRLVHAIA	2037	P15318.2
1155	BORDETELLA PERTUSSIS	AAVEAAEL	2038	P15318.2
1156	BORDETELLA PERTUSSIS	AGANVLNGL	2039	P15318.2
1157	BORDETELLA PERTUSSIS	AGYANAAD	2040	P15318.2
1158	BORDETELLA PERTUSSIS	AGYEQFEFRV	2041	P15318.2
1159	BORDETELLA PERTUSSIS	AITGNADNL	2042	P15318.2
1160	BORDETELLA PERTUSSIS	AKEKNATLM	2043	P15318.2
1161	BORDETELLA PERTUSSIS	AKGVFLSL	2044	P15318.2
1162	BORDETELLA PERTUSSIS	APHEYGFGI	2045	P15318.2
1163	BORDETELLA PERTUSSIS	ARQGNDLEI	2046	P15318.2
1164	BORDETELLA PERTUSSIS	ASVVGAPV	2047	P15318.2
1165	BORDETELLA PERTUSSIS	ATLMFRLV	2048	P15318.2
1166	BORDETELLA PERTUSSIS	AVAAAQRL	2049	P15318.2
1167	BORDETELLA PERTUSSIS	DAGANVLNGL	2050	P15318.2
1168	BORDETELLA PERTUSSIS	DALLAQLYR	2051	P15318.2
1169	BORDETELLA PERTUSSIS	DANGVLKHSI	2052	P15318.2
1170	BORDETELLA PERTUSSIS	DGDMNIGVI	2053	P15318.2
1171	BORDETELLA PERTUSSIS	DHVKNENL	2054	P15318.2
1172	BORDETELLA PERTUSSIS	DIDMFAIM	2055	P15318.2
1173	BORDETELLA PERTUSSIS	DMFAIMPHL	2056	P15318.2
1174	BORDETELLA PERTUSSIS	DNVRNVENV	2057	P15318.2
1175	BORDETELLA PERTUSSIS	DNVRNVENVI	2058	P15318.2
1176	BORDETELLA PERTUSSIS	DTV DYSAM	2059	P15318.2
1177	BORDETELLA PERTUSSIS	DTV DYSAMI	2060	P15318.2

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1178	BORDETELLA PERTUSSIS	DYLRQAGL	2061	P15318.2
1179	BORDETELLA PERTUSSIS	DYYDNVRNV	2062	P15318.2
1180	BORDETELLA PERTUSSIS	EFTTFVEI	2063	P15318.2
1181	BORDETELLA PERTUSSIS	EFTTFVEIV	2064	P15318.2
1182	BORDETELLA PERTUSSIS	EGYVFYEN	2065	P15318.2
1183	BORDETELLA PERTUSSIS	ENVQYRHV	2066	P15318.2
1184	BORDETELLA PERTUSSIS	EQLANS DGL	2067	P15318.2
1185	BORDETELLA PERTUSSIS	FGVGYGHDTI	2068	P15318.2
1186	BORDETELLA PERTUSSIS	FSPDVLETVP	2069	P15318.2
1187	BORDETELLA PERTUSSIS	FSVDHV KNI	2070	P15318.2
1188	BORDETELLA PERTUSSIS	GDDTYLFGV	2071	P15318.2
1189	BORDETELLA PERTUSSIS	GDDVFLQDL	2072	P15318.2
1190	BORDETELLA PERTUSSIS	GEDGNDIFL	2073	P15318.2
1191	BORDETELLA PERTUSSIS	GERFNVRKQL	2074	P15318.2
1192	BORDETELLA PERTUSSIS	GGAGNDTLV	2075	P15318.2
1193	BORDETELLA PERTUSSIS	GGDDFEAV	2076	P15318.2
1194	BORDETELLA PERTUSSIS	GKSEFTTFV	2077	P15318.2
1195	BORDETELLA PERTUSSIS	GKSLFDDGL	2078	P15318.2
1196	BORDETELLA PERTUSSIS	GNADNLKSV	2079	P15318.2
1197	BORDETELLA PERTUSSIS	GQLVEVDTL	2080	P15318.2
1198	BORDETELLA PERTUSSIS	GRSKFSPDV	2081	P15318.2
1199	BORDETELLA PERTUSSIS	GSSAYDTV	2082	P15318.2
1200	BORDETELLA PERTUSSIS	GTVEKWPAL	2083	P15318.2
1201	BORDETELLA PERTUSSIS	GVDYYDNV	2084	P15318.2
1202	BORDETELLA PERTUSSIS	GYEQFEFRV	2085	P15318.2

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1203	BORDETELLA PERTUSSIS	HAVGAQDVV	2086	P15318.2
1204	BORDETELLA PERTUSSIS	IAAGRIGLGI	2087	P15318.2
1205	BORDETELLA PERTUSSIS	IGDAQANTL	2088	P15318.2
1206	BORDETELLA PERTUSSIS	IGLGILADL	2089	P15318.2
1207	BORDETELLA PERTUSSIS	IGNAAGIPL	2090	P15318.2
1208	BORDETELLA PERTUSSIS	IGTSMKDV	2091	P15318.2
1209	BORDETELLA PERTUSSIS	IGVITDFEL	2092	P15318.2
1210	BORDETELLA PERTUSSIS	IPLTADIDM	2093	P15318.2
1211	BORDETELLA PERTUSSIS	ISKSALEL	2094	P15318.2
1212	BORDETELLA PERTUSSIS	ITGNADNL	2095	P15318.2
1213	BORDETELLA PERTUSSIS	KIFVVSAT	2096	P15318.2
1214	BORDETELLA PERTUSSIS	KQLNNANVYR	2097	P15318.2
1215	BORDETELLA PERTUSSIS	KVIGNAAGI	2098	P15318.2
1216	BORDETELLA PERTUSSIS	LAKVVSQL	2099	P15318.2
1217	BORDETELLA PERTUSSIS	LANDYARKI	2100	P15318.2
1218	BORDETELLA PERTUSSIS	LDYLRQAGL	2101	P15318.2
1219	BORDETELLA PERTUSSIS	LGKGFASL	2102	P15318.2
1220	BORDETELLA PERTUSSIS	LGKGFASLM	2103	P15318.2
1221	BORDETELLA PERTUSSIS	LGVDYYDN	2104	P15318.2
1222	BORDETELLA PERTUSSIS	LGVDYYDNV	2105	P15318.2
1223	BORDETELLA PERTUSSIS	LKHSIKLDVI	2106	P15318.2
1224	BORDETELLA PERTUSSIS	LQAGYIPV	2107	P15318.2
1225	BORDETELLA PERTUSSIS	LQLTGGTVE	2108	P15318.2
1226	BORDETELLA PERTUSSIS	LSAAVFGL	2109	P15318.2
1227	BORDETELLA PERTUSSIS	LSLGKGFASL	2110	P15318.2

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1228	BORDETELLA PERTUSSIS	LSPMEIYGL	2111	P15318.2
1229	BORDETELLA PERTUSSIS	NAHDNFLAGG	2112	P15318.2
1230	BORDETELLA PERTUSSIS	NANVYREGV	2113	P15318.2
1231	BORDETELLA PERTUSSIS	NDTLYGGL	2114	P15318.2
1232	BORDETELLA PERTUSSIS	NGLAGNDVL	2115	P15318.2
1233	BORDETELLA PERTUSSIS	NNANVYREGV	2116	P15318.2
1234	BORDETELLA PERTUSSIS	NTVSYAAL	2117	P15318.2
1235	BORDETELLA PERTUSSIS	NVLRNIENAV	2118	P15318.2
1236	BORDETELLA PERTUSSIS	PALTFITPL	2119	P15318.2
1237	BORDETELLA PERTUSSIS	PETSNVLRNI	2120	P15318.2
1238	BORDETELLA PERTUSSIS	PMEIYGLV	2121	P15318.2
1239	BORDETELLA PERTUSSIS	PQAYFEKNL	2122	P15318.2
1240	BORDETELLA PERTUSSIS	PVNPNSKL	2123	P15318.2
1241	BORDETELLA PERTUSSIS	QAGWNASSV	2124	P15318.2
1242	BORDETELLA PERTUSSIS	QAGWNASSVI	2125	P15318.2
1243	BORDETELLA PERTUSSIS	QDAANAGNL	2126	P15318.2
1244	BORDETELLA PERTUSSIS	QDAANAGNLL	2127	P15318.2
1245	BORDETELLA PERTUSSIS	QDSGYDSL	2128	P15318.2
1246	BORDETELLA PERTUSSIS	QQSHYADQL	2129	P15318.2
1247	BORDETELLA PERTUSSIS	RALQGAQAV	2130	P15318.2
1248	BORDETELLA PERTUSSIS	RGGLGLDTL	2131	P15318.2
1249	BORDETELLA PERTUSSIS	RKQLNNANV	2132	P15318.2
1250	BORDETELLA PERTUSSIS	RQDSGYDSL	2133	P15318.2
1251	BORDETELLA PERTUSSIS	RQFRYDGDM	2134	P15318.2
1252	BORDETELLA PERTUSSIS	RSKFSPDVL	2135	P15318.2

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1253	BORDETELLA PERTUSSIS	SAGAAAGAL	2136	P15318.2
1254	BORDETELLA PERTUSSIS	SAHWGQRAL	2137	P15318.2
1255	BORDETELLA PERTUSSIS	SAMIHPGRI	2138	P15318.2
1256	BORDETELLA PERTUSSIS	SAMIHPGRIV	2139	P15318.2
1257	BORDETELLA PERTUSSIS	SAYDTVSGI	2140	P15318.2
1258	BORDETELLA PERTUSSIS	SAYGYEGD	2141	P15318.2
1259	BORDETELLA PERTUSSIS	SGGAGDDVL	2142	P15318.2
1260	BORDETELLA PERTUSSIS	SGLQVAGA	2143	P15318.2
1261	BORDETELLA PERTUSSIS	SGYDSL DGV	2144	P15318.2
1262	BORDETELLA PERTUSSIS	SLLTGALNGI	2145	P15318.2
1263	BORDETELLA PERTUSSIS	SPMEIYGL	2146	P15318.2
1264	BORDETELLA PERTUSSIS	SQMLTRGQL	2147	P15318.2
1265	BORDETELLA PERTUSSIS	SSAYDTVSGI	2148	P15318.2
1266	BORDETELLA PERTUSSIS	SSLAHGHTA	2149	P15318.2
1267	BORDETELLA PERTUSSIS	SSVTSGDSV	2150	P15318.2
1268	BORDETELLA PERTUSSIS	SVIGVQTTEI	2151	P15318.2
1269	BORDETELLA PERTUSSIS	TNTVSYAAL	2152	P15318.2
1270	BORDETELLA PERTUSSIS	TSLIAEGV	2153	P15318.2
1271	BORDETELLA PERTUSSIS	TSLLTGAL	2154	P15318.2
1272	BORDETELLA PERTUSSIS	TVPAS PGL	2155	P15318.2
1273	BORDETELLA PERTUSSIS	VAKEKNATL	2156	P15318.2
1274	BORDETELLA PERTUSSIS	VAPHEYGFGI	2157	P15318.2
1275	BORDETELLA PERTUSSIS	VAVVTSL L	2158	P15318.2
1276	BORDETELLA PERTUSSIS	VFYENRAYG	2159	P15318.2
1277	BORDETELLA PERTUSSIS	VFYENRAYGV	2160	P15318.2

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1278	BORDETELLA PERTUSSIS	VITDFELEV	2161	P15318.2
1279	BORDETELLA PERTUSSIS	VNPHSTSL	2162	P15318.2
1280	BORDETELLA PERTUSSIS	VNPHSTSLI	2163	P15318.2
1281	BORDETELLA PERTUSSIS	VNPNL SKL	2164	P15318.2
1282	BORDETELLA PERTUSSIS	VNPNL SKL F	2165	P15318.2
1283	BORDETELLA PERTUSSIS	VQQPIIEKL	2166	P15318.2
1284	BORDETELLA PERTUSSIS	VQYRHVEL	2167	P15318.2
1285	BORDETELLA PERTUSSIS	VSIAAAASV	2168	P15318.2
1286	BORDETELLA PERTUSSIS	VSIAAAASVV	2169	P15318.2
1287	BORDETELLA PERTUSSIS	VTSLLTGAL	2170	P15318.2
1288	BORDETELLA PERTUSSIS	VVLANASRI	2171	P15318.2
1289	BORDETELLA PERTUSSIS	WPALNLFSV	2172	P15318.2
1290	BORDETELLA PERTUSSIS	WVRKASAL	2173	P15318.2
1291	BORDETELLA PERTUSSIS	YAVQYRRKGG	2174	P15318.2
1292	BORDETELLA PERTUSSIS	YGGLGDDTL	2175	P15318.2
1293	BORDETELLA PERTUSSIS	YGLVQQSHYA	2176	P15318.2
1294	BORDETELLA PERTUSSIS	YGYEGDALL	2177	P15318.2
1295	BORDETELLA PERTUSSIS	YIPVNP NL	2178	P15318.2
1296	BORDETELLA PERTUSSIS	YSAMIHPGRI	2179	P15318.2
1297	BORDETELLA PERTUSSIS	YSQTGAHAGI	2180	P15318.2
1298	CORYNEBACTERIU M DIPHTHERIAE	AYNFVESIINLFQVVHNSYN	2181	CAE11230.1
1299	BORDETELLA PERTUSSIS	SGTTIK	2182	BAF35031.1
1300	BORDETELLA PERTUSSIS	RGHTLESAEGRKIFG	2183	AAA22974.1
1301	BORDETELLA PERTUSSIS	AGAMTVRDVAAAADLALQAGDA	2184	AAA22974.1
1302	BORDETELLA PERTUSSIS	AGAMTVRDVAAAADLALQAGDAL	2185	AAA22974.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1303	BORDETELLA PERTUSSIS	ALAAVLVNP HIFTRIGAAQTSLADGAAG PA	2186	AAA22974.1
1304	BORDETELLA PERTUSSIS	ALSIDSMTALGA	2187	AAA22974.1
1305	BORDETELLA PERTUSSIS	DLSAARGADISGEGR	2188	AAA22974.1
1306	BORDETELLA PERTUSSIS	DQNRYEYIWGLY	2189	AAA22974.1
1307	BORDETELLA PERTUSSIS	DYTVSADAIALA	2190	AAA22974.1
1308	BORDETELLA PERTUSSIS	GPIVVEAGELVSHAGG	2191	AAA22974.1
1309	BORDETELLA PERTUSSIS	GRPEGLKIGAHSA SVSGSFDAL	2192	AAA22974.1
1310	BORDETELLA PERTUSSIS	ITVTSRGGFDNEGKMESNK	2193	AAA22974.1
1311	BORDETELLA PERTUSSIS	LDQNRYEYIWGLYP	2194	AAA22974.1
1312	BORDETELLA PERTUSSIS	LSAARGADISG	2195	AAA22974.1
1313	BORDETELLA PERTUSSIS	NKIRLMGPLQ	2196	AAA22974.1
1314	BORDETELLA PERTUSSIS	NKLGRIRAGEDM	2197	AAA22974.1
1315	BORDETELLA PERTUSSIS	NKLGRIRAGEDMHL DAPRIE	2198	AAA22974.1
1316	BORDETELLA PERTUSSIS	PHLRNTGQVVAG	2199	AAA22974.1
1317	BORDETELLA PERTUSSIS	QVDLHDLAARGADISG	2200	AAA22974.1
1318	BORDETELLA PERTUSSIS	RDVAAAADLALQ	2201	AAA22974.1
1319	BORDETELLA PERTUSSIS	SAARGADISGEG	2202	AAA22974.1
1320	BORDETELLA PERTUSSIS	TKGEMQIAGKGGGSP	2203	AAA22974.1
1321	BORDETELLA PERTUSSIS	TVSADAIALAAQ	2204	AAA22974.1
1322	BORDETELLA PERTUSSIS	VVAGHDIHI	2205	AAA22974.1
1323	BORDETELLA PERTUSSIS	PSGPNHTKV VQLPKISK NALKANG	2206	CAD12823.1
1324	RUBELLA VIRUS	LVGATPERPRLRLVDADDPLLRTAPGPGE VWVTPVIGSQAR	2207	BAA19902.1
1325	RUBELLA VIRUS	QQSRWGLGSPNCHGPDWASPVCQRHSP	2208	BAA19902.1
1326	BORDETELLA PERTUSSIS	AGEAMVLVYYESIAYSF	2209	ACI04548.1
1327	BORDETELLA PERTUSSIS	GGVGLASTLWYAESNALS KRLGEL	2210	AAZ74322.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1328	BORDETELLA PERTUSSIS	GTLVRIAPVIGACMARQA	2211	ACI04548.1
1329	BORDETELLA PERTUSSIS	IRRVTRVYHNGITGETTT	2212	ACI04548.1
1330	BORDETELLA PERTUSSIS	IVKTGERQHGHIHQGSDP	2213	AAZ74322.1
1331	BORDETELLA PERTUSSIS	IVKTGERQHGHIHQGSDPGGVRTA	2214	AAZ74338.1
1332	BORDETELLA PERTUSSIS	LRDTNVTAVPASGAPAAVSVLGAS	2215	AAZ74338.1
1333	BORDETELLA PERTUSSIS	PEAPAPQPPAGRELSAAANAANT	2216	AAZ74322.1
1334	BORDETELLA PERTUSSIS	AAADFAHAE	2217	WP_019247158.1
1335	BORDETELLA PERTUSSIS	AAAEVAGAL	2218	WP_019249248.1
1336	BORDETELLA PERTUSSIS	AAESTFESY	2219	WP_019247158.1
1337	BORDETELLA PERTUSSIS	AAGFDPEVQ	2220	WP_019248145.1
1338	BORDETELLA PERTUSSIS	AALGRGHS	2221	AGS56996.1
1339	BORDETELLA PERTUSSIS	AAMQGAVVH	2222	AGT50936.1
1340	BORDETELLA PERTUSSIS	AAPAAHADW	2223	AGS56996.1
1341	BORDETELLA PERTUSSIS	AAQATVVQR	2224	WP_019247158.1
1342	BORDETELLA PERTUSSIS	AARVAGDNY	2225	WP_019249248.1
1343	BORDETELLA PERTUSSIS	AAVALLNKL	2226	WP_019249248.1
1344	BORDETELLA PERTUSSIS	ADDPPATVY	2227	AAW72734.1
1345	BORDETELLA PERTUSSIS	AEAGRFBVL	2228	AGS56996.1
1346	BORDETELLA PERTUSSIS	AEATQLVTA	2229	WP_019247158.1
1347	BORDETELLA PERTUSSIS	AEGGATLGA	2230	WP_019249248.1
1348	BORDETELLA PERTUSSIS	AEHGEVSIQ	2231	WP_019249248.1
1349	BORDETELLA PERTUSSIS	AEIAFYFKE	2232	WP_019249248.1
1350	BORDETELLA PERTUSSIS	AEKVTTTAV	2233	WP_019247158.1
1351	BORDETELLA PERTUSSIS	AELQTYLRQ	2234	1BCP_C
1352	BORDETELLA PERTUSSIS	AEQSLIEVG	2235	WP_019249248.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1353	BORDETELLA PERTUSSIS	AESNALSKR	2236	AGS56996.1
1354	BORDETELLA PERTUSSIS	AESSEAMAA	2237	AFK26302.1
1355	BORDETELLA PERTUSSIS	AEVKVGYRA	2238	WP_019247158.1
1356	BORDETELLA PERTUSSIS	AEVTDTPSPS	2239	WP_019249248.1
1357	BORDETELLA PERTUSSIS	AGKSLKKKN	2240	WP_019247158.1
1358	BORDETELLA PERTUSSIS	AGLAGPSAV	2241	WP_019249248.1
1359	BORDETELLA PERTUSSIS	AIRVGRGAR	2242	AGT50936.1
1360	BORDETELLA PERTUSSIS	ALAAIASAA	2243	WP_019248145.1
1361	BORDETELLA PERTUSSIS	ALADVPYVL	2244	AAA22983.1
1362	BORDETELLA PERTUSSIS	ALANDGTIV	2245	WP_019248658.1
1363	BORDETELLA PERTUSSIS	ALGRGHSLY	2246	AGS56996.1
1364	BORDETELLA PERTUSSIS	ALILAASPV	2247	WP_019248658.1
1365	BORDETELLA PERTUSSIS	ALMLACTGL	2248	AAA22974.1
1366	BORDETELLA PERTUSSIS	AMQGAVVHL	2249	AGT50936.1
1367	BORDETELLA PERTUSSIS	AMTHLSPAL	2250	AAA22983.1
1368	BORDETELLA PERTUSSIS	AMYGKHITL	2251	WP_019249248.1
1369	BORDETELLA PERTUSSIS	ANEANALLW	2252	WP_019249248.1
1370	BORDETELLA PERTUSSIS	APLSITLQA	2253	AGT50936.1
1371	BORDETELLA PERTUSSIS	APNALAWAL	2254	AAA22974.1
1372	BORDETELLA PERTUSSIS	APPAPKPAP	2255	AGS56996.1
1373	BORDETELLA PERTUSSIS	APPGAGFIY	2256	1BCP_C
1374	BORDETELLA PERTUSSIS	APQAAPLSI	2257	AGT50936.1
1375	BORDETELLA PERTUSSIS	APRIENTAK	2258	WP_019249248.1
1376	BORDETELLA PERTUSSIS	AQGKALLYR	2259	AGT50936.1
1377	BORDETELLA PERTUSSIS	AQITSYVGF	2260	WP_019248658.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1378	BORDETELLA PERTUSSIS	AQLEVRGQR	2261	WP_019249248.1
1379	BORDETELLA PERTUSSIS	AQQLKQADR	2262	WP_019247699.1
1380	BORDETELLA PERTUSSIS	AQVTVAGRY	2263	WP_019249248.1
1381	BORDETELLA PERTUSSIS	ARRSRVRAL	2264	NP_882284.1
1382	BORDETELLA PERTUSSIS	ASPRRARRA	2265	WP_019249248.1
1383	BORDETELLA PERTUSSIS	ASSPDAHVP	2266	AAA22983.1
1384	BORDETELLA PERTUSSIS	ASVSNPGTF	2267	WP_019249248.1
1385	BORDETELLA PERTUSSIS	ATWNFQSTY	2268	WP_019249248.1
1386	BORDETELLA PERTUSSIS	ATYIADSGF	2269	AGS56996.1
1387	BORDETELLA PERTUSSIS	AVAAPAVGA	2270	WP_019249248.1
1388	BORDETELLA PERTUSSIS	AVFMQQRPL	2271	AAA22983.1
1389	BORDETELLA PERTUSSIS	AVLVNPHIF	2272	WP_019249248.1
1390	BORDETELLA PERTUSSIS	CFGKDLKRP	2273	AAA22983.1
1391	BORDETELLA PERTUSSIS	CPSSLGNGV	2274	WP_019248145.1
1392	BORDETELLA PERTUSSIS	DAGHEHDTW	2275	AAA22984.1
1393	BORDETELLA PERTUSSIS	DAKHDLTVT	2276	WP_019249248.1
1394	BORDETELLA PERTUSSIS	DASGQHRLW	2277	AGS56996.1
1395	BORDETELLA PERTUSSIS	DATFETYAL	2278	YP_006628018.1
1396	BORDETELLA PERTUSSIS	DATFQTYAL	2279	1BCP_C
1397	BORDETELLA PERTUSSIS	DATLVGAKF	2280	WP_019247158.1
1398	BORDETELLA PERTUSSIS	DDEVDSVGR	2281	AAA22974.1
1399	BORDETELLA PERTUSSIS	DENGKPQTY	2282	WP_019247158.1
1400	BORDETELLA PERTUSSIS	DGPPSRPTT	2283	WP_019247158.1
1401	BORDETELLA PERTUSSIS	DHLTGRSCQ	2284	AAW72734.1
1402	BORDETELLA PERTUSSIS	DNEGKMESN	2285	WP_019249248.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1403	BORDETELLA PERTUSSIS	DPPATVYRY	2286	AAW72734.1
1404	BORDETELLA PERTUSSIS	EATEGDATL	2287	WP_019247158.1
1405	BORDETELLA PERTUSSIS	EATQQAAGF	2288	WP_019248145.1
1406	BORDETELLA PERTUSSIS	ECSGKQDCP	2289	AAA22983.1
1407	BORDETELLA PERTUSSIS	EGGKLRGKD	2290	AAA22974.1
1408	BORDETELLA PERTUSSIS	EGKMESNKD	2291	WP_019249248.1
1409	BORDETELLA PERTUSSIS	EHRMQEAVE	2292	AAW72734.1
1410	BORDETELLA PERTUSSIS	EKRLDIDDA	2293	WP_019249248.1
1411	BORDETELLA PERTUSSIS	EPASANTLL	2294	AGS56996.1
1412	BORDETELLA PERTUSSIS	EPQAELAVF	2295	AGS56996.1
1413	BORDETELLA PERTUSSIS	EPVKLTLTG	2296	AGT50936.1
1414	BORDETELLA PERTUSSIS	ESAEGRKIF	2297	WP_019249248.1
1415	BORDETELLA PERTUSSIS	ESYSESHNF	2298	WP_019247158.1
1416	BORDETELLA PERTUSSIS	ETFCITTIY	2299	1BCP_C
1417	BORDETELLA PERTUSSIS	EVAGALELS	2300	WP_019249248.1
1418	BORDETELLA PERTUSSIS	EVAKVEVVP	2301	WP_019247158.1
1419	BORDETELLA PERTUSSIS	EVDGIIQEF	2302	WP_019249248.1
1420	BORDETELLA PERTUSSIS	EVRADNNFY	2303	WP_019248344.1
1421	BORDETELLA PERTUSSIS	FAILSSTTE	2304	WP_019247158.1
1422	BORDETELLA PERTUSSIS	FAISAYALK	2305	AAA22984.1
1423	BORDETELLA PERTUSSIS	FALYDGTYL	2306	AFK26303.1
1424	BORDETELLA PERTUSSIS	FDTMLGFAI	2307	AAA22984.1
1425	BORDETELLA PERTUSSIS	FEGKPALEL	2308	AAA22983.1
1426	BORDETELLA PERTUSSIS	FELGADHAV	2309	AGS56996.1
1427	BORDETELLA PERTUSSIS	FEPGITTNV	2310	WP_019248658.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1428	BORDETELLA PERTUSSIS	FETYALTGI	2311	YP_006628018.1
1429	BORDETELLA PERTUSSIS	FIYRETFCI	2312	1BCP_C
1430	BORDETELLA PERTUSSIS	FPTRTTAPG	2313	NP_882284.1
1431	BORDETELLA PERTUSSIS	FQTYALTGI	2314	1BCP_C
1432	BORDETELLA PERTUSSIS	FTHADGWFL	2315	AGS56996.1
1433	BORDETELLA PERTUSSIS	FVRDGQSVI	2316	1BCP_C
1434	BORDETELLA PERTUSSIS	FVRSGQPVI	2317	YP_006628018.1
1435	BORDETELLA PERTUSSIS	FVWYVDTV	2318	WP_019248866.1
1436	BORDETELLA PERTUSSIS	GAASSRQAL	2319	WP_019249248.1
1437	BORDETELLA PERTUSSIS	GAASSYFEY	2320	AAW72734.1
1438	BORDETELLA PERTUSSIS	GAFDLKTF	2321	AFK26303.1
1439	BORDETELLA PERTUSSIS	GAPAAVSVL	2322	AGS56996.1
1440	BORDETELLA PERTUSSIS	GATRAVDSL	2323	AGS56996.1
1441	BORDETELLA PERTUSSIS	GAVPGGAVP	2324	AGT50936.1
1442	BORDETELLA PERTUSSIS	GEAMVLVYY	2325	AFK26302.1
1443	BORDETELLA PERTUSSIS	GEIALGDAT	2326	WP_019249248.1
1444	BORDETELLA PERTUSSIS	GELMAAQVA	2327	WP_019247158.1
1445	BORDETELLA PERTUSSIS	GGVPGGAVP	2328	AAZ74338.1
1446	BORDETELLA PERTUSSIS	GHEHDTWFD	2329	AAA22984.1
1447	BORDETELLA PERTUSSIS	GIGALKAGA	2330	WP_019249248.1
1448	BORDETELLA PERTUSSIS	GIVIPPKAL	2331	1BCP_C
1449	BORDETELLA PERTUSSIS	GKDLKRPGS	2332	AAA22983.1
1450	BORDETELLA PERTUSSIS	GKLPKPVT	2333	WP_019247158.1
1451	BORDETELLA PERTUSSIS	GKSLKKKNQ	2334	WP_019247158.1
1452	BORDETELLA PERTUSSIS	GLDVQQGT	2335	WP_019249248.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1453	BORDETELLA PERTUSSIS	GLTDGVSRI	2336	WP_019249248.1
1454	BORDETELLA PERTUSSIS	GLYPTYTEW	2337	WP_019249248.1
1455	BORDETELLA PERTUSSIS	GLYQTYTEW	2338	YP_006626470.1
1456	BORDETELLA PERTUSSIS	GPPSRPTTP	2339	WP_019247158.1
1457	BORDETELLA PERTUSSIS	GPSAVAAPA	2340	WP_019249248.1
1458	BORDETELLA PERTUSSIS	GVAPTAQQL	2341	WP_019248866.1
1459	BORDETELLA PERTUSSIS	GVGLASTLW	2342	AGS56996.1
1460	BORDETELLA PERTUSSIS	GYEAGFSLG	2343	WP_019247158.1
1461	BORDETELLA PERTUSSIS	HADDGTIVI	2344	WP_019248145.1
1462	BORDETELLA PERTUSSIS	HADWNNQSI	2345	AGS56996.1
1463	BORDETELLA PERTUSSIS	HAEHEKDVR	2346	WP_019247158.1
1464	BORDETELLA PERTUSSIS	HANHYGTRI	2347	WP_019247158.1
1465	BORDETELLA PERTUSSIS	HAQGKALLY	2348	AGT50936.1
1466	BORDETELLA PERTUSSIS	HFIGYIYEV	2349	AAW72734.1
1467	BORDETELLA PERTUSSIS	HLSPALADV	2350	AAA22983.1
1468	BORDETELLA PERTUSSIS	HSLYASYEY	2351	AGS56996.1
1469	BORDETELLA PERTUSSIS	HVRGMLVPV	2352	AAA22974.1
1470	BORDETELLA PERTUSSIS	HVSKEEQYY	2353	YP_006628018.1
1471	BORDETELLA PERTUSSIS	HVTRGWSIF	2354	AFK26303.1
1472	BORDETELLA PERTUSSIS	IADSGFYLD	2355	AGS56996.1
1473	BORDETELLA PERTUSSIS	IAHRTELRG	2356	AGS56996.1
1474	BORDETELLA PERTUSSIS	IENTAKLSG	2357	WP_019249248.1
1475	BORDETELLA PERTUSSIS	IESKISQSV	2358	WP_019249248.1
1476	BORDETELLA PERTUSSIS	IETGGARRF	2359	AGT50936.1
1477	BORDETELLA PERTUSSIS	IIKDAPPGA	2360	1BCP_C

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1478	BORDETELLA PERTUSSIS	IIQEFAADL	2361	WP_019249248.1
1479	BORDETELLA PERTUSSIS	ILAGALATY	2362	AAW72734.1
1480	BORDETELLA PERTUSSIS	ILLENPAAE	2363	AGS56996.1
1481	BORDETELLA PERTUSSIS	ILPILVLAL	2364	NP_882286.1
1482	BORDETELLA PERTUSSIS	IPFQRALRL	2365	WP_019248145.1
1483	BORDETELLA PERTUSSIS	ISVRVHVSK	2366	YP_006628018.1
1484	BORDETELLA PERTUSSIS	ITNETGKTY	2367	WP_019247158.1
1485	BORDETELLA PERTUSSIS	ITNKRAALI	2368	WP_019249248.1
1486	BORDETELLA PERTUSSIS	ITSYVGFSV	2369	WP_019248658.1
1487	BORDETELLA PERTUSSIS	ITVTSRGGF	2370	WP_019249248.1
1488	BORDETELLA PERTUSSIS	IVIPPKALF	2371	1BCP_C
1489	BORDETELLA PERTUSSIS	IVVEAGELV	2372	WP_019249248.1
1490	BORDETELLA PERTUSSIS	KAAKSVNLM	2373	WP_019247158.1
1491	BORDETELLA PERTUSSIS	KAAPLRRTT	2374	AGS56996.1
1492	BORDETELLA PERTUSSIS	KAGKLSATG	2375	WP_019249248.1
1493	BORDETELLA PERTUSSIS	KAGTIAAPW	2376	WP_019249248.1
1494	BORDETELLA PERTUSSIS	KAKSLTTEI	2377	WP_019249248.1
1495	BORDETELLA PERTUSSIS	KATVTTVQV	2378	WP_019247158.1
1496	BORDETELLA PERTUSSIS	KDYRDKDGG	2379	WP_019247158.1
1497	BORDETELLA PERTUSSIS	KEAATIVAA	2380	WP_019249248.1
1498	BORDETELLA PERTUSSIS	KEDVDAAQI	2381	WP_019248658.1
1499	BORDETELLA PERTUSSIS	KEVDGIIQE	2382	WP_019249248.1
1500	BORDETELLA PERTUSSIS	KGPKLAMPW	2383	AGS56996.1
1501	BORDETELLA PERTUSSIS	KLASGGGAV	2384	WP_019249248.1
1502	BORDETELLA PERTUSSIS	KLKGKNQEF	2385	AAA22984.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1503	BORDETELLA PERTUSSIS	KLLHHILPI	2386	NP_882286.1
1504	BORDETELLA PERTUSSIS	KPAPQPGPQ	2387	AGS56996.1
1505	BORDETELLA PERTUSSIS	KPAPTAPPM	2388	WP_019249248.1
1506	BORDETELLA PERTUSSIS	KPAVSVKVA	2389	WP_019249248.1
1507	BORDETELLA PERTUSSIS	KPDRAARVA	2390	WP_019249248.1
1508	BORDETELLA PERTUSSIS	KPLADIAVI	2391	YP_006626470.1
1509	BORDETELLA PERTUSSIS	KPLADIAVV	2392	WP_019249248.1
1510	BORDETELLA PERTUSSIS	KPLPKPLPV	2393	WP_019247158.1
1511	BORDETELLA PERTUSSIS	KQADRDFVW	2394	WP_019247699.1
1512	BORDETELLA PERTUSSIS	KSLPGGKLP	2395	WP_019247158.1
1513	BORDETELLA PERTUSSIS	KSYTLRYLA	2396	WP_019248658.1
1514	BORDETELLA PERTUSSIS	KTNMVVTSV	2397	AAA22983.1
1515	BORDETELLA PERTUSSIS	KVLAPRLYL	2398	AAA22974.1
1516	BORDETELLA PERTUSSIS	KVLSTKTTL	2399	WP_019247158.1
1517	BORDETELLA PERTUSSIS	LAAGAGLTL	2400	WP_019249248.1
1518	BORDETELLA PERTUSSIS	LAAIASAAH	2401	WP_019248145.1
1519	BORDETELLA PERTUSSIS	LAANGNGQW	2402	AGS56996.1
1520	BORDETELLA PERTUSSIS	LAAQVTQRG	2403	WP_019249248.1
1521	BORDETELLA PERTUSSIS	LAARGDGAL	2404	AAA22974.1
1522	BORDETELLA PERTUSSIS	LAAVLVNPH	2405	WP_019249248.1
1523	BORDETELLA PERTUSSIS	LAGSGLFRM	2406	AGS56996.1
1524	BORDETELLA PERTUSSIS	LAKALSAAL	2407	WP_019249248.1
1525	BORDETELLA PERTUSSIS	LALQAGDAL	2408	WP_019249248.1
1526	BORDETELLA PERTUSSIS	LAMPWTFHA	2409	AGS56996.1
1527	BORDETELLA PERTUSSIS	LANDGTIVI	2410	WP_019248658.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1528	BORDETELLA PERTUSSIS	LAPTVGVAF	2411	WP_019247158.1
1529	BORDETELLA PERTUSSIS	LASDGSVDF	2412	AGS56996.1
1530	BORDETELLA PERTUSSIS	LATYQSEYL	2413	AAW72734.1
1531	BORDETELLA PERTUSSIS	LAWALMLAC	2414	AAA22974.1
1532	BORDETELLA PERTUSSIS	LEAGRFRTH	2415	AGS56996.1
1533	BORDETELLA PERTUSSIS	LFTQQGGAY	2416	1BCP_C
1534	BORDETELLA PERTUSSIS	LKRPGSSPM	2417	AAA22983.1
1535	BORDETELLA PERTUSSIS	LLGSHVARA	2418	AFK26303.1
1536	BORDETELLA PERTUSSIS	LLHHILPIL	2419	NP_882286.1
1537	BORDETELLA PERTUSSIS	LLNAGGTLL	2420	WP_019249248.1
1538	BORDETELLA PERTUSSIS	LMGPLQVNA	2421	WP_019249248.1
1539	BORDETELLA PERTUSSIS	LNDSKITMG	2422	WP_019248145.1
1540	BORDETELLA PERTUSSIS	LPEPVKLTL	2423	AGT50936.1
1541	BORDETELLA PERTUSSIS	LPILVLALL	2424	NP_882286.1
1542	BORDETELLA PERTUSSIS	LPKISKNAL	2425	WP_019248145.1
1543	BORDETELLA PERTUSSIS	LPKPVTVKL	2426	WP_019247158.1
1544	BORDETELLA PERTUSSIS	LPLKANPMH	2427	NP_882285.1
1545	BORDETELLA PERTUSSIS	LPPRPVVAE	2428	WP_019247158.1
1546	BORDETELLA PERTUSSIS	LPSIPGTSI	2429	AGS56996.1
1547	BORDETELLA PERTUSSIS	LPTHLYKNF	2430	AAA22984.1
1548	BORDETELLA PERTUSSIS	LPVRGVALV	2431	WP_019249248.1
1549	BORDETELLA PERTUSSIS	LPVSLTALD	2432	WP_019249248.1
1550	BORDETELLA PERTUSSIS	LQGGNKVPV	2433	WP_019249248.1
1551	BORDETELLA PERTUSSIS	LSAALGADW	2434	WP_019249248.1
1552	BORDETELLA PERTUSSIS	LSDAGHEHD	2435	AAA22984.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1553	BORDETELLA PERTUSSIS	LSGEVQRKG	2436	WP_019249248.1
1554	BORDETELLA PERTUSSIS	LSSPSAITV	2437	WP_019249248.1
1555	BORDETELLA PERTUSSIS	LTWLAILAV	2438	AAW72734.1
1556	BORDETELLA PERTUSSIS	LVFSHVGRM	2439	AAA22974.1
1557	BORDETELLA PERTUSSIS	LVSDAGADL	2440	WP_019249248.1
1558	BORDETELLA PERTUSSIS	LVYYESIAY	2441	AFK26302.1
1559	BORDETELLA PERTUSSIS	MAAESTFES	2442	WP_019247158.1
1560	BORDETELLA PERTUSSIS	MAAGHDATL	2443	WP_019249248.1
1561	BORDETELLA PERTUSSIS	MAAWSERAG	2444	AFK26302.1
1562	BORDETELLA PERTUSSIS	MALGALGAA	2445	AGS56996.1
1563	BORDETELLA PERTUSSIS	MAPVMGACM	2446	ADA85123.1
1564	BORDETELLA PERTUSSIS	MATKGEMQI	2447	WP_019249248.1
1565	BORDETELLA PERTUSSIS	MDAKGGTLL	2448	WP_019249248.1
1566	BORDETELLA PERTUSSIS	MESNKDIVI	2449	WP_019249248.1
1567	BORDETELLA PERTUSSIS	MEVMLRAVF	2450	AAA22983.1
1568	BORDETELLA PERTUSSIS	MEYFKTLP	2451	WP_019249248.1
1569	BORDETELLA PERTUSSIS	MHTIASILL	2452	AAA22984.1
1570	BORDETELLA PERTUSSIS	MIYMSGGLAV	2453	1BCP_C
1571	BORDETELLA PERTUSSIS	MLACTGLPL	2454	AAA22974.1
1572	BORDETELLA PERTUSSIS	MPIDRKTL	2455	AFK26303.1
1573	BORDETELLA PERTUSSIS	MPKAPELDL	2456	WP_019249248.1
1574	BORDETELLA PERTUSSIS	MQRQAGLPL	2457	NP_882285.1
1575	BORDETELLA PERTUSSIS	NALAWALML	2458	AAA22974.1
1576	BORDETELLA PERTUSSIS	NITNKRAAL	2459	WP_019249248.1
1577	BORDETELLA PERTUSSIS	NLMAAESTF	2460	WP_019247158.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1578	BORDETELLA PERTUSSIS	NNETMSGRRQ	2461	WP_019249248.1
1579	BORDETELLA PERTUSSIS	NPGSLIAEV	2462	WP_019249248.1
1580	BORDETELLA PERTUSSIS	NPMHTIASI	2463	NP_882285.1
1581	BORDETELLA PERTUSSIS	NPQTQLSNI	2464	WP_019248145.1
1582	BORDETELLA PERTUSSIS	NPYTSRRSV	2465	AFK26302.1
1583	BORDETELLA PERTUSSIS	PAPTAPPMP	2466	WP_019249248.1
1584	BORDETELLA PERTUSSIS	PASANTLLL	2467	AGS56996.1
1585	BORDETELLA PERTUSSIS	PAVALPRPL	2468	WP_019249248.1
1586	BORDETELLA PERTUSSIS	PDAHVPFCF	2469	AAA22983.1
1587	BORDETELLA PERTUSSIS	PELGAAIRV	2470	AGT50936.1
1588	BORDETELLA PERTUSSIS	PFIHKLKDC	2471	WP_019248145.1
1589	BORDETELLA PERTUSSIS	PGPQQPPQ	2472	AGS56996.1
1590	BORDETELLA PERTUSSIS	PGPQQPPQ	2473	AAZ74338.1
1591	BORDETELLA PERTUSSIS	PGPTTDYST	2474	WP_019248145.1
1592	BORDETELLA PERTUSSIS	PGTFTAGKD	2475	WP_019249248.1
1593	BORDETELLA PERTUSSIS	PGTPGDLLE	2476	AAA22984.1
1594	BORDETELLA PERTUSSIS	PKPKPKAER	2477	WP_019247158.1
1595	BORDETELLA PERTUSSIS	PKPKPKPKA	2478	WP_019247158.1
1596	BORDETELLA PERTUSSIS	PKPKPKPKP	2479	WP_019247158.1
1597	BORDETELLA PERTUSSIS	PLPPRPVVA	2480	WP_019247158.1
1598	BORDETELLA PERTUSSIS	PPAPKPAPQ	2481	AGS56996.1
1599	BORDETELLA PERTUSSIS	PPKPAPVAK	2482	WP_019247158.1
1600	BORDETELLA PERTUSSIS	PPRPVAAQV	2483	WP_019247158.1
1601	BORDETELLA PERTUSSIS	PPRPVVAEK	2484	WP_019247158.1
1602	BORDETELLA PERTUSSIS	PPSRPTTPP	2485	WP_019247158.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1603	BORDETELLA PERTUSSIS	PRRARRALR	2486	WP_019249248.1
1604	BORDETELLA PERTUSSIS	QAAPLSITL	2487	AGT50936.1
1605	BORDETELLA PERTUSSIS	QADRDFVWY	2488	WP_019247699.1
1606	BORDETELLA PERTUSSIS	QAIVVGKDL	2489	WP_019249248.1
1607	BORDETELLA PERTUSSIS	QALGALKLY	2490	ACI16088.1
1608	BORDETELLA PERTUSSIS	QELALKLKG	2491	AAA22984.1
1609	BORDETELLA PERTUSSIS	QITQHGGPY	2492	NP_882283.1
1610	BORDETELLA PERTUSSIS	QITQHGPSY	2493	AFK26303.1
1611	BORDETELLA PERTUSSIS	QPLPPRPVA	2494	WP_019247158.1
1612	BORDETELLA PERTUSSIS	QPPAGRELS	2495	AGS56996.1
1613	BORDETELLA PERTUSSIS	QQLKQADRD	2496	WP_019247699.1
1614	BORDETELLA PERTUSSIS	QQVQVLQRQ	2497	WP_019247158.1
1615	BORDETELLA PERTUSSIS	QSIVEAPEL	2498	AGT50936.1
1616	BORDETELLA PERTUSSIS	QVGSSNSAF	2499	AAW72734.1
1617	BORDETELLA PERTUSSIS	RAGLSPATW	2500	WP_019249248.1
1618	BORDETELLA PERTUSSIS	RARRALRQD	2501	WP_019249248.1
1619	BORDETELLA PERTUSSIS	RASASRARI	2502	WP_019249248.1
1620	BORDETELLA PERTUSSIS	RELSAAANA	2503	AGS56996.1
1621	BORDETELLA PERTUSSIS	RETFCITTI	2504	1BCP_C
1622	BORDETELLA PERTUSSIS	RGFAQRQQL	2505	AGS56996.1
1623	BORDETELLA PERTUSSIS	RGSAATFTL	2506	WP_019248295.1
1624	BORDETELLA PERTUSSIS	RGWSIFALY	2507	AFK26303.1
1625	BORDETELLA PERTUSSIS	RKMLYLIYV	2508	YP_006628018.1
1626	BORDETELLA PERTUSSIS	RLRKMLYLI	2509	YP_006628018.1
1627	BORDETELLA PERTUSSIS	RPQITDAVT	2510	WP_019249248.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1628	BORDETELLA PERTUSSIS	RPSVNGGRI	2511	WP_019249248.1
1629	BORDETELLA PERTUSSIS	RRFTHADGW	2512	AGS56996.1
1630	BORDETELLA PERTUSSIS	RSGARATSL	2513	AAA22974.1
1631	BORDETELLA PERTUSSIS	RSRVRALAW	2514	NP_882284.1
1632	BORDETELLA PERTUSSIS	RSRVRALSW	2515	YP_006628019.1
1633	BORDETELLA PERTUSSIS	RTHGVGASL	2516	AGS56996.1
1634	BORDETELLA PERTUSSIS	RTRGQARSG	2517	AAA22974.1
1635	BORDETELLA PERTUSSIS	RVAPPAVAL	2518	WP_019249248.1
1636	BORDETELLA PERTUSSIS	RVLPEPVKL	2519	AGT50936.1
1637	BORDETELLA PERTUSSIS	RVRALAWLL	2520	NP_882284.1
1638	BORDETELLA PERTUSSIS	RVRALSWLL	2521	YP_006628019.1
1639	BORDETELLA PERTUSSIS	RVTVSGGSL	2522	AGT50936.1
1640	BORDETELLA PERTUSSIS	SEAMAAWSE	2523	AFK26302.1
1641	BORDETELLA PERTUSSIS	SESHNFHAS	2524	WP_019247158.1
1642	BORDETELLA PERTUSSIS	SGEGRVNIG	2525	WP_019249248.1
1643	BORDETELLA PERTUSSIS	SGLAVRVHV	2526	1BCP_C
1644	BORDETELLA PERTUSSIS	SLADISLGA	2527	WP_019249248.1
1645	BORDETELLA PERTUSSIS	SLFAILSST	2528	WP_019247158.1
1646	BORDETELLA PERTUSSIS	SLFAPHGNV	2529	AAZ74338.1
1647	BORDETELLA PERTUSSIS	SLSIDNATW	2530	AGS56996.1
1648	BORDETELLA PERTUSSIS	SPMEVMLRA	2531	AAA22983.1
1649	BORDETELLA PERTUSSIS	SPQPIRATV	2532	WP_019247158.1
1650	BORDETELLA PERTUSSIS	SPRRARRAL	2533	WP_019249248.1
1651	BORDETELLA PERTUSSIS	SPSRLAGTL	2534	WP_019249248.1
1652	BORDETELLA PERTUSSIS	SSTPLGSLF	2535	WP_019247158.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1653	BORDETELLA PERTUSSIS	STYELLDYL	2536	WP_019249248.1
1654	BORDETELLA PERTUSSIS	SVAMKPYEV	2537	AAA22983.1
1655	BORDETELLA PERTUSSIS	SVAPNALAW	2538	AAA22974.1
1656	BORDETELLA PERTUSSIS	SVKVAKKLF	2539	WP_019249248.1
1657	BORDETELLA PERTUSSIS	TAFMSGRL	2540	AAA22984.1
1658	BORDETELLA PERTUSSIS	TAGATPFDI	2541	WP_019248658.1
1659	BORDETELLA PERTUSSIS	TAPVTSPAW	2542	AAW72734.1
1660	BORDETELLA PERTUSSIS	TARTGWLW	2543	AAW72734.1
1661	BORDETELLA PERTUSSIS	TEAQGVQVR	2544	WP_019248145.1
1662	BORDETELLA PERTUSSIS	TEVYLEHRM	2545	AAW72734.1
1663	BORDETELLA PERTUSSIS	TFEGKPALE	2546	AAA22983.1
1664	BORDETELLA PERTUSSIS	TFTGKVTNG	2547	WP_019248658.1
1665	BORDETELLA PERTUSSIS	TGDGGGHTD	2548	AGS56996.1
1666	BORDETELLA PERTUSSIS	TLAKALSAA	2549	WP_019249248.1
1667	BORDETELLA PERTUSSIS	TLANVGDTW	2550	AGS56996.1
1668	BORDETELLA PERTUSSIS	TLNASNLTL	2551	WP_019249248.1
1669	BORDETELLA PERTUSSIS	TLSSAHGNV	2552	WP_019249248.1
1670	BORDETELLA PERTUSSIS	TPFDIKLKE	2553	WP_019248658.1
1671	BORDETELLA PERTUSSIS	TPFIKLD	2554	WP_019248145.1
1672	BORDETELLA PERTUSSIS	TPGWSIYGL	2555	1BCP_C
1673	BORDETELLA PERTUSSIS	TPLGSAATF	2556	AGS56996.1
1674	BORDETELLA PERTUSSIS	TPLGSLFAI	2557	WP_019247158.1
1675	BORDETELLA PERTUSSIS	TPLPVSSTA	2558	WP_019249248.1
1676	BORDETELLA PERTUSSIS	TRQGIMDQY	2559	YP_006626873.1
1677	BORDETELLA PERTUSSIS	TSKQDERNY	2560	WP_019247158.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1678	BORDETELLA PERTUSSIS	TSPYDGKYW	2561	YP_006628018.1
1679	BORDETELLA PERTUSSIS	TSRRSVASI	2562	AFK26302.1
1680	BORDETELLA PERTUSSIS	TSRTVTMRY	2563	NP_879898.1
1681	BORDETELLA PERTUSSIS	TTEYPNARY	2564	ADA85123.1
1682	BORDETELLA PERTUSSIS	TTEYSNARY	2565	AFK26302.1
1683	BORDETELLA PERTUSSIS	TTLGLEQTF	2566	WP_019247158.1
1684	BORDETELLA PERTUSSIS	TVLAAGAGL	2567	WP_019249248.1
1685	BORDETELLA PERTUSSIS	TVQELALKL	2568	AAA22984.1
1686	BORDETELLA PERTUSSIS	TVVQRNKHWH	2569	WP_019247158.1
1687	BORDETELLA PERTUSSIS	VAAAADLAL	2570	WP_019249248.1
1688	BORDETELLA PERTUSSIS	VALASQARW	2571	AGS56996.1
1689	BORDETELLA PERTUSSIS	VAMKPYEVT	2572	AAA22983.1
1690	BORDETELLA PERTUSSIS	VARLVKLQG	2573	WP_019249248.1
1691	BORDETELLA PERTUSSIS	VAVAGGRWH	2574	AGS56996.1
1692	BORDETELLA PERTUSSIS	VEASAITTY	2575	WP_019248145.1
1693	BORDETELLA PERTUSSIS	VEDIGGKNY	2576	WP_019247158.1
1694	BORDETELLA PERTUSSIS	VEVSSPPPV	2577	WP_019247158.1
1695	BORDETELLA PERTUSSIS	VGAGGYEAG	2578	WP_019247158.1
1696	BORDETELLA PERTUSSIS	VGGGEHGRW	2579	WP_019249248.1
1697	BORDETELLA PERTUSSIS	VHVSKEEQY	2580	YP_006628018.1
1698	BORDETELLA PERTUSSIS	VIDGQKVLA	2581	AAA22974.1
1699	BORDETELLA PERTUSSIS	VIGACTSPY	2582	YP_006628018.1
1700	BORDETELLA PERTUSSIS	VKLGGVYEA	2583	AAA22974.1
1701	BORDETELLA PERTUSSIS	VLAPRLYLTL	2584	AAA22974.1
1702	BORDETELLA PERTUSSIS	VLVKTNMNV	2585	AAA22983.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1703	BORDETELLA PERTUSSIS	VPASGAPAA	2586	AGS56996.1
1704	BORDETELLA PERTUSSIS	VPFCFGKDL	2587	AAA22983.1
1705	BORDETELLA PERTUSSIS	VPVSEHCTV	2588	AAA22974.1
1706	BORDETELLA PERTUSSIS	VPVTPPKVE	2589	WP_019247158.1
1707	BORDETELLA PERTUSSIS	VRTVSAMEY	2590	WP_019249248.1
1708	BORDETELLA PERTUSSIS	VSGGSLSAP	2591	AGT50936.1
1709	BORDETELLA PERTUSSIS	VSSATKAKG	2592	WP_019248658.1
1710	BORDETELLA PERTUSSIS	VSSPPVSV	2593	WP_019247158.1
1711	BORDETELLA PERTUSSIS	VSVKVAKKL	2594	WP_019249248.1
1712	BORDETELLA PERTUSSIS	VTMRYLASV	2595	WP_019248145.1
1713	BORDETELLA PERTUSSIS	VTSVAMKPY	2596	AAA22983.1
1714	BORDETELLA PERTUSSIS	VVAEKVTP	2597	WP_019247158.1
1715	BORDETELLA PERTUSSIS	VVDGPPSRP	2598	WP_019247158.1
1716	BORDETELLA PERTUSSIS	VVETAQLP	2599	WP_019247158.1
1717	BORDETELLA PERTUSSIS	WLTWLAILA	2600	AAW72734.1
1718	BORDETELLA PERTUSSIS	WTFHAGYRY	2601	AGS56996.1
1719	BORDETELLA PERTUSSIS	WVMTDNSNV	2602	AGS56996.1
1720	BORDETELLA PERTUSSIS	YAEHGEVSI	2603	WP_019249248.1
1721	BORDETELLA PERTUSSIS	Y AidGTAAG	2604	WP_019249248.1
1722	BORDETELLA PERTUSSIS	YALKSRIAL	2605	AAA22984.1
1723	BORDETELLA PERTUSSIS	YATNPQTQL	2606	WP_019248145.1
1724	BORDETELLA PERTUSSIS	YDTGDLIAY	2607	WP_019248658.1
1725	BORDETELLA PERTUSSIS	YEAGFSLGS	2608	WP_019247158.1
1726	BORDETELLA PERTUSSIS	YEDATFETY	2609	YP_006628018.1
1727	BORDETELLA PERTUSSIS	YENKSSTPL	2610	WP_019247158.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1728	BORDETELLA PERTUSSIS	YEVTPTRML	2611	AAA22983.1
1729	BORDETELLA PERTUSSIS	YEYIWGLYP	2612	WP_019249248.1
1730	BORDETELLA PERTUSSIS	YEYIWGLYQ	2613	YP_006626470.1
1731	BORDETELLA PERTUSSIS	YEYSKGPKL	2614	AGS56996.1
1732	BORDETELLA PERTUSSIS	YFEPGPTTD	2615	WP_019248145.1
1733	BORDETELLA PERTUSSIS	YIWGLYPTY	2616	WP_019249248.1
1734	BORDETELLA PERTUSSIS	YIWGLYQTY	2617	YP_006626470.1
1735	BORDETELLA PERTUSSIS	YLRQITPGW	2618	1BCP_C
1736	BORDETELLA PERTUSSIS	YMIYMSGLA	2619	1BCP_C
1737	BORDETELLA PERTUSSIS	YPALRAALI	2620	WP_019248658.1
1738	BORDETELLA PERTUSSIS	YPGTPGDLL	2621	AAA22984.1
1739	BORDETELLA PERTUSSIS	YPTYTEWSV	2622	WP_019249248.1
1740	BORDETELLA PERTUSSIS	YQTYTEWSV	2623	YP_006626470.1
1741	BORDETELLA PERTUSSIS	YSTGDLRAY	2624	WP_019248145.1
1742	BORDETELLA PERTUSSIS	YTLRYLASV	2625	WP_019248658.1
1743	BORDETELLA PERTUSSIS	YVLVKTNMV	2626	AAA22983.1
1744	BORDETELLA PERTUSSIS	YYDYEDATF	2627	YP_006628018.1
1745	BORDETELLA PERTUSSIS 509	AAFIALYPNSQLAPT	2628	Q7VU05
1746	BORDETELLA PERTUSSIS 509	GGAEYNLALGQRRRA	2629	Q7VU04
1747	BORDETELLA PERTUSSIS 509	GGAEYNLALGQRRADA	2630	Q7VU04
1748	BORDETELLA PERTUSSIS 509	IALYPNSQLAPT	2631	Q7VU05
1749	BORDETELLA PERTUSSIS 509	KPDQGEVVAVGPGKKTED	2632	P0A339.1
1750	BORDETELLA PERTUSSIS 509	KPDQGEVVAVGPGKKTEDG	2633	P0A339.1
1751	BORDETELLA PERTUSSIS 509	LAEVLDYHNFVLTQ	2634	Q7VWM1.1
1752	CORYNEBACTERIUM DIPHThERIAE	QSIALSSLMVAQAIP	2635	AAV70486.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1753	CORYNEBACTERIUM DIPHtheriae	SIGVLGYQKTV DHTKVNSKLSLF	2636	AAV70486.1
1754	BORDETELLA PERTUSSIS	AAHADWNNQSIVKT	2637	ABO77783.1
1755	BORDETELLA PERTUSSIS	AALGRG	2638	ABO77783.1
1756	BORDETELLA PERTUSSIS	AALGRGHSLYASYE	2639	ABO77783.1
1757	BORDETELLA PERTUSSIS	AAPLRRTTLAMALG	2640	ABO77783.1
1758	BORDETELLA PERTUSSIS	AAPLSITLQAGAHA	2641	ABO77783.1
1759	BORDETELLA PERTUSSIS	ADAQGDIVATELPS	2642	ABO77783.1
1760	BORDETELLA PERTUSSIS	ADSGFYLDATLRAS	2643	ABO77783.1
1761	BORDETELLA PERTUSSIS	AELA	2644	ABO77783.1
1762	BORDETELLA PERTUSSIS	AELAVFRAGGGAYR	2645	ABO77783.1
1763	BORDETELLA PERTUSSIS	AELQFRNGSVTSSG	2646	ABO77783.1
1764	BORDETELLA PERTUSSIS	AGGRWHLGGLAGYT	2647	ABO77783.1
1765	BORDETELLA PERTUSSIS	AGVAAMQGAVVHLQ	2648	ABO77783.1
1766	BORDETELLA PERTUSSIS	AGYTRGDRGFTGDG	2649	ABO77783.1
1767	BORDETELLA PERTUSSIS	ALASQARWTGATRA	2650	ABO77783.1
1768	BORDETELLA PERTUSSIS	AMPWTFHAGYRYSW	2651	ABO77783.1
1769	BORDETELLA PERTUSSIS	AMQGAVVHLQRATIRRGDAP	2652	ABO77783.1
1770	BORDETELLA PERTUSSIS	ANGLRVRDE	2653	ABO77783.1
1771	BORDETELLA PERTUSSIS	ANGLRVRDEGGSSV	2654	ABO77783.1
1772	BORDETELLA PERTUSSIS	ANKDGKVDIGTYRY	2655	ABO77783.1
1773	BORDETELLA PERTUSSIS	APAAVSVLGASELT	2656	ABO77783.1
1774	BORDETELLA PERTUSSIS	APPAPKPAPQPGPQ	2657	ABO77783.1
1775	BORDETELLA PERTUSSIS	AQGILLENPAELQ	2658	ABO77783.1
1776	BORDETELLA PERTUSSIS	ARWTGATRAVDSLS	2659	ABO77783.1
1777	BORDETELLA PERTUSSIS	ASLEAGRRFTHADG	2660	ABO77783.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1778	BORDETELLA PERTUSSIS	ASYEYSKGPKLAMP	2661	ABO77783.1
1779	BORDETELLA PERTUSSIS	ATFTLANKD	2662	ABO77783.1
1780	BORDETELLA PERTUSSIS	ATFTLANKDQKVDI	2663	ABO77783.1
1781	BORDETELLA PERTUSSIS	ATRAVDLSIDNAT	2664	ABO77783.1
1782	BORDETELLA PERTUSSIS	DDDGIALYVAGEQAQ	2665	ABO77783.1
1783	BORDETELLA PERTUSSIS	DDGIALYVAGEQAQ	2666	ABO77783.1
1784	BORDETELLA PERTUSSIS	DGGHITGGRAAGVA	2667	ABO77783.1
1785	BORDETELLA PERTUSSIS	DGIRRFGLTVTVKAGK	2668	ABO77783.1
1786	BORDETELLA PERTUSSIS	DGSVDFQQPAEAGR	2669	ABO77783.1
1787	BORDETELLA PERTUSSIS	DGYAVKKGKYRTHGV	2670	ABO77783.1
1788	BORDETELLA PERTUSSIS	DIVATELPSIPGTS	2671	ABO77783.1
1789	BORDETELLA PERTUSSIS	DKLVVMQDASGQHR	2672	ABO77783.1
1790	BORDETELLA PERTUSSIS	DLGLSDKLVVMQDA	2673	ABO77783.1
1791	BORDETELLA PERTUSSIS	DNATWVMTDNSNVGA	2674	ABO77783.1
1792	BORDETELLA PERTUSSIS	DNATWVMTDNSNVGALRLA	2675	ABO77783.1
1793	BORDETELLA PERTUSSIS	DNRAGRFRDQKVAG	2676	ABO77783.1
1794	BORDETELLA PERTUSSIS	EAGRFKVLTVNTLA	2677	ABO77783.1
1795	BORDETELLA PERTUSSIS	ELAQSIVEAPELGA	2678	ABO77783.1
1796	BORDETELLA PERTUSSIS	ELGAAIRVGRGARV	2679	ABO77783.1
1797	BORDETELLA PERTUSSIS	ELGADHAVAVAGGR	2680	ABO77783.1
1798	BORDETELLA PERTUSSIS	ELPSIPGTSIGPLD	2681	ABO77783.1
1799	BORDETELLA PERTUSSIS	EPVKLTLTGGADAQ	2682	ABO77783.1
1800	BORDETELLA PERTUSSIS	EQAQASIADSTLQG	2683	ABO77783.1
1801	BORDETELLA PERTUSSIS	ERGANVTVQRSAIV	2684	ABO77783.1
1802	BORDETELLA PERTUSSIS	ERQHGIHIQGSDPG	2685	ABO77783.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1803	BORDETELLA PERTUSSIS	EVGKRIELAGGRQV	2686	ABO77783.1
1804	BORDETELLA PERTUSSIS	FDGAGTVHTNGIAH	2687	ABO77783.1
1805	BORDETELLA PERTUSSIS	FQQPAEAGRFKVLT	2688	ABO77783.1
1806	BORDETELLA PERTUSSIS	FRAGGGAYRAANGL	2689	ABO77783.1
1807	BORDETELLA PERTUSSIS	GAHAQ GKALLYRVL	2690	ABO77783.1
1808	BORDETELLA PERTUSSIS	GARVTVSGGSLSAP	2691	ABO77783.1
1809	BORDETELLA PERTUSSIS	GAYRAANGLRVRDE	2692	ABO77783.1
1810	BORDETELLA PERTUSSIS	GDAPAGGAVPGGAV	2693	ABO77783.1
1811	BORDETELLA PERTUSSIS	GGAVPGGAVPGGFG	2694	ABO77783.1
1812	BORDETELLA PERTUSSIS	GGAVPGGFGPVLDG	2695	ABO77783.1
1813	BORDETELLA PERTUSSIS	GGFGPVLDGWYGV D	2696	ABO77783.1
1814	BORDETELLA PERTUSSIS	GGLHIGALQSLQPE	2697	ABO77783.1
1815	BORDETELLA PERTUSSIS	GGVQIERGANVTVQ	2698	ABO77783.1
1816	BORDETELLA PERTUSSIS	GHSLYASYEYSKGP	2699	ABO77783.1
1817	BORDETELLA PERTUSSIS	GHTDSVHVGGYATY	2700	ABO77783.1
1818	BORDETELLA PERTUSSIS	GIAHRTELRGTRAE	2701	ABO77783.1
1819	BORDETELLA PERTUSSIS	GKALLYRVLPEPVK	2702	ABO77783.1
1820	BORDETELLA PERTUSSIS	GLGMAAALGRGHSL	2703	ABO77783.1
1821	BORDETELLA PERTUSSIS	GNVIETGGARRFAP	2704	ABO77783.1
1822	BORDETELLA PERTUSSIS	GPLDVALASQARWT	2705	ABO77783.1
1823	BORDETELLA PERTUSSIS	GQHRLWVRN	2706	ABO77783.1
1824	BORDETELLA PERTUSSIS	GRGFAQRQQLDNRA	2707	ABO77783.1
1825	BORDETELLA PERTUSSIS	GRLGLEVGKRIELA	2708	ABO77783.1
1826	BORDETELLA PERTUSSIS	GRQVQPYIKASVLQ	2709	ABO77783.1
1827	BORDETELLA PERTUSSIS	GRRFTHADGWFLEPQAELA	2710	ABO77783.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1828	BORDETELLA PERTUSSIS	GSEPASANTLLLVQ	2711	ABO77783.1
1829	BORDETELLA PERTUSSIS	GSSVLGRLGLEVGK	2712	ABO77783.1
1830	BORDETELLA PERTUSSIS	GTTIKVSGRQAQGI	2713	ABO77783.1
1831	BORDETELLA PERTUSSIS	GTVTVKAGKLVADH	2714	ABO77783.1
1832	BORDETELLA PERTUSSIS	HAVAVAGGRWHLGG	2715	ABO77783.1
1833	BORDETELLA PERTUSSIS	IELAGGRQVQPYIK	2716	ABO77783.1
1834	BORDETELLA PERTUSSIS	IHIQGSDFGGVVRTA	2717	ABO77783.1
1835	BORDETELLA PERTUSSIS	IRRFLGTVTVKAGK	2718	ABO77783.1
1836	BORDETELLA PERTUSSIS	IRVGRGARVTVSGG	2719	ABO77783.1
1837	BORDETELLA PERTUSSIS	ITLQAGAHA	2720	ABO77783.1
1838	BORDETELLA PERTUSSIS	ITLQAGAHAQGKAL	2721	ABO77783.1
1839	BORDETELLA PERTUSSIS	IVEAPELGAAIRVG	2722	ABO77783.1
1840	BORDETELLA PERTUSSIS	IVKTGERQHGIHIQ	2723	ABO77783.1
1841	BORDETELLA PERTUSSIS	KAGKLVADHATLAN	2724	ABO77783.1
1842	BORDETELLA PERTUSSIS	KGKYRTHGVGASLE	2725	ABO77783.1
1843	BORDETELLA PERTUSSIS	KPAPQPGPQPPQPP	2726	ABO77783.1
1844	BORDETELLA PERTUSSIS	KVAGFELGADHAVA	2727	ABO77783.1
1845	BORDETELLA PERTUSSIS	KVAGSDGYAVKGKY	2728	ABO77783.1
1846	BORDETELLA PERTUSSIS	KVDIGTYRYRLAAN	2729	ABO77783.1
1847	BORDETELLA PERTUSSIS	KVLTVNTRLAGSGLF	2730	ABO77783.1
1848	BORDETELLA PERTUSSIS	LAANGNGQWSLVGA	2731	ABO77783.1
1849	BORDETELLA PERTUSSIS	LAMPWTFHAGYRYS	2732	ABO77783.1
1850	BORDETELLA PERTUSSIS	LASTLWYAESNALS	2733	ABO77783.1
1851	BORDETELLA PERTUSSIS	LENDFKVAGSDGYA	2734	ABO77783.1
1852	BORDETELLA PERTUSSIS	LENPAELQFRNGS	2735	ABO77783.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1853	BORDETELLA PERTUSSIS	LGAAPAAHADWNNQ	2736	ABO77783.1
1854	BORDETELLA PERTUSSIS	LGGLAGYTRGDRGFTGDG	2737	ABO77783.1
1855	BORDETELLA PERTUSSIS	LLENP	2738	ABO77783.1
1856	BORDETELLA PERTUSSIS	LLVQTPLGSAATFT	2739	ABO77783.1
1857	BORDETELLA PERTUSSIS	LPPSRVVL RDTNVT	2740	ABO77783.1
1858	BORDETELLA PERTUSSIS	LQPEDLPPS	2741	ABO77783.1
1859	BORDETELLA PERTUSSIS	LQPEDLPPSRVVL R	2742	ABO77783.1
1860	BORDETELLA PERTUSSIS	LRASRL ENDFK VAG	2743	ABO77783.1
1861	BORDETELLA PERTUSSIS	LRLASDGSVDFQQP	2744	ABO77783.1
1862	BORDETELLA PERTUSSIS	LSAAANAAVNTGGV	2745	ABO77783.1
1863	BORDETELLA PERTUSSIS	LSAPHGNVIETGGA	2746	ABO77783.1
1864	BORDETELLA PERTUSSIS	LSDDGIRRLGTVT	2747	ABO77783.1
1865	BORDETELLA PERTUSSIS	LVGAKAPPAPKPAP	2748	ABO77783.1
1866	BORDETELLA PERTUSSIS	LYVAGEQAQASIAD	2749	ABO77783.1
1867	BORDETELLA PERTUSSIS	MALGALGAAPAAHA	2750	ABO77783.1
1868	BORDETELLA PERTUSSIS	MNMSLSRIVKAAPL	2751	ABO77783.1
1869	BORDETELLA PERTUSSIS	MQDASGQHR	2752	ABO77783.1
1870	BORDETELLA PERTUSSIS	MQGAVVHLQRATIR	2753	ABO77783.1
1871	BORDETELLA PERTUSSIS	NAAVNTGGVGLAST	2754	ABO77783.1
1872	BORDETELLA PERTUSSIS	NALSKRLGELRLNP	2755	ABO77783.1
1873	BORDETELLA PERTUSSIS	NGQWSLVGAKAPPA	2756	ABO77783.1
1874	BORDETELLA PERTUSSIS	NTLAGSGLFRMNVF	2757	ABO77783.1
1875	BORDETELLA PERTUSSIS	PAGRELSAAANA AV	2758	ABO77783.1
1876	BORDETELLA PERTUSSIS	PAPQPPAGRELSAA	2759	ABO77783.1
1877	BORDETELLA PERTUSSIS	PGPQPPQPPQPQPE	2760	ABO77783.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1878	BORDETELLA PERTUSSIS	PGTSIGPLDVALAS	2761	ABO77783.1
1879	BORDETELLA PERTUSSIS	PLGSAATFTLANKD	2762	ABO77783.1
1880	BORDETELLA PERTUSSIS	PQPEAPAPQPPAGR	2763	ABO77783.1
1881	BORDETELLA PERTUSSIS	PQPPQPQPEAPAPQ	2764	ABO77783.1
1882	BORDETELLA PERTUSSIS	PYIKASVLQEFDGA	2765	ABO77783.1
1883	BORDETELLA PERTUSSIS	RFAPQAAPLSITLQ	2766	ABO77783.1
1884	BORDETELLA PERTUSSIS	RLGELRLNPDAGGA	2767	ABO77783.1
1885	BORDETELLA PERTUSSIS	RLNPDAGGAWGRGF	2768	ABO77783.1
1886	BORDETELLA PERTUSSIS	RNGSVTSSGQLSDD	2769	ABO77783.1
1887	BORDETELLA PERTUSSIS	RRFDQKVAGFELGA	2770	ABO77783.1
1888	BORDETELLA PERTUSSIS	RTTLAMALGALGAA	2771	ABO77783.1
1889	BORDETELLA PERTUSSIS	SAIVDGGLHIGALQ	2772	ABO77783.1
1890	BORDETELLA PERTUSSIS	SANTLLLVQTPLGS	2773	ABO77783.1
1891	BORDETELLA PERTUSSIS	SDPGGVRTASGTTI	2774	ABO77783.1
1892	BORDETELLA PERTUSSIS	SELTLDGGHITGGR	2775	ABO77783.1
1893	BORDETELLA PERTUSSIS	SGLFRMNVF	2776	ABO77783.1
1894	BORDETELLA PERTUSSIS	SGLFRMNVFADLGL	2777	ABO77783.1
1895	BORDETELLA PERTUSSIS	SGSSVELAQSIVEA	2778	ABO77783.1
1896	BORDETELLA PERTUSSIS	SIADSTLQGAGGVQ	2779	ABO77783.1
1897	BORDETELLA PERTUSSIS	SKGPKLAMPWTFHA	2780	ABO77783.1
1898	BORDETELLA PERTUSSIS	SNVGALRLASDGSV	2781	ABO77783.1
1899	BORDETELLA PERTUSSIS	SRIVKAAPLRRTTL	2782	ABO77783.1
1900	BORDETELLA PERTUSSIS	SVLGASELTLDGGH	2783	ABO77783.1
1901	BORDETELLA PERTUSSIS	SVLQEFDGA	2784	ABO77783.1
1902	BORDETELLA PERTUSSIS	SVLQEFDGAGTVHT	2785	ABO77783.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1903	BORDETELLA PERTUSSIS	TELR	2786	ABO77783.1
1904	BORDETELLA PERTUSSIS	TELRGTRAEGLGM	2787	ABO77783.1
1905	BORDETELLA PERTUSSIS	TGDGGGHTDSVHVG	2788	ABO77783.1
1906	BORDETELLA PERTUSSIS	TGGARRFAPQAAPL	2789	ABO77783.1
1907	BORDETELLA PERTUSSIS	TGGRAAGVAAMQGA	2790	ABO77783.1
1908	BORDETELLA PERTUSSIS	TGGVGLASTLWYAE	2791	ABO77783.1
1909	BORDETELLA PERTUSSIS	THGVGASLEAGRRF	2792	ABO77783.1
1910	BORDETELLA PERTUSSIS	TIRRGDAPA	2793	ABO77783.1
1911	BORDETELLA PERTUSSIS	TLANVGDTWDDGI	2794	ABO77783.1
1912	BORDETELLA PERTUSSIS	TLQGAGGVQIERGA	2795	ABO77783.1
1913	BORDETELLA PERTUSSIS	TLTGGADAQGDIVA	2796	ABO77783.1
1914	BORDETELLA PERTUSSIS	TNVTAVPASGAPAA	2797	ABO77783.1
1915	BORDETELLA PERTUSSIS	TRAEGLGLMAAALG	2798	ABO77783.1
1916	BORDETELLA PERTUSSIS	TSSGQLSDDGIRRF	2799	ABO77783.1
1917	BORDETELLA PERTUSSIS	TVHTNGIAHRTEL	2800	ABO77783.1
1918	BORDETELLA PERTUSSIS	TYRYRLAANGNGQW	2801	ABO77783.1
1919	BORDETELLA PERTUSSIS	VADHATLANVGDTW	2802	ABO77783.1
1920	BORDETELLA PERTUSSIS	VHVGGYATYIADSG	2803	ABO77783.1
1921	BORDETELLA PERTUSSIS	VLDGWYGV	2804	ABO77783.1
1922	BORDETELLA PERTUSSIS	VPASGAPAAVSVLG	2805	ABO77783.1
1923	BORDETELLA PERTUSSIS	VRDEGGSSVLGRLG	2806	ABO77783.1
1924	BORDETELLA PERTUSSIS	VRTASGTTIKVSGR	2807	ABO77783.1
1925	BORDETELLA PERTUSSIS	VSGGSLSAPHGNVI	2808	ABO77783.1
1926	BORDETELLA PERTUSSIS	VSGRQAQGILLENP	2809	ABO77783.1
1927	BORDETELLA PERTUSSIS	VTVQRSIAVDGGLH	2810	ABO77783.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1928	BORDETELLA PERTUSSIS	VVLRDTNVTAVPAS	2811	ABO77783.1
1929	BORDETELLA PERTUSSIS	WNNQSIVKTGERQH	2812	ABO77783.1
1930	BORDETELLA PERTUSSIS	WVRNSGSEPASANT	2813	ABO77783.1
1931	BORDETELLA PERTUSSIS	WYAESNALSRLGE	2814	ABO77783.1
1932	BORDETELLA PERTUSSIS	YATYIADSGFYLDA	2815	ABO77783.1
1933	BORDETELLA PERTUSSIS	YGVDVSGSS	2816	ABO77783.1
1934	BORDETELLA PERTUSSIS	YGVDVSGSSVELAQ	2817	ABO77783.1
1935	BORDETELLA PERTUSSIS	YLDATLRASRLND	2818	ABO77783.1
1936	BORDETELLA PERTUSSIS	YRVLPEPVKLTGTG	2819	ABO77783.1
1937	BORDETELLA PERTUSSIS	VKAQNITNKRAALIEA	2820	AAA22974.1
1938	BORDETELLA PERTUSSIS	YYSNVTATRLLSSTNS	2821	AAA83981.1
1939	BORDETELLA PERTUSSIS	SPNLTDERAAQAGVT	2822	CPP72976.1
1940	MEASLES MORBILLIVIRUS	SSRASDERAAHLPTS	2823	BAA33867.1
1941	CORYNEBACTERIUM DIPHTHERIAE	QVVHNSYNRPAYSPG	2824	1007216A
1942	MEASLES VIRUS STRAIN EDMONSTON-B	AEGGEIHEL	2825	AAF85692.1
1943	MEASLES VIRUS STRAIN EDMONSTON-B	AENLISNGIGKY	2826	AAF85698.1
1944	MEASLES VIRUS STRAIN EDMONSTON-B	AEVDGDVKL	2827	CAB43772.1
1945	MEASLES VIRUS STRAIN EDMONSTON-B	AIYTAEIHK	2828	AAF85697.1
1946	MEASLES VIRUS STRAIN EDMONSTON-B	APVFHMTNY	2829	CAB43772.1
1947	MEASLES VIRUS STRAIN EDMONSTON-B	APVFHMTNYLEQPVSN	2830	AAR89413.1
1948	MEASLES VIRUS STRAIN EDMONSTON-B	AQRLNEIY	2831	AAF85698.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1949	MEASLES VIRUS STRAIN EDMONSTON-B	ARVPHAYSL	2832	AAF85698.1
1950	MEASLES VIRUS STRAIN EDMONSTON-B	AVRDLERAM	2833	P03424.1
1951	MEASLES VIRUS STRAIN EDMONSTON-B	AVRDLERAMTTLK	2834	P03424.1
1952	MEASLES VIRUS STRAIN EDMONSTON-B	DALLRLQAM	2835	Q89933.1
1953	MEASLES VIRUS STRAIN EDMONSTON-B	DIKEKVINL	2836	AAF85698.1
1954	MEASLES VIRUS STRAIN EDMONSTON-B	DQGLFKVL	2837	AAF85695.1
1955	MEASLES VIRUS STRAIN EDMONSTON-B	DTGVDTRIW	2838	Q9EMA9.1
1956	MEASLES VIRUS STRAIN EDMONSTON-B	EPIGSLAIEEAM	2839	AAF85692.1
1957	MEASLES VIRUS STRAIN EDMONSTON-B	EPIRDALNAM	2840	P69354.1
1958	MEASLES VIRUS STRAIN EDMONSTON-B	FPKLGKTL	2841	AAF85692.1
1959	MEASLES VIRUS STRAIN EDMONSTON-B	FRSVNAVAF	2842	AAF85695.1
1960	MEASLES VIRUS STRAIN EDMONSTON-B	GKIIDNTEQL	2843	AAF85695.1
1961	MEASLES VIRUS STRAIN EDMONSTON-B	GLNEKLVFY	2844	AAF85695.1
1962	MEASLES VIRUS STRAIN EDMONSTON-B	GMYGGTYLVEK	2845	AAC35876.2
1963	MEASLES VIRUS STRAIN EDMONSTON-B	GPPISLERLDVGTN	2846	P69354.1
1964	MEASLES VIRUS STRAIN EDMONSTON-B	GPRQAQVSFL	2847	Q89933.1
1965	MEASLES VIRUS STRAIN EDMONSTON-B	GRLVPQVRVID	2848	AAF85695.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1966	MEASLES VIRUS STRAIN EDMONSTON-B	GSAPISMGFR	2849	AAF85692.1
1967	MEASLES VIRUS STRAIN EDMONSTON-B	HILAKSTAL	2850	AAF85698.1
1968	MEASLES VIRUS STRAIN EDMONSTON-B	HYREVNLVY	2851	AAF85698.1
1969	MEASLES VIRUS STRAIN EDMONSTON-B	IPPMKNLAL	2852	AAC35876.2
1970	MEASLES VIRUS STRAIN EDMONSTON-B	IPYQSGKGVSF	2853	CAB43772.1
1971	MEASLES VIRUS STRAIN EDMONSTON-B	ISKESQHVY	2854	AAF85698.1
1972	MEASLES VIRUS STRAIN EDMONSTON-B	IVSSHFFVY	2855	AAF85698.1
1973	MEASLES VIRUS STRAIN EDMONSTON-B	KEIKETGRLF	2856	AAF85698.1
1974	MEASLES VIRUS STRAIN EDMONSTON-B	KESQHVVYL	2857	AAF85698.1
1975	MEASLES VIRUS STRAIN EDMONSTON-B	KIIDNTEQL	2858	AAF85695.1
1976	MEASLES VIRUS STRAIN EDMONSTON-B	KKQINRQN	2859	AAA63285.1
1977	MEASLES VIRUS STRAIN EDMONSTON-B	KKVDTNFIYQ	2860	AAF85698.1
1978	MEASLES VIRUS STRAIN EDMONSTON-B	KLIDGFFPA	2861	AAF85698.1
1979	MEASLES VIRUS STRAIN EDMONSTON-B	KPNLSSKRSEL	2862	BAB39848.1
1980	MEASLES VIRUS STRAIN EDMONSTON-B	KVSPYLFTV	2863	AAR89413.1
1981	MEASLES VIRUS STRAIN EDMONSTON-B	LETRTTNQFL	2864	CAB43772.1
1982	MEASLES VIRUS STRAIN EDMONSTON-B	LLKEATEL	2865	AAF85695.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
1983	MEASLES VIRUS STRAIN EDMONSTON-B	LLKKGNSLY	2866	AAF85698.1
1984	MEASLES VIRUS STRAIN EDMONSTON-B	LPAPIGGMNY	2867	AAF85698.1
1985	MEASLES VIRUS STRAIN EDMONSTON-B	MPEETLHQVM	2868	AAF85698.1
1986	MEASLES VIRUS STRAIN EDMONSTON-B	PTTIRGQFS	2869	CAB43772.1
1987	MEASLES VIRUS STRAIN EDMONSTON-B	QEISRHQALGY	2870	P03424.1
1988	MEASLES VIRUS STRAIN EDMONSTON-B	RITHVDTESY	2871	P69354.1
1989	MEASLES VIRUS STRAIN EDMONSTON-B	RPGLKPD L	2872	P69354.1
1990	MEASLES VIRUS STRAIN EDMONSTON-B	RPIYGLEV	2873	AAF85698.1
1991	MEASLES VIRUS STRAIN EDMONSTON-B	RQAGQEMILAV	2874	P69354.1
1992	MEASLES VIRUS STRAIN EDMONSTON-B	SAVRIATVY	2875	AAF85698.1
1993	MEASLES VIRUS STRAIN EDMONSTON-B	SLMPEETLHQV	2876	AAF85698.1
1994	MEASLES VIRUS STRAIN EDMONSTON-B	SMIDLVTKF	2877	AAF85698.1
1995	MEASLES VIRUS STRAIN EDMONSTON-B	SMLNSQAIDNLRA	2878	P69354.1
1996	MEASLES VIRUS STRAIN EDMONSTON-B	SMYRVFEV	2879	CAB43772.1
1997	MEASLES VIRUS STRAIN EDMONSTON-B	SQQGMFHAY	2880	AAF85698.1
1998	MEASLES VIRUS STRAIN EDMONSTON-B	TDTPIVYNDRLLD	2881	Q89933.1
1999	MEASLES VIRUS STRAIN EDMONSTON-B	VIINDDQGLFKV	2882	AAF85695.1

NO.	DISEASE	EPITOPE AMINO ACID SEQUENCE	SEQ ID NO	ACCESS. NO.
2000	MEASLES VIRUS STRAIN EDMONSTON-B	YESGVRIASL	2883	AAF85698.1
2001	MEASLES VIRUS STRAIN EDMONSTON-B	YLKDKALA	2884	AAF85698.1
2002	MEASLES VIRUS STRAIN EDMONSTON-B	YVYDHSGEAVK	2885	AAF85692.1
2003	RUBELLA VIRUS	ARVIDPAAQSFTGVV	2886	BAA28178.1
2004	RUBELLA VIRUS	SDRASARVIDPAAQS	2887	BAA28178.1
2005	RUBELLA VIRUS	VPPGKFVTAALLNTP	2888	BAA28178.1
2006	RUBELLA VIRUS	WVTPVIGSQARKCGL	2889	BAA28178.1
2007	MUMPS RUBULAVIRUS	GTYRLIPNARANLTA	400	AGC97176.1

E. Delivery of multi-flap prime editors

[0809] In another aspect, the present disclosure provides for the delivery of multi-flap prime editors *in vitro* and *in vivo* using various strategies, including on separate vectors using split inteins and as well as direct delivery strategies of the ribonucleoprotein complex (i.e., the prime editor complexed to the PEgRNA and/or the second-site gRNA) using techniques such as electroporation, use of cationic lipid-mediated formulations, and induced endocytosis methods using receptor ligands fused to the ribonucleoprotein complexes. Any such methods are contemplated herein.

Overview of delivery options

[0810] In some aspects, the invention provides methods comprising delivering one or more multi-flap prime editor-encoding polynucleotides, such as or one or more vectors as described herein encoding one or more components of the multi-flap prime editing system described herein, one or more transcripts thereof, and/or one or proteins transcribed therefrom, to a host cell. In some aspects, the invention further provides cells produced by such methods, and organisms (such as animals, plants, or fungi) comprising or produced from such cells. In some embodiments, a multi-flap prime editor as described herein in combination with (and optionally complexed with) a guide sequence is delivered to a cell. Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of a multi-flap prime editor system to cells in culture, or in a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either

episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel & Felgner, TIBTECH 11:211-217 (1993); Mitani & Caskey, TIBTECH 11:162-166 (1993); Dillon, TIBTECH 11:167-175 (1993); Miller, Nature 357:455-460 (1992); Van Brunt, Biotechnology 6(10):1149-1154 (1988); Vigne, Restorative Neurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51(1):31-44 (1995); Haddada et al., in Current Topics in Microbiology and Immunology Doerfler and Bihm (eds) (1995); and Yu et al., Gene Therapy 1:13-26 (1994).

[0811] Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. *in vitro* or *ex vivo* administration) or target tissues (e.g. *in vivo* administration).

[0812] The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res. 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).

[0813] The use of RNA or DNA viral based systems for the delivery of nucleic acids take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be administered directly to patients (*in vivo*) or they can be used to treat cells *in vitro*, and the modified cells may optionally be administered to patients (*ex vivo*). Conventional viral based systems could include retroviral, lentivirus, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues.

[0814] The tropism of a viruses can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lentiviral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral titers. Selection of a retroviral gene transfer system would therefore depend on the target tissue. Retroviral vectors are comprised of cis-acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cis-acting LTRs are sufficient for replication and packaging of the vectors, which are then

used to integrate the therapeutic gene into the target cell to provide permanent transgene expression. Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immuno deficiency virus (SIV), human immuno deficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al., J. Virol. 66:2731-2739 (1992); Johann et al., J. Virol. 66:1635-1640 (1992); Sommerfelt et al., Virol. 176:58-59 (1990); Wilson et al., J. Virol. 63:2374-2378 (1989); Miller et al., J. Virol. 65:2220-2224 (1991); PCT/US94/05700). In applications where transient expression is preferred, adenoviral based systems may be used. Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. Adeno-associated virus ("AAV") vectors may also be used to transduce cells with target nucleic acids, e.g., in the *in vitro* production of nucleic acids and peptides, and for *in vivo* and *ex vivo* gene therapy procedures (see, e.g., West et al., Virology 160:38-47 (1987); U.S. Pat. No. 4,797,368; WO 93/24641; Kotin, Human Gene Therapy 5:793-801 (1994); Muzyczka, J. Clin. Invest. 94:1351 (1994). Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat. No. 5,173,414; Tratschin et al., Mol. Cell. Biol. 5:3251-3260 (1985); Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81:6466-6470 (1984); and Samulski et al., J. Virol. 63:03822-3828 (1989).

[0815] Packaging cells are typically used to form virus particles that are capable of infecting a host cell. Such cells include 293 cells, which package adenovirus, and ψ 2 cells or PA317 cells, which package retrovirus. Viral vectors used in gene therapy are usually generated by producing a cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the polynucleotide(s) to be expressed. The missing viral functions are typically supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy typically only possess ITR sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DNA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. The cell line may also be infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV. Additional methods for the delivery of nucleic acids to cells are known to those skilled in the art. See, for example, US20030087817, incorporated herein by reference.

[0816] In various embodiments, the dual PE constructs (including, the split-constructs) may be engineered for delivery in one or more rAAV vectors. An rAAV as related to any of the methods and compositions provided herein may be of any serotype including any derivative or pseudotype (e.g., 1,

2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 2/1, 2/5, 2/8, 2/9, 3/1, 3/5, 3/8, or 3/9). An rAAV may comprise a genetic load (i.e., a recombinant nucleic acid vector that expresses a gene of interest, such as a whole or split PE fusion protein that is carried by the rAAV into a cell) that is to be delivered to a cell. An rAAV may be chimeric.

[0817] As used herein, the serotype of an rAAV refers to the serotype of the capsid proteins of the recombinant virus. Non-limiting examples of derivatives and pseudotypes include rAAV2/1, rAAV2/5, rAAV2/8, rAAV2/9, AAV2-AAV3 hybrid, AAVrh.10, AAVhu.14, AAV3a/3b, AAVrh32.33, AAV-HSC15, AAV-HSC17, AAVhu.37, AAVrh.8, CHt-P6, AAV2.5, AAV6.2, AAV2i8, AAV-HSC15/17, AAVM41, AAV9.45, AAV6(Y445F/Y731F), AAV2.5T, AAV-HAE1/2, AAV clone 32/83, AAVShH10, AAV2 (Y->F), AAV8 (Y733F), AAV2.15, AAV2.4, AAVM41, and AAVr3.45. A non-limiting example of derivatives and pseudotypes that have chimeric VP1 proteins is rAAV2/5-1VP1u, which has the genome of AAV2, capsid backbone of AAV5 and VP1u of AAV1. Other non-limiting example of derivatives and pseudotypes that have chimeric VP1 proteins are rAAV2/5-8VP1u, rAAV2/9-1VP1u, and rAAV2/9-8VP1u.

[0818] AAV derivatives/pseudotypes, and methods of producing such derivatives/pseudotypes are known in the art (see, e.g., Mol Ther. 2012 Apr;20(4):699-708. doi: 10.1038/mt.2011.287. Epub 2012 Jan 24. The AAV vector toolkit: poised at the clinical crossroads. Asokan A1, Schaffer DV, Samulski RJ.). Methods for producing and using pseudotyped rAAV vectors are known in the art (see, e.g., Duan et al., J. Virol., 75:7662-7671, 2001; Halbert et al., J. Virol., 74:1524-1532, 2000; Zolotukhin et al., Methods, 28:158-167, 2002; and Auricchio et al., Hum. Molec. Genet., 10:3075-3081, 2001).

[0819] Methods of making or packaging rAAV particles are known in the art and reagents are commercially available (see, e.g., Zolotukhin et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158–167; and U.S. Patent Publication Numbers US20070015238 and US20120322861, which are incorporated herein by reference; and plasmids and kits available from ATCC and Cell Biolabs, Inc.). For example, a plasmid comprising a gene of interest may be combined with one or more helper plasmids, e.g., that contain a rep gene (e.g., encoding Rep78, Rep68, Rep52 and Rep40) and a cap gene (encoding VP1, VP2, and VP3, including a modified VP2 region as described herein), and transfected into a recombinant cells such that the rAAV particle can be packaged and subsequently purified.

[0820] Recombinant AAV may comprise a nucleic acid vector, which may comprise at a minimum: (a) one or more heterologous nucleic acid regions comprising a sequence encoding a protein or polypeptide of interest or an RNA of interest (e.g., a siRNA or microRNA), and (b) one or more regions comprising inverted terminal repeat (ITR) sequences (e.g., wild-type ITR sequences or engineered ITR sequences) flanking the one or more nucleic acid regions (e.g., heterologous nucleic acid regions). Herein, heterologous nucleic acid regions comprising a sequence encoding a protein of interest or RNA of interest are referred to as genes of interest.

[0821] Any one of the rAAV particles provided herein may have capsid proteins that have amino acids of different serotypes outside of the VP1u region. In some embodiments, the serotype of the backbone of the VP1 protein is different from the serotype of the ITRs and/or the Rep gene. In some embodiments, the serotype of the backbone of the VP1 capsid protein of a particle is the same as the serotype of the ITRs. In some embodiments, the serotype of the backbone of the VP1 capsid protein of a particle is the same as the serotype of the Rep gene. In some embodiments, capsid proteins of rAAV particles comprise amino acid mutations that result in improved transduction efficiency.

[0822] In some embodiments, the nucleic acid vector comprises one or more regions comprising a sequence that facilitates expression of the nucleic acid (e.g., the heterologous nucleic acid), e.g., expression control sequences operatively linked to the nucleic acid. Numerous such sequences are known in the art. Non-limiting examples of expression control sequences include promoters, insulators, silencers, response elements, introns, enhancers, initiation sites, termination signals, and poly(A) tails. Any combination of such control sequences is contemplated herein (e.g., a promoter and an enhancer).

[0823] Final AAV constructs may incorporate a sequence encoding the PEGRNA. In other embodiments, the AAV constructs may incorporate a sequence encoding the second-site nicking guide RNA. In still other embodiments, the AAV constructs may incorporate a sequence encoding the second-site nicking guide RNA and a sequence encoding the PEGRNA.

[0824] In various embodiments, the PEGRNAs and the second-site nicking guide RNAs can be expressed from an appropriate promoter, such as a human U6 (hU6) promoter, a mouse U6 (mU6) promoter, or other appropriate promoter. The PEGRNAs and the second-site nicking guide RNAs can be driven by the same promoters or different promoters.

[0825] In some embodiments, a rAAV constructs or the herein compositions are administered to a subject enterally. In some embodiments, a rAAV constructs or the herein compositions are administered to the subject parenterally. In some embodiments, a rAAV particle or the herein compositions are administered to a subject subcutaneously, intraocularly, intravitreally, subretinally, intravenously (IV), intracerebro-ventricularly, intramuscularly, intrathecally (IT), intracisternally, intraperitoneally, via inhalation, topically, or by direct injection to one or more cells, tissues, or organs. In some embodiments, a rAAV particle or the herein compositions are administered to the subject by injection into the hepatic artery or portal vein.

Split multi-flap PE vector-based strategies

[0826] In this aspect, the multi-flap prime editors can be divided at a split site and provided as two halves of a whole/complete prime editor. The two halves can be delivered to cells (e.g., as expressed proteins or on separate expression vectors) and once in contact inside the cell, the two halves form the complete prime editor through the self-splicing action of the inteins on each prime editor half. Split

intein sequences can be engineered into each of the halves of the encoded prime editor to facilitate their transplicing inside the cell and the concomitant restoration of the complete, functioning PE.

[0827] These split intein-based methods overcome several barriers to *in vivo* delivery. For example, the DNA encoding prime editors is larger than the rAAV packaging limit, and so requires special solutions. One such solution is formulating the editor fused to split intein pairs that are packaged into two separate rAAV particles that, when co-delivered to a cell, reconstitute the functional editor protein. Several other special considerations to account for the unique features of multi-flap prime editing are described, including the optimization of second-site nicking targets and properly packaging multi-flap prime editors into virus vectors, including lentiviruses and rAAV.

[0828] In this aspect, the multi-flap prime editors can be divided at a split site and provided as two halves of a whole/complete prime editor. The two halves can be delivered to cells (e.g., as expressed proteins or on separate expression vectors) and once in contact inside the cell, the two halves form the complete prime editor through the self-splicing action of the inteins on each prime editor half. Split intein sequences can be engineered into each of the halves of the encoded prime editor to facilitate their transplicing inside the cell and the concomitant restoration of the complete, functioning PE.

[0829] FIG. 66 depicts depicts one embodiment of a prime editor being provided as two PE half proteins which regenerate as whole prime editor through the self-splicing action of the split-intein halves located at the end or beginning of each of the prime editor half proteins. The multi-flap prime editors described herein may also be provided in the same manner. As used herein, the term “PE N-terminal half” refers to the N-terminal half of a complete prime editor and which comprises the “N intein” at the C-terminal end of the PE N-terminal half (i.e., the N-terminal extein) of the complete prime editor. The “N intein” refers to the N-terminal half of a complete, fully-formed split-intein moiety. As used herein, the term “PE C-terminal half” refers to the C-terminal half of a complete prime editor and which comprises the “C intein” at the N-terminal end of the C-terminal half (i.e., the C-terminal extein) of a complete prime editor. When the two half proteins, i.e., the PE N-terminal half and the PE C-terminal half, come into contact with one another, e.g., within the cell, the N intein and the C intein undergo the simultaneous process of self-excision and the formation of a peptide bond between the C-terminal end of the PE N-terminal half and the N-terminal end of the PE C-terminal half to reform the complete prime editor protein comprising the complete napDNAbp domain (e.g., Cas9 nickase) and the RT domain. Although not shown in the drawing, the prime editor may also comprise additional sequences including NLS at the N-terminus and/or C-terminus, as well as amino acid linkers sequences joining each domain.

[0830] In various embodiments, the multi-flap prime editors may be engineered as two half proteins (i.e., a PE N-terminal half and a PE C-terminal half) by “splitting” the whole prime editor as a “split site.” The “split site” refers to the location of insertion of split intein sequences (i.e., the N intein and the C intein) between two adjacent amino acid residues in the prime editor. More specifically, the

“split site” refers to the location of dividing the whole prime editor into two separate halves, wherein in each half is fused at the split site to either the N intein or the C intein motifs. The split site can be at any suitable location in the prime editor fusion protein, but preferably the split site is located at a position that allows for the formation of two half proteins which are appropriately sized for delivery (e.g., by expression vector) and wherein the inteins, which are fused to each half protein at the split site termini, are available to sufficiently interact with one another when one half protein contacts the other half protein inside the cell.

[0831] In some embodiments, the split site is located in the napDNAbp domain. In other embodiments, the split site is located in the RT domain. In other embodiments, the split site is located in a linker that joins the napDNAbp domain and the RT domain.

[0832] In various embodiments, split site design requires finding sites to split and insert an N- and C-terminal intein that are both structurally permissive for purposes of packaging the two half prime editor domains into two different AAV genomes. Additionally, intein residues necessary for trans splicing can be incorporated by mutating residues at the N terminus of the C terminal extein or inserting residues that will leave an intein “scar.”

[0833] Exemplary split configurations of split multi-flap (e.g., dual flap or quadruple flap) prime editors comprising either the SpCas9 nickase or the SaCas9 nickase are as follows.

<p>S. PYOGENES PE, SPLIT AT LINKER, N TERMINAL PORTION STRUCTURE: [N EXTEIN]-[N INTEIN]</p> <p><u>MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDR</u> <u>HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFS NEMAKVDDSSFFH</u> <u>RLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLAL</u> <u>AHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLS</u> <u>KSRRLLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFLAEDAKLQLSKDITYDDDL</u> <u>DNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTL</u> <u>LKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVK</u> <u>LNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNREKIEKILTRIPYY</u> <u>VGPLARGNSRFWMTRKSEETITPWNFEVVDKGASQSFIERMTNFDKNLPNEKVL</u> <u>PKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLK</u> <u>EDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTTL</u> <u>FEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDF</u> <u>LKSDGFANRNFMLIHDDSLTFKEDIQKAQVSGQDSLHEHIANLAGSPAIIKKGILQT</u> <u>VKVVDDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEIEGKELGSQILK</u> <u>EHPVENTQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNK</u> <u>VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSEL</u> <u>DKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKD</u> <u>FQFYKVREINNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIKSE</u> <u>QEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRK</u> <u>VLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSV</u> <u>LVVAKVEKGKSKKLKSVKELLGITIMERSSEFEKNPIDFLEAKGYKEVKKDLIIKLPKYS</u> <u>LELENGRKRMLASAGELQKGNELALPSKYVNFYLYLASHYEKLKGSPEDEQKQLFV</u> <u>EQHKHYLDEIIEQISEFSKRVLADANLDKVL SAYNKH RDKPIREQAENIIHLFTLTNLG</u> <u>APAAFKYFDTTIDRKRYTSTKEVL DATLIHQ SITGLYETRIDLSQLGGDSGGSSGGSCLS</u> <u>YETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHD RGEQEVFEYCLEDGSL</u> <u>IRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNSGGSKRTADGSEFEPKKRKV</u>(SEQ ID NO: 443)</p>
--

KEY:

NLS (SEQ ID NO: 124, 125)

CAS9 (SEQ ID NO: 445)

LINKER (SEQ ID NO: 446)

NPUN INTEIN (SEQ ID NO: 447)

S. PYOGENES PE, SPLIT AT LINKER, C TERMINAL PORTION

STRUCTURE: [C INTEIN]-[C EXTEIN]

MKRTADGSEFESPKKKRKVIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASN**CFNSGSETP**
GTSESATPESSGSSGSSGSSTLNIEDEYRLHETSKEPDVSLGSTWLSDFPOAWAETGGMGLAVR
QAPLIPLKATSTPVSIKOYPMSEARLGIKPHIQRLLDQGILVPCOSPWNTPLLPVKKPGTNDYR
PVODLREVNRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRD
PEMGISGOLTWTRLPOGFKNSTPLFDEALHRDLADFRIOHPDLILLOYVDDLLAATSELDCCOQ
GTRALLQTLGNLGYRASAKKAQICOKQVKYLGILLKEGQRWLTEARKETVMGQTPKTPRQLR
EFLGTAGFCRLWIPGFAEMAAPLYPLTKTGLFNWGPDOQKAYQEIQAALLTAPALGLPDLTKPF
ELFVDEKQGYAKGVLTOKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMG
OPLVILAPHAVEALVKOPDRWLSNARMTHYOALLDTRVOFGPVVALNPATLLPLPEEGLOH
NCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGORKAGAAVTTETEVIWAKALPAGTS
AQRAELIALTOALKMAEGKKLVYTDSTRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKAL
FLPKRLSIHCPGHOKGHSAAEARGNRMADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSE
FEPKKRKV (SEQ ID NO: 450)

KEY:

NLS (SEQ ID NO: 124, 125)

LINKER 1 (SEQ ID NO: 453)

LINKER 2 (SEQ ID NO: 174)

NPUC INTEIN (SEQ ID NO: 452)

RT (SEQ ID NO: 454)

S. AUREUS PE, SPLIT BETWEEN RESIDUES 740/741, N TERMINAL PORTION

STRUCTURE: [N EXTEIN]-[N INTEIN]

MKRTADGSEFESPKKKRKVGKRNYILGLAIGITSVGYGIIDYETRDVIDAGVRLFKEAN
VENNEGRRSKRGARRLKRRRRHRIQRVKLLFDYNLLTDHSELSGINPYEARVKGLS
QKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQL
ERLKKDGEVRGSINRFKTSYVKEAKQLLKVKQKAYHQLDQSFIDTYIDLLETRRTYYE
GPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITR
DENEKLEYEKFQIENVFQKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLK
VYHDIKDITARKEIENAEELDQIAKILTIYQSSEDIQEELTNLNSLTQEEIEQISNLKGY
TGTHNLSLKAJNLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPV
VKRSFIQSIKVINAIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEII
RTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNPNFNYEVDHIIPRSVSFDNS
FNNKVLVKQEENSKKGNRTPFYLSSSDSKISYETFKKHILNLAAGKGRISKTKKEYL
LEERDINRFSVQKDFINRNLVDTRYATRGLMNLRSYFRVNNLDVKVKSINGGFTSFL
RRKWKFKKERNKGYKHHAEADALHANADFIFKEWKKLDKAKKVMENQMFEEKQAE
CLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPAQWHDGRGEQEVFEYCLED
GSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPN**SGGSKRTADGSEFEPKKRKV**
 (SEQ ID NO: 458)

KEY:

NLS (SEQ ID NO: 124, 125)

CAS9 (SEQ ID NO: 460) LINKER (SEQ ID NO: 174) NPUN INTEIN (SEQ ID NO: 462)
S. AUREUS PE, SPLIT BETWEEN RESIDUES 740/741, C TERMINAL PORTION STRUCTURE: [C INTEIN]-[C EXTEIN]
<p> <u>MKRTADGSEFESPKKKRKV</u><u>IKIATRKYL</u><u>GKQNVYDIGVERDHN</u><u>FALKNGFIASN</u><u>CFNEIETE</u><u>Q</u> <u>EYKEIFITPHQIKHIKDF</u><u>KDYKYS</u><u>HRVDKKPNRKL</u><u>INDTLYSTRKDD</u><u>KGNTLIVNNLN</u> <u>GLYDKDNDKLLKLINKS</u><u>PEKLLMYH</u><u>HDPTQYQKLKL</u><u>IMEQYGD</u><u>EKNPLYKY</u><u>YEETG</u> <u>NYLT</u><u>KYSKKDNGPVIK</u><u>IKIYYGN</u><u>KLNAHL</u><u>DITDDYP</u><u>NSRNKV</u><u>VKLSL</u><u>KPYRFD</u><u>VYLD</u> <u>NGVYKFVTVKNL</u><u>DIKKEN</u><u>YEVNS</u><u>KCYEEA</u><u>KKLKKIS</u><u>NAEF</u><u>IASFYK</u><u>NDLIK</u><u>INGE</u> <u>LYRVIGV</u><u>NNDLLNR</u><u>IEVNM</u><u>IDITYRE</u><u>YLENM</u><u>NDKRPP</u><u>HIKTI</u><u>ASKTQ</u><u>SIKKY</u><u>STDIL</u><u>GN</u> <u>LYEVKSKKHPQIIK</u><u>KGSGGSSG</u><u>SETPGT</u><u>SESATP</u><u>ESSGGSSG</u><u>SSTLNIE</u><u>DEYRLHET</u> <u>SKEPDVSLGSTWLSDF</u><u>POAWAETGGMGLAVROAP</u><u>LIPLKATSTP</u><u>VSIOYPM</u><u>SQEARLG</u><u>IKPHIO</u> <u>RLD</u><u>OGILVPC</u><u>OSPWNTPL</u><u>PVKPGTNDYRPVQDL</u><u>REVNKRVEDI</u><u>HPTVPNPYN</u><u>LLSGLP</u><u>PSH</u> <u>OWYTVL</u><u>DLKDAFF</u><u>CLRLHPT</u><u>SOP</u><u>LF</u><u>AFEWRD</u><u>PEMGIS</u><u>QLTWTRL</u><u>POGFKNSPT</u><u>LF</u><u>DEALHRD</u> <u>LAD</u><u>FRIQHPD</u><u>LILLO</u><u>YVDDLLA</u><u>ATSELD</u><u>COQ</u><u>TRALL</u><u>QTLGN</u><u>LG</u><u>YASAKKA</u><u>QICOK</u><u>OVKYL</u><u>GY</u> <u>LLKE</u><u>GORWL</u><u>TEARK</u><u>ETVMG</u><u>OPTPKTP</u><u>ROLREF</u><u>LGTAG</u><u>F</u><u>CRLWIP</u><u>GFAEMA</u><u>APPLYPLT</u><u>KTGT</u><u>LFN</u> <u>WGP</u><u>DOOKAYOEIKO</u><u>ALLTAPAL</u><u>GLPDLTK</u><u>PFELF</u><u>VDEKOGYAK</u><u>GVLTQ</u><u>KLGPWRR</u><u>PVAYLS</u><u>KKL</u> <u>DPVAAGWPPCLRM</u><u>VAAIAV</u><u>LTKDAG</u><u>KLTMG</u><u>QPLVILAP</u><u>HAVEALV</u><u>KOPPDR</u><u>WLSNARM</u><u>THYOA</u> <u>LLD</u><u>TD</u><u>DRVQ</u><u>FGPVVALN</u><u>PATLLPL</u><u>PEEGLQ</u><u>HNCLDILAE</u><u>AHGTRPDLTD</u><u>OPLPDADHT</u><u>WYTDGS</u> <u>SLLOEG</u><u>ORKAGAAV</u><u>TTETE</u><u>VIWAKAL</u><u>PAGTSAQ</u><u>RAELIAL</u><u>TOALKMA</u><u>EGKKLN</u><u>VYTDS</u><u>RYAFATAH</u> <u>IHGEIYRRRGLLT</u><u>SEGKEIK</u><u>NKDEIL</u><u>ALLKAL</u><u>FLPKRLS</u><u>IIHCPGH</u><u>OKGHS</u><u>AEARGN</u><u>MADQAAR</u> <u>KAITETPDTSTLLIENSS</u><u>SGSGSKRTADGSEFEPKKRKV</u>(SEQ ID NO: 465) </p>
KEY: NLS (SEQ ID NO: 124, 125) CAS9 (SEQ ID NO: 467) LINKER 1 (SEQ ID NO: 127) LINKER 2 (SEQ ID NO: 174) NPUC INTEIN (SEQ ID NO: 452) RT (SEQ ID NO: 471)

[0834] In various embodiments, using SpCas9 nickase (SEQ ID NO: 18, 1368 amino acids) as an example, the split can be between any two amino acids between 1 and 1368. Preferred splits, however, will be located between the central region of the protein, e.g., from amino acids 50-1250, or from 100-1200, or from 150-1150, or from 200-1100, or from 250-1050, or from 300-1000, or from 350-950, or from 400-900, or from 450-850, or from 500-800, or from 550-750, or from 600-700 of SEQ ID NO: 18. In specific exemplary embodiments, the split site may be between 740/741, or 801/802, or 1010/1011, or 1041/1042. In other embodiments the split site may be between 1/2, 2/3, 3/4, 4/5, 5/6, 6/7, 7/8, 8/9, 9/10, 10/11, 12/13, 14/15, 15/16, 17/18, 19/20, 20/21, 21/22, 22/23, 23/24, 24/25, 25/26, 26/27, 27/28, 28/29, 29/30, 30/31, 31/32, 32/33, 33/34, 34/35, 35/36, 36/37, 38/39, 39/40, 41/42, 42/43, 43/44, 44/45, 45/46, 46/47, 47/48, 48/49, 49/50, 51/52, 52/53, 53/54, 54/55, 55/56, 56/57, 57/58, 58/59, 59/60, 61/62, 62/63, 63/64, 64/65, 65/66, 66/67, 67/68, 68/69, 69/70, 71/72, 72/73, 73/74, 74/75, 75/76, 76/77, 77/78, 78/79, 79/80, 81/82, 82/83, 83/84, 84/85, 85/86, 86/87, 87/88, 88/89, 89/90, or between any two pairs of adjacent residues between 90-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 450-500, 500-550, 550-600, 600-650, 650-700, 700-

750, 750-800, 800-850, 850-900, 900-950, 950-1000, 1000-1050, 1050-1100, 1100-1150, 1150-1200, 1200-1250, 1250-1300, 1300-1350, and 1350-1368, relative to SpCas9 of SEQ ID NO: 18, at between any two corresponding residues in an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, 99%, or 99.9% sequence identity with SEQ ID NO: 18, or between any two corresponding residues in a variant or equivalent of SpCas9 of any of amino acid sequences SEQ ID NOs. 19-88, or an amino acid sequence having at least 80%, 85%, 90%, 95%, 98%, 99%, or 99.9% sequence identity with any of SEQ ID NOs: 19-88.

[0835] In various embodiments, the split intein sequences can be engineered by from the following intein sequences.

NAME	SEQUENCE OF LIGAND-DEPENDENT INTEIN
2-4 INTEIN:	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGAIVWATPDHKVLTEYGWRAAGELRK GDRVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCV EGMVEIFDMLLATSSRFRMMNLQGE EFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYD LLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDM LAEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 472)
3-2 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGAIVWATPDHKVLTEYGWRAAGELRK GDRVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCV EGMVEIFDMLLATSSRFRMMNLQGE EFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYTNVVPLYD LLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDM LAEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 473)
30R3-1 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRK GDRVAGPGGS GNSLALSLTADQMVSALLDAEPPIPYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCV EGMVEIFDMLLATSSRFRMMNLQGE EFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYD LLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDM LAEGLRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 474)
30R3-2 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRK GDRVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLECAWLEILMIGLVWRSMEHPGKL LFAPNLLLDNRNQGKCV EGMVEIFDMLLATSSRFRMMNLQGE EFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYD LLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDM LAEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 475)
30R3-3 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVA AAKDGTLLARPVVS WFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRK GDRVAGPGGS GNSLALSLTADQMVSALLDAEPPIPYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLECAWLEILMIGLVWRSMEHPGKL

	LFAPNLLLDNRNQGKCVCEGMVEIFDMLLATSSRFMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 476)
37R3-1 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAANKDGTLLARPVVSWFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRKGDRAVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYNPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLERAWLEILMIGLVWRSMHEHPGKL LFAPNLLLDNRNQGKCVCEGMVEIFDMLLATSSRFMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC ((SEQ ID NO: 477)
37R3-2 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAANKDGTLLARPVVSWFD QGTRDVIGLRIAGGAIVWATPDHKVLTEYGWRAAGELRKGDRAVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLERAWLEILMIGLVWRSMHEHPGKL LFAPNLLLDNRNQGKCVCEGMVEIFDMLLATSSRFMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 478)
37R3-3 INTEIN	CLAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAANKDGTLLARPVVSWFD QGTRDVIGLRIAGGATVWATPDHKVLTEYGWRAAGELRKGDRAVAGPGGS GNSLALSLTADQMVSALLDAEPPILYSEYDPTSPFSEASMMGLLTNLADRE LVHMINWAKRVPGFVDLTLHDQAHLLERAWLEILMIGLVWRSMHEHPGKL LFAPNLLLDNRNQGKCVCEGMVEIFDMLLATSSRFMMNLQGEEFVCLKSII LLNSGVYTFLSSTLKSLEEKDHIHRALDKITDTLIHLMAKAGLTLQQQHQR LAQLLLILSHIRHMSNKGMEHLYSMKYKNVVPLYDLLLEMLDAHRLHAG GSGASRVQAFADALDDKFLHDMLEELRYSVIREVLPTRRARTFDLEVEE LHTLVAEGVVVHNC (SEQ ID NO: 479)

[0836] In various other embodiments, the split intein sequences can be used as follows:

INTEIN-N	INTEIN-C
NPU-N CLSYETEILTVEYGLLPKIGKIVEKRIECTV YSVDNNGNIYTQPVQWHDGEQEVFE YCLEDGSLIRATKDHKFMVTDGQMLPID EIFERELDLMRVDNLPNSGGS (SEQ ID NO: 447)	NPU-C IKIATRKYLGKQNVYDIGVERDHNFALKNGFIAS N (SEQ ID NO: 452)

[0837] In various embodiments, the split inteins can be used to separately deliver separate portions of a complete PE fusion protein to a cell, which upon expression in a cell, become reconstituted as a complete PE fusion protein through the trans splicing.

[0838] In some embodiments, the disclosure provides a method of delivering a PE fusion protein to a cell, comprising:

- constructing a first expression vector encoding an N-terminal fragment of the PE fusion protein fused to a first split intein sequence;
- constructing a second expression vector encoding a C-terminal fragment of the PE fusion protein fused to a second split intein sequence;

(c) delivering the first and second expression vectors to a cell, wherein the N-terminal and C-terminal fragment are reconstituted as the PE fusion protein in the cell as a result of trans splicing activity causing self-excision of the first and second split intein sequences.

[0839] The split site in some embodiments can be anywhere in the prime editor fusion, including the napDNABp domain, the linker, or the reverse transcriptase domain.

[0840] In other embodiments, the split site is in the napDNABp domain.

[0841] In still other embodiments, the split site is in the reverse transcriptase or polymerase domain.

[0842] In yet other embodiments, the split site is in the linker.

[0843] In various embodiments, the present disclosure provides multi-flap prime editors comprising a napDNABp (e.g., a Cas9 domain) and a reverse transcriptase wherein one or both of the napDNABp and/or the reverse transcriptase comprise an intein, for example, a ligand-dependent intein. Typically the intein is a ligand-dependent intein which exhibits no or minimal protein splicing activity in the absence of ligand (e.g., small molecules such as 4-hydroxytamoxifen, peptides, proteins, polynucleotides, amino acids, and nucleotides). Ligand-dependent inteins are known, and include those described in U.S. patent application, U.S.S.N. 14/004,280, published as U.S. 2014/0065711 A1, the entire contents of which are incorporated herein by reference. In addition, use of split-Cas9 architecture In some embodiments, the intein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-15, 447, 452, 462, and 472-479.

[0844] In various embodiments, the napDNABp domains are smaller-sized napDNABp domains as compared to the canonical SpCas9 domain of SEQ ID NO: 18.

[0845] The canonical SpCas9 protein is 1368 amino acids in length and has a predicted molecular weight of 158 kilodaltons. The term “small-sized Cas9 variant”, as used herein, refers to any Cas9 variant—naturally occurring, engineered, or otherwise—that is less than at least 1300 amino acids, or at least less than 1290 amino acids, or less than 1280 amino acids, or less than 1270 amino acid, or less than 1260 amino acid, or less than 1250 amino acids, or less than 1240 amino acids, or less than 1230 amino acids, or less than 1220 amino acids, or less than 1210 amino acids, or less than 1200 amino acids, or less than 1190 amino acids, or less than 1180 amino acids, or less than 1170 amino acids, or less than 1160 amino acids, or less than 1150 amino acids, or less than 1140 amino acids, or less than 1130 amino acids, or less than 1120 amino acids, or less than 1110 amino acids, or less than 1100 amino acids, or less than 1050 amino acids, or less than 1000 amino acids, or less than 950 amino acids, or less than 900 amino acids, or less than 850 amino acids, or less than 800 amino acids, or less than 750 amino acids, or less than 700 amino acids, or less than 650 amino acids, or less than 600 amino acids, or less than 550 amino acids, or less than 500 amino acids, but at least larger than about 400 amino acids and retaining the required functions of the Cas9 protein.

[0846] In one embodiment, as depicted in Example 20, the specification embraces the following split-intein PE constructs, which are split between residues 1024 and 1025 of the canonical SpCas9

(SEQ ID NO: 18) (or which may be referred to as residues 1023 and 1024, respectively, relative to a Met-minus SEQ ID NO: 18).

[0847] First, the amino acid sequence of SEQ ID NO: 18 is shown as follows, indicating the location of the split site between 1024 (“K”) and 1025 (“S”) residues:

Description	Sequence	SEQ ID NO:
SpCas9 <i>Streptococcus pyogenes</i> M1 SwissProt Accession No. Q99ZW2 Wild type	M DKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDR HSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYL QEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGNIVD EVAYHEKYPTIYHLRKKLVDSSTDKADRLIYLALAHMIKFR GHFLIEGDLNPDNSDVKLFIQLVQTYNQLFEENPINASGVD AKAILSARLSKSRRLLENLIAQLPGEKKNGLFGNLIASLGLTP NFKSNFDLAEDAQLQSKDITYDDDLNLLAQIGDQYADLF LAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDL TLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFY KFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHL GELHAILRRQEDFYFPLKDNREKIEKILTRIPYYVGPLARGN SRFAWMTRKSEETITPWNFEVVVDKGASQSFIERMTNFDK NLPNEKVLPHSLLEYEFTVYNELTKVKYVTEGMRKPAFLS GEQKKAIVDLLFKTNRKVTQKQKEDYFKKIECFDSVEISGV EDRFNASLGTYHDLLKIKDKDFLDNEENEDILEDIVLTLTLF EDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRSLRKL INGIRDKQSGKTILDFLKSDGFANRNFMLIHDDSLTFKEDIQ KAQVSGQGDSLHEHIANLAGSPAIIKQILQTVKVVDELVKV MGRHKPENIVIAMARENQTTQKQKNSRERMKRIIEGKEL GSQILKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDIN RLSDYDVDHIVPQSFLKDDSIDNKVLTSDKNRGKSDNVPS EEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELD KAGFIKQQLVETRQITKHVAQILDSRMNTKYDENDKLIREV KVITLKSCLVSDFRKDFQFYKVRINNYHHAHDAYLNAV GTALIKKYPKLESEFVYGDYKVYDVRKMIK K SEQEIGKATA KYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKG RDFATVRKVLSPQVNIVKKTEVQTGGFSKESILPKRNSDK LIARKKDWDPKKYGGFDSPTVAYSVLVAKVEKGKSKKLK SVKELLGITIMERSSEKNPIDFLEAKGYKEVKKDLIKLPKY SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHY EKLKGSPEDEQKQLFVEQHKHYLDEIIEQISEFSKRVLADA NLDKVL SAYNKHDKPIREQAENIIHLFTLTNLGAPAAFKYF DTTIDRKRYTSTKEVLDTLIHQSIITGLYETRIDLSQLGGD	SEQ ID NO: 18, indicated with split site 1024/1025 in bold The M at position 1 is not necessarily present in the PE fusion protein in certain embodiments. Thus, the numbering of the split site is 1023/1024 in the case that the amino acid sequence excludes Met at position 1.

[0848] In this configuration, the amino acid sequence of N-terminal half (amino acids 1-1024) is as follows:

[0849] MDKKYSIGLDIGTNSVGWAVITDEYKVPSSKKFKVLGNTDRHSIKKNLIGALLFDSGET
AEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLVEEDKKHERHPIFGN
IVDEVAYHEKYPTIYHLRKKLVDSSTDKADRLIYLALAHMIKFRGHFLIEGDLNPDNSDVKL
FIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLLENLIAQLPGEKKNGLFGNLIASLGL
TPNFKSNFDLAEDAQLQSKDITYDDDLNLLAQIGDQYADLF LAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFY
KFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEVVVDKGASQSFIERMTNFDK

NLPNEKVLPHKSHLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTV
 KQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLF
 EDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGF
 ANRNFMLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIAKKGILQTVKVVDELVKV
 MGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLY
 LYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEE
 VVKMKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQIL
 DSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVINNYHHAHDAYLNAVVGTA
 LIKKYPKLESEFVYGDYKVYDVRKMIAK (SEQ ID NO: 3877).

[0850] In this configuration, the amino acid sequence of N-terminal half (amino acids 1-1023)
 (where the protein is Met-minus at position 1) is as follows:

[0851] DKKYSIGLDIGTNSVGWAVITDEYKVPSSKFKVLGNTDRHSIKKNLIGALLFDSGETA
 EATRLKRTARRRYTRRKNRICYLQEFSNEMAKVDDSSFFHRLEESFLVEEDKKHERHPIFGNI
 VDEVAYHEKYPTIYHLRKKLVDSSTKADLRILIYALAHMIKFRGHFLIEGDLNPDNSDVKL
 FIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRLENLIAQLPGEKKNGLFGNLIALSLGL
 TPNFKNFDLAEDAKLQLSKDTYDDDLNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNT
 EITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFY
 KFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPLKDNR
 EKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEVVDKGASAQSFIERMNTNFDK
 NLPNEKVLPHKSHLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTV
 KQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLF
 EDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGF
 ANRNFMLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIAKKGILQTVKVVDELVKV
 MGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLY
 LYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEE
 VVKMKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQIL
 DSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVINNYHHAHDAYLNAVVGTA
 LIKKYPKLESEFVYGDYKVYDVRKMIAK (SEQ ID NO: 3878).

[0852] In this configuration, the amino acid sequence of C-terminal half (amino acids 1024-1368 (or
 counted as amino acids 1023-1367 in a Met-minus Cas9) is as follows:

[0853] SEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATV
 RKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLV
 VAKVEKGKSKKLKSVKELLGITIMERSSEFKNPIDFLEAKGYKEVKKDLIILPKYSLFELENG
 RKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIE
 QISEFSKRVLADANLDKVL SAYNKHDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKR
 YTSTKEVLDTLIHQSIITGLYETRIDLSQLGGD (SEQ ID NO: 3879).

[0854] As shown in Example 20, the PE2 (which is based on SpCas9 of SEQ ID NO: 18) construct was split at position 1023/1024 (relative to a Met-minus SEQ ID NO: 18) into two separate constructs, as follows:

[0855] SpPE2 split at 1023/1024 N terminal half

[0856] MKRTADGSEFESPKKKRKVDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNT
DRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRL
EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADRLRIYLALAHMIKF
RGHFLIEGDLNPDNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQ
LPGEKKNGLFGNLIASLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLNLLAQIGDQYADLF
LAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQ
SKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLG
ELHAILRRQEDFYFPLKDNREKIEKILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEV
VDKGASAQSFIERMTNFDKNLPNEKVLPHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGE
QKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDF
LDNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWGRLSRKLIN
GIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSP
AIKKGILQTVKVVDELVKVMGRHKPENIVIAMARENQTTQKGQKNSRERMKRIEIGIKELGS
QILKEHPVENTQLQNEKLYLYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDSIDNK
VLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAG
FIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVREI
NNYHHAHDAYLNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIAKCLSYETEILTVEYGLL
PIGKIVEKRIECTVYYSVDNNGNIYTOPVAQWHDRGEOEVFEYCLEDGSLIRATKDHKFMTVDGQM
LPIDEIFERELDMRVDNLPNSGGSGSKRTADGSEFEPKKKRKV (SEQ ID NO: 3875)

[0857] Key: NLS, Cas9, Mutated residues, Linker, NpuN intein, NpuC intein, RT

[0858] SpPE2 split at 1023/1024 C terminal half

MKRTADGSEFESPKKKRKVIKIATRKYLGKONVYDIGVERDHNFAKNGFIASNCFNEIGKATAK
YFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNIVKKT
EVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEGKSKKLKS
VKELLGITIMERSSEKPNIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKG
NELALPSKYVNFLYLASHYEKLKGSPEDEQKQLFVEQHKHYLDEHIEQISEFSKRVLADAN
LDKVL SAYNKH RD KPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVL DATLIHQ
SITGLYETRIDLSQLGGDSGGSSGGSSGSETPGTSESATPESSGGSSGSSSTLNIEDEYRLHE
TSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLKATSTPVS IKQYPMSQEAR
LGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREV NKRVEDIHPTVP
NPYNLLSGLPPSHQWYTVLDLKD AFFCLRLHPTSQPLFAFEWRDP EMGISGQLTWTRL
PQGFKNSPTLFNEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQGGTRALLQTL
GNLGYRASAKKAQICQKQVKYLG YLLKEGQRWLTEARKETVMGQPTPKTPRQLREFL
GKAGFCRLFIGFAEMAAPLYPLTKPGTFLFNWGPDPQKAYQEIKQALLTAPALGLPDL
TKPFELFVDEKQGYAKGVLTQKLGPPWRPVAYLSKKLDPVAAGWPPCLRMVAIAVL
TKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVV
ALNPATLLPLPEEGLQHNC LDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQR
KAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAH

**IHGEIYRRRGWLTSEGKEIKNKDEILALLKALFLPKRLSIHCPGHQKGHSAEARGNRM
ADQAARKAAITETPDTSTLLIENSSPSGGSKRTADGSEFEPKKRK** (SEQ ID NO: 3876)

[0859] Key: NLS, Cas9, Mutated residues, Linker, NpuN.intein, NpuC intein, **RT**

[0860] The present disclosure also contemplates methods of delivering split-intein multi-flap prime editors to cells and/or treating cells with split-intein multi-flap prime editors.

[0861] In some embodiments, the disclosure provides a method of delivering a PE fusion protein to a cell, comprising:

- (a) constructing a first expression vector encoding an N-terminal fragment of the PE fusion protein fused to a first split intein sequence;
- (b) constructing a second expression vector encoding a C-terminal fragment of the PE fusion protein fused to a second split intein sequence;
- (c) delivering the first and second expression vectors to a cell,

wherein the N-terminal and C-terminal fragment are reconstituted as the PE fusion protein in the cell as a result of trans splicing activity causing self-excision of the first and second split intein sequences.

[0862] In certain embodiments, the N-terminal fragment of the PE fusion protein fused to a first split intein sequence is SEQ ID NO: 3875, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99.9% sequence identity with SEQ ID NO: 3875.

[0863] In other embodiments, the C-terminal fragment of the PE fusion protein fused to a first split intein sequence is SEQ ID NO: 3876, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99.9% sequence identity with SEQ ID NO: 3876.

[0864] In other embodiments, the disclosure provides a method of editing a target DNA sequence within a cell, comprising:

- (a) constructing a first expression vector encoding an N-terminal fragment of the PE fusion protein fused to a first split intein sequence;
- (b) constructing a second expression vector encoding a C-terminal fragment of the PE fusion protein fused to a second split intein sequence;
- (c) delivering the first and second expression vectors to a cell,

wherein the N-terminal and C-terminal fragment are reconstituted as the PE fusion protein in the cell as a result of trans splicing activity causing self-excision of the first and second split intein sequences.

[0865] In certain embodiments, the N-terminal fragment of the PE fusion protein fused to a first split intein sequence is SEQ ID NO: 3875, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99.9% sequence identity with SEQ ID NO: 3875.

[0866] In other embodiments, the C-terminal fragment of the PE fusion protein fused to a first split intein sequence is SEQ ID NO: 3876, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99.9% sequence identity with SEQ ID NO: 3876.

Delivery of PE ribonucleoprotein complexes

[0867] In this aspect, the multi-flap prime editors may be delivered by non-viral delivery strategies involving delivery of a multi-flap prime editor complexed with PEgRNA (i.e., a PE ribonucleoprotein complex) by various methods, including electroporation and lipid nanoparticles. Methods of non-viral delivery of nucleic acids include lipofection, nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. *in vitro* or *ex vivo* administration) or target tissues (e.g. *in vivo* administration).

[0868] The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chem. 5:382-389 (1994); Remy et al., Bioconjugate Chem. 5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res. 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).

[0869] Additional reference may be made to the following references that discuss approaches for non-viral delivery of ribonucleoprotein complexes, each of which are incorporated herein by reference.

[0870] Chen, Sean, et al. "Highly efficient mouse genome editing by CRISPR ribonucleoprotein electroporation of zygotes." *Journal of Biological Chemistry* (2016): jbc-M116. PubMed

[0871] Zuris, John A., et al. "Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo." *Nature biotechnology* 33.1 (2015): 73. PubMed

[0872] Rouet, Romain, et al. "Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing." *Journal of the American Chemical Society* 140.21 (2018): 6596-6603. PubMed.

[0873] FIG. 68C provides data showing that various disclosed PE ribonucleoprotein complexes (PE2 at high concentration, PE3 at high concentration and PE3 at low concentration) can be delivered in this manner.

Delivery of PE by mRNA

[0874] Another method that may be employed to deliver multi-flap prime editors and/or PEgRNAs to cells in which multi-flap prime editing-based genome editing is desired is by employing the use of messenger RNA (mRNA) delivery methods and technologies. Examples of mRNA delivery methods and compositions that may be utilized in the present disclosure including, for example, PCT/US2014/028330, US8822663B2, NZ700688A, ES2740248T3, EP2755693A4, EP2755986A4,

WO2014152940A1, EP3450553B1, BR112016030852A2, and EP3362461A1, each of which are incorporated herein by reference in their entireties. Additional disclosure hereby incorporated by reference can be found in Kowalski et al., “Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery,” *Mol Therap.*, 2019; 27(4): 710-728.

[0875] In contrast to DNA vector encoding multi-flap prime editors, the use of RNA as a delivery agent for multi-flap prime editors has the advantage that the genetic material does not have to enter the nucleus to perform its function. The delivered mRNA may be directly translated in the cytoplasm into the desired protein (e.g., prime editor fusion protein) and nucleic acid products (e.g., PEGRNA). However, in order to be more stable (e.g., resist RNA-degrading enzymes in the cytoplasm), it is in some embodiments necessary to stabilize the mRNA to improve delivery efficiency. Certain delivery carriers such as cationic lipids or polymeric delivery carriers can also help protect the transfected mRNA from endogenous RNase enzymes that might otherwise degrade the therapeutic mRNA encoding the desired prime editor fusion proteins. In addition, despite the increased stability of modified mRNA, delivery of mRNA, particularly mRNA encoding full-length protein, to cells in vivo in a manner that allows therapeutic levels of protein production remains a challenge.

[0876] With some exceptions, the intracellular delivery of mRNA is generally more challenging than that of small oligonucleotides, and it requires encapsulation into a delivery nanoparticle, in part due to the significantly larger size of mRNA molecules (300–5,000 kDa, ~1–15 kb) as compared to other types of RNAs (small interfering RNAs [siRNAs], ~14 kDa; antisense oligonucleotides [ASOs], 4–10 kDa).

[0877] mRNA must cross the cell membrane in order to reach the cytoplasm. The cell membrane is a dynamic and formidable barrier to intracellular delivery. It is made up primarily of a lipid bilayer of zwitterionic and negatively charged phospholipids, where the polar heads of the phospholipids point toward the aqueous environment and the hydrophobic tails form a hydrophobic core.

[0878] In some embodiments, the mRNA compositions of the disclosure comprise mRNA (encoding a prime editor and/or PEGRNA), a transport vehicle, and optionally an agent that facilitates contact with the target cell and subsequent transfection.

[0879] In some embodiments, the mRNA can include one or more modifications that confer stability to the mRNA (eg, compared to the wild-type or native version of the mRNA) and is involved in the associated abnormal expression of the protein. One or more modifications to the wild type that correct the defect may also be included. For example, the nucleic acids of the invention can include modifications of one or both of a 5' untranslated region or a 3' untranslated region. Such modifications may include the inclusion of sequences encoding a partial sequence of the cytomegalovirus (CMV) immediate early 1 (IE1) gene, poly A tail, Cap1 structure, or human growth hormone (hGH). In some embodiments, the mRNA is modified to reduce mRNA immunogenicity.

[0880] In one embodiment, the multi-flap prime editor mRNA in the composition of the invention can be formulated in a liposome transfer vehicle to facilitate delivery to target cells. Contemplated transfer vehicles can include one or more cationic lipids, non-cationic lipids, and/or PEG-modified lipids. For example, the transfer vehicle can include at least one of the following cationic lipids: C12-200, DLin-KC2-DMA, DODAP, HGT4003, ICE, HGT5000, or HGT5001. In embodiments, the transfer vehicle comprises cholesterol (chol) and / or PEG modified lipids. In some embodiments, the transfer vehicle comprises DMG-PEG2K. In certain embodiments, the transfer vehicle has the following lipid formulation: C12-200, DOPE, chol, DMG-PEG2K; DODAP, DOPE, cholesterol, DMG-PEG2K; HGT5000, DOPE, chol, DMG-PEG2K, HGT5001, DOPE, chol, one of DMG-PEG2K.

[0881] The present disclosure also provides compositions and methods useful for facilitating transfection of target cells with one or more PE-encoding mRNA molecules. For example, the compositions and methods of the present invention contemplate the use of targeting ligands that can increase the affinity of the composition for one or more target cells. In one embodiment, the targeting ligand is apolipoprotein B or apolipoprotein E, and the corresponding target cells express low density lipoprotein receptors and thus promote recognition of the targeting ligand. A vast number of target cells can be preferentially targeted using the methods and compositions of the present disclosure. For example, contemplated target cells include hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, lung cells, bone cells, stem cells, mesenchymal cells, nerve cells, heart cells, adipocytes, vascular smooth muscle Includes cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testis cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes, and tumor cells However, it is not limited to these.

[0882] In some embodiments, the PE-encoding mRNA may optionally have chemical or biological modifications which, for example, improve the stability and/or half-life of such mRNA or which improve or otherwise facilitate protein production. Upon transfection, a natural mRNA in the compositions of the invention may decay with a half-life of between 30 minutes and several days. The mRNAs in the compositions of the disclosure may retain at least some ability to be translated, thereby producing a functional protein or enzyme. Accordingly, the invention provides compositions comprising and methods of administering a stabilized mRNA. In some embodiments, the activity of the mRNA is prolonged over an extended period of time. For example, the activity of the mRNA may be prolonged such that the compositions of the present disclosure are administered to a subject on a semi-weekly or bi-weekly basis, or more preferably on a monthly, bi-monthly, quarterly or an annual basis. The extended or prolonged activity of the mRNA of the present invention is directly related to the quantity of protein or enzyme produced from such mRNA. Similarly, the activity of the compositions of the present disclosure may be further extended or prolonged by modifications made

to improve or enhance translation of the mRNA. Furthermore, the quantity of functional protein or enzyme produced by the target cell is a function of the quantity of mRNA delivered to the target cells and the stability of such mRNA. To the extent that the stability of the mRNA of the present invention may be improved or enhanced, the half-life, the activity of the produced protein or enzyme and the dosing frequency of the composition may be further extended.

[0883] Accordingly, in some embodiments, the mRNA in the compositions of the disclosure comprise at least one modification which confers increased or enhanced stability to the nucleic acid, including, for example, improved resistance to nuclease digestion *in vivo*. As used herein, the terms "modification" and "modified" as such terms relate to the nucleic acids provided herein, include at least one alteration which preferably enhances stability and renders the mRNA more stable (e.g., resistant to nuclease digestion) than the wild-type or naturally occurring version of the mRNA. As used herein, the terms "stable" and "stability" as such terms relate to the nucleic acids of the present invention, and particularly with respect to the mRNA, refer to increased or enhanced resistance to degradation by, for example nucleases (i.e., endonucleases or exonucleases) which are normally capable of degrading such mRNA. Increased stability can include, for example, less sensitivity to hydrolysis or other destruction by endogenous enzymes (e.g., endonucleases or exonucleases) or conditions within the target cell or tissue, thereby increasing or enhancing the residence of such mRNA in the target cell, tissue, subject and/or cytoplasm. The stabilized mRNA molecules provided herein demonstrate longer half-lives relative to their naturally occurring, unmodified counterparts (e.g. the wild-type version of the mRNA). Also contemplated by the terms "modification" and "modified" as such terms related to the mRNA of the present invention are alterations which improve or enhance translation of mRNA nucleic acids, including for example, the inclusion of sequences which function in the initiation of protein translation (e.g., the Kozak consensus sequence). (Kozak, M., *Nucleic Acids Res* 15 (20): 8125-48 (1987)).

[0884] In some embodiments, the mRNAs used in the compositions of the disclosure have undergone a chemical or biological modification to render them more stable. Exemplary modifications to an mRNA include the depletion of a base (e.g., by deletion or by the substitution of one nucleotide for another) or modification of a base, for example, the chemical modification of a base. The phrase "chemical modifications" as used herein, includes modifications which introduce chemistries which differ from those seen in naturally occurring mRNA, for example, covalent modifications such as the introduction of modified nucleotides, (e.g., nucleotide analogs, or the inclusion of pendant groups which are not naturally found in such mRNA molecules).

[0885] Other suitable polynucleotide modifications that may be incorporated into the PE-encoding mRNA used in the compositions of the disclosure include, but are not limited to, 4'-thio-modified bases: 4'-thio-adenosine, 4'-thio-guanosine, 4'-thio-cytidine, 4'-thio-uridine, 4'-thio-5-methyl-cytidine, 4'-thio-pseudouridine, and 4'-thio-2-thiouridine, pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-

aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, N6-glycylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine, and combinations thereof. The term modification also includes, for example, the incorporation of non-nucleotide linkages or modified nucleotides into the mRNA sequences of the present invention (e.g., modifications to one or both of the 3' and 5' ends of an mRNA molecule encoding a functional protein or enzyme). Such modifications include the addition of bases to an mRNA sequence (e.g., the inclusion of a poly A tail or a longer poly A tail), the alteration of the 3' UTR or the 5' UTR, complexing the mRNA with an agent (e.g., a protein or a complementary nucleic acid molecule), and inclusion of elements which change the structure of an mRNA molecule (e.g., which form secondary structures).

[0886] In some embodiments, PE-encoding mRNAs include a 5' cap structure. A 5' cap is typically added as follows: first, an RNA terminal phosphatase removes one of the terminal phosphate groups from the 5' nucleotide, leaving two terminal phosphates; guanosine triphosphate (GTP) is then added to the terminal phosphates via a guanylyl transferase, producing a 5'5' triphosphate linkage; and the

7-nitrogen of guanine is then methylated by a methyltransferase. Examples of cap structures include, but are not limited to, m⁷G(5')ppp (5'(A,G(5')ppp(5')A and G(5')ppp(5')G. Naturally occurring cap structures comprise a 7-methyl guanosine that is linked via a triphosphate bridge to the 5'-end of the first transcribed nucleotide, resulting in a dinucleotide cap of m⁷G(5')ppp(5')N, where N is any nucleoside. In vivo, the cap is added enzymatically. The cap is added in the nucleus and is catalyzed by the enzyme guanylyl transferase. The addition of the cap to the 5' terminal end of RNA occurs immediately after initiation of transcription. The terminal nucleoside is typically a guanosine, and is in the reverse orientation to all the other nucleotides, i.e., G(5')ppp(5')GpNpNp.

[0887] Additional cap analogs include, but are not limited to, a chemical structures selected from the group consisting of m⁷GpppG, m⁷GpppA, m⁷GpppC; unmethylated cap analogs (e.g., GpppG); dimethylated cap analog (e.g., m²,7GpppG), trimethylated cap analog (e.g., m²,2,7GpppG), dimethylated symmetrical cap analogs (e.g., m⁷Gpppm⁷G), or anti reverse cap analogs (e.g., ARCA; m⁷,2'OmeGpppG, m⁷2'dGpppG, m⁷,3'OmeGpppG, m⁷,3'dGpppG and their tetraphosphate derivatives) (see, e.g., Jemielity, J. et al., "Novel 'anti-reverse' cap analogs with superior translational properties", RNA, 9: 1108-1122 (2003)).

[0888] Typically, the presence of a "tail" serves to protect the mRNA from exonuclease degradation. A poly A or poly U tail is thought to stabilize natural messengers and synthetic sense RNA. Therefore, in certain embodiments a long poly A or poly U tail can be added to an mRNA molecule thus rendering the RNA more stable. Poly A or poly U tails can be added using a variety of art-recognized techniques. For example, long poly A tails can be added to synthetic or in vitro transcribed RNA using poly A polymerase (Yokoe, et al. Nature Biotechnology. 1996; 14: 1252-1256). A transcription vector can also encode long poly A tails. In addition, poly A tails can be added by transcription directly from PCR products. Poly A may also be ligated to the 3' end of a sense RNA with RNA ligase (see, e.g., Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1991 edition)).

[0889] Typically, the length of a poly A or poly U tail can be at least about 10, 50, 100, 200, 300, 400 at least 500 nucleotides. In some embodiments, a poly-A tail on the 3' terminus of mRNA typically includes about 10 to 300 adenosine nucleotides (e.g., about 10 to 200 adenosine nucleotides, about 10 to 150 adenosine nucleotides, about 10 to 100 adenosine nucleotides, about 20 to 70 adenosine nucleotides, or about 20 to 60 adenosine nucleotides). In some embodiments, mRNAs include a 3' poly(C) tail structure. A suitable poly-C tail on the 3' terminus of mRNA typically include about 10 to 200 cytosine nucleotides (e.g., about 10 to 150 cytosine nucleotides, about 10 to 100 cytosine nucleotides, about 20 to 70 cytosine nucleotides, about 20 to 60 cytosine nucleotides, or about 10 to 40 cytosine nucleotides). The poly-C tail may be added to the poly-A or poly U tail or may substitute the poly-A or poly U tail.

[0890] PE-encoding mRNAs according to the present disclosure may be synthesized according to any of a variety of known methods. For example, mRNAs according to the present invention may be synthesized via *in vitro* transcription (IVT). Briefly, IVT is typically performed with a linear or circular DNA template containing a promoter, a pool of ribonucleotide triphosphates, a buffer system that may include DTT and magnesium ions, and an appropriate RNA polymerase (e.g., T3, T7 or SP6 RNA polymerase), DNase I, pyrophosphatase, and/or RNase inhibitor. The exact conditions will vary according to the specific application.

[0891] In embodiments involving mRNA delivery, the ratio of the mRNA encoding the PE fusion protein to the PEgRNA may be important for efficient editing. In certain embodiments, the weight ratio of mRNA (encoding the PE fusion protein) to PEgRNA is 1:1. In certain other embodiments, the weight ratio of mRNA (encoding the PE fusion protein) to PEgRNA is 2:1. In still other embodiments, the weight ratio of mRNA (encoding the PE fusion protein) to PEgRNA is 1:2. In still further embodiments, the weight ratio of mRNA (encoding the PE fusion protein) to PEgRNA is selected from the group consisting of about 1:1000, 1:900; 1:800; 1:700; 1:600; 1:500; 1:400; 1:300; 1:200; 1:100; 1:90; 1:80; 1:70; 1:60; 1:50; 1:40; 1:30; 1:20; 1:10; and 1:1. In other embodiments, the weight ratio of mRNA (encoding the PE fusion protein) to PEgRNA is selected from the group consisting of about 1:1000, 1:900; 800:1; 700:1; 600:1; 500:1; 400:1; 300:1; 200:1; 100:1; 90:1; 80:1; 70:1; 60:1; 50:1; 40:1; 30:1; 20:1; 10:1; and 1:1.

F. Use of multi-flap prime editing for insertion of inducible dimerization domains

[0892] The multi-flap prime editors (as represented by FIGs. 90, 95, 97A, 98A) described herein may also be used to install dimerization domains into one or more protein targets. The dimerization domains may facilitate inducible regulation of the activity associated with the dimerization of the one or more protein targets via a linking moiety (e.g., a small molecule, peptide, or protein) that binds in a bi-specific manner. In various aspects, the dimerization domains, when installed on different proteins (e.g., the same type or different proteins), each bind to the same bi-specific moiety (e.g., a bi-specific small molecule, peptide, or polypeptide having a least two regions that separately bind to the dimerization domains), thereby causing the dimerization of the proteins through their common interaction to the bi-specific ligand. In this manner, the bi-specific ligand functions as an “inducer” of dimerization of two proteins. In some cases, the bi-specific ligand or compound will have two targeting moieties that are the same. In other embodiments, the bi-specific ligand or compound will have targeting moieties that are each different from the other. The bi-specific ligand or compound having the same two targeting moieties will be able to target the same dimerization domain installed on different protein targets. The bi-specific ligand or compound having different targeting moieties will be able to target different dimerization domains installed on different protein targets.

[0893] As used herein, the term “dimerization domain” refers to a ligand-binding domain that binds to a binding moiety of a bi-specific ligand. A “first” dimerization domain binds to a first binding

moiety of a bi-specific ligand and a “second” dimerization domain binds to a second binding moiety of the same bi-specific ligand. When the first dimerization domain is fused to a first protein (e.g., via PE, as discussed herein) and the second dimerization domain (e.g., via PE, as discussed herein) is fused to a second protein, the first and second protein dimerize in the presence of a bi-specific ligand, wherein the bi-specific ligand has at least one moiety that binds to the first dimerization domain and at least another moiety that binds to the second dimerization domain.

[0894] The term “bi-specific ligand” or “bi-specific moiety,” as used herein, refers to a ligand that binds to two different ligand-binding domains. In various embodiments, the bi-specific moiety itself is a dimer of two of same or two different chemical moieties, wherein each moiety specifically and tightly binds to a dimerization domain. In certain embodiments, the ligand is a small molecule compound, or a peptide, or a polypeptide. In other embodiments, ligand-binding domain is a “dimerization domain,” which can be installed as a peptide tag onto a protein. In various embodiments, two proteins each comprising the same or different dimerization domains can be induced to dimerize through the binding of each dimerization domain to the bi-specific ligand. These molecules may also be referred to as “chemical inducers of dimerization” or CIDs. In addition, the bi-specific ligands may be prepared by coupling (e.g., through standardized chemical linkages) two of the same moieties together, or two different moieties together, wherein each moiety tightly and specifically binds to a dimerization domain.

[0895] In various aspects, the dimerization domains installed by multi-flap PE can be the same or different.

[0896] For example, the dimerization domains can be FKBP12, which has the following amino acid sequence:

FKBP12	MGVQVETISPGDGRTPFKRGQTCVVHYTGML EDGKKFDSSRDNRNPKFKMLGKQEVIRGWEE GVAQMSVGQRAKLTISPDYAYGATGHPGIIPPH ATLVFDVELLKLE (SEQ ID NO: 488)
--------	---

[0897] In another example, the dimerization domain can be a mutant of FKBP12 referred to as FKBP12-F36V, a mutant of FKBP12 with an engineered hole that binds a synthetic bumped FK506 mimic (2, Figure 3)¹⁰⁷:



FKBP12-F36V	MGVQVETISPGDGRTPFKRGQTCVVHYTGML EDGKKVDSSRDNRNPKFKMLGKQEVIRGWEE GVAQMSVGQRAKLTISPDYAYGATGHPGIIPPH ATLVFDVELLKLE (SEQ ID NO: 489)
-------------	---



[0898] In another example, the dimerization domain can be cyclophilin, as follows:




CYCLOPHILIN	MVNPTVFFDIAVDGEPLGRVSFELFADKVPKT AENFRALSTGEKGFGYKGSCFHRIIPGFMCGG GDFTRHNGTGGKSIYGEKFEDENFILKHTGPGI LSMANAGPNTNGSQFFICTAKTEWLDGKHVV FGKVKEGMNIVEAMERFGSRNGKTSKKITIAD CGQLE (SEQ ID NO: 490)
-------------	--




[0899] In various embodiments, the amino acid sequences of these dimerization domains may be altered in order to optimize binding or to improve binding orthogonality to native targets. The nucleic acid sequences of the genes encoding small-molecule binding proteins may be altered in order to optimize the efficiency of the PE process, such as by reducing PEgRNA secondary structure.




[0900] Other examples of suitable dimerization domains and a cognate small molecule compound which binds thereto are provided as follows. Note that the cognate small molecule compound could be coupled (e.g., via a chemical linker) to a second small molecule compound (either the same compound or a different compound) in order to form a bi-specific ligand that may bind two dimerization domains. In some cases, such as FK506 and cyclosporin A, dimerization of each (e.g., FK506-FK506 or cyclosporin A-cyclosporin A) reduces or eliminates immunosuppressive activity of the monomeric compounds.




SMALL MOLECULE – BINDS TO THE DIMERIZATION DOMAIN – A DIMER OF THESE MOLECULES WOULD CONSTITUTE A BI-SPECIFIC LIGAND THAT WOULD BIND TWO DIMERIZATION DOMAINS	DIMERIZATION DOMAIN(S)
<p>FK506</p>  <p><i>FK-506</i> FKBP12 Kd 0.4 nM PNAS 1990, 87, 9231.</p> <p>TARGETS: FKBP12 + CALCINEURIN</p>	<p>AMINO ACID SEQUENCE OF FKBP12:</p> <p>MGVQVETISPGDGRTFPKRGQTCVVHYTG MLEDGKKFDSSRDNRNPKFKMLGKQEVIR GWEEGVAQMSVGQRAKLTISPDYAYGATG HPGIIPPHATLVFDVELLKLE (SEQ ID NO: 491)</p> <p>CALCINEURIN:</p>
<p>CYCLOSPORIN A</p> 	<p>AMINO ACID SEQUENCE OF HUMAN CYCLOPHILIN A:</p> <p>MVNPTVFFDIAVDGEPLGRVSFELFAD KVPKTAENFRALSTGEKGFGYKGSCFH RIIPGFMCQGGDFTRHNGTGGKSIYGE KFEDENFILKHTGPGILSMANAGPNTN GSQFFICTAKTEWLDGKHVVFVKVKE GMNIVEAMERFGSRNGKTSKKITIADC GQLE (SEQ ID NO: 490)</p> <p>AMINO ACID SEQUENCE OF HUMAN CYCLOPHILIN B:</p> <p>MLRLSERNMKVLLAAALIAGSVFFLLL PGPSAADEKKKGPKVTVKVYFDLRIG DEDVGRVIFGLFGKTVPKTVDNFVALA TGEKGFGYKNSKFHRVIKDFMIQGGDF</p>

<p>TARGETS: CYCLOPHILIN + CALCINEURIN</p>	<p>TRGDGTGGKSIYGERFPDENFKLKHYG PGWVSMANAGKDTNGSQFFITTVKTA WLDGKHVVFGKVLEGMEVVRKVEST KTDSRDKPLKDVIIADCGKIEVEKPAI AKE (SEQ ID NO: 493)</p> <p>AMINO ACID SEQUENCE OF MURINE CYCLOPHILIN C:</p> <p>MSPGPRLLLLPAVLCLGLGALVSSSGSSG VRKRGPSVTDKVFVDVRIGDKDVGRIV IGLFGNVVPKTVENFVALATGEKGYGY KGSIFHRVIKDFMIQGGDFATDGTGG MSIYGETFPDENFKLKHYGIGWVSMA NAGPDTNGSQFFITLTPTWLDGKHVV FGKVLDMGTVVHSIELQATDGHDRPLT DCTIVNSGKIDVKTPFVVEVPDW (SEQ ID NO: 494)</p>
<p>AP1867</p>  <p><i>AP1867</i> FK-506 mimic FKBP12 F36V Kd 94 pM FKBP12 Kd 67 nM <i>PNAS</i> 1998, <i>95</i>, 10437.</p>	<p>AMINO ACID SEQUENCE OF FKBP12-F36V</p> <p>MGVQVETISPGDGRTFPKRGQTCVVHYTG MLEDGKKVDSSRDNRNPKFKFMLGKQEVIR GWEEGVAQMSVGQRAKLT ISPDYAYGATGHPGIIPPHATLVFDVELLKL E (SEQ ID NO: 495)</p>
<p>TARGET(S): FKBP12</p> <p>METHOTREXATE</p>  <p><i>methotrexate</i> Human DHFR Kd < 10 nM <i>J. Biol. Chem.</i> 1988, <i>263</i>, 10304. <i>E. coli</i> DHFR Kd 9.5 nM <i>PNAS</i> 2002, <i>99</i>, 13481.</p>	<p>AMINO ACID SEQUENCE OF HUMAN DIHYDROFOLATE REDUCTASE</p> <p>MVGSLNCIVAVSQNMGIGKNGDLPWPPLR NEFRYFQRM TTTSSVEGKQNLVIMGKKTW FSIPEKNRPLKGRINLVLSRELKEPPQGAHF LSRSLDDALKLTEQPELANKVDMVWIVGG SSVYKEAMNHPGHLKLFVTRIMQDFESDT FFPEIDLEKYKLLPEYPGVLSDVQEEKGIK YKFEVYEKND (SEQ ID NO: 496)</p>
<p>TARGET(S): DIHYDROFOLATE REDUCTASE</p> <p>TRIMETHOPRIM</p>	<p>AMINO ACID SEQUENCE FOR E. COLI DIHYDROFOLATE REDUCTASE</p>

 <p><i>trimethoprim</i> <i>E. coli</i> DHFR K_i 1.3 nM <i>Biochemistry</i> 1982, 21, 5068.</p> <p>TARGET(S): DIHYDROFOLATE REDUCTASE</p>	<p>MISLIAALAVDRVIGMENAMPWNL PADLA WFKRNTLNKPVIMGRHTWESIGRPLPGRK NIILSSQPGTDDRVTWVKSVD EAIACGDV PEIMVIGGGRVYEQFLPKAQKLYLTHIDAE VEGDTHFPDYEPDDWESVFSEFHDADAQN SHSYCFEILERR (SEQ ID NO: 497)</p>
 <p><i>dexamethasone</i> Human GR K_d 4.6 nM <i>Mol. Endocrin.</i> 1999, 13, 1855.</p> <p>DEXAMETHOSONE</p>	<p>AMINO ACID SEQUENCE FOR HUMAN GLUCOCORTICOID RECEPTOR</p> <p>MDSKESLTPGREENPSSVLAQERGDVMDF YKTLRGGATVKVSASSPSLAVASQSDSKQR RLLVDFPKGSVSNAAQPDLSKAVSLMGL YMGETETKVMGNDLGFPQQGQISLSSGET DLKLL ESIANLNRSTSVENPKSSASTAVS AAPTEKEF PKTHSDVSSEQQHLKGQTGTNGGNVKLYT TDQSTFDILQDLEFSSGSPGKETNESPWRS DLLIDENCLLSPLAGEDDSFLL EGN SNEDC KPLILPDTKPKIKDNGDLVSSPSNVTLPQV KTEKEDFIELCTPGVIKQEKLGTVYCQASF PGANIIGNKMSAISVHGVSTSGGQMYHYD MNTASLSQQQDQKPIFNVIPPIPVGSENWN RCQSGGDDNLTSLGTLNFPGRTVFSNGYSS PSMRPDVSSPPSSSSTAT TGPPPKLCLVCSD EASGCHYGVLTGCKVFFKRAVEGQHNY LCAGRNDCHDKIRRNKNCACRYRKCLQAG MNL EARKTKKKIKGIQQATTGVSQETSEN PGNKTIVPATLPQLTPTLVSLLEVIEPEVLYA GYDSSVPDSTWRIMTTLNMLGGRQVIAAV KWAKAIPGFRNLHLDDQMTLLQYSWMFL MAFALGWSYRQSSANLLCFAPDLIINEQR MTLPCMYDQCKHMLYVSSELHRLQVSYE EYLCMKTL LLLSSVPKDGLKSQELFDEIRM TYIKELGKAIVKREGNSSQN WQRFYQLTK LLDSMHEVVENLLNYCFQTFLDKTMSIEFP EMLAEIITNQIPKYSNGNIKKLLFHQK (SEQ ID NO: 498)</p>
	<p>AMINO ACID SEQUENCE OF FKBP12:</p> <p>MGVQVETISPGDGRTFPKRGQTCVVHYTG MLEDGKKFDSSRDNRNPKFKFMLGKQEVIR GWEEGVAQMSVGQRAKLTISP DYAYGATG HPGIIPPHATLVFDVELLKLE (SEQ ID NO: 491)</p>


RAPAMYCIN	
<p>[0901] Other examples of naturally occurring bifunctional molecules and their dual target receptors are as follows. Prime editing may be used to install the dual target receptors into different proteins. Once the different proteins are modified by PE to contain a bifunctional molecule receptor, the bifunctional molecules may be introduced, thereby causing the dimerization of the proteins modified to comprise the different dimerization domains. Examples of pairings of (1) a biofunctional molecule and (2) their dual target receptors are as follows:</p>	
NATURALLY OCCURRING BIOFUNCTIONAL MOLECULES	TARGET RECEPTORS OF THE BIOFUNCTIONAL MOLECULE
 <p>auxin</p>	<p>Target receptor 1: auxin receptor</p> <p>Target receptor 2: TIR1 E3 ligase</p>
 <p>methyl jasmonate</p>	<p>Target receptor 1: JAZ receptor</p> <p>Target receptor 2: Col1 E3 ligase</p>
<p>brefeldin A</p> 	<p>target receptor 1: GBF1</p> <p>target receptor 2: GTPase Arf1p</p>
<p>abscisic acid</p>	<p>target receptor 1: PYR receptor</p> <p>target receptor 2: phosphoprotein phosphatase 2C</p>

 <p>The chemical structure of Forskolin is shown. It consists of a cyclohexene ring with a ketone group at position 1, a methyl group at position 2, and a hydroxyl group at position 3. A side chain at position 4 contains a double bond, a methyl group, and a carboxylic acid group.</p>	
<p>Forskolin</p>  <p>The chemical structure of fusicoccin A is shown. It is a complex polycyclic molecule with multiple hydroxyl groups, an acetate group (OAc), and a vinyl group.</p>	<p>target receptor 1: adenylyl cyclase monomers</p> <p>target receptor 2: adenylyl cyclase monomers</p>
<p>fusicoccin A</p>  <p>The chemical structure of Rapamycin is shown. It is a complex polycyclic molecule with multiple hydroxyl groups, an acetate group (OAc), a methoxy group (OMe), and a vinyl group.</p>	<p>target receptor 1: 14-3-3 proteins</p> <p>target receptor 2: H⁺-ATPase</p>
<p>Rapamycin</p>	<p>target receptor 1: FKBP12</p> <p>target receptor 2: mTOR</p>


	
<p>sanglifehrin A</p>  <p>Sanglifehrin A (SFA)</p>	<p>target receptor 1: cyclophilin</p> <p>target receptor 2: IMP dehydrogenase 2</p>
<p>cyclosporin A</p> 	<p>target receptor 1: cyclophilin</p> <p>target receptor 2: calcineurin</p>

[0902] Examples of other bifunctional molecules that can be used with this aspect of prime editing are as follows:


[0903] Synstab A:




[0904] Paclitaxel:





[0905] Discodermolide:



[0906] GNE-0011



[0907] ARV-825, and

**[0908]** dBET1

[0909] Synstab A, paclitaxel, and discodermolide are microtubule stabilizers. Thus, these compounds could be used to dimerize proteins modified by PE to comprise microtubule proteins. GNE-0011, ARV-825, and dBET1 comprise a BRD4 binding motif and a CRBN binding motif. Thus, these compounds could be used to dimerize proteins modified by PE to comprise these targeting domains.

[0910] The PEgRNAs for installing dimerization domains may comprising the following structures (in reference to FIG. 3D):

5'-[spacer]-[gRNA core]-[extension arm]-3', wherein the the extension arm comprises 5'-[homology arm]-[edit template]-[primer binding site]-3'; or

5'-[extension arm]-[spacer]-[gRNA core]-3', wherein the the extension arm comprises 5'-[homology arm]-[edit template]-[primer binding site]-3', and wherein with either configuration the "edit template" comprises a nucleotide sequence of a dimerization domain.

[0911] In one example, the PEgRNA for insertion of the FKBP12 dimerization domain at the C-terminal end of human insulin receptor (spacer underlined, gRNA core plain, flap homology bold, FKBP12 insertion in italics, annealing region bold italics):

PEGRNA FOR INSTALLING FKBP12 IN HUMAN INSULIN RECEPTOR	<p><u>CACGGUAGGCACUGUUAGGAGUUUUAGAG</u> CUAGAAAUAGCAAGUUAAAAUAAGGCUAG UCCGUUAUCAACUUGAAAAAGUGGCACCG AGUCGGUGCUUGCCUCGGUCCA<u>AUCCUUC</u> CGGAGUGCAGGUGGAAACCAUCUCCCCAGGA GACGGGCGCACCUUCCCCAAGCGCGGCCAGA CCUGCGUGGUGCACUACACCGGGAUGCUUG AAGAUGGAAAGAAUUUGAUUCCUCCCCGGA CAGAAACAAGCCCUUAAGUUUAUGCUAGGC AAGCAGGAGGUGAUCCGAGGCUGGGAAGAAG GGGUUGCCCAGAUGAGUGUGGGUCAGAGAG CCAAACUGACUAUAUCUCCAGAUUAUGCCUA UGGUGCCACUGGGCACCCAGGCAUCAUCCCA CCACAUGCCACUCUCGUCUUGCAUGUGGAG CUUCUAAAAACUGGAAUAACAGUGCCUACC</p> <p>(SEQ ID NO: 499)</p>
--	--

[0912] In another example, the PEgRNA for insertion of the FKBP12 dimerization domain at the HEK3 locus (for optimization):

PEGRNA FOR INSTALLING FKBP12 IN HEK3	<p>GGCCCAGACTGAGCACGTGAGTTTATAGAGC TAGAAATAGCAAGTTAAAATAAGGCTAGTC CGTTATCAACTTGAAAAAGTGGCACCGAGT CGGTGCTGGAGGAAGCAGGGCTTCCTTTCCT CTGCCATCATTCCAGTTTTAGAAGCTCCACA TCGAAGACGAGAGTGGCATGTGGTGGGATG ATGCCTGGGTGCCAGTGGCACCATAGGCA TAATCTGGAGATATAGTCAGTTTGGCTCTCT GACCCACACTCATCTGGGCAACCCCTTCTTC CCAGCCTCGGATCACCTCCTGCTTGCCTAGC ATAAACTTAAAGGGCTTGTTTCTGTCCCGGG AGGAATCAAATTTCTTTCCATCTTCAAGCAT CCCGGTGTAGTGACACGAGGCTCTGGCC GCGCTTGGGGAAGGTGCGCCCGTCTCCTGG GGAGATGGTTTCCACCTGCACTCCCGTGCTC AGTCTG (SEQ ID NO: 500)</p>
--------------------------------------	--

[0913] The target proteins for installing dimerization domains are not particularly limited; however, it is advantageous their dimerization (once modified by PE) in the presence of a bi-specific ligand produces some advantageous biological effect, e.g., a signaling pathway, decreased immunoresponsiveness, etc. In various aspects, the target proteins that are to be dimerized through the PE-dependent installation of dimerization domains can be the same protein or different proteins. Preferably, the proteins, when dimerized, trigger one or more downstream biological cascades, e.g., a signal transduction cascade, phosphorylation, etc. Exemplary target proteins into which PE may be used to install dimerization domains, include, but are not limited to:

MEMBRANE-BOUND RECEPTOR	KINASE DOMAIN FUSED TO	CID EMPLOYED	SIGNALING CASCADE	REFERENCE
T-CELL RECEPTOR	FKBP12	FK1012 (FK506 DIMER)	T-CELL RECEPTOR SIGNALING	<i>SCIENCE</i> 262, 1019–24 (1993) <i>CHEM. BIOL.</i> 1, 163–172 (1994).
FAS RECEPTOR	MURINE CYCLOPHILIN C	CYCLOSPORIN A DIMER	FAS PATHWAY FOR APOPTOSIS	<i>CHEM. BIOL.</i> 3, 731–738 (1996).
INSULIN RECEPTOR	FKBP12	FK1012 (FK506 DIMER)	INSULIN SIGNALING	<i>CURR. BIOL.</i> 8, 11–18 (1998).
PLATELET-DERIVED GROWTH FACTOR (PDGF) BETA	FKBP12	FK1012 (FK506 DIMER)	PDGF MESODERM FORMATION SIGNALING	<i>CURR. BIOL.</i> 8, 11–18 (1998).
ERYTHROPOIETIN RECEPTOR (EPOR)	FKBP12	FK1012 (FK506 DIMER)	EPOR-MEDIATED PROLIFERATIVE SIGNALING	<i>PROC. NATL. ACAD. SCI.</i> 94, 3076–3081 (2002).

[0914] In one aspect, the multi-flap prime editor systems described herein may be used to install sequences encoding dimerization domains into one or more genes encoding target proteins of interest in a living cell or patient. This may be referred to as the “multi-flap prime editing–CID system,” wherein the CID is the bi-specific ligand that induced dimerization of target proteins, each fused to a dimerization domain installed by multi-flap PE. This edit alone should have no physiological effect. Upon administration of a bi-specific ligand, which typically is a dimeric small molecule that can simultaneously bind to two dimerization domains, each of which is fused to a copy of the target protein, the bi-specific ligand causes dimerization of the targeted protein. This target protein dimerization event then induces a biological signaling event, such as erythropoiesis or insulin signaling. A new method to place dimerization-induced biological processes, such as receptor signaling, under control of a convenient small-molecule drug (i.e., the bi-specific ligand) by the genomic integration of genes encoding small-molecule binding proteins (i.e., the dimerization domains) with multi-flap prime editing is described herein.

[0915] Protein dimerization is a ubiquitous biological process. Notably, homodimerization of many membrane-bound receptors is known to initiate signaling cascades, often with profound biological consequences. A number of small-molecule natural products approved for use as drugs act as chemical inducers of protein dimerization as part of their mechanism of action.⁹² For example, FK506 binds tightly to FKBP12, and the resulting small molecule–protein complex then binds the

phosphatase calcineurin, thereby inhibiting a step in T cell receptor signaling.⁹³ Likewise, cyclosporin A induces dimerization of cyclophilin and calcineurin, and rapamycin induces dimerization of FKBP and mTOR.^{93,94}

[0916] In one embodiment, leveraging the selective, high-affinity binding of the FK506:FKBP12 and cyclosporin A:cyclophilin small molecule:protein binding interaction, synthetic chemical inducers of dimerization have also been developed. In an example, a small molecule comprised of two units of FK506, termed FK1012, was shown to effect signal transduction when the cytoplasmic domains of signaling receptors were tagged with FKBP12.⁹⁵ Chemical inducers of dimerization (CIDs) have since been used to control a number of signaling pathways.⁹⁶⁻¹⁰³

[0917] While useful tools for studying biological processes, one challenge facing synthetic CIDs for therapeutic applications is that introduction of the FKBP12– or cyclophilin–target protein chimeras into patients is challenging.

[0918] The present disclosure brings together multiple concepts to create a previously inaccessible therapeutic process. The first concept is multi-flap prime editing (*e.g.*, dual flap or quadruple flap prime editing), described herein, which allows for precise genome editing, including targeted insertions, in living cells. The second concept is chemical-induced dimerization, a powerful tool that has enabled small-molecule control over signaling and oligomerization processes in cell culture.

[0919] Specific cases in which chemical control over protein dimerization may have had a beneficial therapeutic effect have been identified.

[0920] The insulin receptor is a heterotetrameric transmembrane protein that responds to insulin binding to the extracellular domain by phosphorylation of the cytoplasmic kinase domain.¹⁰⁴ An engineered chimeric protein composed of a membrane-localization component, the C-terminal kinase domain of the insulin receptor, and three copies of FKBP12 responds to FK1012 and initiates the insulin response in cell culture.⁹⁹ Similarly, it is expected that the fusion of FKBP12 to the C-terminal end of the kinase domain of the native insulin receptor in patient cells should allow for FK1012-dependent phosphorylation and initiation of the insulin signaling cascade. This system could replace or complement insulin use in patients who cannot make insulin (*e.g.*, type-1 diabetics), or who respond weakly to insulin (*e.g.*, type-2 diabetics).

[0921] Additionally, erythropoietin stimulates erythrocyte proliferation by binding to the erythropoietin receptor (EpoR), either inducing dimerization or a conformational change in a preformed receptor dimer which results in activation of the Jak/STAT signaling cascade.¹⁰⁵ It has been demonstrated that FK1012-induced oligomerization of the membrane-anchored cytoplasmic domain of EpoR tagged with FKBP12 is sufficient to initiate the Jak/STAT signaling cascade and promote cell proliferation.¹⁰⁶ It is anticipated that fusing FKBP12 to native EpoR by prime editing in patient cells will allow for FK1012-induced control over erythrocyte proliferation (erythropoiesis). This system could be used to trigger red blood cell growth in anemic patients. FK1012-inducible EpoR

could also be employed as an *in vivo* selectable marker for blood cells that have undergone *ex vivo* engineering.

[0922] In principle, any receptor tyrosine kinase could be viable target for a multi-flap prime editing–CID therapeutic. The table below includes a list of all receptor tyrosine kinases in the human genome.¹¹⁰

Family	Receptor	Synonyms	NT Accession	PROT Accession	Chromosome
ALK family	ALK	Ki1	NM_004304	NP_004295	2p23
	LTK	TYK1	NM_002344	NP_002335	15q15.1-q21.1
AXL family	AXL	UFO, Tyro7(r) Ark(m)	NM_001699	NP_001690	19q13.1
	MER	MERTK, NYK, Eyk(ch)	NM_006343	NP_006334	2q14.1
	TYRO3	RSE, SKY, BRT, DTK, TIF	NM_006293	NP_006284	15q15.1-q21.1
DDR family	DDR1	CAK, TRKE, NEP NTRK4, EDDR1, PTK3	NM_013993	NP_001945	6p21.3
	DDR2	TKT, TYRO10, NTRKR3	NM_006182	NP_006173	1q21-q22
EGFR family	EGFR	ERBB, ERBB1	NM_005228	NP_005219	7p12
	ERBB2	HER2, Neu(r), NGL	NM_004448	NP_004439	17q11.2-q12
	ERBB3	HER3	NM_001982	NP_001973	12q13
	ERBB4	HER4	NM_005235	NP_005226	2q33.3-q34
EPH family	EPHA1	EPH, EPHT	NM_005232	NP_005223	7q32-q36
	EPHA2	ECK, Sek(m), Myk2(m)	NM_004431	NP_004422	1p34
	EPHA3	HEK, ETK1, Tyro4(r), Mek4(m), Cek4(ch)	NM_005233	NP_005224	3p11.2
	EPHA4	HEK8, Tyro1(r), Sek1(m), Cek8(ch)	NM_004438	NP_004429	2q36qter
	EPHA5	HEK7, Ehk(r), Bsk(r), Cek7(ch)	L36644	P54756	
	EPHA6	DKFZp434C1418, Ehk2(r)	AL133666		
	EPHA7	HEK11, Mdk1(m), Ebk(m), Ehk3(r), Cek11(ch)	NM_004440	NP_004431	6q21
	EPHA8	HEK3, KIAA1459, Eek(r), Cek10(ch)	AB040892	CAB81612	1q23-q24
	EPHB1	NET, EPHT2, HEK6, Elk(r), Cek6(ch)	NM_004441	NP_004432	3q21-q23
	EPHB2	HEK5, ERK, DRT, EPHT3, Tyro5(r), Nuk(m), Sek3(m), Cek5(ch)	AF025304	AAB94602	1p36.1-p35
	EPHB3	HEK2, Tyro6, Mdk5(m), Sek4(m)	NM_004443	NP_004434	3q21-qter
	EPHB4	HTK, Tyro11(r), Mdk2(m), Myk1(m)	NM_004444	NP_004435	
	EPHB6	HEP, Mep(m), Cek1(ch)	NM_004445	NP_004436	7q33-q35

FGFR family	FGFR1	FLT2, bFGFR, FLG, N-SAM	M34641	AAA35835	8p11.2
	FGFR2	KGFR, K-SAM, Bek(m), CFD1, JWS, Cek3(ch)	NM_000141	NP_000132	10q26
	FGFR3	HBGFR, ACH, Cek2(ch)	NM_000142	NP_000133	4p16.3
	FGFR4		NM_002011	NP_002002	5q35.1-qter
INSR family	IGF1R	JTK13	NM_000875	NP_000866	15q25-q26
	INSR	IR	NM_000208	NP_000199	19p13.3-p13.2
	INSRR	IRR	J05046	AAC31759	1q21-q23
MET Family	MET	HGFR	NM_000245	NP_000236	7q31
	RON	MST1R, CDw136, Fv2(m), STK(m), SEA(ch)	NM_002447	NP_002438	3p21.3
MUSK family	MUSK	Nsk2(m), Mlk1(m), Mk2(m)	NM_005592	NP_005583	9q31.3-q32
PDGFR family	CSF1R	FMS, C-FMS, CD115	NM_005211	NP_005202	5q31-q32
	FLT3	FLK2, STK1, CD135	NM_004119	NP_0041110	13q12
	KIT	Sfr(m), CKIT	NM_000222	NP_000213	4q11-q12
	PDGFRA		NM_006206	NP_006197	4q11-q13
	PDGFRB	PDGFR, JTK12	NM_002609	NP_002600	5q31-q32
PTK7 family	PTK7	CCK4, KLG(ch)	NM_002821	NP_002812	6p21.2-p12.2
RET family	RET	MEN2A/B, HSCR1, MTC1	X12949	P07949	10q11.2
ROR family	ROR1	NTRKR1	NM_005012	NP_005003	1p32-p31
	ROR2	NTRKR2	NM_004560	NP_004551	
ROS family	ROS1	MCF3	NM_002944	NP_002935	6q22
RYK family	RYK	Vlk(m), Mrk(m)	S59184	AAB263411	3q22
TIE family	TEK	TIE2	NM_000459	NP_000450	9p21
	TIE	TIE1, JTK14	NM_005424	NP_005415	1p34-p33
TRK family	NTRK1	TRK, TRKA	NM_002529	NP_002520	1q21-q22
	NTRK2	TRKB	NM_006180	NP_006171	9q22.1
	NTRK3	TRKC	NM_002530	NP_002521	15q25
VEGFR family	VEGFR1	FLT1	NM_002019	NP_002010	13q12
	VEGFR2	KDR, FLK1		AAB88005	4q11-q12
	VEGFR3	FLT4, PCL	NM_002020	NP_002011	5q34-q35
AATYK family	AATYK	AATK, KIAA0641	NM_004920	NP_004911	17q25.3
	AATYK2	KIAA1079	NM_014916	NP_055731	7q21-q22
	AATYK3				19q13.2-q13.3

[0923] There are numerous advantages to the multi-flap prime editing–CID system. One such advantage is that it can replace endogenous ligands, which are typically proteins that pose complications in manufacturing, cost, delivery, production, or storage, with drug-like small-molecules that can be orally administered instead of administered by IV or injection, are readily prepared from FDA-approved drugs (or are themselves already drugs), and do not incur special production or storage costs typically associated with protein drugs. Another advantage is that the edit alone should have no

physiological effect. The amount of target protein dimerization can be controlled by dosing the small-molecule CID. Further, target protein dimerization is readily and rapidly reversible by adding the monomeric form of the CID. Yet another advantage is that in instances where a single ligand targets multiple receptors, selectivity can be achieved by prime-editing only one receptor. Finally, depending on the delivery method used for prime editing, it may also be possible to restrict editing to a localized tissue or organ, allowing for inducible receptor activation only in specific areas.

[0924] If editing efficiencies are high enough with multi-flap prime editing that two separate editing events could occur at high levels, it would also be possible to tag two proteins of interest with different small-molecule binding domains (such as FKBP and cyclophilin) and induce heterodimerizations with small molecule heterodimers (such as an FK506–cyclosporin A dimer).

[0925] The fusion of FKBP12 or other small-molecule binding proteins to native proteins has been accomplished, generally by overexpression from plasmid in tissue culture. Subsequent chemical-induced dimerization has been demonstrated to induce phenotypic changes to cells producing the fusion proteins.

[0926] The following references are cited in the above section and are incorporated herein by reference.

1. Crabtree, G. R. & Schreiber, S. L. Three-part inventions: intracellular signaling and induced proximity. *Trends Biochem. Sci.* 21, 418–22 (1996).
2. Liu, J. *et al.* Calcineurin Is a Common Target of A and FKBP-FK506 Complexes. *Cell* 66, 807–815 (1991).
3. Keith, C. T. *et al.* A mammalian protein targeted by G1-arresting rapamycin–receptor complex. *Nature* 369, 756–758 (2003).
4. Spencer, D. M., Wandless, T. J., Schreiber, S. L. S. & Crabtree, G. R. Controlling signal transduction with synthetic ligands. *Science* 262, 1019–24 (1993).
5. Pruschy, M. N. *et al.* Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. *Chem. Biol.* 1, 163–172 (1994).
6. Spencer, D. M. *et al.* Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. *Curr. Biol.* 6, 839–847 (1996).
7. Belshaw, P. J., Spencer, D. M., Crabtree, G. R. & Schreiber, S. L. Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. *Chem. Biol.* 3, 731–738 (1996).
8. Yang, J. X., Symes, K., Mercola, M. & Schreiber, S. L. Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment. *Curr. Biol.* 8, 11–18 (1998).
9. Belshaw, P. J., Ho, S. N., Crabtree, G. R. & Schreiber, S. L. Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. *Proc. Natl. Acad. Sci.* 93, 4604–4607 (2002).
10. Stockwell, B. R. & Schreiber, S. L. Probing the role of homomeric and heteromeric receptor interactions in TGF- β signaling using small molecule dimerizers. *Curr. Biol.* 8, 761–773 (2004).
11. Spencer, D. M., Graef, I., Austin, D. J., Schreiber, S. L. & Crabtree, G. R. A general strategy for producing conditional alleles of Src-like tyrosine kinases. *Proc. Natl. Acad. Sci.* 92, 9805–9809 (2006).

12. Holsinger, L. J., Spencer, D. M., Austin, D. J., Schreiber, S. L. & Crabtree, G. R. Signal transduction in T lymphocytes using a conditional allele of Sos. *Proc. Natl. Acad. Sci.* 92, 9810–9814 (2006).
13. Myers, M. G. Insulin Signal Transduction and the IRS Proteins. *Annu. Rev. Pharmacol. Toxicol.* 36, 615–658 (1996).
14. Watowich, S. S. The erythropoietin receptor: Molecular structure and hematopoietic signaling pathways. *J. Invest. Med.* 59, 1067–1072 (2011).
15. Blau, C. A., Peterson, K. R., Drachman, J. G. & Spencer, D. M. A proliferation switch for genetically modified cells. *Proc. Natl. Acad. Sci.* 94, 3076–3081 (2002).
16. Clackson, T. *et al.* Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. *Proc. Natl. Acad. Sci.* 95, 10437–10442 (1998).
17. Diver, S. T. & Schreiber, S. L. Single-step synthesis of cell-permeable protein dimerizers that activate signal transduction and gene expression. *J. Am. Chem. Soc.* 119, 5106–5109 (1997).
18. Guo, Z. F., Zhang, R. & Liang, F. Sen. Facile functionalization of FK506 for biological studies by the thiol-ene ‘click’ reaction. *RSC Adv.* 4, 11400–11403 (2014).
19. Robinson, D. R., Wu, Y.-M. & Lin, S.-F. The protein tyrosine kinase family of the human genome. *Oncogene* 19, 5548–5557 (2000).

G. Use of multi-flap prime editing for inserting recombinase target sites

[0927] In another aspect, multi-flap prime editing (e.g., as represented by FIGs. 90, 95, 97A, 98A) may be used to insert recombinase sites (or “recombinase recognition sequences”) into a desired genomic site. Insertion of recombinase sites provides a programmed location for effecting site-specific genetic changes in a genome. Such genetic changes can include, for example, genomic integration of a plasmid, genomic deletion or insertion, chromosomal translocations, and cassette exchanges, among other genetic changes. These exemplary types of genetic changes are illustrated in FIG. 64(b)–(f). The installed recombinase recognition sequences may then be used to conduct site-specific recombination at that site to effectuate a variety of recombination outcomes, such as, excision, integration, inversion, or exchange of DNA fragments. For example, FIG. 65 illustrates the installation of a recombinase site that can then be used to integrate a DNA donor template comprising a GFP expression marker. Cells containing the integrated GFP expression system into the recombinase site will fluoresce.

[0928] The mechanism of installing a recombinase site into the genome is analogous to installing other sequences, such as peptide/protein and RNA tags, into the genome. A schematic exemplifying the installation of a recombinase target sequence is shown in FIG. 64(a). The process begins with selecting a desired target locus into which the recombinase target sequence will be introduced. Next, a prime editor fusion is provided (“RT-Cas9:gRNA”). Here, the “gRNA” refers to a PEgRNA, which can be designed using the principles described herein. The PEgRNA in various embodiments will comprise an architecture corresponding to FIG. 3D (5′-[~20-nt spacer]-[gRNA core]-[extension arm]-3′, wherein the extension arm comprises in the 3′ to 5′ direction, a primer binding site (“A”), an edit template (“B”), and a homology arm (“C”). The edit template (“B”) will comprise a sequence

corresponding to a recombinase site, i.e., a single strand RNA of the PEgRNA that codes for a complementary single strand DNA that is either the sense or the antisense strand of the recombinase site and which is incorporated into the genomic DNA target locus through the multi-flap prime editing process.

[0929] In various aspects, the present disclosure provides for the use of a multi-flap PE to introduce recombinase recognition sequences at high-value loci in human or other genomes, which, after exposure to site-specific recombinase(s), will direct precise and efficient genomic modifications (FIG. 64). In various embodiments shown in FIG. 64, PE may be used to (b) insert a single SSR target for use as a site for genomic integration of a DNA donor template. (c) shows how a tandem insertion of SSR target sites can be used to delete a portion of the genome. (d) shows how a tandem insertion of SSR target sites can be used to invert a portion of the genome. (e) shows how the insertion of two SSR target sites at two distal chromosomal regions can result in chromosomal translocation. (f) shows how the insertion of two different SSR target sites in the genome can be used to exchange a cassette from a DNA donor template. Each of the types of genome modifications are envisioned by using PE to insert SSR targets, but this list also is not meant to be limiting.

[0930] Multi-flap PE-mediated introduction of recombinase recognition sequences could be particularly useful for the treatment of genetic diseases which are caused by large-scale genomic defects, such as gene loss, inversion, or duplication, or chromosomal translocation¹⁻⁷ (Table 6). For example, Williams-Beuren syndrome is a developmental disorder caused by a deletion of 24 in chromosome 721. No technology exists currently for the efficient and targeted insertion of multiple entire genes in living cells (the potential of PE to do such a full-length gene insertion is currently being explored but has not yet been established); however, recombinase-mediated integration at a target inserted by PE offers one approach towards a permanent cure for this and other diseases. In addition, targeted introduction of recombinase recognition sequences could be highly enabling for applications including generation of transgenic plants, animal research models, bioproduction cell lines, or other custom eukaryotic cell lines. For example, recombinase-mediated genomic rearrangement in transgenic plants at multi-flap PE-specific targets could overcome one of the bottlenecks to generating agricultural crops with improved properties^{8,9}.

[0931] **Table 6.** Examples of genetic diseases linked to large-scale genomic modifications that could be repaired through multi-flap PE-based installation of recombinase recognition sequences.

DISEASE	CAUSE
TRISOMY 17P	GENE DUPLICATION
CHARCOT-MARIE-TOOTH DISEASE TYPE I	GENE DUPLICATION
SMITH-MAGENIS SYNDROME	GENE DELETION
WILLIAMS-BEUREN SYNDROME	GENE DELETION

DE LA CHAPELLE SYNDROME	CHROMOSOMAL TRANSLOCATION
DOWN SYNDROME (SOME FORMS)	CHROMOSOMAL TRANSLOCATION
HEMOPHILIA A	GENE INVERSION
HUNTER SYNDROME	GENE INVERSION

[0932] A number of SSR family members have been characterized and their recombinase recognition sequences described, including natural and engineered tyrosine recombinases (Table 7), large serine integrases (Table 8), serine resolvases (Table 9), and tyrosine integrases (Table 10). Modified target sequences that demonstrate enhanced rates of genomic integration have also been described for several SSRs²²⁻³⁰. In addition to natural recombinases, programmable recombinases with distinct specificities have been developed³¹⁻⁴⁰. Using PE, one or more of these recognition sequences could be introduced into the genomic at a specified location, such as a safe harbor locus⁴¹⁻⁴³, depending on the desired application.

[0933] For example, introduction of a single recombinase recognition sequence in the genome by prime editing would result in integrative recombination with a DNA donor template (FIG. 64b). Serine integrases, which operate robustly in human cells, may be especially well-suited for gene integration^{44,45}.

[0934] Additionally, introduction of two recombinase recognition sequences could result in deletion of the intervening sequence, inversion of the intervening sequence, chromosomal translocation, or cassette exchange, depending on the identity and orientation of the targets (FIG. 64c-f). By choosing endogenous sequences that already closely resemble recombinase targets, the scope of editing required to introduce the complete recombinase target would be reduced.

[0935] Finally, several recombinases have been demonstrated to integrate into human or eukaryotic genomes at natively occurring pseudosites⁴⁶⁻⁶⁴. Multi-flap prime editing could be used to modify these loci to enhance rates of integration at these natural pseudosites, or alternatively, to eliminate pseudosites that may serve as unwanted off-target sequences.

[0936] This disclosure describes a general methodology for introducing recombinase target sequences in eukaryotic genomes using multi-flap PE, the applications of which are nearly limitless. The genome editing reactions are intended for use with “prime editors,” a chimeric fusion of a CRISPR/Cas9 protein and a reverse-transcriptase domain, which utilizes a custom prime editing guide RNA (PEgRNA). By extension, Cas9 tools and homology-directed repair (HDR) pathways may also be exploited to introduce recombinase recognition sequences through DNA templates by lowering the rates of indels using several techniques⁶⁵⁻⁶⁷. A proof-of-concept experiment in human cell culture is shown in FIG. 65. In some embodiments, the prime editors are multi-flap prime editors.

[0937] The following several tables are cited in the above description relating to PE-directed installation of recombinase recognition sequences and provide a listing of exemplary recombinases

that may be used, and their cognate recombinase recognition sequences that may be installed by multi-flap PE.

Table 7. Tyrosine recombinases and SSR target sequences.

Recombinase	Recombinase recognition sequence	Name
Cre	ATAACTTCGTATAGCATACATTATACGAAGTTAT (SEQ ID NO: 517)	<i>loxP</i>
Dre	TAACTTTAAATAATGCCAATTATTTAAAGTTA (SEQ ID NO: 518)	<i>rox</i>
VCre	TCAATTTCTGAGAACTGTCATTCTCGGAAATTGA (SEQ ID NO: 519)	<i>loxV</i>
SCre	CTCGTGTCGATAACTGTAATTATCGGACATGAT (SEQ ID NO: 520)	<i>loxS</i>
Flp	GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC (SEQ ID NO: 521)	<i>FRT</i>
B2	GAGTTTCATTAAGGAATAACTAATTCCTAATGAACTC (SEQ ID NO: 522)	<i>loxB</i>
B3	GGTTGCTTAAGAATAAGTAATTCTTAAGCAACC (SEQ ID NO: 523)	<i>loxB3</i>
Kw	ACGAAAAATGGTAAGGAATAGACCATTTCCTTACCATTTTGGT (SEQ ID NO: 524)	
R	TTGATGAAAGAATAACGTATTCTTTCATCAA (SEQ ID NO: 525)	<i>RS</i>
TD1-40	GTGCGTCAAATAATAACGTATTATTTGACACTT (SEQ ID NO: 526)	<i>TDRS</i>
Vika	AATAGGTCTGAGAACGCCATTCTCAGACGTATT (SEQ ID NO: 527)	<i>vox</i>
Nigri	TGAATGTCCTATAATTACACTTATAGGACATTCA (SEQ ID NO: 528)	<i>nox</i>
Panto	GAAACTTTAAATAATAAGTCTTATTTAAAGTTTC (SEQ ID NO: 529)	<i>pox</i>
Kd	AAACGATATCAGACATTTGTCTGATAATGCTTCATTA TCAGACAAATGTCTGATATCGTTT (SEQ ID NO: 530)	<i>loxK</i>
Fre	ATATATACGTATATAGACATATATACGTATATAT (SEQ ID NO: 531)	<i>loxH</i>
CreALSHG	ATAACTCTATATAATGTATGCTATATAGAGTTAT (SEQ ID NO: 532)	<i>loxM7</i>
Tre	ACAACATCCTATTACACCCTATATGCCAACATGG (SEQ ID NO: 533)	<i>loxLTR</i>
Brec1	AACCCACTGCTTAAGCCTCAATAAAGCTTGCCTT (SEQ ID NO: 534)	<i>loxBTR</i>
Cre-R3M3	GATACAACGTATATACCTTTCTATACGTTGTTTA (SEQ ID NO: 535)	<i>loxK2</i>

Table 8. Large serine integrases and SSR target sequences.

Recombinase	Recombinase recognition sequence Left	Recombinase recognition sequence Right
Bxb1	GGTTTGTCTGGTCAACCACCGCGG TCTCAGTGGTGTACGGTACAAACC (SEQ ID NO: 536)	GGCTTGTGCGACGACGGCGGTCTCCGTC GTCAGGATCAT (SEQ ID NO: 537)
phiC31	GTGCCCCAACTGGGGTAACCTTTG AGTTCTCTCAGTTGGGGG (SEQ ID NO: 538)	TGCGGGTGCCAGGGCGTGCCCTTGGG CTCCCCGGGCGGCTACTCC (SEQ ID NO: 539)
R4	TGTTCCCCAAAGCGATAACCACTTG AAGCAGTGGTACTGCTTGTGGGT ACA (SEQ ID NO: 540)	GCATGTTCCCCAAAGCGATAACCACTTG AAGCAGTGGTACTGCTTGTGGGTACA CTCTGCGGGTG (SEQ ID NO: 541)
phiBT1	GGTGCTGGGTTGTTGTCTCTGGAC AGTGATCCATGGGAACTACTCA GCACC (SEQ ID NO: 542)	CAGGTTTTTGACGAAAGTGATCCAGAT GATCCAG (SEQ ID NO: 543)
MJ1 (phiFC1)	ATTTTAGGTATATGATTTTGTATTAT TAGTGTAATAACACTATGTACCT AAAAT (SEQ ID NO: 544)	CAAAGGATCACTGAATCAAAAGTATT GCTCATCCACGCGAAA (SEQ ID NO: 545)
MR11	TTTGTGCGGAACTACGAACAGTTC ATTAATACGAAGTGTACAACTTC CATACAA (SEQ ID NO: 546)	CGAAAATGTATGGAGGCACTTGTATC AATATAGGATGTATACCTTCGAAGAC ACTT (SEQ ID NO: 547)
TP901-1	GAGTTTTTATTTCTGTTTATTTCAAT TAAGGTAACATAAAAACTCCTTTT AAGG (SEQ ID NO: 548)	ATGCCAACACAATTAACATCTCAATCA AGGTAAATGCTTTTTTGTCTTTTTTGC (SEQ ID NO: 549)
A118	TTCCTCGTTTTCTCTCGTTGGAAG AAGAAGAAACGAGAAA (SEQ ID NO: 550)	TTTCGGATCAAGCTATGAAGGACGCA AAGAGGGAACATAA (SEQ ID NO: 551)
U153	TTCCTCGTTTTCTCTCGTTGGAAG GAAACGAATCGAGAAA (SEQ ID NO: 552)	TTTCGGATCAAGCTATGAAGGACGCA AAGAGGGAACATAA (SEQ ID NO: 553)
phiRV1	GTAGTGATCTCACAGGTCCACGG TTGGCCGTGGACTGCTGAAGAAC ATTCC (SEQ ID NO: 554)	GAAGGTGTTGGTGCGGGGTTGGCCGT GGTCGAGGTGGGGT (SEQ ID NO: 555)
phi370.1	AAAAAAATACAGCGTTTTTCATGT ACAACTATACTAGTTGTAGTGCCT AAAA (SEQ ID NO: 556)	TTGTAAAGGAGACTGATAATGGCATG TACAACTATACTCGTCGGTAAAAAGG CA (SEQ ID NO: 557)
TG1	TCCAGCCCAACAGTGTTAGTCTTT GCTCTTACCCAGTTGGGCGGGA (SEQ ID NO: 558)	GATCAGCTCCGCGGGCAAGACCTTTCT CCTTCACGGGGTGGAAGGTC (SEQ ID NO: 559)
WB	CTAGTTTTAAAGTTGGTTATTAGT TACTGTGATATTTATCACGGTACC CAATAACCAATGAAT (SEQ ID NO: 560)	CGGAAGGTAGCGTCAACGATAGGTGT AACTGTCGTGTTTGTAAACGGTACTTCC AACAGCTGGCGCCGCCAC (SEQ ID NO: 561)
BL3	CAATGAAAACTAGGCATGTAGA AGTTGTTTGT (SEQ ID NO: 562)	TTCCACAGACAACCTCACGTGGAGGT AGTCAC (SEQ ID NO: 563)
SprA	TGTAGTAAGTATCTTAATATACAG CTTATCTGTTTTTAAAGATACTTA	CACCCATTGTGTTTACAGGAGATACA GCTTTATCTGTACTGATATTAATGACA

Recombinase	Recombinase recognition sequence Left	Recombinase recognition sequence Right
	CTACTTT (SEQ ID NO: 564)	TGCTG (SEQ ID NO: 565)
phiJoe	AGTTGTGGCCATGTGTCCATCTGG GGGCAGATGGAGACGGGGTCACA (SEQ ID NO: 566)	ATCTGGATGTGGGTGTCCATCTGCGGG CAGACGCCGCGAGTCGAAGCACGG (SEQ ID NO: 567)
--	--	ACCTTGATCTCGGTGTCCATCGCCGGG CAGACGCCGCGAGTCGAAGCACGG (SEQ ID NO: 568)
phiK38	CCCTAATACGCAAGTCGATAACTC TCCTGGGAGCGTTGACAACTTGCG CACCTGATCTG (SEQ ID NO: 569)	GAGCGCCGGATCAGGGAGTGGACGGC CTGGGAGCGCTACACGCTGTGGCTGC GGTCGGTGC (SEQ ID NO: 570)
Int2	GCTCATGTATGTGTCTACGCGAGA TTCTCGCCCGAGAACTTCTGCAAG GCACTGCTCTTGGCT (SEQ ID NO: 571)	GGACGGCGCAGAAGGGGAGTAGCTCT TCGCCGGACCGTCGACATACTGCTCAG CTCGTC (SEQ ID NO: 572)
Int3	ATGGATAAAAAAATACAGCGTTT TTCATGTACAACATACTAGTTGT AGTGCCTAAATAATGCTT (SEQ ID NO: 573)	GTTTGTAAGGAGACTGATAATGGCA TGTACAACATACTCGTCGGTAAAAA GGCATCTTAT (SEQ ID NO: 574)
Int4	AAAAATTACAAAGTTTTCAACCCT TGATTTGAATTAGCGGTCAAATAA TTTGTAATTCGTTT (SEQ ID NO: 575)	TTCCAAAGAGCGCCCAACGCGACCTG AAATTTGAATAAGACTGCTGCTTGTGT AAAGGCGATGATT (SEQ ID NO: 576)
Int7	GTGTTATAAACCTGTGTGAGAGTT AAGTTTACATGCCTAACCTTAAC TTACGCAGGTCAGCTT (SEQ ID NO: 577)	AGACGAGAAACGTTCCGTCCGTCTGG GTCAGTTGGGCAAAGTTGATGACCGG GTCGTCCGTT (SEQ ID NO: 578)
Int8	TTAATAAACTATGGAAGTATGTAC AGTCTTGCAATGTTGAGTGAACA AACTTCCATAATAAAAT (SEQ ID NO: 579)	CAATCATCAGATAACTATGGCGGCAC GTGCATTAACCACGGTTGTATCCCGTC TAAAGTACTCGT (SEQ ID NO: 580)
Int9	GTGGTTGTTTTTGTGGAAGTGTG TATCAGGTATCTGCATAGTTATTC CGAACTTCCAATTA (SEQ ID NO: 581)	TTTATATTGCGAAAAATAATTGGCGAA CGAGGTAAGTGGATACCTCATCCGCC AATTAAATTTG (SEQ ID NO: 582)
Int10	GGAAATATAAATAATTTTAGTA ACCTACATCTCAATCAAGGATAGT AAAACCTCTCACTCTT (SEQ ID NO: 583)	AGCACGCTGATAATCAGCAAGACCAC CAACATTTCCACCAATGTAAAAGCTTT AACCTTAGC (SEQ ID NO: 584)
Int11	GTTTATATGTTTACTAATAAGACG CTCTCAACCCATAAAGTCTTATTA GTAAACATATTTCAACT (SEQ ID NO: 585)	ATGGATTTTGCAGATTCCCAGATGCCC CTACAGAAAGAGGTACAAAACATTTA TTGGAATTAATT (SEQ ID NO: 586)
Int12	TTTTTGTATGTTAGTTGTGTCAGTG GGTAGACCTAAATAGTGACACAA CTGCTATTAATAATTTAA (SEQ ID NO: 587)	GTTTCGTGGTAACTATGGGTGGTACAG GTGCCACATTAGTTGTACCATTTATGT TTATGTGGTTAAC (SEQ ID NO: 588)

Recombinase	Recombinase recognition sequence Left	Recombinase recognition sequence Right
Int13	CAATAACGGTTGTATTTGTAGAAC TTGACCAGTTGTTTTAGTAACATA AATACAACCTCCGAATA (SEQ ID NO: 589)	GCATACATTGTTGTTGTTTTCCAGAT CCAGTTGGTCCTGTAAATATAAGCAAT CCATGTGAGT (SEQ ID NO: 590)
LI	GTTTAGTATCTCGTTATCTCTCGTT GGAGGGAGAAGAAACGGGATACC AAAA (SEQ ID NO: 591)	TAACTTTTTCGGATCGAGTTATGATGG ACGTAAAGAGGGAACAAAGCATCTA (SEQ ID NO: 592)
Peaches	TAGTTTCCAATGTTACAGGAAGT CTGGCAGAATCCAACACATTGGA AGTCG (SEQ ID NO: 593)	CGGTCTCCATCGGGATCTGCTGATCGA GCAGCATGCCGACCA (SEQ ID NO: 594)
Bxz2	TAACCGCAAGTGACATCCCTCGG CTGGCCGAGACAAGTACAGTTGC GACAG (SEQ ID NO: 595)	CGGTCTCCATCGGGATCTGCTGATCGA GCAGCATGCCGACCA (SEQ ID NO: 596)
SV1	ATGTGGTCCTTTAGATCCACTGAC GTGGGTCAGTGTCTCTAAAGGACT CGCG (SEQ ID NO: 597)	CATCAGGGCGGTCAGGCCGTAGATGT GGAAGAAACGGCAGCACGGCGAGGA CG (SEQ ID NO: 598)

Table 9. Serine resolvases and SSR target sequences.

Resolvase	Recombinase recognition sequence Left	Recombinase recognition sequence Right
Gin	CGTTTCCTGTAAACCGAGGTTTTGGA TAAACA (SEQ ID NO: 599)	CGTTTCCTGTAAACCGAGGTTTTGGA TAATGG (SEQ ID NO: 600)
Cin	GAGTTCTCTTAAACCAAGGTTTAGG ATTGAAA (SEQ ID NO: 601)	GAGTTCTCTTAAACCAAGGTATTGG ATAACAG (SEQ ID NO: 602)
Hin	TGGTTCTTGAAAACCAAGGTTTTTGA TAAAGC (SEQ ID NO: 603)	AAATTTTCCTTTTTTGAAGGTTTTTG ATAACCA (SEQ ID NO: 604)
Min	GCCTTCCCCTAAACCAACGTTTTTAT GCCGCC (SEQ ID NO: 605)	GCCTTCCCCCAAACCAAGGTAATCA AGAACGC (SEQ ID NO: 606)
Sin	TTGTGAAATTTGGGTACACCCTAATC ATACAA (SEQ ID NO: 607)	CGTATGATTAGGGTGTATATTAATTT (SEQ ID NO: 608)

Table 10. Tyrosine integrases and target sequences.

Integrase	<i>attP</i>	<i>attB</i>
HK022	CAAATGATTTTATTTTACTAATAATGA CCTACTTACATTAATTTACTGATAATTA AAGAGATTTTAAATATACAACCTTATTC ACCTAAAGGATGACAAAA (SEQ ID NO: 609)	GCACTTTAGGTGAAAAAGGTT (SEQ ID NO: 610)
	TAACATTAATCACTTAAAAATCATCGC ATTACATAATCTGTGGTTAAATGATA GACTACATAATGCGACAAAACGCAACA	

	TATCCAGTCACTATGAATCAACTACTT AGATAGTATTAGTGACCT (SEQ ID NO: 611)	
P22	CTAAGTGGTTTGGGACAAAAATGGGAC ATACAAATCTTTGCATCGGTTTGCAAG GCTTTGCATGTCTTTTGAAGATGGGAC GTGTGAGCGCAGGTATGACGTGGTATG TGTTGACTTAAAAGGTAGTTCTTATAAT TCGTAATGCGAAGGTCGTAGGTTTCGAC TCCTATTATCGGCACCAGTTAAATCAA ATACTTACGTATTATTCGTGCCTTCCTT ATTTTACTGTGGGACATATTTGGGACA GAAGTACCAAAAA (SEQ ID NO: 612)	GCAGCGCATTCGTAATGCGAAG GTCGT (SEQ ID NO: 613)
L5	GCGATCCCCATCCGCGACGTGCCAACT AGGTCTCCTCTCGTCGTGAACAAGGCT ACCGGGTTGCAACTCCTGTGCAACTCT CAGGCTTCAACGCGCTTCTACGACCTG CAATTTCTTTCCACTTAGAGGATGCAG CCGAGAGGGGTAAAAACCTATCTTGAC CGGCCCATATGTGGTCGGCAGACACCC ATTCTTCCAACTAGCTACGCGGGTTC GATTCCCGTCGCCCCGCTCCGCTGGTCA GAGGGTGTTTTCGCCCTCTGGCCATTTT TCTTTCCAGGGGTCTGCAACTCTTGTC GACTCTTCTGACCTGGGCATACGCGGT TGCAACGCATCCCTGATCTGGCTACTTT CGATGCTGACAAACGAATAGAGCCCCC CGCCTGCGCGAACAGACGAGGGGCATT CACA (SEQ ID NO: 614)	GAGCGGGCGACGGGAATCGAA CCCGCGTAGCTAGTTTGAAGA (SEQ ID NO: 615)

[0938] In various other aspects, the present disclosure relates to methods of using multi-flap PE to install one or more recombinase recognition sequences and their use in site-specific recombination.

[0939] In some embodiments, the site-specific recombination may effectuate a variety of recombination outcomes, such as, excision, integration, inversion, or exchange of DNA fragments.

[0940] In some embodiments, the methods are useful for inducing recombination of or between two or more regions of two or more nucleic acid (e.g., DNA) molecules. In other embodiments, the methods are useful for inducing recombination of or between two or more regions in a single nucleic acid molecule (e.g., DNA).

[0941] In some embodiments, the disclosure provides a method for integrating a donor DNA template by site-specific recombination, comprising: (a) installing a recombinase recognition sequence at a genomic locus by multi-flap prime editing; (b) contacting the genomic locus with a DNA donor template that also comprises the recombinase recognition sequence in the presence of a recombinase.

[0942] In other embodiments, the disclosure provides a method for deleting a genomic region by site-specific recombination, comprising: (a) installing a pair of recombinase recognition sequences at a

genomic locus by multi-flap prime editing; (b) contacting the genomic locus with a recombinase, thereby catalyzing the deletion of the genomic region between the pair of recombinase recognition sequences.

[0943] In yet other embodiments, the disclosure provides a method for inverting a genomic region by site-specific recombination, comprising: (a) installing a pair of recombinase recognition sequences at a genomic locus by multi-flap prime editing; (b) contacting the genomic locus with a recombinase, thereby catalyzing the inversion of the genomic region between the pair of recombinase recognition sequences.

[0944] In still other embodiments, the disclosure provides a method for inducing chromosomal translocation between a first genomic site and a second genomic site, comprising: (a) installing a first recombinase recognition sequence at a first genomic locus by prime editing; (b) installing a second recombinase recognition sequence at a second genomic locus by multi-flap prime editing; (c) contacting the first and the second genomic loci with a recombinase, thereby catalyzing the chromosomal translocation of the first and second genomic loci.

[0945] In other embodiments, the disclosure provides a method for inducing cassette exchange between a genomic locus and a donor DNA comprising a cassette, comprising: (a) installing a first recombinase recognition sequence at a first genomic locus by multi-flap prime editing; (b) installing a second recombinase recognition sequence at a second genomic locus by multi-flap prime editing; (c) contacting the first and the second genomic loci with a donor DNA comprising a cassette that is flanked by the first and second recombinase recognition sequences and a recombinase, thereby catalyzing the exchange of the flanked genomic locus and the cassette in the DNA donor.

[0946] In various embodiments involving the insertion of more than one recombinase recognition sequences in the genome, the recombinase recognition sequences can be the same or different. In some embodiments, the recombinase recognition sequences are the same. In other embodiments, that recombinase recognition sequences are different.

[0947] In various embodiments, the recombinase can be a tyrosine recombinase, such as Cre, Dre, Vcre, Scre, Flp, B2, B3, Kw, R, TD1-40, Vika, Nigri, Panto, Kd, Fre, Cre(ALSHG), Tre, Brec1, or Cre-R3M3, as shown in Table 7. In such embodiments, the recombinase recognition sequence may be an RRS of Table 7 that corresponds to the recombinase under use.

[0948] In various other embodiments, the recombinase can be a large serine recombinase, such as Bxb1, PhiC31, R4, phiBT1, MJ1, MR11, TP901-1, A118, V153, phiRV1, phi370.1, TG1, WB, BL3, SprA, phiJoe, phiK38, Int2, Int3, Int4, Int7, Int8, Int9, Int10, Int11, Int12, Int13, L1, peaches, Bxz2, or SV1, as shown in Table 8. In such embodiments, the recombinase recognition sequence may be an RRS of Table 8 that corresponds to the recombinase under use.

[0949] In still other embodiments, the recombinase can be a serine recombinase, such as Bxb1, PhiC31, R4, phiBT1, MJ1, MR11, TP901-1, A118, V153, phiRV1, phi370.1, TG1, WB, BL3, SprA,

phiJoe, phiK38, Int2, Int3, Int4, Int7, Int8, Int9, Int10, Int11, Int12, Int13, L1, peaches, Bxz2, or SV1, as shown in Table 8. In such embodiments, the recombinase recognition sequence may be an RRS of Table 8 that corresponds to the recombinase under use.

[0950] In other embodiments, the recombinase can be a serine resolvase, such as Gin, Cin, Hin, Min, or Sin, as shown in Table 9. In such embodiments, the recombinase recognition sequence may be an RRS of Table 9 that corresponds to the recombinase under use.

[0951] In various other embodiments, the recombinase can be a tyrosine integrase, such as HK022, P22, or L5, as shown in Table 10. In such embodiments, the recombinase recognition sequence may be an RRS of Table 10 that corresponds to the recombinase under use.

[0952] In some embodiments, any of the methods for site-specific recombination with multi-flap PE can be performed *in vivo* or *in vitro*. In some embodiments, any of the methods for site-specific recombination are performed in a cell (e.g., recombine genomic DNA in a cell). The cell can be prokaryotic or eukaryotic. The cell, such as a eukaryotic cell, can be in an individual, such as a subject, as described herein (e.g., a human subject). The methods described herein are useful for the genetic modification of cells *in vitro* and *in vivo*, for example, in the context of the generation of transgenic cells, cell lines, or animals, or in the alteration of genomic sequence, e.g., the correction of a genetic defect, in a cell in a subject.

[8] Embodiments of the multi-flap prime editors described herein

[0953] The following non-limiting embodiments describe aspects of the dual prime editors and their use as described in this application.

1. A system for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited, wherein the system comprises a first prime editor complex and a second prime editor complex, wherein each of the first and second prime editor complexes comprises (1) a prime editor comprising (i) a nucleic acid programmable DNA binding protein (napDNAbp), and (ii) a polypeptide having an RNA-dependent DNA polymerase activity; and (2) a pegRNA comprising a spacer sequence, gRNA core, a DNA synthesis template, and a primer binding site, wherein the DNA synthesis template of the pegRNA of the first prime editor complex encodes a first single-stranded DNA sequence and the DNA synthesis template of the pegRNA of the second prime editor complex encodes a second single-stranded DNA sequence, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence each comprises a region of complementarity to the other, and wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence form a duplex comprising an edited portion as compared to the DNA sequence at the target site to be edited, which integrates into the target site to be edited.
2. The system of embodiment 1, wherein the prime editor of the first prime editor complex, the

second prime editor complex, or both the first prime editor complex and the second prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity.

3. The system of embodiment 1 or 2, wherein the first prime editor complex and the second prime editor complex comprise the same prime editor.
4. The system of embodiment 1 or 2, wherein the first prime editor complex and the second prime editor complex comprise different prime editors.
5. The system of any one of embodiments 1-4, wherein the napDNAbp is a Cas9 domain or variant thereof.
6. The system of any one of embodiments 1-5, wherein the napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, a Cas9 nickase domain, or variant thereof.
7. The system of any one of embodiments 1-4, wherein the napDNAbp is selected from the group consisting of: Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, CasX, CasY, and Argonaute.
8. The system of any one of embodiments 1-7, wherein the napDNAbp has a nickase activity.
9. The system of any one of embodiments 1-4, wherein the napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 18-88, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 18-88.
10. The system of any one of embodiments 1-9, wherein the polypeptide having an RNA-dependent DNA polymerase activity is a reverse transcriptase.
11. The system of any one of embodiments 1-10, wherein the polypeptide having an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 89-100, 105-122, 128-129, 132, 139, 143, 149, 154, 159, and 700-766 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of

SEQ ID NOs: 89-100, 105-122, 128-129, and 132.

12. The system of any one of embodiments 1-11, wherein the prime editor further comprises a linker that joins the napDNAbp and the polypeptide having the RNA-dependent DNA polymerase activity.
13. The system of embodiment 12, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOs: 166-177, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 166-177.
14. The system of embodiment 12 or 13, wherein the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.
15. The system of any one of embodiments 1-14, wherein the pegRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244.
16. The system of any one of embodiments 1-15, wherein the spacer sequence of the pegRNA of the first prime editor complex binds to a first binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.
17. The system of any one of embodiments 1-16, wherein the spacer sequence of the pegRNA of the second prime editor complex binds to a second binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.
18. The system of embodiment 17, whereby the binding of the spacer sequence of the pegRNAs of the first and second prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequences on each strand by the napDNAbps of each of the first and second prime editor complex.

19. The system of embodiment 18, wherein the first and second binding sites define two ends of a contiguous region of double-stranded DNA comprising the target site to be edited.
20. The system of embodiment 19, wherein the contiguous region between the first and second binding sites is at least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.
21. The system of embodiment 19, wherein the contiguous region becomes replaced by the duplex comprising the edited portion.

22. The system of any one of embodiments 1-21, wherein the DNA synthesis template is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.
23. The system of any one of embodiments 1-22, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have the same lengths.
24. The system of any one of embodiments 1-22, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have different lengths.

25. The system of any one of embodiments 1-24, wherein the region of complementarity is at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, or at least 10% of the total length of the first single-stranded DNA sequence or the second single-stranded DNA sequence.
26. The system of embodiment 25, wherein the region of complementarity is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length, and is either less than or equal to the length of the desired DNA sequence and complement thereof.

27. The system of embodiment 25, wherein the region of complementarity of the first single-stranded DNA sequence and the second single-stranded DNA sequence form the duplex comprising the edited portion.
28. The system of any one of embodiments 1-27, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are each single-stranded DNA strands having 3' ends.
29. The system of embodiment 21, wherein the replacement of the contiguous region by the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.
30. A system for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited, said system comprising:
 - (a) a first prime editor complex comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (first napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEGRNA) that binds to a first binding site on a first strand of the double-stranded DNA sequence upstream of the target site to be edited;
 - (b) a second prime editor complex comprising:
 - i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a second prime editing guide RNA (second PEGRNA) that binds to a second binding site on a second strand of the double-stranded DNA sequence downstream of the target site to be edited;

wherein the first PEGRNA comprises a first DNA synthesis template encoding a first single-stranded DNA sequence and the second PEGRNA comprises a second DNA synthesis template encoding a second single-stranded DNA sequence, and wherein the first strand and the second strand

of the double-stranded DNA sequence are complementary to each other.

31. The system of embodiment 30, wherein the prime editor of the first prime editor complex, the second prime editor complex, or both the first prime editor complex and the second prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity.
32. The system of embodiment 30, wherein the first and the second single-stranded DNA sequence each comprise a region of complementarity to the other.
33. The system of embodiment 30, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence form a duplex comprising the edited portion which integrates into the target site to be edited.
34. The system of embodiment 30, wherein the first single-stranded DNA sequence and/or the second single stranded sequence does not comprise sequence homology as compared to the DNA sequence at the target site.
35. The system of embodiment 30, wherein the first PEgRNA further comprises a first spacer sequence, a first gRNA core, and a first primer binding site, and the second PEgRNA further comprises a second spacer sequence, a second gRNA core, and a second primer binding site.
36. The system of any one of embodiments 30-35, wherein the first prime editor complex and the second prime editor complex comprise the same prime editor.
37. The system of any one of embodiments 30-35, wherein the first polypeptide comprising an RNA-dependent DNA polymerase activity and the second polypeptide comprising an RNA-dependent DNA polymerase activity are the same.
38. The system of any one of embodiments 30-37, wherein the first and/or second napDNAbp is a Cas9 domain or variant thereof.
39. The system of any one of embodiments 30-38, wherein the first and/or second napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, a Cas9 nickase domain, or a

variant thereof.

40. The system of any one of embodiments 30-39, wherein the first and/or second napDNAbp is selected from the group consisting of Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, CasX, CasY, and Argonaute.
41. The system of any one of embodiments 30-40, wherein the napDNAbp has a nickase activity.
42. The system of any one of embodiments 30-41, wherein the first and/or second napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 18-88, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 18-88.
43. The system of any one of embodiments 30-42, wherein the first and/or second polypeptide having an RNA-dependent DNA polymerase activity is a reverse transcriptase.
44. The system of any one of embodiments 30-43, wherein the first and/or second polypeptide having an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 89-100, 105-122, 128-129, 132, 139, 143, 149, 154, 159, and 700-766 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 89-100, 105-122, 128-129, and 132.
45. The system of any one of embodiments 30-44, wherein the first prime editor further comprises a linker that joins the first napDNAbp and the first polypeptide having the RNA-dependent DNA polymerase activity; and/or the second prime editor further comprises a linker that joins the second napDNAbp and the second polypeptide having the RNA-dependent DNA polymerase activity.
46. The system of embodiment 45, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOs: 166-177, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 166-177.
47. The system of embodiment 45 or 46, wherein the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,

- 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid in length.
48. The system of any one of embodiments 30-47, wherein the first and/or second pegRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244.
49. The system of any one of embodiments 30-48, wherein the first spacer sequence binds to a first binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.
50. The system of embodiment 49, wherein the second spacer sequence of the second prime editor complex binds to a second binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.
51. The system of embodiment 50, whereby the binding of the spacer sequence of the first and second prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequences on each strand by the first and/or second napDNABps of each of the first and second prime editor complexes.
52. The system of embodiment 51, wherein the first and second binding sites define two ends of a contiguous region of double-stranded DNA comprising the target site to be edited.
53. The system of embodiment 52, wherein the contiguous region between the first and second binding sites is least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31

nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

54. The system of embodiment 53, wherein the contiguous region becomes replaced by the duplex comprising the edited portion.
55. The system of any one of embodiments 30-54, wherein the first and/or second DNA synthesis template is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36

nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

56. The system of any one of embodiments 30-55, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have the same lengths.
57. The system of any one of embodiments 30-55, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have different lengths.
58. The system of any one of embodiments 30-57, wherein the region of complementarity is at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, or at least 10% of the total length of the first single-stranded DNA sequence or the second single-stranded DNA sequence.
59. The system of any one of embodiments 30-58, wherein the region of complementarity is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least

13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

60. The system of any one of embodiments 30-59, wherein the region of complementarity of the first single-stranded DNA sequence and the second single-stranded DNA sequence form a duplex.
61. The system of any one of embodiments 30-60, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are each single-stranded DNA strands having 3' ends.
62. The system of embodiment 54, wherein the replacement of the contiguous region by the

duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.

- 63. A polynucleotide encoding the system of any of embodiments 1-62.
- 64. A polynucleotide encoding the first and second prime editors of any one of embodiments 1-62.
- 65. A polynucleotide encoding the first and/or second pegRNA of any one of embodiments 1-29.
- 66. A polynucleotide encoding the first and/or second pegRNA of any one of embodiments 30-62.
- 67. A polynucleotide encoding the first and second pegRNA of any one of embodiments 1-29.
- 68. A polynucleotide encoding the first and second pegRNA of any one of embodiments 30-62.
- 69. A vector comprising a polynucleotide of any one of embodiments 63-68.
- 70. A cell comprising a polynucleotide of any one of embodiments 63-69 or a vector of embodiment 64.
- 71. A pharmaceutical composition comprising a polynucleotide of any one of embodiments 63-68, a vector of embodiment 69, or a cell of embodiment 70, and a pharmaceutical excipient.
- 72. A kit comprising a polynucleotide of any of embodiments 63-69 or a vector of embodiment 70 and instructions for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited.
- 73. A method for simultaneously editing a first and a second complementary strands of a double-stranded DNA sequence at a target site, said method comprising contacting the double-stranded DNA sequence with a pair of prime editor complexes, said pair comprising:

- a. a first prime editor complex, comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEGRNA) that binds to a first binding site on the first strand of the genomic DNA sequence upstream of the target site;
- b. a second prime editor complex, comprising:
 - i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a second prime editing guide RNA (second PEGRNA) that binds to a second binding site on the second strand of the genomic DNA sequence downstream of the target site;

wherein the first prime editor complex causes a first nick at a sequence complementary to the first binding site and the subsequent polymerization of a first single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the first nick;

wherein the second prime editor complex causes a second nick at a sequence complementary to the second binding site and the subsequent polymerization of a second single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the second nick;

wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are reverse complements over at least a region of complementarity and form a duplex comprising an edit; and

wherein the the duplex replaces the nicked first and second complementary strands of the double-stranded DNA sequence.

74. The method of embodiment 73, wherein the prime editor of the first prime editor complex, the second prime editor complex, or both the first prime editor complex and the second prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity

75. The method of embodiment 73, wherein the first prime editor complex and the second prime editor complex comprise the same prime editor.

76. The method of embodiment 73, wherein the first prime editor complex and the second prime editor complex comprise a different prime editor.
77. The method of any one of embodiments 73-76, wherein the first and/or second napDNAbp is a Cas9 domain or variant thereof.
78. The method of any one of embodiments 73-77, wherein the first and/or second napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, a Cas9 nickase domain, or variant thereof.
79. The method of any one of embodiments 73-76, wherein the first and/or second napDNAbp is selected from the group consisting of: Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, CasX, CasY, and Argonaute.
80. The method of any one of embodiments 73-79, wherein the first and/or second napDNAbp has a nickase activity.
81. The method of any one of embodiments 73-80, wherein the first and/or second napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 18-88, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 18-88.
82. The method of any one of embodiments 73-81, wherein the first and/or second polypeptide having an RNA-dependent DNA polymerase activity is a reverse transcriptase.
83. The method of any one of embodiments 73-82, wherein the first and/or second polypeptide having an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 89-100, 105-122, 128-129, 132, 139, 143, 149, 154, 159, and 700-766 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 89-100, 105-122, 128-129, and 132.
84. The method of any one of embodiments 73-83, wherein the first prime editor further comprises a linker that joins the first napDNAbp and the first polypeptide having the RNA-

dependent DNA polymerase activity, and/or the second prime editor further comprises a linker that joins the second napDNAbp and the second polypeptide having the RNA-dependent DNA polymerase activity.

85. The method of embodiment 84, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOs: 166-177, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 166-177.
86. The method of embodiment 84 or 85, wherein the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.
87. The method of any one of embodiments 73-86, wherein the first and/or second pegRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244.
88. The method of any one of embodiments 73-87, wherein the first and/or second PEgRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244.
89. The method of any one of embodiments 73-88, wherein the first spacer sequence of the first prime editor complex binds to a first binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.
90. The method of any one of embodiments 73-89, wherein the second spacer sequence of the second prime editor complex binds to a second binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.
91. The method of embodiment 90, wherein the binding of the first and second spacer sequences of the first and second prime editor complexes in the presence of a PAM sequence results in

the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequence on each strand by the napDNABps of each first and second prime editor complex.

92. The method of embodiment 91, wherein the first and second binding sites define two ends of a contiguous region of double-stranded DNA comprising the target site to be edited.
93. The method of embodiment 92, wherein the contiguous region between the first and second binding sites is least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

94. The method of embodiment 92 or 93, wherein the contiguous region becomes replaced by the duplex comprising the edited portion.
95. The method of any one of embodiments 73-94, wherein the first and/or second DNA synthesis template is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.
96. The method of any one of embodiments 73-95, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have the same lengths.

97. The method of any one of embodiments 73-95, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have different lengths.
98. The method of any one of embodiments 73-97, wherein the region of complementarity is at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, or at least 10% of the total length of the first single-stranded DNA sequence or the second single-stranded DNA sequence.
99. The method of any one of embodiments 73-98, wherein the region of complementarity is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at

least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length, and is either less than or equal to the length of the desired DNA sequence and complement thereof.

100. The method of any one of embodiments 73-99, wherein the region of complementarity of the first single-stranded DNA sequence and the second single-stranded DNA sequence form the duplex.
101. The method of any one of embodiments 73-100, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are each single-stranded DNA strands having 3' ends.
102. The method of embodiment 94, wherein the replacement of the contiguous region by the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.
103. The method of any one of embodiments 73-102, wherein the duplex comprising an edit comprising one or more recombinase sites.
104. The method of embodiment 103 further comprising providing a recombinase to promote recombinase-mediated editing of the DNA sequence at the target site to be edited.
105. A pair of pegRNAs for use in dual prime editing, wherein the pair comprises:
 - a. a first prime editing guide RNA (first PEGRNA) that binds to a first binding site on a first strand of a double-stranded DNA sequence upstream of a target site to be edited, wherein the first PEGRNA comprises a first spacer sequence, a first gRNA core, a first DNA synthesis template, and a first primer binding site, wherein the first DNA synthesis template encodes a first single-stranded DNA sequence comprising an edited portion;
 - b. a second prime editing guide RNA (second PEGRNA) that binds to a second binding site on a second strand of the double-stranded DNA sequence downstream of the target site to be edited, wherein the second PEGRNA comprises a second spacer sequence, a second gRNA core, a second DNA synthesis template, and a second primer binding site, wherein the second DNA synthesis template encodes a second single-stranded DNA sequence comprising the edited portion, wherein the second single-stranded DNA sequence comprises a region of

complementarity to the first single-stranded DNA sequence.

106. The pair of pegRNAs of embodiment 105, wherein the first PEgRNA comprises the structure:

5'-[first gRNA spacer sequence]-[first gRNA core]-[first DNA synthesis template]-[first primer binding site]-3'; and

wherein the second PEgRNA comprises the structure:

5'-[second gRNA spacer sequence]-[second gRNA core]-[second DNA synthesis template]-[second primer binding site]-3'.

107. The pair of pegRNAs of embodiment 105 or 106, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence form a duplex that integrates into the double-stranded DNA sequence at the target site to be edited.

108. The pair of pegRNAs of embodiment 107, wherein the integration of the duplex results in an insertion, deletion, or replacement of DNA at the target site.

109. The pair of pegRNAs of embodiment 108, wherein the insertion is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least

74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

110. The pair of pegRNAs of embodiment 109, wherein the deletion is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98

nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides, or more in length.

111. The pair of pegRNAs of embodiment 110, wherein the replacement is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides, or more in length.
112. A polynucleotide encoding a pair of pegRNAs of any one of embodiments 105-111.

113. A vector comprising the polynucleotide of embodiment 112 for expressing the pair of pegRNAs in a cell.
114. A cell comprising the vector of embodiment 113.
115. A pharmaceutical composition comprising a pair of pegRNAs of any one of embodiments 105-111, a vector of embodiment 113, or a cell of embodiment 114, and a pharmaceutical excipient.
116. A pair of prime editor complexes, said pair comprises:
- a. a first prime editor complex, comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEGRNA) that binds to a first target sequence on the strand of the genomic DNA sequence upstream of the target site;
 - b. a second prime editor complex, comprising:
 - i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a second prime editing guide RNA (second PEGRNA) that binds to a second target sequence on the second strand of the genomic DNA sequence downstream of the target site.
117. The pair of prime editor complexes of embodiment 116, wherein the prime editor of the first prime editor complex, the second prime editor complex, or both the first prime editor complex and the second prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity.
118. A polynucleotide encoding a pair of prime editor complexes of embodiment 116 or 117.

119. A vector comprising the polynucleotide of embodiment 118 for expressing the pair of prime editor complexes in a cell.
120. A cell comprising the vector of embodiment 119.
121. A pharmaceutical composition comprising a pair of prime editor complexes of embodiment 116 or 117, a vector of embodiment 119, or a cell of embodiment 120, and a pharmaceutical excipient.
122. The system of any one of embodiments 1-62, or the method of any one of embodiments 68-98, wherein integration of the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.
123. The system or method of embodiment 122, wherein the insertion is a peptide tag.
124. The system or method of embodiment 123, wherein the peptide tag is a poly-histidine (e.g., HHHHHH) (SEQ ID NO: 252-262), FLAG (e.g., DYKDDDDK) (SEQ ID NO: 2), V5 (e.g., GKPIPNPLLGLDST) (SEQ ID NO: 3), GCN4, HA (e.g., YPYDVPDYA) (SEQ ID NO: 5), Myc (e.g. EQKLISEED) (SEQ ID NO: 6), or GST.
125. The system or method of embodiment 123, wherein the peptide tag has an amino acid sequence selected from the group consisting of SEQ ID NO: 1-6, 245-249, 252-262, 264-273, 275-276, 281, 278-288, and 622.
126. The system or method of embodiment 122, wherein the insertion is an immunoepitope tag.
127. The system or method of embodiment 126, wherein the immunoepitope tag is selected from the group consisting of: tetanus toxoid (SEQ ID NO: 396); diphtheria toxin mutant CRM197 (SEQ ID NO: 630); mumps immunoepitope 1 (SEQ ID NO: 400); mumps immunoepitope 2 (SEQ ID NO: 402); mumps immunoepitope 3 (SEQ ID NO: 404); rubella virus (SEQ ID NO: 406); hemagglutinin (SEQ ID NO: 408); neuraminidase (SEQ ID NO: 410); TAP1 (SEQ ID NO: 412); TAP2 (SEQ ID NO: 414); hemagglutinin epitopes toward class I HLA (SEQ ID NO: 416);

neuraminidase epitopes toward class I HLA (SEQ ID NO: 418); hemagglutinin epitopes toward class II HLA (SEQ ID NO: 420); neuraminidase epitopes toward class II HLA (SEQ ID NO: 422); hemagglutinin epitope H5N1-bound class I and class II HLA (SEQ ID NO: 424); and neuraminidase epitope H5N1-bound class I and class II HLA (SEQ ID NO: 426).

128. The system or method of embodiment 122, wherein the insertion is a dimerization domain.
129. The system or method of embodiment 128, wherein the dimerization domain is small molecule binding domain of FKBP12 of SEQ ID NO: 488, FKBP12-F36V of SEQ ID NO: 489, or cyclophilin of SEQ ID NOs: 490 or 493-494.
130. A system for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited, the system comprising:
 - a) a first prime editor complex comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (first napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEgRNA) that binds to a first binding site on a first strand of the double-stranded DNA sequence upstream of the target site to be edited;
 - b) a second prime editor complex comprising:
 - iii. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - iv. a second prime editing guide RNA (second PEgRNA) that binds to a second binding site on a second strand of the double-stranded DNA sequence upstream of the target site to be edited;
 - c) a third prime editor complex comprising:
 - iii. a third prime editor comprising a third nucleic acid programmable DNA binding protein (third napDNAbp) and a third polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - iv. a third prime editing guide RNA (third PEgRNA) that binds to a third binding site on the first strand of the double-stranded DNA sequence downstream of the target site to be edited;
 - d) a fourth prime editor complex comprising:

- iii. a fourth prime editor comprising a fourth nucleic acid programmable DNA binding protein (fourth napDNAbp) and a fourth polypeptide comprising an RNA-dependent DNA polymerase activity; and
- iv. a fourth prime editing guide RNA (fourth PEGRNA) that binds to a fourth binding site on the second strand of the double-stranded DNA sequence downstream of the target site to be edited;

wherein the first PEGRNA comprises a first DNA synthesis template encoding a first single-stranded DNA sequence, the second PEGRNA comprises a second DNA synthesis template encoding a second single-stranded DNA sequence, the third PEGRNA comprises a third DNA synthesis template encoding a third single-stranded DNA sequence, and the fourth PEGRNA comprises a fourth DNA synthesis template encoding a fourth single-stranded DNA sequence;

wherein the first and the third single-stranded DNA sequence each comprise a region of complementarity to the other; and wherein, wherein the second and the fourth single-stranded DNA sequence each comprise a region of complementarity to the other.

131. A system for editing one or more double-stranded DNA sequences, the system comprising:

e) a first prime editor complex comprising:

- iii. a first prime editor comprising a first nucleic acid programmable DNA binding protein (first napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
- iv. a first prime editing guide RNA (first PEGRNA) that binds to a first binding site on a first strand of a first double-stranded DNA sequence at a first target site to be edited;

f) a second prime editor complex comprising:

- v. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
- vi. a second prime editing guide RNA (second PEGRNA) that binds to a second binding site on a second strand of the first double-stranded DNA sequence at the first target site to be edited;

g) a third prime editor complex comprising:

- v. a third prime editor comprising a third nucleic acid programmable DNA binding protein (third napDNAbp) and a third polypeptide comprising an RNA-dependent DNA polymerase activity; and
- vi. a third prime editing guide RNA (third PEGRNA) that binds to a first binding site

on a first strand of a second double-stranded DNA sequence at a second target site to be edited;

- h) a fourth prime editor complex comprising:
 - v. a fourth prime editor comprising a fourth nucleic acid programmable DNA binding protein (fourth napDNAbp) and a fourth polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - vi. a fourth prime editing guide RNA (fourth PEGRNA) that binds to a second binding site on a second strand of the second double-stranded DNA sequence at the second target site to be edited;

wherein the first PEGRNA comprises a first DNA synthesis template encoding a first single-stranded DNA sequence, the second PEGRNA comprises a second DNA synthesis template encoding a second single-stranded DNA sequence, the third PEGRNA comprises a third DNA synthesis template encoding a third single-stranded DNA sequence, and the fourth PEGRNA comprises a fourth DNA synthesis template encoding a fourth single-stranded DNA sequence;

wherein the first and the third single-stranded DNA sequence each comprise a region of complementarity to the other; and wherein, wherein the second and the fourth single-stranded DNA sequence each comprise a region of complementarity to the other.

132. The system of embodiment 130 or 131, wherein the prime editor of the first prime editor complex, the second prime editor complex, the third prime editor complex, and/or the fourth prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity

133. The system of any one of embodiments 129-132, wherein

- (i) the first PEGRNA further comprises a first spacer sequence, first gRNA core, and a first primer binding site;
- (ii) the second PEGRNA further comprises a second spacer sequence, a second gRNA core, and a second primer binding site;
- (iii) the third PEGRNA further comprises a third spacer sequence, a third gRNA core, and a third primer binding site; and
- (iv) the fourth PEGRNA comprises a fourth spacer sequence, a fourth gRNA core, a fourth DNA synthesis template, and a fourth primer binding site.

134. The system of embodiment 131, wherein the region of complementarity of the first and third single-stranded DNA sequence, and/or the region of complementarity of the second and fourth single-

stranded DNA sequence, form a duplex.

135. the system of embodiment 134, wherein the first spacer sequence binds to the first binding site of the first double stranded DNA sequence upstream of the first target site to be edited and the second spacer sequence binds to the second binding site on the first double stranded DNA sequence downstream of the first target site to be edited.

136. the system of embodiment 134 or 135, wherein the third spacer sequence binds to the first binding site of the second double stranded DNA sequence upstream of the second target site to be edited and the forth spacer sequence binds to the second binding site on the second double stranded DNA sequence downstream of the second target site to be edited.

137. the system of any one of embodiments 134-136, wherein the first and second binding sites define two ends of a first contiguous region of the first double-stranded DNA.

138. The system of any one of embodiments 134-137, wherein the third and fourth binding sites define two ends of a second contiguous region of the second double-stranded DNA.

139. The system of embodiment 138, wherein the contiguous region between the first and second binding sites or the third and fourth binding sites is least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70

nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

140. The system of any one of embodiments 134-140, wherein the region of complementarity of the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the region of complementarity of the second single-stranded DNA sequence and the fourth single-stranded DNA sequence, form a duplex.

141. The system of embodiment 140, wherein the duplex is incorporated in the first double stranded DNA and/or the second double stranded DNA.

142. The system of any one of embodiments 134-141, wherein the system results in replacement of the first contiguous region by the second contiguous region into the first double-stranded DNA.

143. The system of any one of embodiments 134-141, wherein the system results in exchange of the first contiguous region and the second contiguous region between the first double-stranded DNA and the second double-stranded DNA.

144. The system of any one of embodiments 130-143, wherein the first prime editor complex, the second prime editor complex, the third prime editor complex, and the fourth prime editor complex comprise the same prime editor.

145. The system of any one of embodiments 130-144, wherein the first, second, third, and fourth polypeptide comprising an RNA-dependent DNA polymerase activity are the same.

146. The system of any one of embodiments 130-145, wherein the first, second, third, and/or fourth napDNAbp is a Cas9 domain or variant thereof.

147. The system of any one of embodiments 130-146, wherein the first, second, third, and/or fourth napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, or a Cas9 nickase domain or a variant thereof.
148. The system of any one of embodiments 130-147, wherein the first, second, third, and/or fourth napDNAbp is selected from the group consisting of: Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, and Argonaute.
149. The system of any one of embodiments 130-148, wherein the first, second, third, and/or fourth napDNAbp has nickase activity.
150. The system of any one of embodiments 130-149, wherein the first, second, third, and/or fourth napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 2-65, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 2-65.
151. The system of any one of embodiments 130-150, wherein the first, second, third, and/or fourth polypeptide having an RNA-dependent DNA polymerase activity is a reverse transcriptase.
152. The system of any one of embodiments 130-151, wherein the first, second, third, and/or fourth polypeptide having an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 37, 68-79, 82-98, 81, 98, and 110 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 37, 68-79, 82-98, 81, 98, and 110.
153. The system of any one of embodiments 130-152, wherein
- (i) the first prime editor further comprises a linker that joins the first napDNAbp and the first polypeptide having the RNA-dependent DNA polymerase activity;
 - (ii) the second prime editor further comprises a linker that joins the second napDNAbp and the second polypeptide having the RNA-dependent DNA polymerase activity;
 - (iii) the third prime editor further comprises a linker that joins the third napDNAbp and the third polypeptide having the RNA-dependent DNA polymerase activity; and/or
 - (iv) the fourth prime editor further comprises a linker that joins the fourth napDNAbp and the fourth polypeptide having the RNA-dependent DNA polymerase activity.

154. The system of embodiment 153, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOs: 119-128, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 119-128.
155. The system of embodiment 153 or 154, wherein the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.
156. The system of any one of embodiments 130-155, wherein the first, second, third, and/or fourth PEGRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 192-203, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 192-203.
157. The system of any one of embodiments 130-156, wherein the first spacer sequence binds to a first binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.
158. The system of any one of embodiments 130-157, wherein the second spacer sequence of the second prime editor complex binds to a second binding site on a second strand of the double-stranded DNA sequence upstream from the target site to be edited.
159. The system of any one of embodiments 130-158, wherein the third spacer sequence binds to a third binding site on a first strand of the double-stranded DNA sequence downstream from the target site to be edited.
160. The system of any one of embodiments 130-159, wherein the fourth spacer sequence of the fourth prime editor complex binds to a fourth binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.
161. The system of embodiment 160, wherein the binding of the spacer sequence of the first and second prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequences on each strand by the first and/or second napDNAbps of each first and second prime editor complexes.
162. The system of embodiment 161, wherein the binding of the spacer sequence of the third and

fourth prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequences on each strand by the third and/or fourth napDNABps of each third and fourth prime editor complexes.

163. The system of embodiment 160 or 162, wherein the first and third binding sites, or the second and fourth binding sites, define two ends of a contiguous region of double-stranded DNA.
164. The system of embodiment 163, wherein the contiguous region between the first and third binding sites or the second and fourth binding sites is least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

165. The system of any one of embodiments 130-164, wherein the region of complementarity of the first single-stranded DNA sequence and the third single-stranded DNA sequence, and/or the region of complementarity of the second single-stranded DNA sequence and the fourth single-stranded DNA sequence, form a duplex.
166. The system of embodiment 164 or 165, wherein the contiguous region becomes replaced by the duplex.
167. The system of embodiment 164 or 165, wherein the duplex is incorporated in the double-stranded DNA at the target site.
168. The system of embodiment any one of embodiments 130-167, wherein the first, second, third, and/or fourth DNA synthesis template is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91

nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

169. The system of any one of embodiments 130-168, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded DNA sequence and the fourth single-stranded DNA sequence, have the same lengths.
170. The system of any one of embodiments 130-168, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded DNA sequence and the fourth single-stranded DNA sequence, have different lengths.
171. The system of any one of embodiments 130-170, wherein the region of complementarity of the first, second, third, and/or fourth single-stranded DNA sequence is at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, or at least 10% of the total length of the first single-stranded DNA sequence and the third single-stranded DNA sequence, or the second single-stranded DNA sequence and the fourth single-stranded DNA sequence.
172. The system of any one of embodiments 130-171, wherein the region of complementarity of the first, second, third, and/or fourth single-stranded DNA sequence is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54

nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length, and is either less than or equal to the length of the first single-stranded DNA sequence and the third single-stranded DNA sequence, and the second single-stranded DNA sequence and the fourth single-stranded DNA sequence.

173. The system of any one of embodiments 130-172, wherein the first, second, third, and fourth single-stranded DNA sequence are each single-stranded DNA strands having 3' ends.
174. The system of embodiment 167, wherein the incorporation of the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.
175. A polynucleotide encoding the first, second, third, and fourth prime editors of any one of embodiments 130-174.
176. A polynucleotide encoding the first, second, third, and fourth PEGRNA of any of embodiments 130-174.
177. A vector comprising a polynucleotide of embodiment 175 or 176.
178. A cell comprising a polynucleotide of embodiment 175 or 176 or a vector of embodiment 177.

179. A pharmaceutical composition comprising a polynucleotide of embodiment 175 or 176, a vector of embodiment 177, or a cell of embodiment 178, and a pharmaceutical excipient.
180. A kit comprising a polynucleotide of embodiment 175 or 176 or a vector of embodiment 177 and instructions for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited.
181. A method for simultaneously editing first and second complementary strands of a double-stranded DNA sequence at a target site, the method comprising contacting the double-stranded DNA sequence with a pair of prime editor complexes, the pair comprising:
- (a) a first prime editor complex, comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (first napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEGRNA) that binds to a first target sequence on the first strand of the genomic DNA sequence upstream of the target site;
 - (b) a second prime editor complex, comprising:
 - i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a second prime editing guide RNA (second PEGRNA) that binds to a second target sequence on the second strand of the genomic DNA sequence upstream of the target site;
 - (c) a third prime editor complex, comprising:
 - i. a third prime editor comprising a third nucleic acid programmable DNA binding protein (third napDNAbp) and a third polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a third prime editing guide RNA (third PEGRNA) that binds to a third target sequence on the first strand of the genomic DNA sequence downstream of the target site;
 - (d) a fourth prime editor complex, comprising:
 - i. a fourth prime editor comprising a second nucleic acid programmable DNA binding protein (fourth napDNAbp) and a fourth polypeptide comprising an RNA-dependent

DNA polymerase activity; and

- ii. a fourth prime editing guide RNA (fourth PEGRNA) that binds to a fourth target sequence on the second strand of the genomic DNA sequence downstream of the target site;

wherein the first prime editor complex causes a first nick at the first target sequence and the subsequent polymerization of a first single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the first nick;

wherein the second prime editor complex causes a second nick at the second target sequence and the subsequent polymerization of a second single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the second nick;

wherein the third prime editor complex causes a third nick at the third target sequence and the subsequent polymerization of a third single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the third nick;

wherein the fourth prime editor complex causes a fourth nick at the fourth target sequence and the subsequent polymerization of a fourth single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the fourth nick;

wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are reverse complements over at least a region of complementarity and form a duplex, wherein the duplex replaces the nicked first and second complementary strands of the double-stranded DNA sequence; and

wherein the third single-stranded DNA sequence and the fourth single-stranded DNA sequence are reverse complements over at least a region of complementarity and form a duplex, wherein the duplex replaces the nicked first and second complementary strands of the double-stranded DNA sequence.

182. The method of embodiment 181, wherein the prime editor of the first prime editor complex, the second prime editor complex, the third prime editor complex, and/or the fourth prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity.

183. The method of embodiment 181 or 182, wherein the first prime editor complex, the second prime editor complex, the third prime editor complex, and the fourth prime editor complex comprise the same prime editor.

184. The method of embodiment 181 or 182, wherein the first, second, third, and/or fourth prime editor complex comprise a different prime editor.

185. The method of any one of embodiments 181-184, wherein first, second, third, and/or fourth napDNAbp is a Cas9 domain or variant thereof.
186. The method of any one of embodiments 181-185, wherein first, second, third, and/or fourth napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, or a Cas9 nickase domain or variant thereof.
187. The method of any one of embodiments 181-184, wherein the first, second, third, and/or fourth napDNAbp is selected from the group consisting of: Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c.
188. The method of any one of embodiments 181-187, wherein the first, second, third, and/or fourth napDNAbp has a nickase activity.
189. The method of any one of embodiments 181-188, wherein the first, second, third, and/or fourth napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 2-65, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 2-65.
190. The method of any one of embodiments 181-189, wherein the first, second, third, and/or fourth polypeptide having an RNA-dependent DNA polymerase activity is a reverse transcriptase.
191. The method of any one of embodiments 181-190, wherein the first, second, third, and/or fourth polypeptide having an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 37, 68-79, 82-98, 81, 98, and 110 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 37, 68-79, 82-98, 81, 98, and 110.
192. The method of any one of embodiments 181-191, wherein
- (i) the first prime editor further comprises a linker that joins the first napDNAbp and the first polypeptide having the RNA-dependent DNA polymerase activity;
 - (ii) the second prime editor further comprises a linker that joins the second napDNAbp and the second polypeptide having the RNA-dependent DNA polymerase activity;
 - (iii) the third prime editor further comprises a linker that joins the third napDNAbp

and the third polypeptide having the RNA-dependent DNA polymerase activity; and/or
(iv) the fourth prime editor further comprises a linker that joins the fourth napDNAbp
and the fourth polypeptide having the RNA-dependent DNA polymerase activity.

193. The method of embodiment 192, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOs: 119-128, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 119-128.
194. The method of embodiment 192 or 193, wherein the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.
195. The method of any one of embodiments 181-191, wherein the first, second, third, and/or fourth PEgRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 192-203, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 192-203.
196. The method of any one of embodiments 181-195, wherein the first spacer sequence of the first prime editor complex binds to a first binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.
197. The method of any one of embodiments 181-196, wherein the second spacer sequence of the second prime editor complex binds to a second binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.
198. The method of any one of embodiments 181-197, wherein the third spacer sequence of the third prime editor complex binds to a third binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.
199. The method of any one of embodiments 181-198, wherein the fourth spacer sequence of the fourth prime editor complex binds to a fourth binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.
200. The method of embodiment 197, wherein the binding of the first and second spacer sequences of the first and second prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequence

on each strand by the napDNAbs of each first and second prime editor complex.

201. The method of embodiment 199, wherein the binding of the third and fourth spacer sequences of the third and fourth prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequence on each strand by the napDNAbs of each third and fourth prime editor complex.
202. The method of embodiment 200 or 201, wherein the first and second binding sites, and/or the third and fourth binding sites, define two ends of a contiguous region of double-stranded DNA comprising the target site to be edited.
203. The method of embodiment 202, wherein the contiguous region between the first and second binding sites, and/or the contiguous region between the third and fourth binding sites, is at least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95

nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

204. The method of embodiment 202 or 203, wherein the contiguous region becomes replaced by the duplex.

205. The method of any one of embodiments 181-204, wherein the first, second, third, and/or fourth DNA synthesis template is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107

nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

206. The method of any one of embodiments 181-205, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded-DNA sequence and the fourth single-stranded DNA sequence, have the same lengths.
207. The method of any one of embodiments 181-206, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded-DNA sequence and the fourth single-stranded DNA sequence, have different lengths.
208. The method of any one of embodiments 181-207, wherein the region of complementarity is at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, or at least 10% of the total length of the first single-stranded DNA sequence and the second single-stranded DNA sequence, or the third single-stranded DNA sequence and the fourth single-stranded DNA sequence.
209. The method of any one of embodiments 181-208, wherein the region of complementarity is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77

nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

210. The method of any one of embodiments 181-209, wherein the region of complementarity of the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded-DNA sequence and the fourth single-stranded DNA sequence, form the duplex.
211. The method of any one of embodiments 181-210, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded-DNA sequence and the fourth single-stranded DNA sequence, are each single-stranded DNA strands having 3' ends.
212. The method of embodiment 204, wherein the replacement of the contiguous region by the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.
213. The method of any one of embodiments 181-212, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are on ends of a target DNA sequence, and wherein the third single-stranded DNA sequence and the fourth single-stranded DNA sequence are on opposite ends of the same target DNA sequence.
214. The method of embodiment 213, wherein the target DNA sequence is inverted.
215. The method of any one of embodiments 181-214 further comprising providing a circular DNA donor.
216. The method of embodiment 215, wherein the first single-stranded DNA sequence and the third single-stranded DNA sequence are on opposite ends of the target DNA sequence, and

wherein the second single-stranded DNA sequence and the fourth single-stranded DNA sequence are on the circular DNA donor.

217. The method of embodiment 216, wherein a portion of the circular DNA donor between the second single-stranded DNA sequence and the fourth single-stranded DNA sequence replaces the target sequence between the first single-stranded DNA sequence and the third single-stranded DNA sequence.
218. The method of any one of embodiments 181-214, wherein the first single-stranded DNA sequence and the third single-stranded DNA sequence are on a first nucleic acid molecule, and wherein the second single-stranded DNA sequence and the fourth single-stranded DNA sequence are on a second nucleic acid molecule.
219. The method of embodiment 218, wherein a portion of the first nucleic acid molecule between the first single-stranded DNA sequence and the third single-stranded DNA sequence is incorporated into the second nucleic acid molecule, and wherein a portion of the second nucleic acid molecule between the second single-stranded DNA sequence and the fourth single-stranded DNA sequence is incorporated into the first nucleic acid molecule.
220. The method of embodiment 218 or 219, wherein the first nucleic acid molecule is a first chromosome, and the second nucleic acid molecule is a second chromosome.
221. A set of PEGRNAs for use in multi-flap prime editing, wherein the PEGRNAs comprise:
- (a) a first prime editing guide RNA (first PEGRNA) that binds to a first binding site on a first strand of a double-stranded DNA sequence upstream of a target site to be edited, wherein the first PEGRNA comprises a first spacer sequence, first gRNA core, a first DNA synthesis template, and a first primer binding site, wherein the first DNA synthesis template encodes a first single-stranded DNA sequence;
 - (b) a second prime editing guide RNA (second PEGRNA) that binds to a second binding site on a second strand of the double-stranded DNA sequence upstream of the target site to be edited, wherein the second PEGRNA comprises a second spacer sequence, second gRNA core, a second DNA synthesis template, and a second primer binding site, wherein the second DNA synthesis template encodes a second single-stranded DNA sequence comprising the edited portion, wherein the second single-stranded DNA sequence is complementary to the first single-stranded DNA sequence.
 - (c) a third prime editing guide RNA (third PEGRNA) that binds to a third binding site on

a first strand of a double-stranded DNA sequence downstream of a target site to be edited, wherein the third PEgRNA comprises a third spacer sequence, third gRNA core, a third DNA synthesis template, and a third primer binding site, wherein the third DNA synthesis template encodes a third single-stranded DNA sequence;

(d) a fourth prime editing guide RNA (fourth PEgRNA) that binds to a fourth binding site on a second strand of the double-stranded DNA sequence downstream of the target site to be edited, wherein the fourth PEgRNA comprises a fourth spacer sequence, fourth gRNA core, a fourth DNA synthesis template, and a fourth primer binding site, wherein the fourth DNA synthesis template encodes a fourth single-stranded DNA sequence, wherein the fourth single-stranded DNA sequence comprises a region of complementarity to the third single-stranded DNA sequence.

222. The set of PEgRNAs of embodiment 221, wherein the first PEgRNA comprises the structure:

5'-[first gRNA spacer sequence]-[first gRNA core]-[first DNA synthesis template]-[first primer binding site]-3';

the second PEgRNA comprises the structure:

5'-[second gRNA spacer sequence]-[second gRNA core]-[second DNA synthesis template]-[second primer binding site]-3';

the third PEgRNA comprises the structure:

5'-[third gRNA spacer sequence]-[third gRNA core]-[third DNA synthesis template]-[third primer binding site]-3'; and

the fourth PEgRNA comprises the structure:

5'-[fourth gRNA spacer sequence]-[fourth gRNA core]-[fourth DNA synthesis template]-[fourth primer binding site]-3'.

223. The set of PEgRNAs of embodiment 221 or 222, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded DNA sequence and the fourth single-stranded DNA sequence, form a duplex that becomes integrated into the double-stranded DNA sequence at the target site to be edited.

224. The set of PEgRNAs of any one of embodiments 221-223, wherein the integration of the duplex results in an insertion, deletion, or replacement of DNA at the target site.

225. The set of PEgRNAs of embodiment 224, wherein the insertion is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6

nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

226. The set of PEGRNAs of embodiment 224, wherein the deletion is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides is at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30

nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides, or more in length.

227. The set of PEGRNAs of embodiment 224, wherein the replacement is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58

nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides, or more in length.

228. A polynucleotide encoding a set of PEgRNAs of any of embodiments 221-227.
229. A vector comprising the polynucleotide of embodiment 228 for expressing the plurality of PEgRNAs in a cell.
230. A cell comprising the vector of embodiment 229.
231. A pharmaceutical composition comprising the plurality of PEgRNAs of any one of embodiments 221-227, a vector of embodiment 229, or a cell of embodiment 230, and a pharmaceutical excipient.
232. A method for modifying a genome in a cell, comprising:
- (i) contacting a genome with a dual-flap prime editing system, said system comprising a first prime editor/pegRNA complex capable of installing a first 3' nucleic acid flap at a first nick site on a first strand of a target site and a second prime editor/pegRNA complex capable of installing a second 3' nucleic acid flap at a second nick site on a second strand of a target site, wherein the first 3' nucleic acid flap and the second 3' nucleic acid flap are reverse complement sequences that form a duplex, and wherein the duplex comprises a first recombinase site, and wherein the cell installs the duplex comprising the first recombinase site at the target site in place of an endogenous duplex positioned between the

- first and second nick sites;
- (ii) contacting the first recombinase site with a donor nucleic acid comprising a second recombinase site; and
- (iii) contacting the genome with a recombinase capable recombination between the first and second recombinase sites, thereby integrating the donor nucleic acid at the target site in the genome.

[9] Methods

Methods for multi-flap prime editing

[0954] In one aspect, the present disclosure provides methods for simultaneously editing a first and a second complementary strands of a double-stranded DNA sequence at a target site, said method comprising contacting the double-stranded DNA sequence with a pair of prime editor complexes, said pair comprising:

- a. a first prime editor complex, comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEgRNA) that binds to a first binding site on the first strand of the genomic DNA sequence upstream of the target site;
- b. a second prime editor complex, comprising:
 - i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a second prime editing guide RNA (second PEgRNA) that binds to a second binding site on the second strand of the genomic DNA sequence downstream of the target site;

wherein the first prime editor complex causes a first nick at a sequence complementary to the first binding site and the subsequent polymerization of a first single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the first nick;

wherein the second prime editor complex causes a second nick at a sequence complementary to the second binding site and the subsequent polymerization of a second single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the second nick;

wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are reverse complements over at least a region of complementarity and form a duplex comprising an edit; and

wherein the the duplex replaces the nicked first and second complementary strands of the double-stranded DNA sequence.

[0955] In another aspect, the present disclosure provides methods for simultaneously editing first and second complementary strands of a double-stranded DNA sequence at a target site, the method comprising contacting the double-stranded DNA sequence with a pair of prime editor complexes, the pair comprising:

(a) a first prime editor complex, comprising:

i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (first napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and

ii. a first prime editing guide RNA (first PEgRNA) that binds to a first target sequence on the first strand of the genomic DNA sequence upstream of the target site;

(b) a second prime editor complex, comprising:

i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and

ii. a second prime editing guide RNA (second PEgRNA) that binds to a second target sequence on the second strand of the genomic DNA sequence upstream of the target site;

(c) a third prime editor complex, comprising:

i. a third prime editor comprising a third nucleic acid programmable DNA binding protein (third napDNAbp) and a third polypeptide comprising an RNA-dependent DNA polymerase activity; and

ii. a third prime editing guide RNA (third PEgRNA) that binds to a third target sequence on the first strand of the genomic DNA sequence downstream of the target site;

(d) a fourth prime editor complex, comprising:

i. a fourth prime editor comprising a second nucleic acid programmable DNA binding protein (fourth napDNAbp) and a fourth polypeptide comprising an RNA-dependent DNA polymerase activity; and

ii. a fourth prime editing guide RNA (fourth PEgRNA) that binds to a fourth target sequence on the second strand of the genomic DNA sequence downstream of the target site;

wherein the first prime editor complex causes a first nick at the first target sequence and the subsequent polymerization of a first single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the first nick;

wherein the second prime editor complex causes a second nick at the second target sequence and the subsequent polymerization of a second single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the second nick;

wherein the third prime editor complex causes a third nick at the third target sequence and the subsequent polymerization of a third single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the third nick;

wherein the fourth prime editor complex causes a fourth nick at the fourth target sequence and the subsequent polymerization of a fourth single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the fourth nick;

wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are reverse complements over at least a region of complementarity and form a duplex, wherein the duplex replaces the nicked first and second complementary strands of the double-stranded DNA sequence; and

wherein the third single-stranded DNA sequence and the fourth single-stranded DNA sequence are reverse complements over at least a region of complementarity and form a duplex, wherein the duplex replaces the nicked first and second complementary strands of the double-stranded DNA sequence.

[0956] This Specification describes multi-flap prime editing systems (including, for example, a dual-flap prime editing system and a quadruple-flap prime editing system) that address the challenges associated with flap equilibration and subsequent incorporation of the edit into the non-edited complementary genomic DNA strand by simultaneously editing both DNA strands. In the dual-flap prime editing system, two PEGRNAs are used to target opposite strands of a genomic site and direct the synthesis of two complementary 3' flaps containing edited DNA sequence (**FIG. 90**). In the quadruple-flap prime editing system, four PEGRNAs are used and direct the synthesis of four 3' flaps, two of which are complementary to one another and the other two of which are complementary to one another (**FIG. 95**, **FIG. 96A**, and **FIG. 98A**). Unlike classical prime editing, there is no requirement for the pair of edited DNA strands (3' flaps) to directly compete with 5' flaps in endogenous genomic DNA, as the complementary edited strand is available for hybridization instead. Since both strands of the duplex are synthesized as edited DNA, the multi-flap prime editing system obviates the need for the replacement of the non-edited complementary DNA strand required by classical prime editing. Instead, cellular DNA repair machinery need only excise the paired 5' flaps (original genomic DNA) and ligate the paired 3' flaps (edited DNA) into the locus. Therefore, there is also no need to include sequences homologous to genomic DNA in the newly synthesized DNA strands, allowing selective hybridization of the new strands and facilitating edits that contain minimal genomic homology. Nuclease-active versions of multi-flap prime editors that cut both strands of DNA could also be used to accelerate the removal of the original DNA sequence.

[0957] Like classical prime editing, multi-flap prime editing is a versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a nucleic acid programmable DNA binding protein (“napDNAbp”) working in association with a polymerase (i.e., in the form of a fusion protein or otherwise provided *in trans* with the napDNAbp), wherein the prime editing system is programmed with a prime editing (PE) guide RNA (“PEgRNA”) that both specifies the target site and templates the synthesis of the desired edit in the form of a replacement DNA strand by way of an extension (either DNA or RNA) engineered onto a guide RNA (e.g., at the 5′ or 3′ end, or at an internal portion of a guide RNA). The replacement strand containing the desired edit (e.g., a single nucleobase substitution) shares the same sequence as the endogenous strand of the target site to be edited (with the exception that it includes the desired edit). Through DNA repair and/or replication machinery, the endogenous strand of the target site is replaced by the newly synthesized replacement strand containing the desired edit. In some cases, prime editing may be thought of as a “search-and-replace” genome editing technology since the dual prime editors, as described herein, not only search and locate the desired target site to be edited, but at the same time, encode a replacement strand containing a desired edit which is installed in place of the corresponding target site endogenous DNA strand.

[0958] In dual-flap prime editing, a double-stranded DNA sequence is contacted at a target site with a first and a second prime editor complex. Each complex comprises a fusion protein and a PEgRNA. In some embodiments, each fusion protein comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a polypeptide having an RNA-dependent DNA polymerase activity (e.g., a reverse transcriptase), and each PEgRNA comprises a spacer sequence, a gRNA core, a DNA synthesis template, and a primer binding site. Each DNA synthesis template can encode a single-stranded DNA sequence, which may comprise an edited portion of one or more nucleotides. The two single-stranded DNA sequences encoded may be complementary to one another and form a duplex, which can integrate into the target site to be edited. The various elements of the prime editor complexes (e.g., fusion proteins, napDNAbp, polymerase, PEgRNAs, etc.) may comprise any of the embodiments of the systems disclosed herein.

[0959] In quadruple-flap prime editing, a double-stranded DNA sequence is contacted at a target site with a first, a second, a third, and a fourth prime editor complex. Each complex comprises a fusion protein and a PEgRNA. In some embodiments, each fusion protein comprises a nucleic acid programmable DNA binding protein (napDNAbp) and a polypeptide having an RNA-dependent DNA polymerase activity (e.g., a reverse transcriptase), and each PEgRNA comprises a spacer sequence, a gRNA core, a DNA synthesis template, and a primer binding site. Each DNA synthesis template encodes a single-stranded DNA sequence. The two single-stranded DNA sequences encoded may be complementary to one another and form a duplex, which can integrate into the target site to be edited.

The various elements of the prime editor complexes (e.g., fusion proteins, napDNAbp, polymerase, PEGRNAs, etc.) may comprise any of the embodiments of the systems disclosed herein.

[0960] The methods for multi-flap prime editing provided herein can be used for numerous applications. For example, they can be used to facilitate the inversion of a target DNA sequence. In this application, a first single-stranded DNA sequence encoded by the DNA synthesis template of the first PEGRNA and a second single-stranded DNA sequence encoded by the DNA synthesis template of the second PEGRNA are on opposite ends of a target DNA sequence, and a third single-stranded DNA sequence encoded by the DNA synthesis template of the third PEGRNA and a fourth single-stranded DNA sequence encoded by the DNA synthesis template of a fourth PEGRNA are on opposite ends of the same target DNA sequence.

[0961] In some embodiments, the methods for multi-flap prime editing provided herein further comprise providing a circular DNA donor, part of which can be integrated into a double-stranded nucleic acid at a target site. In this application, a first single-stranded DNA sequence encoded by the DNA synthesis template of the first PEGRNA and a third single-stranded DNA sequence encoded by the DNA synthesis template of the third PEGRNA are on opposite ends of the target DNA sequence, and a second single-stranded DNA sequence encoded by the DNA synthesis template of the second PEGRNA and a fourth single-stranded DNA sequence encoded by the DNA synthesis template of the fourth PEGRNA are on the circular DNA donor. The portion of the circular DNA donor between the second single-stranded DNA sequence and the fourth single-stranded DNA sequence can form a duplex, which replaces the target DNA sequence between the first single-stranded DNA sequence and the third single-stranded DNA sequence.

[0962] In another application, the methods for multi-flap prime editing provided herein allow for translocation of a target DNA sequence from a first nucleic acid molecule (e.g., a first chromosome) to a second nucleic acid molecule (e.g., a second chromosome). In this application, a first single-stranded DNA sequence encoded by the DNA synthesis template of the first PEGRNA and a third single-stranded DNA sequence encoded by the DNA synthesis template of the third PEGRNA are on a first nucleic acid molecule, and a second single-stranded DNA sequence encoded by the DNA synthesis template of the second PEGRNA and a fourth single-stranded DNA sequence encoded by the DNA synthesis template of the fourth PEGRNA are on a second nucleic acid molecule. The portion of the first nucleic acid molecule between the first single-stranded DNA sequence and the third single-stranded DNA sequence can be incorporated into the second nucleic acid molecule, and the portion of the second nucleic acid molecule between the second single-stranded DNA sequence and the fourth single-stranded DNA sequence is incorporated into the first nucleic acid molecule.

Other Methods

[0963] The instant disclosure provides methods for the treatment of a subject diagnosed with a disease associated with or caused by a point mutation, or other mutations (e.g., deletion, insertion,

inversion, duplication, etc.) that can be corrected by the multi-flap prime editing system provided herein, as exemplified, but not limited to prion disease (e.g., Example 5 herein), trinucleotide repeat expansion disease (e.g., Example 3 herein), or CDKL5 Deficiency Disorder (CDD) (e.g., Example 23 herein).

[0964] Virtually any disease-causing genetic defect may be repaired by using multi-flap prime editing, which includes the selection of an appropriate prime editor fusion protein (including a napDNAp and a polymerase (e.g., a reverse transcriptase), and designing of an appropriate PEGRNA designed to (a) target the appropriate target DNA containing an edit site, and (b) provide a template for the synthesis of a single strand of DNA from the 3' end of the nick site that includes the desired edit which displaces and replaces the endogenous strand immediately downstream of the nick site. Multi-flap prime editing can be used, without limitation, to (a) install mutation-correcting changes to a nucleotide sequence, (b) install protein and RNA tags, (c) install immunopeptides on proteins of interest, (d) install inducible dimerization domains in proteins, (e) install or remove sequences to alter that activity of a biomolecule, (f) install recombinase target sites to direct specific genetic changes, and (g) mutagenesis of a target sequence by using an error-prone RT.

[0965] The method of treating a disorder can involve as an early step the design of an appropriate PEGRNA and prime editor fusion protein in accordance with the methods described herein, which include a number of considerations that may be taken into account, such as:

- (a) the target sequence, i.e., the nucleotide sequence in which one or more nucleobase modifications are desired to be installed by the prime editor;
- (b) the location of the cut site within the target sequence, i.e., the specific nucleobase position at which the prime editor will induce a single-strand nick to create a 3' end RT primer sequence on one side of the nick and the 5' end endogenous flap on the other side of the nick (which ultimately is removed by FEN1 or equivalent thereto and replaced by the 3' ssDNA flap. The cut site creates the 3' end primer sequence which becomes extended by the polymerase of the PE fusion protein (e.g., a RT enzyme) during RNA-dependent DNA polymerization to create the 3' ssDNA flap containing the desired edit, which then replaces the 5' endogenous DNA flap in the target sequence.
- (c) the available PAM sequences (including the canonical SpCas9 PAM sites, as well as non-canonical PAM sites recognized by Cas9 variants and equivalents with expanded or differing PAM specificities);
- (d) the spacing between the available PAM sequences and the location of the cut site in the PAM strand;
- (e) the particular Cas9, Cas9 variant, or Cas9 equivalent of the prime editor available to be used (which in part is dictated by the available PAM);
- (f) the sequence and length of the primer binding site;
- (g) the sequence and length of the edit template;

- (h) the sequence and length of the homology arm;
- (i) the spacer sequence and length; and
- (j) the gRNA core sequence.

[0966] A suitable PEgRNA, and optionally a nicking-sgRNA design guide for second-site nicking, can be designed by way of the following exemplarily step-by-step set of instructions which takes into account one or more of the above considerations. The steps reference the examples shown in FIGs. 70A-70I.

1. **Define the target sequence and the edit.** Retrieve the sequence of the target DNA region (~200bp) centered around the location of the desired edit (point mutation, insertion, deletion, or combination thereof). See FIG. 70A.
2. **Locate target PAMs.** Identify PAMs in the proximity to the desired edit location. PAMs can be identified on either strand of DNA proximal to the desired edit location. While PAMs close to the edit position are preferred (i.e., wherein the nick site is less than 30 nt from the edit position, or less than 29 nt, 28 nt, 27 nt, 26 nt, 25 nt, 24 nt, 23 nt, 22 nt, 21 nt, 20 nt, 19 nt, 18 nt, 17 nt, 16 nt, 15 nt, 14 nt, 13 nt, 12 nt, 11 nt, 10 nt, 9 nt, 8 nt, 7 nt, 6 nt, 5 nt, 4 nt, 3 nt, or 2 nt from the edit position to the nick site), it is possible to install edits using protospacers and PAMs that place the nick ≥ 30 nt from the edit position. See FIG. 70B.
3. **Locate the nick sites.** For each PAM being considered, identify the corresponding nick site and on which strand. For Sp Cas9 H840A nickase, cleavage occurs in the PAM-containing strand between the 3rd and 4th bases 5' to the NGG PAM. All edited nucleotides must exist 3' of the nick site, so appropriate PAMs must place the nick 5' to the target edit on the PAM-containing strand. In the example shown below, there are two possible PAMs. For simplicity, the remaining steps will demonstrate the design of a PEgRNA using PAM 1 only. See FIG. 70C.
4. **Design the spacer sequence.** The protospacer of SpCas9 corresponds to the 20 nucleotides 5' to the NGG PAM on the PAM-containing strand. Efficient Pol III transcription initiation requires a G to be the first transcribed nucleotide. If the first nucleotide of the protospacer is a G, the spacer sequence for the PEgRNA is simply the protospacer sequence. If the first nucleotide of the protospacer is not a G, the spacer sequence of the PEgRNA is G followed by the protospacer sequence. See FIG. 70D.
5. **Design a primer binding site (PBS).** Using the starting allele sequence, identify the DNA primer on the PAM-containing strand. The 3' end of the DNA primer is the nucleotide just upstream of the nick site (i.e. the 4th base 5' to the NGG PAM for Sp Cas9). As a general design principle for use with PE2 and PE3, a PEgRNA primer binding site (PBS) containing 12 to 13 nucleotides of complementarity to the DNA primer can be used for sequences that contain ~40-60% GC content. For sequences with low GC content, longer (14- to 15-nt) PBSs

should be tested. For sequences with higher GC content, shorter (8- to 11-nt) PBSs should be tested. Optimal PBS sequences should be determined empirically, regardless of GC content. To design a length- p PBS sequence, take the reverse complement of the first p nucleotides 5' of the nick site in the PAM-containing strand using the starting allele sequence. See FIG. 70E.

6. **Design an RT template (or DNA synthesis template).** The RT template (or DNA synthesis template where the polymerase is not reverse transcriptase) encodes the designed edit and homology to the sequence adjacent to the edit. In one embodiment, these regions correspond to the DNA synthesis template of FIG. 3D and FIG. 3E, wherein the DNA synthesis template comprises the “edit template” and the “homology arm.” Optimal RT template lengths vary based on the target site. For short-range edits (positions +1 to +6), it is recommended to test a short (9 to 12 nt), a medium (13 to 16 nt), and a long (17 to 20 nt) RT template. For long-range edits (positions +7 and beyond), it is recommended to use RT templates that extend at least 5 nt (preferably 10 or more nt) past the position of the edit to allow for sufficient 3' DNA flap homology. For long-range edits, several RT templates should be screened to identify functional designs. For larger insertions and deletions (≥ 5 nt), incorporation of greater 3' homology (~ 20 nt or more) into the RT template is recommended. Editing efficiency is typically impaired when the RT template encodes the synthesis of a G as the last nucleotide in the reverse transcribed DNA product (corresponding to a C in the RT template of the PEGRNA). As many RT templates support efficient prime editing, avoidance of G as the final synthesized nucleotide is recommended when designing RT templates. To design a length- r RT template sequence, use the desired allele sequence and take the reverse complement of the first r nucleotides 3' of the nick site in the strand that originally contained the PAM. Note that compared to SNP edits, insertion or deletion edits using RT templates of the same length will not contain identical homology. See FIG. 70F.
7. **Assemble the full PEGRNA sequence.** Concatenate the PEGRNA components in the following order (5' to 3'): spacer, scaffold, RT template and PBS. See FIG. 70G.
8. **Designing nicking-sgRNAs for PE3.** Identify PAMs on the non-edited strand upstream and downstream of the edit. Optimal nicking positions are highly locus-dependent and should be determined empirically. In general, nicks placed 40 to 90 nucleotides 5' to the position across from the PEGRNA-induced nick lead to higher editing yields and fewer indels. A nicking sgRNA has a spacer sequence that matches the 20-nt protospacer in the starting allele, with the addition of a 5'-G if the protospacer does not begin with a G. See FIG. 70H.
9. **Designing PE3b nicking-sgRNAs.** If a PAM exists in the complementary strand and its corresponding protospacer overlaps with the sequence targeted for editing, this edit could be a candidate for the PE3b system. In the PE3b system, the spacer sequence of the nicking-

sgRNA matches the sequence of the desired edited allele, but not the starting allele. The PE3b system operates efficiently when the edited nucleotide(s) falls within the seed region (~10 nt adjacent to the PAM) of the nicking-sgRNA protospacer. This prevents nicking of the complementary strand until after installation of the edited strand, preventing competition between the PEgRNA and the sgRNA for binding the target DNA. PE3b also avoids the generation of simultaneous nicks on both strands, thus reducing indel formation significantly while maintaining high editing efficiency. PE3b sgRNAs should have a spacer sequence that matches the 20-nt protospacer in the *desired* allele, with the addition of a 5' G if needed. See FIG. 70I.

[0967] The above step-by-step process for designing a suitable PEgRNA and a second-site nicking sgRNA is not meant to be limiting in any way. The disclosure contemplates variations of the above-described step-by-step process which would be derivable therefrom by a person of ordinary skill in the art.

[0968] Once a suitable PEgRNA and PE fusion protein are selected/designed, they may be administered by a suitable methodology, such as by vector-based transfection (in which one or more vectors comprising DNA encoding the PEgRNA and the PE fusion protein and which are expressed within a cell upon transfection with the vectors), direct delivery of the PE fusion protein complexed with the PEgRNA (e.g., RNP delivery) in a delivery format (e.g., lipid particles, nanoparticles), or by a mRNA-based delivery system. Such methods are described herein in the present disclosure and any known method may be utilized.

[0969] The PEgRNA and PE fusion protein (or together, referred to as the PE complex) can be delivered to a cell in a therapeutically effective amount such that upon contacting the target DNA of interest, the desired edit becomes installed therein.

[0970] Any disease is conceivably treatable by such methods so long as delivery to the appropriate cells is feasible. The person having ordinary skill in the art will be able to choose and/or select a PE delivery methodology to suit the intended purpose and the intended target cells.

[0971] For example, in some embodiments, a method is provided that comprises administering to a subject having such a disease, e.g., a cancer associated with a point mutation as described above, an effective amount of the multi-flap prime editing system described herein that corrects the point mutation or introduces a deactivating mutation into a disease-associated gene as mediated by homology-directed repair in the presence of a donor DNA molecule comprising desired genetic change. In some embodiments, a method is provided that comprises administering to a subject having such a disease, e.g., a cancer associated with a point mutation as described above, an effective amount of the multi-flap prime editing system described herein that corrects the point mutation or introduces a deactivating mutation into a disease-associated gene. In some embodiments, the disease is a proliferative disease. In some embodiments, the disease is a genetic disease. In some embodiments,

the disease is a neoplastic disease. In some embodiments, the disease is a metabolic disease. In some embodiments, the disease is a lysosomal storage disease. Other diseases that can be treated by correcting a point mutation or introducing a deactivating mutation into a disease-associated gene will be known to those of skill in the art, and the disclosure is not limited in this respect.

[0972] The instant disclosure provides methods for the treatment of additional diseases or disorders, e.g., diseases or disorders that are associated or caused by a point mutation that can be corrected by TPRT-mediated gene editing. Some such diseases are described herein, and additional suitable diseases that can be treated with the strategies and fusion proteins provided herein will be apparent to those of skill in the art based on the instant disclosure. Exemplary suitable diseases and disorders are listed below. It will be understood that the numbering of the specific positions or residues in the respective sequences depends on the particular protein and numbering scheme used. Numbering might be different, e.g., in precursors of a mature protein and the mature protein itself, and differences in sequences from species to species may affect numbering. One of skill in the art will be able to identify the respective residue in any homologous protein and in the respective encoding nucleic acid by methods well known in the art, e.g., by sequence alignment and determination of homologous residues. Exemplary suitable diseases and disorders include, without limitation: 2-methyl-3-hydroxybutyric aciduria; 3 beta-Hydroxysteroid dehydrogenase deficiency; 3-Methylglutaconic aciduria; 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency; 46,XY sex reversal, type 1, 3, and 5; 5-Oxoprolinase deficiency; 6-pyruvoyl-tetrahydropterin synthase deficiency; Aarskog syndrome; Aase syndrome; Achondrogenesis type 2; Achromatopsia 2 and 7; Acquired long QT syndrome; Acrocallosal syndrome, Schinzel type; Acrocapitofemoral dysplasia; Acrodysostosis 2, with or without hormone resistance; Acroerythrokeratoderma; Acromicric dysplasia; Acth-independent macronodular adrenal hyperplasia 2; Activated PI3K-delta syndrome; Acute intermittent porphyria; deficiency of Acyl-CoA dehydrogenase family, member 9; Adams-Oliver syndrome 5 and 6; Adenine phosphoribosyltransferase deficiency; Adenylate kinase deficiency; hemolytic anemia due to Adenylosuccinate lyase deficiency; Adolescent nephronophthisis; Renal-hepatic-pancreatic dysplasia; Meckel syndrome type 7; Adrenoleukodystrophy; Adult junctional epidermolysis bullosa; Epidermolysis bullosa, junctional, localisata variant; Adult neuronal ceroid lipofuscinosis; Adult neuronal ceroid lipofuscinosis; Adult onset ataxia with oculomotor apraxia; ADULT syndrome; Afibrinogenemia and congenital Afibrinogenemia; autosomal recessive Agammaglobulinemia 2; Age-related macular degeneration 3, 6, 11, and 12; Aicardi Goutieres syndromes 1, 4, and 5; Chilbain lupus 1; Alagille syndromes 1 and 2; Alexander disease; Alkaptonuria; Allan-Herndon-Dudley syndrome; Alopecia universalis congenital; Alpers encephalopathy; Alpha-1-antitrypsin deficiency; autosomal dominant, autosomal recessive, and X-linked recessive Alport syndromes; Alzheimer disease, familial, 3, with spastic paraparesis and apraxia; Alzheimer disease, types, 1, 3, and 4; hypocalcification type and hypomaturational type, IIA1 Amelogenesis imperfecta; Aminoacylase 1

deficiency; Amish infantile epilepsy syndrome; Amyloidogenic transthyretin amyloidosis; Amyloid
 Cardiomyopathy, Transthyretin-related; Cardiomyopathy; Amyotrophic lateral sclerosis types 1, 6, 15
 (with or without frontotemporal dementia), 22 (with or without frontotemporal dementia), and 10;
 Frontotemporal dementia with TDP43 inclusions, TARDBP-related; Andermann syndrome; Andersen
 Tawil syndrome; Congenital long QT syndrome; Anemia, nonspherocytic hemolytic, due to G6PD
 deficiency; Angelman syndrome; Severe neonatal-onset encephalopathy with microcephaly;
 susceptibility to Autism, X-linked 3; Angiopathy, hereditary, with nephropathy, aneurysms, and
 muscle cramps; Angiotensin i-converting enzyme, benign serum increase; Aniridia, cerebellar ataxia,
 and mental retardation; Anonychia; Antithrombin III deficiency; Antley-Bixler syndrome with genital
 anomalies and disordered steroidogenesis; Aortic aneurysm, familial thoracic 4, 6, and 9; Thoracic
 aortic aneurysms and aortic dissections; Multisystemic smooth muscle dysfunction syndrome;
 Moyamoya disease 5; Aplastic anemia; Apparent mineralocorticoid excess; Arginase deficiency;
 Argininosuccinate lyase deficiency; Aromatase deficiency; Arrhythmogenic right ventricular
 cardiomyopathy types 5, 8, and 10; Primary familial hypertrophic cardiomyopathy; Arthrogryposis
 multiplex congenita, distal, X-linked; Arthrogryposis renal dysfunction cholestasis syndrome;
 Arthrogryposis, renal dysfunction, and cholestasis 2; Asparagine synthetase deficiency; Abnormality
 of neuronal migration; Ataxia with vitamin E deficiency; Ataxia, sensory, autosomal dominant;
 Ataxia-telangiectasia syndrome; Hereditary cancer-predisposing syndrome; Atransferrinemia; Atrial
 fibrillation, familial, 11, 12, 13, and 16; Atrial septal defects 2, 4, and 7 (with or without
 atrioventricular conduction defects); Atrial standstill 2; Atrioventricular septal defect 4; Atrophia
 bulborum hereditaria; ATR-X syndrome; Auriculocondylar syndrome 2; Autoimmune disease,
 multisystem, infantile-onset; Autoimmune lymphoproliferative syndrome, type 1a; Autosomal
 dominant hypohidrotic ectodermal dysplasia; Autosomal dominant progressive external
 ophthalmoplegia with mitochondrial DNA deletions 1 and 3; Autosomal dominant torsion dystonia 4;
 Autosomal recessive centronuclear myopathy; Autosomal recessive congenital ichthyosis 1, 2, 3, 4A,
 and 4B; Autosomal recessive cutis laxa type IA and 1B; Autosomal recessive hypohidrotic ectodermal
 dysplasia syndrome; Ectodermal dysplasia 11b; hypohidrotic/hair/tooth type, autosomal recessive;
 Autosomal recessive hypophosphatemic bone disease; Axenfeld-Rieger syndrome type 3; Bainbridge-
 Ropers syndrome; Bannayan-Riley-Ruvalcaba syndrome; PTEN hamartoma tumor syndrome;
 Baraitser-Winter syndromes 1 and 2; Barakat syndrome; Bardet-Biedl syndromes 1, 11, 16, and 19;
 Bare lymphocyte syndrome type 2, complementation group E; Bartter syndrome antenatal type 2;
 Bartter syndrome types 3, 3 with hypocalciuria, and 4; Basal ganglia calcification, idiopathic, 4;
 Beaded hair; Benign familial hematuria; Benign familial neonatal seizures 1 and 2; Seizures, benign
 familial neonatal, 1, and/or myokymia; Seizures, Early infantile epileptic encephalopathy 7; Benign
 familial neonatal-infantile seizures; Benign hereditary chorea; Benign scapuloperoneal muscular
 dystrophy with cardiomyopathy; Bernard-Soulier syndrome, types A1 and A2 (autosomal dominant);

Bestrophinopathy, autosomal recessive; beta Thalassemia; Bethlem myopathy and Bethlem myopathy 2; Bietti crystalline corneoretinal dystrophy; Bile acid synthesis defect, congenital, 2; Biotinidase deficiency; Birk Barel mental retardation dysmorphism syndrome; Blepharophimosis, ptosis, and epicanthus inversus; Bloom syndrome; Borjeson-Forssman-Lehmann syndrome; Boucher Neuhauser syndrome; Brachydactyly types A1 and A2; Brachydactyly with hypertension; Brain small vessel disease with hemorrhage; Branched-chain ketoacid dehydrogenase kinase deficiency; Branchiootic syndromes 2 and 3; Breast cancer, early-onset; Breast-ovarian cancer, familial 1, 2, and 4; Brittle cornea syndrome 2; Brody myopathy; Bronchiectasis with or without elevated sweat chloride 3; Brown-Vialetto-Van laere syndrome and Brown-Vialetto-Van Laere syndrome 2; Brugada syndrome; Brugada syndrome 1; Ventricular fibrillation; Paroxysmal familial ventricular fibrillation; Brugada syndrome and Brugada syndrome 4; Long QT syndrome; Sudden cardiac death; Bull eye macular dystrophy; Stargardt disease 4; Cone-rod dystrophy 12; Bullous ichthyosiform erythroderma; Burn-McKeown syndrome; Candidiasis, familial, 2, 5, 6, and 8; Carbohydrate-deficient glycoprotein syndrome type I and II; Carbonic anhydrase VA deficiency, hyperammonemia due to; Carcinoma of colon; Cardiac arrhythmia; Long QT syndrome, LQT1 subtype; Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency; Cardiofaciocutaneous syndrome; Cardiomyopathy; Danon disease; Hypertrophic cardiomyopathy; Left ventricular noncompaction cardiomyopathy; Carnevale syndrome; Carney complex, type 1; Carnitine acylcarnitine translocase deficiency; Carnitine palmitoyltransferase I, II, II (late onset), and II (infantile) deficiency; Cataract 1, 4, autosomal dominant, autosomal dominant, multiple types, with microcornea, coppock-like, juvenile, with microcornea and glucosuria, and nuclear diffuse nonprogressive; Catecholaminergic polymorphic ventricular tachycardia; Caudal regression syndrome; Cd8 deficiency, familial; Central core disease; Centromeric instability of chromosomes 1,9 and 16 and immunodeficiency; Cerebellar ataxia infantile with progressive external ophthalmoplegia and Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2; Cerebral amyloid angiopathy, APP-related; Cerebral autosomal dominant and recessive arteriopathy with subcortical infarcts and leukoencephalopathy; Cerebral cavernous malformations 2; Cerebrooculofacioskeletal syndrome 2; Cerebro-oculo-facio-skeletal syndrome; Cerebroretinal microangiopathy with calcifications and cysts; Ceroid lipofuscinosis neuronal 2, 6, 7, and 10; Chediak-Higashi syndrome, Chediak-Higashi syndrome, adult type; Charcot-Marie-Tooth disease types 1B, 2B2, 2C, 2F, 2I, 2U (axonal), 1C (demyelinating), dominant intermediate C, recessive intermediate A, 2A2, 4C, 4D, 4H, IF, IVF, and X; Scapuloperoneal spinal muscular atrophy; Distal spinal muscular atrophy, congenital nonprogressive; Spinal muscular atrophy, distal, autosomal recessive, 5; CHARGE association; Childhood hypophosphatasia; Adult hypophosphatasia; Cholecystitis; Progressive familial intrahepatic cholestasis 3; Cholestasis, intrahepatic, of pregnancy 3; Cholesterol storage disease; Cholesterol monooxygenase (side-chain cleaving) deficiency; Chondrodysplasia Blomstrand type; Chondrodysplasia punctata 1, X-linked

recessive and 2 X-linked dominant; CHOPS syndrome; Chronic granulomatous disease, autosomal recessive cytochrome b-positive, types 1 and 2; Chudley-McCullough syndrome; Ciliary dyskinesia, primary, 7, 11, 15, 20 and 22; Citrullinemia type I; Citrullinemia type I and II; Cleidocranial dysostosis; C-like syndrome; Cockayne syndrome type A, ; Coenzyme Q10 deficiency, primary 1, 4, and 7; Coffin Siris/Intellectual Disability; Coffin-Lowry syndrome; Cohen syndrome, ; Cold-induced sweating syndrome 1; COLE-CARPENTER SYNDROME 2; Combined cellular and humoral immune defects with granulomas; Combined d-2- and l-2-hydroxyglutaric aciduria; Combined malonic and methylmalonic aciduria; Combined oxidative phosphorylation deficiencies 1, 3, 4, 12, 15, and 25; Combined partial and complete 17-alpha-hydroxylase/17,20-lyase deficiency; Common variable immunodeficiency 9; Complement component 4, partial deficiency of, due to dysfunctional c1 inhibitor; Complement factor B deficiency; Cone monochromatism; Cone-rod dystrophy 2 and 6; Cone-rod dystrophy amelogenesis imperfecta; Congenital adrenal hyperplasia and Congenital adrenal hypoplasia, X-linked; Congenital amegakaryocytic thrombocytopenia; Congenital aniridia; Congenital central hypoventilation; Hirschsprung disease 3; Congenital contractural arachnodactyly; Congenital contractures of the limbs and face, hypotonia, and developmental delay; Congenital disorder of glycosylation types 1B, 1D, 1G, 1H, 1J, 1K, 1N, 1P, 2C, 2J, 2K, IIIm; Congenital dyserythropoietic anemia, type I and II; Congenital ectodermal dysplasia of face; Congenital erythropoietic porphyria; Congenital generalized lipodystrophy type 2; Congenital heart disease, multiple types, 2; Congenital heart disease; Interrupted aortic arch; Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi; Non-small cell lung cancer; Neoplasm of ovary; Cardiac conduction defect, nonspecific; Congenital microvillous atrophy; Congenital muscular dystrophy; Congenital muscular dystrophy due to partial LAMA2 deficiency; Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, types A2, A7, A8, A11, and A14; Congenital muscular dystrophy-dystroglycanopathy with mental retardation, types B2, B3, B5, and B15; Congenital muscular dystrophy-dystroglycanopathy without mental retardation, type B5; Congenital muscular hypertrophy-cerebral syndrome; Congenital myasthenic syndrome, acetazolamide-responsive; Congenital myopathy with fiber type disproportion; Congenital ocular coloboma; Congenital stationary night blindness, type 1A, 1B, 1C, 1E, 1F, and 2A; Coproporphyrria; Cornea plana 2; Corneal dystrophy, Fuchs endothelial, 4; Corneal endothelial dystrophy type 2; Corneal fragility keratoglobus, blue sclerae and joint hypermobility; Cornelia de Lange syndromes 1 and 5; Coronary artery disease, autosomal dominant 2; Coronary heart disease; Hyperalphalipoproteinemia 2; Cortical dysplasia, complex, with other brain malformations 5 and 6; Cortical malformations, occipital; Corticosteroid-binding globulin deficiency; Corticosterone methyloxidase type 2 deficiency; Costello syndrome; Cowden syndrome 1; Coxa plana; Craniodiaphyseal dysplasia, autosomal dominant; Craniosynostosis 1 and 4; Craniosynostosis and dental anomalies; Creatine deficiency, X-linked; Crouzon syndrome; Cryptophthalmos syndrome;

Cryptorchidism, unilateral or bilateral; Cushing symphalangism; Cutaneous malignant melanoma 1; Cutis laxa with osteodystrophy and with severe pulmonary, gastrointestinal, and urinary abnormalities; Cyanosis, transient neonatal and atypical nephropathic; Cystic fibrosis; Cystinuria; Cytochrome c oxidase i deficiency; Cytochrome-c oxidase deficiency ; D-2-hydroxyglutaric aciduria 2; Darier disease, segmental; Deafness with labyrinthine aplasia microtia and microdontia (LAMM); Deafness, autosomal dominant 3a, 4, 12, 13, 15, autosomal dominant nonsyndromic sensorineural 17, 20, and 65; Deafness, autosomal recessive 1A, 2, 3, 6, 8, 9, 12, 15, 16, 18b, 22, 28, 31, 44, 49, 63, 77, 86, and 89; Deafness, cochlear, with myopia and intellectual impairment, without vestibular involvement, autosomal dominant, X-linked 2; Deficiency of 2-methylbutyryl-CoA dehydrogenase; Deficiency of 3-hydroxyacyl-CoA dehydrogenase; Deficiency of alpha-mannosidase; Deficiency of aromatic-L-amino-acid decarboxylase; Deficiency of bisphosphoglycerate mutase; Deficiency of butyryl-CoA dehydrogenase; Deficiency of ferroxidase; Deficiency of galactokinase; Deficiency of guanidinoacetate methyltransferase; Deficiency of hyaluronoglucosaminidase; Deficiency of ribose-5-phosphate isomerase; Deficiency of steroid 11-beta-monooxygenase; Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase; Deficiency of xanthine oxidase; Dejerine-Sottas disease; Charcot-Marie-Tooth disease, types ID and IVF; Dejerine-Sottas syndrome, autosomal dominant; Dendritic cell, monocyte, B lymphocyte, and natural killer lymphocyte deficiency; Desbuquois dysplasia 2; Desbuquois syndrome; DFNA 2 Nonsyndromic Hearing Loss; Diabetes mellitus and insipidus with optic atrophy and deafness; Diabetes mellitus, type 2, and insulin-dependent, 20; Diamond-Blackfan anemia 1, 5, 8, and 10; Diarrhea 3 (secretory sodium, congenital, syndromic) and 5 (with tufting enteropathy, congenital); Dicarboxylic aminoaciduria; Diffuse palmoplantar keratoderma, Bothnian type; Digitorenocerebral syndrome; Dihydropteridine reductase deficiency; Dilated cardiomyopathy 1A, 1AA, 1C, 1G, 1BB, 1DD, 1FF, 1HH, 1I, 1KK, 1N, 1S, 1Y, and 3B; Left ventricular noncompaction 3; Disordered steroidogenesis due to cytochrome p450 oxidoreductase deficiency; Distal arthrogryposis type 2B; Distal hereditary motor neuropathy type 2B; Distal myopathy Markesbery-Griggs type; Distal spinal muscular atrophy, X-linked 3; Distichiasis-lymphedema syndrome; Dominant dystrophic epidermolysis bullosa with absence of skin; Dominant hereditary optic atrophy; Donnai Barrow syndrome; Dopamine beta hydroxylase deficiency; Dopamine receptor d2, reduced brain density of; Dowling-degos disease 4; Doyme honeycomb retinal dystrophy; Malattia leventinese; Duane syndrome type 2; Dubin-Johnson syndrome; Duchenne muscular dystrophy; Becker muscular dystrophy; Dysfibrinogenemia; Dyskeratosis congenita autosomal dominant and autosomal dominant, 3; Dyskeratosis congenita, autosomal recessive, 1, 3, 4, and 5; Dyskeratosis congenita X-linked; Dyskinesia, familial, with facial myokymia; Dysplasminogenemia; Dystonia 2 (torsion, autosomal recessive), 3 (torsion, X-linked), 5 (Dopa-responsive type), 10, 12, 16, 25, 26 (Myoclonic); Seizures, benign familial infantile, 2; Early infantile epileptic encephalopathy 2, 4, 7, 9, 10, 11, 13, and 14; Atypical Rett syndrome; Early T cell

progenitor acute lymphoblastic leukemia; Ectodermal dysplasia skin fragility syndrome; Ectodermal dysplasia-syndactyly syndrome 1; Ectopia lentis, isolated autosomal recessive and dominant; Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3; Ehlers-Danlos syndrome type 7 (autosomal recessive), classic type, type 2 (progeroid), hydroxylysine-deficient, type 4, type 4 variant, and due to tenascin-X deficiency; Eichsfeld type congenital muscular dystrophy; Endocrine-cerebroosteodysplasia; Enhanced s-cone syndrome; Enlarged vestibular aqueduct syndrome; Enterokinase deficiency; Epidermodysplasia verruciformis; Epidermolysis bullosa simplex and limb girdle muscular dystrophy, simplex with mottled pigmentation, simplex with pyloric atresia, simplex, autosomal recessive, and with pyloric atresia; Epidermolytic palmoplantar keratoderma; Familial febrile seizures 8; Epilepsy, childhood absence 2, 12 (idiopathic generalized, susceptibility to) 5 (nocturnal frontal lobe), nocturnal frontal lobe type 1, partial, with variable foci, progressive myoclonic 3, and X-linked, with variable learning disabilities and behavior disorders; Epileptic encephalopathy, childhood-onset, early infantile, 1, 19, 23, 25, 30, and 32; Epiphyseal dysplasia, multiple, with myopia and conductive deafness; Episodic ataxia type 2; Episodic pain syndrome, familial, 3; Epstein syndrome; Fechtner syndrome; Erythropoietic protoporphyria; Estrogen resistance; Exudative vitreoretinopathy 6; Fabry disease and Fabry disease, cardiac variant; Factor H, VII, X, v and factor viii, combined deficiency of 2, xiii, a subunit, deficiency; Familial adenomatous polyposis 1 and 3; Familial amyloid nephropathy with urticaria and deafness; Familial cold urticarial; Familial aplasia of the vermis; Familial benign pemphigus; Familial cancer of breast; Breast cancer, susceptibility to; Osteosarcoma; Pancreatic cancer 3; Familial cardiomyopathy; Familial cold autoimmune inflammatory syndrome 2; Familial colorectal cancer; Familial exudative vitreoretinopathy, X-linked; Familial hemiplegic migraine types 1 and 2; Familial hypercholesterolemia; Familial hypertrophic cardiomyopathy 1, 2, 3, 4, 7, 10, 23 and 24; Familial hypokalemia-hypomagnesemia; Familial hypoplastic, glomerulocystic kidney; Familial infantile myasthenia; Familial juvenile gout; Familial Mediterranean fever and Familial mediterranean fever, autosomal dominant; Familial porencephaly; Familial porphyria cutanea tarda; Familial pulmonary capillary hemangiomatosis; Familial renal glucosuria; Familial renal hypouricemia; Familial restrictive cardiomyopathy 1; Familial type 1 and 3 hyperlipoproteinemia; Fanconi anemia, complementation group E, I, N, and O; Fanconi-Bickel syndrome; Favism, susceptibility to; Febrile seizures, familial, 11; Feingold syndrome 1; Fetal hemoglobin quantitative trait locus 1; FG syndrome and FG syndrome 4; Fibrosis of extraocular muscles, congenital, 1, 2, 3a (with or without extraocular involvement), 3b; Fish-eye disease; Fleck corneal dystrophy; Floating-Harbor syndrome; Focal epilepsy with speech disorder with or without mental retardation; Focal segmental glomerulosclerosis 5; Forebrain defects; Frank Ter Haar syndrome; Borrone Di Rocco Crovato syndrome; Frasier syndrome; Wilms tumor 1; Freeman-Sheldon syndrome; Frontometaphyseal dysplasia 1 and 3; Frontotemporal dementia; Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 and 4; Frontotemporal Dementia

Chromosome 3-Linked and Frontotemporal dementia ubiquitin-positive; Fructose-biphosphatase deficiency; Fuhrmann syndrome; Gamma-aminobutyric acid transaminase deficiency; Gamstorp-Wohlfart syndrome; Gaucher disease type 1 and Subacute neuronopathic; Gaze palsy, familial horizontal, with progressive scoliosis; Generalized dominant dystrophic epidermolysis bullosa; Generalized epilepsy with febrile seizures plus 3, type 1, type 2; Epileptic encephalopathy Lennox-Gastaut type; Giant axonal neuropathy; Glanzmann thrombasthenia; Glaucoma 1, open angle, e, F, and G; Glaucoma 3, primary congenital, d; Glaucoma, congenital and Glaucoma, congenital, Coloboma; Glaucoma, primary open angle, juvenile-onset; Glioma susceptibility 1; Glucose transporter type 1 deficiency syndrome; Glucose-6-phosphate transport defect; GLUT1 deficiency syndrome 2; Epilepsy, idiopathic generalized, susceptibility to, 12; Glutamate formiminotransferase deficiency; Glutaric acidemia IIA and IIB; Glutaric aciduria, type 1; Glutathione synthetase deficiency; Glycogen storage disease 0 (muscle), II (adult form), IXa2, IXc, type 1A; type II, type IV, IV (combined hepatic and myopathic), type V, and type VI; Goldmann-Favre syndrome; Gordon syndrome; Gorlin syndrome; Holoprosencephaly sequence; Holoprosencephaly 7; Granulomatous disease, chronic, X-linked, variant; Granulosa cell tumor of the ovary; Gray platelet syndrome; Griscelli syndrome type 3; Groenouw corneal dystrophy type I; Growth and mental retardation, mandibulofacial dysostosis, microcephaly, and cleft palate; Growth hormone deficiency with pituitary anomalies; Growth hormone insensitivity with immunodeficiency; GTP cyclohydrolase I deficiency; Hajdu-Cheney syndrome; Hand foot uterus syndrome; Hearing impairment; Hemangioma, capillary infantile; Hematologic neoplasm; Hemochromatosis type 1, 2B, and 3; Microvascular complications of diabetes 7; Transferrin serum level quantitative trait locus 2; Hemoglobin H disease, nondeletional; Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency; Hemophagocytic lymphohistiocytosis, familial, 2; Hemophagocytic lymphohistiocytosis, familial, 3; Heparin cofactor II deficiency; Hereditary acrodermatitis enteropathica; Hereditary breast and ovarian cancer syndrome; Ataxia-telangiectasia-like disorder; Hereditary diffuse gastric cancer; Hereditary diffuse leukoencephalopathy with spheroids; Hereditary factors II, IX, VIII deficiency disease; Hereditary hemorrhagic telangiectasia type 2; Hereditary insensitivity to pain with anhidrosis; Hereditary lymphedema type I; Hereditary motor and sensory neuropathy with optic atrophy; Hereditary myopathy with early respiratory failure; Hereditary neuralgic amyotrophy; Hereditary Nonpolyposis Colorectal Neoplasms; Lynch syndrome I and II; Hereditary pancreatitis; Pancreatitis, chronic, susceptibility to; Hereditary sensory and autonomic neuropathy type IIB and IIA; Hereditary sideroblastic anemia; Hermansky-Pudlak syndrome 1, 3, 4, and 6; Heterotaxy, visceral, 2, 4, and 6, autosomal; Heterotaxy, visceral, X-linked; Heterotopia; Histiocytic medullary reticulosis; Histiocytosis-lymphadenopathy plus syndrome; Holocarboxylase synthetase deficiency; Holoprosencephaly 2, 3, 7, and 9; Holt-Oram syndrome; Homocysteinemia due to MTHFR deficiency, CBS deficiency, and Homocystinuria, pyridoxine-responsive; Homocystinuria-Megaloblastic anemia

due to defect in cobalamin metabolism, cblE complementation type; Howel-Evans syndrome; Hurler syndrome; Hutchinson-Gilford syndrome; Hydrocephalus; Hyperammonemia, type III; Hypercholesterolaemia and Hypercholesterolemia, autosomal recessive; Hyperekplexia 2 and Hyperekplexia hereditary; Hyperferritinemia cataract syndrome; Hyperglycinuria; Hyperimmunoglobulin D with periodic fever; Mevalonic aciduria; Hyperimmunoglobulin E syndrome; Hyperinsulinemic hypoglycemia familial 3, 4, and 5; Hyperinsulinism-hyperammonemia syndrome; Hyperlysineemia; Hypermanganesemia with dystonia, polycythemia and cirrhosis; Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome; Hyperparathyroidism 1 and 2; Hyperparathyroidism, neonatal severe; Hyperphenylalaninemia, bh4-deficient, a, due to partial pts deficiency, BH4-deficient, D, and non-pku; Hyperphosphatasia with mental retardation syndrome 2, 3, and 4; Hypertrichotic osteochondrodysplasia; Hypobetalipoproteinemia, familial, associated with apob32; Hypocalcemia, autosomal dominant 1; Hypocalciuric hypercalcemia, familial, types 1 and 3; Hypochondrogenesis; Hypochromic microcytic anemia with iron overload; Hypoglycemia with deficiency of glycogen synthetase in the liver; Hypogonadotropic hypogonadism 11 with or without anosmia; Hypohidrotic ectodermal dysplasia with immune deficiency; Hypohidrotic X-linked ectodermal dysplasia; Hypokalemic periodic paralysis 1 and 2; Hypomagnesemia 1, intestinal; Hypomagnesemia, seizures, and mental retardation; Hypomyelinating leukodystrophy 7; Hypoplastic left heart syndrome; Atrioventricular septal defect and common atrioventricular junction; Hypospadias 1 and 2, X-linked; Hypothyroidism, congenital, nongoitrous, 1; Hypotrichosis 8 and 12; Hypotrichosis-lymphedema-telangiectasia syndrome; I blood group system; Ichthyosis bullosa of Siemens; Ichthyosis exfoliativa; Ichthyosis prematurity syndrome; Idiopathic basal ganglia calcification 5; Idiopathic fibrosing alveolitis, chronic form; Dyskeratosis congenita, autosomal dominant, 2 and 5; Idiopathic hypercalcemia of infancy; Immune dysfunction with T-cell inactivation due to calcium entry defect 2; Immunodeficiency 15, 16, 19, 30, 31C, 38, 40, 8, due to defect in cd3-zeta, with hyper IgM type 1 and 2, and X-Linked, with magnesium defect, Epstein-Barr virus infection, and neoplasia; Immunodeficiency-centromeric instability-facial anomalies syndrome 2; Inclusion body myopathy 2 and 3; Nonaka myopathy; Infantile convulsions and paroxysmal choreoathetosis, familial; Infantile cortical hyperostosis; Infantile GM1 gangliosidosis; Infantile hypophosphatasia; Infantile nephronophthisis; Infantile nystagmus, X-linked; Infantile Parkinsonism-dystonia; Infertility associated with multi-tailed spermatozoa and excessive DNA; Insulin resistance; Insulin-resistant diabetes mellitus and acanthosis nigricans; Insulin-dependent diabetes mellitus secretory diarrhea syndrome; Interstitial nephritis, karyomegalic; Intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies; Iodotyrosyl coupling defect; IRAK4 deficiency; Iridogoniodysgenesis dominant type and type 1; Iron accumulation in brain; Ischiopatellar dysplasia; Islet cell hyperplasia; Isolated 17,20-lyase deficiency; Isolated lutropin deficiency; Isovaleryl-CoA dehydrogenase deficiency; Jankovic Rivera syndrome; Jervell and Lange-

Nielsen syndrome 2; Joubert syndrome 1, 6, 7, 9/15 (digenic), 14, 16, and 17, and Orofaciodigital syndrome xiv; Junctional epidermolysis bullosa gravis of Herlitz; Juvenile GM β 1< gangliosidosis; Juvenile polyposis syndrome; Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome; Juvenile retinoschisis; Kabuki make-up syndrome; Kallmann syndrome 1, 2, and 6; Delayed puberty; Kanzaki disease; Karak syndrome; Kartagener syndrome; Kenny-Caffey syndrome type 2; Keppen-Lubinsky syndrome; Keratoconus 1; Keratosis follicularis; Keratosis palmoplantaris striata 1; Kindler syndrome; L-2-hydroxyglutaric aciduria; Larsen syndrome, dominant type; Lattice corneal dystrophy Type III; Leber amaurosis; Zellweger syndrome; Peroxisome biogenesis disorders; Zellweger syndrome spectrum; Leber congenital amaurosis 11, 12, 13, 16, 4, 7, and 9; Leber optic atrophy; Aminoglycoside-induced deafness; Deafness, nonsyndromic sensorineural, mitochondrial; Left ventricular noncompaction 5; Left-right axis malformations; Leigh disease; Mitochondrial short-chain Enoyl-CoA Hydratase 1 deficiency; Leigh syndrome due to mitochondrial complex I deficiency; Leiner disease; Leri Weill dyschondrosteosis; Lethal congenital contracture syndrome 6; Leukocyte adhesion deficiency type I and III; Leukodystrophy, Hypomyelinating, 11 and 6; Leukoencephalopathy with ataxia, with Brainstem and Spinal Cord Involvement and Lactate Elevation, with vanishing white matter, and progressive, with ovarian failure; Leukonychia totalis; Lewy body dementia; Lichtenstein-Knorr Syndrome; Li-Fraumeni syndrome 1; Lig4 syndrome; Limb-girdle muscular dystrophy, type 1B, 2A, 2B, 2D, C1, C5, C9, C14; Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies, type A14 and B14; Lipase deficiency combined; Lipid proteinosis; Lipodystrophy, familial partial, type 2 and 3; Lissencephaly 1, 2 (X-linked), 3, 6 (with microcephaly), X-linked; Subcortical laminar heterotopia, X-linked; Liver failure acute infantile; Loeys-Dietz syndrome 1, 2, 3; Long QT syndrome 1, 2, 2/9, 2/5, (digenic), 3, 5 and 5, acquired, susceptibility to; Lung cancer; Lymphedema, hereditary, id; Lymphedema, primary, with myelodysplasia; Lymphoproliferative syndrome 1, 1 (X-linked), and 2; Lysosomal acid lipase deficiency; Macrocephaly, macrosomia, facial dysmorphism syndrome; Macular dystrophy, vitelliform, adult-onset; Malignant hyperthermia susceptibility type 1; Malignant lymphoma, non-Hodgkin; Malignant melanoma; Malignant tumor of prostate; Mandibuloacral dysostosis; Mandibuloacral dysplasia with type A or B lipodystrophy, atypical; Mandibulofacial dysostosis, Treacher Collins type, autosomal recessive; Mannose-binding protein deficiency; Maple syrup urine disease type 1A and type 3; Marden Walker like syndrome; Marfan syndrome; Marinesco-Sjogren syndrome; Martsolf syndrome; Maturity-onset diabetes of the young, type 1, type 2, type 11, type 3, and type 9; May-Hegglin anomaly; MYH9 related disorders; Sebastian syndrome; McCune-Albright syndrome; Somatotroph adenoma; Sex cord-stromal tumor; Cushing syndrome; McKusick Kaufman syndrome; McLeod neuroacanthocytosis syndrome; Meckel-Gruber syndrome; Medium-chain acyl-coenzyme A dehydrogenase deficiency; Medulloblastoma; Megalencephalic leukoencephalopathy with subcortical cysts 1 and 2a; Megalencephaly cutis marmorata telangiectatica

congenital; PIK3CA Related Overgrowth Spectrum; Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2; Megaloblastic anemia, thiamine-responsive, with diabetes mellitus and sensorineural deafness; Meier-Gorlin syndromes 1 and 4; Melnick-Needles syndrome; Meningioma; Mental retardation, X-linked, 3, 21, 30, and 72; Mental retardation and microcephaly with pontine and cerebellar hypoplasia; Mental retardation X-linked syndromic 5; Mental retardation, anterior maxillary protrusion, and strabismus; Mental retardation, autosomal dominant 12, 13, 15, 24, 3, 30, 4, 5, 6, and 9; Mental retardation, autosomal recessive 15, 44, 46, and 5; Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations; Mental retardation, syndromic, Claes-Jensen type, X-linked; Mental retardation, X-linked, nonspecific, syndromic, Hedera type, and syndromic, wu type; Merosin deficient congenital muscular dystrophy; Metachromatic leukodystrophy juvenile, late infantile, and adult types; Metachromatic leukodystrophy; Metatrophic dysplasia; Methemoglobinemia types I and 2; Methionine adenosyltransferase deficiency, autosomal dominant; Methylmalonic acidemia with homocystinuria, ; Methylmalonic aciduria cblB type, ; Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency; METHYLMALONIC ACIDURIA, mut(0) TYPE; Microcephalic osteodysplastic primordial dwarfism type 2; Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation; Microcephaly, hiatal hernia and nephrotic syndrome; Microcephaly; Hypoplasia of the corpus callosum; Spastic paraplegia 50, autosomal recessive; Global developmental delay; CNS hypomyelination; Brain atrophy; Microcephaly, normal intelligence and immunodeficiency; Microcephaly-capillary malformation syndrome; Microcytic anemia; Microphthalmia syndromic 5, 7, and 9; Microphthalmia, isolated 3, 5, 6, 8, and with coloboma 6; Microspherophakia; Migraine, familial basilar; Miller syndrome; Minicore myopathy with external ophthalmoplegia; Myopathy, congenital with cores; Mitchell-Riley syndrome; mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase deficiency; Mitochondrial complex I, II, III, III (nuclear type 2, 4, or 8) deficiency; Mitochondrial DNA depletion syndrome 11, 12 (cardiomyopathic type), 2, 4B (MNGIE type), 8B (MNGIE type); Mitochondrial DNA-depletion syndrome 3 and 7, hepatocerebral types, and 13 (encephalomyopathic type); Mitochondrial phosphate carrier and pyruvate carrier deficiency; Mitochondrial trifunctional protein deficiency; Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; Miyoshi muscular dystrophy 1; Myopathy, distal, with anterior tibial onset; Mohr-Tranebjaerg syndrome; Molybdenum cofactor deficiency, complementation group A; Mowat-Wilson syndrome; Mucopolidosis III Gamma; Mucopolysaccharidosis type VI, type VI (severe), and type VII; Mucopolysaccharidosis, MPS-I-H/S, MPS-II, MPS-III-A, MPS-III-B, MPS-III-C, MPS-IV-A, MPS-IV-B; Retinitis Pigmentosa 73; Gangliosidosis GM1 type1 (with cardiac involvement) 3; Multicentric osteolysis nephropathy; Multicentric osteolysis, nodulosis and arthropathy; Multiple congenital anomalies; Atrial septal defect 2; Multiple congenital anomalies-hypotonia-seizures syndrome 3; Multiple Cutaneous and Mucosal Venous Malformations; Multiple endocrine neoplasia, types 1 and 4; Multiple epiphyseal dysplasia 5

or Dominant; Multiple gastrointestinal atresias; Multiple pterygium syndrome Escobar type; Multiple sulfatase deficiency; Multiple synostoses syndrome 3; Muscle AMP guanine oxidase deficiency; Muscle eye brain disease; Muscular dystrophy, congenital, megaconial type; Myasthenia, familial infantile, 1; Myasthenic Syndrome, Congenital, 11, associated with acetylcholine receptor deficiency; Myasthenic Syndrome, Congenital, 17, 2A (slow-channel), 4B (fast-channel), and without tubular aggregates; Myeloperoxidase deficiency; MYH-associated polyposis; Endometrial carcinoma; Myocardial infarction 1; Myoclonic dystonia; Myoclonic-Atonic Epilepsy; Myoclonus with epilepsy with ragged red fibers; Myofibrillar myopathy 1 and ZASP-related; Myoglobinuria, acute recurrent, autosomal recessive; Myoneural gastrointestinal encephalopathy syndrome; Cerebellar ataxia infantile with progressive external ophthalmoplegia; Mitochondrial DNA depletion syndrome 4B, MNGIE type; Myopathy, centronuclear, 1, congenital, with excess of muscle spindles, distal, 1, lactic acidosis, and sideroblastic anemia 1, mitochondrial progressive with congenital cataract, hearing loss, and developmental delay, and tubular aggregate, 2; Myopia 6; Myosclerosis, autosomal recessive; Myotonia congenital; Congenital myotonia, autosomal dominant and recessive forms; Nail-patella syndrome; Nance-Horan syndrome; Nanophthalmos 2; Navajo neurohepatopathy; Nemaline myopathy 3 and 9; Neonatal hypotonia; Intellectual disability; Seizures; Delayed speech and language development; Mental retardation, autosomal dominant 31; Neonatal intrahepatic cholestasis caused by citrin deficiency; Nephrogenic diabetes insipidus, Nephrogenic diabetes insipidus, X-linked; Nephrolithiasis/osteoporosis, hypophosphatemic, 2; Nephronophthisis 13, 15 and 4; Infertility; Cerebello-oculo-renal syndrome (nephronophthisis, oculomotor apraxia and cerebellar abnormalities); Nephrotic syndrome, type 3, type 5, with or without ocular abnormalities, type 7, and type 9; Nestor-Guillermo progeria syndrome; Neu-Laxova syndrome 1; Neurodegeneration with brain iron accumulation 4 and 6; Neuroferritinopathy; Neurofibromatosis, type 1 and type 2; Neurofibrosarcoma; Neurohypophyseal diabetes insipidus; Neuropathy, Hereditary Sensory, Type IC; Neutral 1 amino acid transport defect; Neutral lipid storage disease with myopathy; Neutrophil immunodeficiency syndrome; Nicolaides-Baraitser syndrome; Niemann-Pick disease type C1, C2, type A, and type C1, adult form; Non-ketotic hyperglycinemia; Noonan syndrome 1 and 4, LEOPARD syndrome 1; Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia; Normokalemic periodic paralysis, potassium-sensitive; Norum disease; Epilepsy, Hearing Loss, And Mental Retardation Syndrome; Mental Retardation, X-Linked 102 and syndromic 13; Obesity; Ocular albinism, type I; Oculocutaneous albinism type 1B, type 3, and type 4; Oculodentodigital dysplasia; Odontohypophosphatasia; Odontotrichomelic syndrome; Oguchi disease; Oligodontia-colorectal cancer syndrome; Opitz G/BBB syndrome; Optic atrophy 9; Oral-facial-digital syndrome; Ornithine aminotransferase deficiency; Orofacial cleft 11 and 7, Cleft lip/palate-ectodermal dysplasia syndrome; Orstavik Lindemann Solberg syndrome; Osteoarthritis with mild chondrodysplasia; Osteochondritis dissecans; Osteogenesis imperfecta type 12, type 5, type 7, type 8, type I, type III, with normal

sclerae, dominant form, recessive perinatal lethal; Osteopathia striata with cranial sclerosis;
 Osteopetrosis autosomal dominant type 1 and 2, recessive 4, recessive 1, recessive 6; Osteoporosis
 with pseudoglioma; Oto-palato-digital syndrome, types I and II; Ovarian dysgenesis 1;
 Ovarioleukodystrophy; Pachyonychia congenita 4 and type 2; Paget disease of bone, familial;
 Pallister-Hall syndrome; Palmoplantar keratoderma, nonepidermolytic, focal or diffuse; Pancreatic
 agenesis and congenital heart disease; Papillon-Lefèvre syndrome; Parangangliomas 3;
 Paramyotonia congenita of von Eulenburg; Parathyroid carcinoma; Parkinson disease 14, 15, 19
 (juvenile-onset), 2, 20 (early-onset), 6, (autosomal recessive early-onset, and 9; Partial albinism;
 Partial hypoxanthine-guanine phosphoribosyltransferase deficiency; Patterned dystrophy of retinal
 pigment epithelium; PC-K6a; Pelizaeus-Merzbacher disease; Pendred syndrome; Peripheral
 demyelinating neuropathy, central dysmyelination; Hirschsprung disease; Permanent neonatal
 diabetes mellitus; Diabetes mellitus, permanent neonatal, with neurologic features; Neonatal insulin-
 dependent diabetes mellitus; Maturity-onset diabetes of the young, type 2; Peroxisome biogenesis
 disorder 14B, 2A, 4A, 5B, 6A, 7A, and 7B; Perrault syndrome 4; Perry syndrome; Persistent
 hyperinsulinemic hypoglycemia of infancy; familial hyperinsulinism; Phenotypes; Phenylketonuria;
 Pheochromocytoma; Hereditary Paranglioma-Pheochromocytoma Syndromes; Parangliomas 1;
 Carcinoid tumor of intestine; Cowden syndrome 3; Phosphoglycerate dehydrogenase deficiency;
 Phosphoglycerate kinase 1 deficiency; Photosensitive trichothiodystrophy; Phytanic acid storage
 disease; Pick disease; Pierson syndrome; Pigmentary retinal dystrophy; Pigmented nodular
 adrenocortical disease, primary, 1; Pilomatrixoma; Pitt-Hopkins syndrome; Pituitary dependent
 hypercortisolism; Pituitary hormone deficiency, combined 1, 2, 3, and 4; Plasminogen activator
 inhibitor type 1 deficiency; Plasminogen deficiency, type I; Platelet-type bleeding disorder 15 and 8;
 Poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis;
 Polycystic kidney disease 2, adult type, and infantile type; Polycystic lipomembranous osteodysplasia
 with sclerosing leukoencephalopathy; Polyglucosan body myopathy 1 with or without
 immunodeficiency; Polymicrogyria, asymmetric, bilateral frontoparietal; Polyneuropathy, hearing
 loss, ataxia, retinitis pigmentosa, and cataract; Pontocerebellar hypoplasia type 4; Popliteal pterygium
 syndrome; Porencephaly 2; Porokeratosis 8, disseminated superficial actinic type; Porphobilinogen
 synthase deficiency; Porphyria cutanea tarda; Posterior column ataxia with retinitis pigmentosa;
 Posterior polar cataract type 2; Prader-Willi-like syndrome; Premature ovarian failure 4, 5, 7, and 9;
 Primary autosomal recessive microcephaly 10, 2, 3, and 5; Primary ciliary dyskinesia 24; Primary
 dilated cardiomyopathy; Left ventricular noncompaction 6; 4, Left ventricular noncompaction 10;
 Paroxysmal atrial fibrillation; Primary hyperoxaluria, type I, type, and type III; Primary hypertrophic
 osteoarthropathy, autosomal recessive 2; Primary hypomagnesemia; Primary open angle glaucoma
 juvenile onset 1; Primary pulmonary hypertension; Primrose syndrome; Progressive familial heart
 block type 1B; Progressive familial intrahepatic cholestasis 2 and 3; Progressive intrahepatic

cholestasis; Progressive myoclonus epilepsy with ataxia; Progressive pseudorheumatoid dysplasia; Progressive sclerosing poliodystrophy; Prolidase deficiency; Proline dehydrogenase deficiency; Schizophrenia 4; Properdin deficiency, X-linked; Propionic academia; Proprotein convertase 1/3 deficiency; Prostate cancer, hereditary, 2; Protan defect; Proteinuria; Finnish congenital nephrotic syndrome; Proteus syndrome; Breast adenocarcinoma; Pseudoachondroplastic spondyloepiphyseal dysplasia syndrome; Pseudohypoadosteronism type 1 autosomal dominant and recessive and type 2; Pseudohypoparathyroidism type 1A, Pseudopseudohypoparathyroidism; Pseudoneonatal adrenoleukodystrophy; Pseudoprimary hyperaldosteronism; Pseudoxanthoma elasticum; Generalized arterial calcification of infancy 2; Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency; Psoriasis susceptibility 2; PTEN hamartoma tumor syndrome; Pulmonary arterial hypertension related to hereditary hemorrhagic telangiectasia; Pulmonary Fibrosis And/Or Bone Marrow Failure, Telomere-Related, 1 and 3; Pulmonary hypertension, primary, 1, with hereditary hemorrhagic telangiectasia; Purine-nucleoside phosphorylase deficiency; Pyruvate carboxylase deficiency; Pyruvate dehydrogenase E1-alpha deficiency; Pyruvate kinase deficiency of red cells; Raine syndrome; Rasopathy; Recessive dystrophic epidermolysis bullosa; Nail disorder, nonsyndromic congenital, 8; Reifenshtein syndrome; Renal adysplasia; Renal carnitine transport defect; Renal coloboma syndrome; Renal dysplasia; Renal dysplasia, retinal pigmentary dystrophy, cerebellar ataxia and skeletal dysplasia; Renal tubular acidosis, distal, autosomal recessive, with late-onset sensorineural hearing loss, or with hemolytic anemia; Renal tubular acidosis, proximal, with ocular abnormalities and mental retardation; Retinal cone dystrophy 3B; Retinitis pigmentosa; Retinitis pigmentosa 10, 11, 12, 14, 15, 17, and 19; Retinitis pigmentosa 2, 20, 25, 35, 36, 38, 39, 4, 40, 43, 45, 48, 66, 7, 70, 72; Retinoblastoma; Rett disorder; Rhabdoid tumor predisposition syndrome 2; Rhegmatogenous retinal detachment, autosomal dominant; Rhizomelic chondrodysplasia punctata type 2 and type 3; Roberts-SC phocomelia syndrome; Robinow Sorauf syndrome; Robinow syndrome, autosomal recessive, autosomal recessive, with brachy-syn-polydactyly; Rothmund-Thomson syndrome; Rapadilino syndrome; RRM2B-related mitochondrial disease; Rubinstein-Taybi syndrome; Salla disease; Sandhoff disease, adult and infant types; Sarcoidosis, early-onset; Blau syndrome; Schindler disease, type 1; Schizencephaly; Schizophrenia 15; Schneckenbecken dysplasia; Schwannomatosis 2; Schwartz Jampel syndrome type 1; Sclerocornea, autosomal recessive; Sclerosteosis; Secondary hypothyroidism; Segawa syndrome, autosomal recessive; Senior-Loken syndrome 4 and 5, ; Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis; Sepiapterin reductase deficiency; SeSAME syndrome; Severe combined immunodeficiency due to ADA deficiency, with microcephaly, growth retardation, and sensitivity to ionizing radiation, atypical, autosomal recessive, T cell-negative, B cell-positive, NK cell-negative of NK-positive; Severe congenital neutropenia; Severe congenital neutropenia 3, autosomal recessive or dominant; Severe congenital neutropenia and 6, autosomal recessive; Severe myoclonic epilepsy in infancy;

Generalized epilepsy with febrile seizures plus, types 1 and 2; Severe X-linked myotubular myopathy; Short QT syndrome 3; Short stature with nonspecific skeletal abnormalities; Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities; Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis; Primordial dwarfism; Short-rib thoracic dysplasia 11 or 3 with or without polydactyly; Sialidosis type I and II; Silver spastic paraplegia syndrome; Slowed nerve conduction velocity, autosomal dominant; Smith-Lemli-Opitz syndrome; Snyder Robinson syndrome; Somatotroph adenoma; Prolactinoma; familial, Pituitary adenoma predisposition; Sotos syndrome 1 or 2; Spastic ataxia 5, autosomal recessive, Charlevoix-Saguenay type, 1,10, or 11, autosomal recessive; Amyotrophic lateral sclerosis type 5; Spastic paraplegia 15, 2, 3, 35, 39, 4, autosomal dominant, 55, autosomal recessive, and 5A; Bile acid synthesis defect, congenital, 3; Spermatogenic failure 11, 3, and 8; Spherocytosis types 4 and 5; Spheroid body myopathy; Spinal muscular atrophy, lower extremity predominant 2, autosomal dominant; Spinal muscular atrophy, type II; Spinocerebellar ataxia 14, 21, 35, 40, and 6; Spinocerebellar ataxia autosomal recessive 1 and 16; Splenic hypoplasia; Spondylacropotarsal synostosis syndrome; Spondylocheiroadysplasia, Ehlers-Danlos syndrome-like, with immune dysregulation, Aggreacan type, with congenital joint dislocations, short limb-hand type, Sedaghatian type, with cone-rod dystrophy, and Kozlowski type; Parastremmatic dwarfism; Stargardt disease 1; Cone-rod dystrophy 3; Stickler syndrome type 1; Kniest dysplasia; Stickler syndrome, types 1(nonsyndromic ocular) and 4; Sting-associated vasculopathy, infantile-onset; Stormorken syndrome; Sturge-Weber syndrome, Capillary malformations, congenital, 1; Succinyl-CoA acetoacetate transferase deficiency; Sucrase-isomaltase deficiency; Sudden infant death syndrome; Sulfite oxidase deficiency, isolated; Supravalvar aortic stenosis; Surfactant metabolism dysfunction, pulmonary, 2 and 3; Symphalangism, proximal, 1b; Syndactyly Cenani Lenz type; Syndactyly type 3; Syndromic X-linked mental retardation 16; Talipes equinovarus; Tangier disease; TARP syndrome; Tay-Sachs disease, B1 variant, Gm2-gangliosidosis (adult), Gm2-gangliosidosis (adult-onset); Temtamy syndrome; Tenorio Syndrome; Terminal osseous dysplasia; Testosterone 17-beta-dehydrogenase deficiency; Tetraamelia, autosomal recessive; Tetralogy of Fallot; Hypoplastic left heart syndrome 2; Truncus arteriosus; Malformation of the heart and great vessels; Ventricular septal defect 1; Thiel-Behnke corneal dystrophy; Thoracic aortic aneurysms and aortic dissections; Marfanoid habitus; Three M syndrome 2; Thrombocytopenia, platelet dysfunction, hemolysis, and imbalanced globin synthesis; Thrombocytopenia, X-linked; Thrombophilia, hereditary, due to protein C deficiency, autosomal dominant and recessive; Thyroid agenesis; Thyroid cancer, follicular; Thyroid hormone metabolism, abnormal; Thyroid hormone resistance, generalized, autosomal dominant; Thyrotoxic periodic paralysis and Thyrotoxic periodic paralysis 2; Thyrotropin-releasing hormone resistance, generalized; Timothy syndrome; TNF receptor-associated periodic fever syndrome (TRAPS); Tooth agenesis, selective, 3 and 4; Torsades de pointes; Townes-Brocks-branchiootorenal-like syndrome; Transient bullous dermolysis of the newborn; Treacher collins

syndrome 1; Trichomegaly with mental retardation, dwarfism and pigmentary degeneration of retina; Trichorhinophalangeal dysplasia type I; Trichorhinophalangeal syndrome type 3; Trimethylaminuria; Tuberous sclerosis syndrome; Lymphangiomyomatosis; Tuberous sclerosis 1 and 2; Tyrosinase-negative oculocutaneous albinism; Tyrosinase-positive oculocutaneous albinism; Tyrosinemia type I; UDPglucose-4-epimerase deficiency; Ullrich congenital muscular dystrophy; Ulna and fibula absence of with severe limb deficiency; Upshaw-Schulman syndrome; Urocanate hydratase deficiency; Usher syndrome, types 1, 1B, 1D, 1G, 2A, 2C, and 2D; Retinitis pigmentosa 39; UV-sensitive syndrome; Van der Woude syndrome; Van Maldergem syndrome 2; Hennekam lymphangiectasia-lymphedema syndrome 2; Variegate porphyria; Ventriculomegaly with cystic kidney disease; Verheij syndrome; Very long chain acyl-CoA dehydrogenase deficiency; Vesicoureteral reflux 8; Visceral heterotaxy 5, autosomal; Visceral myopathy; Vitamin D-dependent rickets, types 1 and 2; Vitelliform dystrophy ; von Willebrand disease type 2M and type 3; Waardenburg syndrome type 1, 4C, and 2E (with neurologic involvement); Klein-Waardenberg syndrome; Walker-Warburg congenital muscular dystrophy; Warburg micro syndrome 2 and 4; Warts, hypogammaglobulinemia, infections, and myelokathexis; Weaver syndrome; Weill-Marchesani syndrome 1 and 3; Weill-Marchesani-like syndrome; Weissenbacher-Zweymuller syndrome; Werdnig-Hoffmann disease; Charcot-Marie-Tooth disease; Werner syndrome; WFS1-Related Disorders; Wiedemann-Steiner syndrome; Wilson disease; Wolfram-like syndrome, autosomal dominant; Worth disease; Van Buchem disease type 2; Xeroderma pigmentosum, complementation group b, group D, group E, and group G; X-linked agammaglobulinemia; X-linked hereditary motor and sensory neuropathy; X-linked ichthyosis with steryl-sulfatase deficiency; X-linked periventricular heterotopia; Oto-palato-digital syndrome, type I; X-linked severe combined immunodeficiency; Zimmermann-Laband syndrome and Zimmermann-Laband syndrome 2; and Zonular pulverulent cataract 3.

[0973] The target nucleotide sequence may comprise a target sequence (e.g., a point mutation) associated with a disease, disorder, or condition. The target sequence may comprise a T to C (or A to G) point mutation associated with a disease, disorder, or condition, and wherein the deamination of the mutant C base results in mismatch repair-mediated correction to a sequence that is not associated with a disease, disorder, or condition. The target sequence may comprise a G to A (or C to T) point mutation associated with a disease, disorder, or condition, and wherein the deamination of the mutant A base results in mismatch repair-mediated correction to a sequence that is not associated with a disease, disorder, or condition. The target sequence may encode a protein, and where the point mutation is in a codon and results in a change in the amino acid encoded by the mutant codon as compared to a wild-type codon. The target sequence may also be at a splice site, and the point mutation results in a change in the splicing of an mRNA transcript as compared to a wild-type transcript. In addition, the target may be at a non-coding sequence of a gene, such as a promoter, and the point mutation results in increased or decreased expression of the gene.

[0974] Thus, in some aspects, the deamination of a mutant C results in a change of the amino acid encoded by the mutant codon, which in some cases can result in the expression of a wild-type amino acid. In other aspects, the deamination of a mutant A results in a change of the amino acid encoded by the mutant codon, which in some cases can result in the expression of a wild-type amino acid.

[0975] The methods described herein involving contacting a cell with a composition or rAAV particle can occur *in vitro*, *ex vivo*, or *in vivo*. In certain embodiments, the step of contacting occurs in a subject. In certain embodiments, the subject has been diagnosed with a disease, disorder, or condition.

[0976] In some embodiments, the methods disclosed herein involve contacting a mammalian cell with a composition or rAAV particle. In particular embodiments, the methods involve contacting a retinal cell, cortical cell or cerebellar cell.

[0977] The split Cas9 protein or split prime editor delivered using the methods described herein preferably have comparable activity compared to the original Cas9 protein or prime editor (*i.e.*, unsplit protein delivered to a cell or expressed in a cell as a whole). For example, the split Cas9 protein or split prime editor retains at least 50% (*e.g.*, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%) of the activity of the original Cas9 protein or prime editor. In some embodiments, the split Cas9 protein or split prime editor is more active (*e.g.*, 2-fold, 5-fold, 10-fold, 100-fold, 1000-fold, or more) than that of an original Cas9 protein or prime editor.

[0978] The compositions described herein may be administered to a subject in need thereof in a therapeutically effective amount to treat and/or prevent a disease or disorder the subject is suffering from. Any disease or disorder that maybe treated and/or prevented using CRISPR/Cas9-based genome-editing technology may be treated by the split Cas9 protein or the split multi- flap prime editor described herein. It is to be understood that, if the nucleotide sequences encoding the split Cas9 protein or the multi-flap prime editor does not further encode a gRNA, a separate nucleic acid vector encoding the gRNA may be administered together with the compositions described herein.

[0979] Exemplary suitable diseases, disorders or conditions include, without limitation the disease or disorder is selected from the group consisting of: cystic fibrosis, phenylketonuria, epidermolytic hyperkeratosis (EHK), chronic obstructive pulmonary disease (COPD), Charcot-Marie-Toot disease type 4J, neuroblastoma (NB), von Willebrand disease (vWD), myotonia congenital, hereditary renal amyloidosis, dilated cardiomyopathy, hereditary lymphedema, familial Alzheimer's disease, prion disease, chronic infantile neurologic cutaneous articular syndrome (CINCA), congenital deafness, Niemann-Pick disease type C (NPC) disease, and desmin-related myopathy (DRM). In particular embodiments, the disease or condition is Niemann-Pick disease type C (NPC) disease.

[0980] In some embodiments, the disease, disorder or condition is associated with a point mutation in an *NPC* gene, a *DNMT1* gene, a *PCSK9* gene, or a *TMC1* gene. In certain embodiments, the point mutation is a T3182C mutation in *NPC*, which results in an I1061T amino acid substitution.

[0981] In certain embodiments, the point mutation is an A545G mutation in *TMC1*, which results in a Y182C amino acid substitution. *TMC1* encodes a protein that forms mechanosensitive ion channels in sensory hair cells of the inner ear and is required for normal auditory function. The Y182C amino acid substitution is associated with congenital deafness.

[0982] In some embodiments, the disease, disorder or condition is associated with a point mutation that generates a stop codon, for example, a premature stop codon within the coding region of a gene.

[0983] Additional exemplary diseases, disorders and conditions include cystic fibrosis (see, *e.g.*, Schwank *et al.*, Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. *Cell stem cell*. **2013**; 13: 653-658; and Wu *et al.*, Correction of a genetic disease in mouse via use of CRISPR-Cas9. *Cell stem cell*. **2013**; 13: 659-662, neither of which uses a deaminase fusion protein to correct the genetic defect); phenylketonuria – *e.g.*, phenylalanine to serine mutation at position 835 (mouse) or 240 (human) or a homologous residue in phenylalanine hydroxylase gene (T>C mutation) – see, *e.g.*, McDonald *et al.*, *Genomics*. **1997**; 39:402-405; Bernard-Soulier syndrome (BSS) – *e.g.*, phenylalanine to serine mutation at position 55 or a homologous residue, or cysteine to arginine at residue 24 or a homologous residue in the platelet membrane glycoprotein IX (T>C mutation) – see, *e.g.*, Noris *et al.*, *British Journal of Haematology*. **1997**; 97: 312-320, and Ali *et al.*, *Hematol*. **2014**; 93: 381-384; epidermolytic hyperkeratosis (EHK) – *e.g.*, leucine to proline mutation at position 160 or 161 (if counting the initiator methionine) or a homologous residue in keratin 1 (T>C mutation) – see, *e.g.*, Chipev *et al.*, *Cell*. **1992**; 70: 821-828, see also accession number P04264 in the UNIPROT database at [www\[dot\]uniprot\[dot\]org](http://www.uniprot.org); chronic obstructive pulmonary disease (COPD) – *e.g.*, leucine to proline mutation at position 54 or 55 (if counting the initiator methionine) or a homologous residue in the processed form of α_1 -antitrypsin or residue 78 in the unprocessed form or a homologous residue (T>C mutation) – see, *e.g.*, Poller *et al.*, *Genomics*. **1993**; 17: 740-743, see also accession number P01011 in the UNIPROT database; Charcot-Marie-Toot disease type 4J – *e.g.*, isoleucine to threonine mutation at position 41 or a homologous residue in FIG4 (T>C mutation) – see, *e.g.*, Lenk *et al.*, *PLoS Genetics*. 2011; 7: e1002104; neuroblastoma (NB) – *e.g.*, leucine to proline mutation at position 197 or a homologous residue in Caspase-9 (T>C mutation) – see, *e.g.*, Kundu *et al.*, *3 Biotech*. **2013**, **3**:225-234; von Willebrand disease (vWD) – *e.g.*, cysteine to arginine mutation at position 509 or a homologous residue in the processed form of von Willebrand factor, or at position 1272 or a homologous residue in the unprocessed form of von Willebrand factor (T>C mutation) – see, *e.g.*, Lavergne *et al.*, *Br. J. Haematol*. **1992**, see also accession number P04275 in the UNIPROT database; 82: 66-72; myotonia congenital – *e.g.*, cysteine to arginine mutation at position 277 or a homologous residue in the muscle chloride channel gene CLCN1 (T>C mutation) – see, *e.g.*,

Weinberger *et al.*, *The J. of Physiology*. **2012**; 590: 3449-3464; hereditary renal amyloidosis – *e.g.*, stop codon to arginine mutation at position 78 or a homologous residue in the processed form of apolipoprotein AII or at position 101 or a homologous residue in the unprocessed form (T>C mutation) – see, *e.g.*, Yazaki *et al.*, *Kidney Int.* **2003**; 64: 11-16; dilated cardiomyopathy (DCM) – *e.g.*, tryptophan to Arginine mutation at position 148 or a homologous residue in the FOXD4 gene (T>C mutation), see, *e.g.*, Minorette *et. al.*, *Int. J. of Mol. Med.* **2007**; 19: 369-372; hereditary lymphedema – *e.g.*, histidine to arginine mutation at position 1035 or a homologous residue in VEGFR3 tyrosine kinase (A>G mutation), see, *e.g.*, Irrthum *et al.*, *Am. J. Hum. Genet.* **2000**; 67: 295-301; familial Alzheimer's disease – *e.g.*, isoleucine to valine mutation at position 143 or a homologous residue in presenilin1 (A>G mutation), see, *e.g.*, Gallo *et. al.*, *J. Alzheimer's disease*. **2011**; 25: 425-431; Prion disease – *e.g.*, methionine to valine mutation at position 129 or a homologous residue in prion protein (A>G mutation) – see, *e.g.*, Lewis *et. al.*, *J. of General Virology*. **2006**; 87: 2443-2449; chronic infantile neurologic cutaneous articular syndrome (CINCA) – *e.g.*, Tyrosine to Cysteine mutation at position 570 or a homologous residue in cryopyrin (A>G mutation) – see, *e.g.*, Fujisawa *et. al.* *Blood*. **2007**; 109: 2903-2911; and desmin-related myopathy (DRM) – *e.g.*, arginine to glycine mutation at position 120 or a homologous residue in $\alpha\beta$ crystallin (A>G mutation) – see, *e.g.*, Kumar *et al.*, *J. Biol. Chem.* **1999**; 274: 24137-24141. The entire contents of all references and database entries is incorporated herein by reference.

Trinucleotide repeat expansion disease

[0984] Trinucleotide repeat expansion is associated with a number of human diseases, including Huntington's Disease, Fragile X syndrome, and Friedreich's ataxia. The most common trinucleotide repeat contains CAG triplets, though GAA triplets (Friedreich's ataxia) and CGG triplets (Fragile X syndrome) also occur. Inheriting a predisposition to expansion, or acquiring an already expanded parental allele, increases the likelihood of acquiring the disease. Pathogenic expansions of trinucleotide repeats could hypothetically be corrected using multi-flap prime editing.

[0985] A region upstream of the repeat region can be nicked by an RNA-guided nuclease, then used to prime synthesis of a new DNA strand that contains a healthy number of repeats (which depends on the particular gene and disease), in accordance with the general mechanism outlined in FIG. 1G or FIG. 22. After the repeat sequence, a short stretch of homology is added that matches the identity of the sequence adjacent to the other end of the repeat (red strand). Invasion of the newly synthesized strand by the TPRT system, and subsequent replacement of the endogenous DNA with the newly synthesized flap, leads to a contracted repeat allele. The term "contracted" refers to a shortening of the length of the nucleotide repeat region, thereby resulting in repairing the trinucleotide repeat region.

[0986] The multi-flap prime editing systems (*e.g.*, dual-flap and quadruple-flap prime editing systems) described herein may be used to contract trinucleotide repeat mutations (or "triplet

expansion diseases”) to treating conditions such as Huntington’s disease and other trinucleotide repeat disorders. Trinucleotide repeat expansion disorders are complex, progressive disorders that involve developmental neurobiology and often affect cognition as well as sensori-motor functions. The disorders show genetic anticipation (i.e. increased severity with each generation). The DNA expansions or contractions usually happen meiotically (i.e. during the time of gametogenesis, or early in embryonic development), and often have sex-bias meaning that some genes expand only when inherited through the female, others only through the male. In humans, trinucleotide repeat expansion disorders can cause gene silencing at either the transcriptional or translational level, which essentially knocks out gene function. Alternatively, trinucleotide repeat expansion disorders can cause altered proteins generated with large repetitive amino acid sequences that either abrogate or change protein function, often in a dominant-negative manner (e.g. poly-glutamine diseases).

[0987] Without wishing to be bound by theory, triplet expansion is caused by slippage during DNA replication or during DNA repair synthesis. Because the tandem repeats have identical sequence to one another, base pairing between two DNA strands can take place at multiple points along the sequence. This may lead to the formation of “loop out” structures during DNA replication or DNA repair synthesis. This may lead to repeated copying of the repeated sequence, expanding the number of repeats. Additional mechanisms involving hybrid RNA:DNA intermediates have been proposed. Multi-flap prime editing may be used to reduce or eliminate these triplet expansion regions by deletion one or more of the offending repeat codon triplets. In an embodiment of this use, FIG. 23, provides a schematic of a PEgRNA design for contracting or reducing trinucleotide repeat sequences with prime editing.

[0988] Multi-flap prime editing may be implemented to contract triplet expansion regions by nicking a region upstream of the triplet repeat region with the prime editor comprising a PEgRNA appropriated targeted to the cut site. The prime editor then synthesizes a new DNA strand (ssDNA flap) based on the PEgRNA as a template (i.e., the edit template thereof) that codes for a healthy number of triplet repeats (which depends on the particular gene and disease). The newly synthesized ssDNA strand comprising the healthy triplet repeat sequence also is synthesized to include a short stretch of homology (i.e., the homology arm) that matches the sequence adjacent to the other end of the repeat (red strand). Invasion of the newly synthesized strand, and subsequent replacement of the endogenous DNA with the newly synthesized ssDNA flap, leads to a contracted repeat allele.

[0989] Depending on the particular trinucleotide expansion disorder, the defect-inducing triplet expansions may occur in “trinucleotide repeat expansion proteins.” Trinucleotide repeat expansion proteins are a diverse set of proteins associated with susceptibility for developing a trinucleotide repeat expansion disorder, the presence of a trinucleotide repeat expansion disorder, the severity of a trinucleotide repeat expansion disorder or any combination thereof. Trinucleotide repeat expansion disorders are divided into two categories determined by the type of repeat. The most common repeat

is the triplet CAG, which, when present in the coding region of a gene, codes for the amino acid glutamine (Q). Therefore, these disorders are referred to as the polyglutamine (polyQ) disorders and comprise the following diseases: Huntington Disease (HD); Spinobulbar Muscular Atrophy (SBMA); Spinocerebellar Ataxias (SCA types 1, 2, 3, 6, 7, and 17); and Dentatorubro-Pallidoluysian Atrophy (DRPLA). The remaining trinucleotide repeat expansion disorders either do not involve the CAG triplet or the CAG triplet is not in the coding region of the gene and are, therefore, referred to as the non-polyglutamine disorders. The non-polyglutamine disorders comprise Fragile X Syndrome (FRAXA); Fragile XE Mental Retardation (FRAXE); Friedreich Ataxia (FRDA); Myotonic Dystrophy (DM); and Spinocerebellar Ataxias (SCA types 8, and 12).

[0990] The proteins associated with trinucleotide repeat expansion disorders can be selected based on an experimental association of the protein associated with a trinucleotide repeat expansion disorder to a trinucleotide repeat expansion disorder. For example, the production rate or circulating concentration of a protein associated with a trinucleotide repeat expansion disorder may be elevated or depressed in a population having a trinucleotide repeat expansion disorder relative to a population lacking the trinucleotide repeat expansion disorder. Differences in protein levels may be assessed using proteomic techniques including but not limited to Western blot, immunohistochemical staining, enzyme linked immunosorbent assay (ELISA), and mass spectrometry. Alternatively, the proteins associated with trinucleotide repeat expansion disorders may be identified by obtaining gene expression profiles of the genes encoding the proteins using genomic techniques including but not limited to DNA microarray analysis, serial analysis of gene expression (SAGE), and quantitative real-time polymerase chain reaction (Q-PCR).

[0991] Non-limiting examples of proteins associated with trinucleotide repeat expansion disorders which can be corrected by multi-flap prime editing include AR (androgen receptor), FMR1 (fragile X mental retardation 1), HTT (huntingtin), DMPK (dystrophia myotonica-protein kinase), FXN (frataxin), ATXN2 (ataxin 2), ATN1 (atrophin 1), FEN1 (flap structure-specific endonuclease 1), TNRC6A (trinucleotide repeat containing 6A), PABPN1 (poly(A) binding protein, nuclear 1), JPH3 (junctophilin 3), MED15 (mediator complex subunit 15), ATXN1 (ataxin 1), ATXN3 (ataxin 3), TBP (TATA box binding protein), CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit), ATXN80S (ATXN8 opposite strand (non-protein coding)), PPP2R2B (protein phosphatase 2, regulatory subunit B, beta), ATXN7 (ataxin 7), TNRC6B (trinucleotide repeat containing 6B), TNRC6C (trinucleotide repeat containing 6C), CELF3 (CUGBP, Elav-like family member 3), MAB21L1 (mab-21-like 1 (C. elegans)), MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)), TMEM185A (transmembrane protein 185A), SIX5 (SIX homeobox 5), CNPY3 (canopy 3 homolog (zebrafish)), FRAXE (fragile site, folic acid type, rare, fra(X)(q28) E), GNB2 (guanine nucleotide binding protein (G protein), beta polypeptide 2), RPL14 (ribosomal protein L14), ATXN8 (ataxin 8), INSR (insulin receptor), TTR (transthyretin), EP400 (E1A binding protein p400), GIGYF2

(GRB10 interacting GYF protein 2), OGG1 (8-oxoguanine DNA glycosylase), STC1 (stanniocalcin 1), CNDP1 (carnosine dipeptidase 1 (metallopeptidase M20 family)), C10orf2 (chromosome 10 open reading frame 2), MAML3 mastermind-like 3 (*Drosophila*), DKC1 (dyskeratosis congenita 1, dyskerin), PAXIP1 (PAX interacting (with transcription-activation domain) protein 1), CASK (calcium/calmodulin-dependent serine protein kinase (MAGUK family)), MAPT (microtubule-associated protein tau), SP1 (Sp1 transcription factor), POLG (polymerase (DNA directed), gamma), AFF2 (AF4/FMR2 family, member 2), THBS1 (thrombospondin 1), TP53 (tumor protein p53), ESR1 (estrogen receptor 1), CGGBP1 (CGG triplet repeat binding protein 1), ABT1 (activator of basal transcription 1), KLK3 (kallikrein-related peptidase 3), PRNP (prion protein), JUN (jun oncogene), KCNN3 (potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3), BAX (BCL2-associated X protein), FRAXA (fragile site, folic acid type, rare, fra(X)(q27.3) A (macroorchidism, mental retardation)), KBTBD10 (kelch repeat and BTB (POZ) domain containing 10), MBNL1 (muscleblind-like (*Drosophila*)), RAD51 (RAD51 homolog (RecA homolog, *E. coli*) (*S. cerevisiae*)), NCOA3 (nuclear receptor coactivator 3), ERDA1 (expanded repeat domain, CAG/CTG 1), TSC1 (tuberous sclerosis 1), COMP (cartilage oligomeric matrix protein), GCLC (glutamate-cysteine ligase, catalytic subunit), RRAD (Ras-related associated with diabetes), MSH3 (mutS homolog 3 (*E. coli*)), DRD2 (dopamine receptor D2), CD44 (CD44 molecule (Indian blood group)), CTCF (CCCTC-binding factor (zinc finger protein)), CCND1 (cyclin D1), CLSPN (claspin homolog (*Xenopus laevis*)), MEF2A (myocyte enhancer factor 2A), PTPRU (protein tyrosine phosphatase, receptor type, U), GAPDH (glyceraldehyde-3-phosphate dehydrogenase), TRIM22 (tripartite motif-containing 22), WT1 (Wilms tumor 1), AHR (aryl hydrocarbon receptor), GPX1 (glutathione peroxidase 1), TPMT (thiopurine S-methyltransferase), NDP (Norrie disease (pseudoglioma)), ARX (aristaless related homeobox), MUS81 (MUS81 endonuclease homolog (*S. cerevisiae*)), TYR (tyrosinase (oculocutaneous albinism IA)), EGR1 (early growth response 1), UNG (uracil-DNA glycosylase), NUMBL (numb homolog (*Drosophila*)-like), FABP2 (fatty acid binding protein 2, intestinal), EN2 (engrailed homeobox 2), CRYGC (crystallin, gamma C), SRP14 (signal recognition particle 14 kDa (homologous Alu RNA binding protein)), CRYGB (crystallin, gamma B), PDCD1 (programmed cell death 1), HOXA1 (homeobox A1), ATXN2L (ataxin 2-like), PMS2 (PMS2 postmeiotic segregation increased 2 (*S. cerevisiae*)), GLA (galactosidase, alpha), CBL (Cas-Br-M (murine) ecotropic retroviral transforming sequence), FTH1 (ferritin, heavy polypeptide 1), IL12RB2 (interleukin 12 receptor, beta 2), OTX2 (orthodenticle homeobox 2), HOXA5 (homeobox A5), POLG2 (polymerase (DNA directed), gamma 2, accessory subunit), DLX2 (distal-less homeobox 2), SIRPA (signal-regulatory protein alpha), OTX1 (orthodenticle homeobox 1), AHRR (aryl-hydrocarbon receptor repressor), MANF (mesencephalic astrocyte-derived neurotrophic factor), TMEM158 (transmembrane protein 158 (gene/pseudogene)), and ENSG00000078687.

[0992] In a particular aspect, the instant disclosure provides TPRT-based methods for the treatment of a subject diagnosed with an expansion repeat disorder (also known as a repeat expansion disorder or a trinucleotide repeat disorder). Expansion repeat disorders occur when microsatellite repeats expand beyond a threshold length. Currently, at least 30 genetic diseases are believed to be caused by repeat expansions. Scientific understanding of this diverse group of disorders came to lights in the early 1990's with the discovery that trinucleotide repeats underlie several major inherited conditions, including Fragile X, Spinal and Bulbar Muscular Atrophy, Myotonic Dystrophy, and Huntington's disease (Nelson et al, "The unstable repeats – three evolving faces of neurological disease," *Neuron*, March 6, 2013, Vol.77; 825-843, which is incorporated herein by reference), as well as Haw River Syndrome, Jacobsen Syndrome, Dentatorubral-pallidoluysian atrophy (DRPLA), Machado-Joseph disease, Synpolydactyly (SPD II), Hand-foot genital syndrome (HFGS), Cleidocranial dysplasia (CCD), Holoprosencephaly disorder (HPE), Congenital central hypventilation syndrome (CCHS), ARX-nonsyndromic X-linked mental retardation (XLMR), and Oculopharyngeal muscular dystrophy (OPMD) (see . Microsatellite repeat instability was found to be a hallmark of these conditions, as was anticipation – the phenomenon in which repeat expansion can occur with each successive generation, which leads to a more severe phenotype and earlier age of onset in the offspring. Repeat expansions are believed to cause diseases via several different mechanisms. Namely, expansions may interfere with cellular functioning at the level of the gene, the mRNA transcript, and/or the encoded protein. In some conditions, mutations act via a loss-of-function mechanism by silencing repeat-containing genes. In others, disease results from gain-of-function mechanisms, whereby either the mRNA transcript or protein takes on new, aberrant functions.

[0993] In one embodiment, a method of treating a trinucleotide repeat disorder is depicted in FIG. 23. In general, the approach involves using TPRT genome editing (i.e., multi-flap prime editing) in combination with an extended gRNA that comprises a region that encodes a desired and healthy replacement trinucleotide repeat sequence that is intended to replace the endogenous diseased trinucleotide repeat sequence through the mechanism of the prime editing process. A schematic of an exemplary gRNA design for contracting trinucleotide repeat sequences and trinucleotide repeat contraction with TPRT genome editing (i.e., multi-flap prime editing) is shown in FIG. 23.

Prion disease

[0994] Multi-flap prime editing can also be used to prevent or halt the progression of prion disease through the installation of one or more protective mutations into prion proteins (PRNP) which become misfolded during the course of disease. Prion diseases or transmissible spongiform encephalopathies (TSEs) are a family of rare progressive neurodegenerative disorders that affect both humans and animals. They are distinguished by long incubation periods, characteristic spongiform changes associated with neuronal loss, and a failure to induce inflammatory response.

[0995] In humans, prion disease includes Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Gerstmann-Straussler-Scheinker Syndrome, Fatal Familial Insomnia, and Kuru. In animals, prion disease includes Bovine Spongiform Encephalopathy (BSE or “mad cow disease”), Chronic Wasting Disease (CWD), Scrapie, Transmissible Mink Encephalopathy, Feline Spongiform Encephalopathy, and Ungulate Spongiform Encephalopathy. Multi-flap prime editing may be used to install protective point mutations into a prion protein in order to prevent or halt the progression of any one of these prion diseases.

[0996] Classic CJD is a human prion disease. It is a neurodegenerative disorder with characteristic clinical and diagnostic features. This disease is rapidly progressive and always fatal. Infection with this disease leads to death usually within 1 year of onset of illness. CJD is a rapidly progressive, invariably fatal neurodegenerative disorder believed to be caused by an abnormal isoform of a cellular glycoprotein known as the prion protein. CJD occurs worldwide and the estimated annual incidence in many countries, including the United States, has been reported to be about one case per million population. The vast majority of CJD patients usually die within 1 year of illness onset. CJD is classified as a transmissible spongiform encephalopathy (TSE) along with other prion diseases that occur in humans and animals. In about 85% of patients, CJD occurs as a sporadic disease with no recognizable pattern of transmission. A smaller proportion of patients (5 to 15%) develop CJD because of inherited mutations of the prion protein gene. These inherited forms include Gerstmann-Straussler-Scheinker syndrome and fatal familial insomnia. No treatment is currently known for CJD.

[0997] Variant Creutzfeldt-Jakob disease (vCJD) is a prion disease that was first described in 1996 in the United Kingdom. There is now strong scientific evidence that the agent responsible for the outbreak of prion disease in cows, bovine spongiform encephalopathy (BSE or ‘mad cow’ disease), is the same agent responsible for the outbreak of vCJD in humans. Variant CJD (vCJD) is not the same disease as classic CJD (often simply called CJD). It has different clinical and pathologic characteristics from classic CJD. Each disease also has a particular genetic profile of the prion protein gene. Both disorders are invariably fatal brain diseases with unusually long incubation periods measured in years, and are caused by an unconventional transmissible agent called a prion. No treatment is currently known for vCJD.

[0998] BSE (bovine spongiform encephalopathy or “mad cow disease”) is a progressive neurological disorder of cattle that results from infection by an unusual transmissible agent called a prion. The nature of the transmissible agent is not well understood. Currently, the most accepted theory is that the agent is a modified form of a normal protein known as prion protein. For reasons that are not yet understood, the normal prion protein changes into a pathogenic (harmful) form that then damages the central nervous system of cattle. There is increasing evidence that there are different strains of BSE: the typical or classic BSE strain responsible for the outbreak in the United Kingdom and two atypical strains (H and L strains). No treatment is currently known for BSE.

[0999] Chronic wasting disease (CWD) is a prion disease that affects deer, elk, reindeer, sika deer and moose. It has been found in some areas of North America, including Canada and the United States, Norway and South Korea. It may take over a year before an infected animal develops symptoms, which can include drastic weight loss (wasting), stumbling, listlessness and other neurologic symptoms. CWD can affect animals of all ages and some infected animals may die without ever developing the disease. CWD is fatal to animals and there are no treatments or vaccines.

[1000] The causative agents of TSEs are believed to be prions. The term “prions” refers to abnormal, pathogenic agents that are transmissible and are able to induce abnormal folding of specific normal cellular proteins called prion proteins that are found most abundantly in the brain. The functions of these normal prion proteins are still not completely understood. The abnormal folding of the prion proteins leads to brain damage and the characteristic signs and symptoms of the disease. Prion diseases are usually rapidly progressive and always fatal.

[1001] As used herein, the term “prion” shall mean an infectious particle known to cause diseases (spongiform encephalopathies) in humans and animals. The term “prion” is a contraction of the words “protein” and “infection” and the particles are comprised largely if not exclusively of PRNP^{Sc} molecules encoded by a PRNP gene which expresses PRNP^C which changes conformation to become PRNP^{Sc}. Prions are distinct from bacteria, viruses and viroids. Known prions include those which infect animals to cause scrapie, a transmissible, degenerative disease of the nervous system of sheep and goats as well as bovine spongiform encephalopathies (BSE) or mad cow disease and feline spongiform encephalopathies of cats. Four prion diseases, as discussed above, known to affect humans are (1) kuru, (2) Creutzfeldt-Jakob Disease (CJD), (3) Gerstmann-Strassler-Scheinker Disease (GSS), and (4) fatal familial insomnia (FFI). As used herein prion includes all forms of prions causing all or any of these diseases or others in any animals used--and in particular in humans and in domesticated farm animals.

[1002] In general, and without wishing to be bound by theory, prion diseases are caused by misfolding of prion proteins. Such diseases—often called deposition diseases—the misfolding of the prion proteins can be accounted for as follows. If A is the normally synthesized gene product that carries out an intended physiologic role in a monomeric or oligomeric state, A* is a conformationally activated form of A that is competent to undergo a dramatic conformational change, B is the conformationally altered state that prefers multimeric assemblies (i.e., the misfolded form which forms depositions) and B_n is the multimeric material that is pathogenic and relatively difficult to recycle. For the prion diseases, PRNP^C and PRNP^{Sc} correspond to states A and B_n where A is largely helical and monomeric and B_n is β -rich and multimeric.

[1003] It is known that certain mutations in prion proteins can be associated with increased risk of prion disease. Conversely, certain mutations in prion proteins can be protective in nature. See Bagynszky et al., “Characterization of mutations in PRNP (prion) gene and their possible roles in

neurodegenerative diseases,” *Neuropsychiatr Dis Treat.*, 2018; 14: 2067-2085, the contents of which are incorporated herein by reference.

[1004] PRNP (NCBI RefSeq No. NP_000302.1 (SEQ ID NO: 291))—the human prion protein—is encoded by a 16 kb long gene, located on chromosome 20 (4686151-4701588). It contains two exons, and the exon 2 carries the open reading frame which encodes the 253 amino acid (AA) long PrP protein. Exon 1 is a noncoding exon, which may serve as transcriptional initiation site. The post-translational modifications result in the removal of the first 22 AA N-terminal fragment (NTF) and the last 23 AA C-terminal fragment (CTF). The NTF is cleaved after PrP transport to the endoplasmic reticulum (ER), while the CTF (glycosylphosphatidylinositol [GPI] signal peptide [GPI-SP]) is cleaved by the GPI anchor. GPI anchor could be involved in PrP protein transport. It may also play a role of attachment of prion protein into the outer surface of cell membrane. Normal PrP is composed of a long N-terminal loop (which contains the octapeptide repeat region), two short β sheets, three α helices, and a C-terminal region (which contains the GPI anchor). Cleavage of PrP results in a 208 AA long glycoprotein, anchored in the cell membrane.

[1005] The 253 amino acid sequence of PRNP (NP_000302.1) is as follows:

MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGGGWGQ
PHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPSKPKTNMKHMAGA
AAAGAVVGGGLGGYMLGSAMSRPIHFGSDYEDRYRENMHRYPNQVYRPMDEYSNQNNF
VHDCVNITIKQHTVTTTTKGENFTETDVKMMERVVEQMCITQYERESQAYYQRGSSMVLFS
PPVILLISFLIFLIVG (SEQ ID NO: 291).

[1006] The 253 amino acid sequence of PRNP (NP_000302.1) is encoded by the following nucleotide sequence (NCBI Ref. Seq No. NM_000311.5, “homo sapiens prion protein (PRNP), transcript variant 1, mRNA), is as follows:

GCGAACCTTGGCTGCTGGATGCTGGTTCTCTTTGTGGCCACATGGAGTGACCTGGGCCTCT
GCAAGAAGCGCCCGAAGCCTGGAGGATGGAACACTGGGGGCAGCCGATACCCGGGGCAG
GGCAGCCCTGGAGGCAACCGCTACCCACCTCAGGGCGGTGGTGGCTGGGGGCAGCCTCA
TGGTGGTGGCTGGGGGCAGCCTCATGGTGGTGGCTGGGGGCAGCCCATGGTGGTGGCTG
GGGACAGCCTCATGGTGGTGGCTGGGGTCAAGGAGGTGGCACCCACAGTCAGTGGAACA
AGCCGAGTAAGCAAAAACCAACATGAAGCACATGGCTGGTGGTGGTGGTGGTGGTGGTGG
GTGGTGGGGGGCCTTGGCGGCTACATGCTGGGAAGTGCCATGAGCAGGCCCATCATACAT
TTCGGCAGTGACTATGAGGACCGTTACTATCGTGAAAACATGCACCGTTACCCCAACCAAG
TGTAATACAGGCCCATGGATGAGTACAGCAACCAGAACAACTTTGTGCACGACTGCGTCA
ATATCACAATCAAGCAGCACACGGTCACCACAACCACCAAGGGGGAGAACTTCACCGAG
ACCGACGTTAAGATGATGGAGCGCGTGGTTGAGCAGATGTGTATCACCCAGTACGAGAGG
GAATCTCAGGCCTATTACCAGAGAGGATCGAGCATGGTCCTCTTCTCCTCTCCACCTGTGA
TCCTCCTGATCTCTTTCCTCATCTTCCTGATAGTGGGATGAGGAAGGTCTTCCTGTTTTAC
CATCTTTCTAATCTTTTCCAGCTTGAGGGAGGCGGTATCCACCTGCAGCCCTTTTAGTGGT
GGTGTCTCACTCTTTCTTCTCTCTTTGTCCCGGATAGGCTAATCAATACCCTTGGCACTGAT
GGGCACTGGAAAACATAGAGTAGACCTGAGATGCTGGTCAAGCCCCCTTTGATTGAGTTC
ATCATGAGCCGTTGCTAATGCCAGGCCAGTAAAAGTATAACAGCAAATAACCATTTGGTTAA
TCTGGACTTATTTTTGGACTTAGTGCAACAGTTGAGGCTAAAACAAATCTCAGAACAGTC
TGAAATACCTTTGCCTGGATACCTCTGGCTCCTTCAGCAGCTAGAGCTCAGTATACTAATGC
CCTATCTTAGTAGAGATTTATAGCTATTTAGAGATATTTCCATTTTAAGAAAACCCGACAA
CATTTCTGCCAGGTTTGTAGGAGGCCACATGATACTTATCAAAAAATCCTAGAGATTCT
TAGCTCTTGGGATGCAGGCTCAGCCCGCTGGAGCATGAGCTCTGTGTGTACCGAGAACTG

GGGTGATGTTTTACTTTTCACAGTATGGGCTACACAGCAGCTGTTCAACAAGAGTAAATAT
 TGTCACAACACTGAACCTCTGGCTAGAGGACATATTCACAGTGAACATAACTGTAACATAT
 ATGAAAGGCTTCTGGGACTTGAAATCAAATGTTTGGGAATGGTGCCCTTGGAGGCAACCT
 CCCATTTTAGATGTTTAAAGGACCCTATATGTGGCATTCTTTCTTTAACTATAGGTAATTA
 AGGCAGCTGAAAAGTAAATTGCCTTCTAGACACTGAAGGCAAATCTCCTTTGTCCATTTAC
 CTGGAAACCAGAATGATTTTGACATACAGGAGAGCTGCAGTTGTGAAAGCACCATCATCA
 TAGAGGATGATGTAATTAATAAATGGTCAGTGTGCAAAGAAAAGAACTGCTTGCATTTCTT
 TATTTCTGTCTCATAATTGTCAAAAACCAGAATTAGGTCAAGTTCATAGTTTCTGTAATTGG
 CTTTTGAATCAAAGAATAGGGAGACAATCTAAAAAATATCTTAGGTTGGAGATGACAGAA
 ATATGATTGATTTGAAGTGGAAAAAGAAATCTGTTAATGTTAATTAAGTAAAATTATTCC
 CTGAATTGTTTGATATTGTCACCTAGCAGATATGTATTACTTTTCTGCAATGTTATTATTGGCT
 TGCACCTTTGTGAGTATTCTATGTAAAAATATATATATATAAAATATATATTGCATAGGACAG
 ACTTAGGAGTTTTGTTTAGAGCAGTTAAACATCTGAAGTGTCTAATGCATTAACCTTTGTAAAG
 GTACTGAATACTTAATATGTGGGAAACCCTTTTGCCTGGTCCTTAGGCTTACAATGTGCACT
 GAATCGTTTCATGTAAGAATCCAAAGTGGACACCATTAAACAGGTCTTTGAAATATGCATGT
 ACTTTATATTTTCTATATTTGTAACCTTGCATGTTCTTGTTTTGTATATAAAAAAATTGTAAA
 TGTTTAATATCTGACTGAAATTAACGAGCGAAGATGAGCACCA (SEQ ID NO: 292)

[1007] Mutation sites relative to PRNP (NP_000302.1) which are linked to CJD and FFI are reported are as follows. These mutations can be removed or installed using the multi-flap prime editors disclosed herein.

MUTATION	AMINO ACID SEQUENCE OF MUTANT PRNP LINKED TO CJD PRION DISEASE (SEE TABLE 1 OF BAGYNSZKY ET AL., 2018) (RELATIVE TO SEQ ID NO: 291 OF PRNP NP_000302.1)
D178N	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHNCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3940)
T188K	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHKVTTTTKGENFTETDVKMMER VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3941)
E196K	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGNFTETDVKMMER VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3942)
E196A	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGANFTETDVKMMER VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 296)
E200K	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTKTDVKMMER VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3943)
E200G	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH

	RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTGTDVKMMER VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 298)
V203I	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDIKMMERV VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3944)
R208H	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERH VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3945)
V210I	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV IEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3946)
E211Q	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3947)
M232R	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3948)

[1008] Mutation sites relative to PRNP (NP_000302.1) (SEQ ID NO: 291) which are linked to GSS are reported, as follows:

MUTATION	AMINO ACID SEQUENCE OF MUTANT PRNP LINKED TO GSS PRION DISEASE (SEE TABLE 2 OF BAGYNSZKY ET AL., 2018) (RELATIVE TO SEQ ID NO: 291 OF PRNP NP_000302.1)
P102L	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKLS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3949)
P105L	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KLKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3950)
A117V	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAVAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMRH YPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3951)
G131V	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLVSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VVEQMCITQYERESQAYYQRGSSMVLFFSPPV (SEQ ID NO: 3952)

V176G	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3953)
H187R	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQRTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3954)
	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 487)
F198S	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENSTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3955)
D202N	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3956)
Q212P	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEPMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3957)
Q217R	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITRYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3958)
M232T	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMH RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3959)

[1009] Mutation sites relative to PRNP (NP_000302.1) (SEQ ID NO: 291) which are linked to a possible protective nature against prion disease, as follows:

MUTATION	AMINO ACID SEQUENCE OF MUTANT PRNP LINKED TO A PROTECTIVE NATURE AGAINST PRION DISEASE (SEE TABLE 4 OF BAGYNSZKY ET AL., 2018) (RELATIVE TO SEQ ID NO: 291 OF PRNP NP_000302.1)
G127S	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGSYMLGSAMSRPIIHFGSDYEDRYRENMR YPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3960)
G127V	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGVYMLGSAMSRPIIHFGSDYEDRYRENMH

	RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3961)
M129V	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYVLGSAMSRPIIHFGSDYEDRYRENMR RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3962)
D167G	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMR RYPNQVYYRPMGEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3963)
D167N	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMR RYPNQVYYRPMNEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3964)
N171S	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMR RYPNQVYYRPMDEYSSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3965)
E219K	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMR RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYKRESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3966)
P238S	MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQG GGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPS KPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYRENMR RYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERV VEQMCITQYERESQAYYQRGSSMVLFSPPV (SEQ ID NO: 3967)

[1010] Thus, in various embodiments, multi-flap prime editing may be used to remove a mutation in PRNP that is linked to prion disease or install a mutation in PRNP that is considered to be protective against prion disease. For example, multi-flap prime editing may be used to remove or restore a D178N, V180I, T188K, E196K, E196A, E200K, E200G, V203I, R208H, V210I, E211Q, I215V, or M232R mutation in the PRNP protein (relative to PRNP of NP_000302.1) (SEQ ID NO: 291). In other embodiments, multi-flap prime editing may be used to remove or restore a P102L, P105L, A117V, G131V, V176G, H187R, F198S, D202N, Q212P, Q217R, or M232T mutation in the PRNP protein (relative to PRNP of NP_000302.1) (SEQ ID NO: 291). By removing or correcting for the presence of such mutations in PRNP using prime editing, the risk of prion disease may be reduced or eliminated.

[1011] In other embodiments, multi-flap prime editing may be used to install a protective mutation in PRNP that is linked to a protective effect against one or more prion diseases. For example, multi-flap prime editing may be used to install a G127S, G127V, M129V, D167G, D167N, N171S, E219K, or P238S protective mutation in PRNP (relative to PRNP of NP_000302.1) (SEQ ID NO: 291). In still other embodiments, the protective mutation may be any alternate amino acid installed at G127, G127,

M129, D167, N171, E219, or P238 in PRNP (relative to PRNP of NP_000302.1) (SEQ ID NO: 291).

[1012] In particular embodiments, multi-flap prime editing may be used to install a G127V protective mutation in PRNP, as illustrated in FIG. 27 and discussed in Example 5.

[1013] In another embodiment, prime editing may be used to install an E219K protective mutation in PRNP.

[1014] The *PRNP* protein and the protective mutation site are conserved in mammals, so in addition to treating human disease it could also be used to generate cows and sheep that are immune to prion disease, or even help cure wild populations of animals that are suffering from prion disease. Prime editing has already been used to achieve ~25% installation of a naturally occurring protective allele in human cells, and previous mouse experiments indicate that this level of installation is sufficient to cause immunity from most prion diseases. This method is the first and potentially only current way to install this allele with such high efficiency in most cell types. Another possible strategy for treatment is to use prime editing or multi-flap prime editing to reduce or eliminate the expression of *PRNP* by installing an early stop codon in the gene.

[1015] Using the principles described herein for PEGRNA design, appropriate PEGRNAs may be designed for installing desired protective mutations, or for removing prion disease-associated mutations from PRNP. For example, the below list of PEGRNAs can be used to install the G127V protective allele and the E219K protective allele in human PRNP, as well as the G127V protective allele in PRNP of various animals.

[10] Pharmaceutical compositions

[1016] Other aspects of the present disclosure relate to pharmaceutical compositions comprising any of the various components of the multi-flap prime editing system described herein (e.g., including, but not limited to, the napDNAbs, reverse transcriptases, fusion proteins (e.g., comprising napDNAbs and reverse transcriptases), extended guide RNAs, and complexes comprising fusion proteins and extended guide RNAs, as well as accessory elements, such as second strand nicking components and 5' endogenous DNA flap removal endonucleases for helping to drive the multi-flap prime editing process towards the edited product formation).

[1017] The term “pharmaceutical composition”, as used herein, refers to a composition formulated for pharmaceutical use. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises additional agents (e.g. for specific delivery, increasing half-life, or other therapeutic compounds).

[1018] As used here, the term “pharmaceutically-acceptable carrier” means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent

encapsulating material, involved in carrying or transporting the compound from one site (e.g., the delivery site) of the body, to another site (e.g., organ, tissue or portion of the body). A pharmaceutically acceptable carrier is “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the tissue of the subject (e.g., physiologically compatible, sterile, physiologic pH, etc.). Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; (22) C2-C12 alcohols, such as ethanol; and (23) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservative and antioxidants can also be present in the formulation. The terms such as “excipient”, “carrier”, “pharmaceutically acceptable carrier” or the like are used interchangeably herein.

[1019] In some embodiments, the pharmaceutical composition is formulated for delivery to a subject, e.g., for gene editing. Suitable routes of administering the pharmaceutical composition described herein include, without limitation: topical, subcutaneous, transdermal, intradermal, intralesional, intraarticular, intraperitoneal, intravesical, transmucosal, gingival, intradental, intracochlear, transtympanic, intraorgan, epidural, intrathecal, intramuscular, intravenous, intravascular, intraosseous, periocular, intratumoral, intracerebral, and intracerebroventricular administration.

[1020] In some embodiments, the pharmaceutical composition described herein is administered locally to a diseased site (e.g., tumor site). In some embodiments, the pharmaceutical composition described herein is administered to a subject by injection, by means of a catheter, by means of a suppository, or by means of an implant, the implant being of a porous, non-porous, or gelatinous material, including a membrane, such as a sialastic membrane, or a fiber.

[1021] In other embodiments, the pharmaceutical composition described herein is delivered in a controlled release system. In one embodiment, a pump may be used (see, e.g., Langer, 1990, Science 249:1527-1533; Sefton, 1989, CRC Crit. Ref. Biomed. Eng. 14:201; Buchwald et al., 1980, Surgery

88:507; Saudek et al., 1989, N. Engl. J. Med. 321:574). In another embodiment, polymeric materials can be used. (See, e.g., Medical Applications of Controlled Release (Langer and Wise eds., CRC Press, Boca Raton, Fla., 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball eds., Wiley, New York, 1984); Ranger and Peppas, 1983, Macromol. Sci. Rev. Macromol. Chem. 23:61. See also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105). Other controlled release systems are discussed, for example, in Langer, *supra*.

[1022] In some embodiments, the pharmaceutical composition is formulated in accordance with routine procedures as a composition adapted for intravenous or subcutaneous administration to a subject, e.g., a human. In some embodiments, pharmaceutical composition for administration by injection are solutions in sterile isotonic aqueous buffer. Where necessary, the pharmaceutical can also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the pharmaceutical is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the pharmaceutical composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.

[1023] A pharmaceutical composition for systemic administration may be a liquid, e.g., sterile saline, lactated Ringer's or Hank's solution. In addition, the pharmaceutical composition can be in solid forms and re-dissolved or suspended immediately prior to use. Lyophilized forms are also contemplated.

[1024] The pharmaceutical composition can be contained within a lipid particle or vesicle, such as a liposome or microcrystal, which is also suitable for parenteral administration. The particles can be of any suitable structure, such as unilamellar or plurilamellar, so long as compositions are contained therein. Compounds can be entrapped in "stabilized plasmid-lipid particles" (SPLP) containing the fusogenic lipid dioleoylphosphatidylethanolamine (DOPE), low levels (5-10 mol%) of cationic lipid, and stabilized by a polyethyleneglycol (PEG) coating (Zhang Y. P. *et al.*, *Gene Ther.* 1999, 6:1438-47). Positively charged lipids such as N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammoniummethylsulfate, or "DOTAP," are particularly preferred for such particles and vesicles. The preparation of such lipid particles is well known. See, e.g., U.S. Patent Nos. 4,880,635; 4,906,477; 4,911,928; 4,917,951; 4,920,016; and 4,921,757; each of which is incorporated herein by reference.

[1025] The pharmaceutical composition described herein may be administered or packaged as a unit dose, for example. The term "unit dose" when used in reference to a pharmaceutical composition of the present disclosure refers to physically discrete units suitable as unitary dosage for the subject, each

unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; *i.e.*, carrier, or vehicle.

[1026] Further, the pharmaceutical composition can be provided as a pharmaceutical kit comprising (a) a container containing a compound of the invention in lyophilized form and (b) a second container containing a pharmaceutically acceptable diluent (e.g., sterile water) for injection. The pharmaceutically acceptable diluent can be used for reconstitution or dilution of the lyophilized compound of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

[1027] In another aspect, an article of manufacture containing materials useful for the treatment of the diseases described above is included. In some embodiments, the article of manufacture comprises a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. In some embodiments, the container holds a composition that is effective for treating a disease described herein and may have a sterile access port. For example, the container may be an intravenous solution bag or a vial having a stopper pierce-able by a hypodermic injection needle. The active agent in the composition is a compound of the invention. In some embodiments, the label on or associated with the container indicates that the composition is used for treating the disease of choice. The article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution, or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

[11] Kits, cells, vectors, and delivery

Kits

[1028] The compositions of the present disclosure may be assembled into kits. In some embodiments, the kit comprises nucleic acid vectors for the expression of the multi-flap prime editors described herein. In other embodiments, the kit further comprises appropriate guide nucleotide sequences (*e.g.*, PEGRNAs and second-site gRNAs) or nucleic acid vectors for the expression of such guide nucleotide sequences, to target the Cas9 protein or prime editor to the desired target sequence.

[1029] The kit described herein may include one or more containers housing components for performing the methods described herein and optionally instructions for use. Any of the kit described herein may further comprise components needed for performing the assay methods. Each component of the kits, where applicable, may be provided in liquid form (*e.g.*, in solution) or in solid form, (*e.g.*, a dry powder). In certain cases, some of the components may be reconstitutable or otherwise

processable (*e.g.*, to an active form), for example, by the addition of a suitable solvent or other species (for example, water), which may or may not be provided with the kit.

[1030] In some embodiments, the kits may optionally include instructions and/or promotion for use of the components provided. As used herein, “instructions” can define a component of instruction and/or promotion, and typically involve written instructions on or associated with packaging of the disclosure. Instructions also can include any oral or electronic instructions provided in any manner such that a user will clearly recognize that the instructions are to be associated with the kit, for example, audiovisual (*e.g.*, videotape, DVD, *etc.*), Internet, and/or web-based communications, *etc.* The written instructions may be in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, which can also reflect approval by the agency of manufacture, use or sale for animal administration. As used herein, “promoted” includes all methods of doing business including methods of education, hospital and other clinical instruction, scientific inquiry, drug discovery or development, academic research, pharmaceutical industry activity including pharmaceutical sales, and any advertising or other promotional activity including written, oral and electronic communication of any form, associated with the disclosure. Additionally, the kits may include other components depending on the specific application, as described herein.

[1031] The kits may contain any one or more of the components described herein in one or more containers. The components may be prepared sterilely, packaged in a syringe and shipped refrigerated. Alternatively, it may be housed in a vial or other container for storage. A second container may have other components prepared sterilely. Alternatively, the kits may include the active agents premixed and shipped in a vial, tube, or other container.

[1032] The kits may have a variety of forms, such as a blister pouch, a shrink-wrapped pouch, a vacuum sealable pouch, a sealable thermoformed tray, or a similar pouch or tray form, with the accessories loosely packed within the pouch, one or more tubes, containers, a box or a bag. The kits may be sterilized after the accessories are added, thereby allowing the individual accessories in the container to be otherwise unwrapped. The kits can be sterilized using any appropriate sterilization techniques, such as radiation sterilization, heat sterilization, or other sterilization methods known in the art. The kits may also include other components, depending on the specific application, for example, containers, cell media, salts, buffers, reagents, syringes, needles, a fabric, such as gauze, for applying or removing a disinfecting agent, disposable gloves, a support for the agents prior to administration, *etc.* Some aspects of this disclosure provide kits comprising a nucleic acid construct comprising a nucleotide sequence encoding the various components of the multi-flap prime editing systems (*e.g.*, dual prime editing and quadruple prime editing systems) described herein (*e.g.*, including, but not limited to, the napDNAbps, reverse transcriptases, polymerases, fusion proteins (*e.g.*, comprising napDNAbps and reverse transcriptases (or more broadly, polymerases), extended

guide RNAs, and complexes comprising fusion proteins and extended guide RNAs, as well as accessory elements, such as second strand nicking components (e.g., second strand nicking gRNA) and 5' endogenous DNA flap removal endonucleases for helping to drive the multi-flap prime editing process towards the edited product formation). In some embodiments, the nucleotide sequence(s) comprises a heterologous promoter (or more than a single promoter) that drives expression of the multi-flap prime editing system components.

[1033] Other aspects of this disclosure provide kits comprising one or more nucleic acid constructs encoding the various components of the multi-flap prime editing systems described herein, e.g., comprising a nucleotide sequence encoding the components of the multi-flap prime editing system capable of modifying a target DNA sequence. In some embodiments, the nucleotide sequence comprises a heterologous promoter that drives expression of the multi-flap prime editing system components.

[1034] Some aspects of this disclosure provide kits comprising a nucleic acid construct, comprising (a) a nucleotide sequence encoding a napDNAbp (e.g., a Cas9 domain) fused to a reverse transcriptase and (b) a heterologous promoter that drives expression of the sequence of (a).

Cells

[1035] Cells that may contain any of the compositions described herein include prokaryotic cells and eukaryotic cells. The methods described herein are used to deliver a Cas9 protein or a multi-flap prime editor into a eukaryotic cell (e.g., a mammalian cell, such as a human cell). In some embodiments, the cell is *in vitro* (e.g., cultured cell). In some embodiments, the cell is *in vivo* (e.g., in a subject such as a human subject). In some embodiments, the cell is *ex vivo* (e.g., isolated from a subject and may be administered back to the same or a different subject).

[1036] Mammalian cells of the present disclosure include human cells, primate cells (e.g., vero cells), rat cells (e.g., GH3 cells, OC23 cells) or mouse cells (e.g., MC3T3 cells). There are a variety of human cell lines, including, without limitation, human embryonic kidney (HEK) cells, HeLa cells, cancer cells from the National Cancer Institute's 60 cancer cell lines (NCI60), DU145 (prostate cancer) cells, Lncap (prostate cancer) cells, MCF-7 (breast cancer) cells, MDA-MB-438 (breast cancer) cells, PC3 (prostate cancer) cells, T47D (breast cancer) cells, THP-1 (acute myeloid leukemia) cells, U87 (glioblastoma) cells, SHSY5Y human neuroblastoma cells (cloned from a myeloma) and Saos-2 (bone cancer) cells. In some embodiments, rAAV vectors are delivered into human embryonic kidney (HEK) cells (e.g., HEK 293 or HEK 293T cells). In some embodiments, rAAV vectors are delivered into stem cells (e.g., human stem cells) such as, for example, pluripotent stem cells (e.g., human pluripotent stem cells including human induced pluripotent stem cells (hiPSCs)). A stem cell refers to a cell with the ability to divide for indefinite periods in culture and to give rise to specialized cells. A pluripotent stem cell refers to a type of stem cell that is capable of differentiating into all tissues of an organism, but not alone capable of sustaining full organismal

development. A human induced pluripotent stem cell refers to a somatic (*e.g.*, mature or adult) cell that has been reprogrammed to an embryonic stem cell-like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells (*see, e.g.*, Takahashi and Yamanaka, *Cell* 126 (4): 663–76, 2006, incorporated by reference herein). Human induced pluripotent stem cell cells express stem cell markers and are capable of generating cells characteristic of all three germ layers (ectoderm, endoderm, mesoderm).

[1037] Additional non-limiting examples of cell lines that may be used in accordance with the present disclosure include 293-T, 293-T, 3T3, 4T1, 721, 9L, A-549, A172, A20, A253, A2780, A2780ADR, A2780cis, A431, ALC, B16, B35, BCP-1, BEAS-2B, bEnd.3, BHK-21, BR 293, BxPC3, C2C12, C3H-10T1/2, C6, C6/36, Cal-27, CGR8, CHO, CML T1, CMT, COR-L23, COR-L23/5010, COR-L23/CPR, COR-L23/R23, COS-7, COV-434, CT26, D17, DH82, DU145, DuCaP, E14Tg2a, EL4, EM2, EM3, EMT6/AR1, EMT6/AR10.0, FM3, H1299, H69, HB54, HB55, HCA2, Hepa1c1c7, High Five cells, HL-60, HMEC, HT-29, HUVEC, J558L cells, Jurkat, JY cells, K562 cells, KCL22, KG1, Ku812, KYO1, LNCap, Ma-Mel 1, 2, 3....48, MC-38, MCF-10A, MCF-7, MDA-MB-231, MDA-MB-435, MDA-MB-468, MDCK II, MG63, MONO-MAC 6, MOR/0.2R, MRC5, MTD-1A, MyEnd, NALM-1, NCI-H69/CPR, NCI-H69/LX10, NCI-H69/LX20, NCI-H69/LX4, NIH-3T3, NW-145, OPCN/OPCT Peer, PNT-1A/PNT 2, PTK2, Raji, RBL cells, RenCa, RIN-5F, RMA/RMAS, S2, Saos-2 cells, Sf21, Sf9, SiHa, SKBR3, SKOV-3, T-47D, T2, T84, THP1, U373, U87, U937, VCaP, WM39, WT-49, X63, YAC-1 and YAR cells.

[1038] Some aspects of this disclosure provide cells comprising any of the constructs disclosed herein. In some embodiments, a host cell is transiently or non-transiently transfected with one or more vectors described herein. In some embodiments, a cell is transfected as it naturally occurs in a subject. In some embodiments, a cell that is transfected is taken from a subject. In some embodiments, the cell is derived from cells taken from a subject, such as a cell line. A wide variety of cell lines for tissue culture are known in the art. Examples of cell lines include, but are not limited to, C8161, CCRF-CEM, MOLT, mIMCD-3, NHDF, HeLa-S3, Huh1, Huh4, Huh7, HUVEC, HASMC, HEKn, HEKa, MiaPaCell, Panc1, PC-3, TF1, CTLL-2, C1R, Rat6, CV1, RPTE, A10, T24, J82, A375, ARH-77, Calu1, SW480, SW620, SKOV3, SK-UT, CaCo2, P388D1, SEM-K2, WEHI-231, HB56, TIB55, Jurkat, J45.01, LRMB, Bcl-1, BC-3, IC21, DLD2, Raw264.7, NRK, NRK-52E, MRC5, MEF, Hep G2, HeLa B, HeLa T4, COS, COS-1, COS-6, COS-M6A, BS-C-1 monkey kidney epithelial, BALB/3T3 mouse embryo fibroblast, 3T3 Swiss, 3T3-L1, 132-d5 human fetal fibroblasts; 10.1 mouse fibroblasts, 293-T, 3T3, 721, 9L, A2780, A2780ADR, A2780cis, A 172, A20, A253, A431, A-549, ALC, B16, B35, BCP-1 cells, BEAS-2B, bEnd.3, BHK-21, BR 293. BxPC3. C3H-10T1/2, C6/36, Cal-27, CHO, CHO-7, CHO-IR, CHO-K1, CHO-K2, CHO-T, CHO Dhfr $-/-$, COR-L23, COR-L23/CPR, COR-L23/5010, COR-L23/R23, COS-7, COV-434, CML T1, CMT, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6/AR1, EMT6/AR10.0, FM3, H1299, H69, HB54, HB55,

HCA2, HEK-293, HeLa, Hepa1c1c7, HL-60, HMEC, HT-29, Jurkat, JY cells, K562 cells, Ku812, KCL22, KG1, KYO1, LNCap, Ma-Mel 1-48, MC-38, MCF-7, MCF-10A, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCK II, MDCK 11, MOR/0.2R, MONO-MAC 6, MTD-1A, MyEnd, NCI-H69/CPR, NCI-H69/LX10, NCI-H69/LX20, NCI-H69/LX4, NIH-3T3, NALM-1, NW-145, OPCN/OPCT cell lines, Peer, PNT-1A/PNT 2, RenCa, RIN-5F, RMA/RMAS, Saos-2 cells, Sf-9, SKBr3, T2, T-47D, T84, THP1 cell line, U373, U87, U937, VCaP, Vero cells, WM39, WT-49, X63, YAC-1, YAR, and transgenic varieties thereof.

[1039] Cell lines are available from a variety of sources known to those with skill in the art (see, e.g., the American Type Culture Collection (ATCC) (Manassus, Va.)). In some embodiments, a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences. In some embodiments, a cell transiently transfected with the components of a CRISPR system as described herein (such as by transient transfection of one or more vectors, or transfection with RNA), and modified through the activity of a CRISPR complex, is used to establish a new cell line comprising cells containing the modification but lacking any other exogenous sequence. In some embodiments, cells transiently or non-transiently transfected with one or more vectors described herein, or cell lines derived from such cells are used in assessing one or more test compounds.

Vectors

[1040] Some aspects of the present disclosure relate to using recombinant virus vectors (e.g., adeno-associated virus vectors, adenovirus vectors, or herpes simplex virus vectors) for the delivery of the multi-flap prime editors or components thereof described herein, e.g., the split Cas9 protein or a split nucleobase multi-flap prime editors, into a cell. In the case of a split-PE approach, the N-terminal portion of a PE fusion protein and the C-terminal portion of a PE fusion are delivered by separate recombinant virus vectors (e.g., adeno-associated virus vectors, adenovirus vectors, or herpes simplex virus vectors) into the same cell, since the full-length Cas9 protein or multi-flap prime editors exceeds the packaging limit of various virus vectors, e.g., rAAV (~4.9 kb).

[1041] Thus, in one embodiment, the disclosure contemplates vectors capable of delivering split multi-flap prime editor fusion proteins, or split components thereof. In some embodiments, a composition for delivering the split Cas9 protein or split prime editor into a cell (e.g., a mammalian cell, a human cell) is provided. In some embodiments, the composition of the present disclosure comprises: (i) a first recombinant adeno-associated virus (rAAV) particle comprising a first nucleotide sequence encoding a N-terminal portion of a Cas9 protein or prime editor fused at its C-terminus to an intein-N; and (ii) a second recombinant adeno-associated virus (rAAV) particle comprising a second nucleotide sequence encoding an intein-C fused to the N-terminus of a C-terminal portion of the Cas9 protein or prime editor. The rAAV particles of the present disclosure

comprise a rAAV vector (*i.e.*, a recombinant genome of the rAAV) encapsidated in the viral capsid proteins.

[1042] In some embodiments, the rAAV vector comprises: (1) a heterologous nucleic acid region comprising the first or second nucleotide sequence encoding the N-terminal portion or C-terminal portion of a split Cas9 protein or a split multi-flap prime editor in any form as described herein, (2) one or more nucleotide sequences comprising a sequence that facilitates expression of the heterologous nucleic acid region (*e.g.*, a promoter), and (3) one or more nucleic acid regions comprising a sequence that facilitate integration of the heterologous nucleic acid region (optionally with the one or more nucleic acid regions comprising a sequence that facilitates expression) into the genome of a cell. In some embodiments, viral sequences that facilitate integration comprise Inverted Terminal Repeat (ITR) sequences. In some embodiments, the first or second nucleotide sequence encoding the N-terminal portion or C-terminal portion of a split Cas9 protein or a split multi-flap prime editor is flanked on each side by an ITR sequence. In some embodiments, the nucleic acid vector further comprises a region encoding an AAV Rep protein as described herein, either contained within the region flanked by ITRs or outside the region. The ITR sequences can be derived from any AAV serotype (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) or can be derived from more than one serotype. In some embodiments, the ITR sequences are derived from AAV2 or AAV6.

[1043] Thus, in some embodiments, the rAAV particles disclosed herein comprise at least one rAAV2 particle, rAAV6 particle, rAAV8 particle, rPHP.B particle, rPHP.eB particle, or rAAV9 particle, or a variant thereof. In particular embodiments, the disclosed rAAV particles are rPHP.B particles, rPHP.eB particles, rAAV9 particles.

[1044] ITR sequences and plasmids containing ITR sequences are known in the art and commercially available (see, *e.g.*, products and services available from Vector Biolabs, Philadelphia, PA; Cellbiolabs, San Diego, CA; Agilent Technologies, Santa Clara, Ca; and Addgene, Cambridge, MA; and Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ. *Proc Natl Acad Sci USA*. 1996 Nov 26;93(24):14082-7; and Curtis A. Machida. *Methods in Molecular Medicine™*. Viral Vectors for Gene Therapy Methods and Protocols. 10.1385/1-59259-304-6:201 © Humana Press Inc. 2003. Chapter 10. Targeted Integration by Adeno-Associated Virus. Matthew D. Weitzman, Samuel M. Young Jr., Toni Cathomen and Richard Jude Samulski; U.S. Pat. Nos. 5,139,941 and 5,962,313, all of which are incorporated herein by reference).

[1045] In some embodiments, the rAAV vector of the present disclosure comprises one or more regulatory elements to control the expression of the heterologous nucleic acid region (*e.g.*, promoters, transcriptional terminators, and/or other regulatory elements). In some embodiments, the first and/or second nucleotide sequence is operably linked to one or more (*e.g.*, 1, 2, 3, 4, 5, or more) transcriptional terminators. Non-limiting examples of transcriptional terminators that may be used in

accordance with the present disclosure include transcription terminators of the bovine growth hormone gene (bGH), human growth hormone gene (hGH), SV40, CW3, ϕ , or combinations thereof. The efficiencies of several transcriptional terminators have been tested to determine their respective effects in the expression level of the split Cas9 protein or the split multi-flap prime editor. In some embodiments, the transcriptional terminator used in the present disclosure is a bGH transcriptional terminator. In some embodiments, the rAAV vector further comprises a Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE). In certain embodiments, the WPRE is a truncated WPRE sequence, such as "W3." In some embodiments, the WPRE is inserted 5' of the transcriptional terminator. Such sequences, when transcribed, create a tertiary structure which enhances expression, in particular, from viral vectors.

[1046] In some embodiments, the vectors used herein may encode the PE fusion proteins, or any of the components thereof (e.g., napDNAbp, linkers, or polymerases). In addition, the vectors used herein may encode the PEGRNAs, and/or the accessory gRNA for second strand nicking. The vectors may be capable of driving expression of one or more coding sequences in a cell. In some embodiments, the cell may be a prokaryotic cell, such as, e.g., a bacterial cell. In some embodiments, the cell may be a eukaryotic cell, such as, e.g., a yeast, plant, insect, or mammalian cell. In some embodiments, the eukaryotic cell may be a mammalian cell. In some embodiments, the eukaryotic cell may be a rodent cell. In some embodiments, the eukaryotic cell may be a human cell. Suitable promoters to drive expression in different types of cells are known in the art. In some embodiments, the promoter may be wild-type. In other embodiments, the promoter may be modified for more efficient or efficacious expression. In yet other embodiments, the promoter may be truncated yet retain its function. For example, the promoter may have a normal size or a reduced size that is suitable for proper packaging of the vector into a virus.

[1047] In some embodiments, the promoters that may be used in the prime editor vectors may be constitutive, inducible, or tissue-specific. In some embodiments, the promoters may be a constitutive promoters. Non-limiting exemplary constitutive promoters include cytomegalovirus immediate early promoter (CMV), simian virus (SV40) promoter, adenovirus major late (MLP) promoter, Rous sarcoma virus (RSV) promoter, mouse mammary tumor virus (MMTV) promoter, phosphoglycerate kinase (PGK) promoter, elongation factor- α (EF α) promoter, ubiquitin promoters, actin promoters, tubulin promoters, immunoglobulin promoters, a functional fragment thereof, or a combination of any of the foregoing. In some embodiments, the promoter may be a CMV promoter. In some embodiments, the promoter may be a truncated CMV promoter. In other embodiments, the promoter may be an EF α promoter. In some embodiments, the promoter may be an inducible promoter. Non-limiting exemplary inducible promoters include those inducible by heat shock, light, chemicals, peptides, metals, steroids, antibiotics, or alcohol. In some embodiments, the inducible promoter may be one that has a low basal (non-induced) expression level, such as, e.g., the Tet-On®

promoter (Clontech). In some embodiments, the promoter may be a tissue-specific promoter. In some embodiments, the tissue-specific promoter is exclusively or predominantly expressed in liver tissue. Non-limiting exemplary tissue-specific promoters include B29 promoter, CD14 promoter, CD43 promoter, CD45 promoter, CD68 promoter, desmin promoter, elastase- 1 promoter, endoglin promoter, fibronectin promoter, Flt-1 promoter, GFAP promoter, GPIIb promoter, ICAM- 2 promoter, INF- β promoter, Mb promoter, Nphs1 promoter, OG-2 promoter, SP-B promoter, SYN1 promoter, and WASP promoter.

[1048] In some embodiments, the prime editor vectors (e.g., including any vectors encoding the prime editor fusion protein and/or the PEGRNAs, and/or the accessory second strand nicking gRNAs) may comprise inducible promoters to start expression only after it is delivered to a target cell. Non-limiting exemplary inducible promoters include those inducible by heat shock, light, chemicals, peptides, metals, steroids, antibiotics, or alcohol. In some embodiments, the inducible promoter may be one that has a low basal (non-induced) expression level, such as, e.g., the Tet-On® promoter (Clontech).

[1049] In additional embodiments, the prime editor vectors (e.g., including any vectors encoding the prime editor fusion protein and/or the PEGRNAs, and/or the accessory second strand nicking gRNAs) may comprise tissue- specific promoters to start expression only after it is delivered into a specific tissue. Non-limiting exemplary tissue-specific promoters include B29 promoter, CD14 promoter, CD43 promoter, CD45 promoter, CD68 promoter, desmin promoter, elastase- 1 promoter, endoglin promoter, fibronectin promoter, Flt-1 promoter, GFAP promoter, GPIIb promoter, ICAM- 2 promoter, INF- β promoter, Mb promoter, Nphs1 promoter, OG-2 promoter, SP-B promoter, SYN1 promoter, and WASP promoter.

[1050] In some embodiments, the nucleotide sequence encoding the PEGRNA (or any guide RNAs used in connection with multi-flap prime editing) may be operably linked to at least one transcriptional or translational control sequence. In some embodiments, the nucleotide sequence encoding the guide RNA may be operably linked to at least one promoter. In some embodiments, the promoter may be recognized by RNA polymerase III (Pol III). Non-limiting examples of Pol III promoters include U6, HI and tRNA promoters. In some embodiments, the nucleotide sequence encoding the guide RNA may be operably linked to a mouse or human U6 promoter. In other embodiments, the nucleotide sequence encoding the guide RNA may be operably linked to a mouse or human HI promoter. In some embodiments, the nucleotide sequence encoding the guide RNA may be operably linked to a mouse or human tRNA promoter. In embodiments with more than one guide RNA, the promoters used to drive expression may be the same or different. In some embodiments, the nucleotide encoding the crRNA of the guide RNA and the nucleotide encoding the tracr RNA of the guide RNA may be provided on the same vector. In some embodiments, the nucleotide encoding the crRNA and the nucleotide encoding the tracr RNA may be driven by the same promoter. In some

embodiments, the crRNA and tracr RNA may be transcribed into a single transcript. For example, the crRNA and tracr RNA may be processed from the single transcript to form a double-molecule guide RNA. Alternatively, the crRNA and tracr RNA may be transcribed into a single-molecule guide RNA.

[1051] In some embodiments, the nucleotide sequence encoding the guide RNA may be located on the same vector comprising the nucleotide sequence encoding the PE fusion protein. In some embodiments, expression of the guide RNA and of the PE fusion protein may be driven by their corresponding promoters. In some embodiments, expression of the guide RNA may be driven by the same promoter that drives expression of the PE fusion protein. In some embodiments, the guide RNA and the PE fusion protein transcript may be contained within a single transcript. For example, the guide RNA may be within an untranslated region (UTR) of the Cas9 protein transcript. In some embodiments, the guide RNA may be within the 5' UTR of the PE fusion protein transcript. In other embodiments, the guide RNA may be within the 3' UTR of the PE fusion protein transcript. In some embodiments, the intracellular half-life of the PE fusion protein transcript may be reduced by containing the guide RNA within its 3' UTR and thereby shortening the length of its 3' UTR. In additional embodiments, the guide RNA may be within an intron of the PE fusion protein transcript. In some embodiments, suitable splice sites may be added at the intron within which the guide RNA is located such that the guide RNA is properly spliced out of the transcript. In some embodiments, expression of the Cas9 protein and the guide RNA in close proximity on the same vector may facilitate more efficient formation of the CRISPR complex.

[1052] The multi-flap prime editor vector system may comprise one vector, or two vectors, or three vectors, or four vectors, or five vector, or more. In some embodiments, the vector system may comprise one single vector, which encodes both the PE fusion protein and PEgRNA. In other embodiments, the vector system may comprise two vectors, wherein one vector encodes the PE fusion protein and the other encodes the PEgRNA. In additional embodiments, the vector system may comprise three vectors, wherein the third vector encodes the second strand nicking gRNA used in the herein methods.

[1053] In some embodiments, the composition comprising the rAAV particle (in any form contemplated herein) further comprises a pharmaceutically acceptable carrier. In some embodiments, the composition is formulated in appropriate pharmaceutical vehicles for administration to human or animal subjects.

[1054] Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil,

safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; (22) C2-C12 alcohols, such as ethanol; and (23) other non-toxic compatible substances employed in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfuming agents, preservative and antioxidants can also be present in the formulation. The terms such as "excipient", "carrier", "pharmaceutically acceptable carrier" or the like are used interchangeably herein.

Delivery methods

[1055] In some aspects, the invention provides methods comprising delivering one or more polynucleotides encoding the various components of the multi-flap prime editors described herein, such as or one or more vectors as described herein, one or more transcripts thereof, and/or one or proteins transcribed therefrom, to a host cell. In some aspects, the invention further provides cells produced by such methods, and organisms (such as animals, plants, or fungi) comprising or produced from such cells. In some embodiments, a base editor as described herein in combination with (and optionally complexed with) a guide sequence is delivered to a cell.

[1056] Exemplary delivery strategies are described herein elsewhere, which include vector-based strategies, PE ribonucleoprotein complex delivery, and delivery of PE by mRNA methods.

[1057] In some embodiments, the method of delivery provided comprises nucleofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA.

[1058] Exemplary methods of delivery of nucleic acids include lipofection, nucleofection, electroporation, stable genome integration (e.g., piggybac), microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™, Lipofectin™ and SF Cell Line 4D-Nucleofector X Kit™ (Lonza)). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery may be to cells (e.g. *in vitro* or *ex vivo* administration) or target tissues (e.g. *in vivo* administration). Delivery may be achieved through the use of RNP complexes.

[1059] The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, Science 270:404-

410 (1995); Blaese *et al.*, *Cancer Gene Ther.* 2:291-297 (1995); Behr *et al.*, *Bioconjugate Chem.* 5:382-389 (1994); Remy *et al.*, *Bioconjugate Chem.* 5:647-654 (1994); Gao *et al.*, *Gene Therapy* 2:710-722 (1995); Ahmad *et al.*, *Cancer Res.* 52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).

[1060] In other embodiments, the method of delivery and vector provided herein is an RNP complex. RNP delivery of fusion proteins markedly increases the DNA specificity of base editing. RNP delivery of fusion proteins leads to decoupling of on- and off-target DNA editing. RNP delivery ablates off-target editing at non-repetitive sites while maintaining on-target editing comparable to plasmid delivery, and greatly reduces off-target DNA editing even at the highly repetitive VEGFA site 2. See Rees, H.A. *et al.*, Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery, *Nat. Commun.* 8, 15790 (2017), U.S. Patent No. 9,526,784, issued December 27, 2016, and U.S. Patent No. 9,737,604, issued August 22, 2017, each of which is incorporated by reference herein.

[1061] Additional methods for the delivery of nucleic acids to cells are known to those skilled in the art. See, for example, US 2003/0087817, incorporated herein by reference.

[1062] Other aspects of the present disclosure provide methods of delivering the multi-flap prime editor constructs into a cell to form a complete and functional prime editor within a cell. For example, in some embodiments, a cell is contacted with a composition described herein (*e.g.*, compositions comprising nucleotide sequences encoding the split Cas9 or the split prime editor or AAV particles containing nucleic acid vectors comprising such nucleotide sequences). In some embodiments, the contacting results in the delivery of such nucleotide sequences into a cell, wherein the N-terminal portion of the Cas9 protein or the prime editor and the C-terminal portion of the Cas9 protein or the prime editor are expressed in the cell and are joined to form a complete Cas9 protein or a complete prime editor.

[1063] It should be appreciated that any rAAV particle, nucleic acid molecule or composition provided herein may be introduced into the cell in any suitable way, either stably or transiently. In some embodiments, the disclosed proteins may be transfected into the cell. In some embodiments, the cell may be transduced or transfected with a nucleic acid molecule. For example, a cell may be transduced (*e.g.*, with a virus encoding a split protein), or transfected (*e.g.*, with a plasmid encoding a split protein) with a nucleic acid molecule that encodes a split protein, or an rAAV particle containing a viral genome encoding one or more nucleic acid molecules. Such transduction may be a stable or transient transduction. In some embodiments, cells expressing a split protein or containing a split protein may be transduced or transfected with one or more guide RNA sequences, for example in delivery of a split Cas9 (*e.g.*, nCas9) protein. In some embodiments, a plasmid expressing a split protein may be introduced into cells through electroporation, transient (*e.g.*, lipofection) and stable

genome integration (e.g., piggybac) and viral transduction or other methods known to those of skill in the art.

[1064] In certain embodiments, the compositions provided herein comprise a lipid and/or polymer. In certain embodiments, the lipid and/or polymer is cationic. The preparation of such lipid particles is well known. See, e.g. U.S. Patent Nos. 4,880,635; 4,906,477; 4,911,928; 4,917,951; 4,920,016; 4,921,757; and 9,737,604, each of which is incorporated herein by reference.

[1065] The guide RNA sequence may be 15-100 nucleotides in length and comprise a sequence of at least 10, at least 15, or at least 20 contiguous nucleotides that is complementary to a target nucleotide sequence. The guide RNA may comprise a sequence of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 contiguous nucleotides that is complementary to a target nucleotide sequence. The guide RNA may be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length.

[1066] In some embodiments, the target nucleotide sequence is a DNA sequence in a genome, e.g. a eukaryotic genome. In certain embodiments, the target nucleotide sequence is in a mammalian (e.g. a human) genome.

[1067] The compositions of this disclosure may be administered or packaged as a unit dose, for example. The term “unit dose” when used in reference to a pharmaceutical composition of the present disclosure refers to physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent, *i.e.*, a carrier or vehicle.

[1068] Treatment of a disease or disorder includes delaying the development or progression of the disease, or reducing disease severity. Treating the disease does not necessarily require curative results.

[1069] As used therein, “delaying” the development of a disease means to defer, hinder, slow, retard, stabilize, and/or postpone progression of the disease. This delay can be of varying lengths of time, depending on the history of the disease and/or individuals being treated. A method that “delays” or alleviates the development of a disease, or delays the onset of the disease, is a method that reduces probability of developing one or more symptoms of the disease in a given time frame and/or reduces extent of the symptoms in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a number of subjects sufficient to give a statistically significant result.

[1070] “Development” or “progression” of a disease means initial manifestations and/or ensuing progression of the disease. Development of the disease can be detectable and assessed using standard clinical techniques as well known in the art. However, development also refers to progression that may be undetectable. For purpose of this disclosure, development or progression refers to the biological course of the symptoms. “Development” includes occurrence, recurrence, and onset.

[1071] As used herein “onset” or “occurrence” of a disease includes initial onset and/or recurrence. Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the isolated polypeptide or pharmaceutical composition to the subject, depending upon the type of disease to be treated or the site of the disease.

[1072] Without further elaboration, it is believed that one skilled in the art can, based on the above description, utilize the present disclosure to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications cited herein are incorporated by reference for the purposes or subject matter referenced herein.

EXAMPLES

EXAMPLE 1. PRIME EDITING (PE) FOR INSTALLING PRECISE NUCLEOTIDE CHANGES IN THE GENOME

[1073] The objective is to develop a transformative genome editing technology for precise and general installation of single nucleotide changes in mammalian genomes. This technology would allow investigators to study the effects of single nucleotide variations in virtually any mammalian gene, and potentially enable therapeutic interventions for correcting pathogenic point mutations in human patients.

[1074] Adoption of the clustered regularly interspaced short palindromic repeat (CRISPR) system for genome editing has revolutionized the life sciences¹⁻³. Although gene disruption using CRISPR is now routine, the precise installation of single nucleotide edits remains a major challenge, despite being necessary for studying or correcting a large number of disease-causative mutations. Homology directed repair (HDR) is capable of achieving such edits, but suffers from low efficiency (often <5%), a requirement for donor DNA repair templates, and deleterious effects of double-stranded DNA break (DSB) formation. Recently, the Liu laboratory developed base editing, which achieves efficient single nucleotide editing without DSBs. Base editors (BEs) combine the CRISPR system with base-modifying deaminase enzymes to convert target C•G or A•T base pairs to A•T or G•C, respectively⁴⁻⁶. Although already widely used by researchers worldwide (> 5,000 Liu lab BE constructs distributed by Addgene), current BEs enable only four of the twelve possible base pair conversions and are unable to correct small insertions or deletions. Moreover, the targeting scope of base editing is limited by the editing of non-target C or A bases adjacent to the target base (“bystander editing”) and by the

requirement that a PAM sequence exist 15 ± 2 bp from the target base. Overcoming these limitations would therefore greatly broaden the basic research and therapeutic applications of genome editing.

[1075] Here, it is proposed to develop a new precision editing approach that offers many of the benefits of base editing—namely, avoidance of double strand breaks and donor DNA repair templates—while overcoming its major limitations. To achieve this ambitious goal, it is aimed to directly install edited DNA strands at target genomic sites using target-primed reverse transcription (TPRT). In the design discussed herein, CRISPR guide RNA (gRNA) will be engineered to carry a template encoding mutagenic DNA strand synthesis, to be executed by an associated reverse transcriptase (RT) enzyme. The CRISPR nuclease (Cas9)-nicked target site DNA will serve as the primer for reverse transcription, allowing for direct incorporation of any desired nucleotide edit.

Section 1

[1076] Establish guide RNA-templated reverse transcription of mutagenic DNA strands. Prior studies have shown that, following DNA cleavage but prior to complex dissociation, Cas9 releases the non-target DNA strand to expose a free 3' terminus. It is hypothesized that this DNA strand is accessible to extension by polymerase enzymes, and that gRNAs can be engineered through extension of their 5' or 3' terminus to serve as templates for DNA synthesis. In preliminary *in vitro* studies, it was established that nicked DNA strands within Cas9:gRNA-bound complexes can indeed prime reverse transcription using the bound gRNA as a template (RT enzyme *in trans*). Next, different gRNA linkers, primer binding sites, and synthesis templates will be explored to determine optimal design rules *in vitro*. Then, different RT enzymes, acting *in trans* or as fusions to Cas9, will be evaluated *in vitro*. Finally, engineered gRNA designs will be identified that retain efficient binding and cutting activity in cells. Successful demonstration of this aim will provide a foundation for carrying out mutagenic strand synthesis in cells.

Section 2

[1077] Establish prime editing in human cells. Based on DNA processing and repair mechanisms, it is hypothesized that mutagenic DNA strands (single stranded flaps) can be used to direct specific and efficient editing of target nucleotides. In encouraging preliminary studies, feasibility for this strategy was established by demonstrating editing with model plasmid substrates containing mutagenic flaps. Concurrent with Aim 1, repair outcomes will be further evaluated by systematically varying the mutagenic flap's length, sequence composition, target nucleotide identity, and 3' terminus. Small 1 to 3 nucleotide insertions and deletions will also be tested. In parallel, and building from Aim 1, Cas9-RT architectures will be evaluated, including fusion proteins and non-covalent recruitment strategies. Cas9-RT architectures and extended gRNAs will be assayed for cellular editing at multiple target sites in the human genome, and will then be optimized for high efficiency. If successful, this aim would immediately establish TPRT genome editing (i.e., prime editing) for basic science applications.

Section 3

[1078] Achieve site-specific editing of pathogenic mutations in cultured human cells. The potential generality of this technology could enable editing of transversion mutations and indels that are not currently correctable by BEs. Guided by the results of Aim 1 and Aim 2, pathogenic transversion mutations will be targeted in cultured human cells, including the sickle cell disease founder mutation in beta globin (requires an A•T to T•A transversion to correct) and the most prevalent Wilson's disease mutation in ATP7B (requires a G•C to T•A transversion to correct). The correction of small insertion and deletion mutations will also be examined, including the 3-nucleotide Δ F508 deletion in *CFTR* that causes cystic fibrosis. If successful, this would lay the foundation for developing powerful therapeutic approaches that address these important human diseases.

Approach

[1079] The objective is to develop a genome editing strategy that directly installs point mutations at targeted genomic sites. In the technology development phase, efforts will focus on protein and RNA engineering to incorporate TPRT functionality into the CRISPR/Cas system. *In vitro* assays will be used to carefully probe the function of each step of TPRT, building from the ground up (Aim 1). The second focus area will evaluate editing outcomes in mammalian cells using a combination of model substrates and engineered CRISPR/Cas systems (Aim 2). Finally, the application phase will use the technology to correct mutations that have been intractable to genome editing by other methods (Aim 3).

[1080] The general editing design is shown in FIGs. 1A-1B. Cas9 nickases contain inactivating mutations to the HNH nuclease domain (Spy Cas9 H840A or N863A), restricting DNA cleavage to the PAM containing strand (non-target strand). Guide RNAs (gRNAs) are engineered to contain a template for reverse transcription (designs detailed on slide 5). Shown is a 5' extension of the gRNA, but 3' extensions can also be implemented. The Cas9 nickase is fused to a reverse transcriptase (RT) enzyme, either through the C-terminus or N-terminus. The gRNA:Cas9-RT complex targets the DNA region of interest and forms an R loop after displacing the non-target strand. Cas9 nicks the non-target DNA strand. Release of the nicked strand exposes a free 3'-OH terminus that is competent to prime reverse transcription using the extended gRNA as a template. This DNA synthesis reaction is carried out by the fused RT enzyme. The gRNA template encodes a DNA sequence that is homologous to the original DNA duplex, with the exception of the nucleotide that is targeted for editing. The product of reverse transcription is a single stranded DNA flap that encodes the desired edit. This flap, which contains a free 3' terminus, can equilibrate with the adjacent DNA strand, resulting in a 5' flap species. The latter species is hypothesized to serve as an efficient substrate for FEN1 (flap endonuclease 1), an enzyme that naturally excises 5' flaps from Okazaki fragments during lagging strand DNA synthesis, and removes 5' flaps following strand displacement synthesis that occurs during long-patch base excision repair. Ligation of the nicked DNA produces a mismatched base pair. This intermediate could either undergo reversion to the original base pair or conversion to the desired

edited base pair via mismatch repair (MMR) processes. Alternatively, semiconservative DNA replication could give rise to one copy each of the reversion and edit.

EXAMPLE 2 - PRIME EDITING: HIGHLY VERSATILE AND PRECISE SEARCH-AND-REPLACE GENOME EDITING IN HUMAN CELLS WITHOUT DOUBLE-STRANDED DNA BREAKS

[1081] Current genome editing methods can disrupt, delete, or insert target genes with accompanying byproducts of double-stranded DNA breaks using programmable nucleases, and install the four transition point mutations at target loci using base editors. Small insertions, small deletions, and the eight transversion point mutations, however, collectively represent most pathogenic genetic variants but cannot be corrected efficiently and without an excess of byproducts in most cell types. Described herein is prime editing, a highly versatile and precise genome editing method that directly writes new genetic information into a specified DNA site using a catalytically impaired Cas9 fused to an engineered reverse transcriptase, programmed with an engineered prime editing guide RNA (PEgRNA) that both specifies the target site and encodes the desired edit. Greater than 175 distinct edits in human cells were performed to establish that prime editing can make targeted insertions, deletions, all 12 possible types of point mutations, and combinations thereof efficiently (typically 20-60%, up to 77% in unsorted cells) and with low byproducts (typically 1-10%), without requiring double-stranded breaks or donor DNA templates. Prime editing was applied in human cells to correct the primary genetic causes of sickle cell disease (requiring an A•T-to-T•A transversion in *HBB*) and Tay-Sachs disease (requiring a 4-base deletion in *HEXA*), in both cases efficiently reverting the pathogenic genomic alleles to wild-type with minimal byproducts. Prime editing was also used to create human cell lines with these pathogenic *HBB* transversion and *HEXA* insertion mutations, to install the G127V mutation in *PRNP* that confers resistance to prion disease (requiring a G•C-to-T•A transversion), and to efficiently insert a His6 tag, a FLAG epitope tag, and an extended *LoxP* site into target loci in human cells. Prime editing offers efficiency and product purity advantages over HDR, and complementary strengths and weaknesses compared to base editing. Consistent with its search-and-replace mechanism, which requires three distinct base-pairing events, prime editing is much less prone to off-target DNA modification at known Cas9 off-target sites than Cas9. Prime editing substantially expands the scope and capabilities of genome editing, and in principle can correct ~89% of known pathogenic human genetic variants.

[1082] The ability to make virtually any targeted change in the genome of any living cell or organism is a longstanding aspiration of the life sciences. Despite rapid advances in genome editing technologies, the majority of the >75,000 known human genetic variants associated with diseases¹¹¹ cannot be corrected or installed in most therapeutically relevant cells (FIG. 38A). Programmable nucleases such as CRISPR-Cas9 make double-stranded DNA breaks (DSBs) that can disrupt genes by inducing mixtures of insertions and deletions (indels) at target sites¹¹²⁻¹¹⁴. Nucleases can also be used

to delete target genes^{115,116}, or insert exogenous genes¹¹⁷⁻¹¹⁹, through homology-independent processes. Double-stranded DNA breaks, however, are also associated with undesired outcomes including complex mixtures of products, translocations¹²⁰, and p53 activation^{121,122}. Moreover, the vast majority of pathogenic alleles differ from their non-pathogenic counterparts by small insertions, deletions, or base substitutions that require much more precise editing technologies to correct (FIG. 38A). Homology-directed repair (HDR) stimulated by nuclease-induced DSBs¹²³ has been widely used to install a variety of precise DNA changes. HDR, however, relies on exogenous donor DNA repair templates, typically generates an excess of indel byproducts from end-joining repair of DSBs, and is inefficient in most therapeutically relevant cell types (T cells and some stem cells being important exceptions)^{124,125}. While enhancing the efficiency and precision of DSB-mediated genome editing remains the focus of promising efforts¹²⁶⁻¹³⁰, these challenges necessitate the exploration of alternative precision genome editing strategies.

[1083] Base editing can efficiently install or correct the four types of transition mutations (C to T, G to A, A to G, and T to C) without requiring DSBs in a wide variety of cell types and organisms, including mammals¹²⁸⁻¹³¹, but cannot currently achieve any of the eight transversion mutations (C to A, C to G, G to C, G to T, A to C, A to T, T to A, and T to G), such as the T•A-to-A•T mutation needed to directly correct the most common cause of sickle cell disease (*HBB* E6V)¹³². In addition, no DSB-free method has been reported to perform target deletions, such as the removal of the 4-base duplication that causes Tay-Sachs disease (*HEXA* 1278+TATC)¹³³, or targeted insertions, such as the precise 3-base insertion required to directly correct the most common cause of cystic fibrosis (*CFTR* ΔF508)¹³⁴. Targeted transversion point mutations, insertions, and deletions thus are difficult to install or correct efficiently and without excess byproducts in most cell types, even though they collectively account for most known pathogenic alleles (FIG. 38A).

[1084] Described herein is the development of prime editing, a new “search-and-replace” genome editing technology that mediates targeted insertions, deletions, and all 12 possible base-to-base conversions at targeted loci in human cells without requiring double-stranded DNA breaks, or donor DNA templates. Prime editors, initially exemplified by PE1, use a reverse transcriptase fused to a programmable nickase and a prime editing extended guide RNA (PEgRNA) to directly copy genetic information from the extension on the PEgRNA into the target genomic locus. A second-generation prime editor (PE2) uses an engineered reverse transcriptase to substantially increase editing efficiencies with minimal (typically <2%) indel formation, while a third-generation PE3 system adds a second guide RNA to nick the non-edited strand, thereby favoring replacement of the non-edited strand and further increasing editing efficiency, typically, to about 20-50% in human cells with about 1-10% indel formation. PE3 offers far fewer byproducts and higher or similar efficiency compared to optimized Cas9 nuclease-initiated HDR, and offers complementary strengths and weaknesses compared to current-generation base editors.

[1085] PE3 was applied at genomic loci in human HEK293T cells to achieve efficient conversion of *HBB* E6V to wild-type *HBB*, deletion of the inserted TATC to restore *HEXA* 1278+TATC to wild-type *HEXA*, installation in *PRNP* of the G127V mutation that confers resistance to prion disease¹³⁵ (requiring a G•C-to-T•A transversion), and targeted insertion of a His₆ tag (18 bp), FLAG epitope tag (24 bp), and extended *LoxP* site for Cre-mediated recombination (44 bp). Prime editing was also successful in three other human cell lines, as well as in post-mitotic primary mouse cortical neurons, with varying efficiencies. Due to a high degree of flexibility in the distance between the initial nick and location of the edit, prime editing is not substantially constrained by the PAM requirement of Cas9 and in principle can target the vast majority of genomic loci. Off-target prime editing is much rarer than off-target Cas9 editing at known Cas9 off-target loci, likely due to the requirement of three distinct DNA base pairing events in order for productive prime editing to take place. By enabling precise targeted insertions, deletions, and all 12 possible classes of point mutations at a wide variety of genomic loci without the need for DSBs or donor DNA templates, prime editing has the potential to advance the study and correction of many gene variants.

Results

Strategy for transferring information from an extended guide RNA into a target DNA locus

[1086] Cas9 targets DNA using a guide RNA containing a spacer sequence that hybridizes to the target DNA site^{112–114,136,137}. The aim was to engineer guide RNAs to both specify the DNA target as in natural CRISPR systems^{138,139}, and also to contain new genetic information that replaces the corresponding DNA nucleotides at the target locus. The direct transfer of genetic information from an extended guide RNA into a specified DNA site, followed by replacement of the original unedited DNA, in principle could provide a general means of installing targeted DNA sequence changes in living cells, without dependence on DSBs or donor DNA templates. To achieve this direct information transfer, the aim was to use genomic DNA, nicked at the target site to expose a 3'-hydroxyl group, to prime the reverse transcription of the genetic information from an extension on the engineered guide RNA (hereafter referred to as the prime editing guide RNA, or PEGRNA) directly into the target site (FIG. 38A).

[1087] These initial steps of nicking and reverse transcription, which resemble mechanisms used by some natural mobile genetic elements¹⁴⁰, result in a branched intermediate with two redundant single-stranded DNA flaps on one strand: a 5' flap that contains the unedited DNA sequence, and a 3' flap that contains the edited sequence copied from the PEGRNA (FIG. 38B). To achieve a successful edit, this branched intermediate must be resolved so that the edited 3' flap replaces the unedited 5' flap. While hybridization of the 5' flap with the unedited strand is likely to be thermodynamically favored since the edited 3' flap can make fewer base pairs with the unedited strand, 5' flaps are the preferred substrate for structure-specific endonucleases such as FEN1¹⁴¹, which excises 5' flaps generated

during lagging-strand DNA synthesis and long-patch base excision repair. It was reasoned that preferential 5' flap excision and 3' flap ligation could drive the incorporation of the edited DNA strand, creating heteroduplex DNA containing one edited strand and one unedited strand (FIG. 38B).

[1088] Permanent installation of the edit could arise from subsequent DNA repair that resolves the mismatch between the two DNA strands in a manner that copies the information in the edited strand to the complementary DNA strand (FIG. 38C). Based on a similar strategy developed to maximize the efficiency of DNA base editing¹³¹⁻¹³³, it was envisioned that nicking the non-edited DNA strand, far enough from the site of the initial nick to minimize double-strand break formation, might bias DNA repair to preferentially replace the non-edited strand.

Validation of prime editing steps *in vitro* and in yeast cells

[1089] Following cleavage of the PAM-containing DNA strand by the RuvC nuclease domain of Cas9, the PAM-distal fragment of this strand can dissociate from otherwise stable Cas9:sgRNA:DNA complexes¹⁴³. It was hypothesized that the 3' end of this liberated strand might be sufficiently accessible to prime DNA polymerization. Guide RNA engineering efforts¹⁴⁴⁻¹⁴⁶ and crystal structures of Cas9:sgRNA:DNA complexes¹⁴⁷⁻¹⁴⁹ suggest that the 5' and 3' termini of the sgRNA can be extended without abolishing Cas9:sgRNA activity. PEgRNAs were designed by extending sgRNAs to include two critical components: a primer binding site (PBS) that allows the 3' end of the nicked DNA strand to hybridize to the PEgRNA, and a reverse transcriptase (RT) template containing the desired edit that would be directly copied into the genomic DNA site as the 3' end of the nicked DNA strand is extended across the RNA template by a polymerase (FIG. 38C).

[1090] These hypotheses were tested *in vitro* using purified *S. pyogenes* Cas9 protein. A series of PEgRNA candidates were constructed by extending sgRNAs on either terminus with a PBS sequence (5 to 6 nucleotides, nt) and an RT template (7 to 22 nt). It was confirmed that 5'-extended PEgRNAs direct Cas9 binding to target DNA, and that both 5'-extended PEgRNAs and 3'-extended PEgRNAs support Cas9-mediated target nicking *in vitro* and DNA cleavage activities in mammalian cells (FIGS. 44A-44C). These candidate PEgRNA designs were tested using pre-nicked 5'-Cy5-labeled dsDNA substrates, catalytically dead Cas9 (dCas9), and a commercial variant of Moloney murine leukemia virus (M-MLV) reverse transcriptase (FIG. 44D). When all components were present, efficient conversion of the fluorescently labeled DNA strand into longer DNA products with gel mobilities, consistent with reverse transcription along the RT template, (FIG. 38D, FIGS. 44D-44E) was observed. Products of desired length were formed with either 5'-extended or 3'-extended PEgRNAs (FIGS. 38D-38E). Omission of dCas9 led to nick translation products derived from reverse transcriptase-mediated DNA polymerization on the DNA template, with no PEgRNA information transfer (FIG. 38D). No DNA polymerization products were observed when the PEgRNA was replaced by a conventional sgRNA, confirming the necessity of the PBS and RT template components

of the PEgRNA (FIG. 38D). These results demonstrate that Cas9-mediated DNA melting exposes a single-stranded R-loop that, if nicked, is competent to prime reverse transcription from either a 5'-extended or 3'-extended PEgRNA.

[1091] Next, non-nicked dsDNA substrates were tested with a Cas9 nickase (H840A mutant) that exclusively nicks the PAM-containing strand¹¹². In these reactions, 5'-extended PEgRNAs generated reverse transcription products inefficiently, possibly due to impaired Cas9 nickase activity (FIG. 44F). However, 3'-extended PEgRNAs enabled robust Cas9 nicking and efficient reverse transcription (FIG. 38E). The use of 3'-extended PEgRNAs generated only a single apparent product, despite the potential, in principle, for reverse transcription to terminate anywhere within the remainder of the PEgRNA. DNA sequencing of the products of reactions with Cas9 nickase, RT, and 3'-extended PEgRNAs revealed that the complete RT template sequence was reverse transcribed into the DNA substrate (FIG. 44G). These experiments established that 3'-extended PEgRNAs can template the reverse transcription of new DNA strands while retaining the ability to direct Cas9 nickase activity.

[1092] To evaluate the eukaryotic cell DNA repair outcomes of 3' flaps produced by PEgRNA-programmed reverse transcription *in vitro*, DNA nicking and reverse transcription using PEgRNAs, Cas9 nickase, and RT *in vitro* on reporter plasmid substrates were performed, and the reaction products were then transformed into yeast (*S. cerevisiae*) cells (FIG. 45A). Encouragingly, when plasmids were edited *in vitro* with 3'-extended PEgRNAs encoding a T•A-to-A•T transversion that corrects the premature stop codon, 37% of yeast transformants expressed both GFP and mCherry proteins (FIG. 38F, FIG. 45C). Consistent with the results in FIG. 38E and FIG. 44F, editing reactions carried out *in vitro* with 5'-extended PEgRNAs yielded fewer GFP and mCherry double-positive colonies (9%) than those with 3'-extended PEgRNAs (FIG. 38F and FIG. 45D). Productive editing was also observed using 3'-extended PEgRNAs that insert a single nucleotide (15% double-positive transformants) or delete a single nucleotide (29% double-positive transformants) to correct frameshift mutations (FIG. 38F and FIGS. 45E-45F). DNA sequencing of edited plasmids recovered from double-positive yeast colonies confirmed that the encoded transversion edit occurred at the desired sequence position (FIG. 45G). These results demonstrate that DNA repair in eukaryotic cells can resolve 3' DNA flaps arising from prime editing to incorporate precise DNA edits including transversions, insertions, and deletions.

Design of prime editor 1 (PE1)

[1093] Encouraged by the results *in vitro* and in yeast, a prime editing system with a minimum number of components capable of editing genomic DNA in mammalian cells was sought for development. It was hypothesized that 3'-extended PEgRNAs (hereafter referred to simply as PEgRNAs, FIG. 39A) and direct fusions of Cas9 H840A to reverse transcriptase via a flexible linker may constitute a functional two-component prime editing system. HEK293T (immortalized human

embryonic kidney) cells were transfected with one plasmid encoding a fusion of wild-type M-MLV reverse transcriptase to either terminus of Cas9 H840A nickase as well as a second plasmid encoding a PEGRNA. Initial attempts led to no detectable T•A-to-A•T conversion at the HEK3 target locus.

[1094] Extension of the PBS in the PEGRNA to 8-15 bases (FIG. 39A), however, led to detectable T•A-to-A•T editing at the HEK3 target site (FIG. 39B), with higher efficiencies for prime editor constructs in which the RT was fused to the C-terminus of Cas9 nickase (3.7% maximal T•A-to-A•T conversion with PBS lengths ranging from 8-15 nt) compared to N-terminal RT–Cas9 nickase fusions (1.3% maximal T•A-to-A•T conversion) (FIG. 39B; all mammalian cell data herein reports values for the entire treated cell population, without selection or sorting, unless otherwise specified). These results suggest that wild-type M-MLV RT fused to Cas9 requires longer PBS sequences for genome editing in human cells compared to what is required *in vitro* using the commercial variant of M-MLV RT supplied in trans. This first-generation wild-type M-MLV reverse transcriptase fused to the C-terminus of Cas9 H840A nickase was designated as PE1.

[1095] The ability of PE1 to precisely introduce transversion point mutations at four additional genomic target sites specified by the PEGRNA (FIG. 39C) was tested. Similar to editing at the HEK3 locus, efficiency at these genomic sites was dependent on PBS length, with maximal editing efficiencies ranging from 0.7-5.5% (FIG. 39C). Indels from PE1 were low, averaging $0.2 \pm 0.1\%$ for the five sites under conditions that maximized each site's editing efficiency (FIG. 46A). PE1 was also able to install targeted insertions and deletions, exemplified by a single-nucleotide deletion (4.0% efficiency), a single-nucleotide insertion (9.7%), and a three-nucleotide insertion (17%) at the HEK3 locus (FIG. 39C). These results establish the ability of PE1 to directly install targeted transversions, insertions, and deletions without requiring double-stranded DNA breaks or DNA templates.

[1096] Design of prime editor 2 (PE2)

[1097] While PE1 can install a variety of edits at several loci in HEK293T cells, editing efficiencies were generally low (typically $\leq 5\%$) (FIG. 39C). It was hypothesized that engineering the reverse transcriptase in PE1 might improve the efficiency of DNA synthesis within the unique conformational constraints of the prime editing complex, resulting in higher genome editing yields. M-MLV RT mutations have been previously reported that increase enzyme thermostability^{150,151}, processivity¹⁵⁰, and DNA:RNA heteroduplex substrate affinity¹⁵², and that inactivate RNaseH activity¹⁵³. 19 PE1 variants were constructed containing a variety of reverse transcriptase mutations to evaluate their prime editing efficiency in human cells.

[1098] First, a series of M-MLV RT variants that previously emerged from laboratory evolution for their ability to support reverse transcription at elevated temperatures¹⁵⁰ were investigated. Successive introduction of three of these amino acid substitutions (D200N, L603W, and T330P) into M-MLV

RT, hereafter referred to as M3, led to a 6.8-fold average increase in transversion and insertion editing efficiency across five genomic loci in HEK293T cells compared to that of PE1 (FIGs. 47A-47S).

[1099] Next, in combination with M3, additional reverse transcriptase mutations that were previously shown to enhance binding to template:PBS complex, enzyme processivity, and thermostability¹⁵² were tested. Among the 14 additional mutants analyzed, a variant with T306K and W313F substitutions, in addition to the M3 mutations, improved editing efficiency an additional 1.3-fold to 3.0-fold compared to M3 for six transversion or insertion edits across five genomic sites in human cells (FIGs. 47A-47S). This pentamutant of M-MLV reverse transcriptase incorporated into the PE1 architecture (Cas9 H840A–M-MLV RT (D200N L603W T330P T306K W313F)) is hereafter referred to as PE2.

[1100] PE2 installs single-nucleotide transversion, insertion, and deletion mutations with substantially higher efficiency than PE1 (FIG. 39C), and is compatible with shorter PBS PEgRNA sequences (FIG. 39C), consistent with an enhanced ability to productively engage transient genomic DNA:PBS complexes. On average, PE2 led to a 1.6- to 5.1-fold improvement in prime editing point mutation efficiency over PE1 (FIG. 39C), and in some cases dramatically improved editing yields up to 46-fold (FIG. 47F and FIG. 47I). PE2 also effected targeted insertions and deletions more efficiently than PE1, achieving the targeted insertion of the 24-bp FLAG epitope tag at the HEK3 locus with 4.5% efficiency, a 15-fold improvement over the efficiency of installing this insertion with PE1 (FIG. 47D), and mediated a 1-bp deletion in HEK3 with 8.6% efficiency, 2.1-fold higher than that of PE1 (FIG. 39C). These results establish PE2 as a more efficient prime editor than PE1.

[1101] Optimization of PEgRNA features

[1102] The relationship between PEgRNA architecture and prime editing efficiency was systematically probed at five genomic loci in HEK293T cells with PE2 (FIG. 39C). In general, priming sites with lower GC content required longer PBS sequences (EMX1 and RNF2, containing 40% and 30% GC content, respectively, in the first 10 nt upstream of the nick), whereas those with greater GC content supported prime editing with shorter PBS sequences (HEK4 and FANCF, containing 80% and 60% GC content, respectively, in the first 10 nt upstream of the nick) (FIG. 39C), consistent with the energetic requirements for hybridization of the nicked DNA strand to the PEgRNA PBS. No PBS length or GC content level was strictly predictive of prime editing efficiency, and other factors such as secondary structure in the DNA primer or PEgRNA extension may also influence editing activity. It is recommended to start with a PBS length of ~13 nt for a typical target sequence, and exploring different PBS lengths if the sequence deviates from ~40-60% GC content. When necessary, optimal PBS sequences should be determined empirically.

[1103] Next, the performance determinants of the RT template portion of the PEgRNA were studied. PEgRNAs with RT templates ranging from 10-20 nt in length were systemically evaluated at five genomic target sites using PE2 (FIG. 39D) and with longer RT templates as long as 31 nt at three

genomic sites (FIGs. 48A-48C). As with PBS length, RT template length also could be varied to maximize prime editing efficiency, although in general many RT template lengths ≥ 10 nt long support more efficient prime editing (FIG. 39D). Since some target sites preferred longer RT templates (>15 nt) to achieve higher editing efficiencies (FANCF, EMX1), while other loci preferred short RT templates (HEK3, HEK4) (FIG. 39D), it is recommended both short and long RT templates be tested when optimizing a PEGRNA, starting with ~ 10 -16 nt.

[1104] Importantly, RT templates that place a C as the nucleotide adjacent to the terminal hairpin of the sgRNA scaffold generally resulted in lower editing efficiency compared to other PEGRNAs with RT templates of similar length (FIGs. 48A-48C). Based on the structure of sgRNAs bound to Cas9^{148,149}, it was speculated that the presence of a C as the first nucleotide of the 3' extension of a canonical sgRNA can disrupt the sgRNA scaffold fold by pairing with G81, a nucleotide that natively forms a pi stack with Tyr 1356 in Cas9 and a non-canonical base pair with sgRNA A68. Since many RT template lengths support prime editing, it is recommended to choose PEGRNAs in which the first base of the 3' extension (the last reverse-transcribed base of the RT template) is not C.

[1105] Design of prime editor 3 systems (PE3 and PE3b)

[1106] While PE2 can transfer genetic information from the PEGRNA to the target locus more efficiently than PE1, the manner in which the cell resolves the resulting heteroduplex DNA created by one edited strand and one unedited strand determines if the edit is durable. A previous development of base editing faced a similar challenge since the initial product of cytosine or adenine deamination is heteroduplex DNA containing one edited and one non-edited strand. To increase the efficiency of base editing, a Cas9 D10A nickase was used to introduce a nick into the non-edited strand and to direct DNA repair to that strand, using the edited strand as a template^{129,130,142}. To exploit this principle to enhance prime editing efficiencies, a similar strategy of nicking the non-edited strand using the Cas9 H840A nickase already present in PE2 and a simple sgRNA to induce preferential replacement of the non-edited strand by the cell (FIG. 40A) was tested. Since the edited DNA strand was also nicked to initiate prime editing, a variety of sgRNA-programmed nick locations were tested on the non-edited strand to minimize the production of double-stranded DNA breaks that lead to indels.

[1107] This PE3 strategy was first tested at five genomic sites in HEK293T cells by screening sgRNAs that induce nicks located 14 to 116 bases from the site of the PEGRNA-induced nick, either 5' or 3' of the PAM. In four of the five sites tested, nicking the non-edited strand increased the amount of indel-free prime editing products compared to the PE2 system by 1.5- to 4.2-fold, to as high as 55% (FIG. 40B). While the optimal nicking position varied depending on the genomic site, nicks positioned 3' of the PAM (positive distances in FIG. 40B) approximately 40-90 bp from the PEGRNA-induced nick generally produced favorable increases in prime editing efficiency (averaging

41%) without excess indel formation (6.8% average indels for the sgRNA resulting in the highest editing efficiency for each of the five sites tested) (FIG. 40B). As expected, at some sites, placement of the non-edited strand nick within 40 bp of the PEgRNA-induced nick led to large increases in indel formation up to 22% (FIG. 40B), presumably due to the formation of a double-strand break from nicking both strands close together. At other sites, however, nicking as close as 14 bp away from the PEgRNA-induced nick produced only 5% indels (FIG. 40B), suggesting that locus-dependent factors control conversion of proximal dual nicks into double-strand DNA breaks. At one tested site (HEK4), complementary strand nicks either provided no benefit or led to indel levels that surpassed editing efficiency (up to 26%), even when placed at distances >70 bp from the PEgRNA-induced nick, consistent with an unusual propensity of the edited strand at that site to be nicked by the cell, or to be ligated inefficiently. It is recommend to start with non-edited strand nicks approximately 50 bp from the PEgRNA-mediated nick, and to test alternative nick locations if indel frequencies exceed acceptable levels.

[1108] This model for how complementary strand nicking improved prime editing efficiency (FIG. 40A) predicted that nicking the non-edited strand only *after* edited strand flap resolution could minimize the presence of concurrent nicks, decreasing the frequency of double-strand breaks that go on to form indels. To achieve temporal control over non-edited strand nicking, sgRNAs with spacer sequences that match the edited strand, but not the original allele, were designed. Using this strategy, referred to hereafter as PE3b, mismatches between the spacer and the unedited allele should disfavor nicking by the sgRNA until after the editing event on the PAM strand takes place. This PE3b approach was tested with five different edits at three genomic sites in HEK293T cells and compared outcomes to those achieved with PE2 and PE3 systems. In all cases, PE3b was associated with substantially lower levels of indels compared to PE3 (3.5- to 30-fold, averaging 12-fold lower indels, or 0.85%), without any evident decrease in overall editing efficiency compared to PE3 (FIG. 40C). Therefore, when the edit lay within a second protospacer, the PE3b system could decrease indels while still improving editing efficiency compared to PE2, often to levels similar to those of PE3 (FIG. 40C).

[1109] Together, these findings established that PE3 systems (Cas9 nickase–optimized reverse transcriptase + PEgRNA + sgRNA) improved editing efficiencies ~3-fold compared with PE2 (FIGs. 40B-40C). PE3 was accompanied by wider ranges of indels than PE2, as expected given the additional nicking activity of PE3. The use of PE3 is recommended when prioritizing prime editing efficiency. When minimization of indels is critical, PE2 offers ~10-fold lower indel frequencies. When it is possible to use a sgRNA that recognizes the installed edit to nick the non-edited strand, the PE3b system can achieve PE3-like editing levels while greatly reducing indel formation.

[1110] To demonstrate the targeting scope and versatility of prime editing with PE3, the installation of all possible single nucleotide substitutions across the +1 to +8 positions (counting the first base 3'

of the PEGRNA-induced nick as position +1) of the HEK3 target site using PE3 and PEGRNAs with 10-nucleotide RT templates (FIG. 41A) was explored. Collectively, these 24 distinct edits cover all four transition mutations and all eight transversion mutations, and proceed with editing efficiencies (containing no indels) averaging $33 \pm 7.9\%$ (ranging between 14% and 48%), with an average of $7.5 \pm 1.8\%$ indels.

[1111] Importantly, long-distance RT templates could also give rise to efficient prime editing with PE3. For example, using PE3 with a 34-nt RT template, point mutations were installed at positions +12, +14, +17, +20, +23, +24, +26, +30, and +33 (12 to 33 bases from the PEGRNA-induced nick) in the HEK3 locus with an average of $36 \pm 8.7\%$ efficiency and $8.6 \pm 2.0\%$ indels (FIG. 41B). Although edits beyond the +10 position at other loci were not attempted, other RT templates ≥ 30 nt at three alternative sites also support efficient editing (FIGs. 48A-C). The viability of long RT templates enabled efficient prime editing for dozens of nucleotides from the initial nick site. Since an NGG PAM on either DNA strand occurs on average every ~ 8 bp, far less than maximum distances between the edit and the PAM that support efficient prime editing, prime editing is not substantially constrained by the availability of a nearby PAM sequence, in contrast with other precision genome editing methods^{125,142,154}. Given the presumed relationship between RNA secondary structure and prime editing efficiency, when designing PEGRNAs for long-range edits it is prudent to test RT templates of various lengths and, if necessary, sequence compositions (e.g., synonymous codons) to optimize editing efficiency.

[1112] To further test the scope and limitations of the PE3 system for introducing transition and transversion point mutations, 72 additional edits covering all 12 possible types of point mutations across six additional genomic target sites (FIG. 41C-41H) were tested. Overall, indel-free editing efficiency averaged $25 \pm 14\%$, while indel formation averaged $8.3 \pm 7.5\%$. Since the PEGRNA RT template included the PAM sequence, prime editing could induce changes to the PAM sequence. In these cases, higher editing efficiency (averaging $39 \pm 9.7\%$) and lower indel generation (averaging $5.0 \pm 2.9\%$) were observed (FIGs. 41A-41K, point mutations at positions +5 or +6). This increase in efficiency and decrease in indel formation for PAM edits may arise from the inability of the Cas9 nickase to re-bind and nick the edited strand prior to the repair of the complementary strand. Since prime editing supports combination edits with no apparent loss of editing efficiency, editing the PAM, in addition to other desired changes, when possible, is recommended.

[1113] Next, 14 targeted small insertions and 14 targeted small deletions at seven genomic sites using PE3 (FIG. 41I) were performed. Targeted 1-bp insertions proceeded with an average efficiency of $32 \pm 9.8\%$, while 3-bp insertions were installed with an average efficiency of $39 \pm 16\%$. Targeted 1-bp and 3-bp deletions were also efficient, proceeding with an average yield of $29 \pm 14\%$ and $32 \pm 11\%$, respectively. Indel generation (beyond the targeted insertion or deletion) averaged $6.8 \pm 5.4\%$. Since insertions and deletions introduced between positions +1 and +6 alter the position or the structure of

the PAM, it was speculated that insertion and deletion edits in this range are typically more efficient due to the inability of Cas9 nickase to re-bind and nick the edited DNA strand prior to repair of the complementary strand, similar to point mutations that edit the PAM.

[1114] PE3 was also tested for its ability to mediate larger precise deletions of 5 bp to 80 bp at the HEK3 site (FIG. 41J). Very high editing efficiencies (52 to 78%) were observed for 5-, 10-, and 15-bp deletions when using a 13-nt PBS and an RT template that contained 29, 24, or 19 bp of homology to the target locus, respectively. Using a 26-nt RT template supported a larger deletion of 25 bp with $72 \pm 4.2\%$ efficiency, while a 20-nt RT template enabled an 80-bp deletion with an efficiency of $52 \pm 3.8\%$. These targeted deletions were accompanied by indel frequencies averaging $11 \pm 4.8\%$ (FIG. 41J).

[1115] Finally, the ability of PE3 to mediate 12 combinations of multiple edits at the same target locus consisting of insertions and deletions, insertions and point mutations, deletions and point mutations, or two point mutations across three genomic sites was tested. These combination edits were very efficient, averaging 55% of the target edit with 6.4% indels (FIG. 41K), and demonstrating the ability of prime editing to make combinations of precision insertions, deletions, and point mutations at individual target sites with high efficiency and low indel frequencies.

[1116] Together, the examples in FIGs. 41A-41K represent 156 distinct transition, transversion, insertion, deletion, and combination edits across seven human genomic loci. These findings establish the versatility, precision, and targeting flexibility of prime editing.

[1117] Prime editing compared with base editing

[1118] Current-generation cytidine base editors (CBEs) and adenine base editors (ABEs) can install C•G-to-T•A transition mutations and A•T-to-G•C transition mutations with high efficiency and low indels^{129,130,142}. The application of base editing can be limited by the presence of multiple cytidine or adenine bases within the base editing activity window (typically ~5-bp wide), which gives rise to unwanted bystander edits^{129,130,142,155}, or by the absence of a PAM positioned approximately 15 ± 2 nt from the target nucleotide^{142,156}. It was anticipated that prime editing could be particularly useful for precise installation of transitions mutations without bystander edits, or when the lack of suitably positioned PAMs precludes favorable positioning the target nucleotide within the CBE or ABE activity window.

[1119] Prime editing and cytosine base editing was compared by editing three genomic loci that contain multiple target cytidines in the canonical base editing window (protospacer positions 4-8, counting the PAM as positions 21-23) using optimized CBEs¹⁵⁷ without nickase activity (BE2max) or with nickase activity (BE4max), or using the analogous PE2 and PE3 prime editing systems. Among the nine total target cytosines within the base editing windows of the three sites, BE4max yielded 2.2-fold higher average total C•G-to-T•A conversion than PE3 for bases in the center of the base editing

window (protospacer positions 5-7, FIG. 42A). Likewise, non-nicking BE2max outperformed PE2 by 1.4-fold on average at these well-positioned bases (FIG. 42A). However, PE3 outperformed BE4max by 2.7-fold, and PE2 outperformed BE2max by 2.0-fold, for cytosines beyond the center of the base editing window (average editing of $40\pm 17\%$ for PE3 vs. $15\pm 18\%$ for BE4max, and $22\pm 11\%$ for PE2 vs. $11\pm 13\%$ for BE2max). Overall, indel frequencies for PE2 were very low (averaging $0.86\pm 0.47\%$), and for PE3 were similar to or modestly higher than that of BE4max (BE4max range: 2.5% to 14%; PE3 range: 2.5% to 21%) (FIG. 42B).

[1120] When comparing the efficiency of base editing to prime editing for installation of *precise* C•G-to-T•A edits (without any bystander editing), the efficiency of prime editing greatly exceeded that of base editing at the above sites, which like most genomic DNA sites, contain multiple cytosines within the ~5-bp base editing window (FIG. 42C). At these sites, such as EMX1, which contains cytosines at protospacer positions C5, C6, and C7, BE4max generated few products containing only the single target base pair conversion with no bystander edits. In contrast, prime editing at this site could be used to selectively install a C•G-to-T•A edit at any position or combination of positions (C5, C6, C7, C5+C6, C6+C7, C5+C7, or C5+C6+C7) (FIG. 42C). All precise one-base or two-base edits (that is, edits that do not modify any other nearby bases) were much more efficient with PE3 or PE2 than with BE4max or BE2, respectively, while the three-base C•G-to-T•A edit was more efficient with BE4max (FIG. 42C), reflecting the propensity of base editors to edit all target bases within the activity window. Taken together, these results demonstrate that cytosine base editors can result in higher levels of editing at optimally positioned target bases than PE2 or PE3, but prime editing can outperform base editing at non-optimally positioned target bases, and can edit with much higher precision with multiple editable bases.

[1121] A•T-to-G•C editing was compared at two genomic loci by an optimized non-nicking ABE (ABEmax¹⁵² with a dCas9 instead of a Cas9 nickase, hereafter referred to as ABEdmax) versus PE2, and by the optimized nicking adenine base editor ABEmax versus PE3. At a site that contains two target adenines in the base editing window (HEK3), ABEs were more efficient than PE2 or PE3 for conversion of A5, but PE3 was more efficient for conversion of A8, which lies at the edge of the ABEmax editing window (FIG. 42D). When comparing the efficiency of precision edits in which only a single adenine is converted, PE3 outperformed ABEmax at both A5 and A8 (FIG. 42E). Overall, ABEs produced far fewer indels at HEK3 than prime editors ($0.19\pm 0.02\%$ for ABEdmax vs. $1.5\pm 0.46\%$ for PE2, and $0.53\pm 0.16\%$ for ABEmax vs. $11\pm 2.3\%$ for PE3, FIG. 42F). At FANCF, in which only a single A is present within the base editing window, ABE2 and ABEmax outperformed their prime editing counterparts in total target base pair conversion by 1.8- to 2.9-fold, with virtually all edited products from both base editing and prime editing containing only the precise edit (FIGS. 42D-42E). As with the HEK3 site, ABEs produced far fewer indels at the FANCF site (FIG. 42F).

[1122] Collectively, these results indicate that base editing and prime editing offer complementary strengths and weaknesses for making targeted transition mutations. For cases in which a single target nucleotide is present within the base editing window, or when bystander edits are acceptable, current base editors are typically more efficient and result in fewer indels than prime editors. When multiple cytosines or adenines are present and bystander edits are undesirable, or when target bases are poorly positioned for base editing relative to available PAMs, prime editors offer substantial advantages.

[1123] Off-target prime editing

[1124] To result in productive editing, prime editing requires target locus:PEgRNA spacer complementary for the Cas9 domain to bind, target locus:PEgRNA PBS complementarity for PEgRNA-primed reverse transcription to initiate, and target locus:reverse transcriptase product complementarity for flap resolution. It was hypothesized that these three distinct DNA hybridization requirements may minimize off-target prime editing compared to that of other genome editing methods. To test this possibility, HEK293T cells were treated with PE3 or PE2 and 16 total PEgRNAs designed to target four on-target genomic loci, with Cas9 and the four corresponding sgRNAs targeting the same protospacers, or with Cas9 and the same 16 PEgRNAs. These four target loci were chosen because each has at least four well-characterized off-target sites for which Cas9 and the corresponding on-target sgRNA in HEK293T cells is known to cause substantial off-target DNA modification^{118,159}. Following treatment, the four on-target loci and the top four known Cas9 off-target sites for each on-target spacer, were sequenced, for a total of 16 off-target sites (Table 1).

[1125] Consistent with previous studies¹¹⁸, Cas9 and the four target sgRNAs modified all 16 of the previously reported off-target loci (FIG. 42G). Cas9 off-target modification efficiency among the four off-target sites for the HEK3 target locus averaged 16%. Cas9 and the sgRNA targeting HEK4 resulted in an average of 60% modification of the four tested known off-target sites. Likewise, off-target sites for EMX1 and FANCF were modified by Cas9:sgRNA at an average frequency of 48% and 4.3%, respectively (FIG. 42G). It was noted that PEgRNAs with Cas9 nuclease modified on-target sites at similar (1- to 1.5-fold lower) efficiency on average compared to sgRNAs, while PEgRNAs with Cas9 nuclease modified off-target sites at ~4-fold lower average efficiency than sgRNAs.

[1126] Strikingly, PE3 or PE2 with the same 16 tested PEgRNAs containing these four target spacers resulted in much lower off-target editing (FIG. 42H). Of the 16 sites known to undergo off-target editing by Cas9+sgRNA, PE3+PEgRNAs or PE2+PEgRNAs resulted in detectable off-target prime editing at only 3 of 16 off-target sites, with only 1 of 16 showing off-target editing efficiency $\geq 1\%$ (FIG. 42H). Average off-target prime editing for the PEgRNAs targeting HEK3, HEK4, EMX1, and FANCF at these 16 known Cas9 off-target sites was $<0.1\%$, $<2.2\pm 5.2\%$, $<0.1\%$, and $<0.13\pm 0.11\%$, respectively (FIG. 42H). Notably, at the HEK4 off-target 3 site that Cas9+PEgRNA1 edits with 97%

efficiency, PE2+PEgRNA1 results in only 0.7% off-target editing despite sharing the same spacer sequence, demonstrating how the two additional DNA hybridization events required for prime editing compared to Cas9 editing can greatly reduce off-target editing. Taken together, these results suggest that PE3 and PEgRNAs induce much lower off-target DNA editing in human cells than Cas9 and sgRNAs that target the same protospacers.

[1127] Reverse transcription of 3'-extended PEgRNAs in principle can proceed into the guide RNA scaffold. If the resulting 3' flap, despite a lack of complementarity at its 3' end with the unedited DNA strand, is incorporated into the target locus, the outcome is insertion of PEgRNA scaffold nucleotides that contributes to indel frequency. We analyzed sequencing data from 66 PE3-mediated editing experiments at four loci in HEK293T cells and observed PEgRNA scaffold insertion at a low frequency, averaging $1.7 \pm 1.5\%$ total insertion of any number of PEgRNA scaffold nucleotides (FIGs. 56A-56D). It is speculated that inaccessibility of the guide RNA scaffold to the reverse transcriptase due to Cas9 domain binding, as well as cellular excision during flap resolution of the mismatched 3' end of the 3' flap that results from PEgRNA scaffold reverse transcription, minimizes products that incorporate PEgRNA scaffold nucleotides. While such events are rare, future efforts to engineer PEgRNAs or prime editor proteins that minimize PEgRNA scaffold incorporation may further decrease indel frequencies.

[1128] Deaminases in some base editors can act in a Cas9-independent manner, resulting in low-level but widespread off-target DNA editing among first-generation CBEs (but not ABEs)¹⁶⁰⁻¹⁶² and off-target RNA editing among first-generation CBEs and ABEs¹⁶³⁻¹⁶⁵, although newer CBE and ABE variants with engineered deaminases greatly reduce Cas9-independent off-target DNA and RNA editing¹⁶³⁻¹⁶⁵. Prime editors lack base-modification enzymes such as deaminases, and therefore have no inherent ability to modify DNA or RNA bases in a Cas9-independent manner.

[1129] While the reverse transcriptase domain in prime editors in principle could process properly primed RNA or DNA templates in cells, it was noted that retrotransposons such as those in the LINE-1 family¹⁶⁶, endogenous retroviruses^{167,168}, and human telomerase all provided active endogenous human reverse transcriptases. Their natural presence in human cells suggests that reverse transcriptase activity itself is not substantially toxic. Indeed, no PE3-dependent differences were observed in HEK293T cell viability compared to that of controls expressing dCas9, Cas9 H840A nickase, or PE2 with R110S+K103L (PE2-dRT) mutations that inactivate the reverse transcriptase¹⁶⁹ (FIGs. 49A-49B).

[1130] The above data and analyses notwithstanding, additional studies are needed to assess off-target prime editing in an unbiased, genome-wide manner, as well as to characterize the extent to which the reverse transcriptase variants in prime editors, or prime editing intermediates, may affect cells.

[1131] Prime editing pathogenic transversion, insertion, and deletion mutations in human cells

[1132] The ability of PE3 to directly install or correct in human cells transversion, small insertion, and small deletion mutations that cause genetic diseases, was tested. Sickle cell disease is most commonly caused by an A•T-to-T•A transversion mutation in HBB, resulting in the mutation of Glu6→Val in beta-globin. Treatment of hematopoietic stem cells *ex vivo* with Cas9 nuclease and a donor DNA template for HDR, followed by enrichment of edited cells, transplantation, and engraftment is a promising potential strategy for the treatment of sickle-cell disease¹⁷⁰. However, this approach still generates many indel-containing byproducts in addition to the correctly edited HBB allele¹⁷⁰⁻¹⁷¹. While base editors generally produce far fewer indels, they cannot currently make the T•A-to-A•T transversion mutation needed to directly restore the normal sequence of HBB.

[1133] PE3 was used to install the HBB E6V mutation in HEK293T cells with 44% efficiency and 4.8% indels (FIG. 43A). From the mixture of PE3-treated cells, we isolated six HEK293T cell lines that are homozygous (triploid) for the HBB E6V allele (FIGs. 53A-53D), demonstrating the ability of prime editing to generate human cell lines with pathogenic mutations. To correct the HBB E6V allele to wild-type HBB, we treated homozygous HBB E6V HEK293T cells with PE3 and a PEgRNA programmed to directly revert the HBB E6V mutation to wild-type HBB. In total, 14 PEgRNA designs were tested. After three days, DNA sequencing revealed that all 14 PEgRNAs when combined with PE3 gave efficient correction of HBB E6V to wild-type HBB ($\geq 26\%$ wild-type HBB without indels), and indel levels averaging $2.8 \pm 0.70\%$ (FIG. 50A). The best PEgRNA resulted in 52% correction of HBB E6V to wild-type with 2.4% indels (FIG. 43A). Introduction of a silent mutation that modifies the PAM recognized by the PEgRNA modestly improved editing efficiency and product purity, to 58% correction with 1.4% indels (FIG. 43A). These results establish that prime editing can install and correct a pathogenic transversion point mutation in a human cell line with high efficiency and minimal byproducts.

[1134] Tay-Sachs disease is most often caused by a 4-bp insertion into the HEXA gene (HEXA 1278+TATC)¹³⁶. PE3 was used to install this 4-bp insertion into HEK293T cells with 31% efficiency and 0.8% indels (FIG. 43B), and isolated two HEK293T cell lines that are homozygous for the HEXA 1278+TATC allele (FIGs. 53A-53D). These cells were used to test 43 PEgRNAs and three nicking sgRNAs with PE3 or PE3b systems for correction of the pathogenic insertion in HEXA (FIG. 50B), either by perfect reversion to the wild-type allele or by a shifted 4-bp deletion that disrupts the PAM and installs a silent mutation. Nineteen of the 43 PEgRNAs tested resulted in $\geq 20\%$ editing. Perfect correction to wild-type HEXA with PE3 or PE3b and the best PEgRNA proceeded with similar average efficiencies (30% for PE3 vs. 33% for PE3b), but the PE3b system was accompanied by 5.3-fold fewer indel products (1.7% for PE3 vs. 0.32% for PE3b) (FIG. 43B and FIG. 50B). These findings demonstrate the ability of prime editing to make precise small insertions and deletions that

install or correct a pathogenic allele in mammalian cells efficiently and with a minimum of byproducts.

[1135] Finally, the installation of a protective SNP into PRNP, the gene encoding the human prion protein (PrP), was tested. PrP misfolding causes progressive and fatal neurodegenerative prion disease that can arise spontaneously, through inherited dominant mutations in the PRNP gene, or through exposure to misfolded PrP¹⁷². A naturally occurring PRNP G127V mutant allele confers resistance to prion disease in humans¹³⁸ and mice¹⁷³. PE3 was used to install G127V into the human PRNP allele in HEK293T cells, which requires a G•C-to-T•A transversion. Four PEgRNAs and three nicking sgRNAs were evaluated with the PE3 system. After three days of exposure to the most effective PE3 and PEgRNA, DNA sequencing revealed 53±11% efficiency of installing the G127V mutation and indel levels of 1.7±0.7% (FIG. 43C). Taken together, these results establish the ability of prime editing in human cells to install or correct transversion, insertion, or deletion mutations that cause or confer resistance to disease efficiently, and with a minimum of byproducts.

[1136] Prime editing in various human cell lines and primary mouse neurons

[1137] Next, prime editing was tested for its ability to edit endogenous sites in three additional human cell lines. In K562 (leukemic bone marrow) cells, PE3 was used to perform transversion edits in the HEK3, EMX1, and FANCF sites, as well as the 18-bp insertion of a 6xHis tag in HEK3. An average editing efficiency of 15-30% was observed for each of these four PE3-mediated edits, with indels averaging 0.85-2.2% (FIG. 43A). In U2OS (osteosarcoma) cells, transversion mutations in HEK3 and FANCF were installed, as well as a 3-bp insertion and 6xHis tag insertion into HEK3, with 7.9-22% editing efficiency that exceeded indel formation 10- to 76 fold(FIG. 43A). Finally, in HeLa (cervical cancer) cells, a 3-bp insertion into HEK3 was performed, with 12% average efficiency and 1.3% indels (FIG. 43A). Collectively, these data indicate that multiple cell lines beyond HEK293T cells support prime editing, although editing efficiencies vary by cell type and are generally less efficient than in HEK293T cells. Editing:indel ratios remained high in all tested human cell lines.

[1138] To determine if prime editing is possible in post-mitotic, terminally differentiated primary cells, primary cortical neurons harvested from E18.5 mice were transduced with a dual split-PE3 lentiviral delivery system in which split-intein splicing²⁰³ reconstitutes PE2 protein from N-terminal and C-terminal halves, each delivered from a separate virus. To restrict editing to post-mitotic neurons, the human synapsin promoter, which is highly specific for mature neurons²⁰⁴, was used to drive expression of both PE2 protein components. GFP was fused through a self-cleaving P2A peptide²⁰⁵ to the N-terminal half of PE2. Nuclei from neurons were isolated two weeks following dual viral transduction and were sequenced directly, or sorted for GFP expression before sequencing. A 7.1±1.2% average prime editing to install a transversion at the DNMT1 locus with 0.58±0.14% average indels in sorted nuclei (FIG. 43D) was observed. Cas9 nuclease in the same split-intein dual

lentivirus system resulted in $31 \pm 5.5\%$ indels among sorted cortical neuron nuclei (FIG. 43D). These data indicate that post-mitotic, terminally differentiated primary cells can support prime editing, and thus establish that prime editing does not require cell replication.

[1139] Prime editing compared with Cas9-initiated HDR

[1140] The performance of PE3 was compared with that of optimized Cas9-initiated HDR^{128,125} in mitotic cell lines that support HDR¹²⁸. HEK293T, HeLa, K562 and U2OS cells were treated with Cas9 nuclease, a sgRNA, and an ssDNA donor oligonucleotide template designed to install a variety of transversion and insertion edits (FIGs. 43E-43G, and FIGs. 51A-51F). Cas9-initiated HDR in all cases successfully installed the desired edit, but with far higher levels of byproducts (predominantly indels), as expected from treatments that cause double-stranded breaks. Using PE3 in HEK293T cells, *HBB* E6V installation and correction proceeded with 42% and 58% average editing efficiency with 2.6% and 1.4% average indels, respectively (FIG. 43E and FIG. 43G). In contrast, the same edits with Cas9 nuclease and an HDR template resulted in 5.2% and 6.7% average editing efficiency, with 79% and 51% average indel frequency (FIG. 43E and FIG. 43G). Similarly, PE3 installed *PRNP* G127V with 53% efficiency and 1.7% indels, whereas Cas9-initiated HDR installed this mutation with 6.9% efficiency and 53% indels (FIG. 43E and FIG. 43G). Thus, the ratio of editing:indels for *HBB* E6V installation, *HBB* E6V correction, and *PRNP* G127V installation on average was 270-fold higher for PE3 than for Cas9-initiated HDR.

[1141] Comparisons between PE3 and HDR in human cell lines other than HEK293T showed similar results, although with lower PE3 editing efficiencies. For example, in K562 cells, PE3-mediated 3-bp insertion into HEK3 proceeded with 25% efficiency and 2.8% indels, compared with 17% editing and 72% indels for Cas9-initiated HDR, a 40-fold editing:indel ratio advantage favoring PE3 (FIGs. 43F-43G). In U2OS cells, PE3 performed this 3-bp insertion with 22% efficiency and 2.2% indels, while Cas9-initiated HDR resulted in 15% editing with 74% indels, a 49-fold lower editing:indel ratio (FIGs. 43F-43G). In HeLa cells, PE3 made this insertion with 12% efficiency and 1.3% indels, versus 3.0% editing and 69% indels for Cas9-initiated HDR, a 210-fold editing:indel ratio difference (FIGs. 43F-43G). Collectively, these data indicated that HDR typically results in similar or lower editing efficiencies and far higher indels than PE3 in the four cell lines tested (FIGs. 51A-51F).

[1142] Discussion and future directions

[1143] The ability to insert DNA sequences with single-nucleotide precision is an especially enabling prime editing capability. For example, PE3 was used to precisely insert into the HEK3 locus in HEK293T cells a His₆ tag (18 bp, 65% average efficiency), a FLAG epitope tag (24 bp, 18% average efficiency), and an extended *LoxP* site (44 bp, 23% average efficiency) that is the native substrate for Cre recombinase. Average indels ranged between 3.0% and 5.9% for these examples (FIG. 43H).

Many biotechnological, synthetic biology, and therapeutic applications are envisioned to arise from the ability to efficiently and precisely introduce new DNA sequences into target sites of interest in living cells.

[1144] Collectively, the prime editing experiments described herein installed 18 insertions up to 44 bp, 22 deletions up to 80 bp, 113 point mutations including 77 transversions, and 18 combination edits, across 12 endogenous loci in the human and mouse genomes at locations ranging from 3 bp upstream to 29 bp downstream of the start of a PAM without making explicit double-stranded DNA breaks. These results establish prime editing as a remarkably versatile genome editing method. Because the overwhelming majority (85-99%) of insertions, deletions, indels, and duplications in ClinVar are ≤ 30 bp (FIGs. 52A-52D), in principle prime editing can correct up to ~89% of the 75,122 currently known pathogenic human genetic variants in ClinVar (transitions, transversions, insertions, deletions, indels, and duplications in FIG. 38A), with additional potential to ameliorate diseases caused by copy number gain or loss.

[1145] Importantly, for any desired edit the flexibility of prime editing offers many possible choices of PEgRNA-induced nick locations, sgRNA-induced second nick locations, PBS lengths, RT template lengths, and which strand to edit first, as demonstrated extensively herein. This flexibility, which contrasts with more limited options typically available for other precision genome editing methods^{125,142,154}, allows editing efficiency, product purity, DNA specificity, or other parameters to be optimized to suit the needs of a given application, as shown in FIGs. 50A-50B in which testing 14 and 43 PEgRNAs covering a range of prime editing strategies optimized correction of pathogenic HBB and HEXA alleles, respectively.

[1146] Much additional research is needed to further understand and improve prime editing. Additional modifications of prime editor systems may be required to expand their compatibility to include other cell types, such as post-mitotic cells. Interfacing prime editing with viral and non-viral *in vitro* and *in vivo* delivery strategies is needed to fully explore the potential of prime editing to enable a wide range of applications including the study and treatment of genetic diseases. By enabling highly precise targeted transitions, transversions, small insertions, and small deletions in the genomes of mammalian cells without requiring double-stranded breaks or HDR, however, prime editing provides a new “search-and-replace” capability that substantially expands the scope of genome editing.

Methods

[1147] General methods

[1148] DNA amplification was conducted by PCR using Phusion U Green Multiplex PCR Master Mix (ThermoFisher Scientific) or Q5 Hot Start High-Fidelity 2x Master Mix (New England BioLabs)

unless otherwise noted. DNA oligonucleotides, including Cy5- labeled DNA oligonucleotides, dCas9 protein, and Cas9 H840A protein were obtained from Integrated DNA Technologies. Yeast reporter plasmids were derived from previously described plasmids⁶⁴ and cloned by the Gibson assembly method. All mammalian editor plasmids used herein were assembled using the USER cloning method as previously described¹⁷⁵. Plasmids expressing sgRNAs were constructed by ligation of annealed oligonucleotides into BsmBI-digested acceptor vector. Plasmids expressing PEGRNAs were constructed by Gibson assembly or Golden Gate assembly using a custom acceptor plasmid (see supplemental 'Golden Gate assembly' outline). Sequences of sgRNA and PEGRNA constructs used herein are listed in Tables 2A-2C and Tables 3A-3R. All vectors for mammalian cell experiments were purified using Plasmid Plus Midiprep kits (Qiagen) or PureYield plasmid miniprep kits (Promega), which include endotoxin removal steps. All experiments using live animals were approved by the Broad Institute Institutional and Animal Care and Use Committees. Wild-type C57BL/6 mice were obtained from Charles River (#027).

[1149] In vitro biochemical assays

[1150] PEGRNAs and sgRNAs were transcribed *in vitro* using the HiScribe T7 *in vitro* transcription kit (New England Biolabs) from PCR-amplified templates containing a T7 promoter sequence. RNA was purified by denaturing urea PAGE and quality- confirmed by an analytical gel prior to use. 5'-Cy5-labeled DNA duplex substrates were annealed using two oligonucleotides (Cy5-AVA024 and AVA025; 1:1.1 ratio) for the non- nicked substrate or three oligonucleotides (Cy5-AVA023, AVA025 and AVA026; 1:1.1:1.1) for the pre-nicked substrate by heating to 95 °C for 3 minutes followed by slowly cooling to room temperature (Tables 2A-2C). Cas9 cleavage and reverse transcription reactions were carried out in 1x cleavage buffer²⁰⁵ supplemented with dNTPs (20 mM HEPES-K, pH 7.5; 100 mM KCl; 5% glycerol; 0.2 mM EDTA, pH 8.0; 3 mM MgCl₂; 0.5 mM dNTP mix; 5 mM DTT). dCas9 or Cas9 H840A (5 μM final) and the sgRNA or PEGRNA (5 μM final) were pre-incubated at room temperature in a 5 μL reaction mixture for 10 minutes prior to the addition of duplex DNA substrate (400 nM final), followed by the addition of Superscript III reverse transcriptase (ThermoFisher Scientific), an undisclosed M-MLV RT variant, when applicable. Reactions were carried out at 37 °C for 1 hour, then diluted to a volume of 10 μL with water, treated with 0.2 μL of proteinase K solution (20 mg/mL, ThermoFisher Scientific), and incubated at room temperature for 30 minutes. Following heat inactivation at 95 °C for 10 minutes, reaction products were combined with 2x formamide gel loading buffer (90% formamide; 10% glycerol; 0.01% bromophenol blue), denatured at 95 °C for 5 minutes, and separated by denaturing urea-PAGE gel (15% TBE-urea, 55 °C, 200V). DNA products were visualized by Cy5 fluorescence signal using a Typhoon FLA 7000 biomolecular imager.

[1151] Electrophoretic mobility shift assays were carried out in 1x binding buffer (1x cleavage buffer + 10 µg/mL heparin) using pre-incubated dCas9:sgRNA or dCas9:PEgRNA complexes (concentration range between 5 nM and 1 µM final) and Cy5-labeled duplex DNA (Cy5- AVA024 and AVA025; 20 nM final). After 15 minutes of incubation at 37 °C, the samples were analyzed by native PAGE gel (10% TBE) and imaged for Cy5 fluorescence.

[1152] For DNA sequencing of reverse transcription products, fluorescent bands were excised and purified from urea-PAGE gels, then 3' tailed with terminal transferase (TdT; New England Biolabs) in the presence of dGTP or dATP according to the manufacturer's protocol. Tailed DNA products were diluted 10-fold with binding buffer (40% saturated aqueous guanidinium chloride + 60% isopropanol) and purified by QIAquick spin column (Qiagen), then used as templates for primer extension by Klenow fragment (New England Biolabs) using primer AVA134 (A-tailed products) or AVA135 (G-tailed products) (Tables 2A-2C). Extension were amplified by PCR for 10 cycles using primers AVA110 and AVA122, then sequenced with AVA037 using the Sanger method (Tables 2A-2C).

[1153] Yeast fluorescent reporter assays

[1154] Dual fluorescent reporter plasmids containing an in- frame stop codon, a +1 frameshift, or a -1 frameshift were subjected to 5'-extended PEgRNA or 3'-extended PEgRNA prime editing reactions *in vitro* as described above. Following incubation at 37 °C for 1 hour, the reactions were diluted with water and plasmid DNA was precipitated with 0.3 M sodium acetate and 70% ethanol. Resuspended DNA was transformed into *S. cerevisiae* by electroporation as previously described⁶⁷ and plated on synthetic complete media without leucine (SC(glucose), L-). GFP and mCherry fluorescence signals were visualized from colonies with the Typhoon FLA 7000 biomolecular imager.

[1155] General mammalian cell culture conditions

[1156] HEK293T (ATCC CRL-3216), U2OS (ATTC HTB-96), K562 (CCL-243), and HeLa (CCL-2) cells were purchased from ATCC and cultured and passaged in Dulbecco's Modified Eagle's Medium (DMEM) plus GlutaMAX (ThermoFisher Scientific), McCoy's 5A Medium (Gibco), RPMI Medium 1640 plus GlutaMAX (Gibco), or Eagle's Minimal Essential Medium (EMEM, ATCC), respectively, each supplemented with 10% (v/v) fetal bovine serum (Gibco, qualified) and 1x Penicillin Streptomycin (Corning). All cell types were incubated, maintained, and cultured at 37 °C with 5% CO₂. Cell lines were authenticated by their respective suppliers and tested negative for mycoplasma.

[1157] HEK293T tissue culture transfection protocol and genomic DNA preparation

[1158] HEK293T cells grown were seeded on 48-well poly-D-lysine coated plates (Corning). 16 to 24 hours post- seeding, cells were transfected at approximately 60% confluency with 1 µL of Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocols and 750 ng

of PE plasmid, 250 ng of PEgRNA plasmid, and 83 ng of sgRNA plasmid (for PE3 and PE3b). Unless otherwise stated, cells were cultured 3 days following transfection, after which the media was removed, the cells were washed with 1x PBS solution (Thermo Fisher Scientific), and genomic DNA was extracted by the addition of 150 μ L of freshly prepared lysis buffer (10 mM Tris-HCl, pH 7.5; 0.05% SDS; 25 μ g/mL Proteinase K (ThermoFisher Scientific)) directly into each well of the tissue culture plate. The genomic DNA mixture was incubated at 37 °C for 1 to 2 hours, followed by an 80 °C enzyme inactivation step for 30 minutes. Primers used for mammalian cell genomic DNA amplification are listed in Table 4. For HDR experiments in HEK293T cells, 231 ng of nuclease-expression plasmid, 69 ng of sgRNA expression plasmid, 50 ng (1.51 pmol) 100-nt ssDNA donor template (PAGE-purified; Integrated DNA Technologies) was lipofected using 1.4 μ L Lipofectamine 2000 (ThermoFisher) per well. Genomic DNA from all HDR experiments was purified using the Agencourt DNAdvance Kit (Beckman Coulter), according to the manufacturer's protocol.

[1159] High-throughput DNA sequencing of genomic DNA samples

[1160] Genomic sites of interest were amplified from genomic DNA samples and sequenced on an Illumina MiSeq as previously described with the following modifications^{129,130}. Briefly, amplification primers containing Illumina forward and reverse adapters (Table 4) were used for a first round of PCR (PCR 1) amplifying the genomic region of interest. 25 μ L PCR 1 reactions were performed with 0.5 μ M of each forward and reverse primer, 1 μ L of genomic DNA extract and 12.5 μ L of Phusion U Green Multiplex PCR Master Mix. PCR reactions were carried out as follows: 98 °C for 2 minutes, then 30 cycles of [98 °C for 10 seconds, 61 °C for 20 seconds, and 72 °C for 30 seconds], followed by a final 72 °C extension for 2 minutes. Unique Illumina barcoding primer pairs were added to each sample in a secondary PCR reaction (PCR 2). Specifically, 25 μ L of a given PCR 2 reaction contained 0.5 μ M of each unique forward and reverse illumina barcoding primer pair, 1 μ L of unpurified PCR 1 reaction mixture, and 12.5 μ L of Phusion U Green Multiplex PCR 2x Master Mix. The barcoding PCR 2 reactions were carried out as follows: 98 °C for 2 minutes, then 12 cycles of [98 °C for 10 seconds, 61 °C for 20 seconds, and 72 °C for 30 seconds], followed by a final 72 °C extension for 2 minutes. PCR products were evaluated analytically by electrophoresis in a 1.5% agarose gel. PCR 2 products (pooled by common amplicons) were purified by electrophoresis with a 1.5% agarose gel using a QIAquick Gel Extraction Kit (Qiagen), eluting with 40 μ L of water. DNA concentration was measured by fluorometric quantification (Qubit, ThermoFisher Scientific) or qPCR (KAPA Library Quantification Kit- Illumina, KAPA Biosystems) and sequenced on an Illumina MiSeq instrument according to the manufacturer's protocols.

[1161] Sequencing reads were demultiplexed using MiSeq Reporter (Illumina). Alignment of amplicon sequences to a reference sequence was performed using CRISPResso2¹⁷⁸. For quantification of point mutation editing, CRISPResso2 was run in standard mode with "discard_indel_reads" on.

Editing efficiency was calculated as: (frequency of specified point mutation in non-discarded reads) x (# of non-discarded reads) ÷ total reads. For insertion or deletion edits, CRISPResso2 was run in HDR mode using the desired allele as the expected allele (e flag), and with “discard_indel_reads” ON. Editing yield was calculated as the number of HDR aligned reads divided by total reads. For all edits, indel yields were calculated as the number of discarded reads divided by total reads.

[1162] Nucleofection of U2OS, K562, and HeLa cells

[1163] Nucleofection was performed in all experiments using K562, HeLa, and U2OS cells. For PE conditions in these cell types, 800ng prime editor-expression plasmid, 200ng PEgRNA-expression plasmid, and 83 ng nicking plasmid was nucleofected in a final volume of 20 µL in a 16-well nucleocuvette strip (Lonza). For HDR conditions in these three cell types, 350 ng nuclease-expression plasmid, 150 ng sgRNA-expression plasmid and 200 pmol (6.6 µg) 100-nt ssDNA donor template (PAGE-purified; Integrated DNA Technologies) was nucleofected in a final volume of 20 µL per sample in a 16-well Nucleocuvette strip (Lonza). K562 cells were nucleofected using the SF Cell Line 4D-Nucleofector X Kit (Lonza) with 5×10^5 cells per sample (program FF-120), according to the manufacturers protocol. U2OS cells were nucleofected using the SE Cell Line 4D-Nucleofector X Kit (Lonza) with $3-4 \times 10^5$ cells per sample (program DN-100), according to the manufacturers protocol. HeLa cells were nucleofected using the SE Cell Line 4D-Nucleofector X Kit (Lonza) with 2×10^5 cells per sample (program CN-114), according to the manufacturers protocol. Cells were harvested 72 hours after nucleofection for genomic DNA extraction.

[1164] Genomic DNA extraction for HDR experiments

[1165] Genomic DNA from all HDR comparison experiments in HEK293T, HEK293T *HBB* E6V, K562, U2OS, and HeLa cells was purified using the Agencourt DNAdvance Kit (Beckman Coulter), according to the manufacturer’s protocol.

[1166] Comparison between PE2, PE3, BE2, BE4max, ABEdmax, and ABEmax

[1167] HEK293T cells were seeded on 48-well poly-D-lysine coated plates (Corning). After 16 to 24 hours, cells were transfected at approximately 60% confluency. For base editing with CBE or ABE constructs, cells were transfected with 750 ng of base editor plasmid, 250 ng of sgRNA expression plasmid, and 1 µL of Lipofectamine 2000 (Thermo Fisher Scientific). PE transfections were performed as described above. Genomic DNA extraction for PE and BE was performed as described above.

[1168] Determination of PE3 activity at known Cas9 off-target sites

[1169] To evaluate PE3 off-target editing activity at known Cas9 off-target sites, genomic DNA extracted from HEK293T cells 3 days after transfection with PE3 was used as template for PCR amplification of 16 previously reported Cas9 off-target genomic sites^{118,159} (the top four off-target sites each for the HEK3, EMX1, FANCF, and HEK4 spacers; primer sequences are listed in Table 4). These genomic DNA samples were identical to those used for quantifying on-target PE3 editing activities shown in FIGs. 41A-41K; PEgRNA and nicking sgRNA sequences are listed in Tables 3A-3R. Following PCR amplification of off-target sites, amplicons were sequenced on the Illumina MiSeq platform as described above (HTS analysis). For determining Cas9 nuclease, Cas9 H840A nickase, dCas9, and PE2-dRT on-target and off-target editing activity, HEK293T cells were transfected with 750 ng of editor plasmid (Cas9 nuclease, Cas9 H840A nickase, dCas9, or PE2-dRT), 250 ng of PEgRNA or sgRNA plasmid, and 1 μ L of Lipofectamine 2000. Genomic DNA was isolated from cells 3 days after transfection as described above. On-target and off-target genomic loci were amplified by PCR using primer sequences in Table 4 and sequenced on an Illumina MiSeq.

[1170] HTS data analysis was performed using CRISPResso2¹⁷⁸. The editing efficiencies of Cas9 nuclease, Cas9 H840A nickase, and dCas9 were quantified as the percent of total sequencing reads containing indels. For quantification of PE3 and PE3-dRT off-targets, aligned sequencing reads were examined for point mutations, insertions, or deletions that were consistent with the anticipated product of PEgRNA reverse transcription initiated at the Cas9 nick site. Single nucleotide variations occurring at <0.1% overall frequency among total reads within a sample were excluded from analysis. For reads containing single nucleotide variations that both occurred at frequencies $\geq 0.1\%$ and were partially consistent with the PEgRNA-encoded edit, t-tests (unpaired, one-tailed, $\alpha = 0.5$) were used to determine if the variants occurred at significantly higher levels compared to samples treated with PEgRNAs that contained the same spacer but encoded different edits. To avoid differences in sequencing errors, comparisons were made between samples that were sequenced simultaneously within the same MiSeq run. Variants that did not meet the criteria of p-value > 0.05 were excluded. Off-target PE3 editing activity was then calculated as the percentage of total sequencing reads that met the above criteria.

[1171] Generation of a HEK293T cell line containing the HBB E6V mutation using Cas9- initiated HDR

[1172] HEK293T cells were seeded in a 48-well plate and transfected at approximately 60% confluency with 1.5 μ L of Lipofectamine 2000, 300 ng of Cas9 D10A nickase plasmid, 100 ng of sgRNA plasmid, and 200 ng of 100-mer ssDNA donor template (Table 5). Three days after transfection, media was exchanged for fresh media. Four days after transfection, cells were dissociated using 30 μ L of TrypLE solution and suspended in 1.5 mL of media. Single cells were isolated into individual wells of two 96-well plates by fluorescence-activated cell sorting (FACS)

(Beckman-Coulter Astrios). See FIGs. 53A-53B for representative FACS sorting examples. Cells were expanded for 14 days prior to genomic DNA sequencing as described above. Of the isolated clonal populations, none was found to be homozygous for the *HBB* E6V mutation, so a second round of editing by lipofection, sorting, and outgrowth was repeated in a partially edited cell line to yield a cell line homozygous for the E6V allele.

[1173] Generation of a HEK293T cell line containing the *HBB* E6V mutation using PE3

[1174] 2.5 x 10⁴ HEK293T cells grown in the absence of antibiotic were seeded on 48-well poly-D-lysine coated plates (Corning). 16 to 24 hours post-seeding, cells were transfected at approximately 70% confluency with 1 µL of Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocols and 750 ng of PE2-P2A-GFP plasmid, 250 ng of PEgRNA plasmid, and 83 ng of sgRNA plasmid. After 3 days post transfection, cells were washed with phosphate-buffered saline (Gibco) and dissociated using TrypLE Express (Gibco). Cells were then diluted with DMEM plus GlutaMax (Thermo Fisher Scientific) supplemented with 10% (v/v) FBS (Gibco) and passed through a 35-µm cell strainer (Corning) prior to sorting. Flow cytometry was carried out on a LE-MA900 cell sorter (Sony). Cells were treated with 3 nM DAPI (BioLegend) 15 minutes prior to sorting. After gating for doublet exclusion, single DAPI- negative cells with GFP fluorescence above that of a GFP-negative control cell population were sorted into 96-well flat-bottom cell culture plates (Corning) filled with pre-chilled DMEM with GlutaMax supplemented with 10% FBS. See FIGs. 53A-53B for representative FACS sorting examples. Cells were cultured for 10 days prior to genomic DNA extraction and characterization by HTS, as described above. A total of six clonal cell lines were identified that are homozygous for the E6V mutation in *HBB*.

[1175] Generation of a HEK293T cell line containing the *HEXA* 1278+TATC insertion using PE3

[1176] HEK293T cells containing the *HEXA* 1278+TATC allele were generated following the protocol described above for creation of the *HBB* E6V cell line; PEgRNA and sgRNA sequences are listed in Tables 2A-2C under the FIGs. 43A-43H subheading. After transfection and sorting, cells were cultured for 10 days prior to genomic DNA extraction and characterization by HTS, as described above. Two heterozygous cell lines were isolated that contained 50% *HEXA* 1278+TATC alleles, and two homozygous cell lines containing 100% *HEXA* 1278+TATC alleles were recovered.

[1177] Cell viability assays

[1178] HEK293T cells were seeded in 48-well plates and transfected at approximately 70% confluency with 750 ng of editor plasmid (PE3, PE3 R110S K103L, Cas9 H840A nickase, or dCas9), 250 ng of HEK3-targeting PEgRNA plasmid, and 1 µL of Lipofectamine 2000, as described above. Cell viability was measured every 24 hours post-transfection for 3 days using the CellTiter-Glo 2.0

assay (Promega) according to the manufacturer's protocol. Luminescence was measured in 96-well flat-bottomed polystyrene microplates (Corning) using a M1000 Pro microplate reader (Tecan) with a 1-second integration time.

[1179] Lentivirus production

[1180] Lentivirus was produced as previously described²⁰⁶. T-75 flasks of rapidly dividing HEK293T cells (ATCC; Manassas, VA, USA) were transfected with lentivirus production helper plasmids pVSV-G and psPAX2 in combination with modified lentiCRISPR_v2 genomes carrying intein-split PE2 editor using FuGENE HD (Promega, Madison, WI, USA) according to the manufacturer's directions. Four split-intein editor constructs were designed: 1) a viral genome encoding a U6-PEgRNA expression cassette and the N-terminal portion (1-573) of Cas9 H840A nickase fused to the Npu N-intein, a self-cleaving P2A peptide, and GFP-KASH; 2) a viral genome encoding the Npu C-intein fused to the C-terminal remainder of PE2; 3) a viral genome encoding the Npu C-intein fused to the C-terminal remainder of Cas9 for the Cas9 control; and 4) a nicking sgRNA for DNMT1. The split-intein mediates trans splicing to join the two halves of PE2 or Cas9, while the P2A GFP-KASH enables co-translational production of a nuclear membrane-localized GFP. After 48 hours, supernatant was collected, centrifuged at 500 g for 5 minutes to remove cellular debris, and filtered using a 0.45 µm filter. Filtered supernatant was concentrated using the PEG-it Virus Precipitation Solution (System Biosciences, Palo Alto, CA, USA) according to the manufacturer's directions. The resulting pellet was resuspended in Opti-MEM (Thermo Fisher Scientific, Waltham, MA, USA) using 1% of the original media volume. Resuspended pellet was flash-frozen and stored at -80°C until use.

[1181] Mouse primary cortical neuron dissection and culture

[1182] E18.5 dissociated cortical cultures were harvested from timed-pregnant C57BL/6 mice (Charles River). Embryos were harvested from pregnant mice after euthanasia by CO₂ followed by decapitation. Cortical caps were dissected in ice-cold Hibernate-E supplemented with penicillin/streptomycin (Life Technologies). Following a rinse with ice-cold Hibernate-E, tissue was digested at 37 °C for 8 minutes in papain/DNase (Worthington/Sigma). Tissue was triturated in NBActiv4 (BrainBits) supplemented with DNase. Cells were counted and plated in 24-well plates at 100,000 cells per well. Half of the media was changed twice per week.

[1183] Prime editing in primary neurons and nuclei isolation

[1184] At DIV 1, 15 µL of lentivirus was added at 10:10:1 ratio of N-terminal:C-terminal:nicking sgRNA. At DIV 14, neuronal nuclei were isolated using the EZ-PREP buffer (Sigma D8938) following the manufacturer's protocol. All steps were performed on ice or at 4 °C. Media was removed from dissociated cultures, and cultures were washed with ice-cold PBS. PBS was aspirated

and replaced with 200 μ L EZ-PREP solution. Following a 5-minute incubation on ice, EZ-PREP was pipetted across the surface of the well to dislodge remaining cells. The sample was centrifuged at 500 g for 5 minutes, and the supernatant removed. Samples were washed with 200 μ L EZ-PREP and centrifuged again at 500 g for 5 minutes. Samples were resuspended with gentle pipetting in 200 μ L ice-cold Nuclei Suspension Buffer (NSB) consisting of 100 μ g/mL BSA and 3.33 μ M Vybrant DyeCycle Ruby (Thermo Fisher) in 1xPBS, then centrifuged at 500 g for 5 minutes. The supernatant was removed and nuclei were resuspended in 100 μ L NSB and sorted into 100 μ L Agencourt DNAdvance lysis buffer using a MoFlo Astrios (Beckman Coulter) at the Broad Institute flow cytometry facility. Genomic DNA was purified according to the manufacturer's Agencourt DNAdvance instructions.

[1185] RNA-sequencing and data analysis

[1186] HEK293T cells were co-transfected with PRNP-targeting or HEXA-targeting PEGRNAs and PE2, PE2-dRT, or Cas9 H840A nickase. 72 hours following transfection, total RNA was harvested from cells using TRIzol reagent (Thermo Fisher) and purified with RNeasy Mini kit (Qiagen) including on-column DNaseI treatment. Ribosomes were depleted from total RNA using the rRNA removal protocol of the TruSeq Stranded Total RNA library prep kit (Illumina) and subsequently washed with RNAClean XP beads (Beckman Coulter). Sequencing libraries were prepared using ribo-depleted RNA on a SMARTer PrepX Apollo NGS library prep system (Takara) following the manufacturer's protocol. Resulting libraries were visualized on a 2200 TapeStation (Agilent Technologies), normalized using a Qubit dsDNA HS assay (Thermo Fisher), and sequenced on a NextSeq 550 using high output v2 flow cell (Illumina) as 75-bp paired-end reads. Fastq files were generated with bcl2fastq2 version 2.20 and trimmed using TrimGalore version 0.6.2 (github.com/FelixKrueger/TrimGalore) to remove low-quality bases, unpaired sequences, and adaptor sequences. Trimmed reads were aligned to a Homo sapiens genome assembly GRCh¹⁴⁸ with a custom Cas9 H840A gene entry using RSEM version 1.3.1²⁰⁷. The limma-voom²⁰⁸ package was used to normalize gene expression levels and perform differential expression analysis with batch effect correction. Differentially expressed genes were called with FDR-corrected p-value < 0.05 and fold-change > 2 cutoffs, and results were visualized in R.

[1187] ClinVar analysis

[1188] The ClinVar variant summary was downloaded from NCBI (accessed July 15, 2019), and the information contained therein was used for all downstream analysis. The list of all reported variants was filtered by allele ID in order to remove duplicates and by clinical significance in order to restrict the analysis to pathogenic variants. The list of pathogenic variants was filtered sequentially by variant type in order to calculate the fraction of pathogenic variants that are insertions, deletions, etc. Single

nucleotide variants (SNVs) were separated into two categories (transitions and transversions) based on the reported reference and alternate alleles. SNVs that did not report reference or alternate alleles were excluded from the analysis.

[1189] The lengths of reported insertions, deletions, and duplications were calculated using reference/alternate alleles, variant start/stop positions, or appropriate identifying information in the variant name. Variants that did not report any of the above information were excluded from the analysis. The lengths of reported indels (single variants that include both insertions and deletions relative to the reference genome) were calculated by determining the number of mismatches or gaps in the best pairwise alignment between the reference and alternate alleles. Frequency distributions of variant lengths were calculated using GraphPad Prism 8.

[1190] Data availability

[1191] High-throughput sequencing data are deposited to the NCBI Sequence Read Archive database. Plasmids encoding PE1, PE2/PE3, and PEgRNA expression vectors will be available from Addgene.

[1192] Code Availability

[1193] The script used to quantify PEgRNA scaffold insertion is provided in FIGs. 60A-60B.

[1194] Supplemental Information: Tables and Sequences

[1195] Table 1: Activities of prime editors, Cas9 nuclease, Cas9 H840A nickase, and PE2-dRT at HEK3, HEK4, EMX1, and FANCF on-target and off-target sites. PE2/PE3 editing is shown as % prime editing alongside % indels (in parentheses). % indels are shown for Cas9, Cas9 H840A nickase (nCas9), and PE2-dRT at the top four previously characterized off-target sites^{179,180}. sgRNA and PEgRNA sequences can be found in Tables 3A-3R, under the FIGs. 42A-42H heading. All values are the average of three independent biological replicates.

PE		HEK3 (PE3)					HEK4 (PE2)					EMX1 (PE3)					FANCF (PE3)				
pegRNA		---	1	2	3	4	---	1	2	3	4	---	1	2	3	4	---	1	2	3	4
Site																					
On-target		44.2	51.2	40.4	48.4		18.2	14.4	9.5	7.8		28.6	14.1	35.7	15.4		56.5	32.4	42.8	47.6	
		(11.9)	(8.8)	(15.5)	(3.3)		(9.9)	(1.5)	(2.0)	(2.2)		(3.5)	(2.4)	(9.3)	(2.8)		(9.2)	(16.7)	(13.5)	(12.0)	
Off-target 1		<0.1	<0.1	<0.1	<0.1		<0.1	0.4	<0.1	0.4		<0.1	<0.1	<0.1	<0.1		<0.1	0.6	<0.1	<0.1	
		(<0.1)	(<0.1)	(<0.1)	(<0.1)		(<0.1)	(<0.1)	(<0.1)	(<0.1)		(0.1)	(0.1)	(0.1)	(0.1)		(0.1)	0.1	(0.1)	(0.1)	
Off-target 2		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1	
		(<0.1)	(<0.1)	(<0.1)	(<0.1)		(0.1)	(0.1)	(0.1)	(0.1)		(<0.1)	(0.1)	(0.1)	(0.1)		(<0.1)	(<0.1)	(0.1)	(<0.1)	
Off-target 3		<0.1	<0.1	<0.1	<0.1		0.2	6.8	19.2	7.8		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1	
		(<0.1)	(<0.1)	(<0.1)	(<0.1)		(0.5)	(1.9)	(0.5)	(3.5)		(0.3)	(0.3)	(0.3)	(0.3)		(<0.1)	(<0.1)	(<0.1)	(<0.1)	
Off-target 4		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1	
		(0.1)	(0.1)	(0.1)	(<0.1)		(<0.1)	(0.1)	(0.2)	(<0.1)		(0.1)	(0.1)	(0.2)	(0.1)		(<0.1)	(<0.1)	(<0.1)	(<0.1)	

Cas9		HEK3					HEK4					EMX1					FANCF				
pegRNA		sgRNA	1	2	3	4	sgRNA	1	2	3	4	sgRNA	1	2	3	4	sgRNA	1	2	3	4
Site																					
On-target		91.8	87.5	89.2	89.1	86.8	71.8	68.6	72.8	72.8	70.9	65.6	79.7	70.6	76.6	76.0	78.7	55.9	56.3	51.8	52.0
Off-target 1		17.2	1.9	5.5	5.2	1.8	54.2	39.5	48.4	49.7	49.2	81.1	63.5	48.1	53.0	59.6	12.6	1.9	1.9	1.7	1.7
Off-target 2		38.0	6.5	12.6	11.8	4.7	42.5	19.5	29.4	27.3	30.3	58.3	12.0	6.0	8.2	12.9	1.1	0.2	0.2	0.2	0.1
Off-target 3		8.8	0.6	1.7	1.5	0.5	98.1	96.9	97.3	97.6	97.5	14.8	4.2	3.1	3.6	4.8	2.4	0.2	<0.1	0.2	0.2
Off-target 4		0.3	<0.1	<0.1	0.1	<0.1	45.3	16.9	28.0	27.5	29.7	39.5	1.3	0.9	0.6	1.3	1.0	0.2	0.2	0.2	0.2

nCas9		HEK3					HEK4					EMX1					FANCF				
pegRNA		---	1	2	3	4	---	1	2	3	4	---	1	2	3	4	---	1	2	3	4
Site																					
Off-target 1		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1		0.1	0.1	<0.1	0.1		<0.1	<0.1	<0.1	<0.1	
Off-target 2		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1		0.3	0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1	
Off-target 3		<0.1	<0.1	<0.1	<0.1		0.3	0.5	0.7	0.7		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1	
Off-target 4		<0.1	<0.1	<0.1	<0.1		<0.1	0.1	<0.1	<0.1		1.5	0.1	0.1	0.4		<0.1	<0.1	<0.1	<0.1	

PE2-dRT		HEK3					HEK4					EMX1					FANCF				
pegRNA		---	1	2	3	4	---	1	2	3	4	---	1	2	3	4	---	1	2	3	4
Site																					
Off-target 1		<0.1	<0.1	<0.1	<0.1		0.1	0.2	<0.1	<0.1		0.1	0.1	0.1	0.1		<0.1	<0.1	<0.1	<0.1	
Off-target 2		<0.1	<0.1	<0.1	<0.1		<0.1	0.1	<0.1	<0.1		<0.1	0.3	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1	
Off-target 3		<0.1	<0.1	<0.1	<0.1		<0.1	0.1	1.4	0.9		<0.1	<0.1	<0.1	<0.1		<0.1	<0.1	<0.1	<0.1	
Off-target 4		<0.1	<0.1	<0.1	<0.1		0.1	0.1	0.1	0.2		0.9	0.1	0.1	0.2		<0.1	<0.1	<0.1	<0.1	

[1196] Tables 2A-2C: Sequences of DNA oligonucleotides, PEgRNAs, and sgRNAs used for *in vitro* experiments.

[1197] Table 2A: DNA oligonucleotides

OLIGONUCLEOTIDE	SEQUENCE
AVA023	5CY5-CCTGGGTCAATCCTTGGGGCCCAGACTGAGCACG (SEQ ID NO: 374)
AVA024	5CY5-CCTGGGTCAATCCTTGGGGCCCAGACTGAGCACGTGATGGCAGAGGAAAGG (SEQ ID NO: 375)

AVA025	5PHOS- CCTTTCTCTGCCATCACGTGCTCAGTCTGGGCCCCAAGGATTGAC CCAGG (SEQ ID NO: 376)
AVA026	5PHOS-TGATGGCAGAGGAAAGG (SEQ ID NO: 377)
AVA037	GCAGGCTTTAAAGGAACCAATTC (SEQ ID NO: 378)
AVA110	GCAGGCTTTAAAGGAACCAATTCCTGGGTCAATCCTTGGGGC (SEQ ID NO: 379)
AVA122	CTCTGGAGGATCTAGCGGAG (SEQ ID NO: 380)
AVA134	CTCTGGAGGATCTAGCGGAGTTTTTTTTTTTTTTTTTTT (SEQ ID NO: 381)
AVA135	CTCTGGAGGATCTAGCGGAGCCCCCCCCCCCCCCC (SEQ ID NO: 382)

[1198] Table 2B: 5'-extended PEgRNAs

PEGRNA	SPACER SEQUENCE	5' EXTENSION SEQUENCE	LINK ER LENG TH (NT)	PBS LENG TH (NT)	RT TEMPL ATE LENGT H (NT)
PEGRNA 1	GGCCCAGACTGA GCACGTGA (SEQ ID NO: 383)	GGCTAACCGTGCCATTT GATCAGGTCA (SEQ ID NO: 429)	15	5	7
PEGRNA 2	GGCCCAGACTGA GCACGTGA (SEQ ID NO: 384)	GGCTAACCGTGCAAATT AACAACTAA (SEQ ID NO: 430)	15	5	7
PEGRNA 3	GGCCCAGACTGA GCACGTGA (SEQ ID NO: 385)	GGCCATCTCGTGCAAAT TAACAACTAA (SEQ ID NO: 431)	15	5	8
PEGRNA 4	GGCCCAGACTGA GCACGTGA (SEQ ID NO: 386)	GGTCCTCTGCCATCTCG TGCAAATTAACAACTA A (SEQ ID NO: 432)	15	5	15
PEGRNA 5	GGCCCAGACTGA GCACGTGA (SEQ ID NO: 387)	GGCTTCCTTTCTCTGC CATCTCGTGCAAATTA CAAATAA (SEQ ID NO: 433)	15	5	22
5'- PEGRNA_RT_7_ A	GGCCCAGACTGA GCACGTGA (SEQ ID NO: 388)	GGCTAACCGTGCCATTT GATCAGGTCA (SEQ ID NO: 434)	15	5	7
5'- PEGRNA_RT_7_ B	GGCCCAGACTGA GCACGTGA (SEQ ID NO: 389)	GGCTAACCGTGCAAATT AACAACTAA (SEQ ID NO: 435)	15	5	7
5'-PEGRNA_RT_8	GGCCCAGACTGA GCACGTGA (SEQ ID NO: 390)	GGCCATCTCGTGCAAAT TAACAACTAA (SEQ ID NO: 436)	15	5	8

5'- PEGRNA_RT_15	GGCCCAGACTGA GCACGTGA (SEQ ID NO: 391)	GGTCCTCTGCCATCTCG TGCAAATTAACAAACTA A (SEQ ID NO: 437)	15	5	15
5'- PEGRNA_RT_22	GGCCCAGACTGA GCACGTGA (SEQ ID NO: 392)	GGCTTCCTTTCTCTGC CATCTCGTGCAAATTA CAAATAA (SEQ ID NO: 438)	15	5	22

[1199] Table 2C: 3'-extended PEgRNAs

PEGRNA	SPACER SEQUENCE	3' EXTENSION SEQUENCE	PBS LENGT H (NT)	RT TEMPLA TE LENGTH (NT)
3'-PEGRNA_10	GGCCCAGACTGAGC ACGTGA (SEQ ID NO: 506)	TCTGCCATCTCGT GCTC (SEQ ID NO: 439)	7	10
3'- PEGRNA_YEAST_TT OA	GGCCCAGACTGAGC ACGTGA (SEQ ID NO: 507)	TCTGCCATCTCGT GCTC (SEQ ID NO: 440)	7	10
3'- PEGRNA_YEAST_+1A INS	GGCCCAGACTGAGC ACGTGA (SEQ ID NO: 508)	TCTGCCATCATCG TGCTC (SEQ ID NO: 441)	7	11
3'- PEGRNA_YEAST_+1T DEL	GGCCCAGACTGAGC ACGTGA (SEQ ID NO: 509)	TCTGCCATCCGTG CTC (SEQ ID NO: 442)	7	9

[1200] Tables 3A-3R: Sequences of PEgRNAs and sgRNAs used in mammalian cell experiments.

All sequences are shown in 5' to 3' orientation. To construct PEgRNAs, spacer sequences listed below were added to the 5' end of the sgRNA scaffold and the 3' extensions listed below containing the primer binding site and RT template were added to the 3' end of the sgRNA scaffold. The sgRNA scaffold sequence is

GTTTTAGAGCTAGAAATAGCAAGTTAAATAAGGCTAGTCCGTTATCAACTTGAAAAAG
TGGCACCGAGTCGGTGC (SEQ ID NO: 131).

[1201] Table 3A: FIGs. 39A-39D PEgRNA

PEGRNA	SPACER SEQUENCE (SEQ ID NOS: 2890- 2996)	3' EXTENSION (SEQ ID NOS: 2997-3103)	PBS LENGT H (NT)	RT TEMPLA TE LENGTH (NT)
HEK3_2B- C_8	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCA	8	10
HEK3_2B- C_9	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCAG	9	10
HEK3_2B- C_10	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCAG T	10	10

HEK3_2B-C_11	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCAG TC	11	10
HEK3_2B-C_12	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCAG TCT	12	10
HEK3_2B-C_13	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCAG TCTG	13	10
HEK3_2B-C_14	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCAG TCTGG	14	10
HEK3_2B-C_15	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCAG TCTGGG	15	10
HEK3_2C_16	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCAG TCTGGGC	16	10
HEK3_2C_17	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCAG TCTGGGCC	17	10
EMX1_2C_9	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCACTTCTTCTTC TGC	9	13
EMX1_2C_10	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCACTTCTTCTTC TGCT	10	13
EMX1_2C_11	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCACTTCTTCTTC TGCTC	11	13
EMX1_2C_12	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCACTTCTTCTTC TGCTCG	12	13
EMX1_2C_13	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCACTTCTTCTTC TGCTCGG	13	13
EMX1_2C_14	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCACTTCTTCTTC TGCTCGGA	14	13
EMX1_2C_15	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCACTTCTTCTTC TGCTCGGAC	15	13
EMX1_2C_16	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCACTTCTTCTTC TGCTCGGACT	16	13
EMX1_2C_17	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCACTTCTTCTTC TGCTCGGACTC	17	13
FANCF_2C_8	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGA	8	17
FANCF_2C_9	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAA	9	17
FANCF_2C_10	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAG	10	17
FANCF_2C_11	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAGG	11	17
FANCF_2C_12	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAGGG	12	17
FANCF_2C_13	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAGGGA	13	17
FANCF_2C_14	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAGGGAT	14	17
FANCF_2C_15	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAGGGATT	15	17
FANCF_2C_16	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAGGGATTCT	16	17
FANCF_2C_17	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAGGGATTCC	17	17

RNF2_2C_9	GTCATCTTAGTCATT ACCTG	GAACACCTCATGTAATGAC T	9	11
RNF2_2C_10	GTCATCTTAGTCATT ACCTG	GAACACCTCATGTAATGAC TA	10	11
RNF2_2C_11	GTCATCTTAGTCATT ACCTG	GAACACCTCATGTAATGAC TAA	11	11
RNF2_2C_12	GTCATCTTAGTCATT ACCTG	GAACACCTCATGTAATGAC TAAG	12	11
RNF2_2C_13	GTCATCTTAGTCATT ACCTG	GAACACCTCATGTAATGAC TAAGA	13	11
RNF2_2C_14	GTCATCTTAGTCATT ACCTG	GAACACCTCATGTAATGAC TAAGAT	14	11
RNF2_2C_15	GTCATCTTAGTCATT ACCTG	GAACACCTCATGTAATGAC TAAGATG	15	11
RNF2_2C_16	GTCATCTTAGTCATT ACCTG	GAACACCTCATGTAATGAC TAAGATGA	16	11
RNF2_2C_17	GTCATCTTAGTCATT ACCTG	GAACACCTCATGTAATGAC TAAGATGAC	17	11
HEK4_2C_7	GGCACTGCGGCTGG AGGTGG	GCTTTAACCCCAACCTCCA G	7	13
HEK4_2C_8	GGCACTGCGGCTGG AGGTGG	GCTTTAACCCCAACCTCCA GC	8	13
HEK4_2C_9	GGCACTGCGGCTGG AGGTGG	GCTTTAACCCCAACCTCCA GCC	9	13
HEK4_2C_10	GGCACTGCGGCTGG AGGTGG	GCTTTAACCCCAACCTCCA GCCG	10	13
HEK4_2C_11	GGCACTGCGGCTGG AGGTGG	GCTTTAACCCCAACCTCCA GCCGC	11	13
HEK4_2C_12	GGCACTGCGGCTGG AGGTGG	GCTTTAACCCCAACCTCCA GCCGCA	12	13
HEK4_2C_13	GGCACTGCGGCTGG AGGTGG	GCTTTAACCCCAACCTCCA GCCGCAG	13	13
HEK4_2C_14	GGCACTGCGGCTGG AGGTGG	GCTTTAACCCCAACCTCCA GCCGCAGT	14	13
HEK4_2C_15	GGCACTGCGGCTGG AGGTGG	GCTTTAACCCCAACCTCCA GCCGCAGTG	15	13
HEK3_2C_1 TDEL	GGCCCAGACTGAGC ACGTGA	TCTGCCATCCGTGCTCAGT CTG	13	10
HEK3_2C_1 AINS	GGCCCAGACTGAGC ACGTGA	TCTGCCATCATCGTGCTCA GTCTG	13	10
HEK3_2C_1 CTTINS	GGCCCAGACTGAGC ACGTGA	TCTGCCATCAAAGCGTGCT CAGTCTG	13	10
HEK3_2D_1 0	GGCCCAGACTGAGC ACGTGA	TCTGCCATCTCGTGCTCAG TCTG	13	10
HEK3_2D_11	GGCCCAGACTGAGC ACGTGA	CTCTGCCATCTCGTGCTCA GTCTG	13	11
HEK3_2D_1 2	GGCCCAGACTGAGC ACGTGA	CCTCTGCCATCTCGTGCTC AGTCTG	13	12
HEK3_2D_1 3	GGCCCAGACTGAGC ACGTGA	TCCTCTGCCATCTCGTGCTC AGTCTG	13	13
HEK3_2D_1 4	GGCCCAGACTGAGC ACGTGA	TTCCTCTGCCATCTCGTGCT CAGTCTG	13	14

HEK3_2D_1 5	GGCCCAGACTGAGC ACGTGA	TTCCTCTGCCATCTCGTGC TCAGTCTG	13	15
HEK3_2D_1 6	GGCCCAGACTGAGC ACGTGA	CTTTCCTCTGCCATCTCGTG CTCAGTCTG	13	16
HEK3_2D_1 7	GGCCCAGACTGAGC ACGTGA	CCTTTCCTCTGCCATCTCGT GCTCAGTCTG	13	17
HEK3_2D_1 8	GGCCCAGACTGAGC ACGTGA	TCCTTTCCTCTGCCATCTCG TGCTCAGTCTG	13	18
HEK3_2D_1 9	GGCCCAGACTGAGC ACGTGA	TTCCTTTCCTCTGCCATCTC GTGCTCAGTCTG	13	19
HEK3_2D_2 0	GGCCCAGACTGAGC ACGTGA	CTTCCTTTCCTCTGCCATCT CGTGCTCAGTCTG	13	20
EMX1_2D_1 0	GAGTCCGAGCAGAA GAAGAA	GGAGCCCTTGTTCTTCTGC TCGG	13	10
EMX1_2D_1 1	GAGTCCGAGCAGAA GAAGAA	GGGAGCCCTTGTTCTTCTG CTCGG	13	11
EMX1_2D_1 2	GAGTCCGAGCAGAA GAAGAA	TGGGAGCCCTTGTTCTTCT GCTCGG	13	12
EMX1_2D_1 3	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCCCTTGTTCTTC TGCTCGG	13	13
EMX1_2D_1 4	GAGTCCGAGCAGAA GAAGAA	GATGGGAGCCCTTGTTCTT CTGCTCGG	13	14
EMX1_2D_1 5	GAGTCCGAGCAGAA GAAGAA	TGATGGGAGCCCTTGTTCT TCTGCTCGG	13	15
EMX1_2D_1 6	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGCCCTTGTTCT TCTGCTCGG	13	16
EMX1_2D_1 7	GAGTCCGAGCAGAA GAAGAA	TGTGATGGGAGCCCTTGTT CTTCTGCTCGG	13	17
EMX1_2D_1 8	GAGTCCGAGCAGAA GAAGAA	ATGTGATGGGAGCCCTTGTT TCTTCTGCTCGG	13	18
EMX1_2D_1 9	GAGTCCGAGCAGAA GAAGAA	GATGTGATGGGAGCCCTTG TTCTTCTGCTCGG	13	19
EMX1_2D_2 0	GAGTCCGAGCAGAA GAAGAA	TGATGTGATGGGAGCCCTT GTTCTTCTGCTCGG	13	20
FANCF_2D_ 10	GGAATCCCTTCTGCA GCACC	CGATCAAGGTGCTGCAGAA GGGA	13	10
FANCF_2D_ 11	GGAATCCCTTCTGCA GCACC	GCGATCAAGGTGCTGCAGA AGGGA	13	11
FANCF_2D_ 12	GGAATCCCTTCTGCA GCACC	AGCGATCAAGGTGCTGCAG AAGGGA	13	12
FANCF_2D_ 13	GGAATCCCTTCTGCA GCACC	AAGCGATCAAGGTGCTGCA GAAGGGA	13	13
FANCF_2D_ 14	GGAATCCCTTCTGCA GCACC	AAAGCGATCAAGGTGCTGC AGAAGGGA	13	14
FANCF_2D_ 15	GGAATCCCTTCTGCA GCACC	AAAAGCGATCAAGGTGCT GCAGAAGGGA	13	15
FANCF_2D_ 16	GGAATCCCTTCTGCA GCACC	GAAAAGCGATCAAGGTGCT TGCAGAAGGGA	13	16
FANCF_2D_ 17	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAGGGA	13	17
FANCF_2D_ 18	GGAATCCCTTCTGCA GCACC	CGGAAAAGCGATCAAGGT GCTGCAGAAGGGA	13	18

FANCF_2D_19	GGAATCCCTTCTGCA GCACC	TCGGAAAAGCGATCAAGG TGCTGCAGAAGGGA	13	19
FANCF_2D_20	GGAATCCCTTCTGCA GCACC	CTCGGAAAAGCGATCAAG GTGCTGCAGAAGGGA	13	20
RNF2_2D_10	GTCATCTTAGTCATT ACCTG	AACACCTCATGTAATGACT AAGATG	15	10
RNF2_2D_11	GTCATCTTAGTCATT ACCTG	GAACACCTCATGTAATGAC TAAGATG	15	11
RNF2_2D_12	GTCATCTTAGTCATT ACCTG	CGAACACCTCATGTAATGA CTAAGATG	15	12
RNF2_2D_13	GTCATCTTAGTCATT ACCTG	ACGAACACCTCATGTAATG ACTAAGATG	15	13
RNF2_2D_14	GTCATCTTAGTCATT ACCTG	AACGAACACCTCATGTAAT GACTAAGATG	15	14
RNF2_2D_15	GTCATCTTAGTCATT ACCTG	CAACGAACACCTCATGTAA TGACTAAGATG	15	15
RNF2_2D_16	GTCATCTTAGTCATT ACCTG	ACAACGAACACCTCATGTA ATGACTAAGATG	15	16
RNF2_2D_17	GTCATCTTAGTCATT ACCTG	TACAACGAACACCTCATGT AATGACTAAGATG	15	17
RNF2_2D_18	GTCATCTTAGTCATT ACCTG	TTACAACGAACACCTCATG TAATGACTAAGATG	15	18
RNF2_2D_19	GTCATCTTAGTCATT ACCTG	GTTACAACGAACACCTCAT GTAATGACTAAGATG	15	19
RNF2_2D_20	GTCATCTTAGTCATT ACCTG	AGTTACAACGAACACCTCA TGTAATGACTAAGATG	15	20
HEK4_2D_7	GGCACTGCGGCTGG AGGTGG	ACCCCAACCTCCAGCCGC	11	7
HEK4_2D_8	GGCACTGCGGCTGG AGGTGG	AACCCCAACCTCCAGCCGC	11	8
HEK4_2D_9	GGCACTGCGGCTGG AGGTGG	TAACCCCAACCTCCAGCCG C	11	9
HEK4_2D_10	GGCACTGCGGCTGG AGGTGG	TTAACCCCAACCTCCAGCC GC	11	10
HEK4_2D_11	GGCACTGCGGCTGG AGGTGG	TTTAACCCCAACCTCCAGC CGC	11	11
HEK4_2D_12	GGCACTGCGGCTGG AGGTGG	CTTTAACCCCAACCTCCAG CCGC	11	12
HEK4_2D_13	GGCACTGCGGCTGG AGGTGG	GCTTTAACCCCAACCTCCA GCCGC	11	13
HEK4_2D_14	GGCACTGCGGCTGG AGGTGG	CGCTTTAACCCCAACCTCC AGCCGC	11	14
HEK4_2D_15	GGCACTGCGGCTGG AGGTGG	CCGCTTTAACCCCAACCTC CAGCCGC	11	15
HEK4_2D_16	GGCACTGCGGCTGG AGGTGG	TCCGCTTTAACCCCAACCT CCAGCCGC	11	16
HEK4_2D_17	GGCACTGCGGCTGG AGGTGG	CTCCGCTTTAACCCCAACC TCCAGCCGC	11	17
HEK4_2D_18	GGCACTGCGGCTGG AGGTGG	CTCCGCTTTAACCCCAACC TCCAGCCGC	11	18
HEK4_2D_19	GGCACTGCGGCTGG AGGTGG	CTCCGCTTTAACCCCAACC TCCAGCCGC	11	19

[1202] Table 3B: FIGs. 40A-40C PEgRNA

PEgRNA	SPACER SEQUENCE (SEQ ID NO: 3104-3112)	3' EXTENSION (SEQ ID NOS: 3113-3121)	PBS LENGT H (NT)	RT TEMPL ATE LENGT H (NT)
RNF2_3B	GTCATCTTAGTCATT ACCTG	AACGAACACCTCATGTAAT GACTAAGATG	15	14
EMX1_3B	GAGTCCGAGCAGAA GAAGAA	ATGGGAGCACTTCTTCTTC TGCTCGGAC	15	13
FANCF_3B	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAGGGATT	15	17
HE3_3B	GGCCCAGACTGAGC ACGTGA	TCTGCCATGACGTGCTCAG TCTG	13	10
HEK4_3B	GGCACTGCGGCTGG AGGTGG	TTAACCCCAACCTCCAGCC	9	10
RNF2_3C_4A TOC	GTCATCTTAGTCATT ACCTG	AACGAACACCGCAGGTAA TGACTAAGATG	15	14
RNF2_3C_4A TOG	GTCATCTTAGTCATT ACCTG	AACGAACACCCCAGGTAA TGACTAAGATG	15	14
FANCF_3C_5 GTOT	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGGTG CTGCAGAAGGGA	13	17
FANCF_3C_7 ATOC	GGAATCCCTTCTGCA GCACC	GGAAAAGCGAGCCAGGTG CTGCAGAAGGGAT	14	17

[1203] Table 3C: FIGs. 40A-40C nicking sgRNA sequences

NICKING SGRNA	SPACER SEQUENCE	SEQ ID NO:
RNF2_2B_+41	GTCAACCATTAAGCAAAACAT	3122
RNF2_2B_+67	GTCTCAGGCTGTGCAGACAAA	3123
EMX1_2B_-116	GGGGCACAGATGAGAACTC	3124
EMX1_2B_-57	GCCGTTTGTACTTTGTCCTC	3125
EMX1_2B_+14	GCGCCACCGGTTGATGTGAT	3126
EMX1_2B_+27	GCTTCGTGGCAATGCGCCAC	3127
EMX1_2B_+53	GACATCGATGTCCTCCCAT	3128
EMX1_2B_+80	GTGGTTGCCCACCCTAGTCAT	3129
FANCF_2B_-78	GCGACTCTCTGCGTACTGAT	3130
FANCF_2B_-50	GCCCTACTTCCGCTTTCACCT	3131
FANCF_2B_-27	GGATTCCATGAGGTGCGCGA	3132
FANCF_2B_-17	GCTGCAGAAGGGATTCCATG	3133
FANCF_2B_+21	GCTTGAGACCGCCAGAAGCT	3134
FANCF_2B_+48	GGGGTCCCAGGTGCTGACGT	3135
HEK3_2B_-108	GCAGAAATAGACTAATTGCA	3136
HEK3_2B_-38	GGATTGACCCAGGCCAGGGC	3137
HEK3_2B_+26	GACGCCCTCTGGAGGAAGCA	3138
HEK3_2B_+37	GCTGTCCTGCGACGCCCTC	3139
HEK3_2B_+63	GCACATACTAGCCCCTGTCT	3140
HEK3_2B_+90	GTCAACCAAGTATCCCGGTGC	3141
HEK4_2B_-95	TCCCTTCCTTCCACCCAGCC	3142
HEK4_2B_-51	CCCTGCCTGTCATCCTGCTT	3143

HEK4_2B_-26	GCAGTGCCACCGGGGCGCCG	3144
HEK4_2B_+52	GCGGGGGCTCAGAGAGGGCA	3145
HEK4_2B_+74	GAGACACACACAGGCCTGG	3146
RNF2_2C_+41	GTCAACCATTAAGCAAAACAT	3147
RNF2_2C_4ATOC_+5	GTGAGTTACAACGAACACCGC	3148
RNF2_2C_4ATOG_+5	GTGAGTTACAACGAACACCCC	3149
FANCF_2C_+48	GGGGTCCCAGGTGCTGACGT	3150
FANCF_2C_5GTOT_+7	GAAGCTCGGAAAAGCGATCA	3151
FANCF_2C_7ATOC_+7	GAAGCTCGGAAAAGCGAGCC	3152
HEK3_2C_+90	GTCAACCAGTATCCCGGTGC	3153

[1204] Table 3D: FIGs. 41A-41K PEgRNA

PEGRNA	SPACER SEQUENCE (SEQ ID NO: 3154-3304)	3' EXTENSION (SEQ ID NO: 3305-3455)	PBS LEN GTH (NT)	RT TEMPLA TE LENGTH (NT)
HEK3_4A_1 TTOA	GGCCCAGACTGAGCA CGTGA	TCTGCCATCTCGTGCTCAGT CTG	13	10
HEK3_4A_1 TTOC	GGCCCAGACTGAGCA CGTGA	TCTGCCATCGCGTGCTCAGT CTG	13	10
HEK3_4A_1 TTOG	GGCCCAGACTGAGCA CGTGA	TCTGCCATCCCGTGCTCAGT CTG	13	10
HEK3_4A_2 GTOA	GGCCCAGACTGAGCA CGTGA	TCTGCCATTACGTGCTCAGT CTG	13	10
HEK3_4A_2 GTOC	GGCCCAGACTGAGCA CGTGA	TCTGCCATGACGTGCTCAGT CTG	13	10
HEK3_4A_2 GTOT	GGCCCAGACTGAGCA CGTGA	TCTGCCATAACGTGCTCAGT CTG	13	10
HEK3_4A_3 ATOC	GGCCCAGACTGAGCA CGTGA	TCTGCCAGCACGTGCTCAG TCTG	13	10
HEK3_4A_3 ATOG	GGCCCAGACTGAGCA CGTGA	TCTGCCACCACGTGCTCAG TCTG	13	10
HEK3_4A_3 ATOT	GGCCCAGACTGAGCA CGTGA	TCTGCCAACACGTGCTCAG TCTG	13	10
HEK3_4A_4 TTOA	GGCCCAGACTGAGCA CGTGA	TCTGCCTTCACGTGCTCAGT CTG	13	10
HEK3_4A_4 TTOC	GGCCCAGACTGAGCA CGTGA	TCTGCCGTCACGTGCTCAG TCTG	13	10
HEK3_4A_4 TTOG	GGCCCAGACTGAGCA CGTGA	TCTGCCCTCACGTGCTCAGT CTG	13	10
HEK3_4A_5 GTOA	GGCCCAGACTGAGCA CGTGA	TCTGCTATCACGTGCTCAGT CTG	13	10
HEK3_4A_5 GTOC	GGCCCAGACTGAGCA CGTGA	TCTGCGATCACGTGCTCAGT CTG	13	10
HEK3_4A_5 GTOT	GGCCCAGACTGAGCA CGTGA	TCTGCAATCACGTGCTCAGT CTG	13	10
HEK3_4A_6 GTOA	GGCCCAGACTGAGCA CGTGA	TCTGTCATCACGTGCTCAGT CTG	13	10
HEK3_4A_6 GTOC	GGCCCAGACTGAGCA CGTGA	TCTGGCATCACGTGCTCAGT CTG	13	10
HEK3_4A_6 GTOT	GGCCCAGACTGAGCA CGTGA	TCTGACATCACGTGCTCAGT CTG	13	10

HEK3_4A_7 CTOA	GGCCCAGACTGAGCA CGTGA	TCTTCCATCACGTGCTCAGT CTG	13	10
HEK3_4A_7 CTOG	GGCCCAGACTGAGCA CGTGA	TCTCCCATCACGTGCTCAGT CTG	13	10
HEK3_4A_7 CTOT	GGCCCAGACTGAGCA CGTGA	TCTACCATCACGTGCTCAGT CTG	13	10
HEK3_4A_8 ATOC	GGCCCAGACTGAGCA CGTGA	TCGGCCATCACGTGCTCAG TCTG	13	10
HEK3_4A_8 ATOG	GGCCCAGACTGAGCA CGTGA	TCCGCCATCACGTGCTCAGT CTG	13	10
HEK3_4A_8 ATOT	GGCCCAGACTGAGCA CGTGA	TCAGCCATCACGTGCTCAG TCTG	13	10
HEK3_4B_1 TTOA	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTTCCTCTGCCATCTCGTGC TCAGTCTG	13	34
HEK3_4B_1 2GTOC	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTTGCTCTGCCATCACGTGC TCAGTCTG	13	34
HEK3_4B_1 4ATOT	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TATCCTCTGCCATCACGTGC TCAGTCTG	13	34
HEK3_4B_1 7GTOC	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTGC TTTCCTCTGCCATCACGTGC TCAGTCTG	13	34
HEK3_4B_2 0GTOC	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGGTTCC TTTCCTCTGCCATCACGTGC TCAGTCTG	13	34
HEK3_4B_2 3CTOG	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCACGGCTTCC TTTCCTCTGCCATCACGTGC TCAGTCTG	13	34
HEK3_4B_2 4TTOA	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCTGGGCTTCC TTTCCTCTGCCATCACGTGC TCAGTCTG	13	34
HEK3_4B_2 6CTOG	GGCCCAGACTGAGCA CGTGA	TGGAGGAACCAGGGCTTCC TTTCCTCTGCCATCACGTGC TCAGTCTG	13	34
HEK3_4B_3 0CTOG	GGCCCAGACTGAGCA CGTGA	TGGACGAAGCAGGGCTTCC TTTCCTCTGCCATCACGTGC TCAGTCTG	13	34
HEK3_4B_3 3CTOG	GGCCCAGACTGAGCA CGTGA	TCGAGGAAGCAGGGCTTCC TTTCCTCTGCCATCACGTGC TCAGTCTG	13	34
RNF2_4C_1 CTOA	GTCATCTTAGTCATTA CCTG	AACGAACACCTCATGTAAT GACTAAGATG	15	14
RNF2_4C_1 CTOG	GTCATCTTAGTCATTA CCTG	AACGAACACCTCACGTAAT GACTAAGATG	15	14
RNF2_4C_1 CTOT	GTCATCTTAGTCATTA CCTG	AACGAACACCTCAAGTAAT GACTAAGATG	15	14
RNF2_4C_2 TTOA	GTCATCTTAGTCATTA CCTG	AACGAACACCTCTGGTAAT GACTAAGATG	15	14
RNF2_4C_2 TTOG	GTCATCTTAGTCATTA CCTG	AACGAACACCTCCGGTAAT GACTAAGATG	15	14
RNF2_4C_3 GTOC	GTCATCTTAGTCATTA CCTG	AACGAACACCTGAGGTAAT GACTAAGATG	15	14

RNF2_4C_4 ATOC	GTCATCTTAGTCATTA CCTG	AACGAACACCGCAGGTAAT GACTAAGATG	15	14
RNF2_4C_4 ATOT	GTCATCTTAGTCATTA CCTG	AACGAACACCACAGGTAAT GACTAAGATG	15	14
RNF2_4C_4 ATOG	GTCATCTTAGTCATTA CCTG	AACGAACACCCCAGGTAAT GACTAAGATG	15	14
RNF2_4C_5 GTOT	GTCATCTTAGTCATTA CCTG	AACGAACACATCAGGTAAT GACTAAGATG	15	14
RNF2_4C_6 GTOA	GTCATCTTAGTCATTA CCTG	AACGAACATCTCAGGTAAT GACTAAGATG	15	14
RNF2_4C_7 TTOC	GTCATCTTAGTCATTA CCTG	AACGAACGCCTCAGGTAAT GACTAAGATG	15	14
FANCF_4D_1 ATOG	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCCAGGCGC TGCAGAAGGGAT	14	17
FANCF_4D_1 ATOT	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCCAGGAGC TGCAGAAGGGAT	14	17
FANCF_4D_2 CTOA	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCCAGTTGC TGCAGAAGGGAT	14	17
FANCF_4D_3 CTOG	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCCACGTGC TGCAGAAGGGAT	14	17
FANCF_4D_3 CTOT	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCCAAGTGC TGCAGAAGGGAT	14	17
FANCF_4D_4 TTOA	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCCTGGTGC TGCAGAAGGGAT	14	17
FANCF_4D_4 TTOG	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCCCGGTGC TGCAGAAGGGAT	14	17
FANCF_4D_5 GTOA	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCTAGGTGC TGCAGAAGGGAT	14	17
FANCF_4D_6 GTOC	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATGCAGGTGC TGCAGAAGGGAT	14	17
FANCF_4D_7 ATOC	GGAATCCCTTCTGCA GCACC	GGAAAAGCGAGCCAGGTG CTGCAGAAGGGAT	14	17
FANCF_4D_8 TTOC	GGAATCCCTTCTGCA GCACC	GGAAAAGCGGTCCAGGTGC TGCAGAAGGGAT	14	17
FANCF_4D_10 GTOT	GGAATCCCTTCTGCA GCACC	GGAAAAGAGATCCAGGTGC TGCAGAAGGGAT	14	17
EMX1_4E_2 ATOC	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGCCCTGCTTC TCTGCTCGGA	14	16
EMX1_4E_2 ATOT	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGCCCTACTTCT TCTGCTCGGA	14	16
EMX1_4E_3 ATOG	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGCCCCTCTTCT TCTGCTCGGA	14	16
EMX1_4E_4 GTOC	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGCCGTCTTCT TCTGCTCGGA	14	16
EMX1_4E_5 GTOA	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGCTCTTCTTCT TCTGCTCGGA	14	16
EMX1_4E_5 GTOT	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGCACTTCTTCT TCTGCTCGGA	14	16
EMX1_4E_7 CTOA	GAGTCCGAGCAGAA GAAGAA	GTGATGGGATCCCTTCTTCT TCTGCTCGGA	14	16
EMX1_4E_8 TTOA	GAGTCCGAGCAGAA GAAGAA	GTGATGGGTGCCCTTCTTCT TCTGCTCGGA	14	16

EMX1_4E_8 TTOC	GAGTCCGAGCAGAA GAAGAA	GTGATGGGGGCCCTTCTTCT TCTGCTCGGA	14	16
EMX1_4E_8 TTOG	GAGTCCGAGCAGAA GAAGAA	GTGATGGGCGCCCTTCTTCT TCTGCTCGGA	14	16
EMX1_4E_9 CTOG	GAGTCCGAGCAGAA GAAGAA	GTGATGGCAGCCCTTCTTCT TCTGCTCGGA	14	16
EMX1_4E_9 CTOT	GAGTCCGAGCAGAA GAAGAA	GTGATGGAAGCCCTTCTTCT TCTGCTCGGA	14	16
RUNX1_4F_ 1CTOA	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCATCTCTTCC TCCTGAAAAT	15	15
RUNX1_4F_ 1CTOG	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCATCCCTTCC TCCTGAAAAT	15	15
RUNX1_4F_ 1CTOT	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCATCACTTCC TCCTGAAAAT	15	15
RUNX1_4F_ 2GTOA	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCATTGCTTCC TCCTGAAAAT	15	15
RUNX1_4F_ 3ATOC	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCAGCGCTTC CTCCTGAAAAT	15	15
RUNX1_4F_ 3ATOG	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCACCGCTTC CTCCTGAAAAT	15	15
RUNX1_4F_ 3ATOT	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCAACGCTTC CTCCTGAAAAT	15	15
RUNX1_4F_ 4TTOA	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCTTCGCTTCC TCCTGAAAAT	15	15
RUNX1_4F_ 4TTOC	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCGTCGCTTC CTCCTGAAAAT	15	15
RUNX1_4F_ 4TTOG	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCCTCGCTTCC TCCTGAAAAT	15	15
RUNX1_4F_ 5GTOT	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCAATCGCTTCC TCCTGAAAAT	15	15
RUNX1_4F_ 6GTOC	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGGCATCGCTTCC TCCTGAAAAT	15	15
VEGFA_4G_ 1TTOA	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCCT CTTCTGGCCTGCAGA	13	22
VEGFA_4G_ 1TTOC	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCCT CGTCTGGCCTGCAGA	13	22
VEGFA_4G_ 1TTOG	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCCT CCTCTGGCCTGCAGA	13	22
VEGFA_4G_ 2GTOA	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCCT TATCTGGCCTGCAGA	13	22
VEGFA_4G_ 3ATOC	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCC GCATCTGGCCTGCAGA	13	22
VEGFA_4G_ 3ATOG	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCC CCATCTGGCCTGCAGA	13	22
VEGFA_4G_ 3ATOT	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCC ACATCTGGCCTGCAGA	13	22
VEGFA_4G_ 5GTOT	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCAC TCATCTGGCCTGCAGA	13	22
VEGFA_4G_ 6GTOC	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGGCC TCATCTGGCCTGCAGA	13	22
VEGFA_4G_ 7CTOA	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGATCCCT CATCTGGCCTGCAGA	13	22

VEGFA_4G_7CTOT	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAACCCCT CATCTGGCCTGCAGA	13	22
VEGFA_4G_9CTOG	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGCAGCCCT CATCTGGCCTGCAGA	13	22
DNMT1_4H_1ATOC	GATTCCTGGTGCCAG AAACA	GTCACCCCTGGTTCTGGCA CCAGG	13	11
DNMT1_4H_1ATOG	GATTCCTGGTGCCAG AAACA	GTCACCCCTGCTTCTGGCA CCAGG	13	11
DNMT1_4H_2CTOA	GATTCCTGGTGCCAG AAACA	GTCACCCCTTTTCTGGCAC CAGG	13	11
DNMT1_4H_2CTOG	GATTCCTGGTGCCAG AAACA	GTCACCCCTCTTCTGGCAC CAGG	13	11
DNMT1_4H_2CTOT	GATTCCTGGTGCCAG AAACA	GTCACCCCTATTTCTGGCAC CAGG	13	11
DNMT1_4H_3ATOT	GATTCCTGGTGCCAG AAACA	GTCACCCAGTTTCTGGCA CCAGG	13	11
DNMT1_4H_4GTOA	GATTCCTGGTGCCAG AAACA	GTCACCCCTGTTTCTGGCAC CAGG	13	11
DNMT1_4H_5GTOT	GATTCCTGGTGCCAG AAACA	GTCACCACTGTTTCTGGCA CCAGG	13	11
DNMT1_4H_6GTOC	GATTCCTGGTGCCAG AAACA	GTCACGCCTGTTTCTGGCA CCAGG	13	11
DNMT1_4H_8TTOA	GATTCCTGGTGCCAG AAACA	GCCCTCCCGTCTCCCCTGTT TCTGGCACCAGG	13	19
DNMT1_4H_8TTOC	GATTCCTGGTGCCAG AAACA	GCCCTCCCGTCGCCCCTGTT TCTGGCACCAGG	13	19
DNMT1_4H_8TTOG	GATTCCTGGTGCCAG AAACA	GCCCTCCCGTCCCCCTGTT TCTGGCACCAGG	13	19
HEK3_4J_D EL1-5	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTTCCTCTGCCGTGCTCAGT CTG	13	29
HEK3_4J_D EL1-10	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTTCCCGTGCTCAGTCTG	13	24
HEK3_4J_D EL1-15	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC CGTGCTCAGTCTG	13	19
HEK3_4J_D EL1-25	GGCCCAGACTGAGCA CGTGA	TGTCCTGCGACGCCCTCTG GAGGAAGCGTGCTCAGTCT G	13	26
HEK3_4J_D EL1-30	GGCCCAGACTGAGCA CGTGA	TGTCCTGCGACGCCCTCTG GACGTGCTCAGTCTG	13	21
HEK3_4J_D EL1-80	GGCCCAGACTGAGCA CGTGA	AGTATCCCGGTGCAGGAGC TCGTGCTCAGTCTG	13	20
HEK3_4I_1 AINS	GGCCCAGACTGAGCA CGTGA	TCTGCCATCATCGTGCTCAG TCTG	13	11
HEK3_4I_1 CTTINS	GGCCCAGACTGAGCA CGTGA	TCTGCCATCAAAGCGTGCT CAGTCTG	13	13
HEK3_4I_1T DEL	GGCCCAGACTGAGCA CGTGA	TCTGCCATCCGTGCTCAGTC TG	13	9
HEK3_4I_1- 3TGADEL	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTTCCTCTGCCACGTGCTCA GTCTG	13	31
RNF2_4I_1T INS	GTCATCTTAGTCATTA CCTG	AACGAACACCTCAGAGTAA TGAATAAGATG	15	15

RNF2_4I_1G TAINS	GTCATCTTAGTCATTA CCTG	AACGAACACCTCAGTACGT AATGACTAAGATG	15	17
RNF2_4I_4A DEL	GTCATCTTAGTCATTA CCTG	AACGAACACCCAGGTAATG ACTAAGATG	15	13
RNF2_4I_3- 5GAGDEL	GTCATCTTAGTCATTA CCTG	AACGAACACAGGTAATGAC TAAGATG	15	11
FANCF_4I_3 CINS	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCCAGGGTG CTGCAGAAGGGAT	14	18
FANCF_4I_4 GATINS	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCCAATCGG TGCTGCAGAAGGGAT	14	20
FANCF_4I_6 GDEL	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAGGTGCT GCAGAAGGGAT	14	16
FANCF_4I_5 -7GGADEL	GGAATCCCTTCTGCA GCACC	GGAAAAGCGAAGGTGCTGC AGAAGGGAT	14	14
EMX1_4I_6 TINS	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGCACCTTCTT CTTCTGCTCGGA	14	17
EMX1_4I_1 TGCINS	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGCCCTTCGCA TTCTTCTGCTCGGA	14	19
EMX1_4I_5 GDEL	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGCCTTCTTCTT CTGCTCGGA	14	15
EMX1_4I_4- 6GGGDEL	GAGTCCGAGCAGAA GAAGAA	GTGATGGGAGTTCTTCTTCT GCTCGGA	14	13
RUNX1_4I_1 CINS	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCATCGGCTTC CTCCTGAAAAT	15	16
RUNX1_4I_1 ATGINS	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCATCCATGCT TCCTCCTGAAAAT	15	18
RUNX1_4I_2 GDEL	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCATGCTTCCT CCTGAAAAT	15	14
RUNX1_4I_2- 4GATDEL	GCATTTTCAGGAGGA AGCGA	TGTCTGAAGCCGCTTCCTCC TGAAAAT	15	12
VEGFA_4I_4 CINS	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCG CTCATCTGGCCTGCAGA	13	23
VEGFA_4I_2 ACAINS	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCCT TGTCATCTGGCCTGCAGA	13	25
VEGFA_4I_3 ADEL	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCC CATCTGGCCTGCAGA	13	21
VEGFA_4I_2- 4GAGDEL	GATGTCTGCAGGCCA GATGA	AATGTGCCATCTGGAGCCAT CTGGCCTGCAGA	13	19
DNMT1_4I_4 CINS	GATTCCTGGTGCCAG AAACA	TCCCGTCACCCGCTGTTTCT GGCACCAGG	13	16
DNMT1_4I_1 TCAINS	GATTCCTGGTGCCAG AAACA	TCCCGTCACCCCTGTGATTT CTGGCACCAGG	13	18
DNMT1_4I_3 ADEL	GATTCCTGGTGCCAG AAACA	TCCCGTCACCCGTTTCTGG CACCAGG	13	14
DNMT1_4I_3- 5AGGDEL	GATTCCTGGTGCCAG AAACA	TCCCGTCACCGTTTCTGGCA CCAGG	13	12
HEK3_4K_1 CTTINS_5G DEL	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTTCCTCTGCATCAAAGCGT GCTCAGTCTG	13	36
HEK3_4K_1 CTTINS_2G TOC	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTTCCTCTGCCATGAAAGCG TGCTCAGTCTG	13	37

HEK3_4K_3 TDEL_5GT OC	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTTCCTCTGCGATCCGTGCT CAGTCTG	13	33
HEK3_4K_3 GTOC_6GT OT	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTTCCTCTGACATGACGTGC TCAGTCTG	13	34
RNF2_4K_2 AAINS_3- 4GADEL	GTCATCTTAGTCATTA CCTG	AACGAACACCATTGGTAAT GACTAAGATG	15	14
RNF2_4K_1 AINS_5GTO C	GTCATCTTAGTCATTA CCTG	AACGAACACGTCAGTGTA TGACTAAGATG	15	15
RNF2_4K_1- 2CTDEL_6G TOT	GTCATCTTAGTCATTA CCTG	AACGAACAACCTCGTAATGA CTAAGATG	15	12
RNF2_4K_1 CTOA_5GT OT	GTCATCTTAGTCATTA CCTG	AACGAACACATCATGTAAT GACTAAGATG	15	14
FANCF_4K_ 1TINS_3- 4TGDEL	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCGGTAGCT GCAGAAGGGAT	14	16
FANCF_4K_ 1TINS_6GT OA	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATTGAGGTAG CTGCAGAAGGGAT	14	18
FANCF_4K_ 2CDEL_5GT OT	GGAATCCCTTCTGCA GCACC	GGAAAAGCGATCAAGTGCT GCAGAAGGGAT	14	16

[1205]

[1206] Table 3E: FIGs. 41A-41K nicking sgRNA

NICKING SGRNA	SPACER SEQUENCE (SEQ ID NOS: 3456-3463)
HEK3_4A_+90	GTCAACCAGTATCCCGGTGC
HEK3_4B_+90	GTCAACCAGTATCCCGGTGC
RNF2_4C_+41	GTCAACCATTAAAGCAAAACAT
FANCF_4D_+48	GGGGTCCCAGGTGCTGACGT
EMX1_4E_+53	GACATCGATGTCCTCCCAT
RUNX1_4F_+38	GATGAAGCACTGTGGGTACGA
VEGFA_4G_+57	GATGTACAGAGAGCCAGGGC
DNMT1_4H_+49	GCCCTTCAGCTAAAATAAAGG

[1207]

[1208] Table 3F: FIGs. 42A-42H PEgRNA

PEGRNA	SPACER SEQUENCE (SEQ ID NOS: 3464-3478)	3' EXTENSION (SEQ ID NOS: 3479-3493)	PBS LENGTH (NT)	RT TEMPLATE LENGTH (NT)
HEK3_5A_C3	GGCCCAGACTGAG CACGTGA	TCTGTCATCACGTGCTCAGTCT G	13	10
HEK3_5A_C4	GGCCCAGACTGAG CACGTGA	TCTGCTATCACGTGCTCAGTCT G	13	10

HEK3_5A_C7	GGCCCAGACTGAG CACGTGA	TCTGCCATTACGTGCTCAGTCT G	13	10
FANCF_5A_C3	GGAATCCCTTCTGC AGCACC	GGAAAAGTGATCCAGGTGCTG CAGAAGGGAT	14	17
FANCF_5A_C7	GGAATCCCTTCTGC AGCACC	GGAAAAGCGATTAGGTGCTG CAGAAGGGAT	14	17
FANCF_5A_C8	GGAATCCCTTCTGC AGCACC	GGAAAAGCGATCTAGGTGCTG CAGAAGGGAT	14	17
EMX1_5A_C5	GAGTCCGAGCAGA AGAAGAA	GTGATGGGAGTCCTTCTTCTTC TGCTCGGA	14	16
EMX1_5A_C6	GAGTCCGAGCAGA AGAAGAA	GTGATGGGAGCTCTTCTTCTTC TGCTCGGA	14	16
EMX1_5A_C7	GAGTCCGAGCAGA AGAAGAA	GTGATGGGAGCCTTTCTTCTTC TGCTCGGA	14	16
EMX1_5C_C5_6	GAGTCCGAGCAGA AGAAGAA	GTGATGGGAGTTCTTCTTCTTC TGCTCGGA	14	16
EMX1_5C_C5_7	GAGTCCGAGCAGA AGAAGAA	GTGATGGGAGTCTTTCTTCTTC TGCTCGGA	14	16
EMX1_5C_C6_7	GAGTCCGAGCAGA AGAAGAA	GTGATGGGAGCTTTTCTTCTTC TGCTCGGA	14	16
EMX1_5C_C5_6_7	GAGTCCGAGCAGA AGAAGAA	GTGATGGGAGTTTTTCTTCTTC TGCTCGGA	14	16
HEK3_5D_A5	GGCCCAGACTGAG CACGTGA	TCTGCCGTCACGTGCTCAGTC TG	13	10
HEK3_5D_A8	GGCCCAGACTGAG CACGTGA	TCTGCCATCGCGTGCTCAGTCT G	13	10

[1209] Table 3G: FIGs. 42A-42H nicking sgRNA

NICKING SGRNA	POSSIBLE SPACER SEQUENCE (SEQ ID NOS: 616-618)	POSSIBLE SPACER SEQUENCE(SEQ ID NOS: 619- 621)
HEK3_5A-F_+90	GTCAACCAGTATCCCGGTGC	GTCAACCAGTATCCCGGTGC
FANCF_5A-F_+48	GGGGTCCCAGGTGCTGACGT	GATGTACAGAGAGCCAGGGC
EMX1_5A-F_+57	GATGTACAGAGAGCCAGGGC	GGGGTCCCAGGTGCTGACGT

[1210] Table 3H: FIGs. 42A-42H base editing sgRNA

BASE EDITING SGRNA	SPACER SEQUENCE
HEK3_5A-F_BE	GTGCCATCACGTGCTCAGTCT (SEQ ID NO: 455)
FANCF_5A-F_BE	GAGCGATCCAGGTGCTGCAGA (SEQ ID NO: 456)
EMX1_5A-F_BE	GGAGCCCTTCTTCTTCTGCT (SEQ ID NO: 457)

[1211] Table 3I: FIGs. 42A-42H on-target sgRNA

ON-TARGET SGRNA	SPACER SEQUENCE
HEK3_5G	GGCCCAGACTGAGCACGTGA (SEQ ID NO: 510)

HEK4_5G	GGCACTGCGGCTGGAGGTGG (SEQ ID NO: 511)
EMX1_5G	GAGTCCGAGCAGAAGAAGAA (SEQ ID NO: 512)
FANCF_5G	GGAATCCCTTCTGCAGCACC (SEQ ID NO: 513)

[1212] Table 3J: FIGs. 42A-42H on-target PEgRNA

ON-TARGET PEgRNA	SPACER SEQUENCE (SEQ ID NO: 663-677)	3' EXTENSION (SEQ ID NO: 678-692)	PBS LENGTH (NT)	RT TEMPLATE LENGTH (NT)
HEK3_5G-H_PEGRNA_1	GGCCCAGACTGAGCACGTGA	TCTGCCATCTCGTGCTCAGTCTG	13	10
HEK3_5G-H_PEGRNA_2	GGCCCAGACTGAGCACGTGA	TCTGCCATCAAAGCGTGCTCAGTCTG	13	13
HEK3_5G-H_PEGRNA_3	GGCCCAGACTGAGCACGTGA	TCTGCCATCCGTGCTCAGTCTG	13	9
HEK3_5G-H_PEGRNA_4	GGCCCAGACTGAGCACGTGA	TCTGCGATCACGTGCTCAGTCTG	13	10
HEK4_5G-H_PEGRNA_1	GGCACTGCGGCTGGAGGTGG	TTAACGCCCCACCTCCAGCC	9	10
HEK4_5G-H_PEGRNA_2	GGCACTGCGGCTGGAGGTGG	TTAACCCCCCTCCAGCC	9	10
HEK4_5G-H_PEGRNA_3	GGCACTGCGGCTGGAGGTGG	TTAACCCCTTACACCTCCAGCC	9	13
HEK4_5G-H_PEGRNA_4	GGCACTGCGGCTGGAGGTGG	TTAACCCCCCTCCAGCC	9	9
EMX1_5G-H_PEGRNA_1	GAGTCCGAGCAGAAGAAGAA	GTGATGGGAGCACTTCTTCTTCTGCTCGGA	14	16
EMX1_5G-H_PEGRNA_2	GAGTCCGAGCAGAAGAAGAA	GTGATGGGAGCCCTGCTTCTTCTGCTCGGA	14	16
EMX1_5G-H_PEGRNA_3	GAGTCCGAGCAGAAGAAGAA	GTGATGGGAGCCCTTCGCACTTCTTCTGCTCGGA	14	19
EMX1_5G-H_PEGRNA_4	GAGTCCGAGCAGAAGAAGAA	GTGATGGGAGTTCTTCTTCTTGCTCGGA	14	13
FANCF_5G-H_PEGRNA_1	GGAATCCCTTCTGCAGCACC	GGAAAAGCGATGCAGGTGCTGCAGAAGGGAT	14	17
FANCF_5G-H_PEGRNA_2	GGAATCCCTTCTGCAGCACC	GGAAAAGCGATCCAGGCGCTGCAGAAGGGAT	14	17
FANCF_5G-H_PEGRNA_3	GGAATCCCTTCTGCAGCACC	GGAAAAGCGATCCAATCGTGCTGCAGAAGGGAT	14	20

[1213] Table 3K: FIGs. 49A-49BPEgRNA

PEgRNA	SPACER SEQUENCE (SEQ ID NO: 3494-3521)	3' EXTENSION (SEQ ID NO: 3522-3540)	PBS LENGTH (NT)	RT TEMPLATE LENGTH (NT)
--------	--	-------------------------------------	-----------------	-------------------------

HEK3_6A_2GT OC	GGCCCAGACTGA GCACGTGA	TCTGCCATGACGTGCTCAG TCTG	13	10
HEK3_6A_2GT OC	GGCCCAGACTGA GCACGTGA			
EMX1_6A_3G TOC	GAGTCCGAGCAG AAGAAGAA	ATGGGAGCCCTTGTCTTC TGCTCGG	13	13
EMX1_6A_3G TOC	GAGTCCGAGCAG AAGAAGAA			
FANCF_6A_5G TOT	GGAATCCCTTCTG CAGCACC	AAAAGCGATCAAGGTGCT GCAGAAGGGA	13	15
FANCF_6A_5G TOT	GGAATCCCTTCTG CAGCACC			
HEK3_6A_1HI S6INS	GGCCCAGACTGA GCACGTGA	TGGAGGAAGCAGGGCTTC CTTTCTCTGCCATCAATG ATGGTGATGATGGTGCGTG CTCAGTCTG	13	52
HEK3_6A_1HI S6INS	GGCCCAGACTGA GCACGTGA			
HEK3_6A_5GT OT	GGCCCAGACTGA GCACGTGA	TCTGCAATCACGTGCTCAG TCTG	13	10
HEK3_6A_5GT OT	GGCCCAGACTGA GCACGTGA			
HEK3_6A_1CT TINS	GGCCCAGACTGA GCACGTGA	TCTGCCATCAAAGCGTGCT CAGTCTG	13	10
HEK3_6A_1CT TINS	GGCCCAGACTGA GCACGTGA			
HBB_6B_INSA LL	GCATGGTGCACCT GACTCCTG	AGACTTCTCCACAGGAGT CAGGTGCAC	13	14
HBB_6B_INSA LL	GCATGGTGCACCT GACTCCTG			
HBB_6B_COR RECT	GCATGGTGCACCT GACTCCTG	AGACTTCTCCTCAGGAGTC AGGTGCAC	13	14
HBB_6B_COR RECT	GCATGGTGCACCT GACTCCTG			
HBB_6B_COR RECT_W_SILE NT	GCATGGTGCACCT GACTCCTG	AGACTTCTCTTCAGGAGTC AGGTGCAC	13	14
HBB_6B_COR RECT_W_SILE NT	GCATGGTGCACCT GACTCCTG			
HEXA_6B_INS TALL	GTACCTGAACCGT ATATCCTA	AGTCAGGGCCATAGGATAG ATATACGGTTC	12	14
HEXA_6B_CO RRECT	GATCCTTCCAGTC AGGGCCAT	ACCTGAACCGTATATCCTAT GGCCCTGACTG	10	21
HEXA_6B_CO RRECT_W_SIL ENT	GATCCTTCCAGTC AGGGCCAT	GTACCTGAACCGTATATCTT ATGGCCCTGACT	9	27
PRNP_6C	GCAGTGGTG GGG GGCCTTGG	ATGTAGACGCCAAGGCCCC CCACC	12	12
HEK3_6E- G_1TTOG	GGCCCAGACTGA GCACGTGA	TCTGCCATCCCGTGCTCAG TCTG	13	10
HEK3_6E- G_1CTTINS	GGCCCAGACTGA GCACGTGA	TCTGCCATCAAAGCGTGCT CAGTCTG	13	10

RNF2_6E-G_1CTOG	GTCATCTTAGTCA TTACCTG	AACGAACACCTCACGTAAT GACTAAGATG	15	14
HBB_6E-G_4ATOT	GCATGGTGCACCT GACTCCTG	AGACTTCTCCACAGGAGT CAGGTGCAC	13	14
HEK3_6H_1HI S6INS	GGCCCAGACTGA GCACGTGA	TGGAGGAAGCAGGGCTTC CTTTCCTCTGCCATCAATG ATGGTGATGATGGTGCGTG CTCAGTCTG	13	52
HEK3_6H_1FL AGINS	GGCCCAGACTGA GCACGTGA	TGGAGGAAGCAGGGCTTC CTTTCCTCTGCCATCACTTA TCGTCGTCATCCTTGTAATC CGTGCTCAGTCTG	13	58

[1214] Table 3L: FIGs. 47A-74D PEgRNA

PEGRNA	SPACER SEQUENCE (SEQ ID NO: 3541-3547)	3' EXTENSION SEQUENCE (SEQ ID NO: 3549-3556)	PBS LEN GTH (NT)	RT TEMPL ATE LENGT H (NT)
HEK3_ED4B_1T DEL	GGCCCAGACTGAGCA CGTGA	TCTGCCATCCGTGCTCAGTC TG	13	9
HEK3_ED4B_1A INS	GGCCCAGACTGAGCA CGTGA	TCTGCCATCATCGTGCTCAG TCTG	13	11
HEK3_ED4B_1C TTINS	GGCCCAGACTGAGCA CGTGA	TCTGCCATCAAAGCGTGCT CAGTCTG	13	13
HEK3_ED4C_2G TOC	GGCCCAGACTGAGCA CGTGA	TCTGCCATGACGTGCTCAGT CTG	13	10
HEK3_ED4D_1F LAGINS	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTTCCTCTGCCATCACTTAT CGTCGTCATCCTTGTAATCC GTGCTCAGTCTG	13	58
RNF2_ED4E_1C TOA	GTCATCTTAGTCATTA CCTG	AACGAACACCTCATGTAAT GACTAAGATG	15	14
EMX1_ED4F_1G TOC	GAGTCCGAGCAGAAG AAGAA	ATGGGAGCCCTTGTTCTTCT GCTCGG	13	13
HBB_ED4G_2TT OA	GTAACGGCAGACTTCT CCTC	ATCTGACTCCTGTGGAGAA GTCTGCC	12	14

[1215] Table 3M: FIGs. 48A-48C PEgRNA

PEGRNA	SPACER SEQUENCE (SEQ ID NO: 3557- 3627)	3' EXTENSION SEQUENCE (SEQ ID NO: 3628-3698)	PBS LENGT H (NT)	RT TEMPL ATE LENGT H (NT)
VEGFA_ED5 A_31	GATGTCTGCAGGCC AGATGA	CCCTCTGACAATGTGCCATCTG GAGCACTCATCTGGCCTGCAG A	13	31
VEGFA_ED5 A_30	GATGTCTGCAGGCC AGATGA	CCTCTGACAATGTGCCATCTGG AGCACTCATCTGGCCTGCAGA	13	30

VEGFA_ED5 A_29	GATGTCTGCAGGCC AGATGA	CTCTGACAATGTGCCATCTGGA GCACTCATCTGGCCTGCAGA	13	29
VEGFA_ED5 A_28	GATGTCTGCAGGCC AGATGA	TCTGACAATGTGCCATCTGGAG CACTCATCTGGCCTGCAGA	13	28
VEGFA_ED5 A_27	GATGTCTGCAGGCC AGATGA	CTGACAATGTGCCATCTGGAGC ACTCATCTGGCCTGCAGA	13	27
VEGFA_ED5 A_26	GATGTCTGCAGGCC AGATGA	TGACAATGTGCCATCTGGAGCA CTCATCTGGCCTGCAGA	13	26
VEGFA_ED5 A_25	GATGTCTGCAGGCC AGATGA	GACAATGTGCCATCTGGAGCAC TCATCTGGCCTGCAGA	13	25
VEGFA_ED5 A_24	GATGTCTGCAGGCC AGATGA	ACAATGTGCCATCTGGAGCACT CATCTGGCCTGCAGA	13	24
VEGFA_ED5 A_23	GATGTCTGCAGGCC AGATGA	CAATGTGCCATCTGGAGCACTC ATCTGGCCTGCAGA	13	23
VEGFA_ED5 A_22	GATGTCTGCAGGCC AGATGA	AATGTGCCATCTGGAGCACTCA TCTGGCCTGCAGA	13	22
VEGFA_ED5 A_21	GATGTCTGCAGGCC AGATGA	ATGTGCCATCTGGAGCACTCAT CTGGCCTGCAGA	13	21
VEGFA_ED5 A_20	GATGTCTGCAGGCC AGATGA	TGTGCCATCTGGAGCACTCATC TGGCCTGCAGA	13	20
VEGFA_ED5 A_19	GATGTCTGCAGGCC AGATGA	GTGCCATCTGGAGCACTCATCT GGCCTGCAGA	13	19
VEGFA_ED5 A_18	GATGTCTGCAGGCC AGATGA	TGCCATCTGGAGCACTCATCTG GCCTGCAGA	13	18
VEGFA_ED5 A_17	GATGTCTGCAGGCC AGATGA	GCCATCTGGAGCACTCATCTGG CCTGCAGA	13	17
VEGFA_ED5 A_16	GATGTCTGCAGGCC AGATGA	CCATCTGGAGCACTCATCTGGC CTGCAGA	13	16
VEGFA_ED5 A_15	GATGTCTGCAGGCC AGATGA	CATCTGGAGCACTCATCTGGCC TGCAGA	13	15
VEGFA_ED5 A_14	GATGTCTGCAGGCC AGATGA	ATCTGGAGCACTCATCTGGCCT GCAGA	13	14
VEGFA_ED5 A_13	GATGTCTGCAGGCC AGATGA	TCTGGAGCACTCATCTGGCCTG CAGA	13	13
VEGFA_ED5 A_12	GATGTCTGCAGGCC AGATGA	CTGGAGCACTCATCTGGCCTGC AGA	13	12
VEGFA_ED5 A_11	GATGTCTGCAGGCC AGATGA	TGGAGCACTCATCTGGCCTGCA GA	13	11
VEGFA_ED5 A_10	GATGTCTGCAGGCC AGATGA	GGAGCACTCATCTGGCCTGCA GA	13	10
VEGFA_ED5 A_9	GATGTCTGCAGGCC AGATGA	GAGCACTCATCTGGCCTGCAG A	13	9

VEGFA_ED5 A_8	GATGTCTGCAGGCC AGATGA	AGCACTCATCTGGCCTGCAGA	13	8
DNMT1_ED5 B_31	GATTCCTGGTGCCA GAAACA	AGGACTAGTTCTGCCCTCCCGT CACCCTGTTTCTGGCACCAGG	13	31
DNMT1_ED5 B_30	GATTCCTGGTGCCA GAAACA	GGACTAGTTCTGCCCTCCCGTC ACCACTGTTTCTGGCACCAGG	13	30
DNMT1_ED5 B_29	GATTCCTGGTGCCA GAAACA	GACTAGTTCTGCCCTCCCGTCA CCACTGTTTCTGGCACCAGG	13	29
DNMT1_ED5 B_28	GATTCCTGGTGCCA GAAACA	ACTAGTTCTGCCCTCCCGTCAC CACTGTTTCTGGCACCAGG	13	28
DNMT1_ED5 B_27	GATTCCTGGTGCCA GAAACA	CTAGTTCTGCCCTCCCGTCACC ACTGTTTCTGGCACCAGG	13	27
DNMT1_ED5 B_26	GATTCCTGGTGCCA GAAACA	TAGTTCTGCCCTCCCGTCACCA CTGTTTCTGGCACCAGG	13	26
DNMT1_ED5 B_25	GATTCCTGGTGCCA GAAACA	AGTTCTGCCCTCCCGTCACCAC TGTTTCTGGCACCAGG	13	25
DNMT1_ED5 B_24	GATTCCTGGTGCCA GAAACA	GTTCTGCCCTCCCGTCACCACT GTTTCTGGCACCAGG	13	24
DNMT1_ED5 B_23	GATTCCTGGTGCCA GAAACA	TTCTGCCCTCCCGTCACCACTG TTTCTGGCACCAGG	13	23
DNMT1_ED5 B_22	GATTCCTGGTGCCA GAAACA	TCTGCCCTCCCGTCACCACTGT TTCTGGCACCAGG	13	22
DNMT1_ED5 B_21	GATTCCTGGTGCCA GAAACA	CTGCCCTCCCGTCACCACTGTT TCTGGCACCAGG	13	21
DNMT1_ED5 B_20	GATTCCTGGTGCCA GAAACA	TGCCCTCCCGTCACCACTGTTT CTGGCACCAGG	13	20
DNMT1_ED5 B_19	GATTCCTGGTGCCA GAAACA	GCCCTCCCGTCACCACTGTTTC TGGCACCAGG	13	19
DNMT1_ED5 B_18	GATTCCTGGTGCCA GAAACA	CCCTCCCGTCACCACTGTTTCT GGCACCAGG	13	18
DNMT1_ED5 B_17	GATTCCTGGTGCCA GAAACA	CCTCCCGTCACCACTGTTTCTG GCACCAGG	13	17
DNMT1_ED5 B_16	GATTCCTGGTGCCA GAAACA	CTCCCGTCACCACTGTTTCTGG CACCAGG	13	16
DNMT1_ED5 B_15	GATTCCTGGTGCCA GAAACA	TCCCGTCACCACTGTTTCTGGC ACCAGG	13	15
DNMT1_ED5 B_14	GATTCCTGGTGCCA GAAACA	CCCGTCACCACTGTTTCTGGCA CCAGG	13	14
DNMT1_ED5 B_13	GATTCCTGGTGCCA GAAACA	CCGTCACCACTGTTTCTGGCAC CAGG	13	13
DNMT1_ED5 B_12	GATTCCTGGTGCCA GAAACA	CGTCACCACTGTTTCTGGCACC AGG	13	12

DNMT1_ED5 B_11	GATTCCTGGTGCCA GAAACA	GTCACCACTGTTTCTGGCACCA GG	13	11
DNMT1_ED5 B_10	GATTCCTGGTGCCA GAAACA	TCACCACTGTTTCTGGCACCAG G	13	10
DNMT1_ED5 B_9	GATTCCTGGTGCCA GAAACA	CACCACTGTTTCTGGCACCAGG	13	9
DNMT1_ED5 B_8	GATTCCTGGTGCCA GAAACA	ACCACTGTTTCTGGCACCAGG	13	8
RUNX1_ED5 C_31	GCATTTTCAGGAGG AAGCGA	AATGACTCAAATATGCTGTCTG AAGCAATCGCTTCCTCCTGAAA AT	15	31
RUNX1_ED5 C_30	GCATTTTCAGGAGG AAGCGA	ATGACTCAAATATGCTGTCTGA AGCAATCGCTTCCTCCTGAAAA T	15	30
RUNX1_ED5 C_29	GCATTTTCAGGAGG AAGCGA	TGACTCAAATATGCTGTCTGAA GCAATCGCTTCCTCCTGAAAAT	15	29
RUNX1_ED5 C_28	GCATTTTCAGGAGG AAGCGA	GACTCAAATATGCTGTCTGAAG CAATCGCTTCCTCCTGAAAAT	15	28
RUNX1_ED5 C_27	GCATTTTCAGGAGG AAGCGA	ACTCAAATATGCTGTCTGAAGC AATCGCTTCCTCCTGAAAAT	15	27
RUNX1_ED5 C_26	GCATTTTCAGGAGG AAGCGA	CTCAAATATGCTGTCTGAAGCA ATCGCTTCCTCCTGAAAAT	15	26
RUNX1_ED5 C_25	GCATTTTCAGGAGG AAGCGA	TCAAATATGCTGTCTGAAGCAA TCGCTTCCTCCTGAAAAT	15	25
RUNX1_ED5 C_24	GCATTTTCAGGAGG AAGCGA	CAAATATGCTGTCTGAAGCAAT CGCTTCCTCCTGAAAAT	15	24
RUNX1_ED5 C_23	GCATTTTCAGGAGG AAGCGA	AAATATGCTGTCTGAAGCAATC GCTTCCTCCTGAAAAT	15	23
RUNX1_ED5 C_22	GCATTTTCAGGAGG AAGCGA	AATATGCTGTCTGAAGCAATCG CTTCCTCCTGAAAAT	15	22
RUNX1_ED5 C_21	GCATTTTCAGGAGG AAGCGA	ATATGCTGTCTGAAGCAATCGC TTCCTCCTGAAAAT	15	21
RUNX1_ED5 C_20	GCATTTTCAGGAGG AAGCGA	TATGCTGTCTGAAGCAATCGCT TCCTCCTGAAAAT	15	20
RUNX1_ED5 C_19	GCATTTTCAGGAGG AAGCGA	ATGCTGTCTGAAGCAATCGCTT CCTCCTGAAAAT	15	19
RUNX1_ED5 C_18	GCATTTTCAGGAGG AAGCGA	TGCTGTCTGAAGCAATCGCTTC CTCCTGAAAAT	15	18
RUNX1_ED5 C_17	GCATTTTCAGGAGG AAGCGA	GCTGTCTGAAGCAATCGCTTCC TCCTGAAAAT	15	17
RUNX1_ED5 C_16	GCATTTTCAGGAGG AAGCGA	CTGTCTGAAGCAATCGCTTCCT CCTGAAAAT	15	16

RUNX1_ED5 C_15	GCATTTTCAGGAGG AAGCGA	TGTCTGAAGCAATCGCTTCCTC CTGAAAAT	15	15
RUNX1_ED5 C_14	GCATTTTCAGGAGG AAGCGA	GTCTGAAGCAATCGCTTCCTCC TGAAAAT	15	14
RUNX1_ED5 C_13	GCATTTTCAGGAGG AAGCGA	TCTGAAGCAATCGCTTCCTCCT GAAAAT	15	13
RUNX1_ED5 C_12	GCATTTTCAGGAGG AAGCGA	CTGAAGCAATCGCTTCCTCCTG AAAAT	15	12
RUNX1_ED5 C_11	GCATTTTCAGGAGG AAGCGA	TGAAGCAATCGCTTCCTCCTGA AAAT	15	11
RUNX1_ED5 C_10	GCATTTTCAGGAGG AAGCGA	GAAGCAATCGCTTCCTCCTGAA AAT	15	10
RUNX1_ED5 C_9	GCATTTTCAGGAGG AAGCGA	AAGCAATCGCTTCCTCCTGAAA AT	15	9

[1216] Table 3N: FIGs. 48A-48C PEgRNA

PEGRNA	SPACER SEQUENCE	3' EXTENSION SEQUENCE	PBS LENG TH (NT)	RT TEMPL ATE LENGT H (NT)
HEK3_ED6_5G TOA	GGCCCAGACTGAGCA CGTGA (SEQ ID NO: 393)	TCTGCTATCACGTGCTC AGTCTG (SEQ ID NO: 394)	13	10

[1217] Table 3O: FIGs. 48A-48C nicking sgRNA

NICKING SGRNA	SPACER SEQUENCE
HEK3_ED6_+63	GCACATACTAGCCCCTGTCT (SEQ ID NO: 395)

[1218] Table 3P: FIGs. 50A-50B PEgRNA

PEGR NA	SPACER (SEQ ID NO: 3699-3754)	3' EXTENSION (5' TO 3')(SEQ ID NO: 3755-3810)	PBS LENG TH (NT)	RT TEMPL ATE LENGT H (NT)
<i>HBB</i> 3.5	GTAACGGCAGACTT CTCCAC	AGACTTCTCCTCAGGAGTCAGGTGC AC	12	14
<i>HBB</i> 3.7	GCATGGTGCACCTG ACTCCTG	AGACTTCTCTTCAGGAGTCAGGTGC AC	13	14
<i>HBB</i> 5.2	GCATGGTGCACCTG ACTCCTG	TAACGGCAGACTTCTCCTCAGGAGT CAGGTGCAC	13	19
<i>HBB</i> 5.3	GCATGGTGCACCTG ACTCCTG	ACGGCAGACTTCTCCTCAGGAGTCA GGTGCAC	13	17
<i>HBB</i> 5.4	GCATGGTGCACCTG ACTCCTG	GGCAGACTTCTCCTCAGGAGTCAGG TGCAC	13	16

HBB 5.5	GCATGGTGCACCTG ACTCCTG	GCAGACTTCTCCTCAGGAGTCAGGT GCAC	13	13
HBB 5.6	GCATGGTGCACCTG ACTCCTG	GACTTCTCCTCAGGAGTCAGGTGCA C	13	12
HBB 5.7	GCATGGTGCACCTG ACTCCTG	ACTTCTCCTCAGGAGTCAGGTGCAC	13	21
HBB 5.8	GCATGGTGCACCTG ACTCCTG	TAACGGCAGACTTCTCCTCAGGAGT CAGGTGCA	12	19
HBB 5.9	GCATGGTGCACCTG ACTCCTG	ACGGCAGACTTCTCCTCAGGAGTCA GGTGCA	12	17
HBB 5.10	GCATGGTGCACCTG ACTCCTG	GGCAGACTTCTCCTCAGGAGTCAGG TGCA	12	16
HBB 5.11	GCATGGTGCACCTG ACTCCTG	GCAGACTTCTCCTCAGGAGTCAGGT GCA	12	13
HBB 5.12	GCATGGTGCACCTG ACTCCTG	GACTTCTCCTCAGGAGTCAGGTGCA	12	12
HBB 5.13	GCATGGTGCACCTG ACTCCTG	ACTTCTCCTCAGGAGTCAGGTGCA	12	14
HEXA S 1	ATCCTTCCAGTCAG GGCCAT	ATATCTTATGGCCCTGACTGGAA	13	14
HEXA S 2	ATCCTTCCAGTCAG GGCCAT	TATATCTTATGGCCCTGACTGGAA	13	15
HEXA S 3	ATCCTTCCAGTCAG GGCCAT	GTATATCTTATGGCCCTGACTGGAA	13	16
HEXA S 4	ATCCTTCCAGTCAG GGCCAT	ACCGTATATCTTATGGCCCTGACTGG AA	13	19
HEXA S 5	ATCCTTCCAGTCAG GGCCAT	AACCGTATATCTTATGGCCCTGACTG GAA	13	20
HEXA S 6	ATCCTTCCAGTCAG GGCCAT	GAACCGTATATCTTATGGCCCTGACT GGAA	13	21
HEXA S 7	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCTTATGGCCCTGAC TGAA	13	22
HEXA S 8	ATCCTTCCAGTCAG GGCCAT	ATATCTTATGGCCCTGACT	9	14
HEXA S 9	ATCCTTCCAGTCAG GGCCAT	TATATCTTATGGCCCTGACT	9	15
HEXA S 10	ATCCTTCCAGTCAG GGCCAT	GTATATCTTATGGCCCTGACT	9	16
HEXA S 11	ATCCTTCCAGTCAG GGCCAT	ACCGTATATCTTATGGCCCTGACT	9	19
HEXA S 12	ATCCTTCCAGTCAG GGCCAT	AACCGTATATCTTATGGCCCTGACT	9	20
HEXA S 13	ATCCTTCCAGTCAG GGCCAT	GAACCGTATATCTTATGGCCCTGACT	9	21
HEXA S 14	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCTTATGGCCCTGAC T	9	22
HEXA S 15	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCTTATGGCCCTGAC	8	22
HEXA S 16	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCTTATGGCCCTGAC TG	10	22
HEXA S 17	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCTTATGGCCCTGAC TGG	11	22

HEXA S 18	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCTTATGGCCCTGAC TGGA	12	22
HEXA S 19	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCTTATGGCCCTGAC TGGA	13	22
HEXA S 20	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCTTATGGCCCTGAC TGGAAG	14	22
HEXA S 21	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCTTATGGCCCTGAC TGGAAGG	15	22
HEXA S 22	ATCCTTCCAGTCAG GGCCAT	ACCTGAACCGTATATCTTATGGCCCT GACT	9	25
HEXA S 23	ATCCTTCCAGTCAG GGCCAT	TACCTGAACCGTATATCTTATGGCCC TGACT	9	26
HEXA S 24	ATCCTTCCAGTCAG GGCCAT	GTACCTGAACCGTATATCTTATGGCC CTGACT	9	27
HEXA S 25	ATCCTTCCAGTCAG GGCCAT	GGTACCTGAACCGTATATCTTATGGC CCTGACT	9	28
HEXA S 26	ATCCTTCCAGTCAG GGCCAT	TGGTACCTGAACCGTATATCTTATGG CCCTGACT	9	29
HEXA 5	ATCCTTCCAGTCAG GGCCAT	ACCTGAACCGTATATCCTATGGCCCT GACTGGAA	13	21
HEXA 6	ATCCTTCCAGTCAG GGCCAT	ACCGTATATCCTATGGCCCTGACTGG AA	13	15
HEXA 7	ATCCTTCCAGTCAG GGCCAT	ACCTGAACCGTATATCCTATGGCCCT GACTGGAAGG	15	21
HEXA 8	ATCCTTCCAGTCAG GGCCAT	ACCTGAACCGTATATCCTATGGCCCT GACTGGAAG	14	21
HEXA 9	ATCCTTCCAGTCAG GGCCAT	ACCTGAACCGTATATCCTATGGCCCT GACTGGA	12	21
HEXA 10	ATCCTTCCAGTCAG GGCCAT	ACCTGAACCGTATATCCTATGGCCCT GACTGG	11	21
HEXA 11	ATCCTTCCAGTCAG GGCCAT	ACCTGAACCGTATATCCTATGGCCCT GACTG	10	21
HEXA 12	ATCCTTCCAGTCAG GGCCAT	AACCGTATATCCTATGGCCCTGACTG GAA	13	16
HEXA 13	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCCTATGGCCCTGAC TGGA	13	18
HEXA 14	ATCCTTCCAGTCAG GGCCAT	TACCTGAACCGTATATCCTATGGCCC TGACTGGAA	13	22
HEXA 15	ATCCTTCCAGTCAG GGCCAT	TGGTACCTGAACCGTATATCCTATGG CCCTGACTGGAA	13	25
HEXA 16	ATCCTTCCAGTCAG GGCCAT	GTACCTGAACCGTATATCCTATGGCC CTGACTGGAA	13	23
HEXA 17	ATCCTTCCAGTCAG GGCCAT	AACCGTATATCCTATGGCCCTGACTG	10	16
HEXA 18	ATCCTTCCAGTCAG GGCCAT	TGAACCGTATATCCTATGGCCCTGAC TG	10	18
HEXA 19	ATCCTTCCAGTCAG GGCCAT	TACCTGAACCGTATATCCTATGGCCC TGACTG	10	22
HEXA 20	ATCCTTCCAGTCAG GGCCAT	TGGTACCTGAACCGTATATCCTATGG CCCTGACTG	10	25

[1219] Table 3Q: FIGs. 50A-50B nicking sgRNA

NICKING SGRNA	SPACER SEQUENCE
<i>HBB</i> _ED7A_+72	GCCTTGATACCAACCTGCCCA (SEQ ID NO: 626)
<i>HEXA</i> _ED7B_+60	GCTGGAACTGGTCACCAAGGC (SEQ ID NO: 627)
<i>HEXA</i> _ED7B_CORRECT_WT_PE3B	GTACCTGAACCGTATATCCTA (SEQ ID NO: 628)
<i>HEXA</i> _ED7B_CORRECT_SILENT_PE3B	GTACCTGAACCGTATATCTTA (SEQ ID NO: 629)

[1220] Table 3R: FIGs. 51A--51G PEgRNA

PEGRNA	SPACER SEQUENCE (SEQ ID NO: 632-640)	3' EXTENSION (SEQ ID NO: 641-649)	PBS LENGTH (NT)	RT TEMPLATE LENGTH (NT)
HEK3_ED8_1T TOG	GGCCCAGACTGAGCA CGTGA	TCTGCCATCCCGTGCTCAGT CTG	13	10
HEK3_ED8_3A TOC	GGCCCAGACTGAGCA CGTGA	TCTGCCAGCACGTGCTCAGT CTG	13	10
HEK3_ED8_3A TOT	GGCCCAGACTGAGCA CGTGA	TCTGCCAACACGTGCTCAGT CTG	13	10
HEK3_ED8_3A TOT_5-6GGTOTT	GGCCCAGACTGAGCA CGTGA	TGGAGGAAGCAGGGCTTCC TTCCTCTGAAAACACGTGC TCAGTCTG	13	34
HEK3_ED8_1C TTINS	GGCCCAGACTGAGCA CGTGA	TCTGCCATCAAAGCGTGCTC AGTCTG	13	10
RNF2_ED8_1C TOA	GTCATCTTAGTCATTA CCTG	AACGAACACCTCATGTAATG ACTAAGATG	15	14
RNF2_ED8_1C TOG	GTCATCTTAGTCATTA CCTG	AACGAACACCTCACGTAATG ACTAAGATG	15	14
RNF2_ED8_1G TAINS	GTCATCTTAGTCATTA CCTG	AACGAACACCTCAGTACGTA ATGACTAAGATG	15	17
<i>HBB</i> _ED8_4AT OT	GTCATCTTAGTCATTA CCTG	AGACTTCTCCACAGGAGTCA GGTGCAC	13	14

[1221] Table 4: Sequences of primers used for mammalian cell genomic DNA amplification and HTS¹⁸¹.

DESCRIPTION	SEQUENCE (SEQ ID NOS: 3811-3863)
HEK3 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNATGTGGGCT GCCTAGAAAGG
HEK3 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCCAGCCAACTTGTCACC
RNF2 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNACGTCTCAT ATGCCCCCTTGG
RNF2 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTACGTAGGAATTTTGGTG GGACA
HEK4 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGAACCCAG GTAGCCAGAGAC

HEK4 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTTCCTTTCAACCCGAACG GAG
EMX1 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCAGCTCAGC CTGAGTGTGTA
EMX1 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCTCGTGGGTTTGTGGTT GC
FANCF FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCATTGCAGA GAGGCGTATCA
FANCF REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTGGGGTCCCAGGTGCTG AC
<i>HBB</i> FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAGGGTTGGC CAATCTACTCCC
<i>HBB</i> REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTGTCTTCTCTGTCTCCAC ATGCC
<i>PRNP</i> FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTCAAGTGA ACAAGCCGAGT
<i>PRNP</i> REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTACTTGGTTGGGGTAACG GTG
<i>HEXA</i> FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCATACAGGT GTGGCGAGAGG
<i>HEXA</i> REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCCAGCCTCCTTTGGTTA GCA
RUNX1 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTCACAAACA AGACAGGGAACTG
RUNX1 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTAGATGTAGGGCTAGAGG GGTG
VEGFA FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNACTTGGTGC CAAATTCTTCTCC
VEGFA REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTAAAGAGGGAATGGGCT TTGGA
DNMT FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCACAACAG CTTCATGTCAGCC
DNMT REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTACGTTAATGTTTCCTGAT GGTCC
HEK3 OFF-TARGET SITE 1 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNTCCCCTGTT GACCTGGAGAA
HEK3 OFF-TARGET SITE 1 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCACTGTACTTGCCCTGA CCA
HEK3 OFF-TARGET SITE 2 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNTTGGTGTTG ACAGGGAGCAA
HEK3 OFF-TARGET SITE 2 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCTGAGATGTGGGCAGA AGGG
HEK3 OFF-TARGET SITE 3 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNTGAGAGGG AACAGAAGGGCT
HEK3 OFF-TARGET SITE 3 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTGTCCAAAGGCCCAAGA ACCT
HEK3 OFF-TARGET SITE 4 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNTCCTAGCAC TTTGGAAGGTCG
HEK3 OFF-TARGET SITE 4 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTGCTCATCTTAATCTGCT CAGCC
HEK4 OFF-TARGET SITE 1 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNGGCATGGCT TCTGAGACTCA

HEK4 OFF-TARGET SITE 1 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTGTCTCCCTTGCACTCCC TGTCTTT
HEK4 OFF-TARGET SITE 2 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTTTGGCAAT GGAGGCATTGG
HEK4 OFF-TARGET SITE 2 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTGAAGAGGCTGCCCATG AGAG
HEK4 OFF-TARGET SITE 3 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGGTCTGAGG CTCGAATCCTG
HEK4 OFF-TARGET SITE 3 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCTGTGGCCTCCATATCC CTG
HEK4 OFF-TARGET SITE 4 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTTTCCACCA GAACTCAGCCC
HEK4 OFF-TARGET SITE 4 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCCTCGGTTCTCCACAA CAC
EMX1 OFF-TARGET SITE 1 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTGGGGAG ATTGTCATCTGTGGAGG
EMX1 OFF-TARGET SITE 1 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTGCTTTTATACCATCTTGG GGTTACAG
EMX1 OFF-TARGET SITE 2 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCAATGTGCT TCAACCCATCACGGC
EMX1 OFF-TARGET SITE 2 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCCATGAATTTGTGATGG ATGCAGTCTG
EMX1 OFF-TARGET SITE 3 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGAGAAGGA GGTGCAGGAGCTAGAC
EMX1 OFF-TARGET SITE 3 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCATCCCGACCTTCATCC CTCCTGG
EMX1 OFF-TARGET SITE 4 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTAGTTCTG ACATTCCTCCTGAGGG
EMX1 OFF-TARGET SITE 4 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTTCAAACAAGGTGCAGA TACAGCA
FANCF OFF-TARGET SITE 1 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCGGGCAG TGGCGTCTTAGTCG
FANCF OFF-TARGET SITE 1 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCCCTGGGTTTGGTTGGC TGCTC
FANCF OFF-TARGET SITE 2 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCTCCTTGCC GCCAGCCGGTC
FANCF OFF-TARGET SITE 2 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTCACTGGGGAAGAGGCG AGGACAC
FANCF OFF-TARGET SITE 3 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCCAGTGTTT CCCATCCCCAACAC
FANCF OFF-TARGET SITE 3 REV	TGGAGTTCAGACGTGTGCTCTTCCGATCTGAATGGATCCCCCCTA GAGCTC
FANCF OFF-TARGET SITE 4 FWD	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCAGGCCAC AGGTCCTTCTGGA

[1222] Table 5: Sequences of 100-mer single-stranded DNA oligonucleotide donor templates used in HDR experiments and in the creation of the *HBB* E6V HEK293T cell line. Oligonucleotides are 100-103 nt in length with homology arms centered around the site of the edit. Oligonucleotides were from Integrated DNA Technologies, purified by PAGE.

HEK3 +3 A TO T	GCTTCTCCAGCCCTGGCCTGGGTCAATCCTTGGGGCCCAGACTG AGCACGTGTTGGCAGAGGAAAGGAAGCCCTGCTTCCTCCAGAG GGCGTCGCAGGAC (SEQ ID NO: 717)
HEK3 +3 A TO T, +5,6 GG TO TT	GCTTCTCCAGCCCTGGCCTGGGTCAATCCTTGGGGCCCAGACTG AGCACGTGTTTTTCAGAGGAAAGGAAGCCCTGCTTCCTCCAGAG GGCGTCGCAGGAC (SEQ ID NO: 718)
HEK3 +1 T TO G	GCTTCTCCAGCCCTGGCCTGGGTCAATCCTTGGGGCCCAGACTG AGCACGGGATGGCAGAGGAAAGGAAGCCCTGCTTCCTCCAGA GGCGTCGCAGGAC (SEQ ID NO: 719)
HEK3 +3 A TO C	GCTTCTCCAGCCCTGGCCTGGGTCAATCCTTGGGGCCCAGACTG AGCACGTGCTGGCAGAGGAAAGGAAGCCCTGCTTCCTCCAGA GGCGTCGCAGGAC (SEQ ID NO: 720)
HEK3 +1 CTT INSERTION	GCTTCTCCAGCCCTGGCCTGGGTCAATCCTTGGGGCCCAGACTG AGCACGCTTTGATGGCAGAGGAAAGGAAGCCCTGCTTCCTCCA GAGGGCGTCGCAGGAC (SEQ ID NO: 721)
RNF2 +1 C TO A	CCCAGTTTACACGTCTCATATGCCCCTTGGCAGTCATCTTAGTCA TTACATGAGGTGTTTCGTTGTAACATATAAACTGAGTTCCCATG TTTTGCTTAA (SEQ ID NO: 722)
RNF2 +1 C TO G	CCCAGTTTACACGTCTCATATGCCCCTTGGCAGTCATCTTAGTCA TTACGTGAGGTGTTTCGTTGTAACATATAAACTGAGTTCCCATG TTTTGCTTAA (SEQ ID NO: 723)
RNF2 +1 GTA INSERTION	CAGTTTACACGTCTCATATGCCCCTTGGCAGTCATCTTAGTCATT ACGTACTGAGGTGTTTCGTTGTAACATATAAACTGAGTTCCCAT GTTTTGCTTA (SEQ ID NO: 724)
<i>HBB</i> E6V INSTALLATION (ALSO USED FOR CREATION OF THE <i>HBB</i> E6V HEK293T CELL LINE)	ACTTCATCCACGTTACCTTGCCCCACAGGGCAGTAACGGCAG ACTTCTCCACAGGAGTCAGATGCACCATGGTGTCTGTTTGAGGT TGCTAGTGAACAC (SEQ ID NO: 725)
<i>HBB</i> E6V CORRECTION PROTOSPACER A	ACTTCATCCACGTTACCTTGCCCCACAGGGCAGTAACGGCAG ACTTCTCCTCAGGAGTCAGGTGCACCATGGTGTCTGTTTGAGGT TGCTAGTGAACAC (SEQ ID NO: 726)
<i>HBB</i> E6V CORRECTION PROTOSPACER B	GTGTTCACTAGCAACCTCAAACAGACACCATGGTGCACCTGAC TCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTG AACGTGGATGAAGT (SEQ ID NO: 727)
<i>HBB</i> E6V CORRECTION PROTOSPACER B, SILENT PAM MUTATION	GTGTTCACTAGCAACCTCAAACAGACACCATGGTGCACCTGAC TCCTGATGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTG AACGTGGATGAAGT (SEQ ID NO: 728)
<i>PRNP</i> G127V	CACATGGCTGGTGTGCTGCAGCAGCTGGGGCAGTGGTGGGGGGCC TTGGCGTCTACATGCTGGGAAGTGCCATGAGCAGGCCCATCATA CATTTCCGCGAGTG (SEQ ID NO: 729)

[1223] Additional Sequences

[1224] Sequences of yeast dual fluorescent reporter plasmids used herein

p425-GFP_stop_mCherry:

ATGTCTAAAGGTGAAGAATTATTCACCTGGTGTGTGCCAATTTTGGTTGAATTAGATGGTGA
TGTTAATGGTCACAAATTTTCTGTCTCCGGTGAAGGTGAAGGTGATGCTACTTACGGTAAA
TTGACCTTAAAATTTATTTGTACTACTGGTAAATTGCCAGTTCCATGGCCAACCTTAGTCAC
TACTTTTCGGTTATGGTGTTCATGTTTTGTAGATACCCAGATCATATGAAACAACATGACT
TTTTCAAGTCTGCCATGCCAGAAGGTTATGTTCAAGAAAGAACTATTTTTTTCAAAGATGA
CGGTAACATAAGACCAGAGCTGAAGTCAAGTTTGAAGGTGATACCTTAGTTAATAGAATC
GAATTAAGAGGTATTGATTTTAAAGAAGATGGTAACATTTTAGGTACAAATTGGAATACA

ACTATAACTCTCACAAATGTTTACATCATGGCTGACAAACAAAAGAATGGTATCAAAGTTAA
CTTCAAAATTAGACACAACATTGAAGATGGTTCTGTTCAATTAGCTGACCATTATCAACAA
AATACTCCAATTGGTGATGGTCCAGTCTTGTTACCAGACAACCATTACTTATCCACTCAATC
TGCCTTATCCAAAGATCCAAACGAAAAGAGAGACCACATGGTCTTGTTAGAATTTGTTACT
GCTGCTGGTATTACCCATGGTATGGATGAATTGTACAAAGCTAGCAACCTGGGTCAATCCTT
GGGGCCCAGACTGAGCACGTGATGGCCAGAGCACAGGAGACGTCATGGTTTTCAAAGGTG
AAGAAGATAATATGGCTATTATTAAAGAATTTATGAGATTTAAAGTTCATATGGAAGGTTCAAGTTAAT
GGTCATGAATTTGAAATTGAAGGTGAAGGTGAAGGTAGACCATATGAAGGTA CTCAAAC TGCTAA
ATTGAAAGTTACTAAAGGTGGTCCATTACCATTGCTTGGGATATTTTGTCAACCACAATTATGTAT
GGTTCAAAGCTTATGTTAAACATCCAGCTGATTTCCAGATTATTTAAATTTGTCATTTCCAGAAG
GTTTTAAATGGGAAAGAGTTATGAATTTGAAGATGGTGGTGTGTTACTGTTACTCAAGATTCAT
CATTACAAGATGGTGAATTTATTATAAAGTTAAATTTGAGAGGTACTAATTTCCATCAGATGGTCC
AGTTATGCAAAAAAACTATGGGTTGGGAAGCTTCATCAGAAAGAAATGTATCCAGAAGATGGTG
CTTTAAAGGTTGAAATTTAAACAAAGATTGAAATTTAAAGATGGTGGTCATTATGATGCTGAAGTTAA
AACTACTTATAAAGCTAAAAAACAGTTCAATTACCAGGTGCTTATAATGTTAATATTAAATTTGGATA
TTACTTCACATAATGAAGATTATACTATTGTTGAACAATATGAAAAGAGCTGAAGGTAGACATTCAAC
TGGTGGTATGGATGAATTATATAAAGGTACCGCTCGAGCAGCTGTGATTGATTGAGTCGACTTG
GTTGAACACGTTGCCAAGGCTTAAGTGAATTTACTTTAAATCTTGCATTTAAATAAATTTTC
TTTTTATAGCTTTATGACTTAGTTTCAATTTATATACTATTTTAATGACATTTTCGATTTCGGATC
CACTAGTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCAGCTTTTGTTCCTTTAGTGAG
GGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTTGTTATCCG
CTCACAATTCCACACAACATAGGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCATA
TGAGTGAGGTAACCTCACATTAATTGCGTTGCGCTCACTGCCCCGCTTCCAGTCGGGAAACC
TGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGAGAGGCGGTTTGCCTATTG
GGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCTCGGTCTCGGCTGCGGCGAG
CGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCGAG
GAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTT
GCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAG
TCAGAGGTGGCGAAACCCGACAGGACTATAAAGATAACCAGGCGTTTTCCCCCTGGAAGCTC
CCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTT
CGGGAAGCGTGCGCTTTCTCATAGCTCAGCTGTAGGTATCTCAGTTCCGTTGATAGGTCGT
TCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCCAGCGCTGCGCCTTATC
CGGTAACATATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGC
CACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTG
GTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCA
GTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGC
GGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGAT
CCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACCTACGTTAAGGGATTT
TGGTCATGAGATTATCAAAAAGGATCTTACCTAGATCCTTTTAAATTTAAAAATGAAGTTTT
AAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGA
GGCACCTATCTCAGCGATCTGTCTATTTCTGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGT
AGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA
CCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCG
CAGAAGTGGTCTCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCT
AGAGTAAGTAGTTCCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCG
TGGTGTACAGCTCGTCTGTTTGGTATGGCTTCATTACGCTCCGGTTCCCAACGATCAAGGCG
AGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTT
GTCAGAAGTAAGTTGGCCGAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTC
TTACTGTCTATGCCATCCGTAAGATGCTTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTC
TGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCCGGCGTCAATACGGGATAATACCG
CGCCACATAGCAGAACTTTAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAAC
TCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTG
ATCTTCAGCATCTTTTACTTTACCAGCGTTTCTGGGTGAGCAAAAAACAGGAAGGCAAAAT
GCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCTTTTTTC

AAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTA
GAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCGAAAAAGTGCCACCTGAACGAAG
CATCTGTGCTTCATTTTGTAGAACAAAAATGCAACGCGAGAGCGCTAATTTTTCAAACAAA
GAATCTGAGCTGCATTTTTACAGAACAGAAATGCAACGCGAAAGCGCTATTTTACCAACG
AAGAATCTGTGCTTCATTTTTGTAAAACAAAAATGCAACGCGAGAGCGCTAATTTTTCAAA
CAAAGAATCTGAGCTGCATTTTTACAGAACAGAAATGCAACGCGAGAGCGCTATTTTACC
AACAAAGAATCTATACTTCTTTTTTGTCTACAAAAATGCATCCCGAGAGCGCTATTTTTCT
AACAAAGCATCTTAGATTACTTTTTTCTCCTTTGTGCGCTCTATAATGCAGTCTCTTGATAA
CTTTTTGCACTGTAGGTCCGTTAAGGTTAGAAGAAGGCTACTTTGGTGTCTATTTTCTCTTC
CATAAAAAAAGCCTGACTCCACTTCCCGCGTTTACTGATTACTAGCGAAGCTGCGGGTGCA
TTTTTCAAGATAAAGGCATCCCGATTATATTCTATACCGATGTGGATTGCGCATACTTTGT
GAACAGAAAGTGATAGCGTTGATGATTCTTCATTGGTCAGAAAATTATGAACGGTTTCTTC
TATTTGTCTCTATATACTACGTATAGGAAATGTTTACATTTTCGTATTGTTTCGATTCACTC
TATGAATAGTTCTTACTACAATTTTTTGTCTAAAGAGTAATACTAGAGATAAACATAAAAA
ATGTAGAGGTCGAGTTTAGATGCAAGTTCAAGGAGCGAAAGGTGGATGGGTAGGTTATATA
GGGATATAGCACAGAGATATATAGCAAAGAGATACTTTTGAGCAATGTTTGTGGAAGCGGT
ATTGCAATATTTTAGTAGCTCGTTACAGTCCGGTGCGTTTTTGGTTTTTGAAGTGCGTC
TTCAGAGCGCTTTTGGTTTTCAAAGCGCTCTGAAGTTCCTATACTTTCTAGAGAATAGGA
ACTTCGGAATAGGAACCTCAAAGCGTTCCGAAAACGAGCGCTCCGAAAATGCAACGCG
AGCTGCGCACATACAGCTCACTGTTACGTCGCACCTATATCTGCGTGTGCGCTGTATATAT
ATATACATGAGAAGAACGGCATAAGTGCCTGTTTATGCTTAAATGCGTACTTATATGCGTCTAT
TTATGTAGGATGAAAGGTAGTCTAGTACCTCCTGTGATATTATCCCATTCATGCGGGGTATC
GTATGCTTCCTTCAGCACTACCCTTTAGCTGTTCTATATGCTGCCACTCCTCAATTGGATTAG
TCTCATCCTTCAATGCTATCATTTCCTTTGATATTGGATCATACTAAGAAACCATTATTATCAT
GACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTTCGTCTCGCGCGTTTCGGTGAT
GACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTGAACGG
GATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTTCGGGG
CTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATCGACTACGTC
GTAAGGCCGTTTCTGACAGAGTAAAATTCTTGAGGGAACCTTTCACCATTATGGGAAATGCT
TCAAGAAGGTATTGACTTAACTCCATCAAATGGTCAGGTCATTGAGTGTTTTTTATTTGTT
GTATTTTTTTTTTTTTTAGAGAAAATCCTCCAATATCAAATTAGGAATCGTAGTTTCATGATT
TCTGTTACACCTAACTTTTTGTGTGGTGCCCTCCTCTGTCAATATTAATGTAAAGTGCA
ATTCTTTTCTCTTATCACGTTGAGCCATTAGTATCAATTTGCTTACCTGTATTCTTTACTATC
CTCCTTTTTCTCCTTCTTGATAAATGTATGTAGATTGCGTATATAGTTTCGTCTACCCTATGAA
CATATTCATTTTGTAATTTTCGTGTCGTTTCTATTATGAATTTCAATTTATAAAGTTTATGTACA
AATATCATAAAAAAAGAGAATCTTTTTAAGCAAGGATTTTCTTAACTTCTTCGGCGACAGC
ATCACCGACTTCGGTGGTACTGTTGGAACCACTAAATCACCAGTTCTGATACCTGCATCC
AAAACCTTTTTAACTGCATCTTCAATGGCCTTACCTTCTTCAGGCAAGTTCAATGACAATTT
CAACATCATTGCAGCAGACAAGATAGTGCGGATAGGGTCAACCTTATTCTTTGGCAAATCT
GGAGCAGAACCCTGGCATGGTTTCGTACAAACCAAATGCGGTGTTCTTGTCTGGCAAAGAG
GCCAAGGACGCAGATGGCAACAAACCAAGGAACCTGGGATAACGGAGGCTTCATCGGA
GATGATATCACCAACATGTTGCTGGTGATTATAATACCATTTAGGTGGGTGGGTCTTAA
CTAGGATCATGGCGGCAGAATCAATCAATTGATGTTGAACCTTCAATGTAGGGAATTCGTT
CTTGATGGTTTCTCCACAGTTTTTCTCCATAATCTTGAAGAGGCCAAAAGATTAGCTTTAT
CCAAGGACCAATAGGCAATGGTGGCTCATGTTGTAGGGCCATGAAAGCGGCCATTCTTG
TGATTCTTTGCACTTCTGGAACGGTGTATTGTTCACTATCCCAAGCGACACCATCACCATCG
TCTTCCTTTCTCTTACCAAAGTAAATACCTCCCACTAATTCTCTGACAACAACGAAGTCAG
TACCTTTAGCAAATTGTGGCTTGATTGGAGATAAGTCTAAAAGAGAGTCGGATGCAAAGTT
ACATGGTCTTAAAGTTGGCGTACAATTGAAGTTCTTTACGGATTTTATAGTAAACCTTGTTTCAG
GTCTAACACTACCGGTACCCATTTAGGACCAGCCACAGCACCTAACAAAACGGCATCAA
CCTTCTTGGAGGCTTCAGCGCCTCATCTGGAAGTGGGACACCTGTAGCATCGATAGCAGC
ACCACCAATTAATGATTTTCGAAATCGAACTTGACATTGGAACGAACATCAGAAATAGCT
TTAAGAACCTTAATGGCTTCGGCTGTGATTCTTGACCAACGTGGTCACCTGGCAAAACGA
CGATCTTCTTAGGGGCAGACATAGGGGCAGACATTAGAATGGTATATCCTTGAAATATATAT

ATATATTGCTGAAATGTAAAAGGTAAGAAAAGTTAGAAAAGTAAGACGATTGCTAACCACCT
ATTGGAAAAACAATAGGTCCTTAAATAATATTGTCAACTTCAAGTATTGTGATGCAAGCAT
TTAGTCATGAACGCTTCTCTATTCTATATGAAAAGCCGGTCCGGCCTCTCACCTTTCTTT
TTCTCCCAATTTTTCAGTTGAAAAAGGTATATGCGTCAGGCGACCTCTGAAATTAACAAAA
AATTTCCAGTCATCGAATTTGATTCTGTGCGATAGCGCCCTGTGTGTTCTCGTTATGTTGA
GGAAAAAATAATGGTTGCTAAGAGATTGCAACTCTTGCATCTTACGATACCTGAGTATTC
CCACAGTTAACTGCGGTCAAGATATTTCTTGAATCAGGCGCCTTAGACCGCTCGGCCAAAC
AACCAATTACTTGTGAGAAATAGAGTATAATTATCCTATAAATATAACGTTTTTGAACACA
CATGAACAAGGAAGTACAGGACAATTGATTTTGAAGAGAATGTGGATTTTGATGTAATTGT
TGGGATTCCATTTTAAATAAGGCAATAATATTAGGTATGTGGATATACTAGAAGTTCTCCTCG
ACCGTCGATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAAATACCGCATCAGG
AAATTGTAAACGTTAATTTTGTAAATTCGCGTTAAATTTTGTAAATCAGCTCATTTT
TTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG
GTTGAGTGTGTTCCAGTTTGGAAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGT
CAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCTAATC
AAGTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCG
ATTTAGAGCTTGACGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCG
AAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTACGCTGCGCGTAACCACCAC
ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCCGCGCCATTGCCATTAGGCTGCG
CAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGG
GGGATGTGCTGCAAGGCGATTAAGTTGGGTAAACGCCAGGGTTTTCCAGTCACGACGTTG
TAAACGACGGCCAGTGAGCGCGCTAATACGACTCACTATAGGGCGAATTGGGTACCGG
GCCCCCCTCGAGGTGACGGTATCGATAAGCTTGATATCGAATTCCTGCAGCCCGGGGA
TCCGTTAGAATCATTTTGAATAAAAAACACGCTTTTTCAGTTTCGAGTTTATCATTATCAATA
CTGCCATTTCAAAGAATACGTAAATAATTAATAGTAGTGATTTTCTTAACCTTTATTTAGTCAA
AAAATTAGCCTTTTAATTCTGCTGTAAACCGTACATGCCCAAATAGGGGCGGGTTACAC
AGAATATATAACATCGTAGGTGTCTGGGTGAACAGTTTATTCCTGGCATCCATAATATAA
TGGAGCCCGCTTTTTTAAGCTGGCATCCAGAAAAAAAAGAATCCCAGCACCAAAATATTG
TTTTCTTACCAACCATCAGTTCATAGGTCCATTCTCTTAGCGCACTACAGAGAACAGGG
GCACAAACAGGCAAAAAACGGGCACAACCTCAATGGAGTGATGCAACCTGCCTGGAGTA
AATGATGACACAAGGCAATTGACCCACGCATGTATCTATCTCATTTTCTTACACCTTCTATTA
CCTTCTGCTCTCTCTGATTTGAAAAAGCTGAAAAAAAAGGTTGAAACCAGTTCCTGAA
ATTATCCCCTACTTGACTAATAAGTATATAAAGACGGTAGGTATTGATTGTAATTCTGTAAA
TCTATTTCTTAAACTTCTTAAATCTACTTTTATAGTTAGTCTTTTTTTTAGTTTTAAACACC
AAGAACTTAGTTTCGAATAAACACACATAAACAAACAAAGAATTC (SEQ ID NO: 730)

p425-GFP_+I_{fs}_mCherry:

ATGTCTAAAGGTGAAGAATTATTCAGTGGTGTGTCCCAATTTTGGTTGAATTAGATGGTGA
TGTTAATGGTCACAAATTTTCTGTCTCCGGTGAAGGTGAAGGTGATGCTACTTACGGTAAA
TTGACCTTAAAATTTATTTGTACTACTGGTAAATTGCCAGTTCCATGGCCAACCTTAGTCAC
TACTTTCGGTTATGGTGTTCATGTTTGTCTAGATACCCAGATCATATGAAACAACATGACT
TTTTCAAGTCTGCCATGCCAGAAGGTTATGTTCAAGAAAGAACTATTTTTTTCAAAGATGA
CGGTAACACAAAGACCAGAGCTGAAGTCAAGTTTGAAGGTGATACCTTAGTTAATAGAATC
GAATTAAGGTATTGATTTTAAAGAAGATGGTAACATTTTAGGTACAAATTGGAATACA
ACTATAACTCTCACAATGTTTACATCATGGCTGACAAACAAAGAATGGTATCAAAGTTAA
CTTCAAAATTAGACACAACATTGAAGATGGTTCTGTTCAATTAGCTGACCATTATCAACAA
AATACTCCAATTGGTGATGGTCCAGTCTTGTTACCAGACAACCATTACTTATCCACTCAATC
TGCCTTATCCAAAGATCCAAACGAAAAGAGAGACCACATGGTCTTGTTAGAAATTTGTTACT
GCTGCTGGTATTACCCATGGTATGGATGAATTGTACAAAGCTAGCAAACCTGGGTCAATCC
TTGGGGCCCCAGACTGAGCACGTGATGGCAGAGCACAGGAGACGTGATGGTTTCAAAGG
TGAAGAAGATAATATGGCTATTATTAAGAATTTATGAGATTTAAAGTTCATATGGAAGGTTCA
ATGGTTCATGAATTTGAAATTGAAGGTGAAGGTGAAGGTAGACCATATGAAGGTACTCAAACCTGCT
AAATTGAAAGTTACTAAAGGTGGTCCATTACCATTTGCTTGGGATATTTGTCAACCACAATTATGT
ATGGTTCAAAGCTTATGTTAAACATCCAGCTGATATTCAGATTATTTAAATTTGTCATTTCCAGA

AGGTTTTAAATGGGAAAGAGTTATGAATTTTGAAGATGGTGGTGTGTTACTGTTACTCAAGATTC
ATCATTACAAGATGGTGAATTTATTTATAAAGTTAAATTGAGAGGTACTAATTTTCCATCAGATGGTC
CAGTTATGCAAAAAAACTATGGGTTGGGAAGCTTCATCAGAAAAGATGTATCCAGAAGATGGT
GCTTTAAAGGTGAAATTAAACAAAGATTGAAATTTAAAGATGGTGGTCATTATGATGCTGAAGTT
AAAACACTTATAAAGCTAAAAAACAGTTCAATTACCAGGTGCTTATAATGTTAATATTAAATTGGA
TATTACTTCACATAATGAAGATTATACTATTGTTGAACAATATGAAAGAGCTGAAGGTAGACATTCA
ACTGGTGGTATGGATGAATTATATAAAGGTACCGCTCGAGCAGCTGTGATTGATTGAGTCGACTT
GGTTGAACACGTTGCCAAGGCTTAAGTGAATTTACTTTAAATCTTGCATTTAAATAAATTTT
CTTTTATAGCTTTATGACTTAGTTTCAATTTATATACTATTTTAATGACATTTTCGATTCCGGAT
CCACTAGTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCAGCTTTTGTCCCTTTAGTGAG
GGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCG
CTCACAATTCCACACAACATAGGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAA
TGAGTGAGGTAATCACATTAATTGCGTTGCGTCACTGCCCCGCTTCCAGTCGGGAAACCT
TGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGAGAGGCGGTTTGCCTATTG
GGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCTCGGCTGCGGCGAG
CGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAG
GAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTT
GCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAG
TCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTC
CCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTT
CGGGAAGCGTGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGAGGTCTGT
TCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTACGCCCCAGCGCTGCGCCTTATC
CGGTAATCATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGC
CACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTG
GTGGCCTAACACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGTGAAGCCA
GTTACCTTCGGAATAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCTGGTAG
GGTGGTTTTTTTGTGTAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGAT
CCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACCTACGTTAAGGGATT
TGGTCATGAGATTATCAAAAAGGATCTTACCTAGATCCTTTTAAATTAATAAATGAAGTTTT
AAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGA
GGCACCTATCTCAGCGATCTGTCTATTTCTGTTTATCCATAGTTGCCTGACTCCCCGTCGTGT
AGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA
CCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCG
CAGAAGTGGTCTTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCT
AGAGTAAGTAGTTCCGCAGTTAATAGTTTGCACAACGTTGTTGCCATTGCTACAGGCATCG
TGGTGTACGCTCGTCTGTTTGGTATGGCTTCAATCAGCTCCGGTTCCCAACGATCAAGGCG
AGTTACATGATCCCCATGTTGTGCAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTT
GTCAGAAGTAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTC
TTACTGTCTATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATT
TGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCG
CGCCACATAGCAGAACTTTAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAAC
TCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGACCCAACTG
ATCTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAAT
GCCGCAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCTTTTCT
AATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTA
GAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGAACGAAG
CATCTGTGCTTCATTTTGTAGAACAAAATGCAACGCGAGAGCGCTAATTTTTCAAAACAA
GAATCTGAGCTGCATTTTTACAGAACAGAAATGCAACGCGAAAGCGCTATTTTACCAACG
AAGAATCTGTGCTTCATTTTTGTAAAAACAAAATGCAACGCGAGAGCGCTAATTTTTCAAA
CAAAGAATCTGAGCTGCATTTTTACAGAACAGAAATGCAACGCGAGAGCGCTATTTTACC
AACAAAGAATCTATACTTCTTTTTTGTCTACAAAATGCATCCCGAGAGCGCTATTTTTCT
AACAAAGCATCTTAGATTACTTTTTTCTCCTTTGTGCGCTCTATAATGCAGTCTCTTGATAA
CTTTTTGCACTGTAGGTCCGTTAAGGTTAGAAGAAGGCTACTTTGGTGTCTATTTTCTCTTC
CATAAAAAAGCCTGACTCCACTTCCCCGCTTACTGATTACTAGCGAAGCTGCGGGTGCA

TTTTTCAAGATAAAGGCATCCCCGATTATATTCTATACCGATGTGGATTGCGCATACTTTGT
GAACAGAAAGTGATAGCGTTGATGATTCTTCATTGGTCAGAAAATTATGAACGGTTTCTTC
TATTTTGTCTCTATATACTACGTATAGGAAATGTTTACATTTTCGTATTGTTTCGATTCACTC
TATGAATAGTTCTTACTACAATTTTTTTGTCTAAAGAGTAATACTAGAGATAAACATAAAAA
ATGTAGAGGTCGAGTTTAGATGCAAGTTCAAGGAGCGAAAGGTGGATGGGTAGGTTATATA
GGGATATAGCACAGAGATATATAGCAAAGAGATACTTTTGAGCAATGTTTGTGGAAGCGGT
ATTCGCAATATTTTAGTAGCTCGTTACAGTCCGGTGCGTTTTTGGTTTTTGAAGTGCGTC
TTCAGAGCGCTTTTGGTTTTCAAAAGCGCTCTGAAGTTCCTATACTTTCTAGAGAATAGGA
ACTTCGGAATAGGAACCTTCAAAGCGTTTCCGAAAACGAGCGCTTCCGAAAATGCAACGCG
AGCTGCGCACATACAGCTCACTGTTACGTCGCACCTATATCTGCGTGTTGCCTGTATATAT
ATATACATGAGAAGAACGGCATAGTGCGTGTTTATGCTTAAATGCGTACTTATATGCGTCTAT
TTATGTAGGATGAAAGGTAGTCTAGTACCTCCTGTGATATTATCCCATTCATGCGGGGTATC
GTATGCTTCCCTTACGACTACCCCTTAGCTGTTCTATATGCTGCCACTCCTCAATTGGATTAG
TCTCATCCTTCAATGCTATCATTTCCTTTGATATTGGATCATACTAAGAAACCATTATTATCAT
GACATTAACCTATAAAAAATAGGCGTATCACGAGGCCCTTTCGTCTCGCGCGTTTCGGTGAT
GACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCG
GATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGG
CTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATCGACTACGTC
GTAAGGCCGTTTCTGACAGAGTAAAATTCTTGAGGGAACCTTTCACCATTATGGGAAATGCT
TCAAGAAGGTATTGACTTAACTCCATCAAATGGTTCAGGTCATTGAGTGTTTTTATTTGTT
GTATTTTTTTTTTTTAGAGAAAATCCTCCAATATCAAATTAGGAATCGTAGTTTCATGATT
TCTGTTACACCTAACTTTTTGTGTGGTGCCCTCCTCCTTGTCATATTAATGTTAAAGTGCA
ATTCTTTTTCTTATCACGTTGAGCCATTAGTATCAATTTGCTTACCTGTATTCCTTTACTATC
CTCCTTTTTCTCCTTCTTGATAAATGTATGTAGATTGCGTATATAGTTTCGTCTACCCATGAA
CATATCCATTTTGTAATTCGTGTCGTTTCTATTATGAATTCATTTATAAAGTTTATGTACA
AATATCAAAAAAAGAGAATCTTTTTAAGCAAGGATTTTCTTAACTTCTTCGCGCAGCAGC
ATCACCGACTTCGGTGGTACTGTTGGAACCACTAAATCACCAGTTCTGATACCTGCATCC
AAAACCTTTTTAACTGCATCTTCAATGGCCTTACCTTCTTCAGGCAAGTTCAATGACAATTT
CAACATCATTGCAGCAGACAAGATAGTGGCGATAGGGTCAACCTTATTCTTTGGCAAATCT
GGAGCAGAACCGTGGCATGGTTTCGTACAAACCAAATGCGGTGTTCTTGTCTGGCAAAGAG
GCCAAGGACGCAGATGGCAACAAACCCAAGGAACCTGGGATAACGGAGGCTTCATCGGA
GATGATATCACCAACATGTTGCTGGTGATTATAATACCATTTAGGTGGGTGGGTTCTTAA
CTAGGATCATGGCGGCAGAAATCAATCAATTGATGTTGAACCTTCAATGTAGGGAATTCGTT
CTTGATGGTTTCTCCACAGTTTTTCTCCATAATCTTGAAGAGGCCAAAAGATTAGCTTTAT
CCAAGGACCAATAGGCAATGGTGGCTCATGTTGTAGGGCCATGAAAGCGGCCATTCTTG
TGATTCTTTGCACTTCTGGAACGGTGTATTGTTCACTATCCCAAGCGACACCATCACCATCG
TCTTCCTTTCTCTTACCAAAGTAAATACCTCCCACTAATTCTCTGACAACAACGAAGTCAG
TACCTTTAGCAAATTGTGGCTTGATTGGAGATAAGTCTAAAAGAGAGTCGGATGCAAAGTT
ACATGGTCTTAAGTTGGCGTACAATTGAAGTTCTTTACGGATTTTTAGTAAACCTTGTTTCA
GTCTAACACTACCGGTACCCCATTTAGGACCAAGCCACAGCACCTAACAAAACGGCATCAA
CCTTCTTGAGGCTTCCAGCGCCTCATCTGGAAGTGGGACACCTGTAGCATCGATAGCAGC
ACCACCAATTAAATGATTTTCGAAATCGAACTTGACATTGGAACGAACATCAGAAATAGCT
TTAAGAACCTTAATGGCTTCGGCTGTGATTCTTGACCAACGTGGTCACCTGGCAAAACGA
CGATCTTCTTAGGGGCAGACATAGGGGCAGACATTAGAATGGTATATCCTTGAAATATATAT
ATATATTGCTGAAATGTAAAAGGTAAGAAAAGTTAGAAAAGTAAGACGATTGCTAACCACT
ATTGGAAAAACAATAGGTCCTTAAATAATATTGTCAACTTCAAGTATTGTGATGCAAGCAT
TTAGTCATGAACGCTTCTCTATTCTATATGAAAAGCCGGTCCGGCCTCTCACCTTTCTTT
TTCTCCCAATTTTTCAGTTGAAAAAGGTATATGCGTCAGGCGACCTCTGAAATTAACAAAA
AATTTCCAGTCATCGAATTTGATTCTGTGCGATAGCGCCCTGTGTGTTCTCGTTATGTTGA
GGAAAAAATAATGGTTGCTAAGAGATTTCGAACTCTTGCACTTACGATACCTGAGTATTC
CCACAGTTAACTGCGGTCAAGATATTTCTGAATCAGGCGCCTTAGACCGCTCGGCCAAAC
AACCAATTACTTGTGAGAAATAGAGTATAATTATCCTATAAATATAACGTTTTTGAACACA
CATGAACAAGGAAGTACAGGACAATTGATTTTGAAGAGAATGTGGATTTTGATGTAATTGT
TGGGATTCCATTTTAATAAGGCAATAATATTAGGTATGTGGATATACTAGAAGTTCTCCTCG

ACCGTCGATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGG
AAATTGTAAACGTTAATATTTTGTAAAATTCGCGTTAAATTTTGTAAATCAGCTCATTTT
TTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAGAATAGACCGAGATAGG
GTTGAGTGTGTTCCAGTTTGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGT
CAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCTAATC
AAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCG
ATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCG
AAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC
ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCGCGCCATTGCCATTAGGCTGCG
CAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGG
GGGATGTGCTGCAAGGCGATTAAGTTGGGTAAACGCCAGGGTTTTCCAGTCACGACGTTG
TAAACGACGGCCAGTGAGCGCGCGTAATACGACTACTATAGGGCGAATTGGGTACCGG
GCCCCCTCGAGGTGACGGTATCGATAAGCTTGATATCGAATTCCTGCAGCCCGGGGA
TCCGTTAGAATCATTTTGAATAAAAAACACGCTTTTTCAGTTCGAGTTTATCATTATCAATA
CTGCCATTTCAAAGAATACGTAAATAATTAATAGTAGTGATTTTCCTAACTTTATTAGTCAA
AAAATTAGCCTTTTAATTCTGCTGTAACCCGTACATGCCCAAATAGGGGGCGGGTTACAC
AGAATATATAACATCGTAGGTGTCTGGGTGAACAGTTTATTCCTGGCATCCACTAAATATAA
TGGAGCCCGCTTTTTAAGCTGGCATCCAGAAAAAAAAGAATCCCAGCACCAAAATATTG
TTTTCTTCACCAACCATCAGTTCATAGGTCCATTCTCTTAGCGCAACTACAGAGAACAGGG
GCACAAACAGGCAAAAAACGGGCACAACCTCAATGGAGTGATGCAACCTGCCTGGAGTA
AATGATGACACAAGGCAATTGACCCACGCATGTATCTATCTCATTTTCTTACACCTTCTATTA
CCTTCTGCTCTCTCTGATTTGGAAAAAGCTGAAAAAAAAGGTTGAAACCAGTTCCTGAA
ATTATCCCCTACTTGACTAATAAGTATATAAAGACGGTAGGTATTGATTGTAATTCTGTA
TCTATTTCTTAACTTCTTAAATTCTACTTTTATAGTTAGTCTTTTTTTTAGTTTTAAACACC
AAGAACTTAGTTTCGAATAAACACACATAAACAAACAAAGAATTC (SEQ ID NO: 731)

p425-GFP_-lfs_mCherry:

ATGTCTAAAGGTGAAGAATTATTCAGTGGTGTGTCCCAATTTTGGTTGAATTAGATGGTGA
TGTTAATGGTCACAAATTTTCTGTCTCCGGTGAAGGTGAAGGTGATGCTACTTACGGTAAA
TTGACCTTAAAATTTATTTGTACTACTGGTAAATTGCCAGTTCCATGGCCAACCTTAGTCAC
TACTTTCCGTTATGGTGTCAATGTTTTGCTAGATACCCAGATCATATGAAACAACATGACT
TTTTCAAGTCTGCCATGCCAGAAGGTTATGTTCAAGAAAGAACTATTTTTTTCAAGATGA
CGGTAACACAGACGAGCTGAAGTCAAGTTTGAAGGTGATACCTTATTAATAGAATC
GAATTAAGGTATTGATTTTAAAGAAGATGGTAACATTTTAGGTACACAAATTGGAATACA
ACTATAACTCTCACAAATGTTTACATCATGGCTGACAAACAAAAGAATGGTATCAAAGTTAA
CTTCAAATTAGACACAACATTGAAGATGGTTCTGTTCAATTAGCTGACCATTATCAACAA
AATACTCCAATTGGTGATGGTCCAGTCTTGTTACCAGACAACCATTAATTATCCACTCAATC
TGCCTTATCCAAAGATCCAAACGAAAAGAGAGACCACATGGTCTTGTTAGAATTTGTTACT
GCTGCTGGTATTACCCATGGTATGGATGAATTGTACAAAGCTAGCAAACCTGGGTCAATCC
TTGGGGCCCGAGCTGAGCAGCTGATGGCAGAGCACAGGACGTCATGGTTTCAAAGGTG
AAGAAGATAATATGGCTATTATTAAGAATTTATGAGATTTAAAGTTCATATGGAAGGTTCAAGTTAAT
GGTCATGAATTTGAAATTGAAGGTGAAGGTGAAGGTAGACCATATGAAGGTACTCAAACCTGCTAA
ATTGAAAGTTACTAAAGGTGGTCCATTACCATTTGCTTGGGATATTTGTACCACAATTTATGTAT
GGTTCAAAGCTTATGTTAAACATCCAGCTGATTTCCAGATTATTTAAATTTGTCATTTCCAGAAG
GTTTAAATGGGAAAGAGTTATGAATTTGAAGATGGTGGTGTGTTACTGTTACTCAAGATTCAT
CATTACAAGATGGTGAATTTATTTATAAAGTTAAATTGAGAGGTACTAATTTTCCATCAGATGGTCC
AGTTATGCAAAAAAACTATGGGTTGGGAAGCTTCATCAGAAAGAAATGTATCCAGAAGATGGTG
CTTAAAAAGGTGAAATTAACAAAGATTGAAATTAAGATGGTGGTCATTATGATGCTGAAGTTAA
AACTACTTATAAAGCTAAAAAACAGTTCAATTACCAGGTGCTTATAATGTTAATATTAATTTGGATA
TTACTTCACATAATGAAGATTATACTATTGTTGAACAATATGAAAGAGCTGAAGGTAGACATTCAAC
TGGTGGTATGGATGAATTATATAAAGGTACCGCTCGAGCAGCTGTGATTGATTGAGTCGACTTG
GTTGAACACGTTGCCAAGGCTTAAGTGAATTTACTTTAAATCTTGCATTTAAATAAATTTTC
TTTTTATAGCTTTATGACTTAGTTTCAATTTATATACTATTTTAATGACATTTTCGATTCCGATC
CACTAGTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCCAGCTTTTGTCCCTTAGTGAG

GGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAAATTGTTATCCG
CTCACAATTCCACACAACATAGGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAA
TGAGTGAGGTAACACTACATTAATTGCGTTGCGCTCACTGCCCCGCTTCCAGTCGGGAAACC
TGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTTCGTATTG
GGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTTCGGCTGCGGCGAG
CGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAG
GAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTT
GCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAG
TCAGAGGTGGCGAAACCCGACAGGACTATAAAGATAACCAGGCGTTTCCCCCTGGAAGCTC
CCTCGTGCGCTCTCCTGTTCCGACCCCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTT
CGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGT
TCGCTCCAAGCTGGGCTGTGTGCACGAACCCCGTTTCAGCCCGACCGCTGCGCCTTATC
CGGTAACATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGC
CACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTG
GTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCA
GTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGC
GGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGAT
CCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTT
TGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAATAAATGAAGTTTT
AAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGA
GGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGT
AGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGA
CCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCG
CAGAAAGTGGTCTCGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCT
AGAGTAAGTAGTTCCGCAGTTAATAGTTTGCACAACGTTGTTGCCATTGCTACAGGCATCG
TGGTGTACGCTCGTCTGTTTGGTATGGCTTCATTAGCTCCGGTTCCCAACGATCAAGGCG
AGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGCTCCTCCGATCGTT
GTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTC
TTACTGTCTATGCCATCCGTAAGATGCTTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTC
TGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCG
CGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAAAC
TCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTG
ATCTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAAT
GCCGCAAAAAAGGGAATAAGGGCGACACGGAATGTTGAATACTCATACTCTTCCTTTTTTC
AATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTA
GAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGAACGAAG
CATCTGTGCTTCATTTTGTAGAACAAAAATGCAACGCGAGAGCGCTAATTTTTCAAACAAA
GAATCTGAGCTGCATTTTTACAGAACAGAAATGCAACGCGAAAGCGCTATTTTACCAACG
AAGAATCTGTGCTTCATTTTTGTAAAACAAAAATGCAACGCGAGAGCGCTAATTTTTCAAA
CAAAGAATCTGAGCTGCATTTTTACAGAACAGAAATGCAACGCGAGAGCGCTATTTTACC
AACAAAGAATCTATACTTCTTTTTTGTCTACAAAAATGCATCCCGAGAGCGCTATTTTTCT
AACAAAGCATCTTAGATTACTTTTTTCTCCTTTGTGCGCTCTATAATGCAGTCTCTTGATAA
CTTTTTGCACTGTAGGTCCGTTAAGGTTAGAAGAAGGCTACTTTGGTGTCTATTTTCTCTTC
CATAAAAAAAGCCTGACTCCACTTCCCGCGTTTACTGATTACTAGCGAAGCTGCGGGTGCA
TTTTTTCAAGATAAAGGCATCCCCGATTATATTCTATACCGATGTGGATTGCGCATACTTTGT
GAACAGAAAGTGATAGCGTTGATGATTCTTCATTGGTCAGAAAATTATGAACGGTTTCTTC
TATTTTGTCTCTATATACTACGTATAGGAAATGTTTACATTTTCGTATTGTTTTCGATTCACTC
TATGAATAGTTCTTACTACAATTTTTTGTCTAAAGAGTAATACTAGAGATAAACATAAAAA
ATGTAGAGGTCGAGTTTAGATGCAAGTTCAAGGAGCGAAAGGTGGATGGGTAGGTTATATA
GGGATATAGCACAGAGATATATAGCAAAGAGATACTTTTGAGCAATGTTTGTGGAAGCGGT
ATTCGCAATATTTTAGTAGCTCGTTACAGTCCGGTGCGTTTTTGGTTTTTTGAAAGTGCGTC
TTCAGAGCGCTTTTGGTTTTTCAAAGCGCTCTGAAGTTCTTATACTTTCTAGAGAATAGGA
ACTTCGGAATAGGAACCTCAAAGCGTTTCCGAAAACGAGCGCTTCCGAAAATGCAACGCG
AGCTGCGCACATACAGCTCACTGTTACGTCGCACCTATATCTGCGTGTTGCCTGTATATAT

ATATACATGAGAAGAACGGCATAGTGCCTGTTTATGCTTAAATGCGTACTTATATGCGTCTAT
TTATGTAGGATGAAAGGTAGTCTAGTACCTCCTGTGATATTATCCCATTCATGCGGGGTATC
GTATGCTTCCTTCAGCACTACCCTTTAGCTGTTCTATATGCTGCCACTCCTCAATTGGATTAG
TCTCATCCTTCAATGCTATCATTTCCTTTGATATTGGATCATACTAAGAAACCATTATTATCAT
GACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTTCGTCTCGCGCGTTTCGGTGAT
GACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCG
GATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTGCGGG
CTGGCTTAACTATGCGGCATCAGAGCAGATTGTAAGTGCACCATATCGACTACGTC
GTAAGGCCGTTTCTGACAGAGTAAAATTCTTGAGGGAACCTTTCACCATTATGGGAAATGCT
TCAAGAAGGTATTGACTTAACTCCATCAAATGGTCAGGTCATTGAGTGTTTTTTATTTGTT
GTATTTTTTTTTTTTTAGAGAAAATCCTCCAATATCAAATTAGGAATCGTAGTTTCATGATTT
TCTGTACACCTAACTTTTTGTGTGGTGCCCTCCTCCTGTCAATATTAATGTTAAAGTGCA
ATTCTTTTTCTTATCAGTTGAGCCATTAGTATCAATTTGCTTACCTGTATTTCCTTTACTATC
CTCCTTTTTCTCCTTCTTGATAAATGTATGTAGATTGCGTATATAGTTTCGTCTACCCTATGAA
CATATTCCATTTTGTAATTTTCGTGTCGTTTCTATTATGAATTTCAATTTATAAAGTTTATGTACA
AATATCATAAAAAAAGAGAATCTTTTTAAGCAAGGATTTTCTTAACTTCTTCGGCGACAGC
ATCACCGACTTCGGTGGTACTGTTGGAACCACCTAAATCACCAGTTCTGATACCTGCATCC
AAAACCTTTTTAACTGCATCTTCAATGGCCTTACCTTCTTCAGGCAAGTTCAATGACAATTT
CAACATCATTGCAGCAGACAAGATAGTGGCGATAGGGTCAACCTTATTCTTTGGCAAATCT
GGAGCAGAACCGTGGCATGGTTTCGTACAAACCAAATGCGGTGTTCTTGTCTGGCAAAGAG
GCCAAGGACGCAGATGGCAACAAACCCAAGGAACCTGGGATAACGGAGGCTTCATCGGA
GATGATATCACCAACATGTTGCTGGTGATTATAATACCATTAGGTGGGTGGGTTCTTAA
CTAGGATCATGGCGGCAGAAATCAATCAATTGATGTTGAACCTTCAATGTAGGGAATTCGTT
CTTGATGGTTTCTCCACAGTTTTTCTCCATAATCTTGAAGAGGCCAAAAGATTAGCTTTAT
CCAAGGACCAAAATAGGCAATGGTGGCTCATGTTGTAGGGCCATGAAAGCGGCCATTCTTG
TGATTCTTTGCACCTTCTGGAACGGTGTATTGTTCACTATCCCAAGCGACACCATCACCCTCG
TCTTCCTTTCTTACCAAAGTAAATACCTCCCACTAATTCTCTGACAACAACGAAGTCAG
TACCTTTAGCAAATTGTGGCTTGATTGGAGATAAGTCTAAAAGAGAGTCGGATGCAAAGTT
ACATGGTCTTAAAGTTGGCGTACAATTGAAGTTCTTTACGGATTTTATAGTAAACCTTGTTCAG
GTCTAACACTACCGGTACCCCATTTAGGACCAGCCACAGCACCTAACAAAACGGCATCAA
CCTTCTTGAGGCTTCCAGCGCCTCATCTGGAAGTGGGACACCTGTAGCATCGATAGCAGC
ACCACCAATTAATGATTTTCGAAATCGAAGTTGACATTGGAACGAACATCAGAAATAGCT
TTAAGAACCTTAATGGCTTCGGCTGTGATTTCTTGACCAACGTGGTCACCTGGCAAAACGA
CGATCTTCTTAGGGGCAGACATAGGGGCAGACATTAGAATGGTATATCCTTGAAATATATAT
ATATATTGCTGAAATGTAAAAGGTAAGAAAAGTTAGAAAAGTAAGACGATTGCTAACCACT
ATTGGAaaaaaacaataggTCCTTAAATAATATTGTCAACTTCAAGTATTGTGATGCAAGCAT
TTAGTCATGAACGCTTCTCTATTCTATATGAAAAGCCGGTTCGGCCTCTCACCTTTCTTT
TTCTCCCAATTTTTAGTTGAAAAGGTATATGCGTCAGGCGACCTCTGAAATTAACAAAA
AATTTCCAGTCATCGAATTTGATTCTGTGCGATAGCGCCCTGTGTGTTCTCGTTATGTTGA
GGAAAAAAATAATGGTTGCTAAGAGATTGCAACTCTTGCACTTACGATACCTGAGTATTC
CCACAGTTAACTGCGGTCAAGATATTTCTGAATCAGGCGCCTTAGACCGCTCGGCCAAAC
AACCAATTACTTGTGAGAAATAGAGTATAATTATCCTATAAATATAACGTTTTTTGAACACA
CATGAACAAGGAAGTACAGGACAATTGATTTTGAAGAGAATGTGGATTTTGATGTAATTGT
TGGGATTCCATTTTAAATAAGGCAATAATATTAGGTATGTGGATATACTAGAAGTTCTCCTCG
ACCGTCGATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAAATACCGCATCAGG
AAATTGTAAACGTTAATATTTTGTAAATTCGCGTTAAATTTTTGTAAATCAGCTCATTTT
TTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGG
GTTGAGTGTGTTCCAGTTTGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGT
CAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCTAATC
AAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCTAAAGGGAGCCCCCG
ATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCG
AAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTACGCTGCGCGTAACCACCAC
ACCCGCCGCGCTAATGCGCCGCTACAGGGCGCGTCGCGCCATTGCGCATTCAGGCTGCG
CAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGG

GGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTG
TAAACGACGGCCAGTGAGCGCGCGTAATACGACTCACTATAGGGCGAATTGGGTACCGG
GCCCCCCTCGAGGTGACGGTATCGATAAGCTTGATATCGAATTCCTGCAGCCCGGGGA
TCCGTTAGAATCATTTTGAATAAAAAACACGCTTTTTCAGTTCGAGTTTATCATTATCAATA
CTGCCATTTCAAAGAATACGTAAATAATTAATAGTAGTGATTTTCCTAACTTTATTTAGTCAA
AAAATTAGCCTTTTAATTCTGCTGTAACCCGTACATGCCCAAATAGGGGGCGGGTTACAC
AGAATATATAACATCGTAGGTGTCTGGGTGAACAGTTTATTCCTGGCATCCACTAAATATAA
TGGAGCCCGCTTTTTAAGCTGGCATCCAGAAAAAAGAATCCCAGCACCAAAATATTG
TTTTCTTCACCAACCATCAGTTCATAGGTCCATTCTCTTAGCGCAACTACAGAGAACAGGG
GCACAAACAGGCAAAAAACGGGCACAACCTCAATGGAGTGATGCAACCTGCCTGGAGTA
AATGATGACACAAGGCAATTGACCCACGCATGTATCTATCTCATTCTTACACCTTCTATTA
CCTTCTGCTCTCTCTGATTGGAAGGCTGAAAAAAGGTTGAAACCAGTTCCTGAA
ATTATCCCCCTAGTTGACTAATAAGTATATAAAGACGGTAGGTATTGATTGTAATCTGTAAA
TCTATTTCTTAACTTCTTAAATTCTATTTTATAGTTAGTCTTTTTTTTAGTTTTAAACACC
AAGAACTTAGTTTCGAATAAACACACATAAACAAACAAAGAATTC (SEQ ID NO: 732)

KEY:

GFP open reading frame

Linker containing stop codon +1 frameshift, or -1 frameshift

mCherry open reading frame

Plasmid backbone (containing the GPD promoter, Leu2 marker, and AmpR)

Protospacer (underlined)

PAM (boldfaced)

[1225] DNA sequences of mammalian prime editor plasmids and example PEgRNA plasmid

pCMV-PE1:

ATGAAACGGACAGCCGACGGAAGCGAGTTCGAGTCACCAAAGAAGAAGCGGAAAGTCG
ACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCA
CCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCAC
AGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTTCGACAGCGGCGAAACAGCCGAGGC
CACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGCT
ATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGAC
TGGAAGAGTCTTCTGCTGGAAGAGGATAAGAAGCAGGAGCGGCACCCCATCTTCGGC
AACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCAACCATCTACCACCTGAGAAAG
AACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCAC
ATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGAC
GTGGACAAGCTGTTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTTCGAGGAAAACCC
ATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAG
ACGGCTGGAAGATCTGATCGCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTTCGGA
ACCTGATTGCCCTGAGCCTGGGCCTGACCCCAACTTCAAGAGCAACTTCGACCTGGCCG
AGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTG
GCCCAGATCGGCGACCAAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCC
ATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCTGAGCGCC
TCTATGATCAAGAGATACGACGAGCACCACAGGACCTGACCCTGCTGAAAGCTCTCGTG
CGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTA
CGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTTCATCAAGCCCAT
CCTGGAAGATGGACGGCACCAGGAAGTCTGCTGAAGCTGAACAGAGAGGACCTGC
TGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCACCAAGATCCACCTGGGAGAG
CTGCACGCCATTCTGCGGCGGCAGGAAGATTTTACCCATTCTGAAGGACAACCGGGAA
AAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGGCCCTCTGGCCAGGGGA
AACAGCAGATTGCCTGGATGACCAGAAAGAGCGAGGAACCATCACCCCTGGAACTT
CGAGGAAGTGGTGGACAAGGGCGCTTCCGCCAGAGCTTCATCGAGCGGATGACCAACT
TCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACT

TCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCC
GCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCG
GAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACT
CCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATC
TGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGG
AAGATATCGTGCTGACCCTGACACTGTTTGGAGACAGAGAGATGATCGAGGAACGGCTGA
AAACCTATGCCACCTGTTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACA
CCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGC
AAGACAATCCTGGATTTCTGAAGTCCGACGGCTTCGCCAACAGAACTTCATGCAGCTG
ATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCA
GGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGG
CATCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAGTGATGGGCCGGCACAAGC
CCGAGAATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAAGGGACAGAAG
AACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGAT
CCTGAAAGAACACCCCGTGGAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACT
ACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCG
ACTACGATGTGGACGCTATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACA
AGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGA
GGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCC
AGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAG
GCCGGCTTCATCAAGAGACAGCTGGTGGAACCCGGCAGATCACAAAGCACGTGGCACA
GATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGT
GAAAGTGATCACCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTAC
AAAGTGCGCGAGATCAACAATAACCACCACGCCACGACGCCTACCTGAACGCCGTCTGTG
GGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCTGTACGGCGACTAC
AAGGTGTACGAGTGCAGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTAC
CGCCAAGTACTTCTTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCTTGCC
AACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGT
GTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCAAGTGAA
TATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAA
GAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCG
GCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAGGGCA
AGTCCAAGAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAGAAGC
AGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAA
GGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTTCGAGCTGGAAAACGGCCGGAAGAG
AATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATA
TGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCGAGGATAA
TGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGC
AGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGT
CCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACC
TGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGA
CCGGAAGAGGTACACCAGCACCAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCA
TCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGTGACTCTGGAGGAT
CTAGCGGAGGATCCTCTGGCAGCGAGACACCAGGAACAAGCGAGTCAGCAACACCAGAGAGC
AGTGGCGGCAGCAGCGGCGGCAGCAGCACCCTAAATATAGAAGATGAGTATCGGCTACA
TGAGACCTCAAAAGAGCCAGATGTTTCTCTAGGGTCCACATGGCTGTCTGATTTTCC
TCAGGCCTGGGCGGAAACCGGGGGCATGGGACTGGCAGTTCGCCAAGCTCCTCTG
ATCATACCTCTGAAAGCAACCTCTACCCCCGTGTCCATAAAACAATACCCCATGTAC
AAGAAGCCAGACTGGGGATCAAGCCCCACATACAGAGACTGTTGGACCAGGGAATA
CTGGTACCCTGCCAGTCCCCCTGGAACACGCCCTGCTACCCGTTAAGAAACCAGG
GACTAATGATTATAGGCCTGTCCAGGATCTGAGAGAAGTCAACAAGCGGGTGAAG
ACATCCACCCACCGTGCCCAACCCTTACAACCTCTTGAGCGGGCTCCACCCGTCCC
ACCAAGTGGTACACTGTGCTTGATTAAAGGATGCCTTTTCTGCCTGAGACTCCACC
CCACCAGTCAGCCTCTCTTCGCCTTTGAGTGGAGAGATCCAGAGATGGGAATCTCA

GGACAATTGACCTGGACCAGACTCCACAGGGTTTCAAAAACAGTCCCACCCTGTT
TGATGAGGCACTGCACAGAGACCTAGCAGACTTCCGGATCCAGCACCCAGACTTGA
TCCTGCTACAGTACGTGGATGACTTACTGCTGGCCGCCACTTCTGAGCTAGACTGCC
AACAAGGTACTCGGGCCCTGTTACAAACCCTAGGGAACCTCGGGTATCGGGCCTCG
GCCAAGAAAGCCCCAAATTTGCCAGAAACAGGTCAAGTATCTGGGGTATCTTCTAAAA
GAGGGTCAGAGATGGCTGACTGAGGCCAGAAAAAGAGACTGTGATGGGGCAGCCTAC
TCCGAAGACCCCTCGACAACCTAAGGGAGTTCTAGGGACGGCAGGCTTCTGTCCGC
TCTGGATCCCTGGGTTTGCAGAAATGGCAGCCCCCTGTACCCTCTCACCAAAACGG
GGACTCTGTTAATTGGGGCCCAGACCAACAAAAAGGCCTATCAAGAAATCAAGCAAG
CTCTTCTAACTGCCCCAGCCCTGGGGTTGCCAGATTTGACTAAGCCCTTTGAACTCT
TTGTCGACGAGAAGCAGGGCTACGCCAAAGGTGTCTAACGCAAAAACCTGGGACCT
TGGCGTCGGCCGGTGGCCTACCTGTCCAAAAAGCTAGACCCAGTAGCAGCTGGGTG
GCCCCCTTGCCCTACGGATGGTAGCAGCCATTGCCGTACTGACAAAGGATGCAGGCA
AGCTAACCTATGGGACAGCCACTAGTCATTCTGGCCCCCATGCAGTAGAGGCAGTAG
TCAAAACAACCCCCCGACCGCTGGCTTTCCAACGCCCGGATGACTCACTATCAGGCCT
TGCTTTTGGACACGGACCGGGTCCAGTTCGGACCGGTGGTAGCCCTGAACCCGGCT
ACGCTGCTCCCACTGCCTGAGGAAGGGCTGCAACACAACCTGCCTTGATATCCTGGC
CGAAGCCCACGGAACCCGACCCGACCTAACGGACCAGCCGCTCCCAGACGCCGACC
ACACCTGGTACACGGATGGAAGCAGTCTCTTACAAGAGGGACAGCGTAAGGCGGGA
GCTGCGGTGACCACCGAGACCGAGGTAATCTGGGCTAAAGCCCTGCCAGCCGGGAC
ATCCGCTCAGCGGGCTGAACTGATAGCACTCACCCAGGCCCTAAAGATGGCAGAAG
GTAAGAAGCTAAATGTTTATACTGATAGCCGTTATGCTTTTGCTACTGCCCATATCCAT
GGAGAAATATACAGAAGGCGTGGGTTGCTCACATCAGAAGGCAAAAGAGATCAAAAA
TAAAGACGAGATCTTGGCCCTACTAAAAGCCCTCTTTCTGCCCAAAAGACTTAGCAT
AATCCATTGTCCAGGACATCAAAAGGGACACAGCGCCGAGGCTAGAGGCAACCCGGA
TGGCTACAGAAGCGGCCGAAAGGCAGCCATCACAGAGACTCCAGACACCTCTACC
CTCCTCATAGAAAATTTCATCACCCCTCTGGCGGCTCAAAAAGAACCGCCGACGCGAGC
GAATTCGAGCCCAAGAAGAAGAGGAAAGTCTAACCGGTCATCATCACCATCACCATTG
AGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGC
CCCTCCCCCGTGCCTTCCCTTGACCCTGGAAGGTGCCACTCCCCTGTCTTTTCTAATAAA
ATGAGAAAATTGCATCGCATTGTCTGAGTAGGTGTCTATTCTATTTCTGGGGGGTGGGGTGGG
GCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGG
GCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCGATACCGTCGACCTCTAGCT
AGAGCTTGCGCTAATCATGGTCATAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATT
CCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCCTAGGGTGCCTAATGAGTGAGC
TAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCTGTGCC
AGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTTCGCTATTGGGCGCTCTT
CCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTTCGCTGCGGCGAGCGGTATCAG
CTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACA
TGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGTGGCGTTT
TTCCATAGGCTCCGCCCCCTGACGAGCATCAAAAAATCGACGCTCAAGTCAGAGGTGG
CGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGC
TCTCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCG
TGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAA
GCTGGGCTGTGTGCACGAACCCCCCGTTACGCCCCGACCGCTGCGCCTTATCCGGTAACAT
CGTCTTGAGTCCAACCCGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAAC
AGGATTAGCAGAGCGAGGTATGTAGGCGGTGTACAGAGTTCTTGAAGTGGTGGCCTAAC
TACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCG
GAAAAAGAGTTGGTAGCTCTTGATCCGGCAACAAACCACCGCTGGTAGCGGTGGTTTTT
TTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCT
TTTCTACGGGTCTGACGCTCAGTGGAAACGAAAACTCACGTTAAGGGATTTTGGTCATGA
GATTATCAAAAAGGATCTTACCTAGATCCTTTTAAATTAATAAATGAAGTTTAAATCAATC
TAAAGTATATATGAGTAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTAT
CTCAGCGATCTGTCTATTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTA

CGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCT
CACCGGCTCCAGATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGCAGAAGT
GGTCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAA
GTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTC
ACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACA
TGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTCAGAA
GTAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTC
ATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAAT
AGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACA
TAGCAGAACTTTAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACCTCTCAAG
GATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCA
GCATCTTTTACTTTACCAGCGTTTCTGGGTGAGCAAAAAACAGGAAGGCAAAATGCCGCA
AAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTCAATATT
ATTGAAGCATTTATCAGGGTTATTGTCTCATGACGCGATACATATTTGAATGTATTTAGAAAA
ATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCGACGGAT
CGGGAGATCGATCTCCCGATCCCCTAGGGTCGACTCTCAGTACAATCTGCTCTGATGCCGC
ATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGC
AAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGG
GTTAGGCGTTTTCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATT
GACTAGTTATTAATAGTAATCAATTACGGGGTTCATTAGTTCATAGCCCATATATGGAGTTCCG
CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCATTG
ACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATG
GGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGT
ACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGA
CCTTATGGGACTTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGA
TGCGGTTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGAATCAGGGGATTTCGAAG
TCTCCACCCCATTGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTTCCA
AAATGTGCTAACAACCTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAG
GTCTATATAAGCAGAGCTGGTTTGTGTAACCGTCAGATCCGCTAGAGATCCGCGGCCGCTA
ATACGACTCACTATAGGGAGAGCCGCCACC (SEQ ID NO: 733)

pCMV-PE2:

ATGAAACGGACAGCCGACGGAAGCGAGTTCGAGTCACCAAAGAAGAAGCGGAAAGTCG
ACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCA
CCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCAC
AGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTTCGACAGCGGCGAAACAGCCGAGGC
CACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGCT
ATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGAC
TGGAAGAGTCTTCTGCTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGC
AACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCACCATCTACCACCTGAGAAAG
AACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCAC
ATGATCAAGTTCCGGGGCCACTTCTGATCGAGGGCGACCTGAACCCGACAACAGCGAC
GTGGACAAGCTGTTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTTCGAGGAAAACCC
ATCAACGCCAGCGGCGTGGACGCCAAGGCCATCTGTCTGCCAGACTGAGCAAGAGCAG
ACGGCTGGAAAATCTGATCGCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTTCGGAA
ACCTGATTGCCCTGAGCCTGGGCCTGACCCCAACTTCAAGAGCAACTTCGACCTGGCCG
AGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTG
GCCAGATCGGCGACCAAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCC
ATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCTGAGCGCC
TCTATGATCAAGAGATACGACGAGCACCACAGGACCTGACCCTGCTGAAAGCTCTCGTG
CGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTA
CGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTTCATCAAGCCAT
CCTGGAAAAGATGGACGGCACCGAGGAAGTCTGCTGAAGCTGAACAGAGAGGACCTGC
TGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCACCAAGATCCACCTGGGAGAG

CTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCTGAAGGACAACCGGGAA
AAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCCTCTGGCCAGGGGA
AACAGCAGATTGCCTGGATGACCAGAAAAGAGCGAGGAAACCATCACCCCCTGGAACCT
CGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCAACT
TCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGTACGAGTACT
TCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCC
GCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCG
GAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAAATCGAGTGCTTCGACT
CCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATC
TGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGG
AAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGA
AAACCTATGCCCACCTGTTTCGACGACAAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACA
CCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGC
AAGACAATCCTGGATTTCTGAAGTCCGACGGCTTCGCCAACAGAACTTCATGCAGCTG
ATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCA
GGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGG
CATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGC
CCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAG
AACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGAT
CCTGAAAGAACACCCCGTGGAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACT
ACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCG
ACTACGATGTGGACGCTATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACA
AGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGA
GGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCC
AGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGGCGCCTGAGCGAACTGGATAAG
GCCGGCTTCATCAAGAGACAGCTGGTGGAACCCCGCAGATCACAAGACAGCTGGGCACA
GATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGT
GAAAGTGATACCCTGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTAC
AAAGTGCGCGAGATCAACAACCTACCACCACGCCCACGACGCCTACCTGAACGCCGTCTGT
GGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTAC
AAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTAC
CGCCAAGTACTTCTTCTACAGCAACATCATGAACCTTTTTCAAGACCGAGATTACCCTGGCC
AACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGT
GTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAA
TATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAA
GAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCG
GCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAGGGCA
AGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGAAAGAAGC
AGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAA
GGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTTCGAGCTGGAAAACCGGCCGGAAGAG
AATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATA
TGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCGAGGATAA
TGAGCAGAAACAGCTGTTTGTGGAACAGCACAAAGCACTACCTGGACGAGATCATCGAGC
AGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGT
CCGCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACC
TGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGA
CCGGAAGAGGTACACCAGCACCAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCA
TCACCGGCCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGTGACTCTGGAGGAT
CTAGCGGAGGATCCTCTGGCAGCGAGACACCAGGAACAAGCGAGTCAGCAACACCAGAG
AGCAGTGGCGGCAGCAGCGGCGGCAGCAGCACCCCTAAATATAGAAGATGAGTATCGGCTA
CATGAGACCTCAAAAGAGCCAGATGTTTCTTAGGGTCCACATGGCTGTCTGATTTTCTC
AGGCCTGGGCGGAAACCGGGGGCATGGGACTGGCAGTTTCGCCAAGCTCCTCTGATCATAC
CTCTGAAAGCAACCTCTACCCCCGTGTCCATAAAACAATACCCCATGTCACAAGAAGCCA
GACTGGGGATCAAGCCCCACATACAGAGACTGTTGGACCAGGGAATACTGGTACCCTGCC

AGTCCCCCTGGAACACGCCCCCTGCTACCCGTTAAGAAACCAGGGACTAATGATTATAGGCC
TGTCCAGGATCTGAGAGAAGTCAACAAGCGGGTGGAAAGACATCCACCCACCGTGCCCA
ACCCTTACAACCTCTTGAGCGGGCTCCACCGTCCCACCAGTGGTACACTGTGCTTGATTT
AAAGGATGCCTTTTTCTGCCTGAGACTCCACCCACCAGTCAGCCTCTCTTCGCTTTGAG
TGGAGAGATCCAGAGATGGGAATCTCAGGACAATTGACCTGGACCAGACTCCCACAGGGT
TTCAAAAACAGTCCCACCCTGTTTAATGAGGCACTGCACAGAGACCTAGCAGACTTCCGG
ATCCAGCACCCAGACTTGATCCTGCTACAGTACGTGGATGACTTACTGCTGGCCGCCACTT
CTGAGCTAGACTGCCAACAAAGGTACTCGGGCCCTGTTACAAACCCTAGGGAACCTCGGGT
ATCGGGCCTCGGCCAAGAAAGCCCAAATTTGCCAGAAACAGGTCAAGTATCTGGGGTATC
TTCTAAAAGAGGGTCAGAGATGGCTGACTGAGGCCAGAAAAGAGACTGTGATGGGGCAG
CCTACTCCGAAGACCCCTCGACAATAAGGGAGTTCTTAGGGAAGGCAGGCTTCTGTGCG
CTCTTCACTCCCTGGGTTTGCCAGAAATGGCAGCCCCCTGTACCCTCTCACCAACCCGGGG
ACTCTGTTTAATTGGGGCCAGACCAACAAAAGGCCTATCAAGAAATCAAGCAAGCTTT
CTAACTGCCCCAGCCCTGGGGTTGCCAGATTTGACTAAGCCCTTTGAACTCTTTGTGACG
AGAAGCAGGGCTACGCCAAAGGTGTCCTAACGCAAAAACTGGGACCTTGGCGTCGGCCG
GTGGCCTACCTGTCCAAAAAGCTAGACCCAGTAGCAGCTGGGTGGCCCCCTTGCTACGG
ATGGTAGCAGCCATTGCCGTACTGACAAAGGATGCAGGCAAGCTAACCATGGGACAGCCA
CTAGTCATTCTGGCCCCCATGCAGTAGAGGCACTAGTCAAACAACCCCCCGACCGCTGG
CTTTCCAACGCCCCGATGACTCACTATCAGGCCCTTGCTTTTGGACACGGACCGGGTCCAGT
TCGGACCGGTGGTAGCCCTGAACCCGGCTACGCTGCTCCCACTGCCTGAGGAAGGGCTGC
AACACAACCTGCCTTGATATCCTGGCCGAAGCCACGGAACCCGACCCGACCTAACGGACC
AGCCGCTCCCAGACGCCGACCACACCTGGTACACGGATGGAAGCAGTCTCTTACAAGAG
GGACAGCGTAAGGCGGGAGCTGCGGTGACCACCGAGACCGAGGTAATCTGGGCTAAAGC
CCTGCCAGCCGGGACATCCGCTCAGCGGGCTGAACTGATAGCACTCACCCAGGCCCTAAA
GATGGCAGAAGGTAAGAAGCTAAATGTTTATACTGATAGCCGTTATGCTTTTGCTACTGCCC
ATATCCATGGAGAAATATACAGAAGGCGTGGGTGGCTCACATCAGAAGGCCAAAGATCA
AAAATAAAGACGAGATCTTGGCCCTACTAAAAGCCCTCTTTCTGCCCAAAAGACTTAGCAT
AATCCATTGTCCAGGACATCAAAAGGGACACAGCGCCGAGGCTAGAGGCAACCGGATGG
CTGACCAAGCGGCCCGAAAGGCAGCCATCACAGAGACTCCAGACACCTCTACCCTCCTCA
TAGAAAATTCATCACCTCTGGCGGCTCAAAAAGAACC GCCGACGGCAGCGAATTCGAGC
CCAAGAAGAAGAGGAAAGTCTAACCGGTCATCATCACCATCACCATTGAGTTTAAACCCG
CTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCTCCCCCGTG
CCTTCCTTGACCCTGGAAGGTGCCACTCCCCTGTCTTTCTAATAAAATGAGAAAATTG
CATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCA
AGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTT
CTGAGGCGGAAAGAACCAGCTGGGGCTCGATACCGTCGACCTCTAGCTAGAGCTTGGCGT
AATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATCCACACAACATA
CGAGCCGGAAGCATAAAGTGTAAGCCTAGGGTGCCTAATGAGTGAGCTAACTCACATTA
ATTGCGTTGCGCTCACTGCCCCGCTTTCAGTCCGGGAAACCTGTCGTGCCAGCTGCATTAAT
GAATCGGCCAACGCGCGGGGAGAGGCGTTTGCGTATTGGGCGCTCTTCCGCTTCTCGC
TCACTGACTCGCTGCGCTCGGTGCTTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGG
CGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAG
GCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGCTGGCGTTTTTCCATAGGCTCC
GCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACA
GGACTATAAAGATAACAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCTGTTCGA
CCCTGCCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCA
TAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTG
CACGAACCCCCCGTTACAGCCCGACCGCTGCGCCTTATCCGGTAACCTATCGTCTTGAGTCCA
ACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAG
CGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTA
GAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTG
GTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTGTTGCAAGCA
GCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTCTACGGGGTCT
GACGCTCAGTGGAACGAAAACCTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGG

ATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAG
TAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTC
TATTTTCGTTTCATCCATAGTTGCCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGC
TTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATT
TATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTAT
CCGCTCCATCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTTAAT
AGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTTTGGTA
TGGCTTCATTAGCTCCGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTG
CAAAAAAGCGTTAGTCTCCTTCGGTCTCCGATCGTTGTGAGAAAGTAAGTTGGCCGAGT
GTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGAT
GCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACC
GAGTTGCTCTTGGCCGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAGAA
GTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGA
GATCCAGTTCGATGTAACCCACTCGTGACCCAACTGATCTTCAGCATCTTTTACTTTCACC
AGCGTTTCTGGGTGAGCAAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGC
GACACGGAAATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAGCATTTATCAGG
GTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTT
CCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCGACGGATCGGGAGATCGATCTCCC
GATCCCCTAGGGTTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATCT
GCTCCCTGCTTGTGTGTTGGAGGTGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAAC
AAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCT
GCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTA
ATCAATTACGGGGTCATTAGTTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGT
AAATGGCCCGCCTGGCTGACCGCCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTAT
GTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGT
AAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGT
CAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTTCTA
CTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTTGGCAGTAC
ATCAATGGGCGTGGATAGCGGTTTGACTACGGGGATTTCCTCAAGTCTCCACCCCATGACG
TCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTC
CGCCCCATTGACGCAAAATGGGCGGTAGGCGGTGACGGTGGGAGGTCTATATAAGCAGAGC
TGGTTTATGTAACCGTCAGATCCGCTAGAGATCCGCGGCCGCTAATACGACTCACTATAGG
GAGAGCCGCCACC (SEQ ID NO: 734)

N-terminal NLS + Cas9 H840A

Flexible linker

M-MLV reverse transcriptase + C-terminal NLS

Plasmid backbone (containing CMV promoter and AmpR)

pU6-HEK3_PEGRNA_CTTins:

GAGGGCCTATTTCCTCATATTTGCATATACGATACAAGGCTGTTAGAGAGAT
AATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAAG
TAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAATGGACTATCATATGCTT
ACCGTAACCTGAAAGTATTTGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACAC
CGGCCAGACTGAGCACGTGAGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTC
CGTTATCAACTTGAAAAAGTGGGACCGAGTCGGTCCTCTGCCATCAAAGCGTGCTCAGT
CTGTTTTTTTAAAGCTTGGGCCGCTCGAGGTACCTCTCTACATATGACATGTGAGCAAAAGG
CCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCG
CCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAG
GACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGAC
CCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGCGCTTTCTCAT
AGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGC
ACGAACCCCCGTTACGCCGACCGCTGCGCCTTATCCGTAACCTATCGTCTTGAGTCCAA
CCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGC

GAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAG
 AAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG
 TAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTTGTTTGAAGCAG
 CAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTG
 ACGCTCAGTGAACGAAAACCTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGA
 TCTTCACCTAGATCCTTTTAAATTAATAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGT
 AAACCTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCT
 ATTTCTGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCT
 TACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTT
 ATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCTGCAACTTTATC
 CGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATA
 GTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCTGTTGGTAT
 GGCTTCATTACGCTCCGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGC
 AAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAAGT
 TTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTTCATGCCATCCGTAAGATGC
 TTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGA
 GTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGT
 GCTCATCATTGGAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCGCTGTTGAG
 ATCCAGTTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCA
 GCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCG
 ACACGGAAATGTTGAATACTCATACTCTTCTTTTTCAATATTATTGAAGCATTATCAGGGT
 TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCC
 GCGCACATTTCCCCGAAAAGTGCCACCTGACGTGCTAGCTGTACAAAAAAGCAGGCTTT
 AAAGGAACCAATTCAGTCGACTGGATCCGGTACCAAGGTCGGGCAGGAA (SEQ ID NO:
 735)

U6 Promoter sequence

Spacer sequence

sgRNA scaffold

3' extension (contains PBS and RT template)

Backbone (contains AmpR)

pLenti-hSyn-N-PE2-NpuN-P2A-GFP-KASH_U6-DNMT1-PEgRNA:

GTCGACGGATCGGGAGATCTCCCGATCCCCTATGGTGCATCTCAGTACAATCTGCTCTGATGCC
 GCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCA
 AAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAG
 GCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTT
 ATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC
 TTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGAC
 GTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGT
 AAACCTGCCCACCTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAAT
 GACGGTAAATGGCCCGCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCA
 GTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTTGGCAGTACATCAATGGGCG
 TGGATAGCGGTTTACTACGGGGATTTCCTCAAGTCTCCACCCATTGACGTCAATGGGAGTTTG
 TTTTGGCACCAAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCATTTGACGCAAA
 TGGGCGGTAGGCGGTACGGTGGGAGGTCTATATAAGCAGCGCGTTTTGCTGTACTGGGTCTC
 TCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCC
 TCAATAAAGCTTGCTTGAAGTCTTCAAGTAGTGTGTGCGGCTCTGTTGTGTGACTCTGGTAAC
 TAGAGATCCCTCAGACCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGG
 ACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCG
 CGCACGGCAAGAGGCGAGGGGCGGCGACTGCTGAGTACGCCAAAAATTTTACTAGCGGAGG
 CTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATG
 GGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAACATATAGTATGGGC

AAGCAGGGAGCTAGAACGATTTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAG
ACAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAAGCTTAGATCATTATAT
AATACAGTAGCAACCTCTATTGTGTGCATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTT
TAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAAGCGGCCGCTGAT
CTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTA
GTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGA
AAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTAT
GGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAG
CAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGC
ATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTG
GGGATTTGGGGTTGCTCTGGAAAATCATTTCACCACTGCTGTGCCTTGGAAATGCTAGTTGGA
GTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTA
ACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAAATG
AACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGG
CTGTGGTATATAAAATTATTACATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTGCT
GTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTACCATTATCGTTTCAGACCCACCTCCC
AACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGA
GACAGATCCATTTCGATTAGTGAACGGATCGGCACTGCGTGCGCCAATTCTGCAGACAAATGGCA
GTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGTACAGTGCAGGGGAAAGAATA
GTAGACATAATAGCAACAGACATACAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAA
ATTTTCGGGTTTATTACAGGGACAGCAGAGATCCAGTTTGGTTAATTAAGGTACCAAGGTCCGG
CAGGAAGAGGGCCTATTTCCCATGATTCCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGA
GATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTAGAAAGT
AATAATTTCTTGGGTAGTTTGCAGTTTTTAAAATTATGTTTTAAAATGGACTATCATATGCTTACCGT
AAC TTGAAAGTATTTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCGGGC
TGGAGCTGTTTCGCGCTTTTAGAGCTAGAAATGCAAGTTAAATAAGGCTAGTCCGTTA
TCAACTTGAAAAAGTGGCACCGAGTCGGTGCAAGATGCAAGCGCGAACAGCTCCAGTTT
TTTTGAATTCAGTGCAAGTGGGTTTTAGGACCAGGATGAGGCGGGGTGGGGGTGCTACCTGACG
ACCGACCCCGACCCACTGGACAAGCACCCCAACCCCAATTCCCAAAATTGCGCATCCCTATCAGAGA
GGGGGAGGGGAAACAGGATGCGGCGAGGCGCGTGCGCACTGCCAGCTTCAGCACCGCGGACAGT
GCCTTCGCCCCCGCTGGCGGCGCGCGCCACCGCCGCTCAGCACTGAAGGCGCGCTGACGTCA
CTCGCCGGTCCCCCGCAAACTCCCTTCCCGGCCACCTTGGTCGCGTCCGCGCCGCGCCGCGCC
AGCCGGACCGCACCGAGGCGCGAGATAGGGGGGCACGGGCGCGACCATCTGCGCTGCGGC
GCCGGCGACTCAGCGCTGCCTCAGTCTGCGGTGGGCAGCGGAGGAGTCGTGTCTGTGCTGAGAGC
GCAGTCGAGAATCTAGAGCGCTGCCACCATGAAACGGACAGCCGACGGAAGCGAGTTCGAGTC
ACCAAAGAAGAAGCGGAAAGTCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACT
CTGTGGGCTGGGCCGTGATCACCGACGAGTACAAGGTGCCAGCAAGAAATTCAAGGTGCTGG
GCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTTCGACAGCGGC
GAAACAGCCGAGGCCACCCGGCTGAAGAGAACCAGCAGAGAAGAAGATACACCAGACGGAAGA
ACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCT
TCCACAGACTGGAAGAGTCCTTCTGCTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCT
TCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCACCCTATACCACCTGAGAA
AGAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCACA
TGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGG
ACAAGCTGTTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTTCGAGGAAAACCCCATCAACG
CCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAA
AATCTGATCGCCAGCTGCCCCGCGAGAAGAAGAATGGCCTGTTTCGGAACCTGATTGCCCTG
AGCCTGGGCTGACCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAG
CTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGCTGGCCAGATCGGCGACCACTGAG
GCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAGA
GTGAACACCGAGATCACCAGGCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCAC
CACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGA
GATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGA
AGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAGAAGATGGACGGCACCGAGGAAGTGCCTCGT

GAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCC
ACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCTT
GAAGGACAACCGGGAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCC
TCTGGCCAGGGGAAACAGCAGATTTCGCTGGATGACCAGAAAGAGCGAGGAAACCATCACCC
CCTGGAACCTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCAGAGCTTCATCGAGCGGATGA
CCAACCTTCGATAAGAACCTGCCCCAACGAGAAGGTGCTGCCCCAAGCACAGCCTGCTGTACGAGT
ACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCC
CCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAA
GTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCCTGTCTACGAGACA
GAGATCCTGACAGTGGAGTATGGCCTGCTGCCAATCGGCAAGATCGTGGAGAAGAGGATCGAGTGA
CCGTGTACTCTGTGGATAACAATGGCAACATCTATACACAGCCCGTGGCACAGTGGCACGATAGGGG
AGAGCAGGAGGTGTTTCGAGTATTGCCTGGAGGACGGCAGCCTGATCAGGGCAACCAAGGACCAAA
GTTTCATGACGTGGATGGCCAGATGCTGCCCATCGACGAGATTTTCGAGCGGGAGCTGGACCTGAT
GAGAGTGGATAACCTGCCTAATAGCGGAGGCAGTAAAAGAACAGCAGACGGGAGTGAGTTTGAGC
CCAAGAAAAAGAGAAAAGGTGGGATCCGGCGCAACAACTTCTCTCTGCTGAAACAAGCCGGAGA
TGTGGAAGAGAATCCTGGACCGGTGAGCAAGGGCGAGGAGCTGTTACCGGGGTGGTGGCCAT
CCTGGTTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGG
CGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCCGTGCC
TGGCCACCCCTCGTGACCACCTGACCTACGGCGTGAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCAGCACTTCTTCAAGTCCGCCATGCCCCAAGGCTACGTCCAGGAGCGCACCATCTT
CTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCTGGT
GAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTG
GAGTACAACCTACAACAGCCACAACGCTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGT
GAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGACGCTCGCCGACCACTACCAGCAG
AACACCCCATCGGGCAGCGCCCCGTGCTGCTGCCCCGACAACCACTACCTGAGCACCAGTCCG
CCCTGAGCAAAAGCCCCAACGAGAAGCGCGATCATGCTGCTGCTGAGTTCGTGACCCGCGC
CGGGTACACTCTCGGCATGGACGAGCTGTACAAGTCCGGACTCAGATCTCGAGAGGGAGGAG
GAGACAGACAGCAGGATGCCCCACCTCGACAGCCCCGGCAGCTCCCAGCCGAGACGCTCCTTCC
TCTCAAGGGTGATCAGGGCAGCGCTACCGTTGCAGCTGCTTCTGCTGCTGCTGCTGCTCCTGGC
CTGCCTGCTACCTGCCTCTGAAGATGACTACAGCTGCACCCAGGCCAACAACTTTGCCCGATCCT
TCTACCCCATGCTGCGGTACACCAACGGGGCACCTCCCACCTAAACGCGTTAAGTCGACAATCA
ACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAAGTATGTTGCTCCTTTTACGCT
ATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTTCATTTTCTCC
TCCTTGATATAAATCCTGGTTGCTGTCTCTTATGAGGAGTTGTGGCCCGTTGTGACGGCAACGTGG
CGTGGTGTGCACTGTGTTTGTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTGAG
CTCCTTTCCGGGACTTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAATCATCGCCGCTGCT
TGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTGTGCGGGGAA
ATCATCGTCCCTTTCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCTTCT
GCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCCTTCCCGCGGCCTGCTGCCGGCTCTGCG
GCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCTCCCCG
CGTCGACTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTTAAAAAGAAAA
GGGGGGACTGGAAGGGCTAATTCACCTCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGG
GTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTT
AAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCCGTCTGTTGTGTGACTCTG
GTAAGTAGAGATCCCTCAGACCCCTTTAGTCAGTGTGGAATAATCTCTAGCAGGGCCCGTTTAAA
CCCCGTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGGCCCTCCCCCGTG
CCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCTTTCCTAATAAAATGAGGAAATGCAATC
GCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGA
GGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGA
AAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGC
GGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCCGTCTTTC
GCTTTCTTCCCTTCTTCTCGCCACGTTCCCGGCTTTCCCGTCAAGCTCTAAATCGGGGGCT
CCCTTTAGGGTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAACTTGATTAGGGTGAT
GGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGT

TCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTT
GATTTATAAGGGATTTTGCCGATTTTCGGCCTATTGGTTAAAAAATGAGCTGATTAAACAAAAATT
TAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAG
CAGGCAGAAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAG
GCTCCCCAGCAGGCAGAAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGTATCCCGCC
CCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCGCGCCCATCTCCGCCCCATGGCTGAC
TAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCTGCCTCTGAGCTATTCCAGAAGTAGTGA
GGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCG
GATCTGATCAGCACGTGTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACAA
GGTGAGGAACTAAACCATGGCCAAGTTGACCAGTGCCGTTCCGGTGCTCACC CGCGCGGACGT
CGCCGGAGCGGTTCGAGTTCTGGACCGACCGGCTCGGGTTCTCCCGGGACTTCGTGGAGGACGA
CTTCGCCGGTGTGGTCCCGGACGACGTGACCCTGTTTCATCAGCGCGGTCCAGGACCAAGTGGT
GCCGACAAACACCTGGCCTGGGTGTGGGTGCGCGGCCTGGACGAGCTGTACGCCAGTAGTGT
CGGAGGTCGTGTCCACGAACCTCCGGGACGCCCTCCGGGCCGGCCATGACCGAGATCGGCGAGC
AGCCGTGGGGGCGGGAGTTTCGCCCTGCGCGACCCGGCCGGCAACTGCGTGCACCTTCGTGGCC
GAGGAGCAGGACTGACACGTGCTACGAGATTTTCGATTCCACCGCCGCCTTCTATGAAAGGTTG
GGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGG
AGTTCTTCGCCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATC
ACAAATTTACAAATAAAGCATTTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAA
TGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCT
GTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAG
TGTAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCG
CTTTCAGTCGGGAAACCTGTCTGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAG
GCGGTTTTCGTATTGGGCGCTCTTCCGCTTCTCGCTCACTGACTCGCTGCGCTCGGTCTGTTTCG
GCTGCGGCGAGCGGTATCAGTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGAT
AACAGGAAAGACATGTGAGCAAAAAGGCCAGCAAAAAGGCCAGGAACCGTAAAAAGGCCG
CGTTGCTGGCGTTTTTCCATAGGCTCCGCCCTTGACGAGCATCACAAAAATCGACGCTCAAG
TCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCT
CGTGCGCTCTCCTGTTCCGACCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAA
GCGTGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCCGGTGTAGGTCTGTTCCGCTCAAG
CTGGGCTGTGTGCACGAACCCCCCGTTACGCCGACCGCTGCGCCTTATCCGGTAACATATCGTC
TTGAGTCCAACCCGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTA
GCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACA
CTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGG
TAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTGTTGCAAGCAGCAG
ATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTC
AGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTA
GATCCTTTTAAATTAATAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGA
CAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGT
TGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCT
GCAATGATACCGCGAGACCCACGCTACCCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCG
GAAGGGCCGAGCGCAGAAAGTGGTCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTG
CCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTTCGCAACGTTGTTGCCATTGCTACA
GGCATCGTGGTGTACGCTCGTCGTTTGGTATGGCTTCATTACGCTCCGGTTCCTCAACGATCAA
GGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGT
TGTCAGAAGTAAGTTGGCCGAGTGTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTA
CTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGA
ATAGTGTATCGGGCGACCGAGTTGCTCTTGCCCGCGCTCAATACGGGATAATACCGCGCCACATA
GCAGAACTTTAAAAGTGCTCATCATTGGAACCGTTCTTCGGGGCGAAAACTCTCAAGGATCTT
ACCGCTGTTGAGATCCAGTTTCGATGTAACCCACTCGTGACCCAACTGATCTTCAGCATCTTTTA
CTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAGGGAATA
AGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAGCATTTATCAG
GGTTATTGTCATGAGCGGATACATATTGAATGTATTAGAAAAATAAACAATAGGGGTTTC
CGCGCACATTTCCCCGAAAAGTGCCACCTGAC (SEQ ID NO: 736)

U6promoter**PEgRNA***hSynpromoter*

N-termPE2

*N-termNpu***P2A-GFP-KASH***pLenti-hSyn-C-PE2-NpuC:*

GTGCACGGATCGGGAGATCTCCCGATCCCCTATGGTGCACCTCTCAGTACAATCTGCTCTGATGCC
 GCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCGAGCA
 AAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAG
 GCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTT
 ATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGGTTACATAAC
 TTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCCATTTGACGTCAATAATGAC
 GTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGT
 AAAGTGGCCACTTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAAT
 GACGGTAAATGGCCCGCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCA
 GTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTTGGCAGTACATCAATGGGCG
 TGGATAGCGGTTTGACTACGGGGATTTCCTAAGTCTCCACCCCATTTGACGTCAATGGGAGTTTG
 TTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCCATTGACGCAAA
 TGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGCGCGTTTTGCCTGTACTGGGTCTC
 TCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCC
 TCAATAAAGCTTGCCCTTGAGTGCTTCAAGTAGTGTGTGCGCGTCTGTTGTGTGACTCTGGTAAC
 TAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAATCTCTAGCAGTGGCGCCCGAACAGGG
 ACTTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCG
 CGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTACTAGCGGAGG
 CTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATG
 GGAAAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAATATAAATTAATAACATATAGTATGGGC
 AAGCAGGGAGCTAGAACGATTTCGAGTTAATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAG
 ACAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAAGCTTAGATCATTATAT
 AATACAGTAGCAACCCCTCTATTGTGTGCATCAAAGGATAGAGATAAAGACACCAAGGAAGCTT
 TAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAAGCGGCGCTGAT
 CTTACAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTA
 GTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGA
 AAAAGAGCAGTGGGAATAGGAGCTTTGTTCCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTAT
 GGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAG
 CAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGC
 ATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAGATACCTAAAGGATCAACAGCTCCTG
 GGGATTGGGGTTGCTCTGGAAAACCTATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGA
 GTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTA
 ACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATG
 AACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGG
 CTGTGGTATATAAATATTTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTGCT
 GTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTTATCGTTTCAGACCCACCTCCC
 AACCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGA
 GACAGATCCATTTCGATTAGTGAACGGATCGGCACTGCGTGCGCCAATTCTGCAGACAAATGGCA
 GTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGTACAGTGCAGGGGAAAGAATA
 GTAGACATAATAGCAACAGACATACAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAA
 ATTTTCGGGTTTATTACAGGGACAGCAGAGATCCAGTTTGGTTAATTAAGGTACCAAGTGCAGT
 GGGTTTTAGGACCAGGATGAGGCGGGGTGGGGGTGCCTACCTGACGACCGACCCCGACCCACT
 GGACAAGCACCCAACCCCATTCCTCCAAATTGCGCATCCCCTATCAGAGAGGGGGGAGGGGAAA
 CAGGATGCGGCGAGGCGCGTGCACACTGCCAGCTTCAGCACCGCGGACAGTGCCTTCGCCCCC
 GCCTGGCGGCGCGCGCCACCGCCGCTCAGCACTGAAGGCGCGCTGACGTCACTCGCCGGTCC

CCCGCAAACCTCCCCTTCCCGGCCACCTTGGTCGCGTCCGCGCCGCGCCGCGGCCAGCCGGACC
GCACCACGCGAGGCGCGAGATAGGGGGGACGCGCGGACCATCTGCGCTGCGGCGCCGCGG
ACTCAGCGCTGCCTCAGTCTGCGGTGGGCAGCGGAGGAGTCGTGTCGTGCCTGAGAGCGCAGT
CGAGAATCTAGAGCGCTGCCACCATGAAACGGACAGCCGACGGAAGCGAGTTTCAGTACCAAAGA
AGAAGCGGAAAGTCATCAAGATTGCTACACGGAAATACCTGGGAAAGCAGAACGTGTACGACATCGG
CGTGGAGCGGGATCAAACTTCGCCCTGAAGAATGGCTTTATCGCCAGCAATTGCTTCGACTCCG
TGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGC
TGAAAATTATCAAGGACAAGGACTTCTGGACAATGAGGAAAAAGAGGACATTCCTGGAA
GATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAA
AACCTATGCCCACCTGTTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACA
CCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGG
CAAGACAATCCTGGATTCTCTGAAGTCCGACGGCTTCGCCAACAGAACTTCATCGAGCT
GATCCACGACGACAGCCTGACCTTTAAGAGGACATCCAGAAAGCCAGGTGTCCGGCC
AGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAG
GGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGGCACA
AGCCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAG
AAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCC
AGATCCTGAAAGAACACCCCGTGGAAGAACACCCAGCTGCAGAACGAGAAGCTGTACCTG
TACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTG
TCCGACTACGATGTGGACCATATCGTGCTCAGAGCTTTCTGAAGGACGACTCCATCGAC
AACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCG
AAGAGGTGCTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATT
ACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGGCGCCTGAGCGAACTGG
ATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCAAAAGCACGTG
GCAAGATCTGGACTCCCGGATGAACATAAGTACGACGAGAATGACAAGCTGATCCG
GGAAGTGAAAGTATCACCTGAAGTCCAAGCTGGTGTCCGATTTCGGGAAGGATTTC
AGTTTTACAAAGTGCGCGAGATCAACAATAACCACCGCCACGACGCTACCTGAACG
CCGTGCTGGGAAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTAC
GGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGG
CAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGAT
TACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCG
GGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATG
CCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTC
TATCCTGCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCTA
AGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAA
GTGGAAGAGGGCAAGTCCAAGAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCAT
CATGGAAGAAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACA
AAGAAGTGAAGAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTTCGAGCTGGAAG
ACGGCCGGAAGAGAAATGCTGGCCTCTGCGGCGAACTGCAGAAGGGAAACGAACTGGC
CCTGCCCTCCAAATATGTGAACTTCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGG
CTCCCCCGAGGATAATGAGCAGAAACAGCTGTTGTGGAACAGCACAAGCACTACCTGG
ACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATC
TGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCC
GAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCGGCCTTCAAGTAC
TTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCAC
CCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGG
GAGGTGACTCTGGCGGCTCAAAAAGAACCGCCGACGGCAGCGAATTTCGAGCCCAAGAA
GAAGAGGAAAGTCTAAACGCGTTAAGTCGACAATCAACCTCTGGATTACAAAATTTGTGAAA
GATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTAAATGCCCTT
GTATCATGCTATTGCTTCCCGTATGGCTTTTCAATTTCTCCTCCTTGATAAATCCTGGTTGCTGTCT
CTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACG
CAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTTCGCTTTCCC
CCTCCCTATTGCCACGGCGGAACATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGG
CTGTTGGGCACTGACAATTCCGTGGTGTGTGCGGGGAAATCATCGTCCTTTTCTTGGCTGCTCG

CCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCC
AGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGC
CCTCAGACGAGTCGGATCTCCCTTTGGGCGCCTCCCCGCGTCGACTTTAAGACCAATGACTTA
CAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCA
CTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGA
GCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAG
TGCTTCAAGTAGTGTGTGCCCCGCTGTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCCTT
TTAGTCAGTGTGGAATACTCTAGCAGGGCCCCGTTTAAACCCGCTGATCAGCCTCGACTGTGCC
TTCTAGTTGCCAGCCATCTGTTGTTTGCCCCCTCCCCCGTGCTTTCCTTGACCCTGGAAGGTGCCA
CTCCCACTGTCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCTATTCT
ATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCA
TGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGG
GTATCCCAACGCGCCCTGTAGCGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGT
GACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCTTTTCGCTTTCTTCCCTTCTTCTCGCCA
CGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTAGTGCT
TTACGGCACCTCGACCCCAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCT
GATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAA
ACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTGATTATAAGGGATTTGCCGATTTCG
GCCTATTGGTTAAAAAATGAGCTGATTAAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTG
TGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAAGTATGCAAAGCATGCAT
CTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAAAGTATGCAA
AGCATGCATCTCAATTAGTCAGCAACCATAAGTCCCGCCCCTAACCTCCGCCCATCCCGCCCCCTAAC
TCCGCCCAGTTCGCCCCATTCTCCGCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCG
AGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTT
TTGCAAAAAGCTCCCGGGAGCTTGATATCCATTTTCGGATCTGATCAGCACGTGTTGACAATTA
ATCATCGGCATATATCGGCATAGTATAATACGACAAGGTGAGGAATAAACCATGGCCAAAGT
TGACCAAGTGCCGTTCCCGGTGCTACCGCGCGCGACGTGCGCGGAGCGGTCTGAGTTCTGGACCG
ACCGGCTCGGGTTCTCCCGGGACTTCGTGGAGGACGACTTCGCCGGTGTGGTCCGGGACGACG
TGACCCTGTTTCATCAGCGCGGTCCAGGACCAGGTGGTGCCGGACAACACCCTGGCCTGGGTGT
GGGTGCGCGCCTGGACGAGCTGTACGCCGAGTGGTTCGGAGGTCGTGTCCACGAACCTCCGG
GACGCCTCCGGGCCGGCCATGACCGAGATCGGCGAGCAGCCGTGGGGGCGGGAGTTCGCCCT
GCGCGACCCGCGCCGGAACCTGCGTGCACCTTCGTGGCCGAGGAGCAGGACTGACACGTGCTAC
GAGATTTGATTCACCGCCGCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGC
CGGCTGGATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTT
ATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTACAAATAAAGCATTTTT
TTCAGTGCATTCTAGTTGTGGTTTGTCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTC
GACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGC
TCACAATTCACACAACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCCTAATGAG
TGAGCTAACTACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTG
CCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCC
GCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCTCGGCTGCGGCGAGCGGTATCAGCTCACT
CAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAA
AAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCC
GCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGA
CTATAAAGATAACAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCCTCTCTGTTCCGACCCTGC
CGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGC
TGTAGGTATCTCAGTTCCGTGTAGGTGCTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCG
TTCAGCCCGACCGCTGCGCCTTATCCGGTAACATATCGTCTTGAGTCCAACCCGGTAAGACACGA
CTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCT
ACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCG
CTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCA
CCGCTGGTAGCGGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTC
AAGAAGATCCTTTGATCTTTTCTACGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGG
GATTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAATAAATGAAGTT

TTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAG
 GCACCTATCTCAGCGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATA
 ACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCT
 CACCGGCTCCAGATTTATCAGCAATAAACAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTC
 CTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTTCG
 CCAGTTAATAGTTTGGCGAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCTCGTCGTT
 TGGTATGGCTTCATTCAGCTCCGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGT
 GCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTCAGAAAGTAAGTTGGCCGCAGTGTT
 ATCACTCATGGTTATGGCAGCACTGCATAATTCTTACTGTATGCCATCCGTAAGATGCTTTTC
 TGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCT
 TGCCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTG
 GAAAACGTTCTTCGGGGCGAAAACCTCTCAAGGATCTTACCCTGTTGAGATCCAGTTCGATGTA
 ACCCACTCGTGCACCCCACTGATCTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGAGCA
 AAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACT
 CATACTCTTCTTTTCAATATTATTGAAGCATTATCAGGGTTATTGTCTCATGAGCGGATACAT
 ATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCGCGCACATTTCCCCGAAAAGTG
 CCACCTGAC (SEQ ID NO: 737)

hSynpromoter

C-termNpu

C-termwtCas9

pLenti-U6-DNMT1_nicking_sgRNA:

TAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGA
 ATAGTTTTTGTCTGACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAG
 ACCCACCTCCCAACCCCGAGGGGACCCAGAGAGGGGCTATTTCCCATGATTCTTCATATTTGCAT
 ATACGATACAAGGCTGTTAGAGAGATAATTAGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAA
 TACGTGACGTAGAAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTAAAATTATGTTTTAAATGGACTATC
 ATATGCTTACCGTAACTTGAAAGTATTTGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACAC
 CGCCGCGCGCGCGAAAAAGCCGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGT
 TATCAACTTGAAAAAGTGGCACCGAGTCGGTGTCTTTTAAAGCTTGGCGTAAGTAGATCTTGAGA
 CAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGG
 GAAAGAATAGTAGACATAATAGCAACAGACATACAACTAAAGAATTACAAAAACAAATTACA
 AAAATTCAAAATTTTCGGGTTTATTACAGGGACAGCAGAGATCCACTTTGGCGCCGGCTCGAGG
 GGGCCCGGGTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTCAGCTAATGGACCT
 TCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGC
 CCACAGTCCCCGAGAAGTTGGGGGGAGGGGTGCGCAATTGATCCGGTGCCTAGAGAAGGTGG
 CGCGGGGTAAACTGGGAAAGTGATGTCGTGTAAGTGGCTCCGCCTTTTTCCCGAGGGTGGGGGA
 GAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTCGCAACGGGTTTGCCGCCAGAA
 CACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTACGGGTTATGGCCCTTGCGT
 GCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGT
 GGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCTTCGCCTCGTGCTTGAGTTGAGGCC
 TGGCCTGGGCGCTGGGGCCGCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTT
 TCGATAAGTCTCTAGCCATTTAAATTTTTGATGACCTGCTGCGACGCTTTTTTCTGGCAAGAT
 AGTCTTGTAATGCGGGCCAAGATCTGCACACTGGTATTTTCGGTTTTTGGGGCCGCGGGCGGCG
 ACGGGGCCCCGTGCGTCCAGCGCACATGTTCCGGCAGGCGGGGCTGCGAGCGCGGCCACCG
 AGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCG
 TGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCCGTGCGCACCAAGTTGCGTGAGCGGAAAGA
 TGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCG
 GGCGGGTGAGTACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGA
 CTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCTG
 TCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTG
 AAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGATCT
 TGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCTGTACG
 TACGGCCACCATGACCGAGTACAAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAG

GGCCGTACGCACCCTCGCCGCCGCGTTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCC
GGACCGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGA
CATCGGCAAGGTGTGGGTCGCGGACGACGGCGCCGCGTGGCGGTCTGGACCACGCCGGAGA
GCGTCAAGCGGGGGCGGTGTTCCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCC
GGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGACCCGGCCCAAGGAGCCCGCG
TGGTTCCTGGCCACCGTCGGAGTCTCGCCCCGACCACAGGGCAAGGGTCTGGGCAGCGCCGTC
GTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCGCCTTCCTGGAGACCTCCGC
GCCCCGCAACCTCCCCCTTCTACGAGCGGGCTCGGCTTCACCGTCACCGCCGACGTGCGAGGTGCC
CGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGAACGCGTTAAGTCGACA
ATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACATATGTTGCTCCTTTTA
CGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTT
CTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTGAGGCAAC
GTGGCGTGGTGTGCTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACT
GTCAGTCTCTTTCCGGGACTTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACATCGCCGCC
TGCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTGTGCG
GGGAAATCATGCTCCTTTTCCTTGGCTGCTCGCTGTGTTGCCACCTGGATTCTGCGCGGGACGT
CCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGC
TCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCC
TCCCCGCGTCGACTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTAAA
AGAAAAGGGGGGACTGGAAGGGCTAATTAACCTCCCAACGAAGACAAGATCTGCTTTTGTGTTG
TACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCA
CTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCCGTCTGTTGTGTG
ACTCTGGTAACTAGAGATCCCTCAGACCCTTTATGTCAGTGTGGAATACTCTAGCAGTACGTAT
AGTAGTTCATGTCATCTTATTATTAGTATTTATAAAGTGAAGCAATAGCATCACAAATTCACAAA
TAAAGACTTTTTCATGCTAGTCTAGTTGTGTTTGTCCAACTCATCAATGTATCTTATCATGT
CTGGCTCTAGCTATCCCGCCCTAATCCGCCCCATCCCGCCCCTAATCCGCCCCAGTTCGCCCCA
TTCTCCGCCCCATGGCTGACTAATTTTTTTTATTATGAGAGGCCGAGGCCGCTCGGCCTCTG
AGCTATTCAGAAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGGACGTACCCAATTCGCCCTAT
AGTGAGTCGTATTACGCGCGCTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCTG
GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGA
GGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGGACGCGCCCTG
TAGCGGCGCATTAAAGCGCGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAG
CGCCCTAGCGCCCCGCTCCTTTCGCTTTCTTCCCTTCTTTCTCGCCACGTTCCGCCGCTTTCCCC
GTCAAGCTCTAAATCGGGGGGCTCCCTTTAGGGTTCGATTTAGTGCTTTACGGCACCTCGACCC
CAAAAAAATTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGC
CCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACCTGGAACAACACTCA
ACCCATCTCGGTCTATTCTTTGATTATAAGGGATTTTGCCGATTTCCGCCTATTGGTTAAAAA
ATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTAGGTG
GCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTCTAAATACATTCAAATATGT
ATCCGCTCATGAGACAATAACCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGT
ATTCAACATTTCCGTGTCGCCCTTATCCCTTTTTTTCGGCATTTTGCCTTCCTGTTTTGCTCAC
CCAGAAACGCTGGTGAAAGTAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACATC
GAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGA
TGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCA
ACTCGGTGCGCCGATACACTATTCTCAGAATGACTTGGTTGAGTACTACCAGTCACAGAAAAG
CATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACA
CTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGACA
ACATGGGGGATCATGTAACCTGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAA
CGACGAGCGTGACACCAGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAAGTGG
CGAACTACTTACTCTAGCTTCCCGGCAACAATTAAGACTGGATGGAGGCGGATAAAGTTGCA
GGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTG
AGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGT
TATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGT

GCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTA
 AAACCTTCATTTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATC
 CCTTAACGTGAGTTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTT
 GAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAACACCGCTACCAGCGGT
 GGTTTGTGTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAAGTGGCTTCAGCAGAGCG
 CAGATACCAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAAGTCTGTAGC
 ACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGT
 GTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCCGGGCTGAACGG
 GGGGTTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGC
 GTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGC
 GGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGAAACGCCTGGTATCTTTA
 TAGTCTGTGCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTACGGGGG
 CGGAGCCTATGGAAAAACGCCAGCAACGCGGCCCTTTTACGGTTCCTGGCCTTTTGTGCTGGCCTT
 TTGCTCACATGTTCTTCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGT
 GAGCTGATACCGCTCGCCGACGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCG
 GAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCAATATGCAGCTGGC
 ACGACAGGTTTCCCGACTGGAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCA
 CTCATTAGGCACCCCAAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGC
 GGATAACAATTTACACAGGAAACAGCTATGACCATGATTACGCCAAGCGCGCAATTAACCCCTC
 ACTAAAGGGAACAAAAGCTGGAGCTGCAAGCTTAATGTAGTCTTATGCAATACTCTTGAGTCT
 TGCAACATGGTAACGATGAGTTAGCAACATGCCTTACAAGGAGAGAAAAAGCACCGTGCATGC
 CGATTGGTGGAAGTAAGGTGGTACGATCGTGCCTTATTAGGAAGGCAACAGACGGGTCTGACAT
 GGATTGGACGAACCACTGAATTGCCGCAATTGCAGAGATATTGTATTTAAGTGCCTAGCTCGATAC
 ATAAACGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACC
 CACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTG
 TGACTCTGGTAAGTACTAGAGATCCCTCAGACCCCTTTAGTCAGTGTGAAAAATCTCTAGCAGTGGC
 GCCCGAAGAGGACTTGAAAGCGAAAGGGAAACCAAGAGGAGCTCTCTCGACGCAGGACTCGG
 CTTGCTGAAGCGCGCACGGCAAGAGGGCAGGGGCGCGACTGGTGAGTACGCCAAAAATTTT
 GACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGAGAA
 TTAGATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGAAAGAAAAAATATAAATTAAC
 ATATAGTATGGGCAAGCAGGGAGCTAGAACGATTGCGAGTTAATCCTGGCCTGTTAGAAACATC
 AGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACT
 TAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAAGACA
 CCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAA
 GCGGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATAT
 AAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTG
 GTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCTTGGGTTCTTGGGAGCAGC
 AGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGG
 TATAGTGCAGCAGCAGAACAAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTC
 ACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGAT
 CAACAGCTCCTGGGGATTGTTGGGGTTGCTCTGGAAACTCATTTGCACCACTGCTGTGCCTTGA
 ATGCTAGTTGGAGTAATAATCTCTGGAACAGATTGGAATCACACGACCTGGATGGAGTGGGA
 CAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGAAAACAGCAA
 GAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAA
 CA (SEQ ID NO: 738)

U6promoter

sgRNA

[1226] Amino acid sequences of Maloney murine leukemia virus reverse transcriptase (M-MLV RT) variants used herein.

PEI M-MLV RT:

TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLKATSTPVSİKQY
PMSQEARLGİKPHİQRLLDQGİLVPCQSPWNTPLLVPKKPGTNDYRPVQDLREVΝKRVEDİHP
TVPNPYNLLSGLPPSHQWYTVLDLKDİAFFCLRLHPTSQPLFAFEWRDPEMGİSGQLTWTRLQP
GFKNSPTLFDEALHRDLADFRIQHPDLİLLQYVDDİLLAATSELDCQQGTRALLQTLGNLGYR
ASAKKAQİCQKQVKYLGİYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGİTAGFCRLWİP
GFAEMAAPLYPLTKTGLFNWGPDQQKAYQEKİQALLTAPALGLPDLTKPFELFVDEKQGYAK
GVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAİAVLTKDAGKLTMGQPLVİLAPHAV
EALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCİLDİLAE
HGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVİWAKALPAGTSAQRAELİ
ALTQALKMAEGKKLNVTDSRYAFATAHİHGİEYRRRGİLLTSEGKEİKNKDEİLALLKALFLP
KRLSİİHCİPGHQKGHSİEARGNRMADQAARKAİTETPDTSTLLİENSİP (SEQ ID NO: 739)

M3 M-MLV RT (D200N, T330P, L603W) (see Baranauskas et al.¹⁸²):

TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLKATSTPVSİKQY
PMSQEARLGİKPHİQRLLDQGİLVPCQSPWNTPLLVPKKPGTNDYRPVQDLREVΝKRVEDİHP
TVPNPYNLLSGLPPSHQWYTVLDLKDİAFFCLRLHPTSQPLFAFEWRDPEMGİSGQLTWTRLQP
GFKNSPTLFNEALHRDLADFRIQHPDLİLLQYVDDİLLAATSELDCQQGTRALLQTLGNLGYR
ASAKKAQİCQKQVKYLGİYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGİTAGFCRLWİP
GFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEKİQALLTAPALGLPDLTKPFELFVDEKQGYAK
GVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAİAVLTKDAGKLTMGQPLVİLAPHAV
EALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCİLDİLAE
HGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVİWAKALPAGTSAQRAELİ
ALTQALKMAEGKKLNVTDSRYAFATAHİHGİEYRRRGWLTSEGKEİKNKDEİLALLKALFLP
KRLSİİHCİPGHQKGHSİEARGNRMADQAARKAİTETPDTSTLLİENSİP (SEQ ID NO: 740)

PE2 M-MLV RT (D200N, T306K, W313F, T330P, L603W):

TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLKATSTPVSİKQY
PMSQEARLGİKPHİQRLLDQGİLVPCQSPWNTPLLVPKKPGTNDYRPVQDLREVΝKRVEDİHP
TVPNPYNLLSGLPPSHQWYTVLDLKDİAFFCLRLHPTSQPLFAFEWRDPEMGİSGQLTWTRLQP
GFKNSPTLFNEALHRDLADFRIQHPDLİLLQYVDDİLLAATSELDCQQGTRALLQTLGNLGYR
ASAKKAQİCQKQVKYLGİYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGİTAGFCRLFİP
GFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEKİQALLTAPALGLPDLTKPFELFVDEKQGYAK
GVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAİAVLTKDAGKLTMGQPLVİLAPHAV
EALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCİLDİLAE
HGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVİWAKALPAGTSAQRAELİ
ALTQALKMAEGKKLNVTDSRYAFATAHİHGİEYRRRGWLTSEGKEİKNKDEİLALLKALFLP
KRLSİİHCİPGHQKGHSİEARGNRMADQAARKAİTETPDTSTLLİENSİP (SEQ ID NO: 741)

M3-deadRT M-MLV RT:

TLNIEDEYRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIPLKATSTPVSİKQY
PMSQEARLGİKPHİQRLLDQGİLVPCQSPWNTPLLVPKLPGTNDYSPVQDLREVΝKRVEDİHP
TVPNPYNLLSGLPPSHQWYTVLDLKDİAFFCLRLHPTSQPLFAFEWRDPEMGİSGQLTWTRLQP
GFKNSPTLFNEALHRDLADFRIQHPDLİLLQYVDDİLLAATSELDCQQGTRALLQTLGNLGYR
ASAKKAQİCQKQVKYLGİYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGİTAGFCRLWİP
GFAEMAAPLYPLTKPGTLFNWGPDQQKAYQEKİQALLTAPALGLPDLTKPFELFVDEKQGYAK
GVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAİAVLTKDAGKLTMGQPLVİLAPHAV
EALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCİLDİLAE
HGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVİWAKALPAGTSAQRAELİ
ALTQALKMAEGKKLNVTDSRYAFATAHİHGİEYRRRGWLTSEGKEİKNKDEİLALLKALFLP
KRLSİİHCİPGHQKGHSİEARGNRMADQAARKAİTETPDTSTLLİENSİP (SEQ ID NO: 742)

References for Example 2

[1227] Each of the following references are cited in Example 12, each of which are incorporated herein by reference.

1. Landrum, M. J. *et al.* ClinVar: public archive of interpretations of clinically relevant variants. *Nucleic Acids Res.* **44**, D862–D868 (2016).
2. Jinek, M. *et al.* A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity. *Science* **337**, 816–821 (2012).
3. Cong, L. *et al.* Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science* **339**, 819– 823 (2013).
4. Mali, P. *et al.* RNA-Guided Human Genome Engineering via Cas9. *Science* **339**, 823–826 (2013).
5. Yang, H. *et al.* One-Step Generation of Mice Carrying Reporter and Conditional Alleles by CRISPR/Cas-Mediated Genome Engineering. *Cell* **154**, 1370–1379 (2013).
6. Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J.-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. *Genome Res.* **24**, 1012–1019 (2014).
7. Orlando, S. J. *et al.* Zinc-finger nuclease-driven targeted integration into mammalian genomes using donors with limited chromosomal homology. *Nucleic Acids Res.* **38**, e152–e152 (2010).
8. Tsai, S. Q. *et al.* GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPRCas nucleases. *Nat. Biotechnol.* **33**, 187–197 (2015).
9. Suzuki, K. *et al.* *In vivo* genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. *Nature* **540**, 144–149 (2016).
10. Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. *Nat. Biotechnol.* **36**, 765–771 (2018).
11. Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response. *Nat. Med.* **24**, 927–930 (2018).
12. Ihry, R. J. *et al.* p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. *Nat. Med.* **24**, 939–946 (2018).
13. Rouet, P., Smih, F. & Jasin, M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. *Proc. Natl. Acad. Sci.* **91**, 6064–6068 (1994).
14. Chapman, J. R., Taylor, M. R. G. & Boulton, S. J. Playing the end game: DNA double-strand break repair pathway choice. *Mol. Cell* **47**, 497–510 (2012).
15. Cox, D. B. T., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. *Nat. Med.* **21**, 121–131 (2015).
16. Paquet, D. *et al.* Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. *Nature* **533**, 125–129 (2016).
17. Chu, V. T. *et al.* Increasing the efficiency of homology-directed repair for CRISPR–Cas9-induced precise gene editing in mammalian cells. *Nat. Biotechnol.* **33**, 543–548 (2015).
18. Maruyama, T. *et al.* Increasing the efficiency of precise genome editing with CRISPR–Cas9 by inhibition of nonhomologous end joining. *Nat. Biotechnol.* **33**, 538–542 (2015).
19. Rees, H. A., Yeh, W.-H. & Liu, D. R. Development of hRad51–Cas9 nickase fusions that mediate HDR without double-stranded breaks. *Nat. Commun.* **10**, 1–12 (2019).
20. Shen, M. W. *et al.* Predictable and precise template-free CRISPR editing of pathogenic variants. *Nature* **563**, 646–651 (2018).
21. Rees, H. A. & Liu, D. R. Base editing: precision chemistry on the genome and transcriptome of living cells. *Nat. Rev. Genet.* **19**, 770 (2018).

22. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* **533**, 420–424 (2016).
23. Gaudelli, N. M. *et al.* Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature* **551**, 464–471 (2017).
24. Gao, X. *et al.* Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. *Nature* **553**, 217–221 (2018).
25. Ingram, V. M. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. *Nature* **178**, 792–794 (1956).
26. Myerowitz, R. & Costigan, F. C. The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. *J. Biol. Chem.* **263**, 18587–18589 (1988).
27. Zielenski, J. Genotype and Phenotype in Cystic Fibrosis. *Respiration* **67**, 117–133 (2000).
28. Mead, S. *et al.* A Novel Protective Prion Protein Variant that Colocalizes with Kuru Exposure. *N. Engl. J. Med.* **361**, 2056–2065 (2009).
29. Marraffini, L. A. & Sontheimer, E. J. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. *Science* **322**, 1843–1845 (2008).
30. Barrangou, R. *et al.* CRISPR provides acquired resistance against viruses in prokaryotes. *Science* **315**, 1709–1712 (2007).
31. Jiang, F. & Doudna, J. A. CRISPR–Cas9 Structures and Mechanisms. *Annu. Rev. Biophys.* **46**, 505–529 (2017).
32. Hille, F. *et al.* The Biology of CRISPR-Cas: Backward and Forward. *Cell* **172**, 1239–1259 (2018).
33. Luan, D. D., Korman, M. H., Jakubczak, J. L. & Eickbush, T. H. Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non-LTR retrotransposition. *Cell* **72**, 595–605 (1993).
34. Liu, Y., Kao, H.-I. & Bambara, R. A. Flap endonuclease 1: a central component of DNA metabolism. *Annu. Rev. Biochem.* **73**, 589–615 (2004).
35. Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. & Corn, J. E. Enhancing homology directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. *Nat. Biotechnol.* **34**, 339–344 (2016).
36. Qi, L. S. *et al.* Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. *Cell* **152**, 1173–1183 (2013).
37. Shechner, D. M., Hacisuleyman, E., Younger, S. T. & Rinn, J. L. Multiplexable, locus-specific targeting of long RNAs with CRISPR-Display. *Nat. Methods* **12**, 664–670 (2015).
38. Tang, W., Hu, J. H. & Liu, D. R. Aptazyme-embedded guide RNAs enable ligand-responsive genome editing and transcriptional activation. *Nat. Commun.* **8**, 15939 (2017).
39. Jinek, M. *et al.* Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. *Science* **343**, 1247997 (2014).
40. Nishimasu, H. *et al.* Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA. *Cell* **156**, 935–949 (2014).
41. Jiang, F., Zhou, K., Ma, L., Gressel, S. & Doudna, J. A. A Cas9–guide RNA complex preorganized for target DNA recognition. *Science* **348**, 1477–1481 (2015).
42. Baranauskas, A. *et al.* Generation and characterization of new highly thermostable and processive M-MuLV reverse transcriptase variants. *Protein Eng. Des. Sel.* **25**, 657–668 (2012).

43. Gerard, G. F. *et al.* The role of template-primer in protection of reverse transcriptase from thermal inactivation. *Nucleic Acids Res.* **30**, 3118–3129 (2002).
44. Arezi, B. & Hogrefe, H. Novel mutations in Moloney Murine Leukemia Virus reverse transcriptase increase thermostability through tighter binding to template-primer. *Nucleic Acids Res.* **37**, 473–481 (2009).
45. Kotewicz, M. L., Sampson, C. M., D'Alessio, J. M. & Gerard, G. F. Isolation of cloned Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity. *Nucleic Acids Res.* **16**, 265–277 (1988).
46. Thuronyi, B. W. *et al.* Continuous evolution of base editors with expanded target compatibility and improved activity. *Nat. Biotechnol.* (2019). doi:10.1038/s41587-019-0193-0
47. Kim, Y. B. *et al.* Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. *Nat. Biotechnol.* **35**, 371–376 (2017).
48. Koblan, L. W. *et al.* Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. *Nat. Biotechnol.* (2018). doi:10.1038/nbt.4172
49. Kleinstiver, B. P. *et al.* High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off target effects. *Nature* **529**, 490–495 (2016).
50. Zuo, E. *et al.* Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. *Science* **364**, 289–292 (2019).
51. Jin, S. *et al.* Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. *Science* **364**, 292–295 (2019).
52. Kim, D., Kim, D., Lee, G., Cho, S.-I. & Kim, J.-S. Genome-wide target specificity of CRISPR RNA guided adenine base editors. *Nat. Biotechnol.* **37**, 430–435 (2019).
53. Grunewald, J. *et al.* Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. *Nature* **569**, 433–437 (2019).
54. Zhou, C. *et al.* Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. *Nature* **571**, 275–278 (2019).
55. Rees, H. A., Wilson, C., Doman, J. L. & Liu, D. R. Analysis and minimization of cellular RNA editing by DNA adenine base editors. *Sci. Adv.* **5**, eaax5717 (2019).
56. Ostertag, E. M. & Kazazian Jr, H. H. Biology of Mammalian L1 Retrotransposons. *Annu. Rev. Genet.* **35**, 501–538 (2001).
57. Griffiths, D. J. Endogenous retroviruses in the human genome sequence. *Genome Biol.* **2**, REVIEWS1017 (2001).
58. Berkhout, B., Jebbink, M. & Zsiros, J. Identification of an Active Reverse Transcriptase Enzyme Encoded by a Human Endogenous HERV-K Retrovirus. *J. Virol.* **73**, 2365–2375 (1999).
59. Halvas, E. K., Svarovskaia, E. S. & Pathak, V. K. Role of Murine Leukemia Virus Reverse Transcriptase Deoxyribonucleoside Triphosphate-Binding Site in Retroviral Replication and In Vivo Fidelity. *J. Virol.* **74**, 10349–10358 (2000).
60. Dever, D. P. *et al.* CRISPR/Cas9 Beta-globin Gene Targeting in Human Hematopoietic Stem Cells. *Nature* **539**, 384–389 (2016).
61. Park, S. H. *et al.* Highly efficient editing of the β -globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. *Nucleic Acids Res.* doi:10.1093/nar/gkz475
62. Collinge, J. Prion diseases of humans and animals: their causes and molecular basis. *Annu. Rev. Neurosci.* **24**, 519–550 (2001).
63. Asante, E. A. *et al.* A naturally occurring variant of the human prion protein completely prevents prion disease. *Nature* **522**, 478–481 (2015).

64. Zettler, J., Schutz, V. & Mootz, H. D. The naturally split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans-splicing reaction. *FEBS Lett.* **583**, 909–914 (2009).
65. Kugler, S., Kilic, E. & Bahr, M. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. *Gene Ther.* **10**, 337–347 (2003).
66. de Felipe, P., Hughes, L. E., Ryan, M. D. & Brown, J. D. Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide. *J. Biol. Chem.* **278**, 11441–11448 (2003).

1. Establish guide RNA-templated reverse transcription of mutagenic DNA strands.

Background and rationale

[1228] In the proposed genome editing strategy, the Cas9-nicked non-target DNA strand (PAM-containing strand that forms the R-loop) acts as the primer for DNA synthesis. It is hypothesized that this is possible based on several pieces of biochemical and structural data. Nuclease protection experiments³², crystallographic studies³³, and base editing windows^{4,24} have demonstrated a large degree of flexibility and disorder for the non-target strand nucleotides -20 through -10 within the so-called R-loop of the Cas9-bound complex (numbering indicates distance 5' from first PAM nucleotide). Moreover, the PAM-distal portion of the cleaved non-target strand can be displaced from tightly bound ternary complexes when complementary ssDNA is added in trans²⁰. These studies support that the non-target strand is highly flexible, is accessible to enzymes, and that after nicking, the 3' terminus of the PAM-distal fragment is released prior to Cas9 dissociation. Furthermore, it is hypothesized that gRNAs can be extended to template DNA synthesis. Prior studies have shown that gRNAs for SpCas9, SaCas9, and LbCas12a (formerly Cpf1) tolerate gRNA extensions with RNA aptamers³⁴, ligand-inducible self-cleaving ribozymes³⁵, and long non-coding RNAs³⁶. This literature establishes precedent for two major features that will be exploited. In assessing this strategy, several CRISPR-Cas systems will be evaluated in conjunction with 5' and 3' extended gRNA designs using a combination of *in vitro* and cellular assays (FIGs. 2A-2C).

[1229] Designs for engineered gRNAs for TRT editing are shown in FIGs. 3A-3B. DNA synthesis proceeds 5' to 3', and thus copies the RNA template in the 3' to 5' direction. The design for the 5' extension contains a linker region, a primer binding site where the nicked DNA strand anneals, and a template for DNA synthesis by reverse transcription. The 3' extended gRNA contains a primer binding site and a reverse transcription template. In some cases, the 3' RNA hairpin of the gRNA core is modified to match the DNA target sequence, as *in vitro* experiments showed that reverse transcription extends ~3 nucleotides into the gRNA core for the 3' extended gRNA constructs (modification of the hairpin sequence appears well tolerated so long as compensatory changes are made that maintain the hairpin RNA structure). DNA synthesis proceed 5' to 3', with nucleotides added to the 3' OH of the growing DNA strand.

Preliminary results

[1230] Cas9 nicked DNA primes reverse transcription of gRNA templates. To evaluate the accessibility of the nicked non-target DNA strand, *in vitro* biochemical assays were performed using the Cas9 nuclease from *S. pyogenes* (SpCas9) and Cy5 fluorescently labeled duplex DNA substrates (51 base pairs). First, a series of gRNAs containing 5' extensions with varying synthesis template lengths were prepared by *in vitro* transcription (overall design shown in FIG. 2B). Electrophoretic mobility shift assays (EMSA) with nuclease dead Cas9 (dCas9) established that 5' extended gRNAs maintain target binding affinity (data not shown). Next, TPRT activity was tested on pre-nicked Cy5-labeled duplex DNA substrates using dCas9, 5'-extended gRNAs, and Molony-Murine Leukemia Virus (M-MLV) reverse transcriptase (Superscript III). After 1 hour of incubation at 37 °C, products were evaluated by denaturing polyacrylamide gel electrophoresis (PAGE) and imaged using Cy5 fluorescence (FIG. 4A). Each 5'-extended gRNA variant led to significant product formation, with the observed DNA product sizes being consistent with the length of the extension template (FIG. 4B). Importantly, in the absence of dCas9, pre-nicked substrates were extended to the full 51-bp length of the DNA substrate, strongly suggesting that the complementary DNA strand, and not the gRNA, was used as the template for DNA synthesis when dCas9 was not present (FIG. 4C). Of note, the system was designed such that the newly synthesized DNA strand mirrors the product that would be required for target site editing (a homologous strand with a single nucleotide change). This result establishes that Cas9:gRNA binding exposes the nicked non-target strand's 3' end, and that the non-target strand is accessible to reverse transcription.

[1231] Next, non-nicked dsDNA substrates were evaluated using the Cas9(H840A) mutant, which nicks the non-target DNA strand. First, to test Cas9(H840A) nickase activity with 5'-extended gRNAs, *in vitro* cleavage assays were performed as previously described³⁷. Although nicking was impaired by comparison to the standard gRNA, appreciable cleavage products were formed (FIG. 4D). Importantly, RT products were also observed when TPRT reactions were carried out with 5'-extended gRNAs and Cas9(H840A), albeit at lower yields that are likely explained by the decreased nicking activity (FIG. 4D). This result establishes that 5'-extended gRNA:Cas9(H840A) complexes can nick DNA and template reverse transcription.

[1232] Finally, 3' gRNA extensions were evaluated for Cas9(H840A) nicking and TPRT. By comparison to 5'-extended gRNAs, DNA cleavage by 3'-extended gRNAs was not impaired to any detectable extent compared to the standard gRNA. Significantly, 3'-extended gRNA templates also supported efficient reverse transcription with both pre-nicked and intact duplex DNA substrates when M-MLV RT was supplied in trans (FIG. 4E). Surprisingly, only a single product was observed for 3'-extended templates, indicating that reverse transcription terminates at a specific location along the gRNA scaffold. Homopolymer tailing of the product with terminal transferase followed by Klenow extension and Sanger sequencing revealed that the full gRNA synthesis template was copied in addition to the terminal 3 nucleotides of the gRNA core. In the future, the flap terminus will be

reprogrammed by modifying the terminal gRNA sequence^{38,39}. This result demonstrates that 3'-extended gRNAs can serve as efficient nuclease targeting guides and can template reverse transcription.

[1233] Cas9-TPRT uses nicked DNA and gRNA in cis. Dual color experiments were used to determine if the RT reaction preferentially occurs with the gRNA in cis (bound in the same complex) (see FIG. 8). Two separate experiments were conducted for 5'-extended and 3'-extended gRNAs. For a given experiment, ternary complexes of dCas9, gRNA, and DNA substrate were formed in separate tubes. In one tube, the gRNA encodes a long RT product and the DNA substrate is labeled with Cy3 (red); in the other, the gRNA encodes a short RT product and the DNA substrate is labeled with Cy5 (blue). After short incubations, the complexes were mixed and then treated with RT enzyme and dNTPs. Products were separated by urea-denaturing PAGE and visualized by fluorescence in the Cy3 and Cy5 channels. Reaction products were found to preferentially form using the gRNA template that was pre-complexed with the DNA substrate, indicating that the RT reaction likely can occur in cis. This results supports that a single Cas9:gRNA complex can target a DNA site and template reverse transcription of a mutagenic DNA strand.

Testing TPRT with other Cas systems

[1234] Similar experiments to those presented in the previous sections will be carried out using other Cas systems, including Cas9 from *S. aureus* and Cas12a from *L. bacterium* (see FIGs. 2A-2C). If TRPT can also be demonstrated for these Cas variants, the potential editing scope and likelihood of overall success in cells would increase.

Testing TPRT with RT-Cas9 fusion proteins

[1235] A series of commercially available or purifiable RT enzymes will first be evaluated in trans for TPRT activity. In addition to the already tested RT from M-MLV, the RT from Avian Myeloblastosis Virus (AMV), the *Geobacillus stearothermophilus* Group II Intron (Gsl-IIC)^{41,42}, and the *Eubacterium rectale* group II intron (Eu.re.I2)^{43,44} will be evaluated. Significantly, the latter two RTs perform TPRT in their natural biological contexts. Where relevant, RNase inactivating mutations and other potentially beneficial RT enzyme modifications will be tested. Once functional RTs are identified when supplied in trans, each will be evaluated as a fusion protein to Cas9 variants. Both N-terminus and C-terminus fusion orientations will be tested, along with various linker lengths and architectures. Kinetic time course experiments will be used to determine whether TPRT can occur using the RT enzyme in cis. If an RT-Cas9 fusion architecture can be constructed that allows for efficient TPRT chemistry, this will greatly increase the likelihood of functional editing in the context of a cell.

Cas9 targeting with engineered gRNAs in cells

[1236] Candidate engineered gRNAs developed in the previous sub-aims will be evaluated in human cell culture experiments (HEK293) to confirm Cas9 targeting efficiency. Using established indel

formation assays employing wild type SpCas9⁴⁵, engineered gRNAs will be compared side-by-side with standard gRNAs across 5 or more sites in the human genome. Genome editing efficiency will be characterized by amplicon sequencing in multiplex using the Illumina MiSeq platform housed in the laboratory. It is anticipated that results from this and the preceding sections will generate insights that inform subsequent iterations of the design-build-test cycle, where gRNAs can be optimized for both templating reverse transcription and efficient Cas9 targeting in cells.

[1237] Results of *in vitro* validations are shown in FIGs. 5-7. *In vitro* experiments demonstrated that the nicked non-target DNA strand is flexible and available for priming DNA synthesis, and that the gRNA extension can serve as a template for reverse transcription (see FIG. 5). This set of experiments used 5'-extended gRNAs (designed as shown in FIGs. 3A-3B) with varying length synthesis templates (listed to the left). Fluorescently labeled (Cy5) DNA targets were used as substrates, and were pre-nicked in this set of experiments. The Cas9 used in these experiments is catalytically dead Cas9 (dCas9), so cannot cut DNA but can still bind efficiently. Superscript III, a commercial RT derived from the Moloney-Murine Leukemia Virus (M-MLV), was supplied in trans. First, dCas9:gRNA complexes were formed from purified components. Then, the fluorescently labeled DNA substrate was added along with dNTPs and the RT enzyme. After 1 hour of incubation at 37 C, the reaction products were analyzed by denaturing urea-polyacrylamide gel electrophoresis (PAGE). The gel image shows extension of the original DNA strand to lengths that are consistent with the length of the reverse transcription template. Of note, reactions carried out in the absence of dCas9 produced DNA products of length 51 nucleotides, regardless of the gRNA used. This product corresponds to use of the complementary DNA strand as the template for DNA synthesis and not the RNA (data not shown). Thus, Cas9 binding is required for directing DNA synthesis to the RNA template. This set of *in vitro* experiments closely parallels those shown in FIG. 5, except that the DNA substrate is not pre-nicked, and a Cas9 nickase (SpyCas9 H840A mutant) is used. As shown in the gel, the nickase efficiently cleaves the DNA strand when the standard gRNA is used (gRNA_0, lane 3). Multiple cleavage products are observed, consistent with prior biochemical studies of SpyCas9. The 5' extension impairs nicking activity (lanes 4-8), but some RT product is still observed. FIG. 7 shows that 3' extensions support DNA synthesis and do not significantly effect Cas9 nickase activity. Pre-nicked substrates (black arrow) are near-quantitatively converted to RT products when either dCas9 or Cas9 nickase is used (lanes 4 and 5). Greater than 50% conversion to the RT product (red arrow) is observed with full substrates (lane 3). To determine the length and sequence of the RT product, the product band was excised from the gel, extracted, and sequenced. This revealed that RT extended 3 nucleotides into the gRNA core's 3' terminal hairpin. Subsequent experiments (not shown) demonstrated that these three nucleotides could be changed to match target DNA sequences, so long as complementary changes were made that maintain the hairpin RNA structure.

Potential difficulties and alternatives

[1238] (1) RT does not function as a fusion: molecular crowding and/or unfavorable geometries could encumber polymerase extension by Cas9-fused RT enzymes. First, linker optimization can be tested. Circularly permuted variants of Cas9, which could re-orient the spatial relationship between the DNA primer, gRNA, and RT enzyme, will be evaluated. Non-covalent RT recruitment strategies as detailed in Aim 2 can be tested. (2) Decreased Cas targeting efficiency by extended gRNA variants: this is most likely to be an issue for 5'-extended gRNAs. Based on structural data²⁴, Cas9 mutants can be designed and screened to identify variants with greater tolerance to gRNA extension. In addition, gRNA libraries could be screened in cells for linkers that improve targeting activity.

Significance

[1239] These preliminary results establish that Cas9 nickases and extended gRNAs can initiate target-primed reverse transcription on bound DNA targets using a reverse transcriptase supplied in trans. Importantly, Cas9 binding was found to be critically important for product formation. Though perhaps not an absolute requirement for genome editing in cells, further development of the system that incorporates RT enzyme function in cis would significantly increase the likelihood of success in cell-based applications. Achievement of the remaining aspects of this Aim would provide a molecular foundation for carrying out precision genome editing in the context of the human genome.

2. Establish prime editing in human cells.

Background and Rationale

[1240] In the proposed strategy, an engineered RT-Cas9:gRNA complex will introduce mutagenic 3' DNA flaps at genomic target sites. It is hypothesized that mutagenic 3' flaps containing a single mismatch will be incorporated by the DNA repair machinery through energetically accessible equilibration with adjacent 5' flaps, which would be preferentially removed (FIGs. 1C-1D). The DNA replication and repair machineries encounter 5' ssDNA flaps when processing Okazaki fragments⁴⁶ and during long-patch base excision repair (LP-BER)⁴⁷. 5' flaps are the preferred substrates for the widely expressed flap endonuclease FEN1, which is recruited to DNA repair sites by the homotrimeric sliding clamp complex PCNA⁴⁸. PCNA also serves as a scaffold for simultaneous recruitment of other repair factors including the DNA ligase Lig1⁴⁹. Acting as a 'toolbelt', PCNA accelerates serial flap cleavage and ligation, which is essential to processing the millions of Okazaki fragments generated during every cell division^{50,51}. Based on resemblance to these natural DNA intermediates, it is hypothesized that mutagenic strands would be incorporated through equilibration with 5' flaps, followed by coordinated 5' flap excision and ligation. Mismatch repair (MMR) should then occur on either strand with equal probability, leading to editing or reversion (FIGs. 1C-1D). Alternatively, DNA replication could occur first and lead directly to the incorporation of the edit in the newly synthesized daughter strand. While the highest expected yield from this process is 50%, multiple substrate editing attempts could drive the reaction toward completion due to the irreversibility of editing repair.

Preliminary result

[1241] DNA flaps induce site-specific mutagenesis in plasmid model substrates in yeast and HEK cells. To test the proposed editing strategy, studies were initiated with model plasmid substrates containing mutagenic 3' flaps that resemble the product of TPRT. A dual fluorescent protein reporter was created that encodes a stop codon between GFP and mCherry. Mutagenic flaps encode a correction to the stop codon (FIG. 9A), enabling mCherry synthesis. Thus, mutagenesis efficiency can be quantified by GFP:mCherry ratios. Plasmid substrates were prepared *in vitro* and introduced into yeast (*S. cerevisiae*) or human cells (HEK293). High frequency mutagenesis was observed in both systems (FIG. 9B), and isolated yeast colonies contained either the reverted base, the mutated base, or a mixture of both products (FIG. 9C). Detection of the latter suggests that plasmid replication occurred prior to MMR in these cases, and further suggests that flap excision and ligation precede MMR. This result establishes the feasibility of DNA editing using 3' mutagenic strands.

- ***Systematic studies with model flap substrates***

[1242] Based on the preliminary results described above, a broader spectrum of flap substrates will be evaluated in HEK cells to infer principles of efficient editing. 3' ssDNA flaps will be systematically varied to determine the influence of mismatch pairings, the location of the mutagenic nucleotide along the flap, and the identity of the terminal nucleotide (FIG. 9D). Single nucleotide insertions and deletions will also be tested. Amplicon sequencing will be used to analyze editing precision. These results will help inform the design of gRNA reverse transcription templates.

[1243] *In vitro* TPRT on plasmid substrates leads to efficient editing outcomes. TPRT reactions developed in Aim 1 were used to induce mutagenesis within a plasmid substrate. The reaction was carried out on circular DNA plasmid substrates (see FIG. 10). This rules out the possibility of DNA strand dissociation as the mechanism for RT extension in the previous *in vitro* experiments. It also allowed for the testing of DNA repair of flap substrates in cells. A dual-fluorescent reporter plasmid was constructed for yeast (*S. cerevisiae*) expression. This plasmid encodes GFP (green fluorescent protein) and mCherry (red fluorescent protein) with an intervening stop codon (TGA). Expression of this construct in yeast produces only GFP. The plasmid was used as a substrate for *in vitro* TRT [Cas9(H840A) nickase, engineered gRNA, MLV RT enzyme, dNTPS]. The gRNA extension encodes a mutation to the stop codon. The flap strand is used for repair of the stop codon and it is anticipated to produce a plasmid that expresses both GFP and mCherry as a fusion protein. Yeast dual-FP plasmid transformants are shown in FIG. 10. Transforming the parent plasmid or an *in vitro* Cas9(H840A) nicked plasmid results in only green GFP expressing colonies. TRT reaction with 5'-extended or 3'-extended gRNAs produces a mix of green and yellow colonies. The latter express both GFP and mCherry. More yellow colonies are observed with the 3'-extended gRNA. A positive control that contains no stop codon is shown as well.

[1244] This result establishes that long double stranded substrates can undergo TPRT, and that TPRT products induce editing in eukaryotic cells.

[1245] Another experiment similar to the foregoing prime editing experiment was carried out, but instead of installing a point mutation in the stop codon, TRT editing installs a single nucleotide insertion (left) or deletion (right) that repairs a frameshift mutation and allows for synthesis of downstream mCherry (see FIG. 11). Both experiments used 3' extended gRNAs. Individual colonies from the TRT transformations were selected and analyzed by Sanger sequencing (see FIG. 12). Green colonies contained plasmids with the original DNA sequence, while yellow colonies contained the precise mutation designed by the TRT editing gRNA. No other point mutations or indels were observed.

Establish prime editing in HEK cells using RT-Cas9 architectures

[1246] The optimized constructs from previous aims will be adapted for mammalian expression and editing at targeted sites in the human genome. Multiple RT enzymes and fusion architectures will be tested, in addition to adjacent targeting with secondary gRNAs (truncated to prevent nicking). Non-covalent RT recruitment will also be evaluated using the Sun-Tag system⁵² and MS2 aptamer system⁵³. Indel formation assays will be used to evaluate targeting efficiency with standard gRNAs and RT-Cas9 fusions (as above). Then, for each genomic site, extended gRNAs and RT-Cas9 pairs will be assayed for single nucleotide editing. Editing outcomes will be evaluated with MiSeq.

[1247] Initial experiments in HEK cells were performed using Cas9-RT fusions. Editing by components expressed within cells requires a Cas9(H840A) nickase, a reverse transcriptase (expressed as a fusion or supplied in trans), and an engineered gRNA with a 3' extension (see FIG. 14). Preliminary studies indicated that the length of the primer binding site within the gRNA extension was important for increasing the efficiency of editing in human cells (see FIG. 15).

Optimize prime editing parameters in HEK cells

[1248] After identifying Cas9-RT architectures that can perform prime editing in cells, the components and design will be optimized to achieve high efficiency editing. The location and nucleotide identity of the encoded point mutation, and the total length of the newly synthesized DNA strand, will be varied to evaluate editing scope and potential limitations. Short insertion and deletion mutations will also be evaluated. Protein expression constructs will be codon optimized. If successful, this would establish efficient prime editing in mammalian cells.

[1249] **Preliminary Result.** Additional gRNAs were designed to bring the RT enzyme to a higher local concentration at the editing locus, in the event that intramolecular reverse transcription by the fused RT enzyme were not possible. These auxiliary guides are truncated at the 5' end (14-15 nt spacer), which has previously been shown to prevent Cas9 cutting but retain binding (see FIG. 16). The HEK3 locus was chosen to explore this strategy.

Potential difficulties and alternatives

[1250] 1) gRNA degradation in cells: if extended gRNA termini are truncated in cells, stabilizing secondary structures could be installed, or synthetic gRNAs with stabilizing modifications could be tested. (2) No observed editing in human cells: additional strategies will be explored, including secondary targeting of RT-Cas9 fusions to adjacent genomic sites⁵⁴. In addition, potential directed evolution strategies in *E. coli* or *S. cerevisiae* could be explored.

Significance

[1251] If prime editing could be established in experimental cell lines, this would have an immediate impact for basic biomedical research by enabling the rapid generation and characterization of a large number of point mutations in human genes. The generality of the method, and its orthogonal editing window with respect to base editors, would provide an approach to installing many currently inaccessible mutations. Moreover, if prime editing could be optimized for high efficiency and product purity, its potential applicability to correcting disease mutations in other human cell types would be significant.

[1252]

3. Achieve site-specific editing of pathogenic mutations in cultured human cells.

Background and Rationale.

[1253] A large number of pathogenic mutations cannot be corrected by current base editors due to PAM restrictions, or a need for transversion or indel mutation correction. With prime editing, all transitions and transversions are theoretically possible, as may be small insertions and deletions. Moreover, in relation to the PAM, the prime editing window (anticipated -3 to +4) is distinct from that of base editors (-18 to -12) (FIG. 13). Mendelian conditions not currently correctable by base editors include: (1) the sickle cell disease Glu6Val founder mutation in hemoglobin beta (requires A•T to T•A transversion); (2) the most common Wilson's disease variant His1069Gln in ATP7B (requires G•C to T•A transversion); and (3) the Δ Phe508 mutation in *CFTR* that causes cystic fibrosis (requires 3-nucleotide insertion). Each of these targets contains an appropriately positioned PAM for SpCas9 targeting and prime editing.

Preliminary Results.

- *T to A editing in HEK3 cells is not achievable by current base editing but is achievable by TRPT editing (see FIGs. 17A-17C).*

[1254] FIG. 17A shows a graph displaying the % T to A conversion at the target nucleotide after transfection of components in human embryonic kidney (HEK) cells. This data presents results using an N-terminal fusion of wild type MLV reverse transcriptase to Cas9(H840A) nickase (32-amino acid linker). Editing efficiency was improved dramatically when the length of the primer binding site is extended from 7 nucleotides to 11 or 12 nucleotides. Additionally, the auxiliary guide A, which is positioned just upstream of the editing locus (see FIG. 16), significantly improves editing activity, particularly for shorter length primer binding sites. Editing efficiency was quantified by amplicon

sequencing using the Illumina MiSeq platform. FIG. 17B also shows % T to A conversion at the target nucleotide after transfection of components in human embryonic kidney (HEK) cells, but this data presents results using a C-terminal fusion of the RT enzyme. Here, the auxiliary guide A does not have as much of an effect, and editing efficiency is overall higher. FIG. 17C shows data presenting results using an N-terminal fusion of wild type MLV reverse transcriptase to Cas9(H840A) nickase similar to that used in FIG. 17A; however the linker between the MLV RT and Cas9 is 60 amino acids long instead of 32 amino acids.

- *T to A editing at HEK3 site by TRPT editing results displays high purity.*

[1255] FIG. 18 shows the output of sequencing analysis by high-throughput amplicon sequencing. The output displays the most abundant genotypes of edited cells. Of note, no major indel products are obtained, and the desired point mutation (T to A) is cleanly installed without bystander edits. The first sequence shows the reference genotype. The top two products are the starting genotype containing an endogenous polymorphism (G or A). The bottom two products represent the correctly edited genotypes.

- *MLV RT mutants improve editing.*

[1256] Mutant reverse transcriptases, described in Baranauskas, et al (doi:10.1093/protein/gzs034), were tested as C-terminal fusions to the Cas9(H840A) nickase for target nucleotide editing in human embryonic kidney (HEK) cells. Cas9-RT editor plasmid was co-transfected with a plasmid encoding a 3'-prime editing guide RNA that templates reverse transcription. Editing efficiency at the target nucleotide (blue bars) is shown alongside indel rates (orange bars) in FIG. 19. WT refers to the wild type MLV RT enzyme. The mutant enzymes (M1 through M4) contain the mutations listed to the right. Editing rates were quantified by high throughput sequencing of genomic DNA amplicons.

Complementary strand nicking with a second gRNA improves editing.

[1257] This experiment evaluates editing efficiency of the target nucleotide when a single strand nick is introduced in the complementary DNA strand in proximity to the target nucleotide, with the hypothesis being that this would direct mismatch repair to preferentially remove the original nucleotide and convert the base pair to the desired edit. The Cas9(H840A)-RT editing construct was co-transfected with two guide RNA encoding plasmids, one of which templates the reverse transcription reaction, while the other targets the complementary DNA strand for nicking. Nicking at various distances from the target nucleotide was tested (orange triangles) (see FIG. 20). Editing efficiency at the target base pair (blue bars) is shown alongside the indel formation rate (orange bars). The “none” example does not contain a complementary strand nicking guide RNA. Editing rates were quantified by high throughput sequencing of genomic DNA amplicons.

[1258] FIG. 21 shows processed high throughput sequencing data showing the desired T to A transversion mutation and general absence of other major genome editing byproducts.

[1259] Scope. The potential scope for the new editing technology is shown in FIG. 13 and is compared to deaminase-mediated base editor technologies. Previously developed base editors target a region $\sim 15 \pm 2$ bp upstream of the PAM. By converting target C or A nucleotides to T or G, respectively, previously developed base editors enable all transition mutations (A:T to G:C conversions). However, previously developed base editors are unable to install transversion mutations (A to T, A to C, G to T, G to C, T to A, T to G, C to A, C to G). Moreover, if there are multiple target nucleotides in the editing window, additional undesired edits can result.

[1260] The new prime editing technology could theoretically install any nucleotide and base pair conversion, and potentially small insertion and deletion edits as well. With respect to the PAM, prime editing windows start at the site of DNA nicking (3 bases upstream of the PAM) and end at an as-of-yet undetermined position downstream of the PAM. Of note, this editing window is distinct from that of deaminase base editors. Because the TPRT systems performs editing using DNA polymerase enzymes, it potentially has all of their benefits including generality, precision, and fidelity.

Correct pathogenic mutations in patient-derived cell lines.

[1261] Cell lines harboring the relevant mutations (sickle cell disease: CD34+ hematopoietic stem cells; Wilson's disease: cultured fibroblasts; cystic fibrosis: cultured bronchial epithelia) will be obtained from ATCC, the Coriell Biobank, or collaborating Harvard/Broad affiliate laboratories. Editing efficiency will be evaluated by high throughput sequencing, and the efficacy of the corrected genotype will be tested using phenotypic assays (hemoglobin HPLC, ATP7B immunostaining, and *CFTR* membrane potential assays).

Characterize off-target editing activity.

[1262] Potential off-target editing will be screened with established methods such as GUIDE-seq⁵⁵ and CIRCLE-seq⁵⁶ using target gRNAs paired with wild type Cas9. If potential off-targets are identified, these loci will be probed in TPRT edited cells to identify true off-target editing events.

Potential difficulties and alternatives.

[1263] (1) Low editing efficiency: prime editor (PE)s may require optimization for each target. In this case, gRNA libraries can be tested to identify the highest functioning variants for specific applications. RT-Cas fusion expression and nuclear localization can be optimized. Liposomal RNP delivery could be used to limit off-target editing.

Upcoming experiments.

[1264] Optimization of gRNA designs can be achieved by further exploration of the primer binding site length and extension of synthesis template. Testing scope and generality will include different nucleotide conversions, small insertions and deletions, as well as, different editing positions with respect to PAM, and multiple sites in the human genome. Optimization of RT component will include exploring mutations in MLV RT to enhance activity (Rnase H inactivation, increase primer-template

binding affinity, adjustments to processivity), and new RT enzymes (group II intro RTs, other retroviral RTs).

Significance.

[1265] Myriad genetic disorders result from single nucleotide changes in individual genes. Developing the genome editing technology described here, and applying it in disease-relevant cell types, would establish a foundation for translation to the clinic. For some diseases, such as Sickle Cell Disease, a single point mutation represents the dominant genotype throughout the population. However, for many other genetic disorders, a large heterogeneity of different point mutations within a single gene is observed throughout the patient population, each of which gives rise to a similar disease phenotype. Therefore, as a general genome editing method that could in theory target a large number of such mutations, this technology could provide enormous potential benefit to many of these patients and their families. If proof of principle for these applications could be established in cells, it would establish the foundation to studies in animal models of disease.

Advantages

[1266] Precision: the desired edit is encoded directed in nucleic acid sequence. Generality: in theory, could be possible to make any base pair conversion, including transversion edits, as well as small insertions or deletions. There is a distinct editing window from that of base editors with respect to Cas9 protospacer adjacent motif (PAM) sequence. This method achieves many of the editing capabilities of homology-directed repair (HDR), but without the major limitations of HDR (inefficient in most cell types, and is usually accompanied by an excess of undesired byproducts such as indels). Also, it does not make double-stranded DNA breaks (DSBs, so few indels, translocations, large deletions, p53 activation, etc.

[1267]

EXAMPLE 3 – PEPTIDE TAGGING WITH PE

[1268] The prime editing systems (i.e., PE systems) described herein may also be used to introduce various peptide tags into protein coding genes. Such tags can include *HEX*Ahistidine tags, FLAG-tag, V5-tag, GCN4-tag, HA-tag, Myc-tag and others. This approach may be useful in applications such as protein fluorescent labeling, immunoprecipitation, immunoblotting, immunohistochemistry, protein recruitment, inducible protein degrons, and genome-wide screening. Embodiments are depicted in FIGs. 25 and 26.

[1269] FIG. 25 is a schematic showing gRNA design for peptide tagging genes at endogenous genomic loci and peptide tagging with TPRT genome editing (i.e., prime editing). The FAsH and ReAsH tagging systems comprise two parts: (1) a fluorophore-biarsenical probe, and (2) a genetically encoded peptide containing a tetracysteine motif, exemplified by the sequence FLNCCPGCCMEP (SEQ ID NO: 1). When expressed within cells, proteins containing the tetracysteine motif can be fluorescently labeled with fluorophore-arsenic probes (see ref: J. Am. Chem. Soc., 2002, 124 (21), pp

6063–6076. DOI: 10.1021/ja017687n). The “sortagging” system employs bacterial sortase enzymes that covalently conjugate labeled peptide probes to proteins containing suitable peptide substrates (see ref: Nat. Chem. Biol. 2007 Nov;3(11):707-8. DOI: 10.1038/nchembio.2007.31). The FLAG-tag (DYKDDDDK (SEQ ID NO: 2)), V5-tag (GKPIPNPLLGLDST (SEQ ID NO: 3)), GCN4-tag (EELLSKNYHLENEVARLKK (SEQ ID NO: 4)), HA-tag (YPYDVPDYA (SEQ ID NO: 5)), and Myc-tag (EQKLISEEDL (SEQ ID NO: 6)) are commonly employed as epitope tags for immunoassays. The pi-clamp encodes a peptide sequence (FCPF) (SEQ ID NO: 622) that can be labeled with a pentafluoro-aromatic substrates (ref: Nat. Chem. 2016 Feb;8(2):120-8. doi: 10.1038/nchem.2413).

[1270] FIG. 26 shows precise installation of a His6-tag and a FLAG-tag into genomic DNA. A guide RNA targeting the HEK3 locus was designed with a reverse transcription template that encodes either an 18-nt His-tag insertion or a 24-nt FLAG-tag insertion. Editing efficiency in transfected HEK cells was assessed using amplicon sequencing. Note that the full 24-nt sequence of the FLAG-tag is outside of the viewing frame (sequencing confirmed full and precise insertion).

EXAMPLE 4 – RNA TAGGING AND MANIPULATION USING PE

[1271] A new method for the insertion of motifs into genetic sequences that tag or otherwise manipulate RNA within mammalian, eukaryotic, and bacterial cells is described herein. While it is estimated that only 1% of the human genome encodes proteins, virtually all of the genome is transcribed at some level. It is an open question how much of the resulting non-coding RNA (ncRNA) plays a functional role, let alone what the roles of most of these putative RNAs are. “Tagging” of these RNA molecules via the insertion of a novel RNA-encoding sequence with a useful property into genes of interest is a useful method for studying the biological functions of RNA molecules in cells. It can also be useful to install tags onto protein-encoding mRNAs as a means to perturb and thus better understand how mRNA modifications can affect cellular function. For instance, a ubiquitous natural RNA tag – polyadenylation – is used by cells to affect transport of mRNA into the cytoplasm. Different types of polyadenylation signals result in different transport rates and different mRNA lifespans and – thus – differences in the levels to which the encoded protein is expressed.

[1272] A common approach for expressing tagged RNAs within cells is to exogenously introduce a synthetic construct using either (i) transient plasmid transfection that produces a short-term burst of gene expression, often at supraphysiologic levels; or (ii) permanent integration of the tagged RNA gene into the genome (at random sites) using lentiviral integration or transposons, which enables prolonged expression. Both of these approaches are limited by production of altered expression levels, and by the absence of natural mechanisms that regulate the expression or activity of the gene. An alternative strategy is to directly tag a gene of interest at its endogenous locus using homology-directed repair (HDR) of double-stranded DNA breaks induced by Cas9 or other targeted DNA nucleases. While this approach enables the generation of a wide range of endogenously tagged genes,

HDR is markedly inefficient and so requires significant screening to identify the desired clonal population of cells that have been successfully tagged. Moreover, HDR is typically very inefficient or entirely inactive in a large number of cell types, most notably in post-mitotic cells. The low efficiency of HDR is further complicated by the generation of undesired indel products, which could be especially problematic in the case of RNA genes as they might lead to the production of an RNA whose activities interfere with the function of normal alleles. Finally, researchers often need to screen various tagging positions within an RNA molecule to achieve optimal performance. Combined, these drawbacks make HDR a less desirable method for installation of tags in RNA.

[1273] Prime editing is a new genome editing technology that enables targeted editing of genomic loci via the transfer of genetic information from RNA to DNA. Using prime editing, RNA genes could be tagged with a variety of components such as RNA aptamers, ribozymes, or other RNA motifs. Prime editing has the potential to be faster, cheaper, and effective in a greater variety of cell types by comparison to HDR strategies. As such, the described invention represents a novel, useful, and non-obvious tool for investigating the biology of RNA genes in health and disease. A new method for the insertion of RNA motifs into genetic sequences that tag or otherwise manipulate RNA using prime editors (PEs) is described herein. PEs are capable of site-specifically inserting, mutating, and/or deleting multiple nucleotides at a desired genomic locus that is targetable by a CRISPR/Cas system. PEs are composed of fusions between Cas9 nuclease domains and reverse transcriptase domains. They are guided to their genomic target by engineered PEgRNAs (prime editing guide RNAs), which contain a guide spacer portion for DNA targeting, as well as a template for reverse transcription that encodes the desired genome edit (see FIG. 28A). It is envisioned that PE can be used to insert motifs that are functional at the RNA level (hereafter RNA motifs) to tag or otherwise manipulate non-coding RNAs or mRNAs. These motifs could serve to increase gene expression, decrease gene expression, alter splicing, change post-transcriptional modification, affect the sub-cellular location of the RNA, enable isolation or determination of the intra- or extra-cellular location of the RNA (using, for instance, fluorescent RNA aptamers such as Spinach, Spinach2, Baby Spinach, or Broccoli), recruit endogenous or exogenous protein or RNA binders, introduce sgRNAs, or induce processing of the RNA, by either self-cleavage or RNases (see FIG. 28B). Due to the flexibility of prime editing, it is not possible to provide a comprehensive list of RNA motifs that could be installed within the genome. A series of examples are shown here that broadly illustrate the predicted scope of PE-installed RNA motifs that could be used to tag RNA genes. It is currently not possible to efficiently and fairly cleanly make these changes in most types of cells (including the many that do not support HDR) using any other reported genome editing method besides PE.

[1274] Gene expression could be affected by encoding a 3' untranslated region (UTR) that results in changes in nuclear transport or retention or mRNA lifespan. For instance, the polyA tail from polyomavirus simian virus 40 (SV40) has additional helper sequences that enable efficient

transcription termination and can increase gene expression relative to other 3' UTRs^{57, 58}. Example sequence of SV40 polyA tail:

SV40 POLYA TAIL	AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCA CAAATTTACAAATAAAGCATTTTTTTCAGTGCATTCTAGTTGTGGTTT GTCCAAACTCATCAATGTATCTTA (SEQ ID NO: 331)
--------------------	--

[1275] Post-translational modification signals, besides polyadenylation signals, could also be encoded by PE. These include signals incorporate N6-methyladenosine, N1-methyladenosine, 5-methylcytosine, and pseudouridine modifications⁵⁹. By using PE to include sequences bound by enzymes that write or remove these modifications within an RNA transcript, it would be possible to induce their writing or erasing. This could be used as a tool to study the effects of these markers, to induce cellular differentiation, affect stress responses, or, given the function of these markers are as yet underexplored, affect targeted cells in other fashions.

[1276] PE could encode mutations that affect subcellular localization. For instance, incorporation of tRNA-Lys within an mRNA can theoretically result in transport to the mitochondria⁶⁰, while various 3' UTRs can result in nuclear retention or transport⁶¹.

[1277] Examples:

[1278] SV40 polyA signal results in transport.

SV40 POLYA TAIL	AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCA CAAATTTACAAATAAAGCATTTTTTTCAGTGCATTCTAGTTGTGGTTT GTCCAAACTCATCAATGTATCTTA (SEQ ID NO: 331)
--------------------	--

[1279] U1 snRNA 3' box results in retention.

U1 SNRNA 3' BOX	TTCATTCAGCAAGTTCAGAGAAATCTGAACTTGCTGGATTTTTGGAGC AGGGAGATGGAATAGGAGCTTGCTCCGTCCACTCCACGCATCGACCTG GTATTGCAGTACCTCCAGGAACGGTGCACCCACTTTCTGGAGTTTCAA AAGTAGACTGTACGCTAAGGGTCATATCTTTTTTTGTTT GGTTTGTGTCTTGTTGGCGTCTTAA (SEQ ID NO: 625)
--------------------	---

[1280] Determining the sub-cellular localization of endogenous RNA can be challenging and requires the addition of exogenous, fluorescently-tagged nucleotide probes, as in the case of FISH, or time-consuming and potentially inaccurate cell fractionation followed by RNA detection. Encoding a probe within the endogenous RNA would obviate many of these issues. One example would be to encode a fluorescent RNA aptamer, such as Spinach⁶² or Broccoli within an endogenous RNA, thereby visualizing the presence of that RNA via addition of a small molecule proto-fluorophore.

[1281] Broccoli aptamer:

BROCCOLI APTAMER	GAGACGGTCGGGTCCAGATATTCGTATCTGTCGAGTAGAGTGTGGGCT C (SEQ ID NO: 357)
---------------------	--

[1282] PE could insert or remove sequences that encode RNA that are recognized by RNA binding proteins, affecting RNA stability, expression, localization, or modification (for instance, see proteins listed⁶³).

[1283] PE could insert sequences that encode sgRNAs within the genome, as a viral or cancer defense mechanism. Similarly, it could be used to insert microRNAs (e.g., pre-microRNAs) to direct silencing of targeted genes.

[1284] PE could insert sequences resulting in processing of the RNA, either by itself, or by external factors, either as a therapy or tool for studying the function of various portions of the RNA. For instance, the HDV ribozyme⁶⁴, when included within an RNA sequence, results in processing of the RNA immediately 5' of the ribozyme, while the hammerhead ribozyme cleaves prior to the third stem within the ribozyme⁶⁵. Other self-cleaving ribozymes include pistol⁶⁶, hatchet⁶⁶, hairpin⁶⁷, *Neuropora* Varkud satellite⁶⁸, glmS⁶⁹, twister⁷⁰, and twister sister⁶⁶. These sequences could include wild-type or engineered or evolved versions of ribozymes. The majority of these ribozymes could have different sequences depending on the region of RNA into which they were associated, depending on where the ribozyme cut site is located. Sequences that would direct the processing of the RNA by external factors, such as sequence specific RNases⁷¹, RNases that recognize specific structures⁷² – such as Dicer⁷³ and Drosha⁷⁴, could also be achieved.

[1285] HDV ribozyme:

HDV RIBOZYME	GGCCGGCATGGTCCCAGCCTCCTCGCTGGCGCCGGCTGGGCAACATG CTTCGGCATGGCGAATGGGAC (SEQ ID NO: 365)
--------------	---

[1286] References for Example 4

[1287] The following references are incorporated herein by reference in their entireties.

1. Schek N, Cooke C, Alwine JC. *Molecular and Cellular Biology*. 1992.
2. Gil A, Proudfoot NJ. *Cell*. 1987.
3. Zhao, B.S., Roundtree, I.A., He, C. *Nat Rev Mol Cell Biol*. 2017.
4. Rubio, M.A.T., Hopper, A.K. *Wiley Interdiscip Rev RNA* 2011.
5. Shechner, D.M., Hacisuleyman E., Younger, S.T., Rinn, J.L. *Nat Methods*. 2015.
6. Paige, J.S., Wu, K.Y., Jaffrey, S.R. *Science* 2011.
7. Ray D., ... Hughes TR. *Nature* 2013.
8. Chadalavada, D. M., Cerrone-Szakal, A. L., Bevilacqua, P.C. *RNA* 2007.
9. Forster AC, Symons RH. *Cell*. 1987.
10. Weinberg Z, Kim PB, Chen TH, Li S, Harris KA, Lünse CE, Breaker RR. *Nat. Chem. Biol*. 2015.
11. Feldstein PA, Buzayan JM, Bruening G. *Gene* 1989.
12. Saville BJ, Collins RA. *Cell*. 1990.
13. Winkler WC, Nahvi A, Roth A, Collins JA, Breaker RR. *Nature* 2004.
14. Roth A, Weinberg Z, Chen AG, Kim PG, Ames TD, Breaker RR. *Nat Chem Biol*. 2013.
15. Choudhury R, Tsai YS, Dominguez D, Wang Y, Wang Z. *Nat Commun*. 2012.
16. MacRae IJ, Doudna JA. *Curr Opin Struct Biol*. 2007.
17. Bernstein E, Caudy AA, Hammond SM, Hannon GJ *Nature* 2001.

18. Filippov V, Solovyev V, Filippova M, Gill SS. Gene 2000.

EXAMPLE 5 – IMMUNOEPITOPE INSERTION BY PE

[1288] Precise genome targeting technologies using the CRISPR/Cas system have recently been explored in a wide range of applications, including the insertion of engineered DNA sequences into targeted genomic loci. Previously, homology-directed repair (HDR) has been used for this application, requiring an ssDNA donor template and repair initiation by means of a double-stranded DNA break (DSB). This strategy offers the broadest range of possible changes to be made in cells and is the only method available to insert large DNA sequences into mammalian cells. However, HDR is hampered by undesired cellular side effects stemming from its initiating DSB, such as high levels of indel formation, DNA translocations, large deletions, and P53 activation. In addition to these drawbacks, HDR is limited by low efficiency in many cell types (T cells are a notable exception to this observation). Recent efforts to overcome these drawbacks include fusing human Rad51 mutants to a Cas9 D10A nickase (RDN), resulting in a DSB-free HDR system that features improved HDR product:indel ratios and lower off target editing, but is still hampered by cell-type dependencies and only modest HDR editing efficiency.

[1289] Recently developed fusions of Cas9 to reverse transcriptases (“Prime editors”) coupled with PEgRNAs represent a novel genome editing technology that offers a number of advantages over existing genome editing methods, including the ability to install any single nucleotide substitution, and to insert or delete any short stretch of nucleotides (up to at least several dozen bases) in a site-specific manner. Notably, PE edits are achieved with generally low rates of unintended indels. As such, PE enables targeted insertion-based editing applications that have been previously impossible or impractical.

[1290] This particular invention describes a method for using prime editing as a means to insert known immunogenicity epitopes into endogenous or foreign genomic DNA, resulting in modification of the corresponding proteins for therapeutic or biotechnological applications (see FIGs. 31 and 32). Prior to the invention of prime editing, such insertions could be achieved only inefficiently and with high rates of indel formation from DSBs. prime editing solves the problem of high indel formation from insertion edits while generally offering higher efficiency than HDR. This lower rate of indel formation presents a major advantage of prime editing over HDR as a method for targeted DNA insertions, especially in the described application of inserting immunogenicity epitopes. The length of epitopes is in a range from few bases to hundreds of bases. Prime editor is the most efficient and cleanest technology to achieve such targeted insertions in mammalian cells.

[1291] The key concept of the invention is the use of prime editors to insert a nucleotide sequence containing previously described immunogenicity epitopes into endogenous or foreign genomic DNA for the downregulation and/or destruction of their protein products and/or expressing cell types. Nucleotide sequences for immunogenic epitope insertion would be targeted to genes in a manner to

produce fusion proteins of the targeted gene's coded protein and the inserted immunogenic epitope's corresponding protein translation. Patient's immune systems will have been previously trained to recognize these epitopes as a result of standard prior immunization from routine vaccination against, for example, tetanus or diphtheria or measles. As a result of the immunogenic nature of the fused epitopes, patient's immune systems would be expected to recognize and disable the prime edited protein (not just the inserted epitope) and potentially the cells from which it was expressed.

[1292] Fusions to targeted genes would be engineered as needed to ensure the inserted epitope protein translation is exposed for immune system recognition. This could include targeted nucleotide insertions resulting in protein translations yielding C-terminal fusions of immunogenicity epitopes to targeted genes, N-terminal fusions of immunogenicity epitopes to targeted genes, or the insertion of nucleotides into genes so that immunogenicity epitopes are coded within surfaced-exposed regions of protein structure.

[1293] Protein linkers encoded as nucleotides inserted between the target gene sequence and the inserted immunogenicity epitope nucleotide sequence may need to be engineered as part of this invention to facilitate immune system recognition, cellular trafficking, protein function, or protein folding of the targeted gene. These inserted nucleotide-encoded protein linkers may include (but are not limited to) variable lengths and sequences of the XTEN linker or variable lengths and sequences of Glycine-Serine linkers. These engineered linkers have been previously used to successfully facilitate protein fusions.

[1294] Distinguishing features of this invention include the ability to use previously acquired immune responses to specific amino acid sequences as a means to induce an immune response against otherwise non-immunogenic proteins. Another distinguishing feature is the ability to insert the nucleotide sequences of these immunogenic epitopes in a targeted manner that does not induce high levels of unwanted indels as a by-product of editing and is efficient in its insertion. The invention discussed herein also has the ability to combine cell type-specific delivery methods (such as AAV serotypes) to insert epitopes in cell types that are of interest to trigger an immune response to.

[1295] Prime editing as a means of inserting immunogenic epitopes into pathogenic genes could be used to program the patient's immune system to fight a wide variety of diseases (not limited to cancer as with immuno-oncology strategies). An immediately relevant use of this technology would be as a cancer therapeutic as it could undermine a tumor's immune escape mechanism by causing an immune response to a relevant oncogene like HER2 or growth factors like EGFR. Such an approach could seem similar to T-cell engineering, but one novel advance of this approach is that it can be utilized in many cell types and for diseases beyond cancer, without needing to generate and introduce engineered T-cells into patients.

[1296] Using PE to insert an immunogenicity epitope which most people are already vaccinated against (tetanus, pertussis, diphtheria, measles, mumps, rubella, etc.) into a foreign or endogenous gene that drives a disease, so the patient's immune system learns to disable that protein.

[1297] Diseases that stand to have a potential therapeutic benefit from the aforementioned strategy include those caused by aggregation of toxic proteins, such as in fatal familial insomnia. Other diseases that could benefit include those caused by pathogenic overexpression of an otherwise nontoxic endogenous protein, and those caused by foreign pathogens.

[1298] Primary therapeutic indications include those mentioned above such as therapeutics for cancer, prion and other neurodegenerative diseases, infectious diseases, and preventative medicine. Secondary therapeutic indications may include preventative care for patients with late-onset genetic diseases. It is expected that current standard of care medicines may be used in conjunction with prime editing for some diseases, like particularly aggressive cancers, or in cases where medications help alleviate disease symptoms until the disease completely cured.

Below are examples of immunogenic epitopes that can be inserted by prime editing can be used to achieve:

Vaccine	Disease	Epitope Amino Acid Sequence	Example Nucleic Acid Sequence (8)
1	Tetanus toxoid	QYIKANSKFIGITEL (SEQ ID NO: 396)	CATGATATAAAAGCAAATTCTAAATTTA TAGGTATAACTGAACTA (SEQ ID NO: 397)
2	Diphtheria toxin mutant CRM197	GADDVVDSSKSFV MENFSSYHGTPG YVDSIQKGIQPKS GTQGNYYDDWKEF YSTDNKYDAAGYS VDNENPLSGKAGG VVKVTYPGLTKVL ALKVDNAETIKKEL GLSLTEPLMEQVGT EEFIKRFQDASRV VLSLPFAEGSSSVE YINNWEQAKALSV ELEINFETRGRKRGQ DAMYEYMAQACA GNRVRSSVSSSLSC INLDWDVIRDKTKT KIESLKEHGPIKNK MSESPNKTVSEEKA KQYLEEFHQTALEH PELSELKTVTGTNP VFAGANYAAWAV NVAQVIDSETADNL EKTTAALSILPGIGS VMGIADGAVHHNT EEIVAQSIALSSLMV AQAIPLVGELVDIG FAAYNFVESIINLFQ VVHNSYNRPAYSP GHKTQPFLLHDGYA VSWNTVEDSIIRTG FQGESGHDIKITAE NTPLPIAGVLLPTIP GKLDVNKSKTHISV NGRKIRMRCRAIDG DVTFCRPKSPVYVG NGVHANLHVAFHR SSSEKIHSNEISSDSI GVLGYQKTVVDHTK VNSKLSLFFEIKS (SEQ ID NO: 630)	GGCGCCGACGACGTGGTGGACAGCAGC AAGAGCTTCGTGATGGAGAACTTCAGC AGCTACCACGGCACCAAGCCCCGGCTAC GTGGACAGCATCCAGAAGGGCATCCAG AAGCCCAAGAGCGGCACCCAGGGCAAC TACGACGACGACTGGAAGGAGTTCTAC AGCACCGACAACAAGTACGACGCCGCC GGCTACAGCGTGGACAACGAGAACCCC CTGAGCGGCAAGGCCGGCGGCGTGGTG AAGGTGACCTACCCCGGCCTGACCAAG GTGCTGGCCCTGAAGGTGGACAACGCC GAGACCATCAAGAAGGAGCTGGGCCTG AGCCTGACCGAGCCCTGATGGAGCAG GTGGGCACCGAGGAGTTCATCAAGAGG TTCGGCGACGGCGCCAGCAGGGTGGTG CTGAGCCTGCCCTTCGCCGAGGGCAGC AGCAGCGTGGAGTACATCAACAACCTGG GAGCAGGCCAAGGCCCTGAGCGTGGAG CTGGAGATCAACTTCGAGACCAAGGGC AAGAGGGGCCAGGACGCCATGTACGAG TACATGGCCCAGGCCTGCGCCGGCAAC AGGGTGAGGAGGAGCGTGGGCAGCAGC CTGAGCTGCATCAACCTGGACTGGGAC GTGATCAGGGACAAGACCAAGACCAAG ATCGAGAGCCTGAAGGAGCACGGCCCC ATCAAGAACAAGATGAGCGAGAGCCCC AACAAGACCGTGAGCGAGGAGAAGGCC AAGCAGTACCTGGAGGAGTTCCACCAG ACCGCCCTGGAGCACCCCGAGCTGAGC GAGCTGAAGACCGTGACCGGCACCAAC CCCGTGTTCCGCCGGCGCCAACTACGCCG CCTGGGCCGTGAACGTGGCCCAAGGTGA TCGACAGCGAGACCGCCGACAACCTGG AGAAGACCACCGCCGCCCTGAGCATCC TGCCCGGCATCGGCAGCGTGATGGGCA TCGCCGACGGCGCCGTGCACCACAACA CCGAGGAGATCGTGGCCCAAGAGCATCG CCCTGAGCAGCCTGATGGTGGCCCAAG CCATCCCCCTGGTGGGCGAGCTGGTGG ACATCGGCTTCGCCGCCTACAACCTTCGT GGAGAGCATCATCAACCTGTTCCAGGT GGTGCAACACAGCTACAACAGGCCCGC CTACAGCCCCGGCCACAAGACCCAGCC CTTCCTGCACGACGGCTACGCCGTGAGC

			<p>TGGAACACCGTGGAGGACAGCATCATC AGGACCGGCTTCCAGGGCGAGAGCGGC CACGACATCAAGATCACCGCCGAGAAC ACCCCCCTGCCCATCGCCGGCGTGCTGC TGCCCAACCATCCCCGGCAAGCTGGACGT GAACAAGAGCAAGACCCACATCAGCGT GAACGGCAGGAAGATCAGGATGAGGTG CAGGGCCATCGACGGCGACGTGACCTT CTGCAGGCCCAAGAGCCCCGTGTACGT GGGCAACGGCGTGCACGCCAACCTGCA CGTGGCCTTCCACAGGAGCAGCAGCGA GAAGATCCACAGCAACGAGATCAGCAG CGACAGCATCGGCGTGCTGGGCTACCA GAAGACCGTGGACCACACCAAGGTGAA CAGCAAGCTGAGCCTGTTCTTCGAGATC AAGAGC (SEQ ID NO: 399)</p>
3	mumps	<p>GTYRLIPNARANLT A (SEQ ID NO: 400)</p>	<p>GGCACCTACAGGCTGATCCCCAACGCC AGGGCCAACTGACCGCC (SEQ ID NO: 401)</p>
4	mumps	<p>PSKFFTISDSATFAP GPVSNA (SEQ ID NO: 402)</p> <p>PSKLFIMLDNATFA PGPVVNA (SEQ ID NO: 404)</p>	<p>Ccgagcaaattttaccattagcgatagegacgttgcgcg ggcccggtgagcaacgcg (SEQ ID NO: 403)</p> <p>Ccgagcaaactgtttattatgctggataacgcgacgttgcgcg ggcccggtggtgaacgcg (SEQ ID NO: 405)</p> <p>Selected examples from Hemagglutinin– neuraminidase (HN) diversity among outbreak strains (table1) Divergence between vaccine strain JL5 and outbreak strains (table2)</p>
5	Rubella virus (RV)	<p>TPPPYQVSCGGESD RASARVIDPAAQS (SEQ ID NO: 406)</p>	<p>ACCCCCCCCCCTACCAGGTGAGCTGCG GCGGCGAGAGCGACAGGGCCAGCGCCA GGGTGATCGACCCCGCCGCCAGAGC (SEQ ID NO: 407)</p>

6	Hemagglutinin	PEYAYKIVKNKKM EDGFLQGMVDGW YGHHSNEQSGLM ENERTLDKANPNN DLCSWSDHEASSN NTNQEDLLQRESRR KKRIGTSTLNQRG CNTKCQTEEARLK REEVSLVKSDQCSN GSLQCRANNSTEQ VD (SEQ ID NO: 408)	CCCGAGTACGCCTACAAGATCGTGAAG AACAAGAAGATGGAGGACGGCTTCCTG CAGGGCATGGTGGACGGCTGGTACGGC CACCACAGCAACGAGCAGGGCAGCGGC CTGATGGAGAACGAGAGGACCCTGGAC AAGGCCAACCCCAACAACGACCTGTGC AGCTGGAGCGACCACGAGGCCAGCAGC AACAACACCAACCAGGAGGACCTGCTG CAGAGGGAGAGCAGGAGGAAGAAGAG GATCGGCACCAGCACCTGAACCAGAG GGGCAACTGCAACACCAAGTCCAGAC CGAGGAGGCCAGGCTGAAGAGGGAGG AGGTGAGCCTGGTGAAGAGCGACCACT GCAGCAACGGCAGCCTGCAGTGCAGGG CCAACAACAGCACCGAGCAGGTGGAC (SEQ ID NO: 409)
7	Neuraminidase	TKSTNSRSGGISGP DNEAPVGEAPSPYG DNPRPNDGNIRIG SKGYNGIITDTIEES CSCYPDAKVVKSV ELDSTIWTSGSSPN QKIITIGWDPNGWT GTPMSPNGAYGTD GPSNGQANQHQA SISAGNSSLCPIRD WHGSNRSWSWPD GAE (SEQ ID NO: 410)	ACCAAGAGCACCAACAGCAGGAGCGGC GGCATCAGCGGCCCCGACAACGAGGGC CCGTGGGCGAGGCCCCCAGCCCCCTAC GGCGACAACCCAGGCCCAACGACGGC AACAACATCAGGATCGGCAGCAAGGGC TACAACGGCATCATCACCGACACCATC GAGGAGAGCTGCAGCTGCTACCCCGAC GCCAAGGTGGTGAAGAGCGTGGAGCTG GACAGCACCATCTGGACCAGCGGCAGC AGCCCCAACCAGAAGATCATCACCATC GGCTGGGACCCCAACGGCTGGACCGGC ACCCCATGAGCCCCAACGGCGCCTAC GGCACCGACGGCCCCAGCAACGGCCAG GCCAACCAGCACCGAGGCCGAGAGCATC AGCGCCGGCAACAGCAGCCTGTGCCCC ATCAGGGACAACCTGGCAGCGCAGCAAC AGGAGCTGGAGCTGGCCCCGACGGCGCC GAG (SEQ ID NO: 411)
8	TAP (transport antigen presentation) on H5N1 virus hemagglutinin	EKIVLLAMMEKIV LLAKCQTPMGAIK AVDGVNKPYPYL SPSF (SEQ ID NO: 412)	GAGAAGATCGTGCTGCTGCTGGCCATG ATGGAGAAGATCGTGCTGCTGCTGGCC AAGTGCCAGACCCCCATGGGCGCCATC AAGGCCGTGGACGGCGTGACCAACAAG TGCCCCCTACCTGGGCAGCCCCAGCTTC (SEQ ID NO: 413)
9	TAP (transport antigen presentation) on h5n1 virus neuraminidase	IRPCFWVELNPNQK IITIRPCFWVELICYP DAGEIT (SEQ ID NO: 414)	ATCAGGCCCTGCTTCTGGGTGGAGCTGA ACCCCAACCAGAAGATCATCACCATCA GGCCCTGCTTCTGGGTGGAGCTGATCTG CTACCCCGACGCGGCGAGATCACC (SEQ ID NO: 415)
10	hemagglutinin epitopes toward class I HLA	MEKIVLLLAEKIVL LLAMCPYLGSPSFK CQTPMGAIKAVDG VTNK (SEQ ID NO: 416)	ATGGAGAAGATCGTGCTGCTGCTGGCC GAGAAGATCGTGCTGCTGCTGGCCATGT GCCCCCTACCTGGGCAGCCCCAGCTTCAA GTGCCAGACCCCATGGGCGCCATCAA

			GGCCGTGGACGGCGTGACCAACAAG (SEQ ID NO: 417)
11	neuraminidase epitopes toward class I HLA	NPNQKIITICYPDAGE ITIRPCFWVELRPCFW VELI (SEQ ID NO: 418)	AACCCCAACCAGAAGATCATCACCATCT GCTACCCCGACGCCGGCGAGATCACCAT CAGGCCCTGCTTCTGGGTGGAGCTGAGGC CCTGCTTCTGGGTGGAGCTGATC (SEQ ID NO: 419)
12	hemagglutinin epitopes toward class II HLA	MVSLVKSDQIGTSTL NQR (SEQ ID NO: 420)	ATGGTGAGCCTGGTGAAGAGCGACCAGA TCGGCACCAGCACCTGAACCAGAGG (SEQ ID NO: 421)
13	neuraminidase epitopes toward class II HLA	YNGIITDTI (SEQ ID NO: 422)	TACAACGGCATCATCACCGACACCATC (SEQ ID NO: 423)
14	hemagglutinin epitope H5N1- bound class I and class II HLA	MEKIVLLLAEKIVLL LAMMVSLVKSDQCP YLGSPSFIGTSTLNQR KCQTPMGAIKAVDG VTNK (SEQ ID NO: 424)	ATGGAGAAGATCGTGCTGCTGCTGGCCG AGAAGATCGTGCTGCTGCTGGCCATGATG GTGAGCCTGGTGAAGAGCGACCAAGTGGC CCTACCTGGGCAGCCCCAGCTTCATCGGC ACCAGCACCTGAACCAGAGG (SEQ ID NO: 425)
15	neuraminidase epitope H5N1- bound class I and class II HLA	NPNQKIITIYNGIITDT ICYPDAGEITIRPCFW VELRPCFWVELI (SEQ ID NO: 426)	AACCCCAACCAGAAGATCATCACCATCT ACAACGGCATCATCACCGACACCATCTGC TACCCCGACGCCGGCGAGATCACCATCA GGCCCTGCTTCTGGGTGGAGCTGAGGCC TGCTTCTGGGTGGAGCTGATC (SEQ ID NO: 427)

[1299] Below are additional examples of epitopes that may be integrated into a target gene for immunoepitope taggin:

References cited in Example 5

[1300] The following references are incorporated by reference in their entireties.

1. X. Wen, K. Wen, D. Cao, G. Li, R. W. Jones, J. Li, S. Szu, Y. Hoshino, L. Yuan, Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus ΔVP8* subunit parenteral vaccines. *Vaccine* 32, 4420-4427 (2014).
2. G. Ada, D. Isaacs, Carbohydrate-protein conjugate vaccines. *Clin Microbiol Infect* 9, 79-85 (2003).
3. E. Malito, B. Bursulaya, C. Chen, P. L. Surdo, M. Picchianti, E. Balducci, M. Biancucci, A. Brock, F. Berti, M. J. Bottomley, M. Nisum, P. Costantino, R. Rappuoli, G. Spraggon, Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. *Proceedings of the National Academy of Sciences* 109, 5229 (2012).

4. J. de Wit, M. E. Emmelot, M. C. M. Poelen, J. Lanfermeijer, W. G. H. Han, C. van Els, P. Kaaijk, The Human CD4(+) T Cell Response against Mumps Virus Targets a Broadly Recognized Nucleoprotein Epitope. *J Virol* 93, (2019).
5. M. May, C. A. Rieder, R. J. Rowe, Emergent lineages of mumps virus suggest the need for a polyvalent vaccine. *Int J Infect Dis* 66, 1-4 (2018).
6. M. Ramamurthy, P. Rajendiran, N. Saravanan, S. Sankar, S. Gopalan, B. Nandagopal, Identification of immunogenic B-cell epitope peptides of rubella virus E1 glycoprotein towards development of highly specific immunoassays and/or vaccine. *Conference Abstract*, (2019).
7. U. S. F. Tambunan, F. R. P. Sipahutar, A. A. Parikesit, D. Kerami, Vaccine Design for H5N1 Based on B- and T-cell Epitope Predictions. *Bioinform Biol Insights* 10, 27-35 (2016).

EXAMPLE 6 – USE OF PE TO ENABLE CHEMICAL-INDUCED DIMERIZATION OF TARGET PROTEINS IN VIVO

[1301] The prime editors described herein may also be used to place dimerization-induced biological processes, such as receptor signaling, under control of a convenient small-molecule drug by the genomic integration of genes encoding small-molecule binding proteins with prime editing is described herein. Using the prime editors described herein, the gene sequence encoding a small-molecule binding protein may be inserted within a gene encoding a target protein of interest in a living cell or patient. This edit alone should have no physiological effect. Upon administration of the small-molecule drug, which typically is a dimeric small molecule that can simultaneously bind to two drug-binding protein domains each of which is fused to a copy of the target protein, the small-molecule induces dimerization of the targeted protein. This target protein dimerization event then induces a biological signaling event, such as erythropoiesis or insulin signaling.

EXAMPLE 7 – DNA SEQUENCE INSERTION, DELETION, AND REPLACEMENT WITH DUAL PRIME EDITORS

[1302] This Example describes the use of multi-flap prime editing, specifically using dual prime editors, for the precise insertion of new DNA sequence, the precise deletion of endogenous genomic DNA sequence, or the replacement of an endogenous genomic DNA sequence with a new DNA sequence. See FIG. 90. This invention addresses a long-standing objective in genome engineering: the programmable insertion, deletion, or replacement of DNA sequences in the genomes of living cells. This technology could be applied to modify or edit the genome of any living cell for research, therapeutic, or industrial applications.

[1303] Previously, homology directed repair (HDR) of nuclease-induced double-strand DNA breaks (DSBs) has been used to insert, delete, or replace DNA sequences in the genomes of living cells. While versatile, the low efficiency of HDR limits its application in many mammalian cell types,

especially therapeutically relevant human cell types¹⁻⁴. Moreover, the generation of DSBs leads to preferential repair by error-prone end-joining mechanisms that produce insertion and deletion (indel) repair products which cannot be subsequently converted to the desired edited DNA sequence⁵⁻¹⁰. As a result, indels typically represent the majority of modified genomic DNA products when nucleases are used in mammalian cells. Moreover, DSBs generated by nucleases can lead to undesired genomic changes such as large deletions and chromosomal translocations¹¹, and the activation of p53^{12,13}. Structural variants (SVs) can also be generated or corrected using programmable nucleases without relying on homologous recombination, though nuclease-based strategies suffer similar drawbacks for these applications. For example, dual-cutting strategies can be used to invert a targeted genomic DNA sequence, but most product alleles contain large deletions between the cut sites instead of the desired inverted sequence, or indels at the individual cut sites.

[1304] Prime editing is a recently reported genome editing technology that enables the insertion, deletion, or replacement of genomic DNA sequences without requiring error-prone double-strand DNA breaks¹⁴. Prime editing uses an engineered Cas9 nickase–reverse transcriptase fusion protein (PE1 or PE2) paired with an engineered prime editing guide RNA (pegRNA) that both directs Cas9 to the target genomic site and encodes the information for installing the desired edit. Prime editing proceeds through a multi-step editing process: 1) the Cas9 domain binds and nicks the target genomic DNA site, which is specified by the pegRNA's spacer sequence; 2) the reverse transcriptase domain uses the nicked genomic DNA as a primer to initiate the synthesis of an edited DNA strand using an engineered extension on the pegRNA as a template for reverse transcription—this generates a single-stranded 3' flap containing the edited DNA sequence; 3) cellular DNA repair resolves the 3' flap intermediate by the displacement of a 5' flap species that occurs via invasion by the edited 3' flap, excision of the 5' flap containing the original DNA sequence, and ligation of the new 3' flap to incorporate the edited DNA strand, forming a heteroduplex of one edited and one unedited strand; and 4) cellular DNA repair replaces the unedited strand within the heteroduplex using the edited strand as a template for repair, completing the editing process.

[1305] Efficient incorporation of the desired edit requires that the newly synthesized 3' flap contains a portion of sequence that is homologous to the genomic DNA site. This homology enables the edited 3' flap to compete with the endogenous DNA strand (the corresponding 5' flap) for incorporation into the DNA duplex. Because the edited 3' flap will contain less sequence homology than the endogenous 5' flap, the competition is expected to favor the 5' flap strand. Thus, the 3' flap, which contains the edit, may fail to effectively invade and displace the 5' flap strand. Moreover, successful 3' flap invasion and removal of the 5' flap only incorporates the edit on one strand of the double-stranded DNA genome. Permanent installation of the edit requires cellular DNA repair to replace the unedited complementary DNA strand using the edited strand as a template. While the cell can be made to favor replacement of the unedited strand over the edited strand (step 4 above) by the introduction of a nick

in the unedited strand adjacent to the edit using a secondary sgRNA (the PE3 system), this process still relies on a second stage of DNA repair. These DNA repair steps may be particularly inefficient for edits which require equilibration of long 5' and 3' flap intermediates or contain long non-homologous regions, such as long insertions or long deletions.

[1306] This Example describes a dual prime editing system (or a dual-flap prime editing system) that addresses the challenges associated with flap equilibration and subsequent incorporation of the edit into the non-edited complementary genomic DNA strand by simultaneously editing both DNA strands. In the dual-flap prime editing system, two pegRNAs are used to target opposite strands of a genomic site and direct the synthesis of two complementary 3' flaps containing edited DNA sequence (**FIG. 91**). Unlike classical prime editing, there is no requirement for the pair of edited DNA strands (3' flaps) to directly compete with 5' flaps in endogenous genomic DNA, as the complementary edited strand is available for hybridization instead. Since both strands of the duplex are synthesized as edited DNA, the dual-flap prime editing system obviates the need for the replacement of the non-edited complementary DNA strand required by classical prime editing. Instead, cellular DNA repair machinery need only excise the paired 5' flaps (original genomic DNA) and ligate the paired 3' flaps (edited DNA) into the locus. Therefore, there is also no need to include sequences homologous to genomic DNA in the newly synthesized DNA strands, allowing selective hybridization of the new strands and facilitating edits that contain minimal genomic homology. Nuclease-active versions of prime editors that cut both strands of DNA could also be used to accelerate the removal of the original DNA sequence.

[1307] Depending on the orientation of the staggered DNA nicks generated by dual prime editors, the system can either replace the sequence between the two nicks with a new desired sequence (5' overhang staggered orientation), or insert new DNA sequence with concomitant target site duplication (3' overhang staggered orientation). **FIG. 90** shows an orientation (5' displaced nicks) where the sequence between the nicks is replaced. Of note, the new 3' flaps need not overlap completely along the length of the new DNA sequence, but instead can be complementary in just a portion of the new sequence. In this way, each flap can be shorter than the full length of the new DNA sequence.

Dual-flap prime editing at the *HEK293 site 3* locus

[1308] Dual-flap prime editing at the *HEK293 site 3* locus in human cells (HEK293T) was used to achieve highly efficient introduction of heterologous DNA sequences. For example, replacement of a 90-bp sequence in the locus with a new 22-bp sequence that encodes a 6xHis tag occurred with greater than 80% efficiency (**FIG. 92** allele table). Similarly, >60% yield was achieved for replacing this same 90-bp sequence with a GFP-11 peptide sequence (52 bp). The GFP-11 tag insertion was also performed at the C-terminus of the *MYC* gene with an efficiency of >20%, occurring with concomitant programmed deletion of a portion of the Myc 3' UTR sequence.

Dual-flap prime editing pegRNAs

[1309] The general designs of pegRNAs used for dual-flap prime editing are shown in FIG. 93. pegRNAs used for dual-flap prime editing have a similar design to those used for classic prime editing, however it is not necessary for the RT template region to encode any homology to the target locus. Instead, the two pegRNAs may contain RT templates that encode the synthesis of 3' flaps whose 3' ends are reverse complement sequences of one another. This complementarity between the 3' flaps promotes their annealing and replacement of the endogenous DNA sequence with the intended new DNA sequence. This necessitates that the 5' regions of the RT templates in the two pegRNAs are reverse complement sequences to one another, and this amount of complementarity can vary (FIG. 93).

Use of dual-flap prime editing to install recombination sites

[1310] Dual-flap prime editing has many potential applications, such as installing peptide tags, RNA tags, immunopeptides, dimerization domains, and recombinase target sites.

[1311] One such application is the installation of recombinase or integrase sequences at user-specified locations in the genome. FIG. 94 illustrates the installation of Bxb1 recombinase *attB* (38 bp) and *attP* (50 bp) sites into a targeted region of the human genome (*HEK293T site 3*, or *HEK3*) with simultaneous deletion of 90 bp of intervening sequence between the two nick sites. Various degrees of complementarity between 3' flaps allow for successful editing, though longer sequences of complementarity produce more favorable ratios of desired edits to indels. Other dual-flap prime editing applications include endogenous tagging of genes with peptide or protein sequences, or the replacement of exons with new DNA sequences that have the potential to substitute for multiple variants for which the mutation falls within the exon sequence.

[1312] Dual-flap prime editing can be used to introduce one or two recombinase sites at targeted positions in the human genome. If single recombinase sites are inserted, these can be used as landing sites for a recombinase-mediated reaction between the genomic recombinase site and a second recombinase site within an exogenously supplied DNA, such as a plasmid. This enables the targeted integration of DNA cargo. If two recombinase sites are inserted in adjacent regions of DNA, depending on the orientation of the recombinase sites, these can be used for recombinase-mediated excision or inversion of the intervening sequence, or for recombinase-mediated cassette exchange with exogenous DNA for cargo integration. Integration of compatible recombinase sites on different chromosomes enables targeted and directional chromosomal translocation. Dual-flap prime editing can be used to efficiently introduce recombinase sites at a number of loci in the human genome (FIG. 94). Thus, the pairing of recombinase site integration by dual-flap prime editing with DNA recombinase enzymes represents a powerful approach for achieving many types of SV edits and target integration of DNA cargo.

**EXAMPLE 8 – DNA SEQUENCE INSERTION, DELETION, INVERSION,
TRANSLOCATION, AND INTEGRATION USING QUADRUPLE-FLAP PRIME EDITING**

[1313] This Example describes the use of multi-flap prime editing, specifically quadruple-flap prime editing, for targeted insertion, deletion, duplication, and replacement of endogenous genomic DNA sequences, and for targeted genomic DNA sequence inversion, targeted chromosomal translocation, and targeted integration of exogenous DNA. This technology has the potential to address long-standing objectives in genome engineering: the programmable installation or correction of structural variants (generally defined as >50 bp of genomic sequence change, often represented by large deletions, insertions/duplications, inversion, and translocations), and the targeted integration of DNA cargo at a specific location in the human genome. The latter could enable gene augmentation therapeutic strategies and other biotechnology applications. This technology could potentially be applied to modify or edit the genome of any living cell for research, therapeutic, or industrial applications.

[1314] This invention describes a multi-flap prime editing system that addresses the challenges associated with flap equilibration and subsequent incorporation of the edit into the non-edited complementary genomic DNA strand by simultaneously editing both DNA strands. It also expands upon the capabilities of traditional prime editing by allowing the newly synthesized 3' flaps to direct larger sequence rearrangements.

[1315] A quadruple-flap prime editing approach was developed that can directly carry out desired sequence alterations without the need for a recombinase enzyme (as in dual-flap prime editing) but with similar versatility. In quadruple-flap prime editing, four different pegRNA sequences are delivered to cells along with the PE2 editor. One pair of pegRNAs template the synthesis of complementary DNA flaps, as with dual-flap prime editing, while the other pair of pegRNAs template the synthesis of an orthogonal pair of complementary DNA flaps. The location of these flaps, their relative orientation, and the pairing of complementarity dictates which class of rearrangement will occur. The junctions of the rearranged DNA contain the sequence encoded by the pegRNA-templated 3' flaps, which direct the orientation of the rearrangement and can serve as useful DNA sequence for downstream processes. Targeted genomic sequence inversion was performed with the quadruple-flap prime editing strategy (FIG. 95). An inversion of a 2.7-kb sequence at the AAVS1 locus in HEK293T cells was achieved using four pegRNAs that place Bxb1 attB and attP sequences at the inversion junctions. Verification of the expected junctions was performed using amplicon sequencing, which demonstrated the correct junctions containing the attB or attP site sequences in $\geq 90\%$ of the sequencing reads (FIG. 96).

[1316] Targeted integration of exogenous DNA plasmids was also achieved with quadruple-flap prime editing. In this approach, two pegRNAs target the endogenous genomic DNA site while two pegRNAs target a region on the cargo plasmid. 3' DNA flaps are synthesized on both the genomic

DNA and plasmid DNA so that the plasmid and genomic DNA will be bridged by hybridized 3' flaps (FIG. 97A). The excision of 5' overhangs and ligation of the nicks results in an integrated plasmid product. The orientation of integration can be controlled by the pairing of pegRNA template sequences.

[1317] A plasmid encoding the expression of a H2B-GFP fusion protein was integrated at the AAVS1 locus in HEK293T cells using quadruple-flap prime editing. This resulted in 1.6% of cells obtaining long-lasting, nuclear localized GFP fluorescence, as assessed by flow cytometry. PCR of a predicted junction showed the expected product containing the pegRNA-templated BxB1 attP sequence (FIG. 97B).

[1318] Chromosomal translocations were also performed using quadruple flap prime editing (FIG. 98A) to direct a chromosomal translocation between the MYC locus on chromosome 8 and the TIMM44 locus on chromosome 19 (FIG. 98B).

[1319] Dual flap prime editing at the IDS locus was performed with 12 pairs of pegRNAs and PE2. HEK293T cells were transfected with PE2 and different pairs of pegRNAs (*e.g.*, in the first column pegRNA A1_a and pegRNA B2_a with templates for installing attP site in the forward direction). The efficiency was measured by HTS. This data showed that dual-flap editing can successfully insert the sequence of interest to the IDS locus with an efficiency up to ~80% (FIG. 99).

[1320] Dual-flap-mediated duplication was also performed at the AAVS1 locus in 293T cells (FIG. 100A). Dual-flap pegRNA with PE2 was used to induce duplication of genetic sequences at AAVS1 (FIG. 100B).

[1321] Multi-flap prime editing induced translocation of MYC-CCR5 was also performed (FIG. 101). MYC-CCR5 translocation was induced by quad-flap pegRNAs and PE2. MYC-CCR5 translocation events were induced by quadruple-pegRNAs. Four different sets of pegRNAs were tested in HEK293T cells. The translocation junction products between derived chr8 and chr3 were amplified by junction primers. The percent of reads aligned to the expected junction alleles are shown in the graph. This shows that quadruple-flap prime editing can mediate translocation of MYC and CCR5 gene with product purity near 100% at junction 1 and ~50% at junction 2. A representative allele plot shows the sequences aligned to the expected allele sequences at junction 1.

[1322] Dual-flap and quadruple-flap prime editing were also performed in other human cell lines (FIGs. 102A-102B). Dual-flap prime editing was performed in four different human cell lines (FIG. 102A). HEK293T and HeLa cells were transfected with dual pegRNAs and PE2 for editing three different genomic loci (IDS, MYC, and TIMM44). U2OS and K562 cells were nucleofected with the same components. Dual-flap prime editing showed robust editing efficiency across all four human cells at the targeted loci, particularly at HEK293T and K562 cells. The cellular mechanisms for enabling dual-flap prime editing are conserved across many human cell types. Multi-flap (quadruple-

pegRNA) directed inversion of a 2.7 kb sequence was also performed at the AAVS1 locus in HeLa cells (FIG. 102B).

[1323] Inversion efficiency was also measured by HTS at the CCR5 locus (FIG. 103A-103B). Percentage of the expected inversion edit allele was measured by HTS. Four quad-pegRNA sets of PE2 were transfected in HEK293T cells, respectively. Dual-flap mediated sequence duplication (~100nt) at the CCR5 locus in HEK293T cells was performed (FIG. 103A). The editing efficiency achieves ~1.5% via HTS 300-cycle pair-end sequencing analysis. Quadruple-flap-mediated sequence inversion (~95-117nt) was also performed at the CCR5 locus in HeLa cells (FIG. 103B). The editing efficiency achieves ~1.2% via HTS 300-cycle pair-end sequencing analysis. This result shows that multi-flap prime editing can successfully mediate duplication and inversion at the CCR5 locus precisely. The editing specificity is high when the targeted sequence is duplicated (percentage of indels < 2%).

[1324] Next, HEK293T cells were transfected with the plasmids that express Exo1, Fen1, Red Fluorescence Protein (control), DNA2, Mlh1 neg, and P53 inhibitor with pegRNA and PE2 (FIGs. 104A-104D). The editing efficiency was measured by HTS. The editing efficiency was compared between the candidate and the RFP control. HEK293T cells were also transfected with the siRNA plasmids and pegRNA and PE2 for each target locus (FIG. 104E). Non-targeting siRNA (siNT) was used as the control. The editing efficiency was measured by HTS. The editing efficiency was compared between each siRNA knockdown and the siNT ctrl at each target locus. HEK293T cells were transfected with dual-pegRNAs, PE2, and the plasmids that express Exo1, Fen1, Red Fluorescence Protein (ctrl), DNA2, Mlh1 neg, and P53 inhibitor, respectively. The editing efficiency was measured by HTS. The editing efficiency was compared between the candidate and the RFP control. It was found that overexpression of FEN1 improves dual flap editing efficiency in all four targeted loci (MYC, TIMM44, IDS, CCR5).

[1325] Dual-flap-mediated sequence duplication was also performed at the AAVS1 locus (FIG. 105A). By using dual pegRNAs that generate two unique 3' flap structures, a ~300bp sequence duplication was induced at AAVS1 locus in 293T cells (FIG. 105B). Expected alleles were amplified with specific primers and subjected for HTS. Approximately 94% of reads were aligned to the expected alleles with duplication. Duplication products were not observed in the untreated samples.

[1326] Targeted IDS genomic sequence inversion was also performed with quadruple-flap prime editing (FIG. 106). Approximately 13% of Hunter syndrome patients have been shown to have an inversion of the IDS gene sequences (Bondeson et al., Human Molecular Genetics, 1995). Quadruple-flap prime editing was applied to induce this pathogenic inversion of the approximately 40kb IDS genomic sequence in the HEK293T cells. Six sets of quadruple pegRNAs were tested by transfecting HEK293T cells with the pegRNAs and PE2. Primers were used to specifically amplify the inverted sequences at junction "ab" and junction "cd". Approximately 95% of the expected inverted allele

sequences were observed at both junctions with IDS_QF1. Other sets of pegRNAs also yield high percentage of the expected allele sequences at both junctions. Inverted junction products are not observed in the untreated samples.

[1327] It was also found that PegRNA 3' motif modification improves dual-flap editing efficiency at the IDS locus (FIG. 107). To further improve the dual flap editing efficiency, a pseudoknot evoPreQ1 motif was introduced to protect the pegRNA 3' end. In comparing the editing efficiency generated by the unmodified and evoPreQ1-modified dual pegRNAs, there was an overall increase of the editing efficiency with modified pegRNAs at the targeted IDS locus. The improvement of dual-flap editing efficiency can reach up to 5.3-fold.

References (Examples 7 and 8):

- [1328]** 1. Rouet, P., Smih, F. & Jasin, M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. *PNAS* 91, 6064–6068 (1994).
- [1329]** 2. Heyer, W.-D., Ehmsen, K. T. & Liu, J. Regulation of homologous recombination in eukaryotes. *Annu. Rev. Genet.* 44, 113–139 (2010).
- [1330]** 3. Chapman, J. R., Taylor, M. R. G. & Boulton, S. J. Playing the end game: DNA double-strand break repair pathway choice. *Mol. Cell* 47, 497–510 (2012).
- [1331]** 4. Cox, D. B. T., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. *Nature Medicine* 21, 121–131 (2015).
- [1332]** 5. Rouet, P., Smih, F. & Jasin, M. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. *Mol Cell Biol* 14, 8096–8106 (1994).
- [1333]** 6. Bibikova, M., Golic, M., Golic, K. G. & Carroll, D. Targeted chromosomal cleavage and mutagenesis in *Drosophila* using zinc-finger nucleases. *Genetics* 161, 1169–1175 (2002).
- [1334]** 7. Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with engineered zinc finger nucleases. *Nat Rev Genet* 11, 636–646 (2010).
- [1335]** 8. Mali, P. et al. RNA-guided human genome engineering via Cas9. *Science* 339, 823–826 (2013).
- [1336]** 9. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. *Science* 339, 819–823 (2013).
- [1337]** 10. Jinek, M. et al. RNA-programmed genome editing in human cells. *eLife* 2, e00471 (2013).
- [1338]** 11. Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. *Nature Biotechnology* 36, 765–771 (2018).

- [1339] 12. Ihry, R. J. et al. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. *Nature Medicine* 24, 939–946 (2018).
- [1340] 13. Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response. *Nature Medicine* 24, 927–930 (2018).
- [1341] 14. Anzalone, A. V. *et al.* Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature* 576, 149–157 (2019).

EXAMPLE 9 – PROGRAMMABLE LARGE DNA DELETION, REPLACEMENT, INTEGRATION, AND INVERSION WITH TWIN PRIME EDITING AND SITE-SPECIFIC RECOMBINASES

[1342] The targeted deletion, replacement, integration, or inversion of DNA sequences at specified locations in the genome can in principle be used to study or treat many human genetic diseases. However, it remains challenging to precisely and efficiently carry out these DNA sequence transformations in the context of a mammalian cell genome. Presented herein is twin prime editing (twinPE), a method for the programmable replacement or excision of DNA sequence at endogenous human genomic sites without requiring double-strand DNA breaks. twinPE employs a prime editor (PE) protein and two prime editing guide RNAs (pegRNAs) that template the synthesis of complementary DNA flaps on opposing strands of genomic DNA, resulting in the replacement of endogenous DNA sequence between the PE-induced nick sites with pegRNA-encoded sequences. It is shown herein that twinPE can perform precise deletions of up to 780 bp and precise replacements of genomic DNA sequence with new sequences of up to 108 bp. By combining single or multiplexed twinPE with site-specific serine recombinases, it is demonstrated that targeted integration of gene-sized DNA plasmids at safe-harbor loci including *AAVS1*, *CCR5*, and *ALB*, and further, a 39-kb inversion at *IDS* that could be used to correct a common Hunter syndrome allele is also demonstrated. TwinPE substantially expands genome editing capabilities without requiring double-strand DNA breaks and, in combination with other genome editing tools, enables the correction or complementation of complex pathogenic allele variants in human cells.

[1343] Disease-associated human genetic variants arise through a variety of sequence changes, ranging from single-base pair substitutions to mega base-scale deletions and rearrangements. Genome editing approaches that can install, correct, or complement these pathogenic variants in human cells have the potential to advance understanding of human genetic disease and could lead to the development of novel therapeutics. Recently, several genome editing approaches based on CRISPR–Cas systems have been developed for genome editing, including nucleases, base editors, and prime editors. CRISPR–Cas nucleases, when used with one guide RNA, can be used to disrupt genes through the generation of double-strand DNA breaks (DSBs) that lead to stochastic indels. Base editors can be used to precisely install C•G-to-T•A or A•T-to-G•C transition base pair edits, or C•G-to-G•C base

pair edits. Prime editors can precisely install of any one of the twelve base pair substitution edits as well as small to medium-sized insertions and deletions. However, these strategies alone are not directly applicable for making more substantial genome edits, such as large deletions, insertions, replacements, or inversions.

[1344] Previously, paired Cas9 nuclease strategies have been developed for the targeted deletion of genomic DNA sequences ranging from ~50 to >100,000 base pairs in length. Moreover, by providing a linear donor DNA sequence, targeted insertion of new DNA sequences can be performed at single cut sites or between paired cut sites through end-joining or homology-directed DNA repair processes. While versatile in many ways, single-nuclease and paired-nuclease approaches are accompanied by several drawbacks. First, the use of paired nucleases for deletions can generate multiple on-target byproducts, including the desired deletion with indels, indels at individual DSB sites without the desired deletion, undesired inversion of the DNA sequence between DSB sites, and unintended integration of exogenous DNA sequence at DSB sites. Furthermore, the precise location of the deletions is restricted by PAM availability and the corresponding cut sites generated by the nuclease. Similar restrictions and byproducts exist for DNA donor knock-in, which often occurs without control of sequence orientation when homology-independent approaches are used. Finally, the simultaneous generation of multiple DSBs at on-target and off-target sites, which becomes more likely with additional guide RNAs, can lead to off-target genome modification, chromosomal rearrangements, or chromothripsis. Therefore, considerable challenges exist relating to product control and purity when applying nuclease-based editing strategies for the excision, replacement, or insertion of larger DNA sequences.

[1345] Prime editing has been shown to be capable of making precise insertions of up to ~40 bp and deletions of up to ~80bp in human cells with high desired product to byproduct ratios. In principle, prime editing could be used to circumvent many of the challenges associated with nucleases by avoiding the generation of DSBs. However, prime editing has not yet been shown to mediate larger insertions and deletions of the size of typical gene coding sequences, and the presumed mechanism of simple prime editing reactions makes these larger DNA changes difficult by requiring long pegRNA reverse transcription templates. Site-specific DNA recombinase enzymes have the ability to perform several DNA transformations, including excision, inversion, integration, or exchange of large DNA sequences. However, challenges with reprogramming site-specific recombinases currently makes it challenging to apply for genome engineering and editing applications.

[1346] Presented herein is the development of twin prime editing (twinPE), which enables the deletion, substitution, or insertion of DNA sequence at endogenous genomic sites with high efficiencies in human cells. In addition to these changes, it is shown that twinPE can be used to integrate one or more recombinase recognition sites with high efficiency at targeted sites in the human genome, which can subsequently be used as substrates for site-specific serine recombinase enzymes

that enable the targeted integration of genetic cargo or the targeted inversion of genomic DNA sequence.

Results

[1347] Prime editing uses a prime editor protein comprising a fusion of a catalytically impaired Cas9 nickase and a wild-type (PE1) or engineered (PE2) MMLV reverse transcriptase enzyme, and a prime editing guide RNA (pegRNA) that both specifies the target genomic site and encodes the desired edit. Upon target site recognition, PE•pegRNA complexes nick the PAM-containing DNA strand and directly reverse transcribe the pegRNA's RT template into genomic DNA using the nicked strand as a primer. Following reverse transcription, the newly synthesized 3' flap invades the adjacent DNA, to which it is largely homologous, to replace the redundant 5' flap sequence. The opposing nonedited strand is then repaired using the edited DNA strand as a template. This proposed editing pathway therefore presents two opportunities at which cellular DNA repair can reject the desired edit and revert the DNA sequence to its original form.

[1348] It was predicted that bypassing potentially disfavored steps in DNA repair could allow prime editing to occur with increased efficiency and enable distinct classes of genome edits. Furthermore, a twin prime editing (twinPE) strategy that uses a pair of pegRNAs, each of which targets one or the other DNA strand and templates the synthesis of a 3' flap DNA sequence that is complementary to the sequence templated by the other pegRNA was envisioned (**FIG. 108A**). It was hypothesized that if the newly synthesized DNA strands were highly dissimilar to the endogenous target site, the 3' flaps would preferentially hybridize to create an intermediate possessing annealed 3' overhangs of new DNA sequence and annealed 5' overhangs of original DNA sequence (**FIG. 108A**). As both edited strands are synthesized by prime editor complexes, there is no requirement for invasion of the target site by edit-containing flap strands, or for the edit to be copied into the complementary DNA strand. Excision of the original DNA sequence (annealed 5' overhangs), filling in of gaps by polymerases, and ligation of the pair of nicks would result in the replacement of the endogenous sequence between the nick sites with the paired 3' flap sequences (**FIG. 108A**). Due to the flexibility in template design, the edit could in principle introduce a new DNA sequence, replace a portion of DNA sequence, or delete a portion of DNA sequence.

[1349] To evaluate the twinPE strategy, the *HEK site 3* locus (previously referred to as *HEK3*) in HEK293T was targeted to replace 90 bp of endogenous sequence with a 38-bp Bxb1 *attB* attachment sequence (**FIG. 108B**). For each protospacer, three pegRNAs were designed with RT templates that contained 30, 34, or 38 nt of the 38-bp *attB* sequence (**FIG. 108C**). Pairwise combinations of these pegRNA are predicted to generate 3' flaps with overlapping complementarity ranging from 22 to 38 bp (**FIG. 108C**). Excitingly, when both pegRNAs were delivered to cells along with PE2 in a plasmid DNA transfection, high efficiency of *attB* site insertion was observed, with some combinations of pegRNAs yielding >80% conversion to the desired product based on amplicon sequencing (**FIG.**

108C). A similar strategy for the insertion of the 50-bp Bxb1 *attP* attachment sequence achieved editing with efficiencies reaching up to 58% (**FIG. 108C**). Notably, it was not necessary for each pegRNA to encode the full insertion sequence, since partially overlapping complementary flaps enabled full-length *attB* or *attP* sequence incorporation. However, 3' flaps with greater overlap led to slightly higher editing efficiencies and fewer indels for insertion of the Bxb1 *attB* and *attP* sequences at *HEK site 3*.

[1350] Next, twinPE was tested to determine if it could support the insertion of DNA sequences larger than that which has been demonstrated using the PE2 or PE3 systems. First, PE3-mediated insertions of FKBP12 coding sequence fragments ranging from 12 to 321 bp were examined. Targeting the *HEK site 3* locus with PE3, modest efficiencies were achieved for the shorter 12-bp and 36-bp insertions (31.8% and 17.3%, respectively), but very little desired product was observed for the 108-bp insertion (0.8%) and no full-length product for the 321-bp insertion (**FIG. 109A**). By contrast, twinPE enabled 16% insertion efficiency for the 108-bp fragment, amounting to a 20-fold improvement over PE3. Furthermore, 113-bp and 103-bp insertions containing paired Bxb1 recombinase sites were achieved with similar efficiencies (10.7% and 9.7%, respectively) at the CCR5 locus (data not shown). These results illustrate the potential for larger sequence insertion using twinPE compared to PE3.

[1351] One potential application of the twinPE strategy is the replacement of exonic coding sequence with recoded DNA sequence that maintains the protein sequence and has the potential to correct any mutation between target twinPE-induced nick sites. To test this approach, the *PAH* gene was targeted, mutations in which cause the genetic metabolic disorder phenylketonuria (PKU). Recoding of portions of exon 4 and exon 7 was tested in *PAH* of wild type HEK293T cells, where corrective editing is detectable. By testing different flap overlap lengths and with the addition of evoPreQ1 motifs to the 3' end of the pegRNAs, the desired sequence recoding was achieved with modest efficiencies reaching up to 9.4% average efficiency for a 64-bp recoding in exon 4, up to 22.7% average efficiency for a 46-bp recoding in exon 7, and up to 27.4% average efficiency for a 64-bp recoding in exon 7 (**FIG. 109B**). Based on mutations annotated in bioPKU database, twinPE editing of these regions collectively allow for the correction of distinct mutations implicated in PKU. Additional exons examined could also be recoded, albeit with lower efficiency (**FIG. 112**). These results demonstrate that twinPE could in principle be used to correct multiple mutations with a single pair of pegRNAs.

[1352] In addition to insertion and replacement of DNA sequences, twinPE should also be able to make precise deletion edits. Paired-nuclease deletion strategies generate deletions that span the two DSB sites and are thus restricted by PAM availability, and desired deletions are often accompanied by undesired indel byproducts. By contrast, twinPE has the potential to make deletions with greater flexibility and precision due to the lack of DSB generation and the ability to write in additional DNA

sequence at the twinPE-induced nick sites. To assess twinPE for precise deletions, three strategies using paired pegRNAs were compared: a “single-anchor” twinPE strategy, a “hybrid-anchor” twinPE strategy, and the recently reported “PrimeDel” strategy (**FIG. 109C**). Each strategy differs in the sequence that is encoded in the complementary flaps, allowing for flexibility in the positioning of the deletion with respect to the nick sites.

[1353] Using the single-anchor strategy, 13-nt complementary flaps were used to delete 77 bp of sequence adjacent to one of the pegRNA-induced nick sites with 14.8% efficiency, and 34-nt complementary flaps were used to precisely excise 56 bp of sequence with 18.8% efficiency (**FIG. 109D**). Using the hybrid-anchor strategy, 64 bp were deleted between the pegRNA-induced nick sites such that the product retains 13 bp of sequence 3' of each nick, with 11.7% efficiency (**FIG. 109D**). Finally, the PrimeDel strategy was tested for the deletion of 90 bp between the pegRNA-induced nick sites, which occurred with 40.4% efficiency (**FIG. 109D**). Of note, the PrimeDel strategy disrupts the PAM sequences on both strands, which likely increases efficiency while also decreasing indels. Editing efficiencies could be improved 1.5-fold to 2.5-fold by the addition of the evoPreQ1 motif the 3' end of the pegRNAs, albeit with accompanied increases in indels in some cases (**FIG. 109D**). Together, these data show that twinPE offers a strategy for performing targeted deletions with high flexibility that does not rely on availability of perfectly positioned nuclease cut sites.

[1354] Lastly, a therapeutically relevant locus, *DMD*, was targeted to apply twinPE for larger deletions. Pathogenic *DMD* alleles, which are responsible for Duchenne muscular dystrophy, commonly contain large deletions in regions containing exons that result in frameshifted mRNA transcripts. Because production of full-length dystrophin protein without replacement of deleted exons can lead to partial rescue of protein function, disruption of a second exon that restores the reading frame has been proposed as a potential therapeutic strategy. Three twinPE deletion strategies were examined along with a previously reported Cas9 nuclease deletion strategy for excising exon 51 in *DMD*. Using single-anchor twinPE deletion approaches, 14.4% to 24% efficiency was observed for the deletion of a 780-bp sequence containing exon 51 in *DMD* (**FIG. 109E**). While the paired Cas9 nuclease strategy achieved higher deletion efficiency (averaging 49.8%) compared to the twinPE strategies (averaging 14% to 24%), paired Cas9 nuclease-mediated deletion was also accompanied by much higher indel levels (33% desired deletion with indels, 11% indels without the desired deletion) compared to twinPE (1% to 12% total indels) (**FIG. 109E**). Exon 51 of *DMD* could also be excised using alternative spacer pairs that generate a 627-bp deletion with the PrimeDel strategy (28.8% average efficiency) or a 590-bp deletion with the single-anchor twinPE strategy (26.4% average efficiency), or by using twinPE to replace a 589-bp sequence with a 38-bp Bxb1 *attB* sequence (up to 40.4% average efficiency) (**FIG. 109E**). These experiments show that twinPE and PrimeDel are capable of generating large deletions at therapeutically relevant loci in human cells with superior product purity compared to paired Cas9 nuclease strategies, albeit with lower average efficiencies.

Targeted DNA integration at safe harbor loci with twinPE and Bxb1 integrase

[1355] Although twinPE is able to perform larger insertion edits than PE3, the upper limits of sequence insertion size were still not sufficient to support the integration of gene-sized DNA fragments. Therefore, having successfully inserted Bxb1 attachment sequences into endogenous human genomic sites with high efficiency using twinPE, twinPE was combined with serine recombinases for the site-specific integration of DNA cargo. To identify locations for DNA cargo integration, the twinPE-mediated insertion of Bxb1 *attB* and *attP* attachment sequences at established safe harbor loci in HEK293T cells. 32 spacer pairs targeting the *AAVS1* locus were screened for insertion of the 50-bp Bxb1 *attP* sequence (data not shown). Of the evaluated spacer pairs, optimal pegRNAs for 18 out of 32 spacer combinations achieved >50% correct insertion efficiency by amplicon sequencing (**FIG. 110A**). Additionally, 19 spacer pairs targeting the *CCR5* locus were screened for insertion of the 38-bp Bxb1 *attB* sequence (data not shown), of which 6 spacer pairs achieved >50% desired editing efficiency by amplicon sequencing (**FIG. 110B**). These results demonstrate that twinPE can be used to insert recombinase attachment sequences at safe harbor loci in human cells with high efficiency.

[1356] Next, twinPE-incorporated Bxb1 *attB* and *attP* sequences were examined to determine if they could serve as target sites for the integration of plasmid DNA cargo harboring partner Bxb1 attachment sites. First, twinPE was used to generate single-cell clones bearing homozygous *attB* site insertions at the *CCR5* locus (data not shown). Transfection of this clonal cell line with a plasmid expressing Bxb1 recombinase and a 5.6-kB *attP*-containing donor DNA plasmid yielded 12-17% knock-in at the target site as measured by ddPCR (**FIG. 113**), consistent with previously reported Bxb1 integration efficiencies. Encouraged by these results, twinPE-mediated attachment site insertion and Bxb1-mediated DNA donor integration were explored to determine if they could be achieved in a single transfection step. Excitingly, transfection of HEK293T cells with plasmids encoding PE2, both pegRNAs, Bxb1, and donor DNA resulted in 1.4 - 6.8% knock-in efficiency as measured by ddPCR (**FIG. 110C**). The expected junction sequences containing the expected *attL* and *attR* recombination products were confirmed by amplicon sequencing, with product purities ranging from 71-95% (**FIG. 114**).

[1357] In an effort to improve the “one-pot” knock-in efficiency, the twinPE-mediated incorporation of either *attB* or *attP* attachment sites, the canonical (GT) Bxb1 core sequence, an alternative (GA) Bxb1 core sequence, and varying flap overlap lengths were tested. It was found that the incorporation of the *attB* site with twinPE performed better than the incorporation of the *attP* site for one-pot knock-in transfections (3.3% vs. 0.5% knock-in, **FIG. 110D**). In addition, it was observed that insertions of attachment sites with the canonical GT core sequence generally led to higher knock-in efficiencies than insertions of attachment sites with the alternative GA sequence (3.3% vs. 0% in the *attB* context, **FIG. 110D**). Of note, however, the canonical and alternative core sequences allow for orthogonal

recombination with corresponding *attP* attachment sites. Reducing overlap between pegRNA-encoded recombinase sequences also improved knock-in efficiency, from 3.3% with 38 base pairs of overlap to 5.5% with 20 base pairs of overlap when inserting attB (**FIG. 110D**), possibly due to the reduced extent of attachment sequence within the pegRNA-expressing plasmid DNA sequence. Although similar twinPE efficiency was observed across overlap lengths, recombination between donor DNA and pegRNA plasmid was reduced (**FIGs. 115A-115B**).

[1358] Next, donor integration was evaluated at the *ALB* locus, which can be coopted for therapeutic protein secretion from hepatocytes. Albumin is actively secreted by the liver and constitutes approximately 60% of human plasma proteins. Therefore, therapeutic transgene integration at the *ALB* locus in a relatively small percentage of hepatocytes could achieve therapeutic levels of protein expression for many diseases. A strategy targeting intron 1 of *ALB* was devised, wherein Bxb1 would mediate the integration of circular DNA containing a splice acceptor sequence followed by the cDNA for a protein of interest. Integration would in principle allow for splicing of the albumin secretion signal, encoded in exon 1, to the therapeutic transgene coding sequence. First, pegRNA pairs were screened for the insertion of the Bxb1 *attB* sequence within intron 1 of *ALB*. After screening pegRNA pairs, a spacer combination that achieved 43% correct insertion of the *attB* sequence by amplicon sequencing was identified (**FIG. 110E**). Single transfection knock-in at this locus was achieved with 1.3% efficiency in HEK293T (**FIG. 110F**). In Huh7 cells, 34% correct insertion of the *attB* sequence, with single transfection knock-in efficiency of 2.6% was observed. Interestingly, knock-in at *ALB* in Huh7 was more efficient than knock-in at CCR5 (2.6% vs. 1.1%), despite CCR5 knock-in being more efficient than *ALB* knock-in in HEK293T cells.

Table 14. DNA donor sequences used in this Example

DNA donor	Sequence	SEQ ID NO:
attB_Puro_GA donor DNA:	gatgccagctcattctcccactcatgatctatagatccccgggctgcaggaattctaccactctgtcgataccccaccgagaccc cattggggccaatacagccccgctttcttcttccccaccaccaccaagttcgggtgaaggccagggctcgagccaacgtc gggcgcgcaagcttacatcgagatcccggtgtcgcagacggcggaactccgtcgtcaggatcatccgtgagcaaggcgagga gctgttcaccggggtgtgcccactctggtcagctggacggcgacgttaaacggccacaagtgcagctgtccggcgagggcga gggcgatgccactacggcaagctgacctgaagtcatctgcaccaccggcaagctgcccgtgcccctggcccacctctgtacc acctgacctacggcggtgcagtgtctcagccgctaccccaccacatgaagcagcagcacttctcaagtccgccatgccgaag gctacgtccaggagcgcaccatcttcaaggacgacggcaactacaagaccgcccaggtgaagtgcagggcgacaccc tggtaaccgcatcgagctgaaggcgcactcaaggaggacggcaacatccctggggcacaagctggagtacaactacaaca gccacaacgtctatcatgcccacaagcagaagaacggcatcaaggtgaactcaagatccgccacaacatcgaggacggca gcgtgcagctcgccgaccactaccagcagaacacccccatcgccgacggccccgtgctgctgcccgaacactacctgagca cccagtcgccctgagcaaaagcccaacgagaagcgcatcacatggtctgtgagttcgtgaccgccggcggtactct cgcatggagcagctgtacaagagcgccctgagggagcagagccaggcgagcaacagcgccgtggacgccaccatggggcga tcgccgggaattgactagtgcggcgctaggatccatgcgatagcgttggtgagtgataaccgtattaccgccaagcttatg catgtgccgtcagtgaggcagagcgcacatcgccacagtcgccgagaagttggggggaggggtcgcaattgaaccggtgcct agagaaggtggcgccgggttaactgggaagtgtatgtgtgtactggctccgctttttcccgagggtgggggagaaccgtatata agtgacgtatgcgcgtgaacgttttttgcacagggtttgccgccagaacacaggttaagtcggtgtgtgtccgcgggct ggctctttacgggttatggcccttgctgctgctgaattactccacctggtcgtcagtagctgattcttgatccgagcttcgggttga agtgggtgggagagttcggagggccttgcttaaggagcccttcgctgtgcttgagttgagcctggcctggcgctggggcc gcccggtgcgaatctggtggcaccttcgcgctgtctcgtgcttgcataagctctagccatttaaaattttgatgacctgctgcga cgttttttgcgaagatagcttgaatgcggccaaagatctgcacactgtatttcggttttggggccggggcgagcggg gcccgtgctgccagcgcacatgttcggcgaggcgggcgctgcgagcgccgaccgagaatcgagcggggtgagtctcaag	4282

	<p>ctggccggcctgctctgggtgcttggcctcgcgcgcgcgtgtatcgcgcccgccctggggcgaaggctggccggctggcaccag ttgctgtagcggaaagatggccgcttccggccctgctgcaggagagctcaaaatggaggacggcgcctgggagagcgggc gggtgagtcacccacaaaaggaaaaggcccttccgtctcagccgtcgttcatgtgactccacggagtaccggcgccgtcc aggcaccctcattagttctcgcgcttttgagtacgtcgtcttaggttgggggaggggtttatgcgatggagttccccacactga gtgggtggagactgaagtttagccagctggcacttgatgaattctccttggaaatttgcctttttagttggatcttgggtcattctca gcctcagacagtgttcaaaatttttccatttcaggtgtcgtgagctagccaccatgaccgagtacaagcccacggctgcct cgccaccggcgcacgacgtccccgggcccgtacgcaccctcgcgcgcgttcgcccactaccggccacggcgccacaccgtcg accgggaccggcacatcgagcgggtcaccgagctgcaagaactcttctcaccgcgcgtcggctcgcacacggcgaaggtgtggg tcgggacgacggcggcgggtggtggtcgtgaccacggcgagagcgtcgaagcggggggggtgttcggcgagatggccc cgcgcatggccgagttgagcgggttccggctggcgcgcagcaacagatggaaggcctcctggcggcaccggcccaagga gcccgcgtggttctgcccaccgtcggcgtcgcgcgaccaccaggggcaagggtctgggcagcggcctgctgctccccggagt ggaggcggcggagcggcgggtgcccgccttctggagacctccgcgcccgcaacctcccccttctacgagcggctcggtt caccgtcaccggcgcacgtcaggtgcccgaaggaccgcgcacctgtgtcatgaccggcaagcccgggtcgccggtcgggagag ggcagagggaagtctgctaactgcgggtgacgtcggaggagaatctggcccaccggctgcaccacggcagctgattaaggagaac atgcacatgaagctgtacatggaggcaccgtggacaaccatcactcaagtgcacatccgagggggaaggcaagccctacgag ggcaccacagaccatgagaatcaaggtgtcgaaggcggccctctcccttgccttgcacatctggtactagcttctctacggc agcaagaccttcataccacaccaggcgatccccgacttcttaagcagtccttccctgagggttcacatgggagagagtcac cacatacgaagacggggcgctgctgaccgctaccaggacaccagcctccaggacggctgctcatctacaacgtcaagatcag agggggtgaacttcacatccaacggccctgtgtatgcagaagaaaactcggctgggagggccttaccggagacgtgtaccggct gacggcgccctggaggcagaaaacgacatggccctgaagctcgtggcgggagccatctgacgcaaacatcaagaccacat agatccaagaaaccgctaagaacctcaagatgcctggcgtctactatgtggactacagactggaaagaaatcaaggaggccaaca acgagacctacgtcagcagcagcaggtggcagtgccagatactgcgacctccctagcaaaactggggcacaagcttaataaga attctctagaggatccagacatgataagatactgtgagtttgacaacacaaactagaatgcagtgaaaaaatgctttatttgg aaatttggatgctattgctttatttgaaccattataagctgcaataaacaagttacaacaacaattgcattcattttatgttcaggttcag ggggaggtgtgggaggtttttaaagcaagtaaaacctctacaatgtgtatggtgattatgacctgcaagcctcgtcggcgccg ttattctgttgacaattaatcatcgcatagatatcgcatagataatcagcaaggtgaggaaactaaaccatgggacgtggccattg aacaagatgattgcacgacggttctcggccgttgggtggagaggtctattcggctatgactggcacaacagacatcgctg ctctgatcccgctgttccggctgtcagcgcaggggcgccggttcttttgaagaccgacctgtccgtggtccctgaatgaact gcaggacgaggcagcgcggctatcgtggtggccacgacggcggttcttgcgcagctgtgctgcagctgtcactgaagcggg aagggactggtctattggcggaagtccggggcagcgtctctgtcctcaccctgctcctggcgaagatcatcatggtc tgatgcaatggcggcgtgcatacgtgtacccggctacctgcccattcgaccaccaagcgaacatcgatcgcagcgcacgta ctcggatggaaagccggctgtgtcgtacagatgacgtggacgaagagcatcaggggctcgcgcagccgaactgttcgccaggt caaggcgcgcacatccccgacggcagggatctcgtcgtgacccatggcgatgcctgttgcgaatatcatggtgaaaaatggccgc ttttctgattcatcgactgtgcccggctgtggtggtgacggcgtatcaggacatagcgttgggtaccgtgatattgtgaagagc ttggcgccgaatggctgaccgcttctcgtgttctacgtatcgcgcgcggcggattcgcagcgcacgccttctatcgccttctgac gagttcttctgagcgggactcgtgggttcgaataaagaccgaccaagcgcgtctgagagctccctggcgaattcggtaccaataa aagagctttatttcatgatctgtgtgtgttttggccgctgtgctggcgtttttccataggctccgccccctgacgagcatcaaaa aatcgcagctcaagtcagaggtggcgaacccgacaggactataaagatacaggcggtttccccctggaagctccctcgtgcgtc tcctgttccgacctgcgcttaccggatacctgtccgcttctccttccgggaagcgtggtcgttctcatagctcagcgtgtaggta tctcagttcgggtgtggtcgttccgctcgaagctggcgtgtgtgcacgaacccccgttaccggcaccgctgcgcttaccggtaac tatcgtcttgatccaacccggaagacacgacttatcgcactggcagcagccactgtaaacaggattagcagagcaggtatgta ggcggtgctacagagttctgaagtgggtgacctacggtacactagaagaacagatttggatctgcgctcgtcgtgaagccag ttaccttgcgaaaaagagttgtgagctctgtatccggcaaacaaaccaccgctgtgtagcgtgtgtttttgttgaagcagcagatt acgcgcgaaaaaaaggatctcaagaagatcctttgatcttttctagtgtcgcg</p>	
attB_Puro donor DNA:	<p>gatgccagctcatctccactcattgatctatagatccccgggctgcagggaattctaccactctgtcgataccccaccgagacc cattggggccaatacgcccgcttttcttcttccccaccgcccccaccccaagttcgggtgaagcccagggtcgcagccaacgtc ggggcggaagcttaccatcgagatccggctgtgcagcagcggcgggtctccgtcgtcaggatcatcgtgagcaaggcgagga gctgttcaccggggtgtgcccactcgtgctgagctggacggcgacgtaaacggccacaagttcagcgttccggcgaggcgga ggcgatgccacctacggcaagctgacctgaagttcatctgcaccaccggcaagctgcccgtgcccaccctcgtgacc acctgacctacggcgtgagtgcttgcagccgtaccccgaccacatgaagcagcagcacttctcaagtcggccatgccgaag gctacgtccaggagcgcaccatcttcaaggacgacggcaactacaagaccggcgaggtgaagttcagggcgacacc tggtgaaccgcatcgagctgaaggcgcacgtcactcaaggagacggcaacatcctggggcacaagctgagtacaaactacaaca gccacaacgtctatcatgcccgaagcagaagaacggcatcaaggtgaactcaagatccgccacaacatcgaggacggca cggtgcagctcggcaccactaccagcagaacacccccatcgcgacggccccgtgctgctgcccgaacactacgtgagca cccagtcggccctgagcaaaagccccaacgagaagcgcgacatcagctgctggtgagttcgtgaccggcgccggtatcactt cggcatggacgagctgtacaagagcggcctgaggagcagagcccaggcgagcaacagcggcgtggacgccaccatggcgga tcggccgggaattgactagtgcggccgctagatccatccgatacgtgtgtggtgagtgataaccgtattaccgcaagcttatg catgtgcccgtcagtgaggcagagcgacatcgcccacagtcgccgagaagttgggggggaggggtcggcaattgaacccgtgcct agagaaggtggcgcggtgaaactgggaaagtgtatcgtgtactggtccgcttcttccgaggggtggggagaaacctatata agtgcagtagtcggcgtgaacgttttttgcgaacgggttgcggccagaacacaggtgaagtcgggtgtgtgttccggcgccct</p>	4283

	<p>ggcctctttacgggttatggcccttgcgtgccttgaaacttccacctggctgcagtagctattctgatccgagcttcgggttgga agtggtgggagaggttcgagcccttgcgttaaggagcccttcgctcgtctgagttgagcctggcctgggctggggcc gccgctgagcaatctggtgcaccttcgcgctgtctcgtcttccgataagctctagccattaaaaattttgatgacctgtcga cgcttttttctggcaagatagctttaaagtgcggcccaagatctgcacactggtatttcggtttttggggccggggcgacggg gcccgtgcgtccagcgacatgttcgagggcggggctgcgagcgccgacgagaaatggacgggggtagtctcaag ctggccgctgctctggtgcttgcgcccgcgctgtatcgcctggcctggcgcaaggctggccggtcggcaccag ttcggtgagcggaagatggccttccggcctgctgcaggagctcaaatggagacggcgctcgggagagcgggc gggtgagtcacccacacaaaggaaaaggccttccgtctcagccgtcgttcatgtgactccacggagaccggcgccgtcc aggcacctcgattagtctcgcgttttgagtagctcgtcttaggtgggggaggggtttatgcgatggagttccacactga gtgggtggagactgaagttagccagcttgacactgtatgtaattctccttggaattggccttttgagtttgatctgttcattctaa gcctcagacagtggtcaaatgttttctccattcaggtgtcgtgagtagccaccatgaccgagtacaagcccacggtgcgct cgccacccgagacgacgtcccccggggcgtagcacccctgcgcccgcgttcgcccactaccccggcagcgccacacccgtg acccggaccgccacatcgagcggtcaccgagctgcaagaactcttctcacgcgctcgggctcgacatcgcaagggtgtgg tcgcgagacgagcgccgctggtgcgtctggaccacgcccggagagcgtcgaagcggggcggtgttcgagatcgggc cgcgcatggccgaggtgagcggttccggctgcccgcgagcaacagatggaaggcctcctgcgccgacccggcccaaggga gcccgcgtggtcctgcccacgctgcgctcgcggaccaccagggaagggtctggcagcgccgtgctcctccggagt ggagcgccgagcgccggggtgcccgttctgagacgtccgccccgaacctcccttctacgagcggtcgtcggt caccgtcaccggcgagctgaggtgcccgaaggaccgacacgtggtgatgacccgcaagccgggtgcccgtcgggagag ggcagagggaagtctgtaacatgcggtgacgtcaggaagaatctgcccacggctcggcaccagcgagctgattaaggaaga atgcacatgaagctgtacatggagggcaccgtggacaacctacactcaagtgcacatccgagggcggaagcgcaacctacgag ggcacccagaccatgagaatcaagggtggtcgaaggcgccctcctcccttgccttcgacatccgtgctactagcttctctacggc agcaagacctcatcaaccacacccaggcgatccccgacttctcaagcagtccttccctgagggcttcacatgggagagagtcac cacatagcaagacggggcgctgctgaccgctacccaggacaccagcctccaggacggctgcctcatctacaagctcaagatcag aggggtgaacttcacatccaacgcccgtgtgatgcagaagaaacactcgctgggagcgcttaccgagacgctgaccccgct gacggcgccctggaaggcagaacgacatggccctgaagctcgtggcgggagaccatctgatcgcaaacatcaagaccacat agatccaagaaacccgctaagaacctcaagatgcctggcgtctactatgttgactacagactggaaggaatcaaggagcccaaca acgagacctacgtcagcagcagaggtggcagtgccagatactgcgacctccctagcaaaactggggcagaagcttaataaga attctctagagagatccagacatgataagatactgatgattggacaaaccacaactagaatgcagtgaaaaaaatgctttattgtg aaatttggatgctattgtcttatttgaaccattataagctgcaataaacaagttaaacaacaatgacattattatgtttcaggttcag ggggaggtgtggaggttttttaagcaagtaaaacctctacaaatgtgtatgctgattatgatcctgcaagcctcgtcggcgcg tttattctgttgacaattaatcatcgcatagtatatcgcatagataatacagaaggtgaggaactaaacctgggacgtgccattg aacaagatggattgcacgaggttctcggccgcttgggtggagaggtatctggtatgactgggcacacagacgacgtcgctg ttctgtgattcactgactgtgcccgtgtgcgagggcgcccggttcttttgtaagaccgacctgtccgggtgcccgtgaaatgaact gcaggacgagcgagcgcggtatcgtgctggtccacgacggcggttcttgcgagctgtgctcaggttgcactgaagcggg aagggactggtgcttattggcggaagtgcggggcgaggtatctctgtatctcacttgcctcctgaggaagatcatcatgtgc tgatgcaatgcgcggtgctgacacgttgatccgctacgtgcccattgaccaccaagcgaacatcgatcgagcgagcagctga ctcgatggaaagccggtctgtgacatcaggtgatctggacgaagagcatcaggggctcggccagccgaactgttcgacggct caaggcgccgatgcccagcgcgaggtatctcgtgacccatggcgatgctgcttgcgcaatatcatgttggaataatggccgc tttctggaattcactgactgtgcccgtgtggtggtgagggaccgctatcaggacatagcgttggtacccgtgataattgtgaagagc ttggcgccgaatgggtgaccgcttctcgtgtttacgggtatcgcccccgttgcgagcgatcgcccttctatcgcttcttgac gagttcttctgagcgggactctgggttcgaataaagaccgaccaagcgagctgtgagagctcctggtgcgaattcggtacaaataa aagagctttatttcatgctgtgtgtgttttggccgctgtgctgctgttttccataggtccgccccctgacgagcatcacaaa aatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagatacaggcggtttccccctggaagctccctcgtgcgctc tctgttccgacctgcccgttaccggatcgtcgccttctccttccgggaagcgtggcgcttctcctatagctcagctgtaggtga tctcagttcgggtgtaggtcttccgtccaagctgggtggtgacgaacccccgttccagcccgaccgctgcgcttaccgttaac tatcgtcttgagtcacaacccgtaagacacgacttatcggcactggcagcagccactggtacagggattagcgagcgaggtatgta ggcggtgctacaggttctgaagtgtggtgacctacggctacactagaagaacagattttggtatctcgtcgtcgtgaagccag ttacctcggaaaaaggttgtagctcttgatccggcaacaaaccaccgctgtagcggtggtttttgttgcaagcagcagatt acgcgcagaaaaaaggatctcaagaagatcctttgatcttttctagtgtgcg</p>	
attP_Puro_G A donor DNA:	<p>gatgcagctcattctcccactcatgatctatagatccccgggctgcaggaattctaccactctgtcgataccccaccgagaccc cattggggccaatacgcggcgttttcttcttccccaccaccaccccccgaagtcgggtgaaggcccagggtcgcagccaacgtc ggggcggaagcttacatcgagatcccggtttgtctggtcaaccaccgcgactcagtggtgtacgtgtacaaccccgtgagcaa ggcgagagctgttaccggggtgtgcccactcgtgctgagctggacggcgacgtaaacggccacaagttcagctgtccgg cgaggcgagggcgatgccacctacggcaagctgacctgaagttcatctgcaccaccggcaagctgcccgtgcccgtgcccac cctcgtgaccacctgacctacggctgagctgttccagccgtaccccaccacatgaagcagcagacttctcaagtcgcca tgccgaaggctacgtccaggagcgacacatcttctcaaggacgacggcaactacaagaccgcccggaggtgaagttcaggg gcgacacctgtgtgaaccgacgtgagctgaaggacatgacttcaaggagggacggcaacatcctggggcacaagctggagtag aactacaacagccacaacgtctatcatgcccgaacagcagaagaacggatcaaggtgaacttcaagatccgccacaacatcg aggacggcagcgtgacgtcggaccactaccagcagaacacccccatcgccagcgccccgtgctgctgcccgaacacac tacctgagcaccagctccgctgagcaagaccccaacgagaagcgcatcatggtcctgctgagttcgtgaccgcc</p>	4284

	<p>gggatcactctggcatggacgagctgtacaagagcgccctgaggagcagagccagcgagcaacagcgccgtggacgcca ccatggcgatgcccgggaattgactagtgcggccgctaggatccatccgatagcgttgggtgagtgataaccgtattaccg ccaagcttatgcatgtcccgtcagtgggcagagcgacacatgccacagctcccagaaagttgggggaggggtcgcaattg aaccgggtcctagagaaggtggcgcggttaaaatgggaaagtgtatgtgtactggctccgcttttccgaggggtgggga gaaccgtatataagtgcagtagtcgccgtgaacgtcttttcgcaacgggttggccgcagaaacagagtaagtccgtgtgtgtt cccggggccctggccttttacgggtatggcccttgcgtgcttgaattacttccacctggctgcagtagctgattcttgatccgag cttcgggttggaaagtgggtgggagagttcagggccttgcgttaaggagcccttcgctcgtgcttggagttgagggcctggcctgg gcgtgtggggcccgccgctgcgaatcgtgggtggacattcgcgcctgtctcgtcttgcataaagctctagccattaaaattttgatg acctgtcgcacgctttttctggcaagatagctgttaaatcgggccaagatctgcacactgtatttctgggttttggggccgagg cgcgacggggcccgctgcgtccagcgacacatgttcggcgaggcggggctgcgagcgccgaccgagaatcgacgggg gtagtctcaagctggccgctgtctgtgctgcctcgcgcgcgtgtatcgccccgctggcgcaagctggtccc gtcggcaccagttgcgtgagcggaaagtggccgttccggccctgctgcaggagctcaaaatggaggacggcgctcgg gagagcgggcggtgagtcacccacacaaaggaaaaggcccttccgtctcagccgtcgttcatgtactccacggagatccg ggcggcgtccaggcaccctcgaattgtctcgtcttggagtagctcgtctttagttgggggaggggtttatgcgattgaggttcc ccacactgagtggtggagactgaagttagggcagcttgcacttgatgaatttctcttggaaatttgccttttggatttggatctt gttcatctcaagcctcagacagtggtcaaaatttttctccatttcagggtgtcgtgagctagcccaccatgaccgagtacaagccca cggtgcgcctcggccaccgacgacgtcccccggccgtacgcacccctgcgcgcgttcgcccactaccccgccacgcgc cacaccgtgacccggaccgcccacatcgagcgggtacccgagctgcaagaactcttctcaccgctcgggctcgacatcgcc aaggtgtgggtcgggacgacggcgccggtggcggtctgaccacgcccggagagcgtcgaagcggggcggtgttcgccc gagatcgcccgcgcatggcagtgagtgagcgttccggctggccgcgagcaacagatggaaagcctcctggcgccgaccg gcccaggagcccgtgtgttctggccaccgtcggcgctcgcgcgaccaccagggcaagggtctggcgacgcccgtgtgc tccccggagtgaggcgccgagcgccggggtgcccgccttcttgagacctccgcgcggcgaacctccccttctacgag cggtcgcgttcaccgtcaccgcccacgtcgaggtggcgaaggaccgacgacactgtgcatgaccgcaagcccgtggccg atcgggagaggcgagaggaagtctgtaacatgcggtgacgtcgaggagaatcctggcccaccggctgcaccagcgagctga ttaaggagaacatgcacatgaagctgtacatggagggcaccgtgacaaacatcacttcaagtgcacatccgagggcgaggcga ccctacgagggcaccagaccatgagaatcaaggtgtcagggcgccctcctcccttcgcttcgacatcgtactcgtacatgt tctctacgagcaagaccttcaacacacaccagggaatcccgacttctcaagcagctcctccctgagggttcacatggg agagagtcacacatacgaagacggggcggtgctgaccgtacccaggacaccagcctccaggacggctgctcctacataacg tcaagatcagaggggtgaacttcacatccaacggccctgtgtatgcagaagaaaactcggctggaggcgcttcaccgagacgt gtaccccgctgacggcgccgtggaagcgagaacacatggccctgaagctcgtggcggggagccatctgacgaaacatca agaccacatagatccaagaacccgtaagaacctcaagatgcctgctgctactatgtggactacagactggaagaatcaag gagggcaacaacagacacacgtcgcagcagcaggggtggcagtgccagatactcgcacctccctagcaaaactggggcaca gcttaattaagaattctctagaggatccagacatgataaagatacattgtagtttggacaaaccacaactgaagtgcagtga atgctttattgtgaatttgtgtgctattgttattgttaaccattataagctgcaataaacaagttaacaacaacattgcattctttat gtttcaggttcagggggaggtgtgggaggtttttaaagcaagtaaaacctctacaatgtgtgtggtgattatgacgtcgaagcc tcgtcgccgctgtttattctgttacaattaatcatcgccatagtatatcgccatagatataacgacaaggtgaggaactaaacatg ggatcgccattgaacaagatgattgcacgaggttctccggccgcttgggtggagaggtctattcggctatgactgggcacaaca gacgatcgctgctgtatgcggcggttccggctgacgcgaggggcgccggttcttttgcagaccgacctgtccggtgc cctgaatgaactgcaggagcagcgagcggtatcgtgctgctgcccacgacgggcttcttgcgacgtgtcctgcagctgtc actgaagcggggaaggactgctgctattggcggaagtgcggggcaggatctcctgtcactcacttgcctcctccgagaaggt atccatcatggtgctgacatgcggcggtgcatacgttgcacggctacgtcccattcgaccaccaagcgaacatcgcatcga gcgagcagctactcgatggaagccggtctgtcgcacagatgacgtgacgaagagcatcaggggctcgcgcagccgaact gttcgccaggtcaagcgccatgcccgcgagcgaggtatcgtcgtgacccatggcgatgcctgttgcggaatatcatggtg gaaaatggccgcttttctgattcatcactgtggtggcgtggtgtggtggaccgctatcaggacatagcgttgggtaccggtgat attgctgaagagcttggcggaatgggtgacccgttctcgtgctttacgggtatcgcggccccgattcgcagcgcatcgctct atcgcttcttgcagagttcttgcagcggtgactgtgggttcgaataaagaccgaacagcgacgtctgagagctccctgcggaat tcggtaccaataaaagagcttttttcatgactgtgtgttgggttttggcgcggtgtggttttccataggtccgccccctgac gagcatcacaaaaatcgacgtcaagtcagaggtggcgaacccgacaggactataaagatacagggcttccccctggaagct ccctcgtcgtctcctgttccgacccgtggttaccggatacctgtcgccttctccttcgggaagcgtggcgcttctcatagct cacgtgtgtagtatcagttcgggtgtaggtcgtcgtccaaagctgggtgtgtgcagacacccccgttcagcccagccgtgcg ccttatccgtaactatcgtcttgatccaacccgtaagacacgacttatcgcactggcagcagccactgttaacaggtattgca gagcgaggatgtaggggtgctacagagttctgaagtgggtggcctaactacgctacactagaagaacagatttggatctgcg ctctgctgaagccagttacctcggaaaaagagttgtgtagctcttgcggaacaaaccaccgctgtagcggtgtttttgtt gcaagcagcagattacgcgcagaaaaaaggatctcaagaagatccttgcattttctagtgtgcg</p>	
attP_Puro donor DNA:	<p>gatgccagctcattctccactcatgatctatagatccccgggtgcaggaattctaccactctgtcgataccccaccgagaccc cattggggccaataaccccgcgttttcttcttccccaccaccacccccaagttcgggtgaaggcccagggtcgcagccaacgtc ggggcgccgaagcttacatcgagatcccggttctgtcgtcaaccaccgggtctcagtggtgtacggtacaaccccgtgagcaag ggcgaggagctgttccacgggggtggtgccatcctggtgagctggagcggcagcgttaaacggccacaaggttcagctgtcggc gagggcgaggcgatgccactacggcaagctgaagttcgtggtggcctaactacgctacactagaagaacagatttggatctgcg ctctgctgaagccagttacctcggaaaaagagttgtgtagctcttgcggaacaaaccaccgctgtagcggtgtttttgtt gcaagcagcagattacgcgcagaaaaaaggatctcaagaagatccttgcattttctagtgtgcg</p>	4285

663

Multiplex editing and recombinase-mediated inversion

[1359] Large structural variants are found in many human pathogenic alleles, such as the large 0.6-Mb inversion at the *F8* locus that causes ~50% of severe hemophilia A cases. Inspired by the high efficiency of recombinase attachment site insertions using twinPE, it was reasoned that multiplexing the insertion of both *attB* and *attP* Bxb1 attachment sites could be used to correct more complex genetic variants by unidirectional deletion or inversion of the intervening DNA sequence. To test this approach on a therapeutically relevant locus, a 39-kb inversion between *IDS* and its pseudogene *IDS2* was attempted. Inversions between these sites have been observed in ~13% of Hunter syndrome cases, and characterization of the breakpoints in pathogenic alleles has revealed that the inversion often occurs within a recombination hotspot of intron 7 that is present in both *IDS* and *IDS2*. Therefore, regions flanking these recombination hotspots were targeted to insert Bxb1 *attP* and *attB* attachment sequences, which when oriented in opposite directions, could be used as substrates for unidirectional inversion by Bxb1 for the correction of the pathogenic allele sequence in patient cells (**FIG. 111A**). After screening 12 pegRNA spacer pairs and optimizing pegRNA sequence features, it was found that pegRNA pairs that are capable of inserting *attP* or *attB* attachment sites at the left and right targeted sites with 73.7% and 69.8% efficiency, respectively (**FIG. 111B**).

[1360] Next, multiplexing twinPE-mediated insertion of both *attP* and *attB* attachment sites were explored with Bxb1 recombinase-mediated inversion of the 39-kb sequence in *IDS* and *IDS2*. Initially, sequential DNA transfections were explored with twinPE components followed by Bxb1 recombinase. A first set of pegRNAs (set 1) was tested that installs a forward-oriented *attP* sequence in intron 3 of *IDS2* and a reverse-oriented *attB* sequence in intron 7 of *IDS*. In addition, a second set of pegRNAs (set 2) was used to install a reverse-oriented *attP* sequence in *IDS2* and a forward-oriented *attB* sequence in *IDS* in a first transfection. 52.3% or 54.5% *attP* sequence insertion and 27.6% or 30.9% *attB* sequence insertion was observed for multiplex editing with pegRNA set 1 and set 2, respectively (**FIG. 111C**). When edited cells were subsequently transfected with Bxb1 recombinase, a significantly decreased percentage of amplified alleles containing *attP* and *attB* sequence was observed compared to mock transfection controls (p-value < 0.05), suggesting that some edited alleles were being used as substrates for Bxb1-mediated recombination (**FIG. 111C**). Amplification of the anticipated inversion junctions followed by amplicon sequencing showed both the *attL* and *attR* sequence signatures of Bxb1-mediated recombination, with product purity at or above 80% at both junctions (**FIG. 111D**).

[1361] To carry out one-pot twinPE and Bxb1-mediated inversion and circumvent unwanted recombination between pegRNA plasmid DNA, all-RNA components comprising PE2 mRNA, synthetic pegRNAs from set 1, and Bxb1 mRNA were nucleofected. Using amplicon sequencing, the expected inverted allele junctions containing *attR* and *attL* sequences were captured. Furthermore, to quantify the inversion efficiency, a reverse primer that can bind to an identical sequence in both the

non-inverted and inverted alleles and therefore amplify both edits using the same primer pair was designed (**FIG. 116**). ~4.6-7.2% and ~1.5-2.3% inversion efficiency for “sequential” and “one-pot” strategy was observed, respectively (**FIG. 111E**). Collectively, these data support that combining twinPE with site-specific serine recombinases could be used to correct a common 39-kb inversion found in Hunter syndrome alleles and could serve as a promising therapeutic platform for targeting other complex pathogenic variants.

Discussion

[1362] As presented herein, a twin prime editing approach that can be used to delete, replace, or insert DNA sequences at targeted location in the genomes of human cells was developed. When combined with site-specific serine recombinase enzymes, twinPE can also support the integration of DNA cargo, or the inversion of DNA sequence.

Methods

General methods

[1363] DNA amplification was conducted by PCR using Phusion U Green Multiplex PCR Master Mix (ThermoFisher Scientific) or Q5 Hot Start High-Fidelity 2x Master Mix (New England BioLabs) unless otherwise noted. DNA oligonucleotides were obtained from Integrated DNA Technologies. Plasmids expressing sgRNAs were constructed by ligation of annealed oligonucleotides into *BsmBI*-digested acceptor vector. Plasmids expressing pegRNAs were constructed by Gibson assembly or Golden Gate assembly as previously described. Sequences of sgRNA and pegRNA constructs used in this Example are listed in Tables 11-12.

Table 11. Sequences of sgRNA used in this Example

sgRNA	Spacer Sequence	SEQ ID NO:
HEK3_3b_+90_nicking	GTCAACCAGTATCCCGGTGC	616
pU6-Sp-sgRNA-DMDExo51-A1	GATTGGCTTTGATTCCCTA	3971
pU6-Sp-sgRNA-DMDExo51-A3	GTATATGATTGTTACTGAGA	3972
pU6-Sp-sgRNA-DMDExo51-B1	Gcagttgcctaagaactggt	3973

Table 12 Sequences of pegRNA used in this Example

pegRNA	Spacer Sequence	Spacer SEQ ID NO:	3' Extension	Extension SEQ ID NO:
HEK3_attB_A_38	ggcccagactgagc acgtga	383	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCCGTGCTCAGTCTG	4029
HEK3_attB_A_34	ggcccagactgagc acgtga	383	TCCTGACGACGGAGACCGCCGTCGTC GACAAGCCCGTGCTCAGTCTG	4030
HEK3_attB_A_30	ggcccagactgagc acgtga	383	GACGACGGAGACCGCCGTCGTCGAC AAGCCCGTGCTCAGTCTG	4031
HEK3_attB_B_38	gtcaaccagtatccc ggtgc	616	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATCCGGGATACTGG	4032
HEK3_attB_B_34	gtcaaccagtatccc ggtgc	616	TGTCGACGACGGCGGTCTCCGTCGTC AGGATCATCCGGGATACTGG	4033
HEK3_attB_B_30	gtcaaccagtatccc ggtgc	616	GACGACGGCGGTCTCCGTCGTCAGGA TCATCCGGGATACTGG	4034

HEK3_attP_A_43	ggcccagactgagc acgtga	383	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCGTGCTCAG TCTG	4035
HEK3_attP_A_39	ggcccagactgagc acgtga	383	GTACACCACTGAGACCGCGGTGGTTG ACCAGACAAACCTCGTGCTCAGTCTG	4036
HEK3_attP_A_35	ggcccagactgagc acgtga	383	ACCACTGAGACCGCGGTGGTTGACCA GACAAACCTCGTGCTCAGTCTG	4037
HEK3_attP_B_44	gtcaaccagtatccc ggtgc	616	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCCGGGATA CTGG	4038
HEK3_attP_B_40	gtcaaccagtatccc ggtgc	616	GGTCAACCACCGCGGTCTCAGTGGTG TACGGTACAAACCTCCGGGATACTGG	4039
HEK3_attP_B_36	gtcaaccagtatccc ggtgc	616	AACCACCGCGGTCTCAGTGGTGTACG GTACAAACCTCCGGGATACTGG	4040
PE3_HEK3_FKBP_ins1 2bp	ggcccagactgagc acgtga	383	tggaggaagcagggttccttctctgccatcacactgcac tcccgtgctcagtctg	4041
PE3_HEK3_FKBP_ins3 6bp	ggcccagactgagc acgtga	383	tggaggaagcagggttccttctctgccatcacactgcac tcccgtgctcagtctg	4042
PE3_HEK3_FKBP_ins1 08bp	ggcccagactgagc acgtga	383	tggaggaagcagggttccttctctgccatcaaaatttcttc catcttcaagcatcccggtgtagtgcaccacgcaggtctggc cgcgcttggggaaggtgcgccgtctcctgggagatggtt ccactgcactcccgtgctcagtctg	4043
PE3_HEK3_FKBP_ins3 21bp	ggcccagactgagc acgtga	383	tggaggaagcagggttccttctctgccatcacactggtt agaagctccacatcgaagacgagagtggcatgtggtggat gatgcttgggtcccagtgccaccataggcataatctggag atatagtcatgttggctcttgaccacactcatctgggcaacc ccttctcccagcctcgatcacctcctgcttgcctagcataaa cttaagggcttgttctgtcccgggaggaatcaaaatttcttc atcttcaagcatcccggtgtagtgcaccacgcaggtctggcc gcgcttggggaaggtgcgccgtctcctgggagatggtt cacctgcactcccgtgctcagtctg	4044
twinPE_HEK3_FKBP_i ns108bp_32bp_overhan g_A	ggcccagactgagc acgtga	383	accacgcaggtctgcccgcgttggggaaggtgcgccgt ctcctgggagatggttccactgcactccgtgctcagtct g	4045
twinPE_HEK3_FKBP_i ns108bp_32bp_overhan g_B	gtcaaccagtatccc ggtgc	616	accttcccaagcgcggcagacctgcgtggtgactacac cgggatgcttgaagatggaagaaattccgggatactgg	4046
pU6-Sp-gRNA- HEK3_del_DF_A_13nt TEMP_Basic	ggcccagactgagc acgtga	383	tcctctgccatcacgtgctcagtctg	4047
pU6-Sp-gRNA- HEK3_del_DF_B_13nt TEMP_Basic	gtcaaccagtatccc ggtgc	616	tgatggcagaggaccgggatactgg	4048
pU6-Sp-gRNA- HEK3_del_DF_A_34nt TEMP_Basic	ggcccagactgagc acgtga	383	tggaggaagcagggttccttctctgccatcacgtgctcag tctg	4049
pU6-Sp-gRNA- HEK3_del_DF_B_34nt TEMP_Basic	gtcaaccagtatccc ggtgc	616	tgatggcagaggaaaggaagccctgcttctccaccgggat actgg	4050
pU6-Sp-gRNA- HEK3_del_DF_A_13- 13TEMP_Hybrid	ggcccagactgagc acgtga	383	tgaggagctgcactcctctgccatcacgtgctcagtctg	4051
pU6-Sp-gRNA- HEK3_del_DF_B_13- 13TEMP_Hybrid	gtcaaccagtatccc ggtgc	616	tgatggcagaggatgcagctcctgcaccgggatactgg	4052
pU6-Sp-gRNA- HEK3_del_DF_A_31nt TEMP_Shendure	ggcccagactgagc acgtga	383	gcccagccaaactgtcaaccagtatcccggcgctgctcagtc tg	4053

pU6-Sp-gRNA- HEK3_del_DF_B_31nt TEMP_Shendure	gtcaaccagtatccc ggtgc	616	gggtcaatccttggggcccagactgagcacgccgggatact gg	4054
pU6-Sp-gRNA- HEK3_del_DF_A_13nt TEMP_Basic_EvoPreQ1	ggcccagactgagc acgtga	383	tctctgccatcacgtgctcagtctgTTAAATAACGC GGTTCTATCTAGTTACGCGTTAAACC AACTAGAA	4055
pU6-Sp-gRNA- HEK3_del_DF_B_13nt TEMP_Basic_EvoPreQ1	gtcaaccagtatccc ggtgc	616	tgatggcagaggaccgggatactggAAAATATACG CGTTCTATCTAGTTACGCGTTAAAC CAACTAGAA	4056
pU6-Sp-gRNA- HEK3_del_DF_A_34nt TEMP_Basic_EvoPreQ1	ggcccagactgagc acgtga	383	tggaggaaagcagggttccttctctgccatcacgtgctcag tctgTTAATAATCGCGTTCTATCTAGT TACGCGTTAAACCAACTAGAA	4057
pU6-Sp-gRNA- HEK3_del_DF_B_34nt TEMP_Basic_EvoPreQ1	gtcaaccagtatccc ggtgc	616	tgatggcagaggaaaggaagccctgcttccaccgggat actggAAAAAAACGCGTTCTATCTAG TTACGCGTTAAACCAACTAGAA	4058
pU6-Sp-gRNA- HEK3_del_DF_A_13- 13TEMP_Hybrid_EvoPr eQ1	ggcccagactgagc acgtga	383	tgaggagctgcatcctctgccatcacgtgctcagtctgAT AAATAACGCGTTCTATCTAGTTACG CGTTAAACCAACTAGAA	4059
pU6-Sp-gRNA- HEK3_del_DF_B_13- 13TEMP_Hybrid_EvoPr eQ1	gtcaaccagtatccc ggtgc	616	tgatggcagaggatgcagctcctgcaccgggatactggAA AAAAGGCGCGTTCTATCTAGTTACG CGTTAAACCAACTAGAA	4060
pU6-Sp-gRNA- HEK3_del_DF_A_31nt TEMP_Shendure_EvoPr eQ1	ggcccagactgagc acgtga	383	gcccagccaaactgtcaaccagtatcccggcgtgctcagtc tgTTAAATACGCGTTCTATCTAGTT ACGCGTTAAACCAACTAGAA	4061
pU6-Sp-gRNA- HEK3_del_DF_B_31nt TEMP_Shendure_EvoPr eQ1	gtcaaccagtatccc ggtgc	616	gggtcaatccttggggcccagactgagcacgccgggatact ggAAAATAATCGCGTTCTATCTAGTT ACGCGTTAAACCAACTAGAA	4062
pU6-Sp-pegRNA- DMDExo51- A1_a_Basic	GATTGGCTTT GATTTCCTA	3971	ttgaataggaagtaaattaattgaagctggaccctagGGA AATCAA	4063
pU6-Sp-pegRNA- DMDExo51- A1_b_Basic	GATTGGCTTT GATTTCCTA	3971	ttgaataggaagtaaattaattgaagctggaccctagGGA AATCAAAG	4064
pU6-Sp-pegRNA- DMDExo51- A1_c_Basic	GATTGGCTTT GATTTCCTA	3971	ttgaataggaagtaaattaattgaagctggaccctagGGA AATCAAAGCC	4065
pU6-Sp-pegRNA- DMDExo51- B1_A1_b_Basic	Gcagttgcctaagaa ctggt	3973	tagggtccagcttcaaattaattacttctattcaaagttcttag gc	4066
pU6-Sp-pegRNA- DMDExo51- B1_A1_c_Basic	Gcagttgcctaagaa ctggt	3973	tagggtccagcttcaaattaattacttctattcaaagttcttag gcaa	4067
pU6-Sp-pegRNA- DMDExo51- A3_c_Basic	GTATATGATT GTTACTGAG A	3972	atgcctggacaagtaacttaagttaataagccttctCAGT AACAATCAT	4068
pU6-Sp-pegRNA- DMDExo51- B1_A3_a_Basic	Gcagttgcctaagaa ctggt	3973	agaaggettatttaacttaagttaactgtccaggcatagttctta g	4069
pu6-sp-pegRNA- dmexo51-a3- b1_a_PrimeDel	GTATATGATT GTTACTGAG A	3972	tgctgagagagaacagttgcctaagaactCAGTAAC AAT	4070
pu6-sp-pegRNA- dmexo51-b1-a3_a- PrimeDel	Gcagttgcctaagaa ctggt	3973	accactccacaatgtatatgattgtactgagttcttagg	4071

pu6-sp-pegRNA- dmexo51-b1-a3_b- PrimeDel	Gcagttgcctaagaa ctggt	3973	accacttcacaatgtatatgattgttactgagttcttaggcaa	4072
pU6-Sp-pegRNA- DMDExo51- A3_b_attB_fwd	GTATATGATT GTTACTGAG A	3972	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCCAGTAACAATC	4073
pU6-Sp-pegRNA- DMDExo51- A3_c_attB_fwd	GTATATGATT GTTACTGAG A	3972	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCCAGTAACAATCATA	4074
pU6-Sp-pegRNA- DMDExo51- B1_b_attB_fwd	Gcagttgcctaagaa ctggt	3973	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATagttcttaggc	4075
pU6-Sp-pegRNA- DMDExo51- B1_c_attB_fwd	Gcagttgcctaagaa ctggt	3973	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATagttcttaggcaac	4076
pU6-Sp-pegRNA- DMDExo51- B2_b_attB_fwd	Gaggagagtaaagt gattgg	3974	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATatcactttactc	4077
pU6-Sp-pegRNA- DMDExo51- B2_c_attB_fwd	Gaggagagtaaagt gattgg	3974	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATatcactttactctcc	4078
A_1077a	GCAGAGCCA GGAACCCCT GT	3975	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGGGTTCCT	4079
A_1077b	GCAGAGCCA GGAACCCCT GT	3975	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGGGTTCCT GG	4080
A_1077c	GCAGAGCCA GGAACCCCT GT	3975	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGGGTTCCT GGCT	4081
A_1098a	GGGAAGGGG CAGGAGAGC CA	3976	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCTCTCCTGC	4082
A_1098b	GGGAAGGGG CAGGAGAGC CA	3976	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCTCTCCTGC CC	4083
A_1098c	GGGAAGGGG CAGGAGAGC CA	3976	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCTCTCCTGC CCCT	4084
A_1246a	GAATATGTC CCAGATAGC AC	3977	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCTATCTGGG	4085
A_1246b	GAATATGTC CCAGATAGC AC	3977	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCTATCTGGG AC	4086
A_1246c	GAATATGTC CCAGATAGC AC	3977	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCTATCTGGG ACAT	4087
A_1267a	GGGGACTCT TTAAGGAAA GA	3978	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTTTTCCTTAAA	4088
A_1267b	GGGGACTCT TTAAGGAAA GA	3978	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTTTTCCTTAAA GA	4089
A_1267c	GGGGACTCT TTAAGGAAA GA	3978	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTTTTCCTTAAA GAGT	4090

A_1293a	GAGAAAGAG AAAGGGAGT AG	3979	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCTCCCTTTC	4091
A_1293b	GAGAAAGAG AAAGGGAGT AG	3979	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCTCCCTTTC TC	4092
A_1293c	GAGAAAGAG AAAGGGAGT AG	3979	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCTCCCTTTC TCTT	4093
A_1307a	GAGTAGAGG CGGCCACGA CC	3980	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCGTGGCCGC	4094
A_1307b	GAGTAGAGG CGGCCACGA CC	3980	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCGTGGCCGC CT	4095
A_1307c	GAGTAGAGG CGGCCACGA CC	3980	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCGTGGCCGC CTCT	4096
A_1582a	GATCAGTGA AACGCACCA GA	3981	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGTGCGTTT	4097
A_1582b	GATCAGTGA AACGCACCA GA	3981	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGTGCGTTT CA	4098
A_1582c	GATCAGTGA AACGCACCA GA	3981	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGTGCGTTT CACT	4099
A_1615a	GCAGCTCAG GTTCTGGGA GA	3982	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCCCAGAACC	4100
A_1615b	GCAGCTCAG GTTCTGGGA GA	3982	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCCCAGAACC TG	4101
A_1615c	GCAGCTCAG GTTCTGGGA GA	3982	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCCCAGAACC TGAG	4102
A_1647a	GTGGCCACT GAGAACCGG GC	3983	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCGGTTCTCA	4103
A_1647b	GTGGCCACT GAGAACCGG GC	3983	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCGGTTCTCA GT	4104
A_1647c	GTGGCCACT GAGAACCGG GC	3983	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCGGTTCTCA GTGG	4105
A_1810a	GAATCTGCCT AACAGGAGG T	3984	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTTCCTGTTAG	4106
A_1810b	GAATCTGCCT AACAGGAGG T	3984	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTTCCTGTTAG GC	4107
A_1810c	GAATCTGCCT AACAGGAGG T	3984	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTTCCTGTTAG GCAG	4108
A_1890a	GTCACCAAT CCTGTCCCTA G	3985	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGGACAGG A	4109

A_1890b	GTCACCAAT CCTGTCCCTA G	3985	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGGACAGG ATT	4110
A_1890c	GTCACCAAT CCTGTCCCTA G	3985	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGGACAGG ATTGG	4111
A_3786a	GCTGGCCCC CCACCGCCC CA	3986	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGCGGTGGG	4112
A_3786b	GCTGGCCCC CCACCGCCC CA	3986	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGCGGTGGG GG	4113
A_3786c	GCTGGCCCC CCACCGCCC CA	3986	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGCGGTGGG GGGC	4114
A_3835a	GACGTCACG GCGCTGCCC CA	3987	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGCAGCGCC	4115
A_3835b	GACGTCACG GCGCTGCCC CA	3987	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGCAGCGCC GT	4116
A_3835c	GACGTCACG GCGCTGCCC CA	3987	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGCAGCGCC GTGA	4117
A_3856a	GGTGTGCTG GGCAGGTCG CG	3988	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGACCTGCCC	4118
A_3856b	GGTGTGCTG GGCAGGTCG CG	3988	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGACCTGCCC AG	4119
A_3856c	GGTGTGCTG GGCAGGTCG CG	3988	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGACCTGCCC AGCA	4120
B_1154a	GTCCTTGGCA AGCCCAGGA G	3989	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCTGGGCTT G	4121
B_1154b	GTCCTTGGCA AGCCCAGGA G	3989	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCTGGGCTT GCC	4122
B_1154c	GTCCTTGGCA AGCCCAGGA G	3989	cTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCTGGGCTT GCCAA	4123
B_1314a	GTGCGTCCTA GGTGTTACC	3990	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTGAACACCT A	4124
B_1314b	GTGCGTCCTA GGTGTTACC	3990	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTGAACACCT AGG	4125
B_1314c	GTGCGTCCTA GGTGTTACC	3990	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTGAACACCTA GGAC	4126
B_1376a	GTCCTGGCA GGGCTGTGG TG	3991	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCACAGCCC T	4127
B_1376b	GTCCTGGCA GGGCTGTGG TG	3991	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCACAGCCC TGC	4128

B_1376c	GTCCTGGCA GGGCTGTGG TG	3991	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTCACAGCCCT GCCA	4129
B_1640a	GTGACCTGC CCGGTTCTCA G	3992	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTAGAACCGG G	4130
B_1640b	GTGACCTGC CCGGTTCTCA G	3992	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTAGAACCGG GCA	4131
B_1640c	GTGACCTGC CCGGTTCTCA G	3992	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTAGAACCGGG CAGG	4132
B_1676a	GAGCTTGGC AGGGGGTGG GA	3993	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCACCCCCT G	4133
B_1676b	GAGCTTGGC AGGGGGTGG GA	3993	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCACCCCCT GCC	4134
B_1676c	GAGCTTGGC AGGGGGTGG GA	3993	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTCACCCCCTG CCAA	4135
B_1701a	GAGCCAGAG AGGATCCTG GG	3994	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTAGGATCCT C	4136
B_1701b	GAGCCAGAG AGGATCCTG GG	3994	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTAGGATCCT CTC	4137
B_1701c	GAGCCAGAG AGGATCCTG GG	3994	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTAGGATCCTC TCTG	4138
B_1705a	GATGGAGCC AGAGAGGAT CC	3995	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTTCCTCTCT G	4139
B_1705b	GATGGAGCC AGAGAGGAT CC	3995	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTTCCTCTCT GGC	4140
B_1705c	GATGGAGCC AGAGAGGAT CC	3995	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTTCCTCTCTG GCTC	4141
B_1883a	GGGGCCACT AGGGACAGG AT	3996	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCTGTCCCT A	4142
B_1883b	GGGGCCACT AGGGACAGG AT	3996	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCTGTCCCT AGT	4143
B_1883c	GGGGCCACT AGGGACAGG AT	3996	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTCTGTCCCTA GTGG	4144
B_1902a	GTCCCCCTCA CCCCACAGT G	3997	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTTGTGGGGT G	4145
B_1902b	GTCCCCCTCA CCCCACAGT G	3997	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTTGTGGGGT GGA	4146
B_1902c	GTCCCCCTCA CCCCACAGT G	3997	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTTGTGGGGTG GAGG	4147

B_1962a	GGGACCACC TTATATTCCC A	3998	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTGAATATAA G	4148
B_1962b	GGGACCACC TTATATTCCC A	3998	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTGAATATAA GGT	4149
B_1962c	GGGACCACC TTATATTCCC A	3998	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTGAATATAAG GTGG	4150
B_3839a	GACCTGCCC AGCACACCC TG	3999	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTGGTGTGCT G	4151
B_3839b	GACCTGCCC AGCACACCC TG	3999	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTGGTGTGCT GGG	4152
B_3839c	GACCTGCCC AGCACACCC TG	3999	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTGGTGTGCTG GGCA	4153
B_3903a	GCGACTCCT GGAAGTGGC CA	4000	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCCACTTCC A	4154
B_3903b	GCGACTCCT GGAAGTGGC CA	4000	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCCACTTCC AGG	4155
B_3903c	GCGACTCCT GGAAGTGGC CA	4000	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTCCACTTCCA GGAG	4156
B_3930a	GGAATTCCC AGTGTGCAT CG	4001	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTTGCACACT G	4157
B_3930b	GGAATTCCC AGTGTGCAT CG	4001	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTTGCACACT GGG	4158
B_3930c	GGAATTCCC AGTGTGCAT CG	4001	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTTGCACACTG GGAA	4159
A_1_223_a	TTTGCAGTTT ATCAGGATG A	4002	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCGCAGTTTATC	4160
A_1_223_b	TTTGCAGTTT ATCAGGATG A	4002	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCGCAGTTTATCAG	4161
A_1_223_c	TTTGCAGTTT ATCAGGATG A	4002	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCGCAGTTTATCAGG	4162
A_2_260_a	GGTTGAGCA GGTAGATGT CA	4003	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCTGAGCAGGT	4163
A_2_260_b	GGTTGAGCA GGTAGATGT CA	4003	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCTGAGCAGGTAG	4164
A_2_260_c	GGTTGAGCA GGTAGATGT CA	4003	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCTGAGCAGGTAGAT	4165
A_3_325_a	CTGGGCGGC AGCATAGTG AG	4004	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCGGCGGCAGC	4166

A_3_325_b	CTGGGCGGC AGCATAGTG AG	4004	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCGGCGGCAGCAT	4167
A_3_325_c	CTGGGCGGC AGCATAGTG AG	4004	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCGGCGGCAGCATAG	4168
A_4_360_a	GTCAAGAGT TGACACATT GT	4005	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAAGAGTTGAC	4169
A_4_360_b	GTCAAGAGT TGACACATT GT	4005	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAAGAGTTGACAC	4170
A_4_360_c	GTCAAGAGT TGACACATT GT	4005	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAAGAGTTGACACA	4171
A_5_507_a	CCCAAGTGA TCACACTTGT C	4006	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAAGTGATCAC	4172
A_5_507_b	CCCAAGTGA TCACACTTGT C	4006	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAAGTGATCACAC	4173
A_5_507_c	CCCAAGTGA TCACACTTGT C	4006	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAAGTGATCACACTT	4174
A_6_510_a	CCACCCAAG TGATCACACT T	4007	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCCCCAAGTGA	4175
A_6_510_b	CCACCCAAG TGATCACACT T	4007	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCCCCAAGTGATC	4176
A_6_510_c	CCACCCAAG TGATCACACT T	4007	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCCCCAAGTGATCAC	4177
A_7_532_a	GGGAGAGAC GCAAACACA GC	4008	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAGAGACGCA	4178
A_7_532_b	GGGAGAGAC GCAAACACA GC	4008	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAGAGACGCAAA	4179
A_7_532_c	GGGAGAGAC GCAAACACA GC	4008	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAGAGACGCAAAACA	4180
B_1_272_a	TCTCTGACCT GTTTTTCCTT	4009	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATCTGACCTG	4181
B_1_272_b	TCTCTGACCT GTTTTTCCTT	4009	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATCTGACCTGT	4182
B_1_272_c	TCTCTGACCT GTTTTTCCTT	4009	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATCTGACCTGTTT	4183
B_2_291_a	TCTTACTGTC CCCTTCTGGG	4010	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATTACTGTCCC	4184
B_2_291_b	TCTTACTGTC CCCTTCTGGG	4010	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATTACTGTCCCCT	4185
B_2_291_c	TCTTACTGTC CCCTTCTGGG	4010	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATTACTGTCCCCTTC	4186
B_3_305_a	TCTGGGCTCA CTATGCTGCC	4011	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGGGCTCACT	4187
B_3_305_b	TCTGGGCTCA CTATGCTGCC	4011	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGGGCTCACTAT	4188

B_3_305_c	TCTGGGCTCA CTATGCTGCC	4011	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGGGCTCACTATGC	4189
B_4_326_a	CCCAGTGGG ACTTTGGAA AT	4012	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATAGTGGGACT	4190
B_4_326_b	CCCAGTGGG ACTTTGGAA AT	4012	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATAGTGGGACTTTG	4191
B_4_326_c	CCCAGTGGG ACTTTGGAA AT	4012	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATAGTGGGACTTTGG	4192
B_5_330_a	GTGGGACTTT GGAAATACA A	4013	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGGACTTTTG	4193
B_5_330_b	GTGGGACTTT GGAAATACA A	4013	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGGACTTTGGAA	4194
B_5_330_c	GTGGGACTTT GGAAATACA A	4013	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGGACTTTGGAAAT	4195
B_6_414_a	CCTGACAAT CGATAGGTA CC	4014	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGACAATCGA	4196
B_6_414_b	CCTGACAAT CGATAGGTA CC	4014	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGACAATCGATA	4197
B_6_414_c	CCTGACAAT CGATAGGTA CC	4014	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGACAATCGATAGG	4198
B_7_538_a	GGAATCATC TTTACCAGAT C	4015	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATATCATCTTTA	4199
B_7_538_b	GGAATCATC TTTACCAGAT C	4015	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATATCATCTTTACC	4200
B_7_538_c	GGAATCATC TTTACCAGAT C	4015	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATATCATCTTTACCAG	4201
B_8_584_a	GCAGCTCTC ATTTTCCATA C	4016	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGCTCTCATT	4202
B_8_584_b	GCAGCTCTC ATTTTCCATA C	4016	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGCTCTCATTTTC	4203
B_8_584_c	GCAGCTCTC ATTTTCCATA C	4016	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGCTCTCATTTTCCA	4204
B_9_601_a	TACAGTCAG TATCAATTCT G	4017	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATAGTCAGTAT	4205
B_9_601_b	TACAGTCAG TATCAATTCT G	4017	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATAGTCAGTATCA	4206
B_9_601_c	TACAGTCAG TATCAATTCT G	4017	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATAGTCAGTATCAAT	4207
A_3_325_a	CTGGGCGGC AGCATAGTG AG	4004	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCGGCGGCAGC	4166

B_6_414_b	CCTGACAAT CGATAGGTA CC	4014	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGACAATCGATA	4197
A_5_507_c	CCCAAGTGA TCACACTTGT C	4006	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAAGTGATCACACTT	4174
A_6_510_b	CCACCCAAG TGATCACACT T	4007	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCCCCAAGTGATC	4176
A_7_532_b	GGGAGAGAC GCAAACACA GC	4008	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAGAGACGCAAA	4179
B_8_584_b	GCAGCTCTC ATTTTCCATA C	4016	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGCTCTCATTTTC	4203
A_1077c	GCAGAGCCA GGAACCCCT GT	3975	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGGGTTTCT GGCT	4081
B_1154c	GTCCTTGGA AGCCAGGA G	3989	cTCTGGTCAACCACCGCGGTCTCAGT GGTGACGGTACAAACCTCTGGGCTT GCCAA	4123
A_3786c	GCTGGCCCC CCACCGCCC CA	3986	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGGCGGTGGG GGGC	4114
B_3903c	GCGACTCCT GGAAAGTGGC CA	4000	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTCCACTTCCA GGAG	4156
B_3930c	GGACTTCCC AGTGTGCAT CG	4001	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTTGACACTG GGAA	4159
A_7_532_b	GGGAGAGAC GCAAACACA GC	4008	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCAGAGACGCAAA	4179
B_8_584_b	GCAGCTCTC ATTTTCCATA C	4016	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGCTCTCATTTTC	4203
A7_attB_30	GGGAGAGAC GCAAACACA GC	4008	TCCTGACGACGGAGACCGCCGTCGTC GACAAGCCAGAGACGCAAA	4208
B8_attB_30	GCAGCTCTC ATTTTCCATA C	4016	TGTCGACGACGGCGGTCTCCGTCGTC AGGATCATGCTCTCATTTTC	4209
A7_attB_20	GGGAGAGAC GCAAACACA GC	4008	ACGACGGAGACCGCCGTCGTCGACA AGCCAGAGACGCAAA	4210
B8_attB_20	GCAGCTCTC ATTTTCCATA C	4016	ACGACGGCGGTCTCCGTCGTCAGGAT CATGCTCTCATTTTC	4211
A7_attB_GA_38	GGGAGAGAC GCAAACACA GC	4008	ATGATCCTGACGACGGAGTCCGCCGT CGTCGACAAGCCAGAGACGCAAA	4212
B8_attB_GA_38	GCAGCTCTC ATTTTCCATA C	4016	GGCTTGTCGACGACGGCGGACTCCGT CGTCAGGATCATGCTCTCATTTTC	4213
A7_attB_GA_30	GGGAGAGAC GCAAACACA GC	4008	TCCTGACGACGGAGTCCGCCGTCGTC GACAAGCCAGAGACGCAAA	4214

B8_attB_GA_30	GCAGCTCTC ATTTTCCATA C	4016	TGTCGACGACGGCGGACTCCGTCGTC AGGATCATGCTCTCATTTTC	4215
A7_attB_GA_20	GGGAGAGAC GCAAACACA GC	4008	ACGACGGAGTCCGCCGTCGTCGACAA GCCAGAGACGCAAA	4216
B8_attB_GA_20	GCAGCTCTC ATTTTCCATA C	4016	ACGACGGCGGACTCCGTCGTCAGGAT CATGCTCTCATTTTC	4217
A7_attP_50	GGGAGAGAC GCAAACACA GC	4008	GGGTTTGTACCGTACACCACTGAGAC CGCGGTGGTTGACCAGACAAACCAA GAGACGCAAA	4218
B8_attP_50	GCAGCTCTC ATTTTCCATA C	4016	TGGTTTGTCTGGTCAACCACCGCGGT CTCAGTGGTGTACGGTACAAACCCGC TCTCATTTTC	4219
A7_attP_40	GGGAGAGAC GCAAACACA GC	4008	TGTACCGTACACCACTGAGACCGCGG TGGTTGACCAGACAAACCAAGAGAC GCAAA	4220
B8_attP_40	GCAGCTCTC ATTTTCCATA C	4016	TGTCTGGTCAACCACCGCGGTCTCAG TGGTGTACGGTACAAACCCGCTCTCA TTTTC	4221
A7_attP_30	GGGAGAGAC GCAAACACA GC	4008	CGTACACCACTGAGACCGCGGTGGTT GACCAGACAAACCAAGAGACGCAAA	4222
B8_attP_30	GCAGCTCTC ATTTTCCATA C	4016	GGTCAACCACCGCGGTCTCAGTGGTG TACGGTACAAACCCGCTCTCATTTTC	4223
A7_attP_GA_50	GGGAGAGAC GCAAACACA GC	4008	GGGTTTGTACCGTACACCACTGAGTC CGCGGTGGTTGACCAGACAAACCAA GAGACGCAAA	4224
B8_attP_GA_50	GCAGCTCTC ATTTTCCATA C	4016	TGGTTTGTCTGGTCAACCACCGCGGA CTCAGTGGTGTACGGTACAAACCCGC TCTCATTTTC	4225
A7_attP_GA_40	GGGAGAGAC GCAAACACA GC	4008	TGTACCGTACACCACTGAGTCCGCGG TGGTTGACCAGACAAACCAAGAGAC GCAAA	4226
B8_attP_GA_40	GCAGCTCTC ATTTTCCATA C	4016	TGTCTGGTCAACCACCGCGGACTCAG TGGTGTACGGTACAAACCCGCTCTCA TTTTC	4227
A7_attP_GA_30	GGGAGAGAC GCAAACACA GC	4008	CGTACACCACTGAGTCCGCGGTGGTT GACCAGACAAACCAAGAGACGCAAA	4228
B8_attP_GA_30	GCAGCTCTC ATTTTCCATA C	4016	GGTCAACCACCGCGGACTCAGTGGTG TACGGTACAAACCCGCTCTCATTTTC	4229
A277_b	GACTGAAAC TTCACAGAA TA	4018	AACTTCACAGAGGCTTGTGACGACG GCGGTCTCCGTCGTCAGGATCAT	4230
A277_c	GACTGAAAC TTCACAGAA TA	4018	GAAACTTCACAGAGGCTTGTGACGAC GCGCGGTCTCCGTCGTCAGGATCAT	4231
B358_b	GATTTATGA GATCAACAG CAC	4019	GGCTTGTGACGACGGCGGTCTCCGT CGTCAGGATCATCTGTTGATCTC	4232
B358_c	GATTTATGA GATCAACAG CAC	4019	GGCTTGTGACGACGGCGGTCTCCGT CGTCAGGATCATCTGTTGATCTCAT	4233

A7_attB_20	GGGAGAGAC GCAAAACACA GC	4008	ACGACGGAGACCGCCGTCGTCGACA AGCCAGAGACGCAAA	4210
B8_attB_20	GCAGCTCTC ATTTTCCATA C	4016	ACGACGGCGGTCTCCGTCGTCAGGAT CATGCTCTCATTTTC	4211
A277_c	GACTGAAAC TTCACAGAA TA	4018	GAAACTTCACAGAGGCTTGTCGACGA CGGCGGTCTCCGTCGTCAGGATCAT	4231
B358_c	GATTTATGA GATCAACAG CAC	4019	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATCTGTTGATCTCAT	4233
pU6-Sp-gRNA- IDS_DF_A1_a_attP_fw d.dna	GACACCAAAA AACTGCCAC AGG	4020	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGTGGCAGTT A	4234
pU6-Sp-gRNA- IDS_DF_A1_a_attP_rev .dna	GACACCAAAA AACTGCCAC AGG	4020	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTGTGGCAGT TA	4235
pU6-Sp-gRNA- IDS_DF_A1_c_attP_fw d.dna	GACACCAAAA AACTGCCAC AGG	4020	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTGTGGCAGTT TTA	4236
pU6-Sp-gRNA- IDS_DF_A1_c_attP_rev .dna	GACACCAAAA AACTGCCAC AGG	4020	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTGTGGCAGT TTTA	4237
pU6-Sp-gRNA- IDS_DF_A4_b_attP_fw d.dna	GCACTCATTT CCTCCAAGCT C	4021	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCTTGAGGA AA	4238
pU6-Sp-gRNA- IDS_DF_A4_b_attP_rev .dna	GCACTCATTT CCTCCAAGCT C	4021	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCTTGAGG AAA	4239
pU6-Sp-gRNA- IDS_DF_B2_a_attP_fw d.dna	GTAGGTACA GGACAGGGC AG	4022	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCCCTGTCC	4240
pU6-Sp-gRNA- IDS_DF_B2_a_attP_rev .dna	GTAGGTACA GGACAGGGC AG	4022	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCCCTGTCC	4241
pU6-Sp-gRNA- IDS_DF_B3_a_attP_fw d.dna	GAGATAGGT AGGTACAGG ACA	4023	TCTGGTCAACCACCGCGGTCTCAGTG GTGTACGGTACAAACCTCCTGTACCT	4242
pU6-Sp-gRNA- IDS_DF_B3_a_attP_rev .dna	GAGATAGGT AGGTACAGG ACA	4023	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCCTGTACCT	4243
pU6-Sp-gRNA- IDS_DF_B4_b_attP_fw d.dna	GTGAAAAGA TAGGTAGGT AC	4024	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTCCTACCTA TCTA	4244
pU6-Sp-gRNA- IDS_DF_B4_b_attP_rev .dna	GTGAAAAGA TAGGTAGGT AC	4024	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTCCTACCTAT CTA	4245
pU6-Sp-gRNA- IDS_DF_B7_b_attP_fw d.dna	GTTATGGTTT ACTCCATCTA	4025	GTCTGGTCAACCACCGCGGTCTCAGT GGTGTACGGTACAAACCTATGGAGTA AACCT	4246
pU6-Sp-gRNA- IDS_DF_B7_b_attP_rev .dna	GTTATGGTTT ACTCCATCTA	4025	TACCGTACACCACTGAGACCGCGGTG GTTGACCAGACAAACCTATGGAGTAA ACC	4247
pU6-Sp-gRNA- IDS_DF_C2_c_attB_fw d.dna	GTTTTGGTTT ACCTATCTA	4026	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCATAGGGTAAACCA	4248

pU6-Sp-gRNA-IDS_DF_C2_c_attB_rev.dna	GTTTTGGTTT ACCCTATCTA	4026	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATATAGGGTAAACCA	4249
pU6-Sp-gRNA-IDS_DF_D1_b_attB_fw.dna	GCTGTGGAA CTGCAACAC ACT	4027	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATGTGTTGCAGT	4250
pU6-Sp-gRNA-IDS_DF_D1_b_attB_rev.dna	GCTGTGGAA CTGCAACAC ACT	4027	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCGTGTTGCAGT	4251
pU6-Sp-gRNA-IDS_DF_D2_c_attB_fw.dna	GTGCCACCT AACAGTGAG CTG	4028	GGCTTGTCGACGACGGCGGTCTCCGT CGTCAGGATCATCTCACTGTTAGGT	4252
pU6-Sp-gRNA-IDS_DF_D2_c_attB_rev.dna	GTGCCACCT AACAGTGAG CTG	4028	ATGATCCTGACGACGGAGACCGCCGT CGTCGACAAGCCCTCACTGTTAGGT	4253

[1364] All vectors for mammalian cell experiments were purified using Plasmid Plus Midiprep kits (Qiagen) or PureYield plasmid miniprep kits (Promega), or QIAprep Spin Miniprep kits.

General mammalian cell culture conditions

[1365] HEK293T (ATCC CRL-3216), U2OS (ATTC HTB-96), K562 (CCL-243), and HeLa (CCL-2) cells were purchased from ATCC and cultured and passaged in Dulbecco's Modified Eagle's Medium (DMEM) plus GlutaMAX (ThermoFisher Scientific), McCoy's 5A Medium (Gibco), RPMI Medium 1640 plus GlutaMAX (Gibco), or Eagle's Minimal Essential Medium (EMEM, ATCC), respectively, each supplemented with 10% (v/v) fetal bovine serum (Gibco, qualified) and 1x Penicillin Streptomycin (Corning). All cell types were incubated, maintained, and cultured at 37 °C with 5% CO₂. Cell lines were authenticated by their respective suppliers and tested negative for mycoplasma.

HEK293T, HeLa, and Huh7 tissue culture transfection protocol and genomic DNA preparation

[1366] HEK293T cells grown were seeded on 48-well poly-D-lysine coated plates (Corning). 16-24 h post-seeding, cells were transfected at approximately 60% confluency with 1 µL of Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocols and either: 750 ng of PE2 plasmid, 125 ng of pegRNA 1, and 125 ng of pegRNA 2 (for twinPE transfections); 750 ng of PE2 plasmid, 250 ng of pegRNA plasmid, and 83 ng of sgRNA plasmid (for PE3 transfections); or, 750 ng of Cas9 and 125 ng of sgRNA 1, and 125 ng of sgRNA 2 (for paired Cas9 nuclease transfections). Unless otherwise stated, cells were cultured 3 days following transfection, after which the media was removed, the cells were washed with 1x PBS solution (Thermo Fisher Scientific), and genomic DNA was extracted by the addition of 150 µL of freshly prepared lysis buffer (10 mM Tris-HCl, pH 7.5; 0.05% SDS; 25 µg/mL Proteinase K (ThermoFisher Scientific)) directly into each well of the tissue culture plate. The genomic DNA mixture was incubated at 37 °C for 1-2 hrs, followed by an 80 °C enzyme inactivation step for 30 min. Primers used for mammalian cell genomic DNA amplification are listed in Table 13.

Table 13. Sequences of primers used in this Example

Primers	Sequence	SEQ ID NO:
HEK3_fwd	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNATGTGGGC TGCCTAGAAAGG	3811
HEK3_rev	TGGAGTTCAGACGTGTGCTCTTCCGATCTCCCAGCCAAACTTGTC AACC	3812
HEK3_fwd	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNATGTGGGC TGCCTAGAAAGG	3811
HEK3_rev	TGGAGTTCAGACGTGTGCTCTTCCGATCTCCCAGCCAAACTTGTC AACC	3812
DMD_UMI_fwd1	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNNNNN NNNNtgcctggccagttactaacaat	4254
DMD_UMI_fwd2	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNNNNN NNNNcagaaagaagatcttaccatcttg	4255
DMD_rev0	TGGAGTTCAGACGTGTGCTCTTCCGATCTggctactttgtattgcatt	4256
AAVS1_AVA171 3	TGGAGTTCAGACGTGTGCTCTTCCGATCTCCAGAGCAGGGTCCC GCTTC	4257
AAVS1_AVA171 7	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNACGGGGCT CAGTCTGAAGAG	4258
AAVS1_AVA165 1	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGCCAAGG ACTCAAACCCAGA	4259
AAVS1_AVA165 2	TGGAGTTCAGACGTGTGCTCTTCCGATCTTCCGTGCGTCAGTTT ACCT	4260
AAVS1_AVA165 3	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAACTGCTT CTCCTCTTGGGAA	4261
AAVS1_AVA171 5	TGGAGTTCAGACGTGTGCTCTTCCGATCTTCCTTGCCAGAACCTC TAAGGT	4262
AAVS1_AVA165 5	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNATCCTCTC TGGCTCCATCGTA	4263
AAVS1_AVA165 6	TGGAGTTCAGACGTGTGCTCTTCCGATCTTCCACTTCAGGACAGC ATGTTT	4264
AAVS1_AVA170 7	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCGCCGGG AACTGCCGCTGGC	4265
AAVS1_AVA171 0	TGGAGTTCAGACGTGTGCTCTTCCGATCTGAGGAGGCCCTCATCT GGCG	4266
CCR5_AVA1678	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNAAATCAATG TGAAGCAAATCGCAGC	4267
CCR5_AVA1679	TGGAGTTCAGACGTGTGCTCTTCCGATCTTCGATTTGTCAGGAGG ATGATGAA	4268
CCR5_AVA1680	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNTCCTTCTT ACTGTCCCTTCTGGGC	4269
CCR5_AVA1681	TGGAGTTCAGACGTGTGCTCTTCCGATCTGCAAACACAGCATGG ACGAC	4270
CCR5_AVA1682	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNACAATCGA TAGGTACCTGGCTGTC	4271
CCR5_AVA1683	TGGAGTTCAGACGTGTGCTCTTCCGATCTACCAGCCCCAAGATG ACTAT	4272
IDS_AVA1763	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNCTGAAAAC CTGAGCTTGGAGG	4273
IDS_AVA1764	TGGAGTTCAGACGTGTGCTCTTCCGATCTGTCTACTCCAGCTTAA TGGAAGTGG	4274
IDS_AVA1765	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGAGAAGA TGTGGAAATGCCTCAC	4275
IDS_AVA1766	TGGAGTTCAGACGTGTGCTCTTCCGATCTAATCAACATGAAGGG TTGTGTTGT	4276
IDS_AVA1769	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNGTCCAC ACATGCGTTCCTC	4277

IDS_AVA1770	TGGAGTTCAGACGTGTGCTCTTCCGATCTGGCATGAAGGGTTGTT TTTAATTGA	4278
IDS_UML_junc1_ fwd	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNNNNN NNNNGCCCTGTCCTGTACCTACCT	4279
IDS_junc2_fwd	ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNTTCAGTTT GGGGTATGTGCCA	4280
IDS_universal_re v	TGGAGTTCAGACGTGTGCTCTTCCGATCTCTCAAATTACCCGTG GCAGC	4281

[1367] For HeLa cells, they were grown and seeded with a density similar to HEK293T cells and each well of cells were transfected with 190ng PE2_P2A_Blast (blasticidin resistance gene), 31.5ng of pegRNA1, and 31.5 ng of pegRNA 2 (for twinPE transfections) with 0.75 uL of HeLa monster reagent (Mirus). Cells were then treated with 10 ug/mL for the selection 24h after transfection. The rest of genomic DNA collection steps are identical to HEK293T cells. Huh7 cells were seeded 150k/well on 24-well poly-D-lysine coated plates (Corning). 16-24 h post-seeding, cells were transfected at high confluency with 2 µL of Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocols and up to 800 ng of plasmid DNA. Genomic DNA collection proceeded as above for HEK293T.

High-throughput DNA sequencing of genomic DNA samples

[1368] Genomic sites of interest were amplified from genomic DNA samples and sequenced on an Illumina MiSeq as previously described with the following modifications. Briefly, amplification primers containing Illumina forward and reverse adapters (Table 13) were used for a first round of PCR (PCR 1) amplifying the genomic region of interest. 25-µL PCR 1 reactions were performed with 0.5 µM of each forward and reverse primer, 1 µL of genomic DNA extract and 12.5 µL of Phusion U Green Multiplex PCR Master Mix. PCR reactions were carried out as follows: 98 °C for 2 min, then 30 cycles of [98 °C for 10 s, 61 °C for 20 s, and 72 °C for 30 s], followed by a final 72 °C extension for 2 min. Unique Illumina barcoding primer pairs were added to each sample in a secondary PCR reaction (PCR 2). Specifically, 25 µL of a given PCR 2 reaction contained 0.5 µM of each unique forward and reverse Illumina barcoding primer pair, 1 µL of unpurified PCR 1 reaction mixture, and 12.5 µL of Phusion U Green Multiplex PCR 2x Master Mix. The barcoding PCR 2 reactions were carried out as follows: 98 °C for 2 min, then 12 cycles of [98 °C for 10 s, 61 °C for 20 s, and 72 °C for 30 s], followed by a final 72 °C extension for 2 min. PCR products were evaluated analytically by electrophoresis in a 1.5% agarose gel. PCR 2 products (pooled by common amplicons) were purified by electrophoresis with a 1.5% agarose gel using a QIAquick Gel Extraction Kit (Qiagen), eluting with 40 µL of water. DNA concentration was measured by fluorometric quantification (Qubit, ThermoFisher Scientific) or qPCR (KAPA Library Quantification Kit-Illumina, KAPA Biosystems) and sequenced on an Illumina MiSeq instrument according to the manufacturer's protocols.

[1369] Sequencing reads were demultiplexed using MiSeq Reporter (Illumina). Alignment of amplicon sequences to a reference sequence was performed using CRISPResso2. For all prime editing

yield quantification, prime editing efficiency was calculated as: % of [# of reads with the desired edit that do not contain indels] ÷ [# of total reads]. For quantification of point mutation editing, CRISPResso2 was run in standard mode with “discard_indel_reads” on. Prime editing for installation of point mutations was then explicitly calculated as: [frequency of specified point mutation in non-discarded reads] x [# of non-discarded reads] ÷ [total reads]. For quantification of editing, CRISPResso2 was run in HDR mode using the desired allele as the expected allele (e flag), and with “discard_indel_reads” on. Editing yield was calculated as: [# of non-discarded HDR aligned reads] ÷ [total reads]. Indel yields were calculated as: [# of indel-containing discarded reads] ÷ [total reads]. Unique molecular identifiers (UMIs) were applied to quantify the deletion efficiency and assess PCR bias in this three-step PCR protocol. Briefly, in the first step of linear amplification, 1 uL of genomic DNA extract was linearly amplified by 0.1 uM of single forward UMI primer that contains 15-bp or 16-bp unique molecular identifiers and 12.5 uL Phusion U Green Multiplex PCR Master Mix in a 25-uL reaction. The PCR products were then purified by 1.6X AmPure beads (Beckman Coulter) and eluted in 20uL QIAGEN elution buffer. In the second step, 1 or 2 uL of linearly amplified PCR eluents were then amplified for 30 cycles with 0.5 uM of each forward and reverse primer, Phusion U Green Multiplex PCR mix in a 25-uL reaction. In this case, the forward primer anneals to the P5 Illumina adaptor sequence that locates at the 5' of the UMI primer and upstream of UMI. The PCR products were purified by 1X ampure beads and eluted in 25 uL elution buffer. In the third step, 1 uL eluent was amplified for 12 cycles as mentioned above for adding unique Illumina barcoding. To assess the large deletion at DMD locus, the top band (unedited large amplicon) and bottom band (edited amplicons with deletions) were excised separately from the 1.5% agarose and the final library (60 pM of top bands v.s. 20 pM of bottom bands) was loaded into two separate Miseq kits to avoid weak clustering of large amplicons (~1 kb) compared to short ones (~300bp)

[1370] Raw sequencing reads were UMI deduplicated using AmpUMI. For paired-end reads, SeqKit was used to concatenate (merge without overlap) R1s with the reverse complement of R2s. The concatenated R1+R2s were UMI deduplicated using the UMI at the 5' end of R1. UMI-deduplicated R1s or concatenated R1+R2s were analyzed using CRISPResso2. For analyzing concatenated R1+R2s, an appropriate concatenated reference amplicon sequence was provided to minimize sequencing alignment artifacts due to the concatenation.

Nucleofection of U2OS and K562

[1371] Nucleofection was performed in all experiments using K562 and U2OS cells. 200,000 cells were used per nucleofection. Counted cells were spun down and washed with PBS and then resuspended in nucleofection solution following the recommendation of Lonza SE Cell Line 4D-Nucleofector Kit. After nucleofection cells in the device, the cells were allowed to incubate in the cuvette at room temperature for 10 minutes. The contents of the cuvette were transferred to a 48 well

plate filled with pre-warmed media. Genomic DNA was extracted and prepared for Illumina Miseq preparation as mentioned above.

One-pot twinPE and BxbI-mediated cargo knock-in and large inversion:

[1372] For the one-pot mediated large inversion experiment, sequential plasmid transfection and one-pot mRNA nucleofection were performed. In the sequential plasmid transfection experiment, HEK293T cells were transfected with 750 ng PE2, 62.5 ng of each pegRNA (four in total) using Lipofectamine 2000 as mentioned above. After three days, cells were trypsinized and plated into 24-well plate and passaged for about seven days. 20K cells were then seeded again and transfected with 500 ng BxbI plasmid. Genomic DNA was extracted and prepared for Illumina Miseq preparation as mentioned above. In the one-pot mRNA nucleofection experiment, 200,000 cells were nucleofected with 1 μ g PE2 mRNA, 30 pmol each synthetic pegRNA (4 pegRNAs in total), and 750ng BxbI mRNA. Synthetic pegRNAs were order from IDT and mRNA transcripts were *in vitro* transcribed following the published protocol. 20 uL mixture of Lonza buffer and cells were electroporated with program CM-130 and recovered with 80 uL warmed media for five minutes. 25 uL samples from the cuvette was then added to each well of the 48-well plate and incubated at 37 °C for 72 hours.

OTHER REFERENCES MENTIONED THROUGHOUT THIS DISCLOSURE

The following references are each incorporated herein by reference in their entireties.

1. Jinek, M. *et al.* A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity. *Science* **337**, 816–821 (2012).
2. Cong, L. *et al.* Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science* **339**, 819–823 (2013).
3. Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. *Cell* **168**, 20–36 (2017).
4. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* **533**, 420–424 (2016).
5. Nishida, K. *et al.* Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. *Science* **353**, aaf8729 (2016).
6. Gaudelli, N. M. *et al.* Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature* **551**, 464–471 (2017).
7. ClinVar, July 2019.

8. Dunbar, C. E. *et al.* Gene therapy comes of age. *Science* **359**, eaan4672 (2018).
9. Cox, D. B. T., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. *Nat. Med.* **21**, 121–131 (2015).
10. Adli, M. The CRISPR tool kit for genome editing and beyond. *Nat. Commun.* **9**, 1911 (2018).
11. Kleinstiver, B. P. *et al.* Engineered CRISPR-Cas9 nucleases with altered PAM specificities. *Nature* **523**, 481–485 (2015).
12. Kleinstiver, B. P. *et al.* High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. *Nature* **529**, 490–495 (2016).
13. Hu, J. H. *et al.* Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. *Nature* **556**, 57–63 (2018).
14. Nishimasu, H. *et al.* Engineered CRISPR-Cas9 nuclease with expanded targeting space. *Science* **361**, 1259–1262 (2018).
15. Jasin, M. & Rothstein, R. Repair of strand breaks by homologous recombination. *Cold Spring Harb. Perspect. Biol.* **5**, a012740 (2013).
16. Paquet, D. *et al.* Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. *Nature* **533**, 125–129 (2016).
17. Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. *Nat. Biotechnol.* **36**, 765–771 (2018).
18. Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response. *Nat. Med.* **24**, 927–930 (2018).
19. Ihry, R. J. *et al.* p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. *Nat. Med.* **24**, 939–946 (2018).
20. Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. & Corn, J. E. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. *Nat. Biotechnol.* **34**, 339–344 (2016).
21. Srivastava, M. *et al.* An Inhibitor of Nonhomologous End-Joining Abrogates Double-Strand Break Repair and Impedes Cancer Progression. *Cell* **151**, 1474–1487 (2012).

22. Chu, V. T. *et al.* Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. *Nat. Biotechnol.* **33**, 543–548 (2015).
23. Maruyama, T. *et al.* Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. *Nat. Biotechnol.* **33**, 538–542 (2015).
24. Kim, Y. B. *et al.* Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. *Nat. Biotechnol.* **35**, 371–376 (2017).
25. Li, X. *et al.* Base editing with a Cpf1–cytidine deaminase fusion. *Nat. Biotechnol.* **36**, 324–327 (2018).
26. Gehrke, J. M. *et al.* An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities. *Nat. Biotechnol.* (2018). doi:10.1038/nbt.4199
27. Rees, H. A. & Liu, D. R. Base editing: precision chemistry on the genome and transcriptome of living cells. *Nat. Rev. Genet.* **1** (2018). doi:10.1038/s41576-018-0059-1.
28. Ostertag, E. M. & Kazazian Jr, H. H. Biology of Mammalian L1 Retrotransposons. *Annu. Rev. Genet.* **35**, 501–538 (2001).
29. Zimmerly, S., Guo, H., Perlman, P. S. & Lambowitz, A. M. Group II intron mobility occurs by target DNA-primed reverse transcription. *Cell* **82**, 545–554 (1995).
30. Luan, D. D., Korman, M. H., Jakubczak, J. L. & Eickbush, T. H. Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non-LTR retrotransposition. *Cell* **72**, 595–605 (1993).
31. Feng, Q., Moran, J. V., Kazazian, H. H. & Boeke, J. D. Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. *Cell* **87**, 905–916 (1996).
32. Jinek, M. *et al.* Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. *Science* **343**, 1247997 (2014).
33. Jiang, F. *et al.* Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage. *Science* aad8282 (2016). doi:10.1126/science.aad8282
34. Qi, L. S. *et al.* Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. *Cell* **152**, 1173–1183 (2013).
35. Tang, W., Hu, J. H. & Liu, D. R. Aptazyme-embedded guide RNAs enable ligand-

- responsive genome editing and transcriptional activation. *Nat. Commun.* **8**, 15939 (2017).
36. Shechner, D. M., Hacisuleyman, E., Younger, S. T. & Rinn, J. L. Multiplexable, locus-specific targeting of long RNAs with CRISPR-Display. *Nat. Methods* **12**, 664–670 (2015).
37. Anders, C. & Jinek, M. Chapter One - *In vitro* Enzymology of Cas9. in *Methods in Enzymology* (eds. Doudna, J. A. & Sontheimer, E. J.) **546**, 1–20 (Academic Press, 2014).
38. Briner, A. E. *et al.* Guide RNA Functional Modules Direct Cas9 Activity and Orthogonality. *Mol. Cell* **56**, 333–339 (2014).
39. Nowak, C. M., Lawson, S., Zerez, M. & Bleris, L. Guide RNA engineering for versatile Cas9 functionality. *Nucleic Acids Res.* **44**, 9555–9564 (2016).
40. Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C. & Doudna, J. A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. *Nature* **507**, 62–67 (2014).
41. Mohr, S. *et al.* Thermostable group II intron reverse transcriptase fusion proteins and their use in cDNA synthesis and next-generation RNA sequencing. *RNA* **19**, 958–970 (2013).
42. Stamos, J. L., Lentzsch, A. M. & Lambowitz, A. M. Structure of a Thermostable Group II Intron Reverse Transcriptase with Template-Primer and Its Functional and Evolutionary Implications. *Mol. Cell* **68**, 926–939.e4 (2017).
43. Zhao, C. & Pyle, A. M. Crystal structures of a group II intron maturase reveal a missing link in spliceosome evolution. *Nat. Struct. Mol. Biol.* **23**, 558–565 (2016).
44. Zhao, C., Liu, F. & Pyle, A. M. An ultraprocessive, accurate reverse transcriptase encoded by a metazoan group II intron. *RNA* **24**, 183–195 (2018).
45. Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* **8**, 2281–2308 (2013).
46. Liu, Y., Kao, H.-I. & Bambara, R. A. Flap endonuclease 1: a central component of DNA metabolism. *Annu. Rev. Biochem.* **73**, 589–615 (2004).
47. Krokan, H. E. & Bjørås, M. Base Excision Repair. *Cold Spring Harb. Perspect. Biol.* **5**, (2013).
48. Kelman, Z. PCNA: structure, functions and interactions. *Oncogene* **14**, 629–640 (1997).

49. Choe, K. N. & Moldovan, G.-L. Forging Ahead through Darkness: PCNA, Still the Principal Conductor at the Replication Fork. *Mol. Cell* **65**, 380–392 (2017).
50. Li, X., Li, J., Harrington, J., Lieber, M. R. & Burgers, P. M. Lagging strand DNA synthesis at the eukaryotic replication fork involves binding and stimulation of FEN-1 by proliferating cell nuclear antigen. *J. Biol. Chem.* **270**, 22109–22112 (1995).
51. Tom, S., Henriksen, L. A. & Bambara, R. A. Mechanism whereby proliferating cell nuclear antigen stimulates flap endonuclease 1. *J. Biol. Chem.* **275**, 10498–10505 (2000).
52. Tanenbaum, M. E., Gilbert, L. A., Qi, L. S., Weissman, J. S. & Vale, R. D. A protein-tagging system for signal amplification in gene expression and fluorescence imaging. *Cell* **159**, 635–646 (2014).
53. Bertrand, E. *et al.* Localization of ASH1 mRNA particles in living yeast. *Mol. Cell* **2**, 437–445 (1998).
54. Dahlman, J. E. *et al.* Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. *Nat. Biotechnol.* **33**, 1159–1161 (2015).
55. Tsai, S. Q. *et al.* GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat. Biotechnol.* **33**, 187–197 (2015).
56. Tsai, S. Q. *et al.* CIRCLE-seq: a highly sensitive *in vitro* screen for genome-wide CRISPR-Cas9 nuclease off-targets. *Nat. Methods* **14**, 607–614 (2017).
57. Schek N, Cooke C, Alwine JC. Molecular and Cellular Biology. (1992).
58. Gil A, Proudfoot NJ. Cell. (1987).
59. Zhao, B.S., Roundtree, I.A., He, C. Nat Rev Mol Cell Biol. (2017).
60. Rubio, M.A.T., Hopper, A.K. Wiley Interdiscip Rev RNA (2011).
61. Shechner, D.M., Hacisuleyman E., Younger, S.T., Rinn, J.L. Nat Methods. (2015).
62. Paige, J.S., Wu, K.Y., Jaffrey, S.R. Science (2011).
63. Ray D., ... Hughes TR. Nature (2013).
64. Chadalavada, D. M., Cerrone-Szakal, A. L., Bevilacqua, P.C. RNA (2007).

65. Forster AC, Symons RH. *Cell*. (1987).
66. Weinberg Z, Kim PB, Chen TH, Li S, Harris KA, Lünse CE, Breaker RR. *Nat. Chem. Biol.* (2015).
67. Feldstein PA, Buzayan JM, Bruening G. *Gene* (1989).
68. Saville BJ, Collins RA. *Cell*. (1990).
69. Winkler WC, Nahvi A, Roth A, Collins JA, Breaker RR. *Nature* (2004).
70. Roth A, Weinberg Z, Chen AG, Kim PG, Ames TD, Breaker RR. *Nat Chem Biol.* (2013).
71. Choudhury R, Tsai YS, Dominguez D, Wang Y, Wang Z. *Nat Commun.* (2012).
72. MacRae IJ, Doudna JA. *Curr Opin Struct Biol.* (2007).
73. Bernstein E, Caudy AA, Hammond SM, Hannon GJ *Nature* (2001).
74. Filippov V, Solovyev V, Filippova M, Gill SS. *Gene* (2000).
75. Cadwell RC and Joyce GF. *PCR Methods Appl.* (1992).
76. McInerney P, Adams P, and Hadi MZ. *Mol Biol Int.* (2014).
77. Esvelt KM, Carlson JC, and Liu DR. *Nature.* (2011).
78. Naorem SS, Hin J, Wang S, Lee WR, Heng X, Miller JF, Guo H. *Proc Natl Acad Sci USA* (2017).
79. Martinez MA, Vartanian JP, Wain-Hobson S. *Proc Natl Acad Sci USA* (1994).
80. Meyer AJ, Ellefson JW, Ellington AD. *Curr Protoc Mol Biol.* (2014).
81. Wang HH, Isaacs FJ, Carr PA, Sun ZZ, Xu G, Forest CR, Church GM. *Nature.* (2009).
82. Nyerges Á et al. *Proc Natl Acad Sci USA.* (2016).
83. Mascola JR, Haynes BF. *Immunol Rev.* (2013).
84. X. Wen, K. Wen, D. Cao, G. Li, R. W. Jones, J. Li, S. Szu, Y. Hoshino, L. Yuan, Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the

- immunogenicity of recombinant rotavirus Δ VP8* subunit parenteral vaccines. *Vaccine* 32, 4420-4427 (2014).
85. G. Ada, D. Isaacs, Carbohydrate-protein conjugate vaccines. *Clin Microbiol Infect* 9, 79-85 (2003).
86. E. Malito, B. Bursulaya, C. Chen, P. L. Surdo, M. Picchianti, E. Balducci, M. Biancucci, A. Brock, F. Berti, M. J. Bottomley, M. Nisum, P. Costantino, R. Rappuoli, G. Spraggon, Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. *Proceedings of the National Academy of Sciences* 109, 5229 (2012).
87. J. de Wit, M. E. Emmelot, M. C. M. Poelen, J. Lanfermeijer, W. G. H. Han, C. van Els, P. Kaaijk, The Human CD4(+) T Cell Response against Mumps Virus Targets a Broadly Recognized Nucleoprotein Epitope. *J Virol* 93, (2019).
88. M. May, C. A. Rieder, R. J. Rowe, Emergent lineages of mumps virus suggest the need for a polyvalent vaccine. *Int J Infect Dis* 66, 1-4 (2018).
89. M. Ramamurthy, P. Rajendiran, N. Saravanan, S. Sankar, S. Gopalan, B. Nandagopal, Identification of immunogenic B-cell epitope peptides of rubella virus E1 glycoprotein towards development of highly specific immunoassays and/or vaccine. *Conference Abstract*, (2019).
90. U. S. F. Tambunan, F. R. P. Sipahutar, A. A. Parikesit, D. Kerami, Vaccine Design for H5N1 Based on B- and T-cell Epitope Predictions. *Bioinform Biol Insights* 10, 27-35 (2016).
91. Asante, EA. et. al. "A naturally occurring variant of the human prion protein completely prevents prion disease". *Nature*. (2015).
92. Crabtree, G. R. & Schreiber, S. L. Three-part inventions: intracellular signaling and induced proximity. *Trends Biochem. Sci.* **21**, 418–22 (1996).
93. Liu, J. *et al.* Calcineurin Is a Common Target of A and FKBP-FK506 Complexes. *Cell* **66**, 807–815 (1991).
94. Keith, C. T. *et al.* A mammalian protein targeted by G1-arresting rapamycin–receptor complex. *Nature* **369**, 756–758 (2003).
95. Spencer, D. M., Wandless, T. J., Schreiber, S. L. S. & Crabtree, G. R. Controlling signal transduction with synthetic ligands. *Science* **262**, 1019–24 (1993).
96. Pruschy, M. N. *et al.* Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. *Chem. Biol.* **1**, 163–172 (1994).

97. Spencer, D. M. *et al.* Functional analysis of Fas signaling *in vivo* using synthetic inducers of dimerization. *Curr. Biol.* **6**, 839–847 (1996).
98. Belshaw, P. J., Spencer, D. M., Crabtree, G. R. & Schreiber, S. L. Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. *Chem. Biol.* **3**, 731–738 (1996).
99. Yang, J. X., Symes, K., Mercola, M. & Schreiber, S. L. Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment. *Curr. Biol.* **8**, 11–18 (1998).
100. Belshaw, P. J., Ho, S. N., Crabtree, G. R. & Schreiber, S. L. Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. *Proc. Natl. Acad. Sci.* **93**, 4604–4607 (2002).
101. Stockwell, B. R. & Schreiber, S. L. Probing the role of homomeric and heteromeric receptor interactions in TGF- β signaling using small molecule dimerizers. *Curr. Biol.* **8**, 761–773 (2004).
102. Spencer, D. M., Graef, I., Austin, D. J., Schreiber, S. L. & Crabtree, G. R. A general strategy for producing conditional alleles of Src-like tyrosine kinases. *Proc. Natl. Acad. Sci.* **92**, 9805–9809 (2006).
103. Holsinger, L. J., Spencer, D. M., Austin, D. J., Schreiber, S. L. & Crabtree, G. R. Signal transduction in T lymphocytes using a conditional allele of Sos. *Proc. Natl. Acad. Sci.* **92**, 9810–9814 (2006).
104. Myers, M. G. Insulin Signal Transduction and the IRS Proteins. *Annu. Rev. Pharmacol. Toxicol.* **36**, 615–658 (1996).
105. Watowich, S. S. The erythropoietin receptor: Molecular structure and hematopoietic signaling pathways. *J. Investig. Med.* **59**, 1067–1072 (2011).
106. Blau, C. A., Peterson, K. R., Drachman, J. G. & Spencer, D. M. A proliferation switch for genetically modified cells. *Proc. Natl. Acad. Sci.* **94**, 3076–3081 (2002).
107. Clackson, T. *et al.* Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. *Proc. Natl. Acad. Sci.* **95**, 10437–10442 (1998).
108. Diver, S. T. & Schreiber, S. L. Single-step synthesis of cell-permeable protein dimerizers that activate signal transduction and gene expression. *J. Am. Chem. Soc.* **119**, 5106–5109 (1997).
109. Guo, Z. F., Zhang, R. & Liang, F. Sen. Facile functionalization of FK506 for biological studies by the thiol-ene ‘click’ reaction. *RSC Adv.* **4**, 11400–11403 (2014).
110. Robinson, D. R., Wu, Y.-M. & Lin, S.-F. The protein tyrosine kinase family of the human genome. *Oncogene* **19**, 5548–5557 (2000).
111. Landrum, M. J. *et al.* ClinVar: public archive of interpretations of clinically relevant variants. *Nucleic Acids Res.* **44**, D862–D868 (2016).

112. Jinek, M. et al. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. *Science* 337, 816–821 (2012).
113. Cong, L. et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science* 339, 819–823 (2013).
114. Mali, P. et al. RNA-Guided Human Genome Engineering via Cas9. *Science* 339, 823– 826 (2013).
115. Yang, H. et al. One-Step Generation of Mice Carrying Reporter and Conditional Alleles by CRISPR/Cas-Mediated Genome Engineering. *Cell* 154, 1370–1379 (2013).
116. Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J.-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. *Genome Res.* 24, 1012–1019 (2014).
117. Orlando, S. J. et al. Zinc-finger nuclease-driven targeted integration into mammalian genomes using donors with limited chromosomal homology. *Nucleic Acids Res.* 38, e152–e152 (2010).
118. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat. Biotechnol.* 33, 187–197 (2015).
119. Suzuki, K. et al. In vivo genome editing via CRISPR/Cas9 mediated homology- independent targeted integration. *Nature* 540, 144–149 (2016).
120. Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. *Nat. Biotechnol.* 36, 765–771 (2018).
121. Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response. *Nat. Med.* 24, 927–930 (2018).
122. Ihry, R. J. et al. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. *Nat. Med.* 24, 939–946 (2018).
123. Chapman, J. R., Taylor, M. R. G. & Boulton, S. J. Playing the end game: DNA double- strand break repair pathway choice. *Mol. Cell* 47, 497–510 (2012).
124. Cox, D. B. T., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. *Nat. Med.* 21, 121–131 (2015).
125. Paquet, D. et al. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. *Nature* 533, 125–129 (2016).
126. Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9- induced precise gene editing in mammalian cells. *Nat. Biotechnol.* 33, 543–548 (2015).
127. Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR- Cas9 by inhibition of nonhomologous end joining. *Nat. Biotechnol.* 33, 538–542 (2015).
128. Rees, H. A., Yeh, W.-H. & Liu, D. R. Development of hRad51–Cas9 nickase fusions that mediate HDR without double-stranded breaks. *Nat. Commun.* 10, 1–12 (2019).

129. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* 533, 420–424 (2016).
130. Gaudelli, N. M. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature* 551, 464–471 (2017).
131. Gao, X. et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. *Nature* 553, 217–221 (2018).
132. Ingram, V. M. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. *Nature* 178, 792–794 (1956).
133. Myerowitz, R. & Costigan, F. C. The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. *J. Biol. Chem.* 263, 18587–18589 (1988).
134. Zielenski, J. Genotype and Phenotype in Cystic Fibrosis. *Respiration* 67, 117–133 (2000).
135. Mead, S. et al. A Novel Protective Prion Protein Variant that Colocalizes with Kuru Exposure. *N. Engl. J. Med.* 361, 2056–2065 (2009).
136. Marraffini, L. A. & Sontheimer, E. J. CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. *Science* 322, 1843–1845 (2008).
137. Barrangou, R. et al. CRISPR provides acquired resistance against viruses in prokaryotes. *Science* 315, 1709–1712 (2007).
138. Jiang, F. & Doudna, J. A. CRISPR–Cas9 Structures and Mechanisms. *Annu. Rev. Biophys.* 46, 505–529 (2017).
139. Hille, F. et al. The Biology of CRISPR-Cas: Backward and Forward. *Cell* 172, 1239–1259 (2018).
140. Luan, D. D., Korman, M. H., Jakubczak, J. L. & Eickbush, T. H. Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non- LTR retrotransposition. *Cell* 72, 595–605 (1993).
141. Liu, Y., Kao, H.-I. & Bambara, R. A. Flap endonuclease 1: a central component of DNA metabolism. *Annu. Rev. Biochem.* 73, 589–615 (2004).
142. Rees, H. A. & Liu, D. R. Base editing: precision chemistry on the genome and transcriptome of living cells. *Nat. Rev. Genet.* 19, 770 (2018).
143. Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. & Corn, J. E. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. *Nat. Biotechnol.* 34, 339–344 (2016).
144. Qi, L. S. et al. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. *Cell* 152, 1173–1183 (2013).

145. Shechner, D. M., Hacisuleyman, E., Younger, S. T. & Rinn, J. L. Multiplexable, locus-specific targeting of long RNAs with CRISPR-Display. *Nat. Methods* 12, 664–670 (2015).
146. Tang, W., Hu, J. H. & Liu, D. R. Aptazyme-embedded guide RNAs enable ligand- responsive genome editing and transcriptional activation. *Nat. Commun.* 8, 15939 (2017).
147. Jinek, M. et al. Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. *Science* 343, 1247997 (2014).
148. Nishimasu, H. et al. Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA. *Cell* 156, 935–949 (2014).
149. Jiang, F., Zhou, K., Ma, L., Gressel, S. & Doudna, J. A. A Cas9–guide RNA complex preorganized for target DNA recognition. *Science* 348, 1477–1481 (2015).
150. Baranauskas, A. et al. Generation and characterization of new highly thermostable and processive M-MuLV reverse transcriptase variants. *Protein Eng. Des. Sel.* 25, 657–668 (2012).
151. Gerard, G. F. et al. The role of template-primer in protection of reverse transcriptase from thermal inactivation. *Nucleic Acids Res.* 30, 3118–3129 (2002).
152. Arezi, B. & Hogrefe, H. Novel mutations in Moloney Murine Leukemia Virus reverse transcriptase increase thermostability through tighter binding to template-primer. *Nucleic Acids Res.* 37, 473–481 (2009).
153. Kotewicz, M. L., Sampson, C. M., D'Alessio, J. M. & Gerard, G. F. Isolation of cloned Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity. *Nucleic Acids Res.* 16, 265–277 (1988).
154. Shen, M. W. et al. Predictable and precise template-free CRISPR editing of pathogenic variants. *Nature* 563, 646–651 (2018).
155. Thuronyi, B. W. et al. Continuous evolution of base editors with expanded target compatibility and improved activity. *Nat. Biotechnol.* (2019). doi:10.1038/s41587-019- 0193-0
156. Kim, Y. B. et al. Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. *Nat. Biotechnol.* 35, 371–376 (2017).
157. Koblan, L. W. et al. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. *Nat. Biotechnol.* (2018). doi:10.1038/nbt.4172
158. Komor, A. C. et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. *Sci. Adv.* 3, eaao4774 (2017).
159. Kleinstiver, B. P. et al. High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. *Nature* 529, 490–495 (2016).
160. Zuo, E. et al. Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. *Science* 364, 289–292 (2019).

161. Jin, S. et al. Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. *Science* 364, 292–295 (2019).
162. Kim, D., Kim, D., Lee, G., Cho, S.-I. & Kim, J.-S. Genome-wide target specificity of CRISPR RNA-guided adenine base editors. *Nat. Biotechnol.* 37, 430–435 (2019).
163. Grünewald, J. et al. Transcriptome-wide off-target RNA editing induced by CRISPR- guided DNA base editors. *Nature* 569, 433–437 (2019).
164. Zhou, C. et al. Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. *Nature* 571, 275–278 (2019).
165. Rees, H. A., Wilson, C., Doman, J. L. & Liu, D. R. Analysis and minimization of cellular RNA editing by DNA adenine base editors. *Sci. Adv.* 5, eaax5717 (2019).
166. Ostertag, E. M. & Kazazian Jr, H. H. Biology of Mammalian L1 Retrotransposons. *Annu. Rev. Genet.* 35, 501–538 (2001).
167. Griffiths, D. J. Endogenous retroviruses in the human genome sequence. *Genome Biol.* 2, REVIEWS1017 (2001).
168. Berkhout, B., Jebbink, M. & Zsifros, J. Identification of an Active Reverse Transcriptase Enzyme Encoded by a Human Endogenous HERV-K Retrovirus. *J. Virol.* 73, 2365–2375 (1999).
169. Halvas, E. K., Svarovskaia, E. S. & Pathak, V. K. Role of Murine Leukemia Virus Reverse Transcriptase Deoxyribonucleoside Triphosphate-Binding Site in Retroviral Replication and In Vivo Fidelity. *J. Virol.* 74, 10349–10358 (2000).
170. Dever, D. P. et al. CRISPR/Cas9 Beta-globin Gene Targeting in Human Hematopoietic Stem Cells. *Nature* 539, 384–389 (2016).
171. Park, S. H. et al. Highly efficient editing of the β -globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease. *Nucleic Acids Res.*
doi:10.1093/nar/gkz475
172. Collinge, J. Prion diseases of humans and animals: their causes and molecular basis. *Annu. Rev. Neurosci.* 24, 519–550 (2001).
173. Asante, E. A. et al. A naturally occurring variant of the human prion protein completely prevents prion disease. *Nature* 522, 478–481 (2015).
174. Anzalone, A. V., Lin, A. J., Zairis, S., Rabadan, R. & Cornish, V. W. Reprogramming eukaryotic translation with ligand-responsive synthetic RNA switches. *Nat. Methods* 13, 453–458 (2016).
175. Badran, A. H. et al. Continuous evolution of *Bacillus thuringiensis* toxins overcomes insect resistance. *Nature* 533, 58–63 (2016).
176. Anders, C. & Jinek, M. Chapter One - In Vitro Enzymology of Cas9. in *Methods in Enzymology* (eds. Doudna, J. A. & Sontheimer, E. J.) 546, 1–20 (Academic Press, 2014).

177. Pirakitikulr, N., Ostrov, N., Peralta-Yahya, P. & Cornish, V. W. PCRless library mutagenesis via oligonucleotide recombination in yeast. *Protein Sci. Publ. Protein Soc.* 19, 2336–2346 (2010).
178. Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. *Nat. Biotechnol.* 37, 224–226 (2019).
179. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. *Nat. Biotechnol.* 33, 187–197 (2015).
180. Kleinstiver, B. P. et al. High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. *Nature* 529, 490–495 (2016).
181. Koblan, L. W. et al. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. *Nat. Biotechnol.* (2018). doi:10.1038/nbt.4172
182. Baranauskas, A. et al. Generation and characterization of new highly thermostable and processive M-MuLV reverse transcriptase variants. *Protein Eng. Des. Sel.* 25, 657–668 (2012).
183. Schechner, DM, Hacisuleyman E., Younger ST, Rinn JL. *Nat Methods* 664-70 (2015).
184. Brown JA, et al. *Nat Struct Mol Biol* 633-40 (2014).
185. Conrad NA and Steitz JA. *EMBO J* 1831-41 (2005).
186. Bartlett JS, et al. *Proc Natl Acad Sci USA* 8852-7 (1996).
187. Mitton-Fry RM, DeGregorio SJ, Wang J, Steitz TA, Steitz JA. *Science* 1244-7 (2010).
188. Forster AC, Symons RH. *Cell*. 1987.
189. Weinberg Z, Kim PB, Chen TH, Li S, Harris KA, Lünse CE, Breaker RR. *Nat. Chem. Biol.* 2015.
190. Feldstein PA, Buzayan JM, Bruening G. *Gene* 1989.
191. Saville BJ, Collins RA. *Cell*. 1990.
192. Roth A, Weinberg Z, Chen AG, Kim PG, Ames TD, Breaker RR. *Nat Chem Biol.* 2013.
193. Borchardt EK, et al. *RNA* 1921-30 (2015).
194. Zhang Y, et al. *Mol Cell* 792-806 (2013).
195. Dang Y, et al. *Genome Biol* 280 (2015).
196. Schaefer M, Kapoor U, and Jantsch MF. *Open Biol* 170077 (2017).
197. Nahar S, et al. *Chem Comm* 2377-80 (2018).
198. Gao Y and Zhao Y. *J Integr Plant Biol* 343-9 (2014).
199. Dubois N, Marquet R, Paillart J, Bernacchi S. *Front Microbiol* 527 (2018).
200. Costa M and Michel F. *EMBO J* 1276-85 (1995).
201. Hu JH, et al. *Nature* 57-63 (2018).
202. Furukawa K, Gu H, Breaker RR. *Methods Mol Biol* 209-20 (2014).

203. Zettler, J., Schütz, V. & Mootz, H. D. The naturally split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans-splicing reaction. *FEBS Lett.* 583, 909–914 (2009).
204. Kügler, S., Kilic, E. & Bähr, M. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. *Gene Ther.* 10, 337–347 (2003).
205. de Felipe, P., Hughes, L. E., Ryan, M. D. & Brown, J. D. Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide. *J. Biol. Chem.* 278, 11441–11448 (2003).
206. Levy, J. M. & Nicoll, R. A. Membrane-associated guanylate kinase dynamics reveal regional and developmental specificity of synapse stability. *J. Physiol.* 595, 1699–1709 (2017).
207. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* 12, 323 (2011).
208. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 43, e47–e47 (2015).

EQUIVALENTS AND SCOPE

[1373] In the articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Embodiments or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

[1374] Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claims that is dependent on the same base claim. Where elements are presented as lists, *e.g.*, in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the disclosure or aspects of the disclosure consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth *in haec verba* herein. It is also

noted that the terms “comprising” and “containing” are intended to be open and permits the inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

[1375] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the embodiments. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the invention can be excluded from any embodiment, for any reason, whether or not related to the existence of prior art.

[1376] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended embodiments. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following embodiments.

CLAIMS

What is claimed is:

1. A system for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited, wherein the system comprises a first prime editor complex and a second prime editor complex, wherein each of the first and second prime editor complexes comprises (1) a prime editor comprising (i) a nucleic acid programmable DNA binding protein (napDNAbp), and (ii) a polypeptide having an RNA-dependent DNA polymerase activity; and (2) a pegRNA comprising a spacer sequence, gRNA core, a DNA synthesis template, and a primer binding site, wherein the DNA synthesis template of the pegRNA of the first prime editor complex encodes a first single-stranded DNA sequence and the DNA synthesis template of the pegRNA of the second prime editor complex encodes a second single-stranded DNA sequence, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence each comprises a region of complementarity to the other, and wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence form a duplex comprising an edited portion as compared to the DNA sequence at the target site to be edited, which integrates into the target site to be edited.
2. The system of claim 1, wherein the prime editor of the first prime editor complex, the second prime editor complex, or both the first prime editor complex and the second prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity.
3. The system of claim 1 or 2, wherein the first prime editor complex and the second prime editor complex comprise the same prime editor.
4. The system of claim 1 or 2, wherein the first prime editor complex and the second prime editor complex comprise different prime editors.
5. The system of any one of claims 1-4, wherein the napDNAbp is a Cas9 domain or variant thereof.
6. The system of any one of claims 1-5, wherein the napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, a Cas9 nickase domain, or variant thereof.
7. The system of any one of claims 1-4, wherein the napDNAbp is selected from the group consisting of: Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, CasX, CasY, and

Argonaute.

8. The system of any one of claims 1-7, wherein the napDNAbp has a nickase activity.
9. The system of any one of claims 1-4, wherein the napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 18-88, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 18-88.
10. The system of any one of claims 1-9, wherein the polypeptide having an RNA-dependent DNA polymerase activity is a reverse transcriptase.
11. The system of any one of claims 1-10, wherein the polypeptide having an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 89-100, 105-122, 128-129, 132, 139, 143, 149, 154, 159, and 700-766 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 89-100, 105-122, 128-129, and 132.
12. The system of any one of claims 1-11, wherein the prime editor further comprises a linker that joins the napDNAbp and the polypeptide having the RNA-dependent DNA polymerase activity.
13. The system of claim 12, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOs: 166-177, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 166-177.
14. The system of claim 12 or 13, wherein the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.
15. The system of any one of claims 1-14, wherein the pegRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244.
16. The system of any one of claims 1-15, wherein the spacer sequence of the pegRNA of the first prime editor complex binds to a first binding site on a first strand of the double-stranded

DNA sequence upstream from the target site to be edited.

17. The system of any one of claims 1-16, wherein the spacer sequence of the pegRNA of the second prime editor complex binds to a second binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.
18. The system of claim 17, whereby the binding of the spacer sequence of the pegRNAs of the first and second prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequences on each strand by the napDNAbs of each of the first and second prime editor complex.
19. The system of claim 18, wherein the first and second binding sites define two ends of a contiguous region of double-stranded DNA comprising the target site to be edited.
20. The system of claim 19, wherein the contiguous region between the first and second binding sites is at least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78

nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

21. The system of claim 19, wherein the contiguous region becomes replaced by the duplex comprising the edited portion.
22. The system of any one of claims 1-21, wherein the DNA synthesis template is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89

nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

23. The system of any one of claims 1-22, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have the same lengths.
24. The system of any one of claims 1-22, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have different lengths.
25. The system of any one of claims 1-24, wherein the region of complementarity is at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, or at least 10% of the total length of the first single-stranded DNA sequence or the second single-stranded DNA sequence.
26. The system of claim 25, wherein the region of complementarity is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least

70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length, and is either less than or equal to the length of the desired DNA sequence and complement thereof.

27. The system of claim 25, wherein the region of complementarity of the first single-stranded DNA sequence and the second single-stranded DNA sequence form the duplex comprising the edited portion.
28. The system of any one of claims 1-27, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are each single-stranded DNA strands having 3' ends.
29. The system of claim 21, wherein the replacement of the contiguous region by the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.
30. A system for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited, said system comprising:
 - a) a first prime editor complex comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (first napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEGRNA) that binds to a first binding site on a first strand of the double-stranded DNA sequence upstream of the target site to be edited;
 - b) a second prime editor complex comprising:
 - iii. a second prime editor comprising a second nucleic acid programmable DNA binding

protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and

- iv. a second prime editing guide RNA (second PEGRNA) that binds to a second binding site on a second strand of the double-stranded DNA sequence downstream of the target site to be edited;

wherein the first PEGRNA comprises a first DNA synthesis template encoding a first single-stranded DNA sequence and the second PEGRNA comprises a second DNA synthesis template encoding a second single-stranded DNA sequence, and wherein the first strand and the second strand of the double-stranded DNA sequence are complementary to each other.

- 31. The system of claim 30, wherein the prime editor of the first prime editor complex, the second prime editor complex, or both the first prime editor complex and the second prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity.
- 32. The system of claim 30, wherein the first and the second single-stranded DNA sequence each comprise a region of complementarity to the other.
- 33. The system of claim 30, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence form a duplex comprising the edited portion which integrates into the target site to be edited.
- 34. The system of claim 30, wherein the first single-stranded DNA sequence and/or the second single stranded sequence does not comprise sequence homology as compared to the DNA sequence at the target site.
- 35. The system of claim 30, wherein the first PEGRNA further comprises a first spacer sequence, a first gRNA core, and a first primer binding site, and the second PEGRNA further comprises a second spacer sequence, a second gRNA core, and a second primer binding site.
- 36. The system of any one of claims 30-35, wherein the first prime editor complex and the second prime editor complex comprise the same prime editor.
- 37. The system of any one of claims 30-36, wherein the first polypeptide comprising an RNA-dependent DNA polymerase activity and the second polypeptide comprising an RNA-dependent DNA polymerase activity are the same.

38. The system of any one of claims 30-37, wherein the first and/or second napDNAbp is a Cas9 domain or variant thereof.
39. The system of any one of claims 30-38, wherein the first and/or second napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, a Cas9 nickase domain, or a variant thereof.
40. The system of any one of claims 30-39, wherein the first and/or second napDNAbp is selected from the group consisting of Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, CasX, CasY, and Argonaute.
41. The system of any one of claims 30-40, wherein the napDNAbp has a nickase activity.
42. The system of any one of claims 30-41, wherein the first and/or second napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 18-88, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 18-88.
43. The system of any one of claims 30-42, wherein the first and/or second polypeptide having an RNA-dependent DNA polymerase activity is a reverse transcriptase.
44. The system of any one of claims 30-43, wherein the first and/or second polypeptide having an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 89-100, 105-122, 128-129, 132, 139, 143, 149, 154, 159, and 700-766 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 89-100, 105-122, 128-129, and 132.
45. The system of any one of claims 30-44, wherein the first prime editor further comprises a linker that joins the first napDNAbp and the first polypeptide having the RNA-dependent DNA polymerase activity; and/or the second prime editor further comprises a linker that joins the second napDNAbp and the second polypeptide having the RNA-dependent DNA polymerase activity.
46. The system of claim 45, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOs: 166-177, or an amino acid sequence having at least an 80%, 85%, 90%, 95%,

or 99% sequence identity with any one of SEQ ID NOs: 166-177.

47. The system of claim 45, wherein the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid in length.
48. The system of any one of claims 30-47, wherein the first and/or second pegRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244.
49. The system of any one of claims 30-48, wherein the first spacer sequence binds to a first binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.
50. The system of claim 35, wherein the second spacer sequence of the second prime editor complex binds to a second binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.
51. The system of claim 35, whereby the binding of the spacer sequence of the first and second prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequences on each strand by the first and/or second napDNAbps of each of the first and second prime editor complexes.
52. The system of claim 30, wherein the first and second binding sites define two ends of a contiguous region of double-stranded DNA comprising the target site to be edited.
53. The system of claim 52, wherein the contiguous region between the first and second binding sites is least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34

nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

54. The system of claim 52, wherein the contiguous region becomes replaced by the duplex comprising the edited portion.
55. The system of any one of claims 30-54, wherein the first and/or second DNA synthesis template is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40

nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

56. The system of any one of claims 30-55, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have the same lengths.
57. The system of any one of claims 30-56, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have different lengths.
58. The system of any one of claims 30-57, wherein the region of complementarity is at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, or at least 10% of the total length of the first single-stranded DNA sequence or the second single-stranded DNA sequence.
59. The system of any one of claims 30-58, wherein the region of complementarity is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21

nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

60. The system of any one of claims 30-59, wherein the region of complementarity of the first single-stranded DNA sequence and the second single-stranded DNA sequence form a duplex.
61. The system of any one of claims 30-60, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are each single-stranded DNA strands having 3' ends.
62. The system of claim 54, wherein the replacement of the contiguous region by the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.
63. A polynucleotide encoding the system of any of claims 1-62.

- 64. A polynucleotide encoding the first and second prime editors of any one of claims 1-62.
- 65. A polynucleotide encoding the first and/or second pegRNA of any one of claims 1-62.
- 66. A polynucleotide encoding the first and/or second pegRNA of any one of claims 30-62.
- 67. A polynucleotide encoding the first and second pegRNA of any one of claims 1-29.
- 68. A polynucleotide encoding the first and second pegRNA of any one of claims 30-62.
- 69. A vector comprising a polynucleotide of any one of claims 63-68.
- 70. A cell comprising a polynucleotide of any one of claims 63-68 or a vector of claim 69.
- 71. A pharmaceutical composition comprising a polynucleotide of any one of claims 63-68, a vector of claim 69, or a cell of claim 70, and a pharmaceutical excipient.
- 72. A kit comprising a polynucleotide of any of claims 63-68 or a vector of claim 69 and instructions for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited.
- 73. A method for simultaneously editing a first and a second complementary strands of a double-stranded DNA sequence at a target site, said method comprising contacting the double-stranded DNA sequence with a pair of prime editor complexes, said pair comprising:
 - a. a first prime editor complex, comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEgRNA) that binds to a first binding site on the first strand of the genomic DNA sequence upstream of the target site;
 - b. a second prime editor complex, comprising:
 - i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a second prime editing guide RNA (second PEgRNA) that binds to a second binding

site on the second strand of the genomic DNA sequence downstream of the target site;

wherein the first prime editor complex causes a first nick at a sequence complementary to the first binding site and the subsequent polymerization of a first single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the first nick;

wherein the second prime editor complex causes a second nick at a sequence complementary to the second binding site and the subsequent polymerization of a second single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the second nick;

wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are reverse complements over at least a region of complementarity and form a duplex comprising an edit; and

wherein the duplex replaces the nicked first and second complementary strands of the double-stranded DNA sequence.

74. The method of claim 73, wherein the prime editor of the first prime editor complex, the second prime editor complex, or both the first prime editor complex and the second prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity
75. The method of claim 73, wherein the first prime editor complex and the second prime editor complex comprise the same prime editor.
76. The method of claim 73, wherein the first prime editor complex and the second prime editor complex comprise a different prime editor.
77. The method of any one of claims 73-76, wherein the first and/or second napDNAbp is a Cas9 domain or variant thereof.
78. The method of any one of claims 73-77, wherein the first and/or second napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, a Cas9 nickase domain, or variant thereof.
79. The method of any one of claims 73-78, wherein the first and/or second napDNAbp is selected from the group consisting of: Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, CasX, CasY, and Argonaute.

80. The method of any one of claims 73-79, wherein the first and/or second napDNAbp has a nickase activity.
81. The method of any one of claims 73-80, wherein the first and/or second napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 18-88, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 18-88.
82. The method of any one of claims 73-81, wherein the first and/or second polypeptide having an RNA-dependent DNA polymerase activity is a reverse transcriptase.
83. The method of any one of claims 73-82, wherein the first and/or second polypeptide having an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 89-100, 105-122, 128-129, 132, 139, 143, 149, 154, 159, and 700-766 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 89-100, 105-122, 128-129, and 132.
84. The method of any one of claims 73-83, wherein the first prime editor further comprises a linker that joins the first napDNAbp and the first polypeptide having the RNA-dependent DNA polymerase activity, and/or the second prime editor further comprises a linker that joins the second napDNAbp and the second polypeptide having the RNA-dependent DNA polymerase activity.
85. The method of claim 84, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOs: 166-177, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 166-177.
86. The method of claim 84 or 85, wherein the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.
87. The method of any one of claims 73-86, wherein the first and/or second pegRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244.

88. The method of any one of claims 73-87, wherein the first and/or second PEgRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 325-330, 499-505, 101-104, 181-183, and 223-244.
89. The method of any one of claims 73-88, wherein the first spacer sequence of the first prime editor complex binds to a first binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.
90. The method of any one of claims 73-89, wherein the second spacer sequence of the second prime editor complex binds to a second binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.
91. The method of claim 90, wherein the binding of the first and second spacer sequences of the first and second prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequence on each strand by the napDNAbps of each first and second prime editor complex.
92. The method of claim 91, wherein the first and second binding sites define two ends of a contiguous region of double-stranded DNA comprising the target site to be edited.
93. The method of claim 92, wherein the contiguous region between the first and second binding sites is least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54

nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

94. The method of claim 92 or 93, wherein the contiguous region becomes replaced by the duplex comprising the edited portion.
95. The method of any one of claims 73-94, wherein the first and/or second DNA synthesis template is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68

nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

96. The method of any one of claims 73-95, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have the same lengths.
97. The method of any one of claims 73-96, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence have different lengths.
98. The method of any one of claims 73-97, wherein the region of complementarity is at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, or at least 10% of the total length of the first single-stranded DNA sequence or the second single-stranded DNA sequence.
99. The method of any one of claims 73-98, wherein the region of complementarity is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49

nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length, and is either less than or equal to the length of the desired DNA sequence and complement thereof.

100. The method of any one of claims 73-99, wherein the region of complementarity of the first single-stranded DNA sequence and the second single-stranded DNA sequence form the duplex.
101. The method of any one of claims 73-100, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are each single-stranded DNA strands having 3' ends.
102. The method of claim 94, wherein the replacement of the contiguous region by the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.
103. The method of any one of claims 73-102, wherein the duplex comprising an edit comprising one or more recombinase sites.
104. The method of claim 103 further comprising providing a recombinase to promote recombinase-mediated editing of the DNA sequence at the target site to be edited.
105. A pair of pegRNAs for use in dual prime editing, wherein the pair comprises:

- a. a first prime editing guide RNA (first PEgRNA) that binds to a first binding site on a first strand of a double-stranded DNA sequence upstream of a target site to be edited, wherein the first PEgRNA comprises a first spacer sequence, a first gRNA core, a first DNA synthesis template, and a first primer binding site, wherein the first DNA synthesis template encodes a first single-stranded DNA sequence comprising an edited portion;
 - b. a second prime editing guide RNA (second PEgRNA) that binds to a second binding site on a second strand of the double-stranded DNA sequence downstream of the target site to be edited, wherein the second PEgRNA comprises a second spacer sequence, a second gRNA core, a second DNA synthesis template, and a second primer binding site, wherein the second DNA synthesis template encodes a second single-stranded DNA sequence comprising the edited portion, wherein the second single-stranded DNA sequence comprises a region of complementarity to the first single-stranded DNA sequence.
106. The pair of pegRNAs of claim 105, wherein the first PEgRNA comprises the structure:
 5'-[first gRNA spacer sequence]-[first gRNA core]-[first DNA synthesis template]-[first primer binding site]-3'; and
 wherein the second PEgRNA comprises the structure:
 5'-[second gRNA spacer sequence]-[second gRNA core]-[second DNA synthesis template]-[second primer binding site]-3'.
107. The pair of pegRNAs of claim 105 or 106, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence form a duplex that integrates into the double-stranded DNA sequence at the target site to be edited.
108. The pair of pegRNAs of claim 107, wherein the integration of the duplex results in an insertion, deletion, or replacement of DNA at the target site.
109. The pair of pegRNAs of claim 108, wherein the insertion is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least

38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

110. The pair of pegRNAs of claim 108, wherein the deletion is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66

nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides, or more in length.

111. The pair of pegRNAs of claim 108, wherein the replacement is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94

- nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides, or more in length.
112. A polynucleotide encoding a pair of pegRNAs of any one of claims 105-111.
113. A vector comprising the polynucleotide of claim 112 for expressing the pair of pegRNAs in a cell.
114. A cell comprising the vector of claim 113.
115. A pharmaceutical composition comprising a pair of pegRNAs of any one of claims 105-111, a vector of claim 113, or a cell of claim 114, and a pharmaceutical excipient.
116. A pair of prime editor complexes, said pair comprises:
- a. a first prime editor complex, comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEGRNA) that binds to a first target sequence on the strand of the genomic DNA sequence upstream of the target site;
 - b. a second prime editor complex, comprising:
 - i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a second prime editing guide RNA (second PEGRNA) that binds to a second target sequence on the second strand of the genomic DNA sequence downstream of the target site.
117. The pair of prime editor complexes of claim 116, wherein the prime editor of the first prime editor complex, the second prime editor complex, or both the first prime editor complex and the second prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity.
118. A polynucleotide encoding a pair of prime editor complexes of claim 116 or 117.

119. A vector comprising the polynucleotide of claim 118 for expressing the pair of prime editor complexes in a cell.
120. A cell comprising the vector of claim 119.
121. A pharmaceutical composition comprising a pair of prime editor complexes of claim 116 or 117, a vector of claim 119, or a cell of claim 120, and a pharmaceutical excipient.
122. The system of any one of claims 1-62, or the method of any one of claims 73-104, wherein integration of the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.
123. The system or method of claim 122, wherein the insertion is a peptide tag.
124. The system or method of claim 123, wherein the peptide tag is a poly-histidine (e.g., HHHHHH) (SEQ ID NO: 252-262), FLAG (e.g., DYKDDDDK) (SEQ ID NO: 2), V5 (e.g., GKPIPNPLLGLDST) (SEQ ID NO: 3), GCN4, HA (e.g., YPYDVPDYA) (SEQ ID NO: 5), Myc (e.g. EQKLISEED) (SEQ ID NO: 6), or GST.
125. The system or method of claim 123, wherein the peptide tag has an amino acid sequence selected from the group consisting of SEQ ID NO: 1-6, 245-249, 252-262, 264-273, 275-276, 281, 278-288, and 622.
126. The system or method of claim 122, wherein the insertion is an immunopeptide tag.
127. The system or method of claim 126, wherein the immunopeptide tag is selected from the group consisting of: tetanus toxoid (SEQ ID NO: 396); diphtheria toxin mutant CRM197 (SEQ ID NO: 630); mumps immunopeptide 1 (SEQ ID NO: 400); mumps immunopeptide 2 (SEQ ID NO: 402); mumps immunopeptide 3 (SEQ ID NO: 404); rubella virus (SEQ ID NO: 406); hemagglutinin (SEQ ID NO: 408); neuraminidase (SEQ ID NO: 410); TAP1 (SEQ ID NO: 412); TAP2 (SEQ ID NO: 414); hemagglutinin epitopes toward class I HLA (SEQ ID NO: 416); neuraminidase epitopes toward class I HLA (SEQ ID NO: 418); hemagglutinin epitopes toward class II HLA (SEQ ID NO: 420); neuraminidase epitopes toward class II HLA (SEQ ID NO: 422); hemagglutinin epitope H5N1-bound class I and class II HLA (SEQ ID NO: 424); and neuraminidase epitope H5N1-bound class I and class II HLA (SEQ ID NO: 426).

128. The system or method of claim 122, wherein the insertion is a dimerization domain.
129. The system or method of claim 128, wherein the dimerization domain is small molecule binding domain of FKBP12 of SEQ ID NO: 488, FKBP12-F36V of SEQ ID NO: 489, or cyclophilin of SEQ ID NOs: 490 or 493-494.
130. A system for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited, the system comprising:
- a) a first prime editor complex comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (first napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEgRNA) that binds to a first binding site on a first strand of the double-stranded DNA sequence upstream of the target site to be edited;
 - b) a second prime editor complex comprising:
 - i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a second prime editing guide RNA (second PEgRNA) that binds to a second binding site on a second strand of the double-stranded DNA sequence upstream of the target site to be edited;
 - c) a third prime editor complex comprising:
 - i. a third prime editor comprising a third nucleic acid programmable DNA binding protein (third napDNAbp) and a third polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a third prime editing guide RNA (third PEgRNA) that binds to a third binding site on the first strand of the double-stranded DNA sequence downstream of the target site to be edited;
 - d) a fourth prime editor complex comprising:
 - i. a fourth prime editor comprising a fourth nucleic acid programmable DNA binding protein (fourth napDNAbp) and a fourth polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a fourth prime editing guide RNA (fourth PEgRNA) that binds to a fourth binding site on the second strand of the double-stranded DNA sequence downstream of the target site to be edited;
- wherein the first PEgRNA comprises a first DNA synthesis template encoding a first

single-stranded DNA sequence, the second PEgRNA comprises a second DNA synthesis template encoding a second single-stranded DNA sequence, the third PEgRNA comprises a third DNA synthesis template encoding a third single-stranded DNA sequence, and the fourth PEgRNA comprises a fourth DNA synthesis template encoding a fourth single-stranded DNA sequence;

wherein the first and the third single-stranded DNA sequence each comprise a region of complementarity to the other; and wherein, wherein the second and the fourth single-stranded DNA sequence each comprise a region of complementarity to the other.

131. A system for editing one or more double-stranded DNA sequences, the system comprising:
- a) a first prime editor complex comprising:
 - i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (first napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a first prime editing guide RNA (first PEgRNA) that binds to a first binding site on a first strand of a first double-stranded DNA sequence at a first target site to be edited;
 - b) a second prime editor complex comprising:
 - i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a second prime editing guide RNA (second PEgRNA) that binds to a second binding site on a second strand of the first double-stranded DNA sequence at the first target site to be edited;
 - c) a third prime editor complex comprising:
 - i. a third prime editor comprising a third nucleic acid programmable DNA binding protein (third napDNAbp) and a third polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a third prime editing guide RNA (third PEgRNA) that binds to a first binding site on a first strand of a second double-stranded DNA sequence at a second target site to be edited;
 - d) a fourth prime editor complex comprising:
 - i. a fourth prime editor comprising a fourth nucleic acid programmable DNA binding protein (fourth napDNAbp) and a fourth polypeptide comprising an RNA-dependent DNA polymerase activity; and
 - ii. a fourth prime editing guide RNA (fourth PEgRNA) that binds to a second binding site on a second strand of the second double-stranded DNA sequence at

the second target site to be edited;

wherein the first PEgRNA comprises a first DNA synthesis template encoding a first single-stranded DNA sequence, the second PEgRNA comprises a second DNA synthesis template encoding a second single-stranded DNA sequence, the third PEgRNA comprises a third DNA synthesis template encoding a third single-stranded DNA sequence, and the fourth PEgRNA comprises a fourth DNA synthesis template encoding a fourth single-stranded DNA sequence;

wherein the first and the third single-stranded DNA sequence each comprise a region of complementarity to the other; and wherein, wherein the second and the fourth single-stranded DNA sequence each comprise a region of complementarity to the other.

132. The system of claim 131, wherein the prime editor of the first prime editor complex, the second prime editor complex, the third prime editor complex, an/or the fourth prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity

133. The system of any one of claims 130-132, wherein

(i) the first PEgRNA further comprises a first spacer sequence, first gRNA core, and a first primer binding site;

(ii) the second PEgRNA further comprises a second spacer sequence, a second gRNA core, and a second primer binding site;

(iii) the third PEgRNA further comprises a third spacer sequence, a third gRNA core, and a third primer binding site; and

(iv) the fourth PEgRNA comprises a fourth spacer sequence, a fourth gRNA core, a fourth DNA synthesis template, and a fourth primer binding site.

134. The system of claim 131, wherein the region of complementarity of the first and third single-stranded DNA sequence, and/or the region of complementarity of the second and fourth single-stranded DNA sequence, form a duplex.

135. The system of claim 134, wherein the first spacer sequence binds to the first binding site of the first double stranded DNA sequence upstream of the first target site to be edited and the second spacer sequence binds to the second binding site on the first double stranded DNA sequence downstream of the first target site to be edited.

136. The system of claim 134 or 135, wherein the third spacer sequence binds to the first binding site of the second double stranded DNA sequence upstream of the second target site to be edited and

the forth spacer sequence binds to the second binding site on the second double stranded DNA sequence downstream of the second target site to be edited.

137. The system of any one of claims 134-136, wherein the first and second binding sites define two ends of a first contiguous region of the first double-stranded DNA.

138. The system of any one of claims 134-137, wherein the third and fourth binding sites define two ends of a second contiguous region of the second double-stranded DNA.

139. The system of claim 134, wherein the contiguous region between the first and second binding sites or the third and fourth binding sites is least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110

nucleotides in length.

140. The system of any one of claims 134-139, wherein the region of complementarity of the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the region of complementarity of the second single-stranded DNA sequence and the fourth single-stranded DNA sequence, form a duplex.

141. The system of claim 140, wherein the duplex is incorporated in the first double stranded DNA and/or the second double stranded DNA.

142. The system of any one of claims 134-141, wherein the system results in replacement of the first contiguous region by the second contiguous region into the first double-stranded DNA.

143. The system of any one of claims 134-142, wherein the system results in exchange of the first contiguous region and the second contiguous region between the first double-stranded DNA and the second double-stranded DNA.

144. The system of any one of claims 134-143, wherein the first prime editor complex, the second prime editor complex, the third prime editor complex, and the fourth prime editor complex comprise the same prime editor.

145. The system of any one of claims 134-144, wherein the first, second, third, and fourth polypeptide comprising an RNA-dependent DNA polymerase activity are the same.

146. The system of any one of claims 134-145, wherein the first, second, third, and/or fourth napDNAbp is a Cas9 domain or variant thereof.

147. The system of any one of claims 134-146, wherein the first, second, third, and/or fourth napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, or a Cas9 nickase domain or a variant thereof.

148. The system of any one of claims 134-147, wherein the first, second, third, and/or fourth napDNAbp is selected from the group consisting of: Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c, and Argonaute.

149. The system of any one of claims 134-148, wherein the first, second, third, and/or fourth napDNAbp has nickase activity.

150. The system of any one of claims 134-149, wherein the first, second, third, and/or fourth napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 2-65, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 2-65.
151. The system of any one of claims 134-150, wherein the first, second, third, and/or fourth polypeptide having an RNA-dependent DNA polymerase activity is a reverse transcriptase.
152. The system of any one of claims 134-151, wherein the first, second, third, and/or fourth polypeptide having an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 37, 68-79, 82-98, 81, 98, and 110 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 37, 68-79, 82-98, 81, 98, and 110.
153. The system of any one of claims 134-152, wherein
- (i) the first prime editor further comprises a linker that joins the first napDNAbp and the first polypeptide having the RNA-dependent DNA polymerase activity;
 - (ii) the second prime editor further comprises a linker that joins the second napDNAbp and the second polypeptide having the RNA-dependent DNA polymerase activity;
 - (iii) the third prime editor further comprises a linker that joins the third napDNAbp and the third polypeptide having the RNA-dependent DNA polymerase activity; and/or
 - (iv) the fourth prime editor further comprises a linker that joins the fourth napDNAbp and the fourth polypeptide having the RNA-dependent DNA polymerase activity.
154. The system of claim 153, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOs: 119-128, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 119-128.
155. The system of claim 153 or 154, wherein the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.
156. The system of any one of claims 134-155, wherein the first, second, third, and/or fourth PEgRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 192-203, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 192-203.

157. The system of any one of claims 134-156, wherein the first spacer sequence binds to a first binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.

158. The system of any one of claims 134-157, wherein the second spacer sequence of the second prime editor complex binds to a second binding site on a second strand of the double-stranded DNA sequence upstream from the target site to be edited.

159. The system of any one of claims 134-158, wherein the third spacer sequence binds to a third binding site on a first strand of the double-stranded DNA sequence downstream from the target site to be edited.

160. The system of any one of claims 134-159, wherein the fourth spacer sequence of the fourth prime editor complex binds to a fourth binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.

161. The system of claim 160, wherein the binding of the spacer sequence of the first and second prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequences on each strand by the first and/or second napDNAbs of each first and second prime editor complexes.

162. The system of claim 161, wherein the binding of the spacer sequence of the third and fourth prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequences on each strand by the third and/or fourth napDNAbs of each third and fourth prime editor complexes.

163. The system of claim 133, wherein the first and third binding sites, or the second and fourth binding sites, define two ends of a contiguous region of double-stranded DNA.

164. The system of claim 163, wherein the contiguous region between the first and third binding sites or the second and fourth binding sites is least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29

nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

165. The system of any one of claims 130-164, wherein the region of complementarity of the first single-stranded DNA sequence and the third single-stranded DNA sequence, and/or the region of complementarity of the second single-stranded DNA sequence and the fourth single-stranded DNA sequence, form a duplex.

166. The system of claim 164, wherein the contiguous region becomes replaced by the duplex.

167. The system of claim 166, wherein the duplex is incorporated in the double-stranded DNA at the target site.

168. The system of claim any one of claims 122-167, wherein the first, second, third, and/or fourth DNA synthesis template is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13

nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

169. The system of any one of claims 122-168, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded DNA sequence and the fourth single-stranded DNA sequence, have the same lengths.

170. The system of any one of claims 122-169, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded DNA sequence and the fourth single-stranded DNA sequence, have different lengths.

171. The system of any one of claims 122-170, wherein the region of complementarity of the first, second, third, and/or fourth single-stranded DNA sequence is at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least

50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, or at least 10% of the total length of the first single-stranded DNA sequence and the third single-stranded DNA sequence, or the second single-stranded DNA sequence and the fourth single-stranded DNA sequence.

172. The system of any one of claims 122-171, wherein the region of complementarity of the first, second, third, and/or fourth single-stranded DNA sequence is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length, and is either less than or equal to the length of the first single-stranded DNA sequence and the third single-stranded DNA sequence, and the second single-stranded DNA sequence and the fourth single-stranded DNA sequence.

173. The system of any one of claims 130-172, wherein the first, second, third, and fourth single-stranded DNA sequence are each single-stranded DNA strands having 3' ends.

174. The system of claim 173, wherein the incorporation of the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.

175. A polynucleotide encoding the first, second, third, and fourth prime editors of any one of claims 130-174.

176. A polynucleotide encoding the first, second, third, and fourth PEGRNA of any of claims 130-175.

177. A vector comprising a polynucleotide of claim 175 or 176.

178. A cell comprising a polynucleotide of claim 175 or 176 or a vector of claim 177.

179. A pharmaceutical composition comprising a polynucleotide of claim 175 or 176, a vector of claim 177, or a cell of claim 178, and a pharmaceutical excipient.

180. A kit comprising a polynucleotide of claim 175 or 176 or a vector of claim 177 and instructions for simultaneously editing both strands of a double-stranded DNA sequence at a target site to be edited.

181. A method for simultaneously editing first and second complementary strands of a double-stranded DNA sequence at a target site, the method comprising contacting the double-stranded DNA sequence with a pair of prime editor complexes, the pair comprising:

(a) a first prime editor complex, comprising:

- i. a first prime editor comprising a first nucleic acid programmable DNA binding protein (first napDNAbp) and a first polypeptide comprising an RNA-dependent DNA polymerase activity; and
- ii. a first prime editing guide RNA (first PEGRNA) that binds to a first target sequence on the first strand of the genomic DNA sequence upstream of the target site;

(b) a second prime editor complex, comprising:

- i. a second prime editor comprising a second nucleic acid programmable DNA binding protein (second napDNAbp) and a second polypeptide comprising an RNA-dependent DNA polymerase activity; and
- ii. a second prime editing guide RNA (second PEGRNA) that binds to a second target

sequence on the second strand of the genomic DNA sequence upstream of the target site;

(c) a third prime editor complex, comprising:

- i. a third prime editor comprising a third nucleic acid programmable DNA binding protein (third napDNAbp) and a third polypeptide comprising an RNA-dependent DNA polymerase activity; and
- ii. a third prime editing guide RNA (third PEGRNA) that binds to a third target sequence on the first strand of the genomic DNA sequence downstream of the target site;

(d) a fourth prime editor complex, comprising:

- i. a fourth prime editor comprising a second nucleic acid programmable DNA binding protein (fourth napDNAbp) and a fourth polypeptide comprising an RNA-dependent DNA polymerase activity; and
- ii. a fourth prime editing guide RNA (fourth PEGRNA) that binds to a fourth target sequence on the second strand of the genomic DNA sequence downstream of the target site;

wherein the first prime editor complex causes a first nick at the first target sequence and the subsequent polymerization of a first single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the first nick;

wherein the second prime editor complex causes a second nick at the second target sequence and the subsequent polymerization of a second single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the second nick;

wherein the third prime editor complex causes a third nick at the third target sequence and the subsequent polymerization of a third single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the third nick;

wherein the fourth prime editor complex causes a fourth nick at the fourth target sequence and the subsequent polymerization of a fourth single-stranded DNA sequence having a 3'-end from the available 5'-end formed by the fourth nick;

wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are reverse complements over at least a region of complementarity and form a duplex, wherein the duplex replaces the nicked first and second complementary strands of the double-stranded DNA sequence; and

wherein the third single-stranded DNA sequence and the fourth single-stranded DNA sequence are reverse complements over at least a region of complementarity and form a duplex, wherein the duplex replaces the nicked first and second complementary strands of the double-stranded DNA sequence.

182. The method of claim 181, wherein the prime editor of the first prime editor complex, the

second prime editor complex, the third prime editor complex, and/or the fourth prime editor complex is a fusion protein comprising the napDNAbp and the polypeptide having an RNA-dependent DNA polymerase activity.

183. The method of claim 181 or 182, wherein the first prime editor complex, the second prime editor complex, the third prime editor complex, and the fourth prime editor complex comprise the same prime editor.

184. The method of any one of claims 181-183, wherein the first, second, third, and/or fourth prime editor complex comprise a different prime editor.

185. The method of any one of claims 181-184, wherein first, second, third, and/or fourth napDNAbp is a Cas9 domain or variant thereof.

186. The method of any one of claims 181-185, wherein first, second, third, and/or fourth napDNAbp is a nuclease active Cas9 domain, a nuclease inactive Cas9 domain, or a Cas9 nickase domain or variant thereof.

187. The method of any one of claims 181-184, wherein the first, second, third, and/or fourth napDNAbp is selected from the group consisting of: Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas13a, Cas12c.

188. The method of any one of claims 181-187, wherein the first, second, third, and/or fourth napDNAbp has a nickase activity.

189. The method of any one of claims 181-188, wherein the first, second, third, and/or fourth napDNAbp comprises an amino acid sequence of any one of SEQ ID NOs: 2-65, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 2-65.

190. The method of any one of claims 181-189, wherein the first, second, third, and/or fourth polypeptide having an RNA-dependent DNA polymerase activity is a reverse transcriptase.

191. The method of any one of claims 181-190, wherein the first, second, third, and/or fourth polypeptide having an RNA-dependent DNA polymerase activity comprises an amino acid sequence of any one of SEQ ID NOs: 37, 68-79, 82-98, 81, 98, and 110 or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 37, 68-79, 82-

98, 81, 98, and 110.

192. The method of any one of claims 181-191, wherein

(i) the first prime editor further comprises a linker that joins the first napDNAbp and the first polypeptide having the RNA-dependent DNA polymerase activity;

(ii) the second prime editor further comprises a linker that joins the second napDNAbp and the second polypeptide having the RNA-dependent DNA polymerase activity;

(iii) the third prime editor further comprises a linker that joins the third napDNAbp and the third polypeptide having the RNA-dependent DNA polymerase activity; and/or

(iv) the fourth prime editor further comprises a linker that joins the fourth napDNAbp and the fourth polypeptide having the RNA-dependent DNA polymerase activity.

193. The method of claim 192, wherein the linker comprises an amino acid sequence of any one of SEQ ID NOs: 119-128, or an amino acid sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 119-128.

194. The method of claim 192 or 193, wherein the linker is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 38, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length.

195. The method of any one of claims 192-194, wherein the first, second, third, and/or fourth PEGRNA comprises a nucleotide sequence of any one of SEQ ID NOs: 192-203, or a nucleotide sequence having at least an 80%, 85%, 90%, 95%, or 99% sequence identity with any one of SEQ ID NOs: 192-203.

196. The method of any one of claims 192-195, wherein the first spacer sequence of the first prime editor complex binds to a first binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.

197. The method of any one of claims 192-196, wherein the second spacer sequence of the second prime editor complex binds to a second binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.

198. The method of any one of claims 192-197, wherein the third spacer sequence of the third prime editor complex binds to a third binding site on a first strand of the double-stranded DNA sequence upstream from the target site to be edited.

199. The method of any one of claims 192-198, wherein the fourth spacer sequence of the fourth prime editor complex binds to a fourth binding site on a second strand of the double-stranded DNA sequence downstream from the target site to be edited.

200. The method of claim 199, wherein the binding of the first and second spacer sequences of the first and second prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequence on each strand by the napDNAbps of each first and second prime editor complex.

201. The method of claim 200, wherein the binding of the third and fourth spacer sequences of the third and fourth prime editor complexes in the presence of a PAM sequence results in the nicking of the first and second strands, respectively, at a nick site proximal to the PAM sequence on each strand by the napDNAbps of each third and fourth prime editor complex.

202. The method of claim 200 or 201, wherein the first and second binding sites, and/or the third and fourth binding sites, define two ends of a contiguous region of double-stranded DNA comprising the target site to be edited.

203. The method of claim 202, wherein the contiguous region between the first and second binding sites, and/or the contiguous region between the third and fourth binding sites, is least 10 nucleobase pairs, at least 11 nucleobase pairs, at least 12 nucleobase pairs, at least 13 nucleobase pairs, at least 14 nucleobase pairs, at least 15 nucleobase pairs, at least 16 nucleobase pairs, at least 17 nucleobase pairs, at least 18 nucleobase pairs, at least 19 nucleobase pairs, at least 20 nucleobase pairs, at least 21 nucleobase pairs, at least 22 nucleobase pairs, at least 23 nucleobase pairs, at least 24 nucleobase pairs, at least 25 nucleobase pairs, at least 26 nucleobase pairs, at least 27 nucleobase pairs, at least 28 nucleobase pairs, at least 29 nucleobase pairs, at least 30 nucleobase pairs, at least 31 nucleobase pairs, at least 32 nucleobase pairs, at least 33 nucleobase pairs, at least 34 nucleobase pairs, at least 35 nucleobase pairs, at least 36 nucleobase pairs, at least 37 nucleobase pairs, at least 37 nucleobase pairs, at least 38 nucleobase pairs, at least 39 nucleobase pairs, or at least 40 nucleobase pairs, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69

nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

204. The method of claim 202 or 203, wherein the contiguous region becomes replaced by the duplex.

205. The method of any one of claims 181-204, wherein the first, second, third, and/or fourth DNA synthesis template is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85

nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

206. The method of any one of claims 181-205, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded-DNA sequence and the fourth single-stranded DNA sequence, have the same lengths.

207. The method of any one of claims 181-206, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded-DNA sequence and the fourth single-stranded DNA sequence, have different lengths.

208. The method of any one of claims 181-207, wherein the region of complementarity is at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, at least 15%, or at least 10% of the total length of the first single-stranded DNA sequence and the second single-stranded DNA sequence, or the third single-stranded DNA sequence and the fourth single-stranded DNA sequence.

209. The method of any one of claims 181-208, wherein the region of complementarity is at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58

nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

210. The method of any one of claims 188-209, wherein the region of complementarity of the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded-DNA sequence and the fourth single-stranded DNA sequence, form the duplex.

211. The method of any one of claims 188-210, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded-DNA sequence and the fourth single-stranded DNA sequence, are each single-stranded DNA strands having 3' ends.

212. The method of claim 204, wherein the replacement of the contiguous region by the duplex comprising the edited portion results in an insertion, deletion, or replacement of DNA at the target site.

213. The method of any one of claims 181-212, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence are on ends of a target DNA sequence, and wherein the third single-stranded DNA sequence and the fourth single-stranded DNA sequence are on opposite ends of the same target DNA sequence.

214. The method of claim 213, wherein the target DNA sequence is inverted.

215. The method of any one of claims 181-214 further comprising providing a circular DNA donor.

216. The method of claim 215, wherein the first single-stranded DNA sequence and the third single-stranded DNA sequence are on opposite ends of the target DNA sequence, and wherein the second single-stranded DNA sequence and the fourth single-stranded DNA sequence are on the circular DNA donor.
217. The method of claim 216, wherein a portion of the circular DNA donor between the second single-stranded DNA sequence and the fourth single-stranded DNA sequence replaces the target sequence between the first single-stranded DNA sequence and the third single-stranded DNA sequence.
218. The method of any one of claims 181-217, wherein the first single-stranded DNA sequence and the third single-stranded DNA sequence are on a first nucleic acid molecule, and wherein the second single-stranded DNA sequence and the fourth single-stranded DNA sequence are on a second nucleic acid molecule.
219. The method of claim 218, wherein a portion of the first nucleic acid molecule between the first single-stranded DNA sequence and the third single-stranded DNA sequence is incorporated into the second nucleic acid molecule, and wherein a portion of the second nucleic acid molecule between the second single-stranded DNA sequence and the fourth single-stranded DNA sequence is incorporated into the first nucleic acid molecule.
220. The method of claim 218 or 219, wherein the first nucleic acid molecule is a first chromosome, and the second nucleic acid molecule is a second chromosome.
221. A set of PEGRNAs for use in multi-flap prime editing, wherein the PEGRNAs comprise:
- (a) a first prime editing guide RNA (first PEGRNA) that binds to a first binding site on a first strand of a double-stranded DNA sequence upstream of a target site to be edited, wherein the first PEGRNA comprises a first spacer sequence, first gRNA core, a first DNA synthesis template, and a first primer binding site, wherein the first DNA synthesis template encodes a first single-stranded DNA sequence;
 - (b) a second prime editing guide RNA (second PEGRNA) that binds to a second binding site on a second strand of the double-stranded DNA sequence upstream of the target site to be edited, wherein the second PEGRNA comprises a second spacer sequence, second gRNA core, a second DNA synthesis template, and a second primer binding site, wherein the second DNA synthesis template encodes a second single-stranded DNA sequence comprising the edited portion, wherein the second single-stranded DNA sequence is complementary to the first single-stranded DNA sequence.

- (c) a third prime editing guide RNA (third PEgRNA) that binds to a third binding site on a first strand of a double-stranded DNA sequence downstream of a target site to be edited, wherein the third PEgRNA comprises a third spacer sequence, third gRNA core, a third DNA synthesis template, and a third primer binding site, wherein the third DNA synthesis template encodes a third single-stranded DNA sequence;
- (d) a fourth prime editing guide RNA (fourth PEgRNA) that binds to a fourth binding site on a second strand of the double-stranded DNA sequence downstream of the target site to be edited, wherein the fourth PEgRNA comprises a fourth spacer sequence, fourth gRNA core, a fourth DNA synthesis template, and a fourth primer binding site, wherein the fourth DNA synthesis template encodes a fourth single-stranded DNA sequence, wherein the fourth single-stranded DNA sequence comprises a region of complementarity to the third single-stranded DNA sequence.
222. The set of PEgRNAs of claim 221, wherein the first PEgRNA comprises the structure:
 5'-[first gRNA spacer sequence]-[first gRNA core]-[first DNA synthesis template]-[first primer binding site]-3';
 the second PEgRNA comprises the structure:
 5'-[second gRNA spacer sequence]-[second gRNA core]-[second DNA synthesis template]-[second primer binding site]-3';
 the third PEgRNA comprises the structure:
 5'-[third gRNA spacer sequence]-[third gRNA core]-[third DNA synthesis template]-[third primer binding site]-3'; and
 the fourth PEgRNA comprises the structure:
 5'-[fourth gRNA spacer sequence]-[fourth gRNA core]-[fourth DNA synthesis template]-[fourth primer binding site]-3'.
223. The set of PEgRNAs of claim 221 or 222, wherein the first single-stranded DNA sequence and the second single-stranded DNA sequence, and/or the third single-stranded DNA sequence and the fourth single-stranded DNA sequence, form a duplex that becomes integrated into the double-stranded DNA sequence at the target site to be edited.
224. The set of PEgRNAs of any one of claims 221-223, wherein the integration of the duplex results in an insertion, deletion, or replacement of DNA at the target site.
225. The set of PEgRNAs of claim 224, wherein the insertion is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides,

at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides in length.

226. The set of PEGRNAs of claim 224, wherein the deletion is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides is at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39

nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67 nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides, or more in length.

227. The set of PEgRNAs of claim 224, wherein the replacement is at least 1 nucleotide, at least 2 nucleotides, at least 3 nucleotides, at least 4 nucleotides, at least 5 nucleotides, at least 6 nucleotides, at least 7 nucleotides, at least 8 nucleotides, at least 9 nucleotides, at least 10 nucleotides, at least 11 nucleotides, at least 12 nucleotides, at least 13 nucleotides, at least 14 nucleotides, at least 15 nucleotides, at least 16 nucleotides, at least 17 nucleotides, at least 18 nucleotides, at least 19 nucleotides, at least 20 nucleotides, at least 21 nucleotides, at least 22 nucleotides, at least 23 nucleotides, at least 24 nucleotides, at least 25 nucleotides, at least 26 nucleotides, at least 27 nucleotides, at least 28 nucleotides, at least 29 nucleotides, at least 30 nucleotides, at least 31 nucleotides, at least 32 nucleotides, at least 33 nucleotides, at least 34 nucleotides, at least 35 nucleotides, at least 36 nucleotides, at least 37 nucleotides, at least 38 nucleotides, at least 39 nucleotides, at least 40 nucleotides, at least 41 nucleotides, at least 42 nucleotides, at least 43 nucleotides, at least 44 nucleotides, at least 45 nucleotides, at least 46 nucleotides, at least 47 nucleotides, at least 48 nucleotides, at least 49 nucleotides, at least 50 nucleotides, at least 51 nucleotides, at least 52 nucleotides, at least 53 nucleotides, at least 54 nucleotides, at least 55 nucleotides, at least 56 nucleotides, at least 57 nucleotides, at least 58 nucleotides, at least 59 nucleotides, at least 60 nucleotides, at least 61 nucleotides, at least 62 nucleotides, at least 63 nucleotides, at least 64 nucleotides, at least 65 nucleotides, at least 66 nucleotides, at least 67

nucleotides, at least 68 nucleotides, at least 69 nucleotides, at least 70 nucleotides, at least 71 nucleotides, at least 72 nucleotides, at least 73 nucleotides, at least 74 nucleotides, at least 75 nucleotides, at least 76 nucleotides, at least 77 nucleotides, at least 78 nucleotides, at least 79 nucleotides, at least 80 nucleotides, at least 81 nucleotides, at least 82 nucleotides, at least 83 nucleotides, at least 84 nucleotides, at least 85 nucleotides, at least 86 nucleotides, at least 87 nucleotides, at least 88 nucleotides, at least 89 nucleotides, at least 90 nucleotides, at least 91 nucleotides, at least 92 nucleotides, at least 93 nucleotides, at least 94 nucleotide at least 95 nucleotides, at least 96 nucleotides, at least 97 nucleotides, at least 98 nucleotides, at least 99 nucleotides, at least 100 nucleotides, at least 101 nucleotides, at least 102 nucleotides, at least 103 nucleotides, at least 104 nucleotides, at least 105 nucleotides, at least 106 nucleotides, at least 107 nucleotides, at least 108 nucleotides, at least 109 nucleotides, or at least 110 nucleotides, or more in length.

228. A polynucleotide encoding a set of PEgRNAs of any of claims 221-227.

229. A vector comprising the polynucleotide of claim 228 for expressing the plurality of PEgRNAs in a cell.

230. A cell comprising the vector of claim 229.

231. A pharmaceutical composition comprising the plurality of PEgRNAs of any one of claims 221-227, a vector of claim 229, or a cell of claim 230, and a pharmaceutical excipient.

232. A method for modifying a genome in a cell, comprising:

- (i) contacting a genome with a dual-flap prime editing system, said system comprising a first prime editor/pegRNA complex capable of installing a first 3' nucleic acid flap at a first nick site on a first strand of a target site and a second prime editor/pegRNA complex capable of installing a second 3' nucleic acid flap at a second nick site on a second strand of a target site,

wherein the first 3' nucleic acid flap and the second 3' nucleic acid flap are reverse complement sequences that form a duplex, and

wherein the duplex comprises a first recombinase site, and

wherein the cell installs the duplex comprising the first recombinase site at the target site in place of an endogenous duplex positioned between the first and second nick sites;

- (ii) contacting the first recombinase site with a donor nucleic acid comprising a second recombinase site; and

(iii) contacting the genome with a recombinase capable recombination between the first and second recombinase sites, thereby integrating the donor nucleic acid at the target site in the genome.